PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Hale, RC; La Guardia, MJ; Harvey, EP; Gaylor, MO; Mainor, TM; Duff, WH				Hale, RC; La Guardia, MJ; Harvey, EP; Gaylor, MO; Mainor, TM; Duff, WH			Flame retardants - Persistent pollutants in land-applied sludges	NATURE			English	Article									Virginia Inst Marine Sci, Dept Environm Sci, Gloucester Point, VA 23062 USA	William & Mary; Virginia Institute of Marine Science	Hale, RC (corresponding author), Virginia Inst Marine Sci, Dept Environm Sci, POB 1346, Gloucester Point, VA 23062 USA.	hale@vims.edu	Hale, Robert C/D-7601-2013	La Guardia, Mark/0000-0003-4866-4992				de Boer J, 1998, NATURE, V394, P28, DOI 10.1038/27798; DICARLO FJ, 1978, ENVIRON HEALTH PERSP, V23, P351, DOI 10.1289/ehp.7823351; *NAT AC SCI, 1996, US RECL WAT SLUD FOO; Renner R, 2000, ENVIRON SCI TECHNOL, V34, p452A, DOI 10.1021/es003482n; Renner R, 2000, ENVIRON SCI TECHNOL, V34, p222A, DOI 10.1021/es003269r; Sellstrom U, 1999, ORGANOHALOGEN COMPD, V40, P383; Strandberg B, 2001, ENVIRON SCI TECHNOL, V35, P1078, DOI 10.1021/es001819f; *US EPA, 1999, EPA530R99009; World Health Organization: Brominated diphenylethers, 1994, ENV HLTH CRIT	9	200	209	7	75	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 12	2001	412	6843					140	141		10.1038/35084130	http://dx.doi.org/10.1038/35084130			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	451AJ	11449259				2022-12-28	WOS:000169778700037
J	Sharma, L; Song, J; Felson, DT; Cahue, S; Shamiyeh, E; Dunlop, DD				Sharma, L; Song, J; Felson, DT; Cahue, S; Shamiyeh, E; Dunlop, DD			The role of knee alignment in disease progression and functional decline in knee osteoarthritis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RADIOGRAPHIC ASSESSMENT; MEDICAL CONDITIONS; CLINICAL-TRIALS; JOINT LOAD; MALALIGNMENT; ARTHRITIS; LAXITY; MENISCECTOMY; STABILITY; DYNAMICS	Context Knee osteoarthritis (OA) is a leading cause of disability in older persons. Few risk factors for disease progression or functional decline have been identified. Hip-knee-ankle align ment influences load distribution at the knee; varus and valgus alignment increase medial and lateral load, respectively. Objective To test the hypotheses that (1) varus alignment increases risk of medial knee OA progression during the subsequent 18 months, (2) valgus alignment increases risk of subsequent lateral knee OA progression, (3) greater severity of malalignment is associated with greater subsequent loss of joint space, and (4) greater burden of malalignment is associated with greater subsequent decline in physical function. Design and Setting Prospective longitudinal cohort study conducted March 1997 to March 2000 at an academic medical center in Chicago, ill. Participants A total of 237 persons recruited from the community with primary knee OA, defined by presence of definite tibiofemoral osteophytes and at least some difficulty with knee-requiring activity; 230 (97%) completed the study. Main Outcome Measures Progression of OA, defined as al-grade increase in severity of joint space narrowing on semiflexed, fluoroscopically confirmed knee radiographs; change in narrowest joint space width; and change in physical function between baseline and 18 months, compared by knee alignment at baseline. Results Varus alignment at baseline was associated with a 4-fold increase in the odds of medial progression, adjusting for age, sex, and body mass index (adjusted odds ratio [OR], 4.09; 95% confidence interval [CI], 2.20-7.62). Valgus alignment at baseline was associated with a nearly 5-fold increase in the odds of lateral progression (adjusted OR, 4.89; 95% CI, 2.13-11.20). Severity of varus correlated with greater medial joint space loss during the subsequent 18 months (R=0.52; 95% CI, 0.40-0.62 in dominant knees), and severity of valgus correlated with greater subsequent lateral joint space loss (R=0.35; 95% CI, 0.21-0.47 in dominant knees). Having alignment of more than 5 degrees (in either direction) in both knees at baseline was associated with significantly greater functional deterioration during the 18 months than having alignment of 5 degrees or less in both knees, after adjusting for age, sex, body mass index, and pain. Conclusion This is, to our knowledge, the first demonstration that in primary knee OA varus alignment increases risk of medial OA progression, that valgus alignment increases risk of lateral OA progression, that burden of malalignment predicts decline in physical function, and that these effects can be detected after as little as 18 months of observation.	Northwestern Univ, Sch Med, Chicago, IL 60611 USA; Boston Univ, Boston, MA 02215 USA	Northwestern University; Boston University	Sharma, L (corresponding author), Northwestern Univ, Sch Med, 303 E Chicago Ave,Ward Bldg 3-315, Chicago, IL 60611 USA.			Felson, David/0000-0002-2668-2447; Sharma, Leena/0000-0002-5571-1622	NCRR NIH HHS [RR-00048] Funding Source: Medline; NIAMS NIH HHS [AR-30692] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR030692] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALLEN PR, 1984, J BONE JOINT SURG BR, V66, P666, DOI 10.1302/0301-620X.66B5.6548755; Altman R, 1996, OSTEOARTHR CARTILAGE, V4, P217, DOI 10.1016/S1063-4584(05)80101-3; ALTMAN RD, 1987, ARTHRITIS RHEUM-US, V30, P1214, DOI 10.1002/art.1780301103; ANDRIACCHI TP, 1994, ORTHOP CLIN N AM, V25, P395; BOE S, 1986, J BONE JOINT SURG BR, V68, P707, DOI 10.1302/0301-620X.68B5.3782228; BRAGE ME, 1994, CLIN ORTHOP RELAT R, P184; Bruns J, 1993, ARCH ORTHOP TRAUMA S, V133, P12; Buckland-Wright JC, 1999, J RHEUMATOL, V26, P2664; BUCKLANDWRIGHT C, 1995, OSTEOARTHR CARTILAGE, V3, P71; BUCKLANDWRIGHT JC, 1995, ANN RHEUM DIS, V54, P872, DOI 10.1136/ard.54.11.872; BUCKLANDWRIGHT JC, 1994, ANN RHEUM DIS, V53, P268, DOI 10.1136/ard.53.4.268; BUCKLANDWRIGHT JC, 1995, ANN RHEUM DIS, V54, P263, DOI 10.1136/ard.54.4.263; BUCKLANDWRIGHT JC, 1995, OSTEOARTHRITIC DISOR, P51; CHAO EYS, 1994, ORTHOP CLIN N AM, V25, P379; COOKE TDV, 1994, ORTHOP CLIN N AM, V25, P387; CUSHNAGHAN J, 1990, ANN RHEUM DIS, V49, P768, DOI 10.1136/ard.49.10.768; Dieppe P, 1995, OSTEOARTHRITIC DISOR, P481; DIEPPE P, 2001, STEPP OA SCI C PREV; DIEPPE P, 1995, OSTEOARTHRITIC DISOR, P7; DOUGADOS M, 1992, J RHEUMATOL, V19, P378; ETTINGER WH, 1994, J CLIN EPIDEMIOL, V47, P809, DOI 10.1016/0895-4356(94)90178-3; FLECKENSTEIN SJ, 1988, J BIOMECH, V21, P915, DOI 10.1016/0021-9290(88)90129-7; GOLDBERG VM, 1992, OSTEOARTHRITIS DIAGN, P599; GUCCIONE AA, 1994, AM J PUBLIC HEALTH, V84, P351, DOI 10.2105/AJPH.84.3.351; GURALNIK JM, 1995, NEW ENGL J MED, V332, P556, DOI 10.1056/NEJM199503023320902; HARRINGTON IJ, 1983, J BONE JOINT SURG AM, V65, P247, DOI 10.2106/00004623-198365020-00016; HILDING MB, 1995, ACTA ORTHOP SCAND, V66, P317, DOI 10.3109/17453679508995552; HSU RWW, 1990, CLIN ORTHOP RELAT R, P215; JOHNSON F, 1980, J BONE JOINT SURG BR, V62, P346, DOI 10.1302/0301-620X.62B3.7410467; KUETTNER KE, 1995, OSTEOARTHRITIC DISOR, pR21; Lawrence RC, 1998, ARTHRITIS RHEUM-US, V41, P778, DOI 10.1002/1529-0131(199805)41:5<778::AID-ART4>3.0.CO;2-V; LEDINGHAM J, 1995, ANN RHEUM DIS, V54, P53, DOI 10.1136/ard.54.1.53; Lequesne M., 1995, OSTEOARTHRITIC DISOR, P427; MARKOLF KL, 1981, J BONE JOINT SURG AM, V63, P570, DOI 10.2106/00004623-198163040-00007; MARKOLF KL, 1978, J BONE JOINT SURG AM, V60, P664, DOI 10.2106/00004623-197860050-00014; Mazzuca SA, 1997, OSTEOARTHR CARTILAGE, V5, P217, DOI 10.1016/S1063-4584(97)80017-9; Mazzuca SA, 1999, RHEUM DIS CLIN N AM, V25, P467, DOI 10.1016/S0889-857X(05)70079-X; MCKELLOP HA, 1994, ORTHOP CLIN N AM, V25, P415; MESSIEH SS, 1990, J BONE JOINT SURG BR, V72, P639, DOI 10.1302/0301-620X.72B4.2380220; MILLER R, 1973, J BONE JOINT SURG AM, VA 55, P956, DOI 10.2106/00004623-197355050-00004; MORELAND JR, 1987, J BONE JOINT SURG AM, V69A, P745, DOI 10.2106/00004623-198769050-00016; MORRISON JB, 1970, J BIOMECH, V3, P51, DOI 10.1016/0021-9290(70)90050-3; *NAT I ARTHR MUSC, 2001, OST IN; NEYRET P, 1993, J BONE JOINT SURG BR, V75, P36, DOI 10.1302/0301-620X.75B1.8421030; NOYES FR, 1991, AM J SPORT MED, V19, P163, DOI 10.1177/036354659101900212; OGILVIE-HARRIS D J, 1991, Arthroscopy, V7, P151, DOI 10.1016/0749-8063(91)90101-3; PAI YC, 1991, ARCH PHYS MED REHAB, V72, P881, DOI 10.1016/0003-9993(91)90004-3; PAI YC, 1994, ARTHRITIS RHEUM-US, V37, P1297, DOI 10.1002/art.1780370905; PELLETIER JP, 1997, ARTHRITIS ALLIED CON, P1969; POTTENGER LA, 1990, ARTHRITIS RHEUM-US, V33, P853, DOI 10.1002/art.1780330612; Ravaud P, 1996, J RHEUMATOL, V23, P1756; RITTER MA, 1994, CLIN ORTHOP RELAT R, P153; SCHIPPLEIN OD, 1991, J ORTHOPAED RES, V9, P113, DOI 10.1002/jor.1100090114; SCHOUTEN JSAG, 1992, ANN RHEUM DIS, V51, P932, DOI 10.1136/ard.51.8.932; SCHULTZ AB, 1992, J BIOMECH, V25, P1383, DOI 10.1016/0021-9290(92)90052-3; SEEMAN TE, 1994, J GERONTOL MED SCI, V49, P97; Sharma L, 1999, ARTHRITIS RHEUM, V42, P861, DOI 10.1002/1529-0131(199905)42:5<861::AID-ANR4>3.0.CO;2-N; Sharma L, 1999, ARTHRITIS RHEUM-US, V42, P25, DOI 10.1002/1529-0131(199901)42:1<25::AID-ANR3>3.0.CO;2-G; TETSWORTH K, 1994, ORTHOP CLIN N AM, V25, P367; Wada M, 1996, BRIT J RHEUMATOL, V35, P560; YASUDA K, 1992, CLIN ORTHOP RELAT R, P186	61	961	1043	1	73	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 11	2001	286	2					188	195		10.1001/jama.286.2.188	http://dx.doi.org/10.1001/jama.286.2.188			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	451JJ	11448282				2022-12-28	WOS:000169798700024
J	Tobin, MJ				Tobin, MJ			Medical progress - Advances in mechanical ventilation	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							RESPIRATORY-DISTRESS SYNDROME; END-EXPIRATORY PRESSURE; ACUTE LUNG INJURY; OBSTRUCTIVE PULMONARY-DISEASE; INTENSIVE-CARE UNIT; TIDAL VOLUME; PERMISSIVE HYPERCAPNIA; PRONE POSITION; ENDOTRACHEAL-TUBE; GAS-EXCHANGE		Edward Hines Jr Vet Affairs Hosp, Div Pulm & Crit Care Med, Hines, IL 60141 USA; Loyola Univ Chicago, Stritch Sch Med, Hines, IL USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Edward Hines Jr. VA Hospital; Loyola University Chicago	Tobin, MJ (corresponding author), Edward Hines Jr Vet Affairs Hosp, Div Pulm & Crit Care Med, Rte 111N, Hines, IL 60141 USA.							Albert RK, 2000, AM J RESP CRIT CARE, V161, P1660, DOI 10.1164/ajrccm.161.5.9901037; AMATO MBP, 1995, AM J RESP CRIT CARE, V152, P1835, DOI 10.1164/ajrccm.152.6.8520744; Amato MBP, 1998, NEW ENGL J MED, V338, P347, DOI 10.1056/NEJM199802053380602; Anzueto A, 1997, CRIT CARE MED, V25, P1187, DOI 10.1097/00003246-199707000-00021; ARGIRAS EP, 1987, BRIT J ANAESTH, V59, P1278, DOI 10.1093/bja/59.10.1278; BROCHARD L, 1994, AM J RESP CRIT CARE, V150, P896, DOI 10.1164/ajrccm.150.4.7921460; BROCHARD L, 1991, ANESTHESIOLOGY, V75, P739, DOI 10.1097/00000542-199111000-00004; Brochard L, 1998, AM J RESP CRIT CARE, V158, P1831, DOI 10.1164/ajrccm.158.6.9801044; Brochard L, 1994, PRINCIPLES PRACTICE, P239; Brochard L., 1998, PRINCIPLES PRACTICE, P597; Brower RG, 1999, CRIT CARE MED, V27, P1492, DOI 10.1097/00003246-199908000-00015; Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801; Carney DE, 1999, AM J RESP CRIT CARE, V160, P1697, DOI 10.1164/ajrccm.160.5.9812031; Coplin WM, 2000, AM J RESP CRIT CARE, V161, P1530, DOI 10.1164/ajrccm.161.5.9905102; Dambrosio M, 1997, ANESTHESIOLOGY, V87, P495, DOI 10.1097/00000542-199709000-00007; Dreyfuss D, 1998, AM J RESP CRIT CARE, V157, P294, DOI 10.1164/ajrccm.157.1.9604014; Ely EW, 1996, NEW ENGL J MED, V335, P1864, DOI 10.1056/NEJM199612193352502; Epstein SK, 1997, CHEST, V112, P186, DOI 10.1378/chest.112.1.186; EPSTEIN SK, 1995, AM J RESP CRIT CARE, V152, P545, DOI 10.1164/ajrccm.152.2.7633705; Esteban A, 1999, AM J RESP CRIT CARE, V159, P512, DOI 10.1164/ajrccm.159.2.9803106; ESTEBAN A, 1995, NEW ENGL J MED, V332, P345, DOI 10.1056/NEJM199502093320601; Esteban A, 2000, AM J RESP CRIT CARE, V161, P1450, DOI 10.1164/ajrccm.161.5.9902018; Feihl F, 2000, AM J RESP CRIT CARE, V162, P209, DOI 10.1164/ajrccm.162.1.9907119; FEIHL F, 1994, AM J RESP CRIT CARE, V150, P1722, DOI 10.1164/ajrccm.150.6.7952641; GATTINONI L, 1991, ANESTHESIOLOGY, V74, P15, DOI 10.1097/00000542-199101000-00004; GATTINONI L, 1988, ANESTHESIOLOGY, V69, P824, DOI 10.1097/00000542-198812000-00005; Gattinoni L, 1998, AM J RESP CRIT CARE, V158, P3, DOI 10.1164/ajrccm.158.1.9708031; Giannouli E, 1999, AM J RESP CRIT CARE, V159, P1716, DOI 10.1164/ajrccm.159.6.9704025; Harris RS, 2000, AM J RESP CRIT CARE, V161, P432; Hickling KG, 1998, AM J RESP CRIT CARE, V158, P194, DOI 10.1164/ajrccm.158.1.9708049; HICKLING KG, 1990, INTENS CARE MED, V16, P372, DOI 10.1007/BF01735174; Hillberg RE, 1997, NEW ENGL J MED, V337, P1746, DOI 10.1056/NEJM199712113372407; HORTON WG, 1975, ARCH SURG-CHICAGO, V110, P395; Jacob B, 1997, CRIT CARE MED, V25, P253, DOI 10.1097/00003246-199702000-00010; Jaeschke RZ, 1997, CRIT CARE MED, V25, P1514, DOI 10.1097/00003246-199709000-00018; Jubran A, 1997, AM J RESP CRIT CARE, V155, P906, DOI 10.1164/ajrccm.155.3.9117025; Jubran A, 1998, AM J RESP CRIT CARE, V158, P1763, DOI 10.1164/ajrccm.158.6.9804056; JUBRAN A, 1995, AM J RESP CRIT CARE, V152, P129, DOI 10.1164/ajrccm.152.1.7599811; Jubran A, 1997, AM J RESP CRIT CARE, V155, P916, DOI 10.1164/ajrccm.155.3.9117026; KANAREK DJ, 1975, AM REV RESPIR DIS, V112, P457; LAGHI F, 1995, J APPL PHYSIOL, V79, P539, DOI 10.1152/jappl.1995.79.2.539; Laghi F, 1999, AM J RESP CRIT CARE, V160, P1766, DOI 10.1164/ajrccm.160.5.9810086; Leach CL, 1996, NEW ENGL J MED, V335, P761, DOI 10.1056/NEJM199609123351101; LEMAIRE F, 1988, ANESTHESIOLOGY, V69, P171, DOI 10.1097/00000542-198808000-00004; Leung P, 1997, AM J RESP CRIT CARE, V155, P1940, DOI 10.1164/ajrccm.155.6.9196100; Lichtwarck-Aschoff M, 2000, AM J RESP CRIT CARE, V162, P2125, DOI 10.1164/ajrccm.162.6.9910018; Lu Q, 1999, AM J RESP CRIT CARE, V159, P275, DOI 10.1164/ajrccm.159.1.9802082; Maldonado A, 2000, AM J RESP CRIT CARE, V161, P171, DOI 10.1164/ajrccm.161.1.9904080; MARINI JJ, 1985, CHEST, V87, P612, DOI 10.1378/chest.87.5.612; MARINI JJ, 1988, AM REV RESPIR DIS, V138, P1169, DOI 10.1164/ajrccm/138.5.1169; Martynowicz MA, 1999, AM J RESP CRIT CARE, V160, P250, DOI 10.1164/ajrccm.160.1.9808101; MEAD J, 1970, J APPL PHYSIOL, V28, P596, DOI 10.1152/jappl.1970.28.5.596; MEAD J, 1959, J APPL PHYSIOL, V14, P669, DOI 10.1152/jappl.1959.14.5.669; Mure M, 2000, J APPL PHYSIOL, V88, P1076, DOI 10.1152/jappl.2000.88.3.1076; MUTOH T, 1992, AM REV RESPIR DIS, V146, P300, DOI 10.1164/ajrccm/146.2.300; Nava S, 1998, ANN INTERN MED, V128, P721, DOI 10.7326/0003-4819-128-9-199805010-00004; Parthasarathy S, 1999, AM J RESP CRIT CARE, V159, P1023; Parthasarathy S, 2000, AM J RESP CRIT CARE, V162, P546, DOI 10.1164/ajrccm.162.2.9901024; Pelosi P, 1998, AM J RESP CRIT CARE, V157, P387, DOI 10.1164/ajrccm.157.2.97-04023; Pelosi P, 1999, AM J RESP CRIT CARE, V159, P872, DOI 10.1164/ajrccm.159.3.9802090; Pierson DJ, 1994, PRINCIPLES PRACTICE, P813; PUDDY A, 1992, AM REV RESPIR DIS, V146, P787, DOI 10.1164/ajrccm/146.3.787; Puybasset L, 1998, AM J RESP CRIT CARE, V158, P1644, DOI 10.1164/ajrccm.158.5.9802003; REID WD, 1994, J APPL PHYSIOL, V76, P176, DOI 10.1152/jappl.1994.76.1.176; Richecoeur J, 1999, AM J RESP CRIT CARE, V160, P77, DOI 10.1164/ajrccm.160.1.9809006; ROUBY JJ, 1993, INTENS CARE MED, V19, P383, DOI 10.1007/BF01724877; ROUPIE E, 1995, AM J RESP CRIT CARE, V152, P121, DOI 10.1164/ajrccm.152.1.7599810; SASSOON CSH, 1993, AM REV RESPIR DIS, V148, P860, DOI 10.1164/ajrccm/148.4_Pt_1.860; SASSOON CSH, 1995, INTENS CARE MED, V21, P159, DOI 10.1007/BF01726540; SASSOON CSH, 1994, PRINCIPLES PRACTICE, P221; Simon PM, 1999, AM J RESP CRIT CARE, V160, P950, DOI 10.1164/ajrccm.160.3.9712057; Sinderby C, 1999, NAT MED, V5, P1433, DOI 10.1038/71012; Stewart TE, 1998, NEW ENGL J MED, V338, P355, DOI 10.1056/NEJM199802053380603; Straus C, 1998, AM J RESP CRIT CARE, V157, P23, DOI 10.1164/ajrccm.157.1.96-10057; STROETZ RW, 1995, AM J RESP CRIT CARE, V152, P1034, DOI 10.1164/ajrccm.152.3.7663780; Tobin M J, 2000, Respir Care, V45, P417; TOBIN MJ, 1986, AM REV RESPIR DIS, V134, P1111; Tobin MJ, 2000, NEW ENGL J MED, V342, P1360, DOI 10.1056/NEJM200005043421808; TOBIN MJ, 1983, CHEST, V84, P202, DOI 10.1378/chest.84.2.202; TOBIN MJ, 1994, NEW ENGL J MED, V330, P1056, DOI 10.1056/NEJM199404143301507; Tobin MJ, 1994, PRINCIPLES PRACTICE, P1177; Tremblay L, 1997, J CLIN INVEST, V99, P944, DOI 10.1172/JCI119259; Vallverdu I, 1998, AM J RESP CRIT CARE, V158, P1855, DOI 10.1164/ajrccm.158.6.9712135; Vieira SRR, 1998, AM J RESP CRIT CARE, V158, P1571, DOI 10.1164/ajrccm.158.5.9802101; Vieira SRR, 1999, AM J RESP CRIT CARE, V159, P1612, DOI 10.1164/ajrccm.159.5.9805112; WEBB HH, 1974, AM REV RESPIR DIS, V110, P556; YANG KL, 1991, NEW ENGL J MED, V324, P1445, DOI 10.1056/NEJM199105233242101	87	256	283	0	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 28	2001	344	26					1986	1996		10.1056/NEJM200106283442606	http://dx.doi.org/10.1056/NEJM200106283442606			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	446HQ	11430329				2022-12-28	WOS:000169508200006
J	Verlinsky, Y; Rechitsky, S; Schoolcraft, W; Strom, C; Kuliev, A				Verlinsky, Y; Rechitsky, S; Schoolcraft, W; Strom, C; Kuliev, A			Preimplantation diagnosis for fanconi anemia combined with HLA matching	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SINGLE-GENE DISORDERS; POLAR BODY ANALYSIS; AMPLIFICATION; POLYMORPHISM; FACC	Context The advent of single-cell polymerase chain reaction (PCR) has presented the opportunity for combined preimplantation genetic diagnosis (PCD) and HLA antigen testing, This is a novel and useful way to preselect a potential donor for an affected sibling requiring stem cell transplantation. Objective To perform in vitro fertilization (IVF) and preimplantation HLA matching combined with PGD for Fanconi anemia (FA), Design DNA analysis for the IVS 4+4 A -->T (adenine to thymine) mutation in the FA complement C (FANCC) gene in single blastomeres, obtained by biopsy of embryos, to identify genetic status and HLA markers of each embryo before intrauterine transfer. Setting In vitro fertilization programs at large medical centers in Chicago, ill, and Denver, Colo. Participants A couple, both carriers of the IVS 4+4 A -->T mutation in the FANCC gene with an affected child requiring an HLA-compatible donor for cord blood transplantation. Main Outcome Measures DNA analysis of single blastomeres to preselect unaffected embryos representing an HLA match for the affected sibling. Results Of 30 embryos tested in 4 IVF attempts, 6 were homozygous affected and 24 were unaffected. Five of these embryos were also found to be HLA-compatible, of which 2 were transferred in the first and 1 in each of the other 3 cycles, resulting in a pregnancy and birth of an unaffected child in the last cycle. Conclusion To our knowledge, this is the first PGD with HLA matching, demonstrating feasibility of preselecting unaffected embryos that can also be an HLA-compatible source for stem cell transplantation for a sibling.	Inst Reprod Genet, Chicago, IL USA; Colorado Ctr Reprod Med, Denver, CO USA		Verlinsky, Y (corresponding author), 2825 N Halsted St, Chicago, IL 60657 USA.		Kuliev, Anver/P-5666-2018	Kuliev, Anver/0000-0002-2486-9339				BLASCZYK R, 1995, TISSUE ANTIGENS, V46, P86, DOI 10.1111/j.1399-0039.1995.tb02483.x; Foissac A, 1998, TISSUE ANTIGENS, V52, P318, DOI 10.1111/j.1399-0039.1998.tb03054.x; Gibson RA, 1996, HUM MUTAT, V8, P140, DOI 10.1002/(SICI)1098-1004(1996)8:2<140::AID-HUMU6>3.0.CO;2-F; GLUCKMAN E, 1989, NEW ENGL J MED, V321, P1174, DOI 10.1056/NEJM198910263211707; GLUCKMAN E, 1980, BRIT J HAEMATOL, V45, P557, DOI 10.1111/j.1365-2141.1980.tb07178.x; HANDYSIDE AH, 1990, NATURE, V344, P768, DOI 10.1038/344768a0; HANDYSIDE AH, 1992, NEW ENGL J MED, V327, P905, DOI 10.1056/NEJM199209243271301; *INT WORK GROUP PR, 2001, J ASSIST REPROD GEN, V18, P66; *INT WORK GROUP PR, 2000, J ASSIST REPROD GEN, V17, P75; Mitsunaga S, 1998, EUR J IMMUNOGENET, V25, P15, DOI 10.1046/j.1365-2370.1998.00093.x; Munne S, 1998, J ASSIST REPROD GEN, V15, P290, DOI 10.1023/A:1022544511198; Rechitsky S, 1999, J ASSIST REPROD GEN, V16, P192, DOI 10.1023/A:1020312823155; Sermon K, 1997, PRENATAL DIAG, V17, P925, DOI 10.1002/(SICI)1097-0223(199710)17:10<925::AID-PD178>3.0.CO;2-4; STRATHDEE CA, 1992, NAT GENET, V1, P196, DOI 10.1038/ng0692-196; STRATHDEE CA, 1992, NATURE, V356, P763, DOI 10.1038/356763a0; VELRINSKY Y, 2000, ATLAS PREIMPLANTATIO; Verlinsky Y, 1999, GENET TEST, V3, P185, DOI 10.1089/gte.1999.3.185; VERLINSKY Y, 1990, HUM REPROD, V5, P826, DOI 10.1093/oxfordjournals.humrep.a137192; Verlinsky Y, 1999, J ASSIST REPROD GEN, V16, P161, DOI 10.1023/A:1020327804500; Verlinsky Yury, 2001, Reprod Biomed Online, V2, P102; WAGNER JE, 1999, HEMATOPOIETIC CELL T, P1204; WHITNEY MA, 1993, NAT GENET, V4, P202, DOI 10.1038/ng0693-202; Xu KP, 1999, JAMA-J AM MED ASSOC, V281, P1701, DOI 10.1001/jama.281.18.1701; YOSHIDA M, 1992, HUM IMMUNOL, V34, P257, DOI 10.1016/0198-8859(92)90025-I	24	244	271	0	15	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 27	2001	285	24					3130	3133		10.1001/jama.285.24.3130	http://dx.doi.org/10.1001/jama.285.24.3130			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	444FF	11427142	Bronze			2022-12-28	WOS:000169388900027
J	Hauck, EW; Weidner, W				Hauck, EW; Weidner, W			Francois de la Peyronie and the disease named after him	LANCET			English	Editorial Material							PEYRONIES-DISEASE; THERAPY		Univ Giessen, Dept Urol, D-35383 Giessen, Germany	Justus Liebig University Giessen	Weidner, W (corresponding author), Univ Giessen, Dept Urol, D-35383 Giessen, Germany.							DELEPEYRONIE F, 1743, MEM ACAD ROY CHIR, V1, P425; Dunsmuir WD, 1996, BRIT J UROL, V78, P613, DOI 10.1046/j.1464-410X.1996.14120.x; GELBARD MK, 1990, J UROLOGY, V144, P1376, DOI 10.1016/S0022-5347(17)39746-X; Hauck EW, 2000, EUR UROL, V38, P663, DOI 10.1159/000020359; Levine LA, 1997, J UROLOGY, V158, P2149, DOI 10.1016/S0022-5347(01)68184-9; Montorsi F, 2000, J ANDROL, V21, P85; Weidner W, 1997, J UROLOGY, V157, P325, DOI 10.1016/S0022-5347(01)65370-9	7	29	30	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 23	2001	357	9273					2049	2051		10.1016/S0140-6736(00)05119-9	http://dx.doi.org/10.1016/S0140-6736(00)05119-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	446JB	11438159				2022-12-28	WOS:000169509200035
J	Robinson, DS; Campbell, D; Barnes, PJ				Robinson, DS; Campbell, D; Barnes, PJ			Addition of leukotriene antagonists to therapy in chronic persistent asthma: a randomised double-blind placebo-controlled trial	LANCET			English	Article							RECEPTOR ANTAGONIST; INHALED CORTICOSTEROIDS; MONTELUKAST; BRONCHOCONSTRICTION; BRONCHODILATION; ZAFIRLUKAST; ASPIRIN; POTENT	Background Controlled trials suggest that leukotriene receptor antagonists can improve lung function and reduce requirement for oral or inhaled corticosteroids in patients with asthma. We aimed to assess whether montelukast, a leukotriene receptor antagonist. can improve symptoms or lung function in patients with chronic asthma with symptoms already taking corticosteroids. Methods We did a double-blind, placebo-controlled, crossover, randomised add-on study in which 100 patients with asthma and symptoms despite treatment with inhaled corticosteroids and additional therapy were given 10 mg montelukast sodium for 14 days in an outpatient clinic setting. Outcome measures were symptoms and peak flow diaries. Findings 72 patients had diary data for analysis. Compared with placebo. addition of montelukast did not result in any significant change in symptom scores (mean difference between the last 7 days of each treatment period 0.05: 95% CI -0.86 to 1.14), rescue inhaled beta (2) agonist use (mean difference in puffs per day 0.41; -0.29 to 0.57), or twice daily peak expiratory flow (PEF) measurements (mean difference in morning PEF 1.18 L/min; -14.29 to 17.14). and mean difference in evening peak flow (-0.50; -17.42 to 12.86). When treatment response was defined as a 15% or greater increase in mean peak flow readings, there were four responders to montelukast and seven responders to placebo. Interpretation Based on PEF data from our previous studies of a similar patient group we would have expected to detect changes of more than 5%. Used as additional therapy in a hospital outpatient clinic setting, montelukast did not provide such additional benefit in patients with moderate or severe asthma.	Natl Heart & Lung Inst, Imperial Coll Sch Med, London SW3 6LY, England; Royal Brompton & Harefield NHS Trust, London, England	Imperial College London; Royal Brompton & Harefield NHS Foundation Trust; Royal Brompton Hospital	Robinson, DS (corresponding author), Natl Heart & Lung Inst, Imperial Coll Sch Med, Dovehouse St, London SW3 6LY, England.			Barnes, Peter/0000-0002-5122-4018				Altman LC, 1998, J ALLERGY CLIN IMMUN, V102, P50, DOI 10.1016/S0091-6749(98)70054-5; *AM THOR SOC, 1995, AM J RESP CRIT CARE, V152, P1007; Barnes PJ, 1998, EUR RESPIR J, V12, P1209, DOI 10.1183/09031936.98.12051209; Chan MTS, 1998, J ALLERGY CLIN IMMUN, V101, P594, DOI 10.1016/S0091-6749(98)70165-4; Dahlen B, 1998, AM J RESP CRIT CARE, V157, P1187, DOI 10.1164/ajrccm.157.4.9707089; Drazen JM, 1999, NAT GENET, V22, P168, DOI 10.1038/9680; Drazen JM, 1999, NEW ENGL J MED, V340, P197, DOI 10.1056/NEJM199901213400306; DWORSKI R, 1994, AM J RESP CRIT CARE, V149, P953, DOI 10.1164/ajrccm.149.4.8143061; GADDY JN, 1992, AM REV RESPIR DIS, V146, P358, DOI 10.1164/ajrccm/146.2.358; Ind PW, 1999, ALLERGY, V54, P43, DOI 10.1111/j.1398-9995.1999.tb05027.x; ISRAEL E, 1993, AM REV RESPIR DIS, V148, P1447, DOI 10.1164/ajrccm/148.6_Pt_1.1447; Laviolette M, 1999, AM J RESP CRIT CARE, V160, P1862, DOI 10.1164/ajrccm.160.6.9803042; Leff JA, 1998, NEW ENGL J MED, V339, P147, DOI 10.1056/NEJM199807163390302; Lofdahl CG, 1999, BMJ-BRIT MED J, V319, P87, DOI 10.1136/bmj.319.7202.87; Nathan RA, 1998, J ALLERGY CLIN IMMUN, V102, P935, DOI 10.1016/S0091-6749(98)70331-8; OSHAUGHNESSY KM, 1993, AM REV RESPIR DIS, V147, P1472, DOI 10.1164/ajrccm/147.6_Pt_1.1472; Pizzichini E, 1999, EUR RESPIR J, V14, P12, DOI 10.1034/j.1399-3003.1999.14a04.x; Reiss TF, 1997, THORAX, V52, P45, DOI 10.1136/thx.52.1.45; Sampson A, 1998, BRIT MED J, V316, P1257, DOI 10.1136/bmj.316.7140.1257; Tashkin DP, 1999, J ALLERGY CLIN IMMUN, V103, P246, DOI 10.1016/S0091-6749(99)70498-7; VIRCHOW JC, 1997, J INVEST MED, V45, pA286	21	113	117	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 23	2001	357	9273					2007	2011		10.1016/S0140-6736(00)05113-8	http://dx.doi.org/10.1016/S0140-6736(00)05113-8			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	446JB	11438132				2022-12-28	WOS:000169509200009
J	Smith, GCS; Pell, JP; Walsh, D				Smith, GCS; Pell, JP; Walsh, D			Pregnancy complications and maternal risk of ischaemic heart disease: a retrospective cohort study of 129,290 births	LANCET			English	Article							MYOCARDIAL-INFARCTION; YOUNG-WOMEN; CIGARETTE-SMOKING; WEIGHT; HYPERTENSION; ASSOCIATION; MORTALITY; SCOTLAND; PREECLAMPSIA; PROGNOSIS	Background Individuals who are small at birth are at increased risk of ischaemic heart disease (IHD) in later life. One hypothesis to explain this association is fetal adaptation to a suboptimum intrauterine environment. We investigated whether pregnancy complications associated with low birthweight are related to risk of subsequent IHD in the mother. Methods Routine discharge data were used to identify all singleton first births in Scotland between 1981 and 1985. Linkage to the mothers' subsequent admissions and deaths provided 15-19 years of follow-up. The mothers' risks of death from any cause or from IHD and admission for or death from IHD were related to adverse obstetric outcomes in the first pregnancy. Hazard ratios were adjusted for socioeconomic deprivation, maternal height and age, and essential hypertension. Findings Complete data were available on 129 920 (95.6%) eligible deliveries. Maternal risk of IHD admission or death was associated with delivering a baby in the lowest birthweight quintile for gestational age (adjusted hazard ratio 1.9 [95% CI 1.5-2.4]), preterm delivery (1.8 [1.3-2.5]), and pre-eclampsia (2.0 [1.5-2.5]). The associations were additive; women with all three characteristics had a risk of IHD admission or death seven times (95% CI 3.3-14.5) greater than the reference category. Interpretation Complications of pregnancy linked to low birthweight are associated with an increased risk of subsequent IHD in the mother. Common genetic risk factors might explain the link between birthweight and risk of IHD in both the individual and the mother.	Univ Glasgow, Dept Obstet & Gynaecol, Glasgow, Lanark, Scotland; Univ Glasgow, Dept Med Cardiol, Glasgow, Lanark, Scotland; Common Serv Agcy, Informat & Stat Div, Edinburgh, Midlothian, Scotland	University of Glasgow; University of Glasgow	Smith, GCS (corresponding author), Queen Mothers Hosp, Dept Obstet & Gynaecol, Glasgow G3 8SJ, Lanark, Scotland.		Smith, Gordon/A-8070-2008	Smith, Gordon/0000-0003-2124-0997; Pell, Jill/0000-0002-8898-7035; Walsh, David/0000-0002-3390-5039				Barker D. J. P., 1994, MOTHERS BABIES DIS L; CHESLEY LC, 1980, KIDNEY INT, V18, P234, DOI 10.1038/ki.1980.131; Conde-Agudelo A, 1999, AM J OBSTET GYNECOL, V181, P1026, DOI 10.1016/S0002-9378(99)70341-8; Dunn NR, 2000, J EPIDEMIOL COMMUN H, V54, P293, DOI 10.1136/jech.54.4.293; Erhardt E, 2000, BIOL NEONATE, V78, P145, DOI 10.1159/000014263; Gurevitz O, 2000, AM J CARDIOL, V85, P806, DOI 10.1016/S0002-9149(99)00871-1; Hattersley AT, 1998, NAT GENET, V19, P268, DOI 10.1038/953; Hocher B, 2000, LANCET, V355, P1241, DOI 10.1016/S0140-6736(00)02094-8; Hosmer D. W., 1999, APPL SURVIVAL ANAL; Jonsdottir LS, 1995, ACTA OBSTET GYN SCAN, V74, P772; KRAMER MS, 1987, B WORLD HEALTH ORGAN, V65, P663; Kupferminc MJ, 1999, NEW ENGL J MED, V340, P9, DOI 10.1056/NEJM199901073400102; Lindsay RS, 2000, DIABETES, V49, P445, DOI 10.2337/diabetes.49.3.445; MARMOT MG, 1984, INT J EPIDEMIOL, V13, P160, DOI 10.1093/ije/13.2.160; MCLOONE P, 1994, BRIT MED J, V309, P1465, DOI 10.1136/bmj.309.6967.1465; Melander O, 1999, J HYPERTENS, V17, P1557, DOI 10.1097/00004872-199917110-00008; Morris JA, 1998, MED HYPOTHESES, V51, P285, DOI 10.1016/S0306-9877(98)90048-2; Rosendaal FR, 1997, BLOOD, V89, P2817, DOI 10.1182/blood.V89.8.2817; Rosendaal FR, 1997, BLOOD, V90, P1747, DOI 10.1182/blood.V90.5.1747; Shah NR, 2000, AM J OBSTET GYNECOL, V182, P465, DOI 10.1016/S0002-9378(00)70240-7; Smith GCS, 2000, AM J EPIDEMIOL, V151, P614, DOI 10.1093/oxfordjournals.aje.a010249; Smith GCS, 1998, NEW ENGL J MED, V339, P1817, DOI 10.1056/NEJM199812173392504; Smith GD, 1997, BRIT MED J, V315, P1189, DOI 10.1136/bmj.315.7117.1189; Smith GD, 2000, BRIT MED J, V320, P839, DOI 10.1136/bmj.320.7238.839; SUSSER M, 1991, AM J CLIN NUTR, V53, P1384, DOI 10.1093/ajcn/53.6.1384; vandenElzen HJ, 1996, BRIT J OBSTET GYNAEC, V103, P117; ZHANG XQ, 2001, J SOC GYNECOL INVEST, V8	27	704	717	2	29	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 23	2001	357	9273					2002	2006		10.1016/S0140-6736(00)05112-6	http://dx.doi.org/10.1016/S0140-6736(00)05112-6			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	446JB	11438131				2022-12-28	WOS:000169509200008
J	Stohr, J; Samant, MG; Luning, J; Callegari, AC; Chaudhari, P; Doyle, JP; Lacey, JA; Lien, SA; Purushothaman, S; Speidell, JL				Stohr, J; Samant, MG; Luning, J; Callegari, AC; Chaudhari, P; Doyle, JP; Lacey, JA; Lien, SA; Purushothaman, S; Speidell, JL			Liquid crystal alignment on carbonaceous surfaces with orientational order	SCIENCE			English	Article							FILMS; DISPLAYS	We used near-edge x-ray absorption fine structure (NEXAFS) spectroscopy to Link the orientational bond order at three carbonaceous surfaces-rubbed polyimide, ion beam-irradiated polyimide, and ion beam-irradiated diamond-like carbon films-with the direction of liquid crystal (LC) alignment on these surfaces. We show that, in general, LC alignment can be created on any carbonaceous substrate by inducing orientational order at its surface. Our results form the scientific basis for LC alignment layers consisting of amorphous carbon films in which orientational order near the surface is induced by a directional low-energy ion beam.	IBM Corp, Almaden Res Ctr, Div Res, San Jose, CA 95120 USA; IBM Corp, Thomas J Watson Res Ctr, Div Res, Yorktown Heights, NY 10598 USA	International Business Machines (IBM); International Business Machines (IBM)	Stohr, J (corresponding author), Stanford Synchrotron Radiat Lab, POB 20450,Mail Stop 69, Stanford, CA 94309 USA.							BERREMAN DW, 1972, PHYS REV LETT, V28, P1683, DOI 10.1103/PhysRevLett.28.1683; Chaudhari P, 1998, JPN J APPL PHYS 2, V37, pL55, DOI 10.1143/JJAP.37.L55; Chaudhari P, 2001, NATURE, V411, P56, DOI 10.1038/35075021; COMELLI G, 1988, PHYS REV B, V38, P7511, DOI 10.1103/PhysRevB.38.7511; DEGENNES PG, 1993, PHYSICS LIQUID CRYST; DEPP SW, 1993, SCI AM, V268, P90; GEARY JM, 1987, J APPL PHYS, V62, P4100, DOI 10.1063/1.339124; GIBBONS WM, 1991, NATURE, V351, P49, DOI 10.1038/351049a0; HAN KY, 1993, P EURODISPLAY 93 C, P13; Hurt RH, 2000, PHYS TODAY, V53, P39, DOI 10.1063/1.883020; KOBAYASHI S, 1994, P SOC PHOTO-OPT INS, V2175, P122, DOI 10.1117/12.172114; LEE KW, 1996, POLYM SURFACE INTERF, P295; MADA H, 1993, JPN J APPL PHYS 2, V32, pL1245, DOI 10.1143/JJAP.32.L1245; OKANO K, 1982, JPN J APPL PHYS 2, V21, pL109, DOI 10.1143/JJAP.21.L109; OKANO K, 1983, JPN J APPL PHYS 2, V22, pL343, DOI 10.1143/JJAP.22.L343; ROBERTSON J, 1992, SURF COAT TECH, V50, P185, DOI 10.1016/0257-8972(92)90001-Q; Samant MG, 1996, MACROMOLECULES, V29, P8334, DOI 10.1021/ma951820c; Schadt M, 1996, NATURE, V381, P212, DOI 10.1038/381212a0; SHANNON PJ, 1994, NATURE, V368, P532, DOI 10.1038/368532a0; Stohr J, 1999, J ELECTRON SPECTROSC, V98, P189, DOI 10.1016/S0368-2048(98)00286-2; TONEY MF, 1995, NATURE, V374, P709, DOI 10.1038/374709a0; Weiss K, 1998, MACROMOLECULES, V31, P1930, DOI 10.1021/ma971075z; ZHUANG X, 1995, PHYS REV LETT, V75, P2144, DOI 10.1103/PhysRevLett.75.2144	23	302	305	0	72	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 22	2001	292	5525					2299	2302		10.1126/science.1059866	http://dx.doi.org/10.1126/science.1059866			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	445KD	11423654				2022-12-28	WOS:000169455900048
J	Karnath, HO; Ferber, S; Himmelbach, M				Karnath, HO; Ferber, S; Himmelbach, M			Spatial awareness is a function of the temporal not the posterior parietal lobe	NATURE			English	Article							RIGHT-HEMISPHERE STROKE; SUNNYBROOK STROKE; VISUAL NEGLECT; LESIONS; MONKEYS; CORTEX; SULCUS; REPRESENTATION; ATTENTION; BEHAVIOR	Our current understanding of spatial behaviour and parietal lobe function is largely based on the belief that spatial neglect in humans (a lack of awareness of space on the side of the body contralateral to a brain injury) is typically associated with lesions of the posterior parietal lobe. However, in monkeys, this disorder is observed after lesions of the superior temporal cortex(1), a puzzling discrepancy between the species. Here we show that, contrary to the widely accepted view, the superior temporal cortex is the neural substrate of spatial neglect in humans, as it is in monkeys. Unlike the monkey brain, spatial awareness in humans is a function largely confined to the right superior temporal cortex, a location topographically reminiscent of that for language on the left(2). Hence, the decisive phylogenetic transition from monkey to human brain seems to be a restriction of a formerly bilateral function to the right side, rather than a shift from the temporal to the parietal lobe. One may speculate that this lateralization of spatial awareness parallels the emergence of an elaborate representation for language on the left side.	Univ Tubingen, Dept Cognit Neurol, D-72076 Tubingen, Germany	Eberhard Karls University of Tubingen	Karnath, HO (corresponding author), Univ Tubingen, Dept Cognit Neurol, Hoppe Seyler Str 3, D-72076 Tubingen, Germany.			Himmelbach, Marc/0000-0002-7771-2968				Binder J, 2000, BRAIN, V123, P2371, DOI 10.1093/brain/123.12.2371; BRUCE C, 1981, J NEUROPHYSIOL, V46, P369, DOI 10.1152/jn.1981.46.2.369; DAMASIO AR, 1980, NEUROPSYCHOLOGIA, V18, P123, DOI 10.1016/0028-3932(80)90058-5; Darling WG, 2001, NEUROPSYCHOLOGIA, V39, P237, DOI 10.1016/S0028-3932(00)00113-5; ETTLINGER G, 1962, J NEUROL NEUROSUR PS, V25, P256, DOI 10.1136/jnnp.25.3.256; FAUGIERGRIMAUD S, 1978, NEUROPSYCHOLOGIA, V16, P151, DOI 10.1016/0028-3932(78)90103-3; Felleman DJ, 1991, CEREB CORTEX, V1, P1, DOI 10.1093/cercor/1.1.1; Gaffan D, 1997, BRAIN, V120, P1647, DOI 10.1093/brain/120.9.1647; GAUTHIER L, 1989, INT J CLIN NEUROPSYC, V11, P49; Heilman K. M, 1983, LOCALIZATION NEUROPS, P471; JONES E G, 1970, Brain Behavior and Evolution, V93, P793, DOI 10.1093/brain/93.4.793; LAMOTTE RH, 1978, BRAIN RES, V139, P309, DOI 10.1016/0006-8993(78)90931-9; Leibovitch FS, 1998, NEUROLOGY, V50, P901, DOI 10.1212/WNL.50.4.901; Leibovitch FS, 1999, HUM BRAIN MAPP, V7, P244, DOI 10.1002/(SICI)1097-0193(1999)7:4<244::AID-HBM3>3.0.CO;2-K; LUH KE, 1986, NEUROPSYCHOLOGIA, V24, P461, DOI 10.1016/0028-3932(86)90091-6; LYNCH JC, 1989, J NEUROPHYSIOL, V61, P74, DOI 10.1152/jn.1989.61.1.74; Mesulam MM, 1999, PHILOS T R SOC B, V354, P1325, DOI 10.1098/rstb.1999.0482; MOTOMURA N, 1986, ACTA NEUROL SCAND, V74, P190, DOI 10.1111/j.1600-0404.1986.tb07854.x; Perenin M.-T., 1997, PARIETAL LOBE CONTRI, P289; RORDEN C, IN PRESS BEHAV NEURO; Samuelsson H, 1997, CORTEX, V33, P271, DOI 10.1016/S0010-9452(08)70004-2; SELTZER B, 1978, BRAIN RES, V149, P1, DOI 10.1016/0006-8993(78)90584-X; Talairach J., 1988, COPLANAR STEREOTAXIC; Tham K, 1996, NEUROPSYCHOL REHABIL, V6, P19, DOI 10.1080/713755496; Ungerleider L.G., 1982, ANAL VISUAL BEHAV, P549; VALLAR G, 1986, NEUROPSYCHOLOGIA, V24, P609, DOI 10.1016/0028-3932(86)90001-1; WATSON RT, 1994, ARCH NEUROL-CHICAGO, V51, P1014, DOI 10.1001/archneur.1994.00540220060015; Weintraub S., 1985, PRINCIPLES BEHAV NEU, P71	28	597	609	2	23	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 21	2001	411	6840					950	953		10.1038/35082075	http://dx.doi.org/10.1038/35082075			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	444EN	11418859				2022-12-28	WOS:000169386200045
J	Imrie, J; Stephenson, JR; Cowan, FM; Wanigaratne, S; Billington, AJP; Copas, AJ; French, L; French, PD; Johnson, AM				Imrie, J; Stephenson, JR; Cowan, FM; Wanigaratne, S; Billington, AJP; Copas, AJ; French, L; French, PD; Johnson, AM		Behav Intervention Gay Men Project	A cognitive behavioural intervention to reduce sexually transmitted infections among gay men: randomised trial	BRITISH MEDICAL JOURNAL			English	Article							RISK; QUESTIONNAIRE; PREVENTION; VALIDITY	Objective To determine the effectiveness of a brief cognitive behavioural intervention in reducing the incidence of sexually transmitted infections among gay men. Design Randomised controlled trial with 12 months' follow up. Setting Sexual health clinic in London. Participants 343 gay men with an acute sexually transmitted infection or who reported having had unprotected anal intercourse in the past year. Main outcome measures Number of new sexually transmitted infections diagnosed during follow up and self reported incidence of unprotected anal intercourse. Results 72% (361/499) of men invited to enter the study did so. 90% (308/343) of participants returned at least one follow up questionnaire or re-attended the clinic and requested a check up for sexually transmitted infections during follow up. At baseline, 37% (63/172) of the intervention group and 30% (50/166) of the control group reported having had unprotected anal intercourse in the past month. At. 12 months, the proportions were 27% (31/114) and 32% (39/124) respectively (P = 0.56). However, 31% (38/123) of the intervention group and 21% (35/168) of controls had had at least one new infection diagnosed at the clinic (adjusted odds ratio 1.66, 95% confidence interval 1.00 to 2.74). Considering only men who requested a check up for sexually transmitted infections, the proportion diagnosed with a new infection was 58% (53/91) for men in the intervention group and 43% (35/81) for men in the control group (adjusted odds ratio 1.84, 0.99 to 3.40). Using a regional database that includes information from 23 sexual health clinics in London, we determined that few participants had attended other sexual health clinics. Conclusions This behavioural intervention was acceptable and feasible to deliver, but it did not reduce the risk of acquiring a new sexually transmitted infection among these gay men at high risk. Even carefully designed interventions should not be assumed to bring benefit. It is important to evaluate their effects in randomised trials with objective clinical end points.	UCL Royal Free & Univ Coll Med Sch, Dept Sexually Transmitted Dis, London WC1E 6AU, England; Camden & Islington Community Hlth Serv NHS Trust, London WC1E 6AU, England	University of London; University College London; UCL Medical School	Imrie, J (corresponding author), UCL Royal Free & Univ Coll Med Sch, Dept Sexually Transmitted Dis, London WC1E 6AU, England.	jimrie@gum.ucl.ac.uk		Copas, Andrew/0000-0001-8968-5963; Cowan, Frances/0000-0003-3087-4422; Johnson, Anne/0000-0003-1330-7100				Aral SO, 1998, LANCET, V351, P33; BANDURA A, 1994, PREVENTING AIDS THEO; Dodds JP, 2000, BRIT MED J, V320, P1510, DOI 10.1136/bmj.320.7248.1510; Fishbein M, 2000, SEX TRANSM DIS, V27, P452, DOI 10.1097/00007435-200009000-00005; HAYS RB, 1990, AIDS, V4, P901, DOI 10.1097/00002030-199009000-00011; HICKMAN M, 1999, STI SURVEILLANCE COM; HOLLAND J, 1994, REV EFFECTIVENESS HL; Kegeles S M, 1998, AIDS, V12 Suppl A, pS209; MARLATT GA, 1985, RELATPSE PREVENTION; OAKLEY A, 1995, AIDS, V9, P479, DOI 10.1097/00002030-199509050-00010; Peterman TA, 2000, SEX TRANSM DIS, V27, P446, DOI 10.1097/00007435-200009000-00004; PROCHASKA JO, 1992, AM PSYCHOL, V47, P1102, DOI 10.1037/0003-066X.47.9.1102; *PUBL HLTH LAB SER, 2000, AIDS HIV Q SURV TABL; ROLLNICK S, 1992, BRIT J ADDICT, V87, P743; Rosenberg M., 1965, SOC ADOLESCENT SELF, DOI DOI 10.1515/9781400876136; Shah D, 1997, AIDS CARE, V9, P471, DOI 10.1080/00222937500770361; Stephenson J, 1998, BMJ-BRIT MED J, V316, P611, DOI 10.1136/bmj.316.7131.611; Stephenson JM, 2000, AIDS, V14, pS115; WANIGARATNE S, 1997, IMPACT AIDS PSYCHOL, P27; YOUNG H, 1991, LANCET, V337, P853, DOI 10.1016/0140-6736(91)92561-F; ZENILMAN JM, 1995, SEX TRANSM DIS, V22, P15, DOI 10.1097/00007435-199501000-00003	21	57	58	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 16	2001	322	7300					1451	1456		10.1136/bmj.322.7300.1451	http://dx.doi.org/10.1136/bmj.322.7300.1451			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	444FJ	11408300	Bronze, Green Submitted, Green Published			2022-12-28	WOS:000169389200023
J	Polonsky, KS; Semenkovich, CF				Polonsky, KS; Semenkovich, CF			The pancreatic beta cell heats up: UCP2 and insulin secretion in diabetes	CELL			English	Review							UNCOUPLING PROTEIN-2; SKELETAL-MUSCLE; OBESITY; DYSFUNCTION; LINK		Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Cell Biol & Physiol, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Polonsky, KS (corresponding author), Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA.	polonsky@im.wustl.edu		Semenkovich, Clay/0000-0003-1163-1871				Ashcroft FM, 1999, DIABETOLOGIA, V42, P903, DOI 10.1007/s001250051247; COLEMAN DL, 1978, DIABETOLOGIA, V14, P141, DOI 10.1007/BF00429772; Fleury C, 1997, NAT GENET, V15, P269, DOI 10.1038/ng0397-269; Guillausseau PJ, 2001, ANN INTERN MED, V134, P721, DOI 10.7326/0003-4819-134-9_Part_1-200105010-00008; Klingenberg M, 1999, BBA-BIOMEMBRANES, V1415, P271, DOI 10.1016/S0005-2736(98)00232-6; Lameloise N, 2001, DIABETES, V50, P803, DOI 10.2337/diabetes.50.4.803; Li B, 2000, NAT MED, V6, P1115, DOI 10.1038/80450; Matschinsky FM, 1998, DIABETES, V47, P307, DOI 10.2337/diabetes.47.3.307; Polonsky KS, 1996, NEW ENGL J MED, V334, P777, DOI 10.1056/NEJM199603213341207; Schaff er I. E., 1999, MITOCHONDRIA, P141; Short KR, 2001, AM J PHYSIOL-ENDOC M, V280, pE761, DOI 10.1152/ajpendo.2001.280.5.E761; Skulachev VP, 1998, BBA-BIOENERGETICS, V1363, P100, DOI 10.1016/S0005-2728(97)00091-1; TOKUYAMA Y, 1995, DIABETES, V44, P1447, DOI 10.2337/diabetes.44.12.1447; VidalPuig A, 1997, BIOCHEM BIOPH RES CO, V235, P79, DOI 10.1006/bbrc.1997.6740; Wang MY, 1999, DIABETES, V48, P1020, DOI 10.2337/diabetes.48.5.1020; Weir GC, 2001, DIABETES, V50, pS154, DOI 10.2337/diabetes.50.2007.S154; Zhang CY, 2001, CELL, V105, P745, DOI 10.1016/S0092-8674(01)00378-6	17	22	23	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 15	2001	105	6					705	707		10.1016/S0092-8674(01)00389-0	http://dx.doi.org/10.1016/S0092-8674(01)00389-0			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	444AE	11440712	Bronze			2022-12-28	WOS:000169375100003
J	Akkerhuis, KM; Deckers, JW; Lincoff, AM; Tcheng, JE; Boersma, E; Anderson, K; Balog, C; Califf, RM; Topol, EJ; Simoons, ML				Akkerhuis, KM; Deckers, JW; Lincoff, AM; Tcheng, JE; Boersma, E; Anderson, K; Balog, C; Califf, RM; Topol, EJ; Simoons, ML			Risk of stroke associated with abciximab among patients undergoing percutaneous coronary intervention	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE MYOCARDIAL-INFARCTION; PLATELET GLYCOPROTEIN IIB/IIIA; THROMBOLYTIC THERAPY; INTRACRANIAL HEMORRHAGE; BALLOON ANGIOPLASTY; PLACEMENT; OUTCOMES	Context Abciximab, a potent inhibitor of the platelet glycoprotein IIb/IIIa receptor, reduces thrombotic complications in patients undergoing percutaneous coronary intervention (PCI), Because of its potent inhibition of platelet aggregation, the effect of abciximab on risk of stroke is a concern. Objective To determine whether abciximab use among patients undergoing PCI is associated with an increased risk of stroke. Design Combined analysis of data from 4 double-blind, placebo-controlled, randomized trials (EPIC, CAPTURE, EPILOG, and EPISTENT) conducted between November 1991 and October 1997 at a total of 257 academic and community hospitals in the United States and Europe. Patients A total of 8555 patients undergoing PCI with or without stent deployment for a variety of indications were randomly assigned to receive a bolus and infusion of abciximab (n=5476) or matching placebo (n=3079). One treatment group in EPIC received a bolus of abciximab only. Main Outcome Measure Risk of hemorrhagic and nonhemorrhagic stroke within 30 days of treatment among abciximab and placebo groups. Results No significant difference in stroke rate was observed between patients assigned abciximab (n=22 [0.40%]) and those assigned placebo (n=9 [0.29%]; P=.46). Excluding the EPIC abciximab bolus-only group, there were 9 strokes (0.30%) among 3023 patients who received placebo and 15 (0.32%) in 4680 patients treated with abciximab bolus plus infusion, a difference of 0.02% (95% confidence interval [Cl], -0.23% to 0.28%), The rate of nonhemorrhagic stroke was 0.17% in patients treated with abciximab and 0.20% in patients treated with placebo (difference, -0.03%; 95% Cl, -0.23% to 0.17%), and the rates of hemorrhagic stroke were 0.15% and 0.10%, respectively (difference, 0.05%; 95% CI, -0.11% to 0.21%), Among patients treated with abciximab, the rate of hemorrhagic stroke in patients receiving standard-dose heparin in EPIC, CAPTURE, and EPILOG was higher than in those receiving low-dose heparin in the EPILOG and EPISTENT trials (0.27% vs 0.04%; P=.057). Conclusions Abciximab in addition to aspirin and heparin does not increase the risk of stroke in patients;undergoing PCI, Patients undergoing PCI and treated with abciximab should receive low-dose, weight-adjusted heparin.	Univ Rotterdam Hosp, Thoraxctr, NL-3015 GD Rotterdam, Netherlands; Cleveland Clin Fdn, Cleveland, OH 44195 USA; Duke Clin Res Inst, Durham, NC USA; Centocor Inc, Malvern, PA 19355 USA	Erasmus University Rotterdam; Erasmus MC; Cleveland Clinic Foundation; Duke University; Johnson & Johnson; Johnson & Johnson USA; Janssen Biotech Inc	Akkerhuis, KM (corresponding author), Univ Rotterdam Hosp, Thoraxctr, H-543,Dr Molewaterpl 40, NL-3015 GD Rotterdam, Netherlands.	k.makkerhuis@freeler.nl		Topol, Eric/0000-0002-1478-4729				Alderman EL, 1996, NEW ENGL J MED, V335, P217; ANTMAN EM, 1994, CIRCULATION, V90, P1624, DOI 10.1161/01.CIR.90.4.1624; Betriu A, 1997, NEW ENGL J MED, V336, P1621; CALIFF RM, 1994, NEW ENGL J MED, V330, P956, DOI 10.1056/nejm199404073301402; DEJAEGERE PP, 1992, J AM COLL CARDIOL, V19, P289, DOI 10.1016/0735-1097(92)90480-B; DORROS G, 1983, CIRCULATION, V67, P723, DOI 10.1161/01.CIR.67.4.723; FISCHMAN DL, 1994, NEW ENGL J MED, V331, P496, DOI 10.1056/NEJM199408253310802; GORE JM, 1995, CIRCULATION, V92, P2811, DOI 10.1161/01.CIR.92.10.2811; Granger CB, 1996, CIRCULATION, V93, P870, DOI 10.1161/01.CIR.93.5.870; GRINES CL, 1993, NEW ENGL J MED, V328, P673, DOI 10.1056/NEJM199303113281001; Hanrath P, 1997, CIRCULATION, V96, P1445; LONGSTRETH WT, 1993, STROKE, V24, P587, DOI 10.1161/01.STR.24.4.587; Mahaffey KW, 1999, CIRCULATION, V99, P2371, DOI 10.1161/01.CIR.99.18.2371; Mahaffey KW, 1998, CIRCULATION, V97, P757, DOI 10.1161/01.CIR.97.8.757; Ronner E, 1998, EUR HEART J, V19, P1608, DOI 10.1053/euhj.1998.1222; Schomig A, 1996, NEW ENGL J MED, V334, P1084, DOI 10.1056/NEJM199604253341702; SERRUYS PW, 1994, NEW ENGL J MED, V331, P489, DOI 10.1056/NEJM199408253310801; Simoons ML, 1997, LANCET, V349, P1429; SIMOONS ML, 1993, LANCET, V342, P1523, DOI 10.1016/S0140-6736(05)80089-3; Tcheng JE, 1997, LANCET, V349, P1422; Tiefenbrunn AJ, 1998, J AM COLL CARDIOL, V31, P1240, DOI 10.1016/S0735-1097(98)00094-1; TOPOL E, 1994, CIRCULATION, V90, P1631; Topol E, 1998, NEW ENGL J MED, V339, P436; Topol EJ, 1998, LANCET, V352, P87, DOI 10.1016/S0140-6736(98)85010-1; Topol EJ, 1997, NEW ENGL J MED, V336, P1689; Tung CY, 1999, CIRCULATION, V99, P370, DOI 10.1161/01.CIR.99.3.370; Weaver WD, 1997, JAMA-J AM MED ASSOC, V278, P2093, DOI 10.1001/jama.278.23.2093; ZIJLSTRA F, 1993, NEW ENGL J MED, V328, P680, DOI 10.1056/NEJM199303113281002	28	39	44	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 4	2001	286	1					78	82		10.1001/jama.286.1.78	http://dx.doi.org/10.1001/jama.286.1.78			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	449GR	11434830	Green Published			2022-12-28	WOS:000169676400026
J	Hellinger, FJ; Young, GJ				Hellinger, FJ; Young, GJ			An analysis of physician antitrust exemption legislation - Adjusting the balance of power	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Current antitrust law restricts physicians from joining together to collectively negotiate. However, such activities may be approved by state laws under the so-called state action immunity doctrine and by federal legislation under an explicit antitrust exemption. In 1999, Texas became the first state to pass physician antitrust exemption legislation allowing physicians, under certain defined circumstances, to collectively negotiate fees with health plans, Last year, similar legislation was introduced in the US Congress, in 18 state legislatures, and in the District of Columbia. This legislation was passed only in the District of Columbia where its implementation was blocked by the city's financial control board, Nonetheless, legislation permitting physicians to collectively negotiate fees with managed care plans has been introduced in 10 state legislatures this year, and there is continued interest in introducing similar legislation in the US Congress. This analysis examines the basic features of this legislation and its potential impact on the balance of power between physicians and managed care plans.	Agcy Healthcare Res & Qual, Ctr Org & Delivery Studies, Rockville, MD 20852 USA; Boston Univ, Management Decis & Res Ctr, Vet Affairs Hlth Serv Res & Dev Serv, Boston, MA 02215 USA; Boston Univ, Sch Publ Hlth, Program Hlth Policy & Management, Boston, MA 02215 USA	Agency for Healthcare Research & Quality; Boston University; Boston University	Hellinger, FJ (corresponding author), Agcy Healthcare Res & Qual, Ctr Org & Delivery Studies, Suite 605,2101 E Jefferson St, Rockville, MD 20852 USA.							BERGSTROM RW, 1985, ANTITRUST ADVISOR, P479; *C RIV ASS INC, 2000, UPD NAT PROJ COST PH; Connor RA., 1998, INT J ECON BUS, V5, P159, DOI [DOI 10.1080/13571519884495, 10.1080/13571519884495]; *DEP JUST FED TRAD, 1996, STAT ANT ENF POL AN; *DEP JUST FED TRAD, 1993, STAT ANT ENF POL AN; *DEP JUST FED TRAD, 1994, STAT ENF POL AN PRIN; DOCTORS EJ, 2000, TEXAS LAWER     0522, P1; DRANOVE D, 1993, J LAW ECON, V36, P179, DOI 10.1086/467270; GREENE J, 2000, AM MED NEWS     0911; GUADAGNINO C, 2000, PHYSICIANS NEWS  MAY, P1; JAPSEN B, 2000, CHICAGO TRIBUNE 0714, pN1; JONES ML, 2001, HILL            0103, P14; KOWALCZYK L, 2000, BOSTON GLOBE    0427, pC19; *NAT HLTH POL FOR, 1995, CONS HLTH CAR MARK A; ROMANO M, 2001, MODERN HEALTHCA 0205, P30; ROSS SF, 1993, PRINCIPLES ANTITRUST; THOMPSON E, 2000, MODERN HEALTHCA 0228, P36	17	10	10	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 4	2001	286	1					83	88		10.1001/jama.286.1.83	http://dx.doi.org/10.1001/jama.286.1.83			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	449GR	11434831				2022-12-28	WOS:000169676400027
J	Mack, V; Burnashev, N; Kaiser, KMM; Rozov, A; Jensen, V; Hvalby, O; Sakmann, B; Seeburg, PH; Sprengel, R				Mack, V; Burnashev, N; Kaiser, KMM; Rozov, A; Jensen, V; Hvalby, O; Sakmann, B; Seeburg, PH; Sprengel, R			Conditional restoration of hippocampal synaptic potentiation in GluR-A-deficient mice	SCIENCE			English	Article							GLUTAMATE RECEPTORS; AMPA RECEPTORS; EXPRESSION; CELLS; LTP; CAMKII	Plasticity of mature hippocampal CA1 synapses is dependent on L-alpha -amino-3-hydroxy-5-methylisoxazole-4-propionate (AMPA) receptors containing the glutamate receptor A (GLuR-A) subunit. In GLuR-A-deficient mice, plasticity could be restored by controlled expression of green fluorescent protein (GFP)-tagged GluRA, which contributes to channel formation and displayed the developmental redistribution of AMPA receptors in CA1 pyramidal neurons. Long-term potentiation (LTP) induced by pairing or tetanic stimulation was rescued in adult GluR-A(-/-) mice when (GFP)GluR-A expression was constitutive or induced in already fully developed pyramidal cells. This shows that GluR-A-independent forms of synaptic plasticity can mediate the establishment of mature hippocampal circuits that are prebuilt to express GluR-A-dependent LTP.	Max Planck Inst Med Res, Dept Mol Neurobiol, D-69120 Heidelberg, Germany; Max Planck Inst Med Res, Dept Cell Physiol, D-69120 Heidelberg, Germany; Univ Oslo, Inst Basic Med Sci, Dept Physiol, N-0462 Oslo, Norway	Max Planck Society; Max Planck Society; University of Oslo	Sprengel, R (corresponding author), Max Planck Inst Med Res, Dept Mol Neurobiol, Jahnstr 29, D-69120 Heidelberg, Germany.		Burnashev, Nail/G-4056-2013; Rozov, Andrei/C-1997-2015					BARON U, 1995, NUCLEIC ACIDS RES, V23, P3605, DOI 10.1093/nar/23.17.3605; Chen HX, 1999, J NEUROPHYSIOL, V82, P526, DOI 10.1152/jn.1999.82.2.526; Dingledine R, 1999, PHARMACOL REV, V51, P7; Gossen Manfred, 1994, Current Opinion in Biotechnology, V5, P516, DOI 10.1016/0958-1669(94)90067-1; Hayashi Y, 2000, SCIENCE, V287, P2262, DOI 10.1126/science.287.5461.2262; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; JENSEN V, UNPUB; KEINANEN K, 1990, SCIENCE, V249, P556, DOI 10.1126/science.2166337; Krestel HE, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.7.e39; Malinow R, 2000, CURR OPIN NEUROBIOL, V10, P352, DOI 10.1016/S0959-4388(00)00099-4; Mayford M, 1996, SCIENCE, V274, P1678, DOI 10.1126/science.274.5293.1678; Petersen SA, 1997, NEURON, V19, P1237, DOI 10.1016/S0896-6273(00)80415-8; Shi SH, 1999, SCIENCE, V284, P1811, DOI 10.1126/science.284.5421.1811; Zamanillo D, 1999, SCIENCE, V284, P1805, DOI 10.1126/science.284.5421.1805; Zhu JJ, 2000, NAT NEUROSCI, V3, P1098, DOI 10.1038/80614; Zolotukhin S, 1996, J VIROL, V70, P4646, DOI 10.1128/JVI.70.7.4646-4654.1996	16	94	96	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 29	2001	292	5526					2501	2504		10.1126/science.1059365	http://dx.doi.org/10.1126/science.1059365			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	448YU	11431570				2022-12-28	WOS:000169658200045
J	Sun, ZYJ; Kim, HS; Wagner, G; Reinherz, EL				Sun, ZYJ; Kim, HS; Wagner, G; Reinherz, EL			Mechanisms contributing to T cell receptor signaling and assembly revealed by the solution structure of an ectodomain fragment of the CD3 epsilon gamma heterodimer	CELL			English	Article							CD3 GAMMA-CHAIN; TCR-ALPHA-BETA; MHC CLASS-II; ANTIGEN RECEPTOR; CRYSTAL-STRUCTURE; TCR/CD3 COMPLEX; SURFACE EXPRESSION; ZETA-CHAIN; T3-MOLECULAR COMPLEX; ACTIVATION MOTIFS	The T cell receptor (TCR) consists of genetically diverse disulfide-linked ru and beta chains in noncovalent association with the invariant CD3 subunits. CD3 epsilon and CD3 gamma are integral components of both the TCR and pre-TCR. Here, we present the solution structure of a heterodimeric CD3 epsilon gamma ectodomain complex. A unique side-to-side hydrophobic interface between the two C2-set immunoglobulin-like domains and parallel pairing of their respective C-terminal beta strands are revealed. Mutational analysis confirms the importance of the distinctive linkage as well as the membrane proximal stalk motif (RxCxxCxE) for domain-domain association. These biochemical and structural analyses offer insights into the modular pairwise association of CD3 invariant chains. More importantly, the findings suggest how the rigidified CD3 elements participate in TCR-based signal transduction.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Immunobiol Lab, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Wagner, G (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Immunobiol Lab, 44 Binney St, Boston, MA 02115 USA.	wagner@wagner.med.harvard.edu; ellis_reinherz@dfci.harvard.edu			NIAID NIH HHS [AI37581, AI19807] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI019807, R56AI019807, R01AI037581, R01AI019807] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Alam SM, 1996, NATURE, V381, P616, DOI 10.1038/381616a0; ALARCON B, 1988, J BIOL CHEM, V263, P2953; ASHWELL JD, 1990, ANNU REV IMMUNOL, V8, P139, DOI 10.1146/annurev.immunol.8.1.139; BARTELS C, 1995, J BIOMOL NMR, V6, P1, DOI 10.1007/BF00417486; Borroto A, 1998, J BIOL CHEM, V273, P12807, DOI 10.1074/jbc.273.21.12807; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; Casasnovas JM, 1998, P NATL ACAD SCI USA, V95, P4134, DOI 10.1073/pnas.95.8.4134; CHOTHIA C, 1985, J MOL BIOL, V186, P651, DOI 10.1016/0022-2836(85)90137-8; CLEVERS H, 1988, ANNU REV IMMUNOL, V6, P629, DOI 10.1146/annurev.iy.06.040188.003213; CONNOLLY ML, 1983, J APPL CRYSTALLOGR, V16, P548, DOI 10.1107/S0021889883010985; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; Dave VP, 1997, EMBO J, V16, P1360, DOI 10.1093/emboj/16.6.1360; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; Degano M, 2000, IMMUNITY, V12, P251, DOI 10.1016/S1074-7613(00)80178-8; DELAHERA A, 1991, J EXP MED, V173, P7, DOI 10.1084/jem.173.1.7; Diethrich EB, 1996, J ENDOVASC SURG, V3, P132, DOI 10.1583/1074-6218(1996)003<0132:IFCASA>2.0.CO;2; Ding YH, 1999, IMMUNITY, V11, P45, DOI 10.1016/S1074-7613(00)80080-1; Ding YH, 1998, IMMUNITY, V8, P403, DOI 10.1016/S1074-7613(00)80546-4; EXLEY M, 1994, J BIOL CHEM, V269, P15140; Garboczi DN, 1996, J IMMUNOL, V157, P5403; Garcia KC, 1998, SCIENCE, V279, P1166, DOI 10.1126/science.279.5354.1166; Garcia KC, 1999, ANNU REV IMMUNOL, V17, P369, DOI 10.1146/annurev.immunol.17.1.369; Garcia KC, 1996, SCIENCE, V274, P209, DOI 10.1126/science.274.5285.209; Ghendler Y, 1998, J EXP MED, V187, P1529, DOI 10.1084/jem.187.9.1529; Ghendler Y, 1998, P NATL ACAD SCI USA, V95, P10061, DOI 10.1073/pnas.95.17.10061; Gobel TWF, 2000, J IMMUNOL, V164, P879, DOI 10.4049/jimmunol.164.2.879; GUNTERT P, 1992, J BIOMOL NMR, V2, P619, DOI 10.1007/BF02192850; Haks MC, 1998, EMBO J, V17, P1871, DOI 10.1093/emboj/17.7.1871; HALL C, 1991, INT IMMUNOL, V3, P359, DOI 10.1093/intimm/3.4.359; Harrison PT, 1996, MOL MEMBR BIOL, V13, P67, DOI 10.3109/09687689609160579; Hennecke J, 2000, EMBO J, V19, P5611, DOI 10.1093/emboj/19.21.5611; HERMANSON GG, 1988, P NATL ACAD SCI USA, V85, P6890, DOI 10.1073/pnas.85.18.6890; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; ISAKOV N, 1995, J EXP MED, V181, P375, DOI 10.1084/jem.181.1.375; KAPPES DJ, 1991, P NATL ACAD SCI USA, V88, P10619, DOI 10.1073/pnas.88.23.10619; Kersh GJ, 1998, IMMUNITY, V9, P817, DOI 10.1016/S1074-7613(00)80647-0; Kim KS, 2000, J MOL BIOL, V302, P899, DOI 10.1006/jmbi.2000.4098; Klimov DK, 2000, P NATL ACAD SCI USA, V97, P7254, DOI 10.1073/pnas.97.13.7254; KONING F, 1990, EUR J IMMUNOL, V20, P299, DOI 10.1002/eji.1830200211; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LETOURNEUR F, 1992, SCIENCE, V255, P79, DOI 10.1126/science.1532456; LEVELT CN, 1993, P NATL ACAD SCI USA, V90, P11401, DOI 10.1073/pnas.90.23.11401; Lin YX, 1999, J BIOMOL NMR, V15, P227, DOI 10.1023/A:1008343915382; LIU CP, 1993, EMBO J, V12, P4863, DOI 10.1002/j.1460-2075.1993.tb06176.x; LOVE PE, 1993, SCIENCE, V261, P918, DOI 10.1126/science.7688481; Lu H, 2000, BIOPHYS J, V79, P51, DOI 10.1016/S0006-3495(00)76273-4; MALISSEN M, 1993, EMBO J, V12, P4347, DOI 10.1002/j.1460-2075.1993.tb06119.x; MALISSEN M, 1995, EMBO J, V14, P4641, DOI 10.1002/j.1460-2075.1995.tb00146.x; MANOLIOS N, 1991, EMBO J, V10, P1643, DOI 10.1002/j.1460-2075.1991.tb07687.x; Marrack P, 1986, Adv Immunol, V38, P1, DOI 10.1016/S0065-2776(08)60005-X; Matsuo H, 1997, NAT STRUCT BIOL, V4, P717, DOI 10.1038/nsb0997-717; MEUER SC, 1983, NATURE, V303, P808, DOI 10.1038/303808a0; MEUER SC, 1983, J EXP MED, V157, P705, DOI 10.1084/jem.157.2.705; MEUER SC, 1983, J EXP MED, V158, P988, DOI 10.1084/jem.158.3.988; MYERS LC, 1993, BIOCHEMISTRY-US, V32, P14089, DOI 10.1021/bi00214a003; Nagata K, 1997, IMMUNITY, V7, P559, DOI 10.1016/S1074-7613(00)80377-5; OHNO H, 1993, INT IMMUNOL, V5, P1403, DOI 10.1093/intimm/5.11.1403; Osman N, 1996, EUR J IMMUNOL, V26, P1063, DOI 10.1002/eji.1830260516; Ottemann KM, 1999, SCIENCE, V285, P1751, DOI 10.1126/science.285.5434.1751; PUNT JA, 1994, J EXP MED, V180, P587, DOI 10.1084/jem.180.2.587; RAVICHANDRAN KS, 1993, SCIENCE, V262, P902, DOI 10.1126/science.8235613; REINHERZ EL, 1982, CELL, V30, P735, DOI 10.1016/0092-8674(82)90278-1; Reinherz EL, 1999, SCIENCE, V286, P1913, DOI 10.1126/science.286.5446.1913; REINHERZ EL, 1983, IMMUNOL REV, V74, P83, DOI 10.1111/j.1600-065X.1983.tb01085.x; Reiser JB, 2000, NAT IMMUNOL, V1, P291, DOI 10.1038/79728; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; Rudd PM, 1999, J MOL BIOL, V293, P351, DOI 10.1006/jmbi.1999.3104; SAINTRUF C, 1994, SCIENCE, V266, P1208, DOI 10.1126/science.7973703; SAITO H, 1987, P NATL ACAD SCI USA, V84, P9131, DOI 10.1073/pnas.84.24.9131; SAKAGUCHI N, 1988, EMBO J, V7, P3457, DOI 10.1002/j.1460-2075.1988.tb03220.x; Sasada T, 2000, EUR J IMMUNOL, V30, P1281, DOI 10.1002/(SICI)1521-4141(200005)30:5<1281::AID-IMMU1281>3.3.CO;2-4; SCHWABE JWR, 1990, NATURE, V348, P458, DOI 10.1038/348458a0; SHINKAI Y, 1994, INT IMMUNOL, V6, P995, DOI 10.1093/intimm/6.7.995; Sondermann P, 1999, EMBO J, V18, P1095, DOI 10.1093/emboj/18.5.1095; SunderPlassmann R, 1997, EUR J IMMUNOL, V27, P2001, DOI 10.1002/eji.1830270826; SUSSMAN JJ, 1988, CELL, V52, P85, DOI 10.1016/0092-8674(88)90533-8; Teng MK, 1998, CURR BIOL, V8, P409, DOI 10.1016/S0960-9822(98)70160-5; TUNNACLIFFE A, 1988, EUR J IMMUNOL, V18, P1639, DOI 10.1002/eji.1830181027; VANWAUWE JP, 1980, J IMMUNOL, V124, P2708; von Boehmer H, 1998, IMMUNOL REV, V165, P111; von Boehmer H, 1999, CURR OPIN IMMUNOL, V11, P135, DOI 10.1016/S0952-7915(99)80024-7; Wang JH, 1998, EMBO J, V17, P10, DOI 10.1093/emboj/17.1.10; Zidovetzki R, 1998, IMMUNOL LETT, V64, P97, DOI 10.1016/S0165-2478(98)00100-X	84	142	154	0	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 29	2001	105	7					913	923		10.1016/S0092-8674(01)00395-6	http://dx.doi.org/10.1016/S0092-8674(01)00395-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	449BK	11439187	Bronze			2022-12-28	WOS:000169664300011
J	Wang, ZX; Schleyer, PV				Wang, ZX; Schleyer, PV			Construction principles of "hyparenes": Families of molecules with planar pentacoordinate carbons	SCIENCE			English	Article							INDEPENDENT CHEMICAL-SHIFTS; AROMATICITY	Density-functional theory calculations predict thai. three borocarbon units with planar pentacoordinate carbons - C3B3-, - C2B4-, and - CB5-, can replace the -(CH)(3)- subunits in aromatic or even in antiaromatic hydrocarbons to construct "hyparenes" (families of molecules with planar pentacoordinate carbons). These borocarbon units contribute two, one, and zero electrons, respectively, to the parent pi system. Depending on the choice of these units, the hyparenes (judging from computed proton and nucleus-independent chemical shifts), can maintain or can interconvert the aromatic or antiaromatic character of the parent compounds. The hyparenes are low-lying Local minima with normal carbon-boron, boron-boron, and carbon-carbon bond Lengths. The multicenter bonding in the hyparenes involves contributions of partial sigma and partial pi bonds to the planar pentacoordinate carbons; the octet rule is not violated. Borocarbon species, for which there is some mass spectrometric evidence, might be observed and identified, for example, in matrix isolation by vibrational spectroscopy.	Univ Georgia, Ctr Computat Quantum Chem, Athens, GA 30602 USA; Univ Sci & Technol China, Grad Sch Beijing, Acad Sinica, Beijing 10039, Peoples R China	University System of Georgia; University of Georgia; Chinese Academy of Sciences; University of Science & Technology of China, CAS	Schleyer, PV (corresponding author), Univ Georgia, Ctr Computat Quantum Chem, Computat Chem Annex, Athens, GA 30602 USA.	schleyer@chem.uga.edu	Wang, Zhi-Xiang/O-4517-2014					BECKER S, 1988, INT J MASS SPECTROM, V82, P287, DOI 10.1016/0168-1176(88)80021-1; BUCHWALD SL, 1989, J AM CHEM SOC, V111, P397, DOI 10.1021/ja00183a075; Exner K, 2000, SCIENCE, V290, P1937, DOI 10.1126/science.290.5498.1937; GE FM, 2001, CHEM J CHINESE U, V18, P1838; GE FM, 2001, CHEM J CHINESE U, V17, P1458; Nagamatsu J, 2001, NATURE, V410, P63, DOI 10.1038/35065039; Olah G. A., 1987, HYPERCARBON CHEM; Patchkovskii S, 2000, J MOL MODEL, V6, P67, DOI 10.1007/PL00010736; REED AE, 1988, CHEM REV, V88, P899, DOI 10.1016/0030-4018(75)90085-1; Rottger D, 1997, ANGEW CHEM INT EDIT, V36, P813; Schleyer PV, 1998, INORG CHEM, V37, P3454, DOI 10.1021/ic980110v; Schleyer PV, 1996, J AM CHEM SOC, V118, P6317, DOI 10.1021/ja960582d; Schleyer PV, 1997, J AM CHEM SOC, V119, P12669, DOI 10.1021/ja9719135; Siebert W, 1999, CHEM SOC REV, V28, P367, DOI 10.1039/a801225c; VANTHOFF JH, ARRANGEMENT ATOMS SP; VANTHOFF JH, 1874, ARCH NEERL SCI EXACT, V445; Wang ZX, 2001, J AM CHEM SOC, V123, P994, DOI 10.1021/ja0038272; WANG ZX, 2001, ORG LETT, V3, P9; Wu J, UNPUB	19	221	226	4	78	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 29	2001	292	5526					2465	2469		10.1126/science.1060000	http://dx.doi.org/10.1126/science.1060000			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	448YU	11431561				2022-12-28	WOS:000169658200034
J	Buchbinder, R; Forbes, A; Hall, S; Dennett, X; Giles, G				Buchbinder, R; Forbes, A; Hall, S; Dennett, X; Giles, G			Incidence of malignant disease in biopsy-proven inflammatory myopathy - A population-based cohort study	ANNALS OF INTERNAL MEDICINE			English	Article							INCLUSION-BODY MYOSITIS; POLYMYOSITIS-DERMATOMYOSITIS; ADULT DERMATOMYOSITIS; TEMPORAL ASSOCIATION; CELL CARCINOMA; CANCER; RISK; CLASSIFICATION	Background: The validity and magnitude of an association between myositis and malignant disease continue to be debated. Such issues as the legitimacy of a myositis diagnosis and distinction among myositis subgroups in previous population-based studies remain unresolved. Objective: To determine the risk for malignant disease in patients with biopsy-proven inflammatory myopathies. Design: Population-based, retrospective cohort study. Setting: Victoria, Australia. Patients: 537 patients in whom a biopsy-positive idiopathic inflammatory myopathy was first diagnosed from 1981 through 1995. Measurements: standardized incidence ratios were calculated to compare the incidence of malignant disease in patients with inflammatory myopathy and the general population. Results: A total of 116 cases of malignant disease were found in 104 patients. Seventy-four cases were identified concurrently with (within 7 days) or after diagnosis of myositis. The highest risk for malignant disease was associated with dermatomyositis (standardized incidence ratio, 6.2 [95% CI, 3.9 to 10.0]). The risk was also increased in polymyositis (standardized incidence ratio, 2.0 [CI, 1.4 to 2.7]), although the relative risk for malignant disease in dermatomyositis compared with polymyositis was 2.4 (CI, 1.3 to 4.2). An increased risk for malignant disease was also found in inclusion-body myositis (standardized incidence ratio, 2.4 [CI, 1.2 to 4.9]). The excess risk for malignant disease diminished with time (standardized incidence ratio, 4.4 [CI, 2.7 to 7.1] in the first year; 3.4 [Cl, 2.3 to 5.1] between 1 and 3 years; 2.2 [Cl, 1.3 to 3.9] between 3 and 5 years; and 1.6 [Cl, 1.0 to 2.6] beyond 5 years [P for trend, 0.002]). Conclusion: The risk for malignant disease is increased in biopsy-proven dermatomyositis and polymyositis and also appears to be increased in inclusion-body myositis.	Cabrini Med Ctr, Dept Clin Epidemiol, Malvern, Vic 3144, Australia; Monash Univ, Dept Epidemiol & Prevent Med, Prahran, Vic 3181, Australia; Anti Canc Council Victoria, Canc Epidemiol Ctr, Canc Control Res Inst, Melbourne, Vic 3053, Australia	Cabrini Health; Monash University; Cancer Council Victoria	Buchbinder, R (corresponding author), Cabrini Med Ctr, Dept Clin Epidemiol, 183 Wattletree Rd,Suite 41, Malvern, Vic 3144, Australia.	rachelle.buchbinder@med.monash.edu.au	Buchbinder, Rachelle/G-2952-2011	Buchbinder, Rachelle/0000-0002-0597-0933; Forbes, Andrew/0000-0003-4269-914X; Giles, Graham/0000-0003-4946-9099				AIRIO A, 1995, J RHEUMATOL, V22, P1300; *ANT COUNC VICT CA, 1996, CANST CANC VICT 1993; BANKER BQ, 1986, MYOLOGY, P1385; BARNES BE, 1976, ANN INTERN MED, V84, P68, DOI 10.7326/0003-4819-84-1-68; BASSETSEGUIN N, 1990, ARCH DERMATOL, V126, P633, DOI 10.1001/archderm.126.5.633; BOHAN A, 1975, NEW ENGL J MED, V292, P344, DOI 10.1056/NEJM197502132920706; BONNETBLANC JM, 1990, DERMATOLOGICA, V180, P212, DOI 10.1159/000248032; Buchbinder R, 1996, AM J IND MED, V29, P171, DOI 10.1002/(SICI)1097-0274(199602)29:2<171::AID-AJIM7>3.0.CO;2-V; CALLEN JP, 1980, ARCH DERMATOL, V116, P295, DOI 10.1001/archderm.116.3.295; CHERKIN DC, 1992, SPINE, V17, P817, DOI 10.1097/00007632-199207000-00015; CHOW WH, 1995, CANCER CAUSE CONTROL, V6, P9, DOI 10.1007/BF00051675; COTE RA, 1980, SYSTEMATIZED NONENCL; COX NH, 1990, ARCH DERMATOL, V126, P61, DOI 10.1001/archderm.126.1.61; DAVIS W, 1987, STAT METHODS CANC RE, V2; DUNCAN AG, 1991, ACTA DERM-VENEREOL, V71, P312; HIDANO A, 1986, Journal of Dermatology (Tokyo), V13, P233; HILTONJONES D, 1992, NEW ENGL J MED, V327, P207; HOFFMAN GS, 1983, AM J MED, V75, P433, DOI 10.1016/0002-9343(83)90344-3; HSIA DC, 1988, NEW ENGL J MED, V318, P352, DOI 10.1056/NEJM198802113180604; Jensen ML, 1997, ARCH PHYS MED REHAB, V78, P327, DOI 10.1016/S0003-9993(97)90043-5; Kankeleit H., 1916, DTSCH ARCH KLIN MED, V120, P335; LAKHANPAL S, 1986, MAYO CLIN PROC, V61, P645, DOI 10.1016/S0025-6196(12)62030-8; Lipskie T L, 1998, Chronic Dis Can, V19, P112; LOTZ BP, 1989, BRAIN, V112, P727, DOI 10.1093/brain/112.3.727; LYON MG, 1989, J RHEUMATOL, V16, P1218; MANCHUL LA, 1985, ARCH INTERN MED, V145, P1835, DOI 10.1001/archinte.145.10.1835; Maoz CR, 1998, SEMIN ARTHRITIS RHEU, V27, P319, DOI 10.1016/S0049-0172(98)80052-8; MASI AT, 1988, MT SINAI J MED, V55, P471; Mautner GH, 1998, CUTIS, V61, P190; MEDSGER TA, 1970, AM J MED, V48, P715, DOI 10.1016/S0002-9343(70)80006-7; *NAT AC SCI, 1980, REL NAT HOSP DISCH S; O'Gradaigh D, 1998, BRIT J RHEUMATOL, V37, P914; ODDIS CV, 1990, J RHEUMATOL, V17, P1329; Patrick M, 1999, J RHEUMATOL, V26, P1094; Pautas E, 1999, AM J MED, V106, P122; SCHULMAN P, 1991, J RHEUMATOL, V18, P1689; SIGURGEIRSSON B, 1992, NEW ENGL J MED, V326, P363, DOI 10.1056/NEJM199202063260602; STERTZ G, 1916, BERL KLIN WOCHENSCHR, V53, P488; WHITMORE SE, 1994, MEDICINE, V73, P153, DOI 10.1097/00005792-199405000-00004; World Health Organization, 1977, INT CLASS DIS; World Health Organization, 1976, INT CLASS DIS ONC; YTTERBERG SR, 1993, ARTHRITIS RHEUM, V36, P416, DOI 10.1002/art.1780360319; ZANTOS D, 1994, J RHEUMATOL, V21, P1855	43	276	294	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 19	2001	134	12					1087	1095		10.7326/0003-4819-134-12-200106190-00008	http://dx.doi.org/10.7326/0003-4819-134-12-200106190-00008			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	442YU	11412048				2022-12-28	WOS:000169313200001
J	Grant, AD; De Cock, KM				Grant, AD; De Cock, KM			ABC of AIDS - HIV infection and AIDS in the developing world	BRITISH MEDICAL JOURNAL			English	Article																			0	29	32	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 16	2001	322	7300					1475	1478		10.1136/bmj.322.7300.1475	http://dx.doi.org/10.1136/bmj.322.7300.1475			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	444FJ	11408309	Green Accepted, Green Published			2022-12-28	WOS:000169389200035
J	Mathers, CD; Sadana, R; Salomon, JA; Murray, CJL; Lopez, AD				Mathers, CD; Sadana, R; Salomon, JA; Murray, CJL; Lopez, AD			Healthy life expectancy in 191 countries, 1999	LANCET			English	Article							GLOBAL BURDEN; DISEASE; DISABILITY; MORTALITY; POLICY; INDICATOR	We describe here the methods used to produce the first estimates of healthy life expectancy (DALE) for 191 countries in 1999. These were based on estimates of the incidence, prevalence, and disability distributions for 109 disease and injury causes by age group, sex, and region of the world, and an analysis of 60 representative health surveys across the world. We used Sullivan's method to compute healthy life expectancy for men and women in each WHO member country. Japan had the highest average healthy life expectancy of 74.5 years at birth in 1999. The bottom ten countries are all in sub-Saharan Africa, where the HIV-AIDS epidemic is most prevalent, resulting in DALE at birth of less than 35 years. Years of healthy life lost due to disability represent 18% of total life expectancy in the bottom countries, and decreases to around 8% in the countries with the highest healthy life expectancies. Globally, the male-female gap is lower for DALE than for total life expectancy. Healthy life expectancy increases across countries at a faster rate than total life expectancy, suggesting that reductions in mortality are accompanied by reductions in disability. Although women live longer, they spend a greater amount of time with disability. As average levels of health expenditure per capita increase, healthy life expectancy increases at a greater rate than total life expectancy.	WHO, Global Programme Evidence Hlth Policy, CH-1211 Geneva 27, Switzerland	World Health Organization	Mathers, CD (corresponding author), WHO, Global Programme Evidence Hlth Policy, CH-1211 Geneva 27, Switzerland.		Lopez, Alan D/F-1487-2010; Salomon, Joshua A/D-3898-2009; Salomon, Joshua/S-1929-2019; Lopez, Alan/AAA-2734-2022	Lopez, Alan D/0000-0001-5818-6512; Salomon, Joshua A/0000-0003-3929-5515; Salomon, Joshua/0000-0003-3929-5515; Mathers, Colin/0000-0002-0617-6731				AMTHERS C, 1999, BURDEN DIS INJURY AU; Barendregt JJ, 1998, J AGING HEALTH, V10, P242, DOI 10.1177/089826439801000207; Crimmins EM, 1997, J GERONTOL B-PSYCHOL, V52, pS59, DOI 10.1093/geronb/52B.2.S59; DEBRUIN A, 1996, WHO REGIONAL PUBLICA, V58; Field M, 1998, SUMMARIZING POPULATI; Lopez A D, 2000, 9 GPE WHO; Manton K. G., 1995, J GERONTOL, V48, pS153; MATHERS C, 2000, 16 GPE WHO; Murray C. J. L., 1996, GLOBAL BURDEN DIS; Murray CJL, 1997, LANCET, V349, P1347, DOI 10.1016/S0140-6736(96)07494-6; Murray CJL, 1997, LANCET, V349, P1498, DOI 10.1016/S0140-6736(96)07492-2; Murray CJL, 1997, LANCET, V349, P1436, DOI 10.1016/S0140-6736(96)07495-8; Murray CJL, 1997, LANCET, V349, P1269, DOI 10.1016/S0140-6736(96)07493-4; Murray CJL, 1996, SCIENCE, V274, P740, DOI 10.1126/science.274.5288.740; MURRAY CJL, 1996, GLOBAL BURDEN DIS, V1; MURRAY CJL, 2000, 35 GPE WHO; *OECD, 1999, EC OECD HLTH DAT 199; POULLIER JP, 2000, 27 GPE WHO; PRESTON SH, 1993, EPIDEMIOLOGICAL TRAN; RASMUSSEN N, 1999, SURVEY DATA DISABILI; Robine JM, 1999, B WORLD HEALTH ORGAN, V77, P181; ROBINE JM, 1996, HLTH MORTALITY ELDER, P182; ROBINE JM, 1999, OECD M IMP DIS AG PO; SADANA R, 2000, 15 GPE WHO; SALOMON J, 2000, 3 GPE WHO; SALOMON J, 2000, 11 GPE WHO; *UN, 1995, GUID HOUS SURV HLTH; vandeWater HPA, 1996, HEALTH POLICY, V36, P117, DOI 10.1016/0168-8510(95)00803-9; Wolfson M C, 1996, Health Rep, V8, P41; *WORLD BANK, 1993, WORLD DEV REP 1993 I; World Health Organization, 2000, WORLD HLTH REP 2000	31	276	289	3	27	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 26	2001	357	9269					1685	1691		10.1016/S0140-6736(00)04824-8	http://dx.doi.org/10.1016/S0140-6736(00)04824-8			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	435UY	11425392				2022-12-28	WOS:000168901600033
J	Glendinning, C; Coleman, A; Shipman, C; Malbon, G				Glendinning, C; Coleman, A; Shipman, C; Malbon, G			Primary care groups - Progress in partnerships	BRITISH MEDICAL JOURNAL			English	Article									Univ Manchester, Natl Primary Care Res & Dev Ctr, Manchester M13 9PL, Lancs, England; Kings Fund, London W1M 0AN, England	University of Manchester	Glendinning, C (corresponding author), Univ Manchester, Natl Primary Care Res & Dev Ctr, Manchester M13 9PL, Lancs, England.							*AUD COMM, 1998, FRUITF PARTN EFF PAR; GILLAM S, IN PRESS BMJ; Glendinning C, 1998, BRIT MED J, V317, P122, DOI 10.1136/bmj.317.7151.122; *LOC GOV ASS, 2000, PARTN HLTH SURV LOC; Rummery K., 2000, PRIMARY CARE SOCIAL; *SECR STAT HLTH, 2000, NHS PLAN PLAN INV PL; Wilkin D, 2001, BRIT MED J, V322, P1464, DOI 10.1136/bmj.322.7300.1464; WILKIN D, 2000, NATL TRACKER SURVEY	8	18	18	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUL 7	2001	323	7303					28	31		10.1136/bmj.323.7303.28	http://dx.doi.org/10.1136/bmj.323.7303.28			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	451WA	11440941	Green Published, Bronze			2022-12-28	WOS:000169824300022
J	Stone, EC				Stone, EC			Perspectives: Planetary science - News from the edge of interstellar space	SCIENCE			English	Editorial Material							HELIOSPHERIC TERMINATION SHOCK; NONUNIFORM SOLAR-WIND; OUTER HELIOSPHERE; MODULATION		CALTECH, Div Phys Math & Astron, Pasadena, CA 91125 USA	California Institute of Technology	Stone, EC (corresponding author), CALTECH, Div Phys Math & Astron, Pasadena, CA 91125 USA.							BELCHER JW, 1993, J GEOPHYS RES-SPACE, V98, P15177, DOI 10.1029/93JA01178; CUMMINGS AJ, COMMUNICATION; Exarhos G, 2000, ASTROPHYS J, V542, P1075, DOI 10.1086/317038; Gloeckler G, 1997, NATURE, V386, P374, DOI 10.1038/386374a0; Gurnett DA, 1996, SPACE SCI REV, V78, P53, DOI 10.1007/BF00170792; HALL DT, 1993, J GEOPHYS RES-SPACE, V98, P15185, DOI 10.1029/93JA01175; le Roux JA, 1999, J GEOPHYS RES-SPACE, V104, P4709, DOI 10.1029/1998JA900089; Linde TJ, 1998, J GEOPHYS RES-SPACE, V103, P1889, DOI 10.1029/97JA02144; McDonald FB, 2000, J GEOPHYS RES-SPACE, V105, P1, DOI 10.1029/1999JA900372; Pauls HL, 1996, J GEOPHYS RES-SPACE, V101, P17081, DOI 10.1029/96JA01298; Pauls HL, 1997, J GEOPHYS RES-SPACE, V102, P19779, DOI 10.1029/97JA01716; Stone E. C., 1999, P 26 INT COSM RAY C, V7, P500; STONE EC, 2001, P 27 INT COSM RAY C; VONSTEIGER R, 1996, SPACE SCI REV, V78, P1; Webber WR, 2001, J GEOPHYS RES-SPACE, V106, P253, DOI 10.1029/2000JA000285; Whang YC, 2000, GEOPHYS RES LETT, V27, P1607, DOI 10.1029/2000GL003748; ZANK GA, UNPUB; Zank GP, 1999, SPACE SCI REV, V89, P413, DOI 10.1023/A:1005155601277	18	33	33	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 6	2001	293	5527					55	56		10.1126/science.1060090	http://dx.doi.org/10.1126/science.1060090			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	451BB	11441168	Green Accepted			2022-12-28	WOS:000169780300022
J	Bhattacharya, S; Hamilton, MPR; Shaaban, M; Khalaf, Y; Seddler, M; Ghobara, T; Braude, P; Kennedy, R; Rutherford, A; Hartshorne, G; Templeton, A				Bhattacharya, S; Hamilton, MPR; Shaaban, M; Khalaf, Y; Seddler, M; Ghobara, T; Braude, P; Kennedy, R; Rutherford, A; Hartshorne, G; Templeton, A			Conventional in-vitro fertilisation versus intracytoplasmic sperm injection for the treatment of non-male-factor infertility: a randomised controlled trial	LANCET			English	Article							TUBAL FACTOR; FERTILIZATION; SEMEN; IMPLANTATION; PROGRAM; EMBRYOS; COUPLES; ICSI; AGE	Background Intracytoplasmic sperm injection (ICSI) is a more invasive option than conventional in-vitro fertilisation (IVF), which can be successful even when semen characteristics are poor. Reports of higher fertilisation rates after ICSI suggest that this technique may be better than the conventional method for all couples seeking IVF. We undertook multicentre randomised controlled trial comparing clinical outcome after ICSI or traditional IVF in couples with non-male-factor infertility. than IVF. conventional undertook. Methods 415 eligible and consenting couples at four UK centres were randomly assigned IVF or ICSI (total 435 treatment cycles: IVF 224; ICSI 211). Usual clinical and laboratory protocols for the two treatment procedures were followed in each of four participating centres. The primary outcome was the implantation rate (number of gestation sacs per embryo replaced expressed as a percentage). Secondary outcomes were pregnancy and fertilisation rates associated with each treatment. Analyses were by intention to treat. Findings The implantation rate was higher in the IVF group than in the ICSI group (95/318 [30%] vs 72/325 [22%]; relative risk 1.35 [95% CI 1.04-1.76]). The pregnancy rate per cycle was also higher after IVF (72 [33%] vs 53 [26%]; 1.17 [0.97-1.35]). Mean associated laboratory time was significantly shorter with IVF than with ICSI (22.9 [SD 12.1] vs 74.0 [38.1] min; 95% CI for difference 45.6-56.6). Interpretation ICSI offers no advantage over IVF in terms of clinical outcome in cases of non-male-factor infertility. Our results support the current practice of reserving ICSI only for severe male-factor problems.	Univ Aberdeen, Aberdeen Matern Hosp, Assisted Reprod Unit, Aberdeen AB25 2ZD, Scotland; Guys & St Thomas Hosp Trust, Assisted Concept Unit, London, England; Leeds Gen Infirm, Assisted Concept Unit, Leeds, W Yorkshire, England; Walsgrave Hosp NHS Trust, Ctr Reprod Med, Coventry, W Midlands, England	University of Aberdeen; Guy's & St Thomas' NHS Foundation Trust; Leeds General Infirmary; University of Leeds	Bhattacharya, S (corresponding author), Univ Aberdeen, Aberdeen Matern Hosp, Assisted Reprod Unit, Aberdeen AB25 2ZD, Scotland.			Bhattacharya, Siladitya/0000-0002-4588-356X				Aboulghar MA, 1996, FERTIL STERIL, V66, P753, DOI 10.1016/S0015-0282(16)58630-0; Aboulghar MA, 1995, HUM REPROD, V10, P2829, DOI 10.1093/oxfordjournals.humrep.a135801; ARTHUR ID, 1994, ACTA OBSTET GYN SCAN, V73, P562, DOI 10.3109/00016349409006273; Bonduelle M, 1995, HUM REPROD, V10, P3327, DOI 10.1093/oxfordjournals.humrep.a135914; Bowen JR, 1998, LANCET, V351, P1529, DOI 10.1016/S0140-6736(98)10168-X; Bukulmez O, 2000, FERTIL STERIL, V73, P38, DOI 10.1016/S0015-0282(99)00449-5; Calderon G, 1995, HUM REPROD, V10, P2835, DOI 10.1093/oxfordjournals.humrep.a135803; Casagrande J. T., 1978, APPLIED STATISTICS, V27, P176; COLLINS JA, 1998, EVIDENCE BASED FERTI, P3; DAIDOH T, 1995, FERTIL STERIL, V63, P87; Dumoulin JCM, 2000, HUM REPROD, V15, P402, DOI 10.1093/humrep/15.2.402; EBRAHIM A, 1993, J ASSIST REPROD GEN, V10, P130, DOI 10.1007/BF01207735; Fishel S, 2000, HUM REPROD, V15, P1278, DOI 10.1093/humrep/15.6.1278; Hull MGR, 1996, FERTIL STERIL, V65, P783, DOI 10.1016/S0015-0282(16)58214-4; Moomjy M, 1998, HUM REPROD, V13, P2212, DOI 10.1093/humrep/13.8.2212; Moreno C, 1998, HUM REPROD, V13, P2126, DOI 10.1093/humrep/13.8.2126; PALERMO G, 1992, LANCET, V340, P17, DOI 10.1016/0140-6736(92)92425-F; Ruiz A, 1997, FERTIL STERIL, V68, P171, DOI 10.1016/S0015-0282(97)81497-5; Schoolcraft WB, 1996, FERTIL STERIL, V65, P258; Staessen C, 1999, HUM REPROD, V14, P2474, DOI 10.1093/humrep/14.10.2474; SVEECK LO, 1995, FERTIL STERIL, V64, P977; Templeton A, 1996, LANCET, V348, P1402, DOI 10.1016/S0140-6736(96)05291-9; TSIRIGOTIS M, 1994, FERTIL STERIL, V62, P781; VANRUMSTE MME, 2000, COCHRANE LIB; VANSTEIRTEGHEM AC, 1993, HUM REPROD, V8, P1061, DOI 10.1093/oxfordjournals.humrep.a138192; Verheyen G, 1999, HUM REPROD, V14, P2313, DOI 10.1093/humrep/14.9.2313; YANG D, 1996, J ASSIST REPROD GEN, V9, P197	27	199	203	0	10	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 30	2001	357	9274					2075	2079		10.1016/S0140-6736(00)05179-5	http://dx.doi.org/10.1016/S0140-6736(00)05179-5			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	447RQ	11445099				2022-12-28	WOS:000169586600009
J	Neumann, FJ; Kastrati, A; Miethke, T; Pogatsa-Murray, G; Mehilli, J; Valina, C; Jogethaei, N; da Costa, CP; Wagner, H; Schomig, A				Neumann, FJ; Kastrati, A; Miethke, T; Pogatsa-Murray, G; Mehilli, J; Valina, C; Jogethaei, N; da Costa, CP; Wagner, H; Schomig, A			Treatment of Chlamydia pneumoniae infection with roxithromycin and effect on neointima proliferation after coronary stent placement (ISAR-3): a randomised, double-blind, placebo-controlled trial	LANCET			English	Article							SERIAL INTRAVASCULAR ULTRASOUND; ENDOTHELIAL-CELLS; ARTERY DISEASE; SMOOTH-MUSCLE; TISSUE FACTOR; TIME-COURSE; RESTENOSIS; ANGIOPLASTY; AZITHROMYCIN; IMPLANTATION	Background Vascular infection with Chlamydia pneumoniae might boost inflammatory responses that play a pivotal part in neointima formation, which is the main cause of restenosis after stenting. Our aim was to investigate whether or not treatment of C pneumoniae infection with antibiotics prevents restenosis after coronary stent placement. Methods We enrolled 1010 consecutive patients with successful coronary stenting into a randomised, double-blind trial. Patients received the macrolide antibiotic roxithromycin 300 mg once daily for 28 days (506), or placebo (504). Primary endpoint was frequency of restenosis (diameter stenosis greater than or equal to 50%) at follow-up angiography, and secondary endpoint was rate of target vessel revascularisation during the year after stenting. A prespecified secondary analysis addressed treatment effect with respect to titre of C pneumoniae in serum. Analysis was by intention to treat. Findings Rate of angiographic restenosis was 31% (157 lesions) in the roxithromycin group and 29% (148) in the placebo group (relative risk 1.08 [95% CI 0.92-1.26]; p=0.43), corresponding to a rate of target vessel revascularisation of 19% (120) and 17% (105), respectively (1.13 [0.95-1.36]; p=0.30). The combined 1-year rates of death and myocardial infarction were 7% (36) in the roxithromycin group and 6% (30) in the placebo group (p=0.45). We showed a significant interaction between treatment and C pneumoniae antibody titre (p=0.038 for restenosis, p=0.006 for revascularisation), favouring roxithromycin at high titres (adjusted odds ratios at a titre of 1/512 were 0.44 [0.19-1.06] and 0.32 [0.13-0.81], respectively). Interpretation Non-selective use of roxithromycin is inadequate for prevention of restenosis after coronary stenting. There is, however, a differential effect dependent on C pneumoniae titres. In patients with high titres, roxithromycin reduced the rate of restenosis.	Tech Univ Munich, Med Klin, D-81675 Munich, Germany; Tech Univ Munich, Deutsch Herzzentrum, D-81675 Munich, Germany; Tech Univ Munich, Inst Med Mikrobiol Immunol & Hyg, D-81675 Munich, Germany	Technical University of Munich; German Heart Center Berlin; German Heart Centre Munich; Technical University of Munich; Technical University of Munich	Neumann, FJ (corresponding author), Tech Univ Munich, Med Klin, D-81675 Munich, Germany.		Mehilli, Julinda/F-2629-2016; , Kastrati/Y-2389-2019					Anderson JL, 1999, CIRCULATION, V99, P1540, DOI 10.1161/01.CIR.99.12.1540; Asakura M, 1998, CIRCULATION, V97, P2003, DOI 10.1161/01.CIR.97.20.2003; Buffon A, 1999, J AM COLL CARDIOL, V34, P1512, DOI 10.1016/S0735-1097(99)00348-4; CARTER AJ, 1994, J AM COLL CARDIOL, V24, P1398, DOI 10.1016/0735-1097(94)90126-0; Dechend R, 1999, CIRCULATION, V100, P1369, DOI 10.1161/01.CIR.100.13.1369; Dirschinger J, 1999, CIRCULATION, V100, P918, DOI 10.1161/01.CIR.100.9.918; Farb A, 1999, CIRCULATION, V99, P44, DOI 10.1161/01.CIR.99.1.44; Feldman LJ, 2000, CIRCULATION, V101, P908, DOI 10.1161/01.CIR.101.8.908; Fryer RH, 1997, J INVEST MED, V45, P168; Gupta S, 1997, CIRCULATION, V96, P404; Gurfinkel E, 1999, EUR HEART J, V20, P121, DOI 10.1053/euhj.1998.1283; HARRELL FE, 1997, PREDICTING OUTCOMES, P113; Hoffmann R, 1996, J AM COLL CARDIOL, V28, P1134, DOI 10.1016/S0735-1097(96)00278-1; Hoffmann R, 1996, CIRCULATION, V94, P1247, DOI 10.1161/01.CIR.94.6.1247; Hu H, 1999, J CLIN INVEST, V103, P747, DOI 10.1172/JCI4582; Kastrati A, 1998, CIRCULATION, V97, P2396, DOI 10.1161/01.CIR.97.24.2396; KASTRATI A, 1993, CIRCULATION, V87, P1498, DOI 10.1161/01.CIR.87.5.1498; Kastrati A, 2000, J AM COLL CARDIOL, V36, P2168, DOI 10.1016/S0735-1097(00)01014-7; Komatsu R, 1998, CIRCULATION, V98, P224, DOI 10.1161/01.CIR.98.3.224; Krull M, 1999, J IMMUNOL, V162, P4834; LINNANMAKI E, 1993, CIRCULATION, V87, P1130, DOI 10.1161/01.CIR.87.4.1130; Maass M, 1998, J AM COLL CARDIOL, V31, P827, DOI 10.1016/S0735-1097(98)00016-3; Muhlestein JB, 1998, CIRCULATION, V97, P633, DOI 10.1161/01.CIR.97.7.633; Muhlestein JB, 1996, J AM COLL CARDIOL, V27, P1555, DOI 10.1016/0735-1097(96)00055-1; Oltrona L, 1997, CIRCULATION, V96, P646; Rogers C, 1998, P NATL ACAD SCI USA, V95, P10134, DOI 10.1073/pnas.95.17.10134; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Simon DI, 2000, J CLIN INVEST, V105, P293, DOI 10.1172/JCI7811; THOM DH, 1992, JAMA-J AM MED ASSOC, V268, P68, DOI 10.1001/jama.268.1.68; Wang SP, 2000, J INFECT DIS, V181, pS421, DOI 10.1086/315622	30	81	88	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 30	2001	357	9274					2085	2089		10.1016/S0140-6736(00)05181-3	http://dx.doi.org/10.1016/S0140-6736(00)05181-3			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	447RQ	11445102				2022-12-28	WOS:000169586600012
J	Kim, J; Swager, TM				Kim, J; Swager, TM			Control of conformational and interpolymer effects in conjugated polymers	NATURE			English	Article							LANGMUIR-BLODGETT-FILMS; INTERCHAIN INTERACTIONS; POLY(P-PHENYLENEETHYNYLENE)S; CHEMOSENSORS; AGGREGATION; MORPHOLOGY; TRANSPORT	The role of conjugated polymers in emerging electronic, sensor and display technologies is rapidly expanding. In spite of extensive investigations(1-11), the intrinsic spectroscopic properties of conjugated polymers in precise conformational and spatial arrangements have remained elusive. The difficulties of obtaining such information are endemic to polymers, which often resist assembly into single crystals or organized structures owing to entropic and polydispersity considerations. Here we show that the conformation of individual polymers and interpolymer interactions in conjugated polymers can be controlled through the use of designed surfactant poly(p-phenylene-ethynylene) Langmuir films. We show that by mechanically inducing reversible conformational changes of these Langmuir monolayers, we can obtain the precise interrelationship of the intrinsic optical properties of a conjugated polymer and a single chain's conformation and/or interpolymer interactions. This method for controlling the structure of conjugated polymers and establishing their intrinsic spectroscopic properties should permit a more comprehensive understanding of fluorescent conjugated materials.	MIT, Dept Chem, Cambridge, MA 02139 USA; MIT, Ctr Sci & Engn, Cambridge, MA 02139 USA; MIT, Dept Mat Sci & Engn, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Swager, TM (corresponding author), MIT, Dept Chem, Cambridge, MA 02139 USA.		Swager, Timothy M/H-7459-2012; Kim, Jinsang/G-3928-2011	Swager, Timothy M/0000-0002-3577-0510; Kim, Jinsang/0000-0002-1235-3327				Buvat P, 1997, MACROMOLECULES, V30, P2685, DOI 10.1021/ma9618080; Cornil J, 1998, J AM CHEM SOC, V120, P1289, DOI 10.1021/ja973761j; CRONWELL E, 1997, TRENDS POLYM SCI, V5, P218; GETTINGER CL, 1994, J CHEM PHYS, V101, P1673, DOI 10.1063/1.468438; HEUN S, 1993, J PHYS-CONDENS MAT, V5, P247, DOI 10.1088/0953-8984/5/2/012; JENEKHE SA, 1994, SCIENCE, V265, P765, DOI 10.1126/science.265.5173.765; JOSEFOWICZ JY, 1993, SCIENCE, V260, P323, DOI 10.1126/science.260.5106.323; Kim J, 2000, ANGEW CHEM INT EDIT, V39, P3868, DOI 10.1002/1521-3773(20001103)39:21<3868::AID-ANIE3868>3.0.CO;2-2; Kim JS, 1999, MACROMOLECULES, V32, P1500, DOI 10.1021/ma981774r; Kloppenburg L, 1999, MACROMOLECULES, V32, P4194, DOI 10.1021/ma9900535; Levitsky IA, 1999, J AM CHEM SOC, V121, P1466, DOI 10.1021/ja982610t; Lucht BL, 1998, J AM CHEM SOC, V120, P4354, DOI 10.1021/ja9743811; McQuade DT, 2000, J AM CHEM SOC, V122, P5885, DOI 10.1021/ja000553+; Miteva T, 2000, MACROMOLECULES, V33, P652, DOI 10.1021/ma9912397; Nguyen TQ, 2000, SCIENCE, V288, P652, DOI 10.1126/science.288.5466.652; Nguyen TQ, 2000, J PHYS CHEM B, V104, P237, DOI 10.1021/jp993190c; Shi Y, 2000, J APPL PHYS, V87, P4254, DOI 10.1063/1.373062; Sirringhaus H, 1999, NATURE, V401, P685, DOI 10.1038/44359; Turro N. J., 1991, MODERN MOL PHOTOCHEM, P183; Yang JS, 1998, J AM CHEM SOC, V120, P11864, DOI 10.1021/ja982293q; Zhang QT, 1997, J AM CHEM SOC, V119, P9624, DOI 10.1021/ja964223u	21	459	472	4	157	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 28	2001	411	6841					1030	1034		10.1038/35082528	http://dx.doi.org/10.1038/35082528			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	446TF	11429599				2022-12-28	WOS:000169528500042
J	Nguyen, VQ; Co, C; Li, JJ				Nguyen, VQ; Co, C; Li, JJ			Cyclin-dependent kinases prevent DNA re-replication through multiple mechanisms	NATURE			English	Article							CELL-CYCLE; S-PHASE; SACCHAROMYCES-CEREVISIAE; SUBCELLULAR-LOCALIZATION; CHROMOSOME-REPLICATION; CDK PHOSPHORYLATION; DISTINCT MODES; NUCLEAR EXPORT; MAMMALIAN CDC6; BUDDING YEAST	The stable propagation of genetic information requires that the entire genome of an organism be faithfully replicated once and only once each cell cycle. In eukaryotes, this replication is initiated at hundreds to thousands of replication origins distributed over the genome, each of which must be prohibited from re-initiating DNA replication within every cell cycle. How cells prevent reinitiation has been a long-standing question in cell biology. In several eukaryotes, cyclin-dependent kinases (CDKs) have been implicated in promoting the block to re-initiation(1), but exactly how they perform this function is unclear. Here we show that B-type CDKs in Saccharomyces cerevisiae prevent re-initiation through multiple overlapping mechanisms, including phosphorylation of the origin recognition complex (ORC), downregulation of Cdc6 activity, and nuclear exclusion of the Mcm2-7 complex. Only when all three inhibitory pathways are disrupted do origins re-initiate DNA replication in G2/M cells. These studies show that each of these three independent mechanisms of regulation is functionally important.	Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco	Li, JJ (corresponding author), Univ Calif San Francisco, Dept Microbiol & Immunol, San Francisco, CA 94143 USA.							BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; BREWER BJ, 1993, COLD SPRING HARB SYM, V58, P425, DOI 10.1101/SQB.1993.058.01.049; BROEK D, 1991, NATURE, V349, P388, DOI 10.1038/349388a0; DAHMANN C, 1995, CURR BIOL, V5, P1257, DOI 10.1016/S0960-9822(95)00252-1; Drury LS, 2000, CURR BIOL, V10, P231, DOI 10.1016/S0960-9822(00)00355-9; Drury LS, 1997, EMBO J, V16, P5966, DOI 10.1093/emboj/16.19.5966; Elsasser S, 1996, MOL BIOL CELL, V7, P1723, DOI 10.1091/mbc.7.11.1723; Elsasser S, 1999, MOL BIOL CELL, V10, P3263, DOI 10.1091/mbc.10.10.3263; Fujita M, 1999, J BIOL CHEM, V274, P25927, DOI 10.1074/jbc.274.36.25927; HENNESSY KM, 1990, GENE DEV, V4, P2252, DOI 10.1101/gad.4.12b.2252; Jallepalli PV, 1997, GENE DEV, V11, P2767, DOI 10.1101/gad.11.21.2767; Jiang W, 1999, P NATL ACAD SCI USA, V96, P6193, DOI 10.1073/pnas.96.11.6193; Kelly TJ, 2000, ANNU REV BIOCHEM, V69, P829, DOI 10.1146/annurev.biochem.69.1.829; Labib K, 1999, NAT CELL BIOL, V1, P415, DOI 10.1038/15649; Liang C, 1997, GENE DEV, V11, P3375, DOI 10.1101/gad.11.24.3375; MOLL T, 1991, CELL, V66, P743, DOI 10.1016/0092-8674(91)90118-I; MUZIFALCONI M, 1996, P NATL ACAD SCI USA, V93, P1666; NEWLON CS, 1993, COLD SPRING HARB SYM, V58, P415, DOI 10.1101/SQB.1993.058.01.048; Nguyen VQ, 2000, CURR BIOL, V10, P195, DOI 10.1016/S0960-9822(00)00337-7; Nishitani H, 2000, NATURE, V404, P625, DOI 10.1038/35007110; NISHITANI H, 1995, CELL, V83, P397, DOI 10.1016/0092-8674(95)90117-5; Noton E, 2000, MOL CELL, V5, P85, DOI 10.1016/S1097-2765(00)80405-0; Pelizon C, 2000, GENE DEV, V14, P2526, DOI 10.1101/gad.176300; Petersen BO, 2000, GENE DEV, V14, P2330, DOI 10.1101/gad.832500; Petersen BO, 1999, EMBO J, V18, P396, DOI 10.1093/emboj/18.2.396; Saha P, 1998, MOL CELL BIOL, V18, P2758, DOI 10.1128/MCB.18.5.2758; SAUER K, 1995, GENE DEV, V9, P1327, DOI 10.1101/gad.9.11.1327; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; VAS A, 2001, IN PRESS MOL CELL BI; Visintin R, 1997, SCIENCE, V278, P460, DOI 10.1126/science.278.5337.460	30	353	357	0	9	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 28	2001	411	6841					1068	1073		10.1038/35082600	http://dx.doi.org/10.1038/35082600			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	446TF	11429609				2022-12-28	WOS:000169528500052
J	Wald, A; Langenberg, AGM; Link, K; Izu, AE; Ashley, R; Warren, T; Tyring, S; Douglas, JM; Corey, L				Wald, A; Langenberg, AGM; Link, K; Izu, AE; Ashley, R; Warren, T; Tyring, S; Douglas, JM; Corey, L			Effect of condoms on reducing the transmission of herpes simplex virus type 2 from men to women	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	39th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)	SEP 26-29, 1999	SAN FRANCISCO, CA				RECOMBINANT GLYCOPROTEIN VACCINE; GENITAL HERPES; RISK-FACTORS; HETEROSEXUAL ADULTS; SEXUAL TRANSMISSION; HIV; INFECTION; PREVALENCE; CELLS; REACTIVATION	Context Herpes simplex virus type 2 (HSV-2) is one of the most common sexually transmitted infections in the United States. No prospective study has shown the ability of condoms to reduce transmission of HSV-2. Objective To evaluate risk factors for HSV-2 acquisition and efficacy of condoms in prevention of HSV-2 transmission. Design Analysis of data from a randomized, double-blind, placebo-controlled trial conducted December 13, 1993, to June 28, 1996, of an ineffective candidate HSV-2 vaccine with 18 months of follow-up. Setting Eighteen clinical trial centers in the United States. Participants A total of 528 monogamous couples discordant for HSV-2 infection, including an HSV-2- susceptible population of 261 men and 267 women. Main Outcome Measure Acquisition of HSV-2 infection by susceptible partners, compared with those remaining free of HSV-2 with regard to demographic characteristics, sexual activity, and condom use. Results Twenty-six women (9.7%) vs 5 men (1.9%) acquired HSV-2, for a rate per 10000 sex acts (episodes of sexual intercourse) of 8.9 vs 1.5, respectively (P<.001). In multivariable analysis, younger age (adjusted hazard ratio [HR] per 5 years, 1.57; 95% confidence interval [Cl], 1.22-2.04), seropositivity for HSV-1 and HSV-2 vs HSV-2 alone in the source partner (adjusted HR, 2.34; 95% Cl, 1.14-4.82), and more frequent sexual activity (adjusted HR per additional sex act per week, 1.10; 95% Cl, 1.01-1.19) were associated with higher risk of HSV-2 acquisition. Condom use during more than 25% of sex acts was associated with protection against HSV-2 acquisition for women (adjusted HR, 0.085; 95% Cl, 0.01-0.67) but not for men (adjusted HR, 2.02; 95% Cl, 0.32-12.50). Risk of HSV-2 transmission declined from 8.5 per 100 person-years in the initial 150-day interval to 0.9 per 100 person-years in the final 150-day interval (P=.002 for trend), concurrent with a decrease in sexual activity and proportion of sex acts occurring when the source partner had genital lesions. Conclusions Condom use offers significant protection against HSV-2 infection in susceptible women. Changes in sexual behavior, correlated with counseling about avoiding sex when a partner has lesions, were associated with reduction in HSV-2 acquisition over time. These data suggest that identification of discordant couples can reduce transmission of HSV-2, especially for heterosexual couples in which the male partner has HSV-2 infection.	Univ Washington, Virol Res Clin, Dept Med, Seattle, WA 98122 USA; Univ Washington, Dept Epidemiol, Seattle, WA 98122 USA; Univ Washington, Dept Lab Med, Seattle, WA 98122 USA; Chiron Corp, Emeryville, CA 94608 USA; Univ Texas, Med Branch, Dept Microbiol, Galveston, TX 77550 USA; Univ Texas, Med Branch, Dept Immunol, Galveston, TX 77550 USA; Univ Texas, Med Branch, Dept Dermatol, Galveston, TX 77550 USA; Univ Texas, Med Branch, Dept Pediat, Galveston, TX 77550 USA; Dept Publ Hlth, Denver, CO USA; Fred Hutchinson Canc Res Ctr, Program Infect Dis, Seattle, WA 98104 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Novartis; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; Fred Hutchinson Cancer Center	Wald, A (corresponding author), Univ Washington, Virol Res Clin, Dept Med, 1001 Broadway,Suite 320, Seattle, WA 98122 USA.	annawald@u.washington.edu	Corey, Lawrence/AAE-1796-2020; Warren, Terri/AAJ-1650-2021; Wald, Anna/B-6272-2012	Corey, Lawrence/0000-0002-2179-2436; Wald, Anna/0000-0003-3486-6438	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI030731] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Anderson JE, 1999, J ACQ IMMUN DEF SYND, V21, P148; [Anonymous], 1998, MMWR Recomm Rep, V47, P1; Ashley R, 1998, SEX TRANSM INFECT, V74, P228; ASHLEY RL, 1988, J CLIN MICROBIOL, V26, P662, DOI 10.1128/JCM.26.4.662-667.1988; Ashley RL, 1998, J CLIN MICROBIOL, V36, P294, DOI 10.1128/JCM.36.1.294-295.1998; Ashley RL, 1998, J INFECT DIS, V178, P1, DOI 10.1086/514253; ASHLEY RL, 1993, GENITOURIN MED, V69, P174; Benedetti JK, 1999, ANN INTERN MED, V131, P14, DOI 10.7326/0003-4819-131-1-199907060-00004; BRYSON Y, 1993, J INFECT DIS, V167, P942, DOI 10.1093/infdis/167.4.942; CATANIA JA, 1995, AM J PUBLIC HEALTH, V85, P1492, DOI 10.2105/AJPH.85.11.1492; CATANIA JA, 1992, SCIENCE, V258, P1101, DOI 10.1126/science.1439818; Corey L, 1999, JAMA-J AM MED ASSOC, V282, P331, DOI 10.1001/jama.282.4.331; DEVINCENZI I, 1994, NEW ENGL J MED, V331, P341, DOI 10.1056/NEJM199408113310601; Downs AM, 1996, J ACQ IMMUN DEF SYND, V11, P388, DOI 10.1097/00042560-199604010-00010; Fleming DT, 1997, NEW ENGL J MED, V337, P1105, DOI 10.1056/NEJM199710163371601; *KAIS FAM FDN, 1998, SEX TRANSM DIS AM MA; LAFFERTY WE, 1987, J CLIN MICROBIOL, V25, P323, DOI 10.1128/JCM.25.2.323-326.1987; LANGENBERG A, 1988, J CLIN MICROBIOL, V26, P1772, DOI 10.1128/JCM.26.9.1772-1774.1988; LANGENBERG AGM, 1995, ANN INTERN MED, V122, P889, DOI 10.7326/0003-4819-122-12-199506150-00001; LANGLADEDEMOYEN P, 1994, J CLIN INVEST, V93, P1293, DOI 10.1172/JCI117085; MERTZ GJ, 1992, ANN INTERN MED, V116, P197, DOI 10.7326/0003-4819-116-3-197; MERTZ GJ, 1985, SEX TRANSM DIS, V12, P33, DOI 10.1097/00007435-198501000-00007; Montgomery RI, 1996, CELL, V87, P427, DOI 10.1016/S0092-8674(00)81363-X; PETERMAN TA, 1988, JAMA-J AM MED ASSOC, V259, P55, DOI 10.1001/jama.259.1.55; ROWLANDJONES S, 1995, NAT MED, V1, P59, DOI 10.1038/nm0195-59; ROWLANDJONES SL, 1993, LANCET, V341, P860, DOI 10.1016/0140-6736(93)93063-7; Royce RA, 1997, NEW ENGL J MED, V336, P1072, DOI 10.1056/NEJM199704103361507; Wald A, 2000, NEW ENGL J MED, V342, P844, DOI 10.1056/NEJM200003233421203; WALD A, 1995, NEW ENGL J MED, V333, P770, DOI 10.1056/NEJM199509213331205; Whitbeck JC, 1997, J VIROL, V71, P6083, DOI 10.1128/JVI.71.8.6083-6093.1997; Whitley RJ, 1998, CLIN INFECT DIS, V26, P541, DOI 10.1086/514600; WUDUNN D, 1989, J VIROL, V63, P52, DOI 10.1128/JVI.63.1.52-58.1989; *YANK PARTN INC, 1999, AM 18 39 ATT KNOWL G	33	230	239	1	10	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 27	2001	285	24					3100	3106		10.1001/jama.285.24.3100	http://dx.doi.org/10.1001/jama.285.24.3100			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	444FF	11427138	Bronze			2022-12-28	WOS:000169388900023
J	Wofsy, SC				Wofsy, SC			Climate change - Where has all the carbon gone?	SCIENCE			English	Editorial Material							UNITED-STATES; DELTA-C-13; FORESTS; BUDGET		Harvard Univ, Dept Earth & Planetary Sci, Cambridge, MA 02139 USA	Harvard University	Wofsy, SC (corresponding author), Harvard Univ, Dept Earth & Planetary Sci, Cambridge, MA 02139 USA.							Battle M, 2000, SCIENCE, V287, P2467, DOI 10.1126/science.287.5462.2467; Fan S, 1998, SCIENCE, V282, P442, DOI 10.1126/science.282.5388.442; Fang JY, 2001, SCIENCE, V292, P2320, DOI 10.1126/science.1058629; HEATH LS, 1993, WATER AIR SOIL POLL, V70, P279, DOI 10.1007/BF01105002; Houghton RA, 1999, SCIENCE, V285, P574, DOI 10.1126/science.285.5427.574; Pacala SW, 2001, SCIENCE, V292, P2316, DOI 10.1126/science.1057320; Rayner PJ, 1999, TELLUS B, V51, P213, DOI 10.1034/j.1600-0889.1999.t01-1-00008.x; Sarmiento J.L., 1999, US CARBON CYCLE SCI, V69; TURNER DP, 1995, ECOL APPL, V5, P421, DOI 10.2307/1942033	9	32	39	3	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 22	2001	292	5525					2261	+		10.1126/science.1061077	http://dx.doi.org/10.1126/science.1061077			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	445KD	11423641				2022-12-28	WOS:000169455900035
J	Bao, SD; Tibbetts, RS; Brumbaugh, KM; Fang, YN; Richardson, DA; Ali, A; Chen, SM; Abraham, RT; Wang, XF				Bao, SD; Tibbetts, RS; Brumbaugh, KM; Fang, YN; Richardson, DA; Ali, A; Chen, SM; Abraham, RT; Wang, XF			ATR/ATM-mediated phosphorylation of human Rad17 is required for genotoxic stress responses	NATURE			English	Article							SLIDING CLAMP; DNA; ATR; FAMILY	Genotoxic stress triggers the activation of checkpoints that delay cell-cycle progression to allow for DNA repair(1). Studies in fission yeast implicate members of the Rad family of checkpoint proteins, which includes Rad17, Rad1, Rad9 and Hus1, as key early-response elements during the activation of both the DNA damage and replication checkpoints(2-5). Here we demonstrate a direct regulatory linkage between the human Rad17 homologue (hRad17) and the checkpoint kinases, ATM and ATR. Treatment of human cells with genotoxic agents induced ATM/ATR-dependent phosphorylation of hRad17 at Ser 635 and Ser 645. Overexpression of a hRad17 mutant (hRad17(AA)) bearing Ala substitutions at both phosphorylation sites abrogated the DNA-damage-induced G(2) checkpoint, and sensitized human fibroblasts to genotoxic stress. In contrast to wild-type hRad17, the hRad17(AA) mutant showed no ionizing-radiation-inducible association with hRad1, a component of the hRad1-hRad9-hHus1 checkpoint complex. These findings demonstrate that ATR/ATM-dependent phosphorylation of hRad17 is a critical early event during checkpoint signalling in DNA-damaged cells.	Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA	Duke University	Wang, XF (corresponding author), Duke Univ, Med Ctr, Dept Pharmacol & Canc Biol, Durham, NC 27710 USA.	wang0011@mc.duke.edu		Tibbetts, Randal/0000-0003-2245-2297; Fang, Yanan/0000-0002-1112-9569				Banin S, 1998, SCIENCE, V281, P1674, DOI 10.1126/science.281.5383.1674; Bao SD, 1998, CELL GROWTH DIFFER, V9, P961; Burtelow MA, 2000, J BIOL CHEM, V275, P26343, DOI 10.1074/jbc.M001244200; Caspari T, 1999, BIOCHIMIE, V81, P173, DOI 10.1016/S0300-9084(99)80050-9; Cliby WA, 1998, EMBO J, V17, P159, DOI 10.1093/emboj/17.1.159; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Kim ST, 1999, J BIOL CHEM, V274, P37538, DOI 10.1074/jbc.274.53.37538; Lowndes NF, 2000, CURR OPIN GENET DEV, V10, P17, DOI 10.1016/S0959-437X(99)00050-7; O'Connell MJ, 2000, TRENDS CELL BIOL, V10, P296, DOI 10.1016/S0962-8924(00)01773-6; Parker AE, 1999, J BIOL CHEM, V274, P24438; Rauen M, 2000, J BIOL CHEM, V275, P29767, DOI 10.1074/jbc.M005782200; Sekulic A, 2000, CANCER RES, V60, P3504; Shiloh Y, 2001, CURR OPIN GENET DEV, V11, P71, DOI 10.1016/S0959-437X(00)00159-3; Thelen MP, 1999, CELL, V96, P769, DOI 10.1016/S0092-8674(00)80587-5; Tibbetts RS, 1999, GENE DEV, V13, P152, DOI 10.1101/gad.13.2.152; Tibbetts RS, 2000, GENE DEV, V14, P2989, DOI 10.1101/gad.851000; Venclovas C, 2000, NUCLEIC ACIDS RES, V28, P2481, DOI 10.1093/nar/28.13.2481; Weinert T, 1997, CANCER SURV, V29, P109; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	19	220	233	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 21	2001	411	6840					969	974		10.1038/35082110	http://dx.doi.org/10.1038/35082110			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	444EN	11418864				2022-12-28	WOS:000169386200050
J	Kane, B				Kane, B			Medical marijuana: The continuing story	ANNALS OF INTERNAL MEDICINE			English	Article																			0	6	6	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 19	2001	134	12					1159	1162		10.7326/0003-4819-134-12-200106190-00035	http://dx.doi.org/10.7326/0003-4819-134-12-200106190-00035			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	442YU	11412075				2022-12-28	WOS:000169313200025
J	Farmer, A				Farmer, A			10-minute consultation - Prostatic symptoms	BRITISH MEDICAL JOURNAL			English	Article									Inst Hlth Sci, Oxford OX3 7LF, England	University of Oxford	Farmer, A (corresponding author), Inst Hlth Sci, Oxford OX3 7LF, England.								0	8	8	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 16	2001	322	7300					1468	1468		10.1136/bmj.322.7300.1468	http://dx.doi.org/10.1136/bmj.322.7300.1468			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	444FJ	11408305	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000169389200032
J	de Leval, MR				de Leval, MR			Lessons from the arterial-switch operation	LANCET			English	Editorial Material							ANATOMIC CORRECTION; TRANSPOSITION		Great Ormond St Hosp Children NHS Trust, Cardiothorac Unit, London WC1N 3JH, England; Inst Child Hlth, London WC1N 3JH, England	University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust; University of London; University College London	de Leval, MR (corresponding author), Great Ormond St Hosp Children NHS Trust, Cardiothorac Unit, Great Ormond St, London WC1N 3JH, England.							Jatene A D, 1975, Arq Bras Cardiol, V28, P461; KANTER KR, 1985, J THORAC CARDIOV SUR, V90, P690; SPODICK DH, 1975, JAMA-J AM MED ASSOC, V232, P35; YACOUB M, 1980, CIRCULATION, V62, P190	4	13	13	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 9	2001	357	9271					1814	1814		10.1016/S0140-6736(00)05006-6	http://dx.doi.org/10.1016/S0140-6736(00)05006-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	440DN	11410182				2022-12-28	WOS:000169160800002
J	Said, G				Said, G			Value of nerve biopsy?	LANCET			English	Editorial Material							NEUROPATHY		Hop Bicetre, Serv Neurol, F-94275 Le Kremlin Bicetre, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Bicetre - APHP; UDICE-French Research Universities; Universite Paris Saclay	Said, G (corresponding author), Hop Bicetre, Serv Neurol, F-94275 Le Kremlin Bicetre, France.							ARGOV Z, 1989, ACTA NEUROL SCAND, V79, P243, DOI 10.1111/j.1600-0404.1989.tb03745.x; Collins MP, 2000, NEUROLOGY, V55, P636, DOI 10.1212/WNL.55.5.636; De Freitas MRG, 1998, ARQ NEURO-PSIQUIAT, V56, P585, DOI 10.1590/S0004-282X1998000400011; Dyck PJ GC, 1993, PERIPHERAL NEUROPATH, P514; Gabriel CM, 2000, J NEUROL NEUROSUR PS, V69, P442, DOI 10.1136/jnnp.69.4.442; HELLMANN DB, 1988, MEDICINE, V67, P145, DOI 10.1097/00005792-198805000-00001; RAPPAPORT WD, 1993, AM J SURG, V166, P252, DOI 10.1016/S0002-9610(05)80968-7; Said G, 1999, MUSCLE NERVE, V22, P1617, DOI 10.1002/(SICI)1097-4598(199912)22:12<1617::AID-MUS1>3.0.CO;2-L; SAID G, 1988, ANN NEUROL, V23, P461, DOI 10.1002/ana.410230506; THOMAS PK, 1995, PERIPHERAL NERVE DIS, V2, P281	10	17	17	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 21	2001	357	9264					1220	1221		10.1016/S0140-6736(00)04449-4	http://dx.doi.org/10.1016/S0140-6736(00)04449-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	425YY	11418142				2022-12-28	WOS:000168323300004
J	Kelley, DS; Karson, JA; Blackman, DK; Fruh-Green, GL; Butterfield, DA; Lilley, MD; Olson, EJ; Schrenk, MO; Roe, KK; Lebon, GT; Rivizzigno, P				Kelley, DS; Karson, JA; Blackman, DK; Fruh-Green, GL; Butterfield, DA; Lilley, MD; Olson, EJ; Schrenk, MO; Roe, KK; Lebon, GT; Rivizzigno, P		AT3-60 Shipboard Party	An off-axis hydrothermal vent field near the Mid-Atlantic Ridge at 30 degrees N	NATURE			English	Article							FRACTURE-ZONE; ULTRAMAFIC ROCKS; ENDEAVOR SEGMENT; SERPENTINIZATION; SYSTEMS; CH4; INTERSECTION; CHEMISTRY; HYDROGEN; OFFSETS	Evidence is growing that hydrothermal venting occurs not only along mid-ocean ridges but also on old regions of the oceanic crust away from spreading centres. Here we report the discovery of an extensive hydrothermal field at 30 degrees N near the eastern intersection of the Mid-Atlantic Ridge and the Atlantis fracture zone. The vent field-named 'Lost City'-is distinctly different from all other known sea-floor hydrothermal fields in that it is located on 1.5-Myr-old crust, nearly 15 km from the spreading axis, and may be driven by the heat of exothermic serpentinization reactions between sea water and mantle rocks. It is located on a dome-like massif and is dominated by steep-sided carbonate chimneys, rather than the sulphide structures typical of 'black smoker' hydrothermal fields. We found that vent fluids are relatively cool (40-75 degrees C) and alkaline (pH 9.0-9.8), supporting dense microbial communities that include anaerobic thermophiles. Because the geological characteristics of the Atlantis massif are similar to numerous areas of old crust along the Mid-Atlantic, Indian and Arctic ridges, these results indicate that a much larger portion of the oceanic crust may support hydrothermal activity and microbial life than previously thought.	Univ Washington, Sch Oceanog, Seattle, WA 98195 USA; Duke Univ, Div Earth & Ocean Sci, Durham, NC 27708 USA; Univ Calif San Diego, Scripps Inst Oceanog, La Jolla, CA 92093 USA; ETH Zentrum, Inst Mineral & Petrol, CH-8092 Zurich, Switzerland; Univ Washington, NOAA, Pacific Marine Environm Lab, Joint Inst Study Atmosphere & Oceans, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; Duke University; University of California System; University of California San Diego; Scripps Institution of Oceanography; Swiss Federal Institutes of Technology Domain; ETH Zurich; National Oceanic Atmospheric Admin (NOAA) - USA; University of Washington; University of Washington Seattle	Kelley, DS (corresponding author), Univ Washington, Sch Oceanog, Seattle, WA 98195 USA.		Matthew, Schrenk/AAH-5682-2020; Butterfield, David/H-3815-2016	Butterfield, David/0000-0002-1595-9279; Schrenk, Matthew/0000-0002-5623-8558				ALLEN DA, 1998, EOS T AM GEOPHYS UN, V79, P58; BARNES I, 1972, CONTRIB MINERAL PETR, V35, P263, DOI 10.1007/BF00371220; BARRIGA FJA, 1998, EOS, V79, P67; Berndt ME, 1996, GEOLOGY, V24, P351, DOI 10.1130/0091-7613(1996)024<0351:ROCDSO>2.3.CO;2; Blackman DK, 1998, J GEOPHYS RES-SOL EA, V103, P21315, DOI 10.1029/98JB01756; BONATTI E, 1980, GEOCHIM COSMOCHIM AC, V44, P1207, DOI 10.1016/0016-7037(80)90074-5; Bougault H, 1998, EARTH PLANET SC LETT, V161, P1, DOI 10.1016/S0012-821X(98)00094-6; BUTTERFIELD DA, 1994, J GEOPHYS RES-SOL EA, V99, P9561, DOI 10.1029/93JB03132; Cann JR, 1997, NATURE, V385, P329, DOI 10.1038/385329a0; Charlou JL, 2000, CHEM GEOL, V171, P49, DOI 10.1016/S0009-2541(00)00244-8; Charlou JL, 1998, GEOCHIM COSMOCHIM AC, V62, P2323, DOI 10.1016/S0016-7037(98)00138-0; COLEMAN RG, 1971, GEOL SOC AM BULL, V82, P897, DOI 10.1130/0016-7606(1971)82[897:PAGNOS]2.0.CO;2; Donval J. P., 1997, EOS T AM GEOPHYS UN, V78, P832; DOUVILLE E, 1997, EOS T AM GEOPHYS UN, V78, P832; FORNARI DJ, 1995, AM GEOPHYSICAL UNION, V91, P1; FOUQUET Y, 1977, EOS, V78, P832; Fruh-Green G. L., 1996, P ODP SCI RESULTS, V147, P255, DOI DOI 10.2973/0DP.PR0C.SR.147.016.1996; Fryer P, 1990, P OCEAN DRILLING PRO, V125, P69, DOI DOI 10.2973/ODP.PROC.IR.125.1990; German CR, 1996, EARTH PLANET SC LETT, V138, P93, DOI 10.1016/0012-821X(95)00224-Z; Gracia E, 2000, EARTH PLANET SC LETT, V177, P89, DOI 10.1016/S0012-821X(00)00034-0; HAGGERTY JA, 1987, AM GEOPHYSICAL MONOG, V47, P175; HANNINGTON MD, 1995, AM GEOPHYSICAL UNION, V91, P115; JAMES RH, 1995, GEOCHIM COSMOCHIM AC, V59, P651, DOI 10.1016/0016-7037(95)00003-I; JANECKY DR, 1986, GEOCHIM COSMOCHIM AC, V50, P1357, DOI 10.1016/0016-7037(86)90311-X; Karson J. A., 1997, P OCEAN DRILLING PRO, V153, P5; Krasnov S.G., 1995, GEOL SOC SPEC PUBL, V87, P43, DOI 10.1144/GSL.SP.1995.087.01.05; Lagabrielle Y, 1998, GEOPH MONOG SERIES, V106, P153; LILLEY MD, 1993, NATURE, V364, P45, DOI 10.1038/364045a0; MACLEOD G, 1994, ORIGINS LIFE EVOL B, V24, P19, DOI 10.1007/BF01582037; NEAL C, 1983, EARTH PLANET SC LETT, V66, P315, DOI 10.1016/0012-821X(83)90144-9; NEAL C, 1984, MINERAL MAG, V48, P237, DOI 10.1180/minmag.1984.048.347.07; Pace NR, 1997, SCIENCE, V276, P734, DOI 10.1126/science.276.5313.734; RONA PA, 1992, GEOLOGY, V20, P783, DOI 10.1130/0091-7613(1992)020<0783:HCSADA>2.3.CO;2; RUSSELL MJ, 1996, J GEOL SOC LONDON, V153, P1; SAKAI R, 1990, EARTH PLANET SC LETT, V100, P291, DOI 10.1016/0012-821X(90)90192-Z; SCHOPF JW, 1983, EARTHS EARLIEST BIOS, P1; SEEWALD JS, 1990, EARTH PLANET SC LETT, V101, P388, DOI 10.1016/0012-821X(90)90168-W; Shock EL, 1998, J GEOPHYS RES-PLANET, V103, P28513, DOI 10.1029/98JE02142; Tivey MK, 1999, J GEOPHYS RES-SOL EA, V104, P22859, DOI 10.1029/1999JB900107; VANDOVER CL, 2000, ECOLOGY DEEP SEA HYD, P63; VONDAMM KL, 1995, AM GEOPHYSICAL UNION, V91, P222; Wetzel LR, 2000, J GEOPHYS RES-SOL EA, V105, P8319, DOI 10.1029/1999JB900382	42	821	880	7	263	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 12	2001	412	6843					145	149		10.1038/35084000	http://dx.doi.org/10.1038/35084000			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	451AJ	11449263				2022-12-28	WOS:000169778700041
J	O'Beirne, JP; Cairns, SR				O'Beirne, JP; Cairns, SR			Cholestatic hepatitis in association with celecoxib	BRITISH MEDICAL JOURNAL			English	Article									Royal Sussex Cty Hosp, Ctr Digest Dis, Brighton BN2 5BE, E Sussex, England	University of Brighton	O'Beirne, JP (corresponding author), Royal Sussex Cty Hosp, Ctr Digest Dis, Brighton BN2 5BE, E Sussex, England.		O'Beirne, James/I-8251-2019; o'beirne, james p/C-5701-2009	O'Beirne, James/0000-0003-3400-2816; o'beirne, james p/0000-0001-8590-396X				Carrillo-Jimenez R, 2000, ARCH INTERN MED, V160, P553, DOI 10.1001/archinte.160.4.553; IVESON TJ, 1990, J HEPATOL, V10, P85, DOI 10.1016/0168-8278(90)90077-5; Maddrey W C, 2000, Am J Ther, V7, P153, DOI 10.1097/00045391-200007030-00003; MCCORMICK PA, 1999, LANCET, V352, P353; Silverstein FE, 2000, JAMA-J AM MED ASSOC, V284, P1247, DOI 10.1001/jama.284.10.1247	5	28	29	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUL 7	2001	323	7303					23	23		10.1136/bmj.323.7303.23	http://dx.doi.org/10.1136/bmj.323.7303.23			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	451WA	11440939	Green Published, Bronze			2022-12-28	WOS:000169824300020
J	Davare, MA; Avdonin, V; Hall, DD; Peden, EM; Burette, A; Weinberg, RJ; Horne, MC; Hoshi, T; Hell, JW				Davare, MA; Avdonin, V; Hall, DD; Peden, EM; Burette, A; Weinberg, RJ; Horne, MC; Hoshi, T; Hell, JW			A beta(2) adrenergic receptor signaling complex assembled with the Ca2+ channel Ca(v)1.2	SCIENCE			English	Article							DEPENDENT PROTEIN-KINASE; NEURONAL CLASS-C; CALCIUM CHANNELS; HIPPOCAMPAL-NEURONS; ADENYLYL-CYCLASE; ALPHA-1 SUBUNIT; GAMMA-SUBUNITS; ION CHANNELS; PHOSPHORYLATION; LOCALIZATION	The existence of a large number of receptors coupled to heterotrimeric guanine nucleotide binding proteins (G proteins) raises the question of how a particular receptor selectively regulates specific targets. We provide insight into this question by identifying a prototypical macromolecular signaling complex. The beta (2) adrenergic receptor was found to be directly associated with one of its ultimate effecters, the class C L-type calcium channel Ca(v)1.2. This complex also contained a C protein, an adenylyl cyclase, cyclic adenosine monophosphate-dependent protein kinase, and the counterbalancing phosphatase PP2A. Our electrophysiological recordings from hippocampal neurons demonstrate highly localized signal transduction from the receptor to the channel. The assembly of this signaling complex provides a mechanism that ensures specific and rapid signaling by a G protein-coupled receptor.	Univ Wisconsin, Dept Pharmacol, Madison, WI 53706 USA; Univ Iowa, Dept Physiol & Biophys, Iowa City, IA 52242 USA; Univ N Carolina, Dept Cell Biol & Anat, Chapel Hill, NC 27599 USA	University of Wisconsin System; University of Wisconsin Madison; University of Iowa; University of North Carolina; University of North Carolina Chapel Hill	Hell, JW (corresponding author), Univ Wisconsin, Dept Pharmacol, Madison, WI 53706 USA.		Hell, Johannes W./P-5085-2019; Hall, Duane/ACD-6815-2022; Weinberg, Richard/AAC-1898-2020	Hall, Duane/0000-0003-2228-0966; Peden, Erik/0000-0002-8436-3217; Davare, Monika/0000-0003-1802-7597; Horne, Mary/0000-0002-2799-3212	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL061645] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056900, T32GM008688] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS035563, R01NS039444] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG017502, R56AG017502] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL61645] Funding Source: Medline; NIA NIH HHS [AG00213, AG17502] Funding Source: Medline; NIGMS NIH HHS [GM56900, GM08688] Funding Source: Medline; NINDS NIH HHS [NS35563, NS39444] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BARSINAI A, 1992, EUR J BIOCHEM, V207, P703, DOI 10.1111/j.1432-1033.1992.tb17098.x; BEAN BP, 1984, NATURE, V307, P371, DOI 10.1038/307371a0; Bunemann M, 1999, J BIOL CHEM, V274, P33851, DOI 10.1074/jbc.274.48.33851; CATTERALL WA, 1995, ANNU REV BIOCHEM, V64, P493, DOI 10.1146/annurev.biochem.64.1.493; Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; Davare MA, 1999, J BIOL CHEM, V274, P30280, DOI 10.1074/jbc.274.42.30280; Davare MA, 2000, J BIOL CHEM, V275, P39710, DOI 10.1074/jbc.M005462200; DeJongh KS, 1996, BIOCHEMISTRY-US, V35, P10392, DOI 10.1021/bi953023c; Edwards SW, 2000, TRENDS PHARMACOL SCI, V21, P304, DOI 10.1016/S0165-6147(00)01513-3; Gao TY, 1997, NEURON, V19, P185, DOI 10.1016/S0896-6273(00)80358-X; Gao TY, 1997, J BIOL CHEM, V272, P19401, DOI 10.1074/jbc.272.31.19401; Gerhardstein BL, 2000, J BIOL CHEM, V275, P8556, DOI 10.1074/jbc.275.12.8556; Gray PC, 1998, CURR OPIN NEUROBIOL, V8, P330, DOI 10.1016/S0959-4388(98)80057-3; GRAY R, 1987, NATURE, V327, P620, DOI 10.1038/327620a0; HELL JW, 1993, J CELL BIOL, V123, P949, DOI 10.1083/jcb.123.4.949; Hell JW, 1996, P NATL ACAD SCI USA, V93, P3362, DOI 10.1073/pnas.93.8.3362; HELL JW, 1993, J BIOL CHEM, V268, P19451; Horne MC, 1996, IMMUNITY, V4, P145, DOI 10.1016/S1074-7613(00)80679-2; MONS N, 1995, P NATL ACAD SCI USA, V92, P8473, DOI 10.1073/pnas.92.18.8473; Porter NM, 1997, J NEUROSCI, V17, P5629; Seibold A, 1998, J BIOL CHEM, V273, P7637, DOI 10.1074/jbc.273.13.7637; STRADER CD, 1983, P NATL ACAD SCI-BIOL, V80, P1840, DOI 10.1073/pnas.80.7.1840; Taylor JM, 1996, J BIOL CHEM, V271, P3336; Valtschanoff JG, 2000, EUR J NEUROSCI, V12, P3605, DOI 10.1046/j.1460-9568.2000.00256.x; Wu GY, 2000, J BIOL CHEM, V275, P9026, DOI 10.1074/jbc.275.12.9026; Xiao RP, 1999, CIRC RES, V85, P1092; Ye CI, 2000, BIOPHYS J, V79, P2547, DOI 10.1016/S0006-3495(00)76495-2	27	414	425	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 6	2001	293	5527					98	101		10.1126/science.293.5527.98	http://dx.doi.org/10.1126/science.293.5527.98			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	451BB	11441182				2022-12-28	WOS:000169780300037
J	Brierley, EJ; Jackson, MJ; Clark, RS; Kenny, RA				Brierley, EJ; Jackson, MJ; Clark, RS; Kenny, RA			Alarming asystole	LANCET			English	Editorial Material							SLEEP		Newcastle Upon Tyne Hosp Trust, Royal Victoria Infirm, Cardiovasc Invest Unit, Care Elderly Off, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England; NE Yorkshire Healthcare NHS Trust, Scarborough Hosp, Dept Med, Scarborough YO12 6QL, England	Newcastle University - UK; Newcastle Upon Tyne Hospitals NHS Foundation Trust; Northumbria University	Brierley, EJ (corresponding author), Newcastle Upon Tyne Hosp Trust, Royal Victoria Infirm, Cardiovasc Invest Unit, Care Elderly Off, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England.			Kenny, Rose Anne/0000-0002-9336-8124				ANDERSSEN SH, 1993, ACTA PAEDIATR, V82, P913, DOI 10.1111/j.1651-2227.1993.tb12598.x; Grubb B, 1996, SYNCOPE OLDER PATIEN, P91; GUILLEMINAULT C, 1984, NEW ENGL J MED, V311, P1006, DOI 10.1056/NEJM198410183111602; NORTHCOTE RJ, 1989, BRIT HEART J, V61, P155; WELLENS HJJ, 1972, CIRCULATION, V46, P661, DOI 10.1161/01.CIR.46.4.661	5	3	3	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 30	2001	357	9274					2100	2100		10.1016/S0140-6736(00)05184-9	http://dx.doi.org/10.1016/S0140-6736(00)05184-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	447RQ	11445105				2022-12-28	WOS:000169586600015
J	McPherson, K				McPherson, K			For and against - Public health does not need to be led by doctors - For	BRITISH MEDICAL JOURNAL			English	Article									Gwent Hlth Author, Pontypool NP4 0YP, Gwent, Wales; Univ London London Sch Hyg & Trop Med, Canc & Publ Hlth Unit, London WC1E 7HT, England; Shetland Hlth Board, Lerwick ZE1 0TG, Shetland, Scotland	University of London; London School of Hygiene & Tropical Medicine	McPherson, K (corresponding author), Gwent Hlth Author, Mamhilad Pk Estate, Pontypool NP4 0YP, Gwent, Wales.							*DEP HLTH, 2000, COR HEART DIS NAT SE; *DEP HLTH, 1998, INT REP PROJ STRENGT; Department of Health, 1998, HLTH NAT POL ASS; LESSOF S, 1999, FEASIBILITY STUDY CA; Mcpherson K, 1998, J EPIDEMIOL COMMUN H, V52, P612, DOI 10.1136/jech.52.10.612; Rose G., 1992, STRATEGY PREVENTATIV; 1988, REPORT COMMITTEE INQ	7	11	13	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 30	2001	322	7302					1593	1594		10.1136/bmj.322.7302.1593	http://dx.doi.org/10.1136/bmj.322.7302.1593			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	449QT	11431305	Green Published, Green Accepted			2022-12-28	WOS:000169699200033
J	Block, JA; Sequeira, W				Block, JA; Sequeira, W			Raynaud's phenomenon	LANCET			English	Review							GENE-RELATED PEPTIDE; SERUM ENDOTHELIN-1 CONCENTRATIONS; SYSTEMIC-SCLEROSIS; DOUBLE-BLIND; ANTICENTROMERE ANTIBODY; GEOGRAPHIC-VARIATION; PHENOMENON SECONDARY; VASCULAR-RESPONSES; ORAL ILOPROST; THERAPY	Raynaud's phenomenon Is characterised by episodic vasospasm of the fingers and toes typically precipitated by exposure to cold. Mild Raynaud's is common and Is not usually a harbinger of clinically important disability; its onset, however, can be startling and uncomfortable for patients, and the well recognised association in some cases with systemic rheumatic conditions often precipitates aggressive assessments for underlying diseases, Advances in vascular physiology have shed light on the role of the endothelium as well as endothelium-independent mechanisms in the altered vasoregulation of Raynaud's. We review clinical aspects of the disorder and new insights with respect to pathophysiology, and we discuss potential new therapeutics based on the disease mechanism, such as prostacyclin analogues, serotonin antagonists, and calcitonin gene-related peptides.	Rush Presbyterian St Lukes Med Ctr, Rheumatol Sect, Rush Med Coll, Chicago, IL 60612 USA; Cook Cty Hosp, Div Rheumatol, Chicago, IL 60612 USA	Rush University; John H Stroger Junior Hospital Cook County	Block, JA (corresponding author), Rush Presbyterian St Lukes Med Ctr, Rheumatol Sect, Rush Med Coll, 1725 W harrison St, Chicago, IL 60612 USA.	jblock@rush.edu		Block, Joel/0000-0002-0330-7353				Appiah R, 1997, J INTERN MED, V241, P119, DOI 10.1046/j.1365-2796.1997.91105000.x; Belch JJF, 1996, DRUGS, V52, P682, DOI 10.2165/00003495-199652050-00006; BIONDI ML, 1988, INT J CARDIOL, V19, P335, DOI 10.1016/0167-5273(88)90238-0; Black CM, 1998, BRIT J RHEUMATOL, V37, P952; BRENNAN P, 1993, BRIT J RHEUMATOL, V32, P357; BUNKER CB, 1993, LANCET, V342, P80, DOI 10.1016/0140-6736(93)91286-U; Bunker CB, 1996, BRIT J DERMATOL, V134, P399; BUNKER CB, 1990, LANCET, V336, P1530, DOI 10.1016/0140-6736(90)93307-B; CARAMASCHI P, 1995, RHEUMATOL INT, V14, P253, DOI 10.1007/BF00262092; Chotani MA, 2000, AM J PHYSIOL-HEART C, V278, pH1075, DOI 10.1152/ajpheart.2000.278.4.H1075; COFFMAN JD, 1994, CLIN SCI, V86, P269, DOI 10.1042/cs0860269; Cutolo M, 2000, J RHEUMATOL, V27, P155; Denton CP, 2000, CLIN EXP RHEUMATOL, V18, P499; Denton CP, 1999, RHEUMATOLOGY, V38, P309, DOI 10.1093/rheumatology/38.4.309; DOLL DC, 1992, SEMIN ONCOL, V19, P580; Dziadzio M, 1999, ARTHRITIS RHEUM-US, V42, P2646, DOI 10.1002/1529-0131(199912)42:12<2646::AID-ANR21>3.0.CO;2-T; Edwards CM, 1998, CLIN SCI, V95, P249, DOI 10.1042/CS19980028; Flavahan NA, 2000, ARTHRITIS RHEUM-US, V43, P1886, DOI 10.1002/1529-0131(200008)43:8<1886::AID-ANR27>3.0.CO;2-S; Fraenkel L, 1999, ARTHRITIS RHEUM, V42, P306, DOI 10.1002/1529-0131(199902)42:2<306::AID-ANR13>3.0.CO;2-G; Freedman RR, 1999, LANCET, V354, P739, DOI 10.1016/S0140-6736(99)03557-6; Freedman RR, 1996, ARTHRITIS RHEUM, V39, P1189, DOI 10.1002/art.1780390717; FREEDMAN RR, 1995, CIRCULATION, V92, P1448, DOI 10.1161/01.CIR.92.6.1448; Gasbarrini A, 1998, DIGEST DIS SCI, V43, P1641, DOI 10.1023/A:1018842527111; Generini S, 1999, ADV EXP MED BIOL, V455, P93; GERBRACHT DD, 1985, ARTHRITIS RHEUM, V28, P87, DOI 10.1002/art.1780280114; Girard D, 1996, AUTOIMMUNITY, V24, P167, DOI 10.3109/08916939608995362; Greenstein D, 1996, ANGIOLOGY, V47, P427, DOI 10.1177/000331979604700501; GRESELE P, 1992, THROMB RES, V66, P259, DOI 10.1016/0049-3848(92)90196-H; HAHN M, 1995, BRIT J DERMATOL, V133, P704; Harel L, 2000, CLIN INFECT DIS, V30, P500, DOI 10.1086/313712; Herrick AL, 2000, CLIN EXP RHEUMATOL, V18, P349; Herrick AL, 1996, ANN RHEUM DIS, V55, P122, DOI 10.1136/ard.55.2.122; HUTTON RA, 1984, J CLIN PATHOL, V37, P182, DOI 10.1136/jcp.37.2.182; Ihata A, 2000, J RHEUMATOL, V27, P1686; JACOBS MJHM, 1991, INT J MICROCIRC, V10, P1; JAFFE IA, 1995, LANCET, V345, P1378, DOI 10.1016/S0140-6736(95)92582-1; Khan F, 1999, J RHEUMATOL, V26, P2389; Khan F, 1997, ARTHRITIS RHEUM, V40, P352, DOI 10.1002/art.1780400220; Khan F, 1999, SCOT MED J, V44, P4, DOI 10.1177/003693309904400102; KOHLI M, 1995, J RHEUMATOL, V22, P1393; Kruit WHJ, 2000, ANN ONCOL, V11, P1501, DOI 10.1023/A:1026586629166; Lakshminarayanan S, 1999, CLIN EXP RHEUMATOL, V17, P260; Landry GJ, 1996, J VASC SURG, V23, P76, DOI 10.1016/S0741-5214(05)80037-0; LAU CS, 1993, ANN RHEUM DIS, V52, P443, DOI 10.1136/ard.52.6.443; LAU CS, 1991, BRIT J RHEUMATOL, V30, P433; LAU CS, 1992, ANN RHEUM DIS, V51, P249, DOI 10.1136/ard.51.2.249; Lekakis J, 1998, AM HEART J, V136, P905, DOI 10.1016/S0002-8703(98)70137-1; Leppert J, 1997, CLIN SCI, V93, P175, DOI 10.1042/cs0930175; LERUT J, 1995, HEPATO-GASTROENTEROL, V42, P209; Levy Y, 1999, J RHEUMATOL, V26, P2383; Linden D, 1998, LANCET, V352, P878, DOI 10.1016/S0140-6736(05)60005-0; Mallia C, 1999, ADV EXP MED BIOL, V455, P517; Maricq H R, 1998, Vasc Med, V3, P109; Maricq HR, 1997, J RHEUMATOL, V24, P879; MARICQ HR, 1993, J RHEUMATOL, V20, P70; McCall TE, 1999, J HAND SURG-AM, V24A, P173; Mondelli M, 2000, RHEUMATOL INT, V19, P165, DOI 10.1007/s002960000049; Noel B, 2000, INT ARCH OCC ENV HEA, V73, P150, DOI 10.1007/s004200050021; Ohtsuka T, 2000, BRIT J DERMATOL, V142, P1013, DOI 10.1046/j.1365-2133.2000.03488.x; OKEEFFE ST, 1992, J RHEUMATOL, V19, P1415; OLSEN N, 1978, SCAND J CLIN LAB INV, V38, P761, DOI 10.3109/00365517809104884; Palesch YY, 1999, J CLIN EPIDEMIOL, V52, P321, DOI 10.1016/S0895-4356(99)00005-0; Pancera P, 1997, J INTERN MED, V242, P373, DOI 10.1046/j.1365-2796.1997.00219.x; PLANCHON B, 1994, ANGIOLOGY, V45, P677, DOI 10.1177/000331979404500802; POPE J, 2000, COCHRANE LIB; RIENTE L, 1995, CLIN EXP IMMUNOL, V102, P354; RIERA G, 1993, J RHEUMATOL, V20, P66; Rucker AT, 1999, LANCET, V354, P1670, DOI 10.1016/S0140-6736(99)04095-7; SARKOZI J, 1987, AM J MED, V83, P893, DOI 10.1016/0002-9343(87)90647-4; Seibold JR, 2000, ANN INTERN MED, V132, P871, DOI 10.7326/0003-4819-132-11-200006060-00004; Seishima M, 2000, EUR J DERMATOL, V10, P55; Smith PJW, 1998, J CARDIOVASC PHARM, V31, pS473, DOI 10.1097/00005344-199800001-00135; Smyth AE, 2000, ANN RHEUM DIS, V59, P870, DOI 10.1136/ard.59.11.870; Spencer-Green G, 1998, ARCH INTERN MED, V158, P595, DOI 10.1001/archinte.158.6.595; Susol E, 2000, ARTHRITIS RHEUM-US, V43, P1641, DOI 10.1002/1529-0131(200007)43:7<1641::AID-ANR30>3.3.CO;2-P; TEH LS, 1995, BRIT J RHEUMATOL, V34, P636; TERBORG EJ, 1994, SEMIN ARTHRITIS RHEU, V24, P40, DOI 10.1016/0049-0172(94)90098-1; TERENGHI G, 1991, J PATHOL, V164, P245, DOI 10.1002/path.1711640310; Tham S, 1997, J HAND SURG-BRIT EUR, V22B, P359, DOI 10.1016/S0266-7681(97)80402-0; Turton EPL, 1998, CARDIOVASC SURG, V6, P431, DOI 10.1016/S0967-2109(98)00054-4; Wigley FM, 1998, ARTHRITIS RHEUM-US, V41, P670, DOI 10.1002/1529-0131(199804)41:4<670::AID-ART14>3.0.CO;2-I; Wigley FM, 2000, ARCH INTERN MED, V160, P1101; Wigley FM, 1996, RHEUM DIS CLIN N AM, V22, P765, DOI 10.1016/S0889-857X(05)70300-8; ZAMORA MR, 1990, LANCET, V336, P1144, DOI 10.1016/0140-6736(90)92766-B	84	258	270	0	14	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 23	2001	357	9273					2042	2048		10.1016/S0140-6736(00)05118-7	http://dx.doi.org/10.1016/S0140-6736(00)05118-7			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	446JB	11438158				2022-12-28	WOS:000169509200034
J	Kirkham, FJ; Hewes, DKM; Prengler, M; Wade, A; Lane, R; Evans, JPM				Kirkham, FJ; Hewes, DKM; Prengler, M; Wade, A; Lane, R; Evans, JPM			Nocturnal hypoxaemia and central-nervous-system events in sickle-cell disease	LANCET			English	Article							OBSTRUCTIVE SLEEP-APNEA; CHILDREN; STROKE; ABNORMALITIES; ANEMIA; RISK; ERYTHROPOIETIN; HEMOGLOBIN; ACTIVATION; PLATELET	Background Central-nervous-system (CNS) events, including strokes, transient ischaemic attacks, and seizures are common in sickle-cell disease. Stroke can be predicted by high velocities in the internal-carotid or middle-cerebral arteries on transcranial doppler ultrasonography. We tested the hypothesis that nocturnal hypoxaemia can predict CNS events better than clinical or haematological features, or transcranial doppler sonography. Methods We screened 95 hospital-based patients with sickle-cell disease (median age 7.7 years [range 1.0-23.1]), but without previous stroke, with transcranial doppler and overnight pulse oximetry. Follow-up continued for a median of 6.01(0.11-8.54) years. Findings 19 patients had CNS events (six ischaemic and one haemorrhagic stroke, eight transient ischaemic attacks, and four seizures). Mean overnight oxygen saturation ([SaO(2)] hazard ratio 0.82 per 1% increase [95% CI 0.71-0.93]; p=0.003) and higher internat-carotid or middle-cerebral artery velocity (1.02 for every increase of 1 cm/s [1.004-1.03]; p=0.009) were independently associated with time to CNS event. After accounting for mean SaO(2), artery velocity, and haemoglobinopathy, high haemoglobin concentration was also associated with an increased risk of CNS event (1.7 per g/dL, [1.18-2.43]; p=0.004). Dips suggestive of obstructive sleep apnoea did not predict CNS events, and adenotonsillectomy seemed to have no effect, although the CI were wide and clinically important effects cannot be excluded. Interpretation Screening for, and appropriate management of, nocturnal hypoxaemia might be a safe and effective alternative to prophylactic blood transfusion for primary prevention of CNS events in sickle-cell disease.	UCL, Inst Child Hlth, Neurosci Unit, London, England; UCL, Inst Child Hlth, Paediat Epidemiol & Biostat Unit, London, England; UCL, Inst Child Hlth, Portex Unit Anaesthesia Intens Care & Resp Med, London, England; UCL, Inst Child Hlth, Dept Haematol, London, England; Great Ormond St Hosp Sick Children, London WC1N 3JH, England	University of London; University College London; University of London; University College London; University of London; University College London; University of London; University College London; University of London; University College London; Great Ormond Street Hospital for Children NHS Foundation Trust	Kirkham, FJ (corresponding author), Wolfson Ctr Magnet Technol, Mecklenburgh Sq, London WC1N 2AP, England.	F.Kirkham@ich.ucl.ac.uk	Kirkham, Fenella/C-2442-2009	Kirkham, Fenella/0000-0002-2443-7958				Adams RJ, 1997, ANN NEUROL, V42, P699, DOI 10.1002/ana.410420505; Adams RJ, 1998, NEW ENGL J MED, V339, P5, DOI 10.1056/NEJM199807023390102; Appenzeller O, 1998, ARCH NEUROL-CHICAGO, V55, P1007, DOI 10.1001/archneur.55.7.1007; Armstrong FD, 1996, PEDIATRICS, V97, P864; BALKARAN B, 1992, J PEDIATR-US, V120, P360, DOI 10.1016/S0022-3476(05)80897-2; Britton TC, 1997, J NEUROL NEUROSUR PS, V63, P808, DOI 10.1136/jnnp.63.6.808; Collett D, 1994, MODELLING SURVIVAL D; Dale GL, 1998, LANCET, V352, P566, DOI 10.1016/S0140-6736(97)11506-9; DAVIES SC, 1989, LANCET, V2, P283; Earley CJ, 1998, NEUROLOGY, V51, P169, DOI 10.1212/WNL.51.1.169; Eisensehr I, 1998, NEUROLOGY, V51, P188, DOI 10.1212/WNL.51.1.188; EMBURY SH, 1984, NEW ENGL J MED, V311, P291, DOI 10.1056/NEJM198408023110504; Gadian DG, 2000, J CHILD NEUROL, V15, P279, DOI 10.1177/088307380001500502; GILLARD JH, 1986, J NEUROL NEUROSUR PS, V49, P1025, DOI 10.1136/jnnp.49.9.1025; Inwald DP, 2000, BRIT J HAEMATOL, V111, P474, DOI 10.1046/j.1365-2141.2000.02353.x; Kinney TR, 1999, PEDIATRICS, V103, P640, DOI 10.1542/peds.103.3.640; Kirkham FJ, 2001, ANN NEUROL, V49, P477; LIU JE, 1994, J NEUROL SCI, V123, P6, DOI 10.1016/0022-510X(94)90196-1; Miller ST, 2000, NEW ENGL J MED, V342, P83, DOI 10.1056/NEJM200001133420203; Miyamoto O, 2000, NEUROLOGY, V54, P362, DOI 10.1212/WNL.54.2.362; Ohene-Frempong K, 1998, BLOOD, V91, P288; PARTINEN M, 1985, LANCET, V2, P1325; POWARS DR, 1984, BLOOD, V63, P921, DOI 10.1182/blood.V63.4.921.921; RACKOFF WR, 1993, BLOOD, V81, P3422; ROBERTSON PL, 1988, ANN NEUROL, V23, P614, DOI 10.1002/ana.410230615; ROTHMAN SM, 1986, ANN NEUROL, V20, P684, DOI 10.1002/ana.410200606; SAMUELS MP, 1992, ARCH DIS CHILD, V67, P925, DOI 10.1136/adc.67.7.925; Setty BNY, 1996, BLOOD, V88, P2311, DOI 10.1182/blood.V88.6.2311.bloodjournal8862311; Steen RG, 1999, ANN NEUROL, V45, P279, DOI 10.1002/1531-8249(199903)45:3<279::AID-ANA2>3.0.CO;2-7; Wang WC, 1998, J PEDIATR-US, V132, P994, DOI 10.1016/S0022-3476(98)70397-X	30	183	189	0	6	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 26	2001	357	9269					1656	1659		10.1016/S0140-6736(00)04821-2	http://dx.doi.org/10.1016/S0140-6736(00)04821-2			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	435UY	11425370				2022-12-28	WOS:000168901600011
J	Laporta, SA; Oakley, RH; Caron, MG				Laporta, SA; Oakley, RH; Caron, MG			Perspectives: Signal transduction - Bringing channels closer to the action!	SCIENCE			English	Editorial Material							PROTEIN		Duke Univ, Med Ctr, Howard Hughes Med Inst Labs, Dept Cell Biol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Howard Hughes Med Inst Labs, Dept Med, Durham, NC 27710 USA	Duke University; Duke University	Caron, MG (corresponding author), Duke Univ, Med Ctr, Howard Hughes Med Inst Labs, Dept Cell Biol, Durham, NC 27710 USA.							Clapham DE, 1997, ANNU REV PHARMACOL, V37, P167, DOI 10.1146/annurev.pharmtox.37.1.167; Davare MA, 2000, J BIOL CHEM, V275, P39710, DOI 10.1074/jbc.M005462200; Davare MA, 2001, SCIENCE, V293, P98, DOI 10.1126/science.293.5527.98; DeFea KA, 2000, J CELL BIOL, V148, P1267, DOI 10.1083/jcb.148.6.1267; Hall RA, 1998, NATURE, V392, P626, DOI 10.1038/33458; Liu F, 2000, NATURE, V403, P274, DOI 10.1038/35002014; Luttrell LM, 1999, SCIENCE, V283, P655, DOI 10.1126/science.283.5402.655; McDonald PH, 2000, SCIENCE, V290, P1574, DOI 10.1126/science.290.5496.1574; Ye CI, 2000, BIOPHYS J, V79, P2547, DOI 10.1016/S0006-3495(00)76495-2	9	11	15	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 6	2001	293	5527					62	63		10.1126/science.1063104	http://dx.doi.org/10.1126/science.1063104			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	451BB	11441172				2022-12-28	WOS:000169780300027
J	Murphy, EL; Collier, AC; Kalish, LA; Assmann, SF; Para, MF; Flanigan, TP; Kumar, PN; Mintz, L; Wallach, FR; Nemo, GJ				Murphy, EL; Collier, AC; Kalish, LA; Assmann, SF; Para, MF; Flanigan, TP; Kumar, PN; Mintz, L; Wallach, FR; Nemo, GJ		Viral Activation Transfusion Study	Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease	ANNALS OF INTERNAL MEDICINE			English	Article							IMMUNODEFICIENCY-VIRUS-INFECTION; PNEUMOCYSTIS-CARINII-PNEUMONIA; CYTOMEGALOVIRUS RETINITIS; COMBINATION THERAPY; PROTEASE INHIBITORS; INCREASING SURVIVAL; DECLINING MORBIDITY; AIDS PATIENTS; IMPACT; RISK	Background: Mortality and morbidity related to AIDS have decreased among HIV-infected patients taking highly active antiretroviral therapy (HAART), but previous studies may have been confounded by other changes in treatment. Objective: To assess the benefit of HAART in patients with advanced AIDS and anemia. Design: Prospective, multicenter cohort study. Setting: The Viral Activation Transfusion Study (VATS), with enrollment from August 1995 through July 1998 and follow-up through June 1999. Patients: 528 HIV-infected patients with cytomegalovirus (CMV) seropositivity or disease who were receiving a first red blood cell transfusion for anemia. Measurements: In a person-year analysis of follow-up before and after initiation of HAART, Poisson regression was used to calculate crude rate ratios and rate ratios adjusted for CD4 count, HIV RNA level, calendar period, time on study, sex, ethnicity, and injection drug use. Results: At baseline, patients had a median CD4(+) lymphocyte count of 0.015 x 10(9) cell/L, median plasma HIV RNA level of 4.8 log(10) copies/mL, and median hemoglobin concentration of 73 g/L. Use of HAART increased from 1% of active patients in January 1996 to 79% of active patients in January 1999. The crude death rate was 0.24 event/person-year among patients taking HAART and 0.88 event/person-year among those not taking HAART (rate ratio, 0.26; adjusted rate ratio, 0.38; P < 0.001 for both comparisons). Rates of non-CMV disease were 0.15 event/ person-year after HAART and 0.45 event/person-year before HAART (crude rate ratio, 0.34 [P < 0.001]; adjusted rate ratio, 0.66 [P < 0.05]). Rates of CMV disease were 0.10 event/person-year after HAART and 0.25 before HAART (crude rate ratio, 0.42 [P < 0.01]; adjusted rate ratio, 1.01 [P > 0.2]). Results were similar in patients with baseline CD4(+) lymphocyte counts less than 0.010 x 10(9) cells/L. Conclusions: The data support an independent reduction in mortality and opportunistic events attributable to HAART, even in patients with very advanced HIV disease. However, patients with CMV infection or disease may not have a reduction in new CMV events due to HAART.	Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA; Univ Washington, Seattle, WA 98104 USA; New England Res Inst, Watertown, MA 02172 USA; Ohio State Univ, Columbus, OH 43210 USA; Brown Univ, Sch Med, Miriam Hosp, Providence, RI 02906 USA; Georgetown Univ, Med Ctr, Washington, DC 20007 USA; Mt Sinai Med Ctr, New York, NY 10029 USA; NHLBI, Bethesda, MD 20892 USA	University of California System; University of California San Francisco; University of Washington; University of Washington Seattle; HealthCore, Inc; University System of Ohio; Ohio State University; Brown University; Lifespan Health Rhode Island; Miriam Hospital; Georgetown University; Icahn School of Medicine at Mount Sinai; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Murphy, EL (corresponding author), Univ Calif San Francisco, Dept Lab Med, Box 0884, San Francisco, CA 94143 USA.	murphy@itsa.ucsf.edu			NHLBI NIH HHS [N01-HB-57121] Funding Source: Medline; DIVISION OF BLOOD DISEASES AND RESOURCES [N01HB057121] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); DIVISION OF BLOOD DISEASES AND RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		[Anonymous], 1992, MMWR Recomm Rep, V41, P1; Brodt HR, 1997, AIDS, V11, P1731, DOI 10.1097/00002030-199714000-00010; Busch MP, 1996, TRANSFUSION, V36, P854, DOI 10.1046/j.1537-2995.1996.361097017169.x; BUSCH MP, 1991, TRANSFUSION, V31, P4, DOI 10.1046/j.1537-2995.1991.31191096183.x; Buskin SE, 1999, J ACQ IMMUN DEF SYND, V20, P201, DOI 10.1097/00042560-199902010-00014; Casado JL, 1999, AIDS, V13, P1497, DOI 10.1097/00002030-199908200-00009; Casado JL, 1998, J ACQ IMMUN DEF SYND, V19, P130, DOI 10.1097/00042560-199810010-00005; Clifford DB, 1999, NEUROLOGY, V52, P623, DOI 10.1212/WNL.52.3.623; Colford JM, 1997, AM J EPIDEMIOL, V146, P115, DOI 10.1093/oxfordjournals.aje.a009242; COLLIER AC, IN PRESS JAMA; COMMENGES D, 1993, STAT MED, V12, P1317, DOI 10.1002/sim.4780121404; Correll PK, 1998, MED J AUSTRALIA, V169, P469, DOI 10.5694/j.1326-5377.1998.tb123370.x; Detels R, 1998, JAMA-J AM MED ASSOC, V280, P1497, DOI 10.1001/jama.280.17.1497; Diggle PJ, 1994, ANAL LONGITUDINAL DA; FAHEY JL, 1990, NEW ENGL J MED, V322, P166, DOI 10.1056/NEJM199001183220305; Gebhardt M, 1998, AIDS, V12, P1195, DOI 10.1097/00002030-199810000-00012; Guest JL, 1999, AM J EPIDEMIOL, V149, pS20; Hogg RS, 1998, JAMA-J AM MED ASSOC, V279, P450, DOI 10.1001/jama.279.6.450; Jacobson MA, 1997, LANCET, V349, P1443, DOI 10.1016/S0140-6736(96)11431-8; Mellors JW, 1996, SCIENCE, V272, P1167, DOI 10.1126/science.272.5265.1167; Michaels SH, 1998, NEW ENGL J MED, V339, P405, DOI 10.1056/NEJM199808063390612; Mocroft A, 1998, LANCET, V352, P1725, DOI 10.1016/S0140-6736(98)03201-2; Mouton Y, 1997, AIDS, V11, pF101, DOI 10.1097/00002030-199712000-00003; Palella FJ, 1998, NEW ENGL J MED, V338, P853, DOI 10.1056/NEJM199803263381301; Pezzotti P, 1999, AIDS, V13, P249, DOI 10.1097/00002030-199902040-00013; *SAN FRANC DEP PUB, 1999, ANN AIDS SURV REP 19; SAS Institute, 1997, SAS STAT SOFTW CHANG; Sendi PP, 1999, AIDS, V13, P1115, DOI 10.1097/00002030-199906180-00016; Sendi PP, 1999, J ACQ IMMUN DEF SYND, V20, P376, DOI 10.1097/00042560-199904010-00008; Spino C, 1997, J ACQ IMMUN DEF SYND, V15, P346, DOI 10.1097/00042560-199708150-00004; Spira R, 1998, J ACQ IMMUN DEF SYND, V18, P358, DOI 10.1097/00042560-199808010-00007; Sullivan PS, 1998, BLOOD, V91, P301, DOI 10.1182/blood.V91.1.301.301_301_308; Torres RA, 1997, NEW ENGL J MED, V336, P1531, DOI 10.1056/NEJM199705223362118; Walsh JC, 1998, AIDS, V12, P613, DOI 10.1097/00002030-199806000-00010; Williams PL, 1999, AIDS, V13, P1035, DOI 10.1097/00002030-199906180-00006	35	438	467	0	15	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 3	2001	135	1					17	26		10.7326/0003-4819-135-1-200107030-00005	http://dx.doi.org/10.7326/0003-4819-135-1-200107030-00005			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	449JC	11434728				2022-12-28	WOS:000169680500003
J	Ducros, A; Denier, C; Joutel, A; Cecillon, M; Lescoat, C; Vahedi, K; Darcel, F; Vicaut, E; Bousser, M; Tournier-Lasserve, E				Ducros, A; Denier, C; Joutel, A; Cecillon, M; Lescoat, C; Vahedi, K; Darcel, F; Vicaut, E; Bousser, M; Tournier-Lasserve, E			The clinical spectrum of familial hemiplegic migraine associated with mutations in a neuronal calcium channel.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CACNA1A GENE MUTATION; DE-NOVO MUTATION; HETEROGENEITY; PREVALENCE; NYSTAGMUS; LOCUS; COMA; AURA; MAPS	Background: Familial hemiplegic migraine, an autosomal dominant disorder characterized by attacks of transient hemiparesis followed by a migraine headache, is divided into pure familial hemiplegic migraine (affecting 80 percent of families) and familial hemiplegic migraine with permanent cerebellar signs (affecting 20 percent of families). Mutations in CACNA1A, which encodes a neuronal calcium channel, are present in 50 percent of families with hemiplegic migraine, including all those with cerebellar signs. We studied the various clinical manifestations associated with mutations in CACNA1A in 28 families with hemiplegic migraine with and without cerebellar signs. Methods: CACNA1A was analyzed and nine mutations were detected in 15 of 16 probands of families affected by hemiplegic migraine and cerebellar signs, in 2 of 3 subjects with sporadic hemiplegic migraine and cerebellar signs, and in 4 of 12 probands of families affected by pure hemiplegic migraine. Genotyping of probands and relatives identified a total of 117 subjects with mutations whose clinical manifestations were assessed in detail. Results: Eighty-nine percent of the subjects with mutations had attacks of hemiplegic migraine. One third had severe attacks with coma, prolonged hemiplegia, or both, with full recovery. All nine mutations, including five newly identified ones, were missense mutations. Six mutations were associated with hemiplegic migraine and cerebellar signs, and 83 percent of the subjects with these six mutations had nystagmus, ataxia, or both. Three mutations were associated with pure hemiplegic migraine. Conclusions: Hemiplegic migraine in subjects with mutations in CACNA1A has a broad clinical spectrum. This clinical variability is partially associated with the various types of mutations. (N Engl J Med 2001;345:17-24.) Copyright (C) 2001 Massachusetts Medical Society.	Fac Med Lariboisiere, INSERM, E9921, Paris, France; Hop Lariboisiere, Dept Neurol, F-75475 Paris 10, France; Hop Lariboisiere, Genet Lab, F-75475 Paris 10, France; CHU, Dept Neurol, Rennes, France; Hop Fernand Widal, Biophys Lab, Paris, France	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; CHU Rennes; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite	Ducros, A (corresponding author), Hop Lariboisiere, Dept Neurol, 2 Rue Ambroise Pare, F-75475 Paris 10, France.	anne.ducros@lrb.ap-hop-paris.fr	Joutel, Anne/K-5601-2017; Tournier-Lasserve, Elisabeth/N-7134-2017; DUCROS, Anne/D-1899-2010	Joutel, Anne/0000-0003-3963-3860; Tournier-Lasserve, Elisabeth/0000-0002-3039-1677; DUCROS, Anne/0000-0001-5560-5013				Battistini S, 1999, NEUROLOGY, V53, P38, DOI 10.1212/WNL.53.1.38; BLAU JN, 1955, LANCET, V2, P1115; Carrera P, 1999, NEUROLOGY, V53, P26, DOI 10.1212/WNL.53.1.26; Clarke JM, 1910, BMJ-BRIT MED J, V1910, P1534; Denier C, 1999, NEUROLOGY, V52, P1816, DOI 10.1212/WNL.52.9.1816; Ducros A, 1997, ANN NEUROL, V42, P885, DOI 10.1002/ana.410420610; Ducros A, 1999, AM J HUM GENET, V64, P89, DOI 10.1086/302192; Elliott MA, 1996, ANN NEUROL, V39, P100, DOI 10.1002/ana.410390115; FITZSIMONS RB, 1985, BRAIN, V108, P555, DOI 10.1093/brain/108.3.555-a; FREEMAN GH, 1951, BIOMETRIKA, V38, P141, DOI 10.1093/biomet/38.1-2.141; Friend KL, 1999, HUM GENET, V105, P261, DOI 10.1007/s004390051099; Gardner K, 1997, NEUROLOGY, V49, P1231, DOI 10.1212/WNL.49.5.1231; Gervil M, 1999, NEUROLOGY, V53, P995, DOI 10.1212/WNL.53.5.995; Geschwind DH, 1997, NEUROLOGY, V49, P1247, DOI 10.1212/WNL.49.5.1247; Hans M, 1999, J NEUROSCI, V19, P1610; HENRY S, 1990, IEEE SOFTWARE, V7, P36, DOI 10.1109/52.50772; Hollander M., 1973, NONPARAMETRIC STAT M; JOUTEL A, 1994, AM J HUM GENET, V55, P1166; JOUTEL A, 1993, NAT GENET, V5, P40, DOI 10.1038/ng0993-40; Kraus RL, 1998, J BIOL CHEM, V273, P5586, DOI 10.1074/jbc.273.10.5586; Kraus RL, 2000, J BIOL CHEM, V275, P9239, DOI 10.1074/jbc.275.13.9239; LANCE JW, 1982, MECH MANAGEMENT HEAD; OHTA M, 1967, NEUROLOGY, V17, P813, DOI 10.1212/WNL.17.8.813; OPHOFF RA, 1994, GENOMICS, V22, P21, DOI 10.1006/geno.1994.1340; Ophoff RA, 1996, CELL, V87, P543, DOI 10.1016/S0092-8674(00)81373-2; ORITA M, 1989, P NATL ACAD SCI USA, V86, P2766, DOI 10.1073/pnas.86.8.2766; Russell MB, 1996, BRAIN, V119, P355, DOI 10.1093/brain/119.2.355; SORGE F, 1988, CEPHALALGIA, V8, P1, DOI 10.1046/j.1468-2982.1988.0801001.x; STEWART WF, 1992, JAMA-J AM MED ASSOC, V267, P64, DOI 10.1001/jama.267.1.64; Terwindt GM, 1998, NEUROLOGY, V50, P1105, DOI 10.1212/WNL.50.4.1105; Ulrich V, 1999, ANN NEUROL, V45, P242, DOI 10.1002/1531-8249(199902)45:2<242::AID-ANA15>3.0.CO;2-1; Vahedi K, 2000, NEUROLOGY, V55, P1040, DOI 10.1212/WNL.55.7.1040; WHITTY CWM, 1953, J NEUROL NEUROSUR PS, V16, P172, DOI 10.1136/jnnp.16.3.172; Yue Q, 1998, AM J MED GENET, V77, P298, DOI 10.1002/(SICI)1096-8628(19980526)77:4<298::AID-AJMG9>3.0.CO;2-J; Zhuchenko O, 1997, NAT GENET, V15, P62, DOI 10.1038/ng0197-62; ZIFKIN B, 1980, ANN NEUROL, V8, P329, DOI 10.1002/ana.410080319	36	373	387	0	21	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 1	2001	345	1					17	U5		10.1056/NEJM200107053450103	http://dx.doi.org/10.1056/NEJM200107053450103			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	449QJ	11439943				2022-12-28	WOS:000169697600003
J	Lauer, GM; Walker, BD				Lauer, GM; Walker, BD			Medical progress: Hepatitis C virus infection.	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							SINGLE-SOURCE OUTBREAK; QUALITY-OF-LIFE; INTERFERON-ALPHA; HCV-RNA; HEPATOCELLULAR-CARCINOMA; RANDOMIZED-TRIAL; NATURAL-HISTORY; RISK-FACTORS; EXPERIMENTAL TRANSMISSION; PEGINTERFERON ALPHA-2A		Massachusetts Gen Hosp E, Partners AIDS Res Ctr, Div Infect Dis, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Harvard Medical School	Walker, BD (corresponding author), Massachusetts Gen Hosp E, Partners AIDS Res Ctr, Div Infect Dis, 149 13th St, Charlestown, MA 02129 USA.	bwalker@helix.mgh.harvard.edu	Yang, Chen/G-1379-2010; Lauer, Georg/J-1467-2018	Lauer, Georg/0000-0002-9792-4271				ABE K, 1987, J INFECT DIS, V155, P1078, DOI 10.1093/infdis/155.5.1078; Agnello V, 1998, HEPATOLOGY, V28, P573, DOI 10.1002/hep.510280240; AGNELLO V, 1992, NEW ENGL J MED, V327, P1490, DOI 10.1056/NEJM199211193272104; ALTER MJ, 1992, NEW ENGL J MED, V327, P1899, DOI 10.1056/NEJM199212313272702; Alter MJ, 1999, NEW ENGL J MED, V341, P556, DOI 10.1056/NEJM199908193410802; [Anonymous], 1999, J Hepatol, V30, P956; [Anonymous], 1997, HEPATOLOGY, V26, pS2; Beld M, 2000, TRANSFUSION, V40, P575, DOI 10.1046/j.1537-2995.2000.40050575.x; Blight KJ, 2000, SCIENCE, V290, P1972, DOI 10.1126/science.290.5498.1972; Bonkovsky HL, 1999, HEPATOLOGY, V29, P264, DOI 10.1002/hep.510290124; Bronowicki JP, 1997, NEW ENGL J MED, V337, P237, DOI 10.1056/NEJM199707243370404; BUSCH MP, 1992, TRANSFUSION, V32, P420, DOI 10.1046/j.1537-2995.1992.32592327714.x; Chung RT, 1999, J MED VIROL, V58, P353, DOI 10.1002/(SICI)1096-9071(199908)58:4&lt;353::AID-JMV6&gt;3.0.CO;2-C; COLOMBO M, 1991, NEW ENGL J MED, V325, P675, DOI 10.1056/NEJM199109053251002; ConryCantilena C, 1996, NEW ENGL J MED, V334, P1691, DOI 10.1056/NEJM199606273342602; Cooper S, 1999, IMMUNITY, V10, P439, DOI 10.1016/S1074-7613(00)80044-8; COUZIGOU P, 1993, GUT, V34, pS59, DOI 10.1136/gut.34.2_Suppl.S59; CRIBIER B, 1995, AIDS, V9, P1131, DOI 10.1097/00002030-199510000-00003; DAVIS GL, 1989, NEW ENGL J MED, V321, P1501, DOI 10.1056/NEJM198911303212203; Davis GL, 1998, NEW ENGL J MED, V339, P1493, DOI 10.1056/NEJM199811193392102; DI BA, 1989, NEW ENGL J MED, V321, P1506; Enomoto N, 1996, NEW ENGL J MED, V334, P77, DOI 10.1056/NEJM199601113340203; Esteban JI, 1996, NEW ENGL J MED, V334, P555, DOI 10.1056/NEJM199602293340902; EYSTER ME, 1991, ANN INTERN MED, V115, P764, DOI 10.7326/0003-4819-115-10-764; Farci P, 1999, J INFECT DIS, V179, P1007, DOI 10.1086/314653; Farci P, 2000, SCIENCE, V288, P339, DOI 10.1126/science.288.5464.339; Farci P, 1996, NEW ENGL J MED, V335, P631, DOI 10.1056/NEJM199608293350904; FARGION S, 1992, HEPATOLOGY, V16, P1322, DOI 10.1002/hep.1840160603; Feray C, 1999, GASTROENTEROLOGY, V117, P619, DOI 10.1016/S0016-5085(99)70454-3; Foster GR, 1998, HEPATOLOGY, V27, P209, DOI 10.1002/hep.510270132; Frank C, 2000, LANCET, V355, P887, DOI 10.1016/S0140-6736(99)06527-7; Gerlach JT, 1999, GASTROENTEROLOGY, V117, P933, DOI 10.1016/S0016-5085(99)70353-7; Gruner NH, 2000, J INFECT DIS, V181, P1528, DOI 10.1086/315450; HADDAD J, 1992, LANCET, V339, P321, DOI 10.1016/0140-6736(92)91645-O; Heathcote EJ, 2000, NEW ENGL J MED, V343, P1673, DOI 10.1056/NEJM200012073432302; Heckmann JG, 1999, J NEUROL, V246, P486, DOI 10.1007/s004150050388; HERNANDEZ ME, 1992, J HEPATOL, V16, P56, DOI 10.1016/S0168-8278(05)80094-7; HOOFNAGLE JH, 1986, NEW ENGL J MED, V315, P1575, DOI 10.1056/NEJM198612183152503; Horcajada JP, 1999, ANN MED, V31, P352, DOI 10.3109/07853899908995902; IKEDA K, 1993, HEPATOLOGY, V18, P47, DOI 10.1016/0270-9139(93)90505-H; John M, 1998, AIDS, V12, P2289, DOI 10.1097/00002030-199817000-00010; Kao JH, 1996, J MED VIROL, V50, P303, DOI 10.1002/(SICI)1096-9071(199612)50:4&lt;303::AID-JMV4&gt;3.0.CO;2-C; Katsoulidou A, 1999, NEPHROL DIAL TRANSPL, V14, P1188, DOI 10.1093/ndt/14.5.1188; Keeffe EB, 1998, HEPATOLOGY, V27, P881, DOI 10.1002/hep.510270336; Kenny-Walsh E, 1999, NEW ENGL J MED, V340, P1228, DOI 10.1056/NEJM199904223401602; Kolykhalov AA, 1997, SCIENCE, V277, P570, DOI 10.1126/science.277.5325.570; Kolykhalov AA, 2000, J VIROL, V74, P2046, DOI 10.1128/JVI.74.4.2046-2051.2000; KOZIEL MJ, 1995, J CLIN INVEST, V96, P2311, DOI 10.1172/JCI118287; Landau A, 2000, AIDS, V14, P839, DOI 10.1097/00002030-200005050-00010; LAU JYN, 1995, J INFECT DIS, V171, P281, DOI 10.1093/infdis/171.2.281; Lechner F, 2000, J EXP MED, V191, P1499, DOI 10.1084/jem.191.9.1499; Legler TJ, 2000, TRANSFUSION, V40, P1192, DOI 10.1046/j.1537-2995.2000.40101192.x; Lohmann V, 1999, SCIENCE, V285, P110, DOI 10.1126/science.285.5424.110; Love RA, 1996, CELL, V87, P331, DOI 10.1016/S0092-8674(00)81350-1; Martinot-Peignoux M, 2000, HEPATOLOGY, V31, P726, DOI 10.1002/hep.510310324; Mathurin P, 1998, HEPATOLOGY, V27, P868, DOI 10.1002/hep.510270333; McHutchison JG, 1998, NEW ENGL J MED, V339, P1485, DOI 10.1056/NEJM199811193392101; MITSUI T, 1992, HEPATOLOGY, V16, P1109, DOI 10.1002/hep.1840160502; Myers RP, 2000, HEPATOLOGY, V31, P834, DOI 10.1053/he.2000.5719; Nelson DR, 2000, GASTROENTEROLOGY, V118, P655, DOI 10.1016/S0016-5085(00)70134-X; Neumann AU, 1998, SCIENCE, V282, P103, DOI 10.1126/science.282.5386.103; Niederau C, 1998, HEPATOLOGY, V28, P1687, DOI 10.1002/hep.510280632; NISHIGUCHI S, 1995, LANCET, V346, P1051, DOI 10.1016/S0140-6736(95)91739-X; OHTO H, 1994, NEW ENGL J MED, V330, P744, DOI 10.1056/NEJM199403173301103; Okuda M, 1999, HEPATOLOGY, V29, P217, DOI 10.1002/hep.510290117; Pawlotsky JM, 1999, J HEPATOL, V31, P71, DOI 10.1016/S0168-8278(99)80378-X; Pawlotsky JM, 1998, HEPATOLOGY, V27, P1700, DOI 10.1002/hep.510270632; Pileri P, 1998, SCIENCE, V282, P938, DOI 10.1126/science.282.5390.938; Pol S, 1999, J HEPATOL, V31, P1, DOI 10.1016/S0168-8278(99)80157-3; Poynard T, 1997, LANCET, V349, P825, DOI 10.1016/S0140-6736(96)07642-8; Poynard T, 1998, LANCET, V352, P1426, DOI 10.1016/S0140-6736(98)07124-4; Reichard O, 1999, J HEPATOL, V30, P783, DOI 10.1016/S0168-8278(99)80129-9; Robertson B, 1998, ARCH VIROL, V143, P2493, DOI 10.1007/s007050050479; Ross RS, 2000, NEW ENGL J MED, V343, P1851, DOI 10.1056/NEJM200012213432505; RoudotThoraval F, 1997, HEPATOLOGY, V26, P485, DOI 10.1002/hep.510260233; Sagnelli E, 1997, INFECTION, V25, P346, DOI 10.1007/BF01740815; SanchezQuijano A, 1995, EUR J CLIN MICROBIOL, V14, P949, DOI 10.1007/BF01691375; Sangiovanni A, 1998, HEPATOLOGY, V27, P853, DOI 10.1002/hep.510270330; Schreiber GB, 1996, NEW ENGL J MED, V334, P1685, DOI 10.1056/NEJM199606273342601; SEEFF LB, 1992, NEW ENGL J MED, V327, P1906, DOI 10.1056/NEJM199212313272703; Seeff LB, 2000, ANN INTERN MED, V132, P105, DOI 10.7326/0003-4819-132-2-200001180-00003; Serfaty L, 1998, HEPATOLOGY, V27, P1435, DOI 10.1002/hep.510270535; Shiffman M, 1999, GASTROENTEROLOGY, V116, pA1275; Silvestri F, 1996, BLOOD, V87, P4296, DOI 10.1182/blood.V87.10.4296.bloodjournal87104296; Soriano V, 1996, CLIN INFECT DIS, V23, P585, DOI 10.1093/clinids/23.3.585; SOTO B, 1994, J INTERN MED, V236, P515, DOI 10.1111/j.1365-2796.1994.tb00838.x; Soto B, 1997, J HEPATOL, V26, P1, DOI 10.1016/S0168-8278(97)80001-3; Takaki A, 2000, NAT MED, V6, P578, DOI 10.1038/75063; Tanei Ryoji, 1995, Journal of Dermatology (Tokyo), V22, P316; Tang SX, 1999, J VIROL, V73, P2359, DOI 10.1128/JVI.73.3.2359-2364.1999; THOMAS DL, 1993, ARCH INTERN MED, V153, P1705, DOI 10.1001/archinte.153.14.1705; Thomas DL, 1998, J INFECT DIS, V177, P1480, DOI 10.1086/515315; TSUKUMA H, 1993, NEW ENGL J MED, V328, P1797, DOI 10.1056/NEJM199306243282501; Vento S, 1998, NEW ENGL J MED, V338, P286, DOI 10.1056/NEJM199801293380503; Vrielink H, 1997, TRANSFUSION, V37, P845, DOI 10.1046/j.1537-2995.1997.37897424409.x; Wiese M, 2000, HEPATOLOGY, V32, P91, DOI 10.1053/jhep.2000.8169; Wyatt CA, 1998, J VIROL, V72, P1725, DOI 10.1128/JVI.72.3.1725-1730.1998; Wyld R, 1997, J INFECTION, V35, P163, DOI 10.1016/S0163-4453(97)91677-7; Yanagi M, 1997, P NATL ACAD SCI USA, V94, P8738, DOI 10.1073/pnas.94.16.8738; Yano M, 1996, HEPATOLOGY, V23, P1334, DOI 10.1002/hep.510230607; Zarski JP, 1998, J HEPATOL, V28, P27, DOI 10.1016/S0168-8278(98)80198-0; Zeuzem S, 2000, NEW ENGL J MED, V343, P1666, DOI 10.1056/NEJM200012073432301; Zeuzem S, 1997, HEPATOLOGY, V25, P740, DOI 10.1002/hep.510250341; Zignego AL, 1999, J HEPATOL, V31, P369, DOI 10.1016/S0168-8278(99)80239-6; ZIGNEGO AL, 1995, J MED VIROL, V47, P58, DOI 10.1002/jmv.1890470112; Zuckerman E, 1997, ANN INTERN MED, V127, P423, DOI 10.7326/0003-4819-127-6-199709150-00002	106	2194	2394	1	145	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 1	2001	345	1					41	52		10.1056/NEJM200107053450107	http://dx.doi.org/10.1056/NEJM200107053450107			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	449QJ	11439948				2022-12-28	WOS:000169697600007
J	Campbell, S; Roland, M; Wilkin, D				Campbell, S; Roland, M; Wilkin, D			Primary care groups - Improving the quality of care through clinical governance	BRITISH MEDICAL JOURNAL			English	Article									Univ Manchester, Natl Primary Care Res & Dev Ctr, Manchester M13 9PL, Lancs, England	University of Manchester	Roland, M (corresponding author), Univ Manchester, Natl Primary Care Res & Dev Ctr, Manchester M13 9PL, Lancs, England.							*SECR STAT HLTH, 1997, CM 3807; *SECR STAT HLTH, 2000, CM 48181; Wilkin D, 2001, BRIT MED J, V322, P1522, DOI 10.1136/bmj.322.7301.1522; WILKIN D, IN PRESS NATL TRACKE; WILKIN D, 2000, NATL TRACKER SURVEY	5	28	29	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 30	2001	322	7302					1580	1582		10.1136/bmj.322.7302.1580	http://dx.doi.org/10.1136/bmj.322.7302.1580			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	449QT	11431301	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000169699200029
J	Coats, TJ; Goode, A				Coats, TJ; Goode, A			Towards improving prehospital trauma care	LANCET			English	Editorial Material									Royal London Hosp, A&E Dept, London E1 1BB, England	Barts Health NHS Trust; Royal London Hospital	Coats, TJ (corresponding author), Royal London Hosp, A&E Dept, London E1 1BB, England.		Coats, Timothy/AAW-1254-2021	Coats, Timothy/0000-0003-2736-2784				BAKER SP, 1987, J TRAUMA, V27, P343, DOI 10.1097/00005373-198704000-00001; Bunn F, 2001, EFFECTIVENESS PREHOS; *DEP HLTH, 1993, HLTH NAT KEY AR HDB; Foex BA, 2001, EMERG MED J, V18, P198, DOI 10.1136/emj.18.3.198; Mock CN, 1998, J TRAUMA, V44, P804, DOI 10.1097/00005373-199805000-00011	5	15	15	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 30	2001	357	9274					2070	2070		10.1016/S0140-6736(00)05225-9	http://dx.doi.org/10.1016/S0140-6736(00)05225-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	447RQ	11445095				2022-12-28	WOS:000169586600004
J	Brandenburg, A				Brandenburg, A			Cosmology - Magnetic mysteries	SCIENCE			English	Editorial Material							FIELDS; GENERATION		NORDITA, DK-2100 Copenhagen, Denmark	Nordic Institute for Theoretical Physics	Brandenburg, A (corresponding author), NORDITA, Blegdamsvej 17, DK-2100 Copenhagen, Denmark.	brandenb@nordita.dk	Brandenburg, Axel/I-6668-2013	Brandenburg, Axel/0000-0002-7304-021X				Beck R, 1996, ANNU REV ASTRON ASTR, V34, P155, DOI 10.1146/annurev.astro.34.1.155; Birkinshaw M, 1999, PHYS REP, V310, P98; Brandenburg A, 2001, ASTROPHYS J, V550, P824, DOI 10.1086/319783; Brandenburg A, 1996, PHYS REV D, V54, P1291, DOI 10.1103/PhysRevD.54.1291; Clarke TE, 2001, ASTROPHYS J, V547, pL111, DOI 10.1086/318896; Gnedin NY, 2000, ASTROPHYS J, V539, P505, DOI 10.1086/309272; Grasso D, 2001, PHYS REP, V348, P163, DOI 10.1016/S0370-1573(00)00110-1; Roettiger K, 1999, ASTROPHYS J, V518, P594, DOI 10.1086/307298; SUBRAMANIAN K, 1994, MON NOT R ASTRON SOC, V271, pL15, DOI 10.1093/mnras/271.1.L15; Volk HJ, 2000, ASTROPHYS J, V541, P88, DOI 10.1086/309395	10	7	7	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 29	2001	292	5526					2440	2441		10.1126/science.1062407	http://dx.doi.org/10.1126/science.1062407			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	448YU	11431553				2022-12-28	WOS:000169658200025
J	Clover, BP; McHenry, CS				Clover, BP; McHenry, CS			The DNA polymerase III holoenzyme: An asymmetric dimeric replicative complex with leading and lagging strand polymerases	CELL			English	Article							ESCHERICHIA-COLI; INITIATION COMPLEX; EPSILON-SUBUNIT; GENE-PRODUCT; CLAMP LOADER; TAU-SUBUNIT; PURIFICATION; PROTEIN; GAMMA; TEMPLATE	The DNA Polymerase III holoenzyme forms initiation complexes on primed DNA in an ATP-dependent reaction. We demonstrate that the nonhydrolyzable ATP analog, ATP gammaS, supports the formation of an isolable leading strand complex that loads and replicates the lagging strand only in the presence of ATP, beta, and the single-stranded DNA binding protein. The single endogenous DnaX complex within DNA polymerase III holoenzyme assembles beta onto both the leading and lagging strand polymerases by an ordered mechanism. The dimeric replication complex disassembles in the opposite order from which it assembled. Upon ATP gammaS-induced dissociation, the leading strand polymerase is refractory to disassembly allowing cycling to occur exclusively on the lagging strand. These results establish holoenzyme as an intrinsic asymmetric dimer with distinguishable leading and lagging strand polymerases.	Univ Colorado, Hlth Sci Ctr, Dept Biochem & Mol Genet, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	McHenry, CS (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Biochem & Mol Genet, 4200 E 9th Ave, Denver, CO 80262 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035695, R01GM036255] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM35695, GM36255] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTS BM, 1982, COLD SPRING HARB SYM, V47, P655, DOI 10.1101/SQB.1983.047.01.077; BURGERS PMJ, 1982, J BIOL CHEM, V257, P1468; DALLMANN HG, 1995, J BIOL CHEM, V270, P29555, DOI 10.1074/jbc.270.49.29555; Glover BP, 2000, J BIOL CHEM, V275, P3017, DOI 10.1074/jbc.275.5.3017; Glover BP, 1998, J BIOL CHEM, V273, P23476, DOI 10.1074/jbc.273.36.23476; GRIEP MA, 1989, J BIOL CHEM, V264, P11294; HAWKER JR, 1987, J BIOL CHEM, V262, P12722; Hingorani MM, 1998, J BIOL CHEM, V273, P24550, DOI 10.1074/jbc.273.38.24550; JOHANSON KO, 1986, J BIOL CHEM, V261, P1460; JOHANSON KO, 1984, J BIOL CHEM, V259, P4589; Kelman Z, 1998, EMBO J, V17, P2436, DOI 10.1093/emboj/17.8.2436; Kim DR, 1996, J BIOL CHEM, V271, P20681, DOI 10.1074/jbc.271.34.20681; Kim S, 1996, J BIOL CHEM, V271, P21406, DOI 10.1074/jbc.271.35.21406; Kim S, 1996, J BIOL CHEM, V271, P4315; Kim SS, 1996, CELL, V84, P643, DOI 10.1016/S0092-8674(00)81039-9; KODAIRA M, 1983, MOL GEN GENET, V192, P80, DOI 10.1007/BF00327650; Kornberg A., 1992, DNA REPLICATION; LEBOWITZ JH, 1986, J BIOL CHEM, V261, P4738; Li XJ, 2000, J BIOL CHEM, V275, P34757, DOI 10.1074/jbc.M006556200; MAKI H, 1988, J BIOL CHEM, V263, P6570; MCHENRY CS, 1982, J BIOL CHEM, V257, P2657; MCHENRY CS, 1988, ANNU REV BIOCHEM, V57, P519; MCHENRY CS, 1988, BIOCHIM BIOPHYS ACTA, V951, P240, DOI 10.1016/0167-4781(88)90092-9; MINDEN JS, 1985, J BIOL CHEM, V260, P9316; MULLIN DA, 1983, MOL GEN GENET, V192, P73, DOI 10.1007/BF00327649; OGAWA T, 1980, ANNU REV BIOCHEM, V49, P421, DOI 10.1146/annurev.bi.49.070180.002225; ONRUST R, 1993, J BIOL CHEM, V268, P11766; ONRUST R, 1995, J BIOL CHEM, V270, P13366, DOI 10.1074/jbc.270.22.13366; Pritchard AE, 2000, EMBO J, V19, P6536, DOI 10.1093/emboj/19.23.6536; REEMS JA, 1994, J BIOL CHEM, V269, P33091; Schulenberg B, 1999, J BIOL CHEM, V274, P34233, DOI 10.1074/jbc.274.48.34233; SHRIMANKAR P, 1992, J BACTERIOL, V174, P7689, DOI 10.1128/JB.174.23.7689-7696.1992; SINHA NK, 1980, J BIOL CHEM, V255, P4290; Stock D, 2000, CURR OPIN STRUC BIOL, V10, P672, DOI 10.1016/S0959-440X(00)00147-0; STUDWELLVAUGHAN PS, 1991, J BIOL CHEM, V266, P19833; WICKNER S, 1976, P NATL ACAD SCI USA, V73, P3511, DOI 10.1073/pnas.73.10.3511; Yuzhakov A, 1999, CELL, V96, P153, DOI 10.1016/S0092-8674(00)80968-X; Yuzhakov A, 1996, CELL, V86, P877, DOI 10.1016/S0092-8674(00)80163-4	38	52	65	1	4	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTES AVE,, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 29	2001	105	7					925	934		10.1016/S0092-8674(01)00400-7	http://dx.doi.org/10.1016/S0092-8674(01)00400-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	449BK	11439188	Bronze			2022-12-28	WOS:000169664300012
J	Gupta, JA; Knobel, R; Samarth, N; Awschalom, DD				Gupta, JA; Knobel, R; Samarth, N; Awschalom, DD			Ultrafast manipulation of electron spin coherence	SCIENCE			English	Article							QUANTUM-WELLS; RESONANCE; DOTS; GAAS	A technique is developed with the potential for coherent all-optical control over electron spins in semiconductors on femtosecond time scales. The experiments show that optical "tipping" pulses can enact substantial rotations of electron spins through a mechanism dependent on the optical Stark effect. These rotations were measured as changes in the amplitude of spin precession after optical excitation in a transverse magnetic field and approach pi /2 radians. A prototype sequence of two tipping pulses indicates that the rotation is reversible, a result that establishes the coherent nature of the tipping process.	Univ Calif Santa Barbara, Dept Phys, Santa Barbara, CA 93106 USA; Penn State Univ, Dept Phys, University Pk, PA 16802 USA	University of California System; University of California Santa Barbara; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Awschalom, DD (corresponding author), Univ Calif Santa Barbara, Dept Phys, Santa Barbara, CA 93106 USA.		Gupta, Jay/AGK-0162-2022; Samarth, Nitin/AAV-2322-2020; Samarth, Nitin/C-4475-2014	Gupta, Jay/0000-0002-3908-7719; Samarth, Nitin/0000-0003-2599-346X; Samarth, Nitin/0000-0003-2599-346X				COHENTANNOUDJI C, 1972, PHYS REV A-GEN PHYS, V5, P968, DOI 10.1103/PhysRevA.5.968; COHENTANNOUDJI C, 1977, J PHYS B-AT MOL OPT, V10, P345, DOI 10.1088/0022-3700/10/3/005; COMBESCOT M, 1988, PHYS REV LETT, V61, P117, DOI 10.1103/PhysRevLett.61.117; Crooker SA, 1997, PHYS REV B, V56, P7574, DOI 10.1103/PhysRevB.56.7574; Gupta JA, 2001, PHYS REV B, V63, DOI 10.1103/PhysRevB.63.085303; Gupta JA, 1999, PHYS REV B, V59, P10421, DOI 10.1103/PhysRevB.59.R10421; HAHN EL, 1950, PHYS REV, V80, P580, DOI 10.1103/PhysRev.80.580; JOFFRE M, 1989, PHYS REV LETT, V62, P74, DOI 10.1103/PhysRevLett.62.74; KACHLISHVILI TZ, 1991, SOLID STATE COMMUN, V80, P283, DOI 10.1016/0038-1098(91)90024-P; Kikkawa JM, 1998, PHYS REV LETT, V80, P4313, DOI 10.1103/PhysRevLett.80.4313; Loss D, 1998, PHYS REV A, V57, P120, DOI 10.1103/PhysRevA.57.120; Ray O, 2000, APPL PHYS LETT, V76, P1167, DOI 10.1063/1.125972; Ray O, 1999, PHYS REV B, V59, P9810, DOI 10.1103/PhysRevB.59.9810; SUTER D, 1991, PHYS REV LETT, V67, P2001, DOI 10.1103/PhysRevLett.67.2001; VONLEHMEN A, 1987, PHYS REV B, V35, P6479, DOI 10.1103/PhysRevB.35.6479	15	233	238	1	57	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 29	2001	292	5526					2458	2461		10.1126/science.1061169	http://dx.doi.org/10.1126/science.1061169			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	448YU	11431559				2022-12-28	WOS:000169658200032
J	Thompson, RB; Ginzburg, VV; Matsen, MW; Balazs, AC				Thompson, RB; Ginzburg, VV; Matsen, MW; Balazs, AC			Predicting the mesophases of copolymer-nanoparticle composites	SCIENCE			English	Article							PHASES	The interactions between mesophase-forming copolymers and nanoscopic particles can lead to highly organized hybrid materials. The morphology of such composites depends not only on the characteristics of the copolymers, but also on the features of the nanoparticles. To explore this vast parameter space and predict the mesophases of the hybrids, we have developed a mean field theory for mixtures of soft, flexible chains and hard spheres. Applied to diblock-nanoparticle mixtures, the theory predicts ordered phases where particles and diblocks self-assemble into spatially periodic structures. The method can be applied to other copolymer-particle mixtures and can be used to design novel composite architectures.	Univ Pittsburgh, Dept Chem Engn, Pittsburgh, PA 15261 USA; Univ Reading, Ctr Polymer Sci, Reading RG6 6AF, Berks, England	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Reading	Balazs, AC (corresponding author), Univ Pittsburgh, Dept Chem Engn, Pittsburgh, PA 15261 USA.		Ginzburg, Valeriy/F-2882-2011; Thompson, Russell B/J-6326-2012	Thompson, Russell B/0000-0002-6571-558X; Balazs, Anna/0000-0002-5555-2692				Bohbot-Raviv Y, 2000, PHYS REV LETT, V85, P3428, DOI 10.1103/PhysRevLett.85.3428; CARNAHAN NF, 1969, J CHEM PHYS, V51, P635, DOI 10.1063/1.1672048; Drolet F, 1999, PHYS REV LETT, V83, P4317, DOI 10.1103/PhysRevLett.83.4317; Hamdoun B, 1996, J PHYS II, V6, P493, DOI 10.1051/jp2:1996106; Huh J, 2000, MACROMOLECULES, V33, P8085, DOI 10.1021/ma000708y; Lauter-Pasyuk V, 1998, PHYSICA B, V248, P243, DOI 10.1016/S0921-4526(98)00241-5; Matsen MW, 1996, MACROMOLECULES, V29, P1091, DOI 10.1021/ma951138i; Stupp SI, 1997, SCIENCE, V277, P1242, DOI 10.1126/science.277.5330.1242; TARAZONA P, 1984, MOL PHYS, V52, P81, DOI 10.1080/00268978400101071; Templin M, 1997, SCIENCE, V278, P1795, DOI 10.1126/science.278.5344.1795; VROEGE GJ, 1992, REP PROG PHYS, V55, P1241, DOI 10.1088/0034-4885/55/8/003; Zhao DY, 1998, SCIENCE, V279, P548, DOI 10.1126/science.279.5350.548	12	650	669	7	190	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 29	2001	292	5526					2469	2472		10.1126/science.1060585	http://dx.doi.org/10.1126/science.1060585			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	448YU	11431562	Green Submitted			2022-12-28	WOS:000169658200035
J	Veasy, LG				Veasy, LG			Time to take soundings in acute rheumatic fever	LANCET			English	Editorial Material							DOPPLER-ECHOCARDIOGRAPHIC FINDINGS; VALVULAR REGURGITATION; MITRAL REGURGITATION; INTERMOUNTAIN AREA; UNITED-STATES; CARDITIS; DIAGNOSIS		Univ Utah, Sch Med, Dept Pediat, Salt Lake City, UT 84113 USA	Utah System of Higher Education; University of Utah	Veasy, LG (corresponding author), Univ Utah, Sch Med, Dept Pediat, Salt Lake City, UT 84113 USA.							ABERNETHY M, 1994, AUST NZ J MED, V24, P530, DOI 10.1111/j.1445-5994.1994.tb01753.x; DAJANI AS, 1992, JAMA-J AM MED ASSOC, V268, P2069, DOI 10.1001/jama.1992.03490150121036; DASILVA CH, 1999, REV HOSP CLIN FAC ME, V54, P85; Elevli M, 1999, ACTA PAEDIATR, V88, P1074, DOI 10.1080/08035259950168117; Figueroa FE, 2001, HEART, V85, P407, DOI 10.1136/heart.85.4.407; FOLGER GM, 1992, BRIT HEART J, V67, P434; FOLGER GM, 1989, AM J CARDIOL, V63, P1278, DOI 10.1016/0002-9149(89)90192-6; Minich LD, 1997, CLIN CARDIOL, V20, P924, DOI 10.1002/clc.4960201105; MORSI MR, 1994, ALEXANDRIA J PEDIAT, V3, P341; STEINFELD L, 1986, CIRCULATION, V74, P385; VEASY LG, 1994, J PEDIATR-US, V124, P9, DOI 10.1016/S0022-3476(94)70247-0; VEASY LG, 1987, NEW ENGL J MED, V316, P421, DOI 10.1056/NEJM198702193160801; WILSON NJ, 1995, INT J CARDIOL, V50, P1, DOI 10.1016/0167-5273(95)02325-Q; YOSHIDA K, 1988, CIRCULATION, V78, P840, DOI 10.1161/01.CIR.78.4.840	14	28	28	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 23	2001	357	9273					1994	1995		10.1016/S0140-6736(00)05134-5	http://dx.doi.org/10.1016/S0140-6736(00)05134-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	446JB	11438128				2022-12-28	WOS:000169509200005
J	Di Cristo, G; Berardi, N; Cancedda, L; Pizzorusso, T; Putignano, E; Ratto, GM; Maffei, L				Di Cristo, G; Berardi, N; Cancedda, L; Pizzorusso, T; Putignano, E; Ratto, GM; Maffei, L			Requirement of ERK activation for visual cortical plasticity	SCIENCE			English	Article							CRITICAL-PERIOD; MAP KINASE; EXPERIENCE; CORTEX; PHOSPHORYLATION; NEUROTROPHINS; CASCADE	Experience-dependent plasticity in the developing visual cortex depends on electrical activity and molecular signals involved in stabilization or removal of inputs. Extracellular signal-regulated kinase 1,2 (also called p42/44 mitogen-activated protein kinase) activation in the cortex is regulated by both factors. We show that two different inhibitors of the ERK pathway suppress the induction of two forms of long-term potentiation (LTP) in rat cortical slices and that their intracortical administration to monocularly deprived rats prevents the shift in ocular dominance towards the nondeprived eye. These results demonstrate that the ERK pathway is necessary for experience-dependent plasticity and for LTP of synaptic transmission in the developing visual cortex.	CNR, Ist Neurofisiol, I-56100 Pisa, Italy; Scuola Normale Super Pisa, I-56126 Pisa, Italy; Univ Florence, Dipartimento Psicol, I-50123 Florence, Italy	Consiglio Nazionale delle Ricerche (CNR); Scuola Normale Superiore di Pisa; University of Florence	Berardi, N (corresponding author), CNR, Ist Neurofisiol, Via Moruzzi 1, I-56100 Pisa, Italy.	berardi@in.pi.cnr.it	Ratto, Gian Michele/AAX-8514-2020; Ratto, Gian Michele/AAB-8719-2021; Pizzorusso, Tommaso/D-1399-2013	Ratto, Gian Michele/0000-0001-9632-7769; Pizzorusso, Tommaso/0000-0001-5614-0668; Cancedda, Laura/0000-0003-0566-057X; Putignano, Elena/0000-0002-4313-408X	Telethon [934] Funding Source: Medline	Telethon(Fondazione Telethon)		Adams JP, 2000, J NEUROCHEM, V75, P2277, DOI 10.1046/j.1471-4159.2000.0752277.x; Atkins CM, 1998, NAT NEUROSCI, V1, P602, DOI 10.1038/2836; Bailey CH, 1997, NEURON, V18, P913, DOI 10.1016/S0896-6273(00)80331-1; Berardi N, 2000, CURR OPIN NEUROBIOL, V10, P138, DOI 10.1016/S0959-4388(99)00047-1; Berman DE, 1998, J NEUROSCI, V18, P10037; BIRCH D, 1979, VISION RES, V19, P933, DOI 10.1016/0042-6989(79)90029-4; Blum S, 1999, J NEUROSCI, V19, P3535; Davies SP, 2000, BIOCHEM J, V351, P95, DOI 10.1042/0264-6021:3510095; FAGIOLINI M, 1994, VISION RES, V34, P709, DOI 10.1016/0042-6989(94)90210-0; Fagiolini M, 2000, NATURE, V404, P183, DOI 10.1038/35004582; Glazewski S, 2000, NAT NEUROSCI, V3, P911, DOI 10.1038/78820; Grewal SS, 1999, CURR OPIN NEUROBIOL, V9, P544, DOI 10.1016/S0959-4388(99)00010-0; Hensch TK, 1998, SCIENCE, V282, P1504, DOI 10.1126/science.282.5393.1504; Huang ZJ, 1999, CELL, V98, P739, DOI 10.1016/S0092-8674(00)81509-3; Jovanovic JN, 1996, P NATL ACAD SCI USA, V93, P3679, DOI 10.1073/pnas.93.8.3679; KIRKWOOD A, 1994, J NEUROSCI, V14, P1634, DOI 10.1523/JNEUROSCI.14-03-01634.1994; KIRKWOOD A, 1995, NATURE, V375, P328, DOI 10.1038/375328a0; Lodovichi C, 2000, J NEUROSCI, V20, P2155; McAllister AK, 1999, ANNU REV NEUROSCI, V22, P295, DOI 10.1146/annurev.neuro.22.1.295; Pham TA, 1999, NEURON, V22, P63, DOI 10.1016/S0896-6273(00)80679-0; Pizzorusso T, 2000, J NEUROSCI, V20, P2809; Quinlan EM, 1999, NAT NEUROSCI, V2, P352, DOI 10.1038/7263; Schafe GE, 2000, J NEUROSCI, V20, P8177; Silva AJ, 1998, ANNU REV NEUROSCI, V21, P127, DOI 10.1146/annurev.neuro.21.1.127	24	161	164	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 22	2001	292	5525					2337	2340						4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	445KD	11423664				2022-12-28	WOS:000169455900060
J	Royer, DL; Wing, SL; Beerling, DJ; Jolley, DW; Koch, PL; Hickey, LJ; Berner, RA				Royer, DL; Wing, SL; Beerling, DJ; Jolley, DW; Koch, PL; Hickey, LJ; Berner, RA			Paleobotanical evidence for near present-day levels of atmospheric CO2 during part of the tertiary	SCIENCE			English	Article							CARBON-DIOXIDE; CLIMATE; MARINE; RECORD; END; RESPONSES; PCO(2); L.	Understanding the Link between the greenhouse gas carbon dioxide (CO2) and Earth's temperature underpins much of paleoclimatology and our predictions of future global warming. Here, we use the inverse relationship between Leaf stomatal indices and the partial pressure of CO2 in modern Ginkgo biloba and Metasequoia glyptostroboides to develop a CO2 reconstruction based on fossil Ginkgo and Metaseguoia cuticles for the middle Paleocene to early Eocene and middle Miocene. Our reconstruction indicates that CO2 remained between 300 and 450 parts per million by volume for these intervals with the exception of a single high estimate near the Paleocene/Eocene boundary. These results suggest that factors in addition to CO2 are required to explain these past intervals of global warmth.	Yale Univ, Dept Geol & Geophys, New Haven, CT 06520 USA; Smithsonian Inst, Dept Paleobiol, Washington, DC 20560 USA; Univ Sheffield, Dept Anim & Plant Sci, Sheffield S10 2TN, S Yorkshire, England; Univ Sheffield, Ctr Palynol, Sheffield S3 7HF, S Yorkshire, England; Univ Calif Santa Cruz, Dept Earth Sci, Santa Cruz, CA 95064 USA	Yale University; Smithsonian Institution; Smithsonian National Museum of Natural History; University of Sheffield; University of Sheffield; University of California System; University of California Santa Cruz	Royer, DL (corresponding author), Yale Univ, Dept Geol & Geophys, POB 208109, New Haven, CT 06520 USA.	dana.royer@yale.edu	Beerling, David J/C-2840-2009	Beerling, David J/0000-0003-1869-4314; Royer, Dana/0000-0003-0976-953X; Wing, Scott/0000-0002-2954-8905				Beerling DJ, 1998, J EXP BOT, V49, P1603, DOI 10.1093/jexbot/49.326.1603; Beerling DJ, 2000, PALAEOGEOGR PALAEOCL, V161, P395, DOI 10.1016/S0031-0182(00)00095-X; Berner RA, 2001, AM J SCI, V301, P182, DOI 10.2475/ajs.301.2.182; CHANEY RALPH W., 1951, TRANS AMER PHIL SOC, V40, P171; Crowley TJ, 2001, SCIENCE, V292, P870, DOI 10.1126/science.1061664; DICKENS GR, 1995, PALEOCEANOGRAPHY, V10, P965, DOI 10.1029/95PA02087; DICKENS GR, IN PRESS GEOPHYS MON, V124; Ekart DD, 1999, AM J SCI, V299, P805, DOI 10.2475/ajs.299.10.805; FRIEDLI H, 1986, NATURE, V324, P237, DOI 10.1038/324237a0; Huber M, 1999, J GEOPHYS RES-ATMOS, V104, P16633, DOI 10.1029/1999JD900272; KENNETT JP, 1991, NATURE, V353, P225, DOI 10.1038/353225a0; KOCH PL, 1992, NATURE, V358, P319, DOI 10.1038/358319a0; Kothavala Z, 1999, GEOPHYS RES LETT, V26, P209, DOI 10.1029/1998GL900275; Lemarchand D, 2000, NATURE, V408, P951, DOI 10.1038/35050058; Norris RD, 1999, NATURE, V401, P775, DOI 10.1038/44545; Pagani M, 1999, PALEOCEANOGRAPHY, V14, P273, DOI 10.1029/1999PA900006; Pearson PN, 2000, NATURE, V406, P695, DOI 10.1038/35021000; Petit JR, 1999, NATURE, V399, P429, DOI 10.1038/20859; Retallack GJ, 2001, NATURE, V411, P287, DOI 10.1038/35077041; Royer DL, 2001, REV PALAEOBOT PALYNO, V114, P1, DOI 10.1016/S0034-6667(00)00074-9; ROYER DL, IN PRESS EARTH SCI R; Rundgren M, 1999, HOLOCENE, V9, P509, DOI 10.1191/095968399677717287; SAVIN SM, 1975, GEOL SOC AM BULL, V86, P1499, DOI 10.1130/0016-7606(1975)86<1499:TMP>2.0.CO;2; SINHA A, 1994, GLOBAL PLANET CHANGE, V9, P297, DOI 10.1016/0921-8181(94)00010-7; Sloan LC, 1996, PALAEOGEOGR PALAEOCL, V119, P275, DOI 10.1016/0031-0182(95)00012-7; Stott LD, 1992, PALEOCEANOGRAPHY, V7, P395, DOI 10.1029/92PA01183; Tajika E, 1998, EARTH PLANET SC LETT, V160, P695, DOI 10.1016/S0012-821X(98)00121-6; THIRY M, 1998, MEM SCI TERRE, V34, P21; TRALAU H, 1968, LETHAIA, V1, P63, DOI 10.1111/j.1502-3931.1968.tb01728.x; VANDERBURGH J, 1993, SCIENCE, V260, P1788, DOI 10.1126/science.260.5115.1788; WALLMANN K, IN PRESS GEOCHIM COS; Wing S.L., 2000, WARM CLIMATES EARTH, P197; WOODWARD FI, 1987, NATURE, V327, P617, DOI 10.1038/327617a0; WOODWARD FI, 1988, J EXP BOT, V39, P1771, DOI 10.1093/jxb/39.12.1771	34	263	292	1	116	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 22	2001	292	5525					2310	2313		10.1126/science.292.5525.2310	http://dx.doi.org/10.1126/science.292.5525.2310			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	445KD	11423657				2022-12-28	WOS:000169455900052
J	Teasley, S; Wolinsky, S				Teasley, S; Wolinsky, S			Policy forum: Communication - Scientific collaborations at a distance	SCIENCE			English	Article									Univ Michigan, Sch Informat, Collab Res Elect Work, Ann Arbor, MI 48109 USA; Northwestern Univ, Dept Med, Chicago, IL 60611 USA	University of Michigan System; University of Michigan; Northwestern University	Teasley, S (corresponding author), Univ Michigan, Sch Informat, Collab Res Elect Work, Ann Arbor, MI 48109 USA.	steasley@umich.edu	Wolinsky, Steven/B-2893-2012	Wolinsky, Steven/0000-0002-9625-6697	NATIONAL CANCER INSTITUTE [P30CA079458] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA79458-03] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Finholt TA, 1997, PSYCHOL SCI, V8, P28, DOI 10.1111/j.1467-9280.1997.tb00540.x; FINHOLT TA, 2001, ANN REV INF SCI TECH, V36; HESSE BW, 1993, COMMUN ACM, V36, P90, DOI 10.1145/163381.163409; National Research Council, 1993, NAT COLL APPL INF TE; Schatz B. R., 1991, Journal of Management Information Systems, V8, P87; STAR SL, 1994, P C COMP SUPP COOP W, P253; Uncapher K., 1989, NATL COLLABORATORY R; WEINBERG AM, 1961, SCIENCE, V134, P161, DOI 10.1126/science.134.3473.161; WULF WA, 1993, SCIENCE, V261, P854, DOI 10.1126/science.8346438	9	53	56	2	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 22	2001	292	5525					2254	2255		10.1126/science.1061619	http://dx.doi.org/10.1126/science.1061619			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	445KD	11423638				2022-12-28	WOS:000169455900029
J	Hansen, B; Turrell, WR; Osterhus, S				Hansen, B; Turrell, WR; Osterhus, S			Decreasing overflow from the Nordic seas into the Atlantic Ocean through the Faroe Bank channel since 1950	NATURE			English	Article							DECADAL VARIABILITY; DEEP-WATER; OUTFLOW	The overflow of cold, dense water from the Nordic seas, across the Greenland-Scotland ridge(1) and into the Atlantic Ocean is the main source for the deep water of the North Atlantic Ocean(2). This flow also helps drive the inflow of warm, saline surface water into the Nordic seas(1). The Faroe Bank channel is the deepest path across the ridge, and the deep flow through this channel accounts for about one-third of the total overflow(1,2). Previous work has demonstrated that the overflow has become warmer and less saline(3,4) over time. Here we show, using direct measurements and historical hydrographic data, that the volume flux of the Faroe Bank channel overflow has also decreased. Estimating the volume flux conservatively, we rnd a decrease by at least 20 per cent relative to 1950. If this reduction in deep flow from the Nordic seas is not compensated by increased flow from other sources, it implies a weakened global thermohaline circulation and reduced inflow of Atlantic water to the Nordic seas.	Faroese Fisheries Lab, FO-110 Torshavn, Faroe Islands, Denmark; FRS Marine Lab, Aberdeen AB11 9DB, Scotland; Bjerknes Ctr Climate Res, N-5024 Bergen, Norway; Inst Geophys, N-5024 Bergen, Norway	Bjerknes Centre for Climate Research	Hansen, B (corresponding author), Faroese Fisheries Lab, POB 3051, FO-110 Torshavn, Faroe Islands, Denmark.		Turrell, William R/A-4185-2011	Turrell, William/0000-0002-1889-1468; Osterhus, Svein/0000-0001-9915-2685				Bacon S, 1998, NATURE, V394, P871, DOI 10.1038/29736; Blindheim J, 2000, DEEP-SEA RES PT I, V47, P655, DOI 10.1016/S0967-0637(99)00070-9; BORENAS KM, 1988, J GEOPHYS RES-OCEANS, V93, P1281, DOI 10.1029/JC093iC02p01281; CAPPELEN J, 1998, 9814 DAN MET I; CLARKE RA, 1990, DEEP-SEA RES, V37, P1385, DOI 10.1016/0198-0149(90)90135-I; Crease J., 1965, DEEP-SEA RES, V12, P143; Dickson B, 1999, NATURE, V397, P243, DOI 10.1038/16680; DICKSON RR, 1994, J GEOPHYS RES-OCEANS, V99, P12319, DOI 10.1029/94JC00530; Hansen B, 2000, PROG OCEANOGR, V45, P109, DOI 10.1016/S0079-6611(99)00052-X; HANSEN B, 1999, RIT FISKIDEILDAR, V16, P13; HURRELL JW, 1995, SCIENCE, V269, P676, DOI 10.1126/science.269.5224.676; Osterhus S, 1999, J CLIMATE, V12, P3297, DOI 10.1175/1520-0442(1999)012<3297:TAOTNS>2.0.CO;2; Osterhus S., 1999, INT WOCE NEWSLETTER, V35, P35; Rahmstorf S, 1999, CLIMATIC CHANGE, V43, P353, DOI 10.1023/A:1005474526406; Rahmstorf S, 1999, NATURE, V399, P523, DOI 10.1038/21066; SAUNDERS PM, 1990, J PHYS OCEANOGR, V20, P29, DOI 10.1175/1520-0485(1990)020<0029:COFTFB>2.0.CO;2; Turrell WR, 1999, DEEP-SEA RES PT I, V46, P1, DOI 10.1016/S0967-0637(98)00067-3; Whitehead JA, 1998, REV GEOPHYS, V36, P423, DOI 10.1029/98RG01014	18	172	179	0	71	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 21	2001	411	6840					927	930		10.1038/35082034	http://dx.doi.org/10.1038/35082034			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	444EN	11418852				2022-12-28	WOS:000169386200038
J	Blans, MJ; Vos, PE; Faber, HJ; Boers, GHJ				Blans, MJ; Vos, PE; Faber, HJ; Boers, GHJ			Coma in a young anorexic woman	LANCET			English	Editorial Material							ORNITHINE-TRANSCARBAMYLASE DEFICIENCY; ENCEPHALOPATHY		Univ Nijmegen Hosp, Dept Intens Care, NL-6500 HB Nijmegen, Netherlands; Univ Nijmegen Hosp, Dept Neurol, NL-6500 HB Nijmegen, Netherlands; Univ Nijmegen Hosp, Dept Internal Med, NL-6500 HB Nijmegen, Netherlands	Radboud University Nijmegen; Radboud University Nijmegen; Radboud University Nijmegen	Blans, MJ (corresponding author), Univ Nijmegen Hosp, Dept Intens Care, POB 9101, NL-6500 HB Nijmegen, Netherlands.		Vos, Pieter/A-6043-2012					Albrecht J, 1999, J NEUROL SCI, V170, P138, DOI 10.1016/S0022-510X(99)00169-0; BATSHAW ML, 1994, ANN NEUROL, V35, P133, DOI 10.1002/ana.410350204; PRIDMORE CL, 1995, J CHILD NEUROL, V10, P369, DOI 10.1177/088307389501000506; ROWE PC, 1986, NEW ENGL J MED, V314, P541, DOI 10.1056/NEJM198602273140903; Schwab S, 1999, J NEUROL, V246, P609, DOI 10.1007/s004150050413	5	11	11	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 16	2001	357	9272					1944	1944		10.1016/S0140-6736(00)05067-4	http://dx.doi.org/10.1016/S0140-6736(00)05067-4			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	444YZ	11425417				2022-12-28	WOS:000169431000015
J	Charatan, F				Charatan, F			Fake prescription drugs are flooding the United States	BRITISH MEDICAL JOURNAL			English	News Item																			0	6	6	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 16	2001	322	7300					1443	1443						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	444FJ	11408295				2022-12-28	WOS:000169389200011
J	Pearn, J				Pearn, J			Bioethical issues in caring for conjoined twins and their parents	LANCET			English	Article							SIAMESE TWINS		Univ Queensland, Royal Childrens Hosp, Dept Paediat & Child Hlth, Brisbane, Qld 4029, Australia	Royal Children's Hospital Brisbane; University of Queensland	Pearn, J (corresponding author), Univ Queensland, Royal Childrens Hosp, Dept Paediat & Child Hlth, Brisbane, Qld 4029, Australia.	j.pearn@uq.edv.av		Pearn, John/0000-0002-8815-2994				ANNAS GJ, 1984, AM J PUBLIC HEALTH, V74, P618, DOI 10.2105/AJPH.74.6.618; ANNAS GJ, 1987, HASTINGS CENT REP, V17, P27, DOI 10.2307/3562040; CAZENEUVE C, 1995, ARCH PEDIATRIE, V2, P452, DOI 10.1016/0929-693X(96)81181-X; Dreger A.D., 1998, STUD HIST PHILOS S C, V29, P1; El-Gohary MA, 1998, PEDIATR SURG INT, V13, P154, DOI 10.1007/s003830050272; Emanuel EJ, 2000, JAMA-J AM MED ASSOC, V284, P2460, DOI 10.1001/jama.284.19.2460; ENGELHARDT HT, 1997, FDN BIOETHICS, P103; ENGLEHARDT HT, 1997, FDN BIOETHICS, P104; GEROULANOS S, 1993, GESNERUS, V5, P179; HALLETT GL, 1995, GREATER GOOD CASE PR, P1; HOOSE B, 1999, DIALOGUE AUSTR   NOV, P17; HOOSE B, 1987, PROPORTIONALISM AM D, P1; Janec M, 1989, Rozhl Chir, V68, P616; MacKenzie D, 2000, NEW SCI, V168, P18; METNEKI J, 1989, ACTA GENET MED GEMEL, V38, P285, DOI 10.1017/S0001566000002695; MILLER K, 1996, LIFE, V19, P44; Nazer J, 1999, REV MED CHILE, V127, P158; Pearn J, 1997, BRIT MED J, V314, P1099, DOI 10.1136/bmj.314.7087.1099; Pearn J, 2000, MIL MED, V165, P351, DOI 10.1093/milmed/165.5.351; PEARN JH, 1973, J MED GENET, V10, P129, DOI 10.1136/jmg.10.2.129; PEARN JH, 1979, COUNSELING GENETICS, P223; POENARU D, 1994, J PEDIATR SURG, V29, P1236, DOI 10.1016/0022-3468(94)90811-7; Raffensperger J, 1997, PEDIATR SURG INT, V12, P249, DOI 10.1007/s003830050124; Rollan Villamarin V, 1991, Cir Pediatr, V4, P112; Sheldon Sally, 1997, Med Law Rev, V5, P149; Tanaka H, 1991, Rinsho Shinkeigaku, V31, P266; Tong S, 1997, LANCET, V349, P843, DOI 10.1016/S0140-6736(96)10003-9; WESTERGAARD T, 1997, BRIT MED J, V34, P775; WILKEY I, 1982, MED SCI LAW, V22, P31, DOI 10.1177/002580248202200105	29	16	17	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 16	2001	357	9272					1968	1971		10.1016/S0140-6736(00)05070-4	http://dx.doi.org/10.1016/S0140-6736(00)05070-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	444YZ	11425439				2022-12-28	WOS:000169431000036
J	Baur, JA; Zou, Y; Shay, JW; Wright, WE				Baur, JA; Zou, Y; Shay, JW; Wright, WE			Telomere position effect in human cells	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; HISTONE DEACETYLASE; CELLULAR SENESCENCE; EXPRESSION; GENE; FIBROBLASTS; REPRESSION; SEQUENCE; RB	In yeast, telomere position effect (TPE) results in the reversible silencing of genes near telomeres. Here we demonstrate the presence of TPE in human cells. HeLa clones containing a luciferase reporter adjacent to a newly formed telomere express 10 times less luciferase than do control clones generated by random integration. Luciferase expression is restored by trichostatin A, a histone deacetylase inhibitor. Overexpression of a human telomerase reverse transcriptase complementary DNA results in telomere elongation and an additional 2- to 10-fold decrease in expression in telomeric clones but not control clones. The dependence of TPE on telomere length provides a mechanism for the modification of gene expression throughout the replicative life-span of human cells.	Univ Texas, SW Med Ctr, Dept Cell Biol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Shay, JW (corresponding author), Univ Texas, SW Med Ctr, Dept Cell Biol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.		Baur, Joseph A/D-8163-2011; Shay, Jerry W/F-7878-2011	Baur, Joseph/0000-0001-8262-6549	NIA NIH HHS [AG07792] Funding Source: Medline	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BAUR J, UNPUB; BAYNE RAL, 1994, HUM MOL GENET, V3, P539; Bryan TM, 1997, HUM MOL GENET, V6, P921, DOI 10.1093/hmg/6.6.921; COOKE H, 1995, TELOMERES, P238; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; HANISH JP, 1994, P NATL ACAD SCI USA, V91, P8861, DOI 10.1073/pnas.91.19.8861; HARA E, 1991, BIOCHEM BIOPH RES CO, V179, P528, DOI 10.1016/0006-291X(91)91403-Y; HARLEY CB, 1991, MUTAT RES, V256, P271, DOI 10.1016/0921-8734(91)90018-7; HAYFLICK L, 1980, ANN REV GERONTOLOGY, V1, P26; Kilburn AE, 2001, MOL CELL BIOL, V21, P126, DOI 10.1128/MCB.21.1.126-135.2001; KYRION G, 1993, GENE DEV, V7, P1146, DOI 10.1101/gad.7.7a.1146; Marks PA, 2000, JNCI-J NATL CANCER I, V92, P1210, DOI 10.1093/jnci/92.15.1210; McChesney Patricia A., 2000, Molecular Cell Biology Research Communications, V3, P312, DOI 10.1006/mcbr.2000.0229; Ofir R, 1999, P NATL ACAD SCI USA, V96, P11434, DOI 10.1073/pnas.96.20.11434; RENAULD H, 1993, GENE DEV, V7, P1133, DOI 10.1101/gad.7.7a.1133; SHAY JW, 1991, EXP CELL RES, V196, P33, DOI 10.1016/0014-4827(91)90453-2; Sprung CN, 1996, NUCLEIC ACIDS RES, V24, P4336, DOI 10.1093/nar/24.21.4336; Tresini M, 1999, J CELL PHYSIOL, V179, P11, DOI 10.1002/(SICI)1097-4652(199904)179:1<11::AID-JCP2>3.3.CO;2-Z; WILEY EA, 1995, GENETICS, V139, P67; Wright WE, 1997, GENE DEV, V11, P2801, DOI 10.1101/gad.11.21.2801; WRIGHT WE, 1992, TRENDS GENET, V8, P193, DOI 10.1016/0168-9525(92)90232-S; Yamano T, 2000, MOL THER, V1, P574, DOI 10.1006/mthe.2000.0074	22	351	365	0	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 15	2001	292	5524					2075	2077		10.1126/science.1062329	http://dx.doi.org/10.1126/science.1062329			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	442KP	11408657				2022-12-28	WOS:000169284700047
J	Lohmann, JU; Hong, RL; Hobe, M; Busch, MA; Parcy, F; Simon, R; Weigel, D				Lohmann, JU; Hong, RL; Hobe, M; Busch, MA; Parcy, F; Simon, R; Weigel, D			A molecular link between stem cell regulation and floral patterning in Arabidopsis	CELL			English	Article							HOMEOTIC GENE; FLOWER DEVELOPMENT; ORGAN IDENTITY; SYNERGISTIC ACTIVATION; NEGATIVE REGULATION; ECTOPIC EXPRESSION; SHOOT MERISTEMS; LEAFY; PLANTS; TRANSCRIPTION	The homeotic gene AGAMOUS (AG) has dual roles in specifying organ fate and limiting stem cell proliferation in Arabidopsis flowers. We show that the floral identity protein LEAFY (LPI), a transcription factor expressed throughout the flower, cooperates with the homeodomain protein WUSCHEL (WUS) to activateAG in the center of flowers. WUS was previously identified because of its role in maintaining stem cell populations in both shoot and floral meristems. The unsuspected additional role of WUS in regulating floral homeotic gene expression supports the hypothesis that floral patterning uses a general meristem patterning system that was present before flowers evolved. We also show that AG represses WUS at later stages of floral development, thus creating a negative feedback loop that is required for the determinate growth of floral meristems.	Salk Inst Biol Studies, Plant Biol Lab, La Jolla, CA 92037 USA; Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA; Univ Cologne, Inst Entwicklungsbiol, D-50923 Cologne, Germany; Max Planck Inst Dev Biol, Dept Mol Biol, D-72076 Tubingen, Germany	Salk Institute; University of California System; University of California San Diego; University of Cologne; Max Planck Society	Weigel, D (corresponding author), Salk Inst Biol Studies, Plant Biol Lab, La Jolla, CA 92037 USA.		Lohmann, Jan/T-3776-2019; Parcy, François/G-9177-2011; Weigel, Detlef/AAR-3312-2021; parcy, francois/A-6031-2009; Weigel, Detlef/C-1418-2008; Weigel, Detlef/GSJ-0799-2022; Simon, Rudiger/T-6755-2018	Lohmann, Jan/0000-0003-3667-187X; Parcy, François/0000-0003-2191-500X; Weigel, Detlef/0000-0002-2114-7963; Weigel, Detlef/0000-0002-2114-7963; Simon, Rudiger/0000-0002-1317-7716	NIGMS NIH HHS [GM07240-24] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bechtold N, 1998, METH MOL B, V82, P259; Blazquez MA, 1997, DEVELOPMENT, V124, P3835; BOWMAN JL, 1991, DEVELOPMENT, V112, P1; BOWMAN JL, 1989, PLANT CELL, V1, P37, DOI 10.1105/tpc.1.1.37; Brand U, 2000, SCIENCE, V289, P617, DOI 10.1126/science.289.5479.617; Busch MA, 1999, SCIENCE, V285, P585, DOI 10.1126/science.285.5427.585; Byzova MV, 1999, GENE DEV, V13, P1002, DOI 10.1101/gad.13.8.1002; CAREY M, 1990, NATURE, V345, P361, DOI 10.1038/345361a0; CARROLL SB, 1994, SCIENCE, V265, P109, DOI 10.1126/science.7912449; CLARK SE, 1993, DEVELOPMENT, V119, P397; COEN ES, 1991, NATURE, V353, P31, DOI 10.1038/353031a0; Conner J, 2000, P NATL ACAD SCI USA, V97, P12902, DOI 10.1073/pnas.230352397; Deyholos MK, 2000, PLANT CELL, V12, P1799, DOI 10.1105/tpc.12.10.1799; DREWS GN, 1991, CELL, V65, P991, DOI 10.1016/0092-8674(91)90551-9; Fletcher LC, 1999, SCIENCE, V283, P1911, DOI 10.1126/science.283.5409.1911; GEHRING WJ, 1994, CELL, V78, P211, DOI 10.1016/0092-8674(94)90292-5; GIETZ RD, 1995, YEAST, V11, P355, DOI 10.1002/yea.320110408; GLEAVE AP, 1992, PLANT MOL BIOL, V20, P1203, DOI 10.1007/BF00028910; GOLEMIS EA, 1996, CURRENT PROTOCOLS MO; Goodrich J, 1997, NATURE, V386, P44, DOI 10.1038/386044a0; GUARENTE L, 1983, CELL, V32, P1279, DOI 10.1016/0092-8674(83)90309-4; Honma T, 2001, NATURE, V409, P525, DOI 10.1038/35054083; HUALA E, 1992, PLANT CELL, V4, P901, DOI 10.1105/tpc.4.8.901; Irish VF, 1999, DEV BIOL, V209, P211, DOI 10.1006/dbio.1999.9226; JACK T, 1994, CELL, V76, P703, DOI 10.1016/0092-8674(94)90509-6; JOFUKU KD, 1994, PLANT CELL, V6, P1211, DOI 10.1105/tpc.6.9.1211; Keys DN, 1999, SCIENCE, V283, P532, DOI 10.1126/science.283.5401.532; Laux T, 1996, DEVELOPMENT, V122, P87; Lee I, 1997, CURR BIOL, V7, P95, DOI 10.1016/S0960-9822(06)00053-4; LIN YS, 1990, NATURE, V345, P359, DOI 10.1038/345359a0; Mayer KFX, 1998, CELL, V95, P805, DOI 10.1016/S0092-8674(00)81703-1; MIZUKAMI Y, 1992, CELL, V71, P119, DOI 10.1016/0092-8674(92)90271-D; MIZUKAMI Y, 1995, PLANT MOL BIOL, V28, P767, DOI 10.1007/BF00042064; MUMBERG D, 1994, NUCLEIC ACIDS RES, V22, P5767, DOI 10.1093/nar/22.25.5767; Ng M, 2001, NAT REV GENET, V2, P186, DOI 10.1038/35056041; OLIVIERO S, 1991, P NATL ACAD SCI USA, V88, P224, DOI 10.1073/pnas.88.1.224; Parcy F, 1998, NATURE, V395, P561, DOI 10.1038/26903; Pelaz S, 2001, CURR BIOL, V11, P182, DOI 10.1016/S0960-9822(01)00024-0; SAUER F, 1995, SCIENCE, V270, P1783, DOI 10.1126/science.270.5243.1783; Schoof H, 2000, CELL, V100, P635, DOI 10.1016/S0092-8674(00)80700-X; SCHULTZ EA, 1991, PLANT CELL, V3, P771, DOI 10.1105/tpc.3.8.771; Sessions A, 1999, PLANT J, V20, P259, DOI 10.1046/j.1365-313x.1999.00594.x; Sieburth LE, 1997, PLANT CELL, V9, P355, DOI 10.1105/tpc.9.3.355; Sieburth LE, 1998, DEVELOPMENT, V125, P4303; SIEBURTH LE, 1995, PLANT CELL, V7, P1249, DOI 10.1105/tpc.7.8.1249; SMYTH DR, 1990, PLANT CELL, V2, P755, DOI 10.1105/tpc.2.8.755; Theissen G, 2000, PLANT MOL BIOL, V42, P115, DOI 10.1023/A:1006332105728; Trotochaud AE, 2000, SCIENCE, V289, P613, DOI 10.1126/science.289.5479.613; von Goethe J. W., 1790, VERSUCH METAMORPHOSE; Wagner D, 1999, SCIENCE, V285, P582, DOI 10.1126/science.285.5427.582; WEIGEL D, 1994, CELL, V78, P203, DOI 10.1016/0092-8674(94)90291-7; WEIGEL D, 1992, CELL, V69, P843, DOI 10.1016/0092-8674(92)90295-N; WEIGEL D, 1995, NATURE, V377, P495, DOI 10.1038/377495a0; YANOFSKY MF, 1990, NATURE, V346, P35, DOI 10.1038/346035a0	54	500	556	8	76	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTES AVE,, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 15	2001	105	6					793	803		10.1016/S0092-8674(01)00384-1	http://dx.doi.org/10.1016/S0092-8674(01)00384-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	444AE	11440721	Bronze, Green Published			2022-12-28	WOS:000169375100012
J	Young, D				Young, D			Leprosy and the genome - not yet a burnt-out case	LANCET			English	Editorial Material									Univ London Imperial Coll Sci Technol & Med, Ctr Mol Microbiol & Infect, London SW7 2AZ, England	Imperial College London	Young, D (corresponding author), Univ London Imperial Coll Sci Technol & Med, Ctr Mol Microbiol & Infect, London SW7 2AZ, England.							Cole ST, 2001, NATURE, V409, P1007, DOI 10.1038/35059006; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; Ng V, 2000, CELL, V103, P511, DOI 10.1016/S0092-8674(00)00142-2; Perna NT, 2001, NATURE, V409, P529, DOI 10.1038/35054089; Siddiqui MR, 2001, NAT GENET, V27, P439, DOI 10.1038/86958; van Soolingen D, 2001, J INTERN MED, V249, P1, DOI 10.1046/j.1365-2796.2001.00772.x; *WHO, 2000, GLOB TUB CONTR; *WHO, 2000, WKLY EPIDEMIOL REC, V75, P226	8	5	5	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 26	2001	357	9269					1639	1640		10.1016/S0140-6736(00)04861-3	http://dx.doi.org/10.1016/S0140-6736(00)04861-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	435UY	11425365				2022-12-28	WOS:000168901600006
J	Melnick, GJ; Neufeld, DA; Ford, KES; Hollenbach, DJ; Ashby, MLN				Melnick, GJ; Neufeld, DA; Ford, KES; Hollenbach, DJ; Ashby, MLN			Discovery of water vapour around IRC+10216 as evidence for comets orbiting another star	NATURE			English	Article							WAVE-ASTRONOMY-SATELLITE; SUBMILLIMETER; MILLIMETER; MOLECULES; SPECTRUM; LINES; HCN	Since 1995, planets with masses comparable to that of Jupiter have been discovered around approximately 60 stars(1). These planets have not been seen directly, but their presence has been inferred from the small reflex motions that they gravitationally induce on the star they orbit; these motions result in small periodic wavelength shifts in the stellar spectrum. The presence of analogues of the smaller bodies in our Solar System cannot, however, be determined using this technique, because the induced reflex motions are too small-so an alternative approach is needed. Here we report the observation of circumstellar water vapour around the ageing carbon star IRC+10216; water is not expected in measurable quantities around such a star. The only plausible explanation for this water is that the recent evolution of IRC+10216, which has been accompanied by a prodigious increase in its luminosity, is causing the vaporization of a collection of orbiting icy bodies-a process considered in an earlier theoretical study(2).	Harvard Smithsonian Ctr Astrophys, Cambridge, MA 02138 USA; Johns Hopkins Univ, Dept Phys & Astron, Baltimore, MD 21218 USA; NASA, Ames Res Ctr, Moffett Field, CA 94035 USA	Harvard University; Smithsonian Astrophysical Observatory; Smithsonian Institution; Johns Hopkins University; National Aeronautics & Space Administration (NASA); NASA Ames Research Center	Melnick, GJ (corresponding author), Harvard Smithsonian Ctr Astrophys, 60 Garden St, Cambridge, MA 02138 USA.							Ashby MLN, 2000, ASTROPHYS J, V539, pL115, DOI 10.1086/312842; Cernicharo J, 1999, ASTROPHYS J, V526, pL41, DOI 10.1086/312360; Cernicharo J, 1996, ASTRON ASTROPHYS, V315, pL201; DELUCIA FC, 1977, J CHEM PHYS, V67, P4262, DOI 10.1063/1.435363; Glassgold AE, 1996, ANNU REV ASTRON ASTR, V34, P241, DOI 10.1146/annurev.astro.34.1.241; Herpin F, 2000, ASTROPHYS J, V530, pL129, DOI 10.1086/312507; Hogerheijde MR, 2000, ASTRON ASTROPHYS, V362, P697; Jewitt D. C., 2000, Protostars and planets 4, P1201; Marcy GW, 2000, PUBL ASTRON SOC PAC, V112, P137, DOI 10.1086/316516; Melnick GJ, 2000, ASTROPHYS J, V539, pL77, DOI 10.1086/312856; Millar TJ, 2000, MON NOT R ASTRON SOC, V316, P195, DOI 10.1046/j.1365-8711.2000.03560.x; Neufeld DA, 1999, ASTROPHYS J, V517, pL147, DOI 10.1086/312036; Pickett HM, 1998, J QUANT SPECTROSC RA, V60, P883, DOI 10.1016/S0022-4073(98)00091-0; Skinner CJ, 1999, MON NOT R ASTRON SOC, V302, P293, DOI 10.1046/j.1365-8711.1999.02113.x; STERN SA, 1990, NATURE, V345, P305, DOI 10.1038/345305a0; Willacy K, 1998, ASTRON ASTROPHYS, V330, P676; WILLIAMS PG, 1992, ASTRON ASTROPHYS, V266, P365; WOOLF NJ, 1964, ASTROPHYS J, V140, P833, DOI 10.1086/147989	18	109	110	0	4	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 12	2001	412	6843					160	163		10.1038/35084024	http://dx.doi.org/10.1038/35084024			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	451AJ	11449266				2022-12-28	WOS:000169778700044
J	Tsuda, A; Osuka, A				Tsuda, A; Osuka, A			Fully conjugated porphyrin tapes with electronic absorption bands that reach into infrared	SCIENCE			English	Article							MOLECULAR WIRES; DIPORPHYRINS; OXIDATION	Scandium(III)-catalyzed oxidation of meso-meso-linked zinc(II)-porphyrin arrays (up to dodecamers) with 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) led to efficient formation of triply meso-meso-, beta-beta-, and beta-beta -linked zinc(II)-oligoiporphyrins with 62 to 91% yields, These fused tape-shaped porphyrin arrays display extremely red-shifted absorption bands that reflect extensively pi -conjugated electronic systems and a low excitation gap. The lowest electronic absorption bands become increasingly intensified and red-shifted upon the increase in the number of porphyrins and eventually reach a peak electronic excitation for the dodecamer at similar to 3500 wavenumber. The one-electron oxidation potentials also decreased progressively upon the,increase in the number of porphyrins. These properties in Long and rigid molecular shapes suggest their potential use as molecular wires.	Kyoto Univ, Grad Sch Sci, Dept Chem, Sakyo Ku, Kyoto 6068502, Japan	Kyoto University	Osuka, A (corresponding author), Kyoto Univ, Grad Sch Sci, Dept Chem, Sakyo Ku, Kyoto 6068502, Japan.		Tsuda, Akihiko/Q-2996-2018; Osuka, Atsuhiro/C-7670-2011	Tsuda, Akihiko/0000-0002-9232-1455; Osuka, Atsuhiro/0000-0001-8697-8488				Anderson HL, 1999, CHEM COMMUN, P2323, DOI 10.1039/a904209a; Aratani N, 2000, ANGEW CHEM INT EDIT, V39, P1458, DOI 10.1002/(SICI)1521-3773(20000417)39:8<1458::AID-ANIE1458>3.0.CO;2-E; ARNOLD DP, 1993, J AM CHEM SOC, V115, P12197, DOI 10.1021/ja00078a081; BILSEL O, 1992, J AM CHEM SOC, V114, P6528, DOI 10.1021/ja00042a037; Chen J, 1999, SCIENCE, V286, P1550, DOI 10.1126/science.286.5444.1550; Clar E, 1936, BER DTSCH CHEM GES, V69, P607, DOI 10.1002/cber.19360690327; CROSSLEY MJ, 1991, J CHEM SOC CHEM COMM, P1569, DOI 10.1039/c39910001569; GOUTERMAN M, 1961, J MOL SPECTROSC, V6, P138, DOI 10.1016/0022-2852(61)90236-3; Graca M, 1999, CHEM COMMUN, P1771; KUHN H, 1949, J CHEM PHYS, V17, P1198, DOI 10.1063/1.1747143; LIN VSY, 1994, SCIENCE, V264, P1105, DOI 10.1126/science.8178169; Martin RE, 1999, ANGEW CHEM INT EDIT, V38, P1350, DOI 10.1002/(SICI)1521-3773(19990517)38:10<1350::AID-ANIE1350>3.0.CO;2-6; Stegeman G., 1995, NONLINEAR OPTICAL MA, P285; TAKAGI A, UNPUB; Tolbert LM, 1997, J AM CHEM SOC, V119, P3253, DOI 10.1021/ja9626953; Tsuda A, 2000, ANGEW CHEM INT EDIT, V39, P2549, DOI 10.1002/1521-3773(20000717)39:14<2549::AID-ANIE2549>3.0.CO;2-A; Tsuda A, 2000, ANGEW CHEM INT EDIT, V39, P558, DOI 10.1002/(SICI)1521-3773(20000204)39:3<558::AID-ANIE558>3.0.CO;2-G	17	784	803	6	186	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 6	2001	293	5527					79	82		10.1126/science.1059552	http://dx.doi.org/10.1126/science.1059552			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	451BB	11441176				2022-12-28	WOS:000169780300031
J	Baird, AE; Dambrosia, J; Janket, SJ; Eichbaum, Q; Chaves, C; Silver, B; Barber, PA; Parsons, M; Darby, D; Davis, S; Caplan, LR; Edelman, RE; Warach, S				Baird, AE; Dambrosia, J; Janket, SJ; Eichbaum, Q; Chaves, C; Silver, B; Barber, PA; Parsons, M; Darby, D; Davis, S; Caplan, LR; Edelman, RE; Warach, S			A three-item scale for the early prediction of stroke recovery	LANCET			English	Article							ISCHEMIC STROKE; CEREBRAL INFARCTION; SCORE; PROGNOSIS; TRIAL	Background Accurate assessment of prognosis in the first hours of stroke is desirable for best patient management. We aimed to assess whether the extent of ischaemic brain injury on magnetic resonance diffusion-weighted imaging (MR DWI) could provide additional prognostic information to clinical factors. Methods In a three-phase study we studied 66 patients from a North American teaching hospital who had: MR DWI within 36 hours of stroke onset; the National Institutes of Health Stroke Scale (NIHSS) score measured at the time of scanning; and the Barthel Index measured no later than 3 months after stroke. We used logistic regression to derive a predictive model for good recovery. This logistic regression model was applied to an independent series of 63 patients from an Australian teaching hospital, and we then developed a three-item scale for the early prediction of stroke recovery. Findings Combined measurements of the NIHSS score (p=0.01), time in hours from stroke onset to MR DWI (p=0.02), and the volume of ischaemic brain tissue on MR DWI (p=0.04) gave the best prediction of stroke recovery. The model was externally validated on the Australian sample with 0.77 sensitivity and 0.88 specificity. Three likelihood levels for stroke recovery-low (0-2), medium (3-4), and high (5-7)-were identified on the three-item scale. Interpretation The combination of clinical and MR DWI factors provided better prediction of stroke recovery than any factor alone, shortly after admission to hospital. This information was incorporated into a three-item scale for clinical use.	NINDS, Bethesda, MD 20892 USA; Vet Affairs Med Ctr, Bedford, MA USA; Harvard Univ, Sch Med, Boston, MA USA; Lahey Clin, Lexington, MA USA; London Hlth Sci Ctr, London, ON, Canada; Auckland Hosp, Auckland, New Zealand; Royal Melbourne Hosp, Melbourne, Vic, Australia; Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA; Evanston NW Healthcare, Evanston, IL USA	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); US Department of Veterans Affairs; Veterans Health Administration (VHA); Harvard University; Harvard Medical School; Lahey Hospital & Medical Center; London Health Sciences Centre; Auckland City Hospital; Royal Melbourne Hospital; Harvard University; Beth Israel Deaconess Medical Center; NorthShore University Health System	Baird, AE (corresponding author), NINDS, Bethesda, MD 20892 USA.		Parsons, Mark W./G-3750-2014; Davis, Stephen M/L-5260-2013; Warach, Steven/R-5074-2019; Davis, Stephen H/B-7344-2009	Davis, Stephen M/0000-0003-0962-2300; Janket, Sok-Ja/0000-0003-0078-3992; Barber, P Alan/0000-0003-2469-9023	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [Z01NS002975, Z01NS002652] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adams HP, 1999, NEUROLOGY, V53, P126, DOI 10.1212/WNL.53.1.126; ALLEN CMC, 1984, J NEUROL NEUROSUR PS, V47, P475, DOI 10.1136/jnnp.47.5.475; Baird AE, 1996, J NEUROL NEUROSUR PS, V61, P26, DOI 10.1136/jnnp.61.1.26; BAIRD AE, 1993, LANCET, V342, P236, DOI 10.1016/0140-6736(93)92322-K; BAMFORD J, 1991, LANCET, V337, P1521, DOI 10.1016/0140-6736(91)93206-O; Barber PA, 2000, LANCET, V355, P1670, DOI 10.1016/S0140-6736(00)02237-6; BROTT T, 1989, STROKE, V20, P864, DOI 10.1161/01.STR.20.7.864; CENSORI B, 1993, STROKE, V24, P532, DOI 10.1161/01.STR.24.4.532; CHAMBERS BR, 1987, NEUROLOGY, V37, P221, DOI 10.1212/WNL.37.2.221; COTE R, 1989, NEUROLOGY, V39, P683; DAVALOS A, 1990, NEUROLOGY, V40, P1865, DOI 10.1212/WNL.40.12.1865; Furlan A, 1999, JAMA-J AM MED ASSOC, V282, P2003, DOI 10.1001/jama.282.21.2003; GRANGER CV, 1979, ARCH PHYS MED REHAB, V60, P14; GRESHAM GE, 1975, NEW ENGL J MED, V293, P954, DOI 10.1056/NEJM197511062931903; Johnston KC, 2000, STROKE, V31, P448, DOI 10.1161/01.STR.31.2.448; JORGENSEN HS, 1994, LANCET, V344, P156; Lovblad KO, 1997, ANN NEUROL, V42, P164; MAHONEY F I, 1965, Md State Med J, V14, P61; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; MARQUARDSEN J, 1976, NATURAL HIST PROGNOS, P24; OXBURY JM, 1975, BRIT MED J, V3, P125, DOI 10.1136/bmj.3.5976.125; RANKIN J, 1957, Scott Med J, V2, P200; Reith J, 1996, LANCET, V347, P422, DOI 10.1016/S0140-6736(96)90008-2; van Everdingen KJ, 1998, STROKE, V29, P1783, DOI 10.1161/01.STR.29.9.1783; WARACH S, 1995, ANN NEUROL, V37, P231, DOI 10.1002/ana.410370214	25	170	174	0	7	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 30	2001	357	9274					2095	2099		10.1016/S0140-6736(00)05183-7	http://dx.doi.org/10.1016/S0140-6736(00)05183-7			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	447RQ	11445104				2022-12-28	WOS:000169586600014
J	Lilburn, TC; Kim, KS; Ostrom, NE; Byzek, KR; Leadbetter, JR; Breznak, JA				Lilburn, TC; Kim, KS; Ostrom, NE; Byzek, KR; Leadbetter, JR; Breznak, JA			Nitrogen fixation by symbiotic and free-living spirochetes	SCIENCE			English	Article							RETICULITERMES FLAVIPES; PHYLOGENETIC DIVERSITY; MICROBIAL COMMUNITY; LOWER TERMITE; GUT; GENES; ACETOGENESIS; DEPENDENCE; INHIBITION; MICROFLORA	Spirochetes from termite hindguts and freshwater sediments possessed homologs of a nitrogenase gene (nifH) and exhibited nitrogenase activity, a previously unrecognized metabolic capability in spirochetes. Fixation of 15-dinitrogen was demonstrated with termite gut Treponema ZAS-9 and free-living Spirochaeta aurantia. Homologs of nifH were also present in human oral and bovine ruminal treponemes. Results implicate spirochetes in the nitrogen nutrition of termites, whose food is typically Low in nitrogen, and in global nitrogen cycling. These results also proffer spirochetes as a Likely origin of certain nifHs observed in termite guts and other environments that were not previously attributable to known microbes.	Michigan State Univ, Ctr Microbial Ecol, E Lansing, MI 48824 USA; Michigan State Univ, Ribosomal Database Project, E Lansing, MI 48824 USA; Michigan State Univ, Dept Microbiol & Mol Genet, E Lansing, MI 48824 USA; Michigan State Univ, Dept Geol Sci, E Lansing, MI 48824 USA; CALTECH, Pasadena, CA 91125 USA	Michigan State University; Michigan State University; Michigan State University; Michigan State University; California Institute of Technology	Breznak, JA (corresponding author), Michigan State Univ, Ctr Microbial Ecol, E Lansing, MI 48824 USA.			Leadbetter, Jared/0000-0002-7033-0844				BOLLAG DM, 1991, PROTEIN METHODS, P45; Breznak JA, 2000, TERMITES: EVOLUTION, SOCIALITY, SYMBIOSES, ECOLOGY, P209; BROWN RE, 1989, ANAL BIOCHEM, V180, P136, DOI 10.1016/0003-2697(89)90101-2; Bruno WJ, 2000, MOL BIOL EVOL, V17, P189, DOI 10.1093/oxfordjournals.molbev.a026231; CANALEPAROLA E, 1992, PROKARYOTES HDB BIOL, V4, P3524; Chien YT, 2000, J BACTERIOL, V182, P3247, DOI 10.1128/JB.182.11.3247-3253.2000; Dean D.R., 1992, BIOL NITROGEN FIXATI, P763; DILWORTH MJ, 1987, NATURE, V327, P167, DOI 10.1038/327167a0; Ebert A, 1997, APPL ENVIRON MICROB, V63, P4039, DOI 10.1128/AEM.63.10.4039-4046.1997; EUTICK ML, 1978, J INSECT PHYSIOL, V24, P363, DOI 10.1016/0022-1910(78)90076-8; Felsenstein J., 1993, PHYLIP PHYLOGENY INF; GARRITY GM, 2000, BERGEYS MANUAL SYSTE, P1; GRABER JR, 2000, AM SOC MICR ABSTR, P475; GUTH JH, 1983, BIOCHEMISTRY-US, V22, P5111, DOI 10.1021/bi00291a010; Kessler PS, 1997, J BACTERIOL, V179, P541, DOI 10.1128/jb.179.2.541-543.1997; Leadbetter JR, 1999, SCIENCE, V283, P686, DOI 10.1126/science.283.5402.686; Lilburn TG, 1999, ENVIRON MICROBIOL, V1, P331; MADDEN MS, 1991, J BACTERIOL, V173, P5403, DOI 10.1128/jb.173.17.5403-5405.1991; MILLER JN, 1992, PROKARYOTES, V4, P3537; MINIGAWA M, 1985, ANAL CHEM, V56, P1859; Neidhardt FC, 1990, PHYSL BACTERIAL CELL; Noda S, 1999, APPL ENVIRON MICROB, V65, P4935; Ohkuma M, 1999, APPL ENVIRON MICROB, V65, P4926; Ohkuma M, 1996, APPL ENVIRON MICROB, V62, P2747, DOI 10.1128/AEM.62.8.2747-2752.1996; Paster BJ, 1996, APPL ENVIRON MICROB, V62, P347, DOI 10.1128/AEM.62.2.347-352.1996; Postgate J.R., 1972, METHODS MICROBIOLOGY, P343, DOI [10.1016/s0580-9517(08)70604-4, DOI 10.1016/S0580-9517(08)70604-4]; RASCHE ME, 1989, PLANT PHYSIOL, V91, P663, DOI 10.1104/pp.91.2.663; SCHULTZ JE, 1978, APPL ENVIRON MICROB, V35, P930, DOI 10.1128/AEM.35.5.930-936.1978; STANTON TB, 1980, ARCH MICROBIOL, V127, P145, DOI 10.1007/BF00428018; Strimmer K, 1996, MOL BIOL EVOL, V13, P964, DOI 10.1093/oxfordjournals.molbev.a025664; Sugimoto A, 2000, TERMITES: EVOLUTION, SOCIALITY, SYMBIOSES, ECOLOGY, P409; TAYASU I, 1994, NATURWISSENSCHAFTEN, V81, P229, DOI 10.1007/s001140050063; Tholen A, 1997, FEMS MICROBIOL ECOL, V24, P137, DOI 10.1016/S0168-6496(97)00053-6; Weinbauer MG, 1998, APPL ENVIRON MICROB, V64, P5000; Young J. P. W., 1992, BIOL NITROGEN FIXATI, V1544, P43	35	176	189	5	69	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 29	2001	292	5526					2495	2498		10.1126/science.1060281	http://dx.doi.org/10.1126/science.1060281			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	448YU	11431569				2022-12-28	WOS:000169658200043
J	Shapiro, CL; Recht, A				Shapiro, CL; Recht, A			Drug therapy - Side effects of adjuvant treatment of breast cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							BONE-MINERAL DENSITY; QUALITY-OF-LIFE; ESTROGEN REPLACEMENT THERAPY; FIRST-LINE THERAPY; 20-YEAR FOLLOW-UP; RADIATION-THERAPY; POSTMENOPAUSAL WOMEN; CONSERVATIVE SURGERY; CONTRALATERAL BREAST; PREMENOPAUSAL WOMEN		Ohio State Univ, Arthur G James Canc Hosp, Dept Hematol & Oncol, Columbus, OH 43210 USA; Ohio State Univ, Richard J Solove Res Inst, Columbus, OH 43210 USA; Beth Israel Deaconess Med Ctr, Dept Radiat Oncol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA USA	James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Shapiro, CL (corresponding author), Ohio State Univ, Arthur G James Canc Hosp, Dept Hematol & Oncol, 320 W 10th St, Columbus, OH 43210 USA.	shapiro-1@medctr.osu.edu						ABE O, 1995, NEW ENGL J MED, V333, P1444; Abe O, 1998, LANCET, V352, P930; Abe O, 1996, NEW ENGL J MED, V334, P1003; Ahsan H, 1998, ANN INTERN MED, V128, P114, DOI 10.7326/0003-4819-128-2-199801150-00007; ARBUCK SG, 1994, HEMATOL ONCOL CLIN N, V8, P121, DOI 10.1016/S0889-8588(18)30191-6; ARRIAGADA R, 1991, LANCET, V338, P535, DOI 10.1016/0140-6736(91)91100-9; Ashing-Giwa K, 1999, CANCER, V85, P418, DOI 10.1002/(SICI)1097-0142(19990115)85:2<418::AID-CNCR20>3.0.CO;2-9; ASHINGGIWA K, 1999, CANCER, V86, P732; Barton DL, 1998, J CLIN ONCOL, V16, P495, DOI 10.1200/JCO.1998.16.2.495; Berenson J., 2000, Breast Cancer Research and Treatment, V64, P32; Bines J, 1996, J CLIN ONCOL, V14, P1718, DOI 10.1200/JCO.1996.14.5.1718; BLOMQVIST C, 1992, BRIT J CANCER, V66, P1171, DOI 10.1038/bjc.1992.430; BOICE JD, 1992, NEW ENGL J MED, V326, P781, DOI 10.1056/NEJM199203193261201; BONADONNA G, 1995, JAMA-J AM MED ASSOC, V253, P542; Bonneterre J, 2000, J CLIN ONCOL, V18, P3748, DOI 10.1200/JCO.2000.18.22.3748; Bower JE, 2000, J CLIN ONCOL, V18, P743, DOI 10.1200/JCO.2000.18.4.743; Brennan MJ, 1998, CANCER, V83, P2821, DOI 10.1002/(SICI)1097-0142(19981215)83:12B+<2821::AID-CNCR33>3.0.CO;2-G; Broeckel JA, 1998, J CLIN ONCOL, V16, P1689, DOI 10.1200/JCO.1998.16.5.1689; BRYCE CJ, 1998, BREAST CANC RES TREA, V50, P284; BUZDAR AU, 1989, AM J CLIN ONCOL-CANC, V12, P123, DOI 10.1097/00000421-198904000-00007; BUZDAR AU, 1979, JAMA-J AM MED ASSOC, V242, P1509, DOI 10.1001/jama.242.14.1509; CAMORIANO JK, 1990, J CLIN ONCOL, V8, P1327, DOI 10.1200/JCO.1990.8.8.1327; Carlson RW, 1999, ONCOLOGY-NY, V13, P41; Chlebowski RT, 1999, J CLIN ONCOL, V17, P130, DOI 10.1200/JCO.1999.17.1.130; CLARK G, 2000, DIS BREAST, V2, P489; Clarke M, 1998, LANCET, V351, P1451; Cobleigh M, 1995, P AN M AM SOC CLIN, V14, P115; COBLEIGH MA, 1994, JAMA-J AM MED ASSOC, V272, P540, DOI 10.1001/jama.272.7.540; COUZI RJ, 1995, J CLIN ONCOL, V13, P2737, DOI 10.1200/JCO.1995.13.11.2737; Cummings SR, 1999, JAMA-J AM MED ASSOC, V282, P2124; Cummings SR, 1999, JAMA-J AM MED ASSOC, V281, P2189, DOI 10.1001/jama.281.23.2189; CURTIS RE, 1992, NEW ENGL J MED, V326, P1745, DOI 10.1056/NEJM199206253262605; CURTIS RE, 1989, J CLIN ONCOL, V7, P21, DOI 10.1200/JCO.1989.7.1.21; Day R, 1999, J CLIN ONCOL, V17, P2659, DOI 10.1200/JCO.1999.17.9.2659; Delmas PD, 1997, NEW ENGL J MED, V337, P1641, DOI 10.1056/NEJM199712043372301; Delmas PD, 1997, J CLIN ONCOL, V15, P955, DOI 10.1200/JCO.1997.15.3.955; DEMARKWAHNEFRIED W, 1993, J CLIN ONCOL, V11, P1418, DOI 10.1200/JCO.1993.11.7.1418; DemarkWahnefried W, 1997, AM J CLIN NUTR, V65, P1495, DOI 10.1093/ajcn/65.5.1495; Diamandidou E, 1996, J CLIN ONCOL, V14, P2722, DOI 10.1200/JCO.1996.14.10.2722; Dorval M, 1998, J CLIN ONCOL, V16, P487, DOI 10.1200/JCO.1998.16.2.487; Ewer MS, 1999, SEMIN ONCOL, V26, P96; FISHER B, 1985, J CLIN ONCOL, V3, P1640, DOI 10.1200/JCO.1985.3.12.1640; FISHER B, 1990, J CLIN ONCOL, V8, P1483, DOI 10.1200/JCO.1990.8.9.1483; Fisher B, 1999, LANCET, V353, P1993, DOI 10.1016/S0140-6736(99)05036-9; Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371; FISHER B, 1994, J NATL CANCER I, V86, P527, DOI 10.1093/jnci/86.7.527; FISHER B, 1989, NEW ENGL J MED, V320, P479, DOI 10.1056/NEJM198902233200802; FISHER B, 2000, P AN M AM SOC CLIN, V19, pA72; FRAASS BA, 1985, INT J RADIAT ONCOL, V11, P485, DOI 10.1016/0360-3016(85)90179-8; Ganz PA, 1998, RECENT RESULTS CANC, V152, P396; GELBER RD, 1992, NIH PUBLICATION, P127; GIANNI L, 1995, J CLIN ONCOL, V13, P2688, DOI 10.1200/JCO.1995.13.11.2688; Goldberg, 1996, J CLIN ONCOL, V14, P2411, DOI 10.1200/JCO.1996.14.8.2411; GOLDBERG RM, 1994, J CLIN ONCOL, V12, P155, DOI 10.1200/JCO.1994.12.1.155; Goldhirsch A, 1998, J NATL CANCER I, V90, P1601, DOI 10.1093/jnci/90.21.1601; Goodwin PJ, 1999, J CLIN ONCOL, V17, P120, DOI 10.1200/JCO.1999.17.1.120; Goodwin PJ, 1999, J CLIN ONCOL, V17, P2365, DOI 10.1200/JCO.1999.17.8.2365; Gyenes G, 1998, RADIOTHER ONCOL, V48, P185, DOI 10.1016/S0167-8140(98)00062-0; HANKEY BF, 1983, J NATL CANCER I, V70, P797; HENDERSON IC, 1998, P AN M AM SOC CLIN, V17, pA101; HERRING MK, 1986, AM J CLIN ONCOL-CANC, V9, P269, DOI 10.1097/00000421-198606000-00018; HOJRIS I, 1998, RADIOTHER ONCOL S1, V48, pS120; HOLDENER EE, 1984, RECENT RESULTS CANC, V96, P188; Hortobagyi GN, 1996, NEW ENGL J MED, V335, P1785, DOI 10.1056/NEJM199612123352401; Jonat W., 2000, Breast Cancer Research and Treatment, V64, P29; JONES AL, 1992, BRIT J CANCER, V66, P744, DOI 10.1038/bjc.1992.350; JORDAN VC, 1987, CANCER RES, V47, P4517; KANNEL WB, 1976, ANN INTERN MED, V85, P447, DOI 10.7326/0003-4819-85-4-447; Kristensen B, 1996, BREAST CANCER RES TR, V39, P321, DOI 10.1007/BF01806160; LINGOS TI, 1991, INT J RADIAT ONCOL, V21, P355, DOI 10.1016/0360-3016(91)90782-Y; Loprinzi CL, 1997, J CLIN ONCOL, V15, P969, DOI 10.1200/JCO.1997.15.3.969; LOPRINZI CL, 1994, NEW ENGL J MED, V331, P347, DOI 10.1056/NEJM199408113310602; LOPRINZI CL, 2000, P AN M AM SOC CLIN, V19, pA2; LOVE RR, 1992, NEW ENGL J MED, V326, P852, DOI 10.1056/NEJM199203263261302; LOVE RR, 1991, ANN INTERN MED, V115, P860, DOI 10.7326/0003-4819-115-11-860; Lowenberg B, 1999, NEW ENGL J MED, V341, P1051, DOI 10.1056/NEJM199909303411407; MAMBY CC, 1994, BREAST CANCER RES TR, V30, P311, DOI 10.1007/BF00665973; MCDONALD CC, 1995, BRIT MED J, V311, P977; Miller KD, 1999, CANCER INVEST, V17, P121; Mortimer JE, 1999, J CLIN ONCOL, V17, P1488, DOI 10.1200/JCO.1999.17.5.1488; Nabholtz JM, 2000, J CLIN ONCOL, V18, P3758, DOI 10.1200/JCO.2000.18.22.3758; Natrajan PK, 1999, AM J OBSTET GYNECOL, V181, P288, DOI 10.1016/S0002-9378(99)70550-8; Nayfield SG, 1996, J CLIN ONCOL, V14, P1018, DOI 10.1200/JCO.1996.14.3.1018; NEUGUT AI, 1993, CANCER, V71, P3054, DOI 10.1002/1097-0142(19930515)71:10<3054::AID-CNCR2820711027>3.0.CO;2-N; NIH Consensus statement, 2000, ADJ THER BREAST CANC, V17, P1, DOI [10.1093/jnci/93.13.979, DOI 10.1093/JNCI/93.13.979]; Nixon AJ, 1998, J CLIN ONCOL, V16, P1374, DOI 10.1200/JCO.1998.16.4.1374; Overgaard M, 1997, NEW ENGL J MED, V337, P949, DOI 10.1056/NEJM199710023371401; Ozer H, 2000, J CLIN ONCOL, V18, P3558, DOI 10.1200/JCO.2000.18.20.3558; Pandya KJ, 2000, ANN INTERN MED, V132, P788, DOI 10.7326/0003-4819-132-10-200005160-00004; PASTA LF, 1999, J CLIN ONCOL, V17, P740; Paszat LF, 1998, J CLIN ONCOL, V16, P2625, DOI 10.1200/JCO.1998.16.8.2625; Paszat LF, 1999, INT J RADIAT ONCOL, V43, P755, DOI 10.1016/S0360-3016(98)00412-X; PHILLIPS KA, 1999, PROG P AM SOC CLIN O, V18, pA74; PIERCE SM, 1992, INT J RADIAT ONCOL, V23, P915, DOI 10.1016/0360-3016(92)90895-O; Powles T, 1996, J CLIN ONCOL, V14, P78, DOI 10.1200/JCO.1996.14.1.78; Powles TJ, 1998, J NATL CANCER I, V90, P704, DOI 10.1093/jnci/90.9.704; Pritchard KI, 1996, J CLIN ONCOL, V14, P2731, DOI 10.1200/JCO.1996.14.10.2731; Quella SK, 2000, J CLIN ONCOL, V18, P1068, DOI 10.1200/JCO.2000.18.5.1068; QUIET CA, 1995, J CLIN ONCOL, V13, P1144, DOI 10.1200/JCO.1995.13.5.1144; Ragaz J, 1997, NEW ENGL J MED, V337, P956, DOI 10.1056/NEJM199710023371402; RECHT A, 1995, CANCER, V76, P1491, DOI 10.1002/1097-0142(19951101)76:9<1491::AID-CNCR2820760902>3.0.CO;2-8; Rizk A N, 1999, Drugs R D, V2, P229; ROSEN PP, 1989, J CLIN ONCOL, V7, P355, DOI 10.1200/JCO.1989.7.3.355; ROSEN PP, 1991, J CLIN ONCOL, V9, P1650, DOI 10.1200/JCO.1991.9.9.1650; Rubagotti A, 1996, ANN ONCOL, V7, P239; Rutqvist LE, 1998, INT J RADIAT ONCOL, V40, P359, DOI 10.1016/S0360-3016(97)00765-7; RUTQVIST LE, 1995, J NATL CANCER I, V87, P645, DOI 10.1093/jnci/87.9.645; RUTQVIST LE, 1993, J NATL CANCER I, V85, P1398, DOI 10.1093/jnci/85.17.1398; Saarto T, 1997, J CLIN ONCOL, V15, P1341, DOI 10.1200/JCO.1997.15.4.1341; SAPHNER T, 1991, J CLIN ONCOL, V9, P286, DOI 10.1200/JCO.1991.9.2.286; Schagen SB, 1999, CANCER, V85, P640, DOI 10.1002/(SICI)1097-0142(19990201)85:3<640::AID-CNCR14>3.0.CO;2-G; Shan K, 1996, ANN INTERN MED, V125, P47, DOI 10.7326/0003-4819-125-1-199607010-00008; Shapiro CL, 1998, J CLIN ONCOL, V16, P3493, DOI 10.1200/JCO.1998.16.11.3493; SHAPIRO CL, 1994, NIH PUBLICATION, P101; SLAMON D, 1998, P AN M AM SOC CLIN, V17, pA98; Smart CR, 1997, CA-CANCER J CLIN, V47, P134, DOI 10.3322/canjclin.47.3.134; Smith R., 2000, Breast Cancer Research and Treatment, V64, P27; STORM HH, 1986, BRIT J CANCER, V54, P483, DOI 10.1038/bjc.1986.201; Strobbe LJA, 1998, BREAST CANCER RES TR, V47, P101, DOI 10.1023/A:1005997017102; Suh-Burgmann EJ, 1999, ANN INTERN MED, V131, P127, DOI 10.7326/0003-4819-131-2-199907200-00009; Swain S, 1999, ONCOLOGY-NY, V13, P859; SWAIN S, 1999, ONCOLOGY HUNTINGT, V13, P871; SWAIN S, 1999, ONCOLOGY HUNTINGT, V13, P875; SWAIN S, 1999, ONCOLOGY HUNTINGT, V13, P865; TAGHIAN A, 1991, INT J RADIAT ONCOL, V21, P361, DOI 10.1016/0360-3016(91)90783-Z; TALLMAN MS, 1995, J CLIN ONCOL, V13, P1557, DOI 10.1200/JCO.1995.13.7.1557; TOUBOUL E, 1992, RADIOTHER ONCOL, V25, P167, DOI 10.1016/0167-8140(92)90263-T; VALAGUSSA P, 1994, ANN ONCOL, V5, P209, DOI 10.1093/oxfordjournals.annonc.a058795; VALAGUSSA P, 1994, ANN ONCOL, V5, P803, DOI 10.1093/oxfordjournals.annonc.a059008; van Dam FSAM, 1998, J NATL CANCER I, V90, P210, DOI 10.1093/jnci/90.3.210; Vassilopoulou-Sellin R, 1999, J CLIN ONCOL, V17, P1482, DOI 10.1200/JCO.1999.17.5.1482; Voth EA, 1997, ANN INTERN MED, V126, P791, DOI 10.7326/0003-4819-126-10-199705150-00008; WOOD WC, 1994, NEW ENGL J MED, V331, P139; WOOD WC, 1994, NEW ENGL J MED, V330, P1253, DOI 10.1056/NEJM199405053301801; Zambetti M, 2001, J CLIN ONCOL, V19, P37, DOI 10.1200/JCO.2001.19.1.37; ZAMBETTI M, 1992, NIH PUBLICATION, P77	136	484	512	0	42	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 28	2001	344	26					1997	2008		10.1056/NEJM200106283442607	http://dx.doi.org/10.1056/NEJM200106283442607			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	446HQ	11430330				2022-12-28	WOS:000169508200007
J	Derdeyn, CP				Derdeyn, CP			Physiological neuroimaging: emerging clinical applications	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							ACUTE ISCHEMIC STROKE; RANDOMIZED CONTROLLED TRIAL; CEREBRAL BLOOD-FLOW; PLASMINOGEN-ACTIVATOR; DIFFUSION; BRAIN; ALTEPLASE; PERFUSION; LESIONS; ECASS		Washington Univ, Sch Med, Edward Mallinckrodt Inst Radiol, Cerebrovasc Sect,Neuroimaging Lab, St Louis, MO 63110 USA; Washington Univ, Sch Med, Edward Mallinckrodt Inst Radiol, Neuroradiol Sect,Intervent Neuroradiol Serv, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)	Derdeyn, CP (corresponding author), Washington Univ, Sch Med, Edward Mallinckrodt Inst Radiol, Cerebrovasc Sect,Neuroimaging Lab, 510 S Kingshighway Blvd, St Louis, MO 63110 USA.			Derdeyn, Colin/0000-0002-5932-2683	PHS HHS [R0139864, K0802029] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BARNETT HJM, 1985, NEW ENGL J MED, V313, P1191, DOI 10.1056/nejm198511073131904; BOGOUSSLAVSKY J, 1986, ARCH NEUROL-CHICAGO, V43, P223, DOI 10.1001/archneur.1986.00520030015005; Broderick J, 1998, STROKE, V29, P415, DOI 10.1161/01.STR.29.2.415; Clark WM, 1999, JAMA-J AM MED ASSOC, V282, P2019, DOI 10.1001/jama.282.21.2019; Derdeyn CP, 1999, NEUROLOGY, V53, P251, DOI 10.1212/WNL.53.2.251; Duong TQ, 1998, MAGN RESON MED, V40, P1, DOI 10.1002/mrm.1910400102; Firlik AD, 1998, NEUROLOGY, V51, P177, DOI 10.1212/WNL.51.1.177; Furlan A, 1999, JAMA-J AM MED ASSOC, V282, P2003, DOI 10.1001/jama.282.21.2003; Grubb RL, 1998, JAMA-J AM MED ASSOC, V280, P1055, DOI 10.1001/jama.280.12.1055; Hacke W, 1998, LANCET, V352, P1245, DOI 10.1016/S0140-6736(98)08020-9; HACKE W, 1995, JAMA-J AM MED ASSOC, V274, P1017, DOI 10.1001/jama.274.13.1017; Katzan IL, 2000, JAMA-J AM MED ASSOC, V283, P1151, DOI 10.1001/jama.283.9.1151; Lee CC, 1999, AM J NEURORADIOL, V20, P1511; MARCHAL G, 1993, LANCET, V341, P925, DOI 10.1016/0140-6736(93)91214-7; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; Molloy J, 1999, STROKE, V30, P1440, DOI 10.1161/01.STR.30.7.1440; Posner MI, 1998, P NATL ACAD SCI USA, V95, P763, DOI 10.1073/pnas.95.3.763; POWERS WJ, 1984, NEUROLOGY, V34, P1168, DOI 10.1212/WNL.34.9.1168; Raichle ME, 1998, P NATL ACAD SCI USA, V95, P765, DOI 10.1073/pnas.95.3.765; Schlaug G, 1999, NEUROLOGY, V53, P1528, DOI 10.1212/WNL.53.7.1528; Sherman DG, 2000, JAMA-J AM MED ASSOC, V283, P2395, DOI 10.1001/jama.283.18.2395; Umemura A, 2000, J NEUROL NEUROSUR PS, V69, P472, DOI 10.1136/jnnp.69.4.472; Warach S, 2000, ANN NEUROL, V48, P713, DOI 10.1002/1531-8249(200011)48:5<713::AID-ANA4>3.3.CO;2-R	23	4	4	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 27	2001	285	24					3065	3068		10.1001/jama.285.24.3065	http://dx.doi.org/10.1001/jama.285.24.3065			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	444FF	11427117				2022-12-28	WOS:000169388900001
J	Georgellis, D; Kwon, O; Lin, ECC				Georgellis, D; Kwon, O; Lin, ECC			Quinones as the redox signal for the Arc two-component system of bacteria	SCIENCE			English	Article							SENSOR-REGULATOR PROTEIN; ESCHERICHIA-COLI; ANAEROBIC REPRESSION; IN-VITRO; TRANSDUCTION; BINDING; GENE; PHOSPHORELAY; REQUIREMENT; PROMOTER	The Arc two-component signal transduction system mediates adaptive responses of Escherichia coli to changing respiratory conditions of growth. Under anaerobic conditions, the ArcB sensor kinase autophosphorylates and then transphosphorylates ArcA, a global transcriptional regulator that controls the expression of numerous operons involved in respiratory or fermentative metabolism. We show that oxidized forms of quinone electron carriers act as direct negative signals that inhibit autophosphorylation of ArcB during aerobiosis. Thus, the Arc signal transduction system provides a link between the electron transport chain and gene expression.	Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Lin, ECC (corresponding author), Harvard Univ, Sch Med, Dept Microbiol & Mol Genet, 200 Longwood Ave, Boston, MA 02115 USA.	elin@hms.harvard.edu	Georgellis, Dimitris/U-2517-2017	Georgellis, Dimitris/0000-0002-6114-795X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040993] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM40993] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bibikov SI, 1997, J BACTERIOL, V179, P4075, DOI 10.1128/jb.179.12.4075-4079.1997; BRONDSTED L, 1994, J BACTERIOL, V176, P5423; Gennis R. B., 1996, ESCHERICHIA COLI SAL, P217; Georgellis D, 1999, J BIOL CHEM, V274, P35950, DOI 10.1074/jbc.274.50.35950; Georgellis D, 1998, J BIOL CHEM, V273, P32864, DOI 10.1074/jbc.273.49.32864; Georgellis D, 1997, J BACTERIOL, V179, P5429, DOI 10.1128/jb.179.17.5429-5435.1997; GEORGELLIS D, UNPUB; Hoch JA, 1995, 2 COMPONENT SIGNAL T; ISHIGE K, 1994, EMBO J, V13, P5195, DOI 10.1002/j.1460-2075.1994.tb06850.x; IUCHI S, 1992, J BACTERIOL, V174, P3972, DOI 10.1128/jb.174.12.3972-3980.1992; IUCHI S, 1993, J BIOL CHEM, V268, P23972; IUCHI S, 1990, J BACTERIOL, V172, P6020, DOI 10.1128/jb.172.10.6020-6025.1990; IUCHI S, 1990, MOL MICROBIOL, V4, P715, DOI 10.1111/j.1365-2958.1990.tb00642.x; IUCHI S, 1988, P NATL ACAD SCI USA, V85, P1888, DOI 10.1073/pnas.85.6.1888; Kwon O, 2000, J BACTERIOL, V182, P3858, DOI 10.1128/JB.182.13.3858-3862.2000; Kwon O, 2000, J BACTERIOL, V182, P2960, DOI 10.1128/JB.182.10.2960-2966.2000; Lynch A. Simon, 1996, P361; Lynch AS, 1996, J BACTERIOL, V178, P6238, DOI 10.1128/JB.178.21.6238-6249.1996; LYNCH AS, 1996, ESCHERICHIA COLI SAL, V1, P1526; Magasanik B., 1996, ESCHERICHIA COLI SAL, P1344; McGuire AM, 1999, MOL MICROBIOL, V32, P219, DOI 10.1046/j.1365-2958.1999.01347.x; NAGASAWA S, 1992, MOL MICROBIOL, V6, P799, DOI 10.1111/j.1365-2958.1992.tb01530.x; PARKINSON JS, 1992, ANNU REV GENET, V26, P71, DOI 10.1146/annurev.ge.26.120192.000443; Pellicer MT, 1999, MOL GEN GENET, V261, P170, DOI 10.1007/s004380050954; Pernestig AK, 2001, J BIOL CHEM, V276, P225, DOI 10.1074/jbc.M001550200; Rebbapragada A, 1997, P NATL ACAD SCI USA, V94, P10541, DOI 10.1073/pnas.94.20.10541; SAWERS G, 1992, J BACTERIOL, V174, P3474, DOI 10.1128/JB.174.11.3474-3478.1992; SILVERMAN PM, 1991, J MOL BIOL, V220, P271, DOI 10.1016/0022-2836(91)90012-U; Soballe B, 1998, MICROBIOL-UK, V144, P361, DOI 10.1099/00221287-144-2-361	29	365	375	0	46	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 22	2001	292	5525					2314	2316		10.1126/science.1059361	http://dx.doi.org/10.1126/science.1059361			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	445KD	11423658				2022-12-28	WOS:000169455900053
J	Istre, GR; McCoy, MA; Osborn, L; Barnard, JJ; Bolton, A				Istre, GR; McCoy, MA; Osborn, L; Barnard, JJ; Bolton, A			Deaths and injuries from house fires.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	Annual Meeting of the American-Public-Health-Association	NOV 15-16, 2000	BOSTON, MASSACHUSETTS	Amer Public Hlth Assoc			FATAL RESIDENTIAL FIRES; HOMES	Background: We sought to define the factors associated with house fires and related injuries by analyzing the data from population-based surveillance. Methods: For 1991 through 1997, we linked the following data for Dallas: records from the fire department of all house fires (excluding fires in apartments and mobile homes), records of patients transported by ambulance, hospital admissions, and reports from the medical examiner of fatal injuries. Results: There were 223 injuries (91 fatal and 132 nonfatal) from 7190 house fires, for a rate of 5.2 injured persons per 100,000 population per year. Rates of injury related to house fires were highest among blacks (relative risk, 2.8; 95 percent confidence interval, 2.1 to 3.6) and in people 65 years of age or older (relative risk, 2.6; 95 percent confidence interval, 1.9 to 3.5). Census tracts with low median incomes had the highest rates of injury related to house fires (relative risk as compared with census tracts with high median incomes, 8.1; 95 percent confidence interval, 2.5 to 32.0). The rate of injuries was higher for fires that began in bedrooms or living areas (relative risk, 3.7); that were started by heating equipment, smoking, or children playing with fire (relative risk, 2.6); or that occurred in houses built before 1980 (relative risk, 6.6). Injuries occurred more often in houses without functioning smoke detectors (relative risk, 1.5; 95 percent confidence interval, 1.0 to 2.4). The prevalence of functioning smoke detectors was lowest in houses in the census tracts with the lowest median incomes (P<0.001). Conclusions: Rates of injuries related to house fires are highest in elderly, minority, and low-income populations and in houses without functioning smoke detectors. Efforts to prevent injuries and deaths from house fires should target these populations. (N Engl J Med 2001;344:1911-6.) Copyright (C) 2001 Massachusetts Medical Society.	Injury Prevent Ctr Greater Dallas, Dallas, TX 75235 USA; PID Associates, Dallas, TX USA; Dallas Fire Dept, Dallas, TX USA; Dallas Fir, Off Chief Med Examiner Dallas Cty, Dallas, TX USA; Univ Alabama, Ctr Comprehens Canc, Birmingham, AL 35294 USA	University of Alabama System; University of Alabama Birmingham	Istre, GR (corresponding author), Injury Prevent Ctr Greater Dallas, POB 36067, Dallas, TX 75235 USA.							Bonnie RJ, 1999, REDUCING BURDEN INJU; Dean A.G., 1994, EPI INFO VERSION 6 W; Douglas MR, 1999, AM J PUBLIC HEALTH, V89, P1112, DOI 10.2105/AJPH.89.7.1112; *FED EM MAN AG, 1997, SOC FACT INC FIR; *FIR ADM, 1999, FIR US 1987 1996; GORMAN RL, 1985, PEDIATRICS, V75, P14; GREENLAND S, 1985, BIOMETRICS, V41, P55, DOI 10.2307/2530643; HEMENWAY D, 1990, Q J ECON, V105, P1063, DOI 10.2307/2937886; ISTRE GR, 1992, PUBLIC HEALTH SURVEILLANCE, P42; Johnson S. W., 1996, 808338 NHTSA DOT HS; Mallonee S, 1996, NEW ENGL J MED, V335, P27, DOI 10.1056/NEJM199607043350106; Marshall SW, 1998, JAMA-J AM MED ASSOC, V279, P1633, DOI 10.1001/jama.279.20.1633; MCLOUGHLIN E, 1985, AM J PUBLIC HEALTH, V75, P858, DOI 10.2105/AJPH.75.8.858; MEHTA CR, 1985, J AM STAT ASSOC, V80, P969, DOI 10.2307/2288562; MIERLEY MC, 1983, JAMA-J AM MED ASSOC, V249, P1466, DOI 10.1001/jama.249.11.1466; PICKENS S, 2000, DALLAS MED J, V86, P251; ROBERTS I, 1995, BRIT MED J, V311, P1381, DOI 10.1136/bmj.311.7017.1381; RUNYAN CW, 1992, NEW ENGL J MED, V327, P859, DOI 10.1056/NEJM199209173271207; Selvin S., 1996, STAT ANAL EPIDEMIOLO; SHULTS R, 1996, EFFORTS INCREASE SMO; Thacker SB, 1996, FIELD EPIDEMIOLOGY, P16; WOODWARD M, 1999, EPIDEMIOLOGY STUDY D, P476	22	121	123	0	16	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 21	2001	344	25					1911	1916		10.1056/NEJM200106213442506	http://dx.doi.org/10.1056/NEJM200106213442506			6	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	443VJ	11419429				2022-12-28	WOS:000169362100006
J	Lutzoni, F; Pagel, M; Reeb, V				Lutzoni, F; Pagel, M; Reeb, V			Major fungal lineages are derived from lichen symbiotic ancestors	NATURE			English	Article							DISCRETE CHARACTERS; PHYLOGENY; EVOLUTIONARY; ORIGINS	About one-fifth of all known extant fungal species form obligate symbiotic associations with green algae, cyanobacteria or with both photobionts. These symbioses, known as lichens, are one way for fungi to meet their requirement for carbohydrates(1,2). Lichens are widely believed to have arisen independently on several occasions, accounting for the high diversity and mixed occurrence of lichenized and non-lichenized (42 and 58%, respectively) fungal species within the Ascomycota(3,4). Depending on the taxonomic classification chosen(2,5,6), 15-18 orders of the Ascomycota include lichen-forming taxa, and 8-11 of these orders (representing about 60% of the Ascomycota species) contain both lichenized and non-lichenized species. Here we report a phylogenetic comparative analysis of the Ascomycota, a phylum that includes greater than 98% of known lichenized fungal species 5. Using a Bayesian phylogenetic tree sampling methodology(7,8) combined with a statistical model of trait evolution(9), we take into account uncertainty about the phylogenetic tree and ancestral state reconstructions. Our results show that lichens evolved earlier than believed, and that gains of lichenization have been infrequent during Ascomycota evolution, but have been followed by multiple independent losses of the lichen symbiosis. As a consequence, major Ascomycota lineages of exclusively non-lichen-forming species are derived from lichen-forming ancestors. These species include taxa with important benefits and detriments to humans, such as Penicillium and Aspergillus(10-12).	Field Museum Nat Hist, Dept Bot, Chicago, IL 60605 USA; Univ Reading, Sch Anim & Microbial Sci, Reading RG6 6AJ, Berks, England; Univ Illinois, Dept Biol Sci, Chicago, IL 60607 USA	Field Museum of Natural History (Chicago); University of Reading; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Lutzoni, F (corresponding author), Duke Univ, Dept Biol, Durham, NC 27708 USA.							Alexopoulos C. J., 1996; BARINAGA M, 1995, SCIENCE, V268, P1437, DOI 10.1126/science.7770768; BERBEE ML, 1995, MYCOLOGIA, V87, P210, DOI 10.2307/3760907; BERBEE ML, 1995, CAN J BOT, V73, pS677; Berbee ML, 2000, MOL PHYLOGENET EVOL, V17, P337, DOI 10.1006/mpev.2000.0835; Bhattacharya D, 2000, MOL BIOL EVOL, V17, P1971, DOI 10.1093/oxfordjournals.molbev.a026298; COLLINS TM, 1994, SYST BIOL, V43, P482, DOI 10.2307/2413547; Elix J. A., 1996, P154; GARGAS A, 1995, SCIENCE, V268, P1492, DOI 10.1126/science.7770775; Hafellner J., 1988, HDB LICHENOLOGY, P41; Hawksworth D.L., 1995, DICT FUNGI, V8th; HAWKSWORTH DL, 1991, MYCOL RES, V95, P641, DOI 10.1016/S0953-7562(09)80810-1; Hibbett DS, 2000, NATURE, V407, P506, DOI 10.1038/35035065; Hillis DM., 1996, MOL SYSTEMATICS, V2nd; Honegger R., 1996, P24; Huelsenbeck JP, 2000, SCIENCE, V288, P2349, DOI 10.1126/science.288.5475.2349; Kranner I., 1999, PLANT RESPONSES ENV, P591; Larget B, 1999, MOL BIOL EVOL, V16, P750, DOI 10.1093/oxfordjournals.molbev.a026160; Liu YJJ, 1999, MOL BIOL EVOL, V16, P1799, DOI 10.1093/oxfordjournals.molbev.a026092; Lutzoni F, 1997, P NATL ACAD SCI USA, V94, P11422, DOI 10.1073/pnas.94.21.11422; LUTZONI F, 1995, CRYPTOG BOT, V5, P82; Lutzoni FM, 1997, SYST BIOL, V46, P373, DOI 10.1093/sysbio/46.3.373; MADDISON DR, 1994, ANNU REV ENTOMOL, V39, P267, DOI 10.1146/annurev.en.39.010194.001411; Pagel M, 1999, SYST BIOL, V48, P612, DOI 10.1080/106351599260184; PAGEL M, 1994, P ROY SOC B-BIOL SCI, V255, P37, DOI 10.1098/rspb.1994.0006; Pagel M, 1999, NATURE, V401, P877, DOI 10.1038/44766; Rambold G., 1992, BIBLIOTHECA LICHENOL, V48, P1; SPATAFORA JW, 1995, CAN J BOT, V73, pS811, DOI 10.1139/b95-326; Suh SO, 1999, MYCOLOGIA, V91, P836, DOI 10.2307/3761537; Wilson IJ, 1998, GENETICS, V150, P499	30	378	402	12	132	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 21	2001	411	6840					937	940		10.1038/35082053	http://dx.doi.org/10.1038/35082053			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	444EN	11418855				2022-12-28	WOS:000169386200041
J	Osterwalder, J				Osterwalder, J			Portal hypertension - Where is evidence for 5% dextrose and pulmonary artery catheter?	BRITISH MEDICAL JOURNAL			English	Letter									Kantonsspital, CH-9007 St Gallen, Switzerland	Kantonsspital Aarau AG (KSA); Kantonsspital St. Gallen	Osterwalder, J (corresponding author), Kantonsspital, CH-9007 St Gallen, Switzerland.							Connors AF, 1996, JAMA-J AM MED ASSOC, V276, P889, DOI 10.1001/jama.276.11.889; DEREK A, 2001, BRIT MED J, V322, P446; Krige JEJ, 2001, BRIT MED J, V322, P348, DOI 10.1136/bmj.322.7282.348	3	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 16	2001	322	7300					1492	1492		10.1136/bmj.322.7300.1492	http://dx.doi.org/10.1136/bmj.322.7300.1492			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	444FJ	11430380	Green Published			2022-12-28	WOS:000169389200065
J	Schmucker, D; Zipursky, SL				Schmucker, D; Zipursky, SL			Signaling downstream of Eph receptors and ephrin ligands	CELL			English	Review							COLLAPSE; CXCR4; AXON; CELL; RHO		Univ Calif Los Angeles, Sch Med, Howard Hughes Med Inst, Dept Biol Chem, Los Angeles, CA 90095 USA	Howard Hughes Medical Institute; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Zipursky, SL (corresponding author), Univ Calif Los Angeles, Sch Med, Howard Hughes Med Inst, Dept Biol Chem, 675 Charles Young Dr, Los Angeles, CA 90095 USA.	zipursky@hhmi.ucla.edu		Zipursky, Stephen/0000-0001-5630-7181				Brown A, 2000, CELL, V102, P77, DOI 10.1016/S0092-8674(00)00012-X; Bruckner K, 1999, NEURON, V22, P511, DOI 10.1016/S0896-6273(00)80706-0; Bruckner K, 1997, SCIENCE, V275, P1640, DOI 10.1126/science.275.5306.1640; De Vries L, 1999, TRENDS CELL BIOL, V9, P138, DOI 10.1016/S0962-8924(99)01515-9; Flanagan JG, 1998, ANNU REV NEUROSCI, V21, P309, DOI 10.1146/annurev.neuro.21.1.309; Henkemeyer M, 1996, CELL, V86, P35, DOI 10.1016/S0092-8674(00)80075-6; Kozma R, 1997, MOL CELL BIOL, V17, P1201, DOI 10.1128/MCB.17.3.1201; Lin MZ, 2000, CELL, V101, P239, DOI 10.1016/S0092-8674(00)80833-8; Lu Q, 2001, CELL, V105, P69, DOI 10.1016/S0092-8674(01)00297-5; Ma Q, 1998, P NATL ACAD SCI USA, V95, P9448, DOI 10.1073/pnas.95.16.9448; O'Shea EK, 2000, NAT CELL BIOL, V2, pE39, DOI 10.1038/35004065; Schmucker D, 2000, CELL, V101, P671, DOI 10.1016/S0092-8674(00)80878-8; Schwartz PM, 1997, NEURON, V19, P269, DOI 10.1016/S0896-6273(00)80938-1; Shamah SM, 2001, CELL, V105, P233, DOI 10.1016/S0092-8674(01)00314-2; Stein E, 2001, SCIENCE, V291, P1928, DOI 10.1126/science.1058445; Steven R, 1998, CELL, V92, P785, DOI 10.1016/S0092-8674(00)81406-3; Wahl S, 2000, J CELL BIOL, V149, P263, DOI 10.1083/jcb.149.2.263; Zou YR, 1998, NATURE, V393, P595, DOI 10.1038/31269	18	73	78	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 15	2001	105	6					701	704		10.1016/S0092-8674(01)00391-9	http://dx.doi.org/10.1016/S0092-8674(01)00391-9			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	444AE	11440711	Bronze			2022-12-28	WOS:000169375100002
J	Rowland, M; Durrani, N; Kenward, M; Mohammed, N; Urahman, H; Hewitt, S				Rowland, M; Durrani, N; Kenward, M; Mohammed, N; Urahman, H; Hewitt, S			Control of malaria in Pakistan by applying deltamethrin insecticide to cattle: a community-randomised trial	LANCET			English	Article							FALCIPARUM; BEDNETS	Background The standard method of malaria control in south Asia, indoor spraying of houses with residual insecticide, is becoming prohibitively expensive to implement and new approaches are needed. Since the region's vector mosquitoes feed predominantly on domestic animals and only secondarily on human beings, to apply insecticide to surfaces of cattle instead might be more costeffective. We aimed to investigate whether domestic livestock treated with deltamethrin (applied by a sponging method) would prove toxic to mosquitoes and therefore aid in malaria control. Methods Six Afghan refugee settlements in Pakistan were randomly assigned to one of two groups. In one group livestock were treated with deltamethrin during the malaria transmission seasons of 1995 and 1997, whereas in the other group livestock were treated during the 1996 season. Malaria was monitored by passive case detection at village clinics and by cross-sectional surveillance. Mosquitoes were also monitored. Findings According to clinic records the incidence of malaria caused by Plasmodium falciparum decreased by 56% (95% CI 14-78%) and P vivax by 31% (5-50%) in livestock treated villages. Cross-sectional surveys showed comparable decreases in parasite prevalence. The density and life expectancy of Anopheles stephensi and A culicifacies populations were reduced in treated villages. The efficacy of livestock treatment was similar to that of indoor spraying but campaign costs were 80% less. When applied in a highly endemic settlement, the incidence of falciparum malaria decreased from 280 episodes per 1000 person-years to nine episodes per 1000 person-years. Interpretations Insecticide treatment of livestock is a costeffective and promising alternative for south Asia and other regions where primary vectors are zoophilic.	Univ London London Sch Hyg & Trop Med, London WC1E 7HT, England; Univ Town, HealthNet Int, Peshawar, Pakistan	University of London; London School of Hygiene & Tropical Medicine	Rowland, M (corresponding author), Univ London London Sch Hyg & Trop Med, Keppel St, London WC1E 7HT, England.							Buck A.A., 1972, HLTH DIS RURAL AFGHA; CHAVASSE DC, 1999, INSECTICIDE TREATED; Hewitt S, 1999, TROP MED INT HEALTH, V4, P481, DOI 10.1046/j.1365-3156.1999.00433.x; HILLS M, 1989, BR J CLIN PHARM, V8, P7; JONES B, 1989, DESIGN ANAL CROSSOVE; McCullagh P., 1989, GEN LINEAR MODELS, V2nd; Misra SP, 1999, T ROY SOC TROP MED H, V93, P456, DOI 10.1016/S0035-9203(99)90335-8; OKELLOONEN J, 1994, TROP ANIM HEALTH PRO, V26, P21, DOI 10.1007/BF02241128; PEGRAM RG, 1989, MED VET ENTOMOL, V3, P313, DOI 10.1111/j.1365-2915.1989.tb00234.x; Pitt S, 1998, LANCET, V352, P1279, DOI 10.1016/S0140-6736(98)00040-3; REISEN WK, 1982, J MED ENTOMOL, V19, P98, DOI 10.1093/jmedent/19.1.98; Rowland M, 1999, T ROY SOC TROP MED H, V93, P465, DOI 10.1016/S0035-9203(99)90341-3; Rowland M, 1997, B WORLD HEALTH ORGAN, V75, P23; SERVICE MW, 1991, REV SAUDE PUBL, V25, P165, DOI 10.1590/S0034-89101991000300002; Shah I, 1997, ANN TROP MED PARASIT, V91, P591, DOI 10.1080/00034989760680; *WHO, 1998, DELT ENV HLTH CRIT; Zaim M, 1998, J AM MOSQUITO CONTR, V14, P421	17	73	75	0	13	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 9	2001	357	9271					1837	1841		10.1016/S0140-6736(00)04955-2	http://dx.doi.org/10.1016/S0140-6736(00)04955-2			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	440DN	11410192				2022-12-28	WOS:000169160800012
J	Boers, M				Boers, M			NSAIDS and selective COX-2 inhibitors: competition between gastroprotection and cardioprotection	LANCET			English	Editorial Material							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; RHEUMATOID-ARTHRITIS; GASTROINTESTINAL TOXICITY; COMPLICATIONS; MISOPROSTOL; MORTALITY; ASPIRIN; RISK		Free Univ Amsterdam Hosp, Dept Clin Epidemiol & Biostat, NL-1007 MB Amsterdam, Netherlands	Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER	Boers, M (corresponding author), Free Univ Amsterdam Hosp, Dept Clin Epidemiol & Biostat, NL-1007 MB Amsterdam, Netherlands.	j.wildbret@azvu.nl						Aranow C, 2000, LUPUS, V9, P166, DOI 10.1191/096120300678828208; Bombardier C, 2000, NEW ENGL J MED, V343, P1520, DOI 10.1056/NEJM200011233432103; Chan FKL, 1998, NEW ENGL J MED, V339, P349; CLELAND JGF, 1995, BRIT HEART J, V74, P215; Dickinson JP, 1998, QJM-INT J MED, V91, P523, DOI 10.1093/qjmed/91.8.523; Hawkey CJ, 2000, BMJ-BRIT MED J, V321, P291, DOI 10.1136/bmj.321.7256.291; Hawkey CJ, 1998, NEW ENGL J MED, V338, P727, DOI 10.1056/NEJM199803123381105; Hawkey CJ, 1999, LANCET, V353, P307, DOI 10.1016/S0140-6736(98)12154-2; Isles C, 1999, LANCET, V353, P148, DOI 10.1016/S0140-6736(05)76185-7; MUTRU O, 1989, CARDIOLOGY, V76, P71, DOI 10.1159/000174474; SILVERSTEIN FE, 1995, ANN INTERN MED, V123, P241, DOI 10.7326/0003-4819-123-4-199508150-00001; Silverstein FE, 2000, JAMA-J AM MED ASSOC, V284, P1247, DOI 10.1001/jama.284.10.1247; WallbergJonsson S, 1997, J RHEUMATOL, V24, P445	13	45	47	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 21	2001	357	9264					1222	1223		10.1016/S0140-6736(00)04451-2	http://dx.doi.org/10.1016/S0140-6736(00)04451-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	425YY	11418144				2022-12-28	WOS:000168323300006
J	D'Agostino, RB; Grundy, S; Sullivan, LM; Wilson, P				D'Agostino, RB; Grundy, S; Sullivan, LM; Wilson, P		CHD Risk Prediction Grp	Validation of the Framingham Coronary Heart Disease prediction scores - Results of a multiple ethnic groups investigation	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RISK PROFILE	Context The Framingham Heart Study produced sex-specific coronary heart disease (CHD) prediction functions for assessing risk of developing incident CHD in a white middle-class population. Concern exists regarding whether these functions can be generalized to other populations. Objective To test the validity and transportability of the Framingham CHD prediction functions per a National Heart, Lung, and Blood Institute workshop organized for this purpose. Design, Setting, and Subjects Sex-specific CHD functions were derived from Framingham data for prediction of coronary death and myocardial infarction. These functions were applied to 6 prospectively studied, ethnically diverse cohorts (n = 23 424), including whites, blacks, Native Americans, Japanese American men, and Hispanic men: the Atherosclerosis Risk in Communities Study (1987-1988), Physicians' Health Study (1982), Honolulu Heart Program (1980-1982), Puerto Rico Heart Health Program (1965-1968), Strong Heart Study (1989-1991), and Cardiovascular Health Study (1989-1990). Main Outcome Measures The performance, or ability to accurately predict CHD risk, of the Framingham functions compared with the performance of risk functions developed specifically from the individual cohorts' data. Comparisons included evaluation of the equality of relative risks for standard CHD risk factors, discrimination, and calibration. Results For white men and women and for black men and women the Framingham functions performed reasonably well for prediction of CHD events within 5 years of follow-up. Among Japanese American and Hispanic men and Native American women, the Framingham functions systematically overestimated the risk of 5-year CHD events. After recalibration, taking into account different prevalences of risk factors and underlying rates of developing CHD, the Framingham functions worked well in these populations. Conclusions The sex-specific Framingham CHD prediction functions perform well among whites and blacks in different settings and can be applied to other ethnic groups after recalibration for differing prevalences of risk factors and underlying rates of CHD events.	Boston Univ, Dept Math & Stat, Boston, MA 02215 USA; Boston Univ, Dept Med, Boston, MA 02215 USA; Framingham Heart Dis Epidemiol Study, Framingham, MA USA; Univ Texas, SW Med Ctr, Ctr Human Nutr, Dallas, TX 75235 USA	Boston University; Boston University; Framingham Heart Study; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	D'Agostino, RB (corresponding author), Boston Univ, Dept Math & Stat, 111 Cummington St, Boston, MA 02215 USA.	ralph@bu.edu		Sullivan, Lisa/0000-0003-0726-7149	NHLBI NIH HHS [N01-HC-380380] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON KM, 1991, CIRCULATION, V83, P356, DOI 10.1161/01.CIR.83.1.356; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; Colette D., 1994, MODELING SURVIVAL DA; DAGOSTINO RB, 1997, AM STAT ASS 1996 P S, P253; Fried LP, 1991, ANN EPIDEMIOL, V1, P1263; GARCIAPALMIERI MR, 1986, PROGR CARDIOLOGY, V14, P101; GIFFORD RW, 1993, ARCH INTERN MED, V153, P154; GORDON T, 1982, AM HEART J, V103, P1031, DOI 10.1016/0002-8703(82)90567-1; GRUNDY SM, 1993, JAMA-J AM MED ASSOC, V269, P3015, DOI 10.1001/jama.269.23.3015; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; KAGAN A, 1975, INT J EPIDEMIOL, V4, P271, DOI 10.1093/ije/4.4.271; KANNEL WB, 1976, AM J CARDIOL, V38, P46, DOI 10.1016/0002-9149(76)90061-8; KANNEL WB, 1979, AM J EPIDEMIOL, V110, P281, DOI 10.1093/oxfordjournals.aje.a112813; LEE ET, 1990, AM J EPIDEMIOL, V132, P1141, DOI 10.1093/oxfordjournals.aje.a115757; Nam BH, 2000, THESIS BOSTON U BOST; *NAT CHOL ED PROGR, 1994, CIRCULATION, V89, P1333; STAMPFER MJ, 1991, NEW ENGL J MED, V325, P373, DOI 10.1056/NEJM199108083250601; Stein D, 2001, CIRCULATION, V104, P81; WILLIAMS OD, 1989, AM J EPIDEMIOL, V129, P687, DOI 10.1093/oxfordjournals.aje.a115184; Wilson PWF, 1998, CIRCULATION, V97, P1837, DOI 10.1161/01.CIR.97.18.1837; [No title captured]	21	1592	1690	0	69	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 11	2001	286	2					180	187		10.1001/jama.286.2.180	http://dx.doi.org/10.1001/jama.286.2.180			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	451JJ	11448281	Bronze			2022-12-28	WOS:000169798700023
J	Cao, XW; Sudhof, TC				Cao, XW; Sudhof, TC			A transcriptively active complex of APP with Fe65 and histone acetyltransferase Tip60	SCIENCE			English	Article							AMYLOID PRECURSOR PROTEIN; PHOSPHOTYROSINE-BINDING DOMAIN; ALZHEIMERS-DISEASE; NUCLEAR ACCESS; NOTCH; PRESENILIN; INTERACTS; PROTEOLYSIS; IDENTIFICATION; TRAFFICKING	Amyloid-beta precursor protein (APP) a widely expressed cell-surface protein. is cleaved in the transmembrane region by gamma -secretase, gamma -Cleavage Of APP produces the extracellular amyloid beta -peptide of Alzheimer's disease and releases an intracellular tail fragment of unknown physiological function. We now demonstrate that the cytoplasmic tail of APP forms a multimeric complex with the nuclear adaptor protein Fe65 and the histone acetyltransferase Tip60. This complex potently stimulates transcription via heterologous Gal4- or LexA-DNA binding domains, suggesting that release of the cytoplasmic tail of APP by gamma -cleavage may function in gene expression.	Univ Texas, SW Med Ctr, Ctr Basic Neurosci, Dept Mol Genet, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Sudhof, TC (corresponding author), Univ Texas, SW Med Ctr, Ctr Basic Neurosci, Dept Mol Genet, Dallas, TX 75390 USA.	Thomas.Sudhof@UTSouthwestern.edu	Cao, Xinwei/N-8183-2018	Cao, Xinwei/0000-0003-0651-5243				Bayer TA, 1999, MOL PSYCHIATR, V4, P524, DOI 10.1038/sj.mp.4000552; Borg JP, 1996, MOL CELL BIOL, V16, P6229; Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3; CAO X, UNPUB; Chan YM, 1998, CELL, V94, P423, DOI 10.1016/S0092-8674(00)81583-4; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; Dhalluin C, 2000, MOL CELL, V6, P921, DOI 10.1016/S1097-2765(00)00089-7; DUILIO A, 1991, NUCLEIC ACIDS RES, V19, P5269, DOI 10.1093/nar/19.19.5269; Fiore F, 1995, J BIOL CHEM, V270, P30853, DOI 10.1074/jbc.270.52.30853; *GENB, AF333983 GENB; Haass C, 1999, SCIENCE, V286, P916, DOI 10.1126/science.286.5441.916; HATA Y, 1993, NATURE, V366, P347, DOI 10.1038/366347a0; Heber S, 2000, J NEUROSCI, V20, P7951; Ikura T, 2000, CELL, V102, P463, DOI 10.1016/S0092-8674(00)00051-9; KAKIDANI H, 1988, CELL, V52, P161, DOI 10.1016/0092-8674(88)90504-1; Kamine J, 1996, VIROLOGY, V216, P357, DOI 10.1006/viro.1996.0071; KOUNNAS MZ, 1995, CELL, V82, P331, DOI 10.1016/0092-8674(95)90320-8; Lu DC, 2000, NAT MED, V6, P397, DOI 10.1038/74656; McLoughlin DM, 1996, FEBS LETT, V397, P197; Minopoli G, 2001, J BIOL CHEM, V276, P6545, DOI 10.1074/jbc.M007340200; Naruse S, 1998, NEURON, V21, P1213, DOI 10.1016/S0896-6273(00)80637-6; Okamoto M, 1997, J BIOL CHEM, V272, P31459, DOI 10.1074/jbc.272.50.31459; Price DL, 1998, ANNU REV GENET, V32, P461, DOI 10.1146/annurev.genet.32.1.461; Ran QT, 2000, GENE, V258, P141, DOI 10.1016/S0378-1119(00)00410-8; Schroeter EH, 1998, NATURE, V393, P382, DOI 10.1038/30756; Selkoe DJ, 1998, TRENDS CELL BIOL, V8, P447, DOI 10.1016/S0962-8924(98)01363-4; SMITH GM, 1988, EMBO J, V7, P3975, DOI 10.1002/j.1460-2075.1988.tb03285.x; SOPHER BL, 1994, MOL BRAIN RES, V26, P207, DOI 10.1016/0169-328X(94)90092-2; Struhl G, 1998, CELL, V93, P649, DOI 10.1016/S0092-8674(00)81193-9; Struhl G, 1999, NATURE, V398, P522, DOI 10.1038/19091; USHKARYOV YA, 1992, SCIENCE, V257, P50, DOI 10.1126/science.1621094; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Wolfe MS, 1999, NATURE, V398, P513, DOI 10.1038/19077; Yamamoto T, 1997, J BIOL CHEM, V272, P30595, DOI 10.1074/jbc.272.49.30595; Yan Y, 2000, MOL CELL, V6, P1195, DOI 10.1016/S1097-2765(00)00116-7; Ye YH, 1999, NATURE, V398, P525, DOI 10.1038/19096; Zambrano N, 1998, J BIOL CHEM, V273, P20128, DOI 10.1074/jbc.273.32.20128; Zwahlen C, 2000, EMBO J, V19, P1505, DOI 10.1093/emboj/19.7.1505	38	997	1034	2	35	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 6	2001	293	5527					115	120		10.1126/science.1058783	http://dx.doi.org/10.1126/science.1058783			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	451BB	11441186				2022-12-28	WOS:000169780300041
J	Dehal, P; Predki, P; Olsen, AS; Kobayashi, A; Folta, P; Lucas, S; Land, M; Terry, A; Zhou, CLE; Rash, S; Zhang, Q; Gordon, L; Kim, J; Elkin, C; Pollard, MJ; Richardson, P; Rokhsar, D; Uberbacher, E; Hawkins, T; Branscomb, E; Stubbs, L				Dehal, P; Predki, P; Olsen, AS; Kobayashi, A; Folta, P; Lucas, S; Land, M; Terry, A; Zhou, CLE; Rash, S; Zhang, Q; Gordon, L; Kim, J; Elkin, C; Pollard, MJ; Richardson, P; Rokhsar, D; Uberbacher, E; Hawkins, T; Branscomb, E; Stubbs, L			Human chromosome 19 and related regions in mouse: Conservative and lineage-specific evolution	SCIENCE			English	Article							PUTATIVE PHEROMONE RECEPTORS; COMPARATIVE MAP; GENE; SEQUENCE; GENOME; FAMILY	To illuminate the function and evolutionary history of both genomes, we sequenced mouse DNA related to human chromosome 19. Comparative sequence alignments yielded confirmatory evidence for hypothetical genes and identified exons, regulatory elements, and candidate genes that were missed by other predictive methods. Chromosome-wide comparisons revealed a difference between single-copy HSA19 genes, which are overwhelmingly conserved in mouse, and genes residing in tandem familiar clusters, which differ extensively in number, coding capacity, and organization between the two species. Finally, we sequenced breakpoints of all 15 evolutionary rearrangements, providing a view of the forces that drive chromosome evolution in mammals.	DOE Joint, Genome Inst, Walnut Creek, CA 94598 USA; Lawrence Livermore Natl Lab, Genome Div, Livermore, CA 94550 USA; Lawrence Livermore Natl Lab, Div Engn, Livermore, CA 94550 USA; Univ Calif Davis, Dept Genet, Davis, CA 95616 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Genome Div, Berkeley, CA 94720 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Div Engn, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Phys, Berkeley, CA 94720 USA; Oak Ridge Natl Lab, Div Life Sci, Oak Ridge, TN 37831 USA	United States Department of Energy (DOE); United States Department of Energy (DOE); Lawrence Livermore National Laboratory; United States Department of Energy (DOE); Lawrence Livermore National Laboratory; University of California System; University of California Davis; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; University of California System; University of California Berkeley; United States Department of Energy (DOE); Oak Ridge National Laboratory	Stubbs, L (corresponding author), DOE Joint, Genome Inst, Walnut Creek, CA 94598 USA.	stubbs5@llnl.gov	Terry, Astrid Y/A-2538-2011; Land, Miriam L/A-6200-2011	Terry, Astrid Y/0000-0002-5234-1224; Land, Miriam L/0000-0001-7102-0031; Stubbs, Lisa/0000-0002-9556-1972; Rokhsar, Daniel/0000-0002-8704-2224				Abrink M, 2001, P NATL ACAD SCI USA, V98, P1422, DOI 10.1073/pnas.041616998; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Band MR, 2000, GENOME RES, V10, P1359, DOI 10.1101/gr.145900; BELLEFROID EJ, 1991, P NATL ACAD SCI USA, V88, P3608, DOI 10.1073/pnas.88.9.3608; Carver EA, 1997, GENOME RES, V7, P1123, DOI 10.1101/gr.7.12.1123; DULAC C, 1995, CELL, V83, P195, DOI 10.1016/0092-8674(95)90161-2; Ewing B, 1998, GENOME RES, V8, P186, DOI 10.1101/gr.8.3.186; FELSENSTEIN J, 1993, PHYLOGENY INFERENCE; FRAZER KA, 1995, NAT GENET, V9, P424, DOI 10.1038/ng0495-424; Gao JL, 1998, GENOMICS, V51, P270, DOI 10.1006/geno.1998.5376; Giorgi D, 2000, GENOME RES, V10, P1979, DOI 10.1101/gr.10.12.1979; HAWKINS TL, 1994, NUCLEIC ACIDS RES, V22, P4543, DOI 10.1093/nar/22.21.4543; Huang XQ, 1996, GENOMICS, V33, P21, DOI 10.1006/geno.1996.0155; Kim J, 2001, GENOMICS, V74, P129, DOI 10.1006/geno.2001.6521; KIM J, UNPUB; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Lapidot M, 2001, GENOMICS, V71, P296, DOI 10.1006/geno.2000.6431; Lynch M, 2000, SCIENCE, V290, P1151, DOI 10.1126/science.290.5494.1151; Matsunami H, 1997, CELL, V90, P775, DOI 10.1016/S0092-8674(00)80537-1; Mombaerts P, 1999, SCIENCE, V286, P707, DOI 10.1126/science.286.5440.707; Murphy WJ, 2000, GENOME RES, V10, P691, DOI 10.1101/gr.10.5.691; Nelson DR, 1999, ARCH BIOCHEM BIOPHYS, V369, P1, DOI 10.1006/abbi.1999.1352; Ostrander EA, 2000, TRENDS GENET, V16, P117, DOI 10.1016/S0168-9525(99)01958-7; Postlethwait JH, 2000, GENOME RES, V10, P1890, DOI 10.1101/gr.164800; Puttagunta R, 2000, GENOME RES, V10, P1369, DOI 10.1101/gr.145200; Richard F, 2000, GENOME RES, V10, P644, DOI 10.1101/gr.10.5.644; Rodriguez I, 2000, NAT GENET, V26, P18, DOI 10.1038/79124; Rouquier S, 2000, P NATL ACAD SCI USA, V97, P2870, DOI 10.1073/pnas.040580197; Rubin EM, 2000, NATURE, V407, P265, DOI 10.1038/35025236; Shannon M, 1998, GENOMICS, V49, P112, DOI 10.1006/geno.1998.5230; SHANNON M, UNPUB; Sullivan SL, 1996, P NATL ACAD SCI USA, V93, P884, DOI 10.1073/pnas.93.2.884; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; YI J, 2000, GENOME RES, V10, P597	35	171	177	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 6	2001	293	5527					104	111		10.1126/science.1060310	http://dx.doi.org/10.1126/science.1060310			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	451BB	11441184				2022-12-28	WOS:000169780300039
J	Herbert, TD; Schuffert, JD; Andreasen, D; Heusser, L; Lyle, M; Mix, A; Ravelo, AC; Stott, LD; Herguera, JC				Herbert, TD; Schuffert, JD; Andreasen, D; Heusser, L; Lyle, M; Mix, A; Ravelo, AC; Stott, LD; Herguera, JC			Collapse of the California Current during glacial maxima linked to climate change on land	SCIENCE			English	Article							SEA-SURFACE TEMPERATURE; DEVILS-HOLE; PACIFIC-OCEAN; ATLANTIC; RECORD; CALIBRATION; INDICATORS; BARBADOS; CALCITE; MARGIN	Time series of alkenone unsaturation indices gathered along the California margin reveal Large (4 degrees to 8 degreesC) glacial-interglacial changes in sea surface temperature (SST) over the past 550,000 years. Interglacial times with SSTs equal to or exceeding that of the Holocene contain peak abundances in the pollen of redwood, the distinctive component of the temperate rainforest of the northwest coast of California. In the region now dominated by the California Current, SSTs warmed 10,000 to 15,000 years in advance of deglaciation at each of the past five glacial maxima. SSTs did not rise in advance of deglaciation south of the modern California Current front. Glacial warming along the California margin therefore is a regional signal of the weakening of the California Current during times when large ice sheets reorganized wind systems over the North Pacific. Both the timing and magnitude of the SST estimates suggest that the Devils Hole (Nevada) calcite record represents regional but not global paleotemperatures, and hence does not pose a fundamental challenge to the orbital ("Milankovitch") theory of the Ice Ages.	Brown Univ, Dept Geol Sci, Providence, RI 02912 USA; Univ Calif Santa Cruz, Santa Cruz, CA 95064 USA; Lamont Doherty Earth Observ, Palisades, NY 10964 USA; Boise State Univ, Ctr Geophys Invest Shallow Subsurface, Boise, ID 83725 USA; Oregon State Univ, Corvallis, OR 97331 USA; Univ So Calif, Los Angeles, CA 90089 USA; Ctr Invest Cient & Educ Super Ensenada, Ensenada 22860, Baja California, Mexico	Brown University; University of California System; University of California Santa Cruz; Columbia University; Idaho; Boise State University; Oregon State University; University of Southern California; CICESE - Centro de Investigacion Cientifica y de Educacion Superior de Ensenada	Herbert, TD (corresponding author), Brown Univ, Dept Geol Sci, Providence, RI 02912 USA.		Herguera, Juan Carlos/B-7812-2016	Herguera, Juan Carlos/0000-0001-8335-2607; Ravelo, Ana Christina/0000-0003-3929-677X				BARD E, 1990, NATURE, V346, P456, DOI 10.1038/346456a0; BENSON LV, 1990, PALAEOGEOGR PALAEOCL, V78, P241, DOI 10.1016/0031-0182(90)90217-U; CROWLEY TJ, 1994, PALEOCEANOGRAPHY, V9, P1, DOI 10.1029/93PA02558; Dean WE, 1997, GEOCHIM COSMOCHIM AC, V61, P4507, DOI 10.1016/S0016-7037(97)00237-8; Doose H, 1997, PALEOCEANOGRAPHY, V12, P615, DOI 10.1029/97PA00821; ELY LL, 1994, J CLIMATE, V7, P977, DOI 10.1175/1520-0442(1994)007<0977:ANPACA>2.0.CO;2; EMERY WJ, 1985, J GEOPHYS RES-OCEANS, V90, P857, DOI 10.1029/JC090iC01p00857; FAIRBANKS RG, 1978, QUATERNARY RES, V10, P181, DOI 10.1016/0033-5894(78)90100-X; GRIGGS GB, 1969, J SEDIMENT PETROL, V39, P1142; Grootes P. M., 1993, CLIMATE CHANGE CONTI, V78, P37; Henderson GM, 2000, NATURE, V404, P61, DOI 10.1038/35003541; Herbert T.D., 1995, PROC OCEAN DRILL SCI, V146, P257; Herbert TD, 1998, PALEOCEANOGRAPHY, V13, P263, DOI 10.1029/98PA00069; Heusser L.E., 1995, PROC OCEAN DRILL SCI, V146, P265; HEUSSER LE, 1979, SCIENCE, V204, P837, DOI 10.1126/science.204.4395.837; HEUSSER LE, 2000, P OC DRILL PROGR SCI, V167, P217; Hickey B. M., 1979, Progress in Oceanography, V8, P191, DOI 10.1016/0079-6611(79)90002-8; IMBRIE J, 1993, NATURE, V363, P531, DOI 10.1038/363531a0; IMBRIE J, 1984, MILANKOVITCH CLIMA 1, P269; Kennett James P., 1995, Proceedings of the Ocean Drilling Program Scientific Results, V146, P281; KENT D, 1971, GEOL SOC AM BULL, V82, P2741, DOI 10.1130/0016-7606(1971)82[2741:CCITNP]2.0.CO;2; KUTZBACH JE, 1985, QUATERNARY SCI REV, V4, P147, DOI 10.1016/0277-3791(85)90024-1; Lea DW, 2000, SCIENCE, V289, P1719, DOI 10.1126/science.289.5485.1719; LUDWIG KR, 1992, SCIENCE, V258, P284, DOI 10.1126/science.258.5080.284; LYLE M, UNPUB; MANABE S, 1985, J GEOPHYS RES-ATMOS, V90, P2167, DOI 10.1029/JD090iD01p02167; MARTINSON DG, 1987, QUATERNARY RES, V27, P1, DOI 10.1016/0033-5894(87)90046-9; Mortyn PG, 1996, PALEOCEANOGRAPHY, V11, P415, DOI 10.1029/96PA01236; Muller PJ, 1998, GEOCHIM COSMOCHIM AC, V62, P1757, DOI 10.1016/S0016-7037(98)00097-0; Ortiz J, 1997, PALEOCEANOGRAPHY, V12, P191, DOI 10.1029/96PA03165; PISIAS NG, IN PRESS QUAT SCI RE; PRAHL FG, 1995, PALEOCEANOGRAPHY, V10, P763, DOI 10.1029/95PA01394; PRAHL FG, 1988, GEOCHIM COSMOCHIM AC, V52, P2303, DOI 10.1016/0016-7037(88)90132-9; Reimers CE, 1992, GLOBAL BIOGEOCHEM CY, V6, P199, DOI 10.1029/92GB00105; ROSANSKI KL, 1993, CLIMAT CHANGE CONTIN, P1; RUDDIMAN WF, 1984, GEOL SOC AM BULL, V95, P381, DOI 10.1130/0016-7606(1984)95<381:ITRACR>2.0.CO;2; Sabin AL, 1996, QUATERNARY RES, V46, P48, DOI 10.1006/qres.1996.0043; SANCETTA C, 1992, QUATERNARY RES, V38, P359, DOI 10.1016/0033-5894(92)90044-J; Schneider R.R., 1995, S ATLANTIC PRESENT P, P527; Schrag DP, 1996, SCIENCE, V272, P1930, DOI 10.1126/science.272.5270.1930; Schuffert JD, 1998, MAR GEOL, V146, P21, DOI 10.1016/S0025-3227(97)00122-9; Shackleton NJ, 2000, SCIENCE, V289, P1897, DOI 10.1126/science.289.5486.1897; SHACKLETON NJ, 1990, T ROY SOC EDIN-EARTH, V81, P251, DOI 10.1017/S0263593300020782; SIMPSON JJ, 1983, GEOPHYS RES LETT, V10, P937, DOI 10.1029/GL010i010p00937; Stott LD, 2000, PALEOCEANOGRAPHY, V15, P161, DOI 10.1029/1999PA000375; THOMPSON PR, 1980, NATURE, V287, P829, DOI 10.1038/287829a0; Villanueva J, 1998, GEOCHIM COSMOCHIM AC, V62, P2421, DOI 10.1016/S0016-7037(98)00180-X; WINOGRAD IJ, 1992, SCIENCE, V258, P255, DOI 10.1126/science.258.5080.255; WINOGRAD IJ, 1996, EOS T AM GEOPHYS UN, V77, pS169	49	217	224	1	56	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 6	2001	293	5527					71	76		10.1126/science.1059209	http://dx.doi.org/10.1126/science.1059209			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	451BB	11441174				2022-12-28	WOS:000169780300029
J	Lydon-Rochelle, M; Holt, VL; Easterling, TR; Martin, DP				Lydon-Rochelle, M; Holt, VL; Easterling, TR; Martin, DP			Risk of uterine rupture during labor among women with a prior cesarean delivery.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							VAGINAL BIRTH; TRIAL; MISOPROSTOL; SECTION	Background: Each year in the United States, approximately 60 percent of women with a prior cesarean delivery who become pregnant again attempt labor. Concern persists that a trial of labor may increase the risk of uterine rupture, an uncommon but serious obstetrical complication. Methods: We conducted a population-based, retrospective cohort analysis using data from all primiparous women who gave birth to live singleton infants by cesarean section in civilian hospitals in Washington State from 1987 through 1996 and who delivered a second singleton child during the same period (a total of 20,095 women). We assessed the risk of uterine rupture for deliveries with spontaneous onset of labor, those with labor induced by prostaglandins, and those in which labor was induced by other means; these three groups of deliveries were compared with repeated cesarean delivery without labor. Results: Uterine rupture occurred at a rate of 1.6 per 1000 among women with repeated cesarean delivery without labor (11 women), 5.2 per 1000 among women with spontaneous onset of labor (56 women), 7.7 per 1000 among women whose labor was induced without prostaglandins (15 women), and 24.5 per 1000 among women with prostaglandin-induced labor (9 women). As compared with the risk in women with repeated cesarean delivery without labor, uterine rupture was more likely among women with spontaneous onset of labor (relative risk, 3.3; 95 percent confidence interval, 1.8 to 6.0), induction of labor without prostaglandins (relative risk, 4.9; 95 percent confidence interval, 2.4 to 9.7), and induction with prostaglandins (relative risk, 15.6; 95 percent confidence interval, 8.1 to 30.0). Conclusions: For women with one prior cesarean delivery, the risk of uterine rupture is higher among those whose labor is induced than among those with repeated cesarean delivery without labor. Labor induced with a prostaglandin confers the highest risk. (N Engl J Med 2001;345:3-8.) Copyright (C) 2001 Massachusetts Medical Society.	Univ Washington, Ctr Womens Hlth Res, Dept Family & Child Nursing, Sch Nursing, Seattle, WA 98195 USA; Univ Washington, Sch Publ Hlth & Community Med, Dept Epidemiol, Seattle, WA 98195 USA; Univ Washington, Sch Med, Dept Obstet & Gynecol, Seattle, WA 98195 USA; Univ Washington, Sch Publ Hlth & Community Med, Dept Hlth Serv, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Lydon-Rochelle, M (corresponding author), Univ Washington, Ctr Womens Hlth Res, Dept Family & Child Nursing, Sch Nursing, Mailstop 357262, Seattle, WA 98195 USA.				AHRQ HHS [5 T32 HS00034] Funding Source: Medline; NINR NIH HHS [T32 NR07039] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [T32HS000034] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NURSING RESEARCH [T32NR007039] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NINR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR)); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL INSTITUTE OF NURSING RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR))		*AM COLL OBST GYN, 1999, 228 ACOG, P1; Caughey AB, 1999, AM J OBSTET GYNECOL, V181, P872, DOI 10.1016/S0002-9378(99)70317-0; FLAMM BL, 1994, OBSTET GYNECOL, V83, P927, DOI 10.1097/00006250-199406000-00005; Gregory KD, 1999, OBSTET GYNECOL, V94, P985, DOI 10.1016/S0029-7844(99)00422-6; LEUNG AS, 1993, AM J OBSTET GYNECOL, V169, P945, DOI 10.1016/0002-9378(93)90032-E; McMahon MJ, 1996, NEW ENGL J MED, V335, P689, DOI 10.1056/NEJM199609053351001; PARRISH KM, 1993, AM J EPIDEMIOL, V138, P119, DOI 10.1093/oxfordjournals.aje.a116834; Plaut MM, 1999, AM J OBSTET GYNECOL, V180, P1535, DOI 10.1016/S0002-9378(99)70049-9; Rageth JC, 1999, OBSTET GYNECOL, V93, P332, DOI 10.1016/S0029-7844(98)00446-3; Raskin KS, 1999, J REPROD MED, V44, P571; SAS Institute, 1990, SAS STAT US GUID VER; Stalnaker BL, 1997, AM J OBSTET GYNECOL, V177, P268, DOI 10.1016/S0002-9378(97)70186-8; VENTURA SJ, 2000, NATL VITAL STAT REP, V48, P13; Wing DA, 1998, OBSTET GYNECOL, V91, P828, DOI 10.1016/S0029-7844(97)00553-X; 1998, ICD 9 CM, V1	15	566	593	1	14	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 1	2001	345	1					3	8		10.1056/NEJM200107053450101	http://dx.doi.org/10.1056/NEJM200107053450101			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	449QJ	11439945	Bronze			2022-12-28	WOS:000169697600001
J	Dearnaley, DP; Huddart, RA; Horwich, A				Dearnaley, DP; Huddart, RA; Horwich, A			Regular review - Managing testicular cancer	BMJ-BRITISH MEDICAL JOURNAL			English	Review							GERM-CELL TUMORS; EUROPEAN ORGANIZATION; COMBINATION CHEMOTHERAPY; RANDOMIZED-TRIAL; BLEOMYCIN; CISPLATIN; ETOPOSIDE; CARBOPLATIN; NONSEMINOMA; VINBLASTINE		Royal Marsden NHS Trust, Acad Unit Clin Oncol, Sutton SM2 5PT, Surrey, England	Royal Marsden NHS Foundation Trust	Dearnaley, DP (corresponding author), Royal Marsden NHS Trust, Acad Unit Clin Oncol, Sutton SM2 5PT, Surrey, England.	davidd@icr.ac.uk	Dearnaley, David P/J-2318-2014	Dearnaley, David P/0000-0002-3954-2806; huddart, robert/0000-0003-3604-1990				Akre O, 1996, J NATL CANCER I, V88, P883, DOI 10.1093/jnci/88.13.883; [Anonymous], 1997, J Clin Oncol, V15, P594; Beyer J, 1996, J CLIN ONCOL, V14, P2638, DOI 10.1200/JCO.1996.14.10.2638; Bower M, 1997, ANN ONCOL, V8, P477, DOI 10.1023/A:1008279222625; *CANC RES CAMP, 1998, 16 CANC RES CAMP; *CLIN ONC INF NEW, 2000, CLIN ONCOL S, V12, pS173; CULLEN MH, 1996, TESTICULAR CANC INVE, P181; de Wit R, 2001, J CLIN ONCOL, V19, P1629, DOI 10.1200/JCO.2001.19.6.1629; DEARNALEY DP, 1991, TESTICULAR CANCER CL, P233; deWit R, 1997, J CLIN ONCOL, V15, P1837, DOI 10.1200/JCO.1997.15.5.1837; EINHORN LH, 1977, ANN INTERN MED, V87, P293, DOI 10.7326/0003-4819-87-3-293; FORMAN D, 1994, BRIT MED J, V308, P1393, DOI 10.1136/bmj.308.6941.1393; Hain SF, 2000, BRIT J CANCER, V83, P863, DOI 10.1054/bjoc.2000.1389; Harland SJ, 1998, J UROLOGY, V160, P1353, DOI 10.1016/S0022-5347(01)62535-7; Horwich A, 2000, BRIT J CANCER, V83, P1623, DOI 10.1054/bjoc.2000.1498; Horwich A, 1997, J CLIN ONCOL, V15, P1844, DOI 10.1200/JCO.1997.15.5.1844; HORWICH A, 1995, BRIT J CANCER, V71, P901, DOI 10.1038/bjc.1995.175; Horwich Alan, 1995, P485; HUDDART R, 2000, P AM SOC CLIN ONC AL, P331; Kaye SB, 1998, J CLIN ONCOL, V16, P692, DOI 10.1200/JCO.1998.16.2.692; Lampe H, 1997, J CLIN ONCOL, V15, P239, DOI 10.1200/JCO.1997.15.1.239; MCINARDI M, 2000, J CLIN ONCOL, V18, P1725; Moynihan C, 1998, BMJ-BRIT MED J, V316, P429, DOI 10.1136/bmj.316.7129.429; Patterson H, 2001, RADIOTHER ONCOL, V59, P5, DOI 10.1016/S0167-8140(00)00240-1; PECKHAM MJ, 1983, BRIT J CANCER, V47, P613, DOI 10.1038/bjc.1983.99; Rapley EA, 2000, NAT GENET, V24, P197, DOI 10.1038/72877; READ G, 1992, J CLIN ONCOL, V10, P1762, DOI 10.1200/JCO.1992.10.11.1762; SHARPE RM, 1993, LANCET, V341, P1392, DOI 10.1016/0140-6736(93)90953-E; SUMMERSGILL B, IN PRESS BR J CANC; THORNHILL JA, 1986, BRIT MED J, V293, P480, DOI 10.1136/bmj.293.6545.480; Travis LB, 1997, JNCI-J NATL CANCER I, V89, P1429, DOI 10.1093/jnci/89.19.1429; WARDE P, 1998, P AM SOC CLIN ONC AL, P1188; WILLIAMS SD, 1987, NEW ENGL J MED, V316, P1435, DOI 10.1056/NEJM198706043162302; Zagars GK, 1996, TESTICULAR CANC INVE, P99	34	94	96	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 30	2001	322	7302					1583	1588		10.1136/bmj.322.7302.1583	http://dx.doi.org/10.1136/bmj.322.7302.1583			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	449QT	11431302	Green Published			2022-12-28	WOS:000169699200030
J	Green, HW				Green, HW			Plate tectonics - A graveyard for buoyant slabs?	SCIENCE			English	Editorial Material							DEEP-FOCUS EARTHQUAKES; MANTLE; CONSTRAINTS; CONVECTION; MECHANISM		Univ Calif Riverside, Inst Geophys & Planetary Phys, Riverside, CA 92521 USA; Univ Calif Riverside, Dept Earth Sci, Riverside, CA 92521 USA	University of California System; University of California Riverside; University of California System; University of California Riverside	Green, HW (corresponding author), Univ Calif Riverside, Inst Geophys & Planetary Phys, Riverside, CA 92521 USA.							Becker TW, 1999, EARTH PLANET SC LETT, V171, P351, DOI 10.1016/S0012-821X(99)00160-0; Chen WP, 2001, SCIENCE, V292, P2475, DOI 10.1126/science.292.5526.2475; DAVIES GF, 1984, J GEOPHYS RES, V89, P6017, DOI 10.1029/JB089iB07p06017; FISCHER KM, 1991, J GEOPHYS RES-SOLID, V96, P14403, DOI 10.1029/90JB02703; Gilbert HJ, 2001, GEOPHYS RES LETT, V28, P1855, DOI 10.1029/2000GL012192; GREEN HW, 1989, NATURE, V341, P733, DOI 10.1038/341733a0; GREEN HW, 1995, ANNU REV EARTH PL SC, V23, P169, DOI 10.1146/annurev.ea.23.050195.001125; GREEN HW, 1994, SCI AM, V271, P64, DOI 10.1038/scientificamerican0994-64; Hofmann AW, 1997, NATURE, V385, P219, DOI 10.1038/385219a0; Jiao WJ, 2000, J GEOPHYS RES-SOL EA, V105, P28125, DOI 10.1029/2000JB900314; Kirby SH, 1996, REV GEOPHYS, V34, P261, DOI 10.1029/96RG01050; Lithgow-Bertelloni C, 1998, REV GEOPHYS, V36, P27, DOI 10.1029/97RG02282; Okal EA, 1998, PHYS EARTH PLANET IN, V109, P25, DOI 10.1016/S0031-9201(98)00116-2; Peacock SM, 2001, GEOLOGY, V29, P299, DOI 10.1130/0091-7613(2001)029<0299:ATLPOD>2.0.CO;2; SILVER PG, 1995, SCIENCE, V268, P69, DOI 10.1126/science.268.5207.69; TACKLEY PJ, 1993, NATURE, V361, P699, DOI 10.1038/361699a0; Turcotte DL, 2001, J GEOPHYS RES-SOL EA, V106, P4265, DOI 10.1029/2000JB900409; ULMER P, 1995, SCIENCE, V268, P858, DOI 10.1126/science.268.5212.858; vanderHilst RD, 1997, NATURE, V386, P578, DOI 10.1038/386578a0; Wyss M, 2001, GEOPHYS RES LETT, V28, P1819, DOI 10.1029/2000GL012558	20	8	8	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 29	2001	292	5526					2445	2446		10.1126/science.1062558	http://dx.doi.org/10.1126/science.1062558			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	448YU	11431557				2022-12-28	WOS:000169658200029
J	Imai, Y; Soda, M; Inoue, H; Hattori, N; Mizuno, Y; Takahashi, R				Imai, Y; Soda, M; Inoue, H; Hattori, N; Mizuno, Y; Takahashi, R			An unfolded putative transmembrane polypeptide, which can lead to endoplasmic reticulum stress, is a substrate of parkin	CELL			English	Article							UBIQUITIN-PROTEIN LIGASE; RECESSIVE JUVENILE PARKINSONISM; ALPHA-SYNUCLEIN; LEWY BODIES; DEGRADATION; DISEASE; ER; RECEPTOR; AGGREGATION; PROTEASOME	A putative G protein-coupled transmembrane polypeptide, named Pael receptor, was identified as an interacting protein with Parkin, a gene product responsible for autosomal recessive juvenile Parkinsonism (AR-JP). When overexpressed in cells, this receptor tends to become unfolded, insoluble, and ubiquitinated in vivo. The insoluble Pael receptor leads to unfolded protein-induced cell death. Parkin specifically ubiquitinates this receptor in the presence of ubiquitin-conjugating enzymes resident in the endoplasmic reticulum and promotes the degradation of insoluble Pael receptor, resulting in suppression of the cell death induced by Pael receptor overexpression. Moreover, the insoluble form of Pael receptor accumulates in the brains of AR-JP patients. Here, we show that the unfolded Pael receptor is a substrate of Parkin, the accumulation of which may cause selective neuronal death in AR-JP.	RIKEN, BSI, Lab Motor Syst Neurodegenerat, Saitama 3510198, Japan; Juntendo Univ, Sch Med, Dept Neurol, Bunkyo Ku, Tokyo 1130033, Japan	RIKEN; Juntendo University	Takahashi, R (corresponding author), RIKEN, BSI, Lab Motor Syst Neurodegenerat, Saitama 3510198, Japan.		Imai, Yuzuru/AAA-6472-2019; Hattori, Nobutaka/ACR-0069-2022	Imai, Yuzuru/0000-0003-2924-5231; Inoue, Haruhisa/0000-0003-4736-9537				Baba M, 1998, AM J PATHOL, V152, P879; Biederer T, 1997, SCIENCE, V278, P1806, DOI 10.1126/science.278.5344.1806; Bordallo J, 1998, MOL BIOL CELL, V9, P209, DOI 10.1091/mbc.9.1.209; Casagrande R, 2000, MOL CELL, V5, P729, DOI 10.1016/S1097-2765(00)80251-8; Donohue PJ, 1998, MOL BRAIN RES, V54, P152, DOI 10.1016/S0169-328X(97)00336-7; Friedlander R, 2000, NAT CELL BIOL, V2, P379, DOI 10.1038/35017001; Gilon T, 2000, MOL CELL BIOL, V20, P7214, DOI 10.1128/MCB.20.19.7214-7219.2000; Goldberg MS, 2000, NAT CELL BIOL, V2, pE115, DOI 10.1038/35017124; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Imai Y, 2000, J BIOL CHEM, V275, P35661, DOI 10.1074/jbc.C000447200; Jackson PK, 2000, TRENDS CELL BIOL, V10, P429, DOI 10.1016/S0962-8924(00)01834-1; JENSEN TJ, 1995, CELL, V83, P129, DOI 10.1016/0092-8674(95)90241-4; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Julien JP, 2001, CELL, V104, P581, DOI 10.1016/S0092-8674(01)00244-6; Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416; Kopito RR, 2000, TRENDS CELL BIOL, V10, P524, DOI 10.1016/S0962-8924(00)01852-3; KOZUTSUMI Y, 1988, NATURE, V332, P462, DOI 10.1038/332462a0; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Mayer TU, 1998, EMBO J, V17, P3251, DOI 10.1093/emboj/17.12.3251; Mizuno Y, 1998, J NEUROCHEM, V71, P893; Morett E, 1999, TRENDS BIOCHEM SCI, V24, P229, DOI 10.1016/S0968-0004(99)01381-X; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Petaja-Repo UE, 2001, J BIOL CHEM, V276, P4416, DOI 10.1074/jbc.M007151200; Plemper RK, 1999, TRENDS BIOCHEM SCI, V24, P266, DOI 10.1016/S0968-0004(99)01420-6; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Sherman MY, 2001, NEURON, V29, P15, DOI 10.1016/S0896-6273(01)00177-5; Shimura H, 2000, NAT GENET, V25, P302, DOI 10.1038/77060; Shimura H, 1999, ANN NEUROL, V45, P668, DOI 10.1002/1531-8249(199905)45:5<668::AID-ANA19>3.0.CO;2-Z; Spillantini MG, 1998, P NATL ACAD SCI USA, V95, P6469, DOI 10.1073/pnas.95.11.6469; Travers KJ, 2000, CELL, V101, P249, DOI 10.1016/S0092-8674(00)80835-1; Trojanowski JQ, 1998, CELL DEATH DIFFER, V5, P832, DOI 10.1038/sj.cdd.4400432; Urano F, 2000, SCIENCE, V287, P664, DOI 10.1126/science.287.5453.664; Valdenaire O, 1998, FEBS LETT, V424, P193, DOI 10.1016/S0014-5793(98)00170-7; WARD CL, 1995, CELL, V83, P121, DOI 10.1016/0092-8674(95)90240-6; Wilhovsky S, 2000, MOL BIOL CELL, V11, P1697, DOI 10.1091/mbc.11.5.1697; Yu H, 1999, J BIOL CHEM, V274, P36852, DOI 10.1074/jbc.274.52.36852; Zeng ZZ, 1997, BIOCHEM BIOPH RES CO, V233, P559, DOI 10.1006/bbrc.1997.6408; Zhang Y, 2000, P NATL ACAD SCI USA, V97, P13354, DOI 10.1073/pnas.240347797; Zuscik MJ, 2000, NAT MED, V6, P1388, DOI 10.1038/82207	40	852	900	0	27	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTES AVE,, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 29	2001	105	7					891	902		10.1016/S0092-8674(01)00407-X	http://dx.doi.org/10.1016/S0092-8674(01)00407-X			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	449BK	11439185	Bronze			2022-12-28	WOS:000169664300009
J	Green, RH; Pavord, ID				Green, RH; Pavord, ID			Leukotriene antagonists and symptom control in chronic persistent asthma	LANCET			English	Editorial Material							EXERCISE-INDUCED BRONCHOCONSTRICTION; RECEPTOR ANTAGONIST; INHALED CORTICOSTEROIDS; CONTROLLED TRIAL; MILD ASTHMA; MONTELUKAST; DIAGNOSIS		Glenfield Hosp, Dept Resp Med, Inst Lung Hlth, Leicester LE3 9QP, Leics, England	University Hospitals of Leicester NHS Trust; University of Leicester; Glenfield Hospital	Green, RH (corresponding author), Glenfield Hosp, Dept Resp Med, Inst Lung Hlth, Leicester LE3 9QP, Leics, England.			Pavord, Ian/0000-0002-4288-5973				CHRISTIAN VJ, 2000, AM J RESP CRIT CARE, V162, P578; Dennis SM, 2000, LANCET, V355, P1675, DOI 10.1016/S0140-6736(00)02238-8; Diamant Z, 1999, CLIN EXP ALLERGY, V29, P42; Drazen JM, 1999, NAT GENET, V22, P168, DOI 10.1038/9680; FINNERTY JP, 1992, AM REV RESPIR DIS, V145, P746, DOI 10.1164/ajrccm/145.4_Pt_1.746; GREENING AP, 1994, LANCET, V344, P219, DOI 10.1016/S0140-6736(94)92996-3; Hunter CJ, 1999, AM J RESP CRIT CARE, V159, pA653; JAMISON JP, 1993, CLIN SCI, V85, P367, DOI 10.1042/cs0850367; Joyce DP, 1996, CHEST, V109, P697, DOI 10.1378/chest.109.3.697; Leff JA, 1998, NEW ENGL J MED, V339, P147, DOI 10.1056/NEJM199807163390302; Lofdahl CG, 1999, BMJ-BRIT MED J, V319, P87, DOI 10.1136/bmj.319.7202.87; MANNING PJ, 1990, NEW ENGL J MED, V323, P1736, DOI 10.1056/NEJM199012203232504; Pauwels RA, 1997, NEW ENGL J MED, V337, P1405, DOI 10.1056/NEJM199711133372001; Pavord ID, 1999, AM J RESP CRIT CARE, V160, P1905, DOI 10.1164/ajrccm.160.6.9903114; Pizzichini E, 1999, EUR RESPIR J, V14, P12, DOI 10.1034/j.1399-3003.1999.14a04.x; Reiss TF, 1997, THORAX, V52, P45, DOI 10.1136/thx.52.1.45; Sampson AP, 2000, THORAX, V55, pS28, DOI 10.1136/thorax.55.suppl_2.S28; SPECTOR SL, 1994, AM J RESP CRIT CARE, V150, P618, DOI 10.1164/ajrccm.150.3.8087328; TAYLOR IK, 1991, LANCET, V337, P690, DOI 10.1016/0140-6736(91)90277-V	19	13	13	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 23	2001	357	9273					1991	1992		10.1016/S0140-6736(00)05132-1	http://dx.doi.org/10.1016/S0140-6736(00)05132-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	446JB	11438126				2022-12-28	WOS:000169509200003
J	Oganov, AR; Brodholt, JP; Price, GD				Oganov, AR; Brodholt, JP; Price, GD			The elastic constants of MgSiO3 perovskite at pressures and temperatures of the Earth's mantle	NATURE			English	Article							MOLECULAR-DYNAMICS; SEISMIC TOMOGRAPHY; CONSTRAINTS; BEHAVIOR; CORE	The temperature anomalies in the Earth's mantle associated with thermal convection(1) can be inferred from seismic tomography, provided that the elastic properties of mantle minerals are known as a function of temperature at mantle pressures. At present, however, such information is difficult to obtain directly through laboratory experiments. We have therefore taken advantage of recent advances in computer technology, and have performed finite-temperature ab initio molecular dynamics simulations(2,3) of the elastic properties of MgSiO3 perovskite, the major mineral of the lower mantle, at relevant thermodynamic conditions. When combined with the results from tomographic images of the mantle, our results indicate that the lower mantle is either significantly anelastic(4) or compositionally heterogeneous on large scales(5). We found the temperature contrast between the coldest and hottest regions of the mantle, at a given depth, to be about 800 K at 1,000 km, 1,500 K at 2,000 km, and possibly over 2,000 K at the core-mantle boundary.	UCL, Dept Geol Sci, London WC1E 6BT, England	University of London; University College London	Oganov, AR (corresponding author), UCL, Dept Geol Sci, Gower St, London WC1E 6BT, England.	a.oganov@ucl.ac.uk	Oganov, Artem R./O-8234-2019; Brodholt, John P/B-7136-2011; Oganov, Artem R/A-1213-2008; Price, Geoffrey D/C-1545-2008; Oganov, Artem R./AAA-1478-2021	Oganov, Artem R./0000-0001-7082-9728; Brodholt, John P/0000-0001-7395-5834; Oganov, Artem R/0000-0001-7082-9728; Price, Geoffrey D/0000-0001-8232-6853; 				Alfe D, 1999, NATURE, V401, P462, DOI 10.1038/46758; Ancilotto F, 1997, SCIENCE, V275, P1288, DOI 10.1126/science.275.5304.1288; ANDERSON DL, 1989, THEORY EARTH; BUDA F, 1990, PHYS REV B, V41, P1680, DOI 10.1103/PhysRevB.41.1680; Castle JC, 2000, J GEOPHYS RES-SOL EA, V105, P21543, DOI 10.1029/2000JB900193; Cavazzoni C, 1999, SCIENCE, V283, P44, DOI 10.1126/science.283.5398.44; da Silva CRS, 2000, PHYS EARTH PLANET IN, V118, P103, DOI 10.1016/S0031-9201(99)00133-8; HOHENBERG P, 1964, PHYS REV B, V136, pB864, DOI 10.1103/PhysRevB.7.1912; KARATO S, 1993, GEOPHYS RES LETT, V20, P1623, DOI 10.1029/93GL01767; Karki BB, 1999, SCIENCE, V286, P1705, DOI 10.1126/science.286.5445.1705; Kennett BLN, 1998, J GEOPHYS RES-SOL EA, V103, P12469, DOI 10.1029/98JB00150; Kesson SE, 1998, NATURE, V393, P252, DOI 10.1038/30466; KNITTLE E, 1991, SCIENCE, V251, P1438, DOI 10.1126/science.251.5000.1438; KOHN W, 1965, PHYS REV, V140, P1133, DOI 10.1103/PhysRev.140.A1133; Kresse G, 1996, COMP MATER SCI, V6, P15, DOI 10.1016/0927-0256(96)00008-0; Masters G, 2000, AGU MONOGRAPH, V171, P63, DOI DOI 10.1029/GM117P0063; MATSUI M, 1991, NATURE, V351, P735, DOI 10.1038/351735a0; NOSE S, 1984, MOL PHYS, V52, P255, DOI 10.1080/00268978400101201; Oganov AR, 2001, EARTH PLANET SC LETT, V184, P555, DOI 10.1016/S0012-821X(00)00363-0; OKEEFFE M, 1979, SCIENCE, V206, P599, DOI 10.1126/science.206.4418.599; Robertson GS, 1996, EARTH PLANET SC LETT, V143, P197, DOI 10.1016/0012-821X(96)00134-3; SHEN GY, 1995, J GEOPHYS RES-SOL EA, V100, P17699, DOI 10.1029/95JB01864; SUGINO O, 1995, PHYS REV LETT, V74, P1823, DOI 10.1103/PhysRevLett.74.1823; Wallace D. C., 1998, THERMODYNAMICS CRYST; WANG Y, 1991, PHYS REV B, V44, P13298, DOI 10.1103/PhysRevB.44.13298; YUEN DA, 1993, GEOPHYS RES LETT, V20, P899, DOI 10.1029/93GL00867	27	160	166	2	64	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 21	2001	411	6840					934	937		10.1038/35082048	http://dx.doi.org/10.1038/35082048			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	444EN	11418854	Green Submitted			2022-12-28	WOS:000169386200040
J	Mires, G; Williams, F; Howie, P				Mires, G; Williams, F; Howie, P			Randomised controlled trial of cardiotocography versus Doppler auscultation of fetal heart at admission in labour in low risk obstetric population	BRITISH MEDICAL JOURNAL			English	Article							CESAREAN-SECTION RATE; OBSERVER VARIABILITY; ANTEPARTUM CARDIOTOCOGRAMS; RATE PATTERNS; INTRAPARTUM; INTEROBSERVER	Objective To compare the effect of admission cardiotocography and Doppler auscultation of the fetal heart on neonatal outcome and levels of obstetric intervention in a low risk obstetric population. Design Randomised controlled trial. Setting Obstetric unit of teaching hospital Participants Pregnant women who had no obstetric complications that warranted continuous monitoring of fetal heart rate in labour. Intervention Women were randomised to receive either cardiotocography or Doppler auscultation of the fetal heart when they were admitted in spontaneous uncomplicated labour. Main outcome measures The primary outcome measure was umbilical arterial metabolic acidosis. Secondary outcome measures included other measures of condition at birth and obstetric intervention. Results There were no significant differences in the incidence of metabolic acidosis or any other measure of neonatal outcome among women who remained at low risk when they were admitted in labour. However, compared with women who received Doppler auscultation, women who had admission cardiotocography were significantly more likely to have continuous fetal heart rate monitoring in labour (odds ratio 1.49, 95% confidence interval 1.26 to 1.76), augmentation of labour (1.26, 1.02 to 1.56), epidural analgesia (1.33, 1.10 to 1.61), and operative delivery (1.36, 1.12 to 1.65). Conclusions Compared with Doppler auscultation of the fetal heart, admission cardiotocography does not benefit neonatal outcome in low risk women. Its use results in increased obstetric intervention, including operative delivery.	Univ Dundee, Ninewells Hosp & Med Sch, Dept Obstet & Gynaecol, Dundee DD1 9SY, Scotland; Univ Dundee, Ninewells Hosp & Med Sch, Dept Epidemiol & Publ Hlth, Dundee DD1 9SY, Scotland	University of Dundee; University of Dundee	Mires, G (corresponding author), Univ Dundee, Ninewells Hosp & Med Sch, Dept Obstet & Gynaecol, Dundee DD1 9SY, Scotland.			Williams, Fiona/0000-0002-3046-9235				BEAULIEU MD, 1982, CAN MED ASSOC J, V127, P214; BORGATTA L, 1988, AM J OBSTET GYNECOL, V159, P554, DOI 10.1016/S0002-9378(88)80006-1; CHAMBERLAIN G, 1993, BRIT J OBSTET GYNAEC, V100, P403, DOI 10.1111/j.1471-0528.1993.tb15260.x; DAWES GS, 1992, BRIT J OBSTET GYNAEC, V99, P791, DOI 10.1111/j.1471-0528.1992.tb14408.x; FLOREY CD, 1995, RANDOMISER; FLYNN AM, 1982, BRIT J OBSTET GYNAEC, V89, P434, DOI 10.1111/j.1471-0528.1982.tb03632.x; Grant A.M, 1993, COCHRANE PREGNANCY C; HELFAND M, 1985, AM J OBSTET GYNECOL, V151, P737, DOI 10.1016/0002-9378(85)90507-1; INGEMARSSON I, 1993, INTRAPARTUM FETAL SU, P45; LIDEGAARD O, 1992, ACTA OBSTET GYN SCAN, V71, P48, DOI 10.3109/00016349209007947; LOTGERING FK, 1982, AM J OBSTET GYNECOL, V144, P701, DOI 10.1016/0002-9378(82)90440-9; MACFARLANE A, 1993, LANCET, V342, P1005, DOI 10.1016/0140-6736(93)92874-S; MCILWAINE G M, 1985, Health Bulletin (Edinburgh), V43, P301; NIELSEN PV, 1987, ACTA OBSTET GYN SCAN, V66, P421, DOI 10.3109/00016348709022046; PELLO LC, 1988, BRIT J OBSTET GYNAEC, V95, P1128, DOI 10.1111/j.1471-0528.1988.tb06790.x; PHELAN JP, 1994, CLIN PERINATOL, V21, P879, DOI 10.1016/S0095-5108(18)30324-5; PRENTICE A, 1997, LANCET, V350, P1375; SARNO AP, 1990, J REPROD MED, V35, P239; THACKER SB, 1995, OBSTET GYNECOL, V86, P613, DOI 10.1016/0029-7844(95)00232-G; THACKER SB, 2000, COCHRANE DATABASE SY; TREFFERS PE, 1993, BMJ-BRIT MED J, V307, P1017, DOI 10.1136/bmj.307.6911.1017; TRIMBOS JB, 1978, BRIT J OBSTET GYNAEC, V85, P900, DOI 10.1111/j.1471-0528.1978.tb15851.x; Wilkinson C, 1998, BRIT J OBSTET GYNAEC, V105, P45, DOI 10.1111/j.1471-0528.1998.tb09349.x	23	58	59	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 16	2001	322	7300					1457	1460		10.1136/bmj.322.7300.1457	http://dx.doi.org/10.1136/bmj.322.7300.1457			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	444FJ	11408301	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000169389200026
J	Lee, SH; Oe, T; Blair, IA				Lee, SH; Oe, T; Blair, IA			Vitamin C-induced decomposition of lipid hydroperoxides to endogenous genotoxins	SCIENCE			English	Article							DNA-ADDUCTS; IN-VIVO; PEROXIDATION; PRODUCT; DAMAGE; ACID; SUBSTRATE; ASCORBATE; APOPTOSIS; RADICALS	Epidemiological data suggest that dietary antioxidants play a protective role against cancer. This has led to the proposal that dietary supplementation with antioxidants such as vitamin C (vit C) may be useful in disease prevention. However, vit C has proved to be ineffective in cancer chemoprevention studies. In addition, concerns have been raised over potentially deleterious transition metal ion-mediated pro-oxidant effects. We have now determined that vit C induces lipid hydroperoxide decomposition to the DNA-reactive bifunctional electrophiles 4-oxo-2-nonenal, 4,5-epoxy-2(E)-decenal, and 4-hydroxy-2-non-enal, The compound 4,5-Epoxy-2(E)-decenal is a precursor of etheno-2'-deoxyadenosine, a highly mutagenic lesion found in human DNA. Vitamin C-mediated formation of genotoxins from lipid hydroperoxides in the absence of transition metal ions could help explain its lack of efficacy as a cancer chemoprevention agent.	Univ Penn, Ctr Canc Pharmacol, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine	Blair, IA (corresponding author), Univ Penn, Ctr Canc Pharmacol, 1254 BRB 2-3,421 Curie Blvd, Philadelphia, PA 19104 USA.		Blair, Ian A/B-3320-2010; Oe, Tomoyuki/AAE-1514-2019	Oe, Tomoyuki/0000-0002-3893-0815; Lee, Seon Hwa/0000-0003-1095-5516	NATIONAL CANCER INSTITUTE [P30CA016520, R01CA065878] Funding Source: NIH RePORTER; NCI NIH HHS [CA65878, CA16520] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AMES BN, 1993, P NATL ACAD SCI USA, V90, P7915, DOI 10.1073/pnas.90.17.7915; Beckman KB, 1997, J BIOL CHEM, V272, P19633, DOI 10.1074/jbc.272.32.19633; Brash AR, 1999, J BIOL CHEM, V274, P23679, DOI 10.1074/jbc.274.34.23679; Buettner GR, 1996, RADIAT RES, V145, P532, DOI 10.2307/3579271; Burcham PC, 1998, MUTAGENESIS, V13, P287, DOI 10.1093/mutage/13.3.287; Burczynski ME, 2001, J BIOL CHEM, V276, P2890, DOI 10.1074/jbc.M006655200; Cadet J, 1999, MUTAT RES-FUND MOL M, V424, P9, DOI 10.1016/S0027-5107(99)00004-4; CHAUDHARY AK, 1994, SCIENCE, V265, P1580, DOI 10.1126/science.8079172; Chung FL, 1996, CARCINOGENESIS, V17, P2105, DOI 10.1093/carcin/17.10.2105; Doerge DR, 2000, CHEM RES TOXICOL, V13, P1259, DOI 10.1021/tx0001575; Gardner HW, 1998, PLANT PHYSIOL, V116, P1359, DOI 10.1104/pp.116.4.1359; HAMBERG M, 1967, J BIOL CHEM, V242, P5336; Hamberg M, 1998, ARCH BIOCHEM BIOPHYS, V349, P376, DOI 10.1006/abbi.1997.0443; Johnson TM, 1996, P NATL ACAD SCI USA, V93, P11848, DOI 10.1073/pnas.93.21.11848; Kamitani H, 1998, J BIOL CHEM, V273, P21569, DOI 10.1074/jbc.273.34.21569; KURNAGAI T, 2000, BIOCHEM BIOPH RES CO, V273, P437; LANEUVILLE O, 1995, J BIOL CHEM, V270, P19330, DOI 10.1074/jbc.270.33.19330; LAUDICINA DC, 1990, ARCH BIOCHEM BIOPHYS, V278, P73, DOI 10.1016/0003-9861(90)90233-O; Lee SH, 2000, CHEM RES TOXICOL, V13, P698, DOI 10.1021/tx000101a; Lee SH, 2000, CHEM RES TOXICOL, V13, P565, DOI 10.1021/tx000057z; Levine M, 1996, P NATL ACAD SCI USA, V93, P3704, DOI 10.1073/pnas.93.8.3704; Levine RL, 2000, CANCER RES, V60, P4098; Lin JM, 1999, LIPIDS, V34, P1117, DOI 10.1007/s11745-999-0463-8; Linn S, 1998, DRUG METAB REV, V30, P313, DOI 10.3109/03602539808996315; Lippman SM, 1998, JNCI-J NATL CANCER I, V90, P1514, DOI 10.1093/jnci/90.20.1514; Marnett LJ, 2000, CARCINOGENESIS, V21, P361, DOI 10.1093/carcin/21.3.361; Proteggente AR, 2000, BIOCHEM BIOPH RES CO, V277, P535, DOI 10.1006/bbrc.2000.3711; PRYOR WA, 1990, FREE RADICAL BIO MED, V8, P541, DOI 10.1016/0891-5849(90)90153-A; Rindgen D, 1999, CHEM RES TOXICOL, V12, P1195, DOI 10.1021/tx990034o; Williams C, 1999, ANN NY ACAD SCI, V889, P72, DOI 10.1111/j.1749-6632.1999.tb08725.x	30	358	389	1	44	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 15	2001	292	5524					2083	2086		10.1126/science.1059501	http://dx.doi.org/10.1126/science.1059501			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	442KP	11408659				2022-12-28	WOS:000169284700050
J	Chaudhari, U; Romano, P; Mulcahy, LD; Dooley, LT; Baker, DG; Gottlieb, AB				Chaudhari, U; Romano, P; Mulcahy, LD; Dooley, LT; Baker, DG; Gottlieb, AB			Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial	LANCET			English	Article							MONOCLONAL-ANTIBODY; TNF-ALPHA; CLINICAL ACTIVITY; BLOCKADE; THERAPY; CELLS	Background Currently available treatments for moderate to severe psoriasis are either incompletely effective in some patients, or are associated with toxic effects. Since tumour necrosis factor alpha (TNF-alpha) is thought to have a role in the pathogenesis of psoriasis, we did a double-blind, randomised trial to assess the clinical benefit and safety of infliximab-a monoclonal antibody against TNF-alpha. Methods 33 patients with moderate to severe plaque psoriasis were randomly assigned intravenous placebo (n=11), infliximab 5 mg/kg (n=11), or infliximab 10 mg/kg (n=11) at weeks 0, 2, and 6. Patients were assessed at week 10 for the primary endpoint (score on the physician's global assessment [PGA]). Analysis was by intention to treat. Findings Of the 33 patients enrolled, three dropped out. Nine of 11 (82%) patients in the Infliximab 5 mg/kg group were responders (good, excellent, or clear rating on PGA), compared with two of 11 (18%) In the placebo group (difference 64% [95% CI 20-89], p=0.0089), and ten of 11 (91%) patients in the infliximab 10 mg/kg group were responders (difference from placebo 73% [30-94], p=0.0019). The median time to response was 4 weeks for patients in both infliximab groups. There were no serious adverse events, and infliximab was well tolerated. Interpretation In this controlled trial, patients receiving the anti-TNF-alpha agent infliximab as monotherapy experienced a high degree of clinical benefit and rapid time to response In the treatment of moderate to severe plaque psoriasis compared with patients who received placebo. These findings suggest that TNF-alpha has a pivotal role in the pathogenesis of psoriasis.	Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Clin Res Ctr, New Brunswick, NJ 08901 USA; Centocor Inc, Malvern, PA 19355 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Johnson & Johnson; Johnson & Johnson USA; Janssen Biotech Inc	Gottlieb, AB (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Clin Res Ctr, 51 French St, New Brunswick, NJ 08901 USA.	gottlieb@umdnj.edu						Abrams JR, 2000, J EXP MED, V192, P681, DOI 10.1084/jem.192.5.681; Asadullah K, 1998, J CLIN INVEST, V101, P783, DOI 10.1172/JCI1476; Baert FJ, 1999, GASTROENTEROLOGY, V116, P22, DOI 10.1016/S0016-5085(99)70224-6; BAETEN D, 2000, ARTHRITIS RHEUM S, V43; BAKER BS, 1992, BRIT J DERMATOL, V126, P1, DOI 10.1111/j.1365-2133.1992.tb08394.x; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; Barone D, 1999, ARTHRITIS RHEUM, V42, pS90; Bos JD, 1999, IMMUNOL TODAY, V20, P40, DOI 10.1016/S0167-5699(98)01381-4; ELLIS CN, 1991, NEW ENGL J MED, V324, P277, DOI 10.1056/NEJM199101313240501; ETTEHADI P, 1994, CLIN EXP IMMUNOL, V96, P146, DOI 10.1111/j.1365-2249.1994.tb06244.x; Feldman SR, 1997, J AM ACAD DERMATOL, V37, P564, DOI 10.1016/S0190-9622(97)70172-5; FREDRIKSSON T, 1978, DERMATOLOGICA, V157, P238, DOI 10.1159/000250839; GEBOES K, 2000, GASTROENTEROLOGY S2, V118; Gottlieb A, 2000, J AM ACAD DERMATOL, V42, P428, DOI 10.1016/S0190-9622(00)90214-7; Gottlieb A., 2000, Journal of Investigative Dermatology, V114, P840; Gottlieb AB, 1997, ARCH DERMATOL, V133, P781, DOI 10.1001/archderm.133.6.781; GOTTLIEB AB, 1998, DIS MANAGE CLIN OUTC, V1, P195; GOTTLIEB AB, IN PRESS DERMATOL CL; GREAVES MW, 1995, NEW ENGL J MED, V332, P581, DOI 10.1056/NEJM199503023320907; Kimber I, 2000, BRIT J DERMATOL, V142, P401, DOI 10.1046/j.1365-2133.2000.03349.x; KNIGHT DM, 1993, MOL IMMUNOL, V30, P1443, DOI 10.1016/0161-5890(93)90106-L; Krueger JG, 2000, J AM ACAD DERMATOL, V43, P448, DOI 10.1067/mjd.2000.106515; MAGILAVY D, 1999, BRIT J DERMATOL, V141, P990; Mease PJ, 2000, LANCET, V356, P385, DOI 10.1016/S0140-6736(00)02530-7; NIKOLAUS S, 2000, GASTROENTEROLOGY S2, V118; Oh CJ, 2000, J AM ACAD DERMATOL, V42, P829, DOI 10.1067/mjd.2000.105948; Ortonne JP, 1996, BRIT J DERMATOL, V135, P1, DOI 10.1111/j.1365-2133.1996.tb15660.x; Scallon B, 2000, ARTHRITIS RHEUM, V43, pS226; SCALLON BJ, 1995, CYTOKINE, V7, P251, DOI 10.1006/cyto.1995.0029; SCHLUTER UG, 2000, GASTROENTEROLOGY S2, V118; Tak PP, 1996, ARTHRITIS RHEUM, V39, P1077, DOI 10.1002/art.1780390702; Taylor PC, 2000, ARTHRITIS RHEUM-US, V43, P38, DOI 10.1002/1529-0131(200001)43:1<38::AID-ANR6>3.0.CO;2-L; Trepicchio W, 1999, J INVEST DERMATOL, V112, P598; WAKEFIELD PE, 1991, J AM ACAD DERMATOL, V24, P675, DOI 10.1016/0190-9622(91)70102-8	34	723	759	2	29	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 9	2001	357	9271					1842	1847		10.1016/S0140-6736(00)04954-0	http://dx.doi.org/10.1016/S0140-6736(00)04954-0			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	440DN	11410193				2022-12-28	WOS:000169160800013
J	Mack, TM				Mack, TM			The new pan-asian paan problem	LANCET			English	Editorial Material							RISK-FACTOR; BETEL QUID; TOBACCO		Univ So Calif, Dept Prevent Med, Los Angeles, CA 90089 USA	University of Southern California	Mack, TM (corresponding author), Univ So Calif, Dept Prevent Med, Los Angeles, CA 90089 USA.	tmack@hsc.usc.edu						Chen CL, 1999, CARCINOGENESIS, V20, P2331, DOI 10.1093/carcin/20.12.2331; Chen JW, 1996, J ORAL PATHOL MED, V25, P140, DOI 10.1111/j.1600-0714.1996.tb00209.x; GUPTA P, 1990, 7 WORLD C TOB HLTH P; Gupta PC, 2000, B WORLD HEALTH ORGAN, V78, P877; HUANG WT, 1990, EC STUDY BETEL NUTS; *IARC, 1972, MON EV CARC RISK CHE, V1, P169; *IARC, 1985, MON EV CARC RISK CHE, V37, P141; Liu CJ, 2000, CAN MED ASSOC J, V162, P359; Merchant A, 2000, INT J CANCER, V86, P128, DOI 10.1002/(SICI)1097-0215(20000401)86:1&lt;128::AID-IJC20&gt;3.0.CO;2-M; Norton SA, 1998, J AM ACAD DERMATOL, V38, P81, DOI 10.1016/S0190-9622(98)70543-2; PINDBORG JJ, 1984, COMMUNITY DENT ORAL, V12, P195, DOI 10.1111/j.1600-0528.1984.tb01438.x; Reichart P A, 1999, Eur J Dent Educ, V3, P126, DOI 10.1111/j.1600-0579.1999.tb00078.x; SARMA AB, 1992, FOOD CHEM TOXICOL, V30, P161, DOI 10.1016/0278-6915(92)90152-B; Tang JG, 1997, COMMUNITY DENT ORAL, V25, P177, DOI 10.1111/j.1600-0528.1997.tb00918.x; Tsai JF, 2001, BRIT J CANCER, V84, P709, DOI 10.1054/bjoc.1999.1597	15	30	31	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 26	2001	357	9269					1638	1639		10.1016/S0140-6736(00)04860-1	http://dx.doi.org/10.1016/S0140-6736(00)04860-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	435UY	11425364				2022-12-28	WOS:000168901600005
J	Perutz, MF; Windle, AH				Perutz, MF; Windle, AH			Cause of neural death in neurodegenerative diseases attributable to expansion of glutamine repeats	NATURE			English	Article							HUNTINGTONS-DISEASE; INTRANUCLEAR INCLUSIONS; CELL-DEATH; DYSFUNCTION; MODEL	Neurodegenerative diseases resulting from expanded repeat sequences of glutamine residues are associated with the formation of protein aggregates in the cell nuclei of the affected neurons, but whether these are pathogenic is controversial. Recent observations indicate that the ages of onset of these diseases are exponential functions of the repeat lengths and that the probability of neural death is constant with time. The only process known to us that could give rise to such behaviour is nucleation of the aggregates.	MRC, Mol Biol Lab, Cambridge CB2 2QH, England; Univ Cambridge, Dept Mat Sci & Met, Cambridge CB2 3QZ, England	MRC Laboratory Molecular Biology; University of Cambridge	Perutz, MF (corresponding author), MRC, Mol Biol Lab, Hills Rd, Cambridge CB2 2QH, England.							Carmichael J, 2000, P NATL ACAD SCI USA, V97, P9701, DOI 10.1073/pnas.170280697; Clarke G, 2000, NATURE, V406, P195, DOI 10.1038/35018098; Davies SW, 1997, CELL, V90, P537, DOI 10.1016/S0092-8674(00)80513-9; DiFiglia M, 1997, SCIENCE, V277, P1990, DOI 10.1126/science.277.5334.1990; Gusella JF, 2000, NAT REV NEUROSCI, V1, P109, DOI 10.1038/35039051; Huang CC, 1998, SOMAT CELL MOLEC GEN, V24, P217, DOI 10.1023/B:SCAM.0000007124.19463.e5; KAZANTSEV A, UNPUB CELL; Kuemmerle S, 1999, ANN NEUROL, V46, P842; Mullins J. W., 1972, CRYSTALLISATION; Narain Y, 1999, J MED GENET, V36, P739, DOI 10.1136/jmg.36.10.739; Nucifora FC, 2001, SCIENCE, V291, P2423, DOI 10.1126/science.1056784; Perutz MF, 1999, TRENDS BIOCHEM SCI, V24, P58, DOI 10.1016/S0968-0004(98)01350-4; PERUTZ MF, 1994, P NATL ACAD SCI USA, V91, P5355, DOI 10.1073/pnas.91.12.5355; Saudou F, 1998, CELL, V95, P55, DOI 10.1016/S0092-8674(00)81782-1; Scherzinger E, 1997, CELL, V90, P549, DOI 10.1016/S0092-8674(00)80514-0; Skinner PJ, 1997, NATURE, V389, P971, DOI 10.1038/40153; Yamamoto A, 2000, CELL, V101, P57, DOI 10.1016/S0092-8674(00)80623-6	17	161	167	0	8	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 12	2001	412	6843					143	144		10.1038/35084141	http://dx.doi.org/10.1038/35084141			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	451AJ	11449262				2022-12-28	WOS:000169778700040
J	Garcia-Monco, JC; Larena, JA				Garcia-Monco, JC; Larena, JA			Vomiting of neurologic origin.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Hosp Galdacano, Galdacano 48960, Vizcaya, Spain	Galdakao Hospital	Garcia-Monco, JC (corresponding author), Hosp Galdacano, Galdacano 48960, Vizcaya, Spain.		Garcia-Monco, Juan Carlos/I-4154-2019	Garcia-Monco, Juan Carlos/0000-0003-2556-1288					0	0	0	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 1	2001	345	1					33	33		10.1056/NEJM200107053450105	http://dx.doi.org/10.1056/NEJM200107053450105			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	449QJ	11439946				2022-12-28	WOS:000169697600005
J	Blau, HM; Brazelton, TR; Weimann, JM				Blau, HM; Brazelton, TR; Weimann, JM			The evolving concept of a stem cell: Entity or function?	CELL			English	Review							BONE-MARROW-CELLS; IN-VIVO; ADULT-RAT; PRECURSOR CELLS; NERVOUS-SYSTEM; CARDIAC-MUSCLE; NEURAL CELLS; DIFFERENTIATION; EXPRESSION; SKELETAL		Stanford Univ, Sch Med, Dept Mol Pharmacol, Stanford, CA 94305 USA	Stanford University	Blau, HM (corresponding author), Stanford Univ, Sch Med, Dept Mol Pharmacol, Stanford, CA 94305 USA.	hblau@stanford.edu			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD018179] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA059717] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065572] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG009521, R37AG009521] Funding Source: NIH RePORTER; NCI NIH HHS [CA59717] Funding Source: Medline; NHLBI NIH HHS [HL65572] Funding Source: Medline; NIA NIH HHS [AG09521] Funding Source: Medline; NICHD NIH HHS [HD 18179] Funding Source: Medline; NIGMS NIH HHS [GM07149] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aboody KS, 2000, P NATL ACAD SCI USA, V97, P12846, DOI 10.1073/pnas.97.23.12846; Alison MR, 2000, NATURE, V406, P257, DOI 10.1038/35018642; ALTMAN J, 1969, J COMP NEUROL, V137, P433, DOI 10.1002/cne.901370404; Alvarez-Buylla A, 2001, NAT REV NEUROSCI, V2, P287, DOI 10.1038/35067582; Anderson DJ, 2001, NEURON, V30, P19, DOI 10.1016/S0896-6273(01)00260-4; Auerbach JM, 2000, EUR J NEUROSCI, V12, P1696, DOI 10.1046/j.1460-9568.2000.00067.x; BARON MH, 1986, CELL, V46, P591, DOI 10.1016/0092-8674(86)90885-8; Beauchamp JR, 2000, J CELL BIOL, V151, P1221, DOI 10.1083/jcb.151.6.1221; BISCHOFF R, 1986, DEV BIOL, V115, P129, DOI 10.1016/0012-1606(86)90234-4; Bittner RE, 1999, ANAT EMBRYOL, V199, P391, DOI 10.1007/s004290050237; Bjornson CRR, 1999, SCIENCE, V283, P534, DOI 10.1126/science.283.5401.534; Blanco-Bose WE, 2001, EXP CELL RES, V265, P212, DOI 10.1006/excr.2001.5191; BLAU HM, 1991, J CELL BIOL, V112, P781, DOI 10.1083/jcb.112.5.781; BLAU HM, 1983, CELL, V32, P1171, DOI 10.1016/0092-8674(83)90300-8; BLAU HM, 1992, ANNU REV BIOCHEM, V61, P1213, DOI 10.1146/annurev.bi.61.070192.010025; BLAU HM, 1985, SCIENCE, V230, P758, DOI 10.1126/science.2414846; Brazelton TR, 2000, SCIENCE, V290, P1775, DOI 10.1126/science.290.5497.1775; Brockes JP, 1997, SCIENCE, V276, P81, DOI 10.1126/science.276.5309.81; Brustle O, 1997, P NATL ACAD SCI USA, V94, P14809, DOI 10.1073/pnas.94.26.14809; BUTCHER EC, 1991, CELL, V67, P1033, DOI 10.1016/0092-8674(91)90279-8; CHIU CP, 1984, CELL, V37, P879, DOI 10.1016/0092-8674(84)90423-9; Clarke DL, 2000, SCIENCE, V288, P1660, DOI 10.1126/science.288.5471.1660; DEWEY MJ, 1977, P NATL ACAD SCI USA, V74, P5564, DOI 10.1073/pnas.74.12.5564; Doetsch F, 1999, CELL, V97, P703, DOI 10.1016/S0092-8674(00)80783-7; Dunnwald M, 2001, EXP DERMATOL, V10, P45, DOI 10.1034/j.1600-0625.2001.100106.x; EGUCHI G, 1988, REGULATORY MECHANISM, P147; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; EVANS MJ, 1981, NATURE, V292, P154, DOI 10.1038/292154a0; Fallon J, 2000, P NATL ACAD SCI USA, V97, P14686, DOI 10.1073/pnas.97.26.14686; Ferrari G, 1998, SCIENCE, V279, P1528, DOI 10.1126/science.279.5356.1528; Fuchs E, 2000, CELL, V100, P143, DOI 10.1016/S0092-8674(00)81691-8; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; Galli R, 2000, NAT NEUROSCI, V3, P986, DOI 10.1038/79924; GOLDMAN SA, 1983, P NATL ACAD SCI-BIOL, V80, P2390, DOI 10.1073/pnas.80.8.2390; Goldman SA, 1998, TRENDS NEUROSCI, V21, P107, DOI 10.1016/S0166-2236(97)01191-0; Goodell MA, 1997, NAT MED, V3, P1337, DOI 10.1038/nm1297-1337; GURDON JB, 1962, J EMBRYOL EXP MORPH, V10, P622; Gussoni E, 1999, NATURE, V401, P390, DOI 10.1038/43919; Hay E.D., 1991, CELL BIOL EXTRACELLU, P419; Heffron DS, 2000, J NEUROSCI, V20, P2287; Hynes M, 2000, NEURON, V28, P11, DOI 10.1016/S0896-6273(00)00079-9; Jackson KA, 1999, P NATL ACAD SCI USA, V96, P14482, DOI 10.1073/pnas.96.25.14482; Jackson KA, 2001, J CLIN INVEST, V107, P1395, DOI 10.1172/JCI12150; Johansson CB, 1999, CELL, V96, P25, DOI 10.1016/S0092-8674(00)80956-3; JONES RJ, 1989, BLOOD, V73, P397; Kawasaki H, 2000, NEURON, V28, P31, DOI 10.1016/S0896-6273(00)00083-0; Kondo T, 2000, SCIENCE, V289, P1754, DOI 10.1126/science.289.5485.1754; Kopen GC, 1999, P NATL ACAD SCI USA, V96, P10711, DOI 10.1073/pnas.96.19.10711; Krause DS, 2001, CELL, V105, P369, DOI 10.1016/S0092-8674(01)00328-2; Kubota H, 2000, P NATL ACAD SCI USA, V97, P12132, DOI 10.1073/pnas.97.22.12132; Lagasse E, 2000, NAT MED, V6, P1229, DOI 10.1038/81326; Lagasse E, 2001, IMMUNITY, V14, P425, DOI 10.1016/S1074-7613(01)00123-6; Lavker RM, 2000, P NATL ACAD SCI USA, V97, P13473, DOI 10.1073/pnas.250380097; Lee SH, 2000, NAT BIOTECHNOL, V18, P675, DOI 10.1038/76536; Liechty KW, 2000, NAT MED, V6, P1282, DOI 10.1038/81395; Lillien L, 2000, DEVELOPMENT, V127, P4993; Magavi SS, 2000, NATURE, V405, P951, DOI 10.1038/35016083; MARTIN GR, 1975, CELL, V5, P229, DOI 10.1016/0092-8674(75)90098-7; Matsuoka S, 2001, BLOOD, V97, P419, DOI 10.1182/blood.V97.2.419; MAURO A, 1961, J BIOPHYS BIOCHEM CY, V9, P493, DOI 10.1083/jcb.9.2.493; Mezey E, 2000, SCIENCE, V290, P1779, DOI 10.1126/science.290.5497.1779; MORRISON SJ, 1994, IMMUNITY, V1, P661, DOI 10.1016/1074-7613(94)90037-X; Morrison SJ, 1999, CELL, V96, P737, DOI 10.1016/S0092-8674(00)80583-8; Odelberg SJ, 2000, CELL, V103, P1099, DOI 10.1016/S0092-8674(00)00212-9; Okabe S, 1996, MECH DEVELOP, V59, P89, DOI 10.1016/0925-4773(96)00572-2; Orlic D, 2001, NATURE, V410, P701, DOI 10.1038/35070587; Ozawa CR, 2000, GENE THERAPY, P61; Palmer TD, 1997, MOL CELL NEUROSCI, V8, P389, DOI 10.1006/mcne.1996.0595; Palmer TD, 1999, J NEUROSCI, V19, P8487; Petersen BE, 1999, SCIENCE, V284, P1168, DOI 10.1126/science.284.5417.1168; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; POWELL PP, 1991, MOL BRAIN RES, V11, P71, DOI 10.1016/0169-328X(91)90023-Q; Qian XM, 2000, NEURON, V28, P69, DOI 10.1016/S0896-6273(00)00086-6; REYNOLDS BA, 1992, SCIENCE, V255, P1707, DOI 10.1126/science.1553558; ROCHAT A, 1994, CELL, V76, P1063, DOI 10.1016/0092-8674(94)90383-2; Sanchez-Ramos J, 2000, EXP NEUROL, V164, P247, DOI 10.1006/exnr.2000.7389; Sato T, 1999, BLOOD, V94, P2548, DOI 10.1182/blood.V94.8.2548.420k38_2548_2554; Schnieke AE, 1997, SCIENCE, V278, P2130, DOI 10.1126/science.278.5346.2130; Seale P, 2000, CELL, V102, P777, DOI 10.1016/S0092-8674(00)00066-0; Sell S, 2001, HEPATOLOGY, V33, P738, DOI 10.1053/jhep.2001.21900; Shen CN, 2000, NAT CELL BIOL, V2, P879, DOI 10.1038/35046522; Shin JJ, 2000, J NEUROSCI, V20, P7404; Smythe GM, 2000, MOL THER, V1, P304, DOI 10.1006/mthe.2000.0049; SPEAR BT, 1990, MOL CELL BIOL, V10, P5047, DOI 10.1128/MCB.10.10.5047; Studer L, 2000, J NEUROSCI, V20, P7377; Taylor G, 2000, CELL, V102, P451, DOI 10.1016/S0092-8674(00)00050-7; Theise ND, 2000, HEPATOLOGY, V32, P11, DOI 10.1053/jhep.2000.9124; Theise ND, 2000, HEPATOLOGY, V31, P235, DOI 10.1002/hep.510310135; Theise ND, 1999, HEPATOLOGY, V30, P1425, DOI 10.1002/hep.510300614; THORGEIRSSON SS, 1993, P SOC EXP BIOL MED, V204, P253; Uchida N, 2000, P NATL ACAD SCI USA, V97, P14720, DOI 10.1073/pnas.97.26.14720; van der Kooy D, 2000, SCIENCE, V287, P1439, DOI 10.1126/science.287.5457.1439; VESCOVI AL, 1993, NEURON, V11, P951, DOI 10.1016/0896-6273(93)90124-A; Vessey CJ, 2001, PATHOLOGY, V33, P130; Wang YZ, 1998, EXP NEUROL, V154, P389, DOI 10.1006/exnr.1998.6965; WEBSTER C, 1988, EXP CELL RES, V174, P252, DOI 10.1016/0014-4827(88)90159-0; Weissman IL, 2000, CELL, V100, P157, DOI 10.1016/S0092-8674(00)81692-X; Woodbury D, 2000, J NEUROSCI RES, V61, P364, DOI 10.1002/1097-4547(20000815)61:4<364::AID-JNR2>3.0.CO;2-C; WRIGHT WE, 1984, EXP CELL RES, V151, P55, DOI 10.1016/0014-4827(84)90355-0; Ye WL, 1998, CELL, V93, P755, DOI 10.1016/S0092-8674(00)81437-3	100	769	879	1	51	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 29	2001	105	7					829	841		10.1016/S0092-8674(01)00409-3	http://dx.doi.org/10.1016/S0092-8674(01)00409-3			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	449BK	11439179	Bronze			2022-12-28	WOS:000169664300004
J	Orr, A; McVean, RJ; Webb, AK; Dodd, ME				Orr, A; McVean, RJ; Webb, AK; Dodd, ME			Questionnaire survey of urinary incontinence in women with cystic fibrosis	BRITISH MEDICAL JOURNAL			English	Article							PREVALENCE		S Manchester Univ Hosp Trust, NW Lung Ctr, Adult Cyst Fibrosis Unit, Manchester M23 9LT, Lancs, England		Orr, A (corresponding author), S Manchester Univ Hosp Trust, NW Lung Ctr, Adult Cyst Fibrosis Unit, Manchester M23 9LT, Lancs, England.							Chiarelli P, 1999, NEUROUROL URODYNAM, V18, P567, DOI 10.1002/(SICI)1520-6777(1999)18:6<567::AID-NAU7>3.0.CO;2-F; Dolan LR, 1999, BJU INT, V83, P760; Gunnarsson M, 1999, NEUROUROL URODYNAM, V18, P613, DOI 10.1002/(SICI)1520-6777(1999)18:6<613::AID-NAU11>3.0.CO;2-B; THOMAS TM, 1980, BRIT MED J, V281, P1243, DOI 10.1136/bmj.281.6250.1243	4	41	41	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 23	2001	322	7301					1521	1521		10.1136/bmj.322.7301.1521	http://dx.doi.org/10.1136/bmj.322.7301.1521			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	446UF	11420273	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000169532000018
J	Wallis, JD; Anderson, KC; Miller, EK				Wallis, JD; Anderson, KC; Miller, EK			Single neurons in prefrontal cortex encode abstract rules	NATURE			English	Article							ORBITOFRONTAL CORTEX; NEURAL ACTIVITY; FRONTAL-CORTEX; WORKING-MEMORY; UNIT-ACTIVITY; PRIMATE; REWARD; MACAQUE; MONKEY	The ability to abstract principles or rules from direct experience allows behaviour to extend beyond specific circumstances to general situations. For example, we learn the 'rules' for restaurant dining from specific experiences and can then apply them in new restaurants. The use of such rules is thought to depend on the prefrontal cortex (PFC) because its damage often results in difficulty in following rules(1). Here we explore its neural basis by recording from single neurons in the PFC of monkeys trained to use two abstract rules. They were required to indicate whether two successively presented pictures were the same or different depending on which rule was currently in effect. The monkeys performed this task with new pictures, thus showing that they had learned two general principles that could be applied to stimuli that they had not yet experienced. The most prevalent neuronal activity observed in the PFC reflected the coding of these abstract rules.	MIT, Ctr Learning & Memory, RIKEN, Neurosci Res Ctr, Cambridge, MA 02139 USA; MIT, Dept Brain & Cognit Sci, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); RIKEN; Massachusetts Institute of Technology (MIT)	Miller, EK (corresponding author), MIT, Ctr Learning & Memory, RIKEN, Neurosci Res Ctr, Cambridge, MA 02139 USA.		Miller, Earl K./AAE-8187-2019	Miller, Earl K./0000-0002-0582-6958; Wallis, Joni/0000-0001-7262-7417				Asaad WF, 2000, J NEUROPHYSIOL, V84, P451, DOI 10.1152/jn.2000.84.1.451; Asaad WF, 1998, NEURON, V21, P1399, DOI 10.1016/S0896-6273(00)80658-3; DIPELLEGRINO G, 1993, J NEUROSCI, V13, P1227; Freedman DJ, 2001, SCIENCE, V291, P312, DOI 10.1126/science.291.5502.312; FUNAHASHI S, 1989, J NEUROPHYSIOL, V61, P331, DOI 10.1152/jn.1989.61.2.331; Fuster JM, 2000, NATURE, V405, P347, DOI 10.1038/35012613; FUSTER JM, 1971, SCIENCE, V173, P652, DOI 10.1126/science.173.3997.652; FUSTER JM, 1973, J NEUROPHYSIOL, V36, P61, DOI 10.1152/jn.1973.36.1.61; FUSTER JM, 1997, PREFRONTAL CORTEX; GOLDMANRAKIC PS, 1995, NEURON, V14, P477, DOI 10.1016/0896-6273(95)90304-6; Hoshi E, 1998, J NEUROPHYSIOL, V80, P3392, DOI 10.1152/jn.1998.80.6.3392; Leon MI, 1999, NEURON, V24, P415, DOI 10.1016/S0896-6273(00)80854-5; Miller EK, 1999, NEURON, V22, P15, DOI 10.1016/S0896-6273(00)80673-X; Miller EK, 1996, J NEUROSCI, V16, P5154; Milner B., 1963, ARCH NEUROL-CHICAGO, V9, P90, DOI DOI 10.1001/ARCHNEUR.1963.00460070100010; NIKI H, 1974, BRAIN RES, V68, P197, DOI 10.1016/0006-8993(74)90389-8; Rainer G, 1998, NATURE, V393, P577, DOI 10.1038/31235; Rainer G, 1999, J NEUROSCI, V19, P5493; Rao SC, 1997, SCIENCE, V276, P821, DOI 10.1126/science.276.5313.821; Roberts AC, 2000, CEREB CORTEX, V10, P252, DOI 10.1093/cercor/10.3.252; Rolls ET, 2000, CEREB CORTEX, V10, P284, DOI 10.1093/cercor/10.3.284; ROLLS ET, 1990, J NEUROPHYSIOL, V64, P1055, DOI 10.1152/jn.1990.64.4.1055; Tremblay L, 1999, NATURE, V398, P704, DOI 10.1038/19525; Watanabe M, 1996, NATURE, V382, P629, DOI 10.1038/382629a0; White IM, 1999, EXP BRAIN RES, V126, P315, DOI 10.1007/s002210050740; Wise SP, 1996, CRIT REV NEUROBIOL, V10, P317, DOI 10.1615/CritRevNeurobiol.v10.i3-4.30	26	686	696	0	65	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 21	2001	411	6840					953	956		10.1038/35082081	http://dx.doi.org/10.1038/35082081			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	444EN	11418860				2022-12-28	WOS:000169386200046
J	Moscicki, AB; Hills, N; Shiboski, S; Powell, K; Jay, N; Hanson, E; Miller, S; Clayton, L; Farhat, S; Broering, J; Darragh, T; Palefsky, J				Moscicki, AB; Hills, N; Shiboski, S; Powell, K; Jay, N; Hanson, E; Miller, S; Clayton, L; Farhat, S; Broering, J; Darragh, T; Palefsky, J			Risks for incident human papillomavirus infection and low-grade squamous intraepithelial lesion development in young females	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SEXUALLY-TRANSMITTED-DISEASE; NATURAL-HISTORY; CIGARETTE-SMOKING; HPV INFECTION; TYPE-16; ASSOCIATION; BEHAVIOR; CANCER; E6; PREVALENCE	Context Low-grade squamous intraepithelial lesions (LSILs) have been described as a benign cytological consequence of active human papillomavirus (HPV) replication. Several studies have reported that certain behavioral and biological risks exist for LSIL, suggesting that HPV alone is not sufficient for the development of LSIL. However, because most of these studies have been cross-sectional, it is not known whether behavioral and biological risks are simply risks for HPV infection itself. Objective To prospectively examine risks of incident HPV infection in HPV-negative females and of incident LSIL development in females with HPV infection. Design Prospective cohort study conducted between 1990-2000, with a median follow-up of 50 months. Setting and Participants Females aged 13 to 21 years who attended 2 family planning clinics in the San francisco bay area; 496 had prevalent HPV infection and 105 were HPV-negative. Main Outcome Measure Incident development of HPV infection and LSIL, analyzed by various demographic, behavioral, and clinical risk factors. Results Fifty-four incident HPV infections occurred in the 105 females who were HPV-negative at study entry (median duration of follow-up for those who remained HPV-negative was 26 months). Multivariable analysis showed that risks of HPV included sexual behavior (relative hazard [RH], 10.10; 95% confidence interval [CI], 3.24-31.50 per new partner per month), history of herpes simplex virus (RH, 3.54; 95% CI, 1.37-9.10), and history of vulvar warts (RH, 2.73; 95% CI, 1.27-5.87). Current use of oral contraceptives had a significantly protective effect (RH, 0.49; 95% CI, 0.28-0.86). Among the 496 individuals who were HPV-positive at baseline or in follow-up, there were 109 incident cases of LSIL during the follow-up interval, with a median follow-up time of 60 months for those who never developed LSIL. Human papillomavirus infection was the most significant risk factor for development of LSIL, The multivariable model showed the following risks for LSIL: HPV infection for less than 1 year(RH, 7.40; 95% CI, 4.74-11.57); HPV infection for 1 to 2 years (RH, 10.27; 95% CI, 5.64-18.69); HPV infection for 2 to 3 years (RH, 6.11; 95% CI, 1.86-20.06); and daily cigarette smoking (RH, 1.67; 95% CI, 1.12-2.48). Conclusion Our results indicate distinct risks for HPV and LSIL. In addition, most women with HPV infection in our study did not develop LSIL within a median follow-up period of 60 months. These findings underscore the hypothesis that certain biological risks thought to be associated with LSIL are, in fact, risks for acquisition of HPV. Cigarette smoking was a risk specific to LSIL, supporting the role of tobacco in neoplastic development.	Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Anat Pathol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Stomatol, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Moscicki, AB (corresponding author), 3333 Calif St,Suite 245, San Francisco, CA 94118 USA.	annam@itsa.ucsf.edu	Moscicki, Anna-Barbara/AAP-3806-2021	Broering, Jeanette/0000-0002-7580-8931	NCI NIH HHS [R37 CA051323, R01CA54053, R01CA51323] Funding Source: Medline; NCRR NIH HHS [M01 RR01271] Funding Source: Medline; PHS HHS [MCJ000978, P01A121912] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA054053, R01CA051323, R37CA051323] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR001271] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		AMBROS RA, 1990, SEMIN DIAGN PATHOL, V7, P158; Arany I, 1996, J INTERF CYTOK RES, V16, P453, DOI 10.1089/jir.1996.16.453; ASHLEY RL, 1988, J CLIN MICROBIOL, V26, P662, DOI 10.1128/JCM.26.4.662-667.1988; BARTON SE, 1988, LANCET, V2, P652; BAUER HM, 1991, JAMA-J AM MED ASSOC, V265, P472, DOI 10.1001/jama.265.4.472; CLARKE EA, 1985, AM J OBSTET GYNECOL, V151, P612, DOI 10.1016/0002-9378(85)90149-8; COPPLESON M, 1979, COLPOSCOPY SCI PRACT; COX JT, 1992, OBSTET GYNECOL, V80, P389; Daling JR, 1996, CANCER EPIDEM BIOMAR, V5, P541; DEVET HCW, 1993, INT J EPIDEMIOL, V22, P798, DOI 10.1093/ije/22.5.798; Ferenczy A, 1996, OBSTET GYN CLIN N AM, V23, P759, DOI 10.1016/S0889-8545(05)70276-X; Gravitt PE, 1998, J CLIN MICROBIOL, V36, P3020, DOI 10.1128/JCM.36.10.3020-3027.1998; HARAHAP RE, 1986, CANCER DETECT PREV, V9, P237; Ho GYF, 1998, NEW ENGL J MED, V338, P423, DOI 10.1056/NEJM199802123380703; HOLMES KK, 1981, SCAND J INFECT DIS, P110; IRWIN KL, 1988, JAMA-J AM MED ASSOC, V259, P59, DOI 10.1001/jama.259.1.59; Kadish AS, 1997, J NATL CANCER I, V89, P1285, DOI 10.1093/jnci/89.17.1285; Kurman RJ, 1994, BETHESDA SYSTEM REPO; LAVECCHIA C, 1986, CANCER, V58, P935, DOI 10.1002/1097-0142(19860815)58:4<935::AID-CNCR2820580422>3.0.CO;2-O; LORINCZ A, 1996, HUMAN PAPILLOMAVIRUS, V1; MOSCICKI AB, 1993, OBSTET GYNECOL, V82, P578; MOSCICKI AB, 1993, J ADOLESCENT HEALTH, V14, P74, DOI 10.1016/1054-139X(93)90088-7; MOSCICKI AB, 1989, J PEDIATR-US, V115, P487, DOI 10.1016/S0022-3476(89)80863-7; MOSCICKI AB, 1990, PEDIATR RES, V28, P507, DOI 10.1203/00006450-199011000-00018; Moscicki AB, 1998, J PEDIATR-US, V132, P277, DOI 10.1016/S0022-3476(98)70445-7; Nakagawa M, 2000, J INFECT DIS, V182, P595, DOI 10.1086/315706; Nakagawa M, 1996, CLIN DIAGN LAB IMMUN, V3, P205, DOI 10.1128/CDLI.3.2.205-210.1996; NASH JD, 1987, OBSTET GYNECOL, V69, P160; NEVINS JR, 1992, SCIENCE, V258, P424; Roberts S, 1997, J VIROL, V71, P3554, DOI 10.1128/JVI.71.5.3554-3562.1997; ROSENFELD WD, 1989, AM J DIS CHILD, V143, P1443, DOI 10.1001/archpedi.1989.02150240065018; SCHACHTER J, 1982, JAMA-J AM MED ASSOC, V248, P2134, DOI 10.1001/jama.248.17.2134; SCHIFFMAN MH, 1987, CANCER RES, V47, P3886; Scott M, 1999, CLIN DIAGN LAB IMMUN, V6, P751, DOI 10.1128/CDLI.6.5.751-755.1999; Smith PJ, 1997, STAT MED, V16, P485, DOI 10.1002/(SICI)1097-0258(19970315)16:5&lt;485::AID-SIM422&gt;3.0.CO;2-#; STONE KM, 1995, EPIDEMIOLOGY, V6, P409, DOI 10.1097/00001648-199507000-00014; Svare EI, 1998, INT J CANCER, V75, P1, DOI 10.1002/(SICI)1097-0215(19980105)75:1&lt;1::AID-IJC1&gt;3.0.CO;2-1; SYRJANEN K, 1992, OBSTET GYNECOL, V79, P675; Tibbetts TA, 1999, BIOL REPROD, V60, P1158, DOI 10.1095/biolreprod60.5.1158; WERNESS BA, 1990, SCIENCE, V248, P76, DOI 10.1126/science.2157286; WINKELSTEIN W, 1984, AM J EPIDEMIOL, V119, P1	41	402	419	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 20	2001	285	23					2995	3002		10.1001/jama.285.23.2995	http://dx.doi.org/10.1001/jama.285.23.2995			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	442AR	11410098	Bronze			2022-12-28	WOS:000169263200022
J	Walter, LC; Brand, RJ; Counsell, SR; Palmer, RM; Landefeld, CS; Fortinsky, RH; Covinsky, KE				Walter, LC; Brand, RJ; Counsell, SR; Palmer, RM; Landefeld, CS; Fortinsky, RH; Covinsky, KE			Development and validation of a prognostic index for 1-year mortality in older adults after hospitalization	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	Annual Meeting of the American-Geriatrics-Society	MAY 17-21, 2000	NASHVILLE, TN	Amer Geriatr Soc			FUNCTIONAL STATUS; SERIOUSLY ILL; DISABILITY; RISK; CARE; PREDICTION; SURVIVAL; OUTCOMES; ELDERS; DEATH	Context For many elderly patients, an acute medical illness requiring hospitalization is followed by a progressive decline, resulting in high rates of mortality in this population during the year following discharge. However, few prognostic indices have focused on predicting posthospital mortality in older adults. Objective To develop and validate a prognostic index for 1 year mortality of older adults after hospital discharge using information readily available at discharge. Design Data analyses derived from 2 prospective studies with 1-year of follow-up, conducted in 1993 through 1997. Setting and Patients We developed the prognostic index in 1495 patients aged at least 70 years who were discharged from a general medical service at a tertiary care hospital (mean age, 81 years; 67% female) and validated it in 1427 patients discharged from a separate community teaching hospital (mean age, 79 years; 61 % female). Main Outcome Measure Prediction of 1-year mortality using risk factors such as demographic characteristics, activities of daily living (ADL) dependency, comorbid conditions, length of hospital stay, and laboratory measurements. Results In the derivation cohort, 6 independent risk factors for mortality were identified and weighted using logistic regression: male sex (1 point); number of dependent ADLs at discharge (1-4 ADLs, 2 points; all 5 ADLs, 5 points); congestive heart failure (2 points); cancer (solitary, 3 points; metastatic, 8 points); creatinine level higher than 3.0 mg/dL (265 mu mol/L) (2 points); and low albumin level (3.0-3.4 g/dL, 1 point; <3.0 g/dL. 2 points). Several variables associated with 1-year mortality in bivariable analyses, such as age and dementia, were not independently associated with mortality after adjustment for functional status. We calculated risk scores for patients by adding the points of each independent risk factor present. In the derivation cohort, 1-year mortality was 13% in the lowest-risk group (0-1 point), 20% in the group with 2 or 3 points, 37% in the group with 4 to 6 points, and 68% in the highest-risk group (>6 points). in the validation cohort, 1-year mortality was 4% in the lowest-risk group, 19% in the group with 2 or 3 points, 34% in the group with 4 to 6 points, and 64% in the highest-risk group. The area under the receiver operating characteristic curve for the point system was 0.75 in the derivation cohort and 0.79 in the validation cohort. Conclusions Our prognostic index, which used 6 risk factors known at discharge and a simple additive point system to stratify medical patients 70 years or older according to 1-year mortality after hospitalization, had good discrimination and calibration and generalized well in an independent sample of patients at a different site. These characteristics suggest that our index may be useful for clinical care and risk adjustment.	Vet Adm Med Ctr, Div Geriatr, San Francisco, CA 94121 USA; Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA; Indiana Univ, Sch Med, Div Gen Internal Med & Geriatr, Indianapolis, IN USA; Cleveland Clin Fdn, Geriatr Med Sect, Cleveland, OH 44195 USA; Univ Connecticut, Ctr Hlth, Div Geriatr, Farmington, CT USA; Univ Connecticut, Ctr Hlth, Ctr Aging, Farmington, CT USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco; Indiana University System; Indiana University-Purdue University Indianapolis; Cleveland Clinic Foundation; University of Connecticut; University of Connecticut	Walter, LC (corresponding author), Vet Adm Med Ctr, Div Geriatr, 111G,4150 Clement St, San Francisco, CA 94121 USA.	louisew@itsa.ucsi.edu			AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [K02HS000006] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [P60AG010418] Funding Source: NIH RePORTER; AHRQ HHS [K02HS00006-01] Funding Source: Medline; NIA NIH HHS [AG10418] Funding Source: Medline; PHS HHS [T-32] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AKKI S, 1991, J AM GERIATR SOC, V39, pA22; [Anonymous], 1999, DEATH FORETOLD PROPH; BROWNER WS, 1992, JAMA-J AM MED ASSOC, V268, P228, DOI 10.1001/jama.268.2.228; CALKINS DR, 1991, ANN INTERN MED, V114, P451, DOI 10.7326/0003-4819-114-6-451; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Charlson ME, 2000, AM J MED, V109, P189, DOI 10.1016/S0002-9343(00)00477-0; Christakis NA, 1998, ARCH INTERN MED, V158, P2389, DOI 10.1001/archinte.158.21.2389; CONCATO J, 1993, ANN INTERN MED, V118, P201, DOI 10.7326/0003-4819-118-3-199302010-00009; CORTI MC, 1994, JAMA-J AM MED ASSOC, V272, P1036, DOI 10.1001/jama.272.13.1036; Counsell SR, 2000, J AM GERIATR SOC, V48, P1572, DOI 10.1111/j.1532-5415.2000.tb03866.x; Covinsky KE, 2000, J AM GERIATR SOC, V48, P164, DOI 10.1111/j.1532-5415.2000.tb03907.x; Covinsky KE, 1997, J GEN INTERN MED, V12, P203, DOI 10.1007/s11606-006-5041-5; CREDITOR MC, 1993, ANN INTERN MED, V118, P219, DOI 10.7326/0003-4819-118-3-199302010-00011; DAVIS RB, 1995, MED CARE, V33, P906, DOI 10.1097/00005650-199509000-00003; Dudley RA, 1998, MILBANK Q, V76, P649, DOI 10.1111/1468-0009.00109; Fortinsky RH, 1999, J GERONTOL A-BIOL, V54, pM521, DOI 10.1093/gerona/54.10.M521; Fried LP, 1998, JAMA-J AM MED ASSOC, V279, P585, DOI 10.1001/jama.279.8.585; Gill TM, 1998, ANN INTERN MED, V128, P96, DOI 10.7326/0003-4819-128-2-199801150-00004; Hamel MB, 1999, ANN INTERN MED, V131, P721, DOI 10.7326/0003-4819-131-10-199911160-00002; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; Iezzoni LI, 1997, RISK ADJUSTMENT MEAS; Inouye SK, 1998, JAMA-J AM MED ASSOC, V279, P1187, DOI 10.1001/jama.279.15.1187; Justice AC, 1999, ANN INTERN MED, V130, P515, DOI 10.7326/0003-4819-130-6-199903160-00016; KATZ S, 1963, JAMA-J AM MED ASSOC, V185, P914, DOI 10.1001/jama.1963.03060120024016; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; KNAUS WA, 1995, ANN INTERN MED, V122, P191, DOI 10.7326/0003-4819-122-3-199502010-00007; KNAUS WA, 1991, CHEST, V100, P1619, DOI 10.1378/chest.100.6.1619; KOHN RR, 1982, JAMA-J AM MED ASSOC, V247, P2793, DOI 10.1001/jama.247.20.2793; LEMESHOW S, 1993, JAMA-J AM MED ASSOC, V270, P2478, DOI 10.1001/jama.270.20.2478; LYNN J, 1995, WESTERN J MED, V163, P250; McGinn TG, 2000, JAMA-J AM MED ASSOC, V284, P79, DOI 10.1001/jama.284.1.79; Meyer B R, 1986, Cardiol Clin, V4, P227; PALMER RM, 1999, PRINCIPLES GERIATRIC, P483; PFEIFFER E, 1975, J AM GERIATR SOC, V23, P433, DOI 10.1111/j.1532-5415.1975.tb00927.x; REUBEN DB, 1992, AM J MED, V93, P663, DOI 10.1016/0002-9343(92)90200-U; RICHEDWARDS JW, 1994, AM J EPIDEMIOL, V140, P1016, DOI 10.1093/oxfordjournals.aje.a117191; Teno JM, 2000, J AM GERIATR SOC, V48, pS16, DOI 10.1111/j.1532-5415.2000.tb03126.x; WASSON JH, 1985, NEW ENGL J MED, V313, P793, DOI 10.1056/NEJM198509263131306; 1998, LIFE TABLES US	39	461	470	0	12	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 20	2001	285	23					2987	2994		10.1001/jama.285.23.2987	http://dx.doi.org/10.1001/jama.285.23.2987			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	442AR	11410097	Bronze			2022-12-28	WOS:000169263200021
J	Bryce, M; Spielman, SR; Greenspan, AM; Kotler, MN				Bryce, M; Spielman, SR; Greenspan, AM; Kotler, MN			Evolving indications for permanent pacemakers	ANNALS OF INTERNAL MEDICINE			English	Review							CONGESTIVE-HEART-FAILURE; HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY; IDIOPATHIC DILATED CARDIOMYOPATHY; RECURRENT ATRIAL-FIBRILLATION; OUTFLOW TRACT OBSTRUCTION; NEURALLY-MEDIATED SYNCOPE; BUNDLE-BRANCH-BLOCK; VASOVAGAL SYNCOPE; DOUBLE-BLIND; HEMODYNAMIC IMPROVEMENT	New indications for permanent cardiac pacing have been developed in recent years, with numerous studies demonstrating improved clinical outcomes in a variety of disorders. Because hypertrophic obstructive cardiomyopathy, dilated cardiomyopathy, heart failure, neurocardiogenic syncope, and atrial fibrillation are common conditions, every clinician should be aware of evolving alternative therapies for them. Observational studies in patients with refractory, symptomatic hypertrophic obstructive cardiomyopathy and significant left ventricular outflow gradient at rest suggest that cardiac pacing may result in symptomatic and hemodynamic improvement. Clinical trials have not shown conclusive evidence regarding the longterm benefit from pacing in these patients, and it is unclear whether pacing will be a preferred treatment option. Preliminary data suggest that pacing is a viable adjunctive therapeutic approach for improving symptoms in patients with dilated cardiomyopathy and heart failure. Mortality benefit has yet to be established, but it is to be hoped that ongoing randomized clinical trials will provide definitive information on that issue. Patients with refractory neurocardiogenic syncope or those who are intolerant of medical treatment may benefit from pacing therapies, especially those that use rate-drop sensor algorithms. Biatrial pacing has emerged as a technique that resynchronizes atrial electrical activity and has been shown to prevent atrial fibrillation. Multisite atrial pacing for the prevention of atrial fibrillation is considered investigational but seems promising. Newer indications for pacing are expected to result in improved clinical outcomes for hypertrophic obstructive cardiomyopathy, dilated cardiomyopathy and heart failure, neurocardiogenic syncope, and the prevention of atrial fibrillation.	Albert Einstein Med Ctr, Div Cardiovasc Dis, Philadelphia, PA 19141 USA	Yeshiva University	Kotler, MN (corresponding author), Albert Einstein Med Ctr, Div Cardiovasc Dis, 5401 Old York Rd,Klein Bldg,Suite 363, Philadelphia, PA 19141 USA.							Aaronson KD, 1997, CIRCULATION, V95, P2660, DOI 10.1161/01.CIR.95.12.2660; ABRAHAM WT, 1999, SAT S AM COLL CARD A; Ammirati F, 1998, PACE, V21, P2178, DOI 10.1111/j.1540-8159.1998.tb01148.x; ANDERSEN HR, 1994, LANCET, V344, P1523, DOI 10.1016/S0140-6736(94)90347-6; Auricchio A, 1999, AM J CARDIOL, V83, p130D; Auricchio A, 1999, CIRCULATION, V99, P2993, DOI 10.1161/01.CIR.99.23.2993; BAKKER P, 1995, PACE, V18, P825; Bakker PF, 1994, PACE, V17, P820; Benditt DG, 1997, PACE, V20, P832, DOI 10.1111/j.1540-8159.1997.tb03916.x; BONOW RO, 1983, AM J CARDIOL, V51, P1386, DOI 10.1016/0002-9149(83)90317-X; CHARDACK WM, 1960, SURGERY, V48, P643; Charles RG, 1997, HEART, V78, P224, DOI 10.1136/hrt.78.3.224; CHIRIFE R, 1994, PACE, V17, P1451, DOI 10.1111/j.1540-8159.1994.tb01508.x; Connolly SJ, 1999, J AM COLL CARDIOL, V33, P16, DOI 10.1016/S0735-1097(98)00549-X; Daubert J. Claude, 1997, P99; Delfaut P, 1998, J AM COLL CARDIOL, V32, P1900, DOI 10.1016/S0735-1097(98)00489-6; Duck H J, 1984, Z Gesamte Inn Med, V39, P437; el-Bedawi K M, 1994, Clin Auton Res, V4, P41; FANANAPAZIR L, 1992, CIRCULATION, V85, P2149, DOI 10.1161/01.CIR.85.6.2149; FANANAPAZIR L, 1994, CIRCULATION, V90, P2731, DOI 10.1161/01.CIR.90.6.2731; FITZPATRICK A, 1991, PACE, V14, P13, DOI 10.1111/j.1540-8159.1991.tb04042.x; FORCINITO M, 1991, J AM COLL CARDIOL, V18, P1, DOI 10.1016/S0735-1097(10)80209-8; Gadler F, 1999, EUR HEART J, V20, P1044, DOI 10.1053/euhj.1998.1331; Gadler F, 1996, J AM COLL CARDIOL, V27, P1219, DOI 10.1016/0735-1097(95)00573-0; Gadler F, 1997, EUR HEART J, V18, P636; GOLD MR, 1995, J AM COLL CARDIOL, V26, P967, DOI 10.1016/0735-1097(95)00292-0; Gras D, 1998, PACE, V21, P2249, DOI 10.1111/j.1540-8159.1998.tb01162.x; Gregoratos G, 1998, CIRCULATION, V97, P1325, DOI 10.1161/01.CIR.97.13.1325; GRINES CL, 1989, CIRCULATION, V79, P845, DOI 10.1161/01.CIR.79.4.845; Hassenstein P, 1967, Verh Dtsch Ges Kreislaufforsch, V33, P242; Hassenstein P, 1975, Thoraxchir Vask Chir, V23, P496; HOCHLEITNER M, 1990, AM J CARDIOL, V66, P198, DOI 10.1016/0002-9149(90)90588-R; HOCHLEITNER M, 1992, AM J CARDIOL, V70, P1320, DOI 10.1016/0002-9149(92)90769-U; JEANRENAUD X, 1992, LANCET, V339, P1318, DOI 10.1016/0140-6736(92)91961-7; Kappenberger L, 1997, EUR HEART J, V18, P1249; KAPPENBERGER L, 1991, ARCH MAL COEUR, V84, P293; Leclercq C., 1998, European Heart Journal, V19, P573; Levy T, 1999, AM J CARDIOL, V84, P426, DOI 10.1016/S0002-9149(99)00327-6; LINDE C, 1995, AM J CARDIOL, V75, P919, DOI 10.1016/S0002-9149(99)80687-0; Maron BJ, 1999, CIRCULATION, V99, P2927, DOI 10.1161/01.CIR.99.22.2927; MENOZZI C, 1993, AM J CARDIOL, V72, P1152, DOI 10.1016/0002-9149(93)90985-L; Misier ARR, 1999, AM J CARDIOL, V83, p237D; Nishimura RA, 1996, J AM COLL CARDIOL, V27, P421, DOI 10.1016/0735-1097(95)00445-9; Nishimura RA, 1997, J AM COLL CARDIOL, V29, P435, DOI 10.1016/S0735-1097(96)00473-1; NISHIMURA RA, 1995, J AM COLL CARDIOL, V25, P281, DOI 10.1016/0735-1097(94)00419-Q; Padeletti L, 1999, J INTERV CARD ELECTR, V3, P35, DOI 10.1023/A:1009867305678; PETERSEN M, 1994, BRIT HEART J, V71, P274; Prakash A., 1997, Journal of the American College of Cardiology, V29, p253A; Prakash A, 1997, PACE, V20, P2434, DOI 10.1111/j.1540-8159.1997.tb06083.x; Raviele A, 1999, CIRCULATION, V99, P1452, DOI 10.1161/01.CIR.99.11.1452; Saksena S, 1996, J AM COLL CARDIOL, V28, P687, DOI 10.1016/0735-1097(96)00232-X; SAMOIL D, 1993, EUR J CARDIAC PACING, V1, P36; Saxon LA, 1999, AM J CARDIOL, V83, p120D; SHAMIM W, 1998, EUR HEART J, V19, P143; Sheldon R, 1999, AM J CARDIOL, V84, p26Q; Sheldon R, 1998, AM J CARDIOL, V81, P158, DOI 10.1016/S0002-9149(97)00891-6; SILVA L, 1989, PACING CLIN ELECTR 2, V12, P1275; SOPHER SM, 1995, CIRCULATION, V92, P2540; SRA JS, 1993, NEW ENGL J MED, V328, P1085, DOI 10.1056/NEJM199304153281504; Sutton R, 1997, PACE, V20, P849, DOI 10.1111/j.1540-8159.1997.tb03920.x; XIAO HB, 1991, BRIT HEART J, V66, P443; XIAO HB, 1992, BRIT HEART J, V68, P403; Yu WC, 1997, CIRCULATION, V96, P2992, DOI 10.1161/01.CIR.96.9.2992; ZOLL PM, 1952, NEW ENGL J MED, V247, P768, DOI 10.1056/NEJM195211132472005	64	5	5	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 19	2001	134	12					1130	1141		10.7326/0003-4819-134-12-200106190-00014	http://dx.doi.org/10.7326/0003-4819-134-12-200106190-00014			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	442YU	11412054				2022-12-28	WOS:000169313200007
J	Glassman, AH; Covey, LS; Stetner, F; Rivelli, S				Glassman, AH; Covey, LS; Stetner, F; Rivelli, S			Smoking cessation and the course of major depression: a follow-up study	LANCET			English	Article							NICOTINE; SMOKERS; CLONIDINE; DISORDER; ADULTS	Background Smokers with a history of major depression who attempt to stop smoking have a higher risk of failure than non-depressed smokers. Anecdotal and post-hoc data suggest that those who successfully abstain are at increased risk of depression compared with individuals who continue to smoke. However, these studies confound effects of abstinence and history of depression. We aimed to assess whether there is an increased risk of depression and for how long that increase lasts. Methods We enrolled 100 smokers (>1 pack per day) with a history of major depression, but who were currently free from major depression and had not been on antidepressant medicine for at least 6 months, in a 2-month smoking-cessation trial. The primary outcome was recurrence of major depression, which we assessed by structured clinical interviews 3 and 6 months after the end of treatment. We: verified smoking status by serum-sample cotinine concentrations. Findings 76 participants (42 successful abstainers, 34 smokers) were followed up. 13 abstainers and two smokers had an episode of major depression (odds ratio 7.17 [95% CI 1.5-34.5]; Kaplan-Meier survival curve, log-rank statistic 9.11 [p=003]). Risk of major depression was similar between the first and second 3 months of follow-up. Interpretations Smokers with a history of depression who abstain from smoking are at significantly increased risk of developing a new episode of major depression. This risk remains high for at least 6 months.	New York State Psychiat Inst, Dept Clin Psychopharmacol, New York, NY 10032 USA; Columbia Univ, Coll Phys & Surg, Dept Psychiat, New York, NY USA	New York State Psychiatry Institute; Columbia University	Glassman, AH (corresponding author), New York State Psychiat Inst, Dept Clin Psychopharmacol, 1051 Riverside Dr, New York, NY 10032 USA.							American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; Borrelli B, 1996, J CLIN PSYCHIAT, V57, P534; BRESLAU N, 1991, ARCH GEN PSYCHIAT, V48, P1069; Covey LS, 1997, AM J PSYCHIAT, V154, P263; COVEY LS, 1990, COMPR PSYCHIAT, V31, P350, DOI 10.1016/0010-440X(90)90042-Q; Covey LS, 1994, TOB CONTROL, V3, P222, DOI DOI 10.1136/TC.3.3.222; COVEY LS, 2000, P 6 ANN M SOC RES NI; First M. B., 1997, STRUCTURED CLIN INTE; FRANK E, 1990, ARCH GEN PSYCHIAT, V47, P1093; Ginsberg D, 1995, EXP CLIN PSYCHOPHARM, V3, P389, DOI 10.1037/1064-1297.3.4.389; GLASSMAN AH, 1990, JAMA-J AM MED ASSOC, V264, P1546, DOI 10.1001/jama.264.12.1546; GLASSMAN AH, 1988, JAMA-J AM MED ASSOC, V259, P2863; GLASSMAN AH, 1993, CLIN PHARMACOL THER, V54, P670, DOI 10.1038/clpt.1993.205; HALL SM, 1994, J CONSULT CLIN PSYCH, V62, P141, DOI 10.1037/0022-006X.62.1.141; HALL SM, 1993, J CONSULT CLIN PSYCH, V61, P761, DOI 10.1037/0022-006X.61.5.761; KENDLER KS, 1993, ARCH GEN PSYCHIAT, V50, P36; KESSLER RC, 1994, ARCH GEN PSYCHIAT, V51, P8; McGehee DS, 1996, CURR OPIN NEUROBIOL, V6, P342, DOI 10.1016/S0959-4388(96)80118-8; PRIEN RF, 1986, AM J PSYCHIAT, V143, P18; SalinPascual RJ, 1996, J CLIN PSYCHIAT, V57, P387; SALIVE ME, 1993, J AM GERIATR SOC, V41, P1313, DOI 10.1111/j.1532-5415.1993.tb06481.x; Solomon DA, 2000, AM J PSYCHIAT, V157, P229, DOI 10.1176/appi.ajp.157.2.229; Stage KB, 1996, J CLIN PSYCHIAT, V57, P467, DOI 10.4088/JCP.v57n1005; Tsoh JY, 2000, AM J PSYCHIAT, V157, P368, DOI 10.1176/appi.ajp.157.3.368	24	284	291	0	8	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 16	2001	357	9272					1929	1932		10.1016/S0140-6736(00)05064-9	http://dx.doi.org/10.1016/S0140-6736(00)05064-9			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	444YZ	11425414				2022-12-28	WOS:000169431000012
J	Nicholson, KG; Colegate, AE; Podda, A; Stephenson, I; Wood, J; Ypma, E; Zambon, MC				Nicholson, KG; Colegate, AE; Podda, A; Stephenson, I; Wood, J; Ypma, E; Zambon, MC			Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza	LANCET			English	Article							A H5N1; VIRUSES; INFECTION; ANTIBODY; IMMUNITY; REPLICATION; RESPONSES	Background In 1997, pathogenic avian influenza A/Hong Kong/97 (H5N1) viruses emerged as a pandemic threat tc human beings, A non-pathogenic variant, influenza A/Duck/Singapore/97 (H5N3), was identified as a leading vaccine candidate. We did an observer-blind, phase I, randomised trial in healthy volunteers to assess safety, tolerability, and antigenicity of MF59-adjuvanted and non-adjuvanted vaccines. Methods 32 participants were randomly assigned MF59, and 33 non-adjuvanted vaccine. Two doses were given 3 weeks apart, of 7.5, 15, or 30 mug haemagglutinin surface-antigen influenza A H5N3 vaccine. Antibody responses were measured by haemagglutination inhibition, microneutralisation, and single radial haemolysis (SRH). The primary outcome was geometric mean antibody titre 21 days after vaccination. Findings The A/Duck/Singapore vaccines were safe and well tolerated. Antibody response to non-adjuvanted vaccine was poor, the best response occurring after two 30 mug doses: one, four, four, and one person of eleven seroconverted by haemagglutination inhibition, microneutralisation, H5N3 SRH, and H5N1 SRH, respectively. The geometric mean titres of antibody, and seroconversion rates, were significantly higher after MF59 adjuvanted vaccine. Two 7.5 mug doses of MF59 adjuvanted vaccine gave the highest seroconversion rates: haemagglutination inhibition, six of ten; microneutralisation, eight of ten; H5N3 SRH, ten of ten; H5N1 SRH, nine of ten. Geometric mean titre of antibody to the pathogenic virus, A/Hong Kong/489/97 (H5N1), was about half that to A/Duck/Singapore virus. Interpretation Non-adjuvanted A/Duck/Singapore/97 (H5N3) vaccines are poorly immunogenic and doses of 7.5-30 mug haemagglutinin alone are unlikely to give protection from A/Hong Kong/97 (H5N1) virus. Addition of MF59 to A/Duck/Singapore/97 vaccines boost the antibody response to protection levels. Our findings have implications for development and assessment of vaccines for future pandemics.	Leicester Royal Infirm, Infect Dis Unit, Leicester LE1 5WW, Leics, England; Chiron Vaccines, Siena, Italy; Natl Inst Biol Stand & Controls, Potters Bar EN6 3QG, Herts, England; Publ Hlth Lab Serv, London NW9 5EQ, England	University of Leicester; Novartis; National Institute for Biological Standards & Control; Public Health England	Nicholson, KG (corresponding author), Leicester Royal Infirm, Infect Dis Unit, Leicester LE1 5WW, Leics, England.	karlgnicholson@doctors.org.uk	Podda, Audino/N-1680-2013	Podda, Audino/0000-0002-1340-4982				ALKHAYATT R, 1984, J HYG-CAMBRIDGE, V93, P301, DOI 10.1017/S0022172400064834; BEAN WJ, 1985, J VIROL, V54, P151, DOI 10.1128/JVI.54.1.151-160.1985; BEARE AS, 1991, ARCH VIROL, V119, P37, DOI 10.1007/BF01314321; Bridges CB, 2000, J INFECT DIS, V181, P344, DOI 10.1086/315213; Claas ECJ, 1998, LANCET, V351, P472, DOI 10.1016/S0140-6736(97)11212-0; Delem A, 1977, Dev Biol Stand, V39, P391; ELLIS J, 1997, EUR J EPIDEMIOL, V13, P1; *EUR COMM PROPR ME, 1996, CPMPBWP21496; HINSHAW VS, 1981, INFECT IMMUN, V34, P354, DOI 10.1128/IAI.34.2.354-361.1981; Katz JM, 1999, J INFECT DIS, V180, P1763, DOI 10.1086/315137; Kodihalli S, 1999, J VIROL, V73, P2094, DOI 10.1128/JVI.73.3.2094-2098.1999; Kurtz J, 1996, LANCET, V348, P901, DOI 10.1016/S0140-6736(05)64783-6; Lu XH, 1999, J VIROL, V73, P5903, DOI 10.1128/JVI.73.7.5903-5911.1999; Martin JT, 1997, BIOLOGICALS, V25, P209, DOI 10.1006/biol.1997.0086; NICHOLSON KG, 1979, J BIOL STAND, V7, P123, DOI 10.1016/S0092-1157(79)80044-X; OXFORD JS, 1982, J HYG-CAMBRIDGE, V88, P325, DOI 10.1017/S0022172400070170; PARKMAN PD, 1977, J INFECT DIS, V136, pS722, DOI 10.1093/infdis/136.Supplement_3.S722; POTTER CW, 1979, BRIT MED BULL, V35, P69, DOI 10.1093/oxfordjournals.bmb.a071545; PROFETA ML, 1986, ARCH VIROL, V90, P355, DOI 10.1007/BF01317384; Rimmelzwaan GF, 1999, VACCINE, V17, P1355, DOI 10.1016/S0264-410X(98)00390-9; Rowe T, 1999, J CLIN MICROBIOL, V37, P937, DOI 10.1128/JCM.37.4.937-943.1999; Shortridge K F, 1992, Semin Respir Infect, V7, P11; Shortridge KF, 1998, VIROLOGY, V252, P331, DOI 10.1006/viro.1998.9488; Treanor JJ, 2001, VACCINE, V19, P1732, DOI 10.1016/S0264-410X(00)00395-9; WEBSTER RG, 1981, NEW ENGL J MED, V304, P911; WEBSTER RG, 1998, TXB INFLUENZA, P109; Wood JM, 1999, VACCINE, V18, P579; WOOD JM, 1998, TXB INFLUENZA, P333; Yuen KY, 1998, LANCET, V351, P467, DOI 10.1016/S0140-6736(98)01182-9	29	365	404	0	20	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 16	2001	357	9272					1937	1943		10.1016/S0140-6736(00)05066-2	http://dx.doi.org/10.1016/S0140-6736(00)05066-2			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	444YZ	11425416				2022-12-28	WOS:000169431000014
J	Premawardhena, A; Fisher, CA; Fathiu, F; de Silva, S; Perera, W; Peto, TEA; Olivieri, NF; Weatherall, DJ				Premawardhena, A; Fisher, CA; Fathiu, F; de Silva, S; Perera, W; Peto, TEA; Olivieri, NF; Weatherall, DJ			Genetic determinants of jaundice and gallstones in haemoglobin E beta thalassaemia	LANCET			English	Article							UDP-GLUCURONOSYLTRANSFERASE-1	Chronic hyperbilirubinaemia, gallstone formation, and bladder disease are unusually common in people with haemoglobin E beta thalassaemia in Sri Lanka. To determine whether this has a genetic basis we compared the bilirubin levels and frequency of gallstones in patients with different alleles of the UGT*1 gene. There was a significantly higher bilirubin level in those with the 7/7 genotypes compared with 6/6 and 6/7 genotype (p=0.032 and 0.0015 respectively), who also appeared more prone to gallstone formation. These results suggest that the UGT*1 genotpe is of importance in the genesis of gallstones in this population of patients.	Univ Oxford, Weatherall Inst Mol Med, Oxford, England; Gen Hosp, Thalassaemia Unit, Kurunegala, Sri Lanka; Hosp Sick Children, Toronto, ON M5G 1X8, Canada; Toronto Gen Hosp, Toronto, ON, Canada	University of Oxford; University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital	Weatherall, DJ (corresponding author), Univ Oxford, Weatherall Inst Mol Med, Oxford, England.		Premawardhena, Anuja/GLN-5388-2022; Olivieri, Nancy/AAI-2250-2020	Premawardhena, Anuja/0000-0003-0605-9081; 				Beutler E, 1998, P NATL ACAD SCI USA, V95, P8170, DOI 10.1073/pnas.95.14.8170; BOSMA PJ, 1995, NEW ENGL J MED, V333, P1171, DOI 10.1056/NEJM199511023331802; de Silva S, 2000, LANCET, V355, P786, DOI 10.1016/S0140-6736(99)08246-X; del Giudice EM, 1999, BLOOD, V94, P2259, DOI 10.1182/blood.V94.7.2259.419k42_2259_2262; Sampietro M, 1999, HAEMATOLOGICA, V84, P150	5	57	58	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 16	2001	357	9272					1945	1946		10.1016/S0140-6736(00)05082-0	http://dx.doi.org/10.1016/S0140-6736(00)05082-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	444YZ	11425418				2022-12-28	WOS:000169431000016
J	Zaslavskaia, LA; Lippmeier, JC; Shih, C; Ehrhardt, D; Grossman, AR; Apt, KE				Zaslavskaia, LA; Lippmeier, JC; Shih, C; Ehrhardt, D; Grossman, AR; Apt, KE			Trophic obligate conversion of an photoautotrophic organism through metabolic engineering	SCIENCE			English	Article							SELECTABLE MARKER; TRANSFORMATION; REPORTER; OCEANOGRAPHY; MICROALGAE; CHLORELLA; GLUCOSE; GLUT1; IRON	Most microalgae are obligate photoautotrophs and their growth is strictly dependent on the generation of photosynthetically derived energy. We show that the microalga Phaeodactylum tricornutum can be genetically engineered to thrive on exogenous glucose in the absence of light through the introduction of a gene encoding a glucose transporter (glut1 or hup1). This demonstrates that a fundamental change in the metabolism of an organism can be accomplished through the introduction of a single gene. This also represents progress toward the use of fermentation technology for large-scale commercial exploitation of algae by reducing limitations associated with light-dependent growth.	Martek Biosci Corp, Columbia, MD 21045 USA; Carnegie Inst Sci, Dept Plant Biol, Stanford, CA 94305 USA	Carnegie Institution for Science	Apt, KE (corresponding author), Martek Biosci Corp, 6480 Dobbin Rd, Columbia, MD 21045 USA.	kirkapt@martekbio.com		Lippmeier, J./0000-0002-8157-1491				Apt KE, 1999, J PHYCOL, V35, P215, DOI 10.1046/j.1529-8817.1999.3520215.x; Apt KE, 1996, MOL GEN GENET, V252, P572, DOI 10.1007/s004380050264; ASANO T, 1991, J BIOL CHEM, V266, P24632; Borowitzka MA, 1999, J BIOTECHNOL, V70, P313, DOI 10.1016/S0168-1656(99)00083-8; Boyle E, 1998, NATURE, V393, P733, DOI 10.1038/31585; Chen F, 1996, TRENDS BIOTECHNOL, V14, P421, DOI 10.1016/0167-7799(96)10060-3; Chisholm SW, 2000, NATURE, V407, P685, DOI 10.1038/35037696; Chiu WL, 1996, CURR BIOL, V6, P325, DOI 10.1016/S0960-9822(02)00483-9; COOKSEY KE, 1974, J PHYCOL, V10, P253, DOI 10.1111/j.0022-3646.1974.00253.x; Droop M.R., 1974, ALGAL PHYSL BIOCH, P530; Falciatore A, 1999, MAR BIOTECHNOL, V1, P239, DOI 10.1007/PL00011773; Fischer H, 1999, J PHYCOL, V35, P113, DOI 10.1046/j.1529-8817.1999.3510113.x; Hallmann A, 1996, P NATL ACAD SCI USA, V93, P669, DOI 10.1073/pnas.93.2.669; Haseloff J, 1997, P NATL ACAD SCI USA, V94, P2122, DOI 10.1073/pnas.94.6.2122; Hellebust JA, 1977, BIOL DIATOMS, P169; Kruckeberg AL, 1996, ARCH MICROBIOL, V166, P283, DOI 10.1007/s002030050385; Landry MR, 2000, MAR ECOL PROG SER, V201, P57, DOI 10.3354/meps201057; Lu LL, 1997, J CHROMATOGR A, V776, P81, DOI 10.1016/S0021-9673(97)00151-9; Mueckler M, 1997, BIOCHEM SOC T, V25, P951, DOI 10.1042/bst0250951; RADMER RJ, 1994, J APPL PHYCOL, V6, P93, DOI 10.1007/BF02186062; Raven JA, 1999, PLANT CELL ENVIRON, V22, P741, DOI 10.1046/j.1365-3040.1999.00419.x; ROESSLER PG, 1987, J PHYCOL, V23, P494, DOI 10.1111/j.1529-8817.1987.tb02536.x; RUNNING JA, 1994, J APPL PHYCOL, V6, P99, DOI 10.1007/BF02186063; SAUER N, 1989, FEBS LETT, V259, P43, DOI 10.1016/0014-5793(89)81489-9; Takeda S, 1998, NATURE, V393, P774, DOI 10.1038/31674; TREGUER P, 1995, SCIENCE, V268, P375, DOI 10.1126/science.268.5209.375; Zaslavskaia LA, 2000, J PHYCOL, V36, P379, DOI 10.1046/j.1529-8817.2000.99164.x; ZASLAVSKAIA LA, UNPUB	28	212	260	3	100	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 15	2001	292	5524					2073	2075		10.1126/science.160015	http://dx.doi.org/10.1126/science.160015			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	442KP	11408656				2022-12-28	WOS:000169284700046
J	Hacking, D; Stewart, M				Hacking, D; Stewart, M			Images in clinical medicine: Neonatal pneumomediastinum	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Royal Childrens Hosp, Melbourne, Vic, Australia	Royal Children's Hospital Melbourne	Hacking, D (corresponding author), Royal Childrens Hosp, Melbourne, Vic, Australia.								0	9	9	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 14	2001	344	24					1839	1839		10.1056/NEJM200106143442405	http://dx.doi.org/10.1056/NEJM200106143442405			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	441LC	11407345				2022-12-28	WOS:000169231000005
J	Jeffcoate, W				Jeffcoate, W			Why did the 5th Earl of Derby die?	LANCET			English	Article								The unexpected death of Ferdinando Stanley, 5th Earl of Derby, on April 16, 1594 was an event of major political importance in the later years of Queen Elizabeth I of England. When he had succeeded his father at the age of 38 he became head of one of the most influential families in the country. He also had a claim to the throne if Elizabeth died without naming a successor. Yet within seven months of entering into his inheritance, this previously fit man was suddenly taken ill and died a fortnight later. His death was so significant that the historian John Stow recorded his illness in great detail (figure 1).(1) Stow's remarkable account is compatible with a sinister interpretation of the cause.	City Hosp, Dept Endocrinol & Diabet, Nottingham NG5 1PB, England	University of Nottingham	Jeffcoate, W (corresponding author), City Hosp, Dept Endocrinol & Diabet, Nottingham NG5 1PB, England.							ARCHER I, 1995, THEATRICAL CITY CULT, P17; Bagley J. J., 1985, EARLS DERBY 1485 198; COWARD B, 1983, STANLEYS STANLEY EAR; FUSSNER FS, 1976, HIST REVOLUTION; MACFALL JEW, 1925, BUCHANANS TXB FORENS; MANLEY L, 1995, THEATRICAL CITY CULT, P35; SEACOME J, 1821, HIST HOUSE STANLEY; Sharpe J. A., 1997, INSTRUMENTS DARKNESS; Stow J., 1631, ANN GEN CHRONICLE EN; 1997, DICT NATL BIOGRAPHY	10	7	7	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 9	2001	357	9271					1876	1879		10.1016/S0140-6736(00)04961-8	http://dx.doi.org/10.1016/S0140-6736(00)04961-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	440DN	11410215				2022-12-28	WOS:000169160800034
J	Kuroda, M; Ohta, T; Uchiyama, I; Baba, T; Yuzawa, H; Kobayashi, I; Cui, LZ; Oguchi, A; Aoki, K; Nagai, Y; Lian, JQ; Ito, T; Kanamori, M; Matsumaru, H; Maruyama, A; Murakami, H; Hosoyama, A; Mizutani-Ui, Y; Takahashi, NK; Sawano, T; Inoue, R; Kaito, C; Sekimizu, K; Hirakawa, H; Kuhara, S; Goto, S; Yabuzaki, J; Kanehisa, M; Yamashita, A; Oshima, K; Furuya, K; Yoshino, C; Shiba, T; Hattori, M; Ogasawara, N; Hayashi, H; Hiramatsu, K				Kuroda, M; Ohta, T; Uchiyama, I; Baba, T; Yuzawa, H; Kobayashi, I; Cui, LZ; Oguchi, A; Aoki, K; Nagai, Y; Lian, JQ; Ito, T; Kanamori, M; Matsumaru, H; Maruyama, A; Murakami, H; Hosoyama, A; Mizutani-Ui, Y; Takahashi, NK; Sawano, T; Inoue, R; Kaito, C; Sekimizu, K; Hirakawa, H; Kuhara, S; Goto, S; Yabuzaki, J; Kanehisa, M; Yamashita, A; Oshima, K; Furuya, K; Yoshino, C; Shiba, T; Hattori, M; Ogasawara, N; Hayashi, H; Hiramatsu, K			Whole genome sequencing of meticillin-resistant Staphylococcus aureus	LANCET			English	Article							PENICILLIN-BINDING PROTEINS; NUCLEOTIDE-SEQUENCE; GENE; CLONING; IDENTIFICATION; EXPRESSION; VIRULENCE; REGULATOR; ELEMENT; ENCODES	Background Staphylococcus aureus is one of the major causes of community-acquired and hospital-acquired infections. It produces numerous toxins including superantigens that cause unique disease entities such as toxic-shock syndrome and staphylococcal scarlet fever, and has acquired resistance to practically all antibiotics. Whole genome analysis is a necessary step towards future development of countermeasures against this organism. Methods Whole genome sequences of two related S aureus strains (N315 and Mu50) were determined by shot-gun random sequencing. N315 is a meticillin-resistant S aureus (MRSA) strain isolated in 1982, and Mu50 is an MRSA strain with vancomycin resistance isolated in 1997. The open reading frames were identified by use of GAMBLER and GLIMMER programs, and annotation of each was done with a BLAST homology search, motif analysis, and protein localisation prediction. Findings The Staphylococcus genome was composed of a complex mixture of genes, many of which seem to have been acquired by lateral gene transfer. Most of the antibiotic resistance genes were carried either by plasmids or by mobile genetic elements including a unique resistance island. Three classes of new pathogenicity islands were identified in the genome: a toxic-shock-syndrome toxin island family, exotoxin islands, and enterotoxin islands. in the latter two pathogenicity islands, clusters of exotoxin and enterotoxin genes were found closely linked with other gene clusters encoding putative pathogenic factors. The analysis also identified 70 candidates for new virulence factors. Interpretation The remarkable ability of S aureus to acquire useful genes from various organisms was revealed through the observation of genome complexity and evidence of lateral gene transfer. Repeated duplication of genes encoding superantigens explains why S aureus is capable of infecting humans of diverse genetic backgrounds, eliciting severe immune reactions. Investigation of many newly identified gene products, including the 70 putative virulence factors, will greatly improve our understanding of the biology of staphylococci and the processes of infectious diseases caused by S aureus.	Juntendo Univ, Dept Bacteriol, Bunkyo Ku, Tokyo 1138421, Japan; Univ Tsukuba, Coll Med Technol & Nursing, Tsukuba, Ibaraki 305, Japan; Okazaki Natl Res Inst, Res Ctr Computat Sci, Okazaki, Aichi, Japan; Univ Tokyo, Inst Med Sci, Div Basic Med Sci, Tokyo, Japan; Univ Tokyo, Grad Sch Pharmaceut Sci, Tokyo, Japan; Natl Inst Technol & Evaluat, Tokyo, Japan; Kyushu Univ, Fac Agr, Fukuoka 812, Japan; Kyoto Univ, Inst Chem Res, Kyoto 606, Japan; Kitasato Univ, Sch Sci, Kanagawa, Japan; RIKEN Genom Sci Ctr, Human Genome Res Grp, Kanagawa, Japan; Nara Inst Sci & Technol, Grad Sch Biol Sci, Nara, Japan; Univ Tsukuba, Inst Basic Med Sci, Tsukuba, Ibaraki 305, Japan	Juntendo University; University of Tsukuba; National Institutes of Natural Sciences (NINS) - Japan; Institute for Molecular Science (IMS); Okazaki Institute for Integrative Bioscience (OIIB); University of Tokyo; University of Tokyo; Kyushu University; Kyoto University; Kitasato University; RIKEN; Nara Institute of Science & Technology; University of Tsukuba	Hiramatsu, K (corresponding author), Juntendo Univ, Dept Bacteriol, Bunkyo Ku, 2-1-1 Hongo, Tokyo 1138421, Japan.		Hattori, Masahira/AAD-3785-2019; Kaito, Chikara/G-1248-2017; Hattori, Masahira/C-6958-2016; Kaito, Chikara/W-1815-2019; Kanehisa, Minoru/R-3081-2018; Ogasawara, Naotake/B-7971-2011	Kaito, Chikara/0000-0002-2895-3386; Hattori, Masahira/0000-0001-9467-0344; Kaito, Chikara/0000-0002-2895-3386; cui (Cui), long zhu (Longzhu)/0000-0002-8909-3885; Uchiyama, Ikuo/0000-0002-9197-5000				ABE J, 1992, P NATL ACAD SCI USA, V89, P4066, DOI 10.1073/pnas.89.9.4066; AGATA N, 1995, MICROBIOL-UK, V141, P983, DOI 10.1099/13500872-141-4-983; Alm RA, 1999, NATURE, V397, P176, DOI 10.1038/16495; AMAKO K, 1979, MICROBIOL IMMUNOL, V23, P329, DOI 10.1111/j.1348-0421.1979.tb00470.x; BISSETT DL, 1974, J BACTERIOL, V119, P698, DOI 10.1128/JB.119.3.698-704.1974; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Chesney P.J., 1997, STAPHYLOCOCCI HUMAN, P509; CHEUNG AL, 1994, J BACTERIOL, V176, P4168, DOI 10.1128/JB.176.13.4168-4172.1994; Cramton SE, 2000, INFECT IMMUN, V68, P2344, DOI 10.1128/IAI.68.4.2344-2348.2000; Dinges MM, 2000, CLIN MICROBIOL REV, V13, P16, DOI 10.1128/CMR.13.1.16-34.2000; Fitzgerald JR, 2001, J BACTERIOL, V183, P63, DOI 10.1128/JB.183.1.63-70.2001; FLANNAGAN SE, 1994, PLASMID, V32, P350, DOI 10.1006/plas.1994.1077; FOSTER TJ, 1994, FEMS MICROBIOL LETT, V118, P199, DOI 10.1016/0378-1097(94)90504-5; Giraudo AT, 1999, FEMS MICROBIOL LETT, V177, P15, DOI 10.1016/S0378-1097(99)00282-7; HAYS JB, 1973, J BIOL CHEM, V248, P941; Hiramatsu K, 1999, BAILLIERE CLIN INF D, V5, P221; HIRAMATSU K, 1997, LANCET, V350, P1668; Ito T, 1999, ANTIMICROB AGENTS CH, V43, P1449, DOI 10.1128/AAC.43.6.1449; Jarraud S, 2001, J IMMUNOL, V166, P669, DOI 10.4049/jimmunol.166.1.669; JEVONS MP, 1961, BRIT MED J, V1, P124, DOI 10.1136/bmj.1.5219.124-a; JONSSON K, 1995, J BIOL CHEM, V270, P21457, DOI 10.1074/jbc.270.37.21457; Karlin S, 1998, MOL MICROBIOL, V29, P1341, DOI 10.1046/j.1365-2958.1998.01008.x; Katayama Y, 2000, ANTIMICROB AGENTS CH, V44, P1549, DOI 10.1128/AAC.44.6.1549-1555.2000; KIL KS, 1994, INFECT IMMUN, V62, P2440, DOI 10.1128/IAI.62.6.2440-2449.1994; Kunst F, 1997, NATURE, V390, P249, DOI 10.1038/36786; Lindsay JA, 1998, MOL MICROBIOL, V29, P527, DOI 10.1046/j.1365-2958.1998.00947.x; Manganelli R, 1999, INFECT IMMUN, V67, P50, DOI 10.1128/IAI.67.1.50-56.1999; Manna A, 2001, INFECT IMMUN, V69, P885, DOI 10.1128/IAI.69.2.885-896.2001; MARSHALL JH, 1981, J BACTERIOL, V147, P900, DOI 10.1128/JB.147.3.900-913.1981; MARTIN C, 1992, J BACTERIOL, V174, P4517, DOI 10.1128/JB.174.13.4517-4523.1992; McNamara PJ, 2000, J BACTERIOL, V182, P3197, DOI 10.1128/JB.182.11.3197-3203.2000; NAITO T, 1995, SCIENCE, V267, P897, DOI 10.1126/science.7846533; PARK W, 1984, J BACTERIOL, V157, P538, DOI 10.1128/JB.157.2.538-544.1984; PENG HL, 1988, J BACTERIOL, V170, P4365, DOI 10.1128/jb.170.9.4365-4372.1988; PROJAN SJ, 1997, STAPHYLOCOCCI HUMAN, P55; Reed SB, 2001, INFECT IMMUN, V69, P1521, DOI 10.1128/IAI.69.3.1521-1527.2001; SCHNEEWIND O, 1992, CELL, V70, P267, DOI 10.1016/0092-8674(92)90101-H; Tegmark K, 2000, MOL MICROBIOL, V37, P398, DOI 10.1046/j.1365-2958.2000.02003.x; Tung HS, 2000, BIOCHEM J, V345, P611, DOI 10.1042/0264-6021:3450611; Wada A, 1998, J BACTERIOL, V180, P2759, DOI 10.1128/JB.180.10.2759-2765.1998; Williams RJ, 2000, INFECT IMMUN, V68, P4407, DOI 10.1128/IAI.68.8.4407-4415.2000; Yamaguchi T, 2000, MOL MICROBIOL, V38, P694, DOI 10.1046/j.1365-2958.2000.02169.x; Yarwood JM, 2001, J BACTERIOL, V183, P1113, DOI 10.1128/JB.183.4.1113-1123.2001	43	1510	3574	10	496	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 21	2001	357	9264					1225	1240		10.1016/S0140-6736(00)04403-2	http://dx.doi.org/10.1016/S0140-6736(00)04403-2			16	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	425YY	11418146				2022-12-28	WOS:000168323300008
J	Dehnhardt, G; Mauck, B; Hanke, W; Bleckmann, H				Dehnhardt, G; Mauck, B; Hanke, W; Bleckmann, H			Hydrodynamic trail-following in harbor seals (Phoca vitulina)	SCIENCE			English	Article							FISH; WAKE	Marine mammals often forage in dark or turbid waters. Whereas dolphins use echolocation under such conditions, pinnipeds apparently lack this sensory ability. For seals hunting in the dark, one source of sensory information may consist of fish-generated water movements, which seals can detect with their highly sensitive whiskers. Water movements in the wake of fishes persist for several minutes. Here we show that blindfolded seals can use their whiskers to detect and accurately follow hydrodynamic trails generated by a miniature submarine. This shows that hydrodynamic information can be used for Long-distance prey location.	Univ Bonn, Inst Zool, D-53115 Bonn, Germany; Ruhr Univ Bochum, D-44780 Bochum, Germany	University of Bonn; Ruhr University Bochum	Dehnhardt, G (corresponding author), Univ Bonn, Inst Zool, Poppelsdorfer Schloss, D-53115 Bonn, Germany.							ADRIAN RJ, 1991, ANNU REV FLUID MECH, V23, P261, DOI 10.1146/annurev.fl.23.010191.001401; Au W. W., 1993, SONAR DOLPHINS; Bell W.J, 1991, SEARCHING BEHAV; BLECKMANN H, 1991, J COMP PHYSIOL A, V168, P749; Bleckmann H, 1994, RECEPTION HYDRODYNAM; BLICKHAN R, 1992, NATURWISSENSCHAFTEN, V79, P220, DOI 10.1007/BF01227131; Coombs S., 1989, MECHANOSENSORY LATER; Davis RW, 1999, SCIENCE, V283, P993, DOI 10.1126/science.283.5404.993; Dehnhardt G, 1998, NATURE, V394, P235, DOI 10.1038/28303; Hanke W, 2000, J EXP BIOL, V203, P1193; Levenson DH, 1999, MAR MAMMAL SCI, V15, P1303, DOI 10.1111/j.1748-7692.1999.tb00892.x; Muller UK, 1997, J EXP BIOL, V200, P2893; Videler J. J, 1993, FISH SWIMMING, P1; Weissburg MJ, 1998, PHILOS T R SOC B, V353, P701, DOI 10.1098/rstb.1998.0236	14	234	241	2	99	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 6	2001	293	5527					102	104		10.1126/science.1060514	http://dx.doi.org/10.1126/science.1060514			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	451BB	11441183				2022-12-28	WOS:000169780300038
J	Frustaci, A; Chimenti, C; Ricci, R; Natale, L; Russo, MA; Pieroni, M; Eng, CM; Desnick, RJ				Frustaci, A; Chimenti, C; Ricci, R; Natale, L; Russo, MA; Pieroni, M; Eng, CM; Desnick, RJ			Brief report: Improvement in cardiac function in the cardiac variant of Fabry's disease with galactose-infusion therapy.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ALPHA-GALACTOSIDASE; A GENE; HYPERTROPHIC CARDIOMYOPATHY; ATYPICAL VARIANT; MUTATIONS; HEMIZYGOTES; IDENTIFICATION; HETEROZYGOTES; LYMPHOBLASTS; PROTEINS		Univ Cattolica Sacro Cuore, Dept Cardiol, Rome, Italy; Univ Cattolica Sacro Cuore, Dept Pediat, Rome, Italy; Univ Cattolica Sacro Cuore, Dept Radiol, Rome, Italy; Univ Roma La Sapienza, Dept Med Sperimentale & Patol, Rome, Italy; Mt Sinai Sch Med, Dept Human Genet, New York, NY 10029 USA	Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli; Sapienza University Rome; Icahn School of Medicine at Mount Sinai	Desnick, RJ (corresponding author), Mt Sinai Sch Med, Dept Human Genet, Box 1498,5th Ave & 100 St, New York, NY 10029 USA.	rjd.fabry@mssm.edu	NATALE, Luigi/C-8234-2016; Chimenti, Cristina/AAC-2437-2019; Pieroni, Maurizio/K-8488-2019	NATALE, Luigi/0000-0002-7949-5119; Pieroni, Maurizio/0000-0002-6830-4292	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P30HD028822] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000071] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK034045] Funding Source: NIH RePORTER; NCRR NIH HHS [MO1 RR00071] Funding Source: Medline; NICHD NIH HHS [P30 HD28822] Funding Source: Medline; NIDDK NIH HHS [R37 DK34045] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		[Anonymous], 2014, METABOLIC MOL BASES; Asano N, 2000, EUR J BIOCHEM, V267, P4179, DOI 10.1046/j.1432-1327.2000.01457.x; Ashton-Prolla P, 2000, J INVEST MED, V48, P227; Bonne G, 1998, CIRC RES, V83, P580, DOI 10.1161/01.RES.83.6.580; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P9; DESNICK RJ, 1973, J LAB CLIN MED, V81, P157; Desnick RJ., 1995, METABOLIC MOL BASES, P2741; ELLEDER M, 1990, VIRCHOWS ARCH A, V417, P449, DOI 10.1007/BF01606034; Elleder M, 1990, Cas Lek Cesk, V129, P369; ENG CM, 1994, HUM MOL GENET, V3, P1795, DOI 10.1093/hmg/3.10.1795; ENG CM, 1993, AM J HUM GENET, V53, P1186; Eng CM, 2001, AM J HUM GENET, V68, P711, DOI 10.1086/318809; Eng CM, 2001, NEW ENGL J MED, V345, P9, DOI 10.1056/NEJM200107053450102; Fan JQ, 1999, NAT MED, V5, P112, DOI 10.1038/4801; Hall C W, 1978, Methods Enzymol, V50, P439; ISHII S, 1993, BIOCHEM BIOPH RES CO, V197, P1585, DOI 10.1006/bbrc.1993.2659; ISHII S, 1994, BBA-PROTEIN STRUCT M, V1204, P265, DOI 10.1016/0167-4838(94)90017-5; Kamisago M, 2000, NEW ENGL J MED, V343, P1688, DOI 10.1056/NEJM200012073432304; KUHN H, 1982, CIRCULATION, V66, P117; Kuznetsov G, 1998, NEW ENGL J MED, V339, P1688, DOI 10.1056/NEJM199812033392307; McClellan AJ, 2001, NAT CELL BIOL, V3, pE51, DOI 10.1038/35055162; MILLER PJ, 1971, MED LAB TECHNOL, V28, P148; NAGAO Y, 1991, CLIN GENET, V39, P233; NAKAO S, 1995, NEW ENGL J MED, V333, P288, DOI 10.1056/NEJM199508033330504; OKUMIYA T, 1995, HUM GENET, V95, P557; OKUMIYA T, 1995, BIOCHEM BIOPH RES CO, V214, P1219, DOI 10.1006/bbrc.1995.2416; SAKURABA H, 1990, AM J HUM GENET, V47, P784; Schiffmann R, 2000, AM J HUM GENET, V67, P38; Towbin J A, 2000, Curr Cardiol Rep, V2, P475, DOI 10.1007/s11886-000-0063-9; VONSCHEIDT W, 1991, NEW ENGL J MED, V324, P395, DOI 10.1056/NEJM199102073240607; Ziegler RJ, 1999, HUM GENE THER, V10, P1667, DOI 10.1089/10430349950017671	31	246	266	0	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 1	2001	345	1					25	32		10.1056/NEJM200107053450104	http://dx.doi.org/10.1056/NEJM200107053450104			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	449QJ	11439944				2022-12-28	WOS:000169697600004
J	Changela, A; DiGate, RJ; Mondragon, A				Changela, A; DiGate, RJ; Mondragon, A			Crystal structure of a complex of a type IA DNA topoisomerase with a single-stranded DNA molecule	NATURE			English	Article							PROTEIN; DOMAIN; IDENTIFICATION; RESIDUES; INSIGHTS; PROGRAM; BINDING; TOPRIM	A variety of cellular processes, including DNA replication, transcription, and chromosome condensation, require enzymes that can regulate the ensuing topological changes occurring in DNA. Such enzymes-DNA topoisomerases-alter DNA topology by catalysing the cleavage of single-stranded DNA (ssDNA) or double-stranded DNA (dsDNA), the passage of DNA through the resulting break, and the rejoining of the broken phosphodiester backbone(1). DNA topoisomerase III from Escherichia coli belongs to the type IA family of DNA topoisomerases, which transiently cleave ssDNA via formation of a covalent 5' phosphotyrosine intermediate. Here we report the crystal structure, at 2.05 Angstrom resolution, of an inactive mutant of E. coli DNA topoisomerase III in a non-covalent complex with an 8-base ssDNA molecule. The enzyme undergoes a conformational change that allows the oligonucleotide to bind within a groove leading to the active site. We note that the ssDNA molecule adopts a conformation like that of B-DNA while bound to the enzyme. The position of the DNA within the realigned active site provides insight into the role of several highly conserved residues during catalysis. These findings confirm various aspects of the type IA topoisomerase mechanism while suggesting functional implications for other topoisomerases and proteins that perform DNA rearrangements.	Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60208 USA; Univ Maryland, Sch Med, Dept Pharmaceut Sci, Baltimore, MD 21201 USA	Northwestern University; University System of Maryland; University of Maryland Baltimore	Mondragon, A (corresponding author), Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, 2153 Sheridan Rd, Evanston, IL 60208 USA.	a-mondragon@northwestern.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051350] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM051350] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aravind L, 1998, NUCLEIC ACIDS RES, V26, P4205, DOI 10.1093/nar/26.18.4205; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Berger JM, 1996, NATURE, V379, P225, DOI 10.1038/379225a0; Berger JM, 1998, P NATL ACAD SCI USA, V95, P7876, DOI 10.1073/pnas.95.14.7876; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chen SJ, 1998, J BIOL CHEM, V273, P6050, DOI 10.1074/jbc.273.11.6050; DOMANICO PL, 1991, J INORG BIOCHEM, V42, P87, DOI 10.1016/0162-0134(91)80035-G; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; Fass D, 1999, NAT STRUCT BIOL, V6, P322; Harp JM, 1998, ACTA CRYSTALLOGR D, V54, P622, DOI 10.1107/S0907444997019008; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1993, J APPL CRYSTALLOGR, V26, P795, DOI 10.1107/S0021889893005588; Keck JL, 2000, SCIENCE, V287, P2482, DOI 10.1126/science.287.5462.2482; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Li ZY, 2000, MOL MICROBIOL, V35, P888, DOI 10.1046/j.1365-2958.2000.01763.x; LIMA CD, 1994, NATURE, V367, P138, DOI 10.1038/367138a0; Liu QY, 1999, P NATL ACAD SCI USA, V96, P881, DOI 10.1073/pnas.96.3.881; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Mondragon A, 1999, STRUCTURE, V7, P1373, DOI 10.1016/S0969-2126(00)80027-1; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nichols MD, 1999, EMBO J, V18, P6177, DOI 10.1093/emboj/18.21.6177; Podobnik M, 2000, J MOL BIOL, V300, P353, DOI 10.1006/jmbi.2000.3844; Redinbo MR, 2000, BIOCHEMISTRY-US, V39, P6832, DOI 10.1021/bi992690t; Sherratt DJ, 1998, CELL, V93, P149, DOI 10.1016/S0092-8674(00)81566-4; WANG JC, 1971, J MOL BIOL, V55, P523, DOI 10.1016/0022-2836(71)90334-2; Wang JC, 1996, ANNU REV BIOCHEM, V65, P635, DOI 10.1146/annurev.bi.65.070196.003223; ZHANG HL, 1994, J BIOL CHEM, V269, P9052; ZHANG HL, 1995, J BIOL CHEM, V270, P23700, DOI 10.1074/jbc.270.40.23700; Zhu CX, 2000, J BIOL CHEM, V275, P5318, DOI 10.1074/jbc.275.8.5318; Zhu CX, 1998, J BIOL CHEM, V273, P8783, DOI 10.1074/jbc.273.15.8783	30	89	91	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 28	2001	411	6841					1077	1081		10.1038/35082615	http://dx.doi.org/10.1038/35082615			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	446TF	11429611				2022-12-28	WOS:000169528500054
J	Ferrari, G; Stornaiuolo, A; Mavilio, F				Ferrari, G; Stornaiuolo, A; Mavilio, F			Bone-marrow transplantation - Failure to correct murine muscular dystrophy	NATURE			English	Article							MUSCLE		H San Raffaele Telethon Inst Gene Therapy, I-20132 Milan, Italy; GeneEra SpA, I-20132 Milan, Italy; Univ Modena, Sch Med, Dept Biomed Sci, I-41100 Modena, Italy	Fondazione Telethon; San Raffaele Telethon Institute For Gene Therapy (Sr-Tiget); Universita di Modena e Reggio Emilia	Ferrari, G (corresponding author), H San Raffaele Telethon Inst Gene Therapy, Via Olgettina 58, I-20132 Milan, Italy.		Ferrari, Giuliana/AAB-5546-2019	Ferrari, Giuliana/0000-0003-0790-3133; Mavilio, Fulvio/0000-0003-0459-4320	Telethon [TGT00D01, TGT06S01] Funding Source: Medline	Telethon(Fondazione Telethon)		Bittner RE, 1999, ANAT EMBRYOL, V199, P391, DOI 10.1007/s004290050237; DANKO I, 1992, PEDIATR RES, V32, P128, DOI 10.1203/00006450-199207000-00025; Emery A.E.H., 1993, DUCHENNE MUSCULAR DY; Ferrari G, 1998, SCIENCE, V279, P1528, DOI 10.1126/science.279.5356.1528; Gussoni E, 1999, NATURE, V401, P390, DOI 10.1038/43919	5	124	133	0	0	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 28	2001	411	6841					1014	1015		10.1038/35082631	http://dx.doi.org/10.1038/35082631			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	446TF	11429592				2022-12-28	WOS:000169528500035
J	Schlosser, N; Reymond, G; Protsenko I; Grangier, P				Schlosser, N; Reymond, G; Protsenko, I; Grangier, P			Sub-poissonian loading of single atoms in a microscopic dipole trap	NATURE			English	Article							NEUTRAL ATOMS; QUANTUM LOGIC; PHOTONS; STATES; GATES	The ability to manipulate individual atoms, ions or photons allows controlled engineering of the quantum state of small sets of trapped particles; this is necessary to encode and process information at the quantum level. Recent achievements in this direction have used either trapped ions(1-3) or trapped photons in cavity quantum-electrodynamical systems(3,4). A third possibility that has been studied theoretically(5,6) is to use trapped neutral atoms. Such schemes would benefit greatly from the ability to trap and address individual atoms with high spatial resolution. Here we demonstrate a method for loading and detecting individual atoms in an optical dipole trap of submicrometre size. Because of the extremely small trapping volume, only one atom can be loaded at a time, so that the statistics of the number of atoms in the trap, N, are strongly sub-poissonian (DeltaN(2) approximate to0.5N). We present a simple model for describing the observed behaviour, and we discuss the possibilities for trapping and addressing several atoms in separate traps, for applications in quantum information processing.	Inst Opt, Lab Charles Fabry, CNRS, UMR 8501, F-91403 Orsay, France	Centre National de la Recherche Scientifique (CNRS); CNRS - Institute of Physics (INP)	Grangier, P (corresponding author), Inst Opt, Lab Charles Fabry, CNRS, UMR 8501, BP 147, F-91403 Orsay, France.	philippe.grangier@iota.u-psud.fr	Protsenko, Igor E/A-9686-2014	Protsenko, Igor E/0000-0002-9462-0221				Brennen GK, 1999, PHYS REV LETT, V82, P1060, DOI 10.1103/PhysRevLett.82.1060; Brennen GK, 2000, PHYS REV A, V61, DOI 10.1103/PhysRevA.61.062309; Calarco T, 2000, J MOD OPTIC, V47, P2137, DOI 10.1080/09500340008235137; Calarco T, 2000, PHYS REV A, V61, DOI 10.1103/PhysRevA.61.022304; DePue MT, 1999, PHYS REV LETT, V82, P2262, DOI 10.1103/PhysRevLett.82.2262; DOHERTY AC, 2001, PHYS REV A, V63; Frese D, 2000, PHYS REV LETT, V85, P3777, DOI 10.1103/PhysRevLett.85.3777; HU Z, 1994, OPT LETT, V19, P1888, DOI 10.1364/OL.19.001888; Jaksch D, 2000, PHYS REV LETT, V85, P2208, DOI 10.1103/PhysRevLett.85.2208; Kuppens SJM, 2000, PHYS REV A, V62, DOI 10.1103/PhysRevA.62.013406; MILLER JD, 1993, PHYS REV A, V47, pR4567, DOI 10.1103/PhysRevA.47.R4567; Morinaga M, 1999, PHYS REV LETT, V83, P4037, DOI 10.1103/PhysRevLett.83.4037; Orzel C, 2001, SCIENCE, V291, P2386, DOI 10.1126/science.1058149; Pinkse PWH, 2000, NATURE, V404, P365, DOI 10.1038/35006006; Rauschenbeutel A, 1999, PHYS REV LETT, V83, P5166, DOI 10.1103/PhysRevLett.83.5166; REMPE G, 1990, PHYS REV A, V42, P1650, DOI 10.1103/PhysRevA.42.1650; Ruschewitz F, 1996, EUROPHYS LETT, V34, P651, DOI 10.1209/epl/i1996-00510-7; Sackett CA, 2000, NATURE, V404, P256, DOI 10.1038/35005011; Steane A, 2000, PHYS REV A, V62, DOI 10.1103/PhysRevA.62.042305; Walther H, 1998, P ROY SOC A-MATH PHY, V454, P431, DOI 10.1098/rspa.1998.0169	20	375	381	3	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 28	2001	411	6841					1024	1027		10.1038/35082512	http://dx.doi.org/10.1038/35082512			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	446TF	11429597				2022-12-28	WOS:000169528500040
J	Gibson, RM				Gibson, RM			Does apoptosis have a role in neurodegeneration?	BRITISH MEDICAL JOURNAL			English	Article							CLEAVAGE; DISEASE		Univ Manchester, Sch Biol Sci, Manchester M13 9PT, Lancs, England	University of Manchester	Gibson, RM (corresponding author), Univ Manchester, Sch Biol Sci, Manchester M13 9PT, Lancs, England.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Barinaga M, 1998, SCIENCE, V281, P1303, DOI 10.1126/science.281.5381.1303; Cattaneo E, 2001, TRENDS NEUROSCI, V24, P182, DOI 10.1016/S0166-2236(00)01721-5; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; Gervais FG, 1999, CELL, V97, P395, DOI 10.1016/S0092-8674(00)80748-5; Goldberg YP, 1996, NAT GENET, V13, P442, DOI 10.1038/ng0896-442; Yamamoto A, 2000, CELL, V101, P57, DOI 10.1016/S0092-8674(00)80623-6	6	24	27	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 23	2001	322	7301					1539	1540		10.1136/bmj.322.7301.1539	http://dx.doi.org/10.1136/bmj.322.7301.1539			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	446UF	11420281	Green Published			2022-12-28	WOS:000169532000025
J	Fang, JY; Chen, AP; Peng, CH; Zhao, SQ; Ci, L				Fang, JY; Chen, AP; Peng, CH; Zhao, SQ; Ci, L			Changes in forest biomass carbon storage in China between 1949 and 1998	SCIENCE			English	Article							UNITED-STATES; BUDGET; CLIMATE; CO2	The Location and mechanisms responsible for the carbon sink in northern mid-latitude Lands are uncertain. Here, we used an improved estimation method of forest biomass and a 50-year national forest resource inventory in China to estimate changes in the storage of Living biomass between 1949 and 1998. Our results suggest that Chinese forests released about 0.68 petagram of carbon between 1949 and 1980, for an annual emission rate of 0.022 petagram of carbon. Carbon storage increased significantly after the Late 1970s from 4.38 to 4.75 petagram of carbon by 1998, for a mean accumulation rate of 0.021 petagram of carbon per year, mainly due to forest expansion and regrowth. Since the mid-1970s, planted forests (afforestation and reforestation) have sequestered 0.45 petagram of carbon, and their average carbon density increased from 15.3 to 31.1 megagrams per hectare, while natural forests have Lost an additional 0.14 petagram of carbon, suggesting that carbon sequestration through forest management practices addressed in the Kyoto Protocol could help offset industrial carbon dioxide emissions.	Peking Univ, Minist Educ, Dept Urban & Environm Sci, Beijing 100871, Peoples R China; Peking Univ, Minist Educ, Key Lab Earth Surface Proc, Beijing 100871, Peoples R China; Minist Nat Resources, Ontario Forest Res Inst, Sault Ste Marie, ON P6A 2E5, Canada; Lakehead Univ, Fac Forestry & Forest Environm, Thunder Bay, ON P7B 5E1, Canada; Chinese Acad Forestry, Inst Forest Ecol & Environm, Beijing 100091, Peoples R China	Peking University; Peking University; Ministry of Natural Resources & Forestry; Natural Resources Canada; Lakehead University; Chinese Academy of Forestry; Research Institute of Forest Ecology, Environment and Protection, CAF	Fang, JY (corresponding author), Peking Univ, Minist Educ, Dept Urban & Environm Sci, Beijing 100871, Peoples R China.	jyfang@urban.pku.edu.cn	Peng, Changhui/G-8248-2012; Chen, Anping/H-9960-2014; Fang, Jingyun/A-4282-2009	Chen, Anping/0000-0003-2085-3863; 				BIRDSEY RA, 1995, RM228 USDA FOR SERV, P1; BROWN S, 1992, INTERCIENCIA, V17, P8; Brown SL, 1999, ECOL APPL, V9, P968, DOI 10.1890/1051-0761(1999)009[0968:SPOAPA]2.0.CO;2; *CHIN MIN FOR, 1965, FOR RES STAT CHIN PE; *DEP FOR RES MAN C, 1996, FOR RES CHIN 1949 93; DIXON RK, 1994, SCIENCE, V263, P185, DOI 10.1126/science.263.5144.185; Fan S, 1998, SCIENCE, V282, P442, DOI 10.1126/science.282.5388.442; Fang JY, 1998, ECOL APPL, V8, P1084, DOI 10.2307/2640963; FANG JY, 2000, FOREST BIOMASS DATAB, P1; FANG JY, 1996, STUDIES EMISSIONS TH, P81; Field CB, 1999, SCIENCE, V285, P544, DOI 10.1126/science.285.5427.544; *FOR MIN CHIN, 1983, TECHN STAND FOR RES; Houghton RA, 1999, SCIENCE, V285, P574, DOI 10.1126/science.285.5427.574; Houghton RA, 2000, GLOBAL ECOL BIOGEOGR, V9, P125, DOI 10.1046/j.1365-2699.2000.00166.x; KAUPPI PE, 1992, SCIENCE, V256, P70, DOI 10.1126/science.256.5053.70; Kurz WA, 1999, ECOL APPL, V9, P526, DOI 10.1890/1051-0761(1999)009[0526:AYRAOC]2.0.CO;2; LI WH, 1996, RES FOREST RESOURCE; Peng CH, 1997, TELLUS B, V49, P393, DOI 10.1034/j.1600-0889.49.issue4.5.x; Potter S. C., 1999, SCIENCE, V283; Schimel D, 2000, SCIENCE, V287, P2004, DOI 10.1126/science.287.5460.2004; SCHLAMADINGER B, 2000, SPECIAL REPORT IPCC, P127; Schroeder P, 1997, FOREST SCI, V43, P424; Schulze ED, 2000, SCIENCE, V289, P2058, DOI 10.1126/science.289.5487.2058; Steffen W, 1998, SCIENCE, V280, P1393; TURNER DP, 1995, ECOL APPL, V5, P421, DOI 10.2307/1942033; WOFSY SC, 1993, SCIENCE, V260, P1314, DOI 10.1126/science.260.5112.1314; Zhang PC, 2000, SCIENCE, V288, P2135, DOI 10.1126/science.288.5474.2135	27	1022	1759	113	1095	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 22	2001	292	5525					2320	2322		10.1126/science.1058629	http://dx.doi.org/10.1126/science.1058629			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	445KD	11423660				2022-12-28	WOS:000169455900055
J	Hatfull, GF				Hatfull, GF			Microbiology - The great escape	SCIENCE			English	Editorial Material							CELL-LYSIS; VIRUSES		Univ Pittsburgh, Dept Biol Sci, Pittsburgh, PA 15241 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Hatfull, GF (corresponding author), Univ Pittsburgh, Dept Biol Sci, Pittsburgh, PA 15241 USA.	gfh@pitt.edu						BERGH O, 1989, NATURE, V340, P467, DOI 10.1038/340467a0; Bernhardt TG, 2000, P NATL ACAD SCI USA, V97, P4297, DOI 10.1073/pnas.97.8.4297; Bernhardt TG, 2001, J BIOL CHEM, V276, P6093, DOI 10.1074/jbc.M007638200; Bernhardt TG, 2001, SCIENCE, V292, P2326, DOI 10.1126/science.1058289; Nanninga N, 1998, MICROBIOL MOL BIOL R, V62, P110, DOI 10.1128/MMBR.62.1.110-129.1998; Nelson D, 2001, P NATL ACAD SCI USA, V98, P4107, DOI 10.1073/pnas.061038398; Wang IN, 2000, ANNU REV MICROBIOL, V54, P799, DOI 10.1146/annurev.micro.54.1.799; WINTER RB, 1983, CELL, V33, P877, DOI 10.1016/0092-8674(83)90030-2; Wommack KE, 2000, MICROBIOL MOL BIOL R, V64, P69, DOI 10.1128/MMBR.64.1.69-114.2000; Young R, 2000, TRENDS MICROBIOL, V8, P120, DOI 10.1016/S0966-842X(00)01705-4	10	6	7	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 22	2001	292	5525					2263	2264		10.1126/science.1062957	http://dx.doi.org/10.1126/science.1062957			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	445KD	11423642				2022-12-28	WOS:000169455900036
J	Pybus, OG; Charleston, MA; Gupta, S; Rambaut, A; Holmes, EC; Harvey, PH				Pybus, OG; Charleston, MA; Gupta, S; Rambaut, A; Holmes, EC; Harvey, PH			The epidemic behavior of the hepatitis C virus	SCIENCE			English	Article							MOLECULAR EPIDEMIOLOGY; RELATIVE PREVALENCE; POPULATION HISTORY; INFECTION; GENOTYPES; DIVERSITY; SUBTYPES; TRANSMISSION; RECIPIENTS; SEQUENCES	Hepatitis C virus (HCV) is a leading worldwide cause of liver disease. Here, we use a new model of HCV spread to investigate the epidemic behavior of the virus and to estimate its basic reproductive number from gene sequence data. We find significant differences in epidemic behavior among HCV subtypes and suggest that these differences are largely the result of subtype-specific transmission patterns. Our model builds a bridge between the disciplines of population genetics and mathematical epidemiology by using pathogen gene sequences to infer the population dynamic history of an infectious disease.	Univ Oxford, Dept Zool, Oxford OX1 3PS, England	University of Oxford	Pybus, OG (corresponding author), Univ Oxford, Dept Zool, S Parks Rd, Oxford OX1 3PS, England.	oliver.pybus@zoo.ox.ac.uk	Charleston, Michael A/O-4903-2017; Holmes, Edward/GVR-9499-2022; Rambaut, Andrew/B-2481-2009; Pybus, Oliver G/B-2640-2012	Charleston, Michael A/0000-0001-8385-341X; Rambaut, Andrew/0000-0003-4337-3707; Pybus, Oliver G/0000-0002-8797-2667; Holmes, Edward/0000-0001-9596-3552				ANDERSON R M, 1991; *CDCP, 1998, MMWR-MORBID MORTAL W, V47, pRR19; Dubois F, 1997, HEPATOLOGY, V25, P1490, DOI 10.1002/hep.510250630; FARCI P, 1992, SCIENCE, V258, P135, DOI 10.1126/science.1279801; FELSENSTEIN J, 1981, J MOL EVOL, V17, P368, DOI 10.1007/BF01734359; FORNS X, 1998, VIRAL HEPAT REV, V4, P1; Frank C, 2000, LANCET, V355, P887, DOI 10.1016/S0140-6736(99)06527-7; Garfein RS, 1996, AM J PUBLIC HEALTH, V86, P655, DOI 10.2105/AJPH.86.5.655; GRIFFITHS RC, 1994, PHILOS T ROY SOC B, V344, P403, DOI 10.1098/rstb.1994.0079; GUPTA S, 1994, SCIENCE, V263, P961, DOI 10.1126/science.8310293; Jeannel D, 1998, J MED VIROL, V55, P92, DOI 10.1002/(SICI)1096-9071(199806)55:2&lt;92::AID-JMV2&gt;3.0.CO;2-I; Kao JH, 2000, J GASTROEN HEPATOL, V15, pE91, DOI 10.1046/j.1440-1746.2000.02108.x; Kimura Y, 2000, J MED VIROL, V61, P37, DOI 10.1002/(SICI)1096-9071(200005)61:1&lt;37::AID-JMV6&gt;3.0.CO;2-E; Kingman J, 1982, J APPL PROB A, V19, P27, DOI DOI 10.2307/3213548; MELLOR J, 1995, J GEN VIROL, V76, P2493, DOI 10.1099/0022-1317-76-10-2493; MILLER RH, 1990, P NATL ACAD SCI USA, V87, P2057, DOI 10.1073/pnas.87.6.2057; Morice Y, 2001, J GEN VIROL, V82, P1001, DOI 10.1099/0022-1317-82-5-1001; NEE S, 1995, PHILOS T ROY SOC B, V349, P25, DOI 10.1098/rstb.1995.0087; PAWLOTSKY JM, 1995, J INFECT DIS, V171, P1607, DOI 10.1093/infdis/171.6.1607; POL S, 1995, GASTROENTEROLOGY, V108, P581, DOI 10.1016/0016-5085(95)90088-8; POWER JP, 1995, LANCET, V345, P1211, DOI 10.1016/S0140-6736(95)91993-7; Prescott LE, 1997, J MED VIROL, V53, P237, DOI 10.1002/(SICI)1096-9071(199711)53:3<237::AID-JMV10>3.3.CO;2-P; Prescott LE, 1996, J MED VIROL, V50, P168, DOI 10.1002/(SICI)1096-9071(199610)50:2&lt;168::AID-JMV10&gt;3.0.CO;2-I; Pybus OG, 1999, MOL BIOL EVOL, V16, P953, DOI 10.1093/oxfordjournals.molbev.a026184; Pybus OG, 2000, GENETICS, V155, P1429; Rambaut A, 2000, BIOINFORMATICS, V16, P395, DOI 10.1093/bioinformatics/16.4.395; Rosen HR, 1999, AM J GASTROENTEROL, V94, P3015, DOI 10.1111/j.1572-0241.1999.01456.x; Seeff LB, 2000, ANN INTERN MED, V132, P105, DOI 10.7326/0003-4819-132-2-200001180-00003; SHERLOCK S, 1993, VIRAL HEPATITIS, P1; Shobokshi OA, 1999, J MED VIROL, V58, P44, DOI 10.1002/(SICI)1096-9071(199905)58:1&lt;44::AID-JMV6&gt;3.0.CO;2-U; SILINI E, 1995, J HEPATOL, V22, P691, DOI 10.1016/0168-8278(95)80225-8; SIMMONDS P, 1993, J GEN VIROL, V74, P2391, DOI 10.1099/0022-1317-74-11-2391; Smith DB, 1997, J GEN VIROL, V78, P321, DOI 10.1099/0022-1317-78-2-321; Smith DB, 1997, J MOL EVOL, V45, P238, DOI 10.1007/PL00006226; *WHO, 1997, WKLY EPIDEMIOL REC, V72, P65; Wong DA, 1998, EUR J EPIDEMIOL, V14, P421, DOI 10.1023/A:1007400304726	36	336	344	0	40	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 22	2001	292	5525					2323	2325		10.1126/science.1058321	http://dx.doi.org/10.1126/science.1058321			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	445KD	11423661				2022-12-28	WOS:000169455900056
J	Mitchell, KJ; Finkelhor, D; Wolak, J				Mitchell, KJ; Finkelhor, D; Wolak, J			Risk factors for and impact of online sexual solicitation of youth	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Context Health care professionals, educators, and others are increasingly called upon to advise parents and policymakers about risks posed to children by Internet use. However, little scientific information exists on the experiences of children online. Objective To assess the risk factors surrounding online sexual solicitations of youth and distress due to solicitation. Design, Setting, and Participants Telephone survey (August 1999-February 2000) of a random sample of 1501 youth aged 10 through 17 years who were regular Internet users. Main Outcome Measurer Demographic and behavioral characteristics associated with solicitation risk and distress due to solicitation. Results Nineteen percent of youth who used the Internet regularly were the targets of unwanted sexual solicitation in the last year. Girls (P<.001), older teens (P=.005), troubled youth (P=.004), frequent Internet users (P=.01), chat room participants (P<.001), and those who communicated online with strangers (P<.001) were at greater risk. Twenty-five percent of the solicited youth reported high levels of distress after solicitation incidents. Risk of distress was more common among the younger youth (P=.005), those who received aggressive solicitations (the solicitor attempted or made off line contact) (P=.001), and those who were solicited on a computer away from their home (P=.001). Conclusions Many young people who use the Internet encounter unwanted sexual overtures. Health care professionals, educators, and parents should be prepared to educate youth about how to respond to online sexual solicitations, including encouraging youth to disclose and report such encounters and to talk about them.	Univ New Hampshire, Crimes Children Res Ctr, Horton Social Sci Ctr 126, Durham, NH 03824 USA	University System Of New Hampshire; University of New Hampshire	Finkelhor, D (corresponding author), Univ New Hampshire, Crimes Children Res Ctr, Horton Social Sci Ctr 126, Durham, NH 03824 USA.							ADERNO R, 1999, J ANXIETY DISORD, V13, P541; AFTAB P, 2000, PARENTS GUIDE PROTEC, P126; BoneyMcCoy S, 1996, J CONSULT CLIN PSYCH, V64, P1406, DOI 10.1037/0022-006X.64.6.1406; Demarest D S, 1984, Child Health Care, V12, P179, DOI 10.1207/s15326888chc1204_5; Dorman SM, 1997, J SCHOOL HEALTH, V67, P355; FINKELHOR D, 1994, PEDIATRICS, V94, P413; Finkelhor D, 2000, ONLINE VICTIMIZATION, P1; HANSON L, 2000, JUVENILE JUSTICE B; JUPP JJ, 1990, AUST PSYCHOL, V25, P165, DOI 10.1080/00050069008260009; Kirby D, 1997, CHILD YOUTH SERV REV, V19, P415, DOI 10.1016/S0190-7409(97)00025-X; *ROP STARCH WORLDW, 1999, AM ON ROP STARCH CYB; Turow J., 1999, ANN PUBL POL CTR C F; *YANK PARTN, 1999, WEBS STUD TEENS THEI, P1; Zhang J, 1998, JAMA-J AM MED ASSOC, V280, P1690, DOI 10.1001/jama.280.19.1690	14	148	150	0	15	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 20	2001	285	23					3011	3014		10.1001/jama.285.23.3011	http://dx.doi.org/10.1001/jama.285.23.3011			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	442AR	11410100	Bronze			2022-12-28	WOS:000169263200024
J	Almeida, C; Braveman, P; Gold, MR; Szwarcwald, CL; Ribeiro, JM; Miglionico, A; Millar, JS; Porto, S; Costa, ND; Rubio, VO; Segall, M; Starfield, B; Travessos, C; Uga, A; Varente, J; Viacava, F				Almeida, C; Braveman, P; Gold, MR; Szwarcwald, CL; Ribeiro, JM; Miglionico, A; Millar, JS; Porto, S; Costa, ND; Rubio, VO; Segall, M; Starfield, B; Travessos, C; Uga, A; Varente, J; Viacava, F			Methodological concerns and recommendations on policy consequences of the World Health Report 2000	LANCET			English	Article							DEVELOPING-COUNTRIES; LIFE-YEARS; INEQUALITIES; CARE; MORTALITY; DISEASE; SYSTEMS; ETHICS; BURDEN; INCOME		Oswaldo Cruz Fdn, Ctr Sci & Technol Informat, Hlth Informat Dept, BR-21045900 Rio De Janeiro, Brazil; Oswaldo Cruz Fdn, Natl Sch Publ Hlth, BR-21045900 Rio De Janeiro, Brazil; Univ Calif San Francisco, Dept Family & Community Med, San Francisco, CA 94143 USA; CUNY, Sch Med, Dept Community Hlth & Social Med, New York, NY 10031 USA; Minist Hlth, Montevideo, Uruguay; Canadian Inst Hlth Informat, Ottawa, ON, Canada; Univ Pompeu Fabra, Dept Econ, Barcelona, Spain; Inst Dev Studies, Hlth Unit, Sussex, England; Johns Hopkins Med Inst, Baltimore, MD 21205 USA	Fundacao Oswaldo Cruz; Fundacao Oswaldo Cruz; University of California System; University of California San Francisco; City University of New York (CUNY) System; Canadian Institute Health Information; Pompeu Fabra University; Johns Hopkins University; Johns Hopkins Medicine	Viacava, F (corresponding author), Oswaldo Cruz Fdn, Ctr Sci & Technol Informat, Hlth Informat Dept, Ave Brasil 4365, BR-21045900 Rio De Janeiro, Brazil.		Costa, Nilson/AAG-7634-2021; Ortun, Vicente R/A-2078-2009	Ortun, Vicente R/0000-0001-9754-4116; Almeida, Cecilia M V B/0000-0002-0473-906X				ALMEIDA C. M., 1999, CIENCIA SAUDE COLETI, V4, P263; Anand S, 1997, J HEALTH ECON, V16, P685, DOI 10.1016/S0167-6296(97)00005-2; [Anonymous], 1997, HUM DEV REP 1997; Arnesen T, 1999, BMJ-BRIT MED J, V319, P1423, DOI 10.1136/bmj.319.7222.1423; Braveman P, 2000, B WORLD HEALTH ORGAN, V78, P232; BRAVEMAN P, IN PRESS BMJ; BRAVEMAN P, 1998, WHOCHSHHS981; BROCK DW, 1995, SOC PHILOS POLICY, V12, P159, DOI 10.1017/S0265052500004714; BUSTELLO E, 1994, PLANEJAMENTO POLITIC, V11, P4; CHAMIE M, 1995, DISABIL REHABIL, V17, P323, DOI 10.3109/09638289509166718; De Silva A, GPE DISCUSSION PAPER, V21; DEKADT E, 1993, PROMOTING EQUITY NEW; Evans R. G., 1994, WHY ARE SOME PEOPLE; Gakidou EE, 2000, B WORLD HEALTH ORGAN, V78, P42; Gold MR, 1996, COST EFFECTIVENESS H; GROCE NE, 1999, INT REHABILITATION R, V49; Gwatkin DR, 1999, LANCET, V354, P586, DOI 10.1016/S0140-6736(99)02108-X; Hyder AA, 1998, AM J PUBLIC HEALTH, V88, P196, DOI 10.2105/AJPH.88.2.196; KANJI N, 1991, SOC SCI MED, V33, P985, DOI 10.1016/0277-9536(91)90003-U; Kaplan GA, 1996, BRIT MED J, V312, P999; Kawachi I, 1997, BMJ-BRIT MED J, V314, P1037, DOI 10.1136/bmj.314.7086.1037; MacIntyre S, 1997, SOC SCI MED, V44, P723, DOI 10.1016/S0277-9536(96)00183-9; Mackenbach JP, 1997, SOC SCI MED, V44, P757, DOI 10.1016/S0277-9536(96)00073-1; Makinen M, 2000, B WORLD HEALTH ORGAN, V78, P55; Mansourian BG, 1996, B WORLD HEALTH ORGAN, V74, P333; MARMOT MG, 1991, LANCET, V337, P1387, DOI 10.1016/0140-6736(91)93068-K; MCPAKE B, 1993, SOC SCI MED, V36, P1397, DOI 10.1016/0277-9536(93)90382-E; Mulligan J, 2000, BRIT MED J, V321, P191, DOI 10.1136/bmj.321.7255.191; Murray CJL, 1999, B WORLD HEALTH ORGAN, V77, P537; Murray CJL, 2000, 28 WHO GPE; Navarro V, 2000, LANCET, V356, P1598, DOI 10.1016/S0140-6736(00)03139-1; Paalman M, 1998, HEALTH POLICY PLANN, V13, P13, DOI 10.1093/heapol/13.1.13; Russell LB, 1996, JAMA-J AM MED ASSOC, V276, P1172, DOI 10.1001/jama.276.14.1172; Sayers BM, 1997, B WORLD HEALTH ORGAN, V75, P383; Segall M, 2000, INT J HEALTH PLAN M, V15, P61, DOI 10.1002/(SICI)1099-1751(200001/03)15:1<61::AID-HPM573>3.0.CO;2-4; Starfield B, 1998, PRIMARY CARE BALANCI; Valentine NB, 2000, GPE DISCUSSION PAPER, V22; VANDOORSLAER W, 1993, EQUITY FINANCE DELIV; VICTORA CG, 1992, INT J EPIDEMIOL, V21, P911, DOI 10.1093/ije/21.5.911; World Health Organization, 2000, WORLD HLTH REP 2000	40	92	106	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 26	2001	357	9269					1692	1697		10.1016/S0140-6736(00)04825-X	http://dx.doi.org/10.1016/S0140-6736(00)04825-X			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	435UY	11425394	Green Published			2022-12-28	WOS:000168901600034
J	Todd, WTA				Todd, WTA			Prospects for the prevention of haemolytic-uraemic syndrome	LANCET			English	Editorial Material							HEMOLYTIC-UREMIC SYNDROME; ESCHERICHIA-COLI O157-H7; INFECTIONS; ANTIBODIES; STOOLS; TOXIN		Monklands Hosp, Lanarkshire Area Infect Dis Unit, Airdale ML6 0JS, Lanark, Scotland	Monklands Hospital	Todd, WTA (corresponding author), Monklands Hosp, Lanarkshire Area Infect Dis Unit, Airdale ML6 0JS, Lanark, Scotland.							CARTER AO, 1987, NEW ENGL J MED, V317, P1496, DOI 10.1056/NEJM198712103172403; Dundas S, 1999, LANCET, V354, P1327, DOI 10.1016/S0140-6736(99)01251-9; FITZPATRICK MM, 1991, BMJ-BRIT MED J, V303, P489, DOI 10.1136/bmj.303.6801.489; GRIFFIN PM, 1991, EPIDEMIOL REV, V13, P60, DOI 10.1093/oxfordjournals.epirev.a036079; KARMALI MA, 1983, LANCET, V1, P619, DOI 10.1016/s0140-6736(83)91795-6; Kimmitt PT, 1999, LANCET, V353, P1588, DOI 10.1016/S0140-6736(99)00621-2; Li YL, 2000, INFECT IMMUN, V68, P5090, DOI 10.1128/IAI.68.9.5090-5095.2000; Louie M, 1998, J CLIN MICROBIOL, V36, P3375, DOI 10.1128/JCM.36.11.3375-3377.1998; Manjarrez-Hernandez HA, 2000, INFECT IMMUN, V68, P5030, DOI 10.1128/IAI.68.9.5030-5036.2000; Martinez MB, 1999, J INFECT DIS, V179, P269, DOI 10.1086/314549; MONNENS L, 2000, INT S WORKSH SHIG TO; Nakao H, 1999, INFECT IMMUN, V67, P5717, DOI 10.1128/IAI.67.11.5717-5722.1999; Obrig Tom G., 1997, Frontiers in Bioscience, V2, pD635; PROULX F, 1992, J PEDIATR-US, V121, P299, DOI 10.1016/S0022-3476(05)81209-0; Takeda T, 1998, ESCHERICHIA COLI O15, P385; Wong CS, 2000, NEW ENGL J MED, V342, P1930, DOI 10.1056/NEJM200006293422601	16	3	3	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 26	2001	357	9269					1636	1638		10.1016/S0140-6736(00)04859-5	http://dx.doi.org/10.1016/S0140-6736(00)04859-5			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	435UY	11425363				2022-12-28	WOS:000168901600004
J	Varma, C; Camm, AJ				Varma, C; Camm, AJ			Pacing for heart failure	LANCET			English	Review							SHORT ATRIOVENTRICULAR DELAY; DILATED CARDIOMYOPATHY; CHAMBER; PERMANENT; IMPROVEMENTS; ACTIVATION; SITES; BLOCK	Pacing for patients with severe heart failure without bradyarrhythmia has been proposed as an addition to medical therapy over the past decade. Alteration of the normal electrical activation sequence of the heart modifies its mechanical action, especially when ventricular function is poor. Both the site of ventricular-lead placement and timing with the atria have been manipulated in attempts to alleviate the symptoms of heart failure. Most recently, in addition to the conventional two leads used for pacing, a third lead to pace the left ventricle has been advocated in some patients with heart failure. We review the evidence for pacing in heart failure.	Univ London St Georges Hosp, Sch Med, Dept Cardiol Sci, London SW17 0RE, England	St Georges University London	Varma, C (corresponding author), Univ London St Georges Hosp, Sch Med, Dept Cardiol Sci, London SW17 0RE, England.	cvarma@sghms.ac.uk						ALPERT MA, 1986, J AM COLL CARDIOL, V7, P925, DOI 10.1016/S0735-1097(86)80358-8; Auricchio A, 1999, CIRCULATION, V99, P2993, DOI 10.1161/01.CIR.99.23.2993; Auricchio A, 1998, J AM COLL CARDIOL, V31, p31A, DOI 10.1016/S0735-1097(97)83850-8; AURICCHIO A, 1999, AM J CARDIOL, V83, P120; Bakker PF, 1994, PACE, V17, P820; Blanc JJ, 1997, CIRCULATION, V96, P3273; BRECKER SJD, 1992, LANCET, V340, P1308, DOI 10.1016/0140-6736(92)92492-X; Buckingham TA, 1997, PACE, V20, P909, DOI 10.1111/j.1540-8159.1997.tb05493.x; BUTTER C, 2000, PACING CLIN ELECTROP, V23, P589; Cazeau S, 2001, NEW ENGL J MED, V344, P873, DOI 10.1056/NEJM200103223441202; CAZEAU S, 1994, PACE, V17, P1974, DOI 10.1111/j.1540-8159.1994.tb03783.x; Cazeau S, 1996, PACE, V19, P1748, DOI 10.1111/j.1540-8159.1996.tb03218.x; COWELL R, 1994, PACE, V17, P1980, DOI 10.1111/j.1540-8159.1994.tb03784.x; Daubert JC, 1998, PACE, V21, P239, DOI 10.1111/j.1540-8159.1998.tb01096.x; DAUBERT JC, 2000, MUSTIC INVESTIGATORS; DEFAYE P, 1996, EUR J CARDIAC PACING, V6, P198; Deshmukh P, 2000, CIRCULATION, V101, P869, DOI 10.1161/01.CIR.101.8.869; Farwell D, 2000, EUR HEART J, V21, P1246, DOI 10.1053/euhj.1999.1985; GOLD MR, 1995, J AM COLL CARDIOL, V26, P967, DOI 10.1016/0735-1097(95)00292-0; Gold MR, 1997, AM J CARDIOL, V79, P679, DOI 10.1016/S0002-9149(96)00841-7; Gras D, 1998, PACE, V21, P2249, DOI 10.1111/j.1540-8159.1998.tb01162.x; Hamdan MH, 2000, CIRCULATION, V102, P1027, DOI 10.1161/01.CIR.102.9.1027; Higgins SL, 2000, J AM COLL CARDIOL, V36, P824, DOI 10.1016/S0735-1097(00)00795-6; HOCHLEITNER M, 1990, AM J CARDIOL, V66, P198, DOI 10.1016/0002-9149(90)90588-R; Kass DA, 1999, CIRCULATION, V99, P1567, DOI 10.1161/01.CIR.99.12.1567; Kerwin WF, 2000, J AM COLL CARDIOL, V35, P1221, DOI 10.1016/S0735-1097(00)00555-6; LANGENFELD H, 1998, PACING CLIN ELECTROP, V21, P559; Leclercq C, 2000, AM J CARDIOL, V85, P1154, DOI 10.1016/S0002-9149(00)00716-5; Leclercq C, 1998, J AM COLL CARDIOL, V32, P1825, DOI 10.1016/S0735-1097(98)00492-6; LINDE C, 1995, AM J CARDIOL, V75, P919, DOI 10.1016/S0002-9149(99)80687-0; Nelson GS, 2000, CIRCULATION, V102, P3053; Nelson GS, 2000, CIRCULATION, V101, P2703, DOI 10.1161/01.CIR.101.23.2703; NISHIMURA RA, 1995, J AM COLL CARDIOL, V25, P281, DOI 10.1016/0735-1097(94)00419-Q; PAPPONE C, 2000, PACING CLIN ELECTROP, V23, P635; Pitt B, 1999, NEW ENGL J MED, V341, P709, DOI 10.1056/NEJM199909023411001; SAXON L, 1999, AM J CARDIOL, V83, P130; SAXON LA, 2000, PACING CLIN ELECTROP, V22, P830; Varma C, 1999, CIRCULATION, V100, P515; VENKATESHAWAR K, 1999, J AM COLL CARDIOL, V33, pA145; Victor F, 1999, J AM COLL CARDIOL, V33, P311, DOI 10.1016/S0735-1097(98)00589-0; Walker S, 2000, PACE, V23, P985, DOI 10.1111/j.1540-8159.2000.tb00885.x; Wiggers CJ, 1925, AM J PHYSIOL, V73, P346, DOI 10.1152/ajplegacy.1925.73.2.346; WILENSKY RL, 1988, AM J CARDIOL, V62, P276, DOI 10.1016/0002-9149(88)90225-1; XIAO HB, 1993, BRIT HEART J, V69, P166; XIAO HB, 1994, BRIT HEART J, V72, P167; XIAO HB, 1992, BRIT HEART J, V68, P403	46	13	25	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 21	2001	357	9264					1277	1283		10.1016/S0140-6736(00)04409-3	http://dx.doi.org/10.1016/S0140-6736(00)04409-3			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	425YY	11418172				2022-12-28	WOS:000168323300032
J	Shimura, H; Schlossmacher, MC; Hattori, N; Frosch, MP; Trockenbacher, A; Schneider, R; Mizuno, Y; Kosik, KS; Selkoe, DJ				Shimura, H; Schlossmacher, MC; Hattori, N; Frosch, MP; Trockenbacher, A; Schneider, R; Mizuno, Y; Kosik, KS; Selkoe, DJ			Ubiquitination of a new form of alpha-synuclein by parkin from human brain: Implications for Parkinson's disease	SCIENCE			English	Article							RECESSIVE JUVENILE PARKINSONISM; PROTEIN LIGASE; SUBCELLULAR-LOCALIZATION; HIF-ALPHA; GENE; MUTATIONS; FIBRILLIZATION; HYDROXYLATION; FAMILIES; COMPLEX	Parkinson's disease (PD) is a common neurodegenerative disorder characterized by the progressive accumulation in selected neurons of protein inclusions containing alpha -synuclein and ubiquitin. Rare inherited forms of PD are caused by autosomal dominant mutations in alpha -synuclein or by autosomal recessive mutations in parkin, an E3 ubiquitin Ligase, We hypothesized that these two gene products interact functionally, namely, that parkin ubiquitinates alpha -synuclein normally and that this process is altered in autosomal recessive PD. We have now identified a protein complex in normal human brain that includes parkin as the E3 ubiquitin Ligase, UbcH7 as its associated E2 ubiquitin conjugating enzyme, and a new 22-kilodalton glycosylated form of alpha -synuclein (alpha Sp22) as its substrate. In contrast to normal parkin, mutant parkin associated with autosomal recessive PD failed to bind alpha Sp22. In an in vitro ubiquitination assay, alpha Sp22 Was modified by normal but not mutant parkin into polyubiquitinated, high molecular weight species. Accordingly, alpha Sp22 accumulated in a nonubiquitinated form in parkin-deficient PD brains. We conclude that alpha Sp22 is a substrate for parkin's ubiquitin Ligase activity in normal human brain and that Loss of parkin function causes pathological alpha Sp22 accumulation. These findings demonstrate a critical biochemical reaction between the two PD-Linked gene products and suggest that this reaction underlies the accumulation of ubiquitinated alpha -synuclein in conventional PD.	Harvard Univ, Brigham & Womens Hosp, Sch Med, Ctr Neurol Dis, Boston, MA 02115 USA; Juntendo Univ, Sch Med, Dept Neurol, Tokyo 113, Japan; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Neurol, Boston, MA 02115 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol, Boston, MA 02115 USA; Univ Innsbruck, Inst Biochem, A-6020 Innsbruck, Austria	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Juntendo University; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of Innsbruck	Schlossmacher, MC (corresponding author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Ctr Neurol Dis, Boston, MA 02115 USA.	schloss@cnd.bwh.harvard.edu	Hattori, Nobutaka/ACR-0069-2022; Frosch, Matthew P/ABD-7456-2021; shimura, hideki/AAA-2864-2020	Frosch, Matthew P/0000-0002-3940-9861; Schlossmacher, Michael/0000-0002-0394-0300	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS038375] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 38375, NS 02127] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552; Cummings CJ, 1999, NEURON, V24, P879, DOI 10.1016/S0896-6273(00)81035-1; Goldberg MS, 2000, NAT CELL BIOL, V2, pE115, DOI 10.1038/35017124; Hattori N, 1998, ANN NEUROL, V44, P935, DOI 10.1002/ana.410440612; Hattori N, 1998, BIOCHEM BIOPH RES CO, V249, P754, DOI 10.1006/bbrc.1998.9134; Hattori N, 2000, ADV RES NEURODEGENER, V8, P101; Hayashi S, 2000, MOVEMENT DISORD, V15, P884, DOI 10.1002/1531-8257(200009)15:5<884::AID-MDS1019>3.0.CO;2-8; Huynh DP, 2000, ANN NEUROL, V48, P737, DOI 10.1002/1531-8249(200011)48:5<737::AID-ANA7>3.3.CO;2-4; Imai Y, 2000, J BIOL CHEM, V275, P35661, DOI 10.1074/jbc.C000447200; Ivan M, 2001, SCIENCE, V292, P464, DOI 10.1126/science.1059817; Jaakkola P, 2001, SCIENCE, V292, P468, DOI 10.1126/science.1059796; Jiang YH, 1999, AM J HUM GENET, V65, P1, DOI 10.1086/302473; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Kahle PJ, 2000, J NEUROSCI, V20, P6365, DOI 10.1523/JNEUROSCI.20-17-06365.2000; Kitada T, 1998, NATURE, V392, P605, DOI 10.1038/33416; Kruger R, 1998, NAT GENET, V18, P106, DOI 10.1038/ng0298-106; Lang AE, 1998, NEW ENGL J MED, V339, P1044, DOI 10.1056/NEJM199810083391506; Leroy E, 1998, NATURE, V395, P451, DOI 10.1038/26652; Lucking CB, 2000, NEW ENGL J MED, V342, P1560, DOI 10.1056/NEJM200005253422103; Mizuno Y, 1999, BIOMED PHARMACOTHER, V53, P109, DOI 10.1016/S0753-3322(99)80075-4; Mori H, 1998, NEUROLOGY, V51, P890, DOI 10.1212/WNL.51.3.890; Polymeropoulos MH, 1997, SCIENCE, V276, P2045, DOI 10.1126/science.276.5321.2045; Rochet JC, 2000, BIOCHEMISTRY-US, V39, P10619, DOI 10.1021/bi001315u; SCHEFFNER M, 1993, CELL, V75, P495, DOI 10.1016/0092-8674(93)90384-3; SCHOSSMACHER MG, UNPUB; Shevchenko A, 1996, ANAL CHEM, V68, P850, DOI 10.1021/ac950914h; Shimura H, 2000, NAT GENET, V25, P302, DOI 10.1038/77060; Shimura H, 1999, ANN NEUROL, V45, P668, DOI 10.1002/1531-8249(199905)45:5<668::AID-ANA19>3.0.CO;2-Z; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; TAKAHASHI H, 1994, NEUROLOGY, V44, P437, DOI 10.1212/WNL.44.3_Part_1.437; Talis AL, 1998, J BIOL CHEM, V273, P6439, DOI 10.1074/jbc.273.11.6439; Tanaka K, 1998, MOL CELLS, V8, P503; Terreni L, 2001, NEUROLOGY, V56, P463, DOI 10.1212/WNL.56.4.463; TROJANOWSKI JQ, 1999, CELL DEATH DIFFER, V5, P823; van de Warrenburg BPC, 2001, NEUROLOGY, V56, P555, DOI 10.1212/WNL.56.4.555; Wells L, 2001, SCIENCE, V291, P2376, DOI 10.1126/science.1058714; Zhang Y, 2000, P NATL ACAD SCI USA, V97, P13354, DOI 10.1073/pnas.240347797	37	842	876	0	69	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 13	2001	293	5528					263	269		10.1126/science.1060627	http://dx.doi.org/10.1126/science.1060627			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	452TK	11431533				2022-12-28	WOS:000169875200048
J	Nixon, J; Khan, KS; Kleijnen, J				Nixon, J; Khan, KS; Kleijnen, J			Summarising economic evaluations in systematic reviews: a new approach	BRITISH MEDICAL JOURNAL			English	Article									Univ York, NHS Ctr Reviews & Disseminat, York YO10 5DD, N Yorkshire, England	University of York - UK	Nixon, J (corresponding author), Univ York, NHS Ctr Reviews & Disseminat, York YO10 5DD, N Yorkshire, England.		Khan, Khalid S/AAT-8824-2020	Khan, Khalid S/0000-0001-5084-7312				[Anonymous], 1999, METHODS EC EVALUATIO; BIRCH S, 1996, MANAGING TECHNOLOGY; BLACK WC, 1990, MED DECIS MAKING, V10, P212, DOI 10.1177/0272989X9001000308; Browne G, 1999, J EVAL CLIN PRACT, V5, P367, DOI 10.1046/j.1365-2753.1999.00191.x; *KWAL GEZ CBO, 1997, GUID CHOL; Lister-Sharp D, 2000, Health Technol Assess, V4, P1; *NHS CTR REV DISS, 2000, UND SYST REV RES EF; *NHS EX, 1999, FAST ACC MOD TREATM; NIXON J, 2000, INT J HLTH TECHNOL A, V16, P1; NIXONJ, 2000, BMJ, V321, P32	10	48	48	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 30	2001	322	7302					1596	1598		10.1136/bmj.322.7302.1596	http://dx.doi.org/10.1136/bmj.322.7302.1596			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	449QT	11431306	Green Published			2022-12-28	WOS:000169699200035
J	Maas, R				Maas, R			Change of plasmid DNA structure, hypermethylation, and Lon-proteolysis as steps in a replicative cascade	CELL			English	Article							ESCHERICHIA-COLI; REPA1 PROTEIN; DAM METHYLTRANSFERASE; LEADER PEPTIDE; INITIATION; REPLICON; ORIR; RESOLUTION; INVITRO; BIOLOGY	I have defined conditions under which RepFIC plasmid DNA can be maintained in a state of lowered helical density. In exponentially growing cultures, the DNA of lowered helical density is present in small amounts but never totally absent, suggesting that it is; a normal variant of plasmid maintenance. It is fully methylated at frequent sites by dam-methyltransferase, some not previously recognized, further suggesting that the variant is a precursor of replication. The low-helical density plasmid is present in dam hosts, indicating that methylation is not essential for the change in helical density. The lowered helical density is stabilized in ion hosts, suggesting that Lon-protease may remove both the protein(s) that lower the helical density and the dam-methyltransferase after each round of replication.	NYU, Sch Med, Dept Microbiol, New York, NY 10016 USA	New York University	Maas, R (corresponding author), NYU, Sch Med, Dept Microbiol, New York, NY 10016 USA.				NIGMS NIH HHS [GM06048] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Berger I, 1996, P NATL ACAD SCI USA, V93, P12116, DOI 10.1073/pnas.93.22.12116; BLOMBERG P, 1992, EMBO J, V11, P2675, DOI 10.1002/j.1460-2075.1992.tb05333.x; BOYE E, 1990, CELL, V62, P981, DOI 10.1016/0092-8674(90)90272-G; CAMPBELL JL, 1990, CELL, V62, P967, DOI 10.1016/0092-8674(90)90271-F; Fu GK, 1997, J BIOL CHEM, V272, P534; JOHNSTON BH, 1985, CELL, V42, P713, DOI 10.1016/0092-8674(85)90268-5; Kornberg A., 1992, DNA REPLICATION; LU M, 1994, CELL, V77, P413, DOI 10.1016/0092-8674(94)90156-2; Maas R, 1997, J BACTERIOL, V179, P3823, DOI 10.1128/jb.179.12.3823-3827.1997; MAAS R, 1991, MOL MICROBIOL, V5, P927, DOI 10.1111/j.1365-2958.1991.tb00767.x; MAAS R, 1989, MOL GEN GENET, V218, P190, DOI 10.1007/BF00331268; Maas R, 1997, J BACTERIOL, V179, P2163, DOI 10.1128/jb.179.7.2163-2168.1997; MASAI H, 1989, J BIOL CHEM, V264, P8082; MASAI H, 1988, NUCLEIC ACIDS RES, V16, P6493, DOI 10.1093/nar/16.14.6493; MASAI H, 1983, P NATL ACAD SCI-BIOL, V80, P6814, DOI 10.1073/pnas.80.22.6814; Maxam A M, 1980, Methods Enzymol, V65, P499; PALMER BR, 1994, GENE, V143, P1, DOI 10.1016/0378-1119(94)90597-5; RICH A, 1984, ANNU REV BIOCHEM, V53, P791, DOI 10.1146/annurev.bi.53.070184.004043; SAADI S, 1987, J BACTERIOL, V169, P1836, DOI 10.1128/jb.169.5.1836-1846.1987; SCHELL MA, 1993, ANNU REV MICROBIOL, V47, P597, DOI 10.1146/annurev.micro.47.1.597; Stephens C, 1996, P NATL ACAD SCI USA, V93, P1210, DOI 10.1073/pnas.93.3.1210; WAGNER BM, 1987, J DRUG DEV S2, V1, P7; WANG AHJ, 1979, NATURE, V282, P680, DOI 10.1038/282680a0; WU RP, 1992, J BACTERIOL, V174, P7620, DOI 10.1128/JB.174.23.7620-7628.1992	24	12	13	0	1	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTES AVE,, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 29	2001	105	7					945	955		10.1016/S0092-8674(01)00402-0	http://dx.doi.org/10.1016/S0092-8674(01)00402-0			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	449BK	11439190	Bronze			2022-12-28	WOS:000169664300014
J	Coates, JD; Chakraborty, R; Lack, JG; O'Connor, SM; Cole, KA; Bender, KS; Achenbach, LA				Coates, JD; Chakraborty, R; Lack, JG; O'Connor, SM; Cole, KA; Bender, KS; Achenbach, LA			Anaerobic benzene oxidation coupled to nitrate reduction in pure culture by two strains of Dechloromonas	NATURE			English	Article							PETROLEUM-CONTAMINATED AQUIFER; POLYCYCLIC AROMATIC-HYDROCARBONS; SULFATE-REDUCING CONDITIONS; HARBOR SEDIMENTS; DEGRADATION; BIOREMEDIATION; TOLUENE; BIODEGRADATION; TRANSFORMATION; BACTERIUM	Benzene contamination is a significant problem. It is used in a wide range of manufacturing processes and is a primary component of petroleum-based fuels. Benzene is a hydrocarbon that is soluble, mobile, toxic and stable, especially in ground and surface waters. It is poorly biodegraded in the absence of oxygen. However, anaerobic benzene biodegradation has been documented under various conditions. Although benzene biomineralization has been demonstrated with nitrate(1), Fe(III)(2-5), sulphate(6,7) or CO28,9 as alternative electron acceptors, these studies were based on sediments or microbial enrichments. Until now there were no organisms in pure culture that degraded benzene anaerobically. Here we report two Dechloromonas strains, RCB and JJ, that can completely mineralize various mono-aromatic compounds including benzene to CO2 in the absence of O-2 with nitrate as the electron acceptor. This is the first example, to our knowledge, of an organism of any type that can oxidize benzene anaerobically, and we demonstrate the potential applicability of these organisms to the treatment of contaminated environments.	So Illinois Univ, Dept Microbiol, Carbondale, IL 62901 USA	Southern Illinois University System; Southern Illinois University	Coates, JD (corresponding author), So Illinois Univ, Dept Microbiol, Carbondale, IL 62901 USA.		Chakraborty, Romy/D-9230-2015	Chakraborty, Romy/0000-0001-9326-554X; Bender, Kelly/0000-0002-0025-2166				Achenbach LA, 2000, ASM NEWS, V66, P714; Achenbach LA, 2001, INT J SYST EVOL MICR, V51, P527, DOI 10.1099/00207713-51-2-527; Anderson R.T., 1999, BIOREMEDIAT J, V3, P121, DOI [DOI 10.1080/10889869991219271, 10.1080/10889869991219271]; Anderson RT, 2000, ENVIRON SCI TECHNOL, V34, P2261, DOI 10.1021/es991211a; Anderson RT, 1998, ENVIRON SCI TECHNOL, V32, P1222, DOI 10.1021/es9704949; Anderson RT, 1997, ADV MICROB ECOL, V15, P289; Bruce RA, 1999, ENVIRON MICROBIOL, V1, P319, DOI 10.1046/j.1462-2920.1999.00042.x; Burland SM, 1999, APPL ENVIRON MICROB, V65, P529; CHRISTENSEN TH, 1994, CRIT REV ENV SCI TEC, V24, P119, DOI 10.1080/10643389409388463; Coates J. D., 1999, BIOREMEDIAT J, V3, P323, DOI [10.1080/10889869991219415, DOI 10.1080/10889869991219415]; Coates JD, 1999, APPL ENVIRON MICROB, V65, P5234; Coates JD, 1996, APPL ENVIRON MICROB, V62, P1099, DOI 10.1128/AEM.62.3.1099-1101.1996; Coates JD, 1997, APPL ENVIRON MICROB, V63, P3589, DOI 10.1128/AEM.63.9.3589-3593.1997; Coates JD, 1996, APPL ENVIRON MICROB, V62, P1531, DOI 10.1128/AEM.62.5.1531-1536.1996; Coates JD, 1996, ENVIRON SCI TECHNOL, V30, P2784, DOI 10.1021/es9600441; Coates JD, 1998, NATURE, V396, P730, DOI 10.1038/25470; Galushko A, 1999, ENVIRON MICROBIOL, V1, P415; GRBICGALIC D, 1987, APPL ENVIRON MICROB, V53, P254; LOVLEY DR, 1994, NATURE, V370, P128, DOI 10.1038/370128a0; Lovley DR, 1997, J IND MICROBIOL BIOT, V18, P75, DOI 10.1038/sj.jim.2900246; Lovley DR, 1996, APPL ENVIRON MICROB, V62, P288, DOI 10.1128/AEM.62.1.288-291.1996; LOVLEY DR, 1995, APPL ENVIRON MICROB, V61, P953, DOI 10.1128/AEM.61.3.953-958.1995; LOVLEY DR, 1990, APPL ENVIRON MICROB, V56, P1858, DOI 10.1128/AEM.56.6.1858-1864.1990; Lovley DR, 1999, ENVIRON MICROBIOL, V1, P89, DOI 10.1046/j.1462-2920.1999.00009.x; RABUS R, 1993, APPL ENVIRON MICROB, V59, P1444, DOI 10.1128/AEM.59.5.1444-1451.1993; RIDGWAY HF, 1990, APPL ENVIRON MICROB, V56, P3565, DOI 10.1128/AEM.56.11.3565-3575.1990; Rooney-Varga JN, 1999, APPL ENVIRON MICROB, V65, P3056; VOGEL TM, 1986, APPL ENVIRON MICROB, V52, P200, DOI 10.1128/AEM.52.1.200-202.1986; Weiner JM, 1998, APPL ENVIRON MICROB, V64, P1937; Weiner JM, 1998, APPL ENVIRON MICROB, V64, P775	30	381	420	1	154	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 28	2001	411	6841					1039	1043		10.1038/35082545	http://dx.doi.org/10.1038/35082545			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	446TF	11429602				2022-12-28	WOS:000169528500045
J	Montalescot, G; Barragan, P; Wittenberg, O; Ecollan, P; Elhadad, S; Villain, P; Boulenc, JM; Morice, MC; Maillard, L; Pansieri, M; Choussat, R; Pinton, P				Montalescot, G; Barragan, P; Wittenberg, O; Ecollan, P; Elhadad, S; Villain, P; Boulenc, JM; Morice, MC; Maillard, L; Pansieri, M; Choussat, R; Pinton, P		ADMIRAL Investigators	Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BALLOON ANGIOPLASTY; RECEPTOR BLOCKADE; PLACEMENT; TRIAL; TICLOPIDINE; THERAPY; THROMBOLYSIS; IMPLANTATION; ANTIPLATELET; RESTENOSIS	Background: When administered in conjunction with primary coronary stenting for the treatment of acute myocardial infarction, a platelet glycoprotein IIb/IIIa inhibitor may provide additional clinical benefit, but data on this combination therapy are limited. Methods: We randomly assigned 300 patients with acute myocardial infarction in a double-blind fashion either to abciximab plus stenting (149 patients) or placebo plus stenting (151 patients) before they underwent coronary angiography. Clinical outcomes were evaluated 30 days and 6 months after the procedure. The angiographic patency of the infarct-related vessel and the left ventricular ejection fraction were evaluated at 24 hours and 6 months. Results: At 30 days, the primary end point - a composite of death, reinfarction, or urgent revascularization of the target vessel - had occurred in 6.0 percent of the patients in the abciximab group, as compared with 14.6 percent of those in the placebo group (P = 0.01); at 6 months, the corresponding figures were 7.4 percent and 15.9 percent (P = 0.02). The better clinical outcomes in the abciximab group were related to the greater frequency of grade 3 coronary flow (according to the classification of the Thrombolysis in Myocardial Infarction trial) in this group than in the placebo group before the procedure (16.8 percent vs. 5.4 percent, P = 0.01), immediately afterward (95.1 percent vs. 86.7 percent, P = 0.04), and six months afterward (94.3 percent vs. 82.8 percent, P = 0.04). One major bleeding event occurred in the abciximab group (0.7 percent); none occurred in the placebo group. Conclusions: As compared with placebo, early administration of abciximab in patients with acute myocardial infarction improves coronary patency before stenting, the success rate of the stenting procedure, the rate of coronary patency at six months, left ventricular function, and clinical outcomes. (N Engl J Med 2001;344:1895-903.) Copyright (C) 2001 Massachusetts Medical Society.	CHU Pitie Salpetriere, Serv Cardiol, F-75013 Paris, France; Hop La Pitie Salpetriere, Dept Anesthesiol, Paris, France; Hop La Pitie Salpetriere, Mobile Intens Care Unit, Paris, France; Beauregard Clin, Div Cardiol, Marseille, France; Des Franciscaines Clin, Div Cardiol, Nimes, France; Lagny Marne la Vallee Hosp, Div Cardiol, Lagny Sur Merne, France; Les Fleurs Clin, Div Cardiol, Ollioules, France; St Joseph Clin, Div Cardiol, Colmar, France; Inst Cardiovasc Paris Sud, Div Cardiol, Antony, France; Trousseau Hosp, Div Cardiol, Tours, France; Henri Duffaut Hosp, Div Cardiol, Avignon, France; Eli Lilly & Co, Cardiovasc Therapeut Unit, St Cloud, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Pitie-Salpetriere - APHP; UDICE-French Research Universities; Sorbonne Universite; UDICE-French Research Universities; Universite Paris Saclay; CHU Tours; Eli Lilly	Montalescot, G (corresponding author), CHU Pitie Salpetriere, Serv Cardiol, 47 Blvd Hop, F-75013 Paris, France.	gilles.montalescot@psl.ap-hop-paris.fr						Azancot I, 1997, J INVASIVE CARDIOL, V9, P96; BARRAGAN P, 1994, CATHETER CARDIO DIAG, V32, P133, DOI 10.1002/ccd.1810320208; Berger PB, 1999, CIRCULATION, V100, P14, DOI 10.1161/01.CIR.100.1.14; Bertrand ME, 2000, CIRCULATION, V102, P624, DOI 10.1161/01.CIR.102.6.624; Bertrand ME, 1998, CIRCULATION, V98, P1597, DOI 10.1161/01.CIR.98.16.1597; Brener SJ, 1998, CIRCULATION, V98, P734, DOI 10.1161/01.CIR.98.8.734; CALIFF RM, 1994, NEW ENGL J MED, V330, P956, DOI 10.1056/nejm199404073301402; Coller BS, 1997, THROMB HAEMOSTASIS, V78, P730; Cutlip DE, 1999, J AM COLL CARDIOL, V34, P698, DOI 10.1016/S0735-1097(99)00271-5; Dalen JE, 1998, CHEST, V114, p439S, DOI 10.1378/chest.114.5_Supplement.439S; Ellis SG, 1999, CIRCULATION, V100, P799; FISCHMAN DL, 1994, NEW ENGL J MED, V331, P496, DOI 10.1056/NEJM199408253310802; Grines CL, 1999, NEW ENGL J MED, V341, P1949, DOI 10.1056/NEJM199912233412601; Lansky A, 1999, TXB INTERVENTIONAL C, P725; LeFree M. T., 1986, Proceedings of the SPIE - The International Society for Optical Engineering, V626, P334, DOI 10.1117/12.975410; Leizorovicz A, 1997, EUR HEART J, V18, P248; Lincoff AM, 1999, NEW ENGL J MED, V341, P319, DOI 10.1056/NEJM199907293410503; Marso SP, 1999, CIRCULATION, V100, P2477, DOI 10.1161/01.CIR.100.25.2477; MONTALESCOT G, 1995, CIRCULATION, V92, P31, DOI 10.1161/01.CIR.92.1.31; Morrison LJ, 2000, JAMA-J AM MED ASSOC, V283, P2686, DOI 10.1001/jama.283.20.2686; Neumann FJ, 2000, J AM COLL CARDIOL, V35, P915, DOI 10.1016/S0735-1097(99)00635-X; Neumann FJ, 1998, CIRCULATION, V98, P2695, DOI 10.1161/01.CIR.98.24.2695; Newby LK, 1996, J AM COLL CARDIOL, V27, P1646; RAO AK, 1988, J AM COLL CARDIOL, V11, P1; Reiber J H, 1984, IEEE Trans Med Imaging, V3, P131, DOI 10.1109/TMI.1984.4307669; ROSS AM, 1993, NEW ENGL J MED, V329, P1615; SANDLER H, 1972, QUANTITATION CARDIOL, P189; Schomig A, 1996, NEW ENGL J MED, V334, P1084, DOI 10.1056/NEJM199604253341702; Serruys P, 1998, LANCET, V352, P1478; SERRUYS PW, 1994, NEW ENGL J MED, V331, P489, DOI 10.1056/NEJM199408253310801; Simoons ML, 1997, LANCET, V349, P1429; Stone GW, 1998, J INVASIVE CARDIOL, V10, p16A; Suryapranata H, 1998, CIRCULATION, V97, P2502, DOI 10.1161/01.CIR.97.25.2502; Tcheng JE, 2000, LANCET, V356, P2037; The GUSTO Angiographic Investigators, 1994, NEW ENGL J MED, V330, P516; TOPOL EJ, 1994, LANCET, V343, P881, DOI 10.1016/S0140-6736(94)90007-8; Topol EJ, 1997, NEW ENGL J MED, V336, P1689; 1997, LANCET, V350, P744	38	854	918	0	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 21	2001	344	25					1895	1903		10.1056/NEJM200106213442503	http://dx.doi.org/10.1056/NEJM200106213442503			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	443VJ	11419426	Bronze			2022-12-28	WOS:000169362100003
J	Cheng, YZ; Endo, K; Wu, K; Rodan, AR; Heberlein, U; Davis, RL				Cheng, YZ; Endo, K; Wu, K; Rodan, AR; Heberlein, U; Davis, RL			Drosophila fasciclinII is required for the formation of odor memories and for normal sensitivity to alcohol	CELL			English	Article							CELL-ADHESION MOLECULES; LONG-TERM-MEMORY; GROWTH CONE GUIDANCE; DEPENDENT PROTEIN-KINASE; CAMP-RESPONSIVE ELEMENT; MUSHROOM BODIES; SYNAPTIC PLASTICITY; IMMUNOGLOBULIN SUPERFAMILY; PHARMACOLOGICAL EVIDENCE; PREFERENTIAL EXPRESSION	Drosophila fasciclinII (fasII) mutants perform poorly after olfactory conditioning due to a defect in encoding, stabilizing, or retrieving short-term memories. Performance was rescued by inducing the expression of a normal transgene just before training and immediate testing. Induction after training but before testing failed to rescue performance, showing that Fas II does not have an exclusive role in memory retrieval processes. The stability of odor memories in fasII mutants are indistinguishable from control animals when initial performance is normalized. Like several other muta nts deficient in odor learning, fasII mutants exhibit a heightened sensitivity to ethanol vapors. A combination of behavioral and genetic strategies have therefore revealed a role for Fas II in the molecular operations of encoding short-term odor memories and conferring alcohol sensitivity. The preferential expression of Fas II in the axons of mushroom body neurons furthermore suggests that short-term odor memories are formed in these neurites.	Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA; Baylor Coll Med, Dept Psychiat & Behav Sci, Houston, TX 77030 USA; Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Program Biol Sci, San Francisco, CA 94143 USA	Baylor College of Medicine; Baylor College of Medicine; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Davis, RL (corresponding author), Baylor Coll Med, Dept Mol & Cellular Biol, Houston, TX 77030 USA.		Davis, Ronald/J-4998-2013	Davis, Ronald/0000-0002-5986-7608; Rodan, Aylin/0000-0001-9202-2378	NINDS NIH HHS [NS19904] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS019904, R37NS019904] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adams MD, 2000, SCIENCE, V287, P2185, DOI 10.1126/science.287.5461.2185; Bailey CH, 1996, P NATL ACAD SCI USA, V93, P13445, DOI 10.1073/pnas.93.24.13445; Beck CDO, 2000, J NEUROSCI, V20, P2944; Beggs HE, 1997, J BIOL CHEM, V272, P8310, DOI 10.1074/jbc.272.13.8310; BOURTCHULADZE R, 1994, CELL, V79, P59, DOI 10.1016/0092-8674(94)90400-6; Byrne JH, 1996, J NEUROSCI, V16, P425; CREMER H, 1994, NATURE, V367, P455, DOI 10.1038/367455a0; Crittenden JR, 1998, LEARN MEMORY, V5, P38; Crossin KL, 2000, DEV DYNAM, V218, P260, DOI 10.1002/(SICI)1097-0177(200006)218:2<260::AID-DVDY3>3.0.CO;2-9; DASH PK, 1990, NATURE, V345, P718, DOI 10.1038/345718a0; DAVIS RL, 1993, NEURON, V11, P1, DOI 10.1016/0896-6273(93)90266-T; DEBELLE JS, 1994, SCIENCE, V263, P692, DOI 10.1126/science.8303280; DOYLE E, 1992, J NEUROCHEM, V59, P1570, DOI 10.1111/j.1471-4159.1992.tb08477.x; DRAIN P, 1991, NEURON, V6, P71, DOI 10.1016/0896-6273(91)90123-H; GARCIAALONSO L, 1995, P NATL ACAD SCI USA, V92, P10501, DOI 10.1073/pnas.92.23.10501; GRENNINGLOH G, 1991, CELL, V67, P45, DOI 10.1016/0092-8674(91)90571-F; GRENNINGLOH G, 1990, COLD SPRING HARB SYM, V55, P323; Grotewiel MS, 1998, NATURE, V391, P455, DOI 10.1038/35079; Han PL, 1996, J NEUROBIOL, V31, P88, DOI 10.1002/(SICI)1097-4695(199609)31:1<88::AID-NEU8>3.0.CO;2-B; HAN PL, 1992, NEURON, V9, P619, DOI 10.1016/0896-6273(92)90026-A; HARRELSON AL, 1988, SCIENCE, V242, P700, DOI 10.1126/science.3187519; HARRIS RA, 1995, P NATL ACAD SCI USA, V92, P3658, DOI 10.1073/pnas.92.9.3658; Holmes AL, 1999, DEVELOPMENT, V126, P261; Holst BD, 1998, P NATL ACAD SCI USA, V95, P2597, DOI 10.1073/pnas.95.5.2597; Ito K, 1998, LEARN MEMORY, V5, P52; Lee T, 1999, DEVELOPMENT, V126, P4065; LEVIN LR, 1992, CELL, V68, P479, DOI 10.1016/0092-8674(92)90185-F; LIN DM, 1994, NEURON, V13, P507, DOI 10.1016/0896-6273(94)90022-1; LIN DM, 1994, NEURON, V13, P1055, DOI 10.1016/0896-6273(94)90045-0; LUTHI A, 1994, NATURE, V372, P777, DOI 10.1038/372777a0; MALINOW R, 1988, NATURE, V335, P820, DOI 10.1038/335820a0; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; Mansuy IM, 1998, CELL, V92, P39, DOI 10.1016/S0092-8674(00)80897-1; Mileusnic R, 1999, LEARN MEMORY, V6, P120; Moore MS, 1998, CELL, V93, P997, DOI 10.1016/S0092-8674(00)81205-2; Muller D, 1996, NEURON, V17, P413, DOI 10.1016/S0896-6273(00)80174-9; Murase S, 1999, CURR OPIN CELL BIOL, V11, P549, DOI 10.1016/S0955-0674(99)00019-8; NASSEL DR, 1992, CELL TISSUE RES, V267, P147, DOI 10.1007/BF00318701; Otmakhov N, 1997, J NEUROSCI, V17, P5357; Preat T, 1998, J NEUROSCI, V18, P8534; Riedel G, 1999, NAT NEUROSCI, V2, P898, DOI 10.1038/13202; ROMAN G, 2001, IN PRESS BIOESSAYS; ROSE SPR, 1995, TRENDS NEUROSCI, V18, P502, DOI 10.1016/0166-2236(95)92774-K; Schmid RS, 1999, J NEUROBIOL, V38, P542, DOI 10.1002/(SICI)1097-4695(199903)38:4<542::AID-NEU9>3.3.CO;2-T; SCHUCH U, 1989, NEURON, V3, P13, DOI 10.1016/0896-6273(89)90111-6; Schuster CM, 1996, NEURON, V17, P641, DOI 10.1016/S0896-6273(00)80197-X; Skoulakis EMC, 1996, NEURON, V17, P931, DOI 10.1016/S0896-6273(00)80224-X; SKOULAKIS EMC, 1993, NEURON, V11, P197, DOI 10.1016/0896-6273(93)90178-T; Waddell S, 2000, CELL, V103, P805, DOI 10.1016/S0092-8674(00)00183-5; WILSON C, 1989, GENE DEV, V3, P1301, DOI 10.1101/gad.3.9.1301; Winder DG, 1998, CELL, V92, P25, DOI 10.1016/S0092-8674(00)80896-X; Wright JW, 1999, DEVELOPMENT, V126, P3217; YIN JCP, 1994, CELL, V79, P49, DOI 10.1016/0092-8674(94)90399-9	53	105	108	1	11	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTES AVE,, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 15	2001	105	6					757	768		10.1016/S0092-8674(01)00386-5	http://dx.doi.org/10.1016/S0092-8674(01)00386-5			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	444AE	11440718	Bronze			2022-12-28	WOS:000169375100009
J	Laughlin, MJ; Barker, J; Bambach, B; Koc, ON; Rizzieri, DA; Wagner, JE; Gerson, SL; Lazarus, HM; Cairo, M; Stevens, CE; Rubinstein, P; Kurtzberg, J				Laughlin, MJ; Barker, J; Bambach, B; Koc, ON; Rizzieri, DA; Wagner, JE; Gerson, SL; Lazarus, HM; Cairo, M; Stevens, CE; Rubinstein, P; Kurtzberg, J			Hematopoietic engraftment and survival in adult recipients of umbilical-cord blood from unrelated donors.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; BONE-MARROW-TRANSPLANTATION; HLA-C DISPARITY; STEM-CELLS; PLACENTAL-BLOOD; EXPRESSION; MOLECULES; CHILDREN; GVHD	Background: Umbilical-cord blood from unrelated donors who are not HLA-identical with the recipients can restore hematopoiesis after myeloablative therapy in children. We studied the use of transplantation of umbilical-cord blood to restore hematopoiesis in adults. Methods: Sixty-eight adults with life-threatening hematologic disorders received intensive chemotherapy or total-body irradiation and then transplants of HLA-mismatched umbilical-cord blood. We evaluated the outcomes in terms of hematologic reconstitution, the occurrence of acute and chronic graft-versus-host disease (GVHD), relapses, and event-free survival. Results: Of the 68 patients, 48 (71 percent) received grafts of umbilical-cord blood that were mismatched for two or more HLA antigens. Of the 60 patients who survived 28 days or more after transplantation, 55 had neutrophil engraftment at a median of 27 days (range, 13 to 59). The estimated probability of neutrophil recovery in the 68 patients was 0.90 (95 percent confidence interval, 0.85 to 1.0). The presence of a relatively high number of nucleated cells in the umbilical-cord blood before it was frozen was associated with faster recovery of neutrophils. Severe acute GVHD (of grade III or IV) occurred in 11 of 55 patients who could be evaluated within the first 100 days after transplantation. Chronic GVHD developed in 12 of 33 patients who survived for more than 100 days after transplantation. The median follow-up for survivors was 22 months (range, 11 to 51). Of the 68 patients, 19 were alive and 18 of these (26 percent) were disease-free 40 months after transplantation. The presence of a high number of CD34+ cells in the graft was associated with improved event-free survival (P = 0.05). Conclusions: Umbilical-cord blood from unrelated donors can restore hematopoiesis in adults who receive myeloablative therapy and is associated with acceptable rates of severe acute and chronic GVHD. (N Engl J Med 2001;344:1815-22.) Copyright (C) 2001 Massachusetts Medical Society.	Case Western Reserve Univ, Univ Hosp Cleveland, Ireland Comprehens Canc Ctr, Cleveland, OH 44106 USA; Univ Minnesota, Dept Med, Minneapolis, MN 55455 USA; Univ Minnesota, Dept Pediat, Minneapolis, MN 55455 USA; Roswell Pk Canc Inst, Dept Med, Buffalo, NY 14263 USA; Roswell Pk Canc Inst, Dept Pediat, Buffalo, NY 14263 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Pediat, Durham, NC 27710 USA; Columbia Univ, Dept Pediat, New York, NY 10027 USA; Babies & Childrens Hosp, Columbia Presbyterian Med Ctr, New York, NY USA; New York Blood Ctr, Lindsley F Kimball Res Inst, Placental Blood Program, New York, NY 10021 USA; Case Western Reserve Univ, Cleveland, OH 44106 USA	Case Western Reserve University; Case Western Reserve University Hospital; University Hospitals of Cleveland; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; Roswell Park Cancer Institute; Roswell Park Cancer Institute; Duke University; Duke University; Columbia University; Columbia University; NewYork-Presbyterian Hospital; New York Blood Center; Case Western Reserve University	Laughlin, MJ (corresponding author), Case Western Reserve Univ, Univ Hosp Cleveland, Ireland Comprehens Canc Ctr, 11100 Euclid Ave,Wearn 433, Cleveland, OH 44106 USA.	mjl13@po.cwru.edu			NCI NIH HHS [P01-CA-65493-05] Funding Source: Medline; NHLBI NIH HHS [N01-HB-67139] Funding Source: Medline; DIVISION OF BLOOD DISEASES AND RESOURCES [N01HB067139] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [P01CA065493] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); DIVISION OF BLOOD DISEASES AND RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bishara A, 1999, HUM IMMUNOL, V60, P833, DOI 10.1016/S0198-8859(99)00065-8; Buchner T, 1997, Curr Opin Oncol, V9, P18; Cairo MS, 1997, BLOOD, V90, P4665, DOI 10.1182/blood.V90.12.4665.4665_4665_4678; Flowers MED, 1999, HEMATOL ONCOL CLIN N, V13, P1091, DOI 10.1016/S0889-8588(05)70111-8; Gluckman E, 1997, NEW ENGL J MED, V337, P373, DOI 10.1056/NEJM199708073370602; Gomi S, 1997, Nihon Ika Daigaku Zasshi, V64, P307; HAN P, 1995, BRIT J HAEMATOL, V89, P733; Hansen JA, 1998, NEW ENGL J MED, V338, P962, DOI 10.1056/NEJM199804023381405; HANSEN JA, 1990, BONE MARROW TRANSPL, V6, P108; Huang S, 1998, EXP HEMATOL, V26, P1162; Kadereit S, 1999, BLOOD, V94, P3101, DOI 10.1182/blood.V94.9.3101.421k04_3101_3107; KERNAN NA, 1993, NEW ENGL J MED, V328, P593, DOI 10.1056/NEJM199303043280901; Kurtzberg J, 1996, NEW ENGL J MED, V335, P157, DOI 10.1056/NEJM199607183350303; Laporte JP, 1996, NEW ENGL J MED, V335, P167, DOI 10.1056/NEJM199607183350304; Laughlin MJ, 1998, LEUKEMIA RES, V22, P215, DOI 10.1016/S0145-2126(97)00171-9; Locatelli F, 1999, BLOOD, V93, P3662; Macmillan ML, 2000, BRIT J HAEMATOL, V109, P121, DOI 10.1046/j.1365-2141.2000.01955.x; Mavroudis D, 1996, BLOOD, V88, P3223, DOI 10.1182/blood.V88.8.3223.bloodjournal8883223; McGlave PB, 2000, BLOOD, V95, P2219, DOI 10.1182/blood.V95.7.2219.007k27_2219_2225; Pasino M, 2000, BRIT J HAEMATOL, V108, P793, DOI 10.1046/j.1365-2141.2000.01949.x; PAULIN T, 1992, CLIN TRANSPLANT, V6, P48; Pecora AL, 2000, BONE MARROW TRANSPL, V25, P797, DOI 10.1038/sj.bmt.1702222; Peled A, 2000, BLOOD, V95, P3289, DOI 10.1182/blood.V95.11.3289.011k33_3289_3296; Petersdorf EW, 1997, BLOOD, V89, P1818, DOI 10.1182/blood.V89.5.1818.1818_1818_1823; PRZEPIORKA D, 1995, BONE MARROW TRANSPL, V15, P825; RISDON G, 1994, CELL IMMUNOL, V154, P14, DOI 10.1006/cimm.1994.1053; Rocha V, 2000, NEW ENGL J MED, V342, P1846, DOI 10.1056/NEJM200006223422501; Roy V, 1999, EXP HEMATOL, V27, P302, DOI 10.1016/S0301-472X(98)00031-9; RUBINSTEIN P, 1995, P NATL ACAD SCI USA, V92, P10119, DOI 10.1073/pnas.92.22.10119; Rubinstein P, 1998, NEW ENGL J MED, V339, P1565, DOI 10.1056/NEJM199811263392201; SAELAND S, 1992, EXP HEMATOL, V20, P24; SCHILLER G, 1994, BRIT J HAEMATOL, V88, P72, DOI 10.1111/j.1365-2141.1994.tb04979.x; Sierra J, 1997, BLOOD, V89, P4226, DOI 10.1182/blood.V89.11.4226; Sobocinski K A, 1994, J Hematother, V3, P95, DOI 10.1089/scd.1.1994.3.95; Szydlo R, 1997, J CLIN ONCOL, V15, P1767, DOI 10.1200/JCO.1997.15.5.1767; WAGNER JE, 1995, LANCET, V346, P214, DOI 10.1016/S0140-6736(95)91268-1; Wagner JE, 1996, BLOOD, V88, P795	37	671	709	0	25	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 14	2001	344	24					1815	1822		10.1056/NEJM200106143442402	http://dx.doi.org/10.1056/NEJM200106143442402			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	441LC	11407342				2022-12-28	WOS:000169231000002
J	Zimmerli, L; Yurtsever, H; Conen, D; Truninger, K				Zimmerli, L; Yurtsever, H; Conen, D; Truninger, K			A diabetic breast lump	LANCET			English	Editorial Material							MASTOPATHY; DISEASE		Cantonal Hosp Aarau, Dept Med, CH-5001 Aarau, Switzerland; Cantonal Hosp Aarau, Dept Pathol, CH-5001 Aarau, Switzerland	Kantonsspital Aarau AG (KSA); Kantonsspital Aarau AG (KSA)	Truninger, K (corresponding author), St Marks Hosp, Imperial Canc Res Fund, Colorectal Canc Unit, Northwick Pk, Harrow HA1 3UJ, Middx, England.							ELYK A, 2000, AM J CLIN PATHOL, V113, P541; LOGAN WW, 1989, RADIOLOGY, V172, P667, DOI 10.1148/radiology.172.3.2672091; Rode S, 1998, DIABETES CARE, V21, P322, DOI 10.2337/diacare.21.2.322a; SOLER NG, 1984, LANCET, V1, P193; TOMASZEWSKI JE, 1992, HUM PATHOL, V23, P780, DOI 10.1016/0046-8177(92)90348-7	5	7	9	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 26	2001	357	9269					1670	1670		10.1016/S0140-6736(00)04823-6	http://dx.doi.org/10.1016/S0140-6736(00)04823-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	435UY	11425372				2022-12-28	WOS:000168901600013
J	Iborra, FJ; Jackson, DA; Cook, PR				Iborra, FJ; Jackson, DA; Cook, PR			Coupled transcription and translation within nuclei of mammalian cells	SCIENCE			English	Article							MONOCLONAL-ANTIBODY; TRANSFER-RNAS; VISUALIZATION; POLYPEPTIDE; PROTEIN; EXPORT; DECAY; SITES	It is widely assumed that the vital processes of transcription and translation are spatially separated in eukaryotes and that no translation occurs in nuclei. We localized translation sites by incubating permeabilized mammalian cells with [H-3]lysine or lysyl-transfer RNA tagged with biotin or BODIPY; although most nascent polypeptides were cytoplasmic, some were found in discrete nuclear sites known as transcription "factories." Some of this nuclear translation also depends on concurrent transcription by RNA polymerase II. This coupling is simply explained if nuclear ribosomes translate nascent transcripts as those transcripts emerge from still-engaged RNA polymerases, much as they do in bacteria.	Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England; Univ Manchester, Inst Sci & Technol, Dept Biomol Sci, Manchester M60 1QD, Lancs, England	University of Oxford; University of Manchester	Cook, PR (corresponding author), Univ Oxford, Sir William Dunn Sch Pathol, S Parks Rd, Oxford OX1 3RE, England.		iborra, francisco j/K-9313-2015; Iborra, Francisco J/A-2943-2009	iborra, francisco j/0000-0002-0692-3696; Cook, Peter/0000-0002-6639-188X				Arts GJ, 1998, EMBO J, V17, P7430, DOI 10.1093/emboj/17.24.7430; CHATTERJEE NK, 1977, ARCH BIOCHEM BIOPHYS, V183, P228, DOI 10.1016/0003-9861(77)90436-2; Cook PR, 1999, SCIENCE, V284, P1790, DOI 10.1126/science.284.5421.1790; EISINGER DP, 1997, MOL CELL BIOL, V17, P5135; ETCHISON D, 1987, J VIROL, V61, P2702, DOI 10.1128/JVI.61.9.2702-2710.1987; GOIDL JA, 1978, TRENDS BIOCHEM SCI, V3, pN225; GREBER UF, 1995, J CELL BIOL, V128, P5, DOI 10.1083/jcb.128.1.5; Hentze MW, 1999, CELL, V96, P307, DOI 10.1016/S0092-8674(00)80542-5; Hollinshead M, 1997, J HISTOCHEM CYTOCHEM, V45, P1053, DOI 10.1177/002215549704500803; IBORRA FJ, 1992, J HISTOCHEM CYTOCHEM, V40, P1865, DOI 10.1177/40.12.1453005; Iborra FJ, 1998, J CELL SCI, V111, P2269; Jackson DA, 2000, FASEB J, V14, P242, DOI 10.1096/fasebj.14.2.242; Jacobson A, 1996, ANNU REV BIOCHEM, V65, P693, DOI 10.1146/annurev.bi.65.070196.003401; LEJBKOWICZ F, 1992, P NATL ACAD SCI USA, V89, P9612, DOI 10.1073/pnas.89.20.9612; Lund E, 1998, SCIENCE, V282, P2082, DOI 10.1126/science.282.5396.2082; MILLER OL, 1970, SCIENCE, V169, P392, DOI 10.1126/science.169.3943.392; Neumann F, 1997, EXP CELL RES, V230, P252, DOI 10.1006/excr.1996.3417; Pederson T, 2000, J CELL BIOL, V148, P1091, DOI 10.1083/jcb.148.6.1091; Pombo A, 1999, EMBO J, V18, P2241, DOI 10.1093/emboj/18.8.2241; RAY MK, 1993, BIOCHEMISTRY-US, V32, P5151, DOI 10.1021/bi00070a026; ROTH MB, 1990, J CELL BIOL, V111, P2217, DOI 10.1083/jcb.111.6.2217; Yotov WV, 1998, MOL CELL BIOL, V18, P1303, DOI 10.1128/MCB.18.3.1303	22	300	311	0	38	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	AUG 10	2001	293	5532					1139	1142		10.1126/science.1061216	http://dx.doi.org/10.1126/science.1061216			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	462RB	11423616				2022-12-28	WOS:000170432600061
J	Dutton, Z; Budde, M; Slowe, C; Hau, LV				Dutton, Z; Budde, M; Slowe, C; Hau, LV			Observation of quantum shock waves created with ultra-compressed slow light pulses in a Bose-Einstein condensate	SCIENCE			English	Article							ELECTROMAGNETICALLY INDUCED TRANSPARENCY; NONLINEAR SCHRODINGER-EQUATIONS; DARK SOLITONS; VORTICES; GASES; INSTABILITY; SCATTERING; COLLISIONS	We have used an extension of our slow light technique to provide a method for inducing small density defects in a Bose-Einstein condensate. These subresolution, micrometer-sized defects evolve into large-amplitude sound waves. We present an experimental observation and theoretical investigation of the resulting breakdown of superfluidity, and we observe directly the decay of the narrow density defects into solitons, the onset of the "snake" instability, and the subsequent nucleation of vortices.	Rowland Inst Sci Inc, Cambridge, MA 02142 USA; Harvard Univ, Lyman Lab Phys, Dept Phys, Cambridge, MA 02138 USA; Harvard Univ, Div Engn & Appl Sci, Cruft Lab, Cambridge, MA 02138 USA	Harvard University; Harvard University	Dutton, Z (corresponding author), Rowland Inst Sci Inc, 100 Edwin H Land Blvd, Cambridge, MA 02142 USA.							Abo-Shaeer JR, 2001, SCIENCE, V292, P476, DOI 10.1126/science.1060182; Anderson BP, 2001, PHYS REV LETT, V86, P2926, DOI 10.1103/PhysRevLett.86.2926; Andreae T, 1997, DISCRETE APPL MATH, V79, P3, DOI 10.1016/S0166-218X(97)00029-2; Andrews MR, 1997, SCIENCE, V275, P637, DOI 10.1126/science.275.5300.637; [Anonymous], 1991, QUANTIZED VORTICES H; Band YB, 2000, PHYS REV LETT, V84, P5462, DOI 10.1103/PhysRevLett.84.5462; Baym G, 1996, PHYS REV LETT, V76, P6, DOI 10.1103/PhysRevLett.76.6; BOWLEY RM, 1992, J LOW TEMP PHYS, V87, P137, DOI 10.1007/BF00114903; Burger S, 1999, PHYS REV LETT, V83, P5198, DOI 10.1103/PhysRevLett.83.5198; Busch T, 2000, PHYS REV LETT, V84, P2298, DOI 10.1103/PhysRevLett.84.2298; Dalfovo F, 1999, REV MOD PHYS, V71, P463, DOI 10.1103/RevModPhys.71.463; Dalfovo F, 2000, PHYS REV A, V61, DOI 10.1103/PhysRevA.61.023605; Denschlag J, 2000, SCIENCE, V287, P97, DOI 10.1126/science.287.5450.97; Feder DL, 2000, PHYS REV A, V62, DOI 10.1103/PhysRevA.62.053606; Fetter AL, 1999, P INT SCH PHYS, V140, P201; Harris SE, 1997, PHYS TODAY, V50, P36, DOI 10.1063/1.881806; HARRIS SE, 1992, PHYS REV A, V46, pR29, DOI 10.1103/PhysRevA.46.R29; Harris SE, 1999, PHYS REV LETT, V82, P4611, DOI 10.1103/PhysRevLett.82.4611; Hau LV, 1999, NATURE, V397, P594, DOI 10.1038/17561; Hau LV, 1998, PHYS REV A, V58, pR54, DOI [10.1103/PhysRevA.58, 10.1103/PhysRevA.58.R54]; Jackson B, 2000, PHYS REV A, V61, DOI 10.1103/PhysRevA.61.051603; JAVANAINEN J, 1995, PHYS REV A, V52, P3033, DOI 10.1103/PhysRevA.52.3033; JONES CA, 1986, J PHYS A-MATH GEN, V19, P2991, DOI 10.1088/0305-4470/19/15/023; JOSSERAND C, 1995, EUROPHYS LETT, V30, P43, DOI 10.1209/0295-5075/30/1/008; Kadomtsev B. B., 1970, Soviet Physics - Doklady, V15, P539; KOONIN SE, 1990, COMPUTATIONAL PHYSIC; Landau L. D., 1976, MECHANICS, V1; Liu C, 2001, NATURE, V409, P490, DOI 10.1038/35054017; Madison KW, 2000, PHYS REV LETT, V84, P806, DOI 10.1103/PhysRevLett.84.806; Mamaev AV, 1996, PHYS REV LETT, V76, P2262, DOI 10.1103/PhysRevLett.76.2262; Matthews MR, 1999, PHYS REV LETT, V83, P2498, DOI 10.1103/PhysRevLett.83.2498; Morgan SA, 1997, PHYS REV A, V55, P4338, DOI 10.1103/PhysRevA.55.4338; PRESS WH, 1992, NUMERICAL RECIPES; Raman C, 1999, PHYS REV LETT, V83, P2502, DOI 10.1103/PhysRevLett.83.2502; Reinhardt WP, 1997, J PHYS B-AT MOL OPT, V30, pL785, DOI 10.1088/0953-4075/30/22/001; Scully M.O., 1997, QUANTUM OPT	37	433	438	1	45	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 27	2001	293	5530					663	668		10.1126/science.1062527	http://dx.doi.org/10.1126/science.1062527			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	458PW	11431534	Green Submitted			2022-12-28	WOS:000170204600046
J	Tishkoff, SA; Varkonyi, R; Cahinhinan, N; Abbes, S; Argyropoulos, G; Destro-Bisol, G; Drousiotou, A; Dangerfield, B; Lefranc, G; Loiselet, J; Piro, A; Stoneking, M; Tagarelli, A; Tagarelli, G; Touma, EH; Williams, SM; Clark, AG				Tishkoff, SA; Varkonyi, R; Cahinhinan, N; Abbes, S; Argyropoulos, G; Destro-Bisol, G; Drousiotou, A; Dangerfield, B; Lefranc, G; Loiselet, J; Piro, A; Stoneking, M; Tagarelli, A; Tagarelli, G; Touma, EH; Williams, SM; Clark, AG			Haplotype diversity and linkage disequilibrium at human G6PD: Recent origin of alleles that confer malarial resistance	SCIENCE			English	Article							GLUCOSE-6-PHOSPHATE-DEHYDROGENASE DEFICIENCY; LOCUS; POPULATION; EVOLUTION; GENE; POLYMORPHISM; SEQUENCE; SAMPLES; AFRICA	The frequencies of Low-activity alleles of glucose-6-phosphate dehydrogenase in humans are highly correlated with the prevalence of malaria. These "deficiency" alleles are thought to provide reduced risk from infection by the Plasmodium parasite and are maintained at high frequency despite the hemopathologies that they cause. Haplotype analysis of "A-" and "Med" mutations at this Locus indicates that they have evolved independently and have increased in frequency at a rate that is too rapid to be explained by random genetic drift. Statistical modeling indicates that the A- allele arose within the past 3840 to 11,760 years and the Med allele arose within the past 1600 to 6640 years. These results support the hypothesis that malaria has had a major impact on humans only since the introduction of agriculture within the past 10,000 years and provide a striking example of the signature of selection on the human genome.	Univ Maryland, Dept Biol, College Pk, MD 20742 USA; Penn State Univ, Dept Biol, Inst Evolutionary Genet, University Pk, PA 16802 USA; Fac Med, Tunis, Tunisia; Inst Pasteur, Tunis, Tunisia; Louisiana State Univ, Pennington Biomed Res Ctr, Baton Rouge, LA 70808 USA; Univ Roma La Sapienza, Dept Human & Anim Biol, Rome, Italy; Cyprus Inst Neurol & Genet, Dept Biochem Genet, Nicosia, Cyprus; Univ Witwatersrand, S African Inst Med Res, Dept Human Genet, Johannesburg, South Africa; Univ Sci, Montpellier, France; CNRS, Montpellier, France; Univ St Joseph, Beirut, Lebanon; CNR, Ist Med Sperimentale & Biotecnol, Mangone, Cosenza, Italy; Max Planck Inst Evolutionary Anthropol, Leipzig, Germany; Meharry Med Coll, Dept Microbiol, Nashville, TN 37208 USA	University System of Maryland; University of Maryland College Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Universite de Tunis-El-Manar; Faculte de Medecine de Tunis (FMT); Le Reseau International des Instituts Pasteur (RIIP); Universite de Tunis-El-Manar; Institut Pasteur Tunis; Louisiana State University System; Louisiana State University; Pennington Biomedical Research Center; Sapienza University Rome; University of Witwatersrand; Centre National de la Recherche Scientifique (CNRS); Saint Joseph University Beirut; Consiglio Nazionale delle Ricerche (CNR); Max Planck Society; Meharry Medical College	Tishkoff, SA (corresponding author), Univ Maryland, Dept Biol, Biol Psychol Bldg, College Pk, MD 20742 USA.	st130@umail.umd.edu	Williams, Scott/B-9491-2012; Williams, Scott/Q-4812-2019; Tagarelli, Giuseppe/N-8140-2015	Williams, Scott/0000-0002-4835-9544; Tagarelli, Giuseppe/0000-0002-4792-023X; Clark, Andrew/0000-0001-7159-8511; Destro Bisol, Giovanni/0000-0002-4232-9715	FIC NIH HHS [T37-TW00043] Funding Source: Medline; NCRR NIH HHS [G12-RR03032] Funding Source: Medline; NHLBI NIH HHS [HL03321] Funding Source: Medline; FOGARTY INTERNATIONAL CENTER [T37TW000043] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [G12RR003032] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Argyropoulos G, 1998, J CLIN INVEST, V102, P1345, DOI 10.1172/JCI4115; BEUTLER E, 1989, BLOOD, V74, P2550; BEUTLER E, 1994, BLOOD, V84, P3613, DOI 10.1182/blood.V84.11.3613.bloodjournal84113613; BEUTLER E, 1990, AM J HUM GENET, V47, P1008; BEUTLER E, 1977, BLOOD, V49, P467; Brooks A., COMMUNICATION; Brooks A. S., 1990, WORLD 18000 BP, V2, P121; Cavalli-Sforza L. L., 1994, HIST GEOGRAPHY HUMAN; CLARK AG, 1990, MOL BIOL EVOL, V7, P111; Collins A, 1996, P NATL ACAD SCI USA, V93, P14771, DOI 10.1073/pnas.93.25.14771; Coluzzi M, 1999, PARASSITOLOGIA, VOL 41, NOS 1-3, SEPTEMBER 1999, P277; DURANDO F, 1997, ANCIENT GREECE DAWN; FILOSA S, 1993, GENOMICS, V17, P6, DOI 10.1006/geno.1993.1276; *GENB, X55448 GENB; Gillespie JH, 2000, GENETICS, V155, P909; HAWLEY ME, 1995, J HERED, V86, P409, DOI 10.1093/oxfordjournals.jhered.a111613; HIRONO A, 1988, P NATL ACAD SCI USA, V85, P3951, DOI 10.1073/pnas.85.11.3951; Kidd JR, 2000, AM J HUM GENET, V66, P1882, DOI 10.1086/302952; LIVINGSTONE FB, 1971, ANNU REV GENET, V5, P33, DOI 10.1146/annurev.ge.05.120171.000341; LIVINGSTONE FB, 1958, AM ANTHROPOL, V60, P533, DOI 10.1525/aa.1958.60.3.02a00110; Luzzatto L, 2001, HEMATOLOGYONCOLOGY C, P4517, DOI [DOI 10.1016/J.HOC.2015.11.006, 10.1016/j.hoc.2015.11.006]; Neuhauser C, 1997, GENETICS, V145, P519; PLATO CC, 1964, AM J HUM GENET, V16, P267; Rich SM, 2000, P NATL ACAD SCI USA, V97, P6994, DOI 10.1073/pnas.97.13.6994; Ruwende C, 1998, J MOL MED, V76, P581, DOI 10.1007/s001090050253; RUWENDE C, 1995, NATURE, V376, P246, DOI 10.1038/376246a0; SAUNDERS M, UNPUB; Sherman Irwin W., 1998, P3; Slatkin M, 2000, ANNU REV GENOM HUM G, V1, P225, DOI 10.1146/annurev.genom.1.1.225; Spedini G, 1999, AM J PHYS ANTHROPOL, V110, P143, DOI 10.1002/(SICI)1096-8644(199910)110:2<143::AID-AJPA3>3.3.CO;2-A; STONEKING M, 1990, GENETICS, V124, P717; Tagarelli A, 2000, FEBS LETT, V466, P139, DOI 10.1016/S0014-5793(99)01776-7; Tagarelli A, 1991, Gene Geogr, V5, P141; TAKIZAWA T, 1987, Genomics, V1, P228, DOI 10.1016/0888-7543(87)90048-6; Tishkoff SA, 2000, AM J HUM GENET, V67, P901, DOI 10.1086/303068; Tishkoff SA, 1998, AM J HUM GENET, V62, P1389, DOI 10.1086/301861; Tishkoff SA, 1996, SCIENCE, V271, P1380, DOI 10.1126/science.271.5254.1380; TOUMA E, 1997, 7 INT C INB ERR MET, P26; Verra F, 2000, MOL BIOCHEM PARASIT, V105, P149, DOI 10.1016/S0166-6851(99)00162-0; VERRELLI BC, UNPUB; VULLIAMY T, 1992, TRENDS GENET, V8, P138, DOI 10.1016/0168-9525(92)90372-B; VULLIAMY TJ, 1991, P NATL ACAD SCI USA, V88, P8568, DOI 10.1073/pnas.88.19.8568; WIESENFELD SL, 1967, SCIENCE, V157, P1134, DOI 10.1126/science.157.3793.1134; Williams SM, 2000, HYPERTENSION, V36, P2, DOI 10.1161/01.HYP.36.1.2; Yellen J.E., 1998, AFR ARCHAEOL REV, V15, P173, DOI [DOI 10.1023/, DOI 10.1023/A:1021659928822]	45	941	959	6	92	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 20	2001	293	5529					455	462		10.1126/science.1061573	http://dx.doi.org/10.1126/science.1061573			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	454HG	11423617				2022-12-28	WOS:000169966700037
J	Steck, DA; Oskay, WH; Raizen, MG				Steck, DA; Oskay, WH; Raizen, MG			Observation of chaos-assisted tunneling between islands of stability	SCIENCE			English	Article							STANDING LIGHT-WAVE; BRAGG SCATTERING; OPTICAL LATTICE; ATOMS; LOCALIZATION; DYNAMICS	We report the direct observation of quantum dynamical tunneling of atoms between separated momentum regions in phase space. We study how the tunneling oscillations are affected as a quantum symmetry is broken and as the initial atomic state is changed. We also provide evidence that the tunneling rate is greatly enhanced by the presence of chaos in the classical dynamics. This tunneling phenomenon represents a dramatic manifestation of underlying classical chaos in a quantum system.	Univ Texas, Dept Phys, Austin, TX 78712 USA	University of Texas System; University of Texas Austin	Raizen, MG (corresponding author), Univ Texas, Dept Phys, Austin, TX 78712 USA.	raizen@physics.utexas.edu						AVERBUKH V, 1995, Z PHYS D ATOM MOL CL, V35, P247, DOI 10.1007/BF01745527; BOHIGAS O, 1993, PHYS REP, V223, P43, DOI 10.1016/0370-1573(93)90109-Q; CHIRIKOV BV, 1995, PHYS REV LETT, V74, P518, DOI 10.1103/PhysRevLett.74.518; DAVIS MJ, 1981, J CHEM PHYS, V75, P246, DOI 10.1063/1.441832; Dembowski C, 2000, PHYS REV LETT, V84, P867, DOI 10.1103/PhysRevLett.84.867; DePue MT, 1999, PHYS REV LETT, V82, P2262, DOI 10.1103/PhysRevLett.82.2262; DYRTING S, 1993, PHYS REV E, V48, P969, DOI 10.1103/PhysRevE.48.969; Frischat SD, 1998, PHYS REV E, V57, P1421, DOI 10.1103/PhysRevE.57.1421; GILTNER DM, 1995, PHYS REV A, V52, P3966, DOI 10.1103/PhysRevA.52.3966; GRAHAM R, 1992, PHYS REV A, V45, pR19, DOI 10.1103/PhysRevA.45.R19; Haycock DL, 2000, PHYS REV LETT, V85, P3365, DOI 10.1103/PhysRevLett.85.3365; Hensinger WK, 2000, J OPT B-QUANTUM S O, V2, P659, DOI 10.1088/1464-4266/2/5/314; Hug M, 2001, PHYS REV A, V63, DOI 10.1103/PhysRevA.63.023413; KASEVICH MA, 1992, THESIS STANFORD U ST; Koch P, COMMUNICATION; Kozuma M, 1999, PHYS REV LETT, V82, P871, DOI 10.1103/PhysRevLett.82.871; MARTIN PJ, 1988, PHYS REV LETT, V60, P515, DOI 10.1103/PhysRevLett.60.515; MOUCHET A, IN PRESS PHYS REV E; Neicu T, 2001, PHYS REV E, V63, DOI 10.1103/PhysRevE.63.026206; PERES A, 1991, PHYS REV LETT, V67, P158, DOI 10.1103/PhysRevLett.67.158; PLATA J, 1992, J PHYS A-MATH GEN, V25, pL303, DOI 10.1088/0305-4470/25/7/004; REICHL IE, 1992, TRANSITION CHAOS CON; Robinson JC, 1996, PHYS REV LETT, V76, P3304, DOI 10.1103/PhysRevLett.76.3304; Steck DA, 2000, PHYS REV E, V62, P3461, DOI 10.1103/PhysRevE.62.3461; TOMSOVIC S, 1994, PHYS REV E, V50, P145, DOI 10.1103/PhysRevE.50.145; UTERMANN R, 1994, PHYS REV E, V49, P273, DOI 10.1103/PhysRevE.49.273	26	298	298	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 13	2001	293	5528					274	278		10.1126/science.1061569	http://dx.doi.org/10.1126/science.1061569			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	452TK	11441148				2022-12-28	WOS:000169875200051
J	Grimm, JW; Hope, BT; Wise, RA; Shaham, Y				Grimm, JW; Hope, BT; Wise, RA; Shaham, Y			Neuroadaptation - Incubation of cocaine craving after withdrawal	NATURE			English	Article							RELAPSE; SENSITIZATION; ABSTINENCE; ADDICTION; STRESS		NIDA, Behav Neurosci Branch, Intramural Res Program, NIH, Baltimore, MD 21224 USA	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); NIH National Institute on Drug Abuse (NIDA)	Grimm, JW (corresponding author), NIDA, Behav Neurosci Branch, Intramural Res Program, NIH, 5500 Nathan Shock Dr, Baltimore, MD 21224 USA.		Wise, Roy A/A-6465-2012; shaham, yavin/G-1306-2014; Hope, Bruce T/A-9223-2010	Hope, Bruce T/0000-0001-5804-7061	Intramural NIH HHS [Z01 DA000434-08] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [Z01DA000434] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		Childress AR, 1999, AM J PSYCHIAT, V156, P11, DOI 10.1176/ajp.156.1.11; deWit H, 1996, EXP CLIN PSYCHOPHARM, V4, P5, DOI 10.1037/1064-1297.4.1.5; GAWIN FH, 1986, ARCH GEN PSYCHIAT, V43, P107; Grimm JW, 2000, NEUROPSYCHOPHARMACOL, V22, P473, DOI 10.1016/S0893-133X(99)00157-8; Nestler EJ, 2001, NAT REV NEUROSCI, V2, P119, DOI 10.1038/35053570; ROBINSON TE, 1993, BRAIN RES REV, V18, P247, DOI 10.1016/0165-0173(93)90013-P; SARNYAI Z, IN PRESS PHARM REV; SATEL SL, 1991, AM J PSYCHIAT, V148, P1712; Shaham Y, 2000, BRAIN RES REV, V33, P13, DOI 10.1016/S0165-0173(00)00024-2; Sinha R, 2000, PSYCHOPHARMACOLOGY, V152, P140, DOI 10.1007/s002130000499; STEWART J, 1983, PROG NEURO-PSYCHOPH, V7, P591, DOI 10.1016/0278-5846(83)90030-1; Vanderschuren LJMJ, 2000, PSYCHOPHARMACOLOGY, V151, P99, DOI 10.1007/s002130000493; White FJ, 1998, DRUG ALCOHOL DEPEN, V51, P141, DOI 10.1016/S0376-8716(98)00072-6	13	696	707	2	38	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 12	2001	412	6843					141	142		10.1038/35084134	http://dx.doi.org/10.1038/35084134			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	451AJ	11449260	Green Accepted			2022-12-28	WOS:000169778700038
J	Lund, JN; Tierney, GM				Lund, JN; Tierney, GM			Hospital autopsy: standardised questionnaire survey to determine junior doctors' perceptions	BRITISH MEDICAL JOURNAL			English	Article									Univ Nottingham Hosp, Directorate Surg, Nottingham NG7 2UH, England	University of Nottingham	Lund, JN (corresponding author), Univ Nottingham Hosp, Directorate Surg, Nottingham NG7 2UH, England.		Lund, Jonathan/K-6631-2019	Lund, Jonathan/0000-0001-5195-2181; Tierney, Gillian/0000-0001-8222-0258				[Anonymous], 1991, REP JOINT WORK PART	1	9	9	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUL 7	2001	323	7303					21	22		10.1136/bmj.323.7303.21	http://dx.doi.org/10.1136/bmj.323.7303.21			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	451WA	11440937	Green Published, Bronze			2022-12-28	WOS:000169824300018
J	Kuypers, MMM; Blokker, P; Erbacher, J; Kinkel, H; Pancost, RD; Schouten, S; Damste, JSS				Kuypers, MMM; Blokker, P; Erbacher, J; Kinkel, H; Pancost, RD; Schouten, S; Damste, JSS			Massive expansion of marine archaea during a mid-Cretaceous oceanic anoxic event	SCIENCE			English	Article							ORGANIC-CARBON; ETHER LIPIDS; SEDIMENTS; PRODUCTS; BIOMASS; EARTH; SEA	Biogeochemical and stable carbon isotopic analysis of black-share sequences deposited during an Albian oceanic anoxic event (similar to 112 million years ago) indicate that up to 80 weight percent of sedimentary organic carbon is derived from marine, nonthermophilic archaea, The carbon-13 content of archaeal molecular fossils indicates that these archaea were Living chemoautotrophically. Their massive expansion may have been a response to the strong stratification of the ocean during this anoxic event. Indeed, the sedimentary record of archaeal membrane lipids suggests that this anoxic event marks a time in Earth history at which certain hyperthermophilic archaea adapted to low-temperature environments.	Netherlands Inst Sea Res, Dept Biogeochem & Toxicol, NL-1790 AB Den Burg, Netherlands; Bundesanstalt Geowissensch & Rohstoffe, D-30655 Hannover, Germany	Utrecht University; Royal Netherlands Institute for Sea Research (NIOZ)	Damste, JSS (corresponding author), Netherlands Inst Sea Res, Dept Biogeochem & Toxicol, POB 59, NL-1790 AB Den Burg, Netherlands.		Damste, Jaap S Sinninghe/F-6128-2011	Damste, Jaap S Sinninghe/0000-0002-8683-1854; Pancost, Richard/0000-0003-0298-4026; Erbacher, Jochen/0000-0003-2793-0307				ARTHUR MA, 1985, NATURE, V315, P216, DOI 10.1038/315216a0; ARTHUR MA, 1988, NATURE, V335, P714, DOI 10.1038/335714a0; ARTHUR MA, 1985, AM GEOPHYS UNION MON, V32, P504; Bralower TJ, 1997, GEOL SOC AM BULL, V109, P1421, DOI 10.1130/0016-7606(1997)109<1421:MCSISO>2.3.CO;2; BRALOWER TJ, 1987, GEOL SOC LOND SPEC P, V26, P345; Damste JSS, 1997, ORG GEOCHEM, V26, P517, DOI 10.1016/S0146-6380(97)00039-9; DeLong EF, 1998, APPL ENVIRON MICROB, V64, P1133; DEROSA M, 1988, PROG LIPID RES, V27, P153, DOI 10.1016/0163-7827(88)90011-2; Erbacher J, 2001, NATURE, V409, P325, DOI 10.1038/35053041; FUHRMAN JA, 1989, MAR ECOL PROG SER, V57, P207, DOI 10.3354/meps057207; Hoefs MJL, 1997, APPL ENVIRON MICROB, V63, P3090, DOI 10.1128/AEM.63.8.3090-3095.1997; Hold IM, 1998, ORG GEOCHEM, V28, P179, DOI 10.1016/S0146-6380(97)00130-7; Hopmans EC, 2000, RAPID COMMUN MASS SP, V14, P585, DOI 10.1002/(SICI)1097-0231(20000415)14:7<585::AID-RCM913>3.3.CO;2-E; Karner MB, 2001, NATURE, V409, P507, DOI 10.1038/35054051; Kuypers MMM, 1999, NATURE, V399, P342, DOI 10.1038/20659; KUYPERS MMM, UNPUB; LARSON RL, 1991, GEOLOGY, V19, P547, DOI 10.1130/0091-7613(1991)019<0547:LPOEEF>2.3.CO;2; OURISSON G, 1992, ACCOUNTS CHEM RES, V25, P398, DOI 10.1021/ar00021a003; PEARSON A, 2001, GEOCHIM COSMOCHIM AC, V196, P67; SCHLANGER S O, 1976, Geologie en Mijnbouw, V55, P179; Schouten S, 1997, ORG GEOCHEM, V26, P409, DOI 10.1016/S0146-6380(97)00011-9; Schouten S, 2000, P NATL ACAD SCI USA, V97, P14421, DOI 10.1073/pnas.97.26.14421; SCHOUTEN S, UNPUB; STETTER KO, 1998, EXTREMOPHILES MICROB, pCH1; VANDERMEER MTJ, IN PRESS FEMS MICROB; Vink A, 1998, GEOCHIM COSMOCHIM AC, V62, P965, DOI 10.1016/S0016-7037(98)00034-9; VOLKMAN JK, 1986, ORG GEOCHEM, V9, P83, DOI 10.1016/0146-6380(86)90089-6	27	188	210	3	68	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 6	2001	293	5527					92	94		10.1126/science.1058424	http://dx.doi.org/10.1126/science.1058424			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	451BB	11441180				2022-12-28	WOS:000169780300035
J	Vincent, A; Palace, J; Hilton-Jones, D				Vincent, A; Palace, J; Hilton-Jones, D			Myasthenia gravis	LANCET			English	Article							ACETYLCHOLINE-RECEPTOR ANTIBODY; NEUROMUSCULAR-JUNCTION; MONOCLONAL-ANTIBODIES; PLASMA-EXCHANGE; HETEROGENEITY; PREVALENCE; DISORDERS; CHINESE; MOTHER; TRIAL	Myasthenia gravis Is an autoimmune disorder mainly caused by antibodies to the muscle acetylcholine receptors (AChRs) at the neuromuscular junction. Loss of these receptors leads to a defect in neuromuscular transmission with muscle weakness and fatigue. AChR antibody tests are widely available and overall incidence and prevalence of the disorder seem to be rising, especially in elderly people. The disease is heterogeneous with respect to age at onset, thymic changes and distribution of muscle weakness, but the roles of immunogenetic factors and thymic abnormalities in the causes of the different forms are unclear. Most patients are now effectively treated with cholinesterase inhibitors and immunosuppressive drugs, and in younger patients by thymectomy. In about 15% of patients with myasthenia gravis, AChR antibodies are absent, and many of these patients have antibodies to another neuromuscular junction protein, muscle specific kinase (MuSK). Myasthenia needs to be distinguished from other rarer but equally well characterised autoimmune, genetic, and toxic disorders of neuromuscular transmission by clinical and laboratory tests.	Inst Mol Med, Neurosci Grp, Oxford OX3 9DS, England; Univ Oxford, Radcliffe Infirm, NHS Trust, Dept Clin Neurol, Oxford, England	University of Oxford; Oxford University Hospitals NHS Foundation Trust; Radcliffe Infirmary; University of Oxford	Vincent, A (corresponding author), Inst Mol Med, Neurosci Grp, Oxford OX3 9DS, England.	angela.vincent@imm.ox.ac.uk	Vincent, Angela/AAE-7310-2019					Aarli JA, 1998, ANN NY ACAD SCI, V841, P505, DOI 10.1111/j.1749-6632.1998.tb10971.x; BARNES PRJ, 1995, NEUROMUSCULAR DISORD, V5, P59, DOI 10.1016/0960-8966(94)E0029-8; Beeson D, 2000, CHANNELOPATHIES - COMMON MECHANISMS IN AURA, ARRHYTHMIA AND ALKALOSIS, P85, DOI 10.1016/B978-044450489-0/50006-9; Beeson D, 1996, NEUROLOGY, V47, P1552, DOI 10.1212/WNL.47.6.1552; Brueton LA, 2000, AM J MED GENET, V92, P1, DOI 10.1002/(SICI)1096-8628(20000501)92:1<1::AID-AJMG1>3.0.CO;2-H; BUCKLEY C, IN PRESS ANN NEUROL; CHIU HC, 1987, NEUROLOGY, V37, P1854, DOI 10.1212/WNL.37.12.1854; COMPSTON DAS, 1980, BRAIN, V103, P579, DOI 10.1093/brain/103.3.579; DRACHMAN DB, 1978, NEW ENGL J MED, V298, P1116, DOI 10.1056/NEJM197805182982004; DRACHMAN DB, 1982, NEW ENGL J MED, V307, P769, DOI 10.1056/NEJM198209233071301; Engel AG, 1999, ARCH NEUROL-CHICAGO, V56, P163, DOI 10.1001/archneur.56.2.163; ENGEL AG, 1984, ANN NEUROL, V16, P519, DOI 10.1002/ana.410160502; ENGEL AG, 1999, CONT NEUROLOGY SERIE, P251; ENGEL AG, 1987, ANN NY ACAD SCI, V505, P326, DOI DOI 10.1111/J.1749-6632.1987.TB51301.X; EVOLI A, 1988, ACTA NEUROL SCAND, V77, P31, DOI 10.1111/j.1600-0404.1988.tb06970.x; Gajdos P, 1997, ANN NEUROL, V41, P789, DOI 10.1002/ana.410410615; GARLEPP MJ, 1983, BRIT MED J, V286, P338, DOI 10.1136/bmj.286.6362.338; GROB D, 1999, CONT NEUROLOGY SERIE, P131; Gronseth GS, 2000, NEUROLOGY, V55, P7, DOI 10.1212/WNL.55.1.7; GUYON T, 1994, J CLIN INVEST, V94, P16, DOI 10.1172/JCI117302; Hart IK, 2000, AM J MED SCI, V319, P209, DOI 10.1097/00000441-200004000-00003; HAWKINS BR, 1984, J NEUROL NEUROSUR PS, V47, P555, DOI 10.1136/jnnp.47.5.555; Hoch W, 2001, NAT MED, V7, P365, DOI 10.1038/85520; KIRCHNER T, 1986, VIRCHOWS ARCH B, V52, P237, DOI 10.1007/BF02889966; Lange Dale J., 1997, Neurology, V48, pS18; LENNON VA, 1980, NATURE, V285, P238, DOI 10.1038/285238a0; LINDSTROM JM, 1976, NEUROLOGY, V26, P1054, DOI 10.1212/WNL.26.11.1054; MacDonald BK, 2000, BRAIN, V123, P665, DOI 10.1093/brain/123.4.665; MAGGI G, 1991, ANN THORAC SURG, V51, P152, DOI 10.1016/0003-4975(91)90478-9; Marx A, 1998, Dev Immunol, V6, P129, DOI 10.1155/1998/49484; MIER AK, 1985, POSTGRAD MED J, V61, P725, DOI 10.1136/pgmj.61.718.725; MOSSMAN S, 1986, LANCET, V1, P116; Newsom-Davis J, 1998, DEV MED CHILD NEUROL, V40, P199; NEWSOMDAVIS J, 1978, NEUROLOGY, V28, P266, DOI 10.1212/WNL.28.3.266; NewsomDavis J, 1997, NEUROSCIENTIST, V3, P337, DOI 10.1177/107385849700300515; NEWSOMDAVIS J, 2000, PRESCRIBERS J, V40, P93; NEWSOMDAVIS J, 2000, CONT NERUOLOGY SERIE, P205; Ohno K, 2001, P NATL ACAD SCI USA, V98, P2017, DOI 10.1073/pnas.98.4.2017; ONG B, 1991, P NATL ACAD SCI USA, V88, P7343, DOI 10.1073/pnas.88.16.7343; Oosterhuis HJ, 1997, MYASTHENIA GRAVIS, P17; OOSTERHUIS HJGH, 1989, J NEUROL NEUROSUR PS, V52, P1121, DOI 10.1136/jnnp.52.10.1121; Oosterhuis HJGH, 1997, MYASTHENIA GRAVIS; Palace J, 1998, NEUROLOGY, V50, P1778, DOI 10.1212/WNL.50.6.1778; PATRICK J, 1973, SCIENCE, V180, P871, DOI 10.1126/science.180.4088.871; Sanders Donald B., 1997, Neurology, V48, pS40; SCADDING GK, 1981, NEUROLOGY, V31, P935, DOI 10.1212/WNL.31.8.935; SCHLUEP M, 1987, ANN NEUROL, V22, P212, DOI 10.1002/ana.410220205; Simpson JA, 1960, SCOT MED J, V5, P419, DOI [10.1177/003693306000501001, DOI 10.1177/003693306000501001]; SOMMER N, 1993, DOC OPHTHALMOL, V84, P309, DOI 10.1007/BF01215447; Somnier FE, 1996, DAN MED BULL, V43, P1; TOYKA KV, 1977, NEW ENGL J MED, V296, P125, DOI 10.1056/NEJM197701202960301; Trivedi R, 2000, LANCET, V356, P565, DOI 10.1016/S0140-6736(00)02585-X; Truffault F, 1997, ANN NEUROL, V41, P731, DOI 10.1002/ana.410410609; TZARTOS SJ, 1982, P NATL ACAD SCI-BIOL, V79, P188, DOI 10.1073/pnas.79.1.188; Uono MI, 1980, INT J NEUROL, V14, P87; VINCENT A, 1987, ANN NY ACAD SCI, V505, P106, DOI DOI 10.1111/J.1749-6632.1987.TB51286.X.PUBMED:2446546	56	366	383	0	59	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 30	2001	357	9274					2122	2128		10.1016/S0140-6736(00)05186-2	http://dx.doi.org/10.1016/S0140-6736(00)05186-2			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	447RQ	11445126				2022-12-28	WOS:000169586600035
J	Hall, PS; Kincaid, C				Hall, PS; Kincaid, C			Diapiric flow at subduction zones: A recipe for rapid transport	SCIENCE			English	Article							UPPER-MANTLE; MELT EXTRACTION; ISLAND ARCS; CONSTRAINTS; MAGMATISM; WATER; LITHOSPHERE; EVOLUTION; ISOTOPES; DYNAMICS	Recent geochemical studies of uranium-thorium series disequilibrium in rocks from subduction zones require magmas to be transported through the mantle from just above the subducting slab to the surface in as Little as similar to 30,000 years. We present a series of Laboratory experiments that investigate the characteristic time scales and flow patterns of the diapiric upwelling model of subduction zone magmatism. Results indicate that the interaction between buoyantly upwelling diapirs and subduction-induced flow in the mantle creates a network of Low-density, Low-viscosity conduits through which buoyant flow is rapid, yielding transport times commensurate with those indicated by uranium-thorium studies.	Univ Rhode Isl, Grad Sch Oceanog, Narragansett, RI 02882 USA	University of Rhode Island	Hall, PS (corresponding author), Univ Rhode Isl, Grad Sch Oceanog, Narragansett, RI 02882 USA.							DAVIES JH, 1992, J GEOPHYS RES-SOL EA, V97, P2037, DOI 10.1029/91JB02571; Elliott T, 1997, J GEOPHYS RES-SOL EA, V102, P14991, DOI 10.1029/97JB00788; FEIGHNER MA, 1995, GEOPHYS RES LETT, V22, P715, DOI 10.1029/95GL00311; FURUKAWA Y, 1993, J GEOPHYS RES-SOL EA, V98, P8309, DOI 10.1029/93JB00350; GREEN DH, 1973, EARTH PLANET SC LETT, V19, P37, DOI 10.1016/0012-821X(73)90176-3; Hawkesworth CJ, 1997, SCIENCE, V276, P551, DOI 10.1126/science.276.5312.551; HIRTH G, 1995, J GEOPHYS RES-SOL EA, V100, P15441, DOI 10.1029/95JB01292; Hirth G, 1996, EARTH PLANET SC LETT, V144, P93, DOI 10.1016/0012-821X(96)00154-9; JARRARD RD, 1986, REV GEOPHYS, V24, P217, DOI 10.1029/RG024i002p00217; Johnson JB, 1998, GEOPHYS RES LETT, V25, P3999, DOI 10.1029/1998GL900102; Kincaid C, 1997, J GEOPHYS RES-SOL EA, V102, P12295, DOI 10.1029/96JB03553; MARSH BD, 1982, AM J SCI, V282, P808, DOI 10.2475/ajs.282.6.808; MARSH BD, 1979, AM SCI, V67, P161; MARSH BD, 1974, J GEOPHYS RES, V79, P1196, DOI 10.1029/JB079i008p01196; MARSH BD, 1979, J GEOL, V87, P687, DOI 10.1086/628460; MARSH BD, 1976, GEOPHYSICS PACIFIC O, V19, P337; MCCULLOCH MT, 1991, EARTH PLANET SC LETT, V102, P358, DOI 10.1016/0012-821X(91)90029-H; MCKENZIE D, 1988, J PETROL, V29, P625, DOI 10.1093/petrology/29.3.625; MORRIS JD, 1990, NATURE, V344, P31, DOI 10.1038/344031a0; NAKADA M, 1995, TECTONOPHYSICS, V246, P147, DOI 10.1016/0040-1951(94)00249-9; OLSON P, 1985, J FLUID MECH, V158, P511, DOI 10.1017/S0022112085002749; SAKUYAMA M, 1983, J VOLCANOL GEOTH RES, V18, P297, DOI 10.1016/0377-0273(83)90013-6; SPIEGELMAN M, 1987, EARTH PLANET SC LETT, V83, P137, DOI 10.1016/0012-821X(87)90057-4; TAMURA Y, 1994, J PETROL, V35, P619, DOI 10.1093/petrology/35.3.619; TATSUMI Y, 1983, J GEOPHYS RES, V88, P5815, DOI 10.1029/JB088iB07p05815; THOMPSON AB, 1992, NATURE, V358, P295, DOI 10.1038/358295a0; Turner S, 1997, NATURE, V389, P568, DOI 10.1038/39257; VOGT PR, 1974, EARTH PLANET SC LETT, V21, P235, DOI 10.1016/0012-821X(74)90159-9; Whitehead J., 1990, MAGMA TRANSPORT STOR, P53	29	127	134	0	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 29	2001	292	5526					2472	2475		10.1126/science.1060488	http://dx.doi.org/10.1126/science.1060488			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	448YU	11431563				2022-12-28	WOS:000169658200036
J	Harwood, AJ				Harwood, AJ			Regulation of GSK-3: A cellular multiprocessor	CELL			English	Review							GLYCOGEN-SYNTHASE KINASE-3; DEPENDENT PROTEIN-KINASE; WNT SIGNALING PATHWAY; SUBSTRATE-SPECIFICITY; CRYSTAL-STRUCTURE; PHOSPHORYLATION; AXIN; TRANSDUCTION; MECHANISM; PEPTIDE		UCL, MRC, Mol Cell Biol Lab, London WC1E 6BT, England; UCL, Dept Biol, London WC1E 6BT, England	University of London; University College London; University of London; University College London	Harwood, AJ (corresponding author), UCL, MRC, Mol Cell Biol Lab, Gower St, London WC1E 6BT, England.	a.hamood@ucl.ac.uk	Harwood, Adrian/A-4350-2010	Harwood, Adrian/0000-0003-3124-5169				Canagarajah BJ, 1997, CELL, V90, P859, DOI 10.1016/S0092-8674(00)80351-7; Cobb MH, 2000, TRENDS BIOCHEM SCI, V25, P7, DOI 10.1016/S0968-0004(99)01508-X; Cohen P, 1999, PHILOS T R SOC B, V354, P485, DOI 10.1098/rstb.1999.0399; Dajani R, 2001, CELL, V105, P721, DOI 10.1016/S0092-8674(01)00374-9; Dale TC, 1998, BIOCHEM J, V329, P209; Ding VW, 2000, J BIOL CHEM, V275, P32475, DOI 10.1074/jbc.M005342200; EMBI N, 1980, EUR J BIOCHEM, V107, P519, DOI 10.1111/j.1432-1033.1980.tb06059.x; Farr GH, 2000, J CELL BIOL, V148, P691, DOI 10.1083/jcb.148.4.691; Frame S, 2001, MOL CELL, V7, P1321, DOI 10.1016/S1097-2765(01)00253-2; Fukumoto S, 2001, J BIOL CHEM, V276, P17479, DOI 10.1074/jbc.C000880200; Harwood AJ, 2000, CURR BIOL, V10, pR116, DOI 10.1016/S0960-9822(00)00307-9; Li L, 1999, EMBO J, V18, P4233, DOI 10.1093/emboj/18.15.4233; Mao JH, 2001, MOL CELL, V7, P801, DOI 10.1016/S1097-2765(01)00224-6; PLYTE SE, 1992, BIOCHIM BIOPHYS ACTA, V1114, P147, DOI 10.1016/0304-419X(92)90012-N; Polakis P, 2000, GENE DEV, V14, P1837; ter Haar E, 2001, NAT STRUCT BIOL, V8, P593, DOI 10.1038/89624; Thomas GM, 1999, FEBS LETT, V458, P247, DOI 10.1016/S0014-5793(99)01161-8; WANG QM, 1994, J BIOL CHEM, V269, P14566; ZHENG JH, 1993, BIOCHEMISTRY-US, V32, P2154, DOI 10.1021/bi00060a005	19	259	266	1	19	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 29	2001	105	7					821	824		10.1016/S0092-8674(01)00412-3	http://dx.doi.org/10.1016/S0092-8674(01)00412-3			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	449BK	11439177	Bronze			2022-12-28	WOS:000169664300002
J	Green, LA; Fryer, GE; Yawn, BP; Lanier, D; Dovey, SM				Green, LA; Fryer, GE; Yawn, BP; Lanier, D; Dovey, SM			The ecology of medical care revisited	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HEALTH-CARE; SYSTEM; ICEBERG		Robert Graham Ctr, Washington, DC 20036 USA; Olmsted Med Ctr, Rochester, MN 55904 USA; Agcy Healthcare Res & Qual, Rockville, MD 20852 USA	Olmsted Medical Center; Agency for Healthcare Research & Quality	Green, LA (corresponding author), Robert Graham Ctr, 2023 Massachusetts Ave NW, Washington, DC 20036 USA.		Greiver, Michelle/N-8764-2015	Greiver, Michelle/0000-0001-8957-0285				AARON H, 1990, SCIENCE, V247, P418, DOI 10.1126/science.2300804; *AG HLTH CAR POL R, 1993, PUTT RES PRACT REP T; [Anonymous], 2000, DOING WHAT COUNTS PA; Bodenheimer T, 1999, NEW ENGL J MED, V340, P584, DOI 10.1056/NEJM199902183400725; *COUNC GRAD MED ED, 1995, DHHS PUBL; *COUNC GRAD MED ED, 1975, DHHS PUBL; DeFriese GH, 1997, HEALTH SERV RES, V32, P3; FUCHS VR, 1990, SCIENCE, V247, P534, DOI 10.1126/science.2300814; *GALL ORG, 2000, FAM MED CAR PREV PHY; Godwin M, 1999, CAN FAM PHYSICIAN, V45, P1405; GREEN LA, 1994, J FAM PRACTICE, V38, P400; Hickey T, 1991, J Appl Gerontol, V10, P169, DOI 10.1177/073346489101000204; *HLTH RES SERV ADM, 1992, NAT PRIM CAR C ROCKV; HORDER J, 1954, Practitioner, V173, P177; *I MED, 1999, ERR IS HUM BUILD SAF; Iglehart JK, 1999, NEW ENGL J MED, V340, P70, DOI 10.1056/NEJM199901073400122; *INT U CONS POL SO, 1996, GUID RES SERV; KOOIKER SE, 1995, SOC SCI MED, V41, P317, DOI 10.1016/0277-9536(94)00340-Y; Kuttner R, 1999, NEW ENGL J MED, V340, P163, DOI 10.1056/NEJM199901143400226; MARCILLE J, 1994, MANAG CARE, V3, P26; Marcille J A, 1994, Manag Care, V3, P22; McWhinney IR., 1981, INTRO FAMILY MED; MONHEIT AC, 1999, INFORMING AM HLTH CA; MULLNER RM, 1984, DHHS PUBLICATION; RAKEL RE, 1998, ESSENTIALS FAMILY PR, P3; Roghmann K J, 1972, Med Care, V10, P143, DOI 10.1097/00005650-197203000-00004; Stoller E P, 1992, J Rural Health, V8, P13, DOI 10.1111/j.1748-0361.1992.tb00323.x; THACKER SB, 1977, INT J EPIDEMIOL, V6, P55, DOI 10.1093/ije/6.1.55; VERBRUGGE LM, 1980, MED CARE, V18, P73, DOI 10.1097/00005650-198001000-00006; VERBRUGGE LM, 1987, MED CARE, V25, P539, DOI 10.1097/00005650-198706000-00008; WHITE KL, 1961, NEW ENGL J MED, V265, P885, DOI 10.1056/NEJM196111022651805; WHITE KL, 1973, SCI AM, V229, P22, DOI 10.1038/scientificamerican0973-22; White KL, 1997, HEALTH SERV RES, V32, P11	33	530	539	0	21	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 28	2001	344	26					2021	2025		10.1056/NEJM200106283442611	http://dx.doi.org/10.1056/NEJM200106283442611			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	446HQ	11430334				2022-12-28	WOS:000169508200011
J	Sahu, KC; Casertano, S; Livio, M; Gilliland, RL; Panagia, N; Albrow, MD; Potter, M				Sahu, KC; Casertano, S; Livio, M; Gilliland, RL; Panagia, N; Albrow, MD; Potter, M			Gravitational microlensing by low-mass objects in the globular cluster M22	NATURE			English	Article							SMALL-MAGELLANIC-CLOUD; STARS; EVENTS; DWARF	Gravitational microlensing offers a means of determining directly the masses of objects ranging from planets to stars, provided that the distances and motions of the lenses and sources can be determined(1,2). A globular cluster observed against the dense stellar field of the Galactic bulge presents ideal conditions for such observations because the probability of lensing is high(3) and the distances and kinematics of the lenses and sources are well constrained. The abundance of low-mass objects in a globular cluster is of particular interest, because it may be representative of the very early stages of star formation in the Universe, and therefore indicative of the amount of dark baryonic matter in such clusters. Here we report a microlensing event associated with the globular cluster M22. We determine the mass of the lens to be 0.13(-0.02)(+0.03) solar masses. We have also detected six events that are unresolved in time. If these are also microlensing events, they imply that a non-negligible fraction of the cluster mass resides in the form of free-floating planetary-mass objects.	Space Telescope Sci Inst, Baltimore, MD 21218 USA	Space Telescope Science Institute	Sahu, KC (corresponding author), Space Telescope Sci Inst, 3700 San Martin Dr, Baltimore, MD 21218 USA.			Sahu, Kailash/0000-0001-6008-1955				Afonso C, 1999, ASTRON ASTROPHYS, V344, pL63; Alcock C, 2000, ASTROPHYS J, V542, P281, DOI 10.1086/309512; BODE MF, 1989, CLASSICAL NOVAE, P5; BURROWS A, 1993, ASTROPHYS J, V406, P158, DOI 10.1086/172427; CUDWORTH KM, 1993, ASTRON J, V105, P168, DOI 10.1086/116417; DellaValle M, 1996, ASTROPHYS J, V457, pL77; DEMARCHI G, 1995, ASTRON ASTROPHYS, V304, P202; Dominik M, 1998, ASTRON ASTROPHYS, V329, P361; DOWNES R, IN PRESS PUBL ASTRON; ELSON RAW, 1995, ASTRON J, V110, P682, DOI 10.1086/117553; FREEMAN KC, 1988, ASTROPHYS J, V325, P563, DOI 10.1086/166027; Gilliland RL, 2000, ASTROPHYS J, V545, pL47, DOI 10.1086/317334; King IR, 1998, ASTROPHYS J, V492, pL37, DOI 10.1086/311082; Marcy GW, 2000, PUBL ASTRON SOC PAC, V112, P137, DOI 10.1086/316516; Paczynski B, 1996, ANNU REV ASTRON ASTR, V34, P419, DOI 10.1146/annurev.astro.34.1.419; PACZYNSKI B, 1994, ACTA ASTRONOM, V44, P235; PACZYNSKI B, 1997, ASTROPH9711007; PARESCE F, 1995, ASTROPHYS J, V440, P216, DOI 10.1086/175263; PETERSON RC, 1994, ASTROPHYS J, V420, P612, DOI 10.1086/173590; PETTERSEN BR, 1989, SOL PHYS, V121, P299; SAHU KC, 1994, PUBL ASTRON SOC PAC, V106, P942, DOI 10.1086/133465; Sahu KC, 1998, ASTROPHYS J, V508, pL147, DOI 10.1086/311746; SAHU KC, 1994, NATURE, V370, P275, DOI 10.1038/370275a0; SAMUS N, 1995, ASTRON ASTROPHYS SUP, V109, P487; Schneider P., 1993, GRAVITATIONAL LENSES; STETSON PB, 1993, STELLAR PHOTOMETRY C, P291; Udalski A, 2000, ACTA ASTRONOM, V50, P1; WARNER B, 1995, CATACLYSMIC VARIABLE, P148; Yanagisawa T, 2000, EXP ASTRON, V10, P519, DOI 10.1023/A:1008178000236	29	39	39	0	0	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 28	2001	411	6841					1022	1024		10.1038/35082507	http://dx.doi.org/10.1038/35082507			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	446TF	11429596				2022-12-28	WOS:000169528500039
J	Lalvani, A; Pathan, AA; Durkan, H; Wilkinson, KA; Whelan, A; Deeks, JJ; Reece, WHH; Latif, M; Pasvol, G; Hill, AVS				Lalvani, A; Pathan, AA; Durkan, H; Wilkinson, KA; Whelan, A; Deeks, JJ; Reece, WHH; Latif, M; Pasvol, G; Hill, AVS			Enhanced contact tracing and spatial tracking of Mycobacterium tuberculosis infection by enumeration of antigen-specific T cells	LANCET			English	Article							ESAT-6 ANTIGEN; RESPONSES; EPIDEMIOLOGY; PROTEIN; DIAGNOSIS; BOVIS; BCG	Background Identification of individuals latently infected with Mycobacterium tuberculosis is an important part of tuberculosis control. The current method, the tuberculin shin test (TST), has poor specificity because of the antigenic cross-reactivity of purified protein derivative (PPD) with M bovis BCG vaccine and environmental mycobacteria. ESAT-6 is a secreted antigen that is highly specific for M tuberculosis complex, but is absent from M bovis BCG. With an enzyme-linked immunospot (ELISPOT) assay for interferon gamma, we have identified ESAT-6-specific T cells as an accurate marker of M tuberculosis infection. Methods We did a prospective, masked study of 50 healthy contacts, with varying but well defined degrees of exposure to M tuberculosis, who attended an urban contact-tracing clinic. We assessed and compared the efficacy of our assay and TST for detection of symptomless infected individuals by correlation of test results with the degree of exposure to an infectious index case. Findings The ESAT-6 ELISPOT assay results had a strong positive relation with increasing intensity of exposure (odds ratio=9.0 per unit increase in level of exposure [95% CI 2.6-31.6], p=0.001), whereas TST results had a weaker relation with exposure (1.9 [1.0-3.5], p=0.05). By contrast, ELISPOT results were not correlated with BCG vaccination status (p=0.7), whereas TST results were significantly more likely to be positive in BCG-vaccinated contacts (12.1 [1.3-115.7], p=0.03). Interpretation This new antigen-specific T cell-based assay could allow more accurate identification of symptom-free individuals recently exposed to M tuberculosis, and thereby help to improve tuberculosis control.	Univ Oxford, John Radcliffe Hosp, Nuffield Dept Clin Med, Oxford OX3 9DU, England; Northwick Pk Hosp & Clin Res Ctr, Imperial Coll Sch Med, Wellcome Ctr Clin Trop Med, Harrow HA1 3UJ, Middx, England; Northwick Pk Hosp & Clin Res Ctr, TB Contact Tracing Clin, Harrow HA1 3UJ, Middx, England; Vet Labs Agcy, Dept Bacterial Dis, TB Res Grp, Weybridge, Surrey, England; Inst Hlth Sci, Ctr Stat Med, Oxford, England	University of Oxford; Imperial College London; Imperial College London; Veterinary Laboratories Agency; University of Oxford	Lalvani, A (corresponding author), Univ Oxford, John Radcliffe Hosp, Nuffield Dept Clin Med, Oxford OX3 9DU, England.	ajit.lalvani@ndm.ox.ac.uk	Wilkinson, Katalin/AAQ-7713-2021; Pasvol, Geoffrey/B-7113-2009; Wilkinson, Katalin/AAF-6805-2020; Whelan, Adam O/C-9497-2011; Deeks, Jon/AAV-5745-2020; HILL, Adrian V>S>/C-1306-2008	Wilkinson, Katalin/0000-0002-9796-2040; Deeks, Jon/0000-0002-8850-1971; Lalvani, Ajit/0000-0002-2396-246X				Andersen P, 2000, LANCET, V356, P1099, DOI 10.1016/S0140-6736(00)02742-2; [Anonymous], 2000, MMWR Recomm Rep, V49, P1; Arend SM, 2000, INFECT IMMUN, V68, P3314, DOI 10.1128/IAI.68.6.3314-3321.2000; Arend SM, 2000, J INFECT DIS, V181, P1850, DOI 10.1086/315448; Barnes PF, 2001, AM J RESP CRIT CARE, V163, P807, DOI 10.1164/ajrccm.163.4.ed0201c; Behr MA, 1999, SCIENCE, V284, P1520, DOI 10.1126/science.284.5419.1520; Brandt L, 1996, J IMMUNOL, V157, P3527; COMSTOCK GW, 1975, AM J EPIDEMIOL, V101, P363, DOI 10.1093/oxfordjournals.aje.a112105; Dye C, 1999, JAMA-J AM MED ASSOC, V282, P677, DOI 10.1001/jama.282.7.677; Fine PEM, 1999, INT J TUBERC LUNG D, V3, P962; GRZYBOWSKI S, 1975, Bulletin of the International Union Against Tuberculosis, V50, P90; Harboe M, 1996, INFECT IMMUN, V64, P16, DOI 10.1128/IAI.64.1.16-22.1996; HMSO, 1996, IMM INF DIS; HOUK VN, 1968, ARCH ENVIRON HEALTH, V16, P26, DOI 10.1080/00039896.1968.10665011; HUEBNER RE, 1993, CLIN INFECT DIS, V17, P968, DOI 10.1093/clinids/17.6.968; Kenyon TA, 1996, NEW ENGL J MED, V334, P933, DOI 10.1056/NEJM199604113341501; KWAMANGA DO, 1995, E AFR MED J, V72, P222; LAIVANI A, 2001, J INFECT DIS, V183, P469; Lalvani A, 1997, J EXP MED, V186, P859, DOI 10.1084/jem.186.6.859; Lalvani A, 2001, AM J RESP CRIT CARE, V163, P824, DOI 10.1164/ajrccm.163.4.2009100; Lein AD, 1999, CLIN DIAGN LAB IMMUN, V6, P606, DOI 10.1128/CDLI.6.4.606-609.1999; Mahairas GG, 1996, J BACTERIOL, V178, P1274, DOI 10.1128/jb.178.5.1274-1282.1996; Ormerod P, 2000, THORAX, V55, P887; Ravn P, 1999, J INFECT DIS, V179, P637, DOI 10.1086/314640; SMALL PM, 1994, NEW ENGL J MED, V330, P1703, DOI 10.1056/NEJM199406163302402; SORENSEN AL, 1995, INFECT IMMUN, V63, P1710; STEAD WW, 1978, JAMA-J AM MED ASSOC, V240, P2544, DOI 10.1001/jama.240.23.2544; THOMPSON NJ, 1982, B WORLD HEALTH ORGAN, V60, P555; Ulrichs T, 1998, EUR J IMMUNOL, V28, P3949, DOI 10.1002/(SICI)1521-4141(199812)28:12<3949::AID-IMMU3949>3.0.CO;2-4; van Pinxteren LAH, 2000, CLIN DIAGN LAB IMMUN, V7, P155, DOI 10.1128/CDLI.7.2.155-160.2000	30	315	333	0	12	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 23	2001	357	9273					2017	2021		10.1016/S0140-6736(00)05115-1	http://dx.doi.org/10.1016/S0140-6736(00)05115-1			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	446JB	11438135				2022-12-28	WOS:000169509200012
J	Holman, WL; Allman, RM; Sansom, M; Kiefe, CI; Peterson, ED; Anstrom, KJ; Sankey, SS; Hubbard, SG; Sherrill, RG				Holman, WL; Allman, RM; Sansom, M; Kiefe, CI; Peterson, ED; Anstrom, KJ; Sankey, SS; Hubbard, SG; Sherrill, RG		Alabama CABG Study Grp	Alabama coronary artery bypass crafting project - Results of a statewide quality improvement initiative	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NEW-YORK-STATE; CARDIAC-SURGERY; OUTCOMES DATA; CARE	Context Efforts to improve quality of care in the cardiac surgery field have focused on reducing the risk-adjusted mortality associated with common surgical procedures, such as coronary artery bypass grafting (CABG). However, the best methodological approach to improvement is under debate. Objective To test an intervention to improve performance of CABG surgery. Design and Setting Quality improvement project based on baseline (July 1, 1995-June 30, 1996) and follow-up (July 1-December 31, 1998) performance measurements from medical record review for all 20 Alabama hospitals that provided CABG surgery. Patients Medicare patients discharged after CABG surgery in Alabama (n=5784), a comparison state (n=3214), and a national sample (n=3758), Intervention Confidential hospital-specific performance feedback and assistance with multimodal improvement interventions, including the option to share relevant experience with peers. Main Outcome Measures Duration of intubation, reintubation rate, aspirin therapy at discharge, use of the internal mammary artery (IMA), hospital readmission rate, and risk-adjusted in-hospital mortality. Results Proportion of extubation within 6 hours increased from 9% to 41% in Alabama, decreased from 40% to 39% in the comparison state, and increased from 12% to 25% in the national sample. Use of IMA increased from 73% to 84%, 48% to 55%, and 74% to 81%, respectively, in the 3 samples, but aspirin use increased only in Alabama (from 88% to 92%). The amount of improvement in all 3 of these process measures was greater in Alabama than in the other samples (IMA use for Alabama vs comparison state was P=.001 and for Alabama vs national sample, P=.02; and P<.001 for all other comparisons). Risk-adjusted mortality decreased in Alabama (4.9% to 2.9%), but this decrease was not statistically significantly different from mortality changes in the other groups (odds ratio, 0.76; 95% confidence interval, 0.54-1.07 vs national sample). Conclusion Confidential peer-based regional performance feedback and process-oriented analysis of shared experience are associated with some improvement in quality of care for patients who underwent CABG surgery.	Univ Alabama, Sch Med, Dept Surg, Birmingham, AL 35294 USA; Univ Alabama, Sch Med, Dept Med, Birmingham, AL USA; Alabama Qual Assurance Fdn, Birmingham, AL USA; Vet Affairs Med Ctr, Birmingham, AL USA; E Alabama Med Ctr, Opelika, AL USA; Duke Univ, Med Ctr, Durham, NC USA; Univ Alabama, Ctr Outcomes & Effectiveness Res & Educ, Birmingham, AL USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham; US Department of Veterans Affairs; Veterans Health Administration (VHA); Duke University; University of Alabama System; University of Alabama Birmingham	Holman, WL (corresponding author), Univ Alabama, Sch Med, Dept Surg, 703 S 19th St,ZRB 719, Birmingham, AL 35294 USA.		Peterson, Eric David/ABF-5033-2021; Allman, Richard M./O-1693-2019; Allman, Richard M/D-5964-2011	Allman, Richard M./0000-0002-1850-6515; 	PHS HHS [500-96-P605] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Chassin MR, 1996, NEW ENGL J MED, V334, P394, DOI 10.1056/NEJM199602083340611; DeLong ER, 1997, STAT MED, V16, P2645, DOI 10.1002/(SICI)1097-0258(19971215)16:23<2645::AID-SIM696>3.0.CO;2-D; DONALDSON MS, 1994, HLTH DATA INFORMATIO, P91; DZIUBAN SW, 1994, ANN THORAC SURG, V58, P1871, DOI 10.1016/0003-4975(94)91730-2; Erickson LC, 2000, JAMA-J AM MED ASSOC, V283, P1976, DOI 10.1001/jama.283.15.1976; Ferguson TB, 2000, ANN THORAC SURG, V69, P680, DOI 10.1016/S0003-4975(99)01538-6; GROVER FL, 1994, ANN THORAC SURG, V58, P1845, DOI 10.1016/0003-4975(94)91725-6; HAMMERMEISTER KE, 1994, ANN SURG, V219, P281, DOI 10.1097/00000658-199403000-00008; Hannan EL, 1997, AM HEART J, V134, P55, DOI 10.1016/S0002-8703(97)70106-6; HANNAN EL, 1994, JAMA-J AM MED ASSOC, V271, P761, DOI 10.1001/jama.271.10.761; Harlan BJ, 2001, J THORAC CARDIOV SUR, V121, P409, DOI 10.1067/mtc.2001.110492; Holman WL, 1999, ANN THORAC SURG, V68, P1592, DOI 10.1016/S0003-4975(99)01000-0; Holman WL, 2000, J THORAC CARDIOV SUR, V120, P1112, DOI 10.1067/mtc.2000.110459; Jencks SF, 2000, JAMA-J AM MED ASSOC, V283, P2015, DOI 10.1001/jama.283.15.2015; Jollis JG, 2001, J AM COLL CARDIOL, V37, P998, DOI 10.1016/S0735-1097(01)01147-0; Kiefe CI, 1998, INT J QUAL HEALTH C, V10, P443, DOI 10.1093/intqhc/10.5.443; KOUCHOUKOS NT, 1988, ANN THORAC SURG, V45, P348, DOI 10.1016/S0003-4975(10)62482-4; Leavitt BJ, 1997, CIRCULATION, V96, P32; OConnor GT, 1996, JAMA-J AM MED ASSOC, V275, P841, DOI 10.1001/jama.275.11.841; PARSONNET V, 1989, CIRCULATION, V79, P1; US Dept of Health and Human Services . International Classification of Diseases, 1988, INT CLASS DIS	21	41	43	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 20	2001	285	23					3003	3010		10.1001/jama.285.23.3003	http://dx.doi.org/10.1001/jama.285.23.3003			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	442AR	11410099				2022-12-28	WOS:000169263200023
J	Cassell, EJ; Leon, AC; Kaufman, SG				Cassell, EJ; Leon, AC; Kaufman, SG			Preliminary evidence of impaired thinking in sick patients	ANNALS OF INTERNAL MEDICINE			English	Article							MINI-MENTAL-STATE	Background: Earlier anecdotal observations suggested to us that certain aspects of judgment in sick adults approximate the thinking of children. Objective: To describe changes in judgment associated with serious illness in otherwise competent adults. Design: Cohort study. Setting: Urban acute-care hospital and senior citizen center. Participants: sicker (Karnofsky score less than or equal to 50; n = 24) and less sick (Karnofsky score > 50; n = 39) hospitalized patients were compared with controls (n = 28). Normal performance on the Mini-Mental State Examination (score greater than or equal to 24) was required for study entrance. Measurements: Seven Piagetian tasks of judgment designed to study childhood cognitive development. Degree of sickness was determined by using the Karnofsky scale of physical function. Results: Patients with Karnofsky scores of 50 or less responded correctly to fewer Piagetian tasks than controls (mean [+/- SD], 1.8 +/- 2.6 vs. 5.9 +/- 1.6; P < 0.001). Furthermore, a smaller proportion of sicker patients responded correctly to each of the seven tasks. Patients with Karnofsky scores greater than 50 did not perform differently than controls, Conclusion: In sicker hospitalized patients, performance on seven Piagetian tasks of judgment was similar to that among children younger than 10 years of age. This evidence of cognitive impairment warrants further investigation.	Cornell Univ, Joan & Sanford I Weill Coll Med, New York, NY USA; Lynbrook Publ Sch Syst, Lynbrook, NY USA	Cornell University	Cassell, EJ (corresponding author), 28 Old Fulton St, Brooklyn, NY 11201 USA.	ecassell@email.msn.com						Bond T. G, 1997, PIAGET VYGOTSKY, P167; BURKE LE, 1991, CHILD DEV; CASSELL EJ, 1985, HEALERS ART, P38; COCKRELL JR, 1988, PSYCHOPHARMACOL BULL, V24, P689; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GINSBURG H, 1969, PIAGETS THEORY INTEL, P168; Karnofsky DA, 1949, EVALUATION CHEMOTHER; Piaget J., 1967, CHILDS CONCEPT SPACE; Piaget J., 1969, PSYCHOL CHILD; Piaget J., 2003, PSYCHOL INTELLIGENCE	10	83	85	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 19	2001	134	12					1120	1123		10.7326/0003-4819-134-12-200106190-00012	http://dx.doi.org/10.7326/0003-4819-134-12-200106190-00012			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	442YU	11412052				2022-12-28	WOS:000169313200005
J	Martinek, S; Inonog, S; Manoukian, AS; Young, MW				Martinek, S; Inonog, S; Manoukian, AS; Young, MW			A role for the segment polarity gene shaggy/GSK-3 in the Drosophila circadian clock	CELL			English	Article							GLYCOGEN-SYNTHASE KINASE-3-BETA; KINASE-I-EPSILON; BEHAVIORAL RHYTHMS; PERIOD GENE; TEMPORAL EXPRESSION; WINGLESS SIGNAL; NERVOUS-SYSTEM; DOUBLE-TIME; PROTEIN; LIGHT	Tissue-specific overexpression of the glycogen synthase kinase-3 (GSK-3) ortholog shaggy (sgg) shortens the period of the Drosophila circadian locomotor activity cycle. The short period phenotype was attributed to premature nuclear translocation of the PERIOD/TIMELESS heterodimer. Reducing SGG/GSK-3 activity lengthens period, demonstrating an intrinsic role for the kinase in circadian rhythmicity. Lowered sgg activity decreased TIMELESS phosphorylation, and it was found that GSK-3 beta specifically phosphorylates TIMELESS in vitro. Overexpression of sgg in vivo converts hypophosphorylated TIMELESS to a hyperphosphorylated protein whose electrophoretic mobility, and light and phosphatase sensitivity, are indistinguishable from the rhythmically produced hyperphosphorylated TIMELESS of wild-type flies. Our results indicate a role for SGG/GSK-3 in TIMELESS phosphorylation and in the regulated nuclear translocation of the PERIOD/TIMELESS heterodimer.	Rockefeller Univ, Genet Lab, New York, NY 10021 USA; Rockefeller Univ, Natl Sci Fdn, Sci & Technol Ctr Biol Timing, New York, NY 10021 USA; Ontario Canc Inst, Div Cell & Mol Biol, Toronto, ON M5G 2M9, Canada	Rockefeller University; National Science Foundation (NSF); NSF - Center for Biological Timing; Rockefeller University; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Young, MW (corresponding author), Rockefeller Univ, Genet Lab, New York, NY 10021 USA.		, 机智的马小跳和机智的羊不愁/ABC-5169-2020		NIGMS NIH HHS [GM 54339] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM054339, R01GM054339] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASCHOFF J, 1965, CIRCADIAN CLOCKS, P94; BAYLIES MK, 1987, NATURE, V326, P390, DOI 10.1038/326390a0; Blau J, 1999, CELL, V99, P661, DOI 10.1016/S0092-8674(00)81554-8; BOUROUIS M, 1990, EMBO J, V9, P2877, DOI 10.1002/j.1460-2075.1990.tb07477.x; Ceriani MF, 1999, SCIENCE, V285, P553, DOI 10.1126/science.285.5427.553; Cermakian N, 2000, NAT REV MOL CELL BIO, V1, P59, DOI 10.1038/35036078; Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; Edery I, 2000, PHYSIOL GENOMICS, V3, P59, DOI 10.1152/physiolgenomics.2000.3.2.59; Emery P, 2000, NEURON, V26, P493, DOI 10.1016/S0896-6273(00)81181-2; Emery P, 2000, NATURE, V404, P456, DOI 10.1038/35006558; Emery P, 1998, CELL, V95, P669, DOI 10.1016/S0092-8674(00)81637-2; EWER J, 1992, J NEUROSCI, V12, P3321; FRISCH B, 1994, NEURON, V12, P555, DOI 10.1016/0896-6273(94)90212-7; Giebultowicz JM, 2000, ANNU REV ENTOMOL, V45, P769, DOI 10.1146/annurev.ento.45.1.769; Hall JC, 2000, CURR OPIN NEUROBIOL, V10, P456, DOI 10.1016/S0959-4388(00)00117-3; Hardin PE, 1999, SCIENCE, V286, P2460, DOI 10.1126/science.286.5449.2460; Helfrich-Forster C, 2000, J NEUROSCI, V20, P3339, DOI 10.1523/JNEUROSCI.20-09-03339.2000; HunterEnsor M, 1996, CELL, V84, P677, DOI 10.1016/S0092-8674(00)81046-6; Kaneko M, 1997, J NEUROSCI, V17, P6745; King DP, 2000, ANNU REV NEUROSCI, V23, P713, DOI 10.1146/annurev.neuro.23.1.713; Kloss B, 1998, CELL, V94, P97, DOI 10.1016/S0092-8674(00)81225-8; KLOSS B, 2001, IN PRESS NEURON; KONOPKA RJ, 1971, P NATL ACAD SCI USA, V68, P2112, DOI 10.1073/pnas.68.9.2112; KONOPKA RJ, 1989, J NEUROGENET, V6, P1, DOI 10.3109/01677068909107096; Li C, 1999, MOL CELL, V3, P77, DOI 10.1016/S1097-2765(00)80176-8; LIU X, 1988, GENE DEV, V2, P228, DOI 10.1101/gad.2.2.228; McNeil GP, 1998, NEURON, V20, P297, DOI 10.1016/S0896-6273(00)80457-2; Myers MP, 1996, SCIENCE, V271, P1736, DOI 10.1126/science.271.5256.1736; Naidoo N, 1999, SCIENCE, V285, P1737, DOI 10.1126/science.285.5434.1737; NEWBY LM, 1993, GENETICS, V135, P1077; Park JH, 2000, P NATL ACAD SCI USA, V97, P3608, DOI 10.1073/pnas.070036197; PEIFER M, 1994, DEVELOPMENT, V120, P369; PEIFER M, 1994, DEV BIOL, V166, P543, DOI 10.1006/dbio.1994.1336; Peters JM, 1999, NATURE, V401, P345, DOI 10.1038/43830; Price JL, 1998, CELL, V94, P83, DOI 10.1016/S0092-8674(00)81224-6; Renn SCP, 1999, CELL, V99, P791, DOI 10.1016/S0092-8674(00)81676-1; Reppert SM, 2000, J BIOL RHYTHM, V15, P357, DOI 10.1177/074873000129001459; Rorth P, 1996, P NATL ACAD SCI USA, V93, P12418, DOI 10.1073/pnas.93.22.12418; Rothenfluh A, 2000, GENETICS, V156, P665; Rothenfluh A, 2000, NEURON, V26, P505, DOI 10.1016/S0896-6273(00)81182-4; RUEL L, 1993, NATURE, V362, P557, DOI 10.1038/362557a0; RUEL L, 1993, EMBO J, V12, P1657, DOI 10.1002/j.1460-2075.1993.tb05811.x; Saez L, 1996, NEURON, V17, P911, DOI 10.1016/S0896-6273(00)80222-6; Sakanaka C, 1999, P NATL ACAD SCI USA, V96, P12548, DOI 10.1073/pnas.96.22.12548; Scully AL, 2000, CELL, V100, P297, DOI 10.1016/S0092-8674(00)80665-0; SEHGAL A, 1992, P NATL ACAD SCI USA, V89, P1423, DOI 10.1073/pnas.89.4.1423; SEHGAL A, 1995, SCIENCE, V270, P808, DOI 10.1126/science.270.5237.808; SEHGAL A, 1994, SCIENCE, V263, P1603, DOI 10.1126/science.8128246; SIEGFRIED E, 1992, CELL, V71, P1167, DOI 10.1016/S0092-8674(05)80065-0; SIEGFRIED E, 1990, NATURE, V345, P825, DOI 10.1038/345825a0; SIEGFRIED E, 1994, NATURE, V367, P76, DOI 10.1038/367076a0; STAMBOLIC V, 1994, BIOCHEM J, V303, P701, DOI 10.1042/bj3030701; Stanewsky R, 1997, J NEUROSCI, V17, P676; Suri V, 2000, J NEUROSCI, V20, P7547; SUTHERLAND C, 1993, BIOCHEM J, V296, P15, DOI 10.1042/bj2960015; VOSSHALL LB, 1994, SCIENCE, V263, P1606, DOI 10.1126/science.8128247; Wager-Smith K, 2000, NAT GENET, V26, P23, DOI 10.1038/79134; Young MW, 2000, TRENDS BIOCHEM SCI, V25, P601, DOI 10.1016/S0968-0004(00)01695-9; Young MW, 1998, ANNU REV BIOCHEM, V67, P135, DOI 10.1146/annurev.biochem.67.1.135; Zeng HK, 1996, NATURE, V380, P129, DOI 10.1038/380129a0; ZENG HK, 1994, EMBO J, V13, P3590, DOI 10.1002/j.1460-2075.1994.tb06666.x	61	433	445	0	28	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTES AVE,, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 15	2001	105	6					769	779		10.1016/S0092-8674(01)00383-X	http://dx.doi.org/10.1016/S0092-8674(01)00383-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	444AE	11440719	Bronze			2022-12-28	WOS:000169375100010
J	Fischereder, M; Luckow, B; Hocher, B; Wuthrich, RP; Rothenpieler, U; Schneeberger, H; Panzer, U; Stahl, RAK; Hauser, IA; Budde, K; Neumayer, HH; Kramer, BK; Land, W; Schlondorff, D				Fischereder, M; Luckow, B; Hocher, B; Wuthrich, RP; Rothenpieler, U; Schneeberger, H; Panzer, U; Stahl, RAK; Hauser, IA; Budde, K; Neumayer, HH; Kramer, BK; Land, W; Schlondorff, D			CC chemokine receptor 5 and renal-transplant survival	LANCET			English	Article							HIV-1 INFECTION; FUNCTIONAL EXPRESSION; ALLOGRAFT-REJECTION; MOLECULAR-CLONING; DELETION ALLELE; RANTES; GENE; RESISTANCE; MIP-1-ALPHA; INDIVIDUALS	Background About 1% of white populations are homozygous carriers of an allele of the gene for the CC chemokine receptor 5 (CCR5) with a 32 bp deletion (CCR5 Delta 32), which leads to an inactive receptor. During acute and chronic transplant rejection, ligands for CCR5 are upregulated, and the graft is infiltrated by CCR5-positive mononuclear cells. We therefore investigated the influence of CCR5 Delta 32 on renal-transplant survival Methods Genomic DNA from peripheral-blood leucocytes of 1227 renal-transplant recipients was screened by PCR for the presence of CCR5 Delta 32. Demographic and clinical data were extracted from hospital records. Complete follow-up data were available for 576 recipients of first renal transplants. Graft survival was analysed by Fisher's exact test and Kaplan-Meier plots compared with a log-rank test. Findings PCR identified 21 patients homozygous for CCR5 Delta 32 (frequency 1.7%). One patient died with a functioning graft. Only one of the remaining patients lost transplant function during follow-up (median 7.2 years) compared with 78 of the 555 patients with a homozygous wild-type or heterozygous CCR5 Delta 32 genotype. Graft survival was significantly longer in the homozygous CCR5 Delta 32 group than in the control group (log-rank p=0.033; hazard ratio 0.367 [95% CI 0.157-0.859]). Interpretation Patients homozygous for CCR5 Delta 32; show longer survival of renal transplants than those with: other genotypes, suggesting a pathophysiological role for CCR5 in transplant Loss. This receptor may be a useful target for the prevention of transplant loss.	Univ Munchen Klinikum, Med Poliklin, D-80336 Munich, Germany; Humboldt Univ, Univ Klinikum, Charite, Berlin, Germany; Univ Spital Zurich, Zurich, Switzerland; Univ Munich, Klinikum Grosshadern, Abt Transplantat Chirurg, D-8000 Munich, Germany; Univ Hamburg, Med Klin & Poliklin, Abt Nephrol Osteol, Hamburg, Germany; Univ Regensburg Klinikum, Klin & Poliklin Innere Med 2, Regensburg, Germany; Univ Erlangen Nurnberg, Med Klin 4, Erlangen, Germany; Univ Frankfurt Klin, Med Klin 4, Funkt Bereich Nephrol, Frankfurt, Germany	University of Munich; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Zurich; University Zurich Hospital; University of Munich; University of Hamburg; University of Regensburg; University of Erlangen Nuremberg; Goethe University Frankfurt; Goethe University Frankfurt Hospital	Schlondorff, D (corresponding author), Univ Munchen Klinikum, Med Poliklin, Pettenkoferstr 8A, D-80336 Munich, Germany.		Budde, Klemens/AAD-2170-2020; Hocher, Berthold/AAC-3510-2020	Budde, Klemens/0000-0002-7929-5942; Land, Walter Gottlieb/0000-0002-0090-0629; Hocher, Berthold/0000-0001-8143-0579				Baggiolini M, 1998, NATURE, V392, P565, DOI 10.1038/33340; Belperio JA, 2000, J IMMUNOL, V165, P461, DOI 10.4049/jimmunol.165.1.461; Biti R, 1997, NAT MED, V3, P252, DOI 10.1038/nm0397-252; Blanpain C, 1999, BLOOD, V94, P1899; Combadiere C, 1996, J LEUKOCYTE BIOL, V60, P147, DOI 10.1002/jlb.60.1.147; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; Dekel B, 1999, INT IMMUNOL, V11, P1673, DOI 10.1093/intimm/11.10.1673; Fischereder M, 1998, TRANSPLANTATION, V65, P936, DOI 10.1097/00007890-199804150-00013; Gao W, 2000, J CLIN INVEST, V105, P35, DOI 10.1172/JCI8126; Garred P, 1998, J RHEUMATOL, V25, P1462; Gong WH, 1998, J BIOL CHEM, V273, P4289, DOI 10.1074/jbc.273.8.4289; Grone HJ, 1999, FASEB J, V13, P1371, DOI 10.1096/fasebj.13.11.1371; Hall IP, 1999, LANCET, V354, P1264, DOI 10.1016/S0140-6736(99)03425-X; Heidenreich S, 1998, J AM SOC NEPHROL, V9, P1309; Libert F, 1998, HUM MOL GENET, V7, P399, DOI 10.1093/hmg/7.3.399; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; Martinson JJ, 1997, NAT GENET, V16, P100, DOI 10.1038/ng0597-100; Murphy PM, 2000, PHARMACOL REV, V52, P145; NADEAU KC, 1995, P NATL ACAD SCI USA, V92, P8729, DOI 10.1073/pnas.92.19.8729; PATTISON J, 1994, LANCET, V343, P209, DOI 10.1016/S0140-6736(94)90992-X; Raport CJ, 1996, J BIOL CHEM, V271, P17161, DOI 10.1074/jbc.271.29.17161; Risch NJ, 2000, NATURE, V405, P847, DOI 10.1038/35015718; Robertson H, 1998, HISTOCHEM CELL BIOL, V110, P207, DOI 10.1007/s004180050283; Rossi D, 2000, ANNU REV IMMUNOL, V18, P217, DOI 10.1146/annurev.immunol.18.1.217; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; Samson M, 1996, BIOCHEMISTRY-US, V35, P3362, DOI 10.1021/bi952950g; Segerer S, 1999, KIDNEY INT, V56, P52, DOI 10.1046/j.1523-1755.1999.00544.x; Sellebjerg F, 2000, J NEUROIMMUNOL, V102, P98, DOI 10.1016/S0165-5728(99)00166-6; Stephens JC, 1998, AM J HUM GENET, V62, P1507, DOI 10.1086/301867	29	250	268	0	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 2	2001	357	9270					1758	1761		10.1016/S0140-6736(00)04898-4	http://dx.doi.org/10.1016/S0140-6736(00)04898-4			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	440BN	11403814				2022-12-28	WOS:000169156200015
J	Nduati, R; Richardson, BA; John, G; Mbori-Ngacha, D; Mwatha, A; Ndinya-Achola, J; Bwayo, J; Onyango, FE; Kreiss, J				Nduati, R; Richardson, BA; John, G; Mbori-Ngacha, D; Mwatha, A; Ndinya-Achola, J; Bwayo, J; Onyango, FE; Kreiss, J			Effect of breastfeeding on mortality among HIV-1 infected women: a randomised trial	LANCET			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; TO-CHILD TRANSMISSION; ENERGY-EXPENDITURE; ORAL ZIDOVUDINE; COTE-DIVOIRE; PREVENTION; LACTATION; COST	Background We have completed a randomised clinical trial of breastfeeding and formula feeding to identify the frequency of breastmilk transmission of HIV-1 to infants. However, we also analysed data from this trial to examine the effect of breastfeeding on maternal death rates during 2 years after delivery. We report our findings from this secondary analysis. Methods Pregnant women attending four Nairobi city council clinics were offered HIV tests. At about 32 weeks' gestation, 425 HIV-1 seropositive women were randomly allocated to either breastfeed or formula feed their infants. After delivery, mother-infant pairs were followed up monthly during the first year and quarterly during the second year until death, or 2 years after delivery, or end of study. Findings Mortality among mothers was higher in the breastfeeding group than in the formula group (18 vs 6 deaths, log rank test, p=0.009). The cumulative probability of maternal death at 24 months after delivery was 10.5% in the breastfeeding group and 3.8% in the formula group (p=0.02). The relative risk of death for breastfeeding mothers versus formula feeding mothers was 3.2 (95% CI 1.3-8.1, p=0.01). The attributable risk of maternal death due to breastfeeding was 69%. There was an association between maternal death and subsequent infant death, even after infant HIV-1 infection status was controlled for (relative risk 7.9, 95% CI 3.3-18.6, p<0.001). Interpretation Our findings suggest that breastfeeding by HIV-1 infected women might result in adverse outcomes for both mother and infant.	Univ Nairobi, Dept Paediat, Nairobi, Kenya; Univ Nairobi, Dept Med Microbiol, Nairobi, Kenya; Univ Washington, Dept Biostat, Seattle, WA 98195 USA; Univ Washington, Dept Med, Seattle, WA 98195 USA; Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA	University of Nairobi; University of Nairobi; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Nduati, R (corresponding author), Univ Nairobi, Dept Paediat, POB 19676, Nairobi, Kenya.		John-Stewart, Grace/L-3650-2019; John-Stewart, Grace/U-3351-2019		FIC NIH HHS [D43-TW00007, D43 TW000007-13, D43 TW000007, T22 TW000001, T22-TW00001] Funding Source: Medline; NIAID NIH HHS [P30 AI027757-12, P30 AI027757] Funding Source: Medline; NICHD NIH HHS [R01 HD023412, HD-23412, R01 HD023412-15] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R01HD023412] Funding Source: NIH RePORTER; FOGARTY INTERNATIONAL CENTER [T22TW000001, D43TW000007] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P30AI027757] Funding Source: NIH RePORTER	FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); FOGARTY INTERNATIONAL CENTER(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADAIR LS, 1992, J NUTR, V122, P1643, DOI 10.1093/jn/122.8.1643; Centers for Disease Control, 1985, MMWR-MORBID MORTAL W, V34; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; Dabis F, 1999, LANCET, V353, P786, DOI 10.1016/S0140-6736(98)11046-2; FRIEDMAN LM, 1998, FUNDAMENTALS CLIN TR, P284; Garcia PM, 1999, NEW ENGL J MED, V341, P394, DOI 10.1056/NEJM199908053410602; Guay LA, 1999, LANCET, V354, P795, DOI 10.1016/S0140-6736(99)80008-7; *JOINT UN PROGR HI, 1996, WKLY EPIDEMIOL REC, V71, P289; LAMBERT G, 1997, J PEDIATR, V130, P830; LINDAN CP, 1992, ANN INTERN MED, V116, P320, DOI 10.7326/0003-4819-116-4-320; McDermott JM, 1996, AM J TROP MED HYG, V55, P66, DOI 10.4269/ajtmh.1996.55.66; MELCHIOR JC, 1993, AM J CLIN NUTR, V57, P614, DOI 10.1093/ajcn/57.5.614; Mulligan K, 1997, NEW ENGL J MED, V336, P70, DOI 10.1056/NEJM199701023360115; Nduati R, 2000, JAMA-J AM MED ASSOC, V283, P1167, DOI 10.1001/jama.283.9.1167; Neilson JR, 1999, J VIROL, V73, P4393, DOI 10.1128/JVI.73.5.4393-4403.1999; REBER PM, 1993, AM J MED, V95, P637, DOI 10.1016/0002-9343(93)90360-2; Semba RD, 1999, J INFECT DIS, V180, P93, DOI 10.1086/314854; Shaffer N, 1999, LANCET, V353, P773, DOI 10.1016/S0140-6736(98)10411-7; Taha TET, 1996, AIDS, V10, P111, DOI 10.1097/00002030-199601000-00021; VANRAAIJ JMA, 1990, AM J CLIN NUTR, V52, P234, DOI 10.1093/ajcn/52.2.234; VANRAAIJ JMA, 1991, AM J CLIN NUTR, V53, P612, DOI 10.1093/ajcn/53.3.612; Wiktor SZ, 1999, LANCET, V353, P781, DOI 10.1016/S0140-6736(98)10412-9	22	130	132	0	7	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 26	2001	357	9269					1651	1655		10.1016/S0140-6736(00)04820-0	http://dx.doi.org/10.1016/S0140-6736(00)04820-0			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	435UY	11425369	Green Accepted			2022-12-28	WOS:000168901600010
J	Warner, P; Critchley, HOD; Lumsden, MA; Campbell-Brown, M; Douglas, A; Murray, G				Warner, P; Critchley, HOD; Lumsden, MA; Campbell-Brown, M; Douglas, A; Murray, G			Referral for menstrual problems: cross sectional survey of symptoms, reasons for referral, and management	BRITISH MEDICAL JOURNAL			English	Article							GENERAL-PRACTICE; BLOOD-LOSS; MENORRHAGIA; WOMEN	Objectives to describe the menstrual experience of women referred for menstrual problems, in particular menorrhagia (excessive menstrual loss), and to assess associations with reasons for referral given by; their general practitioners, the women's understanding of the reasons for their attendance at the hospital-clinics, and clinic outcome. Design Questionnaire survey, with partial review of case notes after 8 months. Setting Three hospital gynaecology clinics in Glasgow. and Edinburgh. Participants 952 women completed the questionnaire, and the first 665 were reviewed. Outcome measures Reason for referral, women's reported menstrual problems and reason for clinic attendance, diagnosis, and treatment. Results Only 38% (95% confidence interval 34% to 41%) of women reported excessive menstrual loss as a severe problem. However 60% (57-63%) gave it;as reason for attending a clinic, and 76% (73-79%) of general practitioners gave it as reason for referral. Reason for referral was significantly biased towards bleeding (McNemar odds ratio 4.01, 3.0 to 5.3, P<0.001), and against pain (0.54, 0.4 to 0.7, P<0.001). Dysfunctional uterine bleeding was diagnosed in 37% (31-42%) of the 259 women who gave as reason for attendance something other than bleeding . Women who were economically disadvantaged differed in prevalence of the main diagnoses and were more likely to fail to reattend. Hysterectomy was associated with referral for bleeding (relative risk 4.9, 1.6 to 15.6, P < 0.001) but not with the patient stating bleeding as the reason for clinic attendance. Conclusions Intolerance of the volume of their bleeding is not a key feature among women attending clinics for bleeding problems. Broad menstrual complaint tends to be reframed as excessive bleeding at referral and during management This may result in women receiving inappropriate care. Conceptualisation and assessment of menorrhagia requires reconsideration.	Univ Edinburgh, Sch Med, Dept Community Hlth Sci, Edinburgh EH8 9AG, Midlothian, Scotland; Univ Edinburgh, Ctr Reprod Biol, Edinburgh EH3 9ET, Midlothian, Scotland; Univ Glasgow, Queen Mothers Hosp, Dept Obstet & Gynaecol, Glasgow G3 8SJ, Lanark, Scotland; Univ Glasgow, Royal Infirm, Dept Obstet & Gynaecol, Glasgow G3 2ER, Lanark, Scotland	University of Edinburgh; University of Edinburgh; University of Glasgow; Royal Infirmary of Edinburgh; University of Glasgow	Warner, P (corresponding author), Univ Edinburgh, Sch Med, Dept Community Hlth Sci, Edinburgh EH8 9AG, Midlothian, Scotland.			CRITCHLEY, HILARY/0000-0003-1913-4044; Murray, Gordon/0000-0001-9866-4734				Barry CA, 2000, BRIT MED J, V320, P1246, DOI 10.1136/bmj.320.7244.1246; Bonnar J, 1996, BRIT MED J, V313, P579; BRADLOW J, 1992, PATTERNS REFERRAL; Carstairs V., 1991, DEPRIVATION HLTH SCO; COULTER A, 1988, SOC SCI MED, V27, P987, DOI 10.1016/0277-9536(88)90289-4; COULTER A, 1991, BRIT J OBSTET GYNAEC, V98, P789, DOI 10.1111/j.1471-0528.1991.tb13484.x; FRASER IS, 1984, AM J OBSTET GYNECOL, V149, P788, DOI 10.1016/0002-9378(84)90123-6; FRASER IS, 1994, BRIT J OBSTET GYNAEC, V101, P3, DOI 10.1111/j.1471-0528.1994.tb13688.x; Gannon MJ, 1996, BRIT J OBSTET GYNAEC, V103, P1029, DOI 10.1111/j.1471-0528.1996.tb09556.x; Grant C, 2000, J EPIDEMIOL COMMUN H, V54, P709, DOI 10.1136/jech.54.9.709; HUTCHINSON A, 1993, BRIT MED J, V307, P1439, DOI 10.1136/bmj.307.6917.1439; *MORI, 1990, WOM HLTH 1990; *NHS DISS CTR, 1995, EFFECT HEALTHCARE B, V9; O'Flynn N, 2000, SOC SCI MED, V50, P651, DOI 10.1016/S0277-9536(99)00318-4; Prentice A, 1999, BRIT MED J, V319, P1343, DOI 10.1136/bmj.319.7221.1343; *ROYAL COLL GEN PR, 1990, 1981 1982 MORB STA 5; *ROYAL COLL OBST G, 1998, IN MAN MEN EV BAS CL; SCAMBLER A, 1985, SOC SCI MED, V20, P1065, DOI 10.1016/0277-9536(85)90264-3; Stirrat GM, 1999, LANCET, V353, P2175, DOI 10.1016/S0140-6736(99)00132-4; Thomas SL, 2000, LANCET, V355, P922, DOI 10.1016/S0140-6736(99)11159-0; WARNER P, 1994, J PSYCHOSOM OBST GYN, V15, P93, DOI 10.3109/01674829409025634	21	55	56	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUL 7	2001	323	7303					24	28		10.1136/bmj.323.7303.24	http://dx.doi.org/10.1136/bmj.323.7303.24			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	451WA	11440940	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000169824300021
J	Holland, PC; Hancock, SW; Hodge, D; Thompson, D; Shires, S; Evans, S				Holland, PC; Hancock, SW; Hodge, D; Thompson, D; Shires, S; Evans, S			Degradation of albumin in meningococcal sepsis	LANCET			English	Article								We postulate that the proteolytic degradation of albumin into fragments could link the rapidity of the shock, rash, and hypocalcaemia associated with meningococcal sepsis, We examined urine of children with meningococcal disease and urine from control children with no sepsis and found albumin fragments of about 45 kDa, 25 kDa, and less than 20 kDa only in the urine of children with meningococcal sepsis and associated purpura, Exogenous or endogenous proteases, or both, may be released in severe meningococcal sepsis and, in association with an inadequate antiprotease response, result In albumin degradation. This may be a contributory factor to the rapid shock, hypocalcaemia, and rash seen in meningococcal sepsis.	Gen Infirm, Dept Paediat, Leeds LS2 9NS, W Yorkshire, England; Gen Infirm, Dept Clin Biochem & Immunol, Leeds LS2 9NS, W Yorkshire, England; Univ Leeds, Mol Epidemiol Unit, Leeds, W Yorkshire, England	Leeds General Infirmary; Leeds General Infirmary; University of Leeds	Holland, PC (corresponding author), Gen Infirm, Dept Paediat, Clarendon Wing, Leeds LS2 9NS, W Yorkshire, England.							Baines PB, 2000, ARCH DIS CHILD, V83, P510, DOI 10.1136/adc.83.6.510; KLEIN NJ, 1992, J CELL SCI, V102, P821; NETTER A, 1917, BRIT J CHILD DIS, V14, P101; Peters T., 1995, ALL ALBUMIN BIOCH GE, P9, DOI [10.1016/B978-012552110-9/50004-0, DOI 10.1016/B978-012552110-9/50004-0]; SELYE H, 1962, CALCIFYLAXIS	5	16	17	0	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 30	2001	357	9274					2102	2104		10.1016/S0140-6736(00)05200-4	http://dx.doi.org/10.1016/S0140-6736(00)05200-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	447RQ	11445107				2022-12-28	WOS:000169586600017
J	Kolber, ZS; Plumley, FG; Lang, AS; Beatty, JT; Blankenship, RE; VanDover, CL; Vetriani, C; Koblizek, M; Rathgeber, C; Falkowski, PG				Kolber, ZS; Plumley, FG; Lang, AS; Beatty, JT; Blankenship, RE; VanDover, CL; Vetriani, C; Koblizek, M; Rathgeber, C; Falkowski, PG			Contribution of aerobic photoheterotrophic bacteria to the carbon cycle in the ocean	SCIENCE			English	Article							ROSEOBACTER-DENITRIFICANS; BACTERIOCHLOROPHYLL ALPHA; PROTEIN COMPLEXES; ELECTRON-TRANSFER; CYTOCHROME; WATERS	The vertical distribution of bacteriochlorophyll a, the numbers of infrared fluorescent cells, and the variable fluorescence signal at 880 nanometers wavelength, all indicate that photosynthetically competent anoxygenic phototrophic bacteria are abundant in the upper open ocean and comprise at Least 11% of the total microbial community. These organisms are facultative photoheterotrophs, metabolizing organic carbon when available, but are capable of photosynthetic Light utilization when organic carbon is scarce. They are globally distributed in the euphotic zone and represent a hitherto unrecognized component of the marine microbial community that appears to be critical to the cycling of; both organic and inorganic carbon in the ocean.	Rutgers State Univ, Inst Marine & Coastal Sci, Environm Biophys & Mol Ecol Program, New Brunswick, NJ 08901 USA; Univ Alaska, Inst Marine Sci, Fairbanks, AK 99775 USA; Univ British Columbia, Dept Microbiol & Immunol, Vancouver, BC V6T 1Z3, Canada; Arizona State Univ, Dept Chem & Biochem, Tempe, AZ 85287 USA; Coll William & Mary, Dept Biol, Williamsburg, VA 23187 USA; Univ Manitoba, Dept Microbiol, Winnipeg, MB R3T 2N2, Canada; Rutgers State Univ, Dept Geol, Piscataway, NJ 08854 USA	Rutgers State University New Brunswick; University of Alaska System; University of Alaska Fairbanks; University of British Columbia; Arizona State University; Arizona State University-Tempe; William & Mary; University of Manitoba; Rutgers State University New Brunswick	Kolber, ZS (corresponding author), Rutgers State Univ, Inst Marine & Coastal Sci, Environm Biophys & Mol Ecol Program, 71 Dudley Rd, New Brunswick, NJ 08901 USA.		Koblizek, Michal/H-2851-2014	Lang, Andrew/0000-0002-4510-7683				Cogdell R. J., 1995, ANOXYGENIC PHOTOSYNT, P315; FELSENSTEIN J, 1981, J MOL EVOL, V17, P368, DOI 10.1007/BF01734359; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; Garcia D, 1998, PHOTOSYNTH RES, V55, P331, DOI 10.1023/A:1005941031263; HARASHIMA K, 1980, PLANT CELL PHYSIOL, V21, P1283, DOI 10.1093/oxfordjournals.pcp.a076127; HICKS RE, 1992, APPL ENVIRON MICROB, V58, P158; KISHINO H, 1989, J MOL EVOL, V29, P170, DOI 10.1007/BF02100115; Kolber ZS, 2000, NATURE, V407, P177, DOI 10.1038/35025044; Kolber ZS, 1998, BBA-BIOENERGETICS, V1367, P88, DOI 10.1016/S0005-2728(98)00135-2; LARSEN N, 1993, NUCLEIC ACIDS RES, V21, P3021, DOI 10.1093/nar/21.13.3021; MOREL A, 1994, J PHYS OCEANOGR, V24, P1652, DOI 10.1175/1520-0485(1994)024<1652:HRWTUO>2.0.CO;2; NISHIMURA Y, 1989, ARCH MICROBIOL, V152, P1, DOI 10.1007/BF00447002; NOGUCHI T, 1992, PHOTOSYNTH RES, V31, P21, DOI 10.1007/BF00049533; PORTER KG, 1980, LIMNOL OCEANOGR, V25, P943, DOI 10.4319/lo.1980.25.5.0943; Schwarze C, 2000, EUR J BIOCHEM, V267, P422, DOI 10.1046/j.1432-1327.2000.01018.x; SHIBA T, 1991, APPL ENVIRON MICROB, V57, P295, DOI 10.1128/AEM.57.1.295-300.1991; SHIBA T, 1979, APPL ENVIRON MICROB, V38, P43, DOI 10.1128/AEM.38.1.43-45.1979; SHIBA T, 1984, J GEN APPL MICROBIOL, V30, P1313; Shimada K., 1995, ANOXYGENIC PHOTOSYNT, P105; TAKEMOTO J, 1977, J BACTERIOL, V129, P1102, DOI 10.1128/JB.129.2.1102-1109.1977; WEISBURG WG, 1991, J BACTERIOL, V173, P697, DOI 10.1128/JB.173.2.697-703.1991; YURKOV V, 1994, INT J SYST BACTERIOL, V44, P427, DOI 10.1099/00207713-44-3-427; Yurkov VV, 1999, J BACTERIOL, V181, P4517, DOI 10.1128/JB.181.15.4517-4525.1999; YURKOV VV, 1993, ARCH MICROBIOL, V159, P84, DOI 10.1007/BF00244268; Yurkov VV, 1998, MICROBIOL MOL BIOL R, V62, P695, DOI 10.1128/MMBR.62.3.695-724.1998	25	323	360	3	79	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 29	2001	292	5526					2492	2495		10.1126/science.1059707	http://dx.doi.org/10.1126/science.1059707			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	448YU	11431568				2022-12-28	WOS:000169658200042
J	Basnyat, B; Graham, L; Lee, SD; Lim, Y				Basnyat, B; Graham, L; Lee, SD; Lim, Y			A language barrier, abdominal pain, and double vision	LANCET			English	Editorial Material									Nepal Int Clin, Kathmandu, Nepal; Himalayan Rescue Assoc, Kathmandu, Nepal; Univ Ulsan, Asan Med Ctr, Coll Med, Dept Internal Med, Seoul, South Korea; Bhaktapur Hosp, Bhaktapur, Nepal	University of Ulsan; Asan Medical Center	Basnyat, B (corresponding author), Nepal Int Clin, GPO Box 3596, Kathmandu, Nepal.	rishibas@wlink.com.np						Basnyat B, 2000, High Alt Med Biol, V1, P167; Bendz B, 2000, LANCET, V356, P1657, DOI 10.1016/S0140-6736(00)03165-2; Boulos P, 1999, ACTA HAEMATOL-BASEL, V102, P104, DOI 10.1159/000040980; SANTORO SA, 1994, BLOOD, V83, P2389	4	13	13	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 23	2001	357	9273					2022	2022		10.1016/S0140-6736(00)05116-3	http://dx.doi.org/10.1016/S0140-6736(00)05116-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	446JB	11438136				2022-12-28	WOS:000169509200013
J	O'Brien, SJ; Eizirik, E; Murphy, WJ				O'Brien, SJ; Eizirik, E; Murphy, WJ			Genomics - On choosing mammalian genomes for sequencing	SCIENCE			English	Editorial Material							PLACENTAL MAMMALS; PROJECT		NCI, Lab Genom Divers, Frederick, MD 21702 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	O'Brien, SJ (corresponding author), NCI, Lab Genom Divers, Frederick, MD 21702 USA.	obrien@ncifcrf.gov	Eizirik, Eduardo/K-8034-2012; OBRIEN, STEPHEN/ABD-1346-2020	Eizirik, Eduardo/0000-0002-9658-0999; OBRIEN, STEPHEN/0000-0001-7857-0757				Cheung VG, 2001, NATURE, V409, P953, DOI 10.1038/35057192; Collins FS, 1998, SCIENCE, V282, P682, DOI 10.1126/science.282.5389.682; Eizirik E, 2001, J HERED, V92, P212, DOI 10.1093/jhered/92.2.212; Gibbons A, 2000, SCIENCE, V289, P1267; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Li W. H, 1997, MOL EVOLUTION; Madsen O, 2001, NATURE, V409, P610, DOI 10.1038/35054544; MAY RM, 1990, NATURE, V347, P129, DOI 10.1038/347129a0; McConkey EH, 2000, SCIENCE, V289, P1295; Murphy WJ, 2001, NATURE, V409, P614, DOI 10.1038/35054550; MURPHY WJ, IN PRESS GENOME BIOL; Nadeau JH, 2001, SCIENCE, V291, P1251, DOI 10.1126/science.1058244; O'Brien SJ, 1999, SCIENCE, V286, P458, DOI 10.1126/science.286.5439.458; Paabo S, 2001, SCIENCE, V291, P1219, DOI 10.1126/science.1056972; Pennisi E, 2000, SCIENCE, V287, P1179, DOI 10.1126/science.287.5456.1179; Pennisi E, 2001, SCIENCE, V291, P1204, DOI 10.1126/science.291.5507.1204; Rettie JC, 1951, CORONET, V29, P21; Rubin GM, 2001, NATURE, V409, P820, DOI 10.1038/35057277; Strausberg RL, 1999, SCIENCE, V286, P455, DOI 10.1126/science.286.5439.455; VandeBerg JL, 2000, SCIENCE, V290, P1504, DOI 10.1126/science.290.5496.1504; VANEWRIGHT RI, 1991, BIOL CONSERV, V55, P235, DOI 10.1016/0006-3207(91)90030-D; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040	22	46	49	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 22	2001	292	5525					2264	2266		10.1126/science.1059393	http://dx.doi.org/10.1126/science.1059393			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	445KD	11423643				2022-12-28	WOS:000169455900037
J	Vance, V; Vaucheret, H				Vance, V; Vaucheret, H			RNA silencing in plants - Defense and counterdefense	SCIENCE			English	Review							DOUBLE-STRANDED-RNA; DNA METHYLATION; VIRUS-RESISTANCE; C-ELEGANS; NICOTIANA-BENTHAMIANA; GENE-EXPRESSION; ANTISENSE RNA; INTERFERENCE; TRANSGENE; ARABIDOPSIS	RNA silencing is a remarkable type of gene regulation based on sequence-specific targeting and degradation of RNA. The term encompasses related pathways found in a broad range of eukaryotic organisms, including fungi, plants, and animals. In plants, it serves as an antiviral defense, and many plant viruses encode suppressors of silencing. The emerging view is that RNA silencing is part of a sophisticated network of interconnected pathways for cellular defense, RNA surveillance, and development and that it may become a powerful tool to manipulate gene expression experimentally.	Univ S Carolina, Dept Biol Sci, Columbia, SC 29208 USA; INRA, Biol Cellulaire Lab, F-78026 Versailles, France	University of South Carolina; University of South Carolina System; University of South Carolina Columbia; INRAE; UDICE-French Research Universities; Universite Paris Saclay	Vance, V (corresponding author), Univ S Carolina, Dept Biol Sci, Columbia, SC 29208 USA.			VAUCHERET, HERVE/0000-0002-9986-0988				Anandalakshmi R, 2000, SCIENCE, V290, P142, DOI 10.1126/science.290.5489.142; Anandalakshmi R, 1998, P NATL ACAD SCI USA, V95, P13079, DOI 10.1073/pnas.95.22.13079; Bass BL, 2000, CELL, V101, P235, DOI 10.1016/S0092-8674(02)71133-1; Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110; Bosher JM, 2000, NAT CELL BIOL, V2, pE31, DOI 10.1038/35000102; Brigneti G, 1998, EMBO J, V17, P6739, DOI 10.1093/emboj/17.22.6739; Caplen NJ, 2000, GENE, V252, P95, DOI 10.1016/S0378-1119(00)00224-9; Catalanotto C, 2000, NATURE, V404, P245, DOI 10.1038/35005169; Cerutti L, 2000, TRENDS BIOCHEM SCI, V25, P481, DOI 10.1016/S0968-0004(00)01641-8; Cogoni C, 1999, SCIENCE, V286, P2342, DOI 10.1126/science.286.5448.2342; Cogoni C, 1999, NATURE, V399, P166, DOI 10.1038/20215; Cogoni C, 1996, EMBO J, V15, P3153, DOI 10.1002/j.1460-2075.1996.tb00678.x; Cogoni C, 2000, CURR OPIN GENET DEV, V10, P638, DOI 10.1016/S0959-437X(00)00134-9; Covey SN, 1997, NATURE, V385, P781, DOI 10.1038/385781a0; Dalmay T, 2000, CELL, V101, P543, DOI 10.1016/S0092-8674(00)80864-8; Dalmay T, 2001, EMBO J, V20, P2069, DOI 10.1093/emboj/20.8.2069; Ding SW, 2000, CURR OPIN BIOTECH, V11, P152, DOI 10.1016/S0958-1669(00)00074-4; Domeier ME, 2000, SCIENCE, V289, P1928, DOI 10.1126/science.289.5486.1928; Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301; Fagard M, 2000, P NATL ACAD SCI USA, V97, P11650, DOI 10.1073/pnas.200217597; Finnegan EJ, 1996, P NATL ACAD SCI USA, V93, P8449, DOI 10.1073/pnas.93.16.8449; Hamilton AJ, 1999, SCIENCE, V286, P950, DOI 10.1126/science.286.5441.950; INGELBRECHT I, 1994, P NATL ACAD SCI USA, V91, P10502, DOI 10.1073/pnas.91.22.10502; Iordanov MS, 2000, MOL CELL BIOL, V20, P617, DOI 10.1128/MCB.20.2.617-627.2000; Jacobsen SE, 1999, DEVELOPMENT, V126, P5231; Jeddeloh JA, 1999, NAT GENET, V22, P94, DOI 10.1038/8803; JI LH, IN PRESS MOL PLANT M; Ketting RF, 1999, CELL, V99, P133, DOI 10.1016/S0092-8674(00)81645-1; LINDBO JA, 1993, PLANT CELL, V5, P1749, DOI 10.1105/tpc.5.12.1749; Llave C, 2000, P NATL ACAD SCI USA, V97, P13401, DOI 10.1073/pnas.230334397; Mallory AC, 2001, PLANT CELL, V13, P571, DOI 10.1105/tpc.13.3.571; Mette MF, 2000, EMBO J, V19, P5194, DOI 10.1093/emboj/19.19.5194; Metzlaff M, 1997, CELL, V88, P845, DOI 10.1016/S0092-8674(00)81930-3; Morel JB, 2000, CURR BIOL, V10, P1591, DOI 10.1016/S0960-9822(00)00862-9; Mourrain P, 2000, CELL, V101, P533, DOI 10.1016/S0092-8674(00)80863-6; Palauqui JC, 1997, EMBO J, V16, P4738, DOI 10.1093/emboj/16.15.4738; Pruss G, 1997, PLANT CELL, V9, P859, DOI 10.1105/tpc.9.6.859; Ratcliff F, 1997, SCIENCE, V276, P1558, DOI 10.1126/science.276.5318.1558; RAY A, COMMUNICATION; Ruiz MT, 1998, PLANT CELL, V10, P937, DOI 10.1105/tpc.10.6.937; Smardon A, 2000, CURR BIOL, V10, P169, DOI 10.1016/S0960-9822(00)00323-7; Smith NA, 2000, NATURE, V407, P319, DOI 10.1038/35030305; Stam M, 2000, PLANT J, V21, P27, DOI 10.1046/j.1365-313x.2000.00650.x; Steimer A, 2000, PLANT CELL, V12, P1165, DOI 10.1105/tpc.12.7.1165; Tabara H, 1999, CELL, V99, P123, DOI 10.1016/S0092-8674(00)81644-X; Timmons L, 2001, GENE, V263, P103, DOI 10.1016/S0378-1119(00)00579-5; Ui-Tei K, 2000, FEBS LETT, V479, P79, DOI 10.1016/S0014-5793(00)01883-4; VAUCHERET H, UNPUB; Voinnet O, 1999, P NATL ACAD SCI USA, V96, P14147, DOI 10.1073/pnas.96.24.14147; Voinnet O, 2000, CELL, V103, P157, DOI 10.1016/S0092-8674(00)00095-7; VOINNET O, 1997, NATURE, V389, P6651; Wang MB, 2000, PLANT MOL BIOL, V43, P67, DOI 10.1023/A:1006490331303; WASSENEGGER M, 1994, CELL, V76, P567, DOI 10.1016/0092-8674(94)90119-8; Waterhouse PM, 1998, P NATL ACAD SCI USA, V95, P13959, DOI 10.1073/pnas.95.23.13959; Williams BRG, 1999, ONCOGENE, V18, P6112, DOI 10.1038/sj.onc.1203127; Wu-Scharf D, 2000, SCIENCE, V290, P1159, DOI 10.1126/science.290.5494.1159; Xie ZX, 2001, P NATL ACAD SCI USA, V98, P6516, DOI 10.1073/pnas.111440998; Zamore PD, 2000, CELL, V101, P25, DOI 10.1016/S0092-8674(00)80620-0	58	454	515	3	53	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 22	2001	292	5525					2277	2280		10.1126/science.1061334	http://dx.doi.org/10.1126/science.1061334			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	445KD	11423650				2022-12-28	WOS:000169455900043
J	Smagdik, P				Smagdik, P			Asthma study death spurs inquiry	NATURE			English	News Item																			0	0	0	0	1	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 21	2001	411	6840					873	873		10.1038/35082200	http://dx.doi.org/10.1038/35082200			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	444EN	11418812	Bronze			2022-12-28	WOS:000169386200004
J	Picco, MF; Goodman, S; Reed, J; Bayless, TM				Picco, MF; Goodman, S; Reed, J; Bayless, TM			Methodologic pitfalls in the determination of genetic anticipation: The case of Crohn disease	ANNALS OF INTERNAL MEDICINE			English	Article							INFLAMMATORY-BOWEL-DISEASE; ONSET ANTICIPATION; AFFECTED PARENT; AGE; BIAS; PREVALENCE; DISORDER; COUNTY; COHORT	Background: The term genetic anticipation is used when genetically transmitted disease manifests at increasingly younger ages with each succeeding generation: that is, if the offspring of patients develop the disease, they will tend to do so at an earlier age than their parents. In some monogenetic disorders, genetic anticipation has a biological basis in expanded genetic triplet repeats; however, some have claimed that it occurs in polygenic disorders, such as Crohn disease, in which its mechanism cannot be explained. Objective: To show how apparent changes in age at diagnosis of Crohn disease between generations, which could suggest genetic anticipation, can be an artifact of inadequate analysis based on age at diagnosis in cohorts that have not been followed for a sufficiently long time. Design: Comparison of ages at diagnosis of Crohn disease among different birth cohorts, before and after adjustment for observation time. Setting: Meyerhoff Center for Inflammatory Bowel Disease, Johns Hopkins Hospital, Baltimore, Maryland. Patients: 928 consecutive outpatients with Crohn disease. Measurements: Trends in age at diagnosis of Crohn disease among birth cohorts were determined by calculating Pearson correlation coefficients and performing Kaplan-Meyer analysis before and after adjustment for observation time. Adjustment for observation time was performed by ensuring that the time during which all included patients were at risk for Crohn disease was equal and that all patients had developed disease by the end of the risk period. Results: Mean age at diagnosis decreased by approximately 5 years with each subsequent 10-year birth cohort on the basis of crude cross-sectional data that could suggest genetic anticipation between generations. However, after adjustment for observation time, the age at diagnosis decreased minimally, if at all, with each successive generation. Conclusions: Apparent genetic anticipation can be explained by observational biases without invoking any additional genetic influences. Claims for genetic anticipation must be based on methods that properly account for the duration of observation in all persons being studied.	Mayo Clin Jacksonville, Jacksonville, FL 32224 USA; Johns Hopkins Univ, Sch Med, Baltimore, MD 21287 USA; St Lukes Hosp, Res Inst, Bethlehem, PA 18105 USA	Mayo Clinic; Johns Hopkins University	Picco, MF (corresponding author), Mayo Clin Jacksonville, 4500 San Pablo Rd, Jacksonville, FL 32224 USA.							Ashley CT, 1995, ANNU REV GENET, V29, P703, DOI 10.1146/annurev.ge.29.120195.003415; BASSETT AS, 1994, AM J HUM GENET, V54, P864; Bayless TM, 1998, AM J GASTROENTEROL, V93, P2322, DOI 10.1111/j.1572-0241.1998.02322.x; BINDER V, 1982, GASTROENTEROLOGY, V83, P563; CHILDS B, 1986, PERSPECT BIOL MED, V29, P437; Fresko I, 1998, ANN RHEUM DIS, V57, P45, DOI 10.1136/ard.57.1.45; Frisch M, 1996, LANCET, V347, P1551, DOI 10.1016/S0140-6736(96)90703-5; Grandbastien B, 1998, GUT, V42, P170, DOI 10.1136/gut.42.2.170; Heiman GA, 1996, PSYCHIAT GENET, V6, P61, DOI 10.1097/00041444-199622000-00005; HODGE SE, 1995, PSYCHIATR GENET, V5, P43, DOI 10.1097/00041444-199521000-00007; HOLFORD TR, 1991, ANNU REV PUBL HEALTH, V12, P425, DOI 10.1146/annurev.pu.12.050191.002233; Inskip H, 1996, LANCET, V347, P1551; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KILDEBO S, 1989, SCAND J GASTROENTERO, V24, P1265, DOI 10.3109/00365528909090797; Lashner B, 2000, INFLAMM BOWEL DIS, P305; Lee JCW, 1999, GUT, V44, P808, DOI 10.1136/gut.44.6.808; Loftus EV, 1998, GASTROENTEROLOGY, V114, P1161, DOI 10.1016/S0016-5085(98)70421-4; Marx G, 1999, CURR OPIN GASTROEN, V15, P322, DOI 10.1097/00001574-199907000-00008; McDermott E, 1996, ANN RHEUM DIS, V55, P475, DOI 10.1136/ard.55.7.475; MCINNIS MG, 1993, AM J HUM GENET, V53, P385; Munkholm P, 1997, DAN MED BULL, V44, P287; PETO R, 1977, BRIT J CANCER, V35, P1, DOI 10.1038/bjc.1977.1; PODOLSKY DK, 1991, NEW ENGL J MED, V325, P928, DOI 10.1056/NEJM199109263251306; Polito JMII, 1996, LANCET, V347, P798, DOI 10.1016/S0140-6736(96)90870-3; Post S, 1996, ANN SURG, V223, P253, DOI 10.1097/00000658-199603000-00005; Rabinowitz D, 1999, BIOMETRICS, V55, P834, DOI 10.1111/j.0006-341X.1999.00834.x; ROSE JDR, 1988, GUT, V29, P346, DOI 10.1136/gut.29.3.346; Rosner B., 2011, FUNDAMENTALS BIOSTAT, V7th; Satsangi J, 1996, GUT, V38, P738, DOI 10.1136/gut.38.5.738; Tsai YY, 1997, GENET EPIDEMIOL, V14, P435, DOI 10.1002/(SICI)1098-2272(1997)14:4<435::AID-GEPI8>3.0.CO;2-1; YANG H, 1993, GUT, V34, P517, DOI 10.1136/gut.34.4.517	31	42	42	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 19	2001	134	12					1124	1129		10.7326/0003-4819-134-12-200106190-00013	http://dx.doi.org/10.7326/0003-4819-134-12-200106190-00013			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	442YU	11412053				2022-12-28	WOS:000169313200006
J	Lewis, S; Clarke, M				Lewis, S; Clarke, M			Forest plots: trying to see the wood and the trees	BMJ-BRITISH MEDICAL JOURNAL			English	Article							BETA		Univ Edinburgh, Western Gen Hosp, Dept Clin Neurosci, Neurosci Trials Unit, Edinburgh EH4 2XU, Midlothian, Scotland; UK Cochrane Ctr, NHS Res & Dev Programme, Oxford OX2 7LG, England	University of Edinburgh; Cochrane Centre	Lewis, S (corresponding author), Univ Edinburgh, Western Gen Hosp, Dept Clin Neurosci, Neurosci Trials Unit, Edinburgh EH4 2XU, Midlothian, Scotland.	steff.lewis@ed.ac.uk		Lewis, Steff/0000-0003-1210-2314				[Anonymous], 1988, BRIT MED J, V296, P320; BIJNENS L, 1996, P 4 COCHR C AD AUSTR; *COCHR COLL, 2001, COCHR LIB; DEMETS DL, 1987, STAT MED, V6, P341, DOI 10.1002/sim.4780060325; FREIMAN JA, 1978, NEW ENGL J MED, V299, P690, DOI 10.1056/NEJM197809282991304; GALBRAITH RF, 1988, STAT MED, V7, P889, DOI 10.1002/sim.4780070807; Lewis JA., 1982, PRIM CARDIOL, V1, P31; MCGILL R, 1978, AM STAT, V32, P12, DOI 10.2307/2683468; Sindhu F, 1996, J ADV NURS, V24, P1152, DOI 10.1111/j.1365-2648.1996.tb01020.x; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7	10	452	456	0	13	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 16	2001	322	7300					1479	1480		10.1136/bmj.322.7300.1479	http://dx.doi.org/10.1136/bmj.322.7300.1479			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	444FJ	11408310	Green Submitted, Green Published			2022-12-28	WOS:000169389200036
J	Wilkin, D; Gillam, S; Smith, K				Wilkin, D; Gillam, S; Smith, K			Primary care groups - Tackling organisational change in the new NHS	BRITISH MEDICAL JOURNAL			English	Article									Univ Manchester, Natl Primary Care Res & Dev Ctr, Manchester M13 9PL, Lancs, England; Kings Fund, Primary Care Programme, London W1M 0AN, England	University of Manchester	Wilkin, D (corresponding author), Univ Manchester, Natl Primary Care Res & Dev Ctr, Manchester M13 9PL, Lancs, England.							*AUD COMM, 1996, WHAT DOCT ORD STUD G; Audit commission, 2000, PCG AG EARL PROGR PR; Bojke C, 2001, BRIT MED J, V322, P599, DOI 10.1136/bmj.322.7286.599; *DEP HLTH, 1998, PRIM CAR GROUPS DEL; GODDARD M, 1997, MERGERSNHS MADE HEAV; Groves T, 1999, BMJ-BRIT MED J, V318, P747, DOI 10.1136/bmj.318.7186.747; HARRISON A, 2000, NHS FACING FUTURE; Hunter M, 2001, BRIT MED J, V322, P696, DOI 10.1136/bmj.322.7288.696; Le Grand J, 1998, LEARNING NHS INTERNA; Majeed A, 1999, BRIT MED J, V318, P772, DOI 10.1136/bmj.318.7186.772; MAYS N, 1998, TOTAL PURCHASING STE; PLACE M, 1999, ROLES FUNCTIONS COST; *SCR STAT HLTH, 2000, CM4818I; *SECR STAT HLTH, 1997, CM3807; Smith J, 2000, GETTING THEIR STRIDE; Smith R, 2001, BMJ-BRIT MED J, V322, P1073, DOI 10.1136/bmj.322.7294.1073; Weil T P, 2000, Health Serv Manage Res, V13, P137; WILKIN D, 2000, NATL TRACHER SURVEY; WILKIN D, IN PRESS NATL TRACKE; Wise J, 2001, BRIT MED J, V322, P1083, DOI 10.1136/bmj.322.7294.1083	20	15	15	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 16	2001	322	7300					1464	1467		10.1136/bmj.322.7300.1464	http://dx.doi.org/10.1136/bmj.322.7300.1464			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	444FJ	11408304	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000169389200031
J	Ribo, JM; Crusats, J; Sagues, F; Claret, J; Rubires, R				Ribo, JM; Crusats, J; Sagues, F; Claret, J; Rubires, R			Chiral sign induction by vortices during the formation of mesophases in stirred solutions	SCIENCE			English	Article							ABSOLUTE ASYMMETRIC-SYNTHESIS; RESONANCE LIGHT-SCATTERING; SYMMETRY-BREAKING; PORPHYRIN; WATER	Achiral diprotonated porphyrins, forming homoassociates in aqueous solution, lead to spontaneous chiral symmetry breaking. The unexpected result is that the chirality sign of these homoassociates can be selected by vortex motion during the aggregation process. This result is confirmed by means of circular dichroism spectra. These experimental findings are rationalized in terms of the asymmetric influence of macroscopic forces on bifurcation scenarios and by considering the specific binding characteristics of the porphyrin units to form the homoassociates.	Univ Barcelona, Dept Organ Chem, E-08028 Barcelona, Catalonia, Spain; Univ Barcelona, Dept Phys Chem, E-08028 Barcelona, Catalonia, Spain	University of Barcelona; University of Barcelona	Ribo, JM (corresponding author), Univ Barcelona, Dept Organ Chem, Marti & Franques 1, E-08028 Barcelona, Catalonia, Spain.	jmr@qo.ub.es	Crusats, Joaquim/K-7367-2017; Ribó, Josep M./K-2052-2017; Sagues, Francesc/K-6414-2015	Ribó, Josep M./0000-0001-6258-1726; Sagues, Francesc/0000-0002-2956-5676; Crusats, Joaquim/0000-0003-3511-4676				Avalos M, 1998, CHEM REV, V98, P2391, DOI 10.1021/cr970096o; Avetisov V, 1996, P NATL ACAD SCI USA, V93, P11435, DOI 10.1073/pnas.93.21.11435; BARRON LD, 1986, CHEM SOC REV, V15, P189, DOI 10.1039/cs9861500189; Berlepsch H., 2000, J PHYS CHEM B, V104, P5255, DOI DOI 10.1021/JP000220Z; Bersuker G, 1999, J CHEM PHYS, V110, P10907, DOI 10.1063/1.479003; BUSTAMANTE C, 1983, P NATL ACAD SCI-BIOL, V80, P3568, DOI 10.1073/pnas.80.12.3568; Collings PJ, 1999, J PHYS CHEM B, V103, P8474, DOI 10.1021/jp991610s; Feringa BL, 1999, ANGEW CHEM INT EDIT, V38, P3419; Girard C, 1998, ANGEW CHEM INT EDIT, V37, P2923, DOI 10.1002/(SICI)1521-3773(19981116)37:21<2922::AID-ANIE2922>3.0.CO;2-1; Harada N., 1983, CIRCULAR DICHROISM S; HELMCHEN G, 1996, HOUBENWEYL METHODS O, V5; HELMCHEN G, 1996, HOUBENWEYL METHODS O, V1; HELMCHEN G, 1996, HOUBENWEYL METHODS O, V6; HELMCHEN G, 1996, HOUBENWEYL METHODS O, V2; HELMCHEN G, 1996, HOUBENWEYL METHODS O, V10; HELMCHEN G, 1996, HOUBENWEYL METHODS O, V7; HELMCHEN G, 1996, HOUBENWEYL METHODS O, V8; HELMCHEN G, 1996, HOUBENWEYL METHODS O, V9; HELMCHEN G, 1996, HOUBENWEYL METHODS O, V4; Jacques J., 1981, ENANTIOMERS RACEMATE; Katzenelson O, 1996, CHEM-EUR J, V2, P174, DOI 10.1002/chem.19960020209; Kondepudi DK, 1999, J AM CHEM SOC, V121, P1448, DOI 10.1021/ja983418u; KONDEPUDI DK, 1984, PHYSICA A, V125, P465, DOI 10.1016/0378-4371(84)90065-7; KONDEPUDI DK, 1993, J AM CHEM SOC, V115, P10211, DOI 10.1021/ja00075a041; KONDEPUDI DK, 1990, SCIENCE, V250, P975, DOI 10.1126/science.250.4983.975; KONDEPUDI DK, 1998, MODERN THERMODYNAMIC, P436; MASON SF, 1984, NATURE, V311, P19, DOI 10.1038/311019a0; Micali N, 2000, J PHYS CHEM B, V104, P5897, DOI 10.1021/jp991909a; Misawa K, 1999, J CHEM PHYS, V110, P5844, DOI 10.1063/1.478483; OHNO O, 1993, J CHEM PHYS, V99, P4128, DOI 10.1063/1.466109; PASTERNACK RF, 1995, SCIENCE, V269, P935, DOI 10.1126/science.7638615; QIU X, 1991, PHYS REV LETT, V67, P703, DOI 10.1103/PhysRevLett.67.703; Ribo JM, 2000, MAT SCI ENG C-BIO S, V11, P107, DOI 10.1016/S0928-4931(00)00147-8; Rubires R, 1999, NEW J CHEM, V23, P189, DOI 10.1039/a808943d; Rubires R, 2001, CHEM-EUR J, V7, P436, DOI 10.1002/1521-3765(20010119)7:2<436::AID-CHEM436>3.3.CO;2-9; Sackmann, 1995, HDB BIOL PHYS A&B, V1, P97; SCHWARTZ DK, 1993, PHYS REV LETT, V70, P1267, DOI 10.1103/PhysRevLett.70.1267	37	549	557	2	193	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 15	2001	292	5524					2063	2066		10.1126/science.1060835	http://dx.doi.org/10.1126/science.1060835			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	442KP	11408653				2022-12-28	WOS:000169284700043
J	Wang, XQ; Ullah, H; Jones, AM; Assmann, SM				Wang, XQ; Ullah, H; Jones, AM; Assmann, SM			G protein regulation of ion channels and abscisic acid signaling in Arabidopsis guard cells	SCIENCE			English	Article							HETEROTRIMERIC G-PROTEIN; INWARD K+ CHANNEL; PLASMA-MEMBRANE; STOMATAL CLOSURE; ALPHA-SUBUNIT; CYTOPLASMIC CALCIUM; POTASSIUM CHANNELS; CYTOSOLIC CALCIUM; ANION CHANNELS; VICIA-FABA	The phytohormone abscisic acid (ABA) promotes plant water conservation by decreasing the apertures of stomatal pores in the epidermis through which water loss occurs. We found that Arabidopsis thaliana plants harboring transferred DNA insertional mutations in the sole prototypical heterotrimeric GTP-binding (G) protein a subunit gene, GPA1, lack both ABA inhibition of guard cell inward K+ channels and pH-independent ABA activation of anion channels. Stomatal opening in gpa1 plants is insensitive to inhibition by ABA, and the rate of water loss from gpa1 mutants is greater than that from wild-type plants. Manipulation of G protein status in guard cells may provide a mechanism for controlling plant water balance.	Penn State Univ, Dept Biol, Mueller Lab 208, University Pk, PA 16802 USA; Univ N Carolina, Dept Biol, Chapel Hill, NC 27599 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; University of North Carolina; University of North Carolina Chapel Hill	Assmann, SM (corresponding author), Penn State Univ, Dept Biol, Mueller Lab 208, University Pk, PA 16802 USA.			Wang, Xi-Qing/0000-0003-4477-9557				Aharon GS, 1998, FEBS LETT, V424, P17, DOI 10.1016/S0014-5793(98)00129-X; Allen GJ, 1999, PLANT CELL, V11, P1785, DOI 10.1105/tpc.11.9.1785; ARMSTRONG F, 1995, PLANT J, V8, P187, DOI 10.1046/j.1365-313X.1995.08020187.x; ASSMANN SM, 1996, SIGNAL TRANSDUCTION, P39; BLATT MR, 1990, PLANTA, V180, P445, DOI 10.1007/BF00198799; BLATT MR, 1993, PLANTA, V191, P330, DOI 10.1007/BF00195690; BROWN AM, 1990, ANNU REV PHYSIOL, V52, P197, DOI 10.1146/annurev.ph.52.030190.001213; FAIRLEYGRENOT K, 1991, PLANT CELL, V3, P1037; Gelli A, 1997, PLANT PHYSIOL, V113, P269, DOI 10.1104/pp.113.1.269; GILROY S, 1990, NATURE, V346, P769, DOI 10.1038/346769a0; Grabov A, 1997, PLANT J, V12, P203, DOI 10.1046/j.1365-313X.1997.12010203.x; HEDRICH R, 1990, EMBO J, V9, P3889, DOI 10.1002/j.1460-2075.1990.tb07608.x; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; IRVING HR, 1992, P NATL ACAD SCI USA, V89, P1790, DOI 10.1073/pnas.89.5.1790; Jacob T, 1999, P NATL ACAD SCI USA, V96, P12192, DOI 10.1073/pnas.96.21.12192; KELLY WB, 1995, PLANT J, V8, P479, DOI 10.1046/j.1365-313X.1995.8040479.x; Krysan PJ, 1999, PLANT CELL, V11, P2283, DOI 10.1105/tpc.11.12.2283; Leckie CP, 1998, P NATL ACAD SCI USA, V95, P15837, DOI 10.1073/pnas.95.26.15837; LEE HJ, 1993, PLANT PHYSIOL, V102, P95, DOI 10.1104/pp.102.1.95; Lee YS, 1996, PLANT PHYSIOL, V110, P987, DOI 10.1104/pp.110.3.987; LEMTIRICHLIEH F, 1994, J MEMBRANE BIOL, V137, P99; Leung J, 1997, PLANT CELL, V9, P759, DOI 10.1105/tpc.9.5.759; Leymarie J, 1998, AUST J PLANT PHYSIOL, V25, P785, DOI 10.1071/PP98031; Li JX, 2000, SCIENCE, V287, P300, DOI 10.1126/science.287.5451.300; MA H, 1990, P NATL ACAD SCI USA, V87, P3821, DOI 10.1073/pnas.87.10.3821; MA H, 1994, PLANT MOL BIOL, V26, P1611, DOI 10.1007/BF00016493; MacRobbie EAC, 2000, P NATL ACAD SCI USA, V97, P12361, DOI 10.1073/pnas.220417197; MacRobbie EAC, 1997, J EXP BOT, V48, P515, DOI 10.1093/jxb/48.Special_Issue.515; MCAINSH MR, 1990, NATURE, V343, P186, DOI 10.1038/343186a0; Pei ZM, 1997, PLANT CELL, V9, P409, DOI 10.1105/tpc.9.3.409; Romano LA, 1998, PLANT CELL PHYSIOL, V39, P1133, DOI 10.1093/oxfordjournals.pcp.a029314; SCHROEDER JI, 1989, NATURE, V338, P427, DOI 10.1038/338427a0; SHEPHERD GM, 1991, CELL, V67, P845, DOI 10.1016/0092-8674(91)90358-6; Staxen I, 1999, P NATL ACAD SCI USA, V96, P1779, DOI 10.1073/pnas.96.4.1779; Ueguchi-Tanaka M, 2000, P NATL ACAD SCI USA, V97, P11638, DOI 10.1073/pnas.97.21.11638; Ullah H, 2001, SCIENCE, V292, P2066, DOI 10.1126/science.1059040; WANG X, UNPUB; Wang XQ, 1998, PLANT PHYSIOL, V118, P1421, DOI 10.1104/pp.118.4.1421; WARPEHA KMF, 1991, P NATL ACAD SCI USA, V88, P8925, DOI 10.1073/pnas.88.20.8925; WICKMAN K, 1995, PHYSIOL REV, V75, P865, DOI 10.1152/physrev.1995.75.4.865; WU WH, 1994, P NATL ACAD SCI USA, V91, P6310, DOI 10.1073/pnas.91.14.6310	41	376	437	4	61	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 15	2001	292	5524					2070	2072		10.1126/science.1059046	http://dx.doi.org/10.1126/science.1059046			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	442KP	11408655	Green Submitted			2022-12-28	WOS:000169284700045
J	Horwitz, BJ; Fisher, RS				Horwitz, BJ; Fisher, RS			Current concepts: The irritable bowel syndrome.	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							DIARRHEA-PREDOMINANT; PRUCALOPRIDE PRU; DOUBLE-BLIND; PATIENTS PTS; PLACEBO; SYMPTOMS; 5-HYDROXYTRYPTAMINE; DYSFUNCTION; MODULATION; TEGASEROD		Temple Univ, Sch Med, Funct Gastrointestinal Dis Ctr, Gastroenterol Sect, Philadelphia, PA 19122 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Fisher, RS (corresponding author), Temple Univ Hosp & Med Sch, Gastroenterol Sect, 3401 N Broad St, Philadelphia, PA 19140 USA.							ALMY TP, 1949, GASTROENTEROLOGY, V12, P425, DOI 10.1016/S0016-5085(49)80125-9; ALMY TP, 1951, AM J MED, V10, P60, DOI 10.1016/0002-9343(51)90219-7; Azpiroz F, 2000, DIGESTION, V62, P66, DOI 10.1159/000007780; Bearcroft CP, 1998, GUT, V42, P42, DOI 10.1136/gut.42.1.42; Bonaz BL, 2000, GASTROENTEROLOGY, V118, pA615, DOI 10.1016/S0016-5085(00)84600-4; Bose M, 2000, GASTROENTEROLOGY, V118, pA563, DOI 10.1016/S0016-5085(00)84387-5; Camilleri M, 2000, LANCET, V355, P1035, DOI 10.1016/S0140-6736(00)02033-X; Camilleri M, 1997, ALIMENT PHARM THERAP, V11, P3, DOI 10.1046/j.1365-2036.1997.84256000.x; CANN PA, 1984, DIGEST DIS SCI, V29, P239, DOI 10.1007/BF01296258; CANN PA, 1984, GUT, V25, P168, DOI 10.1136/gut.25.2.168; CHAUDHARY NA, 1962, Q J MED, V31, P307; CLOUSE RE, 1999, CLIN PERSPECT GASTRO, V2, P348; Cumming W., 1948, LONDON MED GAZ, V59, P969; DAPOIGNY M, 1995, DIGEST DIS SCI, V40, P2244, DOI 10.1007/BF02209014; DROSSMAN DA, 1988, GASTROENTEROLOGY, V95, P701, DOI 10.1016/S0016-5085(88)80017-9; DROSSMAN DA, 1992, ANN INTERN MED, V116, P1009, DOI 10.7326/0003-4819-116-12-1009; DROSSMAN DA, 1995, SCAND J GASTROENTERO, V30, P90, DOI 10.3109/00365529509107768; Drossman DA, 1997, GASTROENTEROLOGY, V112, P2120, DOI 10.1053/gast.1997.v112.agast972120; Drossman DA, 1995, GASTROENTEROL INT, V8, P47; EVERHART JE, 1991, GASTROENTEROLOGY, V100, P998, DOI 10.1016/0016-5085(91)90275-P; Gershon MD, 1999, ALIMENT PHARM THER, V13, P15; Gwee KA, 1999, GUT, V44, P400, DOI 10.1136/gut.44.3.400; Jailwala J, 2000, ANN INTERN MED, V133, P136, DOI 10.7326/0003-4819-133-2-200007180-00013; JALIHAL A, 1990, J GASTROEN HEPATOL, V5, P507, DOI 10.1111/j.1440-1746.1990.tb01432.x; Johanson JF, 2000, GASTROENTEROLOGY, V118, pA175, DOI 10.1016/S0016-5085(00)82777-8; KELLOW JE, 1988, GUT, V29, P1236, DOI 10.1136/gut.29.9.1236; KELLOW JE, 1987, GASTROENTEROLOGY, V92, P1885, DOI 10.1016/0016-5085(87)90620-2; KUMAR D, 1985, LANCET, V2, P973; MCKENDRICK MW, 1994, J INFECTION, V29, P1, DOI 10.1016/S0163-4453(94)94871-2; Mertz H, 2000, GASTROENTEROLOGY, V118, P842, DOI 10.1016/S0016-5085(00)70170-3; Miura M, 1999, DIGEST DIS SCI, V44, P20, DOI 10.1023/A:1026633629141; Mueller-Lissner S, 2000, GASTROENTEROLOGY, V118, pA175, DOI 10.1016/S0016-5085(00)82778-X; Pimentel M, 2000, AM J GASTROENTEROL, V95, P3503, DOI 10.1111/j.1572-0241.2000.03368.x; Prather CM, 2000, GASTROENTEROLOGY, V118, P463, DOI 10.1016/S0016-5085(00)70251-4; PRIOR A, 1987, GUT, V28, P1510, DOI 10.1136/gut.28.11.1510; Rajagopalan M, 1998, J GASTROEN HEPATOL, V13, P738, DOI 10.1111/j.1440-1746.1998.tb00723.x; Ringel Y, 2000, GASTROENTEROLOGY, V118, pA444; Schikowski A, 1999, GASTROENTEROLOGY, V116, pA643; SCIARRETTA G, 1987, GUT, V28, P970, DOI 10.1136/gut.28.8.970; Silverman DHS, 1997, GASTROENTEROLOGY, V112, P64, DOI 10.1016/S0016-5085(97)70220-8; Sloots CEJ, 2000, GASTROENTEROLOGY, V118, pA847, DOI 10.1016/S0016-5085(00)85531-6; SNAPE WJ, 1977, GASTROENTEROLOGY, V72, P383; STEWART GT, 1950, BMJ-BRIT MED J, V1, P405, DOI 10.1136/bmj.1.4650.405; TALLEY NJ, 1995, GASTROENTEROLOGY, V109, P1736, DOI 10.1016/0016-5085(95)90738-6; Thompson W., 2000, FUNCTIONAL GASTROINT, V2nd, P351; TOSKES PP, 1993, ALIMENT PHARM THERAP, V7, P87; VEALE D, 1991, BRIT J RHEUMATOL, V30, P220; WHITE LJ, 1985, ANN INTERN MED, V102, P266, DOI 10.7326/0003-4819-102-2-266; WHITEHEAD WE, 1988, GASTROENTEROLOGY, V95, P709, DOI 10.1016/S0016-5085(88)80018-0; WHITEHEAD WE, 1980, DIGEST DIS SCI, V25, P404, DOI 10.1007/BF01395503	50	137	157	1	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 14	2001	344	24					1846	1850		10.1056/NEJM200106143442407	http://dx.doi.org/10.1056/NEJM200106143442407			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	441LC	11407347				2022-12-28	WOS:000169231000007
J	Lee, TH; Boucher, CA				Lee, TH; Boucher, CA			Noninvasive tests in patients with stable coronary artery disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							AMERICAN-HEART-ASSOCIATION; PHARMACOLOGICAL STRESS ECHOCARDIOGRAPHY; MYOCARDIAL PERFUSION SPECT; TASK-FORCE; RISK STRATIFICATION; PRACTICE GUIDELINES; PROGNOSTIC VALUE; EXERCISE ECHOCARDIOGRAPHY; ACC/AHA GUIDELINES; COST-EFFECTIVENESS		Partners Healthcare Syst, Boston, MA 02199 USA; Brigham & Womens Hosp, Boston, MA 02115 USA; Massachusetts Gen Hosp, Boston, MA 02114 USA	Partners Healthcare System; Harvard University; Brigham & Women's Hospital; Harvard University; Massachusetts General Hospital	Lee, TH (corresponding author), Partners Healthcare Syst, Prudential Tower,11th Fl,800 Boylston St, Boston, MA 02199 USA.	thlee@partners.org						Berman DS, 1996, J AM COLL CARDIOL, V27, P756; BERMAN DS, 1995, J AM COLL CARDIOL, V26, P639, DOI 10.1016/0735-1097(95)00218-S; Cheitlin MD, 1997, CIRCULATION, V95, P1686; Cortigiani L, 1998, J AM COLL CARDIOL, V32, P69, DOI 10.1016/S0735-1097(98)00190-9; DILSIZIAN V, 1990, NEW ENGL J MED, V323, P141, DOI 10.1056/NEJM199007193230301; Fleischmann KE, 1998, JAMA-J AM MED ASSOC, V280, P913, DOI 10.1001/jama.280.10.913; Froelicher VF, 1998, ANN INTERN MED, V128, P965, DOI 10.7326/0003-4819-128-12_Part_1-199806150-00001; Garber AM, 1999, ANN INTERN MED, V130, P719, DOI 10.7326/0003-4819-130-9-199905040-00003; GIANROSSI R, 1989, CIRCULATION, V80, P87, DOI 10.1161/01.CIR.80.1.87; Gibbons RJ, 1997, J AM COLL CARDIOL, V30, P260; Gibbons RJ, 1999, J AM COLL CARDIOL, V34, P314; Gibbons RJ, 1999, J AM COLL CARDIOL, V33, P2092, DOI 10.1016/S0735-1097(99)00150-3; Hachamovitch R, 1996, J AM COLL CARDIOL, V28, P34, DOI 10.1016/0735-1097(96)00095-2; Hachamovitch R, 1996, CIRCULATION, V93, P905, DOI 10.1161/01.CIR.93.5.905; Kuntz KM, 1999, ANN INTERN MED, V130, P709, DOI 10.7326/0003-4819-130-9-199905040-00002; MAHMARIAN JJ, 1991, AM J CARDIOL, V67, pD2, DOI 10.1016/S0002-9149(05)80002-5; MARK DB, 1991, NEW ENGL J MED, V325, P849, DOI 10.1056/NEJM199109193251204; McCully RB, 1998, J AM COLL CARDIOL, V31, P144, DOI 10.1016/S0735-1097(97)00427-0; PINA IL, 1995, CIRCULATION, V91, P912, DOI 10.1161/01.CIR.91.3.912; Pingitore A, 1999, J AM COLL CARDIOL, V34, P1769, DOI 10.1016/S0735-1097(99)00423-4; RITCHIE JL, 1995, J AM COLL CARDIOL, V25, P521, DOI 10.1016/0735-1097(95)90027-6; Rodgers GP, 2000, CIRCULATION, V102, P1726, DOI 10.1161/01.CIR.102.14.1726; Smanio PEP, 1997, J AM COLL CARDIOL, V30, P1687, DOI 10.1016/S0735-1097(97)00363-X; STUART RJ, 1980, CHEST, V77, P94, DOI 10.1378/chest.77.1.94	24	87	98	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 14	2001	344	24					1840	1845		10.1056/NEJM200106143442406	http://dx.doi.org/10.1056/NEJM200106143442406			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	441LC	11407346				2022-12-28	WOS:000169231000006
J	Goodman, S				Goodman, S			Battle to save beleaguered beluga	NATURE			English	News Item																			0	1	1	0	0	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 12	2001	412	6843					108	108		10.1038/35084355	http://dx.doi.org/10.1038/35084355			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	451AJ	11449227	Bronze			2022-12-28	WOS:000169778700009
J	Logothetis, NK; Pauls, J; Augath, M; Trinath, T; Oeltermann, A				Logothetis, NK; Pauls, J; Augath, M; Trinath, T; Oeltermann, A			Neurophysiological investigation of the basis of the fMRI signal	NATURE			English	Article							VISUAL-CORTEX; HUMAN BRAIN; NEURONAL-ACTIVITY; GLUCOSE-METABOLISM; BLOOD OXYGENATION; TEMPORAL BINDING; EEG; ACTIVATION; OSCILLATIONS; STIMULATION	Functional magnetic resonance imaging (fMRI) is widely used to study the operational organization of the human brain, but the exact relationship between the measured fMRI signal and the underlying neural activity is unclear. Here we present simultaneous intracortical recordings of neural signals and fMRI responses. We compared local field potentials (LFPs), single- and multi-unit spiking activity with highly spatio-temporally resolved blood-oxygen-level-dependent (BOLD) fMRI responses from the visual cortex of monkeys. The largest magnitude changes were observed in LFPs, which at recording sites characterized by transient responses were the only signal that significantly correlated with the haemodynamic response. Linear systems analysis on a trial-by-trial basis showed that the impulse response of the neurovascular system is both animal- and site-specific, and that LFPs yield a better estimate of BOLD responses than the multi-unit responses. These findings suggest that the BOLD contrast mechanism reflects the input and intracortical processing of a given area rather than its spiking output.	Max Planck Inst Biol Cybernet, D-72076 Tubingen, Germany	Max Planck Society	Logothetis, NK (corresponding author), Max Planck Inst Biol Cybernet, Spemannstr 38, D-72076 Tubingen, Germany.		Mandelkow, Hendrik/AAQ-2583-2021; anand, amit/A-7222-2009; Logothetis, Nikos/U-9282-2019	Mandelkow, Hendrik/0000-0003-0274-3599; 				BANDETTINI PA, 1992, MAGNET RESON MED, V25, P390, DOI 10.1002/mrm.1910250220; Bonhoeffer Tobias, 1996, P55; Bonmassar G, 1999, NEUROREPORT, V10, P1893, DOI 10.1097/00001756-199906230-00018; Boynton GM, 1999, VISION RES, V39, P257, DOI 10.1016/S0042-6989(98)00113-8; Boynton GM, 1996, J NEUROSCI, V16, P4207, DOI 10.1523/jneurosci.16-13-04207.1996; Buxton RB, 1998, MAGNET RESON MED, V39, P855, DOI 10.1002/mrm.1910390602; Carandini M, 1997, J NEUROSCI, V17, P8621; Clarke DD, 1989, BASIC NEUROCHEMISTRY, P565; ECKHORN R, 1993, J NEUROSCI METH, V49, P175, DOI 10.1016/0165-0270(93)90121-7; ECKHORN R, 1988, BIOL CYBERN, V60, P121, DOI 10.1007/BF00202899; FRAHM J, 1992, JMRI-J MAGN RESON IM, V2, P501, DOI 10.1002/jmri.1880020505; Frahm J, 1996, MAGNET RESON MED, V35, P143, DOI 10.1002/mrm.1910350202; Freeman WJ, 1975, MASS ACTION NERVOUS; GRAY CM, 1989, P NATL ACAD SCI USA, V86, P1698, DOI 10.1073/pnas.86.5.1698; GRUETTER R, 1993, MAGNET RESON MED, V29, P804, DOI 10.1002/mrm.1910290613; HAASE A, 1986, J MAGN RESON, V67, P258, DOI 10.1016/0022-2364(86)90433-6; Hess A, 2000, J NEUROSCI, V20, P3328, DOI 10.1523/JNEUROSCI.20-09-03328.2000; Hu XP, 1997, MAGNET RESON MED, V37, P877, DOI 10.1002/mrm.1910370612; JOLIOT M, 1994, P NATL ACAD SCI USA, V91, P11748, DOI 10.1073/pnas.91.24.11748; Juergens E, 1999, EXP BRAIN RES, V129, P247, DOI 10.1007/s002210050895; Krakow K, 1999, BRAIN, V122, P1679, DOI 10.1093/brain/122.9.1679; Krakow K, 2000, HUM BRAIN MAPP, V10, P10, DOI 10.1002/(SICI)1097-0193(200005)10:1<10::AID-HBM20>3.0.CO;2-T; Kruger G, 1996, MAGNET RESON MED, V35, P797, DOI 10.1002/mrm.1910350602; KWONG KK, 1992, P NATL ACAD SCI USA, V89, P5675, DOI 10.1073/pnas.89.12.5675; LEGATT AD, 1980, J NEUROSCI METH, V2, P203, DOI 10.1016/0165-0270(80)90061-8; Logothetis NK, 1999, NAT NEUROSCI, V2, P555, DOI 10.1038/9210; Magistretti PJ, 1999, SCIENCE, V283, P496, DOI 10.1126/science.283.5401.496; Malonek D, 1996, SCIENCE, V272, P551, DOI 10.1126/science.272.5261.551; Mansfield P., 1977, J PHYS C SOLID STATE, V10, P55, DOI 10.1088/0022-3719/10/3/004; MENON RS, 1992, INVEST RADIOL S, V27, P53; Menon V, 1997, NEUROREPORT, V8, P3029, DOI 10.1097/00001756-199709290-00007; MITZDORF U, 1987, INT J NEUROSCI, V33, P33, DOI 10.3109/00207458708985928; MURTHY VN, 1992, P NATL ACAD SCI USA, V89, P5670, DOI 10.1073/pnas.89.12.5670; OGAWA S, 1990, MAGNET RESON MED, V16, P9, DOI 10.1002/mrm.1910160103; Pan JW, 2000, MAGNET RESON MED, V44, P673, DOI 10.1002/1522-2594(200011)44:5<673::AID-MRM3>3.0.CO;2-L; PELLERIN L, 1994, P NATL ACAD SCI USA, V91, P10625, DOI 10.1073/pnas.91.22.10625; Rainer G, 2001, CURR BIOL, V11, P846, DOI 10.1016/S0960-9822(01)00242-1; Rees G, 2000, NAT NEUROSCI, V3, P716, DOI 10.1038/76673; Rothman DL, 1999, PHILOS T R SOC B, V354, P1165, DOI 10.1098/rstb.1999.0472; Schmitt F., 1998, ECHO PLANAR IMAGING; SCLAR G, 1990, VISION RES, V30, P1, DOI 10.1016/0042-6989(90)90123-3; Shadlen MN, 1999, NEURON, V24, P67, DOI 10.1016/S0896-6273(00)80822-3; Shulman RG, 1998, P NATL ACAD SCI USA, V95, P11993, DOI 10.1073/pnas.95.20.11993; Sibson NR, 1998, P NATL ACAD SCI USA, V95, P316, DOI 10.1073/pnas.95.1.316; SINGER W, 1993, ANNU REV PHYSIOL, V55, P349, DOI 10.1146/annurev.physiol.55.1.349; Singer W, 1999, NEURON, V24, P49, DOI 10.1016/S0896-6273(00)80821-1; TAKAHASHI S, 1995, P NATL ACAD SCI USA, V92, P4616, DOI 10.1073/pnas.92.10.4616; TallonBaudry C, 1997, NEUROREPORT, V8, P1103, DOI 10.1097/00001756-199703240-00008; [No title captured]; [No title captured]	50	4301	4390	14	591	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 12	2001	412	6843					150	157		10.1038/35084005	http://dx.doi.org/10.1038/35084005			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	451AJ	11449264				2022-12-28	WOS:000169778700042
J	Tramer, MR; Carroll, D; Campbell, FA; Reynolds, DJM; Moore, RA; McQuay, HJ				Tramer, MR; Carroll, D; Campbell, FA; Reynolds, DJM; Moore, RA; McQuay, HJ			Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review	BMJ-BRITISH MEDICAL JOURNAL			English	Review							DOUBLE-BLIND; CANCER-CHEMOTHERAPY; ANTIEMETIC EFFICACY; COMPARATIVE TRIAL; CLINICAL-TRIAL; NABILONE; PROCHLORPERAZINE; DELTA-9-TETRAHYDROCANNABINOL; METOCLOPRAMIDE; LEVONANTRADOL	Objective To quantify the antiemetic efficacy and adverse effects of cannabis used for sickness induced by chemotherapy. Design Systematic review Data sources Systematic search (Medline, Embase, Cochrane library bibliographies), any language, to August 2000. Studies 30 randomised comparisons of cannabis with placebo or antiemetics from which dichotomous data on efficacy and harm were available (1366 patients). Oral nabilone, oral dronabind (tetrahydrocannabinol), and intramuscular levonantradol were tested. No cannabis was smoked. Follow up lasted 24 hours. Results Cannabinoids were more effective antiemetics than prochlorperazine, metoclopramide, chlorpromazine, thiethylperazine, haloperidol, domperidone, or alizapride: relative risk 1.38 (95% confidence interval 1.18 to 1.62), number needed to treat 6 for complete control of nausea; 1.28 (1.08 to 1.51), NNT 8 for complete control of vomiting: Cannabinoids were not more effective in patients receiving very low or very high emetogenic chemotherapy. In crossover trials, patients preferred cannabinoids for future chemotherapy cycles: 2.39 (2.05 to 2.78), NNT 3. Some potentially beneficial side effects occurred more often with cannabinoids: "high" 10.6 (6.86 to 16.5), NNT 3; sedation or drowsiness 1.66 (1.46 to 1.89), NNT 5; euphoria 12.5 (3.00 to 52.1), NNT 7. Harmful side effects also occurred more often with cannabinoids: dizziness 2.98 (2.31 to 3.83), NNT 3; dysphoria or depression 8.06 (3.35 to 19.2), NNT 8; hallucinations 6.10 (2.41 to 15.4), NNT 17; paranoia 8.58 (6.35 to 11.5), NNT 20; and arterial hypotension 2.23 (1.75 to 2.83),NNT 7. Patients given cannabinoids were more likely to withdraw due to side effects 4.67 (3.07 to 5.09), NNT 11. Conclusions In selected patients, the cannabinoids tested in these trials may be useful as mood enhancing adjuvants for controlling chemotherapy related sickness. Potentially serious adverse effects, even when taken short term orally or intramuscularly, are likely to limit their widespread use.	Hop Univ, Dept Anesthesiol Pharmacol Clin & Soins Intens Ch, Div Anesthesiol, CH-1211 Geneva 14, Switzerland; Oxford Radcliffe Hosp, Nuffield Dept Anaesthet, Oxford OX3 7LJ, England; Queens Med Ctr, Pain Management Ctr, Nottingham NG7 2UH, England; Radcliffe Infirm, Dept Clin Pharmacol, Oxford OX2 6HE, England	University of Geneva; University of Oxford; University of Nottingham; Radcliffe Infirmary	Tramer, MR (corresponding author), Hop Univ, Dept Anesthesiol Pharmacol Clin & Soins Intens Ch, Div Anesthesiol, CH-1211 Geneva 14, Switzerland.	martin.tramer@hcuge.ch	Côté, Mathieu/A-6735-2008					AHMEDZAI S, 1983, BRIT J CANCER, V48, P657, DOI 10.1038/bjc.1983.247; Altman DG, 1998, BRIT MED J, V317, P1309, DOI 10.1136/bmj.317.7168.1309; BEAL JE, 1995, J PAIN SYMPTOM MANAG, V10, P89, DOI 10.1016/0885-3924(94)00117-4; CHAN HSL, 1987, PEDIATRICS, V79, P946; CHANG AE, 1979, ANN INTERN MED, V91, P819, DOI 10.7326/0003-4819-91-6-819; CHANG AE, 1981, CANCER, V47, P1746; CITRON ML, 1985, CANCER TREAT REP, V69, P109; COLLS BM, 1980, NEW ZEAL MED J, V91, P449; COLLS BM, 1980, LANCET, V1, P1187; COOK RJ, 1995, BRIT MED J, V310, P452, DOI 10.1136/bmj.310.6977.452; CRAWFORD SM, 1986, MED ONCOL TUMOR PHAR, V3, P39; CUNNINGHAM D, 1988, EUR J CANCER CLIN ON, V24, P685, DOI 10.1016/0277-5379(88)90300-8; CUNNINGHAM D, 1985, BRIT MED J, V291, P864, DOI 10.1136/bmj.291.6499.864; DALZELL AM, 1986, ARCH DIS CHILD, V61, P502, DOI 10.1136/adc.61.5.502; DOBLIN RE, 1991, J CLIN ONCOL, V9, P1314, DOI 10.1200/JCO.1991.9.7.1314; EINHORN L, 1982, CANCER TREAT REV, V9, P55, DOI 10.1016/S0305-7372(82)80037-6; EINHORN LH, 1981, J CLIN PHARMACOL, V21, pS64, DOI 10.1002/j.1552-4604.1981.tb02576.x; EKERT H, 1979, MED J AUSTRALIA, V2, P657, DOI 10.5694/j.1326-5377.1979.tb127271.x; FRYTAK S, 1979, ANN INTERN MED, V91, P825, DOI 10.7326/0003-4819-91-6-825; GARB S, 1980, IRCS MED SCI-BIOCHEM, V8, P203; Gavaghan DJ, 2000, PAIN, V85, P415, DOI 10.1016/S0304-3959(99)00302-4; GEORGE M, 1983, BIOMED PHARMACOTHER, V37, P24; GILBERT CJ, 1995, CANCER, V76, P2330, DOI 10.1002/1097-0142(19951201)76:11<2330::AID-CNCR2820761122>3.0.CO;2-F; GRALLA RJ, 1984, CANCER TREAT REP, V68, P163; GRINSPOON L, 1995, JAMA-J AM MED ASSOC, V273, P1875, DOI 10.1001/jama.273.23.1875; HERMAN TS, 1979, NEW ENGL J MED, V300, P1295, DOI 10.1056/NEJM197906073002302; HIGI M, 1982, DEUT MED WOCHENSCHR, V107, P1232, DOI 10.1055/s-2008-1070107; Hubbard JR, 1999, AM FAM PHYSICIAN, V60, P2583; HUTCHEON AW, 1983, EUR J CANCER CLIN ON, V19, P1087, DOI 10.1016/0277-5379(83)90032-9; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; JOHANSSON R, 1982, CANCER TREAT REV, V9, P25, DOI 10.1016/S0305-7372(82)80032-7; JONES SE, 1982, CANCER TREAT REV, V9, P45, DOI 10.1016/S0305-7372(82)80035-2; Kassirer JP, 1997, NEW ENGL J MED, V336, P366, DOI 10.1056/NEJM199701303360509; KLUINNELEMAN JC, 1979, VET HUM TOXICOL, V21, P338; LANE M, 1991, J PAIN SYMPTOM MANAG, V6, P352, DOI 10.1016/0885-3924(91)90026-Z; LANE M, 1990, AM J CLIN ONCOL-CANC, V13, P480, DOI 10.1097/00000421-199012000-00006; LEVITT M, 1982, CANCER TREAT REV, V9, P49, DOI 10.1016/S0305-7372(82)80036-4; LEVITT M, 1981, J CLIN PHARMACOL, V21, pS103, DOI 10.1002/j.1552-4604.1981.tb02583.x; LEWIS IH, 1994, BRIT J ANAESTH, V73, P244, DOI 10.1093/bja/73.2.244; LUCRAFT HH, 1982, CLIN RADIOL, V33, P621, DOI 10.1016/S0009-9260(82)80383-8; MCCABE M, 1988, INVEST NEW DRUG, V6, P243; Moore RA, 1998, BRIT MED J, V316, P333, DOI 10.1136/bmj.316.7128.333; Moore RA, 1998, PAIN, V78, P209, DOI 10.1016/S0304-3959(98)00140-7; MORRIS JA, 1995, STAT CONFIDENCE CONF, P50; Morris K, 1997, LANCET, V350, P1828, DOI 10.1016/S0140-6736(05)63651-3; NEIDHART JA, 1981, J CLIN PHARMACOL, V21, pS38, DOI 10.1002/j.1552-4604.1981.tb02571.x; NIEDERLE N, 1986, KLIN WOCHENSCHR, V64, P362, DOI 10.1007/BF01728184; NIIRANEN A, 1987, AM J CLIN ONCOL-CANC, V10, P325, DOI 10.1097/00000421-198708000-00014; NIIRANEN A, 1985, AM J CLIN ONCOL-CANC, V8, P336, DOI 10.1097/00000421-198508000-00013; Orr L E, 1980, Arch Intern Med, V140, P1431; ORR LE, 1981, J CLIN PHARMACOL, V21, pS76, DOI 10.1002/j.1552-4604.1981.tb02578.x; POMEROY M, 1986, CANCER CHEMOTH PHARM, V17, P285; POSTER DS, 1981, JAMA-J AM MED ASSOC, V245, P2047, DOI 10.1001/jama.245.20.2047; PRIESTMAN SG, 1987, CLIN RADIOL, V38, P543, DOI 10.1016/S0009-9260(87)80151-4; ROFFMAN RA, 1981, J CLIN PHARMACOL, V21, pS133, DOI 10.1002/j.1552-4604.1981.tb02588.x; SALLAN SE, 1980, NEW ENGL J MED, V302, P135, DOI 10.1056/NEJM198001173020302; SALLAN SE, 1975, NEW ENGL J MED, V293, P795, DOI 10.1056/NEJM197510162931603; Schwartz Richard H., 1994, Journal of Addictive Diseases, V13, P53; SEIPP CA, 1980, CANC NURSING     AUG, P271; STAMBAUGH JE, 1984, J CLIN PHARMACOL, V24, P480, DOI 10.1002/j.1552-4604.1984.tb02756.x; STEELE N, 1980, CANCER TREAT REP, V64, P219; UNGE, 1985, AM J CLIN ONCOL-CANC, V8, P142; UNGERLEIDER JT, 1982, CANCER, V50, P636; UNGERLEIDER JT, 1985, AM J CLIN ONCOL-CANC, V8, P142, DOI 10.1097/00000421-198504000-00006; VINCIGUERRA V, 1988, NEW YORK STATE J MED, V88, P525; Voth EA, 1997, ANN INTERN MED, V126, P791, DOI 10.7326/0003-4819-126-10-199705150-00008; WADA JK, 1982, CANCER TREAT REV, V9, P39, DOI 10.1016/S0305-7372(82)80034-0	67	352	371	1	44	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 7	2001	323	7303					16	21		10.1136/bmj.323.7303.16	http://dx.doi.org/10.1136/bmj.323.7303.16			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	451WA	11440936	Green Published, Bronze			2022-12-28	WOS:000169824300017
J	Wallis, LA; Guly, HR				Wallis, LA; Guly, HR			Improving care in accident and emergency departments	BRITISH MEDICAL JOURNAL			English	Article							SUBARACHNOID HEMORRHAGE; COMMUNICATION; DIAGNOSIS; DOCTORS		Derriford Hosp, Dept Accid & Emergency, Plymouth PL6 8DH, Devon, England	Derriford Hospital	Wallis, LA (corresponding author), Derriford Hosp, Dept Accid & Emergency, Plymouth PL6 8DH, Devon, England.			Wallis, Lee/0000-0003-2711-3139				[Anonymous], 1997, J R Coll Physicians Lond, V31, P258; *AUD COMM, 1996, BY ACC DES IMPR A E; Coiera E, 1998, BRIT MED J, V316, P673, DOI 10.1136/bmj.316.7132.673; Cooke MW, 2000, J ACCID EMERG MED, V17, P355; Cooke MW, 1998, J ACCID EMERG MED, V15, P181; *DEP HLTH, 1998, 1 CLASS SERV QUAL NE; Espinosa JA, 2000, BRIT MED J, V320, P737, DOI 10.1136/bmj.320.7237.737; Fook L, 1998, J ROY COLL PHYS LOND, V32, P251; Mann CJ, 1996, J ACCID EMERG MED, V13, P198; Meryn S, 1998, BRIT MED J, V316, P1922, DOI 10.1136/bmj.316.7149.1922; *NAT AUD OFF, 1992, NHS ACC EM DEP ENGL; NeilDwyer G, 1997, J ROY COLL PHYS LOND, V31, P49; THAM KY, 1994, BRIT MED J, V309, P1408, DOI 10.1136/bmj.309.6966.1408a; Thomson S, 2000, J ACCID EMERG MED, V17, P176; THWAITES BC, 1992, J ROY COLL PHYS LOND, V26, P265; VanGijn J, 1997, LANCET, V349, P1492, DOI 10.1016/S0140-6736(05)62095-8; WHEATLY S, 1993, J ROY COLL PHYS LOND, V27, P408; Wyatt JP, 1999, INJURY, V30, P165, DOI 10.1016/S0020-1383(98)00252-6	18	7	8	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUL 7	2001	323	7303					39	42		10.1136/bmj.323.7303.39	http://dx.doi.org/10.1136/bmj.323.7303.39			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	451WA	11440946	Green Published			2022-12-28	WOS:000169824300026
J	Zeki, S				Zeki, S			Artistic creativity and the Brain	SCIENCE			English	Article									UCL, Dept Cognit Neurol, London WC1E 6BT, England; Wellcome Dept Cognit Neurol, London, England	University of London; University College London; University of London; University College London	Zeki, S (corresponding author), UCL, Dept Cognit Neurol, Mortimer St, London WC1E 6BT, England.	zeki.pa@ucl.ac.uk	Zeki, Semir/AAA-1789-2020						0	97	104	2	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 6	2001	293	5527					51	52		10.1126/science.1062331	http://dx.doi.org/10.1126/science.1062331			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	451BB	11441167				2022-12-28	WOS:000169780300019
J	Cadarette, SM; Jaglal, SB; Murray, TM; McIsaac, WJ; Joseph, L; Brown, JP				Cadarette, SM; Jaglal, SB; Murray, TM; McIsaac, WJ; Joseph, L; Brown, JP		Canadian Multicentre Osteoporosis	Evaluation of decision rules for referring women for bone densitometry by dual-energy X-ray absorptiometry	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CANADIAN MULTICENTER OSTEOPOROSIS; CLINICAL-PREDICTION RULES; HIP FRACTURE; RISK-FACTORS; GUIDELINES; DIAGNOSIS; DENSITY; IDENTIFICATION; PREVALENCE; VALIDATION	Context Identification of women with low bone mineral density (BMD) is an important strategy in reducing the incidence of osteoporotic fractures. However, screening all women is not recommended. Objectives To assess the diagnostic properties of 4 decision rules-Simple Calculated Osteoporosis Risk Estimation (SCORE), Osteoporosis Risk Assessment Instrument (ORAI), Age, Body Size, No Estrogen (ABONE), and body weight less than 70 kg (weight criterion)-for selecting women for dual-energy x-ray absorptiometry (DXA) testing and to compare results with recommendations made in the National Osteoporosis Foundation (NOF) practice guidelines. Design and Setting Analysis of data from the Canadian Multicentre Osteoporosis Study, a population-based community sample, collected from 9 study centers across Canada between February 1996 and September 1997. Participants Postmenopausal women aged 45 years or older (N =2365) without bone disease who had DXA data for the femoral neck, data to apply selection criteria, and who were not currently taking estrogens or who had been taking hormone replacement therapy for 5 or more years. Main Outcome Measures Sensitivity, specificity, and area under the receiver operating characteristic (AUROC) curve of each of the 4 decision ru les and the NOF guidelines for identifying women with a BMD T score of less than -1.0 SD, less than -2.0 SD, and no more than -2.5 SD at the femoral neck, and percentages of women recommended for testing, stratified by BMD level and age. Results The percent of women with a BMD T score less than -1, less than -2, and no more than -2.5 were 68.3%, 25.4%, and 10.0%, respectively. The AUROC curves were greatest using SCORE and ORAI. The sensitivity for identifying women with a BMD T score of less than -2.0 was 93.7% (95% confidence interval [Cl], 91.8%-95.6%) using the NOF guidelines and was 97.5% (95% Cl,96.3%-98.8%), 94.2% (95% Cl, 92.3%-96.1%), 79.1% (95% Cl, 75.9%-82.3%), and 79.6% (95% Cl, 76.4%-82.8%), respectively, using the SCORE, ORAI, ABONE, and weight criterion. However, the NOF guidelines also resulted in 74.4% (95% Cl, 71.3%-77.6%) of women with a normal BMD (T score of -1.0 or higher) being tested compared with 69.2% (95% Cl, 65.9%-72.5%), 56.3% (95% Cl, 52.7%-59.8%), 35.8% (95% Cl, 32.4%-39.2%), and 38.1% (95% Cl, 34.6%-41.6%), respectively, using the 4 decision rules. Assessments suggest that ABONE and weight criterion are not useful case-finding approaches. Conclusion The SCORE and ORAI decision rules are better than the NOF guidelines at targeting BMD testing in high-risk patients. The acceptability of these rules in clinical practice merits further investigation given their potential effect on the use of densitometry services.	Univ Toronto, Womens Coll Ambulatory Care Ctr, Osteoporosis Res Program,Dept Hlth Adm, Sunnybrook & Womens Coll Hlth Sci Ctr, Toronto, ON M5S 1B2, Canada; Univ Toronto, Dept Rehabil Sci, Toronto, ON M5S 1B2, Canada; Univ Toronto, St Michaels Hosp, Dept Med, Metab Bone Clin, Toronto, ON M5S 1B2, Canada; Univ Toronto, Mt Sinai Family Med Ctr, Dept Family & Community Med, Toronto, ON M5S 1B2, Canada; McGill Univ, Dept Epidemiol & Biostat, Montreal, PQ, Canada; Univ Laval, Dept Med, Quebec City, PQ G1K 7P4, Canada	University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; McGill University; Laval University	Cadarette, SM (corresponding author), Univ Toronto, Womens Coll Ambulatory Care Ctr, Osteoporosis Res Program,Dept Hlth Adm, Sunnybrook & Womens Coll Hlth Sci Ctr, 76 Grenville St,10th Floor E,Room 1005, Toronto, ON M5S 1B2, Canada.	s.cadarette@utoronto.ca	Cadarette, Suzanne/A-2608-2014	Brown, Jacques/0000-0003-1910-788X; Jaglal, Susan/0000-0002-2930-1443; Cadarette, Suzanne/0000-0002-8584-9649				Ballard PA, 1998, OSTEOPOROSIS INT, V8, P535, DOI 10.1007/s001980050095; Baran DT, 1997, CALCIFIED TISSUE INT, V61, P433, DOI 10.1007/s002239900362; Black DM, 1996, BRIT J OBSTET GYNAEC, V103, P2; Cadarette SM, 2000, CAN MED ASSOC J, V162, P1289; Carroll J, 1997, AM J PREV MED, V13, P447, DOI 10.1016/S0749-3797(18)30140-5; CUMMINGS SR, 1995, NEW ENGL J MED, V332, P767, DOI 10.1056/NEJM199503233321202; DELONG ER, 1988, BIOMETRICS, V44, P837, DOI 10.2307/2531595; Fogelman I, 1999, BRIT MED J, V319, P1148, DOI 10.1136/bmj.319.7218.1148; GENANT HK, 1994, J BONE MINER RES, V9, P1503; Genant HK, 1999, OSTEOPOROSIS INT, V10, P259, DOI 10.1007/s001980050224; Goemaere S, 1999, CALCIFIED TISSUE INT, V65, P354, DOI 10.1007/s002239900712; Gurlek A, 2000, OSTEOPOROSIS INT, V11, P809, DOI 10.1007/s001980070061; Hajcsar EE, 2000, CAN MED ASSOC J, V163, P819; Jonsson B, 1996, SCAND J RHEUMATOL, P30, DOI 10.3109/03009749609103742; Joseph P, 1997, Aust Fam Physician, V26, P1181; Josse R, 1996, CAN MED ASSOC J, V155, P1113; Kamel HK, 2000, AM J MED, V109, P326, DOI 10.1016/S0002-9343(00)00457-5; Kanis JA, 1997, OSTEOPOROSIS INT, V7, P390, DOI 10.1007/BF01623782; Kanis JA, 2000, OSTEOPOROSIS INT, V11, P192, DOI 10.1007/s001980050281; Kanis JA, 2000, TRENDS ENDOCRIN MET, V11, P28, DOI 10.1016/S1043-2760(99)00214-3; Klibanski A, 2001, JAMA-J AM MED ASSOC, V285, P785; Kreiger N, 1999, CAN J AGING, V18, P376, DOI 10.1017/S0714980800009934; Laupacis A, 1997, JAMA-J AM MED ASSOC, V277, P488, DOI 10.1001/jama.277.6.488; Looker AC, 1998, OSTEOPOROSIS INT, V8, P468, DOI 10.1007/s001980050093; Lydick E, 1998, AM J MANAG CARE, V4, P37; McClung MR, 2001, NEW ENGL J MED, V344, P333, DOI 10.1056/NEJM200102013440503; McClung MR, 1999, JAMA-J AM MED ASSOC, V282, P687, DOI 10.1001/jama.282.7.687; McGinn TG, 2000, JAMA-J AM MED ASSOC, V284, P79, DOI 10.1001/jama.284.1.79; Michaelsson K, 1996, OSTEOPOROSIS INT, V6, P120, DOI 10.1007/BF01623934; National Osteoporosis F, 1998, OSTEOPOROS INT S4, V8, pS7, DOI DOI 10.1007/PL00022721; National Osteoporosis Foundation, 1999, PHYS GUID PREV TREAT; Tenenhouse A, 2000, OSTEOPOROSIS INT, V11, P897, DOI 10.1007/s001980070050; Torgerson DJ, 1998, ANN RHEUM DIS, V57, P378, DOI 10.1136/ard.57.6.378; Torgerson DJ, 1998, OSTEOPOROSIS INT, V8, pS57; WASSON JH, 1985, NEW ENGL J MED, V313, P793, DOI 10.1056/NEJM198509263131306; Weinstein L, 2000, AM J OBSTET GYNECOL, V183, P547, DOI 10.1067/mob.2000.106594; 1997, MED J AUST S, V167, pS1	37	144	158	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 4	2001	286	1					57	63		10.1001/jama.286.1.57	http://dx.doi.org/10.1001/jama.286.1.57			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	449GR	11434827	Bronze			2022-12-28	WOS:000169676400023
J	Spelman, D				Spelman, D			Prevention of overwhelming sepsis in asplenic patients: could do better	LANCET			English	Editorial Material									Monash Univ, Alfred Hosp, Dept Microbiol & Infect Dis, Melbourne, Vic 3181, Australia	Florey Institute of Neuroscience & Mental Health; Monash University	Spelman, D (corresponding author), Monash Univ, Alfred Hosp, Dept Microbiol & Infect Dis, Melbourne, Vic 3181, Australia.	d.spelman@alfred.org.au						Cavill I, 1996, BRIT MED J, V312, P430; Hegarty P K, 2000, Hematol J, V1, P357, DOI 10.1038/sj.thj.6200056; Sarangi J, 1997, J PUBLIC HEALTH MED, V19, P208, DOI 10.1093/oxfordjournals.pubmed.a024611; Waghorn DJ, 2001, J CLIN PATHOL, V54, P214, DOI 10.1136/jcp.54.3.214	4	12	12	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 30	2001	357	9274					2072	2072		10.1016/S0140-6736(00)05227-2	http://dx.doi.org/10.1016/S0140-6736(00)05227-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	447RQ	11445096				2022-12-28	WOS:000169586600006
J	[Anonymous]				[Anonymous]			Healthy volunteer dies in US physiology study	LANCET			English	News Item																			0	5	5	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 30	2001	357	9274					2114	2114		10.1016/S0140-6736(00)05248-X	http://dx.doi.org/10.1016/S0140-6736(00)05248-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	447RQ	11445123				2022-12-28	WOS:000169586600033
J	Young, BA; Anthony, LC; Gruber, TM; Arthur, TM; Heyduk, E; Lu, CZ; Sharp, MM; Heyduk, T; Burgess, RR; Gross, CA				Young, BA; Anthony, LC; Gruber, TM; Arthur, TM; Heyduk, E; Lu, CZ; Sharp, MM; Heyduk, T; Burgess, RR; Gross, CA			A coiled-coil from the RNA polymerase beta ' subunit allosterically induces selective nontemplate strand binding by sigma(70)	CELL			English	Article							PROMOTER RECOGNITION; CRYSTAL-STRUCTURE; AMINO-ACIDS; DNA; SEQUENCE; REGION; SITE; ORGANIZATION; MUTANT; DOMAIN	For transcription to initiate, RNA polymerase must recognize and melt promoters. Selective binding to the nontemplate strand of the -10 region of the promoter is central to this process. We show that a 48 amino acid (aa) coiled-coil from the beta' subunit (aa 262-309) induces sigma (70) to perform this function almost as efficiently as core RNA polymerase itself. We provide evidence that interaction between the beta' coiled-coil and region 2.2 of sigma (70) promotes an allosteric transition that allows om to selectively recognize the nontemplate strand. As the beta' 262-309 peptide can function with the previously crystallized portion of sigma (70), nontemplate recognition can be reconstituted with only 47 kDa, or 1/10 of holoenzyme.	Univ Calif San Francisco, Dept Stomatol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Microbiol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Immunol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA; Univ Wisconsin, Dept Bacteriol, Madison, WI 53706 USA; Univ Wisconsin, Dept Oncol, Madison, WI 53706 USA; St Louis Univ, Sch Med, EA Doisy Dept Biochem & Mol Biol, St Louis, MO 63128 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Saint Louis University	Gross, CA (corresponding author), Univ Calif San Francisco, Dept Stomatol, San Francisco, CA 94143 USA.	cgross@cgl.ucsf.edu		Burgess, Richard/0000-0001-9545-3165; Arthur, Terrance/0000-0001-9035-0474	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050514, R21GM050514, R01GM028575] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM50514, GM30477, GM28575] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Arthur TM, 2000, J BIOL CHEM, V275, P23113, DOI 10.1074/jbc.M002040200; Arthur TM, 1998, J BIOL CHEM, V273, P31381, DOI 10.1074/jbc.273.47.31381; Callaci S, 1998, BIOCHEMISTRY-US, V37, P3312, DOI 10.1021/bi972041m; DANIELS D, 1990, P NATL ACAD SCI USA, V87, P8075, DOI 10.1073/pnas.87.20.8075; Dombroski AJ, 1997, J BIOL CHEM, V272, P3487; DOMBROSKI AJ, 1993, GENE DEV, V7, P2446, DOI 10.1101/gad.7.12a.2446; DOMBROSKI AJ, 1992, CELL, V70, P501, DOI 10.1016/0092-8674(92)90174-B; Ebright RH, 2000, J MOL BIOL, V304, P687, DOI 10.1006/jmbi.2000.4309; Fedoriw AM, 1998, BIOCHEMISTRY-US, V37, P11971, DOI 10.1021/bi980980o; Gross CA, 1998, COLD SPRING HARB SYM, V63, P141, DOI 10.1101/sqb.1998.63.141; GROSS CA, 1992, TRANSCRIPTIONAL REGU, P129; GRUBER TM, 2001, IN PRESS MOL CELL; Guo Y, 1998, P NATL ACAD SCI USA, V95, P11655, DOI 10.1073/pnas.95.20.11655; Heyduk E, 1999, J BIOL CHEM, V274, P3315, DOI 10.1074/jbc.274.6.3315; Huang H, 1997, PHYS WORLD, V10, P25; Joo DM, 1997, P NATL ACAD SCI USA, V94, P4907, DOI 10.1073/pnas.94.10.4907; KENNEY TJ, 1989, P NATL ACAD SCI USA, V86, P9109, DOI 10.1073/pnas.86.23.9109; Ko DC, 1998, GENE DEV, V12, P3276, DOI 10.1101/gad.12.20.3276; Korzheva N, 2000, SCIENCE, V289, P619, DOI 10.1126/science.289.5479.619; Kulbachinskiy A, 1999, FEBS LETT, V454, P71, DOI 10.1016/S0014-5793(99)00778-4; LONETTO M, 1992, J BACTERIOL, V174, P3843, DOI 10.1128/jb.174.12.3843-3849.1992; Malhotra A, 1996, CELL, V87, P127, DOI 10.1016/S0092-8674(00)81329-X; MARQUSEE S, 1989, P NATL ACAD SCI USA, V86, P5286, DOI 10.1073/pnas.86.14.5286; Marr MT, 1997, SCIENCE, V276, P1258, DOI 10.1126/science.276.5316.1258; Matlock DL, 2000, BIOCHEMISTRY-US, V39, P12274, DOI 10.1021/bi001433h; Minakhin L, 2001, P NATL ACAD SCI USA, V98, P892, DOI 10.1073/pnas.98.3.892; Naryshkin N, 2000, CELL, V101, P601, DOI 10.1016/S0092-8674(00)80872-7; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; Pace CN, 1989, PROTEIN STRUCTURE PR, P311; Record Jr MT, 1996, ESCHERICHIA COLI SAL, P792; RING BZ, 1994, CELL, V78, P317, DOI 10.1016/0092-8674(94)90300-X; Ring BZ, 1996, CELL, V86, P485, DOI 10.1016/S0092-8674(00)80121-X; Roberts CW, 1996, CELL, V86, P495; SENTENAC A, 1992, TRANSCRIPTIONAL REGU, P27; Severinov K, 1996, J BIOL CHEM, V271, P27969, DOI 10.1074/jbc.271.44.27969; SEVERINOV K, 1992, J BIOL CHEM, V267, P12813; Severinova E, 1996, J MOL BIOL, V263, P637, DOI 10.1006/jmbi.1996.0604; Sharp MM, 1999, GENE DEV, V13, P3015, DOI 10.1101/gad.13.22.3015; SIEGELE DA, 1989, J MOL BIOL, V206, P591, DOI 10.1016/0022-2836(89)90568-8; TAN RY, 1993, CELL, V73, P1031, DOI 10.1016/0092-8674(93)90280-4; Waldspurger J.-L., 1990, ISRAEL MATH C P, V2, P267; YOUNG RA, 1991, ANNU REV BIOCHEM, V60, P689, DOI 10.1146/annurev.biochem.60.1.689; Zhang GY, 1999, CELL, V98, P811, DOI 10.1016/S0092-8674(00)81515-9	43	81	81	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 29	2001	105	7					935	944		10.1016/S0092-8674(01)00398-1	http://dx.doi.org/10.1016/S0092-8674(01)00398-1			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	449BK	11439189	Bronze			2022-12-28	WOS:000169664300013
J	Attri, AK; Kumar, U; Jain, VK				Attri, AK; Kumar, U; Jain, VK			Microclimate - Formation of ozone by fireworks	NATURE			English	Article							CLIMATE; TROPOSPHERE		Jawaharlal Nehru Univ, Sch Environm Sci, New Delhi 110067, India	Jawaharlal Nehru University, New Delhi	Attri, AK (corresponding author), Jawaharlal Nehru Univ, Sch Environm Sci, New Delhi 110067, India.		Kumar, Ujjwal/GRS-9422-2022	Kumar, Ujjwal/0000-0002-9422-8780				BRAUSSER GP, 1990, J GEOPHYS RES, V95, P5639; Chapman S., 1930, MEMOIRS ROYAL METEOR, V3, P103; CRUTZEN PJ, 1991, TELLUS A, V43, P136, DOI 10.1034/j.1600-0870.1991.00012.x; HOLMES HH, 1983, ENCY AM, V11, P263; JOHNSON DW, 1991, NATURE, V353, P617, DOI 10.1038/353617a0; LACIS AA, 1990, J GEOPHYS RES-ATMOS, V95, P9971, DOI 10.1029/JD095iD07p09971; RAMANATHAN V, 1985, J GEOPHYS RES-ATMOS, V90, P5547, DOI 10.1029/JD090iD03p05547; Reader J., 1982, CRC HDB CHEM PHYSICS, pE205; Singh A, 1997, ATMOS ENVIRON, V31, P3421, DOI 10.1016/S1352-2310(97)00138-6; WALCEK CJ, 1995, J APPL METEOROL, V34, P1056, DOI 10.1175/1520-0450(1995)034<1056:CIOTRF>2.0.CO;2; WANG WC, 1980, NATURE, V286, P589, DOI 10.1038/286589a0	11	104	111	4	36	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 28	2001	411	6841					1015	1015		10.1038/35082634	http://dx.doi.org/10.1038/35082634			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	446TF	11429593	Bronze			2022-12-28	WOS:000169528500036
J	Buchbinder, R; Jolley, D; Wyatt, M				Buchbinder, R; Jolley, D; Wyatt, M			Population based intervention to change back pain beliefs and disability: three part evaluation	BRITISH MEDICAL JOURNAL			English	Article							PRIMARY-CARE; PREVENTION; CHALLENGE; ADVICE; TRIAL	Objective To evaluate the effectiveness of a population based, state-wide public health intervention designed to alter beliefs about back pain, influence medical management, and reduce disability and costs of compensation. Design Quasi-experimental, non-randomised, non-equivalent, before and after telephone surveys of the general population and postal surveys of general practitioners with an adjacent state as control group and descriptive analysis of claims database. Setting Two states in Australia. Participants 4730 members of general population before and two and two and a half years after campaign started, in a ratio of 2:1:1; 2556 general Practitioners before and two years after campaign onset Main outcome measures Back beliefs questionnaire, knowledge and attitude statements about back pain, incidence of workers' financial compensation claims for back problems, rate of days compensated, and medical payments for claims related to back pain and other claims. Results In the intervention state beliefs about back pain became more positive between successive surveys (mean improvement in questionnaire score 1.9 (95% confidence interval 1.3 to 2.5), P< 0.001 and 3.2 (2.6 to 3.9), P < 0.001, between baseline and the second and third survey, respectively). Beliefs about back pain also improved among doctors. There was a clear decline in number of claims for back pain, rates of days compensated, and medical payments for claims for back pain over the duration of the campaign. Conclusions A population based strategy of provision of positive messages about back pain improves population and general practitioner beliefs about back pain and seems to influence medical management and reduce disability and workers' compensation costs related to back pain.	Cabrini Hosp, Dept Clin Epidemiol, Malvern, Vic 3144, Australia; Monash Univ, Dept Epidemiol & Prevent Med, Cabrini Med Ctr, Malvern, Vic 3144, Australia; Univ Burwood, Sch Hlth Sci, Burwood, Vic 3125, Australia; Monash Univ, Dept Epidemiol & Prevent Med, Melbourne, Vic 3004, Australia	Cabrini Health; Cabrini Health; Monash University; Monash University	Buchbinder, R (corresponding author), Cabrini Hosp, Dept Clin Epidemiol, Malvern, Vic 3144, Australia.		Buchbinder, Rachelle/G-2952-2011	Buchbinder, Rachelle/0000-0002-0597-0933				*AUSTR BUR STAT, 1996, 1996 CENS POP HOUS; BOMBARDIER C, 1995, ARTHRITIS RHEUM S9, V38, P385; Burton AK, 1999, SPINE, V24, P2484, DOI 10.1097/00007632-199912010-00010; BURTON AK, 1995, SPINE, V20, P722, DOI 10.1097/00007632-199503150-00014; CHERKIN DC, 1995, SPINE, V20, P1, DOI 10.1097/00007632-199501000-00001; Chew-Graham C, 1999, FAM PRACT, V16, P46, DOI 10.1093/fampra/16.1.46; *DESK TOP MARK SYS, 1997, MARK PRO; Deyo RA, 1996, SPINE, V21, P2826, DOI 10.1097/00007632-199612150-00003; Deyo RA, 1996, BRIT MED J, V313, P1343, DOI 10.1136/bmj.313.7069.1343; Frank JW, 1996, SPINE, V21, P2908, DOI 10.1097/00007632-199612150-00024; GRILLI R, 2001, COCHRANE DATABASE SY; Indahl A, 1998, SPINE, V23, P2625, DOI 10.1097/00007632-199812010-00018; LINTON SJ, 2000, NECK BACK PAIN SCI E; Little P, 1996, BMJ-BRIT MED J, V312, P485, DOI 10.1136/bmj.312.7029.485; Little P, 1998, FAM PRACT, V15, P264, DOI 10.1093/fampra/15.3.264; OWEN N, 1995, AM J PUBLIC HEALTH, V85, P244, DOI 10.2105/AJPH.85.2.244; Redman S., 1990, Health Promotion International, V5, P85, DOI 10.1093/heapro/5.1.85; Roland M, 2000, BACK BOOK; ROSE G, 1985, INT J EPIDEMIOL, V14, P32, DOI 10.1093/ije/14.1.32; Rose G., 1992, STRATEGY PREVENTIVE; Sly DF, 2001, TOB CONTROL, V10, P9, DOI 10.1136/tc.10.1.9; Symonds TL, 1995, SPINE, V20, P2738, DOI 10.1097/00007632-199512150-00016; Symonds TL, 1996, OCCUP MED-OXFORD, V46, P25, DOI 10.1093/occmed/46.1.25; van Poppel MNM, 1997, OCCUP ENVIRON MED, V54, P841, DOI 10.1136/oem.54.12.841; *VICT WORKC AUTH, 1996, GUID MAN EMPL COMP L; *VICT WORKC AUTH, 2000, STAT REP 1998 1999; WADDELL G, 1987, SPINE, V12, P632, DOI 10.1097/00007632-198709000-00002; Waddell G, 1997, BRIT J GEN PRACT, V47, P647; WADDELL G, 1993, PAIN, V52, P157, DOI 10.1016/0304-3959(93)90127-B; Weber M, 1996, BRIT J RHEUMATOL, V35, P178; WILLNER I, 1993, BIOORGANIC PHOTOCHEM, V2, P1	31	295	301	0	11	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 23	2001	322	7301					1516	1520		10.1136/bmj.322.7301.1516	http://dx.doi.org/10.1136/bmj.322.7301.1516			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	446UF	11420272	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000169532000017
J	Szulc, P; Meunier, PJ				Szulc, P; Meunier, PJ			Is vitamin K deficiency a risk factor for osteoporosis in Crohn's disease?	LANCET			English	Editorial Material							INFLAMMATORY-BOWEL-DISEASE; SERUM UNDERCARBOXYLATED OSTEOCALCIN; BONE-MINERAL DENSITY; ELDERLY WOMEN; HIP FRACTURE; MENATETRENONE; RESORPTION		Hop Edouard Herriot, INSERM, U403, F-69437 Lyon, France	CHU Lyon; Institut National de la Sante et de la Recherche Medicale (Inserm)	Meunier, PJ (corresponding author), Hop Edouard Herriot, INSERM, U403, F-69437 Lyon, France.		Szulc, Pawel/N-5238-2018	Szulc, Pawel/0000-0003-4168-6697				Bjarnason I, 1997, GUT, V40, P228, DOI 10.1136/gut.40.2.228; Caraballo PJ, 1999, ARCH INTERN MED, V159, P1750, DOI 10.1001/archinte.159.15.1750; CROUCHER PI, 1993, OSTEOPOROSIS INT, V3, P236, DOI 10.1007/BF01623826; HARA K, 1993, J BONE MINER RES, V8, P535; HARA K, 1995, BONE, V16, P179, DOI 10.1016/8756-3282(94)00027-W; HODGES SJ, 1993, J BONE MINER RES, V8, P1005; HODGES SJ, 1993, J BONE MINER RES, V8, P1241; MOTLEY RJ, 1993, BONE MINER, V23, P95, DOI 10.1016/S0169-6009(08)80046-3; NOTOYA K, 1995, BONE, V16, pS349, DOI 10.1016/8756-3282(94)00046-3; ROUX C, 1995, OSTEOPOROSIS INT, V5, P156, DOI 10.1007/BF02106094; Schoon EJ, 2001, GUT, V48, P473, DOI 10.1136/gut.48.4.473; Schulte CMS, 2000, GASTROENTEROLOGY, V119, P909, DOI 10.1053/gast.2000.18158; SHEARER MJ, 1995, LANCET, V345, P229, DOI 10.1016/S0140-6736(95)90227-9; Shiraki M, 2000, J BONE MINER RES, V15, P515, DOI 10.1359/jbmr.2000.15.3.515; Sokoll LJ, 1996, AM J CLIN NUTR, V63, P566, DOI 10.1093/ajcn/63.4.566; Stone KL, 1999, J BONE MINER RES, V14, pS263; SZULC P, 1994, J BONE MINER RES, V9, P1591; SZULC P, 1993, J CLIN INVEST, V91, P1769, DOI 10.1172/JCI116387	18	17	18	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 23	2001	357	9273					1995	1996		10.1016/S0140-6736(00)05135-7	http://dx.doi.org/10.1016/S0140-6736(00)05135-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	446JB	11438129				2022-12-28	WOS:000169509200006
J	Barker, PA; Street-Perrott, FA; Leng, MJ; Greenwood, PB; Swain, DL; Perrott, RA; Telford, RJ; Ficken, KJ				Barker, PA; Street-Perrott, FA; Leng, MJ; Greenwood, PB; Swain, DL; Perrott, RA; Telford, RJ; Ficken, KJ			A 14,000-year oxygen isotope record from diatom silica in two alpine lakes on Mt. Kenya	SCIENCE			English	Article							ATLANTIC-OCEAN; EAST-AFRICA; ICE; CLIMATE; FLUCTUATIONS; QUELCCAYA; EVENTS; IMPACT; BP	Oxygen isotopes are sensitive tracers of climate change in tropical regions. Abrupt shifts of up to 18 per mil in the oxygen isotope ratio of diatom silica have been found in a 14,000-year record from two alpine Lakes on Mt. Kenya. Interpretation of tropical-montane isotope records is controversial, especially concerning the relative roles of precipitation and temperature. Here, we argue that Holocene variations in delta O-18 are better explained by Lake moisture balance than by temperature-induced fractionation. Episodes of heavy convective precipitation dated similar to 11,100 to 8600, 6700 to 5600, 2900 to 1900, and <1300 years before the present were linked to enhanced soil erosion, neoglacial ice advances, and forest expansion on Mt. Kenya.	Univ Lancaster, Dept Geog, HYSED, Lancaster LA1 4YB, England; Univ Wales, Dept Geog, Trop Palaeoenvironm Res Grp, Swansea SA2 8PP, W Glam, Wales; NERC, Isotope Geosci Lab, Nottingham NG12 5GG, England	Lancaster University; UK Research & Innovation (UKRI); Natural Environment Research Council (NERC); NERC British Geological Survey	Barker, PA (corresponding author), Univ Lancaster, Dept Geog, HYSED, Lancaster LA1 4YB, England.		Telford, Richard/C-1668-2008; Barker, Philip/J-5938-2012; Telford, Richard/AAD-2249-2019	Telford, Richard/0000-0001-9826-3076; Telford, Richard/0000-0001-9826-3076; Barker, Philip/0000-0002-5334-9201; Leng, Melanie/0000-0003-1115-5166				Brandriss ME, 1998, GEOCHIM COSMOCHIM AC, V62, P1119, DOI 10.1016/S0016-7037(98)00054-4; Darling W.G., 1996, THESIS OPEN U; DUPLESSY JC, 1980, NATURE, V286, P479, DOI 10.1038/286479a0; Flohn H., 1987, PALAEOECOL AFR, V18, P3; FONTES JC, 1993, ISOTOPE TECHNIQUES S, P231; GASSE F, 1994, EARTH PLANET SC LETT, V126, P435, DOI 10.1016/0012-821X(94)90123-6; Gatebe CK, 1999, J GEOPHYS RES-ATMOS, V104, P14237, DOI 10.1029/1998JD200103; GROOTES PM, 1989, J GEOPHYS RES-ATMOS, V94, P1187, DOI 10.1029/JD094iD01p01187; HASTENRATH S, 1981, GLACIERS EQUATORIAL; Hoffmann G, 1997, QUATERN INT, V37, P115, DOI 10.1016/1040-6182(96)00004-3; Jouzel J, 2000, QUATERNARY SCI REV, V19, P363, DOI 10.1016/S0277-3791(99)00069-4; Karlen W, 1999, AMBIO, V28, P409; KRISHNAMURTHY RV, 1985, NATURE, V317, P160, DOI 10.1038/317160a0; Ngecu WM, 1999, ENVIRON GEOL, V38, P277, DOI 10.1007/s002540050425; Nicholson S.E., 1996, LIMNOLOGY CLIMATOLOG, V1st ed., P25, DOI [DOI 10.1201/9780203748978-2, 10.1201/9780203748978-2]; Njitchoua R, 1999, J HYDROL, V223, P17, DOI 10.1016/S0022-1694(99)00087-6; Peyron O, 2000, QUATERNARY RES, V54, P90, DOI 10.1006/qres.2000.2136; Rietti-Shati M, 1998, SCIENCE, V281, P980, DOI 10.1126/science.281.5379.980; ROZANSKI K, 1996, LIMNOLOGY CLIMATOLOG, P79; Rozanski K., 1993, CLIMATE CHANGE CONTI, V78, P1, DOI DOI 10.1029/GM078P0001; Schmidt M, 2001, GEOCHIM COSMOCHIM AC, V65, P201, DOI 10.1016/S0016-7037(00)00534-2; Sonzogni C, 1998, QUATERNARY SCI REV, V17, P1185, DOI 10.1016/S0277-3791(97)00099-1; Stager JC, 1997, SCIENCE, V276, P1834, DOI 10.1126/science.276.5320.1834; STREETPERROTT FA, 1990, NATURE, V343, P607, DOI 10.1038/343607a0; StreetPerrott FA, 1997, SCIENCE, V278, P1422, DOI 10.1126/science.278.5342.1422; SWAIN DL, 1999, THESIS U WALES SWANS; Thompson LG, 1998, SCIENCE, V282, P1858, DOI 10.1126/science.282.5395.1858; THOMPSON LG, 1979, SCIENCE, V203, P1240, DOI 10.1126/science.203.4386.1240; Thompson LG, 2000, J QUATERNARY SCI, V15, P377, DOI 10.1002/1099-1417(200005)15:4<377::AID-JQS542>3.0.CO;2-L; THOMPSON LG, 1979, SEA LEVEL ICE CLIMAT, V131, P55; VYVERMAN W, 1995, J PALEOLIMNOL, V13, P65, DOI 10.1007/BF00678111	31	121	124	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 22	2001	292	5525					2307	2310		10.1126/science.1059612	http://dx.doi.org/10.1126/science.1059612			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	445KD	11423656				2022-12-28	WOS:000169455900051
J	Pacala, SW; Hurtt, GC; Baker, D; Peylin, P; Houghton, RA; Birdsey, RA; Heath, L; Sundquist, ET; Stallard, RF; Ciais, P; Moorcroft, P; Caspersen, JP; Shevliakova, E; Moore, B; Kohlmaier, G; Holland, E; Gloor, M; Harmon, ME; Fan, SM; Sarmiento, JL; Goodale, CL; Schimel, D; Field, CB				Pacala, SW; Hurtt, GC; Baker, D; Peylin, P; Houghton, RA; Birdsey, RA; Heath, L; Sundquist, ET; Stallard, RF; Ciais, P; Moorcroft, P; Caspersen, JP; Shevliakova, E; Moore, B; Kohlmaier, G; Holland, E; Gloor, M; Harmon, ME; Fan, SM; Sarmiento, JL; Goodale, CL; Schimel, D; Field, CB			Consistent land- and atmosphere-based US carbon sink estimates	SCIENCE			English	Article							WOOD PRODUCTS; UNITED-STATES; MODEL; CO2; STORAGE; TRANSPORT; FORESTS; FLUXES; BUDGET	For the period 1980-89, we estimate a carbon sink in the coterminous United States between 0.30 and 0.58 petagrams of carbon per year (petagrams of carbon = 10(15) grams of carbon). The net carbon flux from the atmosphere to the Land was higher, 0.37 to 0.71 petagrams of carbon per year, because a net flux of 0.07 to 0.13 petagrams of carbon per year was exported by rivers and commerce and returned to the atmosphere elsewhere. These Land-based estimates are Larger than those from previous studies (0.08 to 0.35 petagrams of carbon per year) because of the inclusion of additional processes and revised estimates of some component fluxes. Although component estimates are uncertain, about one-half of the total is outside the forest sector. We also estimated the sink using atmospheric models and the atmospheric concentration of carbon dioxide (the tracer-transport inversion method). The range of results from the atmosphere-based inversions contains the Land-based estimates. Atmosphere- and land-based estimates are thus consistent, within the Large ranges of uncertainty for both methods. Atmosphere-based results for 1980-89 are similar to those for 1985-89 and 1990-94, indicating a relatively stable U.S. sink throughout the period.	Princeton Univ, Dept Ecol & Evolutionary Biol, Princeton, NJ 08544 USA; Princeton Univ, Atmospher & Ocean Sci Program, Princeton, NJ 08544 USA; Univ New Hampshire, Inst Study Earth Oceans & Space, Complex Syst Res Ctr, Durham, NH 03824 USA; Woods Hole Res Ctr, Woods Hole, MA 02543 USA; UPMC, Biogeochim Isotop Lab, CNRS, INRA, Paris, France; US Forest Serv, USDA, Newtown Sq, PA 19073 USA; US Geol Survey, Woods Hole, MA 02543 USA; US Geol Survey, Div Water Resources, Boulder, CO 80303 USA; CEA Saclay, LSCE, F-91191 Gif Sur Yvette, France; Goethe Univ Frankfurt, Zentrum Umweltforsch, D-60325 Frankfurt, Germany; Max Planck Inst Biogeochem, D-07745 Jena, Germany; Oregon State Univ, Dept Forest Sci, Corvallis, OR 97331 USA; Carnegie Inst Sci, Dept Plant Biol, Stanford, CA 94305 USA	Princeton University; National Oceanic Atmospheric Admin (NOAA) - USA; Princeton University; University System Of New Hampshire; University of New Hampshire; Woods Hole Research Center; Centre National de la Recherche Scientifique (CNRS); INRAE; UDICE-French Research Universities; Sorbonne Universite; United States Department of Agriculture (USDA); United States Forest Service; United States Department of the Interior; United States Geological Survey; United States Department of the Interior; United States Geological Survey; UDICE-French Research Universities; Universite Paris Saclay; CEA; Centre National de la Recherche Scientifique (CNRS); Goethe University Frankfurt; Max Planck Society; Oregon State University; Carnegie Institution for Science	Pacala, SW (corresponding author), Princeton Univ, Dept Ecol & Evolutionary Biol, Princeton, NJ 08544 USA.	Pacala@princeton.edu	Noojipady, Praveen/B-2511-2010; Hurtt, George/A-8450-2012; Stallard, Robert F/H-2649-2013; Ciais, Philippe/A-6840-2011; Shevliakova, Elena/J-5770-2014; Fan, Song-Miao/A-8004-2008	Hurtt, George/0000-0001-7278-202X; Stallard, Robert F/0000-0001-8209-7608; Ciais, Philippe/0000-0001-8560-4943; Fan, Song-Miao/0000-0001-8352-8035; Peylin, Philippe/0000-0001-9335-6994; Goodale, Christine/0000-0003-4317-3983; Holland, Elisabeth Ann/0000-0002-3570-621X				[Anonymous], GLOBAL ATMOSPHERIC T; Battle M, 2000, SCIENCE, V287, P2467, DOI 10.1126/science.287.5462.2467; Birdsey RA, 1992, WO59 USDA FOR SERV G; BIRDSEY RA, 1995, PRODUCTIVITY AM FORE, P56; Bousquet P, 2000, SCIENCE, V290, P1342, DOI 10.1126/science.290.5495.1342; Fan S, 1998, SCIENCE, V282, P442, DOI 10.1126/science.282.5388.442; *FED EM MAN AG ARM, 1993, WAT CONTR INFR NAT I; Gloor M, 1999, J GEOPHYS RES-ATMOS, V104, P14245, DOI 10.1029/1999JD900132; HEATH LS, 1993, WATER AIR SOIL POLL, V70, P279, DOI 10.1007/BF01105002; Houghton RA, 1999, SCIENCE, V285, P574, DOI 10.1126/science.285.5427.574; Houghton RA, 2000, GLOBAL ECOL BIOGEOGR, V9, P145, DOI 10.1046/j.1365-2699.2000.00164.x; Houghton RA, 2000, GLOBAL ECOL BIOGEOGR, V9, P125, DOI 10.1046/j.1365-2699.2000.00166.x; Kaminski T, 1999, J GEOPHYS RES-ATMOS, V104, P18555, DOI 10.1029/1999JD900146; MAHLMAN JD, 1978, J ATMOS SCI, V35, P1340, DOI 10.1175/1520-0469(1978)035<1340:TSUAGG>2.0.CO;2; MELILLO J, UNPUB; MOORCROFT P, IN PRESS ECOL MONOGR; Peylin P, 2000, GEOPH MONOG SERIES, V114, P295; PEYLIN P, UNPUB; POTTER CS, 1993, GLOBAL BIOGEOCHEM CY, V7, P811, DOI 10.1029/93GB02725; Rayner PJ, 1999, TELLUS B, V51, P213, DOI 10.1034/j.1600-0889.1999.t01-1-00008.x; Schimel D, 2000, SCIENCE, V287, P2004, DOI 10.1126/science.287.5460.2004; Skog KE, 1998, FOREST PROD J, V48, P75; TANS PP, 1990, SCIENCE, V247, P1431, DOI 10.1126/science.247.4949.1431; TURNER DP, 1995, ECOL APPL, V5, P421, DOI 10.2307/1942033; Winjum JK, 1998, FOREST SCI, V44, P272	25	634	721	14	198	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 22	2001	292	5525					2316	2320		10.1126/science.1057320	http://dx.doi.org/10.1126/science.1057320			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	445KD	11423659	Green Submitted			2022-12-28	WOS:000169455900054
J	Liljeros, F; Edling, CR; Amaral, LAN; Stanley, HE; Aberg, Y				Liljeros, F; Edling, CR; Amaral, LAN; Stanley, HE; Aberg, Y			The web of human sexual contacts	NATURE			English	Article							SMALL-WORLD NETWORKS; COMPLEX NETWORKS		Stockholm Univ, Dept Sociol, S-10691 Stockholm, Sweden; Boston Univ, Ctr Polymer Studies, Boston, MA 02215 USA; Boston Univ, Dept Phys, Boston, MA 02215 USA	Stockholm University; Boston University; Boston University	Liljeros, F (corresponding author), Stockholm Univ, Dept Sociol, S-10691 Stockholm, Sweden.		Amaral, LAN/A-4980-2008; Liljeros, Fredrik G I/I-2667-2018; Amaral, Luis N./C-5485-2009; Edling, Christofer R/C-8541-2013	Amaral, LAN/0000-0002-3762-789X; Liljeros, Fredrik G I/0000-0001-8642-6624; Edling, Christofer R/0000-0002-3909-1080				Albert R, 2000, NATURE, V406, P378, DOI 10.1038/35019019; Amaral LAN, 2000, P NATL ACAD SCI USA, V97, P11149, DOI 10.1073/pnas.200327197; Barabasi AL, 1999, SCIENCE, V286, P509, DOI 10.1126/science.286.5439.509; Barthelemy M, 1999, PHYS REV LETT, V82, P3180, DOI 10.1103/PhysRevLett.82.3180; Hethcote H., 1984, LECT NOTES BIOMATHEM; Kochen Manfred, 1989, SMALL WORLD; Laumann E. O., 1994, SOCIAL ORG SEXUALITY; LEWIN B, 1998, SEX SWEDEN SEXUAL LI; MILGRAM S, 1967, PSYCHOL TODAY, V1, P61; Pastor-Satorras R, 2001, PHYS REV LETT, V86, P3200, DOI 10.1103/PhysRevLett.86.3200; SIMON HA, 1955, BIOMETRIKA, V42, P425; Strogatz SH, 2001, NATURE, V410, P268, DOI 10.1038/35065725; Wasserman S., 1994, STRUCTURAL ANAL SOCI, DOI 10.1017/CBO9780511815478; Watts DJ, 1998, NATURE, V393, P440, DOI 10.1038/30918	14	1118	1172	6	119	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 21	2001	411	6840					907	908		10.1038/35082140	http://dx.doi.org/10.1038/35082140			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	444EN	11418846	Green Submitted			2022-12-28	WOS:000169386200032
J	Xie, SP; Liu, WT; Liu, QY; Nonaka, M				Xie, SP; Liu, WT; Liu, QY; Nonaka, M			Far-reaching effects of the Hawaiian islands on the Pacific Ocean-atmosphere system	SCIENCE			English	Article							TEMPERATURE; EXISTENCE; MODEL; GYRE; WAKE	Using satellite data, we detected a wind wake trailing westward behind the Hawaiian Islands for 3000 kilometers, a length many times greater than observed anywhere else on Earth, This wind wake drives an eastward ocean current that draws warm water from the Asian coast 8000 kilometers away, leaving marked changes in surface and subsurface ocean temperature. Standing in the path of the steady trade winds, Hawaii triggers an air-sea interaction that provides the feedback to sustain the influence of these small islands over a long stretch of the Pacific Ocean.	Univ Hawaii, Sch Ocean & Earth Sci & Technol, Int Pacific Res Ctr, Honolulu, HI 96822 USA; CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA; Ocean Univ Qingdao, Phys Oceanog Lab, Qingdao 266003, Peoples R China; Frontier Res Syst Global Change, Yokohama, Kanagawa 2360001, Japan	University of Hawaii System; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); Ocean University of China; Japan Agency for Marine-Earth Science & Technology (JAMSTEC)	Xie, SP (corresponding author), Univ Hawaii, Sch Ocean & Earth Sci & Technol, Int Pacific Res Ctr, 2525 Correa Rd, Honolulu, HI 96822 USA.	de@soest.hawaii.edu	Nonaka, Masami/G-3417-2014; Xie, Shang-Ping/C-1254-2009	Xie, Shang-Ping/0000-0002-3676-1325; Nonaka, Masami/0000-0003-2522-0686				Chang P, 1997, NATURE, V385, P516, DOI 10.1038/385516a0; CHOPRA KP, 1973, ADV GEOPHYS, V16, P298; DeFelice TP, 2000, B AM METEOROL SOC, V81, P1047; ETLING D, 1989, METEOROL ATMOS PHYS, V41, P157, DOI 10.1007/BF01043134; Flament P., 1998, ATLAS HAWAI, P82; FREILICH MH, 1997, OROGRAPHICALLY MODIF; Kalnay E, 1996, B AM METEOROL SOC, V77, P437, DOI 10.1175/1520-0477(1996)077<0437:TNYRP>2.0.CO;2; Kubokawa A, 1999, J PHYS OCEANOGR, V29, P1303, DOI 10.1175/1520-0485(1999)029<1303:SCIAIO>2.0.CO;2; LIU Q, 2000, CHIN J ATMOS SCI, V24, P363; Liu WT, 2000, GEOPHYS RES LETT, V27, P2545, DOI 10.1029/2000GL011545; NICKERSON EC, 1981, J APPL METEOROL, V20, P868, DOI 10.1175/1520-0450(1981)020<0868:OTEOAV>2.0.CO;2; Okumura Y, 2001, GEOPHYS RES LETT, V28, P1507, DOI 10.1029/2000GL012565; PATZERT WC, 1969, 698 HAW I; Qiu B, 1997, J PHYS OCEANOGR, V27, P431, DOI 10.1175/1520-0485(1997)027<0431:EAFMOT>2.0.CO;2; ROBINSON WA, 2000, B AM METEOROL SOC, V77, P567; SMITH RB, 1993, J ATMOS SCI, V50, P3728, DOI 10.1175/1520-0469(1993)050<3728:AOOHW>2.0.CO;2; Smith RB, 1997, J ATMOS SCI, V54, P606, DOI 10.1175/1520-0469(1997)054<0606:TWOSV>2.0.CO;2; Stammer D, 1996, J GEOPHYS RES-OCEANS, V101, P25779, DOI 10.1029/96JC01754; TAKEUCHI K, 1986, J PHYS OCEANOGR, V16, P919, DOI 10.1175/1520-0485(1986)016<0919:NSOTSV>2.0.CO;2; Wentz, 2000, Science, V288, P847, DOI 10.1126/science.288.5467.847; White WB, 1995, PROG OCEANOGR, V36, P169, DOI 10.1016/0079-6611(95)00017-8; WHITE WB, 1985, J GEOPHYS RES-OCEANS, V90, P7061, DOI 10.1029/JC090iC04p07061; XIE SP, 1994, TELLUS A, V46, P340, DOI 10.1034/j.1600-0870.1994.t01-1-00001.x; Xie SP, 2000, J PHYS OCEANOGR, V30, P2798, DOI 10.1175/1520-0485(2000)030<2798:ITVITN>2.0.CO;2; YAMAGATA T, 1985, COUPLED OCEAN ATMOSP, P637; Yoshida K., 1967, J OCEANOGRAPHICAL SO, V23, P88, DOI [10.5928/kaiyou1942.23.88, DOI 10.5928/KAIYOU1942.23.88]	26	202	212	0	28	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 15	2001	292	5524					2057	2060		10.1126/science.1059781	http://dx.doi.org/10.1126/science.1059781			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	442KP	11408652				2022-12-28	WOS:000169284700041
J	Hille, ETM; den Ouden, AL; Saigal, S; Wolke, D; Lambert, M; Whitaker, A; Pinto-Martin, JA; Hoult, L; Meyer, R; Feldman, JF; Verloove-Vanhorick, SP; Paneth, N				Hille, ETM; den Ouden, AL; Saigal, S; Wolke, D; Lambert, M; Whitaker, A; Pinto-Martin, JA; Hoult, L; Meyer, R; Feldman, JF; Verloove-Vanhorick, SP; Paneth, N			Behavioural problems in children who weigh 1000 g or less at birth in four countries	LANCET			English	Article							VERY-LOW; PRETERM INFANTS; SCHOOL; BORN; AGE; ADJUSTMENT; NEWBORNS; CULTURES; PARENTS; COHORT	Background The increased survival chances of extremely low-birthweight (ELBW) infants (weighing less than or equal to 1000 g at birth) has led to concern about their behavioural outcome in childhood. In reports from several countries with different assessments at various ages, investigators have noted a higher frequency of behavioural problems in such infants, but cross-cultural comparisons are lacking. Our aim was to compare behavioural problems in ELBW children of similar ages from four countries. Methods We prospectively studied 408 ELBW children aged 8-10 years, whose parents completed the child behaviour checklist. The children came from the Netherlands. Germany, Canada, and USA. The checklist provides a total problem score consisting of eight narrow-band scales. Of these, two (aggressive and delinquent behaviour) give a broad-band externalising score, three (anxious, somatic, and withdrawn behaviour) give a broad-band internalising score, and three (social, thought, and attention problems) indicate difficulties fitting neither broad-band dimension. For each cohort we analysed scores in ELBW children and those in normal-birthweight controls (two cohorts) or national normative controls (two cohorts). Across countries, we assessed deviations of the ELBW children from normative or control groups. Findings ELBW children had higher total problem scores than normative or control children, but this increase was only significant in European countries. Narrow-band scores were raised only for the social, thought, and attention difficulty scales, which were 0.5-1.2 SD higher in ELBW children than in others. Except for the increase in internalising scores recorded for one cohort, ELBW children did not differ from normative or control children on internalising or externalising scales. Interpretation Despite cultural differences, types of behavioural problems seen in ELBW children were very similar in the four countries. This finding suggests that biological mechanisms contribute to behavioural problems of ELBW children.	TNO Prevent & Hlth, Child Hlth Div, NL-2301 CE Leiden, Netherlands; McMaster Univ, Hamilton, ON, Canada; Univ Hertfordshire, Hatfield AL10 9AB, Herts, England; Michigan State Univ, E Lansing, MI 48824 USA; Columbia Univ, New York, NY 10027 USA; New York State Psychiat Inst, New York, NY 10032 USA; Univ Penn, Sch Nursing & Med, Philadelphia, PA 19104 USA; Univ Munich, Childrens Hosp, D-8000 Munich, Germany	Netherlands Organization Applied Science Research; McMaster University; University of Hertfordshire; Michigan State University; Columbia University; New York State Psychiatry Institute; University of Pennsylvania; University of Munich	Hille, ETM (corresponding author), TNO Prevent & Hlth, Child Hlth Div, POB 2215, NL-2301 CE Leiden, Netherlands.		Wolke, Dieter/C-5372-2008	Wolke, Dieter/0000-0003-0304-268X	AHRQ HHS [R01 HS-08385] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS008385] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ACHENBACH TM, 1993, J AM ACAD CHILD PSY, V32, P1145, DOI 10.1097/00004583-199311000-00006; ALS H, 1988, INFANT BEHAV DEV, V11, P305, DOI 10.1016/0163-6383(88)90016-1; [Anonymous], 1991, MANUAL CHILD BEHAV C; BRESLAU N, 1988, J AM ACAD CHILD PSY, V27, P605, DOI 10.1097/00004583-198809000-00015; Chapieski ML, 1997, SEMIN PERINATOL, V21, P221, DOI 10.1016/S0146-0005(97)80065-1; Crijnen AAM, 1999, AM J PSYCHIAT, V156, P569; Crijnen AAM, 1997, J AM ACAD CHILD PSY, V36, P1269, DOI 10.1097/00004583-199709000-00020; Dammann O, 1999, PEDIATRICS, V104, P541, DOI 10.1542/peds.104.3.541; KLEBANOV PK, 1994, PEDIATRICS, V94, P700; MCCORMICK MC, 1990, J PEDIATR-US, V117, P687, DOI 10.1016/S0022-3476(05)83322-0; PHAROAH POD, 1994, ARCH DIS CHILD, V70, P271, DOI 10.1136/adc.70.4.271; Pinto-Martin J, 1992, Paediatr Perinat Epidemiol, V6, P273, DOI 10.1111/j.1365-3016.1992.tb00767.x; ROSS G, 1990, PEDIATRICS, V86, P391; Saigal S, 2000, PEDIATRICS, V105, P325, DOI 10.1542/peds.105.2.325; SCHACHAR R, 1991, J CHILD PSYCHOL PSYC, V32, P155, DOI 10.1111/j.1469-7610.1991.tb00007.x; Singer LT, 1999, JAMA-J AM MED ASSOC, V281, P799, DOI 10.1001/jama.281.9.799; Stewart AL, 1999, LANCET, V353, P1653, DOI 10.1016/S0140-6736(98)07130-X; Stjernqvist K, 1999, ACTA PAEDIATR, V88, P557, DOI 10.1080/08035259950169594; Sykes DH, 1997, J CHILD PSYCHOL PSYC, V38, P315, DOI 10.1111/j.1469-7610.1997.tb01516.x; SZATMARI P, 1993, DEV PSYCHOPATHOL, V5, P345, DOI 10.1017/S0954579400004454; Tessier R, 1997, INT J BEHAV DEV, V21, P795, DOI 10.1080/016502597384677; Verhulst F.C., 1996, MANUAL CHILD BEHAV C; Walther FJ, 2000, EARLY HUM DEV, V59, P175, DOI 10.1016/S0378-3782(00)00094-3; Whitaker AH, 1997, ARCH GEN PSYCHIAT, V54, P847; WOLKE D, 1994, EUR J PEDIATR, V153, P906, DOI 10.1007/s004310050239; Wolke D, 1999, DEV MED CHILD NEUROL, V41, P94, DOI 10.1017/S0012162299000201; Wood NS, 2000, NEW ENGL J MED, V343, P378, DOI 10.1056/NEJM200008103430601; YOUNG Y, 1996, DEV CARE PREMATURE B; ZELKOWITZ P, 1995, J CLIN CHILD PSYCHOL, V24, P21, DOI 10.1207/s15374424jccp2401_3; Zubrick SR, 2000, DEV MED CHILD NEUROL, V42, P14, DOI 10.1017/S0012162200000049	30	200	211	0	16	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 26	2001	357	9269					1641	1643		10.1016/S0140-6736(00)04818-2	http://dx.doi.org/10.1016/S0140-6736(00)04818-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	435UY	11425366				2022-12-28	WOS:000168901600007
J	Kristiansen, IS; Forde, OH; Aasland, O; Hotvedt, R; Johnsen, R; Forde, R				Kristiansen, IS; Forde, OH; Aasland, O; Hotvedt, R; Johnsen, R; Forde, R			Threats from patients and their effects on medical decision making: a cross-sectional, randomised trial	LANCET			English	Article							RESPIRATORY-TRACT ILLNESS; GENERAL-PRACTITIONERS; DEFENSIVE MEDICINE; MALPRACTICE CLAIMS; CARE; MANAGEMENT; QUESTIONNAIRE; PHYSICIANS; BEHAVIOR	Background Negative experiences are not uncommon among doctors in Norway. Our aim was to find out about the various types of negative reactions (eg, complaints, negative exposure to the media, financial claims, and notification to the police) received by physicians from patients or relatives in response to treatment, to identify their cause, and to study their effects on subsequent clinical decisions. Methods We posted questionnaires about negative reactions of patients to a random sample (n=1260) of Norwegian doctors. Each doctor was additionally sent five written case simulations and asked to choose one of several proposed clinical strategies. Half (630) the physicians received cases containing threats from the patient or their relatives. Findings 988 (78%) physicians returned the questionnaire, 463 (47%) of whom reported negative experiences. Such experiences were reported more frequently by men (357 [51%]) and family physicians (157 [58%]) than by other participants. Negative experiences did not affect choice of strategy for case simulations. For the first case, chest pain, 217 (44%) physicians presented with a threat chose a defensive strategy compared with 145 (30%) of those who were not (difference 14%: 95% CI 8-20). For the second case, a headache case, the corresponding numbers were 278 (57%) and 118 (25%) (32%; 26-38). Physician age. sex, specialty, or experience of negative reactions of patients did not alter the effect of threats received during our study. Interpretation Negative experiences do not affect subsequent decision making. However, doctors do comply with wishes from patients or relatives when presented with direct threats.	Univ So Denmark, Inst Publ Hlth, DK-5000 Odense C, Denmark	University of Southern Denmark	Kristiansen, IS (corresponding author), Univ So Denmark, Inst Publ Hlth, DK-5000 Odense C, Denmark.							Aasland Olaf Gjerlow, 1997, Tidsskrift for den Norske Laegeforening, V117, P2464; Andersen TF., 1990, CHALLENGES MED PRACT; BALDWIN LM, 1995, JAMA-J AM MED ASSOC, V274, P1606, DOI 10.1001/jama.274.20.1606; ENTMAN SS, 1994, JAMA-J AM MED ASSOC, V272, P1588, DOI 10.1001/jama.272.20.1588; Garg M L, 1978, Leg Aspects Med Pract, V6, P25; HICKSON GB, 1994, JAMA-J AM MED ASSOC, V272, P1583, DOI 10.1001/jama.272.20.1583; Jain A, 1999, BRIT MED J, V318, P1596, DOI 10.1136/bmj.318.7198.1596; JONES TV, 1990, J CLIN EPIDEMIOL, V43, P805, DOI 10.1016/0895-4356(90)90241-G; Klingman D, 1996, J HEALTH POLIT POLIC, V21, P185, DOI 10.1215/03616878-21-2-185; KUYVENHOVEN MM, 1984, FAM PRACT, V1, P14, DOI 10.1093/fampra/1.1.14; Levinson W, 1997, JAMA-J AM MED ASSOC, V277, P553, DOI 10.1001/jama.277.7.553; Macfarlane J, 1997, RESP MED, V91, P427, DOI 10.1016/S0954-6111(97)90258-4; Macfarlane J, 1997, BMJ-BRIT MED J, V315, P1211, DOI 10.1136/bmj.315.7117.1211; MCQUADE JS, 1991, J ROY SOC MED, V84, P408, DOI 10.1177/014107689108400710; Mohr, 2000, JAMA, V284, P827; Morgan B, 1997, BRIT J RADIOL, V70, P256, DOI 10.1259/bjr.70.831.9166050; *NAT BOARD HLTH, 1999, 3 4 FORM COMPL ENDS; NORMAN GR, 1981, MED EDUC, V15, P26, DOI 10.1111/j.1365-2923.1981.tb02311.x; Project, 1971, DUKE LAW J, V5, P939; REDELMEIER DA, 1990, NEW ENGL J MED, V322, P1162, DOI 10.1056/NEJM199004193221620; SUMMERTON N, 1995, BRIT MED J, V310, P27, DOI 10.1136/bmj.310.6971.27; VanBoven K, 1997, J FAM PRACTICE, V44, P468; WENNBERG J, 1973, SCIENCE, V182, P1102, DOI 10.1126/science.182.4117.1102; Williams S V, 1982, Inquiry, V19, P363; Wright J, 1996, FAM PRACT, V13, P259, DOI 10.1093/fampra/13.3.259; 1999, 1998 NORW SYST COMP	26	11	11	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 21	2001	357	9264					1258	1261		10.1016/S0140-6736(00)04407-X	http://dx.doi.org/10.1016/S0140-6736(00)04407-X			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	425YY	11418151				2022-12-28	WOS:000168323300013
J	CHARIOT, P				CHARIOT, P			ZIDOVUDINE MYOPATHY	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											CHARIOT, P (corresponding author), HOP HENRI MONDOR,F-94000 CRETEIL,FRANCE.		Chariot, Patrick/H-6384-2019	Chariot, Patrick/0000-0001-5556-8814					0	3	3	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 10	1993	328	23					1675	1675						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LF054	11407398				2022-12-28	WOS:A1993LF05400005
J	Charatan, F				Charatan, F			US consultants coach doctors in insurance fraud	BRITISH MEDICAL JOURNAL			English	News Item																			0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUL 7	2001	323	7303					7	7						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	451WA	11440926				2022-12-28	WOS:000169824300007
J	Super, H; Spekreijse, H; Lamme, VAF				Super, H; Spekreijse, H; Lamme, VAF			A neural correlate of working memory in the monkey primary visual cortex	SCIENCE			English	Article							PERSISTENCE; FIGURE; V1	The brain frequently needs to store information for short periods. In vision, this means that the perceptual correlate of a stimulus has to be maintained temporally once the stimulus has been removed from the visual scene. However, it is not known how the visual system transfers sensory information into a memory component. Here, we identify a neural correlate of working memory in the monkey primary visual cortex( V1). We propose that this component may Link sensory activity with memory activity.	Univ Amsterdam, Acad Med Ctr, Grad Sch Neurosci Amsterdam, Dept Visual Syst Anal, NL-1100 AA Amsterdam, Netherlands; Netherlands Ophthalm Res Inst, NL-1105 BA Amsterdam, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; Royal Netherlands Academy of Arts & Sciences; Netherlands Institute for Neuroscience (NIN-KNAW)	Super, H (corresponding author), Univ Amsterdam, Acad Med Ctr, Grad Sch Neurosci Amsterdam, Dept Visual Syst Anal, POB 12011, NL-1100 AA Amsterdam, Netherlands.			Super, Hans/0000-0001-9328-0096				Courtney SM, 1997, NATURE, V386, P608, DOI 10.1038/386608a0; DILOLLO V, 1984, J EXP PSYCHOL HUMAN, V10, P144, DOI 10.1037/0096-1523.10.1.144; Fuster JM, 1997, TRENDS NEUROSCI, V20, P451, DOI 10.1016/S0166-2236(97)01128-4; GOLDMANRAKIC PS, 1990, PROGR BRAIN RES, P313; Hupe JM, 1998, NATURE, V394, P784, DOI 10.1038/29537; Lamme VAF, 1998, P NATL ACAD SCI USA, V95, P3263, DOI 10.1073/pnas.95.6.3263; Lamme VAF, 1998, CURR OPIN NEUROBIOL, V8, P529, DOI 10.1016/S0959-4388(98)80042-1; Lamme VAF, 2000, VISION RES, V40, P1507, DOI 10.1016/S0042-6989(99)00243-6; MIYASHITA Y, 1988, NATURE, V331, P68, DOI 10.1038/331068a0; Payne BR, 1996, TRENDS NEUROSCI, V19, P535, DOI 10.1016/S0166-2236(96)10061-8; SHIOIRI S, 1992, VISION RES, V32, P943, DOI 10.1016/0042-6989(92)90037-J; Super H, 2001, NAT NEUROSCI, V4, P304, DOI 10.1038/85170	12	190	191	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 6	2001	293	5527					120	124		10.1126/science.1060496	http://dx.doi.org/10.1126/science.1060496			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	451BB	11441187	Green Published			2022-12-28	WOS:000169780300042
J	Gupta, K; Hooton, TM; Roberts, PL; Stamm, WE				Gupta, K; Hooton, TM; Roberts, PL; Stamm, WE			Patient-initiated treatment of uncomplicated recurrent urinary tract infections in young women	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	38th Annual Meeting of the Infectious-Diseases-Society-of-America	SEP 06-11, 2000	NEW ORLEANS, LA	Infect Dis Soc Amer			CHLAMYDIA-TRACHOMATIS INFECTIONS; ACUTE URETHRAL SYNDROME; THERAPY; MANAGEMENT; OFLOXACIN; DIAGNOSIS; CYSTITIS; TRIAL	Background: Recurrent urinary tract infections (UTIs) are a common outpatient problem, resulting in frequent office visits and often requiring the use of prophylactic antimicrobial agents. Patient-initiated treatment of recurrent UTIs may decrease antimicrobial use and improve patient convenience. Objective: To determine the safety and feasibility of patient-initiated treatment of recurrent UTIs. Design: Uncontrolled, prospective clinical trial. Setting: University-based primary health care clinic. Participants: Women at least 18 years of age with a history of recurrent UTIs and no recent pregnancy, hypertension, diabetes, or renal disease. Intervention: After self-diagnosing UTI on the basis of symptoms, participating women initiated therapy with ofloxacin or levofloxacin. Measurements: Accuracy of self-diagnosis determined by evidence of a definite (culture-positive) or probable (sterile pyuria and no alternative diagnosis) UTI on pretherapy urinalysis and culture. Women with a self-diagnosis of UTI that was not microbiologically confirmed were evaluated for alternative diagnoses. Post-therapy interviews and urine cultures were used to assess clinical and microbiological cure rates, adverse events, and patient satisfaction. Results: 88 of 172 women self-diagnosed a total of 172 UTIs. Laboratory evaluation showed a uropathogen in 144 cases (84%), sterile pyuria in 19 cases (11%), and no pyuria or bacteriuria in 9 cases (5%). Clinical and microbiological cures occurred in 92% and 96%, respectively, of culture-confirmed episodes. No serious adverse events occurred. Conclusion: Adherent women can accurately self-diagnose and self-treat recurrent UTIs.	Univ Washington, Dept Med, Div Allergy & Infect Dis, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Gupta, K (corresponding author), Univ Washington, Dept Med, Div Allergy & Infect Dis, 1959 NE Pacific St,Box 356523, Seattle, WA 98195 USA.	kalg@u.washington.edu			NIDDK NIH HHS [DK 53369, DK 47549] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK053369, R01DK047549] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAUER AW, 1966, AM J CLIN PATHOL, V45, P493; Black CM, 1997, CLIN MICROBIOL REV, V10, P160, DOI 10.1128/CMR.10.1.160; DONNER A, 1988, J CLIN EPIDEMIOL, V41, P899, DOI 10.1016/0895-4356(88)90107-2; Engel JD, 1998, UROL CLIN N AM, V25, P685, DOI 10.1016/S0094-0143(05)70057-4; FOXMAN B, 1985, AM J PUBLIC HEALTH, V75, P1308, DOI 10.2105/AJPH.75.11.1308; Hooton TM, 1997, INFECT DIS CLIN N AM, V11, P551, DOI 10.1016/S0891-5520(05)70373-1; Hooton TM, 1996, NEW ENGL J MED, V335, P468, DOI 10.1056/NEJM199608153350703; HOOTON TM, 1991, ANTIMICROB AGENTS CH, V35, P1479, DOI 10.1128/AAC.35.7.1479; KUNIN CM, 1994, CLIN INFECT DIS, V18, P1, DOI 10.1093/clinids/18.1.1; Lennette E.H, 1985, MANUAL CLIN MICROBIO, V4th ed.; McCarthy JM, 1999, AM J MED, V106, P292, DOI 10.1016/S0002-9343(99)00026-1; Schaeffer AJ, 1999, J UROLOGY, V161, P207, DOI 10.1016/S0022-5347(01)62099-8; Schauffler HH, 1996, J FAM PRACTICE, V42, P62; STAMM WE, 1991, REV INFECT DIS, V13, P77; Stamm WE, 1999, J INFECT DIS, V179, pS380, DOI 10.1086/513844; STAMM WE, 1980, NEW ENGL J MED, V303, P409, DOI 10.1056/NEJM198008213030801; STAMM WE, 1983, SEX TRANSM DIS, V10, P318; STAMM WE, 1993, NEW ENGL J MED, V329, P1328, DOI 10.1056/NEJM199310283291808; STAPLETON A, 1990, JAMA-J AM MED ASSOC, V264, P703, DOI 10.1001/jama.264.6.703; Stapleton A, 1999, LANCET, V353, P7, DOI 10.1016/S0140-6736(05)74875-3; Warren JW, 1999, CLIN INFECT DIS, V29, P745, DOI 10.1086/520427; WONG ES, 1985, ANN INTERN MED, V102, P302, DOI 10.7326/0003-4819-102-3-302; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248	23	144	149	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 3	2001	135	1					9	16		10.7326/0003-4819-135-1-200107030-00004	http://dx.doi.org/10.7326/0003-4819-135-1-200107030-00004			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	449JC	11434727				2022-12-28	WOS:000169680500002
J	Kleinert, S				Kleinert, S			Responding to the changing face of paediatric cardiology	LANCET			English	Editorial Material									The Lancet, London WC1X 8RR, England		Kleinert, S (corresponding author), The Lancet, London WC1X 8RR, England.							BLALOCK A, 1945, JAMA-J AM MED ASSOC, V128, P189, DOI 10.1001/jama.1945.02860200029009; de Leval MR, 2000, J THORAC CARDIOV SUR, V119, P661, DOI 10.1016/S0022-5223(00)70006-7; Ramsay S, 1998, LANCET, V351, P1935, DOI 10.1016/S0140-6736(98)23026-1; Shumway NE, 1999, ANN THORAC SURG, V68, pS34, DOI 10.1016/S0003-4975(99)00814-0; Somerville J, 2001, THORAC CARDIOV SURG, V49, P21, DOI 10.1055/s-2001-9911	5	1	1	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 30	2001	357	9274					2074	2074		10.1016/S0140-6736(00)05229-6	http://dx.doi.org/10.1016/S0140-6736(00)05229-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	447RQ	11445098				2022-12-28	WOS:000169586600008
J	Muller, O; Becher, H; van Zweeden, AB; Ye, Y; Diallo, DA; Konate, AT; Gbangou, A; Kouyate, B; Garenne, M				Muller, O; Becher, H; van Zweeden, AB; Ye, Y; Diallo, DA; Konate, AT; Gbangou, A; Kouyate, B; Garenne, M			Effect of zinc supplementation on malaria and other causes of morbidity in west African children: randomised double blind placebo controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							IMMUNE-RESPONSES; MORTALITY	Objective To study the effects of zinc supplementation on malaria and other causes of morbidity in young children living in an area holoendemic for malaria in west Africa. Design Randomised, double blind, placebo controlled efficacy trial. Setting 18 villages in rural northwestern Burkina Faso. Participants 709 children were enrolled; 685 completed the trial. Intervention Supplementation with zinc (12.5 mg zinc sulphate) or placebo daily for six days a week for six months. Main outcome measures The primary outcome was the incidence of symptomatic falciparum malaria. Secondary outcomes were die severity of malaria episodes, prevalence of malaria parasites, mean parasite densities, mean packed cell volume, prevalence of other morbidity, and all cause mortality. Results The mean number of malaria episodes per child (defined as a temperature greater than or equal to 37.5 degreesC with greater than or equal to 5000 parasites/mul) was 1.7, 99.7% due to infection with Plasmodium falciparum. No difference was found between the zinc and placebo groups in the incidence of falciparum malaria (relative risk 0.98, 95% confidence interval 0.80 to 1.11), mean temperature, and mean parasite densities during malaria episodes, nor in malaria parasite rates, mean parasite densities, and mean packed cell volume during cross sectional surveys. Zinc supplementation was significantly associated with a reduced prevalence of diarrhoea (0.87, 0.79 to 0.95). All cause mortality was non-significantly lower in children given zinc compared with those given placebo (5 v 12, P= 0.1). Conclusions Zinc supplementation has no effect on morbidity from falciparum malaria in children in rural west Africa, but it does reduce morbidity associated with diarrhoea.	Heidelberg Univ, Dept Trop Hyg & Publ Hlth, INF 324, D-69120 Heidelberg, Germany; Ctr Rech Sante Nouna, Nouna, Burkina Faso; Ctr Natl Rech & Format Paludisme, Ouagadougou, Burkina Faso; Ctr Francais Populat & Dev, F-75270 Paris 06, France	Ruprecht Karls University Heidelberg; UDICE-French Research Universities; Universite Paris Cite	Muller, O (corresponding author), Heidelberg Univ, Dept Trop Hyg & Publ Hlth, INF 324, D-69120 Heidelberg, Germany.	olaf.mueller@urz.uni-heidelberg.de	Becher, Heiko/ABI-1234-2020; GARENNE, Michel/A-7712-2013	GARENNE, Michel/0000-0001-6073-7803				BATES CJ, 1993, BRIT J NUTR, V69, P243, DOI 10.1079/BJN19930026; Beck FWJ, 1997, AM J PHYSIOL-ENDOC M, V272, pE1002, DOI 10.1152/ajpendo.1997.272.6.E1002; BEISEL WR, 1982, AM J CLIN NUTR, V35, P417, DOI 10.1093/ajcn/35.2.417; Benzler J, 1998, TROP MED INT HEALTH, V3, P962, DOI 10.1046/j.1365-3156.1998.00340.x; BHURTA ZA, 1999, J PEDIATR, V135, P689; BUTCHER GA, 1992, PARASITOL TODAY, V8, P307, DOI 10.1016/0169-4758(92)90104-A; CHANDRA RK, 1980, AM J CLIN NUTR, V33, P736, DOI 10.1093/ajcn/33.4.736; CHANDRA RK, 1991, AM J CLIN NUTR, V53, P1087, DOI 10.1093/ajcn/53.5.1087; Chandramohan D, 1998, INT J EPIDEMIOL, V27, P296, DOI 10.1093/ije/27.2.296; DALESSANDRO U, 1995, LANCET, V345, P479, DOI 10.1016/S0140-6736(95)90582-0; Gibson RS, 1998, AM J CLIN NUTR, V68, p430S, DOI 10.1093/ajcn/68.2.430S; GREENWOOD BM, 1987, T ROY SOC TROP MED H, V81, P478, DOI 10.1016/0035-9203(87)90170-2; Kilian AHD, 1999, T ROY SOC TROP MED H, V93, P22, DOI 10.1016/S0035-9203(99)90165-7; Marsh K, 1998, LANCET, V352, P924, DOI 10.1016/S0140-6736(05)61510-3; MULLER O, 1990, T ROY SOC TROP MED H, V84, P336, DOI 10.1016/0035-9203(90)90306-Y; Muller O, 1999, LANCET, V353, P673, DOI 10.1016/S0140-6736(05)75469-6; PEKAREK RS, 1979, AM J CLIN NUTR, V32, P1466, DOI 10.1093/ajcn/32.7.1466; Shankar AH, 1998, AM J CLIN NUTR, V68, p447S, DOI 10.1093/ajcn/68.2.447S; Shankar AH, 1997, AM J TROP MED HYG, V57, P249; Snow RW, 1999, B WORLD HEALTH ORGAN, V77, P624; *WHO, 1997, EPIDEMIOL REC, V72, P269	22	136	140	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 30	2001	322	7302					1567	1570		10.1136/bmj.322.7302.1567	http://dx.doi.org/10.1136/bmj.322.7302.1567			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	449QT	11431296	Green Submitted, Bronze, Green Published			2022-12-28	WOS:000169699200024
J	Shann, F				Shann, F			Bacterial pneumonia: commoner than perceived	LANCET			English	Editorial Material							ANTIBIOTIC USE; CHILDREN		Royal Childrens Hosp, Intens Care Unit, Parkville, Vic 3052, Australia	Royal Children's Hospital Melbourne	Shann, F (corresponding author), Royal Childrens Hosp, Intens Care Unit, Flemington Rd, Parkville, Vic 3052, Australia.		Shann, Frank/C-9510-2011					Bullowa JGM, 1935, J AMER MED ASSOC, V105, P1512; CATALANO M, 1990, REV INFECT DIS, V12, pS998; CUNNINGHAM DG, 1983, J PEDIATR-US, V103, P747, DOI 10.1016/S0022-3476(83)80473-9; Drummond P, 2000, ARCH DIS CHILD, V83, P408, DOI 10.1136/adc.83.5.408; GHAFOOR A, 1990, REV INFECT DIS, V12, pS907; HORTAL M, 1990, REV INFECT DIS, V12, pS915; Liu YC, 1999, J CLIN EPIDEMIOL, V52, P539, DOI 10.1016/S0895-4356(99)00027-X; MIMICA I, 1971, AM J DIS CHILD, V122, P278, DOI 10.1001/archpedi.1971.02110040062002; NICHOL KP, 1967, NEW ENGL J MED, V277, P667, DOI 10.1056/NEJM196709282771301; Peters TR, 2000, J PEDIATR-US, V137, P416, DOI 10.1067/mpd.2000.109114; PUCZYNSKI MS, 1987, ANN EMERG MED, V16, P1359, DOI 10.1016/S0196-0644(87)80784-9; Shann F, 1999, LANCET, V354, P1488, DOI 10.1016/S0140-6736(99)00232-9; SHANN F, 1986, PEDIATR INFECT DIS J, V5, P247, DOI 10.1097/00006454-198603000-00017; Sombrero L, 1999, AM J TROP MED HYG, V60, P397, DOI 10.4269/ajtmh.1999.60.397; TAYLOR HG, 1988, EUR J CLIN PHARMACOL, V34, P84; TUPASI TE, 1990, REV INFECT DIS, V12, pS929; *WHO, 1994, WHOARI9434	17	24	27	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 30	2001	357	9274					2070	2072		10.1016/S0140-6736(00)05226-0	http://dx.doi.org/10.1016/S0140-6736(00)05226-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	447RQ	11445094				2022-12-28	WOS:000169586600005
J	Otto, SP; Jarne, P				Otto, SP; Jarne, P			Evolution - Haploids - Hapless or happening?	SCIENCE			English	Editorial Material									Univ British Columbia, Dept Zool, Vancouver, BC V6T 1Z4, Canada; CNRS, CEFE, F-34293 Montpellier 05, France	University of British Columbia; UDICE-French Research Universities; PSL Research University Paris; Ecole Pratique des Hautes Etudes (EPHE); Institut Agro; Montpellier SupAgro; CIRAD; Centre National de la Recherche Scientifique (CNRS); Institut de Recherche pour le Developpement (IRD); Universite Paul-Valery; Universite de Montpellier	Otto, SP (corresponding author), Univ British Columbia, Dept Zool, 6270 Univ Blvd, Vancouver, BC V6T 1Z4, Canada.		Otto, Sarah Perin/K-5625-2012	Otto, Sarah Perin/0000-0003-3042-0818				Adoutte A, 2000, P NATL ACAD SCI USA, V97, P4453, DOI 10.1073/pnas.97.9.4453; BELL G, 1982, MASTERPIECE NATURE E; Bell G., 1994, LECT MATH LIFE SCI, V25, P1; Bull J.J., 1983, EVOLUTION SEX DETERM; Dacks JB, 1999, COMP BIOCHEM PHYS A, V124, P287, DOI 10.1016/S1095-6433(99)00117-8; MASCARENHAS JP, 1990, ANNU REV PLANT PHYS, V41, P317, DOI 10.1146/annurev.pp.41.060190.001533; Maynard Smith J, 1971, GROUP SELECTION; MORTON NE, 1956, P NATL ACAD SCI USA, V42, P855, DOI 10.1073/pnas.42.11.855; PIJNACKER LP, 1981, ACAROLOGIA, V22, P157; Weeks AR, 2001, SCIENCE, V292, P2479, DOI 10.1126/science.1060411; White M. J. D, 1973, ANIMAL CYTOLOGY EVOL; WHITING PW, 1945, Q REV BIOL, V20, P231, DOI 10.1086/394884; Zheng Y, 2001, BIOL REPROD, V64, P1730, DOI 10.1095/biolreprod64.6.1730; Zimmer C, 2001, SCIENCE, V292, P1093, DOI 10.1126/science.292.5519.1093	14	25	28	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 29	2001	292	5526					2441	2443		10.1126/science.1062890	http://dx.doi.org/10.1126/science.1062890			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	448YU	11431554				2022-12-28	WOS:000169658200026
J	Suresh, S				Suresh, S			Graded materials for resistance to contact deformation and damage	SCIENCE			English	Review							ELASTIC PROPERTIES; INDENTATION; NANOINDENTATION; PLASTICITY; INTERFACES; GRADIENTS; STRESSES; LOAD; LINE	The mechanical response of materials with spatial gradients in composition and structure is of considerable interest in disciplines as diverse as tribology, geology, optoelectronics, biomechanics, fracture mechanics, and nanotechnology. The damage and failure resistance of surfaces to normal and sliding contact or impact can be changed substantially through such gradients. This review assess the current understanding of the resistance of graded materials to contact deformation and damage, and outlines future research direction sand possible applications for graded materials.	MIT, Dept Mat Sci & Engn, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Suresh, S (corresponding author), MIT, Dept Mat Sci & Engn, 77 Massachusetts Ave, Cambridge, MA 02139 USA.		Suresh, Subra/B-8289-2008	Suresh, Subra/0000-0002-6223-6831				BOOKER JR, 1985, INT J NUMER ANAL MET, V9, P353, DOI 10.1002/nag.1610090405; CALLADINE CR, 1978, Q J MECH APPL MATH, V31, P507, DOI 10.1093/qjmam/31.4.507; Corcoran SG, 1997, PHYS REV B, V55, P16057, DOI 10.1103/PhysRevB.55.R16057; ERDOGAN F, 1995, COMPOS ENG, V5, P753, DOI 10.1016/0961-9526(95)00029-M; ERDOGAN F, 1991, J APPL MECH, V58, P400; FITZGERALD EA, 1992, J VAC SCI TECHNOL B, V10, P1807, DOI 10.1116/1.586204; FLECK NA, 1994, ACTA METALL MATER, V42, P475, DOI 10.1016/0956-7151(94)90502-9; Giannakopoulos AE, 1997, INT J SOLIDS STRUCT, V34, P2357, DOI 10.1016/S0020-7683(96)00171-0; GIANNAKOPOULOS AE, 1995, ACTA METALL MATER, V43, P1335, DOI 10.1016/0956-7151(94)00360-T; GIBSON RE, 1967, GEOTECHNIQUE, V17, P58, DOI 10.1680/geot.1967.17.1.58; GIBSON RE, 1975, Q J MECH APPL MATH, V28, P233, DOI 10.1093/qjmam/28.2.233; Gleiter H, 2000, ACTA MATER, V48, P1, DOI 10.1016/S1359-6454(99)00285-2; Gouldstone A, 2000, ACTA MATER, V48, P2277, DOI 10.1016/S1359-6454(00)00009-4; HIRAI T, 1996, PROCESSING CERAMICS, P293; HIRANO T, 1995, MRS BULL, V20, P40, DOI 10.1557/S0883769400048922; HOLL DL, 1940, P HIGH RES BOARD, V20, P709; HRUBAN K, 1958, NONH EL PLAST IUTAM, P53; ILSCHNER B, 1994, 3 INT S STRUCT FUNCT; Jitcharoen J, 1998, J AM CERAM SOC, V81, P2301, DOI 10.1111/j.1151-2916.1998.tb02625.x; Johnson KL, 1985, CONTACT MECH, DOI 10.1201/b17110-2; Jorgensen O, 1998, INT J SOLIDS STRUCT, V35, P5097, DOI 10.1016/S0020-7683(97)00209-6; KAYSSER W, 1999, P 5 INT C FUNCT GRAD; Kim AS, 1999, INT J SOLIDS STRUCT, V36, P1845, DOI 10.1016/S0020-7683(98)00062-6; Kim AS, 1997, INT J SOLIDS STRUCT, V34, P3415, DOI 10.1016/S0020-7683(96)00225-9; KOIZUMI M, 1992, CERAM ENG SCI P, V13, P333; Lawn BR., 1993, FRACTURE BRITTLE SOL; MOSSAKOVSKII VI, 1958, PRIKL MAT MEKH, V22, P123; Nix WD, 1998, J MECH PHYS SOLIDS, V46, P411, DOI 10.1016/S0022-5096(97)00086-0; OLIVER WC, 1992, J MATER RES, V7, P1564, DOI 10.1557/JMR.1992.1564; PENDER D, IN PRESS ACTA MAT; ROSTOVTSEV NA, 1971, GEOTECHNIQUE, V35, P1053; SMITH CS, 1960, HIST METALLOGRAPHY, P3; Suresh S, 1999, ACTA MATER, V47, P3915, DOI 10.1016/S1359-6454(99)00205-0; SURESH S, 1999, 991IND MIT LAB EXP C, P3; SURESH S, 1998, FUNDAMENTALS FUNCTIO, P3; TAI LS, 1909, THESIS NATL U SINGAP; TRIMMER WS, 1997, MICROMECHANICS MEMS; WILLIAMSON RL, 1993, J APPL PHYS, V74, P1310, DOI 10.1063/1.354910; 2000, SCIENCE, V290	39	628	665	17	402	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 29	2001	292	5526					2447	2451		10.1126/science.1059716	http://dx.doi.org/10.1126/science.1059716			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	448YU	11431558				2022-12-28	WOS:000169658200030
J	Parton, M; Dowsett, M; Smith, I				Parton, M; Dowsett, M; Smith, I			Studies of apoptosis in breast cancer	BRITISH MEDICAL JOURNAL			English	Review							PREOPERATIVE CHEMOTHERAPY; CELL-DEATH; CARCINOMA; BCL-2; P53; EXPRESSION; PROLIFERATION; RESISTANCE; THERAPY; DRUGS		Royal Marsden Hosp NHS Trust, Breast Unit, London SW3 6JJ, England	Royal Marsden NHS Foundation Trust	Parton, M (corresponding author), Royal Marsden Hosp NHS Trust, Breast Unit, London SW3 6JJ, England.							Aas T, 1996, NAT MED, V2, P811, DOI 10.1038/nm0796-811; ALLAN DJ, 1992, J PATHOL, V167, P25, DOI 10.1002/path.1711670106; Anderson TJ, 1999, ENDOCR-RELAT CANCER, V6, P9, DOI 10.1677/erc.0.0060009; ARCHER C, 1999, P AM SOC CLIN ONC; Berardo MD, 1998, CANCER, V82, P1296, DOI 10.1002/(SICI)1097-0142(19980401)82:7<1296::AID-CNCR12>3.3.CO;2-I; Bergh J, 1999, ENDOCR-RELAT CANCER, V6, P51, DOI 10.1677/erc.0.0060051; BLOOM HJG, 1957, BRIT J CANCER, V11, P359, DOI 10.1038/bjc.1957.43; de Jong JS, 2000, BRIT J CANCER, V82, P368; Ellis PA, 1998, BREAST CANCER RES TR, V48, P107, DOI 10.1023/A:1005933815809; Ellis PA, 1997, LANCET, V349, P849, DOI 10.1016/S0140-6736(05)61752-7; Ellis PA, 1997, INT J CANCER, V72, P608, DOI 10.1002/(SICI)1097-0215(19970807)72:4<608::AID-IJC10>3.0.CO;2-7; Ferreira CG, 1999, ANN ONCOL, V10, P1011, DOI 10.1023/A:1008361818480; FORREST APM, 1986, LANCET, V2, P840; Gandhi A, 1998, BRIT J CANCER, V78, P788, DOI 10.1038/bjc.1998.580; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Gonzalez-Campora R, 2000, PATHOL RES PRACT, V196, P167, DOI 10.1016/S0344-0338(00)80097-7; Hamilton A, 2000, ANN ONCOL, V11, P647, DOI 10.1023/A:1008390429428; HICKMAN JA, 1992, CANCER METAST REV, V11, P121, DOI 10.1007/BF00048059; Kelloff GJ, 2000, CANCER EPIDEM BIOMAR, V9, P127; KERR JF, 1994, CANCER, V73, P3108; KERR JFR, 1994, CANCER-AM CANCER SOC, V73, P2013, DOI 10.1002/1097-0142(19940415)73:8<2013::AID-CNCR2820730802>3.0.CO;2-J; Krajewski S, 1999, ENDOCR-RELAT CANCER, V6, P29, DOI 10.1677/erc.0.0060029; Kumar R, 2000, ENDOCR-RELAT CANCER, V7, P257, DOI 10.1677/erc.0.0070257; Kumar S, 1999, CELL DEATH DIFFER, V6, P1060, DOI 10.1038/sj.cdd.4400600; LIPPONEN P, 1994, EUR J CANCER, V30A, P2068, DOI 10.1016/0959-8049(94)00342-3; McPherson K, 2000, BMJ-BRIT MED J, V321, P624, DOI 10.1136/bmj.321.7261.624; Mommers ECM, 1999, BREAST CANCER RES TR, V58, P163, DOI 10.1023/A:1006396103777; Reed JC, 1999, J CLIN ONCOL, V17, P2941, DOI 10.1200/JCO.1999.17.9.2941; Simoes-Wust AP, 2000, INT J CANCER, V87, P582, DOI 10.1002/1097-0215(20000815)87:4<582::AID-IJC19>3.0.CO;2-P; Tamm I, 2001, LANCET ONCOL, V2, P33, DOI 10.1016/S1470-2045(00)00193-5; TEIXEIRA C, 1995, CANCER RES, V55, P3902; Turner BC, 2001, J CLIN ONCOL, V19, P992, DOI 10.1200/JCO.2001.19.4.992; Vakkala M, 1999, BRIT J CANCER, V81, P592, DOI 10.1038/sj.bjc.6690735; Verheij M, 2000, CELL TISSUE RES, V301, P133, DOI 10.1007/s004410000188; Wolff AC, 2000, J CLIN ONCOL, V18, P1558, DOI 10.1200/JCO.2000.18.7.1558; Zhang GJ, 1998, ANTICANCER RES, V18, P1989	36	103	107	1	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 23	2001	322	7301					1528	1532		10.1136/bmj.322.7301.1528	http://dx.doi.org/10.1136/bmj.322.7301.1528			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	446UF	11420276	Green Published			2022-12-28	WOS:000169532000021
J	Nestler, EJ				Nestler, EJ			Neurobiology - Total recall - The memory of addiction	SCIENCE			English	Editorial Material							NUCLEUS-ACCUMBENS; AMPHETAMINE; SYNAPSES		Univ Texas, SW Med Ctr, Dept Psychiat, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Ctr Basic Neurosci, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Nestler, EJ (corresponding author), Univ Texas, SW Med Ctr, Dept Psychiat, Dallas, TX 75390 USA.	eric.nestler@utsouthwestern.edu	Oka, Yoshitaka/C-9670-2010	Oka, Yoshitaka/0000-0002-3482-3051				Bell K, 2000, NEUROPSYCHOPHARMACOL, V23, P335, DOI 10.1016/S0893-133X(00)00100-7; Berke JD, 2000, NEURON, V25, P515, DOI 10.1016/S0896-6273(00)81056-9; Carlezon WA, 2000, J NEUROSCI, V20; Jones S, 2000, J NEUROSCI, V20, P5575, DOI 10.1523/JNEUROSCI.20-15-05575.2000; Kandel ER, 1997, J CELL PHYSIOL, V173, P124, DOI 10.1002/(SICI)1097-4652(199711)173:2<124::AID-JCP6>3.3.CO;2-5; Malenka RC, 1999, SCIENCE, V285, P1870, DOI 10.1126/science.285.5435.1870; Nestler EJ, 2001, NAT REV NEUROSCI, V2, P119, DOI 10.1038/35053570; Nicola SM, 2000, ANNU REV NEUROSCI, V23, P185, DOI 10.1146/annurev.neuro.23.1.185; Robinson TE, 1997, J NEUROSCI, V17, P8491; Scannevin RH, 2000, NAT REV NEUROSCI, V1, P133, DOI 10.1038/35039075; Ungless MA, 2001, NATURE, V411, P583, DOI 10.1038/35079077; Wolf ME, 1998, PROG NEUROBIOL, V54, P679, DOI 10.1016/S0301-0082(97)00090-7	12	132	155	0	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 22	2001	292	5525					2266	2267		10.1126/science.1063024	http://dx.doi.org/10.1126/science.1063024			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	445KD	11423644				2022-12-28	WOS:000169455900038
J	Ango, F; Prezeau, L; Muller, T; Tu, JC; Xiao, B; Worley, PF; Pin, JP; Bockaert, J; Fagni, L				Ango, F; Prezeau, L; Muller, T; Tu, JC; Xiao, B; Worley, PF; Pin, JP; Bockaert, J; Fagni, L			Agonist-independent activation of metabotropic glutamate receptors by the intracellular protein Homer	NATURE			English	Article							CEREBELLAR GRANULE CELLS; CARBOXYL-TERMINAL DOMAIN; CONSTITUTIVE ACTIVITY; PHARMACOLOGICAL CHARACTERIZATION; PRIMARY CULTURES; SPLICE VARIANTS; K+ CHANNEL; GLUTAMATE-RECEPTOR-1; FAMILY; EXPRESSION	G-protein-coupled receptors (GPCRs) transduce signals from extracellular transmitters to the inside of the cell by activating G proteins. Mutation and overexpression of these receptors have revealed that they can reach their active state even in the absence of agonist, as a result of a natural shift in the equilibrium between their inactive and active conformations(1). Such agonist-independent (constitutive) activity has been observed for the glutamate GPCRs (the metabotropic glutamate receptors mGluR1a and mGluR5) when they are overexpressed in heterologous cells(2). Here we show that in neurons, the constitutive activity of these receptors is controlled by Homer proteins, which bind directly to the receptors' carboxy-terminal intracellular domains(3,4). Disruption of this interaction by mutagenesis or antisense strategies, or expression of endogenous Homer1a (H1a), induces constitutive activity in mGluR1a or mGluR5. Our results show that these glutamate GPCRs can be directly activated by intracellular proteins as well as by agonists.	CNRS, CCIPE, UPR 9023, F-34000 Montpellier, France; Bayer AG, Pharma Res, D-42096 Wuppertal, Germany; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA	Centre National de la Recherche Scientifique (CNRS); Bayer AG; Johns Hopkins University	Fagni, L (corresponding author), CNRS, CCIPE, UPR 9023, 141 Rue Cardonille, F-34000 Montpellier, France.		Pin, Jean-Philippe/Y-6668-2019	Pin, Jean-Philippe/0000-0002-1423-345X; Ango, Fabrice/0000-0002-5548-209X; Xiao, Bo/0000-0002-6161-9478				Ango F, 2000, J NEUROSCI, V20, P8710; Ango F, 1999, NEUROPHARMACOLOGY, V38, P793, DOI 10.1016/S0028-3908(99)00005-2; Brakeman PR, 1997, NATURE, V386, P284, DOI 10.1038/386284a0; Carroll FY, 2001, MOL PHARMACOL, V59, P965, DOI 10.1124/mol.59.5.965; Chavis P, 1998, EUR J NEUROSCI, V10, P2322, DOI 10.1046/j.1460-9568.1998.00243.x; Claeysen S, 1999, MOL PHARMACOL, V55, P910; Claeysen S, 2001, EMBO REP, V2, P61, DOI 10.1093/embo-reports/kve003; FAGNI L, 1991, EUR J NEUROSCI, V3, P778, DOI 10.1111/j.1460-9568.1991.tb01674.x; Galvez T, 2000, J BIOL CHEM, V275, P41166, DOI 10.1074/jbc.M007848200; Hasegawa H, 1996, J BIOL CHEM, V271, P1857, DOI 10.1074/jbc.271.4.1857; JOLY C, 1995, J NEUROSCI, V15, P3970; Kato A, 1997, FEBS LETT, V412, P183, DOI 10.1016/S0014-5793(97)00775-8; Kato A, 1998, J BIOL CHEM, V273, P23969, DOI 10.1074/jbc.273.37.23969; Kenakin T, 1997, TRENDS PHARMACOL SCI, V18, P416, DOI 10.1016/S0165-6147(97)01127-9; Litschig S, 1999, MOL PHARMACOL, V55, P453; Mary S, 1998, J BIOL CHEM, V273, P425, DOI 10.1074/jbc.273.1.425; MATUSLEIBOVITCH N, 1995, J BIOL CHEM, V270, P1041, DOI 10.1074/jbc.270.3.1041; NICOLETTI F, 1986, J NEUROCHEM, V46, P40, DOI 10.1111/j.1471-4159.1986.tb12922.x; Pagano A, 2000, J BIOL CHEM, V275, P33750, DOI 10.1074/jbc.M006230200; PARKER EM, 1991, J BIOL CHEM, V266, P9987; PREZEAU L, 1994, MOL PHARMACOL, V45, P570; Prezeau L, 1996, MOL PHARMACOL, V49, P422; Roche KW, 1999, J BIOL CHEM, V274, P25953, DOI 10.1074/jbc.274.36.25953; SLADECZEK F, 1985, NATURE, V317, P717, DOI 10.1038/317717a0; Tu JC, 1998, NEURON, V21, P717, DOI 10.1016/S0896-6273(00)80589-9; Tu JC, 1999, NEURON, V23, P583, DOI 10.1016/S0896-6273(00)80810-7; Xiao B, 1998, NEURON, V21, P707, DOI 10.1016/S0896-6273(00)80588-7	27	335	343	0	9	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 21	2001	411	6840					962	965		10.1038/35082096	http://dx.doi.org/10.1038/35082096			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	444EN	11418862				2022-12-28	WOS:000169386200048
J	Jain, A; Davis, MM				Jain, A; Davis, MM			Recent advances - Paediatrics	BMJ-BRITISH MEDICAL JOURNAL			English	Review							TO-CHILD TRANSMISSION; PNEUMOCOCCAL CONJUGATE VACCINE; IMMUNODEFICIENCY-VIRUS TYPE-1; OBESITY; HIV-1; PREVALENCE; ZIDOVUDINE; OVERWEIGHT; EFFICACY; EXPOSURE		Univ Chicago, Childrens Hosp, Dept Pediat, Sect Gen Pediat, Chicago, IL 60637 USA; Univ Michigan, Div Gen Pediat, Ann Arbor, MI 48109 USA	University of Chicago; University of Michigan System; University of Michigan	Jain, A (corresponding author), Univ Chicago, Childrens Hosp, Dept Pediat, Sect Gen Pediat, 5841 S Maryland Ave,MC 6082, Chicago, IL 60637 USA.	ajain@peds.bsd.uchicago.edu						ALLEMANT M, 2000, NEW ENGL J MED, V343, P982; Andiman W, 1999, NEW ENGL J MED, V340, P977, DOI 10.1056/NEJM199904013401301; [Anonymous], 2000, MMWR Recomm Rep, V49, P1; [Anonymous], 1999, WORLD HLTH REPORT 19; Birch LL, 1998, PEDIATRICS, V101, P539; Black S, 2000, PEDIATR INFECT DIS J, V19, P187, DOI 10.1097/00006454-200003000-00003; BRUNDTLAND GH, 2001, COMMUNICATION   0423; *CDCP, 2000, JOINT STAT REM THIM; *CDCP, 1999, MMWR-MORBID MORTAL W, V48, P1007; Centers for Disease Control and Prevention (CDC), 2000, MMWR Morb Mortal Wkly Rep, V49, P758; Cohen J, 2000, SCIENCE, V289, P368, DOI 10.1126/science.289.5478.368; Cole TJ, 2000, BMJ-BRIT MED J, V320, P1240, DOI 10.1136/bmj.320.7244.1240; CONNOR EM, 1994, NEW ENGL J MED, V331, P1173, DOI 10.1056/NEJM199411033311801; Coutsoudis A, 1999, LANCET, V354, P471, DOI 10.1016/S0140-6736(99)01101-0; de Onis M, 2000, AM J CLIN NUTR, V72, P1032; Eskola J, 2001, NEW ENGL J MED, V344, P403, DOI 10.1056/NEJM200102083440602; Garza C, 1999, AM J CLIN NUTR, V70, p169S; GERSTLE C, 2000, EUROPEAN COMMITTEE I; Guay LA, 1999, LANCET, V354, P795, DOI 10.1016/S0140-6736(99)80008-7; Hopper JA, 2000, PEDIATRICS, V106, DOI 10.1542/peds.106.4.e47; *I MED, 2001, IMM SAF REV MEASL MU; KUCZMARSKI RJ, 2000, ADV VITAL HLTH STAT, V314; Mayhew Kathryn P., 2000, Drug and Alcohol Dependence, V59, pS61; Mofenson LM, 1999, NEW ENGL J MED, V341, P385, DOI 10.1056/NEJM199908053410601; Must A, 1999, INT J OBESITY, V23, pS2, DOI 10.1038/sj.ijo.0800852; Nduati R, 2000, JAMA-J AM MED ASSOC, V283, P1167, DOI 10.1001/jama.283.9.1167; Parazzini F, 1999, LANCET, V353, P1035, DOI 10.1016/S0140-6736(98)08084-2; Reilly JJ, 1999, BRIT MED J, V319, P1039, DOI 10.1136/bmj.319.7216.1039; Robinson TN, 1999, JAMA-J AM MED ASSOC, V282, P1561, DOI 10.1001/jama.282.16.1561; Semba RD, 1999, J INFECT DIS, V180, P93, DOI 10.1086/314854; Stein RJ, 2000, PEDIATRICS, V106, DOI 10.1542/peds.106.5.e66; Strauss RS, 1999, PEDIATRICS, V103, DOI 10.1542/peds.103.6.e85; Strauss RS, 2000, PEDIATRICS, V105, part. no., DOI 10.1542/peds.105.1.e15; Tess BH, 1998, J ACQ IMMUN DEF SYND, V19, P189, DOI 10.1097/00042560-199810010-00014; Warren CW, 2000, B WORLD HEALTH ORGAN, V78, P868; *WHO, 2001, POL FACT SHEET; *WHO, 2000, REP GLOB HIV AIDS EP	37	3	3	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 16	2001	322	7300					1469	1472		10.1136/bmj.322.7300.1469	http://dx.doi.org/10.1136/bmj.322.7300.1469			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	444FJ	11408306	Green Published			2022-12-28	WOS:000169389200033
J	Mamas, MA; Reynard, JM; Brading, AF				Mamas, MA; Reynard, JM; Brading, AF			Augmentation of nitric oxide to treat detrusor-external sphincter dyssynergia in spinal cord injury	LANCET			English	Article							LOWER URINARY-TRACT; BLOOD-PRESSURE; BLADDER; SYNTHASE; DISRUPTION; NIFEDIPINE; RELAXATION; MICE; PIG	Detrusor-external sphincter dyssynegia (DSD) is a common cause of bladder outlet obstruction in men with spinal cord injuries, which if left untreated leads ultimately to renal failure. External sphincterotomy is currently the main treatment for DSD. However, obstruction persists in a substantial proportion of cases after this procedure. There is no effective drug treatment for DSD. Nitric oxide is an inhibitory neurotransmitter synthesised by nitric oxide synthase. Both animal and human studies suggest that nitric oxide mediates urethral sphincter relaxation. Nitric-oxide-synthase staining neurons have been identified in very high density in the urethral sphincters of a variety of animals and in human beings. Relaxation of the urethral sphincter is abolished by inhibitors of nitric oxide synthase and enhanced by nitric oxide donors. Mice with targeted deletion of the gene, for neuronal nitric oxide have urethral sphincters that do not relax in response to electrical stimulation. We hypothesise that augmentation of external sphincter nitric oxide could be an effective pharmacological treatment for DSD. Currently available nitric oxide donors such as glyceryl trinitrate or isosorbide mononitrate could be used to deliver nitric oxide to the urethral sphincter. The variable pharmacokinetics of these drugs combined with different modes of delivery (sublingual, buccal, or oral) could be used to achieve both short-term and long-term increases in concentrations of sphincter nitric oxide, thereby resulting in either acute or chronic lowering of urethral pressure. The safety and efficacy of this potential treatment for DSD needs to be established in clinical trials of men with spinal cord injures with DSD.	Stoke Mandeville Hosp, Natl Spinal Injuries Ctr, Aylesbury HP21 8AL, Bucks, England; John Radcliffe Hosp, Nuffield Dept Med, Oxford OX3 9DU, England; Univ Oxford, Dept Pharmacol, Oxford OX1 2JD, England	University of Oxford; University of Oxford	Reynard, JM (corresponding author), Stoke Mandeville Hosp, Natl Spinal Injuries Ctr, Aylesbury HP21 8AL, Bucks, England.		Mamas, Mamas Andreas/A-2549-2019	Mamas, Mamas Andreas/0000-0001-9241-8890				BENNETT BC, 1995, J UROLOGY, V153, P2004, DOI 10.1016/S0022-5347(01)67391-9; Burnett AL, 1997, NAT MED, V3, P571, DOI 10.1038/nm0597-571; Catz A, 1997, SPINAL CORD, V35, P48, DOI 10.1038/sj.sc.3100349; DYKSTRA DD, 1987, J UROLOGY, V138, P1155, DOI 10.1016/S0022-5347(17)43533-6; EHREN I, 1994, UROLOGY, V44, P683, DOI 10.1016/S0090-4295(94)80206-8; Fontaine E, 1996, J UROLOGY, V155, P277, DOI 10.1016/S0022-5347(01)66618-7; Fraser MO, 1998, J UROLOGY, V159, P23; GIBBON NOK, 1965, INT J PARAPLEGIA, V2, P264; Ho Kossen M., 1999, Journal of Urology, V161, P40; Kim YH, 1998, J UROLOGY, V159, P493, DOI 10.1016/S0022-5347(01)63957-0; Perkash I, 1995, J Spinal Cord Med, V18, P236; PERSSON K, 1994, EUR J PHARM-MOLEC PH, V268, P159, DOI 10.1016/0922-4106(94)90185-6; ROSS JC, 1958, J UROLOGY, V79, P742, DOI 10.1016/S0022-5347(17)66333-X; Smet PJ, 1996, NEUROSCIENCE, V71, P337, DOI 10.1016/0306-4522(95)00453-X; Sutherland RS, 1997, J UROLOGY, V157, P1109, DOI 10.1016/S0022-5347(01)65151-6; THYBERG M, 1994, PARAPLEGIA, V32, P308, DOI 10.1038/sc.1994.53; Webb DJ, 1999, AM J CARDIOL, V83, p21C; WEI JY, 1981, AM J CARDIOL, V48, P778, DOI 10.1016/0002-9149(81)90157-0; Wein A J, 1998, J Urol, V160, P961; WERKSTROM V, 1995, BRIT J PHARMACOL, V116, P1599, DOI 10.1111/j.1476-5381.1995.tb16379.x	20	22	23	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 16	2001	357	9272					1964	1967		10.1016/S0140-6736(00)05069-8	http://dx.doi.org/10.1016/S0140-6736(00)05069-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	444YZ	11425438				2022-12-28	WOS:000169431000035
J	Charlson, RJ; Seinfeld, JH; Nenes, A; Kulmala, M; Laaksonen, A; Facchini, MC				Charlson, RJ; Seinfeld, JH; Nenes, A; Kulmala, M; Laaksonen, A; Facchini, MC			Atmospheric science - Reshaping the theory of cloud formation	SCIENCE			English	Editorial Material							WATER; DROPLETS; AEROSOL; ALBEDO		Univ Washington, Dept Atmospher Sci, Seattle, WA 98195 USA; Univ Washington, Dept Chem, Seattle, WA 98195 USA; CALTECH, Dept Chem Engn, Pasadena, CA 91125 USA; CALTECH, Div Engn & Appl Sci, Pasadena, CA 91125 USA; Univ Helsinki, Dept Phys, Helsinki 00014, Finland; Univ Kuopio, Dept Appl Phys, FIN-70211 Kuopio, Finland; CNR, Inst Sci Atmosfera & Oceano, I-40129 Bologna, Italy	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; California Institute of Technology; California Institute of Technology; University of Helsinki; University of Eastern Finland; Consiglio Nazionale delle Ricerche (CNR)	Charlson, RJ (corresponding author), Univ Washington, Dept Atmospher Sci, Seattle, WA 98195 USA.		FACCHINI, MARIA CRISTINA/O-1230-2015; Facchini, Maria Cristina/AAA-1592-2019; Facchini, Maria Cristina/B-3369-2014; Kulmala, Markku T/I-7671-2016; Nenes, Athanasios/ABE-6478-2020; Laaksonen, Ari/B-5094-2011	FACCHINI, MARIA CRISTINA/0000-0003-4833-9305; Facchini, Maria Cristina/0000-0003-4833-9305; Facchini, Maria Cristina/0000-0003-4833-9305; Kulmala, Markku T/0000-0003-3464-7825; Nenes, Athanasios/0000-0003-3873-9970; Laaksonen, Ari/0000-0002-1657-2383				Elbert W, 2000, ATMOS ENVIRON, V34, P1109, DOI 10.1016/S1352-2310(99)00351-9; Facchini MC, 1999, J GEOPHYS RES-ATMOS, V104, P26821, DOI 10.1029/1999JD900349; Facchini MC, 1999, NATURE, V401, P257, DOI 10.1038/45758; Frank G., 1998, Contributions to Atmospheric Physics, V71, P65; FUZZI S, 1994, J ATMOS CHEM, V19, P87, DOI 10.1007/BF00696584; FUZZI S, 1992, TELLUS B, V44, P448, DOI 10.1034/j.1600-0889.1992.t01-4-00002.x; *INT PAN CLIM CHAN, 2001, IN PRESS CLIM CHANG; Kohler H, 1936, T FARADAY SOC, V32, P1152, DOI 10.1039/tf9363201152; KOHLER H, 1921, METEOROL Z, V38, P168; KULMALA M, 1993, J GEOPHYS RES-ATMOS, V98, P22949, DOI 10.1029/93JD02070; Laaksonen A, 1998, J ATMOS SCI, V55, P853, DOI 10.1175/1520-0469(1998)055<0853:MOTKHE>2.0.CO;2; Pun BK, 2000, J ATMOS CHEM, V35, P199, DOI 10.1023/A:1006261217691; Saxena P, 1996, J ATMOS CHEM, V24, P57, DOI 10.1007/BF00053823; SHULMAN ML, 1996, GEOPHYS RES LETT, V23, P227; TWOMEY S, 1977, J ATMOS SCI, V34, P1149, DOI 10.1175/1520-0469(1977)034<1149:TIOPOT>2.0.CO;2; Zappoli S, 1999, ATMOS ENVIRON, V33, P2733, DOI 10.1016/S1352-2310(98)00362-8	16	150	154	3	64	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 15	2001	292	5524					2025	2026		10.1126/science.1060096	http://dx.doi.org/10.1126/science.1060096			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	442KP	11408648				2022-12-28	WOS:000169284700035
J	Feringa, BL				Feringa, BL			Chemistry - A new twist on chirality	SCIENCE			English	Editorial Material									Univ Groningen, Dept Chem, Groningen, Netherlands	University of Groningen	Feringa, BL (corresponding author), Univ Groningen, Dept Chem, Groningen, Netherlands.	b.l.feringa@chem.rug.nl	Feringa, Ben L./C-1665-2013					BARRON LD, 1986, CHEM SOC REV, V15, P189, DOI 10.1039/cs9861500189; Berger R, 2000, CHEMPHYSCHEM, V1, P57, DOI 10.1002/1439-7641(20000804)1:1<57::AID-CPHC57>3.0.CO;2-J; Feringa BL, 1999, ANGEW CHEM INT EDIT, V38, P3419; Huck NPM, 1996, SCIENCE, V273, P1686, DOI 10.1126/science.273.5282.1686; PASTEUR L, 1884, B SOC CHIM FR, V41, P215; Ribo JM, 2001, SCIENCE, V292, P2063, DOI 10.1126/science.1060835; Rikken GLJA, 2000, NATURE, V405, P932, DOI 10.1038/35016043; Rowan AE, 1998, ANGEW CHEM INT EDIT, V37, P63, DOI 10.1002/(SICI)1521-3773(19980202)37:1/2<63::AID-ANIE63>3.0.CO;2-4	8	24	24	4	51	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 15	2001	292	5524					2021	2022		10.1126/science.1062070	http://dx.doi.org/10.1126/science.1062070			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	442KP	11408645	Green Published			2022-12-28	WOS:000169284700032
J	Nash, D; Mostashari, F; Fine, A; Miller, J; O'Leary, D; Murray, K; Huang, A; Rosenberg, A; Greenberg, A; Sherman, M; Wong, S; Layton, M; Campbell, GL; Roehrig, JT; Gubler, DJ; Shieh, WJ; Zaki, S; Smith, P				Nash, D; Mostashari, F; Fine, A; Miller, J; O'Leary, D; Murray, K; Huang, A; Rosenberg, A; Greenberg, A; Sherman, M; Wong, S; Layton, M; Campbell, GL; Roehrig, JT; Gubler, DJ; Shieh, WJ; Zaki, S; Smith, P		1999 W Nile Outbreak Response Working	The outbreak of West Nile virus infection in the New York City area in 1999.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ENCEPHALITIS EPIDEMIC; PATHOLOGY; COUNTY; FEVER	Background: In late August 1999, an unusual cluster of cases of meningoencephalitis associated with muscle weakness was reported to the New York City Department of Health. The initial epidemiologic and environmental investigations suggested an arboviral cause. Methods: Active surveillance was implemented to identify patients hospitalized with viral encephalitis and meningitis. Cerebrospinal fluid, serum, and tissue specimens from patients with suspected cases underwent serologic and viral testing for evidence of arboviral infection. Results: Outbreak surveillance identified 59 patients who were hospitalized with West Nile virus infection in the New York City area during August and September of 1999. The median age of these patients was 71 years (range, 5 to 90). The overall attack rate of clinical West Nile virus infection was at least 6.5 cases per million population, and it increased sharply with age. Most of the patients (63 percent) had clinical signs of encephalitis; seven patients died (12 percent). Muscle weakness was documented in 27 percent of the patients and flaccid paralysis in 10 percent; in all of the latter, nerve conduction studies indicated an axonal polyneuropathy. An age of 75 years or older was an independent risk factor for death (relative risk adjusted for the presence or absence of diabetes mellitus, 8.5; 95 percent confidence interval, 1.2 to 59.1), as was the presence of diabetes mellitus (age-adjusted relative risk, 5.1; 95 percent confidence interval, 1.5 to 17.3). Conclusions: This outbreak of West Nile meningoencephalitis in the New York City metropolitan area represents the first time this virus has been detected in the Western Hemisphere. Given the subsequent rapid spread of the virus, physicians along the eastern seaboard of the United States should consider West Nile virus infection in the differential diagnosis of encephalitis and viral meningitis during the summer months, especially in older patients and in those with muscle weakness. (N Engl J Med 2001;344:1807-14.) Copyright (C) 2001 Massachusetts Medical Society.	New York City Dept Hlth, Communicable Dis Program, New York, NY 10013 USA; CDCP, Epidem Intelligence Serv, Epidemiol Program Off, Div Appl Publ Hlth Trainig,State Branch, Atlanta, GA USA; Ctr Dis Control & Prevent, Div Bioterrorism Preparedness, Atlanta, GA USA; Ctr Dis Control & Prevent, Div Vector Borne Infect Dis, Natl Ctr Infect Dis, Ft Collins, CO USA; Westchester Cty Dept Hlth, New Rochelle, NY USA; Nassau Cty Dept Hlth, Mineola, NY USA; New York State Dept Hlth, Albany, NY USA	New York City Department of Health & Mental Hygiene; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; State University of New York (SUNY) System	Nash, D (corresponding author), New York City Dept Hlth, HIV AIDS Surveillance Program, 346 Broadway,Rm 706, New York, NY 10013 USA.	dnash@health.nyc.gov	Nash, Denis/AFI-7485-2022	Roehrig, John/0000-0001-7581-0479; Nash, Denis/0000-0002-3280-5386	PHS HHS [U50/CCU212386-05] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Ahmed S, 2000, NEUROLOGY, V55, P144, DOI 10.1212/WNL.55.1.144; Asnis DS, 2000, CLIN INFECT DIS, V30, P841; Asnis DS, 2000, CLIN INFECT DIS, V30, P413, DOI 10.1086/313737; BENDER BS, 1986, J AM GERIATR SOC, V34, P649, DOI 10.1111/j.1532-5415.1986.tb04906.x; Briese T, 1999, LANCET, V354, P1650; Briese T, 1999, LANCET, V354, P1261, DOI 10.1016/S0140-6736(99)04576-6; CALISHER CH, 1989, J GEN VIROL, V70, P37, DOI 10.1099/0022-1317-70-1-37; Centers for Disease Control and Prevention (CDC), 1999, MMWR Morb Mortal Wkly Rep, V48, P845; Han LL, 1999, J INFECT DIS, V179, P230, DOI 10.1086/314566; Hubalek Z, 1999, EMERG INFECT DIS, V5, P643, DOI 10.3201/eid0505.990505; Johnson AJ, 2000, J CLIN MICROBIOL, V38, P1827, DOI 10.1128/JCM.38.5.1827-1831.2000; Komar N, 2000, REV SCI TECH OIE, V19, P166, DOI 10.20506/rst.19.1.1201; KOMAR N, IN PRESS EMERG INFEC; Lanciotti RS, 2000, J CLIN MICROBIOL, V38, P4066, DOI 10.1128/JCM.38.11.4066-4071.2000; Lanciotti RS, 1999, SCIENCE, V286, P2333, DOI 10.1126/science.286.5448.2333; Lundstrom JO, 1999, J VECTOR ECOL, V24, P1; Lvov D. K., 2000, Voprosy Virusologii, V45, P37; Lvov D. K., 2000, Voprosy Virusologii, V45, P4; Lvov DK, 2000, EMERG INFECT DIS, V6, P373, DOI 10.3201/eid0604.000408; MARBERG K, 1956, AM J HYG, V64, P259, DOI 10.1093/oxfordjournals.aje.a119838; MARFIN AA, 1993, AM J TROP MED HYG, V49, P30, DOI 10.4269/ajtmh.1993.49.30; Martin DA, 2000, J CLIN MICROBIOL, V38, P1823, DOI 10.1128/JCM.38.5.1823-1826.2000; MCINTOSH BM, 1976, S AFR J SCI, V72, P295; MCINTOSH BM, 1994, CRC HDB SERIES ZOONO, P227; NASCI RS, IN PRESS EMERG INFEC; OLEJNIK E., 1952, Bulletin of the Research Council of Israel, V2, P210; POWERS DC, 1993, J INFECT DIS, V167, P584, DOI 10.1093/infdis/167.3.584; Richman DD, 1997, CLIN VIROLOGY; SALTZMAN RL, 1987, REV INFECT DIS, V9, P1127; Sampson BA, 2000, HUM PATHOL, V31, P527, DOI 10.1053/hp.2000.8047; *SAS I, 1990, SAS LANG REF VERS 6; SAS Institute, 1990, SAS PROC GUID VERS 6; Shieh WJ, 2000, EMERG INFECT DIS, V6, P370, DOI 10.3201/eid0604.000407; Steele KE, 2000, VET PATHOL, V37, P208, DOI 10.1354/vp.37-3-208; Szilak I, 2000, NEW ENGL J MED, V342, P59, DOI 10.1056/NEJM200001063420113; TSAI TE, 1994, CRC HDB SERIES ZOO B; Tsai TF, 1998, LANCET, V352, P767, DOI 10.1016/S0140-6736(98)03538-7; TSAI TF, 1988, J INFECT DIS, V157, P351, DOI 10.1093/infdis/157.2.351; WEISS D, IN PRESS EMERG INFEC; YOSHIKAWA TT, 1987, AGING CLIN PRACTICE; 1999, MMWR MORB MORTAL WKL, V48, P890; 2000, MMWR MORB MORTAL WKL, V49, P25; 1999, MMWR MORB MORTAL WKL, V48, P955; 1999, MMWR MORB MORTAL WKL, V48, P944; 2000, MMWR MORB MORTAL WKL, V49, P178	45	863	900	2	100	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 14	2001	344	24					1807	1814		10.1056/NEJM200106143442401	http://dx.doi.org/10.1056/NEJM200106143442401			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	441LC	11407341	Green Published, Bronze			2022-12-28	WOS:000169231000001
J	Hannaford, P				Hannaford, P			Postmarketing surveillance study of Norplant in developing countries	LANCET			English	Editorial Material							IMPLANTS		Univ Aberdeen, Foresterhill Hlth Ctr, Dept Gen Practice & Primary Care, Aberdeen AB25 2AY, Scotland	University of Aberdeen	Hannaford, P (corresponding author), Univ Aberdeen, Foresterhill Hlth Ctr, Dept Gen Practice & Primary Care, Aberdeen AB25 2AY, Scotland.		Hannaford, Philip C/B-7867-2012					Boonstra H, 2000, CONTRACEPTION, V61, P9, DOI 10.1016/S0010-7824(99)00121-3; Du MK, 2000, INT J GYNECOL OBSTET, V68, P249, DOI 10.1016/S0020-7292(99)00214-3; Entwistle VA, 2000, LANCET, V355, P1633, DOI 10.1016/S0140-6736(00)02226-1; Fraser IS, 1998, CONTRACEPTION, V57, P1, DOI 10.1016/S0010-7824(97)00200-X; Meirik O, 2001, OBSTET GYNECOL, V97, P539, DOI 10.1016/S0029-7844(00)01220-5; Sivin I, 1997, CONTRACEPTION, V55, P73, DOI 10.1016/S0010-7824(96)00275-2; Sivin I, 1998, OBSTET GYNECOL, V92, P337, DOI 10.1016/S0029-7844(98)00219-1; SMITH R, 1993, BRIT MED J, V306, P1285, DOI 10.1136/bmj.306.6888.1285; 2000, WORLD POPULATION PRO	9	2	2	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 9	2001	357	9271					1815	1816		10.1016/S0140-6736(00)05007-8	http://dx.doi.org/10.1016/S0140-6736(00)05007-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	440DN	11410183				2022-12-28	WOS:000169160800003
J	Hlatky, MA; Bigger, T				Hlatky, MA; Bigger, T			Cost-effectiveness of the implantable cardioverter defibrillator?	LANCET			English	Editorial Material							AMIODARONE		Stanford Univ, Sch Med, Dept Hlth Res & Policy, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA; Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Pharmacol, New York, NY 10032 USA	Stanford University; Stanford University; Columbia University; Columbia University	Bigger, T (corresponding author), Stanford Univ, Sch Med, Dept Hlth Res & Policy, Stanford, CA 94305 USA.			Hlatky, Mark/0000-0003-4686-9441				Connolly SJ, 2000, CIRCULATION, V101, P1297, DOI 10.1161/01.CIR.101.11.1297; Connolly SJ, 2000, EUR HEART J, V21, P2071, DOI 10.1053/euhj.2000.2476; Glikson M, 2001, LANCET, V357, P1107, DOI 10.1016/S0140-6736(00)04263-X; HEIDENREICH PA, IN PRESS AM HEART J; LARSEN GC, 1997, CIRCULATION S1, V96, P77; McAnulty J, 1997, NEW ENGL J MED, V337, P1576; Moss AJ, 1996, NEW ENGL J MED, V335, P1933, DOI 10.1056/NEJM199612263352601; Mushlin AI, 1998, CIRCULATION, V97, P2129, DOI 10.1161/01.CIR.97.21.2129; O'Brien BJ, 2001, CIRCULATION, V103, P1416, DOI 10.1161/01.CIR.103.10.1416; Owens DK, 1997, ANN INTERN MED, V126, P1, DOI 10.7326/0003-4819-126-1-199701010-00001; Sheldon R, 2000, CIRCULATION, V101, P1660; SULLIVAN SD, 2000, MED DECIS MAKING, V20, P488	12	19	19	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 9	2001	357	9271					1817	1818		10.1016/S0140-6736(00)05009-1	http://dx.doi.org/10.1016/S0140-6736(00)05009-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	440DN	11410185				2022-12-28	WOS:000169160800005
J	Ala'Aldeen, DAA; Grundmann, H				Ala'Aldeen, DAA; Grundmann, H			Unveiling of genetic basis of resistance of S aureus to antibiotics	LANCET			English	Editorial Material							STAPHYLOCOCCUS-AUREUS		Univ Nottingham Hosp, Fac Med & Hlth Sci, Sch Clin Lab Sci, Div Microbiol,Mol Bacteriol & Immunol Grp, Nottingham NG7 2UH, England	University of Nottingham	Ala'Aldeen, DAA (corresponding author), Univ Nottingham Hosp, Fac Med & Hlth Sci, Sch Clin Lab Sci, Div Microbiol,Mol Bacteriol & Immunol Grp, Nottingham NG7 2UH, England.							Day NPJ, 2001, SCIENCE, V292, P114, DOI 10.1126/science.1056495; Feil EJ, 2001, P NATL ACAD SCI USA, V98, P182, DOI 10.1073/pnas.98.1.182; Gottlieb T, 1998, J ANTIMICROB CHEMOTH, V42, P67, DOI 10.1093/jac/42.1.67; Hiramatsu K, 1997, J ANTIMICROB CHEMOTH, V40, P135, DOI 10.1093/jac/40.1.135; Ogston A., 1880, ARCH KLIN CHIRURGIE, V25, P599; Sieradzki K, 1996, FEMS MICROBIOL LETT, V142, P161; SMITH IM, 1960, LANCET, V1, P1318; 2000, COMMUN DIS REP, V10, P99	8	1	1	1	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 21	2001	357	9264					1218	1219		10.1016/S0140-6736(00)04447-0	http://dx.doi.org/10.1016/S0140-6736(00)04447-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	425YY	11418140				2022-12-28	WOS:000168323300002
J	Schellenberg, JRMA; Abdulla, S; Nathan, R; Mukasa, O; Marchant, TJ; Kikumbih, N; Mushi, AK; Mponda, H; Minja, H; Mshinda, H; Tanner, M; Lengeler, C				Schellenberg, JRMA; Abdulla, S; Nathan, R; Mukasa, O; Marchant, TJ; Kikumbih, N; Mushi, AK; Mponda, H; Minja, H; Mshinda, H; Tanner, M; Lengeler, C			Effect of large-scale social marketing of insecticide-treated nets on child survival in rural Tanzania	LANCET			English	Article							PLASMODIUM-FALCIPARUM TRANSMISSION; MALARIA MORBIDITY; MORTALITY; AFRICA; LIMITATIONS; POPULATION; PROGRAM; HEALTH; AREA	Background Insecticide-treated nets have proven efficacy as a malaria-control tool in Africa. However, the transition from efficacy to effectiveness cannot be taken for granted. We assessed coverage and the effect on child survival of a large-scale social marketing programme for insecticide-treated nets in two rural districts of southern Tanzania with high perennial malaria transmission. Methods Socially marketed insecticide-treated nets were introduced stepwise over a 2-year period from May, 1997, in a population of 480 000 people. Cross-sectional coverage surveys were done at baseline and after 1, 2, and 3 years. A demographic surveillance system (DSS) was set up in an area of 60 000 people to record population, births, and deaths. Within the DSS area, the effect of insecticide-treated nets on child survival was assessed by a case-control approach. Cases were deaths in children aged between 1 month and 4 years. Four controls for each case were chosen from the DSS database. Use of insecticide-treated nets and potential confounding factors were assessed by questionnaire. Individual effectiveness estimates from the case-control study were combined with coverage to estimate community effectiveness. Findings Insecticide-treated net coverage of infants in the DSS area rose from less than 10% at baseline to more than 50% 3 years later. Insecticide-treated nets were associated with a 27% increase in survival in children aged 1 month to 4 years (95% CI 3-45). Coverage in such children was higher in areas with longer access to the programme. The modest average coverage achieved by 1999 in the two districts (18% in children younger than 5 years) suggests that insecticide-treated nets prevented 1 in 20 child deaths at that time. Interpretation Social marketing of insecticide-treated nets has great potential for effective malaria control in rural African settings.	Ifakara Hlth Res & Dev Ctr, Ifakara, Tanzania; Swiss Trop Inst, CH-4002 Basel, Switzerland	Ifakara Health Institute; University of Basel; Swiss Tropical & Public Health Institute	Schellenberg, JRMA (corresponding author), Orchard Ground Cottage, Cublington LU7 0LJ, Beds, England.	dajobelo@aol.com		Marchant, Tanya/0000-0002-4228-4334; Schellenberg, Joanna/0000-0002-0708-3676				Abdulla S, 2001, BMJ-BRIT MED J, V322, P270, DOI 10.1136/bmj.322.7281.270; ANDREASEN AR, 1995, MARKETING SOCIAL CHA, P1; Binka FN, 1999, J BIOSOC SCI, V31, P375, DOI 10.1017/S0021932099003752; CHAVASSE D, 1999, INSECTICIDE TREATED, P1; DALESSANDRO U, 1995, LANCET, V345, P479, DOI 10.1016/S0140-6736(95)90582-0; Drakeley CJ, 1999, TROP MED INT HEALTH, V4, P639, DOI 10.1046/j.1365-3156.1999.00470.x; Habicht JP, 1999, INT J EPIDEMIOL, V28, P10, DOI 10.1093/ije/28.1.10; Hatz C, 1998, TROP MED INT HEALTH, V3, P498, DOI 10.1046/j.1365-3156.1998.00250.x; HOSMER DW, 1989, APPL LOGISTIC REGRES; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Langeler C, 1996, B WORLD HEALTH ORGAN, V74, P325; Lengeler C, 1999, TROP MED INT HEALTH, V4, P409, DOI 10.1046/j.1365-3156.1999.00422.x; LENGELER C, 2001, COCHRANE LIB; *MAL CONS, 1999, 2 INT C INS TREAT NE; Menendez C, 1997, LANCET, V350, P844, DOI 10.1016/S0140-6736(97)04229-3; MINJA H, 2001, THESIS U BASEL BASEL; MOLINEAUX L, 1985, HLTH POLICY SOCIAL P, P13; *NAT BUR STAT TANZ, 2000, TANZ REPR CHILD HLTH; PREGIBON D, 1981, ANN STAT, V9, P705, DOI 10.1214/aos/1176345513; Schellenberg D, 1999, AM J TROP MED HYG, V61, P431, DOI 10.4269/ajtmh.1999.61.431; SCHELLENBERG JRM, 2001, INDEPTH MONOGRAPH SE, V1; Schellenberg JRMA, 1999, T ROY SOC TROP MED H, V93, P225, DOI 10.1016/S0035-9203(99)90001-9; SMITH T, 1993, ACTA TROP, V54, P55, DOI 10.1016/0001-706X(93)90068-M; SNOW RW, 1992, LANCET, V340, P351, DOI 10.1016/0140-6736(92)91414-4; Snow RW, 1997, LANCET, V349, P1650, DOI 10.1016/S0140-6736(97)02038-2; Snow RW, 1999, B WORLD HEALTH ORGAN, V77, P624; TANNER M, 1992, DIS MORTALITY SUBSAH, P286; TODD JE, 1994, ANN TROP PAEDIATR, V14, P31, DOI 10.1080/02724936.1994.11747689; Trape JF, 1996, PARASITOL TODAY, V12, P236, DOI 10.1016/0169-4758(96)10015-6; WHO, 2000, AB DECL PLAN ACT EXT	30	215	216	2	23	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 21	2001	357	9264					1241	1247		10.1016/S0140-6736(00)04404-4	http://dx.doi.org/10.1016/S0140-6736(00)04404-4			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	425YY	11418148				2022-12-28	WOS:000168323300010
J	Butler, D				Butler, D			Institutes prepare for pioneering bioinformatics work	NATURE			English	News Item																		FORTOS F, 2001, NATURE, V411, P631; KAFATOS F, 2001, NATURE, V411, P229	2	1	1	0	1	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 12	2001	412	6843					106	106		10.1038/35084343	http://dx.doi.org/10.1038/35084343			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	451AJ	11449223	Bronze			2022-12-28	WOS:000169778700005
J	Juni, P; Altman, DG; Egger, M				Juni, P; Altman, DG; Egger, M			Systematic reviews in health care - Assessing the quality of controlled clinical trials	BMJ-BRITISH MEDICAL JOURNAL			English	Review							RANDOMIZED CONTROL TRIALS; BIAS; RE		Univ Bristol, Dept Social Med, MRC, Hlth Serv Res Collaborat, Bristol BS8 2PR, Avon, England; Univ Bern, Dept Social & Prevent Med, CH-3012 Bern, Switzerland; Inst Hlth Sci, Ctr Stat Med, Imperial Canc Res Fund, Med Stat Grp, Oxford OX3 7LF, England	University of Bristol; University of Bern; University of Oxford	Egger, M (corresponding author), Univ Bristol, Dept Social Med, MRC, Hlth Serv Res Collaborat, Bristol BS8 2PR, Avon, England.	m.egger@bristol.ac.uk	Juni, Peter/Q-8700-2016	Juni, Peter/0000-0002-5985-0670; Egger, Matthias/0000-0001-7462-5132				ALTMAN DG, 1991, BRIT MED J, V302, P1481, DOI 10.1136/bmj.302.6791.1481; Altman DG, 1999, BRIT MED J, V318, P1209; APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; Campbell D. T., 1963, HDB RES TEACHING, P171; CAMPBELL DT, 1957, PSYCHOL BULL, V54, P297, DOI 10.1037/h0040950; CANNER PL, 1980, NEW ENGL J MED, V303, P1038; CHALMERS TC, 1981, CONTROL CLIN TRIALS, V2, P31, DOI 10.1016/0197-2456(81)90056-8; CLARKE M, 1999, COCHRANE LIB; COOK DJ, 1995, J CLIN EPIDEMIOL, V48, P167, DOI 10.1016/0895-4356(94)00172-M; DETSKY AS, 1992, J CLIN EPIDEMIOL, V45, P255, DOI 10.1016/0895-4356(92)90085-2; Devereaux PJ, 2001, JAMA-J AM MED ASSOC, V285, P2000, DOI 10.1001/jama.285.15.2000; Egger M, 2001, JAMA-J AM MED ASSOC, V285, P1996, DOI 10.1001/jama.285.15.1996; FEINSTEIN AR, 1995, J CLIN EPIDEMIOL, V48, P71, DOI 10.1016/0895-4356(94)00110-C; GREENLAND S, 1994, AM J EPIDEMIOL, V140, P300, DOI 10.1093/oxfordjournals.aje.a117250; Gueyffier F, 1999, LANCET, V353, P793, DOI 10.1016/S0140-6736(98)08127-6; Hollis S, 1999, BRIT MED J, V319, P670, DOI 10.1136/bmj.319.7211.670; Hotopf M, 1997, J EPIDEMIOL COMMUN H, V51, P354, DOI 10.1136/jech.51.4.354; Juni P, 1999, JAMA-J AM MED ASSOC, V282, P1054, DOI 10.1001/jama.282.11.1054; JUNI P, 2000, P 3 S SYST REV BAS S, P19; JUNI P, 2001, SYSTEMATIC REV HLTH; KEIRSE MJNC, 1988, ACTA OBSTET GYN SCAN, V67, P731, DOI 10.3109/00016349809004298; KJAERGARD LL, 1999, P 7 COCHR C U S TOMM, P57; LIBERATI A, 1986, J CLIN ONCOL, V4, P942, DOI 10.1200/JCO.1986.4.6.942; Lindsley SL, 1999, WESTERN J COMM, V63, P1; MAY GS, 1981, CIRCULATION, V64, P669, DOI 10.1161/01.CIR.64.4.669; Moher D, 1998, LANCET, V352, P609, DOI 10.1016/S0140-6736(98)01085-X; Moher D, 2001, JAMA-J AM MED ASSOC, V285, P1987, DOI 10.1001/jama.285.15.1987; MOHER D, 1995, CONTROL CLIN TRIALS, V16, P62, DOI 10.1016/0197-2456(94)00031-W; MOHER D, 1999, HLTH TECHNOL ASSESS, pI3; Murphy E.A., 1976, LOGIC MED; NOSEWORTHY JH, 1994, NEUROLOGY, V44, P16, DOI 10.1212/WNL.44.1.16; SACKETT DL, 1979, NEW ENGL J MED, V301, P1410, DOI 10.1056/NEJM197912273012602; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V274, P1456; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; Schulz KF, 1996, LANCET, V348, P596, DOI 10.1016/S0140-6736(96)01201-9; STERNE JAC, 2001, IN PRESS BMJ; Thompson S G, 1993, Stat Methods Med Res, V2, P173, DOI 10.1177/096228029300200205	37	2078	2259	2	104	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 7	2001	323	7303					42	46		10.1136/bmj.323.7303.42	http://dx.doi.org/10.1136/bmj.323.7303.42			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	451WA	11440947	Green Published			2022-12-28	WOS:000169824300027
J	Humpherys, D; Eggan, K; Akutsu, H; Hochedlinger, K; Rideout, WM; Biniszkiewicz, D; Yanagimachi, R; Jaenisch, R				Humpherys, D; Eggan, K; Akutsu, H; Hochedlinger, K; Rideout, WM; Biniszkiewicz, D; Yanagimachi, R; Jaenisch, R			Epigenetic instability in ES cells and cloned mice	SCIENCE			English	Article							EMBRYONIC STEM-CELLS; NUCLEAR TRANSFER; SOMATIC-CELLS; H19 GENE; ADULT; METHYLATION; CLONING; MOUSE; FETAL; EXPRESSION	Cloning by nuclear transfer (NT) is an inefficient process in which most clones die before birth and survivors often display growth abnormalities. In an effort to correlate gene expression with survival and fetal overgrowth, we have examined imprinted gene expression in both mice cloned by nuclear transfer and in the embryonic stem (ES) cell donor populations from which they were derived. The epigenetic state of the ES cell genome was found to be extremely unstable. Similarly, variation in imprinted gene expression was observed in most cloned mice, even in those derived from ES cells of the same subclone. Many of the animals survived to adulthood despite widespread gene dysregulation, indicating that mammalian development may be rather tolerant to epigenetic aberrations of the genome. These data imply that even apparently normal cloned animals may have subtle abnormalities in gene expression.	MIT, Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; MIT, Dept Biol, Cambridge, MA 02142 USA; Univ Hawaii, John A Burns Sch Med, Dept Anat & Reprod Biol, Honolulu, HI 96822 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); University of Hawaii System	Jaenisch, R (corresponding author), MIT, Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.		Eggan, Kevin/P-7119-2018		NCI NIH HHS [R01-CA84198, 5-R35-CA44339] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA044339, R01CA084198] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Baguisi A, 1999, NAT BIOTECHNOL, V17, P456, DOI 10.1038/8632; Bartolomei MS, 1997, ANNU REV GENET, V31, P493, DOI 10.1146/annurev.genet.31.1.493; Dean W, 1998, DEVELOPMENT, V125, P2273; Eggan K, 2001, P NATL ACAD SCI USA, V98, P6209, DOI 10.1073/pnas.101118898; Hill JR, 1999, THERIOGENOLOGY, V51, P1451, DOI 10.1016/S0093-691X(99)00089-8; Kato Y, 1998, SCIENCE, V282, P2095, DOI 10.1126/science.282.5396.2095; Kono T, 1998, REPROD FERT DEVELOP, V10, P593, DOI 10.1071/RD98056; LEIGHTON PA, 1995, NATURE, V375, P34, DOI 10.1038/375034a0; NAGY A, 1990, DEVELOPMENT, V110, P815; NAGY A, 1993, P NATL ACAD SCI USA, V90, P8424, DOI 10.1073/pnas.90.18.8424; Onishi A, 2000, SCIENCE, V289, P1188, DOI 10.1126/science.289.5482.1188; Ono Y, 2001, BIOL REPROD, V64, P44, DOI 10.1095/biolreprod64.1.44; Polejaeva IA, 2000, NATURE, V407, P86, DOI 10.1038/35024082; Reik W, 2001, NAT REV GENET, V2, P21, DOI 10.1038/35047554; Rideout WM, 2000, NAT GENET, V24, P109, DOI 10.1038/72753; TREMBLAY KD, 1995, NAT GENET, V9, P407, DOI 10.1038/ng0495-407; Tucker KL, 1996, GENE DEV, V10, P1008, DOI 10.1101/gad.10.8.1008; Wakayama T, 1998, NATURE, V394, P369, DOI 10.1038/28615; Wakayama T, 1999, P NATL ACAD SCI USA, V96, P14984, DOI 10.1073/pnas.96.26.14984; Wakayama T, 1999, NAT GENET, V22, P127, DOI 10.1038/9632; Wang ZQ, 1997, MECH DEVELOP, V62, P137, DOI 10.1016/S0925-4773(97)00655-2; Wilmut I, 1997, NATURE, V385, P810, DOI 10.1038/385810a0; Young LE, 2000, THERIOGENOLOGY, V53, P627, DOI 10.1016/S0093-691X(99)00263-0; Young LE, 1998, REV REPROD, V3, P155, DOI 10.1530/revreprod/3.3.155	24	559	613	3	43	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 6	2001	293	5527					95	97		10.1126/science.1061402	http://dx.doi.org/10.1126/science.1061402			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	451BB	11441181				2022-12-28	WOS:000169780300036
J	Casarett, DJ; Inouye, SK				Casarett, DJ; Inouye, SK		Amer Coll Physicians Amer Soc In	Diagnosis and management of delirium near the end of life	ANNALS OF INTERNAL MEDICINE			English	Article							ACUTE CONFUSIONAL STATES; DOUBLE-BLIND; BEHAVIORAL SYMPTOMS; TERMINAL CANCER; OPIOID ROTATION; MENTAL STATUS; HALOPERIDOL; LORAZEPAM; OLDER; IMPAIRMENT	Delirium is a common and distressing symptom that constitutes a significant challenge for end-of-life care. However, reliable techniques are available for the diagnosis of delirium, and effective therapies exist as well. This consensus paper uses a case-based format that begins with an overview of the definition and presentation of delirium. Next, strategies for diagnosis are suggested, with attention to the unique challenges that clinicians face in pursuing a diagnostic work-up for patients near the end of life. The paper concludes with a review of therapeutic options.	Vet Affairs Med Ctr, Philadelphia, PA USA; Univ Penn, Philadelphia, PA 19104 USA; Yale Univ, Sch Med, New Haven, CT 06520 USA	University of Pennsylvania; Pennsylvania Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Philadelphia Veterans Affairs Medical Center; University of Pennsylvania; Yale University	Casarett, DJ (corresponding author), Care of Snyder L, Amer Coll Phys, Amer Soc Internal Med, 190 N Independence Mall W, Philadelphia, PA 19106 USA.		Inouye, Sharon/R-7216-2019		NIA NIH HHS [AG00949] Funding Source: Medline	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Albert M S, 1992, J Geriatr Psychiatry Neurol, V5, P14; American Psychiatric Association, 1994, DSM 4 DIAGNOSTIC STA; Beasley CM, 1997, J CLIN PSYCHIAT, V58, P13; Breitbart W, 1997, J PAIN SYMPTOM MANAG, V13, P128, DOI 10.1016/S0885-3924(96)00316-8; Breitbart W, 1996, AM J PSYCHIAT, V153, P231; BRUERA E, 1989, PAIN, V39, P13, DOI 10.1016/0304-3959(89)90169-3; BRUERA E, 1992, J PAIN SYMPTOM MANAG, V7, P192, DOI 10.1016/0885-3924(92)90074-R; BRUERA E, 1995, J PAIN SYMPTOM MANAG, V10, P287, DOI 10.1016/0885-3924(95)00005-J; Burstein HJ, 1999, NEW ENGL J MED, V340, P1733, DOI 10.1056/NEJM199906033402206; Caraceni A, 2000, CANCER-AM CANCER SOC, V89, P1145, DOI 10.1002/1097-0142(20000901)89:5<1145::AID-CNCR24>3.0.CO;2-X; Casarett DJ, 2000, J PAIN SYMPTOM MANAG, V20, P130, DOI 10.1016/S0885-3924(00)00164-0; Christensen DB, 1998, J AM GERIATR SOC, V46, P620, DOI 10.1111/j.1532-5415.1998.tb01081.x; Conley RR, 2000, J CLIN PSYCHIAT, V61, P26; De Deyn PP, 2000, INT J GERIATR PSYCH, V15, pS14, DOI 10.1002/1099-1166(200007)15:1+<::AID-GPS168>3.0.CO;2-#; De Deyn PP, 1999, NEUROLOGY, V53, P946, DOI 10.1212/WNL.53.5.946; DESTOUTZ ND, 1995, J PAIN SYMPTOM MANAG, V10, P378, DOI 10.1016/0885-3924(95)90924-C; DHONNEUR G, 1994, ANESTHESIOLOGY, V81, P87, DOI 10.1097/00000542-199407000-00013; Fainsinger R, 1991, J Palliat Care, V7, P5; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; FRANCIS J, 1988, CLIN RES, V36, pA711; GUSTAFSON Y, 1991, J AM GERIATR SOC, V39, P760, DOI 10.1111/j.1532-5415.1991.tb02697.x; GUSTAFSON Y, 1988, J AM GERIATR SOC, V36, P525, DOI 10.1111/j.1532-5415.1988.tb04023.x; Inouye SK, 1999, NEW ENGL J MED, V340, P669, DOI 10.1056/NEJM199903043400901; Inouye SK, 1996, JAMA-J AM MED ASSOC, V275, P852, DOI 10.1001/jama.275.11.852; INOUYE SK, 1990, ANN INTERN MED, V113, P941, DOI 10.7326/0003-4819-113-12-941; LEIPZIG RM, 1987, PHARMACOLOGY, V35, P47, DOI 10.1159/000138294; MARCANTONIO ER, 1994, JAMA-J AM MED ASSOC, V272, P1518, DOI 10.1001/jama.272.19.1518; MASSIE MJ, 1983, AM J PSYCHIAT, V140, P1048; McCollam JS, 1999, CRIT CARE MED, V27, P2454, DOI 10.1097/00003246-199911000-00022; Mercadante S, 1999, CANCER, V86, P1856, DOI 10.1002/(SICI)1097-0142(19991101)86:9<1856::AID-CNCR30>3.0.CO;2-G; Minagawa H, 1996, CANCER, V78, P1131, DOI 10.1002/(SICI)1097-0142(19960901)78:5<1131::AID-CNCR26>3.0.CO;2-2; NYGAARD HA, 1992, CURR MED RES OPIN, V12, P615, DOI 10.1185/03007999209111528; Olmos M, 2000, ANESTH ANALG, V90, P1157, DOI 10.1097/00000539-200005000-00029; Paramore LC, 1997, J PAIN SYMPTOM MANAG, V13, P83, DOI 10.1016/S0885-3924(96)00299-0; PATT RB, 1994, J PAIN SYMPTOM MANAG, V9, P446, DOI 10.1016/0885-3924(94)90201-1; Pereira J, 1997, CANCER-AM CANCER SOC, V79, P835; POMPEI P, 1995, ARCH INTERN MED, V155, P301, DOI 10.1001/archinte.155.3.301; PORTENOY RK, 1991, PAIN, V47, P13, DOI 10.1016/0304-3959(91)90005-I; Quill TE, 2000, ANN INTERN MED, V132, P408, DOI 10.7326/0003-4819-132-5-200003070-00012; SCHOR JD, 1992, JAMA-J AM MED ASSOC, V267, P827, DOI 10.1001/jama.267.6.827; Steiner N, 1998, J PALLIAT CARE, V14, P6, DOI 10.1177/082585979801400202; Street JS, 2000, ARCH GEN PSYCHIAT, V57, P968, DOI 10.1001/archpsyc.57.10.968; Sulmasy DP, 2000, ANN INTERN MED, V133, P564, DOI 10.7326/0003-4819-133-7-200010030-00027; Swart EL, 1999, CRIT CARE MED, V27, P1461, DOI 10.1097/00003246-199908000-00009; Tariot PN, 1996, J CLIN PSYCHIAT, V57, P21; TRZEPACZ PT, 1988, PSYCHIAT RES, V23, P89, DOI 10.1016/0165-1781(88)90037-6; TRZEPACZ PT, 1995, GEN HOSP PSYCHIAT, V17, P75, DOI 10.1016/0163-8343(94)00095-U; Ventafridda V, 1990, J Palliat Care, V6, P7; Wood MM, 1998, J PAIN SYMPTOM MANAG, V16, P112, DOI 10.1016/S0885-3924(98)00043-8	49	106	110	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 3	2001	135	1					32	40		10.7326/0003-4819-135-1-200107030-00011	http://dx.doi.org/10.7326/0003-4819-135-1-200107030-00011			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	449JC	11434730				2022-12-28	WOS:000169680500005
J	Goodnow, CC				Goodnow, CC			Pathways for self-tolerance and the treatment of autoimmune diseases	LANCET			English	Article							T-CELLS; LYMPHOCYTE RESPONSES; B-CELLS; KAPPA-B; RECEPTOR; INDUCTION; DEATH; MICE; PROLIFERATION; INACTIVATION	Antigen delivers both immunogenic and tolerogenic signals to lymphocytes. The outcome of antigen exposure represents a complex integration of the timing of antigen binding with signals from many other immunogenic and tolerogenic costimulatory pathways. A road map of these signalling pathways is only beginning to be charted, revealing the mechansim of action and limitations of current immunotherapeutic agents and the points of attack for new agents. Ciclosporin and tacrolimus interfere with tolerogenic signals from antigen in addition to blocking immunogenic signals, thus preventing active establishment of tolerance. Corticosteroids inhibit a key immunogenic pathway, NF kappaB, and more specific inhibitors of this pathway may allow tolerance to be actively established while immune responses are blocked. New experimental therapies aim to mimic tolerogenic antigen signals by chronically stimulating antigen receptors with antigen or antibodies to the receptor, or aim to block costimulatory pathways involving CD40 ligand, B7, or interleukin 2. Obtaining the desired response with these strategies is unpredictable because many of these signals have both tolerogenic and immunogenic roles. The cause of autoimmune diseases has been determined for several rare monogenic disorders, revealing inherited deficiencies in tolerogenic costimulatory pathways such as FAS. Common autoimmune disorders may have a biochemically related pathogenesis.	Australian Natl Univ, John Curtin Sch Med Res, Med Genome Ctr, Australian Canc Res Fdn,Genet Lab, Canberra, ACT 2601, Australia	Australian National University; John Curtin School of Medical Research	Goodnow, CC (corresponding author), Australian Natl Univ, John Curtin Sch Med Res, Med Genome Ctr, Australian Canc Res Fdn,Genet Lab, POB 334, Canberra, ACT 2601, Australia.	chris.goodnow@anu.edu.au	Goodnow, Christopher C/V-8108-2018	Goodnow, Christopher C/0000-0001-5296-6155				Akkaraju S, 1997, IMMUNITY, V7, P255, DOI 10.1016/S1074-7613(00)80528-2; Akkaraju S, 1997, J EXP MED, V186, P2005, DOI 10.1084/jem.186.12.2005; BACHMANN MF, 1993, SCIENCE, V262, P1448, DOI 10.1126/science.8248784; Bajpai UD, 2000, J EXP MED, V191, P1735, DOI 10.1084/jem.191.10.1735; Barnes PJ, 1998, CLIN SCI, V94, P557, DOI 10.1042/cs0940557; Beutler B, 2000, CURR OPIN MICROBIOL, V3, P23, DOI 10.1016/S1369-5274(99)00046-6; Brennan FM, 1998, SPRINGER SEMIN IMMUN, V20, P133, DOI 10.1007/BF00832003; Chambers CA, 1999, CURR OPIN CELL BIOL, V11, P203, DOI 10.1016/S0955-0674(99)80027-1; Cobbold S, 1998, CURR OPIN IMMUNOL, V10, P518, DOI 10.1016/S0952-7915(98)80217-3; COOKE MP, 1994, J EXP MED, V179, P425, DOI 10.1084/jem.179.2.425; Cope AP, 1998, CURR OPIN IMMUNOL, V10, P669, DOI 10.1016/S0952-7915(98)80087-3; Fadok VA, 2000, NATURE, V405, P85, DOI 10.1038/35011084; Fearon DT, 2000, ANNU REV IMMUNOL, V18, P393, DOI 10.1146/annurev.immunol.18.1.393; Fukaura H, 1996, J CLIN INVEST, V98, P70, DOI 10.1172/JCI118779; Gallucci S, 1999, NAT MED, V5, P1249, DOI 10.1038/15200; Gerondakis S, 1999, ONCOGENE, V18, P6888, DOI 10.1038/sj.onc.1203236; Glynne R, 2000, NATURE, V403, P672, DOI 10.1038/35001102; GOODNOW CC, 1989, NATURE, V342, P385, DOI 10.1038/342385a0; Goodnow CC, 1996, P NATL ACAD SCI USA, V93, P2264, DOI 10.1073/pnas.93.6.2264; Green EA, 1999, CURR OPIN IMMUNOL, V11, P663, DOI 10.1016/S0952-7915(99)00034-5; Green EA, 1999, IMMUNOL REV, V169, P11, DOI 10.1111/j.1600-065X.1999.tb01302.x; Grewal IS, 1998, ANNU REV IMMUNOL, V16, P111, DOI 10.1146/annurev.immunol.16.1.111; Healy JI, 1998, ANNU REV IMMUNOL, V16, P645, DOI 10.1146/annurev.immunol.16.1.645; JUNE CH, 1994, IMMUNOL TODAY, V15, P321, DOI 10.1016/0167-5699(94)90080-9; Kirk AD, 1999, NAT MED, V5, P686, DOI 10.1038/9536; Kouskoff V, 2000, SCIENCE, V287, P2501, DOI 10.1126/science.287.5462.2501; Krammer P H, 1999, Adv Immunol, V71, P163; Lenardo M, 1999, ANNU REV IMMUNOL, V17, P221, DOI 10.1146/annurev.immunol.17.1.221; Letterio JJ, 1998, ANNU REV IMMUNOL, V16, P137, DOI 10.1146/annurev.immunol.16.1.137; Marrack P, 2000, NAT IMMUNOL, V1, P107, DOI 10.1038/77778; Medzhitov R, 2000, NEW ENGL J MED, V343, P338, DOI 10.1056/NEJM200008033430506; Mueller DL, 2000, CURR BIOL, V10, pR227, DOI 10.1016/S0960-9822(00)00400-0; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; NOSSAL GJV, 1983, ANNU REV IMMUNOL, V1, P33, DOI 10.1146/annurev.iy.01.040183.000341; OHASHI PS, 1991, CELL, V65, P305, DOI 10.1016/0092-8674(91)90164-T; Pickering MC, 2000, RHEUMATOLOGY, V39, P133, DOI 10.1093/rheumatology/39.2.133; Podolin PL, 2000, CYTOKINE, V12, P477, DOI 10.1006/cyto.1999.0609; Puel A, 1998, NAT GENET, V20, P394, DOI 10.1038/3877; RATHMELL JC, 1994, J IMMUNOL, V153, P2831; Rathmell JC, 1996, CELL, V87, P319, DOI 10.1016/S0092-8674(00)81349-5; Ravetch JV, 1998, ANNU REV IMMUNOL, V16, P421, DOI 10.1146/annurev.immunol.16.1.421; Ridgway WM, 1999, CURR OPIN IMMUNOL, V11, P638, DOI 10.1016/S0952-7915(99)00030-8; Salomon B, 2000, IMMUNITY, V12, P431, DOI 10.1016/S1074-7613(00)80195-8; Sauter B, 2000, J EXP MED, V191, P423, DOI 10.1084/jem.191.3.423; Schild H, 2000, NAT IMMUNOL, V1, P100, DOI 10.1038/77770; STEINBERG BJ, 1982, J CLIN INVEST, V70, P587, DOI 10.1172/JCI110651; Streilein JW, 1999, SPRINGER SEMIN IMMUN, V21, P95; Todd JA, 1999, BIOESSAYS, V21, P164, DOI 10.1002/(SICI)1521-1878(199902)21:2<164::AID-BIES10>3.3.CO;2-W; Townsend SE, 1999, IMMUNOL TODAY, V20, P217, DOI 10.1016/S0167-5699(98)01440-6; Van Parijs L, 1999, IMMUNITY, V11, P281, DOI 10.1016/S1074-7613(00)80103-X; VONHERRATH MG, 1994, J EXP MED, V180, P1901, DOI 10.1084/jem.180.5.1901; Vyse TJ, 1996, CELL, V85, P311, DOI 10.1016/S0092-8674(00)81110-1	52	63	90	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 30	2001	357	9274					2115	2121						7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	447RQ	11445125				2022-12-28	WOS:000169586600034
J	Bicknell, AB; Lomthaisong, K; Woods, RJ; Hutchinson, EG; Bennett, HPJ; Gladwell, RT; Lowry, PJ				Bicknell, AB; Lomthaisong, K; Woods, RJ; Hutchinson, EG; Bennett, HPJ; Gladwell, RT; Lowry, PJ			Characterization of a serine protease that cleaves pro-gamma-melanotropin at the adrenal to stimulate growth	CELL			English	Article							PANCREATIC TRYPSIN-INHIBITOR; PROOPIOMELANOCORTIN PEPTIDES; UNILATERAL ADRENALECTOMY; CRYSTAL-STRUCTURE; RAT; EXPRESSION; CORTEX; ADRENOCORTICOTROPIN; DEXAMETHASONE; HYPERTROPHY	The adrenal gland requires stimuli from peptides derived from the ACTH precursor, pro-opiomelanocortin (POMC), to maintain its tonic state. Studies have proposed that a specific postsecretional cleavage of the nonmitogenic N-terminal 16 kDa fragment, also known as pro-gamma -melanotropin (pro-gamma -MSH), is required, releasing shorter fragments that promote adrenal growth. Here, we provide evidence for this hypothesis by the cloning and characterization of a serine protease that is upregulated during growth of the adrenal cortex. It is expressed exclusively in the outer adrenal cortex, the site of cell proliferation, and in the Y1 adrenal cell line. We also show that it is required for growth of Y1 cells, remains bound to the cell surface, and cleaves its substrate, pro-gamma -MSH, at a specific bond.	Univ Reading, Sch Anim & Microbial Sci, Reading RG6 6AJ, Berks, England; McGill Univ, Montreal, PQ, Canada	University of Reading; McGill University	Bicknell, AB (corresponding author), Univ Reading, Sch Anim & Microbial Sci, POB 228, Reading RG6 6AJ, Berks, England.	a.b.bicknell@rdg.ac.uk		Lomthaisong, Khomsorn/0000-0002-0645-5757				Bicknell AB, 2000, J NEUROENDOCRINOL, V12, P977, DOI 10.1046/j.1365-2826.2000.00543.x; BODE W, 1984, EUR J BIOCHEM, V144, P185, DOI 10.1111/j.1432-1033.1984.tb08447.x; BRANSOME ED, 1968, ENDOCRINOLOGY, V83, P956, DOI 10.1210/endo-83-5-956; BROWN JR, 1966, BIOCHEM J, V101, P933; DALLMAN MF, 1980, ENDOCRINOLOGY, V107, P1397, DOI 10.1210/endo-107-5-1397; DALLMAN MF, 1976, AM J PHYSIOL, V231, P408, DOI 10.1152/ajplegacy.1976.231.2.408; DUNLAP NE, 1984, ENDOCRINOLOGY, V114, P1490, DOI 10.1210/endo-114-5-1490; ESTIVARIZ FE, 1982, NATURE, V297, P419, DOI 10.1038/297419a0; ESTIVARIZ FE, 1992, ADRENAL GLAND, P43; HOLZWARTH M, 1988, INT CONGR SER, V799, P841; HORNSBY P J, 1984, Endocrine Research, V10, P259; JAMES S, 1985, J CHROMATOGR, V326, P329, DOI 10.1016/S0021-9673(01)87458-6; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KRISTENSEN P, 1986, HISTOCHEMISTRY, V85, P431, DOI 10.1007/BF00982674; Lazure C, 1998, J BIOL CHEM, V273, P8572, DOI 10.1074/jbc.273.15.8572; LIPSCOMB HS, 1968, EXCERPTA MED, V222, P79; LOWRY PJ, 1983, NATURE, V306, P70, DOI 10.1038/306070a0; MIN HY, 1986, NUCLEIC ACIDS RES, V14, P8879; Morley SD, 1996, MOL ENDOCRINOL, V10, P585, DOI 10.1210/me.10.5.585; NAKAI K, 1992, GENOMICS, V14, P897, DOI 10.1016/S0888-7543(05)80111-9; NAKANISHI S, 1979, NATURE, V278, P423, DOI 10.1038/278423a0; PELLEGRINO C, 1963, EXP CELL RES, V31, P167, DOI 10.1016/0014-4827(63)90165-4; RAO AJ, 1978, ENDOCRINOLOGY, V102, P371, DOI 10.1210/endo-102-2-371; Ross JT, 2000, ENDOCRINOLOGY, V141, P2153, DOI 10.1210/en.141.6.2153; RUHLMANN A, 1973, J MOL BIOL, V77, P417, DOI 10.1016/0022-2836(73)90448-8; SAPHIER PW, 1993, ENDOCRINOLOGY, V133, P1459, DOI 10.1210/en.133.3.1459; Shutter JR, 1997, GENE DEV, V11, P593, DOI 10.1101/gad.11.5.593; VINSON GP, 1985, CELL BIOCHEM FUNCT, V3, P235, DOI 10.1002/cbf.290030402; WRIGHT NA, 1974, J ENDOCRINOL, V62, P527, DOI 10.1677/joe.0.0620527; Yamaoka K, 1998, J BIOL CHEM, V273, P11895, DOI 10.1074/jbc.273.19.11895; Yaswen L, 1999, NAT MED, V5, P1066, DOI 10.1038/12506	31	103	105	0	4	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	JUN 29	2001	105	7					903	912		10.1016/S0092-8674(01)00403-2	http://dx.doi.org/10.1016/S0092-8674(01)00403-2			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	449BK	11439186	Bronze			2022-12-28	WOS:000169664300010
J	Mayfield, JA; Fiebig, A; Johnstone, SE; Preuss, D				Mayfield, JA; Fiebig, A; Johnstone, SE; Preuss, D			Gene families from the Arabidopsis thaliana pollen coat proteome	SCIENCE			English	Article							INTRAGENIC RECOMBINATION; STIGMA INTERACTIONS; ALLELIC DIVERSITY; RAPID EVOLUTION; SELECTION; LOCUS; RESISTANCE; PROTEINS; REVEALS; GENOME	The pollen extracellular matrix contains proteins mediating species specificity and components needed for efficient pollination. We identified all proteins >10 kilodaltons in the Arabidopsis pollen coating and showed that most of the corresponding genes reside in two genomic clusters. One cluster encodes six Lipases, whereas the other contains six lipid-binding oleosin genes, including GRP17, a gene that promotes efficient pollination. Individual oleosins exhibit extensive divergence between eco types, but the entire cluster remains intact. Analysis of the syntenic region in Brassica oleracea revealed even greater divergence, but a similar clustering of the genes. Such allelic flexibility may promote speciation in plants.	Univ Chicago, Dept Mol Genet & Cell Biol, Chicago, IL 60637 USA; Univ Chicago, Dept Biochem & Mol Biol, Chicago, IL 60637 USA; Univ Chicago, Howard Hughes Med Inst, Chicago, IL 60637 USA	University of Chicago; University of Chicago; Howard Hughes Medical Institute; University of Chicago	Preuss, D (corresponding author), Univ Chicago, Dept Mol Genet & Cell Biol, 920 E 58Th St, Chicago, IL 60637 USA.	dpreuss@midway.uchicago.edu		Mayfield, Jacob/0000-0002-5762-6755; Fiebig, Aretha/0000-0002-0612-5029				Alonso-Blanco C, 1998, PLANT J, V14, P259, DOI 10.1046/j.1365-313X.1998.00115.x; Cavell AC, 1998, GENOME, V41, P62, DOI 10.1139/gen-41-1-62; DEOLIVEIRA DE, 1993, PLANT J, V3, P495, DOI 10.1046/j.1365-313X.1993.03040495.x; Dickinson HG, 2000, TRENDS GENET, V16, P373, DOI 10.1016/S0168-9525(00)02083-7; Ferris PJ, 1997, P NATL ACAD SCI USA, V94, P8634, DOI 10.1073/pnas.94.16.8634; Fiebig A, 2000, PLANT CELL, V12, P2001, DOI 10.1105/tpc.12.10.2001; HUGHES AL, 1988, NATURE, V335, P167, DOI 10.1038/335167a0; Kasahara M, 1997, TRENDS GENET, V13, P90, DOI 10.1016/S0168-9525(97)01065-2; Kaul S, 2000, NATURE, V408, P796, DOI 10.1038/35048692; Lynch M, 2000, SCIENCE, V290, P1151, DOI 10.1126/science.290.5494.1151; Mayfield JA, 2000, NAT CELL BIOL, V2, P128, DOI 10.1038/35000084; McDowell JM, 1998, PLANT CELL, V10, P1861, DOI 10.1105/tpc.10.11.1861; Michelmore RW, 1998, GENOME RES, V8, P1113, DOI 10.1101/gr.8.11.1113; Richman AD, 1996, SCIENCE, V273, P1212, DOI 10.1126/science.273.5279.1212; Ruiter RK, 1997, PLANT CELL, V9, P1621, DOI 10.1105/tpc.9.9.1621; SommerKnudsen J, 1997, SEX PLANT REPROD, V10, P253, DOI 10.1007/s004970050095; UPTON C, 1995, TRENDS BIOCHEM SCI, V20, P178, DOI 10.1016/S0968-0004(00)89002-7; Vacquier VD, 1998, SCIENCE, V281, P1995, DOI 10.1126/science.281.5385.1995; Wang X, 2001, PLANT PHYSIOL, V125, P1012, DOI 10.1104/pp.125.2.1012; Wolters-Arts M, 1998, NATURE, V392, P818, DOI 10.1038/33929; Wyckoff GJ, 2000, NATURE, V403, P304, DOI 10.1038/35002070; Zinkl GM, 2000, ANN BOT-LONDON, V85, P15, DOI 10.1006/anbo.1999.1066	22	163	194	1	46	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 29	2001	292	5526					2482	2485		10.1126/science.1060972	http://dx.doi.org/10.1126/science.1060972			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	448YU	11431566				2022-12-28	WOS:000169658200039
J	Trimmer, BA; Aprille, JR; Dudzinski, DM; Lagace, CJ; Lewis, SM; Michel, T; Qazi, S; Zayas, RM				Trimmer, BA; Aprille, JR; Dudzinski, DM; Lagace, CJ; Lewis, SM; Michel, T; Qazi, S; Zayas, RM			Nitric oxide and the control of firefly flashing	SCIENCE			English	Article							MITOCHONDRIAL RESPIRATION; MANDUCA-SEXTA; OCTOPAMINE; DROSOPHILA; NEURONS; INHIBITION; SYNTHASE; OXYGEN	Bioluminescent flashing is essential for firefly reproduction, yet the specific molecular mechanisms that control Light production are not well understood. We report that Light production by fireflies can be stimulated by nitric oxide (NO) gas in the presence of oxygen and that NO scavengers block bioluminescence induced by the neurotransmitter octopamine, NO synthase is robustly expressed in the firefly Lantern in cells interposed between nerve endings and the light-producing photocytes, These results suggest that NO synthesis is a key determinant of flash control in fireflies.	Tufts Univ, Dept Biol, Medford, MA 02155 USA; Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA; Harvard Univ, Sch Med, Vet Affairs Boston Healthcare Syst, Boston, MA 02115 USA	Tufts University; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Boston Healthcare System	Trimmer, BA (corresponding author), Tufts Univ, Dept Biol, Medford, MA 02155 USA.			Zayas, Ricardo M./0000-0002-6272-0519; Trimmer, Barry/0000-0003-1782-7373				Achenbach H, 1997, NEUROREPORT, V8, P3737, DOI 10.1097/00001756-199712010-00016; Bicker G, 1998, TRENDS NEUROSCI, V21, P349, DOI 10.1016/S0166-2236(98)01236-3; Borutaite V, 2000, BBA-BIOENERGETICS, V1459, P405, DOI 10.1016/S0005-2728(00)00178-X; Branham MA, 1996, NATURE, V381, P745, DOI 10.1038/381745b0; Brown GC, 1999, BBA-BIOENERGETICS, V1411, P351, DOI 10.1016/S0005-2728(99)00025-0; BUCK JB, 1948, ANN NY ACAD SCI, V49, P397, DOI 10.1111/j.1749-6632.1948.tb30944.x; Case J.F., 1978, P331; CHRISTENSEN TA, 1983, NEUROSCIENCE, V9, P183, DOI 10.1016/0306-4522(83)90055-6; CLEETER MWJ, 1994, FEBS LETT, V345, P50, DOI 10.1016/0014-5793(94)00424-2; Clementi E, 1999, P NATL ACAD SCI USA, V96, P1559, DOI 10.1073/pnas.96.4.1559; COPE FW, 1976, PHYSIOL CHEM PHYS M, V8, P343; DAWSON TM, 1991, P NATL ACAD SCI USA, V88, P7797, DOI 10.1073/pnas.88.17.7797; Ghiradella H, 1998, MICROSCOPIC ANATOMY OF INVERTEBRATES, VOL 11 A-C, P363; Gibbs SM, 1998, NEURON, V20, P83, DOI 10.1016/S0896-6273(00)80436-5; Grueber WB, 1999, J COMP NEUROL, V404, P127, DOI 10.1002/(SICI)1096-9861(19990201)404:1<127::AID-CNE10>3.0.CO;2-M; HASEMZADEH H, 1985, LIFE SCI, V37, P433; Lloyd J.E., 1979, P293; MULLER U, 1994, EUR J NEUROSCI, V6, P1362, DOI 10.1111/j.1460-9568.1994.tb00327.x; NATHANSON JA, 1979, SCIENCE, V203, P65, DOI 10.1126/science.214856; SMITH DS, 1963, J CELL BIOL, V16, P323, DOI 10.1083/jcb.16.2.323; VAUGHN M, 1998, AM J PHYSIOL, V274, P1705; Wilson T, 1998, ANNU REV CELL DEV BI, V14, P197, DOI 10.1146/annurev.cellbio.14.1.197; Wingrove JA, 1999, CELL, V98, P105, DOI 10.1016/S0092-8674(00)80610-8; WOOD J, 1994, NEUROPHARMACOLOGY, V33, P1235, DOI 10.1016/0028-3908(94)90022-1; Zayas RM, 2000, J COMP NEUROL, V419, P422	25	103	111	3	61	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 29	2001	292	5526					2486	2488		10.1126/science.1059833	http://dx.doi.org/10.1126/science.1059833			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	448YU	11431567				2022-12-28	WOS:000169658200040
J	Yeh, JC; Hiraoka, N; Petryniak, B; Nakayama, J; Ellies, LG; Rabuka, D; Hindsgaul, O; Marth, JD; Lowe, JB; Fukuda, M				Yeh, JC; Hiraoka, N; Petryniak, B; Nakayama, J; Ellies, LG; Rabuka, D; Hindsgaul, O; Marth, JD; Lowe, JB; Fukuda, M			Novel sulfated lymphocyte homing receptors and their control by a core1 extension beta 1,3-N-acetylglucosaminyltransferase	CELL			English	Article							POLY-N-ACETYLLACTOSAMINE; HIGH ENDOTHELIAL VENULES; L-SELECTIN; MOLECULAR-CLONING; HEPARAN-SULFATE; FUNCTIONAL-CHARACTERIZATION; SULFOTRANSFERASE GENE; LEUKOCYTE TRAFFICKING; MONOCLONAL-ANTIBODY; EXPRESSION CLONING	L-selectin mediates lymphocyte homing by facilitating lymphocyte adhesion to addressins expressed in the high endothelial venules (HEV) of secondary lymphoid organs. Peripheral node addressin recognized by the MECA-79 antibody is apparently part of the L-selectin ligand, but its chemical nature has been undefined. We now identify a sulfated extended core1 mucin-type O-glycan, Gal beta1-->4(sulfo-->6)GlcNAc beta1-->3Gal beta1--> 3GalNAc, as the MECA-79 epitope. Molecular cloning of a HEV-expressed core1-beta1,3-N-acetylglucosaminyltransferase (Core1-beta 3GlcNAcT) enabled the construction of the 6-sulfo sialyl Lewis x on extended core1 O-glycans, recapitulating the potent L-selectin-mediated, shear-dependent adhesion observed with novel L-selectin ligands derived from core2 beta1,6-N-acetylglucosaminyltransferase-I null mice. These results identify Core1-beta 3GlcNAcT and its cognate extended core1 O-glycans as essential participants in the expression of the MECA-79-positive, HEV-specific L-selectin ligands required for lymphocyte homing.	Burnham Inst, Ctr Canc Res, Glycobiol Program, La Jolla, CA 92037 USA; Univ Michigan, Sch Med, Dept Pathol, Howard Hughes Med Inst, Ann Arbor, MI 48109 USA; Shinshu Univ, Grad Sch Med, Inst Organ Transplants Reconstruct Med & Tissue E, Matsumoto, Nagano 3908621, Japan; Univ Calif San Diego, Howard Hughes Med Inst, Div Cellular & Mol Med, La Jolla, CA 92093 USA	Sanford Burnham Prebys Medical Discovery Institute; Howard Hughes Medical Institute; University of Michigan System; University of Michigan; Shinshu University; Howard Hughes Medical Institute; University of California System; University of California San Diego	Fukuda, M (corresponding author), Burnham Inst, Ctr Canc Res, Glycobiol Program, La Jolla, CA 92037 USA.				NATIONAL CANCER INSTITUTE [R01CA048737, F32CA079130] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048247] Funding Source: NIH RePORTER; NCI NIH HHS [F32CA79130, CA48737, P01CA79132] Funding Source: Medline; NIDDK NIH HHS [DK48247] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akama TO, 2000, NAT GENET, V26, P237, DOI 10.1038/79987; Angata K, 2001, J BIOL CHEM, V276, P15369, DOI 10.1074/jbc.M100576200; ARBONES ML, 1994, IMMUNITY, V1, P247, DOI 10.1016/1074-7613(94)90076-0; BARGATZE RF, 1995, IMMUNITY, V3, P99, DOI 10.1016/1074-7613(95)90162-0; BAUMHUETER S, 1993, SCIENCE, V262, P436, DOI 10.1126/science.7692600; BERG EL, 1993, NATURE, V366, P695, DOI 10.1038/366695a0; BIERHUIZEN MFA, 1992, P NATL ACAD SCI USA, V89, P9326, DOI 10.1073/pnas.89.19.9326; Bistrup A, 1999, J CELL BIOL, V145, P899, DOI 10.1083/jcb.145.4.899; Bruehl RE, 2000, J BIOL CHEM, V275, P32642, DOI 10.1074/jbc.M001703200; Bullock SL, 1998, GENE DEV, V12, P1894, DOI 10.1101/gad.12.12.1894; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; Capon C, 1997, J BIOL CHEM, V272, P31957, DOI 10.1074/jbc.272.51.31957; Clark RA, 1998, J CELL BIOL, V140, P721, DOI 10.1083/jcb.140.3.721; Constantin G, 2000, IMMUNITY, V13, P759, DOI 10.1016/S1074-7613(00)00074-1; DUIJVESTIJN AM, 1988, AM J PATHOL, V130, P147; Ellies LG, 1998, IMMUNITY, V9, P881, DOI 10.1016/S1074-7613(00)80653-6; FIETE D, 1991, CELL, V67, P1103, DOI 10.1016/0092-8674(91)90287-9; GIRARD JP, 1995, IMMUNITY, V2, P113, DOI 10.1016/1074-7613(95)90083-7; HEMMERICH S, 1994, J EXP MED, V180, P2219, DOI 10.1084/jem.180.6.2219; HEMMERICH S, 1995, J BIOL CHEM, V270, P12035, DOI 10.1074/jbc.270.20.12035; Hiraoka N, 2000, J BIOL CHEM, V275, P20188, DOI 10.1074/jbc.M002443200; Hiraoka N, 1999, IMMUNITY, V11, P79, DOI 10.1016/S1074-7613(00)80083-7; IMAI Y, 1993, NATURE, V361, P555; Kansas GS, 1996, BLOOD, V88, P3259, DOI 10.1182/blood.V88.9.3259.bloodjournal8893259; Kumamoto K, 1998, BIOCHEM BIOPH RES CO, V247, P514, DOI 10.1006/bbrc.1998.8824; LASKY LA, 1992, CELL, V69, P927, DOI 10.1016/0092-8674(92)90612-G; Lee JK, 1999, BIOCHEM BIOPH RES CO, V263, P543, DOI 10.1006/bbrc.1999.1324; LEE N, 1990, J BIOL CHEM, V265, P20476; Maly P, 1996, CELL, V86, P643, DOI 10.1016/S0092-8674(00)80137-3; MCEVER RP, 1995, J BIOL CHEM, V270, P11025, DOI 10.1074/jbc.270.19.11025; Misra AK, 2000, BIOORG MED CHEM LETT, V10, P1505, DOI 10.1016/S0960-894X(00)00207-9; Priatel JJ, 2000, IMMUNITY, V12, P273, DOI 10.1016/S1074-7613(00)80180-6; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; Rosen SD, 1999, AM J PATHOL, V155, P1013, DOI 10.1016/S0002-9440(10)65201-7; Sasaki K, 1997, P NATL ACAD SCI USA, V94, P14294, DOI 10.1073/pnas.94.26.14294; Sassetti C, 1998, J EXP MED, V187, P1965, DOI 10.1084/jem.187.12.1965; SCHACHTER H, 1994, MOL GLYCOBIOLOGY, P88; Schwientek T, 2000, J BIOL CHEM, V275, P11106, DOI 10.1074/jbc.275.15.11106; Shukla D, 1999, CELL, V99, P13, DOI 10.1016/S0092-8674(00)80058-6; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Stein JV, 1999, J EXP MED, V189, P37, DOI 10.1084/jem.189.1.37; STREETER PR, 1988, J CELL BIOL, V107, P1853, DOI 10.1083/jcb.107.5.1853; Suzuki A, 1996, BLOOD, V87, P3550, DOI 10.1182/blood.V87.9.3550.bloodjournal8793550; Tsuda M, 1999, NATURE, V400, P276, DOI 10.1038/22336; Uchimura K, 1998, J BIOL CHEM, V273, P22577, DOI 10.1074/jbc.273.35.22577; Ujita M, 2000, J BIOL CHEM, V275, P15868, DOI 10.1074/jbc.M001034200; USHIYAMA S, 1993, J BIOL CHEM, V268, P15229; WATANABE K, 1979, J BIOL CHEM, V254, P3221; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; Yeh JC, 1999, J BIOL CHEM, V274, P3215, DOI 10.1074/jbc.274.5.3215; Zhou DP, 1999, P NATL ACAD SCI USA, V96, P406, DOI 10.1073/pnas.96.2.406	51	283	297	0	5	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTES AVE,, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 29	2001	105	7					957	969		10.1016/S0092-8674(01)00394-4	http://dx.doi.org/10.1016/S0092-8674(01)00394-4			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	449BK	11439191	Bronze			2022-12-28	WOS:000169664300015
J	Brookfield, JFY				Brookfield, JFY			Predicting the future	NATURE			English	Editorial Material									Univ Nottingham, Inst Genet, Nottingham NG7 2UH, England	University of Nottingham	Brookfield, JFY (corresponding author), Univ Nottingham, Inst Genet, Nottingham NG7 2UH, England.							Maynard Smith, 1998, EVOL GENET	1	6	6	0	3	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 28	2001	411	6841					999	999		10.1038/35082701	http://dx.doi.org/10.1038/35082701			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	446TF	11429579				2022-12-28	WOS:000169528500024
J	Bergelson, J; Kreitman, M; Stahl, EA; Tian, DC				Bergelson, J; Kreitman, M; Stahl, EA; Tian, DC			Evolutionary dynamics of plant R-genes	SCIENCE			English	Review							DISEASE-RESISTANCE GENES; DOWNY MILDEW RESISTANCE; LEUCINE-RICH REPEATS; ARABIDOPSIS-THALIANA; RUST RESISTANCE; AVIRULENCE DETERMINANTS; NUCLEOTIDE SUBSTITUTION; PERONOSPORA-PARASITICA; OVERDOMINANT SELECTION; DIVERGENT SELECTION	Plant R-genes involved in gene-for-gene interactions with pathogens are expected to undergo coevolutionary arms races in which plant specificity and pathogen virulence continually adapt in response to each other. Lending support to this idea, the solvent-exposed amino acid residues of Leucine-rich repeats, a region of R-genes involved in recognizing pathogens, often evolve at unusually fast rates. But within-species polymorphism is also common in R-genes, implying that the adaptive substitution process is not simply one of successive selective sweeps. Here we document these features in available data and discuss them in Light of the evolutionary dynamics they likely reflect.	Univ Chicago, Dept Ecol & Evolut, Chicago, IL 60637 USA	University of Chicago	Bergelson, J (corresponding author), Univ Chicago, Dept Ecol & Evolut, 1101 E 57th St, Chicago, IL 60637 USA.			Bergelson, Joy/0000-0001-7893-7387	NIGMS NIH HHS [R01 GM057994] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057994] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABBOTT RJ, 1989, HEREDITY, V62, P411, DOI 10.1038/hdy.1989.56; Banerjee D, 2001, GENETICS, V158, P439; BERGELSON JM, UNPUB; Bittner-Eddy PD, 2000, PLANT J, V21, P177, DOI 10.1046/j.1365-313x.2000.00664.x; Botella MA, 1998, PLANT CELL, V10, P1847, DOI 10.1105/tpc.10.11.1847; Caicedo AL, 1999, P NATL ACAD SCI USA, V96, P302, DOI 10.1073/pnas.96.1.302; Clark AG, 1997, GENETICS, V147, P713; Clay K, 1996, ANNU REV PHYTOPATHOL, V34, P29, DOI 10.1146/annurev.phyto.34.1.29; Ellis J, 2000, CURR OPIN PLANT BIOL, V3, P278, DOI 10.1016/S1369-5266(00)00080-7; Ellis JG, 1999, PLANT CELL, V11, P495, DOI 10.1105/tpc.11.3.495; FLOR HH, 1956, ADV GENET, V8, P29, DOI 10.1016/S0065-2660(08)60498-8; Grant MR, 1998, P NATL ACAD SCI USA, V95, P15843, DOI 10.1073/pnas.95.26.15843; HUDSON RR, 1988, GENETICS, V120, P831; HUGHES AL, 1988, NATURE, V335, P167, DOI 10.1038/335167a0; HUGHES AL, 1989, P NATL ACAD SCI USA, V86, P958, DOI 10.1073/pnas.86.3.958; Hulbert SH, 1997, ANNU REV PHYTOPATHOL, V35, P293, DOI 10.1146/annurev.phyto.35.1.293; Jones DA, 1997, ADV BOT RES, V24, P89; LAWLOR DA, 1988, NATURE, V335, P268, DOI 10.1038/335268a0; Leister RT, 2000, PLANT J, V22, P345, DOI 10.1046/j.1365-313x.2000.00744.x; Li W. H, 1997, MOL EVOLUTION; Luck JE, 2000, PLANT CELL, V12, P1367, DOI 10.1105/tpc.12.8.1367; MAURICIO R, UNPUB; MAY RM, 1983, PROC R SOC SER B-BIO, V219, P281, DOI 10.1098/rspb.1983.0075; MAYER WE, 1988, EMBO J, V7, P2765, DOI 10.1002/j.1460-2075.1988.tb03131.x; McDowell JM, 1998, PLANT CELL, V10, P1861, DOI 10.1105/tpc.10.11.1861; Meyers BC, 1998, PLANT CELL, V10, P1833, DOI 10.1105/tpc.10.11.1833; Michelmore RW, 1998, GENOME RES, V8, P1113, DOI 10.1101/gr.8.11.1113; Noel L, 1999, PLANT CELL, V11, P2099, DOI 10.1105/tpc.11.11.2099; Parniske M, 1997, CELL, V91, P821, DOI 10.1016/S0092-8674(00)80470-5; Stahl EA, 1999, NATURE, V400, P667, DOI 10.1038/23260; Stahl EA, 2000, CURR OPIN PLANT BIOL, V3, P299, DOI 10.1016/S1369-5266(00)00083-2; SUDUPAK MA, 1993, GENETICS, V133, P119; The Arabidopsis Genome Initiative, 2000, NATURE, V408, P796; VANVALEN L, 1971, EVOL THEORY, V1, P1; Wang GL, 1998, PLANT CELL, V10, P765, DOI 10.1105/tpc.10.5.765; Young ND, 2000, CURR OPIN PLANT BIOL, V3, P285, DOI 10.1016/S1369-5266(00)00081-9	36	389	403	2	55	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 22	2001	292	5525					2281	2285		10.1126/science.1061337	http://dx.doi.org/10.1126/science.1061337			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	445KD	11423651				2022-12-28	WOS:000169455900044
J	Gasse, F				Gasse, F			Paleoclimate - Hydrological changes in Africa	SCIENCE			English	Editorial Material							EAST-AFRICA; CLIMATE; FLUCTUATIONS; MIDHOLOCENE; VEGETATION; TROPICS; LAKES		CEREGE, F-13454 Aix En Provence 4, France	UDICE-French Research Universities; Aix-Marseille Universite	Gasse, F (corresponding author), CEREGE, BP 80, F-13454 Aix En Provence 4, France.							Barker PA, 2001, SCIENCE, V292, P2307, DOI 10.1126/science.1059612; Birkett C, 1999, GEOPHYS RES LETT, V26, P1031, DOI 10.1029/1999GL900165; CHALIE F, PALAEOGEOGR PALAEOCL; Claussen M, 1999, GEOPHYS RES LETT, V26, P2037, DOI 10.1029/1999GL900494; CREMASHI M, 1998, AFR ARCHAEOL REV, V10, P211; FONTES JC, 1993, ISOTOPE TECHNIQUES S, P231; Ganopolski A, 1998, SCIENCE, V280, P1916, DOI 10.1126/science.280.5371.1916; Gasse F, 2000, QUATERNARY SCI REV, V19, P189, DOI 10.1016/S0277-3791(99)00061-X; Kerr RA, 2001, SCIENCE, V292, P660, DOI 10.1126/science.292.5517.660; KUTZBACH JE, 1985, NATURE, V317, P130, DOI 10.1038/317130a0; Nicholson S.E., 1996, LIMNOLOGY CLIMATOLOG, V1st ed., P25, DOI [DOI 10.1201/9780203748978-2, 10.1201/9780203748978-2]; Rietti-Shati M, 1998, SCIENCE, V281, P980, DOI 10.1126/science.281.5379.980; Rozanski K., 1993, GEOPHYS MONOGR SER, V78, P1, DOI DOI 10.1029/GM078P0001; Schmidt GA, 2001, PAGES NEWS, V9, P10; STREETPERROTT FA, 1990, NATURE, V343, P607, DOI 10.1038/343607a0; Verschuren D, 2000, NATURE, V403, P410, DOI 10.1038/35000179; Webster PJ, 1998, J GEOPHYS RES-OCEANS, V103, P14451, DOI 10.1029/97JC02719	17	35	38	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 22	2001	292	5525					2259	2260		10.1126/science.1061940	http://dx.doi.org/10.1126/science.1061940			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	445KD	11423639				2022-12-28	WOS:000169455900033
J	Oliver, D; He, DZZ; Klocker, N; Ludwig, J; Schulte, U; Waldegger, S; Ruppersberg, JP; Dallos, P; Fakler, B				Oliver, D; He, DZZ; Klocker, N; Ludwig, J; Schulte, U; Waldegger, S; Ruppersberg, JP; Dallos, P; Fakler, B			Intracellular anions as the voltage sensor of prestin, the outer hair cell motor protein	SCIENCE			English	Article							CHANNELS; MOTILITY; CAPACITANCE; SALICYLATE; MECHANISM; COCHLEA	Outer hair cells (OHCs) of the mammalian cochlea actively change their cell Length in response to changes in membrane potential. This electromotility, thought to be the basis of cochlear amplification, is mediated by a voltage-sensitive motor molecule recently identified as the membrane protein prestin. Here, we show that voltage sensitivity is conferred to prestin by the intracellular anions chloride and bicarbonate. Removal of these anions abolished fast voltage-dependent motility, as well as the characteristic nonlinear charge movement ("gating currents") driving the underlying structural rearrangements of the protein. The results support a model in which anions act as extrinsic voltage sensors, which bind to the prestin molecule and thus trigger the conformational changes required for motility of OHCs.	Univ Tubingen, Dept Physiol 2, D-72074 Tubingen, Germany; Boys Town Natl Res Hosp, Omaha, NE 68131 USA; Univ Marburg, Ctr Pediat, D-35037 Marburg, Germany; Northwestern Univ, Dept Neurobiol & Physiol, Auditory Physiol Lab, Evanston, IL 60208 USA	Eberhard Karls University of Tubingen; Boys Town National Research Hospital; Philipps University Marburg; Northwestern University	Fakler, B (corresponding author), Univ Tubingen, Dept Physiol 2, D-72074 Tubingen, Germany.		Ludwig, Jost/K-3446-2017; Dallos, Peter/Q-9360-2019; Oliver, Dominik/F-5845-2013	Dallos, Peter/0000-0002-9731-6591; Oliver, Dominik/0000-0002-8368-0923; He (he zhi zhou), Zhi-Zhou/0000-0001-8383-9634	NIDCD NIH HHS [DC00089] Funding Source: Medline	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		Ashmore J. F., 1989, MECH HEARING, P107; ASHMORE JF, 1987, J PHYSIOL-LONDON, V388, P323, DOI 10.1113/jphysiol.1987.sp016617; Belyantseva IA, 2000, J NEUROSCI, V20, part. no.; BROWNELL WE, 1985, SCIENCE, V227, P194, DOI 10.1126/science.3966153; DALLOS P, 1991, NATURE, V350, P155, DOI 10.1038/350155a0; DALLOS P, 1992, J NEUROSCI, V12, P4575; Fahlke C, 1997, J GEN PHYSIOL, V110, P551, DOI 10.1085/jgp.110.5.551; Frank G, 1999, P NATL ACAD SCI USA, V96, P4420, DOI 10.1073/pnas.96.8.4420; HE D, UNPUB; HE DZZ, 1994, HEARING RES, V78, P77, DOI 10.1016/0378-5955(94)90046-9; HERRINGTON JD, 1995, PULSE CONTROL V4 7; IWASA KH, 1994, J ACOUST SOC AM, V96, P2216, DOI 10.1121/1.410094; Kakehata S, 1996, J NEUROSCI, V16, P4881; KALINEC F, 1992, P NATL ACAD SCI USA, V89, P8671, DOI 10.1073/pnas.89.18.8671; Klocker N, 2001, MOL CELL NEUROSCI, V17, P514, DOI 10.1006/mcne.2000.0956; Ludwig J, 2001, P NATL ACAD SCI USA, V98, P4178, DOI 10.1073/pnas.071613498; Oliver D, 1999, J PHYSIOL-LONDON, V519, P791, DOI 10.1111/j.1469-7793.1999.0791n.x; Oliver D, 2000, NEURON, V26, P595, DOI 10.1016/S0896-6273(00)81197-6; OLIVER D, UNPUB; SANTOS-SACCHI J, 1991, J NEUROSCI, V11, P3096, DOI 10.1523/jneurosci.11-10-03096.1991; Santos-Sacchi J, 2001, J PHYSIOL-LONDON, V531, P661, DOI 10.1111/j.1469-7793.2001.0661h.x; Schulte U, 1999, P NATL ACAD SCI USA, V96, P15298, DOI 10.1073/pnas.96.26.15298; Scott DA, 2000, AM J PHYSIOL-CELL PH, V278, pC207, DOI 10.1152/ajpcell.2000.278.1.C207; TUNSTALL MJ, 1995, J PHYSIOL-LONDON, V485, P739, DOI 10.1113/jphysiol.1995.sp020765; Waldegger S, 2001, GENOMICS, V72, P43, DOI 10.1006/geno.2000.6445; Zheng J, 2000, NATURE, V405, P149, DOI 10.1038/35012009	26	341	356	0	40	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 22	2001	292	5525					2340	2343		10.1126/science.1060939	http://dx.doi.org/10.1126/science.1060939			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	445KD	11423665				2022-12-28	WOS:000169455900061
J	VanDemark, AP; Hofmann, RM; Tsui, C; Pickart, CM; Wolberger, C				VanDemark, AP; Hofmann, RM; Tsui, C; Pickart, CM; Wolberger, C			Molecular insights into polyubiquitin chain assembly: Crystal structure of the Mms2/Ubc13 heterodimer	CELL			English	Article							UBIQUITIN-CONJUGATING-ENZYME; RING FINGER PROTEINS; DNA-REPAIR; MULTIUBIQUITIN CHAIN; PROTEOLYSIS; COMPLEX; RAD6; GENE; INHIBITION; PROGRAM	While the signaling properties of ubiquitin depend on the topology of polyubiquitin chains, little is known concerning the molecular basis of specificity in chain assembly and recognition. UEV/Ubc complexes have been implicated in the assembly of Lys63-linked polyubiquitin chains that act as a novel signal in postreplicative DNA repair and I kappaB alpha kinase activation. The crystal structure of the Mms2/Ubc13 heterodimer shows the active site of Ubc13 at the intersection of two channels that are potential binding sites for the two substrate ubiquitins. Mutations that destabilize the heterodimer interface confer a marked UV sensitivity, providing direct evidence that the intact heterodimer is necessary for DNA repair. Selective mutations in the channels suggest a molecular model for specificity in the assembly of Lys63-linked polyubiquitin signals.	Johns Hopkins Univ, Sch Med, Dept Biophys & Biophys Chem, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Publ Hlth, Dept Biochem, Baltimore, MD 21205 USA; Johns Hopkins Univ, Howard Hughes Med Inst, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Howard Hughes Medical Institute; Johns Hopkins University	Wolberger, C (corresponding author), Johns Hopkins Univ, Sch Med, Dept Biophys & Biophys Chem, Baltimore, MD 21205 USA.	cwolberg@jhmi.edu		VanDemark, Andrew/0000-0003-3424-4831; Wolberger, Cynthia/0000-0001-8578-2969	NIGMS NIH HHS [GM60372] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060372] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALANI E, 1987, GENETICS, V116, P541, DOI 10.1534/genetics.112.541.test; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Beal R, 1996, P NATL ACAD SCI USA, V93, P861, DOI 10.1073/pnas.93.2.861; Broomfield S, 1998, P NATL ACAD SCI USA, V95, P5678, DOI 10.1073/pnas.95.10.5678; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Brusky J, 2000, CURR GENET, V37, P168, DOI 10.1007/s002940050515; Buschmann T, 2000, CELL, V101, P753, DOI 10.1016/S0092-8674(00)80887-9; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; Chen ZJ, 1996, CELL, V84, P853, DOI 10.1016/S0092-8674(00)81064-8; CHEN ZJ, 1991, J BIOL CHEM, V266, P15698; COOK WJ, 1992, J BIOL CHEM, V267, P15116; COOK WJ, 1993, BIOCHEMISTRY-US, V32, P13809, DOI 10.1021/bi00213a009; Deng L, 2000, CELL, V103, P351, DOI 10.1016/S0092-8674(00)00126-4; FINLEY D, 1994, MOL CELL BIOL, V14, P5501, DOI 10.1128/MCB.14.8.5501; Gabb HA, 1997, J MOL BIOL, V272, P106, DOI 10.1006/jmbi.1997.1203; Galan JM, 1997, EMBO J, V16, P5847, DOI 10.1093/emboj/16.19.5847; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hicke L, 1999, TRENDS CELL BIOL, V9, P107, DOI 10.1016/S0962-8924(98)01491-3; Hofmann RM, 1999, CELL, V96, P645, DOI 10.1016/S0092-8674(00)80575-9; Huang L, 1999, SCIENCE, V286, P1321, DOI 10.1126/science.286.5443.1321; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; JENTSCH S, 1987, NATURE, V329, P131, DOI 10.1038/329131a0; Jiang F, 1999, BIOCHEMISTRY-US, V38, P6471, DOI 10.1021/bi9901329; Joazeiro CAP, 2000, CELL, V102, P549, DOI 10.1016/S0092-8674(00)00077-5; Joazeiro CAP, 1999, SCIENCE, V286, P309, DOI 10.1126/science.286.5438.309; JOHNSON RE, 1992, MOL CELL BIOL, V12, P3807, DOI 10.1128/MCB.12.9.3807; Kaiser P, 2000, CELL, V102, P303, DOI 10.1016/S0092-8674(00)00036-2; Koegl M, 1999, CELL, V96, P635, DOI 10.1016/S0092-8674(00)80574-7; Koepp DM, 1999, CELL, V97, P431, DOI 10.1016/S0092-8674(00)80753-9; Koonin EV, 1997, NAT GENET, V16, P330, DOI 10.1038/ng0897-330; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Miura T, 1999, J MOL BIOL, V290, P213, DOI 10.1006/jmbi.1999.2859; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Piotrowski J, 1997, J BIOL CHEM, V272, P23712, DOI 10.1074/jbc.272.38.23712; Rock KL, 1999, ANNU REV IMMUNOL, V17, P739, DOI 10.1146/annurev.immunol.17.1.739; Sancho E, 1998, MOL CELL BIOL, V18, P576, DOI 10.1128/MCB.18.1.576; SPENCE J, 1995, MOL CELL BIOL, V15, P1265; Spence J, 2000, CELL, V102, P67, DOI 10.1016/S0092-8674(00)00011-8; Thomson TM, 1998, FEBS LETT, V423, P49, DOI 10.1016/S0014-5793(98)00060-X; Ulrich HD, 2000, EMBO J, V19, P3388, DOI 10.1093/emboj/19.13.3388; Vagin A, 1997, J APPL CRYSTALLOGR, V30, P1022, DOI 10.1107/S0021889897006766; Worthylake DR, 1998, J BIOL CHEM, V273, P6271, DOI 10.1074/jbc.273.11.6271; Xiao W, 1998, NUCLEIC ACIDS RES, V26, P3908, DOI 10.1093/nar/26.17.3908; Xiao W, 2000, GENETICS, V155, P1633; You JX, 1999, BIOTECHNIQUES, V27, P950, DOI 10.2144/99275st01; Zheng N, 2000, CELL, V102, P533, DOI 10.1016/S0092-8674(00)00057-X	48	253	264	0	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 15	2001	105	6					711	720		10.1016/S0092-8674(01)00387-7	http://dx.doi.org/10.1016/S0092-8674(01)00387-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	444AE	11440714	Bronze			2022-12-28	WOS:000169375100005
J	Lawrence, G; Tudehope, D; Baumann, K; Jeffery, H; Gill, A; Cole, M; Drew, J; McPhee, A; Ratcliffe, J; Reynolds, G; Simes, J; Swanson, C; Cartwright, D; Davis, P; Humphrey, I; Berry, A				Lawrence, G; Tudehope, D; Baumann, K; Jeffery, H; Gill, A; Cole, M; Drew, J; McPhee, A; Ratcliffe, J; Reynolds, G; Simes, J; Swanson, C; Cartwright, D; Davis, P; Humphrey, I; Berry, A			Enteral human IgG for prevention of necrotising enterocolitis: a placebo-controlled, randomised trial	LANCET			English	Article							BIRTH-WEIGHT INFANTS; NEONATAL NECROTIZING ENTEROCOLITIS; GLOBULIN	Background Neonatal necrotising enterocolitis is a serious, commonly fatal disease in premature neonates. Although feeding with expressed breast milk and other good nursery practices are partly protective, preventive measures are needed. Treating neonates enterally with a mixture of human IgA and IgG, prepared from donated blood, has been claimed to protect against necrotising enterocolitis. However, no IgA preparation is available in Australia. Our aim, therefore, was to identify whether or not enteral IgG could prevent the disorder. Methods We did a multicentre, double-blind, placebo-controlled trial. We randomly assigned 768 infants to receive human IgG 1200 mg/kg daily, and 761 to receive placebo, for up to 28 days. Treatment began at the same time as enteral feeding. The primary outcome measure was the proportion of infants who developed definite necrotising enterocolitis during the trial, and any deaths that resulted from the disorder in the treatment and placebo groups. Analysis was on an intention-to-treat basis. Findings 43 infants developed definite necrotising enterocolitis in the IgG group, ten of whom died. In the placebo group, 41 infants contracted the disorder and six died (p=0.47). 25 infants on IgG and 36 on placebo had suspect necrotising enterocolitis (p=0.14). Interpretation Supplementation of enteral feeds with human IgG does not reduce necrotising enterocolitis.	Queensland Inst Med Res, Brisbane, Qld 4029, Australia; Mater Mothers Hosp, Brisbane, Qld, Australia; Royal Prince Alfred Hosp, Camperdown, NSW 2050, Australia; John Hunter Hosp, New Lambton, NSW, Australia; Westmead Hosp & Med Ctr, Westmead, NSW, Australia; Mercy Matern Hosp, Melbourne, NSW, Australia; Women & Childrens Hosp, Adelaide, SA, Australia; Univ Queensland, Div Radiol, St Lucia, Qld 4067, Australia; Canberra Hosp, Dept Neonatol, Canberra, ACT, Australia; NHMRC Clin Trials Ctr, Camperdown, NSW, Australia; Univ Queensland, Dept Surg, St Lucia, Qld 4067, Australia; Royal Womens Hosp, Brisbane, Qld, Australia; Royal Womens Hosp, Carlton, Vic, Australia; Royal Womens Hosp, Glen Waverley, Vic, Australia; Royal Womens Hosp, Wentworthville, NSW, Australia	QIMR Berghofer Medical Research Institute; University of Sydney; John Hunter Hospital; University of Sydney; University of Queensland; Australian National University; Canberra Hospital; University of Sydney; University of Queensland; Royal Brisbane & Women's Hospital	Lawrence, G (corresponding author), Queensland Inst Med Res, PO Royal Brisbane Hosp, Brisbane, Qld 4029, Australia.	gregL@QIMR.edu.au	Tudehope, David I/G-5123-2013; Cartwright, David W/M-7330-2013; Swanson, Cheryl/F-4847-2010					BARNES GL, 1982, LANCET, V1, P1371; BAUER CR, 1984, PEDIATRICS, V73, P682; BAUER CR, 1992, EFFECTIVE CARE NEWBO, P605; BELL MJ, 1978, ANN SURG, V187, P1, DOI 10.1097/00000658-197801000-00001; BLUM PM, 1981, PEDIATR RES, V15, P1256, DOI 10.1203/00006450-198109000-00006; CARRION V, 1990, J PEDIATR GASTR NUTR, V11, P317, DOI 10.1097/00005176-199010000-00006; EIBL MM, 1988, NEW ENGL J MED, V319, P1, DOI 10.1056/NEJM198807073190101; FAST C, 1994, ACTA PAEDIATR, V83, P86, DOI 10.1111/j.1651-2227.1994.tb13253.x; GELLER NL, 1987, BIOMETRICS, V43, P213, DOI 10.2307/2531962; KLIEGMAN RM, 1984, NEW ENGL J MED, V310, P1093, DOI 10.1056/NEJM198404263101707; KLIEGMAN RM, 1990, REV INFECT DIS, V12, pS443; LUCAS A, 1990, LANCET, V336, P1519, DOI 10.1016/0140-6736(90)93304-8; MEHTA CR, 1985, J AM STAT ASSOC, V80, P969, DOI 10.2307/2288562; ROWLEY MP, 1978, LANCET, V2, P532; Siu YK, 1998, ARCH DIS CHILD-FETAL, V79, pF105, DOI 10.1136/fn.79.2.F105; ZABIELSKI PB, 1989, JPEN-PARENTER ENTER, V13, P520, DOI 10.1177/0148607189013005520	16	16	17	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 30	2001	357	9274					2090	2094		10.1016/S0140-6736(00)05182-5	http://dx.doi.org/10.1016/S0140-6736(00)05182-5			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	447RQ	11445103				2022-12-28	WOS:000169586600013
J	Weiss, R				Weiss, R			AIDS: unbeatable 20 years on	LANCET			English	Editorial Material									UCL, Dept Viral Oncol Immunol & Mol Pathol, London W1T 4JF, England	University of London; University College London	Weiss, R (corresponding author), UCL, Dept Viral Oncol Immunol & Mol Pathol, London W1T 4JF, England.	r.weiss@ucl.ac.uk						BARRESINOUSSI F, 1983, SCIENCE, V220, P868, DOI 10.1126/science.6189183; *CDCP, 1981, MMWR-MORBID MORTAL W, V30, P305; *CDCP, 1981, MMWR-MORBID MORTAL W, V30, P250; Cohen Jon, 2001, SHOTS DARK WAYWARD S; GOTTLIEB MS, 1981, NEW ENGL J MED, V305, P1425, DOI 10.1056/NEJM198112103052401; Piot P, 2001, NATURE, V410, P968, DOI 10.1038/35073639	6	6	5	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	JUN 30	2001	357	9274					2073	2074		10.1016/S0140-6736(00)05228-4	http://dx.doi.org/10.1016/S0140-6736(00)05228-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	447RQ	11445097				2022-12-28	WOS:000169586600007
J	Chen, WP; Brudzinski, MR				Chen, WP; Brudzinski, MR			Evidence for a large-scale remnant of subducted lithosphere beneath Fiji	SCIENCE			English	Article							DEEP-FOCUS EARTHQUAKES; DESCENDING LITHOSPHERE; NORTHWEST PACIFIC; MANTLE CONVECTION; TONGA ARC; SLABS; PHASE; DISCONTINUITY; SEISMICITY; MECHANISM	We combine spatial variations of P- and S-wave speeds, 1000 fault plane solutions, and 6600 well-determined hypocenters to investigate the nature of subducted lithosphere and deep earthquakes beneath the Tonga back-are. We show that perplexing patterns in seismicity and fault plane solutions can be accounted for by the juxtaposition of a steep-dipping Wadati-Benioff zone and a subhorizontal remnant of slab that is no Longer attached to the actively subducting Lithosphere. The detached slab may be from a previous episode of subduction along the fossil Vitiaz trench about 5 to 8 million years ago. The juxtaposition of slabs retains a large amount of subducted material in the transition zone of the mantle. Such a configuration, if common in the past, would allow the preservation of a primordial component in the Lower mantle.	Univ Illinois, Dept Geol, Urbana, IL 61801 USA; Univ Illinois, Mid Amer Earthquake Ctr, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Chen, WP (corresponding author), Univ Illinois, Dept Geol, Urbana, IL 61801 USA.	w-chen@uiuc.edu	Brudzinski, Michael/A-8301-2011					ALBAREDE F, 1999, EOS T AM GEOPHYS UN, V80, P535; BARAZANGI M, 1973, NATURE, V242, P98, DOI 10.1038/242098a0; BEVIS M, 1995, NATURE, V374, P249, DOI 10.1038/374249a0; BILLINGTON S, 1980, THESIS CORNELL U ITH; Bina CR, 1996, GEOPHYS RES LETT, V23, P3563, DOI 10.1029/96GL03483; Brudzinski MR, 2000, J GEOPHYS RES-SOL EA, V105, P21661, DOI 10.1029/2000JB900160; BRUDZINSKI MR, 1999, EOS, V80, pF667; CHASE CG, 1971, GEOL SOC AM BULL, V82, P3087, DOI 10.1130/0016-7606(1971)82[3087:THOTFP]2.0.CO;2; CHEN CY, 1983, NATURE, V302, P785, DOI 10.1038/302785a0; CREAGER KC, 1986, J GEOPHYS RES-SOLID, V91, P3573, DOI 10.1029/JB091iB03p03573; DZIEWONSKI AM, 1981, J GEOPHYS RES, V86, P2825, DOI 10.1029/JB086iB04p02825; Engdahl ER, 1998, B SEISMOL SOC AM, V88, P722; FAUL UH, 1994, GEOPHYS RES LETT, V21, P29, DOI 10.1029/93GL03051; FISCHER KM, 1991, J GEOPHYS RES-SOLID, V96, P14403, DOI 10.1029/90JB02703; Fujisawa H, 1998, J GEOPHYS RES-SOL EA, V103, P9591, DOI 10.1029/98JB00024; FUKAO Y, 1992, J GEOPHYS RES-SOL EA, V97, P4809, DOI 10.1029/91JB02749; GIARDINI D, 1986, NATURE, V319, P551, DOI 10.1038/319551a0; GIARDINI D, 1984, NATURE, V307, P505, DOI 10.1038/307505a0; Grand SP., 1997, GSA TODAY, V7, P1; GREEN HW, 1989, NATURE, V341, P733, DOI 10.1038/341733a0; GREEN HW, 1995, ANNU REV EARTH PL SC, V23, P169, DOI 10.1146/annurev.ea.23.050195.001125; HAMBURGER MW, 1987, J GEOPHYS RES-SOLID, V92, P13841, DOI 10.1029/JB092iB13p13841; Inoue T, 1998, EARTH PLANET SC LETT, V160, P107, DOI 10.1016/S0012-821X(98)00077-6; ISACKS B, 1968, J GEOPHYS RES, V73, P5855, DOI 10.1029/JB073i018p05855; ISACKS B, 1971, REV GEOPHYS SPACE GE, V9, P103, DOI 10.1029/RG009i001p00103; ISACKS B, 1969, NATURE, V223, P1121, DOI 10.1038/2231121a0; KATSURA T, 1989, J GEOPHYS RES-SOLID, V94, P15663, DOI 10.1029/JB094iB11p15663; Kellogg LH, 1999, SCIENCE, V283, P1881, DOI 10.1126/science.283.5409.1881; KERN S, 1982, P S WAVE VELOCITIES; KIRBY SH, 1991, SCIENCE, V252, P216, DOI 10.1126/science.252.5003.216; Kirby SH, 1996, REV GEOPHYS, V34, P261, DOI 10.1029/96RG01050; LAY T, 1994, ANNU REV EARTH PL SC, V22, P33, DOI 10.1146/annurev.ea.22.050194.000341; Lithgow-Bertelloni C, 1998, REV GEOPHYS, V36, P27, DOI 10.1029/97RG02282; Marton FC, 1999, GEOPHYS RES LETT, V26, P119, DOI 10.1029/1998GL900230; Mckenzie DP., 1970, TECTONOPHYSICS, V10, P357, DOI [10.1016/0040-1951(70)90115-0, DOI 10.1016/0040-1951(70)90115-0]; MEADE C, 1991, SCIENCE, V252, P68, DOI 10.1126/science.252.5002.68; MOLNAR P, 1979, GEOPHYS J ROY ASTR S, V56, P41, DOI 10.1111/j.1365-246X.1979.tb04766.x; Okal EA, 1998, PHYS EARTH PLANET IN, V109, P25, DOI 10.1016/S0031-9201(98)00116-2; RICHARDS MA, 1992, NATURE, V355, P437, DOI 10.1038/355437a0; RICHTER FM, 1979, J GEOPHYS RES, V84, P6783, DOI 10.1029/JB084iB12p06783; RINGWOOD AE, 1988, NATURE, V331, P131, DOI 10.1038/331131a0; SHEARER PM, 1992, NATURE, V355, P791, DOI 10.1038/355791a0; SILVER PG, 1995, SCIENCE, V268, P69, DOI 10.1126/science.268.5207.69; SILVER PG, 1988, ANNU REV EARTH PL SC, V16, P477, DOI 10.1146/annurev.ea.16.050188.002401; SKOMURSKI FN, 1999, EOS, V80, pF667; Stein SC.SteinA, 1996, SUBDUCTION TOP BOTTO, V96, P1; STROBACH K, 1973, J GEOPHYS, V39, P819; Turcotte DL, 2001, J GEOPHYS RES-SOL EA, V106, P4265, DOI 10.1029/2000JB900409; van der Hilst RD, 1999, SCIENCE, V283, P1885, DOI 10.1126/science.283.5409.1885; VANDERHILST RD, 1993, GEOPHYS J INT, V115, P264, DOI 10.1111/j.1365-246X.1993.tb05603.x; vanderHilst RD, 1997, NATURE, V386, P578, DOI 10.1038/386578a0; Vidale JE, 2001, GEOPHYS RES LETT, V28, P859, DOI 10.1029/2000GL012428; WIENS DA, 1993, NATURE, V364, P790, DOI 10.1038/364790a0; YAMAOKA K, 1986, REV GEOPHYS, V24, P27, DOI 10.1029/RG024i001p00027	54	97	101	0	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 29	2001	292	5526					2475	2479		10.1126/science.292.5526.2475	http://dx.doi.org/10.1126/science.292.5526.2475			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	448YU	11431564				2022-12-28	WOS:000169658200037
J	Chippindale, S; French, L				Chippindale, S; French, L			ABC of AIDS - HIV counselling and the psychosocial management of patients with HIV or AIDS	BRITISH MEDICAL JOURNAL			English	Article																			0	16	18	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 23	2001	322	7301					1533	1535		10.1136/bmj.322.7301.1533	http://dx.doi.org/10.1136/bmj.322.7301.1533			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	446UF	11420278	Green Published			2022-12-28	WOS:000169532000022
J	Brennan, J; Lu, CC; Norris, DP; Rodriguez, TA; Beddington, RSP; Robertson, EJ				Brennan, J; Lu, CC; Norris, DP; Rodriguez, TA; Beddington, RSP; Robertson, EJ			Nodal signalling in the epiblast patterns the early mouse embryo	NATURE			English	Article							ANTERIOR PRIMITIVE ENDODERM; RIGHT ASYMMETRIC EXPRESSION; VISCERAL ENDODERM; TRANSCRIPTION FACTOR; POSTERIOR POLARITY; NEURAL PLATE; GASTRULATION; AXIS; SPECIFICATION; REQUIREMENT	Shortly after implantation the mouse embryo comprises three tissue layers. The founder tissue of the embryo proper, the epiblast, forms a radially symmetric cup of epithelial cells that grows in close apposition to the extra-embryonic ectoderm and the visceral endoderm. This simple cylindrical structure exhibits a distinct molecular pattern along its proximal-distal axis(1). The anterior-posterior axis of the embryo is positioned later by coordinated cell movements that rotate the pre-existing proximal-distal axis(2-5). The transforming growth factor-beta family member Nodal is known to be required for formation of the anterior-posterior axis(6). Here we show that signals from the epiblast are responsible for the initiation of proximal-distal polarity. Nodal acts to promote posterior cell fates in the epiblast and to maintain molecular pattern in the adjacent extra-embryonic ectoderm. Both of these functions are independent of Smad2. Moreover, Nodal signals from the epiblast also pattern the visceral endoderm by activating the Smad2-dependent pathway required for specification of anterior identity in overlying epiblast cells. Our experiments show that proximal-distal and subsequent anterior-posterior polarity of the pregastrulation embryo result from reciprocal cell-cell interactions between the epiblast and the two extra-embryonic tissues.	Harvard Univ, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA; Natl Inst Med Res, Div Mammalian Dev, London NW7 1AA, England	Harvard University; MRC National Institute for Medical Research	Robertson, EJ (corresponding author), Harvard Univ, Dept Mol & Cellular Biol, 16 Divin Ave, Cambridge, MA 02138 USA.			Rodriguez, Tristan/0000-0002-3415-8493; Brennan, Jane/0000-0003-3222-5485				Acampora D, 1998, DEVELOPMENT, V125, P5091; Adachi H, 1999, GENE DEV, V13, P1589, DOI 10.1101/gad.13.12.1589; ANG SL, 1994, DEVELOPMENT, V120, P2979; Beddington RSP, 1999, CELL, V96, P195, DOI 10.1016/S0092-8674(00)80560-7; Belo JA, 1997, MECH DEVELOP, V68, P45, DOI 10.1016/S0925-4773(97)00125-1; BLUM M, 1992, CELL, V69, P1097, DOI 10.1016/0092-8674(92)90632-M; Collignon J, 1996, NATURE, V381, P155, DOI 10.1038/381155a0; CONLON FL, 1994, DEVELOPMENT, V120, P1919; Ding JX, 1998, NATURE, V395, P702, DOI 10.1038/27215; Gritsman K, 1999, CELL, V97, P121, DOI 10.1016/S0092-8674(00)80720-5; Kimura C, 2000, DEV BIOL, V225, P304, DOI 10.1006/dbio.2000.9835; Kumar A, 2001, J BIOL CHEM, V276, P656, DOI 10.1074/jbc.M004649200; Liu PT, 1999, NAT GENET, V22, P361, DOI 10.1038/11932; Meno C, 1999, MOL CELL, V4, P287, DOI 10.1016/S1097-2765(00)80331-7; Norris DP, 1999, GENE DEV, V13, P1575, DOI 10.1101/gad.13.12.1575; Perea-Gomez A, 1999, DEVELOPMENT, V126, P4499; POIRIER F, 1992, DEVELOPMENT, V115, P143; POIRIER F, 1991, DEVELOPMENT, V113, P1105; Rhinn M, 1998, DEVELOPMENT, V125, P845; ROSNER MH, 1990, NATURE, V345, P686, DOI 10.1038/345686a0; Russ AP, 2000, NATURE, V404, P95, DOI 10.1038/35003601; Saijoh Y, 2000, MOL CELL, V5, P35, DOI 10.1016/S1097-2765(00)80401-3; Schier AF, 2000, NATURE, V403, P385, DOI 10.1038/35000126; Thomas P, 1996, CURR BIOL, V6, P1487, DOI 10.1016/S0960-9822(96)00753-1; Thomas PQ, 1998, DEVELOPMENT, V125, P85; Tremblay KD, 2000, DEVELOPMENT, V127, P3079; Varlet I, 1997, DEVELOPMENT, V124, P1033; Waldrip WR, 1998, CELL, V92, P797, DOI 10.1016/S0092-8674(00)81407-5; Whitman M, 1998, GENE DEV, V12, P2445, DOI 10.1101/gad.12.16.2445; ZHOU XL, 1993, NATURE, V361, P543, DOI 10.1038/361543a0	30	382	399	0	15	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 21	2001	411	6840					965	969		10.1038/35082103	http://dx.doi.org/10.1038/35082103			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	444EN	11418863				2022-12-28	WOS:000169386200049
J	Thornton, JM				Thornton, JM			From genome to function	SCIENCE			English	Article							PROTEIN-STRUCTURE PREDICTION; DATABASE; FAMILIES; MODEL; CLASSIFICATION; SUPERFAMILIES; DICTIONARY; EVOLUTION; SEQUENCES; DOMAINS		UCL, Dept Biochem & Mol Biol, London WC1E 6BT, England; Univ London Birkbeck Coll, Dept Crystallog, London WC1E 6BT, England	University of London; University College London; University of London; Birkbeck University London	Thornton, JM (corresponding author), UCL, Dept Biochem & Mol Biol, Mortimer St, London WC1E 6BT, England.	thornton@biochem.ucl.ac.uk		Thornton, Janet/0000-0003-0824-4096				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Apweiler R, 2001, NUCLEIC ACIDS RES, V29, P37, DOI 10.1093/nar/29.1.37; Bateman A, 2000, NUCLEIC ACIDS RES, V28, P263, DOI 10.1093/nar/28.1.263; Bates PA, 1999, PROTEINS, P47; Bray JE, 2000, PROTEIN ENG, V13, P153, DOI 10.1093/protein/13.3.153; CHOTHIA C, 1992, NATURE, V357, P543, DOI 10.1038/357543a0; Dietmann S, 2001, NUCLEIC ACIDS RES, V29, P55, DOI 10.1093/nar/29.1.55; Huynen M, 2000, GENOME RES, V10, P1204, DOI 10.1101/gr.10.8.1204; JONES DT, 1992, NATURE, V358, P86, DOI 10.1038/358086a0; Jones DT, 2000, CURR OPIN STRUC BIOL, V10, P371, DOI 10.1016/S0959-440X(00)00099-3; KROGH A, 1994, NUCLEIC ACIDS RES, V22, P4768, DOI 10.1093/nar/22.22.4768; Martin ACR, 1997, PROTEINS, P14; Moult J, 1999, PROTEINS, P2; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; Pearl FMG, 2000, NUCLEIC ACIDS RES, V28, P277, DOI 10.1093/nar/28.1.277; Peitsch MC, 1996, BIOCHEM SOC T, V24, P274, DOI 10.1042/bst0240274; Salamov AA, 1999, PROTEIN SCI, V8, P771; Sanchez R, 1999, J COMPUT PHYS, V151, P388, DOI 10.1006/jcph.1999.6200; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; Simons KT, 2001, J MOL BIOL, V306, P1191, DOI 10.1006/jmbi.2000.4459; Tatusov RL, 2000, NUCLEIC ACIDS RES, V28, P33, DOI 10.1093/nar/28.1.33; TEICHMANN SA, IN PRESS CURR OPIN S; Todd AE, 2001, J MOL BIOL, V307, P1113, DOI 10.1006/jmbi.2001.4513; Wallace AC, 1997, PROTEIN SCI, V6, P2308	24	66	72	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 15	2001	292	5524					2095	+		10.1126/science.292.5524.2095	http://dx.doi.org/10.1126/science.292.5524.2095			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	442KP	11408660				2022-12-28	WOS:000169284700053
J	Horton, R				Horton, R			The Lancet - now less Sharp	LANCET			English	Editorial Material									Lancet, London WC1X 8RR, England		Horton, R (corresponding author), Lancet, London WC1X 8RR, England.							Sharp D, 1999, LANCET, V353, P1728, DOI 10.1016/S0140-6736(99)00191-9	1	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 9	2001	357	9271					1820	1820		10.1016/S0140-6736(00)05012-1	http://dx.doi.org/10.1016/S0140-6736(00)05012-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	440DN	11410188				2022-12-28	WOS:000169160800008
J	Pedersen-Bjergaard, U; Agerholm-Larsen, B; Pramming, S; Hougaard, P; Thorsteinsson, B				Pedersen-Bjergaard, U; Agerholm-Larsen, B; Pramming, S; Hougaard, P; Thorsteinsson, B			Activity of angiotensin-converting enzyme and risk of severe hypoglycaemia in type 1 diabetes mellitus	LANCET			English	Article							ACE GENE POLYMORPHISM; HYPOGLYCEMIA; PERFORMANCE; BRADYKININ; ALLELE	Background The insertion (I) allele of the angiotensin-converting-enzyme (ACE) gene occurs at increased frequency in endurance athletes. This association suggests that low ACE activity is favourable for performance in conditions with limited substrate availability. Such conditions occur in endurance athletes during competition and in diabetic patients during insulin-induced hypoglycaemia. Patients rely on preserved functional capacity to recognise hypoglycaemic episodes and avoid progression by self-treatment. We studied whether ACE activity is related to the risk of severe hypoglycaemia in type 1 diabetes. Methods Consecutive adult outpatients with type 1 diabetes, untreated with ACE inhibitors or angiotensin-II-receptor antagonists (n=207) reported their experience of mild and severe hypoglycaemia during the previous 1 year and 2 years. The patients were further characterised by diabetes history, degree of hypoglycaemia awareness, measurement of C-peptide, haemoglobin A(1c), and serum ACE concentrations, and determination of ACE genotype. Findings Patients with the DD genotype had a relative risk of severe hypoglycaemia in the preceding 2 years of 3.2 (95% CI 1.4-7.4) compared with those who had the II genotype. There was a significant relation between serum ACE activity and the rate of severe hypoglycaemia (relative risk per 10 U/L increment 1.4 [1.2-1.6]), corresponding to a 3.5 times higher risk for patients in the highest quartile than for those in the lowest quartile, Multiple regression analysis showed that the effect of the ACE genotype was explained by its influence on serum ACE activity and that the only other significant determinants of the risk of severe hypoglycaemia were the degree of hypoglycaemia awareness, beta -cell function, and duration of diabetes of more than 20 years. Interpretation ACE activity is a clinically significant marker of the risk of severe hypoglycaemia in patients with type 1 diabetes, especially in those with impaired defence against hypoglycaemia, These findings need to be confirmed in prospective studies.	Hillerod Hosp, Dept Internal Med F, DK-3400 Hillerod, Denmark; Novo Nordisk AS, DK-2880 Bagsvaerd, Denmark; Herlev Univ Hosp, Dept Clin Biochem, DK-2730 Herlev, Denmark	University of Copenhagen; Novo Nordisk; University of Copenhagen; Herlev & Gentofte Hospital	Pedersen-Bjergaard, U (corresponding author), Hillerod Hosp, Dept Internal Med F, Helsevej 2, DK-3400 Hillerod, Denmark.	ulpebj@fa.dk	Pedersen-Bjergaard, Ulrik/AAI-2425-2019	Pedersen-Bjergaard, Ulrik/0000-0003-0588-4880				Agerholm-Larsen B, 1999, ATHEROSCLEROSIS, V147, P425; AgerholmLarsen B, 1997, CIRCULATION, V95, P2358, DOI 10.1161/01.CIR.95.10.2358; AMIEL SA, 1993, DIABETES CARE, V16, P48, DOI 10.2337/diacare.16.3.48; Amouyel P, 1996, NEUROSCI LETT, V217, P203, DOI 10.1016/S0304-3940(96)13092-5; [Anonymous], 1997, DIABETES, V46, P271, DOI 10.2337/diab.46.2.271; BARNES JM, 1990, J CARDIOVASC PHARM, V16, P234, DOI 10.1097/00005344-199008000-00009; Brown NJ, 1998, J CARDIOVASC PHARM, V32, P373, DOI 10.1097/00005344-199809000-00006; CHAI SY, 1992, CLIN EXP PHARMACOL P, P7, DOI 10.1111/j.1440-1681.1992.tb02803.x; Chaturvedi N, 1997, LANCET, V349, P1787, DOI 10.1016/S0140-6736(96)10244-0; Cryer PE, 1999, DIABETES-METAB RES, V15, P42, DOI 10.1002/(SICI)1520-7560(199901/02)15:1<42::AID-DMRR1>3.0.CO;2-B; DCCT Res Grp, 1991, AM J MED, V90, P450, DOI 10.1016/0002-9343(91)80085-Z; Gayagay G, 1998, HUM GENET, V103, P48, DOI 10.1007/s004390050781; Georgiev V, 1999, METHOD FIND EXP CLIN, V21, P463; GOLD AE, 1994, DIABETES CARE, V17, P697, DOI 10.2337/diacare.17.7.697; HEPBURN DA, 1990, DIABETIC MED, V7, P711, DOI 10.1111/j.1464-5491.1990.tb01475.x; HERINGS RMC, 1995, LANCET, V345, P1195, DOI 10.1016/S0140-6736(95)91988-0; JASPARD E, 1993, J BIOL CHEM, V268, P9496; MADSBAD S, 1982, DIABETOLOGIA, V23, P499; MADSEN BK, 1992, AM J HYPERTENS, V5, P361, DOI 10.1093/ajh/5.6.361; Montgomery HE, 1998, NATURE, V393, P221, DOI 10.1038/30374; Pramming S, 2000, DIABETOLOGIA, V43, pA194; PRAMMING S, 1991, DIABETIC MED, V8, P217, DOI 10.1111/j.1464-5491.1991.tb01575.x; RIGAT B, 1990, J CLIN INVEST, V86, P1343, DOI 10.1172/JCI114844; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; Wall TM, 1996, EUR J PHARMACOL, V306, P165, DOI 10.1016/0014-2999(96)00030-1; Williams AG, 2000, NATURE, V403, P614, DOI 10.1038/35001141; Worck RH, 1997, AM J PHYSIOL-ENDOC M, V272, pE415, DOI 10.1152/ajpendo.1997.272.3.E415	27	74	77	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 21	2001	357	9264					1248	1253		10.1016/S0140-6736(00)04405-6	http://dx.doi.org/10.1016/S0140-6736(00)04405-6			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	425YY	11418149				2022-12-28	WOS:000168323300011
J	Ang-Lee, MK; Moss, J; Yuan, CS				Ang-Lee, MK; Moss, J; Yuan, CS			Herbal medicines and perioperative care	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							GINKGO-BILOBA EXTRACT; ST. JOHNS WORT; KAVA PIPER-METHYSTICUM; DIETARY-SUPPLEMENTS; DRUG-INTERACTIONS; UNITED-STATES; MA-HUANG; EPHEDRINE NEPHROLITHIASIS; VALERIANA-OFFICINALIS; HYPERICUM-PERFORATUM	Context Widespread use of herbal medications among the presurgical population may have a negative impact on perioperative patient care. Objectives To review the literature on commonly used herbal medications in the context of the perioperative period and provide rational strategies for managing their preoperative use. Data Sources The MEDLINE and Cochrane Collaboration databases were searched for articles published between January 1966 and December 2000 using the search terms herbal medicine, phytotherapy, and alternative medicine and the names of the 16 most commonly used herbal medications. Additional data sources were obtained from manual searches of recent journal articles and textbooks. Study Selection We selected studies, case reports, and reviews addressing the safety and pharmacology of 8 commonly used herbal medications for which safety information pertinent to the perioperative period was available. Data Extraction We extracted safety, pharmacodynamic, and pharmacokinetic information from the selected literature and reached consensus about any discrepancies. Data Synthesis Echinacea, ephedra, garlic, ginkgo, ginseng, kava, St John's wort, and valerian are commonly used herbal medications that may pose a concern during the perioperative period. Complications can arise from these herbs' direct and pharmacodynamic or pharmacokinetic effects. Direct effects include bleeding from garlic, ginkgo, and ginseng; cardiovascular instability from ephedra; and hypoglycemia from ginseng, Pharmacodynamic herb-drug interactions include potentiation of the sedative effect of anesthetics by kava and valerian, Pharmacokinetic herb-drug interactions include increased metabolism of many drugs used in the perioperative period by St John's wort. Conclusions During the preoperative evaluation, physicians should explicitly elicit and document a history of herbal medication use. Physicians should be familiar with the potential perioperative effects of the commonly used herbal medications to prevent, recognize, and treat potentially serious problems associated with their use and discontinuation.	Univ Chicago, Pritzker Sch Med, Dept Anesthesia & Crit Care, Chicago, IL 60637 USA; Univ Chicago, Pritzker Sch Med, Comm Clin Pharmacol, Chicago, IL 60637 USA; Univ Chicago, Pritzker Sch Med, Tang Ctr Herbal Med Res, Chicago, IL 60637 USA	University of Chicago; University of Chicago; University of Chicago	Yuan, CS (corresponding author), Univ Chicago, Pritzker Sch Med, Dept Anesthesia & Crit Care, 5841 S Maryland Ave,MC 4028, Chicago, IL 60637 USA.							Abbot NC, 1996, NATURE, V381, P361, DOI 10.1038/381361a0; Ali M, 2000, PROSTAG LEUKOTR ESS, V62, P253, DOI 10.1054/plef.2000.0152; Almeida JC, 1996, ANN INTERN MED, V125, P940, DOI 10.7326/0003-4819-125-11-199612010-00023; APITZCASTRO R, 1986, THROMB RES, V42, P303, DOI 10.1016/0049-3848(86)90259-8; Attele AS, 1999, BIOCHEM PHARMACOL, V58, P1685, DOI 10.1016/S0006-2952(99)00212-9; BACKHAUSS C, 1992, EUR J PHARMACOL, V215, P265, DOI 10.1016/0014-2999(92)90037-5; Barnes J, 1998, BRIT J CLIN PHARMACO, V45, P496, DOI 10.1046/j.1365-2125.1998.00715.x; Biber A, 1998, PHARMACOPSYCHIATRY, V31, P36, DOI 10.1055/s-2007-979344; Blau JJ, 1998, J UROLOGY, V160, P825, DOI 10.1016/S0022-5347(01)62796-4; Blendon RJ, 2001, ARCH INTERN MED, V161, P805, DOI 10.1001/archinte.161.6.805; Boullata JI, 2000, PHARMACOTHERAPY, V20, P257, DOI 10.1592/phco.20.4.257.34886; Bovill JG, 1997, J CLIN ANESTH, V9, pS3, DOI 10.1016/S0952-8180(97)00119-0; Breidenbach T, 2000, LANCET, V355, P1912, DOI 10.1016/S0140-6736(05)73359-6; BREKHMAN II, 1969, ANNU REV PHARMACOLOG, V9, P419, DOI 10.1146/annurev.pa.09.040169.002223; Brown TM, 2000, AM J EMERG MED, V18, P231, DOI 10.1016/S0735-6757(00)90030-5; CHEN S E, 1980, European Journal of Drug Metabolism and Pharmacokinetics, V5, P161; CHUNG KF, 1987, LANCET, V1, P248; Cirigliano M, 1998, JAMA-J AM MED ASSOC, V280, P1565, DOI 10.1001/jama.280.18.1565-a; *COMM DIET SUPPL L, 1997, REP COMM DIET SUPPL; Coppes MJ, 1998, NEW ENGL J MED, V339, P846, DOI 10.1056/NEJM199809173391213; EDWARDS R, 1995, BRIT MED J, V311, P1569, DOI 10.1136/bmj.311.7019.1569b; Eisenberg DM, 1997, ANN INTERN MED, V127, P61, DOI 10.7326/0003-4819-127-1-199707010-00010; EISENBERG DM, 1993, NEW ENGL J MED, V328, P246, DOI 10.1056/NEJM199301283280406; Eisenberg DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/jama.280.18.1569; Elder NC, 1997, ARCH FAM MED, V6, P181, DOI 10.1001/archfami.6.2.181; Ernst E, 1998, AM J MED, V104, P170, DOI 10.1016/S0002-9343(97)00397-5; Ernst E, 1999, LANCET, V354, P2014, DOI 10.1016/S0140-6736(99)00418-3; ESPINOZA EO, 1995, NEW ENGL J MED, V333, P803, DOI 10.1056/NEJM199509213331217; Fessenden JM, 2001, AM SURGEON, V67, P33; Franklin M, 1999, BIOL PSYCHIAT, V46, P581, DOI 10.1016/S0006-3223(99)00102-X; Fugh-Berman A, 2000, LANCET, V355, P134, DOI 10.1016/S0140-6736(99)06457-0; Garges HP, 1998, JAMA-J AM MED ASSOC, V280, P1566, DOI 10.1001/jama.280.18.1566-a; Gaster B, 2000, ARCH INTERN MED, V160, P152, DOI 10.1001/archinte.160.2.152; Gilbert GJ, 1997, NEUROLOGY, V48, P1137, DOI 10.1212/WNL.48.4.1137; Gruenwald J., 2000, PDR HERBAL MED, P261; Gurley BJ, 2000, AM J HEALTH-SYST PH, V57, P963, DOI 10.1093/ajhp/57.10.963; Gurley BJ, 1998, THER DRUG MONIT, V20, P439, DOI 10.1097/00007691-199808000-00015; Haller CA, 2000, NEW ENGL J MED, V343, P1833, DOI 10.1056/NEJM200012213432502; HENDRIKS H, 1981, PLANTA MED, V42, P62, DOI 10.1055/s-2007-971547; Hensrud DD, 1999, MAYO CLIN PROC, V74, P443; Houghton PJ, 1999, J PHARM PHARMACOL, V51, P505, DOI 10.1211/0022357991772772; Hoyer S, 1999, J NEURAL TRANSM, V106, P1171, DOI 10.1007/s007020050232; JAMIESON DD, 1989, ARCH INT PHARMACOD T, V301, P66; Janetzky K, 1997, AM J HEALTH-SYST PH, V54, P692, DOI 10.1093/ajhp/54.6.692; Johne A, 1999, CLIN PHARMACOL THER, V66, P338, DOI 10.1053/cp.1999.v66.a101944; JUNG F, 1990, ARZNEIMITTELFORSCH, V40-1, P589; KASSLER WJ, 1991, ARCH INTERN MED, V151, P2281, DOI 10.1001/archinte.151.11.2281; Kaye AD, 2000, J CLIN ANESTH, V12, P468, DOI 10.1016/S0952-8180(00)00195-1; Kaye AD, 2000, J APPL PHYSIOL, V89, P353, DOI 10.1152/jappl.2000.89.1.353; Kennedy JM, 2000, BRIT J CLIN PHARMACO, V49, P353, DOI 10.1046/j.1365-2125.2000.00145.x; Kerb R, 1996, ANTIMICROB AGENTS CH, V40, P2087, DOI 10.1128/AAC.40.9.2087; Kessler DA, 2000, NEW ENGL J MED, V342, P1742, DOI 10.1056/NEJM200006083422309; KIMURA Y, 1988, J PHARM PHARMACOL, V40, P838, DOI 10.1111/j.2042-7158.1988.tb06285.x; Ko RJ, 1998, NEW ENGL J MED, V339, P847, DOI 10.1056/NEJM199809173391214; KUO SC, 1990, PLANTA MED, V56, P164, DOI 10.1055/s-2006-960916; Lantz MS, 1999, J GERIATR PSYCH NEUR, V12, P7, DOI 10.1177/089198879901200103; LEAK JA, 2000, ASA NEWSLETTER, P64; LeBars PL, 1997, JAMA-J AM MED ASSOC, V278, P1327, DOI 10.1001/jama.278.16.1327; LEUSCHNER J, 1993, ARZNEIMITTEL-FORSCH, V43-1, P638; MAITRA I, 1995, BIOCHEM PHARMACOL, V49, P1649, DOI 10.1016/0006-2952(95)00089-I; MARWICK C, 1995, JAMA-J AM MED ASSOC, V273, P607, DOI 10.1001/jama.273.8.607; Matthews HB, 1999, ENVIRON HEALTH PERSP, V107, P773, DOI 10.2307/3454572; Matthews MK, 1998, NEUROLOGY, V50, P1933, DOI 10.1212/WNL.50.6.1933; McAlindon TE, 2000, JAMA-J AM MED ASSOC, V283, P1469, DOI 10.1001/jama.283.11.1469; MELCHART D, 2000, COCHRANE DATABASE SY; Meyer H J, 1967, Psychopharmacol Bull, V4, P10; Miller LG, 1998, ARCH INTERN MED, V158, P2200, DOI 10.1001/archinte.158.20.2200; Mills S, 2000, PRINCIPLES PRACTICE, P404; MONMANEY T, 1998, LOS ANGELES TIM 0831, pA10; Muller WE, 1997, PHARMACOPSYCHIATRY, V30, P102, DOI 10.1055/s-2007-979528; Muller WE, 1998, PHARMACOPSYCHIATRY, V31, P16, DOI 10.1055/s-2007-979341; Mullins RJ, 1998, MED J AUSTRALIA, V168, P170, DOI 10.5694/j.1326-5377.1998.tb126773.x; Neary JT, 1999, BRAIN RES, V816, P358, DOI 10.1016/S0006-8993(98)01126-3; Nightingale SL, 1997, JAMA-J AM MED ASSOC, V278, P15, DOI 10.1001/jama.278.1.15; Nortier JL, 2000, NEW ENGL J MED, V342, P1686, DOI 10.1056/NEJM200006083422301; NORTON SA, 1994, J AM ACAD DERMATOL, V31, P89, DOI 10.1016/S0190-9622(94)70142-3; Obach RS, 2000, J PHARMACOL EXP THER, V294, P88; Oken BS, 1998, ARCH NEUROL-CHICAGO, V55, P1409, DOI 10.1001/archneur.55.11.1409; Ortiz JG, 1999, NEUROCHEM RES, V24, P1373, DOI 10.1023/A:1022576405534; Park HJ, 1996, BIOL PHARM BULL, V19, P1434, DOI 10.1248/bpb.19.1434; Pepping J, 1999, AM J HEALTH-SYST PH, V56, P957, DOI 10.1093/ajhp/56.10.957; Pepping J, 1999, AM J HEALTH-SYST PH, V56, P121, DOI 10.1093/ajhp/56.2.121; PERHARIC L, 1993, LANCET, V342, P180, DOI 10.1016/0140-6736(93)91389-4; Piscitelli SC, 2000, LANCET, V355, P547, DOI 10.1016/S0140-6736(99)05712-8; Pittler MH, 2000, J CLIN PSYCHOPHARM, V20, P84, DOI 10.1097/00004714-200002000-00014; Powell T, 1998, AM J KIDNEY DIS, V32, P153, DOI 10.1053/ajkd.1998.v32.pm9669437; RASMUSSEN AK, 1979, XENOBIOTICA, V9, P1; Reginster JY, 2001, LANCET, V357, P251, DOI 10.1016/S0140-6736(00)03610-2; Rehman J, 1999, IMMUNOL LETT, V68, P391, DOI 10.1016/S0165-2478(99)00085-1; ROIZEN MF, 1994, ANESTHESIA, P903; ROSE KD, 1990, NEUROSURGERY, V26, P880, DOI 10.1227/00006123-199005000-00026; Rosenblatt M, 1997, NEW ENGL J MED, V336, P1108, DOI 10.1056/NEJM199704103361518; Rowin J, 1996, NEUROLOGY, V46, P1775, DOI 10.1212/WNL.46.6.1775; Ruschitzka F, 2000, LANCET, V355, P548, DOI 10.1016/S0140-6736(99)05467-7; SANTOS MS, 1994, ARCH INT PHARMACOD T, V327, P220; See DM, 1997, IMMUNOPHARMACOLOGY, V35, P229, DOI 10.1016/S0162-3109(96)00125-7; Shelton RC, 2001, JAMA-J AM MED ASSOC, V285, P1978, DOI 10.1001/jama.285.15.1978; SILAGY CAS, 1994, J HYPERTENS, V12, P463; Slifman NR, 1998, NEW ENGL J MED, V339, P806, DOI 10.1056/NEJM199809173391204; SRIVASTAVA KC, 1986, PROSTAG LEUKOTR ESS, V22, P313, DOI 10.1016/0262-1746(86)90142-3; Stevinson C, 2000, ANN INTERN MED, V133, P420, DOI 10.7326/0003-4819-133-6-200009190-00009; SUZUKI O, 1984, PLANTA MED, V50, P272, DOI 10.1055/s-2007-969700; TENG CM, 1989, BIOCHIM BIOPHYS ACTA, V990, P315, DOI 10.1016/S0304-4165(89)80051-0; Thompson CA, 1998, AM J HEALTH-SYST PH, V55, P2341, DOI 10.1093/ajhp/55.22.2341; Tonnesen H, 1999, BMJ-BRIT MED J, V318, P1311, DOI 10.1136/bmj.318.7194.1311; Tsen LC, 2000, ANESTHESIOLOGY, V93, P148, DOI 10.1097/00000542-200007000-00025; Vale S, 1998, LANCET, V352, P36, DOI 10.1016/S0140-6736(05)79516-7; VANDERSTRICHT BI, 1994, BRIT MED J, V308, P1162, DOI 10.1136/bmj.308.6937.1162; Vuksan V, 2000, ARCH INTERN MED, V160, P1009, DOI 10.1001/archinte.160.7.1009; Wagner H, 1999, ENVIRON HEALTH PERSP, V107, P779, DOI 10.2307/3454573; Watson DG, 1999, J CHROMATOGR B, V723, P203, DOI 10.1016/S0378-4347(98)00509-X; White LM, 1997, J CLIN PHARMACOL, V37, P116, DOI 10.1002/j.1552-4604.1997.tb04769.x; Windrum P, 2000, LANCET, V355, P1019, DOI 10.1016/S0140-6736(05)74767-X; Winslow LC, 1998, ARCH INTERN MED, V158, P2192, DOI 10.1001/archinte.158.20.2192; Yu PH, 2000, PHARMACOPSYCHIATRY, V33, P60, DOI 10.1055/s-2000-7970; Yue QY, 2000, LANCET, V355, P576, DOI 10.1016/S0140-6736(05)73227-X; Zaacks SM, 1999, J TOXICOL-CLIN TOXIC, V37, P485, DOI 10.1081/CLT-100102440; 1995, CONSUMER REPORTS NOV, P698; 2000, NUTR BUSINESS J; 1999, CONSUMER REPORTS MAR, P44	120	543	565	2	118	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 11	2001	286	2					208	216		10.1001/jama.286.2.208	http://dx.doi.org/10.1001/jama.286.2.208			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	451JJ	11448284				2022-12-28	WOS:000169798700026
J	Schrag, SJ; Pena, C; Fernandez, J; Sanchez, J; Gomez, V; Perez, E; Feris, JM; Besser, RE				Schrag, SJ; Pena, C; Fernandez, J; Sanchez, J; Gomez, V; Perez, E; Feris, JM; Besser, RE			Effect of short-course, high-dose amoxicillin therapy on resistant pneumococcal carriage - A randomized trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE OTITIS-MEDIA; VS. 10 DAYS; STREPTOCOCCUS-PNEUMONIAE; ANTIBIOTIC-THERAPY; RISK-FACTORS; YOUNG-CHILDREN; ANTIMICROBIAL RESISTANCE; HAEMOPHILUS-INFLUENZAE; EPIDEMIOLOGY; INTERVENTION	Context Emerging drug resistance threatens the effectiveness of existing therapies for pneumococcal infections. Modifying the dose and duration of antibiotic therapy may limit the spread of resistant pneumococci. Objective To determine whether short-course, high-dose amoxicillin therapy reduces risk of posttreatment resistant pneumococcal carriage among children with respiratory tract infections. Design and Setting Randomized trial conducted in an outpatient clinic in Santo Domingo, Dominican Republic, October 1999 through July 2000. Participants Children aged 6 to 59 months who were receiving antibiotic prescriptions for respiratory tract illness (n=795). Interventions Children were randomly assigned to receive 1 of 2 twice-daily regimens of amoxicillin: 90 mg/kg per day for 5 days (n=398) or 40 mg/kg per day for 10 days (n=397). Main Outcome Measures Penicillin-nonsusceptible Streptococcus pneumoniae carriage, assessed in nasopharyngeal specimens collected at days 0, 5, 10, and 28; baseline risk factors for nonsusceptible pneumococcal carriage; and adherence to regimen, compared between the 2 groups. Results At the day 28 visit, risk of penicillin-nonsusceptible pneumococcal carriage was significantly lower in the short-course, high-dose group (24%) compared with the standard-course group (32%); relative risk (RR), 0.77; 95% confidence interval (CI), 0.60-0.97; P=.03; risk of trimethoprim-sulfamethoxazole nonsusceptibility was also lower in the short-course, high-dose group (RR, 0.77; 95% Cl,0.58-1.03; P=.08). The protective effect of short-course, high-dose therapy was stronger in households with 3 or more children (RR, 0.72; 95% CI, 0.52-0.98). Adherence to treatment was higher in the short-course, high-dose group (82% vs 74%; P=.02). Conclusion Short-course, high-dose outpatient antibiotic therapy appears promising as an intervention to minimize the impact of antibiotic use on the spread of drug-resistant pneumococci.	CDCP, Resp Dis Branch, Div Bacterial & Mycot Dis, Natl Ctr Infect Dis, Atlanta, GA 30333 USA; CDCP, Epidem Intelligence Serv, Epidemiol Program Off, Atlanta, GA 30333 USA; Clin Infantil Dr Robert REid Cabral, Dept Enfermedades Infecciosas, Santo Domingo, Dominican Rep	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA	Schrag, SJ (corresponding author), CDCP, Resp Dis Branch, Div Bacterial & Mycot Dis, Natl Ctr Infect Dis, MS C23,1600 Clifton Rd, Atlanta, GA 30333 USA.			Perez-Then, Eddy/0000-0001-7724-0668				AMITAI Y, 1985, ISRAEL J MED SCI, V21, P340; Arason VA, 1996, BMJ-BRIT MED J, V313, P387; Arnold KE, 1996, J PEDIATR-US, V128, P757, DOI 10.1016/S0022-3476(96)70326-8; Baquero F, 1996, CURR OPIN INFECT DIS, V9, P372, DOI 10.1097/00001432-199612000-00003; BRONSDON MA, 1998, 38 INT C ANT AG CHEM; CHARNEY E, 1967, PEDIATRICS, V40, P188; Cohen R, 1998, J PEDIATR-US, V133, P634, DOI 10.1016/S0022-3476(98)70103-9; Cohen R, 2000, PEDIATR INFECT DIS J, V19, P458, DOI 10.1097/00006454-200005000-00013; Cohen R, 1999, PEDIATR INFECT DIS J, V18, P403, DOI 10.1097/00006454-199905000-00002; Craig WA, 1998, CLIN INFECT DIS, V26, P1, DOI 10.1086/516284; DAGAN R, 1999, PEDIATR INFECT DIS J, V18, P543; Dowell SF, 1997, AM FAM PHYSICIAN, V55, P1647; Dowell SF, 1999, PEDIATR INFECT DIS J, V18, P1, DOI 10.1097/00006454-199901000-00002; DOWELL SF, 1997, AM FAM PHYSICIAN, V55, P1657; Ekdahl K, 1998, MICROB DRUG RESIST, V4, P99, DOI 10.1089/mdr.1998.4.99; Gonzales R, 1999, JAMA-J AM MED ASSOC, V281, P1512, DOI 10.1001/jama.281.16.1512; Guillemot D, 1998, JAMA-J AM MED ASSOC, V279, P365, DOI 10.1001/jama.279.5.365; Hoberman A, 2000, PEDIATR INFECT DIS J, V19, P471, DOI 10.1097/00006454-200005000-00015; KLUGMAN KP, 1990, CLIN MICROBIOL REV, V3, P171, DOI 10.1128/CMR.3.2.171-196.1990; Kristinsson KG, 1997, MICROB DRUG RESIST, V3, P117, DOI 10.1089/mdr.1997.3.117; Kristinsson KG, 1995, MICROB DRUG RESIST, V1, P121, DOI 10.1089/mdr.1995.1.121; LEIBOVITZ E, 2000, 40 INT C ANT AG CHEM; Lim WS, 2000, J ANTIMICROB CHEMOTH, V46, P835, DOI 10.1093/jac/46.5.835; Lipsitch M, 2001, CLIN INFECT DIS, V32, P1044, DOI 10.1086/319604; Low DE, 1998, JAMA-J AM MED ASSOC, V279, P394, DOI 10.1001/jama.279.5.394; *NAT COMM CLIN LAB, 2000, MIC INT STAND MUG ML; Obaro SK, 1996, BMJ-BRIT MED J, V312, P1521, DOI 10.1136/bmj.312.7045.1521; Ostroff SM, 1996, CLIN INFECT DIS, V23, P1069, DOI 10.1093/clinids/23.5.1069; PALLARES R, 1987, NEW ENGL J MED, V317, P18, DOI 10.1056/NEJM198707023170104; Pichichero ME, 1997, PEDIATR INFECT DIS J, V16, P680, DOI 10.1097/00006454-199707000-00011; Raymond J, 2000, J INFECT DIS, V181, P1983, DOI 10.1086/315505; Saah A J, 1980, JAMA, V243, P1924, DOI 10.1001/jama.243.18.1924; Scott JAG, 1998, CLIN INFECT DIS, V27, P1442, DOI 10.1086/515013; Seppala H, 1997, NEW ENGL J MED, V337, P441, DOI 10.1056/NEJM199708143370701; TRUCCO O, 1998, REV CHIL PEDIATR, V67, P195; Varon E, 2000, CLIN INFECT DIS, V31, P477, DOI 10.1086/313981; Vives M, 1997, PEDIATR INFECT DIS J, V16, P852, DOI 10.1097/00006454-199709000-00007; Yagupsky P, 1998, J INFECT DIS, V177, P1003, DOI 10.1086/515239	38	170	178	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 4	2001	286	1					49	56		10.1001/jama.286.1.49	http://dx.doi.org/10.1001/jama.286.1.49			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	449GR	11434826	Bronze			2022-12-28	WOS:000169676400022
J	Ridker, PM; Rifai, N; Clearfield, M; Downs, JR; Weis, SE; Miles, JS; Gotto, AM				Ridker, PM; Rifai, N; Clearfield, M; Downs, JR; Weis, SE; Miles, JS; Gotto, AM		Air Force Texas Coronary Atheroscl	Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							AVERAGE CHOLESTEROL LEVELS; HEART-DISEASE; COST-EFFECTIVENESS; ATHEROSCLEROSIS PREVENTION; CARDIOVASCULAR-DISEASE; MYOCARDIAL-INFARCTION; RISK; INFLAMMATION; MEN; PRAVASTATIN	Background: Elevated levels of C-reactive protein, even in the absence of hyperlipidemia, are associated with an increased risk of coronary events. Statin therapy reduces the level of C-reactive protein independently of its effect on lipid levels. We hypothesized that statins might prevent coronary events in persons with elevated C-reactive protein levels who did not have overt hyperlipidemia. Methods: The level of C-reactive protein was measured at base line and after one year in 5742 participants in a five-year randomized trial of lovastatin for the primary prevention of acute coronary events. Results: The rates of coronary events increased significantly with increases in the base-line levels of C-reactive protein. Lovastatin therapy reduced the C-reactive protein level by 14.8 percent (P<0.001), an effect not explained by lovastatin-induced changes in the lipid profile. As expected, lovastatin was effective in preventing coronary events in participants whose base-line ratio of total cholesterol to high-density lipoprotein (HDL) cholesterol was higher than the median ratio, regardless of the level of C-reactive protein (number needed to treat for five years to prevent 1 event, 47; P=0.005). However, lovastatin was also effective among those with a ratio of total to HDL cholesterol that was lower than the median and a C-reactive protein level higher than the median (number needed to treat, 43; P=0.02). In contrast, lovastatin was ineffective among participants with a ratio of total to HDL cholesterol and a C-reactive protein level that were both lower than the median (number needed to treat, 983; P=0.87). Conclusions: Statin therapy may be effective in the primary prevention of coronary events among persons with relatively low lipid levels but with elevated levels of C-reactive protein. (N Engl J Med 2001;344:1959-65.) Copyright (C) 2001 Massachusetts Medical Society.	Brigham & Womens Hosp, Ctr Cardiovasc Dis Prevent, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA USA; Univ N Texas, Hlth Sci Ctr, Ft Worth, TX USA; Wilford Hall USAF Med Ctr, Lackland AFB, TX 78236 USA; Cornell Univ, Weill Med Coll, New York, NY USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; University of North Texas System; University of North Texas Health Science Center; United States Department of Defense; United States Air Force; Cornell University	Ridker, PM (corresponding author), Brigham & Womens Hosp, Ctr Cardiovasc Dis Prevent, 900 Commonwealth Ave E, Boston, MA 02215 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL058755] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL58755] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Braunwald E, 1997, NEW ENGL J MED, V337, P1360, DOI 10.1056/NEJM199711063371906; Danesh J, 2000, BMJ-BRIT MED J, V321, P199, DOI 10.1136/bmj.321.7255.199; Downs JR, 1997, AM J CARDIOL, V80, P287, DOI 10.1016/S0002-9149(97)00347-0; Downs JR, 1998, JAMA-J AM MED ASSOC, V279, P1615, DOI 10.1001/jama.279.20.1615; Farmer J A, 2000, Curr Atheroscler Rep, V2, P208, DOI 10.1007/s11883-000-0022-3; Ferro D, 2000, J AM COLL CARDIOL, V36, P427, DOI 10.1016/S0735-1097(00)00771-3; Garber AM, 2000, ANN INTERN MED, V132, P833, DOI 10.7326/0003-4819-132-10-200005160-00012; GOLDMAN L, 1991, JAMA-J AM MED ASSOC, V265, P1145, DOI 10.1001/jama.265.9.1145; Gotto AM, 2000, CIRCULATION, V101, P477, DOI 10.1161/01.CIR.101.5.477; GRUNDY SM, 1993, JAMA-J AM MED ASSOC, V269, P3015, DOI 10.1001/jama.269.23.3015; Jacobson TA, 1998, ARCH INTERN MED, V158, P1977, DOI 10.1001/archinte.158.18.1977; Koenig W, 1999, CIRCULATION, V99, P237, DOI 10.1161/01.CIR.99.2.237; LIBBY P, 1995, CIRCULATION, V91, P2844, DOI 10.1161/01.CIR.91.11.2844; RICKER PM, 2000, NEW ENGL J MED, V342, P836; Ridker PM, 1998, CIRCULATION, V97, P2007, DOI 10.1161/01.CIR.97.20.2007; Ridker PM, 2001, CIRCULATION, V103, P1191; Ridker PM, 1997, NEW ENGL J MED, V337, P356; Ridker PM, 2001, CIRCULATION, V103, P1813, DOI 10.1161/01.CIR.103.13.1813; Ridker PM, 1998, CIRCULATION, V98, P839, DOI 10.1161/01.CIR.98.9.839; Ridker PM, 1999, ANN INTERN MED, V130, P933, DOI 10.7326/0003-4819-130-11-199906010-00018; Ridker PM, 1999, CIRCULATION, V100, P230, DOI 10.1161/01.CIR.100.3.230; Ridker PM, 1997, NEW ENGL J MED, V336, P973, DOI 10.1056/NEJM199704033361401; Ridker PM, 2001, JAMA-J AM MED ASSOC, V285, P2481, DOI 10.1001/jama.285.19.2481; Rifai N, 1999, CLIN CHEM, V45, P2136; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; Visser M, 1999, JAMA-J AM MED ASSOC, V282, P2131, DOI 10.1001/jama.282.22.2131	27	1249	1324	1	26	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 28	2001	344	26					1959	1965		10.1056/NEJM200106283442601	http://dx.doi.org/10.1056/NEJM200106283442601			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	446HQ	11430324				2022-12-28	WOS:000169508200001
J	Hill, AVS				Hill, AVS			Immunogenetics and genomics	LANCET			English	Review							DEPENDENT DIABETES-MELLITUS; INFLAMMATORY-BOWEL-DISEASE; ALZHEIMERS-DISEASE; CELIAC-DISEASE; ANKYLOSING-SPONDYLITIS; HETEROZYGOTE ADVANTAGE; PROMOTER POLYMORPHISM; RHEUMATOID-ARTHRITIS; NATURAL-RESISTANCE; GENE POLYMORPHISMS	Immunogenetic analysis of disease susceptibility has been encouraged by the identification of strong HLA associations with several diseases of uncertain cause. Weaker HLA associations exist with a large number of infectious and noninfectious diseases and the mechanisms of these effects are beginning to be uncovered. Extensive analyses of non-HLA immunogenetic variants have also been undertaken and associations with a variety of genes identified. Genetic linkage analysis of multicase families has recently identified new major susceptibility loci for a few immunologically determined common diseases. However, the greatest potential for the future lies in genome-wide searches for susceptibility genes that individually might have quite modest effects but cumulatively have a large Impact on individual risk. This new era of Immunogenomics promises to provide key insights into disease pathogenesis and Identify multiple molecular targets for intervention strategies.	Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England	University of Oxford; Wellcome Centre for Human Genetics	Hill, AVS (corresponding author), Univ Oxford, Wellcome Trust Ctr Human Genet, Roosevelt Dr, Oxford OX3 7BN, England.	adrian.hill@well.ox.ac.uk	HILL, Adrian V>S>/C-1306-2008					Aitman TJ, 2000, NATURE, V405, P1015, DOI 10.1038/35016636; Anderson RP, 2000, NAT MED, V6, P337, DOI 10.1038/73200; Arbour NC, 2000, NAT GENET, V25, P187, DOI 10.1038/76048; Arentz-Hansen H, 2000, J EXP MED, V191, P603, DOI 10.1084/jem.191.4.603; BELL GI, 1984, DIABETES, V33, P176, DOI 10.2337/diabetes.33.2.176; Bellamy R, 1998, NEW ENGL J MED, V338, P640, DOI 10.1056/NEJM199803053381002; Bellamy R, 2000, LANCET, V355, P588, DOI 10.1016/S0140-6736(99)00426-2; Blackwell JM, 1999, MICROBES INFECT, V1, P95, DOI 10.1016/S1286-4579(99)80020-3; Brown MA, 1997, ARTHRITIS RHEUM, V40, P1823, DOI 10.1002/art.1780401015; Carrington M, 1999, SCIENCE, V283, P1748, DOI 10.1126/science.283.5408.1748; DOHERTY PC, 1975, LANCET, V1, P1406, DOI 10.1016/S0140-6736(75)92610-0; Donner H, 1997, J CLIN ENDOCR METAB, V82, P143, DOI 10.1210/jc.82.1.143; Du Y, 2000, NEUROLOGY, V55, P480, DOI 10.1212/WNL.55.4.480; Edwards-Smith CJ, 1999, HEPATOLOGY, V30, P526, DOI 10.1002/hep.510300207; El-Omar EM, 2000, NATURE, V404, P398, DOI 10.1038/35006081; Eskdale J, 1998, LANCET, V352, P1282, DOI 10.1016/S0140-6736(05)70489-X; Fishman D, 1998, J CLIN INVEST, V102, P1369, DOI 10.1172/JCI2629; Gambaro G, 2000, LANCET, V355, P308, DOI 10.1016/S0140-6736(99)07202-5; Gilbert SC, 1997, NAT BIOTECHNOL, V15, P1280, DOI 10.1038/nbt1197-1280; Gilbert SC, 1998, SCIENCE, V279, P1173, DOI 10.1126/science.279.5354.1173; Grimaldi LME, 2000, ANN NEUROL, V47, P361, DOI 10.1002/1531-8249(200003)47:3<361::AID-ANA12>3.3.CO;2-E; Hampe J, 2001, LANCET, V357, P1925, DOI 10.1016/S0140-6736(00)05063-7; Helminen M, 1999, J INFECT DIS, V180, P496, DOI 10.1086/314883; Hill AVS, 1998, ANNU REV IMMUNOL, V16, P593, DOI 10.1146/annurev.immunol.16.1.593; HILL AVS, 1991, NATURE, V352, P595, DOI 10.1038/352595a0; Horikawa Y, 2000, NAT GENET, V26, P163, DOI 10.1038/79876; Hugot JP, 2001, NATURE, V411, P599, DOI 10.1038/35079107; Jepson A, 1997, INFECT IMMUN, V65, P872, DOI 10.1128/IAI.65.3.872-876.1997; Keavney B, 2000, LANCET, V355, P434; Kruglyak L, 1999, NAT GENET, V22, P139, DOI 10.1038/9642; Lipshutz RJ, 1999, NAT GENET, V21, P20, DOI 10.1038/4447; Liu HL, 1999, P NATL ACAD SCI USA, V96, P4581, DOI 10.1073/pnas.96.8.4581; Liu R, 1996, CELL, V86, P367, DOI 10.1016/S0092-8674(00)80110-5; Lonjou C, 2000, P NATL ACAD SCI USA, V97, P10942, DOI 10.1073/pnas.97.20.10942; LOPEZLARREA C, 1995, TISSUE ANTIGENS, V45, P169, DOI 10.1111/j.1399-0039.1995.tb02436.x; Maliarik MJ, 2000, AM J RESP CELL MOL, V22, P672, DOI 10.1165/ajrcmb.22.6.3745; Marquet S, 1996, NAT GENET, V14, P181, DOI 10.1038/ng1096-181; Marron MP, 1997, HUM MOL GENET, V6, P1275, DOI 10.1093/hmg/6.8.1275; McGuire W, 1999, J INFECT DIS, V179, P287, DOI 10.1086/314533; Nemetz A, 1999, IMMUNOGENETICS, V49, P527, DOI 10.1007/s002510050530; Nicoll JAR, 2000, ANN NEUROL, V47, P365, DOI 10.1002/1531-8249(200003)47:3<365::AID-ANA13>3.0.CO;2-G; Ogura Y, 2001, NATURE, V411, P603, DOI 10.1038/35079114; Platonov AE, 1998, CLIN INFECT DIS, V27, P746, DOI 10.1086/514935; Proudfoot AEI, 1999, BIOCHEM PHARMACOL, V57, P451; Rihet P, 1998, AM J HUM GENET, V63, P498, DOI 10.1086/301967; RISCH N, 1987, AM J HUM GENET, V40, P1; Risch NJ, 2000, NATURE, V405, P847, DOI 10.1038/35015718; Roses AD, 1997, NEUROGENETICS, V1, P3, DOI 10.1007/s100480050001; Sanjeevi CB, 2000, ARTHRITIS RHEUM-US, V43, P1397, DOI 10.1002/1529-0131(200006)43:6<1397::AID-ANR25>3.0.CO;2-6; Smith MW, 1997, SCIENCE, V277, P959, DOI 10.1126/science.277.5328.959; SOLLID LM, 1989, J EXP MED, V169, P345, DOI 10.1084/jem.169.1.345; Tagore A, 1999, TISSUE ANTIGENS, V54, P386, DOI 10.1034/j.1399-0039.1999.540408.x; Tang C, 1999, LANCET, V354, P336, DOI 10.1016/S0140-6736(05)75240-5; Thursz M, 1999, LANCET, V354, P2119, DOI 10.1016/S0140-6736(99)91443-5; Thursz MR, 1997, NAT GENET, V17, P11, DOI 10.1038/ng0997-11; VIDAL SM, 1993, CELL, V73, P469, DOI 10.1016/0092-8674(93)90135-D; Walley AJ, 1996, J MED GENET, V33, P689, DOI 10.1136/jmg.33.8.689	57	48	50	0	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 23	2001	357	9273					2037	2041		10.1016/S0140-6736(00)05117-5	http://dx.doi.org/10.1016/S0140-6736(00)05117-5			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	446JB	11438157				2022-12-28	WOS:000169509200033
J	Gostin, LO				Gostin, LO			National health information privacy - Regulations under the Health Insurance Portability and Accountability Act	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PERSONAL PRIVACY	Health information privacy is important in US society, but existing federal and state law does not offer adequate protection, The Department of Health and Human Services, under powers granted by the Health Insurance Portability and Accountability Act of 1996, recently issued a final rule providing systematic, nationwide health information privacy protection. The rule is extensive in its scope, applying to health plans, health care clearinghouses, and health care providers (hospitals. clinics, and health departments) who conduct financial transactions electronically ("covered entities"). The rule applies to personally identifiable information in any form, whether communicated electronically, on paper, or orally, The rule does not preempt state law that affords more stringent privacy protection; thus, the health care industry will have to comply with multiple layers of federal and state law, The rule affords patients rights to education about privacy safeguards, access to their medical records, and a process for correction of records. It also requires the patient's permission for disclosures of personal information. While privacy is an important value, it may conflict with public responsibilities to use data for social goods. The rule has special provisions for disclosure of health information for research, public health, law enforcement, and commercial marketing. The privacy debate will continue in Congress and within the president's administration. The primary focus will be on the costs and burdens on health care providers, the ability of health care professionals to use and share full medical information when treating patients, the provision of patient care in a timely and efficient manner, and parents' access to information about the health of their children.	Georgetown Univ, Ctr Law & Publ Hlth, Washington, DC USA; Johns Hopkins Univ, Sch Publ Hlth, Baltimore, MD USA	Georgetown University; Johns Hopkins University	Gostin, LO (corresponding author), Georgetown Univ, Ctr Law, 600 New Jersey Ave NW, Washington, DC 20001 USA.	gostin@law.georgetown.edu						[Anonymous], 1999, MMWR Recomm Rep, V48, P1; Botkin JR, 2001, JAMA-J AM MED ASSOC, V285, P207, DOI 10.1001/jama.285.2.207; Department of Agriculture Department of Energy National Aeronautics and Space Administration Department of Commerce Consumer Product Safety Commission International Development Cooperation Agency Agency for International Development Department of Housing and Urban Development Department of Justice Department of Defense Department of Education Department of Veterans Affairs Environmental Protection Agency Department of Health and Human Services National Science Foundation and Department of Transportation, 1991, FED REGISTER, V56, P28003; Gostin LO, 1998, ANN INTERN MED, V129, P833, DOI 10.7326/0003-4819-129-10-199811150-00017; Gostin LO, 1996, JAMA-J AM MED ASSOC, V275, P1921, DOI 10.1001/jama.275.24.1921; Gostin LO, 1997, KENNEDY INST ETHIC J, V7, P361, DOI 10.1353/ken.1997.0033; Gostin LO, 2000, PUBLIC HLTH LAW POWE; GOSTIN LO, 1998, JURIMETRICS J, V40, P21; GOSTIN LO, IN PRESS AM J PUBLIC; *HARR EQ, HLTH INF PRIV; *HLTH PRIV PROJ, 2001, COMM FIN STAND PRIV; *I HLTH CAR RES PO, 1999, STAT HLTH PRIV UN TE; *I MED, 2001, PROT DAT PRIV HLTH S; LANDERS SJ, 2001, A MED NEWS      0312, P1; Lowrance WW, 1997, PRIVACY HLTH RES REP; *NAT RES COUNC, 1997, REC PROT EL HLTH INF; *OFF HUM RES PROT, 1978, PRIV PROT RES SUBJ C; Starr P, 1999, AM J LAW MED, V25, P193; *WHIT HOUS, 2000, PRES CLINT ISS STRON; *WORKGR EL DAT INT, 1992, OBST EDI CURR HLTH C; FED REG, V64, P82771; 2001, FED REG         0226, V64, P12434; 2001, FED REG         0228, V64, P12738; 1999, FED REG         1103, V64, P59918	24	76	76	0	15	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 20	2001	285	23					3015	3021		10.1001/jama.285.23.3015	http://dx.doi.org/10.1001/jama.285.23.3015			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	442AR	11410101				2022-12-28	WOS:000169263200025
J	Al-Khatib, SM; Califf, RM; Hasselblad, V; Alexander, JH; McCrory, DC; Sugarman, J				Al-Khatib, SM; Califf, RM; Hasselblad, V; Alexander, JH; McCrory, DC; Sugarman, J			Medicine - Placebo-controls in short-term clinical trials of hypertension	SCIENCE			English	Editorial Material							BLOOD-PRESSURE		Duke Univ, Med Ctr, Dept Med, Duke Clin Res Inst, Durham, NC 27710 USA; Duke Univ, Med Ctr, Div Gen Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Ctr Study Med Eth & Humanities, Durham, NC 27710 USA	Duke University; Duke University; Duke University	Al-Khatib, SM (corresponding author), Duke Univ, Med Ctr, Dept Med, Duke Clin Res Inst, Durham, NC 27710 USA.	aIkha001@mc.duke.edu	Alexander, John/GVS-7271-2022	Sugarman, Jeremy/0000-0001-7022-8332; Alexander, John/0000-0002-1444-2462				ADDINGTON D, 1995, CAN J PSYCHIAT, V40, P171, DOI 10.1177/070674379504000403; [Anonymous], 1991, JAMA, V265, P3255; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; DAHLOF B, 1991, LANCET, V338, P1281, DOI 10.1016/0140-6736(91)92589-T; *EUR AG EV MED PRO, 2000, INT C HARM TECHN REQ; Hennekens C H, 1998, Am J Med, V104, p50S; Keane WF, 1997, NEPHROL DIAL TRANSPL, V12, P75; Maggs DG, 1999, ANN INTERN MED, V130, P241, DOI 10.7326/0003-4819-130-3-199902020-00014; PETERSON WL, 1980, GASTROENTEROLOGY, V79, P585; Preston RA, 2000, ARCH INTERN MED, V160, P1449, DOI 10.1001/archinte.160.10.1449; ROTHMAN KJ, 1994, NEW ENGL J MED, V331, P394, DOI 10.1056/NEJM199408113310611; Staessen JA, 1997, LANCET, V350, P757, DOI 10.1016/S0140-6736(97)05381-6; Temple R, 2000, ANN INTERN MED, V133, P455, DOI 10.7326/0003-4819-133-6-200009190-00014; *WORLD MED ASS, 2000, 52 WORLD MED ASS ED	14	28	28	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 15	2001	292	5524					2013	+		10.1126/science.1057783	http://dx.doi.org/10.1126/science.1057783			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	442KP	11408643				2022-12-28	WOS:000169284700030
J	Gale, EAM				Gale, EAM			Lessons from the glitazones: a story of drug development	LANCET			English	Review							TYPE-2 DIABETES-MELLITUS; PLACEBO-CONTROLLED TRIAL; INSULIN-RESISTANCE; DOUBLE-BLIND; PPAR-GAMMA; TROGLITAZONE MONOTHERAPY; GLYCEMIC CONTROL; METFORMIN; THIAZOLIDINEDIONES; ROSIGLITAZONE	Troglitazone, the first in the thiazolidinediane class of oral hypoglycaemic agents, was launched in the USA in March, 1997. It reached Europe later that year, only to be withdrawn within weeks on the grounds of liver toxicity. Meanwhile it went on to generate sales of over $2 billion in the. USA, and caused at least 90 cases of liver failure (70 resulting in death or transplantation) before it was withdrawn in March, 2000. Rosiglitazone and pioglitazone reached the US market in 1999:as first-line agents to be used alone or in combination with other drugs, but in Europe the same dossiers were used one year later to apply for a limited licence as second-line agents restricted to oral combination therapy. How should we use the glitazones? And how did they achieve blockbuster status without any clear evidence of advantage over existing therapy?	Southmead Hosp, Med Sch Unit, Bristol 10HA 5NB, Avon, England	Southmead Hospital	Gale, EAM (corresponding author), Southmead Hosp, Med Sch Unit, Bristol 10HA 5NB, Avon, England.							Auwerx J, 1999, DIABETOLOGIA, V42, P1033, DOI 10.1007/s001250051268; Aviles-Santa L, 1999, ANN INTERN MED, V131, P182, DOI 10.7326/0003-4819-131-3-199908030-00004; Balfour JAB, 1999, DRUGS, V57, P921; Buchanan TA, 2000, DIABETES, V49, P782, DOI 10.2337/diabetes.49.5.782; Charbonnel B, 1999, DIABETES, V48, pA114; Dent THS, 1997, BMJ-BRIT MED J, V315, P1248, DOI 10.1136/bmj.315.7118.1248; Ellenberg SS, 2000, ANN INTERN MED, V133, P464, DOI 10.7326/0003-4819-133-6-200009190-00015; Fonseca V, 2000, DIABETES CARE, V23, P354, DOI 10.2337/diacare.23.3.354; Fonseca V, 2000, JAMA-J AM MED ASSOC, V283, P1695, DOI 10.1001/jama.283.13.1695; Fonseca VA, 1998, J CLIN ENDOCR METAB, V83, P3169, DOI 10.1210/jc.83.9.3169; Ghazzi MN, 1997, DIABETES, V46, P433, DOI 10.2337/diabetes.46.3.433; HERMANN LS, 1994, DIABETES CARE, V17, P1100, DOI 10.2337/diacare.17.10.1100; Horton ES, 1998, DIABETES CARE, V21, P1462, DOI 10.2337/diacare.21.9.1462; Horton R, 1999, BRIT MED J, V319, P865, DOI 10.1136/bmj.319.7214.865; Inzucchi SE, 1998, NEW ENGL J MED, V338, P867, DOI 10.1056/NEJM199803263381303; Krentz AJ, 2000, BMJ-BRIT MED J, V321, P252, DOI 10.1136/bmj.321.7256.252; Krische D, 2000, WESTERN J MED, V173, P54, DOI 10.1136/ewjm.173.1.54; Kumar S, 1996, DIABETOLOGIA, V39, P701; Lonnqvist F, 1999, DIABETOLOGIA, V42, pA231; Lord J, 2000, CLIN EFFECTIVENESS C; LUMPKIN MM, 2000, FDA ADV COMM MAY 19; Maggs DG, 1998, ANN INTERN MED, V128, P176, DOI 10.7326/0003-4819-128-3-199802010-00002; Makimattila S, 1999, DIABETOLOGIA, V42, P406, DOI 10.1007/s001250051172; MELE J, 1999, 73 M FDA END MET DRU, P91; Olefsky JM, 2000, J CLIN INVEST, V106, P467, DOI 10.1172/JCI10843; Raskin P, 2000, DIABETOLOGIA, V43, P278, DOI 10.1007/s001250050045; Saltiel AR, 1996, DIABETES, V45, P1661, DOI 10.2337/diabetes.45.12.1661; Schoonjans K, 2000, LANCET, V355, P1008, DOI 10.1016/S0140-6736(00)90002-3; Schwartz S, 1998, NEW ENGL J MED, V338, P861, DOI 10.1056/NEJM199803263381302; Seed B, 1998, NAT MED, V4, P1004, DOI 10.1038/1990; *SMITH KLIN BEECH, 2000, SUMM PROD CHAR; Spiegelman BM, 1998, DIABETES, V47, P507, DOI 10.2337/diabetes.47.4.507; Stern MP, 1999, DIABETES CARE, V22, P844, DOI 10.2337/diacare.22.5.844; Sykes R, 1998, BRIT MED J, V317, P1172, DOI 10.1136/bmj.317.7167.1172; Temple R, 2000, ANN INTERN MED, V133, P455, DOI 10.7326/0003-4819-133-6-200009190-00014; Willms B, 1999, DIABETIC MED, V16, P755, DOI 10.1046/j.1464-5491.1999.00149.x; Yki-Jarvinen H, 1999, ANN INTERN MED, V130, P389, DOI 10.7326/0003-4819-130-5-199903020-00002; 1997, CURRENT PROB PHARMAC, V23, P13; 2000, LOS ANGELES TIM 0818	39	213	220	0	11	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 9	2001	357	9271					1870	1875		10.1016/S0140-6736(00)04960-6	http://dx.doi.org/10.1016/S0140-6736(00)04960-6			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	440DN	11410214				2022-12-28	WOS:000169160800033
J	Springer, J; Chollet, A				Springer, J; Chollet, A			A traumatic car crash	LANCET			English	Editorial Material							BRAIN INJURY; HYPOPITUITARISM		Amer Assoc Clin Endocrinologists, Overland Pk, KS 66210 USA		Springer, J (corresponding author), Amer Assoc Clin Endocrinologists, Overland Pk, KS 66210 USA.							Benvenga S, 2000, J CLIN ENDOCR METAB, V85, P1353, DOI 10.1210/jc.85.4.1353; *CDCP, 1996, EP TRAUM BRAIN INJ U; *GROWTH HORM TASK, 1998, AACE CLIN PRACT GUID; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; Salazar AM, 2000, JAMA-J AM MED ASSOC, V283, P3075, DOI 10.1001/jama.283.23.3075	5	24	24	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 9	2001	357	9271					1848	1848		10.1016/S0140-6736(00)04953-9	http://dx.doi.org/10.1016/S0140-6736(00)04953-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	440DN	11410194				2022-12-28	WOS:000169160800014
J	Sam, M; Vora, S; Malnic, B; Ma, WD; Novotny, MV; Buck, LB				Sam, M; Vora, S; Malnic, B; Ma, WD; Novotny, MV; Buck, LB			Neuropharmacology - Odorants may arouse instinctive behaviours	NATURE			English	Article							NEURONS; ODORS		Harvard Univ, Sch Med, Howard Hughes Med Inst, Dept Neurobiol, Boston, MA 02115 USA; Indiana Univ, Dept Chem, Inst Pheromone Res, Bloomington, IN 47405 USA	Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Indiana University System; Indiana University Bloomington	Sam, M (corresponding author), Harvard Univ, Sch Med, Howard Hughes Med Inst, Dept Neurobiol, Boston, MA 02115 USA.	lbuck@hms.harvard.edu	Malnic, Bettina/A-4905-2008	Malnic, Bettina/0000-0002-5877-4784				BINDER BF, 1995, J CHEM ECOL, V21, P1315, DOI 10.1007/BF02027564; Buck LB, 2000, CELL, V100, P611, DOI 10.1016/S0092-8674(00)80698-4; Dobson HEM, 1996, AM J BOT, V83, P877, DOI 10.2307/2446264; HALPERN M, 1987, ANNU REV NEUROSCI, V10, P325, DOI 10.1146/annurev.ne.10.030187.001545; Kielty JP, 1996, J INSECT BEHAV, V9, P237, DOI 10.1007/BF02213868; Leinders-Zufall T, 2000, NATURE, V405, P792, DOI 10.1038/35015572; Malnic B, 1999, CELL, V96, P713, DOI 10.1016/S0092-8674(00)80581-4; NOVOTNY M, 1990, CHEM SIGNAL, V5, P1; SATO T, 1994, J NEUROPHYSIOL, V72, P2980, DOI 10.1152/jn.1994.72.6.2980; Wysocki C.J., 1987, P125	10	182	188	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 12	2001	412	6843					142	142		10.1038/35084137	http://dx.doi.org/10.1038/35084137			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	451AJ	11449261	Bronze			2022-12-28	WOS:000169778700039
J	Heki, K				Heki, K			Seasonal modulation of interseismic strain buildup in northeastern Japan driven by snow leads	SCIENCE			English	Article							EARTHQUAKE OCCURRENCE; DEFORMATION; PLATE	Distinct periodic variations with annual frequencies are often found in the time series of continuous Global Positioning System (GPS) site coordinates in northeastern Japan, They show maximum are-normal contraction of a few millimeters as well as maximum subsidence of 1 to 2 centimeters, both in March, In northeastern Japan, it snows heavily on the western flank of the backbone range, attaining a maximum depth of several meters in March, When observed snow depths were compared with the Load distribution estimated from the CPS data, the surface loads caused by the snow were found to be largely responsible for the annual displacement of GPS sites, The snow load modulates secular strain buildup in northeastern Japan due to the Pacific Plate subduction, but its relevance to the seasonal change of earthquake occurrences remains uncertain.	Natl Astron Observ, Div Earth Rotat, Mizusawa, Iwate 0230861, Japan	National Institutes of Natural Sciences (NINS) - Japan; National Astronomical Observatory of Japan (NAOJ)	Heki, K (corresponding author), Natl Astron Observ, Div Earth Rotat, 2-12 Hoshigaoka, Mizusawa, Iwate 0230861, Japan.							FARRELL WE, 1972, REV GEOPHYS SPACE GE, V10, P761, DOI 10.1029/RG010i003p00761; Gao SS, 2000, NATURE, V406, P500, DOI 10.1038/35020045; Heki K, 1997, NATURE, V386, P595, DOI 10.1038/386595a0; Heki K, 1999, J GEOPHYS RES-SOL EA, V104, P29147, DOI 10.1029/1999JB900295; ICHIKAWA R, 2000, 3 JOINT M US JAP NAT; MACMILLAN DS, 1995, GEOPHYS RES LETT, V22, P1041, DOI 10.1029/95GL00887; Miyazaki S, 2001, J GEOPHYS RES-SOL EA, V106, P4305, DOI 10.1029/2000JB900312; Miyazaki S., 1997, B GEOGR SURV I, V43, P23; Mogi K., 1969, B EARTHQ RES I TOKYO, V47, P419; MURAKAMI M, IN PRESS GEOPHYS RES; *NAT ASTR OBS, 2000, CHRON SCI TABL, P74; Ohtake M, 1999, PURE APPL GEOPHYS, V155, P689, DOI 10.1007/s000240050283; OMORI F, 1902, PUB EARTHQ INV COMM, V8, P1; Sillard P, 1998, GEOPHYS RES LETT, V25, P3223, DOI 10.1029/98GL52489; Stein RS, 1999, NATURE, V402, P605, DOI 10.1038/45144; TSUJI H, 1995, GEOPHYS RES LETT, V22, P1669, DOI 10.1029/95GL01659; van Dam T, 2001, GEOPHYS RES LETT, V28, P651, DOI 10.1029/2000GL012120; YAMAYA M, 2000, TOHOKU J NATURAL DIS, V36, P171	18	103	107	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 6	2001	293	5527					89	92		10.1126/science.1061056	http://dx.doi.org/10.1126/science.1061056			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	451BB	11441179				2022-12-28	WOS:000169780300034
J	Albert, MA; Danielson, E; Rifai, N; Ridker, PM				Albert, MA; Danielson, E; Rifai, N; Ridker, PM		PRINCE Investigators	Effect of statin therapy on C-reactive protein levels - The Pravastatin Inflammation/CRP Evaluation (PRINCE): A randomized trial and cohort study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HMG-COA REDUCTASE; CORONARY HEART-DISEASE; AVERAGE CHOLESTEROL LEVELS; CARDIOVASCULAR-DISEASE; MYOCARDIAL-INFARCTION; PLASMA-CONCENTRATION; ATHEROSCLEROSIS; HYPERCHOLESTEROLEMIA; EXPRESSION; PREVENTION	Context Plasma levels of the inflammatory biomarker C-reactive protein (CRP) predict cardiovascular risk, and retrospective studies suggest that 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (stations) may lower CRP in a manner largely independent of low-density lipoprotein cholesterol (LDL-C). However, prospective trial data directly evaluating this anti-inflammatory effect of statins are not available. Objective to test the hypothesis that pravastation has anti-inflammatory effects as evidenced by CRP reduction. Design, Setting, and Participants Community-based, prospective, randomized, double-blind trial including 1702 men and women with no prior history of cardiovascular disease (primary prevention cohort) and open-label study including 1182 patients with known cardiovascular disease (secondary prevention cohort) who provided at least baseline and 12-week blood samples. The study was conducted in US office-based practices from February to December 2000. Interventions Participants in the double-blind primary prevention trial were randomly assigned to receive 40 mg/d of pravastatin (n=865) or placebo (n=837) for 24 weeks. Participants in the secondary prevention cohort received 40 mg/d of open-label pravastatin for 24 weeks. Main Outcome Measure Change in CRP levels from baseline to 24 weeks. Results In the primary prevention trial, compared with placebo, pravastatin reduced median CRP levels by 16.9% (P<.001) at 24 weeks, reflecting a decrease of 0.02 mg/dL in the pravastatin group while no change in CRP levels was observed in the placebo group. This effect was seen as early as 12 weeks (median reduction in CRP with pravastatin, 14.7%; P<.001) and was present among all prespecified subgroups according to sex, age, smoking status, body mass index, baseline lipid levels. presence of diabetes, and use of aspirin or hormone replacement therapy. No significant association was observed between baseline CRP and baseline LDL-C levels, end-of-study CRP and end-of-study LDL-C levels, or change in CRP and change in LDL-C over time. In linear regression analyses, the only significant predictors of change in CRP on a log scale were randomized pravastatin allocation and baseline CRP levels (P<.001 for both). Similar reductions in CRP levels were observed at 12 weeks (-14.3%) and 24 weeks (-13.1%) in the secondary prevention cohort treated with pravastatin (P<.005 for both). Conclusions In this prospective trial, pravastatin reduced CRP levels at both 12 and 24 weeks in a largely LDL-C-independent manner. These data provide evidence that statin may have anti-inflammatory effects in additions to lipid-lowering effects.	Brigham & Womens Hosp, Ctr Cardiovasc Dis Prevent, Div Cardiol, Boston, MA 02215 USA; Brigham & Womens Hosp, Ctr Cardiovasc Dis Prevent, Div Prevent Med, Boston, MA 02215 USA; Childrens Hosp, Med Ctr, Dept Lab Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Leducq Ctr Cardiovasc Res, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School	Ridker, PM (corresponding author), Brigham & Womens Hosp, Ctr Cardiovasc Dis Prevent, Div Cardiol, 900 Commonwealth Ave E, Boston, MA 02215 USA.			Patt, Mitchell/0000-0001-9696-4477				Aikawa M, 2001, CIRCULATION, V103, P276; Albert MA, 2001, AM HEART J, V141, P893, DOI 10.1067/mhj.2001.115297; Bellosta S, 1998, ARTERIOSCL THROM VAS, V18, P1671, DOI 10.1161/01.ATV.18.11.1671; Bustos C, 1998, J AM COLL CARDIOL, V32, P2057, DOI 10.1016/S0735-1097(98)00487-2; Byington RP, 2001, CIRCULATION, V103, P387; Crisby M, 2001, CIRCULATION, V103, P926, DOI 10.1161/01.cir.103.7.926; Cushman M, 1999, CIRCULATION, V100, P717, DOI 10.1161/01.CIR.100.7.717; Danesh J, 2000, BMJ-BRIT MED J, V321, P199, DOI 10.1136/bmj.321.7255.199; Ferro D, 2000, J AM COLL CARDIOL, V36, P427, DOI 10.1016/S0735-1097(00)00771-3; Freeman DJ, 2001, CIRCULATION, V103, P357; Fukumoto Y, 2001, CIRCULATION, V103, P993; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; Kennon S, 2001, J AM COLL CARDIOL, V37, P1266, DOI 10.1016/S0735-1097(01)01130-5; Niwa S, 1996, INT J IMMUNOPHARMACO, V18, P669, DOI 10.1016/S0192-0561(96)00068-9; Ridker PM, 2001, CIRCULATION, V103, P1191; Ridker PM, 1999, CIRCULATION, V100, P713, DOI 10.1161/01.CIR.100.7.713; Ridker PM, 2001, CIRCULATION, V103, P1813, DOI 10.1161/01.CIR.103.13.1813; Ridker PM, 1998, CIRCULATION, V98, P839, DOI 10.1161/01.CIR.98.9.839; Ridker PM, 1999, CIRCULATION, V100, P230, DOI 10.1161/01.CIR.100.3.230; Ridker PM, 1997, NEW ENGL J MED, V336, P973, DOI 10.1056/NEJM199704033361401; Ridker PM, 2001, JAMA-J AM MED ASSOC, V285, P2481, DOI 10.1001/jama.285.19.2481; Ridker PM, 2000, NEW ENGL J MED, V342, P836, DOI 10.1056/NEJM200003233421202; RIDKER PM, IN PRESS N ENGL J ME; Roberts WL, 2001, CLIN CHEM, V47, P418; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; Shiomi M, 1999, BRIT J PHARMACOL, V126, P961, DOI 10.1038/sj.bjp.0702382; Tonkin A, 1998, NEW ENGL J MED, V339, P1349; Williams JK, 1998, J AM COLL CARDIOL, V31, P684, DOI 10.1016/S0735-1097(97)00537-8	30	1284	1375	0	51	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 4	2001	286	1					64	70		10.1001/jama.286.1.64	http://dx.doi.org/10.1001/jama.286.1.64			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	449GR	11434828				2022-12-28	WOS:000169676400024
J	Yee, AMF; Pochapin, MB				Yee, AMF; Pochapin, MB			Treatment of complicated sarcoidosis with infliximab anti-tumor necrosis factor-alpha therapy	ANNALS OF INTERNAL MEDICINE			English	Article							PROTEIN-LOSING ENTEROPATHY; PULMONARY SARCOIDOSIS; ALVEOLAR MACROPHAGES; MUSCLE INVOLVEMENT; INTERFERON-GAMMA; CELLS; MANIFESTATIONS; INDUCTION; MYOSITIS; RELEASE	Background: Tumor necrosis factor-alpha (TNF-alpha) may have an important role in the clinical exacerbation of sarcoidosis. Objective: To treat sarcoidosis with infliximab, a chimeric human-murine anti-human TNF-alpha monoclonal antibody. Design: Case report. Setting: U.S. academic medical center. Patient: A 72-year-old woman with sarcoidosis presenting with severe protein-losing enteropathy, hypoalbuminemia, and proximal myopathy who had not responded adequately to corticosteroid therapy and whose clinical course was further complicated by acute tubular necrosis and renal failure requiring long-term hemodialysis. Intervention: Intravenous infusion of infliximab, 5 mg/kg of ideal body weight; infusion was repeated at 2 and 6 weeks. Measurements: Clinical response of enteropathic and myopathic symptoms and serum albumin level. Results: Enteropathic and myopathic symptoms resolved after infliximab therapy, and the serum albumin level also improved. However, the clinical course was complicated by the development of a hypercoagulable state associated with circulating anticardiolipin antibodies, which prompted discontinuation of infliximab therapy. Conclusions: Infliximab therapy was successful in a patient with sarcoidosis. Tumor necrosis factor-a may be an important mediator of clinical disease in sarcoidosis and could be an attractive target for therapeutic intervention. However, infliximab may cause adverse effects associated with cytokine cascade manipulation.	Cornell Univ, Weill Med Coll, Hosp Special Surg, Div Rheumat Dis, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, New York Presbyterian Hosp, Div Digest Dis, New York, NY 10021 USA	Cornell University; Cornell University; NewYork-Presbyterian Hospital	Yee, AMF (corresponding author), Cornell Univ, Weill Med Coll, Hosp Special Surg, Div Rheumat Dis, 535 E 70th St, New York, NY 10021 USA.			Pochapin, Mark/0000-0001-5564-0441				BAUGHMAN RP, 1990, J LAB CLIN MED, V115, P36; DRENICK EJ, 1976, JAMA-J AM MED ASSOC, V236, P269, DOI 10.1001/jama.236.3.269; INA Y, 1994, CHEST, V105, P1179, DOI 10.1378/chest.105.4.1179; Ioannou Y, 2000, ARTHRITIS RHEUM-US, V43, P1431, DOI 10.1002/1529-0131(200007)43:7<1431::AID-ANR3>3.0.CO;2-E; KALOVIDOURIS AE, 1995, J RHEUMATOL, V22, P1698; Kassiotis G, 2001, J EXP MED, V193, P427, DOI 10.1084/jem.193.4.427; LINDGREN A, 1995, EUR J GASTROEN HEPAT, V7, P1005, DOI 10.1097/00042737-199510000-00019; Muller-Quernheim J, 1998, EUR RESPIR J, V12, P716, DOI 10.1183/09031936.98.12030716; MULLERQUERNHEIM J, 1992, AM REV RESPIR DIS, V145, P187; OST D, 1995, CHEST, V107, P879, DOI 10.1378/chest.107.3.879; POPOVIC OS, 1980, GASTROENTEROLOGY, V78, P119; ROSS CB, 1989, BAILLIERE CLIN RHEUM, V3, P339, DOI 10.1016/S0950-3579(89)80025-1; Satti SD, 1999, VASC MED, V4, P37; SILVERSTEIN A, 1969, ARCH NEUROL-CHICAGO, V21, P235, DOI 10.1001/archneur.1969.00480150025002; SWIDER C, 1995, CLIN EXP IMMUNOL, V100, P401; Vander Els NJ, 2000, CHEST, V117, P294, DOI 10.1378/chest.117.1.294; WALLAERT B, 1992, AM REV RESPIR DIS, V145, P1440, DOI 10.1164/ajrccm/145.6.1440; ZHENG LX, 1995, NATURE, V377, P348, DOI 10.1038/377348a0; Zhou T, 1996, J IMMUNOL, V156, P2661; Ziegenhagen MW, 1997, AM J RESP CRIT CARE, V156, P1586, DOI 10.1164/ajrccm.156.5.97-02050	20	178	178	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 3	2001	135	1					27	31		10.7326/0003-4819-135-1-200107030-00010	http://dx.doi.org/10.7326/0003-4819-135-1-200107030-00010			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	449JC	11434729				2022-12-28	WOS:000169680500004
J	Devine, JF; McCarter, TG				Devine, JF; McCarter, TG			Tension pneumoperitoneum	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Evangel Community Hosp, Lewisburg, PA 17837 USA; Tenet Hlth Syst, Philadelphia, PA 19146 USA		Devine, JF (corresponding author), Evangel Community Hosp, Lewisburg, PA 17837 USA.								0	5	5	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 28	2001	344	26					1985	1985		10.1056/NEJM200106283442605	http://dx.doi.org/10.1056/NEJM200106283442605			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	446HQ	11430328				2022-12-28	WOS:000169508200005
J	Goldie, SJ; Kuhn, L; Denny, L; Pollack, A; Wright, TC				Goldie, SJ; Kuhn, L; Denny, L; Pollack, A; Wright, TC			Policy analysis of cervical cancer screening strategies in low-resource settings - Clinical benefits and cost-effectiveness	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-PAPILLOMAVIRUS INFECTION; SQUAMOUS INTRAEPITHELIAL LESIONS; HUMAN-IMMUNODEFICIENCY-VIRUS; NATURAL-HISTORY; HIGH-RISK; HIV-INFECTION; SOUTH-AFRICA; DEVELOPING-COUNTRIES; VISUAL INSPECTION; UTERINE CERVIX	Context Cervical cancer is a leading cause of cancer-related death among women in developing countries. In such low-resource settings, cytology-based screening is difficult to implement, and less complex strategies may offer additional options. Objective To assess the cost-effectiveness of several cervical cancer screening strategies using population-specific data. Design and Setting Cost-effectiveness analysis using a mathematical model and a hypothetical cohort of previously unscreened 30-year-old black South African women. Screening tests included direct visual inspection (DVI) of the cervix, cytologic methods, and testing for high-risk types of human papillomavirus (HPV) DNA, Strategies differed by number of clinical visits, screening frequency, and response to a positive test result. Data sources included a South African screening study, national surveys and fee schedules, and published literature. Main Outcome Measures Years of life saved (YLS), lifetime costs in US dollars, and incremental cost-effectiveness ratios (cost per YLS). Results When analyzing all strategies performed as a single lifetime screen at age 35 years compared with no screening, HPV testing followed by treatment of screen-positive women at a second visit, cost $39/YLS (27% cancer incidence reduction); DVI, coupled with immediate treatment of screen-positive women at the first visit was next most effective (26% cancer incidence reduction) and was cost saving; cytology, followed by treatment of screen-positive women at a second visit was least effective (19% cancer incidence reduction) at a cost of $81/YLS, For any given screening frequency, when strategies were compared incrementally, HPV DNA testing generally was more effective but also more costly than DVI, and always was more effective and less costly than cytology. When comparing all strategies simultaneously across screening frequencies, DVI was the nondominated strategy up to a frequency of every 3 years (incremental cost-effectiveness ratio, $460/YLS), and HPV testing every 3 years (incremental cost-effectiveness ratio, $11 500/YLS) was the most effective strategy. Conclusion Cervical cancer screening strategies that incorporate DVI or HPV DNA testing and eliminate colposcopy may offer attractive alternatives to cytology-based screening programs in low-resource settings.	Harvard Univ, Sch Publ Hlth, Ctr Risk Anal, Dept Hlth Policy & Management, Boston, MA 02115 USA; Univ Cape Town, Dept Obstet & Gynecol, ZA-7925 Cape Town, South Africa; Columbia Univ, Joseph L Mailman Sch Publ Hlth, Div Epidemiol, New York, NY USA; Columbia Univ, Coll Phys & Surg, Gertrude H Sergievsky Ctr, New York, NY USA; EngenderHlth, New York, NY USA; Columbia Univ, Coll Phys & Surg, Dept Pathol, New York, NY USA	Harvard University; Harvard T.H. Chan School of Public Health; University of Cape Town; Columbia University; Columbia University; Columbia University	Goldie, SJ (corresponding author), Harvard Univ, Sch Publ Hlth, Ctr Risk Anal, Dept Hlth Policy & Management, 718 Huntington Ave,Suite 2, Boston, MA 02115 USA.							ANDERSEN ES, 1992, GYNECOL ONCOL, V45, P240, DOI 10.1016/0090-8258(92)90297-V; [Anonymous], 1997, CONFR AIDS PUBL PRIO; Bailie RS, 1996, INT J EPIDEMIOL, V25, P488, DOI 10.1093/ije/25.3.488; BALLEGOOLJEN M, 1992, EUR J CANCER, V28, P1703; *CENTR STAT SERV, 1997, S AFR LIV STAND DEV; *CENTR STAT SERV, 1997, 1994 HOUS SURV; *CENTR STAT SERV, 1997, CONS PRIC IND; Clavel C, 1999, BRIT J CANCER, V80, P1306, DOI 10.1038/sj.bjc.6690523; CREASMAN WT, 1984, OBSTET GYNECOL, V63, P145; Cuzick J, 1999, BRIT J CANCER, V81, P554, DOI 10.1038/sj.bjc.6690730; CUZICK J, 1999, HEALTH TECHNOL ASSES, V3, P1; Denny L, 2000, AM J OBSTET GYNECOL, V183, P383, DOI 10.1067/mob.2000.105871; Denny L, 2000, CANCER-AM CANCER SOC, V89, P826, DOI 10.1002/1097-0142(20000815)89:4&lt;826::AID-CNCR15&gt;3.0.CO;2-5; DENNY L, 2000, THESIS U CAPE TOWN; DORRINGTON R, 1999, ESTIMATES LEVEL SHAP; Ellerbrock TV, 2000, JAMA-J AM MED ASSOC, V283, P1031, DOI 10.1001/jama.283.8.1031; Enger C, 1996, JAMA-J AM MED ASSOC, V275, P1329, DOI 10.1001/jama.275.17.1329; FAHEY MT, 1995, AM J EPIDEMIOL, V141, P680, DOI 10.1093/oxfordjournals.aje.a117485; Freedberg KA, 1998, JAMA-J AM MED ASSOC, V279, P130, DOI 10.1001/jama.279.2.130; Gaffikin L, 1999, LANCET, V353, P869; Gilson L, 1997, LANCET, V350, P1805, DOI 10.1016/S0140-6736(97)08222-6; Gold MR, 1996, COST EFFECTIVENESS H; Goldie SJ, 1999, ANN INTERN MED, V130, P97, DOI 10.7326/0003-4819-130-2-199901190-00003; Grant A D, 1997, AIDS, V11 Suppl B, pS43; Harper DM, 1999, J FAM PRACTICE, V48, P531; Herrero R, 2000, JNCI-J NATL CANCER I, V92, P464, DOI 10.1093/jnci/92.6.464; HILDESHEIM A, 1994, J INFECT DIS, V169, P235, DOI 10.1093/infdis/169.2.235; Hillemanns P, 1999, LANCET, V354, P1970, DOI 10.1016/S0140-6736(99)04110-0; HO GYF, 1995, JNCI-J NATL CANCER I, V87, P1365, DOI 10.1093/jnci/87.18.1365; Ho GYF, 1998, NEW ENGL J MED, V338, P423, DOI 10.1056/NEJM199802123380703; Holowaty P, 1999, JNCI-J NATL CANCER I, V91, P252, DOI 10.1093/jnci/91.3.252; *INT AG RES CANC, 1995, IARC MON EV CARC RIS, V64; Jenkins D, 1996, INT J CANCER, V65, P768; Kitchener HC, 1999, LANCET, V353, P856, DOI 10.1016/S0140-6736(98)00417-6; KOUTSKY LA, 1992, NEW ENGL J MED, V327, P1272, DOI 10.1056/NEJM199210293271804; Kuhn L, 2000, JNCI-J NATL CANCER I, V92, P818, DOI 10.1093/jnci/92.10.818; Londesborough P, 1996, INT J CANCER, V69, P364; LONGINI IM, 1989, STAT MED, V8, P831, DOI 10.1002/sim.4780080708; LOPEZ A, 2001, LIFETABLES 191 COUNT; Mandelblatt JS, 1997, J GEN INTERN MED, V12, P551, DOI 10.1046/j.1525-1497.1997.07107.x; MATHERS C, 2001, 16 WHO GLOB PROGR EV; MCCRORY D, 1999, AHCPR PUB; *MED ASS S AFR, 1999, 1999 GUID FEES MED S; Mitchell MF, 1998, OBSTET GYNECOL, V92, P737, DOI 10.1097/00006250-199811000-00001; Moscicki AB, 1998, J PEDIATR-US, V132, P277, DOI 10.1016/S0022-3476(98)70445-7; Myers ER, 2000, AM J EPIDEMIOL, V151, P1158, DOI 10.1093/oxfordjournals.aje.a010166; Nanda K, 2000, ANN INTERN MED, V132, P810, DOI 10.7326/0003-4819-132-10-200005160-00009; Nene BM, 1996, INT J CANCER, V68, P770, DOI 10.1002/(SICI)1097-0215(19961211)68:6<770::AID-IJC14>3.0.CO;2-4; Nobbenhuis MAE, 1999, LANCET, V354, P20, DOI 10.1016/S0140-6736(98)12490-X; OLATUNBOSUN OA, 1992, INT J GYNECOL OBSTET, V38, P305, DOI 10.1016/0020-7292(92)91023-H; OSTOR AG, 1993, INT J GYNECOL PATHOL, V12, P186; Palefsky JM, 1999, JNCI-J NATL CANCER I, V91, P226, DOI 10.1093/jnci/91.3.226; Parkin DM, 1999, INT J CANCER, V80, P827, DOI 10.1002/(SICI)1097-0215(19990315)80:6&lt;827::AID-IJC6&gt;3.0.CO;2-P; Parkin DM, 1999, AIDS, V13, P2563, DOI 10.1097/00002030-199912240-00010; Pecorelli S, 1999, INT J GYNECOL OBSTET, V65, P243, DOI 10.1016/S0020-7292(99)00070-3; Peters DH, 2000, B WORLD HEALTH ORGAN, V78, P761; PETTERSSON F, 1985, INT J EPIDEMIOL, V14, P521, DOI 10.1093/ije/14.4.521; Pisani P, 1999, INT J CANCER, V83, P18, DOI 10.1002/(SICI)1097-0215(19990924)83:1&lt;18::AID-IJC5&gt;3.0.CO;2-M; PONTEN J, 1995, INT J CANCER, V60, P1, DOI 10.1002/ijc.2910600102; REMMINK AJ, 1995, INT J CANCER, V61, P306, DOI 10.1002/ijc.2910610305; ROGO KO, 1990, INT J GYNECOL OBSTET, V33, P249, DOI 10.1016/0020-7292(90)90010-I; Rozendaal L, 1996, INT J CANCER, V68, P766, DOI 10.1002/(SICI)1097-0215(19961211)68:6<766::AID-IJC13>3.0.CO;2-Z; Sankaranarayanan R, 1998, IARC Sci Publ, P135; Sankaranarayanan R, 1998, CANCER-AM CANCER SOC, V83, P2150, DOI 10.1002/(SICI)1097-0142(19981115)83:10<2150::AID-CNCR13>3.3.CO;2-S; SCHIFFMAN M, 2000, JAMA-J AM MED ASSOC, V28, P2525; Sellors JW, 2000, CAN MED ASSOC J, V163, P513; Serwadda D, 1999, J INFECT DIS, V180, P1316, DOI 10.1086/315026; SherlawJohnson C, 1997, INT J CANCER, V72, P210, DOI 10.1002/(SICI)1097-0215(19970717)72:2&lt;210::AID-IJC2&gt;3.0.CO;2-U; Sitas F, 1997, BRIT J CANCER, V75, P1704, DOI 10.1038/bjc.1997.290; SITAS F, 1994, S AFR MED J, V84, P344; SOLOMON D, 1989, JAMA-J AM MED ASSOC, V262, P931; Sun XW, 1997, NEW ENGL J MED, V337, P1343, DOI 10.1056/NEJM199711063371903; SYRJANEN K, 1992, OBSTET GYNECOL, V79, P675; *U CAP TOWN, 1993, COST COMP STUD SEV M; *US DHHS, 2001, CANC STAT REV; Wallin KL, 1999, NEW ENGL J MED, V341, P1633, DOI 10.1056/NEJM199911253412201; Womack SD, 2000, INT J CANCER, V85, P206, DOI 10.1002/(SICI)1097-0215(20000115)85:2%3C206::AID-; *WORLD BANK AIDS E, 2000, PUBL PRIOR GLOB EP C; Wright TC, 2000, JAMA-J AM MED ASSOC, V283, P81, DOI 10.1001/jama.283.1.81	79	229	242	0	19	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 27	2001	285	24					3107	3115		10.1001/jama.285.24.3107	http://dx.doi.org/10.1001/jama.285.24.3107			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	444FF	11427139	Bronze			2022-12-28	WOS:000169388900024
J	Galarreta, M; Hestrin, S				Galarreta, M; Hestrin, S			Spike transmission and synchrony detection in networks of GABAergic interneurons	SCIENCE			English	Article							CAT VISUAL-CORTEX; LAYER-V NEURONS; SOMATOSENSORY CORTEX; PYRAMIDAL NEURONS; NEOCORTICAL NEURONS; PRINCIPAL NEURONS; CORTICAL-NEURONS; RAT HIPPOCAMPUS; SYNAPSES; RECEPTORS	The temporal pattern and relative timing of action potentials among neocortical neurons may carry important information. However, how cortical circuits detect or generate coherent activity remains unclear. Using paired recordings in rat neocortical slices, we found that the firing of fast-spiking cells can reflect the spiking pattern of single-axon pyramidal inputs. Moreover, this property allowed groups of fast-spiking cells interconnected by electrical and gamma -aminobutyric acid (GABA)-releasing (GABAergic) synapses to detect the relative timing of their excitatory inputs. These results indicate that networks of fast-spiking cells may play a role in the detection and promotion of synchronous activity within the neocortex.	Stanford Univ, Sch Med, Dept Comparat Med, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Neurol & Neurol Sci, Stanford, CA 94305 USA	Stanford University; Stanford University	Galarreta, M (corresponding author), Stanford Univ, Sch Med, Dept Comparat Med, Stanford, CA 94305 USA.		Hestrin, Shaul/F-4410-2010		NEI NIH HHS [EY09120, EY12114] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY009120, R01EY012114] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Angulo MC, 1999, J NEUROPHYSIOL, V82, P1295, DOI 10.1152/jn.1999.82.3.1295; Azouz R, 2000, P NATL ACAD SCI USA, V97, P8110, DOI 10.1073/pnas.130200797; Buhl EH, 1997, J PHYSIOL-LONDON, V500, P689, DOI 10.1113/jphysiol.1997.sp022053; BUZSAKI G, 1995, CURR OPIN NEUROBIOL, V5, P504, DOI 10.1016/0959-4388(95)80012-3; Chow A, 1999, J NEUROSCI, V19, P9332; COPE TC, 1987, J PHYSIOL-LONDON, V390, P161, DOI 10.1113/jphysiol.1987.sp016692; Csicsvari J, 1998, NEURON, V21, P179, DOI 10.1016/S0896-6273(00)80525-5; Fricker D, 2000, NEURON, V28, P559, DOI 10.1016/S0896-6273(00)00133-1; Galarreta M, 1998, NAT NEUROSCI, V1, P587, DOI 10.1038/2822; Galarreta M, 1999, NATURE, V402, P72, DOI 10.1038/47029; Geiger JRP, 1997, NEURON, V18, P1009, DOI 10.1016/S0896-6273(00)80339-6; GEIGER JRP, 1995, NEURON, V15, P193, DOI 10.1016/0896-6273(95)90076-4; Gibson JR, 1999, NATURE, V402, P75, DOI 10.1038/47035; GRAY CM, 1989, P NATL ACAD SCI USA, V86, P1698, DOI 10.1073/pnas.86.5.1698; Gupta A, 2000, SCIENCE, V287, P273, DOI 10.1126/science.287.5451.273; Jefferys JGR, 1996, TRENDS NEUROSCI, V19, P202, DOI 10.1016/S0166-2236(96)10023-0; Jones MS, 2000, J NEUROPHYSIOL, V84, P1505, DOI 10.1152/jn.2000.84.3.1505; Kawaguchi Y, 1997, CEREB CORTEX, V7, P476, DOI 10.1093/cercor/7.6.476; Lambolez B, 1996, P NATL ACAD SCI USA, V93, P1797, DOI 10.1073/pnas.93.5.1797; MAINEN ZF, 1995, SCIENCE, V268, P1503, DOI 10.1126/science.7770778; Martina M, 1997, J PHYSIOL-LONDON, V505, P593, DOI 10.1111/j.1469-7793.1997.593ba.x; Martina M, 1998, J NEUROSCI, V18, P8111; Martina M, 2000, SCIENCE, V287, P295, DOI 10.1126/science.287.5451.295; MILES R, 1990, J PHYSIOL-LONDON, V428, P61, DOI 10.1113/jphysiol.1990.sp018200; Reyes A, 1998, NAT NEUROSCI, V1, P279, DOI 10.1038/1092; Shadlen MN, 1998, J NEUROSCI, V18, P3870; Singer W, 1999, NEURON, V24, P49, DOI 10.1016/S0896-6273(00)80821-1; STAFSTROM CE, 1984, J NEUROPHYSIOL, V52, P244, DOI 10.1152/jn.1984.52.2.244; STAFSTROM CE, 1985, J NEUROPHYSIOL, V53, P153, DOI 10.1152/jn.1985.53.1.153; Steinmetz PN, 2000, NATURE, V404, P187, DOI 10.1038/35004588; STUART G, 1995, NEURON, V15, P1065, DOI 10.1016/0896-6273(95)90095-0; Swadlow HA, 1998, J NEUROPHYSIOL, V79, P567, DOI 10.1152/jn.1998.79.2.567; Tamas G, 2000, NAT NEUROSCI, V3, P366, DOI 10.1038/73936; Tamas G, 1997, J PHYSIOL-LONDON, V500, P715, DOI 10.1113/jphysiol.1997.sp022054; Tamas G, 1998, J NEUROSCI, V18, P4255; THOMSON AM, 1988, J NEUROPHYSIOL, V60, P1896, DOI 10.1152/jn.1988.60.6.1896; Thomson AM, 1996, J PHYSIOL-LONDON, V496, P81, DOI 10.1113/jphysiol.1996.sp021667; Timofeev I, 2001, P NATL ACAD SCI USA, V98, P1924, DOI 10.1073/pnas.041430398; VAADIA E, 1995, NATURE, V373, P515, DOI 10.1038/373515a0; Venance L, 2000, P NATL ACAD SCI USA, V97, P10260, DOI 10.1073/pnas.160037097	40	287	290	1	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 22	2001	292	5525					2295	2299		10.1126/science.1061395	http://dx.doi.org/10.1126/science.1061395			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	445KD	11423653				2022-12-28	WOS:000169455900047
J	Hampe, J; Cuthbert, A; Croucher, PJP; Mirza, MM; Mascheretti, S; Fisher, S; Frenzel, H; King, K; Hasselmeyer, A; MacPherson, AJS; Bridger, S; van Deventer, S; Forbes, A; Nikolaus, S; Lennard-Jones, JE; Foelsch, UR; Krawczak, M; Lewis, C; Schreiber, S; Mathew, CG				Hampe, J; Cuthbert, A; Croucher, PJP; Mirza, MM; Mascheretti, S; Fisher, S; Frenzel, H; King, K; Hasselmeyer, A; MacPherson, AJS; Bridger, S; van Deventer, S; Forbes, A; Nikolaus, S; Lennard-Jones, JE; Foelsch, UR; Krawczak, M; Lewis, C; Schreiber, S; Mathew, CG			Association between insertion mutation in NOD2 gene and Crohn's disease in German and British populations	LANCET			English	Article							INFLAMMATORY-BOWEL-DISEASE; LARGE EUROPEAN COHORT; FACTOR KAPPA-B; SUPPORTS LINKAGE; CHROMOSOME-16; ACTIVATION; FAMILIES; COLITIS; LOCUS; CELLS	Background Genetic predisposition to inflammatory bowel disease (IBD) has been shown by epidemiological and linkage studies. Genetic linkage of IBD to chromosome 16 has been previously observed and replicated in independent populations. The recently identified NOD2 gene is a good positional and functional candidate gene since it is located in the region of linkage on chromosome 16q12, and activates nuclear factor (NF) KB in response to bacterial lipopolysaccharides. Methods We sequenced the coding region of the NOD2 gene and genotyped an insertion polymorphism affecting the leucine-rich region of the protein product in 512 individuals with IBD from 309 German or British families, 369 German trios (ie, German patients with sporadic IBD and their unaffected parents), and 272 normal controls. We then tested for association with Crohn's disease and ulcerative colitis. Findings Family-based association analyses were consistently positive in 95 British and 99 German affected sibling pairs with Crohn's disease (combined p<0.0001); the association was confirmed in the 304 German trios with Crohn's disease. No association was seen in the 115 sibling pairs and 65 trios with ulcerative colitis. The genotype-specific disease risks conferred by heterozygous and homozygous mutant genotypes were 2.6 (95% CI 1.5-4.5)and 42.1(4.3-<infinity>), respectively. Interpretation The insertion mutation in the NOD2 gene confers a substantially increased susceptibility to Crohn's disease but not to ulcerative colitis.	Univ Kiel, Dept Gen Internal Med, Kiel, Germany; Guys Kings & St Thomas Sch Med, Div Med & Mol Genet, London, England; Guys Kings & St Thomas Sch Med, Div Med, London, England; AMC Amsterdam, Dept Gastroenterol, Amsterdam, Netherlands; St Marks Hosp, Harrow, Middx, England; Cardiff Univ, Inst Med Genet, Cardiff CF4 4XN, S Glam, Wales	University of Kiel; University of London; King's College London; University of London; King's College London; University of Amsterdam; Academic Medical Center Amsterdam; Imperial College London; Cardiff University	Schreiber, S (corresponding author), Univ Kiel, Dept Med 1, Schittenhelmstr 12, D-24105 Kiel, Germany.	S.Schreiber@mucosa.de	Mathew, Christopher G/G-3434-2015; Lewis, Cathryn M/A-5225-2010; Lewis, Cathryn/M-8766-2019; Hampe, Jochen/A-2555-2010; Krawczak, Michael/A-8964-2010	Mathew, Christopher G/0000-0003-4178-1838; Lewis, Cathryn M/0000-0002-8249-8476; Lewis, Cathryn/0000-0002-8249-8476; Hampe, Jochen/0000-0002-2421-6127; Krawczak, Michael/0000-0003-2603-1502; Forbes, Alastair/0000-0001-7416-9843	MRC [G9800001] Funding Source: UKRI; Medical Research Council [G9800001] Funding Source: Medline	MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		Annese V, 1999, EUR J HUM GENET, V7, P567, DOI 10.1038/sj.ejhg.5200328; Brant SR, 1998, GASTROENTEROLOGY, V115, P1056, DOI 10.1016/S0016-5085(98)70073-3; Cavanaugh J, 2001, AM J HUM GENET, V68, P1165, DOI 10.1086/320119; Clayton D, 1999, AM J HUM GENET, V65, P1170, DOI 10.1086/302577; Clayton D, 1999, AM J HUM GENET, V65, P1161, DOI 10.1086/302566; Curran ME, 1998, GASTROENTEROLOGY, V115, P1066, DOI 10.1016/S0016-5085(98)70075-7; Fleiss J. L., 1981, STAT METHODS RATES P, V2; Hampe J, 1999, AM J HUM GENET, V64, P808, DOI 10.1086/302294; Hampe J, 1998, INT J COLORECTAL DIS, V13, P260, DOI 10.1007/s003840050173; HAMPE J, IN PRESS BIOINFORMAT; HENNEKENS CH, 1987, EPIDEMIOLOGY MED, P77; Hugot JP, 2001, NATURE, V411, P599, DOI 10.1038/35079107; Hugot JP, 1996, NATURE, V379, P821, DOI 10.1038/379821a0; Inohara N, 2000, J BIOL CHEM, V275, P27823; INOHARA N, 2000, J BIOL CHEM, V31, P31; LENNARDJONES JE, 1989, SCAND J GASTROENTERO, V24, P2, DOI 10.3109/00365528909091339; Neurath MF, 1996, NAT MED, V2, P998, DOI 10.1038/nm0996-998; Nikolaus S, 2000, LANCET, V356, P1475, DOI 10.1016/S0140-6736(00)02871-3; Ogura Y, 2001, NATURE, V411, P603, DOI 10.1038/35079114; Ogura Y, 2001, J BIOL CHEM, V276, P4812, DOI 10.1074/jbc.M008072200; Olavesen MG, 2000, IMMUNOGENETICS, V51, P1, DOI 10.1007/s002510050001; ORHOLM M, 1991, NEW ENGL J MED, V324, P84, DOI 10.1056/NEJM199101103240203; Rogler G, 1998, GASTROENTEROLOGY, V115, P357, DOI 10.1016/S0016-5085(98)70202-1; Schreiber S, 1998, GUT, V42, P477, DOI 10.1136/gut.42.4.477; SCHREIBER S, 1991, GASTROENTEROLOGY, V101, P1020, DOI 10.1016/0016-5085(91)90729-5; Shivananda S, 1996, GUT, V39, P690, DOI 10.1136/gut.39.5.690; Targan SR, 1997, NEW ENGL J MED, V337, P1029, DOI 10.1056/NEJM199710093371502; Thompson NP, 1996, BRIT MED J, V312, P95; TRUELOVE SC, 1976, GUT, V17, P192, DOI 10.1136/gut.17.3.192; TYSK C, 1988, GUT, V29, P990, DOI 10.1136/gut.29.7.990	30	905	947	2	30	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 16	2001	357	9272					1925	1928		10.1016/S0140-6736(00)05063-7	http://dx.doi.org/10.1016/S0140-6736(00)05063-7			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	444YZ	11425413				2022-12-28	WOS:000169431000011
J	van Heel, DA; McGovern, DPB; Jewell, DP				van Heel, DA; McGovern, DPB; Jewell, DP			Crohn's disease: genetic susceptibility, bacteria, and innate immunity	LANCET			English	Editorial Material							KAPPA-B		Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England; Univ Oxford, Gastroenterol Unit, Oxford OX3 7BN, England	University of Oxford; Wellcome Centre for Human Genetics; University of Oxford	van Heel, DA (corresponding author), Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England.			van Heel, David/0000-0002-0637-2265				AUPHAN N, 1995, SCIENCE, V270, P286, DOI 10.1126/science.270.5234.286; Cavanaugh J, 2001, AM J HUM GENET, V68, P1165, DOI 10.1086/320119; Hugot JP, 2001, NATURE, V411, P599, DOI 10.1038/35079107; Hugot JP, 1996, NATURE, V379, P821, DOI 10.1038/379821a0; Inohara N, 2001, J BIOL CHEM, V276, P2551, DOI 10.1074/jbc.M009728200; Ogura Y, 2001, NATURE, V411, P603, DOI 10.1038/35079114; Ogura Y, 2001, J BIOL CHEM, V276, P4812, DOI 10.1074/jbc.M008072200; Papadakis KA, 2000, GASTROENTEROLOGY, V119, P1148, DOI 10.1053/gast.2000.18160; Poltorak A, 1998, SCIENCE, V282, P2085, DOI 10.1126/science.282.5396.2085; Schreiber S, 1998, GUT, V42, P477, DOI 10.1136/gut.42.4.477; Zareie M, 2001, AM J PATHOL, V158, P1101, DOI 10.1016/S0002-9440(10)64057-6	11	47	48	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 16	2001	357	9272					1902	1904		10.1016/S0140-6736(00)05091-1	http://dx.doi.org/10.1016/S0140-6736(00)05091-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	444YZ	11425408				2022-12-28	WOS:000169431000006
J	Cantley, LC				Cantley, LC			Transcription - Translocating tubby	SCIENCE			English	Editorial Material							GENE; PROTEINS; MUTATION		Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Beth Israel Deaconess Med Ctr, Div Signal Transduct, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center	Cantley, LC (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA.		Cantley, Lewis C/D-1800-2014	Cantley, Lewis C/0000-0002-1298-7653				Boggon TJ, 1999, SCIENCE, V286, P2119, DOI 10.1126/science.286.5447.2119; Kapeller R, 1999, J BIOL CHEM, V274, P24980, DOI 10.1074/jbc.274.35.24980; Kleyn PW, 1996, CELL, V85, P281, DOI 10.1016/S0092-8674(00)81104-6; NobenTrauth K, 1996, NATURE, V380, P534, DOI 10.1038/380534a0; Odom AR, 2000, SCIENCE, V287, P2026, DOI 10.1126/science.287.5460.2026; Santagata S, 2001, SCIENCE, V292, P2041, DOI 10.1126/science.1061233; Stubdal H, 2000, MOL CELL BIOL, V20, P878, DOI 10.1128/MCB.20.3.878-882.2000; TECOTT LH, 1995, NATURE, V374, P542, DOI 10.1038/374542a0	8	15	16	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 15	2001	292	5524					2019	+		10.1126/science.1062796	http://dx.doi.org/10.1126/science.1062796			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	442KP	11408644				2022-12-28	WOS:000169284700031
J	Cullen, BR				Cullen, BR			Journey to the center of the cell	CELL			English	Review							IMMUNODEFICIENCY-VIRUS TYPE-1; NUCLEAR-PORE COMPLEX; PROTEIN IMPORT; IN-VITRO; TRANSPORT; ENTRY; DNA; INFECTION; PATHWAY		Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Genet, Durham, NC 27710 USA	Duke University; Howard Hughes Medical Institute; Duke University	Cullen, BR (corresponding author), Duke Univ, Med Ctr, Howard Hughes Med Inst, Durham, NC 27710 USA.							Bouyac-Bertoia M, 2001, MOL CELL, V7, P1025, DOI 10.1016/S1097-2765(01)00240-4; Braaten D, 1996, J VIROL, V70, P3551, DOI 10.1128/JVI.70.6.3551-3560.1996; Bui M, 1996, J VIROL, V70, P8391, DOI 10.1128/JVI.70.12.8391-8401.1996; BUKRINSKY MI, 1993, NATURE, V365, P666, DOI 10.1038/365666a0; Greber UF, 1997, EMBO J, V16, P5998, DOI 10.1093/emboj/16.19.5998; Greber UF, 1996, EMBO J, V15, P1766, DOI 10.1002/j.1460-2075.1996.tb00525.x; GREBER UF, 1993, CELL, V75, P477, DOI 10.1016/0092-8674(93)90382-Z; Miller MD, 1997, J VIROL, V71, P5382, DOI 10.1128/JVI.71.7.5382-5390.1997; Nakielny S, 1999, CELL, V99, P677, DOI 10.1016/S0092-8674(00)81666-9; Ojala PM, 2000, MOL CELL BIOL, V20, P4922, DOI 10.1128/MCB.20.13.4922-4931.2000; ONEILL RE, 1995, J BIOL CHEM, V270, P22701, DOI 10.1074/jbc.270.39.22701; PINTO LH, 1992, CELL, V69, P517, DOI 10.1016/0092-8674(92)90452-I; Saphire ACS, 2000, J BIOL CHEM, V275, P4298, DOI 10.1074/jbc.275.6.4298; Sodeik B, 1997, J CELL BIOL, V136, P1007, DOI 10.1083/jcb.136.5.1007; Vodicka MA, 1998, GENE DEV, V12, P175, DOI 10.1101/gad.12.2.175; WEINBERG JB, 1991, J EXP MED, V174, P1477, DOI 10.1084/jem.174.6.1477; Whittaker GR, 2000, ANNU REV CELL DEV BI, V16, P627, DOI 10.1146/annurev.cellbio.16.1.627; Zennou V, 2000, CELL, V101, P173, DOI 10.1016/S0092-8674(00)80828-4; Zhou ZH, 1999, J VIROL, V73, P3210, DOI 10.1128/JVI.73.4.3210-3218.1999	19	66	68	0	7	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTES AVE,, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 15	2001	105	6					697	700		10.1016/S0092-8674(01)00392-0	http://dx.doi.org/10.1016/S0092-8674(01)00392-0			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	444AE	11440710	Bronze			2022-12-28	WOS:000169375100001
J	Tranel, D				Tranel, D			Combs, ducks, and the brain	LANCET			English	Editorial Material							RETRIEVAL; NOUNS; VERBS; SYSTEMS; KNOWLEDGE		Univ Iowa Hosp & Clin, Dept Neurol, Div Behav Neurol & Cognit Neurosci, Iowa City, IA 52242 USA	University of Iowa	Tranel, D (corresponding author), Univ Iowa Hosp & Clin, Dept Neurol, Div Behav Neurol & Cognit Neurosci, Iowa City, IA 52242 USA.			Tranel, Daniel/0000-0002-1338-1389				CARAMAZZA A, 1991, NATURE, V349, P788, DOI 10.1038/349788a0; Caramazza A, 1998, J COGNITIVE NEUROSCI, V10, P1, DOI 10.1162/089892998563752; DAMASIO AR, 1993, P NATL ACAD SCI USA, V90, P4957, DOI 10.1073/pnas.90.11.4957; Damasio H, 2001, NEUROIMAGE, V13, P1053, DOI 10.1006/nimg.2001.0775; Federmeier KD, 2000, BRAIN, V123, P2552, DOI 10.1093/brain/123.12.2552; GOODGLASS H, 1994, NEUROPSYCHOLOGY, V8, P598, DOI DOI 10.1037/0894-4105.8.4.598; HILLIS AE, 1995, J COGNITIVE NEUROSCI, V7, P396, DOI 10.1162/jocn.1995.7.3.396; HUMPHREYS GW, IN PRESS BEHAV BRAIN; James LE, 2000, J EXP PSYCHOL LEARN, V26, P1378, DOI 10.1037//0278-7393.26.6.1378; MCCARTHY R, 1985, NEUROPSYCHOLOGIA, V23, P709, DOI 10.1016/0028-3932(85)90079-X; Pulvermuller F, 1999, CEREB CORTEX, V9, P497, DOI 10.1093/cercor/9.5.497; TRANEL D, 1991, BRAIN COGNITION, V15, P187, DOI 10.1016/0278-2626(91)90025-4; Tranel D, 1997, NEUROPSYCHOLOGIA, V35, P1319, DOI 10.1016/S0028-3932(97)00085-7; TRANEL D, IN PRESS COGN NEUROP; WARRINGTON EK, 1994, NEUROPSYCHOLOGIA, V32, P1465, DOI 10.1016/0028-3932(94)90118-X; ZINGESER LB, 1990, BRAIN LANG, V39, P14, DOI 10.1016/0093-934X(90)90002-X	16	7	7	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 9	2001	357	9271					1818	1819		10.1016/S0140-6736(00)05010-8	http://dx.doi.org/10.1016/S0140-6736(00)05010-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	440DN	11410186				2022-12-28	WOS:000169160800006
J	McPherson, K				McPherson, K			Are disease prevention initiatives working?	LANCET			English	Editorial Material							BREAST-CANCER		Univ London London Sch Hyg & Trop Med, Dept Epidemiol & Populat Hlth, Canc Publ Hlth Unit, London WC1E 7HT, England	University of London; London School of Hygiene & Tropical Medicine	McPherson, K (corresponding author), Univ London London Sch Hyg & Trop Med, Dept Epidemiol & Populat Hlth, Canc Publ Hlth Unit, London WC1E 7HT, England.							Acheson D, 1988, REPORT COMMITTEE INQ; ASHTON J, 2000, HLTH PROMOTION NEW D, P13; Beaglehole R, 1997, PUBLIC HLTH CROSSROA; Brandt AM, 2000, AM J PUBLIC HEALTH, V90, P707, DOI 10.2105/AJPH.90.5.707; BRITTON A, 2000, MONITORING PROGR 201; DAY N, 1998, MONITORING PROGR 201; Edmondson Ricca, 2000, HLTH PROMOTION NEW D, P71; Fitzpatrick M., 2001, TYRANNY HLTH DOCTORS; Gotzsche PC, 2000, LANCET, V355, P129, DOI 10.1016/S0140-6736(99)06065-1; Le Fanu J., 1999, RISE FALL MODERN MED; LESSOF S, 1999, FEASIBILITY STUDY CA; MCPHERSON K, 1994, J EPIDEMIOL COMMUN H, V48, P6, DOI 10.1136/jech.48.1.6; MCPHERSON K, 1997, PROGR PUBLIC HLTH, P269; MCPHERSON K, 1999, LOOKING FUTURE MAKIN; MCPHERSON K, 2000, HLTH PROMOTION MULTI, P129; MCPHERSON K, 1995, PREVENTING CORONARY; McPherson K, 1977, COSTS RISKS BENEFITS, P308; Peto R, 2000, LANCET, V355, P1822, DOI 10.1016/S0140-6736(00)02277-7; Rose G., 1992, STRATEGY PREVENTIVE; Sommer A, 2000, AM J PUBLIC HEALTH, V90, P845, DOI 10.2105/AJPH.90.6.845; 1999, PUBLIC HLTH WORKFORC; 1999, NAT HEART FOR FEB; 2000, INFORMING PUBLIC HLT; 1995, LANCET, V345, P597; 1998, INTERIM REPORT PROJE	25	3	3	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 2	2001	357	9270					1790	1792		10.1016/S0140-6736(00)04905-9	http://dx.doi.org/10.1016/S0140-6736(00)04905-9			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	440BN	11403835				2022-12-28	WOS:000169156200035
J	Navarro, V				Navarro, V			World Health Report 2000: responses to Murray and Frenk	LANCET			English	Editorial Material									Johns Hopkins Univ, Publ Policy Program, Baltimore, MD 21205 USA; Pompeu Fabra Univ, Barcelona, Spain	Johns Hopkins University; Pompeu Fabra University	Navarro, V (corresponding author), Johns Hopkins Univ, Publ Policy Program, Baltimore, MD 21205 USA.	vnavarro@jhsph.edu	Navarro, Vicente/E-8174-2014	Navarro, Vicente/0000-0002-3310-3984				Murray C, 2001, LANCET, V357, P1698, DOI 10.1016/S0140-6736(00)04826-1; Navarro V, 2000, LANCET, V356, P1598, DOI 10.1016/S0140-6736(00)03139-1; NAVARRO V, 1994, HLTH INEQUALITIES SP; Schalick LM, 2000, INT J HEALTH SERV, V30, P13, DOI 10.2190/8QMH-4FAB-XAWP-VU95	4	19	19	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 26	2001	357	9269					1701	1702		10.1016/S0140-6736(00)04827-3	http://dx.doi.org/10.1016/S0140-6736(00)04827-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	435UY	11425396				2022-12-28	WOS:000168901600036
J	Ayuk, J; Matthews, T; Tayebjee, M; Gittoes, NJL				Ayuk, J; Matthews, T; Tayebjee, M; Gittoes, NJL			A blind panic	LANCET			English	Editorial Material									Queen Elizabeth Hosp, Div Med Sci, Birmingham B15 2TH, W Midlands, England; City Hosp, Dept Neuroophthalmol, Birmingham, W Midlands, England	University of Birmingham; University of Birmingham	Gittoes, NJL (corresponding author), Queen Elizabeth Hosp, Div Med Sci, Birmingham B15 2TH, W Midlands, England.	n.j.gittoes@bham.ac.uk						BAJANDAS FJ, 1976, NEUROLOGY, V26, P451, DOI 10.1212/WNL.26.5.451; LUTTWIG G, 1903, THESIS MUNICH; SAMBROOK MA, 1977, J NEUROL NEUROSUR PS, V40, P1015, DOI 10.1136/jnnp.40.10.1015; SHELDON RS, 1987, CAN J NEUROL SCI, V14, P622; Velasco PJ, 1999, PSYCHOSOMATICS, V40, P486	5	5	7	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 21	2001	357	9264					1262	1262		10.1016/S0140-6736(00)04408-1	http://dx.doi.org/10.1016/S0140-6736(00)04408-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	425YY	11418152				2022-12-28	WOS:000168323300014
J	Potenza, MN; Kosten, TR; Rounsaville, BJ				Potenza, MN; Kosten, TR; Rounsaville, BJ			Pathological gambling	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							PROBLEM GAMBLERS; PREVALENCE; DISORDERS		Yale Univ, Sch Med, Connecticut Mental Hlth Ctr,Div Subst Abuse, Dept Psychiat,Problem Gambling Clin, New Haven, CT 06519 USA	Yale University	Potenza, MN (corresponding author), Yale Univ, Sch Med, Connecticut Mental Hlth Ctr,Div Subst Abuse, Dept Psychiat,Problem Gambling Clin, Room S-104,34 Pk St, New Haven, CT 06519 USA.				NIDA NIH HHS [P50-DA12762, K05-DA00454, K12-DA00366] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [P50DA012762, K05DA000454, K12DA000366] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		American Psychiatric Association, 1980, DIAGN STAT MAN MENT, V3; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Bechara A, 2001, Semin Clin Neuropsychiatry, V6, P205, DOI 10.1053/scnp.2001.22927; Blanco C, 2001, Semin Clin Neuropsychiatry, V6, P167, DOI 10.1053/scnp.2001.22921; Cunningham-Williams R M, 2001, Semin Clin Neuropsychiatry, V6, P155, DOI 10.1053/scnp.2001.22919; Cunningham-Williams RM, 1998, AM J PUBLIC HEALTH, V88, P1093, DOI 10.2105/AJPH.88.7.1093; DeCaria CM, 1996, J CLIN PSYCHIAT, V57, P80; Hollander E, 2000, BIOL PSYCHIAT, V47, P813, DOI 10.1016/S0006-3223(00)00241-9; James KC, 1999, NATL GAMBLING IMPACT; Kim S W, 2001, Semin Clin Neuropsychiatry, V6, P184, DOI 10.1053/scnp.2001.22924; Kownacki RJ, 1999, SUBST USE MISUSE, V34, P1897, DOI 10.3109/10826089909039431; National Opinion Research Centre, 1999, GAMBL IMP BEH STUD; Pasternak AV, 1999, ARCH FAM MED, V8, P515, DOI 10.1001/archfami.8.6.515; Petry N M, 2001, Semin Clin Neuropsychiatry, V6, P177, DOI 10.1053/scnp.2001.22920; Phillips DP, 1997, SUICIDE LIFE-THREAT, V27, P373; Potenza M N, 2001, Semin Clin Neuropsychiatry, V6, P217, DOI 10.1053/scnp.2001.22929; Potenza MN, 2000, J AM ACAD PSYCHIATRY, V28, P389; POTENZA MN, IN PRESS NEUROPSYCHO; Shaffer HJ, 1999, AM J PUBLIC HEALTH, V89, P1369, DOI 10.2105/AJPH.89.9.1369; Slutske WS, 2000, ARCH GEN PSYCHIAT, V57, P666, DOI 10.1001/archpsyc.57.7.666; STEWART RM, 1988, BRIT J PSYCHIAT, V152, P284, DOI 10.1192/bjp.152.2.284; Sullivan S, 2000, NEW ZEAL MED J, V113, P204; SULLIVAN S, 1999, THESIS AUCKLAND; SULLIVAN S, 2000, NEW ETHICALS J, V3, P11; Sylvain C, 1997, J CONSULT CLIN PSYCH, V65, P727, DOI 10.1037/0022-006X.65.5.727	25	109	111	0	9	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 11	2001	286	2					141	144		10.1001/jama.286.2.141	http://dx.doi.org/10.1001/jama.286.2.141			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	451JJ	11448261				2022-12-28	WOS:000169798700001
J	Smith, DC				Smith, DC			Marine biology - Expansion of the marine Archaea	SCIENCE			English	Editorial Material							CRENARCHAEOTA		Univ Rhode Isl, Grad Sch Oceanog, Kingston, RI 02881 USA	University of Rhode Island	Smith, DC (corresponding author), Univ Rhode Isl, Grad Sch Oceanog, Kingston, RI 02881 USA.		Smith, David/A-8309-2013	Smith, David/0000-0003-0627-5788				Blochl E, 1997, EXTREMOPHILES, V1, P14; Delong EF, 1999, BIOL BULL-US, V196, P363, DOI 10.2307/1542971; HAYES JM, 1990, ORG GEOCHEM, V16, P1115, DOI 10.1016/0146-6380(90)90147-R; Hershberger KL, 1996, NATURE, V384, P420, DOI 10.1038/384420a0; Hoefs MJL, 1997, APPL ENVIRON MICROB, V63, P3090, DOI 10.1128/AEM.63.8.3090-3095.1997; Karner MB, 2001, NATURE, V409, P507, DOI 10.1038/35054051; Kuypers MMM, 2001, SCIENCE, V293, P92, DOI 10.1126/science.1058424; WOESE CR, 1990, P NATL ACAD SCI USA, V87, P4576, DOI 10.1073/pnas.87.12.4576	8	2	2	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 6	2001	293	5527					56	57		10.1126/science.1063491	http://dx.doi.org/10.1126/science.1063491			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	451BB	11441169				2022-12-28	WOS:000169780300023
J	Siminoff, LA; Gordon, N; Hewlett, J; Arnold, RM				Siminoff, LA; Gordon, N; Hewlett, J; Arnold, RM			Factors influencing families' consent for donation of solid organs for transplantation	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							UNITED-STATES; PROCUREMENT; DONORS; COMMUNICATION; SHORTAGE; MEMBERS	Context Transplantation has become the therapy of choice for patients with organ failure. However, the low rate of consent by families of donor-eligible patients is a major limiting factor in the success of organ transplantation. Objective To explore factors associated with the decision to donate among families of potential solid organ donors. Design and Setting Data collection via chart reviews, telephone interviews with health care practitioners (HCPs) or organ procurement organization (OPO) staff, and face-to-face interviews with family for all donor-eligible deaths at 9 trauma hospitals in southwestern Pennsylvania and northeastern Ohio from 1994 to 1999. Participants Family members, HCPs, and OPO staff involved in the donation decision for 420 donor-eligible patients. Main Outcome Measure Factors associated with family decision to donate or not donate organs for transplantation. Results A total of 238 of the 420 cases led to organ donation; 182 did not. Univariate analysis revealed numerous factors associated with the donation decision. Multivariable analysis of associated variables revealed that family and patient sociodemographics (ethnicity, patient's age and cause of death) and prior knowledge of the patients' wishes were significantly associated with willingness to donate (adjusted odds ratio [OR], 7.68; 95% confidence interval [Cl], 6.55-9.01), Families who discussed more topics and had more conversations about organ donation were more likely to donate (adjusted OR, 5.22; 95% Cl, 4.32-6.30), as were families with more contact with OPO staff (adjusted OR, 3.08; 95% Cl, 2.63-3.60) and those who experienced an optimal request pattern (adjusted OR, 2.96; 95%,Cl, 2.58-3.40). Socioemotional and communication variables acted as intervening variables. Conclusions Public education is needed to modify attitudes about organ donation prior to a donation opportunity. Specific steps can be taken by HCPs and OPO staff to maximize the opportunity to persuade families to donate their relatives' organs.	Case Western Reserve Univ, Sch Med, Dept Med, Cleveland, OH 44106 USA; Case Western Reserve Univ, Sch Med, Dept Epidemiol & Biostat, Cleveland, OH 44106 USA; Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA USA	Case Western Reserve University; Case Western Reserve University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Siminoff, LA (corresponding author), Case Western Reserve Univ, Sch Med, Dept Med, 10900 Euclid Ave,WG-37, Cleveland, OH 44106 USA.		Siminoff, Laura A/H-6277-2012		AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS008209] Funding Source: NIH RePORTER; AHRQ HHS [R01-HS08209] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		Bartucci M R, 1987, J Neurosci Nurs, V19, P305; Beasley C L, 1997, J Transpl Coord, V7, P6; Bosch X, 1999, JAMA-J AM MED ASSOC, V282, P17, DOI 10.1001/jama.282.1.17; CUTLER JA, 1993, TRANSPLANTATION, V56, P225; DeJong W, 1998, Am J Crit Care, V7, P13; Ehrle R N, 1999, Crit Care Nurse, V19, P21; Ehrle RN, 1999, CRIT CARE NURSE, V19, P32; EVANS RW, 1992, JAMA-J AM MED ASSOC, V267, P239, DOI 10.1001/jama.267.2.239; Franz H G, 1997, J Transpl Coord, V7, P14; GARRISON RN, 1991, SURG GYNECOL OBSTET, V173, P391; Gortmaker S L, 1998, J Transpl Coord, V8, P210; *I MED, 1997, NONH BEAT DON MED ET; Kopfman JE, 1996, J APPL COMMUN RES, V24, P33, DOI 10.1080/00909889609365438; Kopfman JE, 1998, J APPL COMMUN RES, V26, P279, DOI 10.1080/00909889809365508; MORRIS JA, 1989, J TRAUMA, V29, P782, DOI 10.1097/00005373-198906000-00014; PELLETIER M, 1992, J ADV NURS, V17, P90, DOI 10.1111/j.1365-2648.1992.tb01822.x; PELLETIER ML, 1993, HEART LUNG, V22, P151; PERKINS KA, 1987, AM PSYCHOL, V42, P921, DOI 10.1037/0003-066X.42.10.921; ROBBINS RA, 1993, J TRANSPLANT COORD, V3, P14; SIMINOFF LA, 1995, J TRAUMA, V39, P553; SIMINOFF LA, 1995, ANN INTERN MED, V123, P10, DOI 10.7326/0003-4819-123-1-199507010-00037; SIMINOFF LA, IN PRESS CAMB Q HEAL; Smith S. W., 1994, HEALTH COMMUN, V6, P1, DOI DOI 10.1207/S15327027HC0601_; SOPHIE LR, 1983, HEART LUNG, V12, P261; The Gallup Organization, 1993, AM PUBL ATT ORG DON; *UN NETW ORG SHAR, 2001, WAIT LIST; *UN NETW ORG SHAR, 2000, 1999 SR OPTN ANN REP; WINKEL FW, 1984, SOC SCI MED, V19, P957, DOI 10.1016/0277-9536(84)90325-3	28	468	478	0	48	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 4	2001	286	1					71	77		10.1001/jama.286.1.71	http://dx.doi.org/10.1001/jama.286.1.71			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	449GR	11434829	Bronze			2022-12-28	WOS:000169676400025
J	Graef, IA; Chen, F; Chen, L; Kuo, A; Crabtree, GR				Graef, IA; Chen, F; Chen, L; Kuo, A; Crabtree, GR			Signals transduced by Ca2+/calcineurin and NFATc3/c4 pattern the developing vasculature	CELL			English	Article							BLOOD-VESSEL FORMATION; RECEPTOR TYROSINE KINASE; TRANSCRIPTION FACTOR MEF2C; CARDIAC DEVELOPMENT; CARDIOVASCULAR DEVELOPMENT; NEUREGULIN RECEPTOR; ENDOTHELIAL-CELLS; DEFICIENT MICE; CYCLOSPORINE-A; NF-ATC	Vascular development requires an orderly exchange of signals between growing vessels and their supporting tissues, but little is known of the intracellular signaling pathways underlying this communication. We find that mice with disruptions of both NFATc4 and the related NFATc3 genes die around E11 with generalized defects in vessel assembly as well as excessive and disorganized growth of vessels into the neural tube and somites. Since calcineurin is thought to control nuclear localization of NFATc proteins, we introduced a mutation into the calcineurin a gene that prevents phosphatase activation by Ca2+ signals. These CnB mutant mice exhibit vascular developmental abnormalities similar to the NFATc3/c4 null mice. We show that calcineurin function is transiently required between E7.5 and E8.5. Hence, early calcineurin/NFAT signaling initiates the later cross-talk between vessels and surrounding tissues that pattern the vasculature.	Stanford Univ, Howard Hughes Med Inst, Dept Dev Biol, Stanford, CA 94305 USA; Stanford Univ, Howard Hughes Med Inst, Dept Pathol, Stanford, CA 94305 USA	Howard Hughes Medical Institute; Stanford University; Howard Hughes Medical Institute; Stanford University	Crabtree, GR (corresponding author), Stanford Univ, Howard Hughes Med Inst, Dept Dev Biol, Stanford, CA 94305 USA.							Adams RH, 2001, CELL, V104, P57, DOI 10.1016/S0092-8674(01)00191-X; Adams RH, 1999, GENE DEV, V13, P295, DOI 10.1101/gad.13.3.295; Bi WZ, 1999, DEV BIOL, V211, P255, DOI 10.1006/dbio.1999.9307; Carmeliet P, 1996, NATURE, V383, P73, DOI 10.1038/383073a0; Carmeliet P, 1999, CELL, V98, P147, DOI 10.1016/S0092-8674(00)81010-7; Carmeliet P, 1996, NATURE, V380, P435, DOI 10.1038/380435a0; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; Crabtree GR, 1999, CELL, V96, P611, DOI 10.1016/S0092-8674(00)80571-1; de la Pompa JL, 1998, NATURE, V392, P182, DOI 10.1038/32419; DICKSON MC, 1995, DEVELOPMENT, V121, P1845; Dumont DJ, 1998, SCIENCE, V282, P946, DOI 10.1126/science.282.5390.946; DUMONT DJ, 1994, GENE DEV, V8, P1897, DOI 10.1101/gad.8.16.1897; Erickson SL, 1997, DEVELOPMENT, V124, P4999; Esser S, 1998, J CELL SCI, V111, P1853; Ferrara N, 1996, NATURE, V380, P439, DOI 10.1038/380439a0; FLANAGAN WM, 1991, NATURE, V352, P803, DOI 10.1038/352803a0; Folkman J, 1996, CELL, V87, P1153, DOI 10.1016/S0092-8674(00)81810-3; FONG GH, 1995, NATURE, V376, P66, DOI 10.1038/376066a0; GASSMANN M, 1995, NATURE, V378, P390, DOI 10.1038/378390a0; Gerety SS, 1999, MOL CELL, V4, P403, DOI 10.1016/S1097-2765(00)80342-1; Graef IA, 2001, P NATL ACAD SCI USA, V98, P5740, DOI 10.1073/pnas.101602398; GRIFFITH JP, 1995, CELL, V82, P507, DOI 10.1016/0092-8674(95)90439-5; Hellstrom M, 1999, DEVELOPMENT, V126, P3047; KLEE CB, 1979, P NATL ACAD SCI USA, V76, P6270, DOI 10.1073/pnas.76.12.6270; Klee CB, 1998, J BIOL CHEM, V273, P13367, DOI 10.1074/jbc.273.22.13367; LEE KF, 1995, NATURE, V378, P394, DOI 10.1038/378394a0; Lin Q, 1998, DEVELOPMENT, V125, P4565; Lin Q, 1997, SCIENCE, V276, P1404, DOI 10.1126/science.276.5317.1404; Lindahl P, 1997, SCIENCE, V277, P242, DOI 10.1126/science.277.5323.242; LIU J, 1991, CELL, V66, P807, DOI 10.1016/0092-8674(91)90124-H; MEYER D, 1995, NATURE, V378, P386, DOI 10.1038/378386a0; Molkentin JD, 1998, CELL, V93, P215, DOI 10.1016/S0092-8674(00)81573-1; Oh SP, 2000, P NATL ACAD SCI USA, V97, P2626, DOI 10.1073/pnas.97.6.2626; Olson EN, 2000, CELL, V101, P689, DOI 10.1016/S0092-8674(00)80880-6; Oukka M, 1998, IMMUNITY, V9, P295, DOI 10.1016/S1074-7613(00)80612-3; PURI MC, 1995, EMBO J, V14, P5884, DOI 10.1002/j.1460-2075.1995.tb00276.x; Ranger AM, 1998, NATURE, V392, P186, DOI 10.1038/32426; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; SATO TN, 1995, NATURE, V376, P70, DOI 10.1038/376070a0; SHALABY F, 1995, NATURE, V376, P62, DOI 10.1038/376062a0; Suri C, 1996, CELL, V87, P1171, DOI 10.1016/S0092-8674(00)81813-9; UMESS LD, 2000, NAT GENET, V26, P328; Wang HU, 1998, CELL, V93, P741, DOI 10.1016/S0092-8674(00)81436-1; Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215; Yang X, 1999, DEVELOPMENT, V126, P1571	45	341	364	2	17	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTES AVE,, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 29	2001	105	7					863	875		10.1016/S0092-8674(01)00396-8	http://dx.doi.org/10.1016/S0092-8674(01)00396-8			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	449BK	11439183	Bronze			2022-12-28	WOS:000169664300007
J	Hager, G				Hager, G			Alan Wolffe (1954-2001) - Obituary	CELL			English	Biographical-Item									NCI, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Hager, G (corresponding author), NCI, Bethesda, MD 20892 USA.								0	0	0	0	0	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTES AVE,, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 29	2001	105	7					849	850		10.1016/S0092-8674(01)00413-5	http://dx.doi.org/10.1016/S0092-8674(01)00413-5			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	449BK	11439181	Bronze			2022-12-28	WOS:000169664300005
J	Wang, DZ; Chang, PS; Wang, ZG; Sutherland, L; Richardson, JA; Small, E; Krieg, PA; Olson, EN				Wang, DZ; Chang, PS; Wang, ZG; Sutherland, L; Richardson, JA; Small, E; Krieg, PA; Olson, EN			Activation of cardiac gene expression by myocardin, a transcriptional cofactor for serum response factor	CELL			English	Article							ALPHA-ACTIN GENE; TINMAN-RELATED GENES; C-FOS PROMOTER; TERNARY COMPLEX; SMOOTH-MUSCLE; ELEMENT; SKELETAL; CELLS; DNA; SM22-ALPHA	Serum response factor (SRF) regulates transcription of numerous muscle and growth factor-inducible genes. Because SRF is not muscle specific, It has been postulated to activate muscle genes by recruiting myogenic accessory factors. Using a bioinformatics-based screen for unknown cardiac-specific genes, we identified a novel and highly potent transcription factor, named myocardin, that is expressed in cardiac and smooth muscle cells. Myocardin belongs to the SAP domain family of nuclear proteins and activates cardiac muscle promoters by associating with SRF. Expression of a dominant negative mutant of myocardin in Xenopus embryos interferes with myocardial cell differentiation. Myocardin is the founding member of a class of muscle transcription factors and provides a mechanism whereby SRF can convey myogenic activity to cardiac muscle genes.	Univ Texas, SW Med Ctr, Dept Mol Biol, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Pathol, Dallas, TX 75390 USA; Univ Arizona, Coll Med, Dept Cell Biol & Anat, Tucson, AZ 85724 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Arizona	Olson, EN (corresponding author), Univ Texas, SW Med Ctr, Dept Mol Biol, 6000 Harry Hines Blvd, Dallas, TX 75390 USA.		Wang, Zhigao/ABE-9411-2021	Wang, Zhigao/0000-0002-6544-4302	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL053351, P01HL063926] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL63926, R01 HL053351] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Aravind L, 2000, TRENDS BIOCHEM SCI, V25, P112, DOI 10.1016/S0968-0004(99)01537-6; Belaguli NS, 2000, MOL CELL BIOL, V20, P7550, DOI 10.1128/MCB.20.20.7550-7558.2000; Black BL, 1998, ANNU REV CELL DEV BI, V14, P167, DOI 10.1146/annurev.cellbio.14.1.167; Chang PS, 2001, J BIOL CHEM, V276, P17206, DOI 10.1074/jbc.M010983200; Chen CY, 1996, MOL CELL BIOL, V16, P6372; CHOW KL, 1990, MOL CELL BIOL, V10, P528, DOI 10.1128/MCB.10.2.528; Cleaver OB, 1996, DEVELOPMENT, V122, P3549; Croissant JD, 1996, DEV BIOL, V177, P250, DOI 10.1006/dbio.1996.0160; Faber J., 1994, NORMAL TABLE XENOPUS, P2; Fu YC, 1998, DEVELOPMENT, V125, P4439; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; GILMAN MZ, 1986, MOL CELL BIOL, V6, P4305, DOI 10.1128/MCB.6.12.4305; Grow MW, 1998, DEV BIOL, V204, P187, DOI 10.1006/dbio.1998.9080; HARLAND RM, 1991, METHOD CELL BIOL, V36, P685; HAUSCHKA SD, 1994, MYOLOGY, P3; Hines WA, 1999, MOL CELL BIOL, V19, P1841; Kim S, 1997, MOL CELL BIOL, V17, P2266, DOI 10.1128/MCB.17.4.2266; Kipp M, 2000, MOL CELL BIOL, V20, P7480, DOI 10.1128/MCB.20.20.7480-7489.2000; LEE TC, 1991, MOL CELL BIOL, V11, P5090, DOI 10.1128/MCB.11.10.5090; Li L, 1996, CIRC RES, V78, P188, DOI 10.1161/01.RES.78.2.188; Li L, 1997, DEV BIOL, V187, P311, DOI 10.1006/dbio.1997.8621; Lien CL, 1999, DEVELOPMENT, V126, P75; LINTS TJ, 1993, DEVELOPMENT, V119, P419; Lu JR, 1999, MOL CELL BIOL, V19, P4495; Mack CP, 1999, CIRC RES, V84, P852; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; McFadden DG, 2000, DEVELOPMENT, V127, P5331; Morin S, 2001, MOL CELL BIOL, V21, P1036, DOI 10.1128/MCB.21.4.1036-1044.2001; Nakagawa O, 2000, P NATL ACAD SCI USA, V97, P13655, DOI 10.1073/pnas.250485597; NORMAN C, 1988, CELL, V55, P989, DOI 10.1016/0092-8674(88)90244-9; Paradis P, 1996, J BIOL CHEM, V271, P10827, DOI 10.1074/jbc.271.18.10827; PRYWES R, 1992, NUCLEIC ACIDS RES, V20, P513, DOI 10.1093/nar/20.3.513; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; REECY J, 1998, HEART DEV, P273; Santelli E, 2000, J MOL BIOL, V297, P437, DOI 10.1006/jmbi.2000.3568; SHAW PE, 1989, CELL, V56, P563, DOI 10.1016/0092-8674(89)90579-5; SHORE P, 1995, EUR J BIOCHEM, V229, P1, DOI 10.1111/j.1432-1033.1995.tb20430.x; Sotiropoulos A, 1999, CELL, V98, P159, DOI 10.1016/S0092-8674(00)81011-9; SPRENKLE AB, 1995, CIRC RES, V77, P1060, DOI 10.1161/01.RES.77.6.1060; TREISMAN R, 1994, CURR OPIN GENET DEV, V4, P96, DOI 10.1016/0959-437X(94)90097-3; Wang DZ, 1999, DEVELOPMENT, V126, P1281; ZHU H, 1991, MOL CELL BIOL, V11, P2273, DOI 10.1128/MCB.11.4.2273	42	721	765	1	31	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTES AVE,, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 29	2001	105	7					851	862		10.1016/S0092-8674(01)00404-4	http://dx.doi.org/10.1016/S0092-8674(01)00404-4			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	449BK	11439182	Bronze			2022-12-28	WOS:000169664300006
J	Arcas, BAY; Fairhall, A				Arcas, BAY; Fairhall, A			Archaeology of type	NATURE			English	Editorial Material									Princeton Univ, Scheide Lib, Princeton, NJ 08544 USA; NEC Res Inst, Princeton, NJ 08540 USA	Princeton University; NEC Corporation	Arcas, BAY (corresponding author), Princeton Univ, Scheide Lib, Princeton, NJ 08544 USA.								0	3	3	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 28	2001	411	6841					997	997		10.1038/35082698	http://dx.doi.org/10.1038/35082698			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	446TF	11429578	Bronze			2022-12-28	WOS:000169528500023
J	Myung, K; Chen, C; Kolodner, RD				Myung, K; Chen, C; Kolodner, RD			Multiple pathways cooperate in the suppression of genome instability in Saccharomyces cerevisiae	NATURE			English	Article							STRAND-BREAK REPAIR; CHROMOSOMAL REARRANGEMENTS; DNA HELICASE; YEAST; RECOMBINATION; MAINTENANCE; TELOMERASE; ENDS; REPLICATION; MUTANTS	Gross chromosome rearrangements (GCRs), such as translocations, deletion of a chromosome arm, interstitial deletions and inversions, are often observed in cancer cells(1-3). Spontaneous GCRs are rare in Saccharomyces cerevisiae; however, the existence of mutator mutants with increased genome instability suggests that GCRs are actively suppressed(4,5). Here we show by genetic analysis that these genome rearrangements probably result from DNA replication errors and are suppressed by at least three interacting pathways or groups of proteins: S-phase checkpoint functions 5, recombination proteins(4) and proteins that prevent de novo addition of telomeres at double-strand breaks (DSBs). Mutations that inactivate these pathways cause high rates of GCRs and show synergistic interactions, indicating that the pathways that suppress GCRs all compete for the same DNA substrates.	Univ Calif San Diego, Sch Med, Ctr Canc, Ludwig Inst Canc Res, La Jolla, CA 92093 USA; Univ Calif San Diego, Sch Med, Dept Med, La Jolla, CA 92093 USA	Ludwig Institute for Cancer Research; University of California System; University of California San Diego; University of California System; University of California San Diego	Kolodner, RD (corresponding author), Univ Calif San Diego, Sch Med, Ctr Canc, Ludwig Inst Canc Res, La Jolla, CA 92093 USA.		Chen, Clark C/C-8714-2013	Chen, Clark C/0000-0001-6258-9277				Bai Y, 1996, GENE DEV, V10, P2025, DOI 10.1101/gad.10.16.2025; Boulton SJ, 1996, EMBO J, V15, P5093, DOI 10.1002/j.1460-2075.1996.tb00890.x; Bryan TM, 1999, CURR OPIN CELL BIOL, V11, P318, DOI 10.1016/S0955-0674(99)80043-X; Chen C, 1998, MOL CELL, V2, P9, DOI 10.1016/S1097-2765(00)80109-4; Chen C, 1999, NAT GENET, V23, P81, DOI 10.1038/12687; Chen QJ, 2001, MOL CELL BIOL, V21, P1819, DOI 10.1128/MCB.21.5.1819-1827.2001; Diede SJ, 1999, CELL, V99, P723, DOI 10.1016/S0092-8674(00)81670-0; Grandin N, 1997, GENE DEV, V11, P512, DOI 10.1101/gad.11.4.512; HABER J E, 1992, Current Opinion in Cell Biology, V4, P401, DOI 10.1016/0955-0674(92)90005-W; Herrmann G, 1998, EMBO J, V17, P4188, DOI 10.1093/emboj/17.14.4188; Khanna KK, 2001, NAT GENET, V27, P247, DOI 10.1038/85798; LAHAYE A, 1991, EMBO J, V10, P997, DOI 10.1002/j.1460-2075.1991.tb08034.x; Lee SE, 1998, CELL, V94, P399, DOI 10.1016/S0092-8674(00)81482-8; Lee SE, 1999, CURR BIOL, V9, P767, DOI 10.1016/S0960-9822(99)80339-X; Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292; Lewis LK, 2000, MUTAT RES-FUND MOL M, V451, P71, DOI 10.1016/S0027-5107(00)00041-5; Lundblad V, 2000, MUTAT RES-FUND MOL M, V451, P227, DOI 10.1016/S0027-5107(00)00052-X; Michel B, 2000, TRENDS BIOCHEM SCI, V25, P173, DOI 10.1016/S0968-0004(00)01560-7; MITELMAN F, 1991, CATALOG CHROMOSOME A; Moore JK, 1996, MOL CELL BIOL, V16, P2164, DOI 10.1128/mcb.16.5.2164; Myung KJ, 2001, CELL, V104, P397, DOI 10.1016/S0092-8674(01)00227-6; Nugent CI, 1996, SCIENCE, V274, P249, DOI 10.1126/science.274.5285.249; Padilla-Nash HM, 1999, GENE CHROMOSOME CANC, V25, P53, DOI 10.1002/(SICI)1098-2264(199905)25:1<53::AID-GCC8>3.0.CO;2-T; Pennock E, 2001, CELL, V104, P387, DOI 10.1016/S0092-8674(01)00226-4; Petrini JHJ, 2000, CURR OPIN CELL BIOL, V12, P293, DOI 10.1016/S0955-0674(00)00091-0; SCHULZ VP, 1994, CELL, V76, P145, DOI 10.1016/0092-8674(94)90179-1; Signon L, 2001, MOL CELL BIOL, V21, P2048, DOI 10.1128/MCB.21.6.2048-2056.2001; Teo SH, 1997, EMBO J, V16, P4788, DOI 10.1093/emboj/16.15.4788; Vessey CJ, 2000, PROG NUCLEIC ACID RE, V63, P189, DOI 10.1016/S0079-6603(08)60723-0; Zhou JQ, 2000, SCIENCE, V289, P771, DOI 10.1126/science.289.5480.771	30	292	294	0	11	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 28	2001	411	6841					1073	1076		10.1038/35082608	http://dx.doi.org/10.1038/35082608			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	446TF	11429610				2022-12-28	WOS:000169528500053
J	Schmidt, B; Davis, P; Moddemann, D; Ohlsson, A; Roberts, RS; Saigal, S; Solimano, A; Vincer, M; Wright, LL				Schmidt, B; Davis, P; Moddemann, D; Ohlsson, A; Roberts, RS; Saigal, S; Solimano, A; Vincer, M; Wright, LL		Trial Indomethacin Prophylaxis Pre	Long-term effects of indomethacin prophylaxis in extremely-low-birth-weight infants	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LOW-DOSE INDOMETHACIN; INTRAVENTRICULAR HEMORRHAGE; PREMATURE-INFANTS; PREVENTION; HEMODYNAMICS; PREDICTION; OUTCOMES; CHILDREN	Background: The prophylactic administration of indomethacin reduces the frequency of patent ductus arteriosus and severe intraventricular hemorrhage in very-low-birth-weight infants (those with birth weights below 1500 g). Whether prophylaxis with indomethacin confers any long-term benefits that outweigh the risks of drug-induced reductions in renal, intestinal, and cerebral blood flow is not known. Methods: Soon after they were born, we randomly assigned 1202 infants with birth weights of 500 to 999 g (extremely low birth weight) to receive either indomethacin (0.1 mg per kilogram of body weight) or placebo intravenously once daily for three days. The primary outcome was a composite of death, cerebral palsy, cognitive delay, deafness, and blindness at a corrected age of 18 months. Secondary long-term outcomes were hydrocephalus necessitating the placement of a shunt, seizure disorder, and microcephaly within the same time frame. Secondary short-term outcomes were patent ductus arteriosus, pulmonary hemorrhage, chronic lung disease, ultrasonographic evidence of intracranial abnormalities, necrotizing enterocolitis, and retinopathy. Results: Of the 574 infants with data on the primary outcome who were assigned to prophylaxis with indomethacin, 271 (47 percent) died or survived with impairments, as compared with 261 of the 569 infants (46 percent) assigned to placebo (odds ratio, 1.1; 95 percent confidence interval, 0.8 to 1.4; P=0.61). Indomethacin reduced the incidence of patent ductus arteriosus (24 percent, vs. 50 percent in the placebo group; odds ratio, 0.3; P<0.001) and of severe periventricular and intraventricular hemorrhage (9 percent, vs. 13 percent in the placebo group; odds ratio, 0.6; P=0.02). No other outcomes were altered by the prophylactic administration of indomethacin. Conclusions: In extremely-low-birth-weight infants, prophylaxis with indomethacin does not improve the rate of survival without neurosensory impairment at 18 months, despite the fact that it reduces the frequency of patent ductus arteriosus and severe periventricular and intraventricular hemorrhage. (N Engl J Med 2001;344:1966-72.) Copyright (C) 2001 Massachusetts Medical Society.	McMaster Univ, Dept Pediat, Hamilton, ON L8N 3Z5, Canada; McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON L8N 3Z5, Canada; Royal Womens Hosp, Melbourne, Vic, Australia; Univ Manitoba, Dept Pediat & Child Hlth, Winnipeg, MB R3T 2N2, Canada; Univ Toronto, Dept Pediat, Toronto, ON, Canada; Univ Toronto, Dept Obstet & Gynecol, Toronto, ON, Canada; Univ Toronto, Dept Hlth Adm, Toronto, ON, Canada; Univ British Columbia, Dept Pediat, Vancouver, BC V6T 1W5, Canada; Dalhousie Univ, Dept Pediat, Halifax, NS, Canada; NICHHD, Neonatal Res Network, Bethesda, MD 20892 USA	McMaster University; McMaster University; University of Manitoba; University of Toronto; University of Toronto; University of Toronto; University of British Columbia; Dalhousie University; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Schmidt, B (corresponding author), McMaster Univ, Dept Pediat, HSC 3N11E,1200 Main St W, Hamilton, ON L8N 3Z5, Canada.	schmidt@mcmaster.ca	Pritchard, Margo A/G-5188-2010	Pritchard, Margo A/0000-0002-1058-9117; Kohan, Rolland/0000-0002-6859-2634	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [U10HD021364, U10HD027851, U10HD021373] Funding Source: NIH RePORTER; NICHD NIH HHS [U10 HD21373, U10 HD27851, U10 HD21364] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ARBUCKLE TE, 1989, CAN MED ASSOC J, V140, P157; ARBUCKLE TE, 1989, CMAJ, V1450, P157; Bada HS, 1996, PEDIATRICS, V98, P784; DAVIS P, 1995, ARCH PEDIAT ADOL MED, V149, P1136, DOI 10.1001/archpedi.1995.02170230090013; EDWARDS AD, 1990, LANCET, V335, P1491, DOI 10.1016/0140-6736(90)93030-S; FOWLIE PW, 2000, COCHRANE LIB, V4; GARNER A, 1984, PEDIATRICS, V74, P127; LAUPACIS A, 1988, NEW ENGL J MED, V318, P1728, DOI 10.1056/NEJM198806303182605; Ment LR, 2000, PEDIATRICS, V105, P485, DOI 10.1542/peds.105.3.485; Ment LR, 1996, PEDIATRICS, V98, P714; MENT LR, 1994, PEDIATRICS, V93, P543; PAGANO M, 1993, PRINCIPLES BIOSTATIS; PAPILE LA, 1978, J PEDIATR-US, V92, P529, DOI 10.1016/S0022-3476(78)80282-0; PATZ A, 1987, ARCH OPHTHALMOL-CHIC, V105, P905, DOI 10.1001/archopht.1987.01060070041024; PINTOMARTIN JA, 1995, PEDIATRICS, V95, P249; SHENNAN AT, 1988, PEDIATRICS, V82, P527; The International Committee for the Classification of the Late Stages of Retinopathy of Prematurity, 1987, ARCH OPHTHALMOL-CHIC, V105; Tin W, 1998, ARCH DIS CHILD-FETAL, V79, pF83, DOI 10.1136/fn.79.2.F83; Vohr BR, 2000, PEDIATRICS, V105, P1216, DOI 10.1542/peds.105.6.1216; Wood NS, 2000, NEW ENGL J MED, V343, P378, DOI 10.1056/NEJM200008103430601; Yanowitz TD, 1998, J PEDIATR-US, V132, P28, DOI 10.1016/S0022-3476(98)70480-9; Yi S.H., 1993, MANUAL BAYLEY SCALES; YUSUF S, 1990, STAT MED, V9, P73, DOI 10.1002/sim.4780090114	23	467	484	0	14	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 28	2001	344	26					1966	1972		10.1056/NEJM200106283442602	http://dx.doi.org/10.1056/NEJM200106283442602			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	446HQ	11430325				2022-12-28	WOS:000169508200002
J	Schulz, R; Beach, SR; Lind, B; Martire, LM; Zdaniuk, B; Hirsch, C; Jackson, S; Burton, L				Schulz, R; Beach, SR; Lind, B; Martire, LM; Zdaniuk, B; Hirsch, C; Jackson, S; Burton, L			Involvement in caregiving and adjustment to death of a spouse - Findings from the caregiver health effects study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BEREAVEMENT; DEPRESSION; PREDICTORS	Context Most deaths in the United States occur among older persons who have 1 or more disabling conditions. As a result, many deaths are preceded by an extended period during which family members provide care to their disabled relative. Objective To better understand the effect of bereavement on family caregivers by examining predeath vs postdeath changes in self-reported and objective health outcomes among elderly persons providing varying levels of care prior to their spouse's death. Design and Setting Prospective, population-based cohort study conducted in 4 US communities between 1993 and 1998. Participants One hundred twenty-nine individuals aged 66 to 96 years whose spouse died during an average 4-year follow-up. Individuals were classified as noncaregivers (n=40), caregivers who reported no strain (n=37), or strained caregivers (n=52). Main Outcome Measures Changes in depression symptoms (assessed by the 10-item Center for Epidemiological Studies-Depression [CES-D] scale), antidepressant medication use, 6 health risk behaviors, and weight among the 3 groups of participants. Results Controlling for age, sex, race, education, prevalent cardiovascular disease at baseline, and interval between predeath and postdeath assessments, CES-D scores remained high but did not change among strained caregivers (9.44 vs 9.19; P=.76), while these scores increased for both noncaregivers (4.74 vs 8.25; F-1,F-116=14.33; P<.001) and nonstrained caregivers (4.94 vs 7.13; F-1,F-116=4.35; P= .04) Noncaregivers were significantly more likely to be using nontricyclic antidepressant medications following the death than the nonstrained caregiver group (odds ratio [OR], 12.85; 95% confidence interval [Cl], 1.02-162.13; P=.05). The strained caregiver group experienced significant improvement in health risk behaviors following the death of their spouse (1.47 vs 0.66 behaviors; F-1,F-118=20.23; P<.001), while the noncaregiver and nonstrained caregiver groups showed little change (0.27 vs 0.27 [P=.99] and 0.46 vs 0.27 [P=.39] behaviors, respectively). Noncaregivers experienced significant weight loss following the death (149.1 vs 145.3 lb [67.1 vs 65.4 kg]; F-1,F-101=8.12; P=.005), while the strained and nonstrained caregiving groups did not show significant weight change (156.2 vs 155.2 lb [70.3 vs 69.8 kg] [P= 41] and 156.2 vs 154.0 lb [70.3 vs 69.3 kg] [P=.12], respectively). Conclusions These data indicate that the impact of losing one's spouse among older persons Varies as a function of the caregiving experiences that precede the death. Among individuals who are already strained prior to the death of their spouse, the death itself does not increase their level of distress. Instead, they show reductions in health risk behaviors. Among noncaregivers, losing one's spouse results in increased depression and weight loss.	Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Univ Ctr Social & Urban Res, Pittsburgh, PA 15260 USA; Univ Washington, Dept Biostat, Seattle, WA 98195 USA; Univ Calif Davis, Davis Med Ctr, Div Gen Med, Davis, CA USA; Wake Forest Univ, Sch Med, Dept Publ Hlth Sci, Epidemiol Sect, Winston Salem, NC 27109 USA; Johns Hopkins Univ, Sch Hyg & Publ Hlth, Hlth Serv & Dev Ctr, Baltimore, MD USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Washington; University of Washington Seattle; University of California System; University of California Davis; Wake Forest University; Johns Hopkins University	Schulz, R (corresponding author), Univ Pittsburgh, Dept Psychiat, 121 Univ Pl, Pittsburgh, PA 15260 USA.				DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS [N01HC085086, N01HC085079] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL065111, P50HL065112] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [P30MH052247, R01MH046015, T32MH019986] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [U01AG013305] Funding Source: NIH RePORTER; NHLBI NIH HHS [N01-HC-85086, HL65111, HL65112, N01-HC-85079] Funding Source: Medline; NIA NIH HHS [AG13305, AG01532] Funding Source: Medline; NIMH NIH HHS [R01 MH52247, T32 MH19986, R01 MH46015] Funding Source: Medline	DIVISION OF EPIDEMIOLOGY AND CLINICAL APPLICATIONS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BODNAR JC, 1994, PSYCHOL AGING, V9, P372; Emanuel EJ, 1999, NEW ENGL J MED, V341, P956, DOI 10.1056/NEJM199909233411306; Emanuel EJ, 2000, ANN INTERN MED, V132, P451, DOI 10.7326/0003-4819-132-6-200003210-00005; Fried Linda P., 1991, Annals of Epidemiology, V1, P263; Kurtz ME, 1997, SUPPORT CARE CANCER, V5, P53, DOI 10.1007/BF01681962; MCHORNEY CA, 1988, MED CARE, V26, P882, DOI 10.1097/00005650-198809000-00007; Park CL, 1997, J PERS, V65, P421, DOI 10.1111/j.1467-6494.1997.tb00960.x; Psaty Bruce M., 1995, Annals of Epidemiology, V5, P270, DOI 10.1016/1047-2797(94)00092-8; SCHULZ R, 1995, GERONTOLOGIST, V35, P771, DOI 10.1093/geront/35.6.771; Schulz R, 1997, ANN BEHAV MED, V19, P110, DOI 10.1007/BF02883327; Schulz R, 1997, AGING MENT HEALTH, V1, P269, DOI 10.1080/13607869757173; Schulz R, 1999, JAMA-J AM MED ASSOC, V282, P2215, DOI 10.1001/jama.282.23.2215; SHROUT PE, 1989, J CLIN EPIDEMIOL, V42, P69, DOI 10.1016/0895-4356(89)90027-9; Tell G S, 1993, Ann Epidemiol, V3, P358, DOI 10.1016/1047-2797(93)90062-9	14	179	182	1	15	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 27	2001	285	24					3123	3129		10.1001/jama.285.24.3123	http://dx.doi.org/10.1001/jama.285.24.3123			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	444FF	11427141				2022-12-28	WOS:000169388900026
J	Donhauser, ZJ; Mantooth, BA; Kelly, KF; Bumm, LA; Monnell, JD; Stapleton, JJ; Price, DW; Rawlett, AM; Allara, DL; Tour, JM; Weiss, PS				Donhauser, ZJ; Mantooth, BA; Kelly, KF; Bumm, LA; Monnell, JD; Stapleton, JJ; Price, DW; Rawlett, AM; Allara, DL; Tour, JM; Weiss, PS			Conductance switching in single molecules through conformational changes	SCIENCE			English	Article							NEGATIVE DIFFERENTIAL RESISTANCE; SCANNING-TUNNELING-MICROSCOPY; MONOLAYERS; SURFACE; CONDUCTIVITY; ELECTRONICS	We tracked over time the conductance switching of single and bundled phenylene ethynylene oligomers isolated in matrices of alkanethiolate monolayers. The persistence times for isolated and bundled molecules in either the ON or OFF switch state range from seconds to tens of hours. When the surrounding matrix is well ordered, the rate at which the inserted molecules switch is low. Conversely, when the surrounding matrix is poorly ordered, the inserted molecules switch more often. We conclude that the switching is a result of conformational changes in the molecules or bundles, rather than electrostatic effects of charge transfer.	Penn State Univ, Dept Chem, University Pk, PA 16802 USA; Rice Univ, Dept Chem, Houston, TX 77005 USA; Rice Univ, Ctr Nanoscale Sci & Technol, Houston, TX 77005 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Rice University; Rice University	Allara, DL (corresponding author), Penn State Univ, Dept Chem, University Pk, PA 16802 USA.	dla3@psu.edu; tour@rice.edu; stm@psu.edu	Weiss, Paul S/A-2575-2011; Bumm, Lloyd/B-5738-2011; Kelly, Kevin F/F-8969-2015; Mantooth, Brent A/K-5559-2012; Weiss, Paul/P-8016-2019	Weiss, Paul S/0000-0001-5527-6248; Bumm, Lloyd/0000-0003-2301-8193; Kelly, Kevin F/0000-0003-0492-596X; Mantooth, Brent A/0000-0001-6838-1741; Weiss, Paul/0000-0001-5527-6248; Tour, James/0000-0002-8479-9328				Akpati HC, 1997, SURF SCI, V372, P9, DOI 10.1016/S0039-6028(96)01117-X; Bumm LA, 1996, SCIENCE, V271, P1705, DOI 10.1126/science.271.5256.1705; Chen J, 2000, APPL PHYS LETT, V77, P1224, DOI 10.1063/1.1289650; Chen J, 1999, SCIENCE, V286, P1550, DOI 10.1126/science.286.5444.1550; Collier CP, 2000, SCIENCE, V289, P1172, DOI 10.1126/science.289.5482.1172; Collier CP, 1999, SCIENCE, V285, P391, DOI 10.1126/science.285.5426.391; Cygan MT, 1998, J AM CHEM SOC, V120, P2721, DOI 10.1021/ja973448h; Di Ventra M, 2000, PHYS REV LETT, V84, P979, DOI 10.1103/PhysRevLett.84.979; Dunbar TD, 2000, J PHYS CHEM B, V104, P4880, DOI 10.1021/jp993724+; Gittins DI, 2000, NATURE, V408, P67, DOI 10.1038/35040518; Herrmann CF, 1999, J PHYS CHEM B, V103, P4207, DOI 10.1021/jp990155x; JOACHIM C, 1995, PHYS REV LETT, V74, P2102, DOI 10.1103/PhysRevLett.74.2102; Moerner WE, 1999, SCIENCE, V283, P1670, DOI 10.1126/science.283.5408.1670; Moresco F, 2001, PHYS REV LETT, V86, P672, DOI 10.1103/PhysRevLett.86.672; Poirier GE, 1997, CHEM REV, V97, P1117, DOI 10.1021/cr960074m; Poirier GE, 1996, SCIENCE, V272, P1145, DOI 10.1126/science.272.5265.1145; Reed MA, 2001, APPL PHYS LETT, V78, P3735, DOI 10.1063/1.1377042; Seminario JM, 2000, J AM CHEM SOC, V122, P3015, DOI 10.1021/ja992936h; Seminario JM, 1998, J AM CHEM SOC, V120, P3970, DOI 10.1021/ja973639k; Tans SJ, 1998, NATURE, V393, P49, DOI 10.1038/29954; Tour JM, 2000, ACCOUNTS CHEM RES, V33, P791, DOI 10.1021/ar0000612; Tour JM, 1998, J AM CHEM SOC, V120, P8486, DOI 10.1021/ja9808090; Weiss PS, 1998, ANN NY ACAD SCI, V852, P145, DOI 10.1111/j.1749-6632.1998.tb09869.x; Xie XS, 1996, ACCOUNTS CHEM RES, V29, P598, DOI 10.1021/ar950246m	24	1183	1195	4	247	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 22	2001	292	5525					2303	2307		10.1126/science.1060294	http://dx.doi.org/10.1126/science.1060294			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	445KD	11423655				2022-12-28	WOS:000169455900050
J	Cannon, CP; Weintraub, WS; Demopoulos, LA; Vicari, R; Frey, MJ; Lakkis, N; Neumann, FJ; Robertson, DH; DeLucca, PT; DiBattiste, PM; Gibson, CM; Braunwald, E				Cannon, CP; Weintraub, WS; Demopoulos, LA; Vicari, R; Frey, MJ; Lakkis, N; Neumann, FJ; Robertson, DH; DeLucca, PT; DiBattiste, PM; Gibson, CM; Braunwald, E		TACTICS Thrombolysis Myocardial	Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							WAVE MYOCARDIAL-INFARCTION; TROPONIN-I LEVELS; RECEPTOR INHIBITION; BALLOON ANGIOPLASTY; ARTERY-DISEASE; PLUS HEPARIN; ANGINA; MANAGEMENT; STRATIFICATION; ENOXAPARIN	Background: There is continued debate as to whether a routine, early invasive strategy is superior to a conservative strategy for the management of unstable angina and myocardial infarction without ST-segment elevation. Methods: We enrolled 2220 patients with unstable angina and myocardial infarction without ST-segment elevation who had electrocardiographic evidence of changes in the ST segment or T wave, elevated levels of cardiac markers, a history of coronary artery disease, or all three findings. All patients were treated with aspirin, heparin, and the glycoprotein IIb/IIIa inhibitor tirofiban. They were randomly assigned to an early invasive strategy, which included routine catheterization within 4 to 48 hours and revascularization as appropriate, or to a more conservative (selectively invasive) strategy, in which catheterization was performed only if the patient had objective evidence of recurrent ischemia or an abnormal stress test. The primary end point was a composite of death, nonfatal myocardial infarction, and rehospitalization for an acute coronary syndrome at six months. Results: At six months, the rate of the primary end point was 15.9 percent with use of the early invasive strategy and 19.4 percent with use of the conservative strategy (odds ratio, 0.78; 95 percent confidence interval, 0.62 to 0.97; P=0.025). The rate of death or nonfatal myocardial infarction at six months was similarly reduced (7.3 percent vs. 9.5 percent; odds ratio, 0.74; 95 percent confidence interval, 0.54 to 1.00; P<0.05). Conclusions: In patients with unstable angina and myocardial infarction without ST-segment elevation who were treated with the glycoprotein IIb/IIIa inhibitor tirofiban, the use of an early invasive strategy significantly reduced the incidence of major cardiac events. These data support a policy involving broader use of the early inhibition of glycoprotein IIb/IIIa in combination with an early invasive strategy in such patients. (N Engl J Med 2001;344:1879-87.) Copyright (C) 2001 Massachusetts Medical Society.	Brigham & Womens Hosp, Div Cardiovasc, TIMI Study Grp, Boston, MA 02115 USA; Emory Univ, Atlanta, GA 30322 USA; Holmes Reg Med Ctr, Melbourne, FL USA; Heart Ctr Sarasota, Sarasota, FL USA; Baylor Coll Med, Houston, TX 77030 USA; Tech Univ Munich, Med Klin, D-8000 Munich, Germany; Harvard Clin Res Inst, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Emory University; Baylor College of Medicine; Technical University of Munich; Harvard University; Harvard Medical School	Cannon, CP (corresponding author), Brigham & Womens Hosp, Div Cardiovasc, TIMI Study Grp, 75 Francis St, Boston, MA 02115 USA.	cpcannon@partners.org	Cannon, Christopher P/AAY-7644-2020; Gibson, C. Michael/AAE-8212-2019	Cannon, Christopher P/0000-0003-4596-2791; 				Alexander JH, 2000, JAMA-J AM MED ASSOC, V283, P347, DOI 10.1001/jama.283.3.347; ANDERSON HV, 1995, J AM COLL CARDIOL, V26, P1643, DOI 10.1016/0735-1097(95)00404-1; Anderson HV, 2000, J AM COLL CARDIOL, V35, P263; [Anonymous], 1994, Circulation, V89, P1545; Antman EM, 2000, JAMA-J AM MED ASSOC, V284, P835, DOI 10.1001/jama.284.7.835; Antman EM, 1999, CIRCULATION, V100, P1593, DOI 10.1161/01.CIR.100.15.1593; Antman EM, 1999, CIRCULATION, V100, P1602, DOI 10.1161/01.CIR.100.15.1602; Antman EM, 1996, NEW ENGL J MED, V335, P1342, DOI 10.1056/NEJM199610313351802; Barr E, 1998, CIRCULATION, V98, P504; Bazzino O, 1998, NEW ENGL J MED, V338, P1498; Bazzino O, 1998, NEW ENGL J MED, V338, P1488; Boden WE, 1998, NEW ENGL J MED, V338, P1785, DOI 10.1056/NEJM199806183382501; Boden WE, 1998, NEW ENGL J MED, V339, P1091; Boersma E, 1999, CIRCULATION, V100, P2045, DOI 10.1161/01.CIR.100.20.2045; BRAUNWALD E, 1994, CIRCULATION, V90, P613, DOI 10.1161/01.CIR.90.1.613; BRAUNWALD E, 1989, CIRCULATION, V80, P410, DOI 10.1161/01.CIR.80.2.410; Braunwald E, 2000, J AM COLL CARDIOL, V36, P970, DOI 10.1016/S0735-1097(00)00889-5; Cannon CP, 1998, AM J CARDIOL, V82, P731, DOI 10.1016/S0002-9149(98)00540-2; Cannon CP, 2000, CIRCULATION, V102, P149, DOI 10.1161/01.CIR.102.2.149; FISCHMAN DL, 1994, NEW ENGL J MED, V331, P496, DOI 10.1056/NEJM199408253310802; Gunnar R M, 1990, Circulation, V82, P664; Hamm CW, 1999, NEW ENGL J MED, V341, P548; HAMM CW, 1992, NEW ENGL J MED, V327, P146, DOI 10.1056/NEJM199207163270302; Heeschen C, 1999, LANCET, V354, P1757, DOI 10.1016/S0140-6736(99)10285-X; Januzzi JL, 2000, AM J CARDIOL, V86, P713, DOI 10.1016/S0002-9149(00)01068-7; Kong DF, 1998, CIRCULATION, V98, P2829, DOI 10.1161/01.CIR.98.25.2829; Lincoff AM, 2000, CIRCULATION, V102, P1093, DOI 10.1161/01.CIR.102.10.1093; Lindahl B, 1997, J AM COLL CARDIOL, V29, P43, DOI 10.1016/S0735-1097(96)00447-0; McCullough PA, 1998, J AM COLL CARDIOL, V32, P596, DOI 10.1016/S0735-1097(98)00284-8; Morrow DA, 2000, J AM COLL CARDIOL, V36, P1812, DOI 10.1016/S0735-1097(00)00942-6; Ohman EM, 1996, NEW ENGL J MED, V335, P1333, DOI 10.1056/NEJM199610313351801; Oler A, 1996, JAMA-J AM MED ASSOC, V276, P811, DOI 10.1001/jama.276.10.811; *PLAT REC INH ISCH, 1998, NEW ENGL J MED, V339, P415; Schwaab B, 1999, J AM COLL CARDIOL, V33, P317, DOI 10.1016/S0735-1097(98)00562-2; SERRUYS PW, 1994, NEW ENGL J MED, V331, P489, DOI 10.1056/NEJM199408253310801; THEROUX P, 1988, NEW ENGL J MED, V319, P1105, DOI 10.1056/NEJM198810273191701; Topol E, 1998, NEW ENGL J MED, V339, P436; Wallentin L, 1999, LANCET, V354, P708; Wallentin L, 2000, LANCET, V356, P9, DOI 10.1016/S0140-6736(00)02427-2; WALLENTIN L, 1990, LANCET, V336, P827; Zhao XQ, 1999, CIRCULATION, V100, P1609, DOI 10.1161/01.CIR.100.15.1609	41	1510	1599	1	33	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 21	2001	344	25					1879	1887		10.1056/NEJM200106213442501	http://dx.doi.org/10.1056/NEJM200106213442501			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	443VJ	11419424	Bronze			2022-12-28	WOS:000169362100001
J	Koch, C; Crick, F				Koch, C; Crick, F			The zombie within	NATURE			English	Editorial Material									CALTECH, Div Biol, Pasadena, CA 91125 USA; CALTECH, Div Engn & Appl Sci, Pasadena, CA 91125 USA; Salk Inst, La Jolla, CA 92037 USA	California Institute of Technology; California Institute of Technology; Salk Institute	Koch, C (corresponding author), CALTECH, Div Biol, Pasadena, CA 91125 USA.			Koch, Christof/0000-0001-6482-8067				Crick F., 1994, ASTONISHING HYPOTHES; MINER AD, 1995, VISUAL BRAIN ACTION	2	80	80	0	26	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 21	2001	411	6840					893	893		10.1038/35082161	http://dx.doi.org/10.1038/35082161			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	444EN	11418835	Green Accepted, Bronze			2022-12-28	WOS:000169386200023
J	Kivipelto, M; Helkala, EL; Laakso, MP; Hanninen, T; Hallikainen, M; Alhainen, K; Soininen, H; Tuomilehto, J; Nissien, A				Kivipelto, M; Helkala, EL; Laakso, MP; Hanninen, T; Hallikainen, M; Alhainen, K; Soininen, H; Tuomilehto, J; Nissien, A			Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							APOLIPOPROTEIN-E; BLOOD-PRESSURE; DEMENTIA; ATHEROSCLEROSIS; HYPERTENSION	Objective To examine the relation of midlife raised blood pressure and serum cholesterol concentrations to Alzheimer's disease in later life. Design Prospective, population based study. Setting Populations of Kuopio and Joensuu, eastern Finland. Participants Participants were derived from random, population based samples previously studied in a survey carried out in 1972, 1977, 1982, or 1987. After an average of 21 years' follow up, a total of 1449 (73%) participants aged 65-79 took part in the re-examination in 1998. Main outcome measures Midlife blood pressure and cholesterol concentrations and development of Alzheimer's disease in later life. Results People with raised systolic blood pressure (greater than or equal to 160 mm Hg) or high serum cholesterol concentration (greater than or equal to6.5 mmol/l) in midlife had a significantly higher risk of Alzheimer's disease in later life, even after adjustment for age, body mass index, education, vascular events, smoking status, and alcohol consumption, than those with normal systolic blood pressure (odds ratio 2.3, 95% confidence interval 1.0 to 5.5) or serum cholesterol (odds ratio 2.1, 1.0 to 4.4). Participants with both of these risk factors in midlife had a significantly higher risk of developing Alzheimer's disease than those with either of the risk factors alone (odds ratio 3.5, 1.6 to 7.9). Diastolic blood pressure in midlife had no significant effect on the risk of Alzheimer's disease. Conclusion Raised systolic blood pressure and high serum cholesterol concentration, and in particular the combination of these risks, in midlife increase the risk of Alzheimer's disease in later life.	Univ Kuopio, Dept Neurol & Neurosci, FIN-70211 Kuopio, Finland; Univ Kuopio, Dept Publ Hlth & Gen Practice, FIN-70211 Kuopio, Finland; Dept Clin Radiol, Kuopio 70211, Finland; Kuopio Univ Hosp, Dept Neurol, SF-70210 Kuopio, Finland; N Karelia Cent Hosp, Joensuu 80210, Finland; Natl Publ Hlth Inst, SF-00300 Helsinki, Finland	University of Eastern Finland; University of Eastern Finland; Kuopio University Hospital; University of Eastern Finland; Finland National Institute for Health & Welfare	Kivipelto, M (corresponding author), Univ Kuopio, Dept Neurol & Neurosci, POB 1627, FIN-70211 Kuopio, Finland.	miia.kivipelto@uku.fi	Kivipelto, Miia/AAS-3557-2021; Laakso, Mikko/AHB-7022-2022	Laakso, Mikko/0000-0003-1250-3425; Kivipelto, Miia/0000-0003-0992-3875				American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; APPLEGATE WB, 1989, ANN INTERN MED, V110, P901, DOI 10.7326/0003-4819-110-11-901; Braak E, 1999, EUR ARCH PSY CLIN N, V249, P14; Brookmeyer R, 1998, AM J PUBLIC HEALTH, V88, P1337, DOI 10.2105/AJPH.88.9.1337; DAVIGNON J, 1988, ARTERIOSCLEROSIS, V8, P1, DOI 10.1161/01.ATV.8.1.1; Forette F, 1998, LANCET, V352, P1347, DOI 10.1016/S0140-6736(98)03086-4; HACHINSKI VC, 1975, ARCH NEUROL-CHICAGO, V32, P632, DOI 10.1001/archneur.1975.00490510088009; Hofman A, 1997, LANCET, V349, P151, DOI 10.1016/S0140-6736(96)09328-2; Klungel OH, 2000, STROKE, V31, P420, DOI 10.1161/01.STR.31.2.420; Kosunen O, 1996, ACTA NEUROPATHOL, V91, P185, DOI 10.1007/s004010050412; Launer LJ, 2000, NEUROBIOL AGING, V21, P49, DOI 10.1016/S0197-4580(00)00096-8; LAUNER LJ, 1994, AM J EPIDEMIOL, V139, P803, DOI 10.1093/oxfordjournals.aje.a117077; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; Notkola IL, 1998, NEUROEPIDEMIOLOGY, V17, P14, DOI 10.1159/000026149; Skoog I, 1999, ALZ DIS ASSOC DIS, V13, pS106, DOI 10.1097/00002093-199912003-00016; Skoog I, 1996, LANCET, V347, P1141, DOI 10.1016/S0140-6736(96)90608-X; VARTIAINEN E, 1994, INT J EPIDEMIOL, V23, P495, DOI 10.1093/ije/23.3.495	17	1146	1188	1	63	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 16	2001	322	7300					1447	1451		10.1136/bmj.322.7300.1447	http://dx.doi.org/10.1136/bmj.322.7300.1447			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	444FJ	11408299	Green Submitted, Bronze, Green Published			2022-12-28	WOS:000169389200022
J	Po, ALW				Po, ALW			Too much, too little, or none at all: dealing with substandard and fake drugs	LANCET			English	Editorial Material							COUNTERFEIT DRUGS		Aston Univ, Ctr Evidence Based Pharmacotherapy, Birmingham B4 7ET, W Midlands, England	Aston University	Po, ALW (corresponding author), Aston Univ, Ctr Evidence Based Pharmacotherapy, Aston Triangle, Birmingham B4 7ET, W Midlands, England.							Csillag C, 1998, LANCET, V352, P553, DOI 10.1016/S0140-6736(05)79267-9; Fugh-Berman A, 2000, LANCET, V355, P134, DOI 10.1016/S0140-6736(99)06457-0; Geiling EMK., 1938, J AM MED ASS, V111, P919, DOI [10.1001/jama.1938.72790360005007, DOI 10.1001/JAMA.1938.72790360005007]; HO RJ, 1998, NEW ENGL J MED, V339, P847; LAND T, 1992, NATURE, V355, P192, DOI 10.1038/355192a0; Rozendaal J, 2001, LANCET, V357, P890, DOI 10.1016/S0140-6736(05)71830-4; RUBIN BK, 1990, CHEST, V97, P959, DOI 10.1378/chest.97.4.959; VANDERSTRICHT BI, 1994, BRIT MED J, V308, P1162, DOI 10.1136/bmj.308.6937.1162; WAX DM, 1995, ANN INTERN MED, V5, P456; *WHO, 1997, WHO PHARM NEWSLETTER; World Health Organization, 1999, COUNT SUBST DRUGS MY, P1	11	21	21	0	6	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 16	2001	357	9272					1904	1904		10.1016/S0140-6736(00)05092-3	http://dx.doi.org/10.1016/S0140-6736(00)05092-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	444YZ	11425409				2022-12-28	WOS:000169431000007
J	Rowbotham, DJ				Rowbotham, DJ			Endogenous opioids, placebo response, and pain	LANCET			English	Editorial Material							ANALGESIA; MORPHINE; RECEPTOR; PHARMACOKINETICS; NOCICEPTIN		Leicester Royal Infirm, Leicester Warwick Med Sch, Dept Anaesthesia & Pain Management, Leicester LE1 5WW, Leics, England	University of Leicester	Rowbotham, DJ (corresponding author), Leicester Royal Infirm, Leicester Warwick Med Sch, Dept Anaesthesia & Pain Management, Leicester LE1 5WW, Leics, England.							Amanzio M, 2001, PAIN, V90, P205, DOI 10.1016/S0304-3959(00)00486-3; BAILLIE SP, 1989, AGE AGEING, V18, P258, DOI 10.1093/ageing/18.4.258; Calo' G, 2000, BRIT J PHARMACOL, V129, P1183, DOI 10.1038/sj.bjp.0703169; Calo G, 2000, BRIT J PHARMACOL, V129, P1261, DOI 10.1038/sj.bjp.0703219; Darland T, 1998, TRENDS NEUROSCI, V21, P215, DOI 10.1016/S0166-2236(97)01204-6; Gear RW, 1996, NAT MED, V2, P1248, DOI 10.1038/nm1196-1248; GLARE PA, 1991, THER DRUG MONIT, V13, P1, DOI 10.1097/00007691-199101000-00001; Horvath G, 2000, PHARMACOL THERAPEUT, V88, P437, DOI 10.1016/S0163-7258(00)00100-5; Hrobjartsson A, 2001, NEW ENGL J MED, V344, P1594, DOI 10.1056/NEJM200105243442106; LEVINE JD, 1978, LANCET, V2, P654, DOI 10.1016/S0140-6736(78)92762-9; MANSOUR A, 1988, TRENDS NEUROSCI, V11, P308, DOI 10.1016/0166-2236(88)90093-8; Picard PR, 1997, PAIN, V72, P309, DOI 10.1016/S0304-3959(97)00040-7; PLEUVRY BJ, 1991, BRIT J ANAESTH, V66, P370, DOI 10.1093/bja/66.3.370; PORTENOY RK, 1990, PAIN, V43, P273, DOI 10.1016/0304-3959(90)90025-9; Price DD, 1999, PAIN, V83, P147, DOI 10.1016/S0304-3959(99)00081-0; Stein C, 1997, PAIN, V71, P119, DOI 10.1097/00006396-199706000-00001; ter Riet G, 1998, PAIN, V76, P273, DOI 10.1016/S0304-3959(98)00057-8; YAKSH TL, 1978, PAIN, V4, P299, DOI 10.1016/0304-3959(77)90145-2; Zadina JE, 1997, NATURE, V386, P499, DOI 10.1038/386499a0	19	15	15	1	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 16	2001	357	9272					1901	1902		10.1016/S0140-6736(00)05090-X	http://dx.doi.org/10.1016/S0140-6736(00)05090-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	444YZ	11425407				2022-12-28	WOS:000169431000005
J	Rigby, P				Rigby, P			Rosa Beddington - Obituary	CELL			English	Biographical-Item									Inst Canc Res, London SW3 6JB, England	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Rigby, P (corresponding author), Inst Canc Res, London SW3 6JB, England.								0	0	0	0	0	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTES AVE,, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 15	2001	105	6					709	710		10.1016/S0092-8674(01)00393-2	http://dx.doi.org/10.1016/S0092-8674(01)00393-2			2	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	444AE	11440713	Bronze			2022-12-28	WOS:000169375100004
J	Stephanopoulos, G; Kelleher, J				Stephanopoulos, G; Kelleher, J			Biochemistry - How to make a superior cell	SCIENCE			English	Editorial Material									MIT, Dept Chem Engn, Cambridge, MA 02139 USA; George Washington Univ, Sch Med & Hlth Sci, Dept Physiol & Expt Med, Washington, DC 20037 USA	Massachusetts Institute of Technology (MIT); George Washington University	Stephanopoulos, G (corresponding author), MIT, Dept Chem Engn, Cambridge, MA 02139 USA.	gregstep@mit.edu						BAILEY JE, 1991, SCIENCE, V252, P1668, DOI 10.1126/science.2047876; Farmer WR, 2000, NAT BIOTECHNOL, V18, P533, DOI 10.1038/75398; Fell D., 1997, UNDERSTANDING CONTRO; Keasling JD, 1999, TRENDS BIOTECHNOL, V17, P452, DOI 10.1016/S0167-7799(99)01376-1; Kolkman JA, 2001, NAT BIOTECHNOL, V19, P423, DOI 10.1038/88084; MURDOCK D, 1993, BIO-TECHNOL, V11, P381, DOI 10.1038/nbt0393-381; Ostergaard S, 2000, NAT BIOTECHNOL, V18, P1283, DOI 10.1038/82400; Pfeifer BA, 2001, SCIENCE, V291, P1790, DOI 10.1126/science.1058092; Schwartz MA, 1999, CURR OPIN CELL BIOL, V11, P197, DOI 10.1016/S0955-0674(99)80026-X; Stephanopoulos G., 1998, METAB ENG; Ye XD, 2000, SCIENCE, V287, P303, DOI 10.1126/science.287.5451.303; Zaslavskaia LA, 2001, SCIENCE, V292, P2073, DOI 10.1126/science.160015	12	30	31	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 15	2001	292	5524					2024	2025		10.1126/science.1062556	http://dx.doi.org/10.1126/science.1062556			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	442KP	11408647				2022-12-28	WOS:000169284700034
J	Fischer, A				Fischer, A			Primary immunodeficiency diseases: an experimental model for molecular medicine	LANCET			English	Article							LINKED LYMPHOPROLIFERATIVE-DISEASE; COMMON VARIABLE IMMUNODEFICIENCY; HYPER-IGM SYNDROME; STEM-CELL TRANSPLANTATION; V(D)J RECOMBINATION; TYROSINE KINASE; IN-VIVO; GENE; MUTATIONS; DEFICIENCY	Primary immunodeficiency diseases represent a vast array of inherited disorders of the immune system. Major advances in the understanding of genetic basis and molecular mechanisms have occurred within the past 10 years, as a result of the tools of modern genetics. About three quarters of 100 primary immunodeficiency diseases can now be reliably diagnosed with molecular probes. In many cases, gene identification has enabled significant insight into the physiopathology of the related conditions. Therapeutic progress based on protein engineering and possibly gene therapy will also ensue.	Hop Necker Enfants Malad, INSERM, U429, F-75015 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Fischer, A (corresponding author), Hop Necker Enfants Malad, INSERM, U429, 149 Rue Sevres, F-75015 Paris, France.	fischer@necker.fr						Barbosa MDFS, 1996, NATURE, V382, P262, DOI 10.1038/382262a0; BASILE GD, 1991, J CLIN INVEST, V87, P1352; Bennett CL, 2001, NAT GENET, V27, P20, DOI 10.1038/83713; BLUNT T, 1995, CELL, V80, P813, DOI 10.1016/0092-8674(95)90360-7; Bousso P, 2000, P NATL ACAD SCI USA, V97, P274, DOI 10.1073/pnas.97.1.274; Brown MP, 1998, NAT MED, V4, P1253, DOI 10.1038/3233; Buckley RH, 1999, NEW ENGL J MED, V340, P508, DOI 10.1056/NEJM199902183400703; Bykowsky MJ, 1996, AM J HUM GENET, V58, P477; Cavazzana-Calvo M, 2000, SCIENCE, V288, P669, DOI 10.1126/science.288.5466.669; Coffey AJ, 1998, NAT GENET, V20, P129, DOI 10.1038/2424; CONLEY ME, 1994, J CLIN INVEST, V94, P1404, DOI 10.1172/JCI117476; DERRY JMJ, 1994, CELL, V78, P635, DOI 10.1016/0092-8674(94)90528-2; Doffinger R, 2001, NAT GENET, V27, P277, DOI 10.1038/85837; Fischer A, 1998, SCIENCE, V280, P237, DOI 10.1126/science.280.5361.237; GATTI RA, 1968, LANCET, V2, P1366; Hammarstrom L, 2000, CLIN EXP IMMUNOL, V120, P225, DOI 10.1046/j.1365-2249.2000.01131.x; Hirschhorn R, 1996, NAT GENET, V13, P290, DOI 10.1038/ng0796-290; Howie D, 2000, CURR OPIN IMMUNOL, V12, P474, DOI 10.1016/S0952-7915(00)00123-0; Jain A, 2001, NAT IMMUNOL, V2, P223, DOI 10.1038/85277; Jirapongsananuruk O, 1999, CLIN EXP IMMUNOL, V118, P1; Leonard WJ, 1996, ANNU REV MED, V47, P229; Levy Y, 1998, P NATL ACAD SCI USA, V95, P13135, DOI 10.1073/pnas.95.22.13135; Lubke T, 2001, NAT GENET, V28, P73, DOI 10.1038/88299; Luhn K, 2001, NAT GENET, V28, P69, DOI 10.1038/ng0501-69; MACCHI P, 1995, NATURE, V377, P65, DOI 10.1038/377065a0; Mansour S, 2001, AM J MED GENET, V99, P172, DOI 10.1002/1096-8628(2001)9999:9999<::AID-AJMG1155>3.0.CO;2-Y; Masternak K, 1998, NAT GENET, V20, P273, DOI 10.1038/3081; Menasche G, 2000, NAT GENET, V25, P173, DOI 10.1038/76024; Minegishi Y, 1999, J CLIN INVEST, V104, P1115, DOI 10.1172/JCI7696; Minegishi Y, 1999, SCIENCE, V286, P1954, DOI 10.1126/science.286.5446.1954; Minegishi Y, 1998, J EXP MED, V187, P71, DOI 10.1084/jem.187.1.71; Moshous D, 2001, CELL, V105, P177, DOI 10.1016/S0092-8674(01)00309-9; Nagle DL, 1996, NAT GENET, V14, P307, DOI 10.1038/ng1196-307; Nichols KE, 1998, P NATL ACAD SCI USA, V95, P13765, DOI 10.1073/pnas.95.23.13765; Nicolas N, 1998, J EXP MED, V188, P627, DOI 10.1084/jem.188.4.627; Notarangelo LD, 2000, CLIN EXP IMMUNOL, V120, P399, DOI 10.1046/j.1365-2249.2000.01142.x; Notarangelo LD, 1999, CURR OPIN IMMUNOL, V11, P435, DOI 10.1016/S0952-7915(99)80073-9; Parolini S, 2000, J EXP MED, V192, P337, DOI 10.1084/jem.192.3.337; Patel DD, 2000, NEW ENGL J MED, V342, P1325, DOI 10.1056/NEJM200005043421804; Puel A, 1998, NAT GENET, V20, P394, DOI 10.1038/3877; Revy P, 2000, CELL, V102, P565, DOI 10.1016/S0092-8674(00)00079-9; Ridanpaa M, 2001, CELL, V104, P195, DOI 10.1016/S0092-8674(01)00205-7; RUSSELL SM, 1995, SCIENCE, V270, P797, DOI 10.1126/science.270.5237.797; Satterthwaite AB, 2000, IMMUNOL REV, V175, P120, DOI 10.1034/j.1600-065X.2000.017504.x; SAVITSKY K, 1995, SCIENCE, V268, P1749, DOI 10.1126/science.7792600; Sayos J, 1998, NATURE, V395, P462, DOI 10.1038/26683; Schroeder HW, 1998, MOL MED, V4, P72, DOI 10.1007/BF03401731; Schwarz K, 1996, SCIENCE, V274, P97, DOI 10.1126/science.274.5284.97; STEIMLE V, 1995, GENE DEV, V9, P1021, DOI 10.1101/gad.9.9.1021; STEIMLE V, 1994, SCIENCE, V265, P106, DOI 10.1126/science.8016643; Stepp SE, 1999, SCIENCE, V286, P1957, DOI 10.1126/science.286.5446.1957; Sugamura K, 1996, ANNU REV IMMUNOL, V14, P179, DOI 10.1146/annurev.immunol.14.1.179; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; Villa A, 1998, CELL, V93, P885, DOI 10.1016/S0092-8674(00)81448-8; Villard J, 1997, NEW ENGL J MED, V337, P748, DOI 10.1056/NEJM199709113371104; Vorechovsky I, 1999, AM J HUM GENET, V64, P1096, DOI 10.1086/302326; Vorechovsky I, 2000, J IMMUNOL, V164, P4408, DOI 10.4049/jimmunol.164.8.4408; Wildin RS, 2001, NAT GENET, V27, P18, DOI 10.1038/83707; Yel L, 1996, NEW ENGL J MED, V335, P1486, DOI 10.1056/NEJM199611143352003; ZONANA J, ANJ HUM GENET, V67, P1555	61	72	75	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 9	2001	357	9271					1863	1869		10.1016/S0140-6736(00)04959-X	http://dx.doi.org/10.1016/S0140-6736(00)04959-X			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	440DN	11410213				2022-12-28	WOS:000169160800032
J	Miller, AB				Miller, AB			Natural history of cervical human papillomavirus infections	LANCET			English	Editorial Material							HPV		Deutsch Krebsforschungszentrum, Div Clin Epidemiol, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ)	Miller, AB (corresponding author), Deutsch Krebsforschungszentrum, Div Clin Epidemiol, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.	a.miller@dkfz-heidelberg.de						Black WC, 2000, J NATL CANCER I, V92, P1280, DOI 10.1093/jnci/92.16.1280; Blumenthal PD, 2001, INT J GYNECOL OBSTET, V72, P47, DOI 10.1016/S0020-7292(00)00329-5; Cuzick J, 1999, BRIT J CANCER, V81, P554, DOI 10.1038/sj.bjc.6690730; Hakama M, 1986, IARC SCI PUBL, P133; Ho GYF, 1998, NEW ENGL J MED, V338, P423, DOI 10.1056/NEJM199802123380703; Holowaty P, 1999, JNCI-J NATL CANCER I, V91, P252, DOI 10.1093/jnci/91.3.252; Liaw KL, 1999, J NATL CANCER I, V91, P954, DOI 10.1093/jnci/91.11.954; Miller Anthony B., 2000, International Journal of Cancer, V86, P440, DOI 10.1002/(SICI)1097-0215(20000501)86:3<440::AID-IJC22>3.3.CO;2-1; OSTOR AG, 1993, INT J GYNECOL PATHOL, V12, P186; Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F	10	17	17	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 9	2001	357	9271					1816	1816		10.1016/S0140-6736(00)05008-X	http://dx.doi.org/10.1016/S0140-6736(00)05008-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	440DN	11410184				2022-12-28	WOS:000169160800004
J	Richards, AM; Lainchbury, JG; Nicholls, MG				Richards, AM; Lainchbury, JG; Nicholls, MG			Unsatisfactory redefinition of myocardial Infarction	LANCET			English	Editorial Material							TROPONIN-T		Univ Otago, Christchurch Sch Med, Christchurch Cardioendocrine Res Grp, Christchurch, New Zealand; Christchurch Hosp, Dept Cardiol, Christchurch, New Zealand	University of Otago; Christchurch Hospital New Zealand	Richards, AM (corresponding author), Univ Otago, Christchurch Sch Med, Christchurch Cardioendocrine Res Grp, Christchurch, New Zealand.							Alpert JS, 2000, EUR HEART J, V21, P1502, DOI 10.1053/euhj.2000.2305; Alpert JS, 2000, J AM COLL CARDIOL, V36, P959, DOI 10.1016/S0735-1097(00)00804-4; Antman EM, 1997, AM HEART J, V133, P596, DOI 10.1016/S0002-8703(97)70156-X; Apple FS, 1997, CLIN CHEM, V43, P2047; Beller GA, 2000, J AM COLL CARDIOL, V36, P957, DOI 10.1016/S0735-1097(00)00844-5; Gibbons RJ, 2000, CIRCULATION, V101, P101, DOI 10.1161/01.CIR.101.1.101; HAMM CW, 1992, NEW ENGL J MED, V327, P146, DOI 10.1056/NEJM199207163270302; Lindahl B, 1996, CIRCULATION, V93, P1651, DOI 10.1161/01.CIR.93.9.1651; Tardiff BE, 1999, J AM COLL CARDIOL, V33, P88, DOI 10.1016/S0735-1097(98)00551-8; Tunstall-Pedoe H, 2001, EUR HEART J, V22, P613, DOI 10.1053/euhj.2000.2579; Tunstall-Pedoe H, 2001, J AM COLL CARDIOL, V37, P1472, DOI 10.1016/S0735-1097(01)01154-8; TUNSTALLPEDOE H, 1994, CIRCULATION, V90, P583, DOI 10.1161/01.CIR.90.1.583; Wu E, 2001, LANCET, V357, P21, DOI 10.1016/S0140-6736(00)03567-4	13	29	29	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 26	2001	357	9269					1635	1636		10.1016/S0140-6736(00)04858-3	http://dx.doi.org/10.1016/S0140-6736(00)04858-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	435UY	11425362				2022-12-28	WOS:000168901600003
J	Coleman, PG; Perry, BD; Woolhouse, MEJ				Coleman, PG; Perry, BD; Woolhouse, MEJ			Endemic stability - a veterinary idea applied to human public health	LANCET			English	Article							PLASMODIUM-FALCIPARUM TRANSMISSION; SEVERE MALARIA; COST-EFFECTIVENESS; EPIDEMIOLOGY; MORTALITY; MORBIDITY; ECONOMICS; DISEASES	Endemic stability is an epidemiological state of a population, in which clinical disease is scarce despite high level of infection. The notion was developed to describe patterns of tick-borne disease in cattle. However, we propose a general model of endemic stability that is applicable to a broader range of diseases that are important in public health, including malaria, rubella, and mumps. We postulate that endemic stability requires only that (1) the probability, or severity, of clinical disease after infection increases with age, and (2) after one infection, the probability that subsequent infections result in disease is reduced. We present these criteria in simple mathematical terms. Our hypothesis predicts that partial disease control activities might, under certain mathematical circumstances, interventions.	Univ Edinburgh, Ctr Trop Vet Med, Roslin EH25 9RG, Midlothian, Scotland; Int Livestock Res Inst, Nairobi, Kenya	University of Edinburgh; CGIAR; International Livestock Research Institute (ILRI)	Coleman, PG (corresponding author), Univ Edinburgh, Ctr Trop Vet Med, Easter Bush, Roslin EH25 9RG, Midlothian, Scotland.	p.coleman@cgiar.org		Perry, Brian/0000-0002-6962-2102				ADES AE, 1993, AM J EPIDEMIOL, V137, P1022, DOI 10.1093/oxfordjournals.aje.a116758; ANDERSON R M, 1991; Bruce D, 1910, P R SOC LOND B-CONTA, V82, P256, DOI 10.1098/rspb.1910.0016; Coleman PG, 1999, TROP MED INT HEALTH, V4, P175, DOI 10.1046/j.1365-3156.1999.43382.x; COOK AJC, 1991, TROP ANIM HEALTH PRO, V23, P161, DOI 10.1007/BF02356997; DEEM SL, 1993, PREV VET MED, V16, P171, DOI 10.1016/0167-5877(93)90064-Z; Gupta S, 1999, NAT MED, V5, P340, DOI 10.1038/6560; Guyatt HL, 1999, PHILOS T R SOC B, V354, P827, DOI 10.1098/rstb.1999.0434; MAHONEY DF, 1972, AUST VET J, V48, P292, DOI 10.1111/j.1751-0813.1972.tb05160.x; MELNICK JL, 1985, VIROLOGY, P739; METTAM RWM, 1936, PARASITOLOGY, V28, P245; MILLER G, 1985, VIROLOGY, P563; Norval R. A. I., 1983, Zimbabwe Veterinary Journal, V14, P19; NORVAL RAI, 1992, EPIDEMIOLOGY THELERI; O'Callaghan CJ, 1998, PARASITOLOGY, V117, P49, DOI 10.1017/S0031182098002790; Panagiotopoulos T, 1999, BRIT MED J, V319, P1462, DOI 10.1136/bmj.319.7223.1462; Perry BD, 1995, PREV VET MED, V25, P107, DOI 10.1016/0167-5877(95)00546-3; Snow RW, 1998, BRIT MED BULL, V54, P293, DOI 10.1093/oxfordjournals.bmb.a011689; SNOW RW, 1995, PARASITOL TODAY, V11, P188, DOI 10.1016/0169-4758(95)80156-1; Snow RW, 1997, LANCET, V349, P1650, DOI 10.1016/S0140-6736(97)02038-2; Snow RW, 1998, J INFECT DIS, V177, P819, DOI 10.1086/517818; Trape JF, 1996, PARASITOL TODAY, V12, P236, DOI 10.1016/0169-4758(96)10015-6; UILENBERG G, 1995, VET PARASITOL, V57, P19, DOI 10.1016/0304-4017(94)03107-8	23	76	76	0	18	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 21	2001	357	9264					1284	1286		10.1016/S0140-6736(00)04410-X	http://dx.doi.org/10.1016/S0140-6736(00)04410-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	425YY	11418173				2022-12-28	WOS:000168323300033
J	Ford, WCL				Ford, WCL			Biological mechanisms of male infertility	LANCET			English	Editorial Material							VITAMIN-E; IN-VITRO; SPERMATOZOA; MOTILITY; MEN		St Michaels Hosp, Univ Div Obstet & Gynaecol, Bristol BS2 8EG, Avon, England		Ford, WCL (corresponding author), St Michaels Hosp, Univ Div Obstet & Gynaecol, Bristol BS2 8EG, Avon, England.	chris.ford@bristol.ac.uk						AITKEN RJ, 1991, AM J OBSTET GYNECOL, V164, P542, DOI 10.1016/S0002-9378(11)80017-7; Bronson RA, 1999, J REPROD IMMUNOL, V45, P159; De Kretser DM, 2000, INT J ANDROL, V23, P30; LILFORD R, 1994, BMJ-BRIT MED J, V309, P570, DOI 10.1136/bmj.309.6954.570; Mallidis KMC, 2000, EUR J ENDOCRINOL, V142, P418, DOI 10.1530/eje.0.1420418; Oosterhuis GJE, 2000, FERTIL STERIL, V74, P245, DOI 10.1016/S0015-0282(00)00623-3; Rolf C, 1999, HUM REPROD, V14, P1028, DOI 10.1093/humrep/14.4.1028; Ruiz-Pesini E, 2000, AM J HUM GENET, V67, P682, DOI 10.1086/303040; Sakkas D, 1999, EXP CELL RES, V251, P350, DOI 10.1006/excr.1999.4586; Sharma RK, 1999, HUM REPROD, V14, P2801, DOI 10.1093/humrep/14.11.2801; Shetty J, 1999, BIOL REPROD, V61, P61, DOI 10.1095/biolreprod61.1.61; SUKCHAROEN N, 1995, FERTIL STERIL, V63, P1293, DOI 10.1016/S0015-0282(16)57614-6; Suleiman SA, 1996, J ANDROL, V17, P530; Tesarik J, 1999, FERTIL STERIL, V72, P809, DOI 10.1016/S0015-0282(99)00379-9	14	11	11	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 21	2001	357	9264					1223	1224		10.1016/S0140-6736(00)04452-4	http://dx.doi.org/10.1016/S0140-6736(00)04452-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	425YY	11418145				2022-12-28	WOS:000168323300007
J	Horton, R				Horton, R			Euthanasia and assisted suicide: what does the Dutch vote mean?	LANCET			English	Editorial Material							OF-LIFE CARE; END		Lancet, London WC1X 8RR, England		Horton, R (corresponding author), Lancet, London WC1X 8RR, England.							Asch DA, 1997, SOC SCI MED, V45, P1661, DOI 10.1016/S0277-9536(97)00125-1; Bolmsjo I, 2000, J PALLIAT CARE, V16, P20, DOI 10.1177/082585970001600204; Carron A T, 1999, Ann Intern Med, V130, P82; Dworkin R, 1997, NEW YORK REV BOOKS, V44, P41; Ferrand E, 2001, LANCET, V357, P9, DOI 10.1016/S0140-6736(00)03564-9; Ganzini L, 2000, NEW ENGL J MED, V343, P151; Ganzini L, 2000, NEW ENGL J MED, V342, P557, DOI 10.1056/NEJM200002243420806; Groenewoud JH, 2000, NEW ENGL J MED, V342, P551, DOI 10.1056/NEJM200002243420805; HORTON R, 2000, NEW YORK REV    0810, P30; Kohlwes RJ, 2001, ARCH INTERN MED, V161, P657, DOI 10.1001/archinte.161.5.657; Prendergast TJ, 1998, AM J RESP CRIT CARE, V158, P1163, DOI 10.1164/ajrccm.158.4.9801108; Rabow MW, 2000, JAMA-J AM MED ASSOC, V283, P771, DOI 10.1001/jama.283.6.771; Roscoe LA, 2000, NEW ENGL J MED, V343, P1735, DOI 10.1056/NEJM200012073432315; Singer PA, 1999, JAMA-J AM MED ASSOC, V281, P163, DOI 10.1001/jama.281.2.163; Sullivan AD, 2001, NEW ENGL J MED, V344, P605, DOI 10.1056/NEJM200102223440811; Weber W, 2001, LANCET, V357, P1189, DOI 10.1016/S0140-6736(00)04400-7	16	12	12	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	APR 21	2001	357	9264					1221	1222		10.1016/S0140-6736(00)04450-0	http://dx.doi.org/10.1016/S0140-6736(00)04450-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	425YY	11418143				2022-12-28	WOS:000168323300005
J	Kuhr, S; Alt, W; Schrader, D; Muller, M; Gomer, V; Meschede, D				Kuhr, S; Alt, W; Schrader, D; Muller, M; Gomer, V; Meschede, D			Deterministic delivery of a single atom	SCIENCE			English	Article							DECOHERENCE; ENTANGLEMENT; MANIPULATION; GENERATION; STATE; PAIRS	We report the realization of a deterministic source of single atoms. A standing-wave dipole trap is Loaded with one or any desired number of cold cesium atoms from a magneto-optical trap. By controlling the motion of the standing wave, we adiabatically transport the atom with submicrometer precision over macroscopic distances on the order of a centimeter. The displaced atom is observed directly in the dipole trap by fluorescence detection. The trapping field can also be accelerated to eject a single atom into free flight with well-defined velocities.	Univ Bonn, Inst Angew Phys, D-53115 Bonn, Germany	University of Bonn	Kuhr, S (corresponding author), Univ Bonn, Inst Angew Phys, Wegelerstr 8, D-53115 Bonn, Germany.	kuhr@iap.uni-bonn.de	Kuhr, Stefan/F-7296-2011; Kuhr, Stefan/ABC-8654-2020	Kuhr, Stefan/0000-0001-8386-5357; Kuhr, Stefan/0000-0001-8386-5357				ASHKIN A, 1970, PHYS REV LETT, V24, P156, DOI 10.1103/PhysRevLett.24.156; Balykin VI, 2000, REP PROG PHYS, V63, P1429, DOI 10.1088/0034-4885/63/9/202; Beige A, 2000, PHYS REV LETT, V85, P1762, DOI 10.1103/PhysRevLett.85.1762; BenDahan M, 1996, PHYS REV LETT, V76, P4508, DOI 10.1103/PhysRevLett.76.4508; CHU S, 1986, PHYS REV LETT, V57, P314, DOI 10.1103/PhysRevLett.57.314; CHU S, 1991, SCIENCE, V253, P861, DOI 10.1126/science.253.5022.861; Frese D, 2000, PHYS REV LETT, V85, P3777, DOI 10.1103/PhysRevLett.85.3777; Grimm R, 2000, ADV ATOM MOL OPT PHY, V42, P95, DOI 10.1016/S1049-250X(08)60186-X; Hagley E, 1997, PHYS REV LETT, V79, P1, DOI 10.1103/PhysRevLett.79.1; Hamann SE, 1998, PHYS REV LETT, V80, P4149, DOI 10.1103/PhysRevLett.80.4149; Hansel W, 2001, PHYS REV LETT, V86, P608, DOI 10.1103/PhysRevLett.86.608; Hennrich M, 2000, PHYS REV LETT, V85, P4872, DOI 10.1103/PhysRevLett.85.4872; Hood CJ, 2000, SCIENCE, V287, P1447, DOI 10.1126/science.287.5457.1447; HU Z, 1994, OPT LETT, V19, P1888, DOI 10.1364/OL.19.001888; Law CK, 1997, J MOD OPTIC, V44, P2067, DOI 10.1080/095003497152357; Lo H-K., 1998, INTRO QUANTUM COMPUT; MESCHEDE D, 2000, LIGHT MATTER INTERAC; Metcalf HJ., 1999, LASER COOLING TRAPPI; Morinaga M, 1999, PHYS REV LETT, V83, P4037, DOI 10.1103/PhysRevLett.83.4037; NEUHAUSER W, 1980, PHYS REV A, V22, P1137, DOI 10.1103/PhysRevA.22.1137; PELLIZZARI T, 1995, PHYS REV LETT, V75, P3788, DOI 10.1103/PhysRevLett.75.3788; Pinkse PWH, 2000, NATURE, V404, P365, DOI 10.1038/35006006; RAAB EL, 1987, PHYS REV LETT, V59, P2631, DOI 10.1103/PhysRevLett.59.2631; Rauschenbeutel A, 2000, SCIENCE, V288, P2024, DOI 10.1126/science.288.5473.2024; Roos C, 1999, PHYS REV LETT, V83, P4713, DOI 10.1103/PhysRevLett.83.4713; Sackett CA, 2000, NATURE, V404, P256, DOI 10.1038/35005011; Turchette QA, 1998, PHYS REV LETT, V81, P3631, DOI 10.1103/PhysRevLett.81.3631; WEHNER E, 1994, OPT COMMUN, V110, P655, DOI 10.1016/0030-4018(94)90268-2; Wilkinson SR, 1996, PHYS REV LETT, V76, P4512, DOI 10.1103/PhysRevLett.76.4512	29	216	219	4	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 13	2001	293	5528					278	280		10.1126/science.1062725	http://dx.doi.org/10.1126/science.1062725			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	452TK	11408622				2022-12-28	WOS:000169875200052
J	Meriles, CA; Sakellariou, D; Heise, H; Moule, AJ; Pines, A				Meriles, CA; Sakellariou, D; Heise, H; Moule, AJ; Pines, A			Approach to high-resolution ex situ NMR spectroscopy	SCIENCE			English	Article							NUCLEAR MAGNETIC-RESONANCE; SPECTRA; FIELDS	Nuclear magnetic resonance (NMR) experiments are typically performed with samples immersed in a magnet shimmed to high homogeneity. However, there are many circumstances in which it is impractical or undesirable to insert objects or subjects into the bore of a high-field magnet. Here we present a methodology based on an adaptation of nutation echoes that provides resolved spectra in the presence of matched inhomogeneous static and radiofrequency fields, thereby opening the way to high-resolution exsitu NMR, The observation of chemical shifts is regained through the use of multiple-pulse sequences of correlated, composite z-rotation pulses, producing resolved NMR spectra of liquid samples.	Univ Calif Berkeley, Lawrence Berkeley Lab, Div Mat Sci, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; University of California System; University of California Berkeley	Pines, A (corresponding author), Univ Calif Berkeley, Lawrence Berkeley Lab, Div Mat Sci, Berkeley, CA 94720 USA.		Heise, Henrike/A-7703-2010; Sakellariou, Dimitrios/F-2846-2010; Sakellariou, Dimitrios/O-7949-2019; Moule, Adam/B-9484-2013	Heise, Henrike/0000-0002-9081-3894; Sakellariou, Dimitrios/0000-0001-7424-5543; Sakellariou, Dimitrios/0000-0001-7424-5543; Moule, Adam/0000-0003-1354-3517				ACKERMAN JJH, 1980, NATURE, V283, P167, DOI 10.1038/283167a0; ALBERT MS, 1994, NATURE, V370, P199, DOI 10.1038/370199a0; ANDREW ER, 1962, DISCUSS FARADAY SOC, P38, DOI 10.1039/df9623400038; ANDREW ER, 1958, NATURE, V182, P1659, DOI 10.1038/1821659a0; Ardelean I, 2000, J MAGN RESON, V146, P43, DOI 10.1006/jmre.2000.2146; Balbach JJ, 1997, CHEM PHYS LETT, V277, P367, DOI 10.1016/S0009-2614(97)00858-0; Blumich B, 1998, MAGN RESON IMAGING, V16, P479, DOI 10.1016/S0730-725X(98)00069-1; CHMELKA BF, 1989, SCIENCE, V246, P71, DOI 10.1126/science.246.4926.71; de Swiet TM, 1998, J MAGN RESON, V133, P385, DOI 10.1006/jmre.1998.1459; FRANK S, 1993, NATURE, V363, P334, DOI 10.1038/363334a0; HALL LD, 1987, J AM CHEM SOC, V109, P7579, DOI 10.1021/ja00258a080; Hurlimann MD, 2000, J MAGN RESON, V143, P120, DOI 10.1006/jmre.1999.1967; Jerschow A, 1998, CHEM PHYS LETT, V296, P466, DOI 10.1016/S0009-2614(98)01032-X; KLEINBERG RL, 1992, J MAGN RESON, V97, P466, DOI 10.1016/0022-2364(92)90028-6; LEVITT MH, 1997, ENCY NMR, P1396; Navon G, 1996, SCIENCE, V271, P1848, DOI 10.1126/science.271.5257.1848; RICHTER W, 1995, SCIENCE, V267, P654, DOI 10.1126/science.7839140; Scharfenecker A, 2001, J MAGN RESON, V148, P363, DOI 10.1006/jmre.2000.2250; STEBBINS JF, 1989, SCIENCE, V245, P257, DOI 10.1126/science.245.4915.257; WEITEKAMP DP, 1981, J AM CHEM SOC, V103, P3578, DOI 10.1021/ja00402a057	20	142	149	0	44	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 6	2001	293	5527					82	85		10.1126/science.1061498	http://dx.doi.org/10.1126/science.1061498			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	451BB	11441177				2022-12-28	WOS:000169780300032
J	McGovern, MC; Glasgow, JFT; Stewart, MC				McGovern, MC; Glasgow, JFT; Stewart, MC			Lesson of the week - Reye's syndrome and aspirin: lest we forget	BRITISH MEDICAL JOURNAL			English	Review							ASSOCIATION; CHILDREN		Royal Belfast Hosp Sick Children, Dept Accid & Emergency, Belfast BT12 6BE, Antrim, North Ireland; Queens Univ Belfast, Dept Child Hlth, Belfast BT12 6BE, Antrim, North Ireland	Queens University Belfast	Glasgow, JFT (corresponding author), Royal Belfast Hosp Sick Children, Dept Accid & Emergency, Belfast BT12 6BE, Antrim, North Ireland.							Belay ED, 1999, NEW ENGL J MED, V340, P1377, DOI 10.1056/NEJM199905063401801; FORSYTH BW, 1989, JAMA-J AM MED ASSOC, V261, P2517, DOI 10.1001/jama.261.17.2517; GUY M, 1998, 12 ROYAL COLL PAED C, P8; Hall SM, 1999, NEW ENGL J MED, V341, P845; HALL SM, 1988, ARCH DIS CHILD, V63, P857, DOI 10.1136/adc.63.7.857; Hardie RM, 1996, ARCH DIS CHILD, V74, P400, DOI 10.1136/adc.74.5.400; Monto AS, 1999, NEW ENGL J MED, V340, P1423, DOI 10.1056/NEJM199905063401809; PORTER JDH, 1990, ARCH DIS CHILD, V65, P826, DOI 10.1136/adc.65.8.826; RENNEBOHM RM, 1985, J PEDIATR-US, V107, P877, DOI 10.1016/S0022-3476(85)80179-7; *ROYAL COLL PAED C, 1999, MED CHILDR; SOUMERAI SB, 1992, MILBANK Q, V70, P155, DOI 10.2307/3350088; 1986, BMJ, V292, P1590	12	12	15	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 30	2001	322	7302					1591	1592		10.1136/bmj.322.7302.1591	http://dx.doi.org/10.1136/bmj.322.7302.1591			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	449QT	11431304	Green Published			2022-12-28	WOS:000169699200032
J	Fenchel, T				Fenchel, T			Ecology - Marine bugs and carbon flow	SCIENCE			English	Editorial Material							BACTERIA		Univ Copenhagen, Marine Biol Lab, DK-3000 Helsingor, Denmark	University of Copenhagen	Fenchel, T (corresponding author), Univ Copenhagen, Marine Biol Lab, Strandpromenaden 5, DK-3000 Helsingor, Denmark.	tfenchel@zi.ku.dk	Fenchel, Tom/F-8979-2011	Fenchel, Tom/0000-0003-0023-2402				BLANKENSHIP RE, 1995, ANOXYGENIC PHOTOSYNT; BRATBAK G, 1994, MICROBIAL ECOL, V28, P209, DOI 10.1007/BF00166811; FENCHEL T, 1982, MAR ECOL PROG SER, V9, P35, DOI 10.3354/meps009035; GOERICKE R, 1993, DEEP-SEA RES PT I, V40, P2283, DOI 10.1016/0967-0637(93)90104-B; Hagstrom A, 2000, AQUAT MICROB ECOL, V21, P231, DOI 10.3354/ame021231; ITURRIAGA R, 1986, MAR ECOL PROG SER, V28, P291, DOI 10.3354/meps028291; Kolber ZS, 2000, NATURE, V407, P177, DOI 10.1038/35025044; Kolber ZS, 2001, SCIENCE, V292, P2492, DOI 10.1126/science.1059707; Schlegel H.G., 1989, AUTOTROPHIC BACTERIA; SHIBA T, 1991, APPL ENVIRON MICROB, V57, P295, DOI 10.1128/AEM.57.1.295-300.1991; Steele JH, 1974, STRUCTURE MARINE ECO; Stoecker DK, 1998, EUR J PROTISTOL, V34, P281, DOI 10.1016/S0932-4739(98)80055-2; WILLIAMS PJL, 1981, KIELER MEERESFORSCH, V5, P1; ZWEIFEL UL, 1995, APPL ENVIRON MICROB, V61, P2180, DOI 10.1128/AEM.61.6.2180-2185.1995	14	13	18	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 29	2001	292	5526					2444	2445		10.1126/science.1062799	http://dx.doi.org/10.1126/science.1062799			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	448YU	11431556				2022-12-28	WOS:000169658200028
J	Ergon, T; Lambin, X; Stenseth, NC				Ergon, T; Lambin, X; Stenseth, NC			Life-history traits of voles in a fluctuating population respond to the immediate environment	NATURE			English	Article							DENSITY-DEPENDENCE; SMALL MAMMALS; IN-FIELD; CYCLES; PREDATION; DYNAMICS; PATTERNS	Life-history traits relating to growth and reproduction vary greatly among species and populations(1,2) and among individuals within populations(3). In vole populations, body size and age at maturation may vary considerably among locations and among years within the same location(4-8). Individuals in increasing populations are typically larger and start reproduction earlier in the spring than those in declining populations(6-8). The cause of such life-history variation within populations has been subject of much discussion(7,9,10). Much of the controversy concerns whether the memory of past conditions, leading to delayed effects on life-history traits, resides in the environment (for example, predators(11,12), pathogens(13) or food(14,15)) or intrinsically within populations or individuals (age distribution(16,17), physiological state(3), genetic(18) or maternal effects(19,20)). Here we report from an extensive field transplant experiment in which voles were moved before the breeding season between sites that differed in average overwintering body mass. Transplanted voles did not retain the characteristics of their source population, and we demonstrate an over-riding role of the immediate environment in shaping life-history traits of small rodents.	Univ Oslo, Dept Biol, Div Zool, N-0316 Oslo, Norway; Univ Aberdeen, Dept Zool, Aberdeen AB24 2TZ, Scotland	University of Oslo; University of Aberdeen	Stenseth, NC (corresponding author), Univ Oslo, Dept Biol, Div Zool, POB 1050 Blindern, N-0316 Oslo, Norway.	x.lambin@abdn.ac.uk; n.c.stenseth@bio.uio.no	Lambin, Xavier/E-8284-2011; Stenseth, Nils Chr./G-5212-2016	Lambin, Xavier/0000-0003-4643-2653; Stenseth, Nils Chr./0000-0002-1591-5399				AGRELL J, 1995, P ROY SOC B-BIOL SCI, V262, P65, DOI 10.1098/rspb.1995.0177; AGRELL J, 1992, CAN J ZOOL, V70, P494, DOI 10.1139/z92-074; Batzli G.O., 1992, WILDLIFE 2001 POPULA; BOONSTRA R, 1994, EVOL ECOL, V8, P196, DOI 10.1007/BF01238250; BOONSTRA R, 1987, EVOLUTION, V41, P929, DOI 10.1111/j.1558-5646.1987.tb05868.x; Burnham KP., 2004, MODEL SELECTION MULT, V2, DOI 10.1007/b97636; CHITTY D, 1952, PHILOS T ROY SOC B, V236, P505, DOI 10.1098/rstb.1952.0009; Chitty D., 1967, Proceedings of the Ecological Society of Australia, V2, P51; Inchausti P, 1998, J ANIM ECOL, V67, P180, DOI 10.1046/j.1365-2656.1998.00189.x; KENDALL WL, 1995, BIOMETRICS, V51, P293, DOI 10.2307/2533335; Korpimaki E, 1996, BIOSCIENCE, V46, P754, DOI 10.2307/1312851; Krebs C.J., 1974, ADV ECOL RES, V8, P267, DOI DOI 10.1016/S0065-2504(08)60280-9; Krebs CJ, 1996, J MAMMAL, V77, P8, DOI 10.2307/1382705; Lambin X, 2000, J ANIM ECOL, V69, P106, DOI 10.1046/j.1365-2656.2000.00380.x; Lambin X, 1998, P ROY SOC B-BIOL SCI, V265, P1491, DOI 10.1098/rspb.1998.0462; LEBRETON JD, 1992, ECOL MONOGR, V62, P67, DOI 10.2307/2937171; Littell R. C, 1996, SAS SYSTEM MIXED MOD; Mappes T, 1998, OIKOS, V82, P365, DOI 10.2307/3546977; McNamara JM, 1996, NATURE, V380, P215, DOI 10.1038/380215a0; NELSON RJ, 1987, AM NAT, V130, P350, DOI 10.1086/284715; NICHOLS JD, 1992, BIOSCIENCE, V42, P94, DOI 10.2307/1311650; Roff Derek A., 1992; Soveri T, 2000, COMP IMMUNOL MICROB, V23, P73, DOI 10.1016/S0147-9571(99)00057-0; Stearns S.C., 1992, pi; Stenseth NC, 1999, OIKOS, V87, P427, DOI 10.2307/3546809; TAST J, 1984, WINTER ECOLOGY SMALL, P59; Tkadlec E, 1998, EVOL ECOL, V12, P191, DOI 10.1023/A:1006583713042; [No title captured], DOI DOI 10.1016/J.FORECO.2007.08.005	28	98	100	1	50	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 28	2001	411	6841					1043	1045		10.1038/35082553	http://dx.doi.org/10.1038/35082553			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	446TF	11429603				2022-12-28	WOS:000169528500046
J	Ochsenbein, AF; Sierro, S; Odermatt, B; Pericin, M; Karrer, U; Hermans, IF; Hemmi, S; Hengartner, H; Zinkernagel, RM				Ochsenbein, AF; Sierro, S; Odermatt, B; Pericin, M; Karrer, U; Hermans, IF; Hemmi, S; Hengartner, H; Zinkernagel, RM			Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction	NATURE			English	Article							ANTIGEN-PRESENTING CELLS; IMMUNE-RESPONSES; LYMPHOID ORGANS; BONE-MARROW; IN-VIVO; LYMPHOCYTES; COSTIMULATION; MICE; REJECTION; MATURATION	The vertebrate immune system has evolved to protect against infections that threaten survival before reproduction. Clinically manifest tumours mostly arise after the reproductive years and somatic mutations allow even otherwise antigenic tumours to evade the attention of the immune system(1-3). Moreover, the lack of immunological co-stimulatory molecules on solid tumours could result in T-cell tolerance(4-8); that is, the failure of T cells to respond. However, this may not generally apply(9,10). Here we report several important findings regarding the immune response to tumours, on the basis of studies of several tumour types. First, tumour-specific induction of protective cytotoxic T cells (CTLs) depends on sufficient tumour cells reaching secondary lymphatic organs early and for a long enough duration. Second, diffusely invading systemic tumours delete CTLs. Third, tumours that stay strictly outside secondary lymphatic organs, or that are within these organs but separated from T cells by barriers, are ignored by T cells but do not delete them. Fourth, co-stimulatory molecules on tumour cells do not influence CTL priming but enhance primed CTL responses in peripheral solid tumours. Last, cross priming of CTLs by tumour antigens, mediated by major histocompatibility complex (MHC) class I molecules of antigen-presenting host cells, is inefficient and not protective. These rules of T-cell induction and maintenance not only change previous views but also rationales for anti-tumour immunotherapy(1,2).	Univ Zurich Hosp, Inst Expt Immunol, CH-8091 Zurich, Switzerland; Univ Zurich, Inst Mol Biol, CH-8057 Zurich, Switzerland; Malaghan Inst Med Res, Wellington, New Zealand	University of Zurich; University Zurich Hospital; University of Zurich; Malaghan Institute; Victoria University Wellington	Zinkernagel, RM (corresponding author), Univ Zurich Hosp, Inst Expt Immunol, CH-8091 Zurich, Switzerland.	adrian.ochsenbein@insel.ch; rolf.zinkernagel@pty.usz.ch	Hermans, Ian/I-3961-2013	Ochsenbein, Adrian/0000-0003-1773-5436				BEVAN MJ, 1976, J EXP MED, V143, P1283, DOI 10.1084/jem.143.5.1283; BOON T, 1994, ANNU REV IMMUNOL, V12, P337, DOI 10.1146/annurev.immunol.12.1.337; Braun S, 2000, NEW ENGL J MED, V342, P525, DOI 10.1056/NEJM200002243420801; Carbone FR, 1998, IMMUNOL TODAY, V19, P368, DOI 10.1016/S0167-5699(98)01301-2; CHEN YM, 1993, MOL CRYST LIQ CRYS B, V4, P71; HAHN H, 1981, REV INFECT DIS, V3, P1221; HARLAN DM, 1994, P NATL ACAD SCI USA, V91, P3137, DOI 10.1073/pnas.91.8.3137; HELLSTROM KE, 1995, IMMUNOL REV, V145, P123, DOI 10.1111/j.1600-065X.1995.tb00079.x; Hermans IF, 1998, CANCER RES, V58, P3909; HUANG AYC, 1994, SCIENCE, V264, P961, DOI 10.1126/science.7513904; Jeannin P, 2000, NAT IMMUNOL, V1, P502, DOI 10.1038/82751; Karrer U, 1997, J EXP MED, V185, P2157, DOI 10.1084/jem.185.12.2157; KUNDIG TM, 1995, SCIENCE, V268, P1343, DOI 10.1126/science.7761853; Lu ZB, 2000, J EXP MED, V191, P541, DOI 10.1084/jem.191.3.541; Maric M, 1998, CANCER RES, V58, P3376; MATZINGER P, 1994, ANNU REV IMMUNOL, V12, P991, DOI 10.1146/annurev.iy.12.040194.005015; Ochsenbein AF, 1999, P NATL ACAD SCI USA, V96, P2233, DOI 10.1073/pnas.96.5.2233; OEHEN SU, 1994, CELL IMMUNOL, V158, P342, DOI 10.1006/cimm.1994.1281; OLD LJ, 1992, CURR OPIN IMMUNOL, V4, P603, DOI 10.1016/0952-7915(92)90034-C; Ossendorp F, 1998, J EXP MED, V187, P693, DOI 10.1084/jem.187.5.693; Oxenius A, 1998, EUR J IMMUNOL, V28, P390, DOI 10.1002/(SICI)1521-4141(199801)28:01<390::AID-IMMU390>3.0.CO;2-O; Prevost-Blondel A, 1998, J IMMUNOL, V161, P2187; RAMARATHINAM L, 1994, J EXP MED, V179, P1205, DOI 10.1084/jem.179.4.1205; SCHWARTZ RH, 1992, CELL, V71, P1065, DOI 10.1016/S0092-8674(05)80055-8; SHAHINIAN A, 1993, SCIENCE, V261, P609, DOI 10.1126/science.7688139; Staveley-O'Carroll K, 1998, P NATL ACAD SCI USA, V95, P1178, DOI 10.1073/pnas.95.3.1178; Toes REM, 1996, CANCER RES, V56, P3782; TOWNSEND SE, 1993, SCIENCE, V259, P368, DOI 10.1126/science.7678351; WU TC, 1995, J EXP MED, V182, P1415, DOI 10.1084/jem.182.5.1415; Yewdell JW, 1999, ADV IMMUNOL, V73, P1, DOI 10.1016/S0065-2776(08)60785-3	30	420	449	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 28	2001	411	6841					1058	1064		10.1038/35082583	http://dx.doi.org/10.1038/35082583			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	446TF	11429607				2022-12-28	WOS:000169528500050
J	Yu, QY; Geng, Y; Sicinski, P				Yu, QY; Geng, Y; Sicinski, P			Specific protection against breast cancers by cyclin D1 ablation	NATURE			English	Article							TRANSGENIC MICE; CELL-PROLIFERATION; SIGNALING PATHWAY; NEU ONCOGENE; EXPRESSION; RAS; OVEREXPRESSION; TRANSFORMATION; PROGRESSION; GENE	Breast cancer is the most common malignancy among women. Most of these cancers overexpress cyclin D1, a component of the core cell-cycle machinery. We previously generated mice lacking cyclin D1 using gene targeting. Here we report that these cyclin D1-deficient mice are resistant to breast cancers induced by the neu and ras oncogenes. However, animals lacking cyclin D1 remain fully sensitive to other oncogenic pathways of the mammary epithelium, such as those driven by c-myc or Wnt-1. Our analyses revealed that, in mammary epithelial cells, the Neu-Ras pathway is connected to the cell-cycle machinery by cyclin D1, explaining the absolute dependency on cyclin D1 for malignant transformation in this tissue. Our results suggest that an anti-cyclin D1 therapy might be highly specific in treating human breast cancers with activated Neu-Ras pathways.	Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	Sicinski, P (corresponding author), Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA.							ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; Alevizopoulos K, 1997, EMBO J, V16, P5322, DOI 10.1093/emboj/16.17.5322; BALL RK, 1988, EMBO J, V7, P2089, DOI 10.1002/j.1460-2075.1988.tb03048.x; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; BARTKOVA J, 1994, INT J CANCER, V57, P353, DOI 10.1002/ijc.2910570311; BIECHE I, 1995, GENE CHROMOSOME CANC, V14, P227, DOI 10.1002/gcc.2870140402; DICKINSON AJ, 1990, OPHTHALMIC PAED GEN, V11, P1, DOI 10.3109/13816819009012942; FANTL V, 1995, GENE DEV, V9, P2364, DOI 10.1101/gad.9.19.2364; FILMUS J, 1994, ONCOGENE, V9, P3627; Geng Y, 1999, CELL, V97, P767, DOI 10.1016/S0092-8674(00)80788-6; Gillett C, 1996, INT J CANCER, V69, P92, DOI 10.1002/(SICI)1097-0215(19960422)69:2<92::AID-IJC4>3.3.CO;2-I; GILLETT C, 1994, CANCER RES, V54, P1812; JANES PW, 1994, ONCOGENE, V9, P3601; Lavoie JN, 1996, J BIOL CHEM, V271, P20608, DOI 10.1074/jbc.271.34.20608; Lee RJ, 2000, MOL CELL BIOL, V20, P672, DOI 10.1128/MCB.20.2.672-683.2000; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; LUKAS J, 1995, ONCOGENE, V10, P2125; MCINTOSH GG, 1995, ONCOGENE, V11, P885; MULLER WJ, 1988, CELL, V54, P105, DOI 10.1016/0092-8674(88)90184-5; Rimerman RA, 2000, J BIOL CHEM, V275, P14736, DOI 10.1074/jbc.M910241199; Robles AI, 1998, GENE DEV, V12, P2469, DOI 10.1101/gad.12.16.2469; Santoni-Rugiu E, 2000, MOL CELL BIOL, V20, P3497, DOI 10.1128/MCB.20.10.3497-3509.2000; Sherr CJ, 1999, GENE DEV, V13, P1501, DOI 10.1101/gad.13.12.1501; SICINSKI P, 1995, CELL, V82, P621, DOI 10.1016/0092-8674(95)90034-9; Sicinski P, 1996, NATURE, V384, P470, DOI 10.1038/384470a0; SINN E, 1987, CELL, V49, P465, DOI 10.1016/0092-8674(87)90449-1; STEWART TA, 1984, CELL, V38, P627, DOI 10.1016/0092-8674(84)90257-5; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; TSUKAMOTO AS, 1988, CELL, V55, P619, DOI 10.1016/0092-8674(88)90220-6; WANG TC, 1994, NATURE, V369, P669, DOI 10.1038/369669a0; WEINSTATSASLOW D, 1995, NAT MED, V1, P1257, DOI 10.1038/nm1295-1257	31	783	819	0	29	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 28	2001	411	6841					1017	1021		10.1038/35082500	http://dx.doi.org/10.1038/35082500			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	446TF	11429595				2022-12-28	WOS:000169528500038
J	Tu, JV; Austin, PC; Chan, BTB				Tu, JV; Austin, PC; Chan, BTB			Relationship between annual volume of patients treated by admitting physician and mortality after acute myocardial infarction	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY ANGIOPLASTY VOLUME; ELDERLY PATIENTS; HOSPITAL VOLUME; ASSOCIATION	Context Acute myocardial infarction (AMI) is a common condition that is treated by physicians with varying levels of clinical experience, but whether the level of experience affects outcome remains uncertain. Objective To evaluate the relationship between the average annual volume of cases treated by admitting physicians and mortality after AMI. Design, Setting, and Patients Retrospective cohort study using linked administrative databases containing patient admission information for 98 194 patients treated by 5374 physicians between April 1, 1992, and March 31, 1998, in Ontario, Canada. Main Outcome Measures Mortality risk rates for 30 days and 1 year post-AMI, adjusted by physician volume and patient, physician, and hospital characteristics. Results The 30-day mortality rate was 13.5% and the 1-year mortality rate was 21.8%, A strong inverse relationship between the average annual volume of AMI cases treated by the admitting physician and mortality after an AMI was observed. The 30-day risk-adjusted mortality rate was 15.3% for physicians who treated 5 or fewer AMI cases per year (lowest quartile) compared with 11.8% for physicians who treated more than 24 AMI cases annually (highest quartile; P<.001). The 1-year risk-adjusted mortality rate was 24.2% for physicians who treated 5 or fewer AMI cases per year (lowest quartile) compared with 19.6% for physicians who treated more than 24 AMI cases annually (highest quartile; P<.001). Conclusion Patients with AMI who are treated by high-volume admitting physicians are more likely to survive at 30 days and 1 year.	Sunnybrook & Womens Coll, Hlth Sci Ctr, Inst Clin Evaluat Sci, Toronto, ON M4N 3M5, Canada; Sunnybrook & Womens Coll, Hlth Sci Ctr, Div Gen Internal Med & Clin Epidemiol, Toronto, ON M4N 3M5, Canada; Sunnybrook & Womens Coll, Hlth Sci Ctr, Hlth Care Res Program, Toronto, ON M4N 3M5, Canada; Univ Toronto, Fac Med, Dept Med, Toronto, ON, Canada; Univ Toronto, Fac Med, Dept Publ Hlth Sci, Toronto, ON, Canada; Univ Toronto, Fac Med, Dept Hlth Adm, Toronto, ON, Canada; Univ Toronto, Fac Med, Dept Family & Community Med, Toronto, ON, Canada	University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Toronto; University of Toronto; University of Toronto; University of Toronto	Tu, JV (corresponding author), Sunnybrook & Womens Coll, Hlth Sci Ctr, Inst Clin Evaluat Sci, G-106,2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.	tu@ices.on.ca		Tu, Jack/0000-0003-0111-722X; Austin, Peter/0000-0003-3337-233X				Alter DA, 1999, NEW ENGL J MED, V341, P1359, DOI 10.1056/NEJM199910283411806; Commission on Professional and Hospital Activities, 1992, INT CLASS DIS; Goldstein H., 1998, USERS GUIDE MLWIN; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; HANNAN EL, 1995, JAMA-J AM MED ASSOC, V273, P209, DOI 10.1001/jama.273.3.209; Hannan EL, 1997, JAMA-J AM MED ASSOC, V277, P892, DOI 10.1001/jama.277.11.892; HOSMER DW, 1989, APPL LOGISTIC REGRES; Ivanov J, 1998, ANN THORAC SURG, V66, P1471; JOLLIS JG, 1993, ANN INTERN MED, V119, P844, DOI 10.7326/0003-4819-119-8-199310150-00011; Jollis JG, 1997, CIRCULATION, V95, P2485, DOI 10.1161/01.CIR.95.11.2485; Jollis JG, 1996, NEW ENGL J MED, V335, P1880, DOI 10.1056/NEJM199612193352505; KIRKLIN JW, 1991, CIRCULATION, V83, P1125; Nash IS, 1999, AM J CARDIOL, V83, P650, DOI 10.1016/S0002-9149(98)00961-8; ROSENBAUM PR, 1984, J AM STAT ASSOC, V79, P516, DOI 10.2307/2288398; Ryan TJ, 1996, J AM COLL CARDIOL, V28, P1328; Thiemann DR, 1999, NEW ENGL J MED, V340, P1640, DOI 10.1056/NEJM199905273402106; Tu JV, 2001, J AM COLL CARDIOL, V37, P992, DOI 10.1016/S0735-1097(01)01109-3; Tu JV., 1999, CARDIOVASCULAR HLTH, P83; TU JV, 1999, CARDIOVASCULAR HLTH, P199; Tu LV, 1999, CAN MED ASSOC J, V161, P1257; Willison DJ, 2000, MED CARE, V38, P1092, DOI 10.1097/00005650-200011000-00004	21	112	113	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 27	2001	285	24					3116	3122		10.1001/jama.285.24.3116	http://dx.doi.org/10.1001/jama.285.24.3116			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	444FF	11427140	Bronze			2022-12-28	WOS:000169388900025
J	Wilkin, D; Dowswell, T; Leese, B				Wilkin, D; Dowswell, T; Leese, B			Primary care groups - Modernising primary and community health services	BRITISH MEDICAL JOURNAL			English	Article									Univ Manchester, Natl Primary Care Res & Dev Ctr, Manchester M13 9PL, Lancs, England; Univ Leeds, Ctr Res Primary Care, Leeds LS2 9PL, W Yorkshire, England	University of Manchester; University of Leeds	Wilkin, D (corresponding author), Univ Manchester, Natl Primary Care Res & Dev Ctr, Manchester M13 9PL, Lancs, England.							*AUD COMM, 2000, PCG AGENDA EARLY PRO; HALLAM L, 1999, 24 HOUR PRIMARY CARE, P63; Hunter M, 2001, BRIT MED J, V322, P696, DOI 10.1136/bmj.322.7288.696; Lucas K, 2000, J PUBLIC HEALTH MED, V22, P211, DOI 10.1093/pubmed/22.2.211; Majeed A, 2000, BRIT MED J, V321, P1057, DOI 10.1136/bmj.321.7268.1057; MAYS N, 1998, TOTAL PURCHASING STE; REGEN E, 1999, 1 STARTING BLOCK LES; *SECR STAT HLTH, 1997, CM3807; *SECR STAT HLTH, 2000, CM4818I; Wilkin D, 2001, BRIT MED J, V322, P1464, DOI 10.1136/bmj.322.7300.1464; WILKIN D, 2000, NATL TRACKER SURVEY; WILKIN D, 2000, IN PRESS NATL TRACKE	12	11	11	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 23	2001	322	7301					1522	1524		10.1136/bmj.322.7301.1522	http://dx.doi.org/10.1136/bmj.322.7301.1522			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	446UF	11420274	Bronze, Green Accepted, Green Submitted, Green Published			2022-12-28	WOS:000169532000019
J	Brown, CE; Howe, L; Sousa, K; Alley, SC; Carrozza, MJ; Tan, S; Workman, JL				Brown, CE; Howe, L; Sousa, K; Alley, SC; Carrozza, MJ; Tan, S; Workman, JL			Recruitment of HAT complexes by direct activator interactions with the ATM-related tra1 subunit	SCIENCE			English	Article							HISTONE ACETYLTRANSFERASE COMPLEXES; IN-VIVO; TRANSCRIPTIONAL ADAPTER; BASAL TRANSCRIPTION; ESSENTIAL COFACTOR; C-MYC; YEAST; PROTEIN; DOMAIN; BINDING	Promoter-specific recruitment of histone acetyltransferase activity is often critical for transcriptional activation. We present a detailed study of the interaction between the histone acetyltransferase complexes SAGA and NuA4, and transcription activators. We demonstrate by affinity chromatography and photo-cross-linking Label transfer that acidic activators directly interact with Tra1p, a shared subunit of SAGA and NUA4. Mutations within the COOH-terminus of Tra1p disrupted its interaction with activators and resulted in gene-specific transcriptional defects that correlated with Lowered promoter-specific histone acetylation. These data demonstrate that the essential Tra1 protein serves as a common target for activators in both SAGA and NuA4 acetyltransferases.	Penn State Univ, Howard Hughes Med Inst, Althouse Lab 306, University Pk, PA 16802 USA; Penn State Univ, Dept Biochem & Mol Biol, Althouse Lab 306, University Pk, PA 16802 USA; Penn State Univ, Dept Chem, Althouse Lab 306, University Pk, PA 16802 USA	Howard Hughes Medical Institute; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park	Workman, JL (corresponding author), Penn State Univ, Howard Hughes Med Inst, Althouse Lab 306, University Pk, PA 16802 USA.			Brown, Christine/0000-0003-4915-8207	NIGMS NIH HHS [GM19492] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM019492] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allard S, 1999, EMBO J, V18, P5108, DOI 10.1093/emboj/18.18.5108; Alley SC, 2000, J AM CHEM SOC, V122, P6126, DOI 10.1021/ja000591t; BALASUBRAMANIAN R, UNPUB; BARLEV NA, 1995, J BIOL CHEM, V270, P19337, DOI 10.1074/jbc.270.33.19337; BERGER SL, 1990, CELL, V61, P1199, DOI 10.1016/0092-8674(90)90684-7; BERGER SL, 1992, CELL, V70, P251, DOI 10.1016/0092-8674(92)90100-Q; Brown CE, 2000, TRENDS BIOCHEM SCI, V25, P15, DOI 10.1016/S0968-0004(99)01516-9; BROWN CM, UNPUB; Candau R, 1997, EMBO J, V16, P555, DOI 10.1093/emboj/16.3.555; Candau R, 1996, J BIOL CHEM, V271, P5237; DRYSDALE CM, 1995, MOL CELL BIOL, V15, P1220, DOI 10.1128/MCB.15.3.1220; Eberharter A, 1998, METHODS, V15, P315, DOI 10.1006/meth.1998.0635; Galarneau L, 2000, MOL CELL, V5, P927, DOI 10.1016/S1097-2765(00)80258-0; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; Grant PA, 1998, MOL CELL, V2, P863, DOI 10.1016/S1097-2765(00)80300-7; Gregory PD, 1999, EMBO J, V18, P6407, DOI 10.1093/emboj/18.22.6407; Henriksson A, 1997, MOL CELL BIOL, V17, P3065, DOI 10.1128/MCB.17.6.3065; Ikeda K, 1999, MOL CELL BIOL, V19, P855; Jia MH, 2000, PHYSIOL GENOMICS, V3, P83, DOI 10.1152/physiolgenomics.2000.3.2.83; Kuo MH, 1998, GENE DEV, V12, P627, DOI 10.1101/gad.12.5.627; LU H, 1995, P NATL ACAD SCI USA, V92, P5154, DOI 10.1073/pnas.92.11.5154; McMahon SB, 1998, CELL, V94, P363, DOI 10.1016/S0092-8674(00)81479-8; McMahon SB, 2000, MOL CELL BIOL, V20, P556, DOI 10.1128/MCB.20.2.556-562.2000; Saleh A, 1998, J BIOL CHEM, V273, P26559, DOI 10.1074/jbc.273.41.26559; SELLECK W, IN PRESS NATURE STRU; SELLECK W, UNPUB; Sil AK, 1999, MOL CELL BIOL, V19, P7828; THUT CJ, 1995, SCIENCE, V267, P100, DOI 10.1126/science.7809597; Uesugi M, 1997, SCIENCE, V277, P1310, DOI 10.1126/science.277.5330.1310; Utley RT, 1998, NATURE, V394, P498, DOI 10.1038/28886; Vignali M, 2000, EMBO J, V19, P2629, DOI 10.1093/emboj/19.11.2629; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545	32	285	289	1	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 22	2001	292	5525					2333	2337		10.1126/science.1060214	http://dx.doi.org/10.1126/science.1060214			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	445KD	11423663				2022-12-28	WOS:000169455900059
J	Huntsman, DG; Carneiro, F; Lewis, FR; MacLeod, PM; Hayashi, A; Monaghan, KG; Maung, R; Seruca, R; Jackson, CE; Caldas, C				Huntsman, DG; Carneiro, F; Lewis, FR; MacLeod, PM; Hayashi, A; Monaghan, KG; Maung, R; Seruca, R; Jackson, CE; Caldas, C			Early gastric cancer in young, asymptomatic carriers of germ-line E-cadherin mutations.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FAMILIAL ADENOMATOUS POLYPOSIS; CARCINOMA; WOMEN	Background: Germ-line truncating mutations in the E-cadherin (CDH1) gene have been found in families with hereditary diffuse gastric cancer. These families are characterized by a highly penetrant susceptibility to diffuse gastric cancer with an autosomal dominant pattern of inheritance, predominantly in young persons. We describe genetic screening, surgical management, and pathological findings in young persons with truncating mutations in CDH1 from two unrelated families with hereditary diffuse gastric cancer. Methods: Mutation-specific predictive genetic testing was performed by polymerase-chain-reaction amplification, followed by restriction-enzyme digestion and DNA sequencing in Family 1 and by heteroduplex analysis in Family 2. A total gastrectomy was performed prophylactically in five carriers of mutations who were between 22 and 40 years old. In each case, the entire mucosa of the stomach was extensively sampled for microscopical analysis. Results: Superficial infiltrates of malignant signet-ring cells were identified in the surgical samples from all five persons who underwent gastrectomy. These early diffuse gastric cancers were multifocal in three of the five cases, and in one person infiltrates of malignant signet-ring cells were present in 65 of the 140 tissue blocks analyzed, representing in aggregate less than 2 percent of the gastric mucosa. Conclusions: We recommend genetic counseling and consideration of prophylactic gastrectomy in young, asymptomatic carriers of germ-line truncating CDH1 mutations who belong to families with highly penetrant hereditary diffuse gastric cancer. (N Engl J Med 2001;344:1904-9.) Copyright (C) 2001 Massachusetts Medical Society.	British Columbia Canc Agcy, Dept Pathol, Hereditary Canc Program, Vancouver, BC V5Z 1L3, Canada; Univ British Columbia, Dept Pathol & Lab Med, Vancouver, BC V5Z 1M9, Canada; Victoria Gen Hosp, Med Genet Sect, Victoria, BC, Canada; Victoria Gen Hosp, Sect Surg, Victoria, BC, Canada; Victoria Gen Hosp, Sect Pathol, Victoria, BC, Canada; Univ Porto, Inst Patal & Imunol Mol, P-4100 Porto, Portugal; Univ Porto, Fac Med, P-4100 Porto, Portugal; Henry Ford Hosp, Dept Surg, Detroit, MI 48202 USA; Henry Ford Hosp, Dept Med Genet, Detroit, MI 48202 USA; Univ Cambridge, Addenbrookes Hosp, Dept Oncol, Cambridge CB2 2XY, England	British Columbia Cancer Agency; University of British Columbia; University of Victoria; University of Victoria; University of Victoria; Universidade do Porto; Universidade do Porto; Henry Ford Health System; Henry Ford Hospital; Henry Ford Health System; Henry Ford Hospital; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	Huntsman, DG (corresponding author), British Columbia Canc Agcy, Dept Pathol, Hereditary Canc Program, 600 W 10th Ave, Vancouver, BC V5Z 1L3, Canada.		Caldas, Carlos/A-7543-2008; Carneiro, Fatima/J-6432-2013; seruca, raquel/F-8187-2011; Caldas, Carlos/U-7250-2019; Huntsman, David/ABE-6082-2020; Carneiro, Fatima/AAV-8677-2021	Carneiro, Fatima/0000-0002-1964-1006; Caldas, Carlos/0000-0003-3547-1489; Carneiro, Fatima/0000-0002-1964-1006; Seruca, Raquel/0000-0002-8851-4166				Berx G, 1995, EMBO J, V14, P6107, DOI 10.1002/j.1460-2075.1995.tb00301.x; Caldas C, 1999, J MED GENET, V36, P873; Gayther SA, 1998, CANCER RES, V58, P4086; Grady WM, 2000, NAT GENET, V26, P16, DOI 10.1038/79120; Grann VR, 2000, CANCER J SCI AM, V6, P13; Guilford P, 1998, NATURE, V392, P402, DOI 10.1038/32918; Guilford PJ, 1999, HUM MUTAT, V14, P249, DOI 10.1002/(SICI)1098-1004(1999)14:3<249::AID-HUMU8>3.0.CO;2-9; Hartmann LC, 1999, NEW ENGL J MED, V340, P77, DOI 10.1056/NEJM199901143400201; JONES E. G., 1964, NEW ZEAL MED J, V63, P287; Kashiwagi H, 2000, SURG TODAY, V30, P675, DOI 10.1007/s005950070077; Keller G, 1999, AM J PATHOL, V155, P337, DOI 10.1016/S0002-9440(10)65129-2; King JE, 2000, MAYO CLIN PROC, V75, P57, DOI 10.4065/75.1.57; Lallier M, 1998, J PEDIATR SURG, V33, P846, DOI 10.1016/S0022-3468(98)90656-X; LAUREN P, 1965, ACTA PATHOL MIC SC, V64, P31, DOI 10.1111/apm.1965.64.1.31; Richards FM, 1999, HUM MOL GENET, V8, P607, DOI 10.1093/hmg/8.4.607; SHAFIUDDIN M, 1995, AM J GASTROENTEROL, V90, P2062; Sokoloff B., 1938, AM J SURG, V40, P673; Steinbach G, 2000, NEW ENGL J MED, V342, P1946, DOI 10.1056/NEJM200006293422603	18	281	297	0	25	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 21	2001	344	25					1904	1909		10.1056/NEJM200106213442504	http://dx.doi.org/10.1056/NEJM200106213442504			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	443VJ	11419427				2022-12-28	WOS:000169362100004
J	Fuentes, F; Lopez-Miranda, J; Sanchez, E; Sanchez, F; Paez, J; Paz-Rojas, E; Marin, C; Gomez, P; Jimenez-Pereperez, J; Ordovas, JM; Perez-Jimenez, F				Fuentes, F; Lopez-Miranda, J; Sanchez, E; Sanchez, F; Paez, J; Paz-Rojas, E; Marin, C; Gomez, P; Jimenez-Pereperez, J; Ordovas, JM; Perez-Jimenez, F			Mediterranean and low-fat diets improve endothelial function in hypercholesterolemic men	ANNALS OF INTERNAL MEDICINE			English	Article							IN-VITRO; ATHEROSCLEROSIS; DYSFUNCTION; FOREARM; RISK; ACID	Background: The regulatory function of the endothelium is altered in hypercholesterolemia, and the subsequent endothelial dysfunction plays a central role in the development of atherosclerosis. Objective: To determine whether endothelial function in hypercholesterolemic patients is affected by replacing a saturated fat-enriched diet with a low-fat, low-saturated fat diet (the U,S, National Cholesterol Education Program stage 1 [NCEP-1] diet) or a diet rich in monounsaturated fat (such as that common in Mediterranean countries). Design: Intervention dietary study with a baseline phase and two randomized crossover dietary periods. Setting: Hospital Universitario Reina Sofia, Cordoba, Spain, Patients: 22 hypercholesterolemic men. Intervention: Patients followed a diet high in saturated fat, then were assigned in a crossover design to the NCEP-1 diet or a Mediterranean diet. Each dietary period lasted 28 days. Measurements: Plasma P-seledin levels, lipid concentrations, and endothelial function, Results: Compared with the saturated fat diet, flow-mediated dilatation increased during the Mediterranean diet but not during the NCEP-1 diet In addition, levels of plasma cholesterol, low-density lipoprotein cholesterol, apolipoprotein B, and P-selectin decreased during the NCEP-1 and Mediterranean diets. Conclusion: In hypercholesterolemic men, diets low in fat (especially saturated fat) and diets rich in monounsaturated fats improve endothelial function.	Hosp Univ Reina Sofia, Unidad Lipidos & Arteriosclerosis, Cordoba 14004, Spain; Tufts Univ, Jean Meyer US Dept Agr Human Nutr Res Ctr Aging, Boston, MA 02111 USA	Hospital Universitario Reina Sofia - Cordoba; Tufts University	Perez-Jimenez, F (corresponding author), Hosp Univ Reina Sofia, Unidad Lipidos & Arteriosclerosis, Avda Menendez Pidal S-N, Cordoba 14004, Spain.	fperez@sofia.hrs.sas.cica.es	Marin Hinojosa, Carmen/AFO-1294-2022; Lopez-Miranda, Jose/Y-8306-2019; Ordovas, Jose/B-8727-2013; FUENTES JIMENEZ, FRANCISCO/G-4311-2016	Marin Hinojosa, Carmen/0000-0003-2884-4806; Lopez-Miranda, Jose/0000-0002-8844-0718; Sanchez Tejero, Elias Alberto/0000-0003-3169-4474; Ordovas, Jose/0000-0002-7581-5680; Perez Jimenez, Francisco/0000-0001-9808-1280; Perez-Jimenez, Francisco/0000-0001-7499-7681; FUENTES JIMENEZ, FRANCISCO/0000-0002-4584-7366				BONANOME A, 1988, NEW ENGL J MED, V318, P1244, DOI 10.1056/NEJM198805123181905; CELERMAJER DS, 1992, LANCET, V340, P1111, DOI 10.1016/0140-6736(92)93147-F; Celermajer DS, 1997, J AM COLL CARDIOL, V30, P325, DOI 10.1016/S0735-1097(97)00189-7; CREAGER MA, 1990, J CLIN INVEST, V86, P228, DOI 10.1172/JCI114688; De Caterina R, 2000, AM J CLIN NUTR, V71, p213S, DOI 10.1093/ajcn/71.1.213S; de Lorgeril M, 1999, CIRCULATION, V99, P779, DOI 10.1161/01.CIR.99.6.779; GAUTHIER TW, 1995, ARTERIOSCL THROM VAS, V15, P1652, DOI 10.1161/01.ATV.15.10.1652; Goode GK, 1997, CIRCULATION, V96, P2802, DOI 10.1161/01.CIR.96.9.2802; HARRISON DG, 1987, J CLIN INVEST, V80, P1808, DOI 10.1172/JCI113276; HOCHBERG Y, 1988, BIOMETRIKA, V75, P800, DOI 10.1093/biomet/75.4.800; KEYS A, 1986, AM J EPIDEMIOL, V124, P903, DOI 10.1093/oxfordjournals.aje.a114480; Mata P, 1996, ARTERIOSCL THROM VAS, V16, P1347, DOI 10.1161/01.ATV.16.11.1347; *NAT CHOL ED PROGR, 1994, CIRCULATION, V889, P1333; OHARA Y, 1993, J CLIN INVEST, V91, P2546, DOI 10.1172/JCI116491; Perez-Jimenez F, 1999, ATHEROSCLEROSIS, V145, P351, DOI 10.1016/S0021-9150(99)00116-1; SORENSEN KE, 1994, J CLIN INVEST, V93, P50, DOI 10.1172/JCI116983; STROES ESG, 1995, LANCET, V346, P467, DOI 10.1016/S0140-6736(95)91322-X; VANE JR, 1990, NEW ENGL J MED, V323, P27; Vogel RA, 2000, J AM COLL CARDIOL, V36, P1455, DOI 10.1016/S0735-1097(00)00896-2; YASUE H, 1990, CIRCULATION, V81, P482, DOI 10.1161/01.CIR.81.2.482	20	171	177	0	22	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 19	2001	134	12					1115	1119		10.7326/0003-4819-134-12-200106190-00011	http://dx.doi.org/10.7326/0003-4819-134-12-200106190-00011			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	442YU	11412051				2022-12-28	WOS:000169313200004
J	Topol, EJ; Califf, RM; Van de Werf, F; Willerson, JT; Booth, J; White, H; Clayman, M; Deckelbaum, L; Lincoff, AM; Ohman, EM; Bates, E; Gibler, WB; Hochman, J; Kleiman, N; Grinfeld, L; Aylward, P; Armstrong, PW; Heikkila, J; Vahanian, A; Steg, G; Bode, C; Adgy, AAJ; Guetta, V; Ardissino, D; Savonitto, S; Bar, F; Simoons, M; Kontny, F; White, H; Sadowski, Z; Seabra-Gomes, R; Dalby, A; Betriu, A; Swahn, E; Wilcox, R; Frye, RL; Bertrand, ME; DeMets, D; Fox, KKA; Fuster, V; Lee, KL; McCarthy, C; Waller, M; Scherer, J; van de Kerkhove, A; Kukulewicz, L; Booth, JE; Del Valle, M; Hibert, D; Brannon, D				Topol, EJ; Califf, RM; Van de Werf, F; Willerson, JT; Booth, J; White, H; Clayman, M; Deckelbaum, L; Lincoff, AM; Ohman, EM; Bates, E; Gibler, WB; Hochman, J; Kleiman, N; Grinfeld, L; Aylward, P; Armstrong, PW; Heikkila, J; Vahanian, A; Steg, G; Bode, C; Adgy, AAJ; Guetta, V; Ardissino, D; Savonitto, S; Bar, F; Simoons, M; Kontny, F; White, H; Sadowski, Z; Seabra-Gomes, R; Dalby, A; Betriu, A; Swahn, E; Wilcox, R; Frye, RL; Bertrand, ME; DeMets, D; Fox, KKA; Fuster, V; Lee, KL; McCarthy, C; Waller, M; Scherer, J; van de Kerkhove, A; Kukulewicz, L; Booth, JE; Del Valle, M; Hibert, D; Brannon, D		GUSTO V Investigators	Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO randomised trial	LANCET			English	Article							THROMBOLYSIS	Background Plasminogen activator therapy for acute myocardial infarction is limited by lack of achievement of early, complete, and sustained reperfusion in a substantial proportion of patients. Many phase II trials have supported the potential of combined fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition for improving reperfusion. We did a randomised, open-label trial to compare the effect of reteplase alone with reteplase plus abciximab in patients with acute myocardial infarction. Methods 16 588 patients in the first 6 h of evolving ST-segment elevation myocardial infarction were randomly assigned standard-dose reteplase (n=8260) or half-dose reteplase and full-dose abciximab (n=8328). The primary endpoint was 30-day mortality, and secondary endpoints included various complications of myocardial infarction. Analysis was by intention to treat. Findings At 30 days, 488 (5.9%) of patients in the reteplase group had died, compared with 468 (5.6%) in the combined reteplase and abciximab group (odds ratio 0.95 [95% CI 0.83-1.08], p=0.43). There were fewer deaths or non-fatal reinfarctions with the combination than with reteplase alone, and there was less need for urgent revascularisation and fewer major non-fatal ischaemic complications of acute myocardial infarction. On the other hand, there were snore non-intracranial bleeding complications in the combination group. The rates of intracranial haemorrhage and non-fatal disabling stroke were similar. Interpretation Although combined reteplase and abciximab was not superior to standard reteplase, the 0.3% absolute (5% relative) decrease in 30-day mortality fulfilled the criteria of non-inferiority. Combination therapy led to a consistent reduction in hey secondary complications of myocardial infarction including reinfarction, which was partly by increased non-intracranial bleeding counterbalanced complications.	Cleveland Clin Fdn, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Topol, EJ (corresponding author), Cleveland Clin Fdn, Desk F25,9500 Euclid Ave, Cleveland, OH 44195 USA.	topole@ccf.org	Ardissino, Diego/AAC-4041-2022; Fuster, Valentin/H-4319-2015	Fuster, Valentin/0000-0002-9043-9986; Topol, Eric/0000-0002-1478-4729				[Anonymous], 1988, LANCET, V2, P349; Antman EM, 1999, CIRCULATION, V99, P2720, DOI 10.1161/01.CIR.99.21.2720; Barbash GI, 2001, CIRCULATION, V103, P954; Brener SJ, 1999, CIRCULATION, V100, P649; CALIFF RM, 1994, NEW ENGL J MED, V330, P956, DOI 10.1056/nejm199404073301402; Dunnett CW, 1996, STAT MED, V15, P1729; *GRUPP IT STUD STR, 1986, LANCET, V1, P389; Hanrath P, 1997, CIRCULATION, V96, P1445; Hasselblad V, 2001, DRUG INF J, V35, P435, DOI 10.1177/009286150103500212; LAN KKG, 1983, BIOMETRIKA, V70, P659, DOI 10.2307/2336502; LINCOFF AM, 1993, CIRCULATION, V88, P1361, DOI 10.1161/01.CIR.88.3.1361; MOLITERNO DJ, 1995, AM J CARDIOL, V75, P559, DOI 10.1016/S0002-9149(99)80616-X; Pilote L, 2001, AM HEART J, V141, P559, DOI 10.1067/mhj.2001.113226; Tcheng JE, 1997, LANCET, V349, P1422; Tcheng JE, 2000, LANCET, V356, P2037; Topol E, 1997, NEW ENGL J MED, V337, P1118; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; Topol EJ, 2000, CIRCULATION, V101, P2788; Topol EJ, 1998, CIRCULATION, V97, P211, DOI 10.1161/01.CIR.97.2.211; Topol EJ, 1998, LANCET, V352, P87, DOI 10.1016/S0140-6736(98)85010-1; Topol EJ, 1997, NEW ENGL J MED, V336, P1689; Topol EJ, 1998, CIRCULATION, V98, P1802, DOI 10.1161/01.CIR.98.17.1802; Van de Werf F, 1999, LANCET, V354, P716, DOI 10.1016/S0140-6736(99)07403-6	23	450	479	0	12	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 16	2001	357	9272					1905	1914						10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	444YZ	11425410				2022-12-28	WOS:000169431000008
J	Verheugt, FWA				Verheugt, FWA			GUSTO V: the bottom line of fibrinolytic reperfusion therapy	LANCET			English	Editorial Material							ACUTE MYOCARDIAL-INFARCTION; PRIMARY ANGIOPLASTY; THROMBOLYSIS; TRIAL		Radboud Univ Nijmegen Med Ctr, Heartctr, Div Cardiol, NL-6525 Nijmegen, Netherlands	Radboud University Nijmegen	Verheugt, FWA (corresponding author), Radboud Univ Nijmegen Med Ctr, Heartctr, Div Cardiol, NL-6525 Nijmegen, Netherlands.	f.verheugt@cardio.azn.nl	Verheugt, F.W.A./H-8105-2014					[Anonymous], 1988, LANCET, V2, P349; Antman EM, 1999, CIRCULATION, V99, P2720, DOI 10.1161/01.CIR.99.21.2720; *ASSENT 2 STEER CO, 1999, LANCET, V354, P1716; Lupker RV, 2000, JAMA-J AM MED ASSOC, V284, P60; Ross AM, 1999, J AM COLL CARDIOL, V34, P1954, DOI 10.1016/S0735-1097(99)00444-1; ROSS AM, 1993, NEW ENGL J MED, V329, P1615; Topol E, 1997, NEW ENGL J MED, V337, P1118; TOPOL E, 1993, NEW ENGL J MED, V329, P673, DOI 10.1056/nejm199309023291001; Topol EJ, 2000, CIRCULATION, V101, P2788; Topol EJ, 1996, NEW ENGL J MED, V335, P775; Veen G, 1999, AM J CARDIOL, V84, P763, DOI 10.1016/S0002-9149(99)00434-8; Verheugt FWA, 1996, J AM COLL CARDIOL, V27, P766, DOI 10.1016/0735-1097(95)00492-0; White HD, 1999, LANCET, V354, P695, DOI 10.1016/S0140-6736(99)00263-9	13	11	11	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 16	2001	357	9272					1898	1899		10.1016/S0140-6736(00)05087-X	http://dx.doi.org/10.1016/S0140-6736(00)05087-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	444YZ	11425404				2022-12-28	WOS:000169431000002
J	Ma, F; Wills, BJ				Ma, F; Wills, BJ			Discovery of hidden blazars	SCIENCE			English	Article							ACTIVE GALACTIC NUCLEI; BROAD-LINE CLOUDS; EMISSION-LINES; REDSHIFT QUASARS; RADIO STRUCTURE; VARIABILITY; SPECTRA; MODELS; QSOS	Every radio-loud quasar may have blazar activities, according to a unified scheme where the differences in both optical and radio observations of radio-loud quasars are the result of different viewing angles, We have predicted that blazars may be detected using emission line ratio variations caused by variable illumination of gas clouds in the broad emission line region. In a spectroscopic search of 62 quasars at a redshift of about 2, we have discovered large (>20%) variations of the emission tine ratios, CIV/CIII] or CIV/Ly alpha, when compared with data taken more than 10 years ago. This result is consistent with our prediction and supports the unification scheme for radio-loud quasars.	Univ Texas, Prc Mrc, Austin, TX 78712 USA; Univ Texas, McDonald Observ, Austin, TX 78712 USA; Univ Texas, Dept Astron, Austin, TX 78712 USA	University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin	Ma, F (corresponding author), Univ Texas, Prc Mrc, 2nd Floor,R9950, Austin, TX 78712 USA.	feng@astro.as.utexas.edu	Wills, Beverley/ABI-7712-2020					ALEXANDER T, 1994, MON NOT R ASTRON SOC, V270, P781, DOI 10.1093/mnras/270.4.781; ANTONUCCI R, 1993, ANNU REV ASTRON ASTR, V31, P473, DOI 10.1146/annurev.aa.31.090193.002353; Arav N, 1998, MON NOT R ASTRON SOC, V297, P990, DOI 10.1046/j.1365-8711.1998.297004990.x; Baldwin J, 1999, ASTR SOC P, V162, P475; BALDWIN JA, 1977, ASTROPHYS J, V214, P679, DOI 10.1086/155294; BARTHEL PD, 1988, NATURE, V333, P319, DOI 10.1038/333319a0; BARTHEL PD, 1990, ASTRON ASTROPHYS SUP, V82, P339; BARTHEL PD, 1988, ASTRON ASTROPHYS SUP, V73, P515; BLANDFORD RD, 1977, MON NOT R ASTRON SOC, V179, P433, DOI 10.1093/mnras/179.3.433; Corbin MR, 2000, ASTROPHYS J, V532, P136, DOI 10.1086/308560; Cristiani S, 1996, ASTRON ASTROPHYS, V306, P395; Hawkins MRS, 2000, ASTRON ASTROPHYS SUP, V143, P465, DOI 10.1051/aas:2000190; HILLS JG, 1975, NATURE, V254, P295, DOI 10.1038/254295a0; HOOK IM, 1994, MON NOT R ASTRON SOC, V268, P305, DOI 10.1093/mnras/268.2.305; Kaspi S, 2000, ASTROPHYS J, V533, P631, DOI 10.1086/308704; Kaspi S, 1999, ASTROPHYS J, V524, P71, DOI 10.1086/307804; Laor A, 2000, ASTROPHYS J, V543, pL111, DOI 10.1086/317280; Ma F, 1998, ASTROPHYS J, V504, pL65, DOI 10.1086/311573; MA F, 2000, THESIS U TEXAS AUSTI; MAOZ D, 1994, ASTROPHYS J, V421, P34, DOI 10.1086/173624; MITTON S, 1977, MON NOT R ASTRON SOC, V179, P569, DOI 10.1093/mnras/179.4.569; MURRAY N, 1995, ASTROPHYS J, V451, P498, DOI 10.1086/176238; Nilsson K, 1998, ASTRON ASTROPHYS SUP, V132, P31, DOI 10.1051/aas:1998442; PEREZ E, 1989, MON NOT R ASTRON SOC, V239, P55, DOI 10.1093/mnras/239.1.55; PETERSON BM, 1986, NATURE, V324, P345, DOI 10.1038/324345a0; REID IN, 1991, PUBL ASTRON SOC PAC, V103, P661, DOI 10.1086/132866; SHIELDS GA, 1978, NATURE, V272, P706, DOI 10.1038/272706a0; SHIELDS JC, 1995, ASTROPHYS J, V441, P507, DOI 10.1086/175378; Small TA, 1997, ASTRON J, V114, P2254, DOI 10.1086/118645; URRY CM, 1995, PUBL ASTRON SOC PAC, V107, P803, DOI 10.1086/133630; VERONCETTY MP, 1996, 17 ESO; WEBB JR, 1990, ASTRON J, V100, P1452, DOI 10.1086/115609	32	3	3	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 15	2001	292	5524					2050	2053		10.1126/science.1060412	http://dx.doi.org/10.1126/science.1060412			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	442KP	11408650	Green Submitted			2022-12-28	WOS:000169284700039
J	Ullah, H; Chen, JG; Young, JC; Im, KH; Sussman, MR; Jones, AM				Ullah, H; Chen, JG; Young, JC; Im, KH; Sussman, MR; Jones, AM			Modulation of cell proliferation by heterotrimeric G protein in Arabidopsis	SCIENCE			English	Article							SIGNAL-TRANSDUCTION; COUPLED RECEPTORS; CRYSTAL-STRUCTURE; ALPHA-SUBUNIT; EXPANSION; THALIANA; PATHWAYS; DIVISION; GROWTH; LEAVES	The alpha subunit of a prototypical heterotrimeric GTP-binding protein (G protein), which is encoded by a single gene (GPA 1) in Arabidopsis, is a modulator of plant cell proliferation. gpa1 null mutants have reduced cell division in aerial tissues throughout development. Inducible overexpression of GPA1 in Arabidopsis confers inducible ectopic cell division. GPA1 overexpression in synchronized BY-2 cells causes premature advance of the nuclear cycle and the premature appearance of a division wall, Results from loss of function and ectopic expression and activation of GPA1 indicate that this subunit is a positive modulator of cell division in plants.	Univ N Carolina, Dept Biol, Chapel Hill, NC 27599 USA; Univ Wisconsin, Cell & Mol Biol Program, Madison, WI 53706 USA; Univ Wisconsin, Dept Hort, Madison, WI 53706 USA	University of North Carolina; University of North Carolina Chapel Hill; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison	Jones, AM (corresponding author), Univ N Carolina, Dept Biol, CB 3280, Chapel Hill, NC 27599 USA.	alan_jones@unc.edu	Chen, Jin-Gui/A-4773-2011; Chen, Jin-Gui/AFV-6337-2022	Chen, Jin-Gui/0000-0002-1752-4201; Chen, Jin-Gui/0000-0002-1752-4201				Ashikari M, 1999, P NATL ACAD SCI USA, V96, P10284, DOI 10.1073/pnas.96.18.10284; Dhanasekaran N., 1995, Endocrine Reviews, V16, P259; Dhanasekaran N, 1998, ONCOGENE, V17, P1383, DOI 10.1038/sj.onc.1202242; Donnelly PM, 1999, DEV BIOL, V215, P407, DOI 10.1006/dbio.1999.9443; FRANCIS D, 1998, PORTLAND PRESS RES M; Gendreau E, 1997, PLANT PHYSIOL, V114, P295, DOI 10.1104/pp.114.1.295; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; HABER AH, 1962, AM J BOT, V49, P583, DOI 10.2307/2439715; HEMERLY A, 1995, EMBO J, V14, P3925, DOI 10.1002/j.1460-2075.1995.tb00064.x; Jelacic TM, 2000, J BIOL CHEM, V275, P36211, DOI 10.1074/jbc.M007087200; Jones AM, 1998, SCIENCE, V282, P1114, DOI 10.1126/science.282.5391.1114; Kim GT, 1999, P NATL ACAD SCI USA, V96, P9433, DOI 10.1073/pnas.96.16.9433; Kovtun Y, 1998, NATURE, V395, P716, DOI 10.1038/27240; Krysan PJ, 1999, PLANT CELL, V11, P2283, DOI 10.1105/tpc.11.12.2283; Lambright DG, 1996, NATURE, V379, P311, DOI 10.1038/379311a0; LAMORTE VJ, 1992, J BIOL CHEM, V267, P691; Liebmann C, 2000, CURR MED CHEM, V7, P911, DOI 10.2174/0929867003374589; Lopez I, 2001, J BIOL CHEM, V276, P2758, DOI 10.1074/jbc.M008119200; MA H, 1994, PLANT MOL BIOL, V26, P1611, DOI 10.1007/BF00016493; Nishida M, 2000, NATURE, V408, P492, DOI 10.1038/35044120; Selbie LA, 1998, TRENDS PHARMACOL SCI, V19, P87, DOI 10.1016/S0165-6147(97)01166-8; Sondek J, 1996, NATURE, V379, P369, DOI 10.1038/379369a0; Sprang SR, 1997, ANNU REV BIOCHEM, V66, P639, DOI 10.1146/annurev.biochem.66.1.639; Tsuge T, 1996, DEVELOPMENT, V122, P1589; Vernoux T, 2000, PLANT CELL, V12, P97, DOI 10.1105/tpc.12.1.97; Wang XQ, 2001, SCIENCE, V292, P2070, DOI 10.1126/science.1059046; WATKINS DC, 1992, SCIENCE, V258, P1373, DOI 10.1126/science.1455234; Weiss CA, 1997, FEBS LETT, V407, P361, DOI 10.1016/S0014-5793(97)00378-5	28	277	311	3	41	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 15	2001	292	5524					2066	2069		10.1126/science.1059040	http://dx.doi.org/10.1126/science.1059040			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	442KP	11408654	Green Submitted			2022-12-28	WOS:000169284700044
J	Pretre, R; Tamisier, D; Bonheoffer, P; Mauriat, P; Pouard, P; Sidi, D; Vouhe, P				Pretre, R; Tamisier, D; Bonheoffer, P; Mauriat, P; Pouard, P; Sidi, D; Vouhe, P			Results of the arterial switch operation in neonates with transposed great arteries	LANCET			English	Article								Background The arterial switch operation is judged: the best palliative operation for neonates with transposed great arteries. We aimed to assess the value of analysing a large series of unselected cases by this technically demanding operation and formulate a realistic prognosis. Methods We reviewed ail 432 neonates (mean age at operation 7 days, mean weight 3.25 hg) who underwent an arterial switch operation between 1987 and 1999. Follow-up (mean time: 4.9 years) was complete in 412 patients. Findings Survival probability and freedom from reoperation was 94% and 78% at 10 years, respectively. 26 patients died, 16 because of myocardial ischaemia. Risk factors for death included early experience, low weight, associated cardiovascular malformations (especially hypoplasia of the right ventricle or aortic arch), and difficult patterns of coronary arteries. The risk of the coronary artery pattern was greatly reduced in those who had recent operations. At last follow-up, 90% of patients had normal life without treatment, and 94% a normal heart function on echocardiography. Interpretation The arterial switch operation in neonates achieves excellent results mid-term. Obstruction of the translocated coronary arteries is responsible for most deaths and a substantial number of reoperations. Although confirmation is needed, these results allow anticipation of a favourable long-term prognosis.	Hop Laennec Necker, Dept Cardiovasc Surg, F-75743 Paris 15, France; Hop Laennec Necker, Dept Cardiol, F-75743 Paris, France; Hop Laennec Necker, Dept Anaesthesia, F-75743 Paris 15, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP	Vouhe, P (corresponding author), Hop Laennec Necker, Dept Cardiovasc Surg, F-75743 Paris 15, France.							Blume ED, 1999, J AM COLL CARDIOL, V33, P1702, DOI 10.1016/S0735-1097(99)00071-6; Bonhoeffer P, 1997, J AM COLL CARDIOL, V29, P202, DOI 10.1016/S0735-1097(96)00433-0; Bonnet D, 1996, EUR J CARDIO-THORAC, V10, P482, DOI 10.1016/S1010-7940(96)80126-6; BOVE EL, 1988, CIRCULATION, V78, P26; DELEVAL MR, 1994, J THORAC CARDIOV SUR, V107, P914; Haas F, 1999, ANN THORAC SURG, V68, P1692, DOI 10.1016/S0003-4975(99)01039-5; JOURNOIS D, 1994, ANESTHESIOLOGY, V81, P1181, DOI 10.1097/00000542-199411000-00011; Kirjavainen M, 1999, J THORAC CARDIOV SUR, V117, P488, DOI 10.1016/S0022-5223(99)70329-6; Massin MM, 1999, J CARDIOVASC SURG, V40, P517; Nogi S, 1998, J THORAC CARDIOV SUR, V115, P557, DOI 10.1016/S0022-5223(98)70317-4; PLANCHE C, 1988, J THORAC CARDIOV SUR, V96, P354; QUAEGEBEUR JM, 1986, J THORAC CARDIOV SUR, V92, P361; SERRAF A, 1993, J AM COLL CARDIOL, V22, P193, DOI 10.1016/0735-1097(93)90834-N; TSUDA E, 1992, AM HEART J, V124, P1551, DOI 10.1016/0002-8703(92)90071-3; WERNOVSKY G, 1988, CIRCULATION, V77, P1333, DOI 10.1161/01.CIR.77.6.1333; WERNOVSKY G, 1995, J THORAC CARDIOV SUR, V109, P289, DOI 10.1016/S0022-5223(95)70391-8; YAMAGUCHI M, 1990, J THORAC CARDIOV SUR, V100, P261	17	167	191	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 9	2001	357	9271					1826	1830		10.1016/S0140-6736(00)04957-6	http://dx.doi.org/10.1016/S0140-6736(00)04957-6			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	440DN	11410190				2022-12-28	WOS:000169160800010
J	Flor, H; Denke, C; Schaefer, M; Grusser, S				Flor, H; Denke, C; Schaefer, M; Grusser, S			Effect of sensory discrimination training on cortical reorganisation and phantom limb pain	LANCET			English	Article								Phantom limb pain is a frequent consequence of the amputation of a body part. Based on the finding that phantom limb pain is closely associated with plastic changes in the primary somatosensory cortex and animal data showing that behaviourally relevant training alters the cortical map, we devised a sensory discrimination training programme for patients with intractable phantom limb pain. Compared with a control group of medically treated patients, the training group had significant reductions in phantom limb pain (p=0.002) and cortical reorganisation (p=0.05) that were positively associated with improved sensory discrimination ability.	Cent Inst Mental Hlth, D-68159 Mannheim, Germany; Humboldt Univ, D-10117 Berlin, Germany	Central Institute of Mental Health; Humboldt University of Berlin	Flor, H (corresponding author), Cent Inst Mental Hlth, J5, D-68159 Mannheim, Germany.			Flor, Herta/0000-0003-4809-5398				FLOR H, 1995, NATURE, V375, P482, DOI 10.1038/375482a0; JENKINS WM, 1990, J NEUROPHYSIOL, V63, P82, DOI 10.1152/jn.1990.63.1.82; JENSEN TS, 1983, PAIN, V17, P243, DOI 10.1016/0304-3959(83)90097-0; MORGENSTERN FS, 1964, J NEUROL NEUROSUR PS, V27, P58, DOI 10.1136/jnnp.27.1.58; SHERMAN RA, 1997, PHANTOM LIMB PAIN PS	5	357	364	1	52	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 2	2001	357	9270					1763	1764		10.1016/S0140-6736(00)04890-X	http://dx.doi.org/10.1016/S0140-6736(00)04890-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	440BN	11403816				2022-12-28	WOS:000169156200017
J	Gorre, ME; Mohammed, M; Ellwood, K; Hsu, N; Paquette, R; Rao, PN; Sawyers, CL				Gorre, ME; Mohammed, M; Ellwood, K; Hsu, N; Paquette, R; Rao, PN; Sawyers, CL			Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification	SCIENCE			English	Article							CHRONIC MYELOGENOUS LEUKEMIA; CHRONIC MYELOID-LEUKEMIA; KINASE INHIBITOR STI571; TYROSINE KINASE; CELL-LINES; PHILADELPHIA-CHROMOSOME; ONCOGENE; CRKL; IDENTIFICATION; TRANSFORMATION	Clinical studies with the AN tyrosine kinase inhibitor STI-571 in chronic myeloid leukemia demonstrate that many patients with advanced stage disease respond initially but then relapse. Through biochemical and molecular analysis of clinical material, we find that drug resistance is associated with the reactivation of BCR-ABL signal transduction in all cases examined. In six of nine patients, resistance was associated with a single amino acid substitution in a threonine residue of the AN kinase domain known to form a critical hydrogen bond with the drug. This substitution of threonine with isoleucine was sufficient to confer STI-571 resistance in a reconstitution experiment. In three patients, resistance was associated with progressive BCR-ABL gene amplification. These studies provide evidence that genetically complex cancers retain dependence on an initial oncogenic event and suggest a strategy for identifying inhibitors of STI-571 resistance.	Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Pathol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Sawyers, CL (corresponding author), Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90095 USA.	csawyers@mednet.ucla.edu	Sawyers, Charles/G-5327-2016		NIGMS NIH HHS [GM07185] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abruzzese E, 1998, CANCER GENET CYTOGEN, V105, P164, DOI 10.1016/S0165-4608(98)00020-X; Chin L, 1999, NATURE, V400, P468, DOI 10.1038/22788; CLARK SS, 1987, SCIENCE, V235, P85, DOI 10.1126/science.3541203; CLARK SS, 1988, SCIENCE, V239, P775, DOI 10.1126/science.3422516; DALEY GQ, 1990, SCIENCE, V247, P824, DOI 10.1126/science.2406902; Druker BJ, 2001, NEW ENGL J MED, V344, P1038, DOI 10.1056/NEJM200104053441402; Druker BJ, 1996, NAT MED, V2, P561, DOI 10.1038/nm0596-561; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; Faderl S, 1999, NEW ENGL J MED, V341, P164, DOI 10.1056/NEJM199907153410306; Felsher DW, 1999, MOL CELL, V4, P199, DOI 10.1016/S1097-2765(00)80367-6; Gambacorti-Passerini C, 2000, JNCI-J NATL CANCER I, V92, P1641, DOI 10.1093/jnci/92.20.1641; GOGA A, 1995, CELL, V82, P981, DOI 10.1016/0092-8674(95)90277-5; GORRE ME, UNPUB; HEISTERKAMP N, 1990, NATURE, V344, P251, DOI 10.1038/344251a0; Huettner CS, 2000, NAT GENET, V24, P57, DOI 10.1038/71691; KONOPKA JB, 1985, P NATL ACAD SCI USA, V82, P1810, DOI 10.1073/pnas.82.6.1810; le Coutre P, 2000, BLOOD, V95, P1758, DOI 10.1182/blood.V95.5.1758.005a41_1758_1766; Liu Y, 1999, CHEM BIOL, V6, P671, DOI 10.1016/S1074-5521(99)80118-5; Mahon FX, 2000, BLOOD, V96, P1070, DOI 10.1182/blood.V96.3.1070.015k17_1070_1079; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; NICHOLS GL, 1994, BLOOD, V84, P2912; ODA T, 1994, J BIOL CHEM, V269, P22925; Sawyers CL, 1999, NEW ENGL J MED, V340, P1330, DOI 10.1056/NEJM199904293401706; Schindler T, 2000, SCIENCE, V289, P1938, DOI 10.1126/science.289.5486.1938; Senechal K, 1996, J BIOL CHEM, V271, P23255, DOI 10.1074/jbc.271.38.23255; TENHOEVE J, 1994, BLOOD, V84, P1731; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Weisberg E, 2000, BLOOD, V95, P3498, DOI 10.1182/blood.V95.11.3498.011k27_3498_3505	28	2533	2728	3	150	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 3	2001	293	5531					876	880		10.1126/science.1062538	http://dx.doi.org/10.1126/science.1062538			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	459FU	11423618				2022-12-28	WOS:000170241000048
J	Havlir, DV; Bassett, R; Levitan, D; Gilbert, P; Tebas, P; Collier, AC; Hirsch, MS; Ignacio, C; Condra, J; Gunthard, HF; Richman, DD; Wong, JK				Havlir, DV; Bassett, R; Levitan, D; Gilbert, P; Tebas, P; Collier, AC; Hirsch, MS; Ignacio, C; Condra, J; Gunthard, HF; Richman, DD; Wong, JK			Prevalence and predictive value of intermittent viremia with combination HIV therapy	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; ACTIVE ANTIRETROVIRAL THERAPY; PROTEASE INHIBITOR THERAPY; TRIPLE-DRUG THERAPY; VIROLOGICAL RESPONSE; VIRAL REPLICATION; INDUCTION THERAPY; GENETIC-VARIATION; PERIPHERAL-BLOOD; IN-VIVO	Context In HIV-infected patients having virologic suppression (plasma HIV RNA <50 copies/mL) with antiretroviral therapy, intermittent episodes of low-level viremia have been correlated with slower decay rates of latently infected cells and increased levels of viral evolution, but the clinical significance of these episodes is unknown. Objective To determine if HIV-infected patients with intermittent viremia have a higher risk of virologic failure (confirmed HIV RNA >200 copies/mL). Design and Setting Retrospective analysis of subjects in well-characterized cohorts, the AIDS Clinical Trials Group (ACTG) 343 trial of induction-maintenance therapy (August 1997 to November 1998) and the Merck 035 trial (ongoing since March 1995). Patients Two hundred forty-one ACTG 343 patients, of whom 101 received triple-drug therapy throughout the study, and a small group of 13 patients from Merck 035 having virologic suppression after 6 months of indinavir-zidovudine-lamivudine. Main Outcome Measures Association of intermittent viremia (plasma HIV RNA >50 copies/mL) with a subsequent measure (50 copies/mL) with virologic failure (2 consecutive plasma HIV RNA measures >200 copies/mL) in both study groups; evidence of drug resistance in 7 patients from the small (n=13) study group with long-term follow-up. Results Intermittent viremia occurred in 96 (40%) of the 241 ACTG 343 patients of whom 32 (13%) had 2 consecutive HIV RNA values >50 copies/mL. during the median 84 weeks of observation (median duration of observation after first intermittent viremia episode was 46 weeks). Of the 101 individuals receiving triple-drug therapy throughout, 29% had intermittent viremia; the proportion of episodes occurring during the maintenance period was 64% for the entire cohort and 68% for the group not receiving triple-drug therapy throughout vs 55% for those who did (P=.25), Intermittent viremia did not predict virologic failure: 10 (10.4%) of 96 patients with and 20 (13.8%) of 145 patients without intermittent viremia had virologic failure (relative risk, 0.76; 95% confidence interval [CI], 0.29-1.72). In a Cox proportional hazards model, the risk for virologic failure was not significantly greater in the ACTG 343 patients with intermittent viremia (hazard ratio, 1.28; 95% CI, 0.59-2.79). Median Viral load in 10 ACTG 343 patients assessed between 24 and 60 weeks of therapy using an ultrasensitive 2.5-copies/mL detection level assay was 23 copies/mL in those with intermittent viremia vs <2.5 copies/mL in those without (P=.15). intermittent viremia occurred in 6 of 13 patients from the small study group assessed after 76 to 260 weeks of therapy (using the 2.5-copies/mL detection level assay) and was associated with a higher steady state of viral replication (P=.03), but not virologic failure over 4.5 years of observation. Viral DNA sequences from 7 patients did not show evolution of drug resistance. Conclusions Intermittent viremia occurred frequently and was associated with higher levels of replication (Merck 035), but was not associated with virologic failure in patients receiving initial combination therapy of indinavir-zidovudine-lamivudine (ACTG 343 and Merck 035). In this population, treatment changes may not be necessary to maintain long-term virologic suppression with low-level or intermittent viremia.	Univ Calif San Diego, Dept Med, San Diego, CA 92103 USA; Univ Calif San Diego, Dept Pathol, San Diego, CA 92103 USA; San Diego VA Healthcare Syst, San Diego, CA USA; Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA; Harvard Univ, Dept Med, Infect Dis Unit, Boston, MA 02115 USA; Washington Univ, Dept Internal Med, St Louis, MO USA; Univ Washington, Sch Med, Dept Allergy & Infect Dis, Seattle, WA 98195 USA; Merck Res Lab, W Point, PA USA; Univ Zurich, Dept Med, Div Infect Dis & Hosp Epidemiol, Zurich, Switzerland	University of California System; University of California San Diego; University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA San Diego Healthcare System; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Washington University (WUSTL); University of Washington; University of Washington Seattle; Merck & Company; University of Zurich	Havlir, DV (corresponding author), Univ Calif San Diego, Dept Med, 150 W Washington,Suite 100, San Diego, CA 92103 USA.		Tebas, Pablo/A-7061-2008; gunthard, huldrych f/F-1724-2011	gunthard, huldrych f/0000-0002-1142-6723; Tebas, Pablo/0000-0001-5345-7942	NIAID NIH HHS [AI38858, AI29164, AI38855, AI36214, AI43752, AI27670] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI029164, R01AI029164, R01AI043752, U01AI038858, U01AI027670, U01AI038855, P30AI036214] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ACOSTA EP, 2000, 7 C RETR OPP INF SAN, P162; Carpenter CCJ, 2000, JAMA-J AM MED ASSOC, V283, P381, DOI 10.1001/jama.283.3.381; CLAVEL F, 1989, J VIROL, V63, P1455, DOI 10.1128/JVI.63.3.1455-1459.1989; COFFIN JM, 1992, CURR TOP MICROBIOL, V176, P143; COFFIN JM, 1995, SCIENCE, V267, P483, DOI 10.1126/science.7824947; Dornadula G, 1999, JAMA-J AM MED ASSOC, V282, P1627, DOI 10.1001/jama.282.17.1627; Drusano GL, 1998, J INFECT DIS, V178, P360, DOI 10.1086/515631; Furtado MR, 1999, NEW ENGL J MED, V340, P1614, DOI 10.1056/NEJM199905273402102; Grabar S, 2000, AIDS, V14, P141, DOI 10.1097/00002030-200001280-00009; GRAMBSCH PM, 1994, BIOMETRIKA, V81, P515; Grossman Z, 1999, NAT MED, V5, P1099, DOI 10.1038/13410; Grossman Z, 1998, P NATL ACAD SCI USA, V95, P6314, DOI 10.1073/pnas.95.11.6314; Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; Gunthard HF, 1999, J VIROL, V73, P9404; Haslett PAJ, 2000, J INFECT DIS, V181, P1264, DOI 10.1086/315381; Havlir DV, 1998, NEW ENGL J MED, V339, P1261, DOI 10.1056/NEJM199810293391801; Kempf DJ, 1998, AIDS, V12, pF9, DOI 10.1097/00002030-199805000-00001; Martinez-Picado J, 2000, P NATL ACAD SCI USA, V97, P10948, DOI 10.1073/pnas.97.20.10948; Mocroft A, 1998, AIDS, V12, P2161, DOI 10.1097/00002030-199816000-00011; O'Brien TR, 2000, AIDS, V14, P821, DOI 10.1097/00002030-200005050-00008; OBRIEN WA, 1995, BLOOD, V86, P1082; Paredes R, 2000, ARCH INTERN MED, V160, P1123, DOI 10.1001/archinte.160.8.1123; Paris D, 1999, AIDS RES HUM RETROV, V15, P1631, DOI 10.1089/088922299309676; Paterson DL, 2000, ANN INTERN MED, V133, P21, DOI 10.7326/0003-4819-133-1-200007040-00004; Pialoux G, 1998, NEW ENGL J MED, V339, P1269, DOI 10.1056/NEJM199810293391802; Pilcher CD, 1999, AIDS, V13, P1337, DOI 10.1097/00002030-199907300-00010; Powderly WG, 1999, AIDS, V13, P1873, DOI 10.1097/00002030-199910010-00009; Raboud JM, 1999, J INFECT DIS, V180, P1347, DOI 10.1086/314998; Raboud JM, 1998, AIDS, V12, P1619, DOI 10.1097/00002030-199813000-00008; Ramratnam B, 2000, NAT MED, V6, P82, DOI 10.1038/71577; Reijers MHE, 1998, LANCET, V352, P185, DOI 10.1016/S0140-6736(98)06193-5; TEMIN HM, 1993, P NATL ACAD SCI USA, V90, P6900, DOI 10.1073/pnas.90.15.6900; US Department of Health and Human Services, 2001, GUID US ANT AG HIV I; Wit FWNM, 1999, J INFECT DIS, V179, P790, DOI 10.1086/314675; Yerly S, 2000, AIDS, V14, P243, DOI 10.1097/00002030-200002180-00006; Zennou V, 1998, J VIROL, V72, P3300, DOI 10.1128/JVI.72.4.3300-3306.1998; Zhang LQ, 1999, NEW ENGL J MED, V340, P1605, DOI 10.1056/NEJM199905273402101	37	288	289	1	10	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 11	2001	286	2					171	179		10.1001/jama.286.2.171	http://dx.doi.org/10.1001/jama.286.2.171			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	451JJ	11448280	Bronze			2022-12-28	WOS:000169798700022
J	Reilly, BM				Reilly, BM			Brave, waiting for Pasteur	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 4	2001	286	1					19	20		10.1001/jama.286.1.19	http://dx.doi.org/10.1001/jama.286.1.19			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	449GR	11434810				2022-12-28	WOS:000169676400001
J	Holmes, G; Holmes, F; McMorrough, J				Holmes, G; Holmes, F; McMorrough, J			The death of young King Edward VI.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MEASLES; IMMUNOSUPPRESSION; TUBERCULOSIS; MECHANISM		Univ Kansas, Med Ctr, Kansas City, KS 66160 USA; Perry Dean Rogers Partners, Boston, MA 02109 USA	University of Kansas; University of Kansas Medical Center	Holmes, G (corresponding author), Univ Kansas, Med Ctr, Kansas City, KS 66160 USA.							Allison M. J., 1981, PREHISTORIC TUBERCUL, P49; BARNES DS, 1995, MAKING SOCIAL DIS TU, P166; CHAPMAN HW, 1958, LAST TUDOR KING STUD, P29; DALE PM, 1952, MED BIOGRAPHIES AILM, P20; EILERTSEN E, 1959, Acta Tuberc Scand, V37, P203; FLINT A, 1875, PHTHISIS ITS MORBID, P65; GREEN GH, 1985, SURG GYNECOL OBSTET, V161, P490; HAYWARD J, 1636, LIFE REIGNE EDWARD 6, P401; Hernandez-Pando R, 2000, LANCET, V356, P2133, DOI 10.1016/S0140-6736(00)03493-0; JORDAN WK, 1970, EDWARD 6 THRESHOLD P, P423; JORDAN WK, 1966, EDWARD 6 KING ENGLAN, P117; Karp CL, 1997, SCIENCE, V275, P1053; Karp CL, 1999, IMMUNOL REV, V168, P91, DOI 10.1111/j.1600-065X.1999.tb01285.x; Karp CL, 1996, SCIENCE, V273, P228, DOI 10.1126/science.273.5272.228; KLEBS AC, 1909, TUBERCULOSIS TREATIS, P89; LEE S, 1968, DICT NATL BIOGRAPHY, V6, P502; LODGE E, 1835, PORTRAITS ILLUSTRIOU, P10; MAJOR RH, 1945, CLASSIC DESCRIPTIONS, P51; MANCHESTER K, 1984, MED HIST, V28, P162, DOI 10.1017/S0025727300035705; MORTON R, 1694, PHTHISIOLOGIA TREATI, P294; NICHOLS JG, 1857, LIT REMAINS EDWARD 6, P159; PICKERING LK, 2000, 2000 RED BOOK REPORT, P389; Poulsen A., 1947, ACTA TUBERC SCAND, V21, P58; RAVIGLIONE MC, 1995, JAMA-J AM MED ASSOC, V273, P220, DOI 10.1001/jama.273.3.220; STARR S, 1964, NEW ENGL J MED, V270, P386, DOI 10.1056/NEJM196402202700802; Starr SE, 1996, LANCET, V348, P1257, DOI 10.1016/S0140-6736(05)65753-4; STOW J, 1565, SUMMARIE ENGLYSHE CH, P220; TYNDALL J, 1896, NEW FRAGMENTS, P412; *UK PUBL REC OFF, 1973, CAL STAT PAP VEN SER, P532; von Pirquet C, 1908, DEUT MED WOCHENSCHR, V34, P1297	30	2	2	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 1	2001	345	1					60	62		10.1056/NEJM200107053450111	http://dx.doi.org/10.1056/NEJM200107053450111			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	449QJ	11439952				2022-12-28	WOS:000169697600011
J	Irnich, D; Behrens, N; Molzen, H; Konig, A; Gleditsch, J; Krauss, M; Natalis, M; Senn, E; Beyer, A; Schops, P				Irnich, D; Behrens, N; Molzen, H; Konig, A; Gleditsch, J; Krauss, M; Natalis, M; Senn, E; Beyer, A; Schops, P			Randomised trial of acupuncture compared with conventional massage and "sham" laser acupuncture for treatment of chronic neck pain	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Objectives To compare the efficacy of acupuncture and conventional massage for the treatment of chronic neck pain. Design Prospective, randomised, placebo controlled trial. Setting Three outpatient departments in Germany. Participants 177 patients aged 18-85 years with chronic neck pain. Interventions Patients were randomly allocated to five treatments over three weeks with acupuncture (56), massage (60, or "sham" laser acupuncture (61). Main outcome measures Primary outcome measure: maximum pain related to motion (visual analogue scale) irrespective of direction of movement one week after treatment. Secondary outcome measures: range of motion (3D ultrasound real time motion analyser), pain related to movement in sic six directions (visual analogue scale), pressure pain threshold (pressure algometer), changes of spontaneous pain, motion related pain, global complaints (seven point scale), and quality of life (SF-36). Assessments were performed before, during,and one week and three months after treatment. Patients' beliefs in treatment were assessed. Results One week after five treatments the acupuncture group showed a significantly greater improvement in motion related pain compared with massage (difference 24.22 (95% confidence interval 16.5 to 31.9), P=0.005) but not compared with sham laser (17.28 (10.0 to 24.6), P=0.33). Differences between acupuncture and massage or sham laser were greater in the subgroup who had had pain for longer than five years (n=75) and in patients with myofascial pain syndrome (n=129). The acupuncture group had the best results in most secondary outcome measures. There were no differences in patients' beliefs in treatment. Conclusion Acupuncture is a effective short term treatment for patients with chronic neck pain, but there is only limited evidence for long term effects after five treatments.	Univ Munich, Dept Anaesthesiol, D-81377 Munich, Germany; Univ Munich, Dept Phys Med & Rehabil, D-81377 Munich, Germany; Biometr Ctr Therapeut Studies, D-80336 Munich, Germany; Univ Wurzburg, Dept Orthopaed, D-97074 Wurzburg, Germany; Reha Klin Bellikon, CH-5454 Bellikon, Switzerland	University of Munich; University of Munich; University of Wurzburg	Irnich, D (corresponding author), Univ Munich, Dept Anaesthesiol, Marchioninistr 15, D-81377 Munich, Germany.	Dominik.Irnich@lrz.uni-muenchen.de		Cummings, Mike/0000-0003-2224-8835				Aker PD, 1996, BMJ-BRIT MED J, V313, P1291; ATKINS CJ, 1992, ARTHRITIS RHEUM, V35, P407, DOI 10.1002/art.1780350408; Bland JH., 1987, DISORDERS CERVICAL S; Bogduk N, 1984, Aust Fam Physician, V13, P26; Borghouts JAJ, 1998, PAIN, V77, P1, DOI 10.1016/S0304-3959(98)00058-X; BOVIM G, 1994, SPINE, V19, P1307, DOI 10.1097/00007632-199406000-00001; BRAVERMAN DL, 1999, PHYS MED REHABIL CLI, V3, P631; Cheng X, 1987, CHINESE ACUPUNCTURE; FISHER P, 1994, BRIT MED J, V309, P107, DOI 10.1136/bmj.309.6947.107; FRICTON JR, 1985, ORAL SURG ORAL MED O, V60, P615, DOI 10.1016/0030-4220(85)90364-0; Frymoyer J, 1997, ADULT SPIEN PRINCIPL, P130; GROSS AR, 2000, COCHRANE DATABASE SY; IRNICH D, 1999, DTSCH Z AKUPUNKT, V2, P81; Natalis M, 1999, ULTRASCHALL MED, V20, P70, DOI 10.1055/s-1999-14237; Ramsay DJ, 1998, JAMA-J AM MED ASSOC, V280, P1518; Schops P, 2000, SCHMERZ, V14, P160, DOI 10.1007/s004820070041; Smith LA, 2000, PAIN, V86, P119, DOI 10.1016/S0304-3959(00)00234-7; Stovner LJ, 1996, SPINE, V21, P2735, DOI 10.1097/00007632-199612010-00006; Thompson JW, 1993, ACUPUNCTURE TRIGGER, V2nd; Travell J.G., 1992, MYOFASCIAL PAIN DYSF; Vincent C, 1990, COMPLEMENT MED RES, V4, P8; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; White AR, 1999, RHEUMATOLOGY, V38, P143, DOI 10.1093/rheumatology/38.2.143	23	176	180	0	18	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 30	2001	322	7302					1574	1577		10.1136/bmj.322.7302.1574	http://dx.doi.org/10.1136/bmj.322.7302.1574			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	449QT	11431299	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000169699200026
J	Mochizuki, N; Yamashita, S; Kurokawa, K; Ohba, Y; Nagai, T; Miyawaki, A; Matsuda, M				Mochizuki, N; Yamashita, S; Kurokawa, K; Ohba, Y; Nagai, T; Miyawaki, A; Matsuda, M			Spatio-temporal images of growth-factor-induced activation of Ras and Rap1	NATURE			English	Article							GREEN FLUORESCENT PROTEIN; SIGNAL-REGULATED KINASE; DEPENDENT ACTIVATION; MOLECULAR SWITCH; PHOSPHORYLATION; PATHWAYS; GENE; CREB	G proteins of the Ras family function as molecular switches in many signalling cascades(1-3); however, little is known about where they become activated in living cells. Here we use FRET (fluorescent resonance energy transfer)-based sensors to report on the spatio-temporal images of growth-factor-induced activation of Ras and Rap1. Epidermal growth factor activated Ras at the peripheral plasma membrane and Rap1 at the intracellular perinuclear region of COS-1 cells. In PC12 cells, nerve growth factor-induced activation of Ras was initiated at the plasma membrane and transmitted to the whole cell body. After three hours, high Ras activity was observed at the extending neurites. By using the FRAP (fluorescence recovery after photobleaching) technique, we found that Ras at the neurites turned over rapidly; therefore, the sustained Ras activity at neurites was due to high GTP/GDP exchange rate and/or low GTPase activity, but not to the retention of the active Ras. These observations may resolve long-standing questions as to how Ras and Rap1 induce different cellular responses(4) and how the signals for differentiation and survival are distinguished by neuronal cells(5).	Natl Cardiovasc Ctr, Res Inst, Dept Struct Anal, Suita, Osaka 5658565, Japan; Int Med Ctr Japan, Res Inst, Dept Pathol, Shinjuku Ku, Tokyo 1628655, Japan; Osaka Univ, Inst Microbial Dis, Dept Tumor Virol, Suita, Osaka 5650871, Japan; RIKEN, Brain Sci Inst, Lab Cell Funct & Dynam, Wako, Saitama 3510198, Japan	National Cerebral & Cardiovascular Center - Japan; National Center for Global Health & Medicine - Japan; Osaka University; RIKEN	Matsuda, M (corresponding author), Natl Cardiovasc Ctr, Res Inst, Dept Struct Anal, 5-7-1 Fujishirodai, Suita, Osaka 5658565, Japan.		Kurokawa, Kazuo/E-9130-2013; Miyawaki, Atsushi/K-3569-2014; Ohba, Yusuke/E-7944-2011	Kurokawa, Kazuo/0000-0003-3549-4795; Miyawaki, Atsushi/0000-0002-2329-3235; Matsuda, Michiyuki/0000-0002-5876-9969; Nagai, Takeharu/0000-0003-2650-9895				BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; Bos JL, 1998, EMBO J, V17, P6776, DOI 10.1093/emboj/17.23.6776; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; HOSHINO M, 1988, MOL CELL BIOL, V8, P4169, DOI 10.1128/MCB.8.10.4169; Hu CD, 1997, J BIOL CHEM, V272, P11702, DOI 10.1074/jbc.272.18.11702; Ichiba T, 1999, J BIOL CHEM, V274, P14376, DOI 10.1074/jbc.274.20.14376; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; Lippincott-Schwartz J, 1999, METHOD CELL BIOL, V58, P261; LOWY DR, 1993, ANNU REV BIOCHEM, V62, P851, DOI 10.1146/annurev.bi.62.070193.004223; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Miyawaki A, 1999, P NATL ACAD SCI USA, V96, P2135, DOI 10.1073/pnas.96.5.2135; Miyawaki A, 2000, METHOD ENZYMOL, V327, P472, DOI 10.1016/S0076-6879(00)27297-2; Miyawaki A, 1997, NATURE, V388, P882, DOI 10.1038/42264; Mochizuki N, 1999, NATURE, V400, P891, DOI 10.1038/23738; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; Ohba Y, 2000, MOL CELL BIOL, V20, P6074, DOI 10.1128/MCB.20.16.6074-6083.2000; Riccio A, 1997, SCIENCE, V277, P1097, DOI 10.1126/science.277.5329.1097; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; SATOH T, 1992, J BIOL CHEM, V267, P24149; SCHELL DL, 1994, J SOC GYNECOL INVEST, V1, P269, DOI 10.1177/107155769400100405; SCHLESSINGER J, 1994, COLD SPRING HARB SYM, V59, P173, DOI 10.1101/SQB.1994.059.01.021; Vojtek AB, 1998, J BIOL CHEM, V273, P19925, DOI 10.1074/jbc.273.32.19925; Xing J, 1998, MOL CELL BIOL, V18, P1946, DOI 10.1128/MCB.18.4.1946; Zhang YZ, 2000, J NEUROSCI, V20, P5671, DOI 10.1523/JNEUROSCI.20-15-05671.2000	25	475	496	1	69	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 28	2001	411	6841					1065	1068		10.1038/35082594	http://dx.doi.org/10.1038/35082594			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	446TF	11429608				2022-12-28	WOS:000169528500051
J	Bates, DW				Bates, DW			A 40-year-old woman who noticed a medication error	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ADVERSE DRUG EVENTS; PHYSICIAN ORDER ENTRY; HOSPITALIZED-PATIENTS; HIV-INFECTION; MANAGEMENT; PREVENTION; INTERVENTION; GUIDELINES; MODEL		Brigham & Womens Hosp, Dept Med, Div Gen Med, Boston, MA 02115 USA; Partners Healthcare Syst, Ctr Appl Med Informat Syst Res, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Partners Healthcare System	Bates, DW (corresponding author), Brigham & Womens Hosp, Dept Med, Div Gen Med, 75 Francis St, Boston, MA 02115 USA.	dbates@partners.org	Bates, David/AAE-7283-2019					Bates DW, 1998, JAMA-J AM MED ASSOC, V280, P1311, DOI 10.1001/jama.280.15.1311; Bates DW, 2000, BRIT MED J, V320, P788, DOI 10.1136/bmj.320.7237.788; BATES DW, 1995, J GEN INTERN MED, V10, P199, DOI 10.1007/BF02600255; Bates DW, 1999, ARCH INTERN MED, V159, P2553, DOI 10.1001/archinte.159.21.2553; BATES DW, 1995, JAMA-J AM MED ASSOC, V274, P29, DOI 10.1001/jama.274.1.29; Bates DW, 1999, J AM MED INFORM ASSN, V6, P313, DOI 10.1136/jamia.1999.00660313; BERENS MJ, 2001, NURSING ACCIDENTS UN; COHEN MR, 1997, HOSP PHARM, V32, P338; Cook RI, 1994, HUMAN ERROR MED, P255; Evans RS, 1998, NEW ENGL J MED, V338, P232, DOI 10.1056/NEJM199801223380406; EVANS RS, 1994, ANN PHARMACOTHER, V28, P523, DOI 10.1177/106002809402800417; Gandhi TK, 2000, J GEN INTERN MED, V15, P149, DOI 10.1046/j.1525-1497.2000.04199.x; GLASER J, 1996, P 1996 HEALTHC INF M; HALAMKA JD, 2000, PROVIDER CONSUMER PO; *I MED, 1999, ERR IS HUM BUILD SAF; Jaber LA, 1996, ANN PHARMACOTHER, V30, P238, DOI 10.1177/106002809603000305; JOHNSON JA, 1995, ARCH INTERN MED, V155, P1949, DOI 10.1001/archinte.155.18.1949; *KAIS FAM FDN, 2001, DEC 2000 NAT SURV AM; Kraman SS, 1999, ANN INTERN MED, V131, P963, DOI 10.7326/0003-4819-131-12-199912210-00010; Lambert BL, 1999, MED CARE, V37, P1214, DOI 10.1097/00005650-199912000-00005; Lazarou J, 1998, JAMA-J AM MED ASSOC, V279, P1200, DOI 10.1001/jama.279.15.1200; LEAPE LL, 1994, JAMA-J AM MED ASSOC, V272, P1851, DOI 10.1001/jama.272.23.1851; LEAPE LL, 1995, JAMA-J AM MED ASSOC, V274, P35, DOI 10.1001/jama.1995.03530010049034; Leape LL, 1999, JAMA-J AM MED ASSOC, V282, P267, DOI 10.1001/jama.282.3.267; Nightingale PG, 2000, BMJ-BRIT MED J, V320, P750, DOI 10.1136/bmj.320.7237.750; Paterson DL, 2000, ANN INTERN MED, V133, P21, DOI 10.7326/0003-4819-133-1-200007040-00004; *PRINC SURV RES AS, 1999, DEC 1999 HLTH NEW IN; Purdy BD, 2000, ANN PHARMACOTHER, V34, P833, DOI 10.1345/aph.19399; RAISCH DW, 1993, ANN PHARMACOTHER, V27, P1173, DOI 10.1177/106002809302701002; Raschke RA, 1998, JAMA-J AM MED ASSOC, V280, P1317, DOI 10.1001/jama.280.15.1317; Reason J., 1991, HUMAN ERROR, DOI 10.1017/cbo9781139062367; SAFRAN C, 1995, LANCET, V346, P341, DOI 10.1016/S0140-6736(95)92226-1; Schiff GD, 1998, JAMA-J AM MED ASSOC, V279, P1024, DOI 10.1001/jama.279.13.1024; Urquhart J, 1997, CLIN PHARMACOKINET, V32, P345, DOI 10.2165/00003088-199732050-00001; *US DEP JUST, 2001, CURR US EL PRESCR; Winker MA, 2000, JAMA-J AM MED ASSOC, V283, P1600, DOI 10.1001/jama.283.12.1600; 2001, BUILDING INFORMATION	37	19	22	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 27	2001	285	24					3134	3140		10.1001/jama.285.24.3134	http://dx.doi.org/10.1001/jama.285.24.3134			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	444FF	11427143				2022-12-28	WOS:000169388900028
J	Poulter, NR				Poulter, NR			Birthweights, maternal cardiovascular events, and Barker hypothesis	LANCET			English	Editorial Material							SYSTOLIC BLOOD-PRESSURE; BIRTH-WEIGHT; ASSOCIATION; DISEASE		Imperial Coll Sch Med, Cardiovasc Studies Unit, London W2 1PG, England	Imperial College London	Poulter, NR (corresponding author), Imperial Coll Sch Med, Cardiovasc Studies Unit, St Marys Campus, London W2 1PG, England.							Barker D. J. P., 1994, MOTHERS BABIES DIS L; BENSHLOMO Y, 1994, BRIT MED J, V309, P274, DOI 10.1136/bmj.309.6949.274; Hattersley AT, 1999, LANCET, V353, P1789, DOI 10.1016/S0140-6736(98)07546-1; Huxley RR, 2000, J HYPERTENS, V18, P815, DOI 10.1097/00004872-200018070-00002; LANGLEY SC, 1994, CLIN SCI, V86, P217, DOI 10.1042/cs0860217; PANETH N, 1995, BRIT MED J, V310, P411, DOI 10.1136/bmj.310.6977.411; Poulter NR, 1999, BRIT MED J, V319, P1330, DOI 10.1136/bmj.319.7221.1330; Smith GD, 2000, LANCET, V356, P2066, DOI 10.1016/S0140-6736(00)03406-1; Susser M, 1999, BMJ-BRIT MED J, V318, P885, DOI 10.1136/bmj.318.7188.885	9	11	11	1	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 23	2001	357	9273					1990	1991		10.1016/S0140-6736(00)05131-X	http://dx.doi.org/10.1016/S0140-6736(00)05131-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	446JB	11438125				2022-12-28	WOS:000169509200002
J	Watkins, RE; Wisely, GB; Moore, LB; Collins, JL; Lambert, MH; Williams, SP; Willson, TM; Kliewer, SA; Redinbo, MR				Watkins, RE; Wisely, GB; Moore, LB; Collins, JL; Lambert, MH; Williams, SP; Willson, TM; Kliewer, SA; Redinbo, MR			The human nuclear xenobiotic receptor PXR: Structural determinants of directed promiscuity	SCIENCE			English	Article							PREGNANE-X-RECEPTOR; LIGAND-BINDING DOMAIN; CRYSTAL-STRUCTURE; JOHNS-WORT; SIGNALING PATHWAY; MOLECULAR-BASIS; CHOLESTEROL; COACTIVATOR; ANTAGONISM; ACTIVATION	The human nuclear pregnane X receptor (hPXR) activates cytochrome P450-3A expression in response to a wide variety of xenobiotics and plays a critical role in mediating dangerous drug-drug interactions. We present the crystal structures of the ligand-binding domain of hPXR both alone and in complex with the cholesterol-lowering drug SR12813 at resolutions of 2.5 and 2.75 angstroms, respectively. The hydrophobic ligand-binding cavity of hPXR contains a small number of polar residues, permitting SR12813 to bind in three distinct orientations. The position and nature of these polar residues were found to be critical for establishing the precise pharmacologic activation profile of PXR. Our findings provide important insights into how hPXR detects xenobiotics and may prove useful in predicting and avoiding drug-drug interactions.	Univ N Carolina, Dept Chem, Chapel Hill, NC 27599 USA; Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA; Univ N Carolina, Sch Med, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; GlaxoSmithKline, Nucl Receptor Discovery Res, Res Triangle Pk, NC 27709 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; GlaxoSmithKline	Redinbo, MR (corresponding author), Univ N Carolina, Dept Chem, Chapel Hill, NC 27599 USA.		feinstein, doug/M-9414-2019	Williams, Shawn/0000-0001-8311-2638				Berkhout TA, 1996, J BIOL CHEM, V271, P14376, DOI 10.1074/jbc.271.24.14376; Berkhout TA, 1997, ATHEROSCLEROSIS, V133, P203, DOI 10.1016/S0021-9150(97)00131-7; Bertilsson G, 1998, P NATL ACAD SCI USA, V95, P12208, DOI 10.1073/pnas.95.21.12208; Blumberg B, 1998, GENE DEV, V12, P3195, DOI 10.1101/gad.12.20.3195; BOURGUET W, 1995, NATURE, V375, P377, DOI 10.1038/375377a0; BRUNGER AT, 1993, ACTA CRYSTALLOGR D, V49, P24, DOI 10.1107/S0907444992007352; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Brzozowski AM, 1997, NATURE, V389, P753, DOI 10.1038/39645; Gampe RT, 2000, MOL CELL, V5, P545, DOI 10.1016/S1097-2765(00)80448-7; Goodwin B, 1999, MOL PHARMACOL, V56, P1329, DOI 10.1124/mol.56.6.1329; Jones SA, 2000, MOL ENDOCRINOL, V14, P27, DOI 10.1210/me.14.1.27; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kliewer SA, 1998, CELL, V92, P73, DOI 10.1016/S0092-8674(00)80900-9; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Lehmann JM, 1998, J CLIN INVEST, V102, P1016, DOI 10.1172/JCI3703; MAUREL P, 1996, CYTOCHROMES P450 MET, P241; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Moore LB, 2000, P NATL ACAD SCI USA, V97, P7500, DOI 10.1073/pnas.130155097; Moore LB, 2000, J BIOL CHEM, V275, P15122, DOI 10.1074/jbc.M001215200; Moras D, 1998, CURR OPIN CELL BIOL, V10, P384, DOI 10.1016/S0955-0674(98)80015-X; Navaza J, 1997, METHOD ENZYMOL, V276, P581, DOI 10.1016/S0076-6879(97)76079-8; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; ONATE SA, 1995, SCIENCE, V270, P1354; Piscitelli SC, 2000, LANCET, V355, P547, DOI 10.1016/S0140-6736(99)05712-8; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; RENAUD JP, 1995, NATURE, V378, P681, DOI 10.1038/378681a0; Rochel N, 2000, MOL CELL, V5, P173, DOI 10.1016/S1097-2765(00)80413-X; Ruschitzka F, 2000, LANCET, V355, P548, DOI 10.1016/S0140-6736(99)05467-7; Savas U, 2000, DRUG METAB DISPOS, V28, P529; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Weatherman RV, 1999, ANNU REV BIOCHEM, V68, P559, DOI 10.1146/annurev.biochem.68.1.559; Wentworth JM, 2000, J ENDOCRINOL, V166, pR11, DOI 10.1677/joe.0.166R011; Williams SP, 1998, NATURE, V393, P392, DOI 10.1038/30775; Xie W, 2000, NATURE, V406, P435, DOI 10.1038/35019116	35	635	661	1	31	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 22	2001	292	5525					2329	2333		10.1126/science.1060762	http://dx.doi.org/10.1126/science.1060762			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	445KD	11408620				2022-12-28	WOS:000169455900058
J	Chuang, HH; Prescott, ED; Kong, HY; Shields, S; Jordt, SE; Basbaum, AI; Chao, MV; Julius, D				Chuang, HH; Prescott, ED; Kong, HY; Shields, S; Jordt, SE; Basbaum, AI; Chao, MV; Julius, D			Bradykinin and nerve growth factor release the capsaicin receptor from PtdIns(4,5)P-2-mediated inhibition	NATURE			English	Article							SENSORY NEURONS; SIGNALING COMPLEX; DIRECT ACTIVATION; MICE LACKING; PAIN; HYPERALGESIA; CHANNELS; PHOTOTRANSDUCTION; SENSITIZATION; RESPONSES	Tissue injury generates endogenous factors that heighten our sense of pain by increasing the response of sensory nerve endings to noxious stimuli(1,2). Bradykinin and nerve growth factor (NGF) are two such pro-algesic agents that activate G-protein-coupled (BK2) and tyrosine kinase (TrkA) receptors, respectively, to stimulate phospholipase C (PLC) signalling pathways in primary afferent neurons(3,4). How these actions produce sensitization to physical or chemical stimuli has not been elucidated at the molecular level. Here, we show that bradykinin- or NGF-mediated potentiation of thermal sensitivity in vivo requires expression of VR1, a heat-activated ion channel on sensory neurons. Diminution of plasma membrane phosphatidylinositol-4,5-bisphosphate (PtdIns(4,5)P-2) levels through antibody sequestration or PLC-mediated hydrolysis mimics the potentiating effects of bradykinin or NGF at the cellular level. Moreover, recruitment of PLC-gamma to TrkA is essential for NGF-mediated potentiation of channel activity, and biochemical studies suggest that VR1 associates with this complex. These studies delineate a biochemical mechanism through which bradykinin and NGF produce hypersensitivity and might explain how the activation of PLC signalling systems regulates other members of the TRP channel family.	Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA; NYU, Sch Med, Skirball Inst Biomol Med, Mol Neurobiol Program, New York, NY 10016 USA; Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA; Univ Calif San Francisco, WM Keck Ctr Neurosci, San Francisco, CA 94143 USA	University of California System; University of California San Francisco; New York University; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Julius, D (corresponding author), Univ Calif San Francisco, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA.	julius@socrates.ucsf.edu	Jordt, Sven-Eric/ABE-6517-2020	Jordt, Sven-Eric/0000-0001-6171-5622; Chao, Moses/0000-0002-6969-3744; Shields, Shannon/0000-0002-8006-7103				Bergmann I, 1998, NEUROSCI LETT, V255, P87, DOI 10.1016/S0304-3940(98)00713-7; Bevan S., 1999, TXB PAIN, P85; BURGESS GM, 1989, J NEUROSCI, V9, P3314; Caterina MJ, 2000, SCIENCE, V288, P306, DOI 10.1126/science.288.5464.306; Caterina MJ, 1997, NATURE, V389, P816, DOI 10.1038/39807; Cesare P, 1999, NEURON, V23, P617, DOI 10.1016/S0896-6273(00)80813-2; Chevesich J, 1997, NEURON, V18, P95, DOI 10.1016/S0896-6273(01)80049-0; Davis JB, 2000, NATURE, V405, P183, DOI 10.1038/35012076; Estacion M, 2001, J PHYSIOL-LONDON, V530, P1, DOI 10.1111/j.1469-7793.2001.0001m.x; Ganju P, 1998, EUR J NEUROSCI, V10, P1995, DOI 10.1046/j.1460-9568.1998.00209.x; Harteneck C, 2000, TRENDS NEUROSCI, V23, P159, DOI 10.1016/S0166-2236(99)01532-5; Hofmann T, 1999, NATURE, V397, P259, DOI 10.1038/16711; Huang CL, 1998, NATURE, V391, P803, DOI 10.1038/35882; Jordt SE, 2000, P NATL ACAD SCI USA, V97, P8134, DOI 10.1073/pnas.100129497; Koltzenburg M, 1999, PAIN, pS93, DOI 10.1016/S0304-3959(99)00142-6; Koltzenburg M, 1999, EUR J NEUROSCI, V11, P1698, DOI 10.1046/j.1460-9568.1999.00590.x; Li HS, 1999, NEURON, V24, P261, DOI 10.1016/S0896-6273(00)80838-7; MCMAHON SB, 1999, TXB PAIN, P105; Nicholas RS, 1999, NEUROSCIENCE, V91, P1425, DOI 10.1016/S0306-4522(98)00706-4; Premkumar LS, 2000, NATURE, V408, P985, DOI 10.1038/35050121; Scott K, 1998, NATURE, V395, P805, DOI 10.1038/27448; Shu XQ, 1999, NEUROSCI LETT, V274, P159, DOI 10.1016/S0304-3940(99)00701-6; Shu XQ, 1999, P NATL ACAD SCI USA, V96, P7693, DOI 10.1073/pnas.96.14.7693; STEPHENS RM, 1994, NEURON, V12, P691, DOI 10.1016/0896-6273(94)90223-2; Tominaga M, 1998, NEURON, V21, P531, DOI 10.1016/S0896-6273(00)80564-4; Womack KB, 2000, J NEUROSCI, V20, P2792; Woolf CJ, 1996, PHILOS T ROY SOC B, V351, P441, DOI 10.1098/rstb.1996.0040; Woolf CJ, 2000, SCIENCE, V288, P1765, DOI 10.1126/science.288.5472.1765; ZHANG Z, 1983, CHINESE ANN MATH B, V4, P1; Zygmunt PM, 1999, NATURE, V400, P452, DOI 10.1038/22761	30	943	1005	1	48	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 21	2001	411	6840					957	962		10.1038/35082088	http://dx.doi.org/10.1038/35082088			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	444EN	11418861				2022-12-28	WOS:000169386200047
J	Joshipura, KJ; Hu, FB; Manson, JE; Stampfer, MJ; Rimm, EB; Speizer, FE; Colditz, G; Ascherio, A; Rosner, B; Spiegelman, D; Willett, WC				Joshipura, KJ; Hu, FB; Manson, JE; Stampfer, MJ; Rimm, EB; Speizer, FE; Colditz, G; Ascherio, A; Rosner, B; Spiegelman, D; Willett, WC			The effect of fruit and vegetable intake on risk for coronary heart disease	ANNALS OF INTERNAL MEDICINE			English	Article							FOOD FREQUENCY QUESTIONNAIRE; VITAMIN-E CONSUMPTION; DIETARY PATTERNS; CLINICAL-TRIAL; MEN; MORTALITY; WOMEN; STROKE; HEALTH; FIBER	Background: Many constituents of fruits and vegetables may reduce the risk for coronary heart disease, but data on the relationship between fruit and vegetable consumption and risk for coronary heart disease are sparse. Objective: To evaluate the association of fruit and vegetable consumption with risk for coronary heart disease. Design: Prospective cohort study. Setting: The Nurses' Health Study and the Health Professionals' Follow-Up Study. Participants: 84 251 women 34 to 59 years of age who were followed for 14 years and 42 148 men 40 to 75 years who were followed for 8 years. All were free of diagnosed cardiovascular disease, cancer, and diabetes at baseline. Measurements: The main outcome measure was incidence of nonfatal myocardial infarction or fatal coronary heart disease (1127 cases in women and 1063 cases in men). Diet was assessed by using food-frequency questionnaires. Results: After adjustment for standard cardiovascular risk factors, persons in the highest quintile of fruit and vegetable intake had a relative risk for coronary heart disease of 0.80 (95% CI, 0.69 to 0.93) compared with those in the lowest quintile of intake. Each 1-serving/d increase in intake of fruits or vegetables was associated with a 4% lower risk for coronary heart disease (relative risk, 0.96 [CI, 0.94 to 0.99]; P = 0.01, test for trend). Green leafy vegetables (relative risk with 1-serving/d increase, 0.77 [CI, 0.64 to 0.93]), and vitamin C-rich fruits and vegetables (relative risk with 1-serving/d increase, 0.94 [CI, 0.88 to 0.99]) contributed most to the apparent protective effect of total fruit and vegetable intake. Conclusions: Consumption of fruits and vegetables, particularly green leafy vegetables and vitamin C-rich fruits and vegetables, appears to have a protective effect against coronary heart disease.	Harvard Univ, Sch Dent Med, Dept Oral Hlth Policy & Epidemiol, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA; Brigham & Womens Hosp, Channing Lab, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Harvard School of Dental Medicine; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Joshipura, KJ (corresponding author), Harvard Univ, Sch Dent Med, Dept Oral Hlth Policy & Epidemiol, 188 Longwood Ave, Boston, MA 02115 USA.		Hu, Frank/C-1919-2013; Joshipura, Kaumudi J/AAA-3852-2020; Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291; Joshipura, Kaumudi/0000-0003-1964-7579	NATIONAL CANCER INSTITUTE [R01CA040356, R37CA040356] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034595, R01HL035464] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [R01DE012102] Funding Source: NIH RePORTER; NCI NIH HHS [CA40356, CA55075] Funding Source: Medline; NHLBI NIH HHS [HL35464, HL34595] Funding Source: Medline; NIDCR NIH HHS [DE12102] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Appel LJ, 1997, NEW ENGL J MED, V336, P1117, DOI 10.1056/NEJM199704173361601; ASCHERIO A, 1992, CIRCULATION, V86, P1475, DOI 10.1161/01.CIR.86.5.1475; Ascherio A, 1998, CIRCULATION, V98, P1198, DOI 10.1161/01.CIR.98.12.1198; CAAN B, 1991, EPIDEMIOLOGY, V2, P430, DOI 10.1097/00001648-199111000-00007; Chatellier G, 1996, BRIT MED J, V312, P426; DAGOSTINO RB, 1990, STAT MED, V9, P1501, DOI 10.1002/sim.4780091214; de Lorgeril M, 1999, CIRCULATION, V99, P779, DOI 10.1161/01.CIR.99.6.779; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; FESKANICH D, 1993, J AM DIET ASSOC, V93, P790, DOI 10.1016/0002-8223(93)91754-E; FRASER GE, 1992, ARCH INTERN MED, V152, P1416, DOI 10.1001/archinte.152.7.1416; GABH Rose, 1982, WHO MONOGRAPH SERIES; GILLMAN MW, 1995, JAMA-J AM MED ASSOC, V273, P1113, DOI 10.1001/jama.273.14.1113; Hirayama T, 1986, Prog Clin Biol Res, V206, P299; Hu FB, 1999, AM J EPIDEMIOL, V149, P531, DOI 10.1093/oxfordjournals.aje.a009849; Hu FB, 1997, NEW ENGL J MED, V337, P1491, DOI 10.1056/NEJM199711203372102; Joshipura KJ, 1999, JAMA-J AM MED ASSOC, V282, P1233, DOI 10.1001/jama.282.13.1233; KHAW KT, 1987, AM J EPIDEMIOL, V126, P1093, DOI 10.1093/oxfordjournals.aje.a114748; KHAW KT, 1987, NEW ENGL J MED, V316, P235, DOI 10.1056/NEJM198701293160502; Knekt P, 1996, BRIT MED J, V312, P478, DOI 10.1136/bmj.312.7029.478; KNEKT P, 1994, AM J EPIDEMIOL, V139, P1180, DOI 10.1093/oxfordjournals.aje.a116964; Kushi LH, 1996, NEW ENGL J MED, V334, P1156, DOI 10.1056/NEJM199605023341803; KUSHI LH, 1985, NEW ENGL J MED, V312, P811, DOI 10.1056/NEJM198503283121302; Miller ER, 1998, CIRCULATION, V98, P2390, DOI 10.1161/01.CIR.98.22.2390; MORRIS JN, 1977, BMJ-BRIT MED J, V2, P1307, DOI 10.1136/bmj.2.6098.1307; Ness AR, 1997, INT J EPIDEMIOL, V26, P1, DOI 10.1093/ije/26.1.1; RIMM EB, 1992, AM J EPIDEMIOL, V135, P1114, DOI 10.1093/oxfordjournals.aje.a116211; Rimm EB, 1998, JAMA-J AM MED ASSOC, V279, P359, DOI 10.1001/jama.279.5.359; Rimm EB, 1996, JAMA-J AM MED ASSOC, V275, P447, DOI 10.1001/jama.275.6.447; RIMM EB, 1993, NEW ENGL J MED, V328, P1450, DOI 10.1056/NEJM199305203282004; SALVINI S, 1989, INT J EPIDEMIOL, V18, P858, DOI 10.1093/ije/18.4.858; STAMPFER MJ, 1984, AM J EPIDEMIOL, V119, P837, DOI 10.1093/oxfordjournals.aje.a113804; STAMPFER MJ, 1993, NEW ENGL J MED, V328, P1444, DOI 10.1056/NEJM199305203282003; STEINMETZ KA, 1993, CANCER RES, V53, P536; Willett W., 2012, NUTR EPIDEMIOLOGY	34	980	1026	0	128	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 19	2001	134	12					1106	1114		10.7326/0003-4819-134-12-200106190-00010	http://dx.doi.org/10.7326/0003-4819-134-12-200106190-00010			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	442YU	11412050	Green Published			2022-12-28	WOS:000169313200003
J	Niaura, R; Abrams, DB				Niaura, R; Abrams, DB			Stopping smoking: a hazard for people with a history of major depression?	LANCET			English	Editorial Material							SMOKERS		Brown Univ, Miriam Hosp, Sch Med, Ctr Behav Med, Providence, RI 02903 USA; Brown Univ, Miriam Hosp, Sch Med, Ctr Prevent Med, Providence, RI 02903 USA	Brown University; Lifespan Health Rhode Island; Miriam Hospital; Brown University; Lifespan Health Rhode Island; Miriam Hospital	Niaura, R (corresponding author), Brown Univ, Miriam Hosp, Sch Med, Ctr Behav Med, Providence, RI 02903 USA.		Abrams, David B/AAY-7699-2020; Niaura, Raymond/AAE-7319-2019	Abrams, David B/0000-0002-0868-4350; Niaura, Raymond/0000-0002-0856-3540				Berlin I, 2001, INT J NEUROPSYCHOPH, V4, P33, DOI 10.1017/S1461145701002188; Fowler JS, 2000, AM J PSYCHIAT, V157, P1864, DOI 10.1176/appi.ajp.157.11.1864; Hitsman B, 1999, J CONSULT CLIN PSYCH, V67, P547, DOI 10.1037/0022-006X.67.4.547; Kendler KS, 2001, PSYCHOL MED, V31, P617, DOI 10.1017/S0033291701003798; SalinPascual RJ, 1996, J CLIN PSYCHIAT, V57, P387	5	13	14	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 16	2001	357	9272					1900	1901		10.1016/S0140-6736(00)05089-3	http://dx.doi.org/10.1016/S0140-6736(00)05089-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	444YZ	11425406				2022-12-28	WOS:000169431000004
J	Ellis, BE; Miles, GP				Ellis, BE; Miles, GP			Plant biology - One for all?	SCIENCE			English	Editorial Material							SUPPRESSION		Univ British Columbia, Biotechnol Lab, Vancouver, BC V6T 1Z4, Canada	University of British Columbia	Ellis, BE (corresponding author), Univ British Columbia, Biotechnol Lab, Vancouver, BC V6T 1Z4, Canada.							Fujisawa Y, 1999, P NATL ACAD SCI USA, V96, P7575, DOI 10.1073/pnas.96.13.7575; Gutkind JS, 1998, J BIOL CHEM, V273, P1839, DOI 10.1074/jbc.273.4.1839; Kovtun Y, 1998, NATURE, V395, P716, DOI 10.1038/27240; Lee CH, 1999, J IND ENG CHEM, V5, P40; Plakidou-Dymock S, 1998, CURR BIOL, V8, P315, DOI 10.1016/S0960-9822(98)70131-9; Ullah H, 2001, SCIENCE, V292, P2066, DOI 10.1126/science.1059040; Wang XQ, 2001, SCIENCE, V292, P2070, DOI 10.1126/science.1059046	7	14	15	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 15	2001	292	5524					2022	2023		10.1126/science.1062790	http://dx.doi.org/10.1126/science.1062790			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	442KP	11408646				2022-12-28	WOS:000169284700033
J	Kalir, S; McClure, J; Pabbaraju, K; Southward, C; Ronen, M; Leibler, S; Surette, MG; Alon, U				Kalir, S; McClure, J; Pabbaraju, K; Southward, C; Ronen, M; Leibler, S; Surette, MG; Alon, U			Ordering genes in a flagella pathway by analysis of expression kinetics from living bacteria	SCIENCE			English	Article							ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; SALMONELLA-TYPHIMURIUM; MUTANTS; REGULON; UNITS	The recent advances in large-scale monitoring of gene expression raise the challenge of mapping systems on the basis of kinetic expression data in living cells. To address this, we measured promoter activity in the flagellar system of Escherichia coli at high accuracy and temporal resolution by means of reporter plasmids. The genes in the pathway were ordered by analysis algorithms without dependence on mutant strains. The observed temporal program of transcription was much more detailed than was previously thought and was associated with multiple steps of flagella assembly.	Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Dept Phys Complex Syst, IL-76100 Rehovot, Israel; Univ Calgary, Dept Microbiol & Infect Dis, Calgary, AB T2N 4N1, Canada; Princeton Univ, Dept Mol Biol, Howard Hughes Med Inst, Princeton, NJ 08544 USA; Princeton Univ, Dept Phys, Princeton, NJ 08544 USA	Weizmann Institute of Science; Weizmann Institute of Science; University of Calgary; Howard Hughes Medical Institute; Princeton University; Princeton University	Alon, U (corresponding author), Weizmann Inst Sci, Dept Mol Cell Biol, IL-76100 Rehovot, Israel.	urialon@weizmann.ac.il	Rosa, Bruce/F-6393-2010; Surette, Michael G/AAE-8825-2020	McClure, JoAnn/0000-0003-4165-744X				Alon U, 1999, NATURE, V397, P168, DOI 10.1038/16483; AMSLER CD, 1993, J BACTERIOL, V175, P6238, DOI 10.1128/JB.175.19.6238-6244.1993; BLAIR DF, 1988, SCIENCE, V242, P1678, DOI 10.1126/science.2849208; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; BLOCK SM, 1984, NATURE, V309, P470, DOI 10.1038/309470a0; Chilcott GS, 2000, MICROBIOL MOL BIOL R, V64, P694, DOI 10.1128/MMBR.64.4.694-708.2000; Chu S, 1998, SCIENCE, V282, P699, DOI 10.1126/science.282.5389.699; Cluzel P, 2000, SCIENCE, V287, P1652, DOI 10.1126/science.287.5458.1652; Cormack BP, 1996, GENE, V173, P33, DOI 10.1016/0378-1119(95)00685-0; Dimster-Denk D, 1999, J LIPID RES, V40, P850; Duda R. O., 1973, PATTERN CLASSIFICATI; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; HUGHES KT, 1993, SCIENCE, V262, P1277, DOI 10.1126/science.8235660; Karlinsey JE, 2000, MOL MICROBIOL, V37, P1220, DOI 10.1046/j.1365-2958.2000.02081.x; KOMEDA Y, 1980, GENETICS, V94, P277; KOMEDA Y, 1982, J BACTERIOL, V150, P16, DOI 10.1128/JB.150.1.16-26.1982; KOMEDA Y, 1986, J BACTERIOL, V168, P1315, DOI 10.1128/jb.168.3.1315-1318.1986; KUTSUKAKE K, 1990, J BACTERIOL, V172, P741, DOI 10.1128/jb.172.2.741-747.1990; Lutz R, 1997, NUCLEIC ACIDS RES, V25, P1203, DOI 10.1093/nar/25.6.1203; Macnab R., 1996, ESCHERICHIA COLI SAL, V2nd ed, P119; OHNISHI K, 1992, MOL MICROBIOL, V6, P3149, DOI 10.1111/j.1365-2958.1992.tb01771.x; PARKINSON JS, 1982, J BACTERIOL, V151, P106, DOI 10.1128/JB.151.1.106-113.1982; Pruss BM, 1997, J BACTERIOL, V179, P5602; Reid BG, 1997, BIOCHEMISTRY-US, V36, P6786, DOI 10.1021/bi970281w; Spellman PT, 1998, MOL BIOL CELL, V9, P3273, DOI 10.1091/mbc.9.12.3273; Waldo GS, 1999, NAT BIOTECHNOL, V17, P691, DOI 10.1038/10904; Zhao RB, 2000, GENE DEV, V14, P981	27	269	276	2	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 15	2001	292	5524					2080	2083		10.1126/science.1058758	http://dx.doi.org/10.1126/science.1058758			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	442KP	11408658				2022-12-28	WOS:000169284700049
J	Staessen, JA; Nawrot, T; Den Hond, E; Thijs, L; Fagard, R; Hoppenbrouwers, K; Koppen, G; Nelen, V; Schoeters, G; Vanderschueren, D; Van Hecke, E; Verschaeve, L; Vlietinck, R; Roels, HA				Staessen, JA; Nawrot, T; Den Hond, E; Thijs, L; Fagard, R; Hoppenbrouwers, K; Koppen, G; Nelen, V; Schoeters, G; Vanderschueren, D; Van Hecke, E; Verschaeve, L; Vlietinck, R; Roels, HA		Environm Hlth Study Grp	Renal function, cytogenetic measurements, and sexual development in adolescents in relation to environmental pollutants: a feasibility study of biomarkers	LANCET			English	Article							POLYCYCLIC AROMATIC-HYDROCARBONS; GENERAL-POPULATION; PUBERTAL CHANGES; TOBACCO-SMOKE; LEAD SMELTER; EXPOSURE; HEALTH; CHILDREN; DIOXIN; PCBS	Background Human exposure to chemicals is normally monitored by measurement of environmental pollutants in external media. We investigated whether biomarkers in adolescents can show exposure to, and health effects of, common environmental pollutants. Methods We recruited 200 17-year-old adolescents (120 girls) from a rural control area and from two suburbs polluted by a lead smelter and two waste incinerators. We measured biomarkers of exposure and of effect in blood and urine samples, and obtained questionnaire data. School doctors measured testicular volume and staged sexual maturation. Findings Internal exposure was mostly within current standards, Concentrations of lead and cadmium in blood, PCBs (polychlorinated biphenyls) and dioxin-like compounds In serum samples, and metabolites of VOCs (volatile organic compounds) in urine were higher in one or both suburbs than in the control area, Children who lived near the waste incinerators matured sexually at an older age than others, and testicular volume was smaller in boys from the suburbs than in controls. Biomarkers of glomerular or tubular renal dysfunction in individuals were positively correlated with blood lead. Biomarkers of DNA damage were positively correlated with urinary metabolites of PAHs (polycyclic aromatic hydrocarbons) and VOCs, Interpretation Biomarkers can be used to detect environmental exposure to pollutants and measure their biological effects before overt disease develops. Our findings suggest that current environmental standards are insufficient to avoid measurable biological effects.	Katholieke Univ Leuven, Studiecoordinatiectr Hypertensie & Cardiovasc Rev, Dept Mol & Cardiovasc Onderzoek, Louvain, Belgium; Katholieke Univ Leuven, Dienst Jeugdgezondheidszorg, Dept Maatschappelijke Gezondheidszorg, Louvain, Belgium; Katholieke Univ Leuven, Afdeling Expt Geneeskunde, Dept Ontwikkelingsbiol, Louvain, Belgium; Katholieke Univ Leuven, Inst Sociale & Econ Geog, Louvain, Belgium; Katholieke Univ Leuven, Afdeling Genet Epidemiol, Ctr Menselijke Erfelijkheid, Dept Med Celbiol, Louvain, Belgium; Vlaamse Instelling Technol Onderzoek, Afdeling Leefmillieu, Onderzoekseenheid Milieutoxicol, Mol, Belgium; Prov Inst Hyg, Antwerp, Belgium; Catholic Univ Louvain, Unite Toxicol Ind & Med Travail, B-1200 Brussels, Belgium	KU Leuven; KU Leuven; KU Leuven; KU Leuven; KU Leuven; VITO; Universite Catholique Louvain	Staessen, JA (corresponding author), Studiecoordinatiectr, Lab Hypertensie, Campus Gasthuisberg,Gebouw Onderwijs Navorsing,He, B-3000 Louvain, Belgium.	jan.staessen@med.kuleuven.ac.be	Nawrot, Tim/AAA-4531-2019; Koppen, Gudrun/Q-4011-2018; Staessen, Jan A/A-1065-2011	Staessen, Jan A/0000-0002-3026-1637; Thijs, Lutgarde/0000-0002-8108-2356; Schoeters, Greta/0000-0002-6556-4814; vanderschueren, dirk/0000-0003-1395-0104; Nawrot, Tim/0000-0002-3583-3593				ABDULLA M, 1990, BIOL TRACE ELEM RES, V23, P25, DOI 10.1007/BF02917176; AELVOET W, 1997, GEZONDHEIDSINDICATOR, P130; AERTS JMM, 1996, ORGANOHALOGEN COMP, V27, P285; [Anonymous], [No title captured]; Arai T, 1998, INT J FERTIL WOMEN M, V43, P40; Bernard A, 1999, NATURE, V401, P231, DOI 10.1038/45717; BERNARD AM, 1995, ENVIRON RES, V68, P91, DOI 10.1006/enrs.1995.1012; Bertazzi PA, 1998, ENVIRON HEALTH PERSP, V106, P625, DOI 10.2307/3433813; Bokenkamp A, 1998, PEDIATRICS, V101, P875, DOI 10.1542/peds.101.5.875; BREEDVELD BC, 1996, NEDERLANDSE VOEDINGS; Brouwer A, 1999, ENVIRON HEALTH PERSP, V107, P639, DOI 10.2307/3434557; BROUWER A, 1995, EUR J PHARM-ENVIRON, V293, P1; BUCHET JP, 1990, LANCET, V336, P699, DOI 10.1016/0140-6736(90)92201-R; CLAEYS F, 1992, CADMIUM HUMAN ENV TO, P83; Clapp R, 2000, LANCET, V355, P1838, DOI 10.1016/S0140-6736(00)02280-7; Davis DL, 1998, JAMA-J AM MED ASSOC, V279, P1018, DOI 10.1001/jama.279.13.1018; DORNBERGER V, 1987, ANDROLOGIA, V19, P487; Duarte-Davidson R, 2001, OCCUP ENVIRON MED, V58, P2, DOI 10.1136/oem.58.1.2; Elinder CG., 1985, CADMIUM HLTH TOXICOL, P23; Faustman EM, 2000, ENVIRON HEALTH PERSP, V108, P13, DOI 10.2307/3454629; FLOYD RA, 1990, CARCINOGENESIS, V11, P1147; Golub MS, 2000, ENVIRON HEALTH PERSP, V108, P355, DOI 10.2307/3454355; Hagmar L, 1998, CANCER RES, V58, P4117; Hansen LG, 1998, ENVIRON HEALTH PERSP, V106, P171, DOI 10.2307/3433919; Haufroid V, 1998, INT ARCH OCC ENV HEA, V71, P162, DOI 10.1007/s004200050266; Hotz P, 1997, INT ARCH OCC ENV HEA, V70, P29, DOI 10.1007/s004200050183; KIMBROUGH RD, 1995, CRIT REV TOXICOL, V25, P133, DOI 10.3109/10408449509021611; KOOPMANESSEBOOM C, 1994, CHEMOSPHERE, V28, P1721, DOI 10.1016/0045-6535(94)90428-6; MARSHALL WA, 1969, ARCH DIS CHILD, V44, P291, DOI 10.1136/adc.44.235.291; MARSHALL WA, 1970, ARCH DIS CHILD, V45, P13, DOI 10.1136/adc.45.239.13; Mocarelli P, 2000, LANCET, V355, P1858, DOI 10.1016/S0140-6736(00)02290-X; ORTH JM, 1988, ENDOCRINOLOGY, V122, P787, DOI 10.1210/endo-122-3-787; Pauwels A, 2000, ENVIRON HEALTH PERSP, V108, P553, DOI 10.1289/ehp.00108553; Persons DL, 1998, CANCER GENET CYTOGEN, V106, P11, DOI 10.1016/S0165-4608(98)00036-3; Phillips DH, 1999, MUTAT RES-GEN TOX EN, V443, P139, DOI 10.1016/S1383-5742(99)00016-2; Pierce CH, 1998, INT ARCH OCC ENV HEA, V71, P433, DOI 10.1007/s004200050303; ROELS HA, 1980, ENVIRON RES, V22, P81, DOI 10.1016/0013-9351(80)90121-8; ROELS HA, 1978, ENVIRON RES, V15, P290, DOI 10.1016/0013-9351(78)90105-6; SCHOETERS G, 1998, 1998TOXR0097 DEP GEZ; SCHWARTZ GG, 1990, BIOL MARKERS EPIDEMI, P147; SHARPE RM, 1993, LANCET, V341, P1392, DOI 10.1016/0140-6736(93)90953-E; Siegel S., 1988, NONPARAMETRIC STAT B, P284; Staessen J A, 1996, J Cardiovasc Risk, V3, P26, DOI 10.1097/00043798-199602000-00005; STAESSEN JA, 1994, AM J HYPERTENS, V7, P685, DOI 10.1093/ajh/7.8.685; STAESSEN JA, 1992, NEW ENGL J MED, V327, P151, DOI 10.1056/NEJM199207163270303; Tagesson C, 1993, Pol J Occup Med Environ Health, V6, P357; Timbrell J.A., 1996, BIOMARKERS, V1, P1; van Zeeland AA, 1999, MUTAT RES-GEN TOX EN, V439, P249, DOI 10.1016/S1383-5718(98)00192-2; VanGoethem F, 1997, MUTAT RES-GEN TOX EN, V392, P31, DOI 10.1016/S0165-1218(97)00043-8; VANHUMMELEN P, 1993, MUTAT RES, V300, P231, DOI 10.1016/0165-1218(93)90055-I; VANROOIJ JGM, 1994, INT ARCH OCC ENV HEA, V66, P55, DOI 10.1007/BF00386580; *VLAAMS MIL, 2000, STAT NIEUWS MEETR DI; *WOLT ATL PROD, 1997, WOLT KLEIN WER, P1	53	168	171	3	32	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 26	2001	357	9269					1660	1669		10.1016/S0140-6736(00)04822-4	http://dx.doi.org/10.1016/S0140-6736(00)04822-4			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	435UY	11425371				2022-12-28	WOS:000168901600012
J	Weeks, AR; Marec, F; Breeuwer, JAJ				Weeks, AR; Marec, F; Breeuwer, JAJ			A mite species that consists entirely of haploid females	SCIENCE			English	Article							RIBOSOMAL DNA; NO EVIDENCE; EVOLUTION; REPRODUCTION; ARTHROPODS; DIPLOIDY	The dominance of the diploid state in higher organisms, with haploidy generally confined to the gametic phase, has Led to the perception that diploidy is favored by selection. This view is highlighted by the fact that no known female organism within the Metazoa exists exclusively (or even for a prolonged period) in a haploid state. We used fluorescence microscopy and variation at nine microsatellite Loci to show that the false spider mite, Brevipalpus phoenicis, consists of haploid female parthenogens. We show that this reproductive anomaly is caused by infection by an undescribed endosymbiotic bacterium, which results in feminization of haploid genetic males.	Univ Amsterdam, Inst Biodivers & Ecosyst Dynam, Sect Populat Biol, NL-1098 SM Amsterdam, Netherlands; Univ Amsterdam, Inst Biodivers & Ecosyst Dynam, Sect Evolutionary Biol, NL-1098 SM Amsterdam, Netherlands; Acad Sci Czech Republ, Inst Entomol, CZ-37005 Ceske Budejovice, Czech Republic	University of Amsterdam; University of Amsterdam; Czech Academy of Sciences; Biology Centre of the Czech Academy of Sciences	Weeks, AR (corresponding author), Monash Univ, Dept Biol Sci, Ctr Environm Stress & Adaptat Res, Clayton, Vic 3168, Australia.		Marec, Frantisek/G-7943-2014; Weeks, Andrew/ABC-3048-2020	Marec, Frantisek/0000-0002-6745-5603; Weeks, Andrew/0000-0003-3081-135X				Blackman RL, 1996, CHROMOSOME RES, V4, P314, DOI 10.1007/BF02263684; Bordenstein SR, 2001, NATURE, V409, P707, DOI 10.1038/35055543; *GENB, AF350221 GENB; Grasso DA, 2000, ETHOL ECOL EVOL, V12, P309; HELLE W, 1980, GENETICA, V54, P45, DOI 10.1007/BF00122407; HELLE W, 1972, EXPERIENTIA, V28, P707, DOI 10.1007/BF01944992; Kennedy JS, 1996, J APPL ENTOMOL, V120, P493, DOI 10.1111/j.1439-0418.1996.tb01641.x; KONDRASHOV AS, 1991, NATURE, V351, P314, DOI 10.1038/351314a0; Kurtti TJ, 1996, J INVERTEBR PATHOL, V67, P318, DOI 10.1006/jipa.1996.0050; Mable BK, 1998, BIOESSAYS, V20, P453, DOI 10.1002/(SICI)1521-1878(199806)20:6<453::AID-BIES3>3.0.CO;2-N; MARTIN G, 1990, GEN COMP ENDOCR, V80, P349, DOI 10.1016/0016-6480(90)90183-M; Norton Roy A., 1993, P8; ORR HA, 1995, GENETICS, V139, P1441; PerrotMinnot MJ, 1997, CAN ENTOMOL, V129, P691, DOI 10.4039/Ent129691-4; PIJNACKER LP, 1980, GENETICA, V51, P211, DOI 10.1007/BF00121613; PIJNACKER LP, 1981, ACAROLOGIA, V22, P157; Rigaud T, 1997, BIOESSAYS, V19, P409, DOI 10.1002/bies.950190508; ROUSSET F, 1992, P ROY SOC B-BIOL SCI, V250, P91, DOI 10.1098/rspb.1992.0135; Sahara K, 1999, CHROMOSOME RES, V7, P449, DOI 10.1023/A:1009297729547; SIMON C, 1994, ANN ENTOMOL SOC AM, V87, P651, DOI 10.1093/aesa/87.6.651; Stouthamer R, 1999, ANNU REV MICROBIOL, V53, P71, DOI 10.1146/annurev.micro.53.1.71; Suomalainen E, 1987, CYTOLOGY EVOLUTION P; Weeks AR, 2000, EXP APPL ACAROL, V24, P775, DOI 10.1023/A:1006486400800; WEISBURG WG, 1991, J BACTERIOL, V173, P697, DOI 10.1128/JB.173.2.697-703.1991; Welch DM, 2000, SCIENCE, V288, P1211, DOI 10.1126/science.288.5469.1211; Wenseleers T, 2000, J EVOLUTION BIOL, V13, P277, DOI 10.1046/j.1420-9101.2000.00168.x; Wenseleers T, 1998, P ROY SOC B-BIOL SCI, V265, P1447, DOI 10.1098/rspb.1998.0456; Wrensch Dana L., 1994, P282; ZCHORIFEIN E, COMMUNICATION	29	201	216	0	49	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 29	2001	292	5526					2479	2482		10.1126/science.1060411	http://dx.doi.org/10.1126/science.1060411			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	448YU	11431565				2022-12-28	WOS:000169658200038
J	Thomas, GL; Thorne, RE				Thomas, GL; Thorne, RE			Night-time predation by Steller sea lions	NATURE			English	Article									Prince William Sound Sci Ctr, Cordova, AK 99574 USA		Thomas, GL (corresponding author), Prince William Sound Sci Ctr, POB 705, Cordova, AK 99574 USA.							CASTELLINI M, 1993, AKSG9301, P4; Loughlin TR., 1998, BIOSPH CONSER NAT WI, V1, P91, DOI [10.20798/biospherecons.1.2_91, DOI 10.20798/BIOSPHERECONS.1.2_91]; MacLennan D.N., 1992, SPRINGER SCI BUS MED; Mantua NJ, 1997, B AM METEOROL SOC, V78, P1069, DOI 10.1175/1520-0477(1997)078<1069:APICOW>2.0.CO;2; Merrick RL, 1997, CAN J FISH AQUAT SCI, V54, P1342, DOI 10.1139/cjfas-54-6-1342; MERRICK RL, 1994, POLAR RES, V13, P105, DOI 10.1111/j.1751-8369.1994.tb00441.x; National Research Council, 1996, BER SEA EC; Thomas G. L., 1997, DEV SUSTAINING WORLD, P606; THORNE RE, 1983, FAO FISH REP, V300, P217	9	53	53	2	8	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 28	2001	411	6841					1013	1013		10.1038/35082745	http://dx.doi.org/10.1038/35082745			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	446TF	11429591				2022-12-28	WOS:000169528500033
J	Chakrabarti, S; Fombonne, E				Chakrabarti, S; Fombonne, E			Pervasive developmental disorders in preschool children	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							AUTISM DIAGNOSTIC INTERVIEW; MEDICAL CONDITIONS; ABNORMALITIES; EPIDEMIOLOGY; INSTRUMENT; SPECTRUM	Context Prevalence rates of autism-spectrum disorders are uncertain, and speculation that their incidence is increasing continues to cause concern. Objective To estimate the prevalence of pervasive developmental disorders (PDDs) in a geographically defined population of preschool children. Design, Setting, and Participants Survey conducted July 1998 to June 1999 in Staffordshire, England. The area's 15500 children aged 2.5 to 6.5 years were screened for developmental problems. Children with symptoms suggestive of a PDD were intensively assessed by a multidisciplinary team, which conducted standardized diagnostic interviews and administered psychometric tests. Main Outcome Measure Prevalence estimates for subtypes of PDDs. Results A total of 97 children (79.4% male) were confirmed to have a PDD. The prevalence of PDDs was estimated to be 62.6 (95% confidence interval, 50.8-76.3) per 10000 children. Prevalences were 16.8 per 10000 for autistic disorder and 45.8 per 10000 for other PDDs. The mean age at diagnosis was 41 months, and 81% were originally referred by health visitors (nurse specialists). Of the 97 children with a PDD, 25.8% had some degree of mental retardation and 9.3% had an associated medical condition. Conclusions Our results suggest that rates of PDD are higher than previously reported. Methodological limitations in existing epidemiological investigations preclude interpretation of recent high rates as indicative of increased incidence of these disorders although this hypothesis requires further rigorous testing. Attention is nevertheless drawn to the important needs of a substantial minority of preschool children.	Kings Coll London, Inst Psychiat, Dept Child & Adolescent Psychiat, MRC,Child Psychiat Unit, London SE5 8AF, England; Cent Clin, Child Dev Ctr, Stafford, England	University of London; King's College London	Fombonne, E (corresponding author), Kings Coll London, Inst Psychiat, Dept Child & Adolescent Psychiat, MRC,Child Psychiat Unit, Denmark Hill, London SE5 8AF, England.	e.fombonne@iop.kcl.ac.uk	Fombonne, Eric/M-4893-2018; Chakrabarti, Suniti/J-7554-2015	Fombonne, Eric/0000-0002-8605-3538; Chakrabarti, Suniti/0000-0002-3657-364X				American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; BAILEY A, 1995, PSYCHOL MED, V25, P63, DOI 10.1017/S0033291700028099; Baird G, 2000, J AM ACAD CHILD PSY, V39, P694, DOI 10.1097/00004583-200006000-00007; BARTKO JJ, 1976, PSYCHOL BULL, V83, P762, DOI 10.1037/0033-2909.83.5.762; Barton M, 1998, J AUTISM DEV DISORD, V28, P273, DOI 10.1023/A:1026052417561; *CA DEP DEV SERV, 2001, CHANG POP PERS QUT P; *CDCP, 2001, PREV AUT BRICK TOWNS; Dales L, 2001, JAMA-J AM MED ASSOC, V285, P1183, DOI 10.1001/jama.285.9.1183; De Giacomo A, 1998, EUR CHILD ADOLES PSY, V7, P131, DOI 10.1007/s007870050058; Filipek PA, 2000, J AUTISM DEV DISORD, V30, P81; Filipek PA, 1999, J AUTISM DEV DISORD, V29, P439, DOI 10.1023/A:1021943802493; Fombonne E, 1997, J AM ACAD CHILD PSY, V36, P1561, DOI 10.1016/S0890-8567(09)66566-7; Fombonne E, 1999, PSYCHOL MED, V29, P769, DOI 10.1017/S0033291799008508; FOMBONNE E, 1992, J AUTISM DEV DISORD, V22, P563, DOI 10.1007/BF01046328; Fombonne E, 2001, PEDIATRICS, V107, P411, DOI 10.1542/peds.107.2.411; FOMBONNE E, 2001, ED CHILDREN AUTISM; FOMBONNE E, J AM ACAD CHILD ADOL; FOMBONNE E, IN PRESS MOL PSYCHIA; HALL D, 1996, HLTH ALL CHILDR REP; Howlin P., 1997, AUTISM, V1, P135, DOI [DOI 10.1177/1362361397012003, 10.1177/1362361397012003]; *IMM SAF REV COMM, 2001, MEASL MUMPS RUB VACC; Kielinen M, 2000, EUR CHILD ADOLES PSY, V9, P162, DOI 10.1007/s007870070039; LECOUTEUR A, 1989, J AUTISM DEV DISORD, V19, P363, DOI 10.1007/BF02212936; Lord C, 2000, J AUTISM DEV DISORD, V30, P205, DOI 10.1023/A:1005592401947; LORD C, 1994, J AUTISM DEV DISORD, V24, P659, DOI 10.1007/BF02172145; Lotter V., 1966, SOC PSYCHIATR, V1, P124, DOI [10.1007/BF00584048, https://doi.org/10.1007/BF00584048]; *NAT AC SCI, 2001, REP COMM ED INT CHIL; ROGERS JS, 1990, J AM ACAD CHILD ADOL, V29, P207; Rogers SJ, 1996, J AUTISM DEV DISORD, V26, P243, DOI 10.1007/BF02172020; RUTTER M, 1994, J CHILD PSYCHOL PSYC, V35, P311, DOI 10.1111/j.1469-7610.1994.tb01164.x; *STAT CORP, 1997, STAT DAT AN; Stone WL, 2000, J AUTISM DEV DISORD, V30, P607, DOI 10.1023/A:1005647629002; STUTSMAN R, 1948, MERRILPALMER SCALE 3; Szatmari P, 1998, J AUTISM DEV DISORD, V28, P351, DOI 10.1023/A:1026096203946; Wakefield AJ, 1999, LANCET, V354, P949, DOI 10.1016/S0140-6736(05)75696-8; WESCHLER D, 1990, MANUAL WECHSLER PRES; WING L, 1979, J AUTISM DEV DISORD, V9, P11, DOI 10.1007/BF01531288	37	711	736	0	60	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 27	2001	285	24					3093	3099		10.1001/jama.285.24.3093	http://dx.doi.org/10.1001/jama.285.24.3093			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	444FF	11427137	Bronze			2022-12-28	WOS:000169388900022
J	Parker, RA; Hartman, EE				Parker, RA; Hartman, EE			A 26-year-old woman with shoulder pain, 1 year later	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article																		Burkhart SS, 2000, JAMA-J AM MED ASSOC, V284, P1559, DOI 10.1001/jama.284.12.1559	1	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 27	2001	285	24					3140	3140		10.1001/jama.285.24.3140	http://dx.doi.org/10.1001/jama.285.24.3140			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	444FF	11427144				2022-12-28	WOS:000169388900029
J	Hubinette, A; Cnattingius, S; Ekbom, A; de Faire, U; Kramer, M; Lichtenstein, P				Hubinette, A; Cnattingius, S; Ekbom, A; de Faire, U; Kramer, M; Lichtenstein, P			Birthweight, early environment, and genetics: a study of twins discordant for acute myocardial infarction	LANCET			English	Article							CORONARY HEART-DISEASE; FETAL-ORIGINS HYPOTHESIS; LOW-BIRTH-WEIGHT; TYPE-2 DIABETES-MELLITUS; BLOOD-PRESSURE; ASSOCIATION; COHORT; DEATH; GROWTH; SUSCEPTIBILITY	Background Epidemiological studies that used birthweight as a crude marker of fetal growth have suggested that low birthweight is associated with increased risk of coronary heart disease. Through investigation of this association within same-sexed twin pairs, confounding by genetic and early environmental factors can be greatly decreased. We undertook a case-control study in twins discordant for acute myocardial infarction (AMI). Methods The case-control study was nested within the population-based Swedish Twin Registry and linked with the national cause-of-death and hospital-discharge registries. We manually retrieved birth records containing information on birth and maternal characteristics for 132 same-sexed twin pairs discordant for AMI and 118 individually matched control twin pairs. Findings In comparisons between AMI cases and external matched control twins, cases had significantly lower birthweight (mean 2556 [SD 500] vs 2699 [530] g, p=0.04), birth length (47.1 [2.8] vs 47.9 [2.7] cm, p=0.04), and head circumference (33.0 [1.8] vs 33.5 [2.0] cm, p=0.03) than controls. In within-pair comparisons between AMI cases and healthy co-twins, no significant differences in birth measurements were found (birthweight 2458 [510] vs 2534 [530] g, p=0.73; birth length 47.1[2.8] vs 47.2 [2.8] cm, p=0.91; head circumference 33.0 [1.7] vs 33.0 [1.8] cm, p=0.92). Interpretation The lack of an association between birth characteristics and AMI within twin pairs suggests that previously reported associations may be influenced by genetic and early environmental factors, or possibly. by unmeasured maternal factors that operate independently of birthweight.	Karolinska Inst, Dept Med Epidemiol, SE-17177 Stockholm, Sweden; Karolinska Inst, Inst Environm Med, Div Cardiovasc Epidemiol, SE-17177 Stockholm, Sweden; Karolinska Hosp, Dept Med, Ctr Clin Cardiovasc Res, S-10401 Stockholm, Sweden; McGill Univ, Dept Epidemiol & Biostat, Montreal, PQ, Canada; McGill Univ, Dept Pediat, Montreal, PQ, Canada	Karolinska Institutet; Karolinska Institutet; Karolinska Institutet; Karolinska University Hospital; McGill University; McGill University	Hubinette, A (corresponding author), Karolinska Inst, Dept Med Epidemiol, POB 281, SE-17177 Stockholm, Sweden.			lichtenstein, paul/0000-0003-3037-5287				BARKER DJP, 1989, LANCET, V2, P577; Bo S, 2000, DIABETIC MED, V17, P365, DOI 10.1046/j.1464-5491.2000.00288.x; Busch CP, 1999, PHARMACOGENETICS, V9, P351, DOI 10.1097/00008571-199906000-00010; CEDERLOEF R, 1961, ACTA GENET STAT MED, V11, P338; Cederlof R, 1978, Prog Clin Biol Res, V24 Pt B, P189; CHRISTENSEN K, 1995, BRIT MED J, V310, P432, DOI 10.1136/bmj.310.6977.432; Clausson B, 2000, BRIT J OBSTET GYNAEC, V107, P375, DOI 10.1111/j.1471-0528.2000.tb13234.x; Dwyer T, 1999, BMJ-BRIT MED J, V319, P1325, DOI 10.1136/bmj.319.7221.1325; Elbein SC, 1997, J NUTR, V127, pS1891, DOI 10.1093/jn/127.9.1891S; Eriksson JG, 1999, BMJ-BRIT MED J, V318, P427, DOI 10.1136/bmj.318.7181.427; Eriksson M, 1997, J EPIDEMIOL COMMUN H, V51, P19, DOI 10.1136/jech.51.1.19; Hoet JJ, 1999, J PHYSIOL-LONDON, V514, P617, DOI 10.1111/j.1469-7793.1999.617ad.x; IJzerman RG, 2000, HYPERTENSION, V36, P1008, DOI 10.1161/01.HYP.36.6.1008; Joseph KS, 1996, EPIDEMIOL REV, V18, P158, DOI 10.1093/oxfordjournals.epirev.a017923; Kramer MS, 2000, AM J EPIDEMIOL, V152, P605, DOI 10.1093/aje/152.7.605; Kuh D, 1997, LIFE COURSE APPROACH; Leon DA, 1999, BMJ-BRIT MED J, V319, P1313, DOI 10.1136/bmj.319.7221.1313; Leon DA, 1998, BMJ-BRIT MED J, V317, P241, DOI 10.1136/bmj.317.7153.241; Lucas A, 1999, BRIT MED J, V319, P245, DOI 10.1136/bmj.319.7204.245; Lunde A S, 1980, Vital Health Stat 2, P1; MAGNUS P, 1984, CLIN GENET, V25, P15; MAGNUS P, 1984, CLIN GENET, V26, P289; MARENBERG ME, 1994, NEW ENGL J MED, V330, P1041, DOI 10.1056/NEJM199404143301503; PANETH N, 1995, BRIT MED J, V310, P411, DOI 10.1136/bmj.310.6977.411; PHILLIPS DIW, 1993, LANCET, V341, P1008, DOI 10.1016/0140-6736(93)91086-2; Poulsen P, 1997, DIABETOLOGIA, V40, P439, DOI 10.1007/s001250050698; Poulter NR, 1999, BRIT MED J, V319, P1330, DOI 10.1136/bmj.319.7221.1330; Roseboom TJ, 2000, HEART, V84, P595, DOI 10.1136/heart.84.6.595; *STAT SWED, 1950, OFF STAT SWED STAT A; *STAT SWED, 1960, OFF STAT SWED HIST S; *SWED COUNC PLANN, 2000, SCI EV SWED TWIN REG; *SWED NAT BOARD HL, 1999, SWED HOSP DISCH REG; *SWED NAT BOARD HL, 1998, CAUS DEATH; VAGERO D, 1994, LANCET, V343, P260, DOI 10.1016/S0140-6736(94)91112-6; *WHO, 1955, MAN INT CLASS DIS IN; Williams S, 1999, BRIT MED J, V318, P897, DOI 10.1136/bmj.318.7188.897	36	56	58	0	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 23	2001	357	9273					1997	2001		10.1016/S0140-6736(00)05111-4	http://dx.doi.org/10.1016/S0140-6736(00)05111-4			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	446JB	11438130				2022-12-28	WOS:000169509200007
J	Bernhardt, TG; Wang, IN; Struck, DK; Young, R				Bernhardt, TG; Wang, IN; Struck, DK; Young, R			A protein antibiotic in the phage Q beta virion: Diversity in lysis targets	SCIENCE			English	Article							ESCHERICHIA-COLI; CELL-LYSIS; ELEMENTS; STRAINS	A(2), a capsid protein of RNA phage Q beta, is also responsible for host Lysis. A(2) blocked synthesis of murein precursors in vivo by inhibiting MurA, the catalyst of the committed step of murein biosynthesis. An A(2)-resistance mutation mapped to an exposed surface near the substrate-binding cleft of MurA. Moreover, purified Q beta virions inhibited wild-type MurA, but not the mutant MurA, in vitro. Thus, the two small phages characterized for their Lysis strategy, Q beta and the small DNA phage phi X174, effect host Lysis by targeting different enzymes in the multistep, universally conserved pathway of cell wall biosynthesis.	Texas A&M Univ, Dept Biochem & Biophys, College Stn, TX 77843 USA; Texas A&M Univ, Hlth Sci Ctr, Dept Med Biochem & Genet, College Stn, TX 77843 USA	Texas A&M University System; Texas A&M University College Station; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center	Young, R (corresponding author), Texas A&M Univ, Dept Biochem & Biophys, 2128 TAMU, College Stn, TX 77843 USA.			Young, Ry/0000-0001-8001-2914	NIGMS NIH HHS [R01 GM027099] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Berlyn MKB, 1998, MICROBIOL MOL BIOL R, V62, P814, DOI 10.1128/MMBR.62.3.814-984.1998; Bernhardt TG, 2000, P NATL ACAD SCI USA, V97, P4297, DOI 10.1073/pnas.97.8.4297; Bernhardt TG, 2001, J BIOL CHEM, V276, P6093, DOI 10.1074/jbc.M007638200; BERNHARDT TM, UNPUB; Chaplin MF, 1986, CARBOHYDRATE ANAL PR; KOZAK M, 1971, NATURE-NEW BIOL, V234, P209, DOI 10.1038/newbio234209a0; Lutz R, 1997, NUCLEIC ACIDS RES, V25, P1203, DOI 10.1093/nar/25.6.1203; MARQUARDT JL, 1992, J BACTERIOL, V174, P5748, DOI 10.1128/JB.174.17.5748-5752.1992; Miller J.H., 1972, EXPT MOL GENETICS; PARANCHYCH W, 1975, RNA PHAGES, pCH4; ROOF W, UNPUB; Sektas M, 1999, BIOTECHNIQUES, V27, P911, DOI 10.2144/99275bm07; SINGER M, 1989, MICROBIOL REV, V53, P1; STRAUSS JH, 1963, J MOL BIOL, V7, P43, DOI 10.1016/S0022-2836(63)80017-0; VANDUIN J, 1988, BACTERIOPHAGES, V1, pCH4; WANG IC, UNPUB; Wang IN, 2000, ANNU REV MICROBIOL, V54, P799, DOI 10.1146/annurev.micro.54.1.799; WINTER RB, 1983, CELL, V33, P877, DOI 10.1016/0092-8674(83)90030-2; WITTE A, 1990, BIOCHIMIE, V72, P191, DOI 10.1016/0300-9084(90)90145-7; Young R, 2000, TRENDS MICROBIOL, V8, P120, DOI 10.1016/S0966-842X(00)01705-4	20	100	108	1	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 22	2001	292	5525					2326	2329		10.1126/science.1058289	http://dx.doi.org/10.1126/science.1058289			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	445KD	11423662				2022-12-28	WOS:000169455900057
J	Hines, PJ; Marx, J				Hines, PJ; Marx, J			The endless race between plant and pathogen	SCIENCE			English	Editorial Material																			0	4	4	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 22	2001	292	5525					2269	2269		10.1126/science.292.5525.2269	http://dx.doi.org/10.1126/science.292.5525.2269			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	445KD	11423645				2022-12-28	WOS:000169455900039
J	Hudson, EW; Lang, KM; Madhavan, V; Pan, SH; Eisaki, H; Uchida, S; Davis, JC				Hudson, EW; Lang, KM; Madhavan, V; Pan, SH; Eisaki, H; Uchida, S; Davis, JC			Interplay of magnetism and high-Tc superconductivity at individual Ni impurity atoms in Bi2Sr2CaCu2O8+delta	NATURE			English	Article							NONMAGNETIC IMPURITIES; SPIN-FLUCTUATION; ZN SUBSTITUTION; BOUND-STATES; NMR; MOMENTS; CU; EXCITATIONS; METALS; PROBE	Magnetic interactions and magnetic impurities are destructive to superconductivity in conventional superconductors(1). By contrast, in some unconventional macroscopic quantum systems (such as superfluid He-3 and superconducting UGe2), the superconductivity (or superfluidity) is actually mediated by magnetic interactions. A magnetic mechanism has also been proposed for high-temperature superconductivity(2-6). Within this context, the fact that magnetic Ni impurity atoms have a weaker effect on superconductivity than non-magnetic Zn atoms in the high-Tc superconductors has been put forward as evidence supporting a magnetic mechanism(5,6). Here we use scanning tunnelling microscopy to determine directly the influence of individual Ni atoms on the local electronic structure of Bi2Sr2CaCu2O8+delta. At each Ni site we observe two d-wave impurity states(7,8) of apparently opposite spin polarization, whose existence indicates that Ni retains a magnetic moment in the superconducting state. However, analysis of the impurity-state energies shows that quasiparticle scattering at Ni is predominantly non-magnetic. Furthermore, we show that the superconducting energy gap and correlations are unimpaired at Ni. This is in strong contrast to the effects of non-magnetic Zn impurities, which locally destroy superconductivity(9). These results are consistent with predictions for impurity atom phenomena(5,6) derived from a magnetic mechanism.	Univ Calif Berkeley, Dept Phys, Berkeley, CA 94720 USA; Natl Inst Stand & Technol, Gaithersburg, MD 20899 USA; Boston Univ, Dept Phys, Boston, MA 02215 USA; Univ Tokyo, Dept Superconduct, Bunkyo Ku, Tokyo 1138656, Japan; Stanford Univ, Dept Appl Phys, Stanford, CA 94205 USA	University of California System; University of California Berkeley; National Institute of Standards & Technology (NIST) - USA; Boston University; University of Tokyo; Stanford University	Davis, JC (corresponding author), Univ Calif Berkeley, Dept Phys, Berkeley, CA 94720 USA.	jcdavis@physics.berkeley.edu	Eisaki, Hiroshi/F-6317-2018; Hudson, Eric/C-4170-2017; Hudson, Eric/C-2746-2008	Eisaki, Hiroshi/0000-0002-8299-6416; Hudson, Eric/0000-0001-7064-0351; Hudson, Eric/0000-0001-7064-0351				ABRIKOSOV AA, 1961, SOV PHYS JETP-USSR, V12, P1243; BALATSKY AV, 1995, PHYS REV B, V51, P15547, DOI 10.1103/PhysRevB.51.15547; Bernhard C, 1996, PHYS REV LETT, V77, P2304, DOI 10.1103/PhysRevLett.77.2304; BICKERS NE, 1989, PHYS REV LETT, V62, P961, DOI 10.1103/PhysRevLett.62.961; Bobroff J, 2001, PHYS REV LETT, V86, P4116, DOI 10.1103/PhysRevLett.86.4116; Bobroff J, 1999, PHYS REV LETT, V83, P4381, DOI 10.1103/PhysRevLett.83.4381; BONN DA, 1994, PHYS REV B, V50, P4051, DOI 10.1103/PhysRevB.50.4051; Flatte ME, 1997, PHYS REV LETT, V78, P3761, DOI 10.1103/PhysRevLett.78.3761; Flatte ME, 1998, PHYS REV LETT, V80, P4546, DOI 10.1103/PhysRevLett.80.4546; Flatte ME, 2000, PHYS REV B, V61, P14920, DOI 10.1103/PhysRevB.61.R14920; Haas S, 2000, PHYS REV LETT, V85, P2172, DOI 10.1103/PhysRevLett.85.2172; ISHIDA K, 1993, J PHYS SOC JPN, V62, P2803, DOI 10.1143/JPSJ.62.2803; Julien MH, 2000, PHYS REV LETT, V84, P3422, DOI 10.1103/PhysRevLett.84.3422; Kuo YK, 1997, PHYS REV B, V56, P6201, DOI 10.1103/PhysRevB.56.6201; MAEDA A, 1990, PHYS REV B, V41, P4112, DOI 10.1103/PhysRevB.41.4112; MAHAJAN AV, 1994, PHYS REV LETT, V72, P3100, DOI 10.1103/PhysRevLett.72.3100; MARTIN I, CONDMAT0012446; MENDELS P, 1994, PHYSICA C, V235, P1595, DOI 10.1016/0921-4534(94)92023-0; MONTHOUX P, 1992, PHYS REV B, V46, P14803, DOI 10.1103/PhysRevB.46.14803; MONTHOUX P, 1994, PHYS REV B, V49, P4261, DOI 10.1103/PhysRevB.49.4261; MORIYA T, 1990, J PHYS SOC JPN, V59, P2905, DOI 10.1143/JPSJ.59.2905; Pan SH, 2000, NATURE, V403, P746, DOI 10.1038/35001534; Pines D, 1997, PHYSICA C, V282, P273, DOI 10.1016/S0921-4534(97)00253-0; Salkola MI, 1997, PHYS REV B, V55, P12648, DOI 10.1103/PhysRevB.55.12648; Salkola MI, 1996, PHYS REV LETT, V77, P1841, DOI 10.1103/PhysRevLett.77.1841; Sidis Y, 2000, PHYS REV LETT, V84, P5900, DOI 10.1103/PhysRevLett.84.5900; Tokunaga Y, 1997, SOLID STATE COMMUN, V103, P43, DOI 10.1016/S0038-1098(97)00112-9; Tsuchiura H, 2000, PHYS REV LETT, V84, P3165, DOI 10.1103/PhysRevLett.84.3165; Williams GVM, 2000, PHYS REV B, V61, P4319, DOI 10.1103/PhysRevB.61.4319; Yazdani A, 1999, PHYS REV LETT, V83, P176, DOI 10.1103/PhysRevLett.83.176; Yazdani A, 1997, SCIENCE, V275, P1767, DOI 10.1126/science.275.5307.1767; Zhang GM, 2001, PHYS REV LETT, V86, P704, DOI 10.1103/PhysRevLett.86.704	32	299	301	0	64	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 21	2001	411	6840					920	924		10.1038/35082019	http://dx.doi.org/10.1038/35082019			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	444EN	11418850	Green Submitted			2022-12-28	WOS:000169386200036
J	Honein, MA; Paulozzi, LJ; Mathews, TJ; Erickson, JD; Wong, LYC				Honein, MA; Paulozzi, LJ; Mathews, TJ; Erickson, JD; Wong, LYC			Impact of folic acid fortification of the US food supply on the occurrence of neural tube defects	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PRENATAL-DIAGNOSIS; BIRTH-DEFECTS; ELECTIVE TERMINATION; FOLATE LEVELS; PREVENTION; PREVALENCE; CERTIFICATES; HOMOCYSTEINE; DECISION; GRAIN	Context Daily consumption of 400 mug of folic acid before conception and during early pregnancy dramatically reduces the occurrence of neural tube defects (NTDs), Before food fortification, however, only an estimated 29% of US reproductive-aged women were taking a supplement containing 400 mug of folic acid daily. The US Food and Drug Administration authorized addition of folic acid to enriched grain products in March 1996, with compliance mandatory by January 1998. Objective To evaluate the impact of food fortification with folic acid on NTD birth prevalence. Design, Setting, and Population National study of birth certificate data for live births to women in 45 US states and Washington, DC, between January 1990 and December 1999, Main Outcome Measure Birth certificate reports of spina bifida and anencephaly before fortification (October 1995 through December 1996) compared with after mandatory fortification (October 1998 through December 1999). Results The birth prevalence of NTDs reported on birth certificates decreased from 37.8 per 100000 live births before fortification to 30.5 per 100000 live births conceived after mandatory folic acid fortification, representing a 19% decline (prevalence ratio [PR], 0.81; 95% confidence interval [CI], 0.75-0.87), During the same period, NTD birth prevalence declined from 53.4 per 100000 to 46.5 per 100000 (PR, 0.87; 95% CI, 0.64-1.18) for women who received only third-trimester or no prenatal care. Conclusions A 19% reduction in NTD birth prevalence occurred following folic acid fortification of the US food supply. However, factors other than fortification may have contributed to this decline.	Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Atlanta, GA 30341 USA; Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Div Vital Stat, Atlanta, GA 30341 USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; CDC National Center for Health Statistics (NCHS)	Honein, MA (corresponding author), Ctr Dis Control & Prevent, Natl Ctr Birth Defects & Dev Disabil, Mailstop F-45,4770 Buford Hwy NE, Atlanta, GA 30341 USA.	MHonein@cdc.gov						Adams T, 1996, AM J PUBLIC HEALTH, V86, P593, DOI 10.2105/AJPH.86.4.593; Allen WP, 1996, PRENATAL DIAG, V16, P531, DOI 10.1002/(SICI)1097-0223(199606)16:6<531::AID-PD914>3.0.CO;2-1; [Anonymous], 1991, Lancet, V338, P131, DOI 10.1016/0140-6736(91)90133-A; [Anonymous], 1992, MMWR Recomm Rep, V41, P1; *CDC, 2000, TRENDS SPIN BIF AN U; *CDC, 2000, MMWR-MORBID MORTAL W, V49, P962; Centers for Disease Control and Prevention (CDC), 1999, MMWR Morb Mortal Wkly Rep, V48, P325; COHEN SA, 1998, GUTTMACHER REP PUBLI, V1, P6; Committee on Medical Aspects of Food and Nutrition Policy, 2000, FOL AC PREV DIS; Cornel MC, 1997, TERATOLOGY, V55, P134; CROWDER SV, 1987, J QUAL TECHNOL, V19, P161, DOI 10.1080/00224065.1987.11979055; CZEIZEL AE, 1992, NEW ENGL J MED, V327, P1832, DOI 10.1056/NEJM199212243272602; DALY LE, 1995, JAMA-J AM MED ASSOC, V274, P1698, DOI 10.1001/jama.274.21.1698; Daly S, 1997, LANCET, V350, P1666, DOI 10.1016/S0140-6736(97)07247-4; Daly S, 1998, CURR OPIN OBSTET GYN, V10, P85, DOI 10.1097/00001703-199804000-00002; Forrester MB, 1998, AM J EPIDEMIOL, V148, P1206; FREEDMAN MA, 1988, AM J PUBLIC HEALTH, V78, P168, DOI 10.2105/AJPH.78.2.168; Freire WB, 2000, EUR J PEDIATR SURG, V10, P42; Gregory JF, 1997, EUR J CLIN NUTR, V51, pS54; GREVENGOOD C, 1994, FETAL DIAGN THER, V9, P273, DOI 10.1159/000263947; Hook EB, 1997, LANCET, V350, P513, DOI 10.1016/S0140-6736(97)01342-1; Jacques PF, 1999, NEW ENGL J MED, V340, P1449, DOI 10.1056/NEJM199905133401901; Lawrence JM, 1999, LANCET, V354, P915, DOI 10.1016/S0140-6736(99)03227-4; Mulinare J, 1997, TERATOLOGY, V56, P17, DOI 10.1002/(SICI)1096-9926(199707/08)56:1/2<17::AID-TERA5>3.0.CO;2-Z; Nelen WLDM, 2000, OBSTET GYNECOL, V95, P519, DOI 10.1016/S0029-7844(99)00610-9; Olsen CL, 1996, PAEDIATR PERINAT EP, V10, P161, DOI 10.1111/j.1365-3016.1996.tb00040.x; PIPER JM, 1993, AM J EPIDEMIOL, V137, P758, DOI 10.1093/oxfordjournals.aje.a116736; PRYDE PG, 1992, OBSTET GYNECOL, V80, P52; Rader JI, 2000, FOOD CHEM, V70, P275, DOI 10.1016/S0308-8146(00)00116-3; ROBERTS HE, 1995, PEDIATRICS, V96, P880; ROMANO PS, 1995, AM J PUBLIC HEALTH, V85, P667, DOI 10.2105/AJPH.85.5.667; ROSENFIELD A, 1993, AM J OBSTET GYNECOL, V169, P128, DOI 10.1016/0002-9378(93)90146-A; Skeaff M, 1998, NEW ZEAL MED J, V111, P417; TAFFEL SM, 1989, BIRTH-ISS PERINAT C, V16, P188, DOI 10.1111/j.1523-536X.1989.tb00896.x; TOLSON GC, 1991, VITAL HLTH STAT 4, V28, P1; Turner LA, 1998, CAN MED ASSOC J, V158, P773; Velie EM, 1996, AM J EPIDEMIOL, V144, P473; Ventura SJ., 2000, BIRTHS FINAL DATA 19, V48; Wald NJ, 1998, LANCET, V351, P834, DOI 10.1016/S0140-6736(05)78966-2; Wald NJ, 2001, AM J MED GENET, V98, P204, DOI 10.1002/1096-8628(20010115)98:2<204::AID-AJMG1032>3.0.CO;2-D; Watkins ML, 1996, AM J PUBLIC HEALTH, V86, P731, DOI 10.2105/AJPH.86.5.731; Watkins ML, 1999, NEW ENGL J MED, V341, P923; Wynn Margaret, 1998, Nutrition and Health (Bicester), V12, P147; 1996, FED REG, V61, P8781	44	711	732	2	57	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 20	2001	285	23					2981	2986		10.1001/jama.285.23.2981	http://dx.doi.org/10.1001/jama.285.23.2981			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	442AR	11410096				2022-12-28	WOS:000169263200020
J	Simoons, ML; Armstrong, P; Califf, R; Barnathan, E; Hoynck, M; Scherer, J; Wallentin, L				Simoons, ML; Armstrong, P; Califf, R; Barnathan, E; Hoynck, M; Scherer, J; Wallentin, L		GUSTO IV-ACS Investigators	Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial	LANCET			English	Article							ACUTE MYOCARDIAL-INFARCTION; REFRACTORY UNSTABLE ANGINA; PLATELET; INHIBITION; ANGIOPLASTY; INTERVENTION; THROMBOLYSIS; EFFICACY; BENEFIT	Background Glycoprotein IIb/IIIa blockers reduce procedure-related thrombotic complications of percutaneous coronary intervention, and the risk of death and myocardial infarction in patients with acute coronary syndromes. The effect on risk of death and myocardial infarction is particularly apparent in patients undergoing early percutaneous coronary interventions. We did a randomised, multicentre trial to study the effect of the glycoprotein IIb/IIIa blocker abciximab on patients with acute coronary syndromes who were not undergoing early revascularisation. Methods We enrolled 7800 patients who were admitted to hospital with chest pain and either ST-segment depression or raised troponin T or I concentrations. 2598 were randomly assigned placebo, 2590 an abciximab bolus and 24 h infusion, and 2612 an abciximab bolus and 48 h infusion; all patients received aspirin and either unfractionated or low-molecular-weight heparin. The primary endpoint was death or myocardial infarction at 30 days after randomisation. Analysis was by intention to treat. Findings There were no dropouts. 209 (8.0%) patients on placebo, 212 (8.2%) on 24 h abciximab, and 238 (9.1%) on 48 h abciximab died or had a myocardial infarction before day 30 (odds ratio 1.0 [95% CI 0.83-1.24], for difference between placebo and 24 h abciximab, and 1.1[0.94-1.39] for difference between placebo and 48 h abciximab). The lack of benefit from treatment with abciximab was consistent in most subgroups investigated; in particular, no benefit was seen in patients with raised cardiac troponin T or concentrations at enrolment, although these patients did have a strongly increased risk of subsequent events. Bleeding rates were low, but increased with abciximab, particularly when continued for 48 h. Additionally, thrombocytopenia was more frequent with abciximab than with placebo. Interpretations Although the explanations for our findings are unclear, this study indicates that abciximab is not beneficial as first-line medical treatment in patients admitted with acute coronary syndromes.	Univ Rotterdam Hosp, Thoraxctr, NL-3000 CA Rotterdam, Netherlands; Centocor Inc, Malvern, PA 19355 USA; Eli Lilly & Co, Indianapolis, IN 46285 USA	Erasmus University Rotterdam; Erasmus MC; Johnson & Johnson; Johnson & Johnson USA; Janssen Biotech Inc; Eli Lilly	Simoons, ML (corresponding author), Univ Rotterdam Hosp, Thoraxctr, Room H 560,POB 2040, NL-3000 CA Rotterdam, Netherlands.		Manolis, Antonis/F-5003-2014	Manolis, Antonis/0000-0002-0336-4745				*ADMIRAL INV, IN PRESS N ENGL J ME; Akkerhuis KM, 2000, EUR HEART J, V21, P371, DOI 10.1053/euhj.1999.1743; Alpert JS, 2000, EUR HEART J, V21, P1502, DOI 10.1053/euhj.2000.2305; Ault KA, 1999, J AM COLL CARDIOL, V33, P634, DOI 10.1016/S0735-1097(98)00635-4; Bazzino O, 1998, NEW ENGL J MED, V338, P1498; Bazzino O, 1998, NEW ENGL J MED, V338, P1488; Boersma E, 1999, CIRCULATION, V100, P2045, DOI 10.1161/01.CIR.100.20.2045; Brener SJ, 1998, CIRCULATION, V98, P734, DOI 10.1161/01.CIR.98.8.734; CALIFF RM, 1994, NEW ENGL J MED, V330, P956, DOI 10.1056/nejm199404073301402; Cannon CP, 2000, CIRCULATION, V102, P149, DOI 10.1161/01.CIR.102.2.149; Ellis SG, 1999, CIRCULATION, V100, P799; FALK E, 1995, CIRCULATION, V92, P657, DOI 10.1161/01.CIR.92.3.657; Fredrickson BJ, 2000, CIRCULATION, V101, P1122, DOI 10.1161/01.CIR.101.10.1122; Hamm CW, 1999, NEW ENGL J MED, V340, P1623, DOI 10.1056/NEJM199905273402103; Hanrath P, 1997, CIRCULATION, V96, P1445; Heeschen C, 1999, LANCET, V354, P1757, DOI 10.1016/S0140-6736(99)10285-X; Kereiakes DJ, 1999, J THROMB THROMBOLYS, V7, P265, DOI 10.1023/A:1008931126871; Kleiman NS, 2000, CIRCULATION, V101, P751, DOI 10.1161/01.CIR.101.7.751; LEEBEEK FWG, IN PRESS EUR HEART J; Lindahl B, 2000, NEW ENGL J MED, V343, P1139, DOI 10.1056/NEJM200010193431602; Neumann FJ, 2000, J AM COLL CARDIOL, V35, P915, DOI 10.1016/S0735-1097(99)00635-X; O'Neill WW, 2000, NEW ENGL J MED, V342, P1316, DOI 10.1056/NEJM200005043421803; RAO AK, 1988, J AM COLL CARDIOL, V11, P1; Simoons ML, 1997, LANCET, V349, P1429; SIMOONS ML, 1994, CIRCULATION, V89, P596, DOI 10.1161/01.CIR.89.2.596; SIMOONS ML, 1999, LANCET S2, V353, P1; Steinhubl SR, 2001, CIRCULATION, V103, P2572; Tcheng JE, 2000, LANCET, V356, P2037; Theroux P, 1998, CIRCULATION, V97, P1195, DOI 10.1161/01.CIR.97.12.1195; Topol CE, 2000, LANCET, V355, P337; Topol E, 1998, NEW ENGL J MED, V339, P436; Topol EJ, 1998, LANCET, V352, P87, DOI 10.1016/S0140-6736(98)85010-1; Topol EJ, 1997, NEW ENGL J MED, V336, P1689; Van Belle E, 1998, CIRCULATION, V97, P26, DOI 10.1161/01.CIR.97.1.26; van den Brand M, 1999, EUR HEART J, V20, P1572, DOI 10.1053/euhj.1999.1662	35	457	480	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 16	2001	357	9272					1915	1924						10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	444YZ	11425411				2022-12-28	WOS:000169431000009
J	Bartolazzi, A; Gasbarri, A; Papotti, M; Bussolati, G; Lucante, T; Khan, A; Inohara, H; Marandino, F; Orlandi, F; Nardi, F; Vecchione, A; Tecce, R; Larsson, O				Bartolazzi, A; Gasbarri, A; Papotti, M; Bussolati, G; Lucante, T; Khan, A; Inohara, H; Marandino, F; Orlandi, F; Nardi, F; Vecchione, A; Tecce, R; Larsson, O		Thyroid Canc Study Grp	Application of an immunodiagnostic method for improving preoperative diagnosis of nodular thyroid lesions	LANCET			English	Article							FINE-NEEDLE-ASPIRATION; HASHIMOTO THYROIDITIS; EXPRESSION; GALECTIN-3; CD44; CARCINOMA; MARKER; CYTOLOGY; FUSION; TUMORS	Background Thyroid cancer is the most common endocrine malignant disease, but preoperative diagnosis remains a challenge. Fine-needle aspiration cytology has greatly improved the clinical management of thyroid nodules, but the preoperative characterisation of follicular lesions is very difficult. Many patients are thus referred to surgery more for diagnosis than for therapeutic necessity. We undertook an international multicentre study to assess the usefulness of immunohistocytochemical staining for two potential markers of malignant thyrocytes. Methods Expression of galectin-3 and CD44v6 was tested on 1009 thyroid lesions (tissue specimens and cytological cell-blocks) and 226 fresh cytological samples obtained preoperatively by ultrasound-guided fine-needle aspiration of thyroid nodules (prospective analysis). The test used monoclonal antibodies specific for CD44v6 and galectin-3, the indirect avidin-biotin complex immunoperoxidase method, and 3-amino-9-ethylcarbazole as substrate. Findings The sensitivity, specificity, positive predictive value, and diagnostic accuracy of this test method (for coexpression of the two markers) in the prospective analysis were 88%, 98%, 91%, and 97%, respectively. The sensitivity and specificity of galectin-3 immunodetection alone in discriminating benign from malignant thyroid lesions were more than 99% and 98% respectively, and the positive predictive value and diagnostic accuracy were 92% and 99%. Interpretation The integration of galectin-3 immunostaining with conventional cytomorphological and clinical diagnostic procedures represents a sensitive and reliable diagnostic approach for preoperative identification of thyroid carcinomas. This test method improves the diagnostic accuracy of conventional cytology and provides the molecular basis for a new nosological assignation of the not yet classified thyroid neoplasms of indeterminate malignant behaviour.	Karolinska Hosp, Canc Ctr Karolinska, Dept Oncol Pathol Cellular & Mol Tumor Pathol, S-17176 Stockholm, Sweden; Regina Elena Inst Canc Res, Dept Pathol, Rome, Italy; Regina Elena Inst Canc Res, Dept Immunol, Rome, Italy; Univ Turin, Dept Biomed Sci & Human Oncol, I-10124 Turin, Italy; Univ Turin, Dept Biol & Clin Sci, I-10124 Turin, Italy; Univ Roma La Sapienza, Policlin Umberto I, Dept Pathol & Expt Med, I-00161 Rome, Italy; Univ Roma La Sapienza, Policlin Umberto I, Dept Cytopathol, I-00161 Rome, Italy; Univ Massachusetts, Sch Med, Dept Pathol, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Div Anat Pathol, Worcester, MA 01605 USA; Osaka Univ, Grad Sch Med, Dept Otolaryngol, Osaka, Japan; Osaka Univ, Grad Sch Med, Dept Sensory Organ Surg, Osaka, Japan	Karolinska Institutet; Karolinska University Hospital; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; University of Turin; University of Turin; Sapienza University Rome; University Hospital Sapienza Rome; Sapienza University Rome; University Hospital Sapienza Rome; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; Osaka University; Osaka University	Bartolazzi, A (corresponding author), Karolinska Hosp, Canc Ctr Karolinska, Dept Oncol Pathol Cellular & Mol Tumor Pathol, S-17176 Stockholm, Sweden.	Armando.Bartolazzi@cck.ki.se	MARANDINO, FERDINANDO/AAB-2537-2019; Bartolazzi, Armando/K-9708-2016	Bartolazzi, Armando/0000-0001-7820-5127				Baloch ZW, 1998, THYROID, V8, P565, DOI 10.1089/thy.1998.8.565; Bartolazzi A, 2000, LANCET, V355, P1661, DOI 10.1016/S0140-6736(00)02233-9; CARAWAY NP, 1993, DIAGN CYTOPATHOL, V9, P345, DOI 10.1002/dc.2840090320; CHIARIOTTI L, 1992, ONCOGENE, V7, P2507; EISENBERG BL, 1989, ARCH SURG-CHICAGO, V124, P1045; ERMAK G, 1995, CANCER RES, V55, P4594; Fernandez PL, 1997, J PATHOL, V181, P80; Gasbarri A, 1999, J CLIN ONCOL, V17, P3494, DOI 10.1200/JCO.1999.17.11.3494; Gu J, 1998, PATHOL INT, V48, P184, DOI 10.1111/j.1440-1827.1998.tb03891.x; GUNTHERT U, 1991, CELL, V65, P13, DOI 10.1016/0092-8674(91)90403-L; HALL TL, 1989, CANCER, V63, P718, DOI 10.1002/1097-0142(19890215)63:4<718::AID-CNCR2820630420>3.0.CO;2-N; HEDINGER CE, 1993, SCHWEIZ MED WSCHR, V123, P1673; Inohara H, 1999, CANCER, V85, P2475, DOI 10.1002/(SICI)1097-0142(19990601)85:11<2475::AID-CNCR25>3.3.CO;2-T; Kini SR, 1987, GUIDE CLIN ASPIRATIO, V3; Kroll TG, 2000, SCIENCE, V289, P1357, DOI 10.1126/science.289.5483.1357; Naor D, 1997, ADV CANCER RES, V71, P241, DOI 10.1016/S0065-230X(08)60101-3; NUNEZ C, 1989, PATHOL ANNU, V24, P161; Orlandi F, 1998, CANCER RES, V58, P3015; Ponta H., 1998, FRONT BIOSCI, V3, P650; Raber W, 1997, WIEN KLIN WOCHENSCHR, V109, P116; Rosai J., 1992, ATLAS TUMOR PATHOL, P1; Schlinkert RT, 1997, MAYO CLIN PROC, V72, P913, DOI 10.1016/S0025-6196(11)63360-0; SCLAFANI AP, 1993, LARYNGOSCOPE, V103, P845; SCREATON GR, 1992, P NATL ACAD SCI USA, V89, P12160, DOI 10.1073/pnas.89.24.12160; Sidawy MK, 1997, CANCER CYTOPATHOL, V81, P253, DOI 10.1002/(SICI)1097-0142(19970825)81:4<253::AID-CNCR7>3.0.CO;2-Q; SILVERMAN JF, 1986, CANCER-AM CANCER SOC, V57, P1164, DOI 10.1002/1097-0142(19860315)57:6<1164::AID-CNCR2820570617>3.0.CO;2-S; TAKASHIMA S, 1992, RADIOLOGY, V185, P125, DOI 10.1148/radiology.185.1.1523294; Tuttle RM, 1998, THYROID, V8, P377, DOI 10.1089/thy.1998.8.377; Wirtschafter A, 1997, LARYNGOSCOPE, V107, P95, DOI 10.1097/00005537-199701000-00019; XU XC, 1995, AM J PATHOL, V147, P815	30	318	346	0	17	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 26	2001	357	9269					1644	1650		10.1016/S0140-6736(00)04817-0	http://dx.doi.org/10.1016/S0140-6736(00)04817-0			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	435UY	11425367				2022-12-28	WOS:000168901600008
J	Murray, C; Frenk, J				Murray, C; Frenk, J			World Health Report 2000: a step towards evidence-based health policy	LANCET			English	Article							SYSTEM; COST		WHO, CH-1211 Geneva 27, Switzerland; Govt Mexico, Minist Hlth, Mexico City, DF, Mexico	World Health Organization	Murray, C (corresponding author), WHO, 20 Ave Appia, CH-1211 Geneva 27, Switzerland.	MurrayC@who.ch						Aigner D., 1977, J EC, V6, P21; BHARGAVA A, 2000, 33 GPE WHO; BLENDON RJ, 1990, HEALTH AFFAIR, V9, P185, DOI 10.1377/hlthaff.9.2.185; Blendon RJ, 1995, HEALTH AFFAIR, V14, P220, DOI 10.1377/hlthaff.14.4.220; DARBY C, 2000, 23 GPE WHO; Donelan K, 1999, HEALTH AFFAIR, V18, P206, DOI 10.1377/hlthaff.18.3.206; Evans D. B., 2000, 29 GPE WHO; GAKIDOU E, 2000, 20 GEP GHO; GALLUPS J, 1998, GEOGRAPHY EC DEV DIS; Greene W.H., 1997, HDB APPL ECONOMETRIC, V2, P81; HELMS R, 2000, WALL STREET J   0629; Mackenbach JP, 1997, LANCET, V349, P1655, DOI 10.1016/S0140-6736(96)07226-1; Murray CJL, 2000, HEALTH ECON, V9, P235, DOI 10.1002/(SICI)1099-1050(200004)9:3<235::AID-HEC502>3.0.CO;2-O; Murray CJL, 2000, B WORLD HEALTH ORGAN, V78, P717; Navarro V, 2000, LANCET, V356, P1598, DOI 10.1016/S0140-6736(00)03139-1; SEN A, 1999, HUMAN DEV REPORT 199; Sihvonen AP, 1998, SOC SCI MED, V47, P303, DOI 10.1016/S0277-9536(98)00020-3; TANDON A, 2000, 30 GPE WHO; *WHO COMM MACR HLT, HLTH EC GROWTH POV R; World Health Organization, 2000, WORLD HLTH REP 2000; XU K, 2000, 25 GPE WHO	21	64	68	0	7	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	MAY 26	2001	357	9269					1698	1700		10.1016/S0140-6736(00)04826-1	http://dx.doi.org/10.1016/S0140-6736(00)04826-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	435UY	11425395				2022-12-28	WOS:000168901600035
J	Studdert, DM; Brennan, TA				Studdert, DM; Brennan, TA			No-fault compensation for medical injuries - The prospect for error prevention	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							QUALITY IMPROVEMENT TOOL; MALPRACTICE CLAIMS DATA; ADVERSE DRUG EVENTS; REDUCING ERRORS; PHYSICIANS; LIABILITY; EXPERIENCE; MISTAKES; SYSTEM; RISK	Leading patient safety proposals promote the design and implementation of error prevention strategies that target systems used to deliver care and eschew individual blame, They also call for candor among practitioners about the causes and consequences of medical injury. Both goals collide with fundamental tenets of the medical malpractice system. Thus, the challenge of addressing error in medicine demands a thorough reconsideration of the legal mechanisms currently used to deal with harms in health care. In this article, we describe an alternative to litigation that does not predicate compensation on proof of practitioner fault, suggest how it might be operationalized, and argue that there is a pressing need to test its promise. We tackle traditional criticisms of "no-fault" compensation systems for medical injury-specifically, concerns about their cost and the presumption that eliminating liability will dilute incentives to deliver high-quality care. Our recent empirical work suggests that a model designed around avoidable or preventable injuries, as opposed to negligent ones, would not exceed the costs of current malpractice systems in the United States. Implementation of such a model promises to promote quality by harmonizing injury compensation with patient safety objectives, especially if it is linked to reforms that make institutions, rather than individuals, primarily answerable for injuries.	Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health	Brennan, TA (corresponding author), Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.	tabrennan@partners.org	Studdert, David/AAF-3116-2021	Studdert, David/0000-0003-0585-5537	AHRQ HHS [K02HS11285] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [K02HS011285] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		ABRAHAM KS, 1994, AM J LAW MED, V20, P29; ABRAHAM KS, 1994, HARVARD LAW REV, V108, P381, DOI 10.2307/1341896; Bates DW, 1998, JAMA-J AM MED ASSOC, V280, P1311, DOI 10.1001/jama.280.15.1311; Berwick DM, 1999, BRIT MED J, V319, P136, DOI 10.1136/bmj.319.7203.136; Bogner MS, 1994, HUMAN ERROR MED; Bosk CL, 1979, FORGIVE REMEMBER MAN, DOI DOI 10.7208/CHICAGO/9780226924687.001.0001; Bovbjerg RR, 1998, U CINCI LAW REV, V67, P53; BRAHAMS D, 1988, LANCET, V2, P733; Brennan T., 1996, NEW RULES REGULATION; COOPER JB, 1989, INT ANESTHESIOL CLIN, V27, P148, DOI 10.1097/00004311-198902730-00003; DANZON PM, 1994, J LEGAL MED, V15, P199, DOI 10.1080/01947649409510944; DAVIS B, 1999, US TODAY, pA1; Devlin Rose Anne, 1992, CONTRIBUTIONS INSURA; ESPERSSON C, 1992, BALL COLL FEBR OXF E; Espinosa JA, 2000, BRIT MED J, V320, P737, DOI 10.1136/bmj.320.7237.737; Gardner J, 2000, Mod Healthc, V30, P30; GAWANDE A, 2000, NEW YORKER      0807, P60; GOODMAN E, 1999, BOSTON GLOBE    1209, pA23; Gostin L, 2000, JAMA-J AM MED ASSOC, V283, P1742, DOI 10.1001/jama.283.13.1742; HALLAM K, 2000, MODERN HEALTHCARE, V30, P32; Horwitz J, 1995, HEALTH AFFAIR, V14, P164, DOI 10.1377/hlthaff.14.4.164; JOHNSON KB, 1989, VANDERBILT LAW REV, V42, P1365; *KAIS FAM FDN AG H, 2001, NAT SURV AM HLTH CAR; Keeton W., 1984, PROSSER KEETON LAW T; KOCHANOWSKI PS, 1985, J RISK INSUR, V52, P269, DOI 10.2307/252515; Kohn LTCJ., BUILDING SAFER HLTH; KRAVITZ RL, 1991, JAMA-J AM MED ASSOC, V266, P2087, DOI 10.1001/jama.266.15.2087; LANDES EM, 1982, J LAW ECON, V25, P49, DOI 10.1086/467006; LAWTHERS AG, 1992, J HEALTH POLIT POLIC, V17, P463, DOI 10.1215/03616878-17-3-463; LEAPE LL, 1994, JAMA-J AM MED ASSOC, V272, P1851, DOI 10.1001/jama.272.23.1851; LEAPE LL, 1995, JAMA-J AM MED ASSOC, V274, P35, DOI 10.1001/jama.1995.03530010049034; Leape LL, 1999, J EVAL CLIN PRACT, V5, P1, DOI 10.1046/j.1365-2753.1999.00162.x; Liang BA, 1999, J HEALTH POLIT POLIC, V24, P27, DOI 10.1215/03616878-24-1-27; Liang BA, 2000, HEALTH AFFAIR, V19, P112, DOI 10.1377/hlthaff.19.5.112; MAURINO DE, 1995, AVIATION HUMAN FACTO; Miller R, 1993, MARYLAND LAW REV, V52, P1070; NIGHTINGALE PG, 2000, BRIT MED J, V320, P737; PALMER LI, 1999, HOUSTON LAW REV, V36, P1609; PEAR R, 2000, NY TIMES        0701, pA1; Pear Robert, 1999, N Y Times Web, pA20; PETERSEN LA, 1994, ANN INTERN MED, V121, P866, DOI 10.7326/0003-4819-121-11-199412010-00008; Peterson L M, 1990, J Clin Ethics, V1, P207; Pretzer M, 2000, Med Econ, V77, P25; Reason J, 2000, BMJ-BRIT MED J, V320, P768, DOI 10.1136/bmj.320.7237.768; Reason J., 1991, HUMAN ERROR, DOI 10.1017/cbo9781139062367; Reason J., 1997, MANAGING RISK ORG AC; *RISK MAN FDN, 2001, FOR ARCH; ROGERS AS, 1988, ARCH INTERN MED, V148, P1596, DOI 10.1001/archinte.148.7.1596; ROLPH JE, 1991, JAMA-J AM MED ASSOC, V266, P2093, DOI 10.1001/jama.266.15.2093; Ross LM, 2000, ARCH DIS CHILD, V83, P492, DOI 10.1136/adc.83.6.492; RUSER JW, 1991, J LABOR ECON, V9, P325, DOI 10.1086/298272; SAGE WM, 1994, AM J LAW MED, V20, P1; SAKS MJ, 1994, WM MARY L REV, V35, P693; SCHEUTZOW SO, 1992, J LAW HLTH, V7, P169; SCHWARTZ GT, 1994, UCLA LAW REV, V42, P377; SCOTT HD, 1990, JAMA-J AM MED ASSOC, V263, P1785, DOI 10.1001/jama.263.13.1785; SLOAN FA, 1994, J STUD ALCOHOL, V55, P454, DOI 10.15288/jsa.1994.55.454; SLOAN FA, 1990, AM ECON REV, V80, P128; Sloan FA, 1997, INT REV LAW ECON, V17, P245, DOI 10.1016/S0144-8188(97)00005-7; Sloan FA, 1997, LAW CONTEMP PROBL, V60, pA35; Spieler Emily A., 1994, HOUS L REV, V31, P119; Studdert DM, 1999, HEALTH AFFAIR, V18, P7, DOI 10.1377/hlthaff.18.6.7; Studdert DM, 1997, LAW CONTEMP PROBL, V60, pA1; Studdert DM, 2000, J HEALTH POLIT POLIC, V25, P499, DOI 10.1215/03616878-25-3-499; STUDDERT DM, IN PRESS AM J LAW ME; Thomas EJ, 1999, INQUIRY-J HEALTH CAR, V36, P255; VISCUSI WK, 1989, RAND J ECON, V20, P499; Weiler PC, 1993, MD L REV, V52, P908; Witman AB, 1996, ARCH INTERN MED, V156, P2565, DOI 10.1001/archinte.156.22.2565; WORRALL JD, 1988, WORKERS COMPENSATION; Wu AW, 1997, J GEN INTERN MED, V12, P770, DOI 10.1046/j.1525-1497.1997.07163.x; ZADOR P, 1986, J RISK INSUR, V53, P226, DOI 10.2307/252373	73	129	131	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 11	2001	286	2					217	223		10.1001/jama.286.2.217	http://dx.doi.org/10.1001/jama.286.2.217			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	451JJ	11448285				2022-12-28	WOS:000169798700027
J	Hay, PJ; Bacaltchuk, J				Hay, PJ; Bacaltchuk, J			Extracts from "Clinical Evidence" - Bulimia nervosa	BMJ-BRITISH MEDICAL JOURNAL			English	Review							COGNITIVE-BEHAVIORAL TREATMENT; EATING-DISORDERS; FOLLOW-UP; ANTIDEPRESSANTS; METAANALYSIS; FLUVOXAMINE; PREVALENCE; FLUOXETINE; ATTITUDES		Univ Adelaide, Dept Psychiat, Adelaide, SA, Australia; Univ Fed Sao Paulo, Dept Psychiat, Sao Paulo, Brazil	University of Adelaide; Universidade Federal de Sao Paulo (UNIFESP)	Hay, PJ (corresponding author), Univ Adelaide, Dept Psychiat, Adelaide, SA, Australia.	phillipa.hay@adelaide.edu.au		Hay, Phillipa/0000-0003-0296-6856				AGRAS WS, 1994, J CLIN PSYCHIAT, V55, P179; Agras WS, 2000, ARCH GEN PSYCHIAT, V57, P459, DOI 10.1001/archpsyc.57.5.459; AGRAS WS, 1992, AM J PSYCHIAT, V149, P82; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; Bacaltchuk J, 1999, J CLIN PHARM THER, V24, P23, DOI 10.1046/j.1365-2710.1999.00192.x; Bacaltchuk J, 2000, ACTA PSYCHIAT SCAND, V101, P256, DOI 10.1111/j.1600-0447.2000.tb10923.x; Bacaltchuk J, 2000, AUST NZ J PSYCHIAT, V34, P310, DOI 10.1080/j.1440-1614.2000.00709.x; Bachar E, 1999, J Psychother Pract Res, V8, P115; BUSHNELL JA, 1990, PSYCHOL MED, V20, P671, DOI 10.1017/S0033291700017190; CHOUDRY IY, 1992, INT J EAT DISORDER, V11, P243, DOI 10.1002/1098-108X(199204)11:3&lt;243::AID-EAT2260110307&gt;3.0.CO;2-P; COKER S, 1993, INT J EAT DISORDER, V13, P35, DOI 10.1002/1098-108X(199301)13:1&lt;35::AID-EAT2260130105&gt;3.0.CO;2-N; COLLINGS S, 1994, BRIT J PSYCHIAT, V164, P80, DOI 10.1192/bjp.164.1.80; FAHY TA, 1993, INT J EAT DISORDER, V14, P135, DOI 10.1002/1098-108X(199309)14:2&lt;135::AID-EAT2260140203&gt;3.0.CO;2-D; Fairburn CG, 2000, ARCH GEN PSYCHIAT, V57, P659, DOI 10.1001/archpsyc.57.7.659; Fairburn CG, 1997, ARCH GEN PSYCHIAT, V54, P509; FAIRBURN CG, 1995, ARCH GEN PSYCHIAT, V52, P304; Fichter MM, 1996, J CLIN PSYCHOPHARM, V16, P9, DOI 10.1097/00004714-199602000-00003; Fichter MM, 1997, PHARMACOPSYCHIATRY, V30, P85, DOI 10.1055/s-2007-979488; Gard MCE, 1996, INT J EAT DISORDER, V20, P1, DOI 10.1002/(SICI)1098-108X(199607)20:1&lt;1::AID-EAT1&gt;3.0.CO;2-M; GARFINKEL PE, 1995, AM J PSYCHIAT, V152, P1052; HALL A, 1991, PSYCHOL MED, V21, P697, DOI 10.1017/S0033291700022339; HAY PJ, 2000, COCHRANE DATABASE SY; Jacobi C, 1997, PSYCHOTHER PSYCH MED, V47, P346; JOHNSON C, 1990, INT J EAT DISORDER, V9, P617, DOI 10.1002/1098-108X(199011)9:6&lt;617::AID-EAT2260090604&gt;3.0.CO;2-V; Keel PK, 1999, ARCH GEN PSYCHIAT, V56, P63, DOI 10.1001/archpsyc.56.1.63; Keel PK, 1997, AM J PSYCHIAT, V154, P313; KENDLER KS, 1991, AM J PSYCHIAT, V148, P1627; LAESSLE RG, 1987, PSYCHOTHER PSYCHOSOM, V48, P141, DOI 10.1159/000288044; Lewandowski LM, 1997, CLIN PSYCHOL REV, V17, P703, DOI 10.1016/S0272-7358(97)00026-3; Loeb KL, 2000, BEHAV RES THER, V38, P259, DOI 10.1016/S0005-7967(99)00041-8; PYLE RL, 1990, AM J PSYCHIAT, V147, P871; ROSSITER EM, 1993, INT J EAT DISORDER, V13, P349, DOI 10.1002/1098-108X(199305)13:4<349::AID-EAT2260130403>3.0.CO;2-C; StriegelMoore RH, 1996, OBES RES, V4, P109, DOI 10.1002/j.1550-8528.1996.tb00522.x; Treasure JL, 1999, BEHAV RES THER, V37, P405, DOI 10.1016/S0005-7967(98)00149-1; WALLER G, 1999, EVIDENCED BASED MED, V4, P145; WALSH BT, 1991, AM J PSYCHIAT, V148, P1206; Walsh BT, 2000, AM J PSYCHIAT, V157, P1332, DOI 10.1176/appi.ajp.157.8.1332; WHEADON DE, 1992, J CLIN PSYCHIAT, V53, P235; Whittal ML, 1999, BEHAV THER, V30, P117, DOI 10.1016/S0005-7894(99)80049-5; Wilson GT, 1998, TREATMENTS WORK, P5012503	40	14	16	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 7	2001	323	7303					33	37		10.1136/bmj.323.7303.33	http://dx.doi.org/10.1136/bmj.323.7303.33			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	451WA	11440944	Green Published			2022-12-28	WOS:000169824300024
J	Phillips, PS; Nolan, JP				Phillips, PS; Nolan, JP			Training in basic and advanced life support in UK medical schools: questionnaire survey	BRITISH MEDICAL JOURNAL			English	Article							CARDIOPULMONARY RESUSCITATION		Univ Southampton, Southampton Gen Hosp, Fac Med, Southampton SO16 6YD, Hants, England; Royal United Hosp, Dept Anaesthesia & Intens Care Med, Bath BA1 3NG, Avon, England	University of Southampton	Phillips, PS (corresponding author), Univ Southampton, Southampton Gen Hosp, Fac Med, Southampton SO16 6YD, Hants, England.		Nolan, Jerry P./ABF-2561-2020	Nolan, Jerry/0000-0003-3141-3812				CASEY WF, 1984, J ROY SOC MED, V77, P921, DOI 10.1177/014107688407701105; *GEN MED COUNC, 1997, NEW DOCT REC GEN CLI; Perkins GD, 1999, RESUSCITATION, V41, P19, DOI 10.1016/S0300-9572(99)00037-4; SKINNER DV, 1985, BRIT MED J, V290, P1549, DOI 10.1136/bmj.290.6481.1549; The Royal College of Physicians of London, 1987, J ROY COLL PHYS LOND, V21, P175	5	53	53	1	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUL 7	2001	323	7303					22	23		10.1136/bmj.323.7303.22	http://dx.doi.org/10.1136/bmj.323.7303.22			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	451WA	11440938	Green Published, Bronze			2022-12-28	WOS:000169824300019
J	Bard, E				Bard, E			Paleoclimate - Extending the calibrated radiocarbon record	SCIENCE			English	Editorial Material							C-14 AGES; CORALS; BP; SEDIMENTS; BARBADOS; TAHITI		Univ Aix Marseille 3, Ctr Europeen Rech & Enseignement Geosci Environm, CNRS, UMR 6635, F-13545 Aix En Provence 4, France	UDICE-French Research Universities; Aix-Marseille Universite; PSL Research University Paris; College de France; Centre National de la Recherche Scientifique (CNRS); Institut de Recherche pour le Developpement (IRD)	Bard, E (corresponding author), Univ Aix Marseille 3, Ctr Europeen Rech & Enseignement Geosci Environm, CNRS, UMR 6635, Europole Arbois, F-13545 Aix En Provence 4, France.	bard@cerege.fr	Bard, Edouard/G-7717-2014					BARD E, 1990, NATURE, V345, P405, DOI 10.1038/345405a0; Bard E, 1996, NATURE, V382, P241, DOI 10.1038/382241a0; Bard E, 1998, RADIOCARBON, V40, P1085, DOI 10.1017/S0033822200019135; BOND G, 1993, NATURE, V365, P143, DOI 10.1038/365143a0; CLOTTES J, 1995, CR ACAD SCI II, V320, P1133; EDWARDS RL, 1993, SCIENCE, V260, P962, DOI 10.1126/science.260.5110.962; EDWARDS RL, 1987, EARTH PLANET SC LETT, V81, P175, DOI 10.1016/0012-821X(87)90154-3; Hughen KA, 1998, NATURE, V391, P65, DOI 10.1038/34150; Kitagawa H, 1995, RADIOCARBON, V37, P371, DOI 10.1017/S0033822200030848; Kitagawa H, 1998, SCIENCE, V279, P1187, DOI 10.1126/science.279.5354.1187; Mellars P, 1999, CURR ANTHROPOL, V40, P341, DOI 10.1086/200024; Stuiver M, 1998, RADIOCARBON, V40, P1041, DOI 10.1017/S0033822200019123; Voelker AHL, 1998, RADIOCARBON, V40, P517; Zilhao J, 1999, J WORLD PREHIST, V13, P1, DOI 10.1023/A:1022348410845	14	10	10	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 29	2001	292	5526					2443	2444		10.1126/science.1058375	http://dx.doi.org/10.1126/science.1058375			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	448YU	11431555				2022-12-28	WOS:000169658200027
J	Schwartlander, B; Stover, J; Walker, N; Bollinger, L; Gutierrez, JP; McGreevey, M; Opuni, M; Forsythe, S; Kumaranayake, L; Watts, C; Bertozzi, S				Schwartlander, B; Stover, J; Walker, N; Bollinger, L; Gutierrez, JP; McGreevey, M; Opuni, M; Forsythe, S; Kumaranayake, L; Watts, C; Bertozzi, S			AIDS - Resource needs for HIV/AIDS	SCIENCE			English	Editorial Material									UNAIDS, Joint United Nations Programme HIV AIDS, Geneva, Switzerland; Futures Grp Int, Washington, DC 20036 USA; Natl Inst Publ Hlth, Cuernavaca, Morelos, Mexico; London Sch Hyg & Trop Med, Dept Publ Hlth & Policy, London WC1, England	UNAIDS; Instituto Nacional de Salud Publica; University of London; London School of Hygiene & Tropical Medicine	Schwartlander, B (corresponding author), UNAIDS, Joint United Nations Programme HIV AIDS, Geneva, Switzerland.		Forsythe, Steven/AAL-7558-2020; Gutierrez, Juan Pablo/A-4253-2010	Forsythe, Steven/0000-0002-4409-5991; Gutierrez, Juan Pablo/0000-0002-0557-5562; Bertozzi, Stefano M/0000-0002-1723-7085; Opuni, Marjorie/0000-0002-0939-7695				BOLLINGER L, UNIT COSTS HIV AIDS; Bonnel R, 2000, COSTS SCALING HIV PR; Cantor CH, 1997, ARCH SUICIDE RES, V3, P5, DOI 10.1023/A:1009699126206; FORSYTHE S, 2001, UNPUB CURRENT SPENDI; FOSTER S, 2000, FEDERAL HIV AIDS SPE; KUMARANAYAKE L, 2001, 5 WHO COMM MACR HLTH; Merson MH, 2000, AIDS, V14, pS68; *UNAIDS, 2000, REP GLOB HIV AIDS EP; World Bank, 2000, WORLD DEV REP 1999 2	9	116	118	1	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 29	2001	292	5526					2434	2436		10.1126/science.1062876	http://dx.doi.org/10.1126/science.1062876			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	448YU	11423619				2022-12-28	WOS:000169658200022
J	Weston, CR; Davis, RJ				Weston, CR; Davis, RJ			Signal transduction - Signaling specificity - a complex affair	SCIENCE			English	Editorial Material							GLYCOGEN-SYNTHASE KINASE-3; SUBSTRATE-SPECIFICITY; MAP KINASES; TRANSCRIPTION; INSULIN; 3-BETA; GSK3		Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Howard Hughes Med Inst, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester; Howard Hughes Medical Institute; University of Massachusetts System; University of Massachusetts Worcester	Weston, CR (corresponding author), Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA 01605 USA.	roger.davis@umassmed.edu						Coghlan MP, 2000, CHEM BIOL, V7, P793, DOI 10.1016/S1074-5521(00)00025-9; CROSS DAE, 1995, NATURE, V378, P785, DOI 10.1038/378785a0; Dajani R, 2001, CELL, V105, P721, DOI 10.1016/S0092-8674(01)00374-9; Ding VW, 2000, J BIOL CHEM, V275, P32475, DOI 10.1074/jbc.M005342200; Frame S, 2001, MOL CELL, V7, P1321, DOI 10.1016/S1097-2765(01)00253-2; Kim L, 2000, CURR OPIN GENET DEV, V10, P508, DOI 10.1016/S0959-437X(00)00120-9; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Tanoue T, 2001, EMBO J, V20, P466, DOI 10.1093/emboj/20.3.466; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Williams RSB, 2000, TRENDS PHARMACOL SCI, V21, P61, DOI 10.1016/S0165-6147(99)01428-5; WOODGETT JR, 1990, EMBO J, V9, P2431, DOI 10.1002/j.1460-2075.1990.tb07419.x; Yang SH, 1998, EMBO J, V17, P1740, DOI 10.1093/emboj/17.6.1740	12	56	60	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 29	2001	292	5526					2439	2440		10.1126/science.1063279	http://dx.doi.org/10.1126/science.1063279			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	448YU	11431552				2022-12-28	WOS:000169658200024
J	Hirsh, AE; Fraser, HB				Hirsh, AE; Fraser, HB			Protein dispensability and rate of evolution	NATURE			English	Article							SUBSTITUTION RATE; GENES EVOLVE; GENOME; YEAST; CONSTRAINTS; REGION; SITES; TIME	If protein evolution is due in large part to slightly deleterious amino acid substitutions(1,2), then the rate of evolution should be greater in proteins that contribute less to individual fitness. The rationale for this prediction is that relatively dispensable proteins should be subject to weaker purifying selection, and should therefore accumulate mildly deleterious substitutions more rapidly. Although this argument was presented(3) over twenty years ago, and is fundamental to many applications of evolutionary theory(4), the prediction has proved difficult to confirm. In fact, a recent study showed that essential mouse genes do not evolve more slowly than non-essential ones(5). Thus, although a variety of factors influencing the rate of protein evolution have been supported by extensive sequence analysis(6-12), the relationship between protein dispensability and evolutionary rate has remained unconfirmed. Here we use the results from a highly parallel growth assay of single gene deletions in yeast(13) to assess protein dispensability, which we relate to evolutionary rate estimates that are based on comparisons of sequences drawn from twenty-one fully annotated genomes. Our analysis reveals a highly significant relationship between protein dispensability and evolutionary rate, and explains why this relationship is not detectable by categorical comparison of essential versus nonessential proteins. The relationship is highly conserved, so that protein dispensability in yeast is also predictive of evolutionary rate in a nematode worm.	Stanford Univ, Ctr Computat Genet & Biol Molding, Dept Biol Sci, Stanford, CA 94305 USA	Stanford University	Hirsh, AE (corresponding author), Stanford Univ, Ctr Computat Genet & Biol Molding, Dept Biol Sci, Stanford, CA 94305 USA.							Ashburner M, 1999, GENETICS, V153, P179; Chervitz SA, 1998, SCIENCE, V282, P2022, DOI 10.1126/science.282.5396.2022; Ewens W. J., 1979, MATH POPULATION GENE; Feng DF, 1997, J MOL EVOL, V44, P361, DOI 10.1007/PL00006155; Fraser AG, 2000, NATURE, V408, P325, DOI 10.1038/35042517; GRISHIN NV, 1995, J MOL EVOL, V41, P675; Grishin NV, 2000, GENOME RES, V10, P991, DOI 10.1101/gr.10.7.991; Hughes AL, 1997, MOL BIOL EVOL, V14, P1, DOI 10.1093/oxfordjournals.molbev.a025694; Hurst LD, 1999, CURR BIOL, V9, P747, DOI 10.1016/S0960-9822(99)80334-0; Huynen MA, 1998, P NATL ACAD SCI USA, V95, P5849, DOI 10.1073/pnas.95.11.5849; KIMURA M, 1962, GENETICS, V47, P713; KUMA K, 1995, MOL BIOL EVOL, V12, P123, DOI 10.1093/oxfordjournals.molbev.a040181; Makalowski W, 1998, J MOL EVOL, V47, P119, DOI 10.1007/PL00006367; OHTA T, 1992, ANNU REV ECOL SYST, V23, P263, DOI 10.1146/annurev.es.23.110192.001403; OHTA T, 1973, NATURE, V246, P96, DOI 10.1038/246096a0; Rivera MC, 1998, P NATL ACAD SCI USA, V95, P6239, DOI 10.1073/pnas.95.11.6239; Robinson M, 1998, MOL BIOL EVOL, V15, P1091, DOI 10.1093/oxfordjournals.molbev.a026016; SARICH VM, 1973, SCIENCE, V179, P1144, DOI 10.1126/science.179.4078.1144; Smith V, 1996, SCIENCE, V274, P2069, DOI 10.1126/science.274.5295.2069; Stockbauer KE, 1998, P NATL ACAD SCI USA, V95, P3128, DOI 10.1073/pnas.95.6.3128; Tatusov RL, 2000, NUCLEIC ACIDS RES, V28, P33, DOI 10.1093/nar/28.1.33; Tourasse NJ, 2000, MOL BIOL EVOL, V17, P656, DOI 10.1093/oxfordjournals.molbev.a026344; Wagner A, 2000, NAT GENET, V24, P355, DOI 10.1038/74174; Williams EJB, 2000, NATURE, V407, P900, DOI 10.1038/35038066; WILSON AC, 1977, ANNU REV BIOCHEM, V46, P573, DOI 10.1146/annurev.bi.46.070177.003041; Winzeler EA, 1999, SCIENCE, V285, P901, DOI 10.1126/science.285.5429.901; WU CI, 1985, P NATL ACAD SCI USA, V82, P1741, DOI 10.1073/pnas.82.6.1741; Yamaguchi Y, 1997, P NATL ACAD SCI USA, V94, P1264, DOI 10.1073/pnas.94.4.1264; Zhang JZ, 1998, GENETICS, V149, P1615	29	316	321	0	25	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 28	2001	411	6841					1046	1049		10.1038/35082561	http://dx.doi.org/10.1038/35082561			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	446TF	11429604				2022-12-28	WOS:000169528500047
J	Wilhelms, A; Larter, SR; Head, I; Farrimond, P; di-Primio, R; Zwach, C				Wilhelms, A; Larter, SR; Head, I; Farrimond, P; di-Primio, R; Zwach, C			Biodegradation of oil in uplifted basins prevented by deep-burial sterilization	NATURE			English	Article							NORTH-SEA; ARCHAEA; LIFE; BIOSPHERE; RATES; FIELD	Biodegradation of crude oil by bacterial activity-which has occurred in the majority of the Earth's oil reserves(1)-is known to reduce greatly the quality of petroleum in reservoirs(2). For economically successful prospecting for oil, it is therefore important to understand the processes and conditions in geological formations that lead to oil biodegradation. Although recent studies speculate that bacterial activity can potentially occur up to temperatures as high as 150 degreesC (refs 3, 4), it is generally accepted that effective petroleum biodegradation over geological timescales generally occurs in reservoirs with temperatures below 80 degreesC (ref. 2). This appears, however, to be at odds with the observation that non-degraded oils can still be found in reservoirs below this temperature. Here we compile data regarding the extent of oil biodegradation in several oil reservoirs, and rnd that the extensive occurrence of non-biodegraded oil in shallow, cool basins is restricted to those that have been uplifted from deeper, hotter regions of the Earth. We suggest that these petroleum reservoirs were sterilized by heating to a temperature around 80-90 degreesC during deep burial, inactivating hydrocarbon-degrading organisms that occur in the deep biosphere. Even when such reservoirs are subsequently uplifted to much cooler regions and filled with oil, degradation does not occur, implying that the sterilized sediments are not recolonized by hydrocarbon-degrading bacteria.	Univ Newcastle, Fossil Fuels & Environm Geochem Postgrad Inst, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England; Norsk Hydro AS, N-5020 Bergen, Norway	Newcastle University - UK; Norsk Hydro ASA	Larter, SR (corresponding author), Univ Newcastle, Fossil Fuels & Environm Geochem Postgrad Inst, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.	Steve.Larter@ncl.ac.uk	Abu Laban, Nidal/E-5809-2011	Larter, Stephen/0000-0001-7195-1477; Head, Ian/0000-0002-5373-162X; , Zeinab/0000-0001-7975-7943				BARNARD PC, 1991, GEOLOGICAL SOC SPECI, V59, P167; Blochl E, 1997, EXTREMOPHILES, V1, P14; Bray RJ, 1998, GEOL SOC SPEC PUBL, V133, P199, DOI 10.1144/GSL.SP.1998.133.01.09; Cannan J, 1984, ADV PETROLEUM GEOCHE, P299, DOI DOI 10.1016/B978-0-12-032001-1.50011-0; CHAPELLE FH, 1990, APPL ENVIRON MICROB, V56, P1865, DOI 10.1128/AEM.56.6.1865-1874.1990; CORNFORD C, 1988, ORG GEOCHEM, V13, P399, DOI 10.1016/0146-6380(88)90062-9; CORNFORD C, 1990, INTRO PETROLEUM GEOL, P294; Daniel RM, 2000, CELL MOL LIFE SCI, V57, P250, DOI 10.1007/PL00000688; Evans J, 1998, GEOL SOC SPEC PUBL, V133, P407, DOI 10.1144/GSL.SP.1998.133.01.22; FREDRICKSON JK, 1995, MOL ECOL, V4, P619, DOI 10.1111/j.1365-294X.1995.tb00262.x; Grassia GS, 1996, FEMS MICROBIOL ECOL, V21, P47; Horstad I, 1997, AAPG BULL, V81, P222; JOBSON A, 1972, APPL MICROBIOL, V23, P1082, DOI 10.1128/AEM.23.6.1082-1089.1972; LARTER SR, 2000, P GEOC 2000 CSPG GAC, P1; LHARIDON S, 1995, NATURE, V377, P223, DOI 10.1038/377223a0; LINJORDET A, 1992, AAPG MEMOIR, V54, P349; Murphy EM, 1998, GEOCHIM COSMOCHIM AC, V62, P3395, DOI 10.1016/S0016-7037(98)00254-3; Nilsen RK, 1996, APPL ENVIRON MICROB, V62, P1793, DOI 10.1128/AEM.62.5.1793-1798.1996; ORPHAN VJ, 1999, APPL ENVIRON MICROB, V65, P700; PARKES RJ, 1994, NATURE, V371, P410, DOI 10.1038/371410a0; Pedersen K, 2000, FEMS MICROBIOL LETT, V185, P9, DOI 10.1016/S0378-1097(00)00061-6; Roadifer R.E., 1987, AAPG STUDIES GEOLOGY, V23, P3; RUETER P, 1994, NATURE, V372, P455, DOI 10.1038/372455a0; SCHROEDER FW, 1993, NPF SPECIAL PUBLICAT, V3, P469; STETTER KO, 1990, FEMS MICROBIOL LETT, V75, P117, DOI 10.1111/j.1574-6968.1990.tb04089.x; STETTER KO, 1993, NATURE, V365, P743, DOI 10.1038/365743a0; Stetter KO, 1996, FEMS MICROBIOL REV, V18, P149, DOI 10.1111/j.1574-6976.1996.tb00233.x; Takahata Y, 2000, APPL ENVIRON MICROB, V66, P73, DOI 10.1128/AEM.66.1.73-79.2000; THEIS NJ, 1993, NPF SPECIAL PUBLICAT, V3, P433; Zengler K, 1999, NATURE, V401, P266, DOI 10.1038/45777; ZOBELL CE, 1945, SCIENCE, V102, P364, DOI 10.1126/science.102.2650.364	31	219	236	0	57	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 28	2001	411	6841					1034	1037		10.1038/35082535	http://dx.doi.org/10.1038/35082535			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	446TF	11429600				2022-12-28	WOS:000169528500043
J	Uwaifo, GI; Robey, PG; Akintoye, SO; Collins, MT				Uwaifo, GI; Robey, PG; Akintoye, SO; Collins, MT			Clinical picture: Fuel on the fire	LANCET			English	Editorial Material									NIH, Dev Endocrinol Branch, Bethesda, MD 20892 USA; NIH, Craniofacial & Skeletal Dis Branch, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA	Uwaifo, GI (corresponding author), NIH, Dev Endocrinol Branch, Bldg 10, Bethesda, MD 20892 USA.		Uwaifo, Gabriel I/M-2361-2016; Akintoye, Sunday/S-4400-2019; Robey, Pamela Gehron/H-1429-2011	Uwaifo, Gabriel I/0000-0002-6962-9304; Robey, Pamela Gehron/0000-0002-5316-5576	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000649] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000649] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))			0	11	11	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 23	2001	357	9273					2011	2011		10.1016/S0140-6736(00)05121-7	http://dx.doi.org/10.1016/S0140-6736(00)05121-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	446JB	11438133	Bronze			2022-12-28	WOS:000169509200010
J	Jordan, P; Fromme, P; Witt, HT; Klukas, O; Saenger, W; Krauss, N				Jordan, P; Fromme, P; Witt, HT; Klukas, O; Saenger, W; Krauss, N			Three-dimensional structure of cyanobacterial photosystem I at 2.5 angstrom resolution	NATURE			English	Article							PHOTOSYNTHETIC REACTION CENTERS; ELECTRON-TRANSFER; SYNECHOCOCCUS SP; 4-ANGSTROM RESOLUTION; 2 PHYLLOQUINONES; CHLOROPHYLL-A; ACCEPTOR; COMPLEX; PROTEIN; MODEL	Life on Earth depends on photosynthesis, the conversion of light energy from the Sun to chemical energy. In plants, green algae and cyanobacteria, this process is driven by the cooperation of two large protein-cofactor complexes, photosystems I and II, which are located in the thylakoid photosynthetic membranes. The crystal structure of photosystem I from the thermophilic cyanobacterium Synechococcus elongatus described here provides a picture at atomic detail of 12 protein subunits and 127 cofactors comprising 96 chlorophylls, 2 phylloquinones, 3 Fe4S4 clusters, 22 carotenoids, 4 lipids, a putative Ca2+ ion and 201 water molecules. The structural information on the proteins and cofactors and their interactions provides a basis for understanding how the high efficiency of photosystem I in light capturing and electron transfer is achieved.	Tech Univ Berlin, Max Volmer Lab Biophys Chem, Inst Chem, Fak 2, D-10623 Berlin, Germany; Free Univ Berlin, Inst Chem Kristallog, D-14195 Berlin, Germany	Technical University of Berlin; Free University of Berlin	Fromme, P (corresponding author), Tech Univ Berlin, Max Volmer Lab Biophys Chem, Inst Chem, Fak 2, Str 17,Juni 135, D-10623 Berlin, Germany.			Fromme, Petra/0000-0003-0953-4909; Krauss, Norbert/0000-0002-7128-4632				ADMAN ET, 1973, J BIOL CHEM, V248, P3987; Artz K, 1997, P NATL ACAD SCI USA, V94, P13582, DOI 10.1073/pnas.94.25.13582; ASHIKAWA I, 1986, BIOCHEMISTRY-US, V25, P6154, DOI 10.1021/bi00368a049; Bittl R, 1997, BIOCHEMISTRY-US, V36, P12001, DOI 10.1021/bi971645n; BOEKEMA EJ, 1987, FEBS LETT, V217, P283, DOI 10.1016/0014-5793(87)80679-8; Brettel K, 1997, BBA-BIOENERGETICS, V1318, P322, DOI 10.1016/S0005-2728(96)00112-0; CHAMOROVSKY SK, 1982, PHOTOBIOCH PHOTOBIOP, V4, P195; COGDELL RJ, 1985, PURE APPL CHEM, V57, P723, DOI 10.1351/pac198557050723; COUFAL J, 1989, PHOTOSYNTHETICA, V23, P603; DEISENHOFER J, 1995, J MOL BIOL, V246, P429, DOI 10.1006/jmbi.1994.0097; FALZONE CJ, 1994, BIOCHEMISTRY-US, V33, P6052, DOI 10.1021/bi00186a004; FISH LE, 1985, J BIOL CHEM, V260, P1413; Fleming GR, 1997, CURR OPIN STRUC BIOL, V7, P738, DOI 10.1016/S0959-440X(97)80086-3; Foerster T., 1948, ANN PHYS, V2, P55; FROMME P, 1994, BBA-BIOENERGETICS, V1187, P99, DOI 10.1016/0005-2728(94)90092-2; Fromme P, 1998, BBA-BIOENERGETICS, V1365, P175, DOI 10.1016/S0005-2728(98)00059-0; Golbeck JH, 1999, PHOTOSYNTH RES, V61, P107, DOI 10.1023/A:1006281802710; GOLBECK JH, 1994, ADV PHOTOSYNTHESIS M, P319; Guergova-Kuras M, 2001, P NATL ACAD SCI USA, V98, P4437, DOI 10.1073/pnas.081078898; Hippler M, 1999, J BIOL CHEM, V274, P4180, DOI 10.1074/jbc.274.7.4180; IKEUCHI M, 1991, FEBS LETT, V287, P5, DOI 10.1016/0014-5793(91)80003-L; IWAKI M, 1991, BIOCHEMISTRY-US, V30, P5347, DOI 10.1021/bi00236a004; Joliot P, 1999, BIOCHEMISTRY-US, V38, P11130, DOI 10.1021/bi990857c; Kamlowski A, 1998, J PHYS CHEM B, V102, P8278, DOI 10.1021/jp9824611; Karapetyan NV, 1999, FEBS LETT, V460, P395, DOI 10.1016/S0014-5793(99)01352-6; Kass H, 2001, J PHYS CHEM B, V105, P1225, DOI 10.1021/jp0032311; Klukas O, 1999, J BIOL CHEM, V274, P7361, DOI 10.1074/jbc.274.11.7361; KOIKE H, 1989, FEBS LETT, V253, P257, DOI 10.1016/0014-5793(89)80971-8; KRATKY C, 1977, J MOL BIOL, V113, P431, DOI 10.1016/0022-2836(77)90151-6; Krauss N, 1996, NAT STRUCT BIOL, V3, P965, DOI 10.1038/nsb1196-965; Lancaster CRD, 2000, J BIOL CHEM, V275, P39364, DOI 10.1074/jbc.M008225200; Makewicz A, 1996, Z NATURFORSCH C, V51, P319; Makewicz Anja, 1995, P156; Mayer KL, 1999, BIOCHEMISTRY-US, V38, P13736, DOI 10.1021/bi9910373; MOSER CC, 1992, BIOCHIM BIOPHYS ACTA, V1101, P171, DOI 10.1016/S0005-2728(05)80012-X; Muhlenhoff U, 1996, EMBO J, V15, P488, DOI 10.1002/j.1460-2075.1996.tb00381.x; MUHLENHOFF U, 1993, GENE, V127, P71, DOI 10.1016/0378-1119(93)90618-D; NITSCHKE W, 1991, TRENDS BIOCHEM SCI, V16, P241, DOI 10.1016/0968-0004(91)90095-D; Palsson LO, 1998, BIOPHYS J, V74, P2611, DOI 10.1016/S0006-3495(98)77967-6; Scheer H., 1991, CHLOROPHYLLS; Schlodder E, 1998, BIOCHEMISTRY-US, V37, P9466, DOI 10.1021/bi973182r; Schubert WD, 1998, J MOL BIOL, V280, P297, DOI 10.1006/jmbi.1998.1824; Sun J, 1999, J BIOL CHEM, V274, P19048, DOI 10.1074/jbc.274.27.19048; VALKUNAS L, 1995, PHOTOSYNTH RES, V43, P149, DOI 10.1007/BF00042972; WATANABE T, 1985, FEBS LETT, V191, P252, DOI 10.1016/0014-5793(85)80019-3; Webber AN, 1996, BIOCHEMISTRY-US, V35, P12857, DOI 10.1021/bi961198w; XU QA, 1994, J BIOL CHEM, V269, P3205; Yang F, 1998, J PHYS CHEM B, V102, P8288, DOI 10.1021/jp981952i; ZHAO JD, 1992, BIOCHEMISTRY-US, V31, P5093, DOI 10.1021/bi00137a001; Zouni A, 2001, NATURE, V409, P739, DOI 10.1038/35055589	50	1968	2098	7	420	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 21	2001	411	6840					909	917		10.1038/35082000	http://dx.doi.org/10.1038/35082000			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	444EN	11418848				2022-12-28	WOS:000169386200034
J	Lenhard, M; Bohnert, A; Jurgens, G; Laux, T				Lenhard, M; Bohnert, A; Jurgens, G; Laux, T			Termination of stem cell maintenance in Arabidopsis floral meristems by interactions between WUSCHEL and AGAMOUS	CELL			English	Article							HOMEOTIC GENE; FLOWER DEVELOPMENT; NEGATIVE REGULATION; ORGAN IDENTITY; EXPRESSION; SHOOT; ACTIVATION; THALIANA; PLANTS; SEPARATION	Floral meristems and shoot apical meristems (SAMs) are homologous, self-maintaining stem cell systems. Unlike SAMs, floral meristems are determinate, and stem cell maintenance is abolished once all floral organs are initiated. to investigate the underlying regulatory mechanisms, we analyzed the interactions between WUSCHEL (WUS), which specifies stem cell identity, and AGAMOUS (AG), which is required for floral determinacy. Our results show that repression of WUS by AG is essential for terminating the floral meristem and that WUS can induce AG expression in developing flowers. Together, this suggests that floral determinacy depends on a negative autoregulatory mechanism involving WUS and AG, which terminates stem cell maintenance.	Univ Tubingen, ZMBP Entwicklungsgenet, D-72076 Tubingen, Germany	Eberhard Karls University of Tubingen	Laux, T (corresponding author), Univ Freiburg, Inst Biol 3, Schanzlestr 1, D-79104 Freiburg, Germany.		Lenhard, Michael/J-1554-2015					BARTON MK, 1993, DEVELOPMENT, V119, P823; BECKER D, 1992, PLANT MOL BIOL, V20, P1195, DOI 10.1007/BF00028908; Bowman J., 1994, ARABIDOPSIS ATLAS MO, V102, P117; BOWMAN JL, 1991, PLANT CELL, V3, P749, DOI 10.1105/tpc.3.8.749; BOWMAN JL, 1989, PLANT CELL, V1, P37, DOI 10.1105/tpc.1.1.37; Brand U, 2000, SCIENCE, V289, P617, DOI 10.1126/science.289.5479.617; Busch MA, 1999, SCIENCE, V285, P585, DOI 10.1126/science.285.5427.585; Clough SJ, 1998, PLANT J, V16, P735, DOI 10.1046/j.1365-313x.1998.00343.x; Deyholos MK, 2000, PLANT CELL, V12, P1799, DOI 10.1105/tpc.12.10.1799; DREWS GN, 1991, CELL, V65, P991, DOI 10.1016/0092-8674(91)90551-9; Endrizzi K, 1996, PLANT J, V10, P967, DOI 10.1046/j.1365-313X.1996.10060967.x; GUSTAFSONBROWN C, 1994, CELL, V76, P131, DOI 10.1016/0092-8674(94)90178-3; IRISH VF, 1990, PLANT CELL, V2, P741, DOI 10.1105/tpc.2.8.741; JACK T, 1992, CELL, V68, P683, DOI 10.1016/0092-8674(92)90144-2; Jack T, 1997, PLANT J, V11, P825, DOI 10.1046/j.1365-313X.1997.11040825.x; KONCZ C, 1986, MOL GEN GENET, V204, P383, DOI 10.1007/BF00331014; Laux T, 1996, DEVELOPMENT, V122, P87; Mayer KFX, 1998, CELL, V95, P805, DOI 10.1016/S0092-8674(00)81703-1; MIZUKAMI Y, 1992, CELL, V71, P119, DOI 10.1016/0092-8674(92)90271-D; MIZUKAMI Y, 1995, PLANT MOL BIOL, V28, P767, DOI 10.1007/BF00042064; Mizukami Y, 1997, PLANT CELL, V9, P393, DOI 10.1105/tpc.9.3.393; Moore I, 1998, P NATL ACAD SCI USA, V95, P376, DOI 10.1073/pnas.95.1.376; Schoof H, 2000, CELL, V100, P635, DOI 10.1016/S0092-8674(00)80700-X; SCHULTZ EA, 1991, PLANT CELL, V3, P771, DOI 10.1105/tpc.3.8.771; Sieburth LE, 1997, PLANT CELL, V9, P355, DOI 10.1105/tpc.9.3.355; Sieburth LE, 1998, DEVELOPMENT, V125, P4303; SIEBURTH LE, 1995, PLANT CELL, V7, P1249, DOI 10.1105/tpc.7.8.1249; Steeves T.A., 1989, PATTERNS PLANT DEV, DOI 10.1017/CBO9780511626227; WEIGEL D, 1993, SCIENCE, V261, P1723, DOI 10.1126/science.261.5129.1723; WEIGEL D, 1992, CELL, V69, P843, DOI 10.1016/0092-8674(92)90295-N; WEIGEL D, 1995, NATURE, V377, P495, DOI 10.1038/377495a0; YANOFSKY MF, 1990, NATURE, V346, P35, DOI 10.1038/346035a0	32	405	443	6	78	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTES AVE,, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 15	2001	105	6					805	814		10.1016/S0092-8674(01)00390-7	http://dx.doi.org/10.1016/S0092-8674(01)00390-7			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	444AE	11440722	Bronze			2022-12-28	WOS:000169375100013
J	Pietzsch, O; Kubetzka, A; Bode, M; Wiesendanger, R				Pietzsch, O; Kubetzka, A; Bode, M; Wiesendanger, R			Observation of magnetic hysteresis at the nanometer scale by spin-polarized scanning tunneling spectroscopy	SCIENCE			English	Article							PERPENDICULAR MAGNETIZATION; DIPOLAR ANTIFERROMAGNETISM; NANOSTRIPE ARRAYS; MICROSCOPY; REVERSAL; NANOSTRUCTURES; RESOLUTION; W(110); MOTION; FILMS	Using spin-polarized scanning tunneling microscopy in an external magnetic field, we have observed magnetic hysteresis on a nanometer scale in an ultrathin ferromagnetic film. An array of iron nanowires, being two atomic layers thick, was grown on a stepped tungsten (110) substrate, The microscopic sources of hysteresis in this system-domain wall motion, domain creation, and annihilation-were observed with nanometer spatial resolution. A residual domain 6.5 nanometers by 5 nanometers in size has been found which is inherently stable in saturation fields. Its stability is the consequence of a 360 degrees spin rotation. With magnetic memory bit sizes approaching the superparamagnetic limit with sub-10 nanometer characteristic lengths, the understanding of the basic physical phenomena at this scale is of fundamental importance.	Univ Hamburg, Inst Phys Appl, D-20355 Hamburg, Germany; Univ Hamburg, Microstruct Res Ctr, D-20355 Hamburg, Germany	University of Hamburg; University of Hamburg	Pietzsch, O (corresponding author), Univ Hamburg, Inst Phys Appl, Jungiusstr 11, D-20355 Hamburg, Germany.		Wiesendanger, Roland/P-9726-2016; Bode, Matthias/S-3249-2016	Wiesendanger, Roland/0000-0002-0472-4183; Bode, Matthias/0000-0001-7514-5560				Bode M, 1998, PHYS REV LETT, V81, P4256, DOI 10.1103/PhysRevLett.81.4256; Eimuller T, 2000, J APPL PHYS, V87, P6478, DOI 10.1063/1.372743; Elmers HJ, 1999, PHYS REV B, V59, P3688, DOI 10.1103/PhysRevB.59.3688; ELMERS HJ, 1999, MAGNETISCHE SCHICHTS; Hauschild J, 1998, APPL PHYS LETT, V72, P3211, DOI 10.1063/1.121552; Heinze S, 2000, SCIENCE, V288, P1805, DOI 10.1126/science.288.5472.1805; Himpsel FJ, 1998, ADV PHYS, V47, P511, DOI 10.1080/000187398243519; Kirk KJ, 1999, APPL PHYS LETT, V75, P3683, DOI 10.1063/1.125428; NOLTING W, 1986, QUANTENTHEORIE MAGNE, V1, P229; PIERCE DT, 1988, PHYS SCRIPTA, V38, P291, DOI 10.1088/0031-8949/38/2/035; Pietzsch O, 2000, REV SCI INSTRUM, V71, P424, DOI 10.1063/1.1150218; Pietzsch O, 2000, PHYS REV LETT, V84, P5212, DOI 10.1103/PhysRevLett.84.5212; Rippard WH, 2000, APPL PHYS LETT, V77, P1357, DOI 10.1063/1.1290150; Rippard WH, 1999, APPL PHYS LETT, V75, P1001, DOI 10.1063/1.124578; Rippard WH, 2000, PHYS REV LETT, V84, P971, DOI 10.1103/PhysRevLett.84.971; SCHLOMANN E, 1973, J APPL PHYS, V44, P1873; SLONCZEW.JC, 1973, J APPL PHYS, V44, P1759, DOI 10.1063/1.1662444; Volkov VV, 2000, J MAGN MAGN MATER, V214, P204, DOI 10.1016/S0304-8853(00)00195-5; WIESENDANGER R, 1992, SCIENCE, V255, P583, DOI 10.1126/science.255.5044.583; WIESENDANGER R, 1990, PHYS REV LETT, V65, P247, DOI 10.1103/PhysRevLett.65.247	20	99	104	1	40	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 15	2001	292	5524					2053	2056		10.1126/science.1060513	http://dx.doi.org/10.1126/science.1060513			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	442KP	11408651				2022-12-28	WOS:000169284700040
J	Pande, SD; Hossenbocus, A				Pande, SD; Hossenbocus, A			A swollen right leg	LANCET			English	Editorial Material							EMPHYSEMA		Purley Hosp, Surrey CR8 2YL, England		Pande, SD (corresponding author), Purley Hosp, Surrey CR8 2YL, England.			Pande, shrikant/0000-0003-2614-2931				FRANZ MG, 1995, AM SURGEON, V61, P40; Gutknecht DR, 1997, J CLIN GASTROENTEROL, V25, P685, DOI 10.1097/00004836-199712000-00027; JAGER GJ, 1990, GASTROINTEST RADIOL, V15, P253, DOI 10.1007/BF01888788; MARKERT B, 1989, RADIAT ENVIRON BIOPH, V28, P213, DOI 10.1007/BF01211258; NICELL P, 1975, SURGERY, V78, P555	5	4	4	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 2	2001	357	9270					1762	1762		10.1016/S0140-6736(00)04899-6	http://dx.doi.org/10.1016/S0140-6736(00)04899-6			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	440BN	11403815				2022-12-28	WOS:000169156200016
J	Mathanga, D; Molyneux, ME				Mathanga, D; Molyneux, ME			Bednets and malaria in Africa	LANCET			English	Editorial Material							MORTALITY; TRANSMISSION; MORBIDITY; CHILDREN		Univ Malawi, Coll Med, Malawi Liverpool Wellcome Trust Clin Res Programm, Blantyre 3, Malawi	University of Malawi	Molyneux, ME (corresponding author), Univ Malawi, Coll Med, Malawi Liverpool Wellcome Trust Clin Res Programm, Box 30096, Blantyre 3, Malawi.							Abdulla S, 2001, BMJ-BRIT MED J, V322, P270, DOI 10.1136/bmj.322.7281.270; DALESSANDRO U, 1995, LANCET, V345, P479, DOI 10.1016/S0140-6736(95)90582-0; Evans DB, 1997, HEALTH POLICY PLANN, V12, P107, DOI 10.1093/heapol/12.2.107; GARNHAM PCC, 1949, ANN TROP MED PARASIT, V43, P47, DOI 10.1080/00034983.1949.11685394; Greenwood BM, 1997, PARASITOL TODAY, V13, P90, DOI 10.1016/S0169-4758(97)01002-8; LENGELER C, 2001, COCHRANE LIB; Molineaux L, 1997, ANN TROP MED PARASIT, V91, P811, DOI 10.1080/00034989760572; SNOW RW, 1995, PARASITOL TODAY, V11, P188, DOI 10.1016/0169-4758(95)80156-1; Trape JF, 1996, PARASITOL TODAY, V12, P236, DOI 10.1016/0169-4758(96)10015-6; Wilson D. B., 1950, Tropical Diseases Bulletin, V47, P677	10	4	4	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	APR 21	2001	357	9264					1219	1220		10.1016/S0140-6736(00)04448-2	http://dx.doi.org/10.1016/S0140-6736(00)04448-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	425YY	11418141	Green Published			2022-12-28	WOS:000168323300003
J	BRAUN, HA; WISSING, H; SCHAFER, K; HIRSCH, MC				BRAUN, HA; WISSING, H; SCHAFER, K; HIRSCH, MC			OSCILLATION AND NOISE DETERMINE SIGNAL-TRANSDUCTION IN SHARK MULTIMODAL SENSORY CELLS	NATURE			English	Article							NEURONS; TRANSMISSION; INFORMATION	OSCILLATING membrane potentials that generate rhythmic impulse patterns are considered to be of particular significance for neuronal information processing1-4. In contrast, noise is usually seen as a disturbance which limits the accuracy of information transfer5-8. We show here, however, that noise in combination with intrinsic oscillations can provide neurons with particular encoding properties, a discovery we made when recording from single electro-sensory afferents of a fish. The temporal sequence of the impulse trains indicates oscillations that operate near the spike-triggering threshold. The oscillation frequency determines the basic rhythm of impulse generation, but whether or not an impulse is actually triggered essentially depends on superimposed noise. The probability of impulse generation can be altered considerably by minor modifications of oscillation baseline and amplitude, which may underlie the exquisite sensitivity of these receptors to thermal and electrical stimuli. Additionally, thermal, but not electrical, stimuli alter the oscillation frequency, allowing dual sensory messages to be conveyed in a single spike train. These findings demonstrate novel properties of sensory transduction which may be relevant for neuronal signalling in general.			BRAUN, HA (corresponding author), UNIV MARBURG,INST PHYSIOL,DEUTSCHHAUSSTR 2,D-35037 MARBURG,GERMANY.							Akoev G.N., 1981, Advances in Physiological Sciences, V31, P57; ALDENHOFF JB, 1989, PHARMACOPSYCHIATRY, V22, P227, DOI 10.1055/s-2007-1014606; ALONSO A, 1993, J NEUROPHYSIOL, V70, P128, DOI 10.1152/jn.1993.70.1.128; BIALEK W, 1992, TRENDS NEUROSCI, V15, P428, DOI 10.1016/0166-2236(92)90005-S; BRAUN HA, 1980, PFLUG ARCH EUR J PHY, V386, P1, DOI 10.1007/BF00584180; BRAUN HA, 1990, THERMORECEPTION AND TEMPERATURE REGULATION, P19; BRAUN HA, 1984, SENSORY RECEPTOR MEC, P147; BRINK F, 1946, ANN NY ACAD SCI, V47, P457; BROMM B, 1975, EXPERIENTIA, V31, P615, DOI 10.1007/BF01932490; BULLER AJ, 1953, J PHYSIOL-LONDON, V122, P409, DOI 10.1113/jphysiol.1953.sp005011; BULLOCK TH, 1970, J GEN PHSL, V5, P565; CONNORS BW, 1990, TRENDS NEUROSCI, V13, P99, DOI 10.1016/0166-2236(90)90185-D; DOUGLASS JK, 1993, NATURE, V365, P337, DOI 10.1038/365337a0; DYKES RW, 1975, BRAIN RES, V98, P485, DOI 10.1016/0006-8993(75)90368-6; FITZHUGH R, 1958, J GEN PHYSIOL, V40, P675; FOHLMEISTER JF, 1974, J NEUROPHYSIOL, V37, P1213, DOI 10.1152/jn.1974.37.6.1213; HENSEL H, 1955, Z VERGL PHYSIOL, V37, P509, DOI 10.1007/BF00341377; IGGO A, 1969, J PYSL LOND, V200, P391; KALMIJN AJ, 1966, NATURE, V212, P1232, DOI 10.1038/2121232b0; KNIGHT BW, 1972, J GEN PHYSIOL, V59, P734, DOI 10.1085/jgp.59.6.734; LLINAS RR, 1988, SCIENCE, V242, P1654, DOI 10.1126/science.3059497; LONGTIN A, 1991, PHYS REV LETT, V67, P656, DOI 10.1103/PhysRevLett.67.656; LONGTIN A, 1993, J STAT PHYS, V70, P309, DOI 10.1007/BF01053970; MADDOX J, 1991, NATURE, V325, P469; MCGORMICK DA, 1990, NEUROSCIENCE, V39, P103; SCHAFER K, 1990, EXPERIENTIA, V47, P47; SCHAFER K, 1991, PFLUGERS ARCH, V417, P91; SCHREINER RC, 1978, J NEUROPHYSIOL, V41, P338, DOI 10.1152/jn.1978.41.2.338; SOKABE M, 1993, J NEUROPHYSIOL, V70, P275, DOI 10.1152/jn.1993.70.1.275; WALTMAN BERNARD, 1966, ACTA PHYSIOL SCAND, V66, P1	30	340	360	0	18	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JAN 20	1994	367	6460					270	273		10.1038/367270a0	http://dx.doi.org/10.1038/367270a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MR494	11407413				2022-12-28	WOS:A1994MR49400056
J	Rutter, J; Reick, M; Wu, LC; McKnight, SL				Rutter, J; Reick, M; Wu, LC; McKnight, SL			Regulation of clock and NPAS2 DNA binding by the redox state of NAD cofactors	SCIENCE			English	Article							NICOTINAMIDE-ADENINE DINUCLEOTIDE; SUPRACHIASMATIC NUCLEUS; CIRCADIAN CLOCK; ANTICIPATORY ACTIVITY; AEROBIC GLYCOLYSIS; EXPRESSION; LACTATE; BRAIN; ORGANIZATION; ENTRAINMENT	Clock:BMAL1 and NPAS2:BMAL1 are heterodimeric transcription factors that control gene expression as a function of the Light-dark cycle. Although built to fluctuate at or near a 24-hour cycle, the clock can be entrained by Light, activity, or food. Here we show that the DNA-binding activity of the Clock:BMAL1 and NPAS2:BMAL1 heterodimers is regulated by the redox state of nicotinamide adenine dinucleotide (NAD) cofactors in a purified system. The reduced forms of the redox cofactors, NAD(H) and NADP(H), strongly enhance DNA binding of the Clock:BMAL1 and NPAS2:BMAL1 heterodimers, whereas the oxidized forms inhibit. These observations raise the possibility that food, neuronal activity, or both may entrain the circadian clock by direct modulation of cellular redox state.	Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	McKnight, SL (corresponding author), Univ Texas, SW Med Ctr, Dept Biochem, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	smckni@biochem.swmed.edu	Jansen, Heiko T./A-5770-2008	Jansen, Heiko T./0000-0003-0178-396X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008291] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH059388] Funding Source: NIH RePORTER; NIGMS NIH HHS [NIH5-T32-GM08-291-12] Funding Source: Medline; NIMH NIH HHS [1RO1MH59388] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Abe H, 1998, NEUROSCI LETT, V258, P93, DOI 10.1016/S0304-3940(98)00877-5; Bergmeyer H.U., 1974, METHODS ENZYMATIC AN, V4; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; Damiola F, 2000, GENE DEV, V14, P2950, DOI 10.1101/gad.183500; Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; Garcia JA, 2000, SCIENCE, V288, P2226, DOI 10.1126/science.288.5474.2226; GAROFALO O, 1988, J NEUROCHEM, V51, P172, DOI 10.1111/j.1471-4159.1988.tb04851.x; Gekakis N, 1998, SCIENCE, V280, P1564, DOI 10.1126/science.280.5369.1564; Gerich JE, 2000, DIABETES OBES METAB, V2, P345, DOI 10.1046/j.1463-1326.2000.00085.x; Griffin EA, 1999, SCIENCE, V286, P768, DOI 10.1126/science.286.5440.768; Hogenesch JB, 1998, P NATL ACAD SCI USA, V95, P5474, DOI 10.1073/pnas.95.10.5474; INOUYE ST, 1979, P NATL ACAD SCI USA, V76, P5962, DOI 10.1073/pnas.76.11.5962; King DP, 1997, CELL, V89, P641, DOI 10.1016/S0092-8674(00)80245-7; KONOPKA RJ, 1971, P NATL ACAD SCI USA, V68, P2112, DOI 10.1073/pnas.68.9.2112; Kopperschlager G, 1996, J CHROMATOGR B, V684, P25, DOI 10.1016/0378-4347(96)00133-8; Kume K, 1999, CELL, V98, P193, DOI 10.1016/S0092-8674(00)81014-4; MAGISTRETTI PJ, COMMUNICATION; MISTLBERGER RE, 1994, NEUROSCI BIOBEHAV R, V18, P171, DOI 10.1016/0149-7634(94)90023-X; MOORE RY, 1995, CIBA F SYMP, V183, P88; Pellerin L, 1998, P NATL ACAD SCI USA, V95, P3990, DOI 10.1073/pnas.95.7.3990; Pellerin L, 1996, DEV NEUROSCI-BASEL, V18, P336, DOI 10.1159/000111426; PELLERIN L, 1994, P NATL ACAD SCI USA, V91, P10625, DOI 10.1073/pnas.91.22.10625; Peters A., 1991, FINE STRUCTURE NERVO; PHELPS ME, 1979, ANN NEUROL, V6, P371, DOI 10.1002/ana.410060502; PITTENDRIGH CS, 1993, ANNU REV PHYSIOL, V55, P16; Reick M, 2001, SCIENCE, V293, P506, DOI 10.1126/science.1060699; REICK M, UNPUB; RUTTER J, UNPUB; Schurr A, 1999, J NEUROSCI, V19, P34, DOI 10.1523/JNEUROSCI.19-01-00034.1999; SCHURR A, 1988, SCIENCE, V240, P1326, DOI 10.1126/science.3375817; SCHWARTZ WJ, 1977, SCIENCE, V197, P1089, DOI 10.1126/science.887940; Sheffield P, 1999, PROTEIN EXPRES PURIF, V15, P34, DOI 10.1006/prep.1998.1003; SOKOLOFF L, 1977, J NEUROCHEM, V28, P897, DOI 10.1111/j.1471-4159.1977.tb10649.x; STEPHAN FK, 1979, BEHAV NEURAL BIOL, V25, P545, DOI 10.1016/S0163-1047(79)90332-7; Stokkan KA, 2001, SCIENCE, V291, P490, DOI 10.1126/science.291.5503.490; TAKAHASHI JS, 1995, ANNU REV NEUROSCI, V18, P531, DOI 10.1146/annurev.neuro.18.1.531; TAKAHASHI S, 1995, P NATL ACAD SCI USA, V92, P4616, DOI 10.1073/pnas.92.10.4616; VEECH RL, 1969, BIOCHEM J, V115, P609, DOI 10.1042/bj1150609a; Wakamatsu H, 2001, EUR J NEUROSCI, V13, P1190, DOI 10.1046/j.0953-816x.2001.01483.x; WILLIAMSON DH, 1967, BIOCHEM J, V103, P514, DOI 10.1042/bj1030514; Yamazaki S, 1998, J NEUROSCI, V18, P10709; Zhou YD, 1997, P NATL ACAD SCI USA, V94, P713, DOI 10.1073/pnas.94.2.713	42	718	742	0	44	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 20	2001	293	5529					510	514		10.1126/science.1060698	http://dx.doi.org/10.1126/science.1060698			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	454HG	11441146				2022-12-28	WOS:000169966700051
J	Zuccato, C; Ciammola, A; Rigamonti, D; Leavitt, BR; Goffredo, D; Conti, L; MacDonald, ME; Friedlander, RM; Silani, V; Hayden, MR; Timmusk, T; Sipione, S; Cattaneo, E				Zuccato, C; Ciammola, A; Rigamonti, D; Leavitt, BR; Goffredo, D; Conti, L; MacDonald, ME; Friedlander, RM; Silani, V; Hayden, MR; Timmusk, T; Sipione, S; Cattaneo, E			Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease	SCIENCE			English	Article							NEUROTROPHIC FACTOR; MOUSE MODEL; CELLULAR-LOCALIZATION; TARGETED DISRUPTION; GABAERGIC NEURONS; TRANSGENIC MICE; MESSENGER-RNA; RAT-BRAIN; IN-VITRO; EXPRESSION	Huntingtin is a 350-kilodalton protein of unknown function that is mutated in Huntington's disease (HD), a neurodegenerative disorder. The mutant protein is presumed to acquire a toxic gain of function that is detrimental to striatal neurons in the brain. However, Loss of a beneficial activity of wild-type huntingtin may also cause the death of striatal neurons. Here we demonstrate that wild-type huntingtin up-regulates transcription of brain-derived neurotrophic factor (BDNF), a pro-survival factor produced by cortical neurons that is necessary for survival of striatal neurons in the brain. We show that this beneficial activity of huntingtin is Lost when the protein becomes mutated, resulting in decreased production of cortical BDNF. This Leads to insufficient neurotrophic support for striatal neurons, which then die. Restoring wild-type huntingtin activity and increasing BDNF production may be therapeutic approaches for treating HD.	Univ Milan, Dept Pharmacol Sci, I-20133 Milan, Italy; Univ Milan, Ctr Excellance Neurodegenerat Dis, I-20133 Milan, Italy; Univ Milan, IRCCS Osped Maggiore, Sch Med, Ctr Dino Ferrari,Dept Neurol Sci, I-20133 Milan, Italy; Univ British Columbia, Dept Med Genet, Vancouver, BC, Canada; Massachusetts Gen Hosp, Mol Neurogenet Unit, Charlestown, MA 02129 USA; Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Neurosurg, Boston, MA 02115 USA; Univ Helsinki, Inst Biotechnol, Program Mol Neurosci, Helsinki, Finland; Uppsala Univ, Ctr Biomed, Dept Dev Neurosci, Uppsala, Sweden	University of Milan; University of Milan; IRCCS Ca Granda Ospedale Maggiore Policlinico; University of Milan; University of British Columbia; Harvard University; Massachusetts General Hospital; Harvard University; Brigham & Women's Hospital; Harvard Medical School; University of Helsinki; Uppsala University	Cattaneo, E (corresponding author), Univ Milan, Dept Pharmacol Sci, Via Balzaretti 9, I-20133 Milan, Italy.	elena.cattaneo@unimi.it	Conti, Luciano/H-4184-2012; Hayden, Michael R/D-8581-2011; Leavitt, Blair R/G-1934-2012; Friedlander, Robert M/A-2845-2016; Silani, Vincenzo/P-4421-2017; Timmusk, Tonis/H-4889-2015	Conti, Luciano/0000-0002-2050-9846; Hayden, Michael R/0000-0001-5159-1419; Friedlander, Robert M/0000-0003-4423-9219; Silani, Vincenzo/0000-0002-7698-3854; CATTANEO, ELENA/0000-0002-0755-4917; Timmusk, Tonis/0000-0002-1015-3348; leavitt, Blair/0000-0002-4532-766X; ZUCCATO, CHIARA/0000-0003-1771-3392	Telethon [E.0840] Funding Source: Medline	Telethon(Fondazione Telethon)		Altar CA, 1997, NATURE, V389, P856, DOI 10.1038/39885; Bachoud-Levi A, 2000, LANCET, V356, P1975, DOI 10.1016/S0140-6736(00)03310-9; Canals JM, 2001, J NEUROSCI, V21, P117, DOI 10.1523/JNEUROSCI.21-01-00117.2001; Cattaneo E, 2001, TRENDS NEUROSCI, V24, P182, DOI 10.1016/S0166-2236(00)01721-5; Cha JHJ, 1998, P NATL ACAD SCI USA, V95, P6480, DOI 10.1073/pnas.95.11.6480; Cha JHJ, 2000, TRENDS NEUROSCI, V23, P387, DOI 10.1016/S0166-2236(00)01609-X; Conner JM, 1997, J NEUROSCI, V17, P2295; Dragatsis I, 2000, NAT GENET, V26, P300, DOI 10.1038/81593; DUYAO MP, 1995, SCIENCE, V269, P407, DOI 10.1126/science.7618107; Fusco FR, 1999, J NEUROSCI, V19, P1189; HARPER PS, 1996, HUNTINGTONS DIS, P317; HAYDEN MR, 1981, HUNTINGTONS CHOREA, P140; Hilditch-Maguire P, 2000, HUM MOL GENET, V9, P2789, DOI 10.1093/hmg/9.19.2789; Hodgson JG, 1999, NEURON, V23, P181, DOI 10.1016/S0896-6273(00)80764-3; HOFER M, 1990, EMBO J, V9, P2459, DOI 10.1002/j.1460-2075.1990.tb07423.x; Ivkovic S, 1999, J NEUROSCI, V19, P5409; Kegel KB, 2000, J NEUROSCI, V20, P7268, DOI 10.1523/jneurosci.20-19-07268.2000; Leavitt BR, 2001, AM J HUM GENET, V68, P313, DOI 10.1086/318207; LIU ZQ, 1995, CHEM RES CHINESE U, V11, P155; Luthi-Carter R, 2000, HUM MOL GENET, V9, P1259, DOI 10.1093/hmg/9.9.1259; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; METSIS M, 1993, P NATL ACAD SCI USA, V90, P8802, DOI 10.1073/pnas.90.19.8802; MIZUNO K, 1994, DEV BIOL, V165, P243, DOI 10.1006/dbio.1994.1250; NASIR J, 1995, CELL, V81, P811, DOI 10.1016/0092-8674(95)90542-1; O'Kusky JR, 1999, BRAIN RES, V818, P468, DOI 10.1016/S0006-8993(98)01312-2; Ona VO, 1999, NATURE, V399, P263, DOI 10.1038/20446; Rigamonti D, 2000, J NEUROSCI, V20, P3705, DOI 10.1523/JNEUROSCI.20-10-03705.2000; SHARP AH, 1995, NEURON, V14, P1065, DOI 10.1016/0896-6273(95)90345-3; TIMMUSK T, 1995, J CELL BIOL, V128, P185, DOI 10.1083/jcb.128.1.185; TIMMUSK T, 1994, NEUROSCIENCE, V60, P287, DOI 10.1016/0306-4522(94)90242-9; TIMMUSK T, 1993, NEURON, V10, P475, DOI 10.1016/0896-6273(93)90335-O; Trettel F, 2000, HUM MOL GENET, V9, P2799, DOI 10.1093/hmg/9.19.2799; TROTTIER Y, 1995, NAT GENET, V10, P104, DOI 10.1038/ng0595-104; Velier J, 1998, EXP NEUROL, V152, P34, DOI 10.1006/exnr.1998.6832; VENTIMIGLIA R, 1995, EUR J NEUROSCI, V7, P213, DOI 10.1111/j.1460-9568.1995.tb01057.x; Wheeler VC, 1999, HUM MOL GENET, V8, P115, DOI 10.1093/hmg/8.1.115; White JK, 1997, NAT GENET, V17, P404, DOI 10.1038/ng1297-404	37	955	994	2	80	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 20	2001	293	5529					493	498		10.1126/science.1059581	http://dx.doi.org/10.1126/science.1059581			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	454HG	11408619				2022-12-28	WOS:000169966700048
J	Habib, S				Habib, S			Quantum physics - No mere anarchy	SCIENCE			English	Editorial Material							CHAOS		Univ Calif Los Alamos Natl Lab, Div Theoret, Los Alamos, NM 87545 USA	United States Department of Energy (DOE); Los Alamos National Laboratory	Habib, S (corresponding author), Univ Calif Los Alamos Natl Lab, Div Theoret, Los Alamos, NM 87545 USA.							Bhattacharya T, 2000, PHYS REV LETT, V85, P4852, DOI 10.1103/PhysRevLett.85.4852; DAVIS MJ, 1981, J CHEM PHYS, V75, P246, DOI 10.1063/1.441832; EINSTEIN A, 1917, VERH DTSCH PHYS GES, V19, P9; Gutzwiller M.C., 1990, CHAOS CLASSICAL QUAN; Haycock DL, 2000, PHYS REV LETT, V85, P3365, DOI 10.1103/PhysRevLett.85.3365; Hensinger WK, 2001, NATURE, V412, P52, DOI 10.1038/35083510; Hood CJ, 2000, SCIENCE, V287, P1447, DOI 10.1126/science.287.5457.1447; LIN WA, 1990, PHYS REV LETT, V65, P2927, DOI 10.1103/PhysRevLett.65.2927; MOORE FL, 1995, PHYS REV LETT, V75, P4598, DOI 10.1103/PhysRevLett.75.4598; Poincare H., 1957, NEW METHODS CELESTIA; Steck DA, 2001, SCIENCE, V293, P274, DOI 10.1126/science.1061569; TOMSOVIC S, 1994, PHYS REV E, V50, P145, DOI 10.1103/PhysRevE.50.145; Wilkinson SR, 1997, NATURE, V387, P575, DOI 10.1038/42418; [No title captured]	14	0	0	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 13	2001	293	5528					221	+		10.1126/science.1062985	http://dx.doi.org/10.1126/science.1062985			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	452TK	11441149				2022-12-28	WOS:000169875200031
J	Pardini, AT; Jones, CS; Noble, LR; Kreiser, B; Malcolm, H; Bruce, BD; Stevens, JD; Cliff, G; Scholl, MC; Francis, M; Duffy, CAJ; Martin, AP				Pardini, AT; Jones, CS; Noble, LR; Kreiser, B; Malcolm, H; Bruce, BD; Stevens, JD; Cliff, G; Scholl, MC; Francis, M; Duffy, CAJ; Martin, AP			Sex-biased dispersal of great white sharks - In some respects, these sharks behave more like whales and dolphins than other fish.	NATURE			English	Article							MITOCHONDRIAL		Univ Aberdeen, Dept Zool, Aberdeen AB24 2TZ, Scotland; Univ So Mississippi, Dept Biol Sci, Hattiesburg, MS 39406 USA; Univ Colorado, Dept Environm Populat & Organism Biol, Boulder, CO 80309 USA; CSIRO, Marine Res Labs, Hobart, Tas 7000, Australia; Natal Sharks Board, ZA-4320 Umhlanga Rocks, South Africa; Natl Inst Water & Atmospher Res, Wellington, New Zealand	University of Aberdeen; University of Southern Mississippi; University of Colorado System; University of Colorado Boulder; Commonwealth Scientific & Industrial Research Organisation (CSIRO); National Institute of Water & Atmospheric Research (NIWA) - New Zealand	Pardini, AT (corresponding author), Univ Aberdeen, Dept Zool, Tillydrone Ave, Aberdeen AB24 2TZ, Scotland.	am@stripe.colorado.edu	Scholl, Michael Christoph/ABF-5665-2021	Cliff, Geremy/0000-0003-1790-6055; Noble, leslie/0000-0003-3076-0759				BASS J, 1978, SENSORY BIOL SHARKS, P545; Cliff G, 1996, GREAT WHITE SHARKS, P393, DOI 10.1016/B978-012415031-7/50037-9; Compagno LJV, 1997, ENVIRON BIOL FISH, V50, P61, DOI 10.1023/A:1007308406137; Economakis AE, 1998, ENVIRON BIOL FISH, V51, P129, DOI 10.1023/A:1007416813214; Escorza-Trevino S, 2000, MOL ECOL, V9, P1049, DOI 10.1046/j.1365-294x.2000.00959.x; Goodman SJ, 1997, MOL ECOL, V6, P881, DOI 10.1046/j.1365-294X.1997.00260.x; GREENWOOD PJ, 1980, ANIM BEHAV, V28, P1140, DOI 10.1016/S0003-3472(80)80103-5; Klimley A.P., 1985, Memoirs of the Southern California Academy of Sciences, V9, P15; KLIMLEY AP, 1987, ENVIRON BIOL FISH, V18, P27, DOI 10.1007/BF00002325; Lyrholm T, 1999, P ROY SOC B-BIOL SCI, V266, P347, DOI 10.1098/rspb.1999.0644; Pardini AT, 2000, MOL ECOL, V9, P1176, DOI 10.1046/j.1365-294x.2000.00954-4.x; Strong WR, 1996, GREAT WHITE SHARKS, P401, DOI 10.1016/B978-012415031-7/50038-0; WEIR BS, 1984, EVOLUTION, V38, P1358, DOI [10.2307/2408641, 10.1111/j.1558-5646.1984.tb05657.x]	13	236	242	5	112	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 12	2001	412	6843					139	140		10.1038/35084125	http://dx.doi.org/10.1038/35084125			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	451AJ	11449258				2022-12-28	WOS:000169778700036
J	Thompson, DWJ; Wallace, JM				Thompson, DWJ; Wallace, JM			Regional climate impacts of the Northern Hemisphere annular mode	SCIENCE			English	Article							EXTRATROPICAL CIRCULATION; ATLANTIC OSCILLATION; TEMPERATURE; TRENDS; REANALYSIS	The Northern Hemisphere annular mode (NAM) (also known as the North Atlantic Oscillation) is shown to exert a strong influence on wintertime climate, not only over the Euro-Atlantic half of the hemisphere as documented in previous studies, but over the Pacific half as well. It affects not only the mean conditions, but also the day-to-day variability, modulating the intensity of mid-latitude storms and the frequency of occurrence of high-latitude blocking and cold air outbreaks throughout the hemisphere. The recent trend in the NAM toward its high-index polarity with stronger subpolar westerlies has tended to reduce the severity of winter weather over most middle- and high-latitude Northern Hemisphere continental legions.	Colorado State Univ, Dept Atmospher Sci, Ft Collins, CO 80523 USA; Univ Washington, Dept Atmospher Sci, Seattle, WA 98195 USA	Colorado State University; University of Washington; University of Washington Seattle	Thompson, DWJ (corresponding author), Colorado State Univ, Dept Atmospher Sci, Ft Collins, CO 80523 USA.		Thompson, David W J/F-9627-2012	Thompson, David W J/0000-0002-5413-4376				Baldwin MP, 1999, J GEOPHYS RES-ATMOS, V104, P30937, DOI 10.1029/1999JD900445; BALDWIN MP, UNPUB SCIENCE; Cullen HM, 2000, INT J CLIMATOL, V20, P853, DOI 10.1002/1097-0088(20000630)20:8&lt;853::AID-JOC497&gt;3.0.CO;2-M; Hurrell JW, 1996, GEOPHYS RES LETT, V23, P665, DOI 10.1029/96GL00459; HURRELL JW, 1995, SCIENCE, V269, P676, DOI 10.1126/science.269.5224.676; Hurrell JW, 1997, CLIMATIC CHANGE, V36, P301, DOI 10.1023/A:1005314315270; JONES PD, 1994, J CLIMATE, V7, P1794, DOI 10.1175/1520-0442(1994)007<1794:HSATVA>2.0.CO;2; Kalnay E, 1996, B AM METEOROL SOC, V77, P437, DOI 10.1175/1520-0477(1996)077<0437:TNYRP>2.0.CO;2; Latif M, 1998, J GEOPHYS RES-OCEANS, V103, P14375, DOI 10.1029/97JC03413; LORENZ EN, 1951, J METEOROL, V8, P52, DOI 10.1175/1520-0469(1951)008<0052:SAIVOT>2.0.CO;2; NAMIAS J, 1950, J METEOROL, V7, P130, DOI 10.1175/1520-0469(1950)007<0130:TICAIR>2.0.CO;2; Rigor IG, 2000, J CLIMATE, V13, P896, DOI 10.1175/1520-0442(2000)013<0896:VISATO>2.0.CO;2; Rossby CG, 1939, J MAR RES, V2, P38, DOI 10.1357/002224039806649023; Shindell DT, 1999, NATURE, V399, P452, DOI 10.1038/20905; SHUKLA J, 1983, MON WEATHER REV, V111, P388, DOI 10.1175/1520-0493(1983)111<0388:SAGVOB>2.0.CO;2; Thompson DWJ, 2000, J CLIMATE, V13, P1018, DOI 10.1175/1520-0442(2000)013<1018:AMITEC>2.0.CO;2; Thompson DWJ, 2000, J CLIMATE, V13, P1000, DOI 10.1175/1520-0442(2000)013<1018:AMITEC>2.0.CO;2; Thompson DWJ, 1998, GEOPHYS RES LETT, V25, P1297, DOI 10.1029/98GL00950; VANLOON H, 1978, MON WEATHER REV, V106, P296, DOI 10.1175/1520-0493(1978)106<0296:TSIWTB>2.0.CO;2; Walker G T, 1932, MEM R METEOROL SOC, V4, P53; WALLACE JM, 1985, TELLUS A, V37, P478, DOI 10.1111/j.1600-0870.1985.tb00445.x; Wallace JM, 2000, Q J ROY METEOR SOC, V126, P791, DOI 10.1256/smsqj.56401	22	655	725	2	133	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 6	2001	293	5527					85	89		10.1126/science.1058958	http://dx.doi.org/10.1126/science.1058958			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	451BB	11441178				2022-12-28	WOS:000169780300033
J	Kontiokari, T; Sundqvist, K; Nuutinen, M; Pokka, T; Koskela, M; Uhari, M				Kontiokari, T; Sundqvist, K; Nuutinen, M; Pokka, T; Koskela, M; Uhari, M			Randomised trial of cranberry-lingonberry juice and Lactobacillus GG drink for the prevention of urinary tract infections in women	BMJ-BRITISH MEDICAL JOURNAL			English	Article							FIMBRIATED ESCHERICHIA-COLI; ADHERENCE; UROPATHOGENS; INHIBITION; RECURRENCE	Objective To determine whether recurrences of urinary tract infection can be prevented with cranberry-lingonberry juice or with Lactobacillus GC drink. Design Open, randomised controlled 12 month follow up trial. Setting Health centres for university students and staff of university hospital. Participants 150 women with urinary tract infection caused by Escherichia coli randomly allocated into three groups. Interventions 50 ml of cranberry-lingonberry juice concentrate daily for six months or 100 mi of lactobacillus drink five days a week for one year; or no intervention. Main outcome measure First recurrence of symptomatic urinary tract infection, defined as bacterial growth greater than or equal to 10(5) colony forming units/ml in a clean voided midstream urine specimen. Results The cumulative rate of first recurrence of urinary tract infection during thr 12 month follow up differed significantly between groups (P = 0.048). At six months, eight (16%) women in the cranberry group, 19 (39%) in the lactobacillus group, and 18 (36%) in the control group had had at least one recurrence, This is a 20% reduction in absolute risk in the cranberry group, compared with the control group (95% confidence interval 3% to 36%, P = 0.023, number needed to treat = 5, 95% confidence interval 3 to 34). Conclusion Regular drinking of cranberry juice but not lactobacillus seems to reduce the recurrence of urinary tract. infection.	Univ Oulu, Dept Pediat, FIN-90220 Oulu, Finland; Finnish Student Hlth Serv, Oulu, Finland; Oulu Univ Hosp, Lab Clin Microbiol, FIN-90220 Oulu, Finland	University of Oulu; University of Oulu	Kontiokari, T (corresponding author), Univ Oulu, Dept Pediat, FIN-90220 Oulu, Finland.	tero.kontiokari@oulu.fi						Ahuja S, 1998, J UROLOGY, V159, P559, DOI 10.1016/S0022-5347(01)63983-1; AVORN J, 1994, JAMA-J AM MED ASSOC, V271, P751, DOI 10.1001/jama.271.10.751; Blatherwick NR, 1914, ARCH INTERN MED, V14, P409; CHAN RCY, 1985, INFECT IMMUN, V47, P84, DOI 10.1128/IAI.47.1.84-89.1985; Foxman B, 2000, ANN EPIDEMIOL, V10, P509, DOI 10.1016/S1047-2797(00)00072-7; Gibson GR, 1998, BRIT J NUTR, V80, pS209, DOI 10.1017/S0007114500006048; Gupta K, 1999, JAMA-J AM MED ASSOC, V281, P736, DOI 10.1001/jama.281.8.736; Howell AB, 1998, NEW ENGL J MED, V339, P1085, DOI 10.1056/NEJM199810083391516; Ikaheimo R, 1996, CLIN INFECT DIS, V22, P91, DOI 10.1093/clinids/22.1.91; JEPSON RG, 2000, COCHRANE DB SYST REV; OFEK I, 1991, NEW ENGL J MED, V324, P1599; RAZ R, 1993, NEW ENGL J MED, V329, P753, DOI 10.1056/NEJM199309093291102; REID G, 1992, CLIN THER, V14, P11; SAXELIN M, 1995, INT J FOOD MICROBIOL, V25, P199, DOI 10.1016/0168-1605(94)00091-J; SCHLAGER TA, 1999, J PEDIAT, V135, P98; SCHMIDT DR, 1988, MICROBIOS, V55, P173; SOBOTA AE, 1984, J UROLOGY, V131, P1013, DOI 10.1016/S0022-5347(17)50751-X; ZAFRIRI D, 1989, ANTIMICROB AGENTS CH, V33, P92, DOI 10.1128/AAC.33.1.92	18	274	288	4	43	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 30	2001	322	7302					1571	1573		10.1136/bmj.322.7302.1571	http://dx.doi.org/10.1136/bmj.322.7302.1571			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	449QT	11431298	Green Submitted, Bronze, Green Published			2022-12-28	WOS:000169699200025
J	Oehninger, S				Oehninger, S			Place of intracytoplasmic sperm injection in management of male infertility	LANCET			English	Editorial Material							OXIDATIVE STRESS; IMPACT		Eastern Virginia Med Sch, Jones Inst Reprod Med, Div Reprod Endocrinol, Norfolk, VA 23507 USA	Eastern Virginia Medical School	Oehninger, S (corresponding author), Eastern Virginia Med Sch, Jones Inst Reprod Med, Div Reprod Endocrinol, Norfolk, VA 23507 USA.	OehninSC@EVMS.edu	Oehninger, Sergio/AAZ-8443-2020					Aitken RJ, 1998, BIOL REPROD, V59, P1037, DOI 10.1095/biolreprod59.5.1037; Barroso G, 2000, HUM REPROD, V15, P1338, DOI 10.1093/humrep/15.6.1338; Bonduelle M, 1999, HUM REPROD, V14, P243, DOI 10.1093/humrep/14.suppl_1.243; Brinkworth MH, 2000, INT J ANDROL, V23, P123, DOI 10.1046/j.1365-2605.2000.00222.x; *CDCP, 1998, ASS REPR TECHN SUCC, P12; Chandley AC, 1998, HUM REPROD, V13, P76, DOI 10.1093/humrep/13.suppl_3.76; CUMMINS JM, 1994, HUM REPROD, V9, P1214, DOI 10.1093/oxfordjournals.humrep.a138681; Irvine DS, 1998, HUM REPROD, V13, P33, DOI 10.1093/humrep/13.suppl_1.33; Kent-First MG, 1996, MOL HUM REPROD, V2, P943, DOI 10.1093/molehr/2.12.943; Martin RH, 1998, J ASSIST REPROD GEN, V15, P240, DOI 10.1023/A:1022528007564; Oehninger S, 2000, J ANDROL, V21, P814; Oehninger S, 2000, MOL CELL ENDOCRINOL, V169, P73, DOI 10.1016/S0303-7207(00)00355-5; OEHNINGER S, 1995, FERTIL STERIL, V63, P87; PALERMO G, 1992, LANCET, V340, P17, DOI 10.1016/0140-6736(92)92425-F; Pfeffer J, 1999, FERTIL STERIL, V72, P472, DOI 10.1016/S0015-0282(99)00279-4; VANSTEIRTEGHEM AC, 1993, HUM REPROD, V8, P1061, DOI 10.1093/oxfordjournals.humrep.a138192	16	34	34	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 30	2001	357	9274					2068	2069		10.1016/S0140-6736(00)05223-5	http://dx.doi.org/10.1016/S0140-6736(00)05223-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	447RQ	11445092				2022-12-28	WOS:000169586600002
J	Sjogren, M				Sjogren, M			EDRF transcripts and diagnosis of variant Creutzfeldt-Jakob disease	LANCET			English	Editorial Material									Univ Gothenburg, Inst Clin Neurosci, SE-43180 Molndal, Sweden	University of Gothenburg	Sjogren, M (corresponding author), Univ Gothenburg, Inst Clin Neurosci, SE-43180 Molndal, Sweden.		Sjogren, Magnus/M-2668-2015	Sjogren, Magnus/0000-0003-2060-1914				Hill AF, 1999, LANCET, V353, P183, DOI 10.1016/S0140-6736(98)12075-5; Ironside JW, 2000, LANCET, V355, P1693, DOI 10.1016/S0140-6736(00)02243-1; Miele G, 2001, NAT MED, V7, P361, DOI 10.1038/85515; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363	4	3	3	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 30	2001	357	9274					2069	2070		10.1016/S0140-6736(00)05224-7	http://dx.doi.org/10.1016/S0140-6736(00)05224-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	447RQ	11445093				2022-12-28	WOS:000169586600003
J	Allen, GJ; Chu, SP; Harrington, CL; Schumacher, K; Hoffman, T; Tang, YY; Grill, E; Schroeder, JI				Allen, GJ; Chu, SP; Harrington, CL; Schumacher, K; Hoffman, T; Tang, YY; Grill, E; Schroeder, JI			A defined range of guard cell calcium oscillation parameters encodes stomatal movements	NATURE			English	Article							CYTOSOLIC-FREE CALCIUM; ABSCISIC-ACID; SIGNAL-TRANSDUCTION; GENE-EXPRESSION; ANION CHANNELS; ARABIDOPSIS; FREQUENCY; GROWTH; SPECIFICITY; INCREASES	Oscillations in cytosolic calcium concentration ([Ca2+](cyt)) are central regulators of signal transduction cascades(1), although the roles of individual [Ca2+](cyt) oscillation parameters in regulating downstream physiological responses remain largely unknown. In plants, guard cells integrate environmental and endogenous signals to regulate the aperture of stomatal pores(2) and [Ca2+](cyt) oscillations are a fundamental component of stomatal closure(3,4). Here we systematically vary [Ca2+](cyt) oscillation parameters in Arabidopsis guard cells using a 'calcium clamp'(3,5-7) and show that [Ca2+](cyt) controls stomatal closure by two mechanisms. Shortterm 'calcium-reactive' closure occurred rapidly when [Ca2+](cyt) was elevated, whereas the degree of long-term steady-state closure was 'calcium programmed' by [Ca2+](cyt) oscillations within a defined range of frequency, transient number, duration and amplitude. Furthermore, in guard cells of the gca2 mutant(8), [Ca2+](cyt) oscillations induced by abscisic acid and extracellular calcium had increased frequencies and reduced transient duration, and steady-state stomatal closure was abolished. Experimentally imposing [Ca2+](cyt) oscillations with parameters that elicited closure in the wild type restored long-term closure in gca2 stomata. These data show that a defined window of guard cell [Ca2+](cyt) oscillation parameters programs changes in steady-state stomatal aperture.	Univ Calif San Diego, Div Biol, Cell & Dev Biol Sect, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Mol Genet, La Jolla, CA 92093 USA; Univ Tubingen, ZMBP Pflanzenphysiol, D-72076 Tubingen, Germany; Tech Univ, Lehrstuhl Bot, D-85350 Freising Weihenstephan, Germany	University of California System; University of California San Diego; University of California System; University of California San Diego; Eberhard Karls University of Tubingen	Schroeder, JI (corresponding author), Univ Calif San Diego, Div Biol, Cell & Dev Biol Sect, La Jolla, CA 92093 USA.		Schumacher, Karin/E-8500-2014	Schumacher, Karin/0000-0001-6484-8105				Allen GJ, 1999, PLANT J, V19, P735, DOI 10.1046/j.1365-313x.1999.00574.x; Allen GJ, 2000, SCIENCE, V289, P2338, DOI 10.1126/science.289.5488.2338; Berridge MJ, 1997, NATURE, V386, P759, DOI 10.1038/386759a0; Blatt MR, 2000, CURR OPIN PLANT BIOL, V3, P196, DOI 10.1016/S1369-5266(00)00064-9; CAMACHO P, 1993, SCIENCE, V260, P226, DOI 10.1126/science.8385800; Cutler S, 1996, SCIENCE, V273, P1239, DOI 10.1126/science.273.5279.1239; Dal Santo P, 1999, CELL, V98, P757, DOI 10.1016/S0092-8674(00)81510-X; De Koninck P, 1998, SCIENCE, V279, P227, DOI 10.1126/science.279.5348.227; Dolmetsch RE, 1998, NATURE, V392, P933, DOI 10.1038/31960; Ehrhardt DW, 1996, CELL, V85, P673, DOI 10.1016/S0092-8674(00)81234-9; FELLE H, 1988, PLANTA, V174, P495, DOI 10.1007/BF00634478; GILROY S, 1991, PLANT CELL, V3, P333, DOI 10.1105/tpc.3.4.333; Gomez TM, 1999, NATURE, V397, P350, DOI 10.1038/16927; Grabov A, 1998, P NATL ACAD SCI USA, V95, P4778, DOI 10.1073/pnas.95.8.4778; GU XN, 1995, NATURE, V375, P784, DOI 10.1038/375784a0; Hamilton DWA, 2000, P NATL ACAD SCI USA, V97, P4967, DOI 10.1073/pnas.080068897; Himmelbach A, 1998, PHILOS T R SOC B, V353, P1439, DOI 10.1098/rstb.1998.0299; HoldawayClarke TL, 1997, PLANT CELL, V9, P1999, DOI 10.1105/tpc.9.11.1999; KOORNNEEF M, 1984, PHYSIOL PLANTARUM, V61, P377, DOI 10.1111/j.1399-3054.1984.tb06343.x; Li WH, 1998, NATURE, V392, P936, DOI 10.1038/31965; MacRobbie EAC, 1997, J EXP BOT, V48, P515, DOI 10.1093/jxb/48.Special_Issue.515; MCAINSH MR, 1995, PLANT CELL, V7, P1207, DOI 10.1105/tpc.7.8.1207; McAinsh MR, 1998, TRENDS PLANT SCI, V3, P32, DOI 10.1016/S1360-1385(97)01150-3; Miyawaki A, 1999, P NATL ACAD SCI USA, V96, P2135, DOI 10.1073/pnas.96.5.2135; Pei ZM, 2000, NATURE, V406, P731, DOI 10.1038/35021067; Pei ZM, 1997, PLANT CELL, V9, P409, DOI 10.1105/tpc.9.3.409; Pei ZM, 1998, SCIENCE, V282, P287, DOI 10.1126/science.282.5387.287; SCHROEDER JI, 1990, P NATL ACAD SCI USA, V87, P9305, DOI 10.1073/pnas.87.23.9305; Staxen I, 1999, P NATL ACAD SCI USA, V96, P1779, DOI 10.1073/pnas.96.4.1779; Trewavas AJ, 1998, CURR OPIN PLANT BIOL, V1, P428, DOI 10.1016/S1369-5266(98)80268-9	30	412	456	6	117	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 28	2001	411	6841					1053	1057		10.1038/35082575	http://dx.doi.org/10.1038/35082575			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	446TF	11429606				2022-12-28	WOS:000169528500049
J	Jones, PL				Jones, PL			Extracellular matrix and tenascin-C in pathogenesis of breast cancer	LANCET			English	Editorial Material							MALIGNANT GLIOMAS; PHASE-I; CARCINOGENESIS; EXPRESSION; INVASION; RECEPTOR; 81C6		Univ Colorado, Hlth Sci Ctr, Dept Pediat, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Jones, PL (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Pediat, Denver, CO 80262 USA.			Jones, Peter Lloyd/0000-0003-1445-4081				Bergers G, 2000, NAT CELL BIOL, V2, P737, DOI 10.1038/35036374; BIGNER DD, 1995, J NEURO-ONCOL, V24, P109, DOI 10.1007/BF01052668; Cokgor I, 2000, J CLIN ONCOL, V18, P3862, DOI 10.1200/JCO.2000.18.22.3862; Goepel C, 2000, GYNECOL ONCOL, V79, P372, DOI 10.1006/gyno.2000.5978; Hansen RK, 2000, ENDOCR-RELAT CANCER, V7, P95, DOI 10.1677/erc.0.0070095; Jahkola T, 1998, BRIT J CANCER, V78, P1507, DOI 10.1038/bjc.1998.714; Jahkola T, 1998, EUR J CANCER, V34, P1687, DOI 10.1016/S0959-8049(98)00215-9; Jones FS, 2000, DEV DYNAM, V218, P235, DOI 10.1002/(SICI)1097-0177(200006)218:2<235::AID-DVDY2>3.3.CO;2-7; Jones PL, 2000, MATRIX BIOL, V19, P581, DOI 10.1016/S0945-053X(00)00106-2; Kuukasjarvi T, 1996, J CLIN ONCOL, V14, P2584, DOI 10.1200/JCO.1996.14.9.2584; LEMAISTRE CF, 1994, BREAST CANCER RES TR, V32, P97, DOI 10.1007/BF00666210; Silletti S, 2001, P NATL ACAD SCI USA, V98, P119, DOI 10.1073/pnas.011343298; Sternlicht MD, 1999, CELL, V98, P137, DOI 10.1016/S0092-8674(00)81009-0; Wang F, 1998, P NATL ACAD SCI USA, V95, P14821, DOI 10.1073/pnas.95.25.14821; Woodward TL, 2000, ENDOCRINOLOGY, V141, P2814, DOI 10.1210/en.141.8.2814	15	20	20	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 23	2001	357	9273					1992	1994		10.1016/S0140-6736(00)05133-3	http://dx.doi.org/10.1016/S0140-6736(00)05133-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	446JB	11438127				2022-12-28	WOS:000169509200004
J	Gopfert, MC; Robert, D				Gopfert, MC; Robert, D			Turning the key on Drosophila audition	NATURE			English	Article							MECHANOSENSORY TRANSDUCTION; MUTATIONS		Univ Zurich, Inst Zool, CH-8057 Zurich, Switzerland	University of Zurich	Gopfert, MC (corresponding author), Univ Zurich, Inst Zool, Winterthurerstr 190, CH-8057 Zurich, Switzerland.			Gopfert, Martin/0000-0001-8201-5334				BENNETCLARK HC, 1971, NATURE, V234, P255, DOI 10.1038/234255a0; Carlson JR, 1996, TRENDS GENET, V12, P175, DOI 10.1016/0168-9525(96)10015-9; Eberl DF, 1997, P NATL ACAD SCI USA, V94, P14837, DOI 10.1073/pnas.94.26.14837; Eberl DF, 2000, J NEUROSCI, V20, P5981, DOI 10.1523/JNEUROSCI.20-16-05981.2000; Gopfert MC, 2000, P ROY SOC B-BIOL SCI, V267, P453, DOI 10.1098/rspb.2000.1021; HALL JC, 1994, SCIENCE, V264, P1702, DOI 10.1126/science.8209251; KERNAN M, 1994, NEURON, V12, P1195, DOI 10.1016/0896-6273(94)90437-5; *RYB CONS, 1999, NUCLEIC ACIDS RES, V28, P85; Walker RG, 2000, SCIENCE, V287, P2229, DOI 10.1126/science.287.5461.2229; Yager DD, 1999, MICROSC RES TECHNIQ, V47, P380, DOI 10.1002/(SICI)1097-0029(19991215)47:6<380::AID-JEMT3>3.0.CO;2-P	10	78	81	0	11	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 21	2001	411	6840					908	908		10.1038/35082144	http://dx.doi.org/10.1038/35082144			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	444EN	11418847	Bronze			2022-12-28	WOS:000169386200033
J	May, R				May, R			Risk and uncertainty	NATURE			English	Editorial Material									Royal Soc, London SW1Y 5AG, England		May, R (corresponding author), Royal Soc, Carlton House Terrace, London SW1Y 5AG, England.								0	13	13	1	13	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 21	2001	411	6840					891	891		10.1038/35082158	http://dx.doi.org/10.1038/35082158			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	444EN	11418834	Bronze			2022-12-28	WOS:000169386200022
J	Zhang, CY; Baffy, G; Perret, P; Krauss, S; Peroni, O; Grujic, D; Hagen, T; Vidal-Puig, AJ; Boss, O; Kim, YB; Zheng, XX; Wheeler, MB; Shulman, GI; Chan, CB; Lowell, BB				Zhang, CY; Baffy, G; Perret, P; Krauss, S; Peroni, O; Grujic, D; Hagen, T; Vidal-Puig, AJ; Boss, O; Kim, YB; Zheng, XX; Wheeler, MB; Shulman, GI; Chan, CB; Lowell, BB			Uncoupling protein-2 negatively regulates insulin secretion and is a major link between obesity, beta cell dysfunction, and type 2 diabetes	CELL			English	Article							SENSITIVE K+ CHANNELS; BROWN ADIPOSE-TISSUE; FATTY-ACIDS; CARBOHYDRATE-METABOLISM; PANCREATIC-ISLETS; THYROID-HORMONE; RECEPTOR GENE; KNOCKOUT MICE; NORMAL MEN; EXPRESSION	B cells sense glucose through its metabolism and the resulting increase in ATP, which subsequently stimulates insulin secretion. Uncoupling protein-2 (UCP2) mediates mitochondrial proton leak, decreasing ATP production. In the present study, we assessed UCP2's role in regulating insulin secretion. UCP2-deficient mice had higher islet ATP levels and increased glucose-stimulated insulin secretion, establishing that UCP2 negatively regulates insulin secretion. Of pathophysiologic significance, UCP2 was markedly upregulated in islets of ob/ob mice, a model of obesity-induced diabetes. Importantly, ob/ob mice lacking UCP2 had restored first-phase insulin secretion, increased serum insulin levels, and greatly decreased levels of glycemia. These results establish UCP2 as a key component of beta cell glucose sensing, and as a critical link between obesity, B cell dysfunction, and type 2 diabetes.	Beth Israel Deaconess Med Ctr, Div Endocrinol, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Dept Med, Div Immunol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA; Brigham & Womens Hosp, Dept Med, Div Gastroenterol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06520 USA; Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06520 USA; Univ Toronto, Fac Med, Dept Med & Physiol, Toronto, ON M5F 1A8, Canada; Univ Prince Edward Isl, Atlantic Vet Coll, Dept Anat & Physiol, Charlottetown, PE C1A 4P3, Canada	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Yale University; Howard Hughes Medical Institute; Yale University; University of Toronto; University of Prince Edward Island	Lowell, BB (corresponding author), Beth Israel Deaconess Med Ctr, Div Endocrinol, 99 Brookline Ave, Boston, MA 02215 USA.	blowell@caregroup.harvard.edu	Baffy, Gyorgy/P-7986-2018; Perret, Pascale/M-3911-2014; Shulman, Gerald I./P-7176-2019; Chan, Catherine/C-1162-2011; Perret, pascale/O-7382-2019	Baffy, Gyorgy/0000-0002-8334-0400; Perret, Pascale/0000-0003-0804-8247; Shulman, Gerald I./0000-0003-1529-5668; Chan, Catherine/0000-0003-3882-0592; Perret, pascale/0000-0003-0804-8247; Vidal-Puig, Antonio/0000-0003-4220-9577; Wheeler, Michael B./0000-0002-7480-7267	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053477, T32DK007533, P30DK057521, P30DK046200, R01DK040936, R37DK053477] Funding Source: NIH RePORTER; NIDDK NIH HHS [R37 DK053477, T32 DK07533, R01 DK040936, R01-DK53477, DK57521, DK46200] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ADRA CN, 1987, GENE, V60, P65, DOI 10.1016/0378-1119(87)90214-9; Arsenijevic D, 2000, NAT GENET, V26, P435, DOI 10.1038/82565; Ashcroft FM, 1999, DIABETOLOGIA, V42, P903, DOI 10.1007/s001250051247; BELOFFCHAIN A, 1975, HORM METAB RES, V7, P374, DOI 10.1055/s-0028-1093730; BODEN G, 1991, DIABETES, V40, P686, DOI 10.2337/diabetes.40.6.686; BODEN G, 1991, J CLIN INVEST, V88, P960, DOI 10.1172/JCI115399; Boss O, 1997, FEBS LETT, V408, P39, DOI 10.1016/S0014-5793(97)00384-0; BRICHARD SM, 1990, DIABETES, V39, P1326, DOI 10.2337/diabetes.39.11.1326; Brun T, 1997, DIABETES, V46, P393, DOI 10.2337/diabetes.46.3.393; CAWTHORN EG, 1991, MOL CELL ENDOCRINOL, V75, P197, DOI 10.1016/0303-7207(91)90161-K; Chan CB, 1999, DIABETES, V48, P1482, DOI 10.2337/diabetes.48.7.1482; CHAN CB, 2001, IN PRESS DIABETES; Chao L, 2000, J CLIN INVEST, V106, P1221, DOI 10.1172/JCI11245; Chung WK, 1997, OBES RES, V5, P183, DOI 10.1002/j.1550-8528.1997.tb00291.x; COLEMAN DL, 1982, DIABETES, V31, P1; Cortez-Pinto H, 1999, GASTROENTEROLOGY, V116, P1184, DOI 10.1016/S0016-5085(99)70022-3; DEFRONZO RA, 1988, DIABETES, V37, P667, DOI 10.2337/diab.37.6.667; Echtay KS, 2001, P NATL ACAD SCI USA, V98, P1416, DOI 10.1073/pnas.98.4.1416; Enerback S, 1997, NATURE, V387, P90, DOI 10.1038/387090a0; Fleury C, 1997, NAT GENET, V15, P269, DOI 10.1038/ng0397-269; GEMBAL M, 1993, J CLIN INVEST, V91, P871, DOI 10.1172/JCI116308; GEPTS W, 1960, DIABETES, V9, P63, DOI 10.2337/diab.9.1.63; Gimeno RE, 1997, DIABETES, V46, P900, DOI 10.2337/diabetes.46.5.900; Gong DW, 1997, J BIOL CHEM, V272, P24129, DOI 10.1074/jbc.272.39.24129; Gong DW, 2000, J BIOL CHEM, V275, P16251, DOI 10.1074/jbc.M910177199; HELLMAN B, 1961, ACTA ENDOCRINOL-COP, V36, P606; HIMMSHAGEN J, 1989, PROG LIPID RES, V28, P67, DOI 10.1016/0163-7827(89)90009-X; Hinz W, 1999, FEBS LETT, V448, P57, DOI 10.1016/S0014-5793(99)00331-2; Hong Y, 2001, ENDOCRINOLOGY, V142, P249, DOI 10.1210/en.142.1.249; Jaburek M, 1999, J BIOL CHEM, V274, P26003, DOI 10.1074/jbc.274.37.26003; Kahn Steven E., 2000, American Journal of Medicine, V108, p2S, DOI 10.1016/S0002-9343(00)00336-3; Kim JK, 2000, J CLIN INVEST, V105, P1791, DOI 10.1172/JCI8305; Klingenberg M, 1999, BBA-BIOMEMBRANES, V1415, P271, DOI 10.1016/S0005-2736(98)00232-6; Lameloise N, 2001, DIABETES, V50, P803, DOI 10.2337/diabetes.50.4.803; LI E, 1993, P NATL ACAD SCI USA, V90, P1590, DOI 10.1073/pnas.90.4.1590; Matschinsky FM, 1998, DIABETES, V47, P307, DOI 10.2337/diabetes.47.3.307; Miki T, 1998, P NATL ACAD SCI USA, V95, P10402, DOI 10.1073/pnas.95.18.10402; Pick A, 1998, DIABETES, V47, P358, DOI 10.2337/diabetes.47.3.358; Poitout V, 1996, ANNU REV MED, V47, P69; Reilly JM, 2000, BIOCHEM BIOPH RES CO, V277, P541, DOI 10.1006/bbrc.2000.3705; Rial E, 1999, EMBO J, V18, P5827, DOI 10.1093/emboj/18.21.5827; Ronner P, 1999, ANAL BIOCHEM, V275, P208, DOI 10.1006/abio.1999.4317; SAKO Y, 1990, ENDOCRINOLOGY, V127, P1580, DOI 10.1210/endo-127-4-1580; Schaff er I. E., 1999, MITOCHONDRIA, P141; Segall L, 1999, AM J PHYSIOL-ENDOC M, V277, pE521, DOI 10.1152/ajpendo.1999.277.3.E521; Seghers V, 2000, J BIOL CHEM, V275, P9270, DOI 10.1074/jbc.275.13.9270; Shulman GI, 2000, J CLIN INVEST, V106, P171, DOI 10.1172/JCI10583; Skulachev VP, 1998, BBA-BIOENERGETICS, V1363, P100, DOI 10.1016/S0005-2728(97)00091-1; TAYLOR SI, 1992, DIABETES, V41, P1473, DOI 10.2337/diabetes.41.11.1473; UNGER RH, 1995, DIABETES, V44, P863, DOI 10.2337/diabetes.44.8.863; Vidal-Puig AJ, 2000, J BIOL CHEM, V275, P16258, DOI 10.1074/jbc.M910179199; VidalPuig A, 1997, BIOCHEM BIOPH RES CO, V235, P79, DOI 10.1006/bbrc.1997.6740; Wang MY, 1999, DIABETES, V48, P1020, DOI 10.2337/diabetes.48.5.1020; ZAVARONI I, 1987, J CLIN ENDOCR METAB, V65, P494, DOI 10.1210/jcem-65-3-494; Zhang CY, 1999, FEBS LETT, V449, P129, DOI 10.1016/S0014-5793(99)00441-X; ZHOU YP, 1995, J CLIN ENDOCR METAB, V80, P1584, DOI 10.1210/jc.80.5.1584	56	717	749	0	46	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 15	2001	105	6					745	755		10.1016/S0092-8674(01)00378-6	http://dx.doi.org/10.1016/S0092-8674(01)00378-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	444AE	11440717	Bronze			2022-12-28	WOS:000169375100008
J	van Straten, W; Bailes, M; Britton, M; Kulkarni, SR; Anderson, SB; Manchester, RN; Sarkissian, J				van Straten, W; Bailes, M; Britton, M; Kulkarni, SR; Anderson, SB; Manchester, RN; Sarkissian, J			A test of general relativity from the three-dimensional orbital geometry of a binary pulsar	NATURE			English	Article							MILLISECOND PULSAR; PROPER MOTION; PSR-1913+16; COMPANION; BRIGHT; DECAY	Binary pulsars provide an excellent system for testing general relativity because of their intrinsic rotational stability and the precision with which radio observations can be used to determine their orbital dynamics. Measurements of the rate of orbital decay of two pulsars have been shown(1,2) to be consistent with the emission of gravitational waves as predicted by general relativity, but independent verification was not possible. Such verification can in principle be obtained by determining the orbital inclination in a binary pulsar system using only classical geometrical constraints. This would permit a measurement of the expected retardation of the pulse signal arising from the general relativistic curvature of space-time in the vicinity of the companion object (the 'Shapiro delay'). Here we report high-precision radio observations of the binary millisecond pulsar PSR J0437-4715, which establish the three-dimensional structure of its orbit. We see the Shapiro delay predicted by general relativity, and we determine the mass of the neutron star and its white dwarf companion. The determination of such masses is necessary in order to understand the origin and evolution of neutron stars(3).	Swinburne Univ Technol, Ctr Astrophys & Supercomp, Hawthorn, Vic 3122, Australia; CALTECH, Div Phys Math & Astron, Pasadena, CA 91125 USA; Australia Telescope Natl Facil, CSIRO, Epping, NSW 1710, Australia	Swinburne University of Technology; California Institute of Technology; Commonwealth Scientific & Industrial Research Organisation (CSIRO)	van Straten, W (corresponding author), Swinburne Univ Technol, Ctr Astrophys & Supercomp, POB 218, Hawthorn, Vic 3122, Australia.			van Straten, Willem/0000-0003-2519-7375; Bailes, Matthew/0000-0003-3294-3081				Backer DC, 1998, ASTROPHYS J, V493, P873, DOI 10.1086/305167; BELL JF, 1993, NATURE, V364, P603, DOI 10.1038/364603a0; Bell JF, 1996, ASTROPHYS J, V456, pL33, DOI 10.1086/309862; CAMILO F, 1994, ASTROPHYS J, V437, pL39, DOI 10.1086/187677; CANNON WH, 1997, VISTAS ASTRON, V41, P297; DAMOUR T, 1991, ASTROPHYS J, V366, P501, DOI 10.1086/169585; DAMOUR T, 1986, ANN I H POINCARE-PHY, V44, P263; DANZIGER IJ, 1993, ASTRON ASTROPHYS, V276, P382; JOHNSTON S, 1993, NATURE, V361, P613, DOI 10.1038/361613a0; KOPEIKIN SM, 1995, ASTROPHYS J, V439, pL5, DOI 10.1086/187731; McHugh MP, 1996, PHYS REV D, V54, P5993, DOI 10.1103/PhysRevD.54.5993; Stairs IH, 1998, ASTROPHYS J, V505, P352, DOI 10.1086/306151; TAAM RE, 1986, ASTROPHYS J, V305, P235, DOI 10.1086/164243; TAYLOR JH, 1982, ASTROPHYS J, V253, P908, DOI 10.1086/159690; TAYLOR JH, 1992, PHILOS T ROY SOC A, V341, P117, DOI 10.1098/rsta.1992.0088; Thorsett SE, 1999, ASTROPHYS J, V512, P288, DOI 10.1086/306742; VANSTRATEN W, 2000, IAU C, V177, P283	19	158	158	0	7	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 12	2001	412	6843					158	160		10.1038/35084015	http://dx.doi.org/10.1038/35084015			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	451AJ	11449265	Green Accepted			2022-12-28	WOS:000169778700043
J	Langer, R				Langer, R			Perspectives: Drug delivery - Drugs on target	SCIENCE			English	Editorial Material									MIT, Dept Chem Engn, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Langer, R (corresponding author), MIT, Dept Chem Engn, 77 Massachusetts Ave, Cambridge, MA 02139 USA.							Affleck DG, 2001, GENE THER, V8, P349, DOI 10.1038/sj.gt.3301395; Carino GP, 1999, ADV DRUG DELIVER REV, V35, P249, DOI 10.1016/S0169-409X(98)00075-1; Daugherty AL, 1999, PHARM SCI TECHNOL TO, V2, P144, DOI 10.1016/S1461-5347(99)00142-X; de Lima MCP, 2001, ADV DRUG DELIVER REV, V47, P277, DOI 10.1016/S0169-409X(01)00110-7; EDWARDS DA, 1999, ENCY CONTROLLED DRUG, V2, P936; Hwang SJ, 2001, CURR OPIN MOL THER, V3, P183; Hwang SJ, 2001, BIOCONJUGATE CHEM, V12, P280, DOI 10.1021/bc0001084; Langer R, 1998, NATURE, V392, P5; Luo D, 2000, NAT BIOTECHNOL, V18, P33, DOI 10.1038/71889; SANTINI JT, 2000, ANGEW CHEM INT EDIT, V39, P2396	10	478	515	2	137	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 6	2001	293	5527					58	59		10.1126/science.1063273	http://dx.doi.org/10.1126/science.1063273			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	451BB	11441170				2022-12-28	WOS:000169780300024
J	Crutch, SJ; Isaacs, R; Rossor, MN				Crutch, SJ; Isaacs, R; Rossor, MN			Some workmen can blame their tools: artistic change in an individual with Alzheimer's disease	LANCET			English	Editorial Material							DEMENTIA; CREATIVITY		Inst Neurol, Dept Clin Neurol, Dementia Res Grp, London WC1N 3BG, England	University of London; University College London	Rossor, MN (corresponding author), Inst Neurol, Dept Clin Neurol, Dementia Res Grp, Queen Sq, London WC1N 3BG, England.		Rossor, Martin/C-1598-2008	Rossor, Martin/0000-0001-8215-3120; Crutch, Sebastian/0000-0002-4160-0139				American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; ARRIGONI G, 1964, CORTEX, V1, P170; CUMMINGS JL, 1987, JAMA-J AM MED ASSOC, V258, P2731, DOI 10.1001/jama.258.19.2731; Espinel CH, 1996, LANCET, V347, P1096, DOI 10.1016/S0140-6736(96)90285-8; Fox NC, 1998, BRAIN, V121, P1631, DOI 10.1093/brain/121.9.1631; Gardner H., 1993, CREATING MINDS ANATO; Gibson PH, 1996, LANCET, V347, P1838; HENDERSON VW, 1989, ARCH NEUROL-CHICAGO, V46, P391, DOI 10.1001/archneur.1989.00520400045018; HUFF FJ, 1987, NEUROLOGY, V37, P1119, DOI 10.1212/WNL.37.7.1119; KIRK A, 1991, ARCH NEUROL-CHICAGO, V48, P73, DOI 10.1001/archneur.1991.00530130083024; Meulenberg F, 1996, LANCET, V347, P1838, DOI 10.1016/S0140-6736(96)91659-1; Miller BL, 1998, NEUROLOGY, V51, P978, DOI 10.1212/WNL.51.4.978; Miller BL, 1996, LANCET, V348, P1744, DOI 10.1016/S0140-6736(05)65881-3; MORRIS JC, 1989, NEUROLOGY, V39, P1159, DOI 10.1212/wnl.43.12.2457; Ravin J G, 1978, Ohio State Med J, V74, P78; SIMONTON DK, 1984, GENIUS CREATIVITY LE; Storr R., 1995, W DEKOONING LATE PAI, P39; Warrington E.K., 1984, RECOGNITION MEMORY T; WARRINGTON EK, 1966, BRAIN, V89, P52; 2000, EXTRACT EXHIBITION N	20	49	49	0	11	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 30	2001	357	9274					2129	2133		10.1016/S0140-6736(00)05187-4	http://dx.doi.org/10.1016/S0140-6736(00)05187-4			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	447RQ	11445128				2022-12-28	WOS:000169586600037
J	White, LE; Coppola, DM; Fitzpatrick, D				White, LE; Coppola, DM; Fitzpatrick, D			The contribution of sensory experience to the maturation of orientation selectivity in ferret visual cortex	NATURE			English	Article							SHREW STRIATE CORTEX; DARK-REARED KITTENS; HORIZONTAL CONNECTIONS; CORTICOCORTICAL CONNECTIONS; CAT; MAPS; SPECIFICITY; ARRANGEMENT; DEPRIVATION; PREFERENCE	Sensory experience begins when neural circuits in the cerebral cortex are still immature; however, the contribution of experience to cortical maturation remains unclear. In the visual cortex, the selectivity of neurons for oriented stimuli at the time of eye opening is poor(1-5) and increases dramatically after the onset of visual experience(3-8). Here we investigate whether visual experience has a significant role in the maturation of orientation selectivity and underlying cortical circuits(9-12) using two forms of deprivation: dark rearing, which completely eliminates experience, and binocular lid suture, which alters the pattern of sensory driven activity(13). Orientation maps were present in dark-reared ferrets, but fully mature levels of tuning were never attained. In contrast, only rudimentary levels of orientation selectivity were observed in lid-sutured ferrets. Despite these differences, horizontal connections in both groups were less extensive and less clustered than normal, suggesting that long-range cortical processing is not essential for the expression of orientation selectivity, but may be needed for the full maturation of tuning. Thus, experience is beneficial or highly detrimental to cortical maturation, depending on the pattern of sensory driven activity.	Duke Univ, Med Ctr, Dept Neurobiol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Community & Family Med, Div Phys Therapy, Durham, NC 27710 USA; Centenary Coll Louisiana, Dept Biol, Shreveport, LA 71134 USA	Duke University; Duke University	White, LE (corresponding author), Duke Univ, Med Ctr, Dept Neurobiol, Durham, NC 27710 USA.	white033@mc.duke.edu						BLAKEMORE C, 1975, J PHYSIOL-LONDON, V248, P663, DOI 10.1113/jphysiol.1975.sp010995; Bonhoeffer Tobias, 1996, P55; Bosking WH, 1997, J NEUROSCI, V17, P2112; Bosking WH, 2000, J NEUROSCI, V20, P2346; CALLAWAY EM, 1991, P NATL ACAD SCI USA, V88, P745, DOI 10.1073/pnas.88.3.745; CHAPMAN B, 1993, J NEUROSCI, V13, P5251, DOI 10.1523/JNEUROSCI.13-12-05251.1993; Chapman B, 2000, J NEUROSCI, V20, P1922; Chapman B, 1996, J NEUROSCI, V16, P6443; Chapman B, 1999, J NEUROBIOL, V41, P18, DOI 10.1002/(SICI)1097-4695(199910)41:1<18::AID-NEU4>3.0.CO;2-V; Crair MC, 1998, SCIENCE, V279, P566, DOI 10.1126/science.279.5350.566; DAW N, 1995, VISUAL DEV; Durack JC, 1996, CEREB CORTEX, V6, P178, DOI 10.1093/cercor/6.2.178; FREGNAC Y, 1978, J PHYSIOL-LONDON, V278, P27, DOI 10.1113/jphysiol.1978.sp012290; FREGNAC Y, 1984, PHYSIOL REV, V64, P325, DOI 10.1152/physrev.1984.64.1.325; GILBERT CD, 1989, J NEUROSCI, V9, P2432; Godecke I, 1997, EUR J NEUROSCI, V9, P1754; HUBEL DH, 1963, J NEUROPHYSIOL, V26, P994, DOI 10.1152/jn.1963.26.6.994; Krug K, 2001, J NEUROPHYSIOL, V85, P1436, DOI 10.1152/jn.2001.85.4.1436; LUBKE J, 1992, J COMP NEUROL, V323, P42, DOI 10.1002/cne.903230105; Miller KD, 1999, J NEUROBIOL, V41, P44, DOI 10.1002/(SICI)1097-4695(199910)41:1<44::AID-NEU7>3.0.CO;2-V; MOWER GD, 1981, BRAIN RES, V220, P255, DOI 10.1016/0006-8993(81)91216-6; Ruthazer ES, 1996, J NEUROSCI, V16, P7253; Sengpiel F, 1999, NAT NEUROSCI, V2, P727, DOI 10.1038/11192; SHERMAN SM, 1982, PHYSIOL REV, V62, P738, DOI 10.1152/physrev.1982.62.2.738; Shouval HZ, 2000, J NEUROSCI, V20, P1119, DOI 10.1523/JNEUROSCI.20-03-01119.2000; Weliky M, 1997, NATURE, V386, P680, DOI 10.1038/386680a0; WIESEL TN, 1974, J COMP NEUROL, V158, P307, DOI 10.1002/cne.901580306; Wong ROL, 1996, NEURON, V16, P1087, DOI 10.1016/S0896-6273(00)80135-X; Zufferey PD, 1999, EUR J NEUROSCI, V11, P2669, DOI 10.1046/j.1460-9568.1999.00683.x	29	161	163	0	9	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 28	2001	411	6841					1049	1052		10.1038/35082568	http://dx.doi.org/10.1038/35082568			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	446TF	11429605				2022-12-28	WOS:000169528500048
J	Reynolds, NJ; Franklin, V; Gray, JC; Diffey, BL; Farr, PM				Reynolds, NJ; Franklin, V; Gray, JC; Diffey, BL; Farr, PM			Narrow-band ultraviolet B and broad-band ultraviolet A phototherapy in adult atonic eczema: a randomised controlled trial	LANCET			English	Article							ATOPIC-DERMATITIS; UVB PHOTOTHERAPY; T-CELLS; PSORIASIS; PHOTOCHEMOTHERAPY; CYCLOSPORINE; INDUCTION; APOPTOSIS; EXPOSURE; THERAPY	Background Narrow-band ultraviolet B (UVB) is an effective treatment for psoriasis, and open studies suggest that this phototherapy might improve atopic eczema. We did a randomised controlled trial to compare narrow-band UVB, UVA, and visible light phototherapy as second-line, adjunctive treatments in adult patients with moderate to severe atopic eczema. Methods Phototherapy was administered twice a week for 12 weeks. 26 patients were randomly assigned narrow-band UVB, 24 were assigned UVA, and 23 visible fluorescent light. The primary endpoints were change in total disease activity (sum of scores at six body sites) and change in extent of disease after 24 treatments compared with baseline. Data were analysed by the method of summary measures. Findings 13 patients withdrew or were excluded from analysis. Mean reductions in total disease activity over 24 treatments in patients who received narrow-band UVB and UVA, respectively, were 9.4 points (95% CI 3.6 to 15.2)and 4.4 points ( - 1.0 to 9.8) more than in patients who received visible light. Mean reductions in extent of disease after 24 treatments with narrow-band UVB and UVA were 6.7% (1.5 to 11.9) and -1.0% (-5.3 to 3.3)compared with visible light. A small proportion of patients developed erythema after phototherapy or had a flare in their eczema sufficient to withdraw from treatment. Interpretation Narrow-band UVB is an effective adjunctive treatment for moderate to severe atopic eczema, and the treatment is well tolerated by most patients.	Newcastle Univ, Sch Med, Dept Dermatol, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Univ Teesside, Postgrad Inst Hlth, Middlesbrough, Cleveland, England; Newcastle Gen Hosp, Dept Reg Med Phys, Newcastle Upon Tyne NE4 6BE, Tyne & Wear, England	Newcastle University - UK; University of Teesside; Newcastle General Hospital	Reynolds, NJ (corresponding author), Newcastle Univ, Sch Med, Dept Dermatol, Framlington Pl, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	n.j.reynolds@ncl.ac.uk		Reynolds, Nick/0000-0002-6484-825X				Barr RM, 1999, J INVEST DERMATOL, V112, P692, DOI 10.1046/j.1523-1747.1999.00570.x; BerthJones J, 1996, BRIT J DERMATOL, V135, P25, DOI 10.1111/j.1365-2133.1996.tb00706.x; Bilsland D, 1997, BRIT J DERMATOL, V137, P327, DOI 10.1046/j.1365-2133.1997.18441939.x; Charman CR, 1999, BRIT J DERMATOL, V140, P109; deBerker DAR, 1997, J AM ACAD DERMATOL, V36, P577, DOI 10.1016/S0190-9622(97)70246-9; ENK CD, 1995, J IMMUNOL, V154, P4851; FISCHER T, 1976, ACTA DERM-VENEREOL, V56, P473; GEORGE SA, 1993, BRIT J DERMATOL, V128, P49, DOI 10.1111/j.1365-2133.1993.tb00147.x; GIBBS NK, 1995, J INVEST DERMATOL, V104, P359, DOI 10.1111/1523-1747.ep12665385; Gordon PM, 1998, BRIT J DERMATOL, V139, P811; HARPER J, 1994, BRIT MED J, V308, P489, DOI 10.1136/bmj.308.6927.489; HERSEY P, 1983, J IMMUNOL, V131, P171; HudsonPeacock MJ, 1996, BRIT J DERMATOL, V135, P332, DOI 10.1111/j.1365-2133.1996.tb01179.x; JECKLER J, 1988, BRIT J DERMATOL, V119, P697, DOI 10.1111/j.1365-2133.1988.tb03490.x; JEKLER J, 1991, BRIT J DERMATOL, V125, P569, DOI 10.1111/j.1365-2133.1991.tb14796.x; JEKLER J, 1990, J AM ACAD DERMATOL, V22, P49, DOI 10.1016/0190-9622(90)70006-4; KRUEGER JG, 1995, J EXP MED, V182, P2057, DOI 10.1084/jem.182.6.2057; Krutmann J, 1999, J INVEST DERM SYMP P, V4, P70, DOI 10.1038/sj.jidsp.5640185; Krutmann J, 1998, J AM ACAD DERMATOL, V38, P589, DOI 10.1016/S0190-9622(98)70123-9; MATTHEWS JNS, 1993, STAT MED, V12, P27, DOI 10.1002/sim.4780120105; MATTHEWS JNS, 1990, BRIT MED J, V300, P230, DOI 10.1136/bmj.300.6719.230; McGinley J, 1998, BRIT J DERMATOL, V139, P428; MORISON WL, 1979, BRIT J DERMATOL, V101, P513, DOI 10.1111/j.1365-2133.1979.tb15094.x; Morita A, 1997, J EXP MED, V186, P1763, DOI 10.1084/jem.186.10.1763; Ozawa M, 1999, J EXP MED, V189, P711, DOI 10.1084/jem.189.4.711; Powles AV, 1998, BRIT J DERMATOL, V138, P443; SHEEHAN MP, 1992, LANCET, V340, P13, DOI 10.1016/0140-6736(92)92424-E; SOWDEN JM, 1991, LANCET, V338, P137, DOI 10.1016/0140-6736(91)90134-B; VANWEELDEN H, 1988, BRIT J DERMATOL, V119, P11; Walters IB, 1999, J AM ACAD DERMATOL, V40, P893, DOI 10.1016/S0190-9622(99)70076-9; WILLIAMS HC, 1994, BRIT J DERMATOL, V131, P383, DOI 10.1111/j.1365-2133.1994.tb08530.x; YOUNG AR, 1995, LANCET, V345, P1431, DOI 10.1016/S0140-6736(95)92617-8	33	163	173	0	12	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 23	2001	357	9273					2012	2016		10.1016/S0140-6736(00)05114-X	http://dx.doi.org/10.1016/S0140-6736(00)05114-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	446JB	11438134				2022-12-28	WOS:000169509200011
J	Martinez, F; Goodliffe, AM; Taylor, B				Martinez, F; Goodliffe, AM; Taylor, B			Metamorphic core complex formation by density inversion and lower-crust extrusion	NATURE			English	Article							PAPUA-NEW-GUINEA; DENTRECASTEAUX-ISLANDS; NORMAL FAULTS; TECTONIC EVOLUTION; SEA; BASIN; EXTENSION; ORIGIN	Metamorphic core complexes are domal uplifts of metamorphic and plutonic rocks bounded by shear zones that separate them from unmetamorphosed cover rocks(1). Interpretations of how these features form are varied and controversial, and include models involving extension on low-angle normal faults(2), plutonic intrusions(3) and flexural rotation of initially high-angle normal faults(4). The D'Entrecasteaux islands of Papua New Guinea are actively forming metamorphic core complexes located within a continental rift that laterally evolves to sea-floor spreading(5). The continental rifting is recent (since similar to6 Myr ago)(5), seismogenic(6) and occurring at a rapid rate (similar to 25 mmyr(-1))(5). Here we present evidence-based on isostatic modelling, geological data and heat-flow measurements that the D'Entrecasteaux core complexes accommodate extension through the vertical extrusion of ductile lower-crust material, driven by a crustal density inversion. Although buoyant extrusion is accentuated in this region by the geological structure present which consists of dense ophiolite overlaying less-dense continental crust this mechanism may be generally applicable to regions where thermal expansion lowers crustal density with depth.	Univ Hawaii, Sch Ocean & Earth Sci & Technol, Hawaii Inst Geophys & Planetol, Honolulu, HI 96822 USA; Univ Hawaii, Sch Ocean & Earth Sci & Technol, Dept Geol & Geophys, Honolulu, HI 96822 USA	University of Hawaii System; University of Hawaii System	Martinez, F (corresponding author), Univ Hawaii, Sch Ocean & Earth Sci & Technol, Hawaii Inst Geophys & Planetol, Honolulu, HI 96822 USA.							Abers GA, 1997, J GEOPHYS RES-SOL EA, V102, P15301, DOI 10.1029/97JB00787; BALDWIN SL, 1993, TECTONICS, V12, P611, DOI 10.1029/93TC00235; BALDWIN SL, 2000, EOS, V81, pF1307; BUCK WR, 1988, TECTONICS, V7, P959, DOI 10.1029/TC007i005p00959; BUCK WR, 1988, TECTONICS, V7, P213, DOI 10.1029/TC007i002p00213; CONEY PJ, 1980, CORDILLERAN METAMORP, P7; DAVIES HL, 1988, TECTONICS, V7, P1, DOI 10.1029/TC007i001p00001; DAVIES HL, 1992, CONTRIB MINERAL PETR, V112, P463, DOI 10.1007/BF00310778; DAVIES HL, 1984, BMR J AUST GEOL GEOP, V9, P49; DAVIES HL, 1971, B BUR MINERAL RESOUR, V128; FANG J, 2000, THESIS COLUMBIA U; FERRIS A, 2000, EOS, V81, pF881; FINLAYSON DM, 1976, VOLCANISM AUSTRALASI, P259; FRANCIS G, 1987, GEO-MAR LETT, V7, P121, DOI 10.1007/BF02238041; HILL EJ, 1992, GEOLOGY, V20, P907, DOI 10.1130/0091-7613(1992)020<0907:UOAMCC>2.3.CO;2; LANGSETH MG, 1980, J GEOPHYS RES, V85, P3740, DOI 10.1029/JB085iB07p03740; LISTER GS, 1993, GEOLOGY, V21, P607, DOI 10.1130/0091-7613(1993)021<0607:PATOOM>2.3.CO;2; MILSOM J, 1973, GEOL MIJNBOUW, V52, P13; OLLIER CD, 1980, J GEOL SOC AUST, V27, P33, DOI DOI 10.1080/00167618008729116; Rogerson R., P PAC RIM C, V87, P579; ROYDEN L, 1980, EARTH PLANET SC LETT, V51, P343, DOI 10.1016/0012-821X(80)90216-2; SCLATER JG, 1970, TECTONOPHYSICS, V10, P283; SEAGER WR, 1970, GEOL SOC AM BULL, V81, P1517, DOI 10.1130/0016-7606(1970)81[1517:LGGSIT]2.0.CO;2; STECKLER MS, 1981, THESIS COLUMBIA U; TAYLOR B, 1995, NATURE, V374, P534, DOI 10.1038/374534a0; Taylor B, 1999, J GEOPHYS RES-SOL EA, V104, P7497, DOI 10.1029/1998JB900115; Taylor B, 1999, P ODP INIT REPTS, V180, P1; WEISSEL JK, 1979, J GEOPHYS RES, V84, P4572, DOI 10.1029/JB084iB09p04572; WERNICKE B, 1981, NATURE, V291, P645, DOI 10.1038/291645a0	29	80	84	0	9	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 21	2001	411	6840					930	934		10.1038/35082042	http://dx.doi.org/10.1038/35082042			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	444EN	11418853				2022-12-28	WOS:000169386200039
J	Brady, AJB; Oliver, MA; Pittard, JB				Brady, AJB; Oliver, MA; Pittard, JB			Secondary prevention in 24,431 patients with coronary heart disease: survey in primary care	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Univ Glasgow, Glasgow Royal Infirm, Dept Med Cardiol, Glasgow G31 2ER, Lanark, Scotland; Merck Sharp & Dohme Ltd, Hoddesdon EN11 9BU, Herts, England; Staines & Thameside Med, Staines TW18 3JH, Surrey, England	University of Glasgow; Merck & Company	Brady, AJB (corresponding author), Univ Glasgow, Glasgow Royal Infirm, Dept Med Cardiol, Glasgow G31 2ER, Lanark, Scotland.	a.j.brady@clinmed.gla.ac.uk						Bowker TJ, 1996, HEART, V75, P334, DOI 10.1136/hrt.75.4.334; Campbell NC, 1998, BMJ-BRIT MED J, V316, P1430, DOI 10.1136/bmj.316.7142.1430; *DEP HLTH, 2000, NAT SERV FRAM COR HE; Flanagan DEH, 1999, QJM-INT J MED, V92, P245, DOI 10.1093/qjmed/92.5.245	4	57	57	0	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 16	2001	322	7300					1463	1463		10.1136/bmj.322.7300.1463	http://dx.doi.org/10.1136/bmj.322.7300.1463			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	444FJ	11408303	Green Accepted, Green Published, Bronze, Green Submitted			2022-12-28	WOS:000169389200030
J	McNamee, D				McNamee, D			Review of clinical protocols at The Lancet	LANCET			English	Editorial Material							JOURNALS		Lancet, London WC1X 8RR, England		McNamee, D (corresponding author), Lancet, London WC1X 8RR, England.							ALTMAN DG, 1994, BRIT MED J, V308, P283, DOI 10.1136/bmj.308.6924.283; Brown MM, 2001, LANCET, V357, P1729; Chalmers I, 1999, LANCET, V353, P490, DOI 10.1016/S0140-6736(98)07618-1; Foss A, 1997, BRIT MED J, V314, P1691, DOI 10.1136/bmj.314.7095.1691a; Hansson L, 1998, LANCET, V351, P1755, DOI 10.1016/S0140-6736(98)04311-6; Horton R, 1997, LANCET, V349, P6, DOI 10.1016/S0140-6736(05)62158-7; Kenyon SL, 2001, LANCET, V357, P989, DOI 10.1016/S0140-6736(00)04234-3; Kenyon SL, 2001, LANCET, V357, P979, DOI 10.1016/S0140-6736(00)04233-1; McNamee D, 1997, LANCET, V350, P6, DOI 10.1016/S0140-6736(05)66237-X; O'Brien J, 2000, LANCET, V355, P1295; Roy LP, 1999, LANCET, V353, P428, DOI 10.1016/S0140-6736(98)00229-3; Tonks L, 1999, BMJ-BRIT MED J, V319, P1565, DOI 10.1136/bmj.319.7224.1565	12	9	9	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 9	2001	357	9271					1819	1820		10.1016/S0140-6736(00)05011-X	http://dx.doi.org/10.1016/S0140-6736(00)05011-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	440DN	11410187				2022-12-28	WOS:000169160800007
J	Woodman, CBJ; Collins, S; Winter, H; Bailey, A; Ellis, J; Prior, P; Yates, M; Rollason, TP; Young, LS				Woodman, CBJ; Collins, S; Winter, H; Bailey, A; Ellis, J; Prior, P; Yates, M; Rollason, TP; Young, LS			Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study	LANCET			English	Article							INTRAEPITHELIAL NEOPLASIA; HIGH-GRADE; RISK-FACTOR; LESIONS; TYPE-16; PROGRESSION; SMEARS; DNA	Background Laboratory and epidemiological research suggests an association between human papillomavirus (HPV) and cervical intraepithelial neoplasia (CIN). We studied the natural history of incident cervical HPV infection and its relation to the development of CIN. Methods We recruited 2011 women aged 15-19 years who had recently become sexually active. We took a cervical smear every 6 months and stored samples for virological analysis. We immediately referred all women with any cytological abnormality for colposcopic assessment, out postponed treatment until there was histological evidence of progression to high-grade CIN. Findings IN 1075 women who were cytologically normal and HPV negative at recruitment, the cumulative risk at 3 years of any HPV infection was 44% (95% CI 40-48): HPV 16 was the most common type. The cumulative risk at 3 years of detecting an HPV type not present in the first positive sample was 26% (20-32). 246 women had an abnormal smear during follow-up, of whom 28 progressed to high-grade CIN. The risk of high-grade CIN was greatest in women who tested positive for HPV 16 (risk ratio 8.5 [3.7-19.2]); this risk was maximum 6-12 months after first detection of HPV 16. All HPV types under consideration were associated with cytologically abnormal smears. Although abnormality was significantly less likely to be associated with low-viral-load samples, the cumulative risk at 3 years of a high-viral-load sample after a low-viral-load sample was 45% (95% CI 35-56). Five women who progressed to high-grade CIN consistently tested negative for HPV. Interpretation Our findings suggest that attempts to exploit the association between cervical neoplasia and HPV infection to improve effectiveness of cervical screening programmes might be undermined by the limited inferences that can be drawn from the characterisation of a woman's HPV status at a single point in time, and the short lead time gained by its detection.	Univ Manchester, Ctr Canc Epidemiol, Manchester M20 4QL, Lancs, England; Cent Manchester Healthcare Trust, Dept Clin Virol, Manchester, Lancs, England; Univ Birmingham, Dept Publ Hlth, Birmingham B15 2TT, W Midlands, England; Univ Birmingham, CRC, Inst Canc Studies, Birmingham B15 2TT, W Midlands, England; Birmingham Womens Hosp, Dept Pathol, Birmingham, W Midlands, England; Birmingham Womens Hosp, Acad Dept Obstet & Gynaecol, Birmingham, W Midlands, England	University of Manchester; University of Birmingham; University of Birmingham; Birmingham Women's Hospital; Birmingham Women's Hospital	Woodman, CBJ (corresponding author), Univ Manchester, Ctr Canc Epidemiol, Manchester M20 4QL, Lancs, England.	ciaran.woodman@cce.man.ac.uk	Young, Lawrence S/B-7213-2009	Young, Lawrence S/0000-0003-3919-4298				Bauer HM, 1992, DIAGNOSTIC MOL PATHO, P131; BERNARD HU, 1994, J INFECT DIS, V170, P1077, DOI 10.1093/infdis/170.5.1077; Burger MPM, 1996, BRIT J CANCER, V73, P831, DOI 10.1038/bjc.1996.146; Chenoy R, 1996, BRIT J OBSTET GYNAEC, V103, P457, DOI 10.1111/j.1471-0528.1996.tb09773.x; DOWNEY GP, 1994, LANCET, V344, P432, DOI 10.1016/S0140-6736(94)91768-X; FLANNELLY G, 1995, J MED VIROL, V47, P6, DOI 10.1002/jmv.1890470103; Herrington CS, 1999, J PATHOL, V189, P1; HILDESHEIM A, 1994, J INFECT DIS, V169, P235, DOI 10.1093/infdis/169.2.235; HIPPELAINEN MI, 1994, SEX TRANSM DIS, V21, P76, DOI 10.1097/00007435-199403000-00004; HO GYF, 1995, JNCI-J NATL CANCER I, V87, P1365, DOI 10.1093/jnci/87.18.1365; Ho GYF, 1998, INT J CANCER, V78, P594, DOI 10.1002/(SICI)1097-0215(19981123)78:5&lt;594::AID-IJC11&gt;3.0.CO;2-B; Ho GYF, 1998, NEW ENGL J MED, V338, P423, DOI 10.1056/NEJM199802123380703; HUSMAN AMDR, 1995, J GEN VIROL, V76, P1057; Kjellberg L, 1999, J GEN VIROL, V80, P391, DOI 10.1099/0022-1317-80-2-391; KOUTSKY LA, 1992, NEW ENGL J MED, V327, P1272, DOI 10.1056/NEJM199210293271804; Kruger-Kjaer S, 1998, INT J CANCER, V76, P613, DOI 10.1002/(SICI)1097-0215(19980529)76:5&lt;613::AID-IJC1&gt;3.0.CO;2-T; Liaw KL, 1999, J NATL CANCER I, V91, P954, DOI 10.1093/jnci/91.11.954; Luostarinen T, 1999, INT J CANCER, V80, P818, DOI 10.1002/(SICI)1097-0215(19990315)80:6&lt;818::AID-IJC4&gt;3.0.CO;2-T; Nobbenhuis MAE, 1999, LANCET, V354, P20, DOI 10.1016/S0140-6736(98)12490-X; Park JJ, 1998, GYNECOL ONCOL, V70, P386, DOI 10.1006/gyno.1998.5100; RAFFLE AE, 1995, LANCET, V345, P1469, DOI 10.1016/S0140-6736(95)91036-0; RICHART RM, 1969, AM J OBSTET GYNECOL, V105, P386, DOI 10.1016/0002-9378(69)90268-3; Shah KV, 1996, INT J GYNECOL PATHOL, V15, P127, DOI 10.1097/00004347-199604000-00006; Silins I, 1999, J GEN VIROL, V80, P2931, DOI 10.1099/0022-1317-80-11-2931; SOLER C, 1991, J VIROL METHODS, V35, P143, DOI 10.1016/0166-0934(91)90130-R; Swan DC, 1999, J CLIN MICROBIOL, V37, P1030, DOI 10.1128/JCM.37.4.1030-1034.1999; Tabrizi SN, 1999, BRIT J OBSTET GYNAEC, V106, P252, DOI 10.1111/j.1471-0528.1999.tb08239.x; VANDENBRULE AJC, 1990, J CLIN MICROBIOL, V28, P2739, DOI 10.1128/JCM.28.12.2739-2743.1990; VANDENVELDE C, 1992, J MED VIROL, V36, P279, DOI 10.1002/jmv.1890360409; Vonka V, 1999, INT J CANCER, V80, P365, DOI 10.1002/(SICI)1097-0215(19990129)80:3&lt;365::AID-IJC5&gt;3.0.CO;2-C; Walboomers JMM, 1999, J PATHOL, V189, P12, DOI 10.1002/(SICI)1096-9896(199909)189:1&lt;12::AID-PATH431&gt;3.0.CO;2-F; Wideroff L, 1999, J INFECT DIS, V180, P1424, DOI 10.1086/315055; 1997, REVISED GUIDELINES C; 1995, HUMAN PAPILLOMAVIRUS, V64	34	590	649	0	26	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 9	2001	357	9271					1831	1836		10.1016/S0140-6736(00)04956-4	http://dx.doi.org/10.1016/S0140-6736(00)04956-4			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	440DN	11410191				2022-12-28	WOS:000169160800011
J	Poliakoff, M; King, P				Poliakoff, M; King, P			Phenomenal fluids	NATURE			English	Editorial Material									Univ Nottingham, Sch Phys & Astron, Nottingham NG7 2RD, England; Univ Nottingham, Sch Chem, Nottingham NG7 2RD, England	University of Nottingham; University of Nottingham	Poliakoff, M (corresponding author), Univ Nottingham, Sch Chem, Nottingham NG7 2RD, England.							Adam D, 2000, NATURE, V407, P938, DOI 10.1038/35039717; JESSOP PG, 1999, CHEM SYNTHESIS USING; McHugh M., 1994, SUPERCRITICAL FLUID, Vsecond; NOYORI R, 1999, CHEM REV, V99	4	58	61	0	5	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 12	2001	412	6843					125	125		10.1038/35084292	http://dx.doi.org/10.1038/35084292			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	451AJ	11449245				2022-12-28	WOS:000169778700025
J	Schwetz, BA				Schwetz, BA			New treatment for chronic myelogenous leukemia	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item									US FDA, Off Commissioner, Rockville, MD 20857 USA	US Food & Drug Administration (FDA)	Schwetz, BA (corresponding author), US FDA, Off Commissioner, HF-1,Room 14-71,5600 Fishers Ln, Rockville, MD 20857 USA.							Stephenson J, 2001, JAMA-J AM MED ASSOC, V285, P2841, DOI 10.1001/jama.285.22.2841	1	8	8	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 4	2001	286	1					35	35		10.1001/jama.286.1.35	http://dx.doi.org/10.1001/jama.286.1.35			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	449GR	11434814				2022-12-28	WOS:000169676400005
J	Gupta, K; Hooton, TM; Stamm, WE				Gupta, K; Hooton, TM; Stamm, WE			Increasing antimicrobial resistance and the management of uncomplicated community-acquired urinary tract infections	ANNALS OF INTERNAL MEDICINE			English	Review							ESCHERICHIA-COLI; TRIMETHOPRIM-SULFAMETHOXAZOLE; CLINICAL PHARMACOKINETICS; RANDOMIZED-TRIAL; GENERAL-PRACTICE; RISK-FACTORS; WOMEN; CIPROFLOXACIN; AMOXICILLIN; BACTERIA	Community-acquired urinary tract infections (UTIs) are among the most common bacterial infections in women. Therapy for these infections is usually begun before results of microbiological tests are known. Furthermore, in women with acute uncomplicated cystitis, empirical therapy without a pretherapy urine culture is often used. The rationale for this approach is based on the highly predictable spectrum of etiologic agents causing UTI and their antimicrobial resistance patterns. However, antimicrobial resistance among uropathogens causing community-acquired UTIs, both cystitis and pyelonephritis, is increasing. Most important has been the increasing resistance to trimethoprim-sulfamethoxazole (TMP-SMX), the current drug of choice for treatment of acute uncomplicated cystitis in women. What implications do these trends have for treatment of community-acquired UTIs? Preliminary data suggest that clinical cure rates may be lower among women with uncomplicated cystitis treated with TMP-SMX when the infecting pathogen is resistant to TMP-SMX. Women with pyelonephritis also have less bacterial eradication and lower clinical cure rates when treated with TMP-SMX for an infection that is resistant to the drug. Therefore, in the outpatient setting, identifying risk factors for TMP-SMX resistance and knowing the prevalence of TMP-SMX resistance in the local community are important steps in choosing an appropriate therapeutic agent. When choosing a treatment regimen, physicians should consider such factors as in vitro susceptibility, adverse effects, cost-effectiveness, and selection of resistant strains. Using a management strategy that takes these variables into account is essential for maintaining the safety and efficacy of treatment for acute UTI.	Univ Washington, Sch Med, Div Allergy & Infect Dis, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle	Stamm, WE (corresponding author), Univ Washington, Sch Med, Div Allergy & Infect Dis, 1959 NE Pacific St,BB1225,Box 356523, Seattle, WA 98195 USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK053369] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 53369] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Acar JF, 1997, CLIN INFECT DIS, V24, pS67, DOI 10.1093/clinids/24.Supplement_1.S67; AMSDEN GW, 2000, MANDELL DOUGLAS BENN, P551; ARANCIBIA A, 1980, ANTIMICROB AGENTS CH, V17, P199, DOI 10.1128/AAC.17.2.199; BAILEY RR, 1995, NEW ZEAL MED J, V108, P465; Christiaens T, 1998, ACTA CLIN BELG, V53, P184, DOI 10.1080/17843286.1998.11754161; COLE M, 1978, J ANTIMICROB CHEMOTH, V4, P580, DOI 10.1093/jac/4.6.580; Dyer IE, 1998, WESTERN J MED, V169, P265; ENA J, 1995, J UROLOGY, V153, P117, DOI 10.1097/00005392-199501000-00040; Fish DN, 1997, CLIN PHARMACOKINET, V32, P101, DOI 10.2165/00003088-199732020-00002; Garcia-Rodriguez JA, 1998, CHEMOTHERAPY, V44, P28, DOI 10.1159/000048461; GRUNEBERG RN, 1994, J ANTIMICROB CHEMOTH, V33, P1; Gupta K, 1999, JAMA-J AM MED ASSOC, V281, P736, DOI 10.1001/jama.281.8.736; GUPTA K, IN PRESS CLIN INFECT; HOOTON TM, 1995, JAMA-J AM MED ASSOC, V273, P41; Hooton TM, 1997, INFECT DIS CLIN N AM, V11, P551, DOI 10.1016/S0891-5520(05)70373-1; Iqbal J, 1997, JPN J MED SCI BIOL, V50, P241, DOI 10.7883/yoken1952.50.241; MASTERTON RG, 1995, J ANTIMICROB CHEMOTH, V35, P129, DOI 10.1093/jac/35.1.129; McCarthy JM, 1999, AM J MED, V106, P292, DOI 10.1016/S0002-9343(99)00026-1; *MICR INC, 2001, MICR HEALTHC SER DAT, V108; MURRAY BE, 1990, ANTIMICROB AGENTS CH, V34, P515, DOI 10.1128/AAC.34.4.515; NICOLLE LE, 1993, SCAND J INFECT DIS, V25, P631, DOI 10.3109/00365549309008553; NIGHTINGALE CH, 1975, J PHARM SCI-US, V64, P1899, DOI 10.1002/jps.2600641202; Orrett F. A., 1998, SMJ, V39, P256; PATEL RB, 1980, CLIN PHARMACOKINET, V5, P405, DOI 10.2165/00003088-198005050-00001; Patel SS, 1997, DRUGS, V53, P637, DOI 10.2165/00003495-199753040-00007; Perrin M, 1999, J HOSP INFECT, V41, P273, DOI 10.1053/jhin.1998.0521; RECKENDORF HK, 1962, ANTIMICROBIAL AGENTS, V2, P531; REVES RR, 1990, ANTIMICROB AGENTS CH, V34, P1429, DOI 10.1128/AAC.34.7.1429; RUBIN RH, 1980, JAMA-J AM MED ASSOC, V244, P561, DOI 10.1001/jama.244.6.561; RUSSO TA, 1995, J INFECT DIS, V172, P440, DOI 10.1093/infdis/172.2.440; RYDBERG J, 1986, SCAND J INFECT DIS, V18, P457, DOI 10.3109/00365548609032364; Sahm DF, 2001, ANTIMICROB AGENTS CH, V45, P1402, DOI 10.1128/AAC.45.5.1402-1406.2001; SAHM DF, 1999, 39 INT C ANT AG CHEM; SPENCER RC, 1994, J ANTIMICROB CHEMOTH, V33, P121, DOI 10.1093/jac/33.suppl_A.121; STAMM WE, 1993, NEW ENGL J MED, V329, P1328, DOI 10.1056/NEJM199310283291808; Steinke DT, 1999, J ANTIMICROB CHEMOTH, V43, P841, DOI 10.1093/jac/43.6.841; Talan DA, 2000, JAMA-J AM MED ASSOC, V283, P1583, DOI 10.1001/jama.283.12.1583; TRIENEKENS T, 1994, J ANTIMICROB CHEMOTH, V33, P1064, DOI 10.1093/jac/33.5.1064; VANCEBRYAN K, 1990, CLIN PHARMACOKINET, V19, P434, DOI 10.2165/00003088-199019060-00003; Warren JW, 1999, CLIN INFECT DIS, V29, P745, DOI 10.1086/520427; Weber G, 1997, EUR J CLIN MICROBIOL, V16, P834, DOI 10.1007/BF01700414; Wright SW, 1999, J GEN INTERN MED, V14, P606, DOI 10.1046/j.1525-1497.1999.10128.x; Zhanel GG, 2000, ANTIMICROB AGENTS CH, V44, P1089, DOI 10.1128/AAC.44.4.1089-1092.2000; 1997, MED LETT DRUGS THER, V39, P66	44	377	401	0	15	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 3	2001	135	1					41	50		10.7326/0003-4819-135-1-200107030-00012	http://dx.doi.org/10.7326/0003-4819-135-1-200107030-00012			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	449JC	11434731				2022-12-28	WOS:000169680500006
J	Mather, HM				Mather, HM			Specialist registrars' plans for working part time as consultants in medical specialties: questionnaire study	BRITISH MEDICAL JOURNAL			English	Article									Royal Coll Phys, London NW1 4LE, England	Royal College of Physicians	Mather, HM (corresponding author), Ealing Hosp, Southall UB1 3HW, Middx, England.							*BMA, 2000, 5 BMA; Dumelow C, 2000, BRIT MED J, V320, P1437, DOI 10.1136/bmj.320.7247.1437; Evans J, 2000, MED EDUC, V34, P355, DOI 10.1046/j.1365-2923.2000.00620.x; Mather HM, 2000, J ROY COLL PHYS LOND, V34, P289	4	10	10	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 30	2001	322	7302					1578	1579		10.1136/bmj.322.7302.1578	http://dx.doi.org/10.1136/bmj.322.7302.1578			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	449QT	11431300	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000169699200028
J	Sheng, M; Lee, SH				Sheng, M; Lee, SH			AMPA receptor trafficking and the control of synaptic transmission	CELL			English	Review							LONG-TERM POTENTIATION; PLASTICITY; SYNAPSES; MEMBRANE; LTP		Massachusetts Gen Hosp, Dept Neurobiol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Howard Hughes Med Inst, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Howard Hughes Medical Institute; Harvard University; Harvard Medical School	Sheng, M (corresponding author), MIT, Ctr Learning & Memory, 77 Massachusetts Ave, Cambridge, MA 02139 USA.			Sheng, Morgan/0000-0002-8703-5366				Beattie EC, 2000, NAT NEUROSCI, V3, P1291, DOI 10.1038/81823; Carroll RC, 2001, NAT REV NEUROSCI, V2, P315, DOI 10.1038/35072500; Chen L, 2000, NATURE, V408, P936, DOI 10.1038/35050030; Ehlers MD, 2000, NEURON, V28, P511, DOI 10.1016/S0896-6273(00)00129-X; Hayashi Y, 2000, SCIENCE, V287, P2262, DOI 10.1126/science.287.5461.2262; Lin JW, 2000, NAT NEUROSCI, V3, P1282, DOI 10.1038/81814; Lledo PM, 1998, SCIENCE, V279, P399, DOI 10.1126/science.279.5349.399; Luscher C, 2000, NAT NEUROSCI, V3, P545, DOI 10.1038/75714; Luscher C, 1999, NEURON, V24, P649, DOI 10.1016/S0896-6273(00)81119-8; LYNCH G, 1984, SCIENCE, V224, P1057, DOI 10.1126/science.6144182; Malenka RC, 1999, SCIENCE, V285, P1870, DOI 10.1126/science.285.5435.1870; Malinow R, 2000, CURR OPIN NEUROBIOL, V10, P352, DOI 10.1016/S0959-4388(00)00099-4; Man HY, 2000, NEURON, V25, P649, DOI 10.1016/S0896-6273(00)81067-3; Nusser Z, 2000, CURR OPIN NEUROBIOL, V10, P337, DOI 10.1016/S0959-4388(00)00086-6; Scannevin RH, 2000, NAT REV NEUROSCI, V1, P133, DOI 10.1038/35039075; Sheng M, 2000, ANNU REV PHYSIOL, V62, P755, DOI 10.1146/annurev.physiol.62.1.755; Shi SH, 2001, CELL, V105, P331, DOI 10.1016/S0092-8674(01)00321-X; Shi SH, 1999, SCIENCE, V284, P1811, DOI 10.1126/science.284.5421.1811; Wenthold RJ, 1996, J NEUROSCI, V16, P1982; Zhu JJ, 2000, NAT NEUROSCI, V3, P1098, DOI 10.1038/80614	20	160	163	0	11	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTES AVE,, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 29	2001	105	7					825	828		10.1016/S0092-8674(01)00406-8	http://dx.doi.org/10.1016/S0092-8674(01)00406-8			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	449BK	11439178	Bronze			2022-12-28	WOS:000169664300003
J	Renehan, AG; Booth, C; Potten, CS				Renehan, AG; Booth, C; Potten, CS			What is apoptosis, and why is it important?	BMJ-BRITISH MEDICAL JOURNAL			English	Article							FORM		Christie Hosp NHS Trust, Paterson Inst Canc Res, Canc Res Campaign, Dept Epithelial Biol, Manchester M20 4BX, Lancs, England	Christie NHS Foundation Trust; Christie Hospital; Paterson Institute for Cancer Research	Potten, CS (corresponding author), EpiStem Ltd, Incubator Bldg, Manchester M13 9XX, Lancs, England.	arenehan@picr.man.ac.uk	Renehan, Andrew/K-5992-2015	Renehan, Andrew/0000-0003-4309-4396				KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Martin K, 1998, EXP CELL RES, V241, P316, DOI 10.1006/excr.1998.4001; Nicholson DW, 2000, NATURE, V407, P810, DOI 10.1038/35037747; Norimura T, 1996, NAT MED, V2, P577, DOI 10.1038/nm0596-577; O'Connell J, 1999, NAT MED, V5, P267, DOI 10.1038/6477; Potten CS, 1997, COMP BIOCHEM PHYS B, V118, P473, DOI 10.1016/S0305-0491(97)00219-8; Potten CS, 1996, BRIT J CANCER, V74, P1743, DOI 10.1038/bjc.1996.624; Renehan AG, 2001, CAN J GASTROENTEROL, V15, P166, DOI 10.1155/2001/164727; Renehan AG, 2001, BRIT J SURG, V88, P107, DOI 10.1046/j.1365-2168.2001.01645.x; Sperandio S, 2000, P NATL ACAD SCI USA, V97, P14376, DOI 10.1073/pnas.97.26.14376; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Wyllie AH, 1999, BRIT J CANCER, V80, P34	12	156	166	0	9	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 23	2001	322	7301					1536	1538		10.1136/bmj.322.7301.1536	http://dx.doi.org/10.1136/bmj.322.7301.1536			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	446UF	11420279	Green Published			2022-12-28	WOS:000169532000023
J	Staskawicz, BJ; Mudgett, MB; Dangl, JL; Galan, JE				Staskawicz, BJ; Mudgett, MB; Dangl, JL; Galan, JE			Common and contrasting themes of plant and animal diseases	SCIENCE			English	Review							PROTEIN-TYROSINE-PHOSPHATASE; RESISTANCE GENE-PRODUCT; HRP SECRETION PATHWAY; PSEUDOMONAS-SYRINGAE; III SECRETION; AVR PROTEINS; VIRULENCE; PATHOGENICITY; RECEPTOR; BACTERIA	Recent studies in bacterial pathogenesis reveal common and contrasting mechanisms of pathogen virulence and host resistance in plant and animal diseases, This review presents recent developments in the study of plant and animal pathogenesis, with respect to bacterial colonization and the delivery of effector proteins to the host. Furthermore, host defense responses in both plants and animals are discussed in relation to mechanisms of pathogen recognition and defense signaling. Future studies will greatly add to our understanding of the molecular events defining host-pathogen interactions.	Univ Calif Berkeley, Dept Plant & Microbial Biol, Berkeley, CA 94720 USA; Univ N Carolina, Dept Biol, Chapel Hill, NC 27599 USA; Univ N Carolina, Curriculum Genet & Mol Biol, Chapel Hill, NC 27599 USA; Yale Univ, Sch Med, Boyer Ctr Mol Med, New Haven, CT 06536 USA	University of California System; University of California Berkeley; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Yale University	Staskawicz, BJ (corresponding author), Univ Calif Berkeley, Dept Plant & Microbial Biol, Berkeley, CA 94720 USA.	stask@nature.berkeley.edu						Aderem A, 2000, NATURE, V406, P782, DOI 10.1038/35021228; Alfano JR, 1997, J BACTERIOL, V179, P5655, DOI 10.1128/jb.179.18.5655-5662.1997; Anderson DM, 1999, P NATL ACAD SCI USA, V96, P12839, DOI 10.1073/pnas.96.22.12839; Anderson KV, 2000, CURR OPIN IMMUNOL, V12, P13, DOI 10.1016/S0952-7915(99)00045-X; Boyes DC, 1998, P NATL ACAD SCI USA, V95, P15849, DOI 10.1073/pnas.95.26.15849; Burril TJ, 1878, T ILL STATE HORTIC S, V11, P79; Chen ZY, 2000, MOL PLANT MICROBE IN, V13, P1312, DOI 10.1094/MPMI.2000.13.12.1312; Cornelis GR, 2000, ANNU REV MICROBIOL, V54, P735, DOI 10.1146/annurev.micro.54.1.735; Ellis J, 2000, CURR OPIN PLANT BIOL, V3, P278, DOI 10.1016/S1369-5266(00)00080-7; FENSELAU S, 1992, MOL PLANT MICROBE IN, V5, P390, DOI 10.1094/MPMI-5-390; FLOR HH, 1955, PHYTOPATHOLOGY, V45, P680; Fu YX, 1999, NATURE, V401, P293, DOI 10.1038/45829; Galan JE, 1999, SCIENCE, V284, P1322, DOI 10.1126/science.284.5418.1322; GALYOV EE, 1993, NATURE, V361, P730, DOI 10.1038/361730a0; Gassmann W, 2000, J BACTERIOL, V182, P7053, DOI 10.1128/JB.182.24.7053-7059.2000; Gaudriault S, 1997, MOL MICROBIOL, V26, P1057, DOI 10.1046/j.1365-2958.1997.6442015.x; GINOCCHIO CC, 1994, CELL, V76, P717, DOI 10.1016/0092-8674(94)90510-X; Gomez-Gomez L, 2000, MOL CELL, V5, P1003, DOI 10.1016/S1097-2765(00)80265-8; Guttman DS, 2001, MOL PLANT MICROBE IN, V14, P145, DOI 10.1094/MPMI.2001.14.2.145; He SY, 1998, ANNU REV PHYTOPATHOL, V36, P363, DOI 10.1146/annurev.phyto.36.1.363; Hedlund M, 2001, J INFECT DIS, V183, pS47, DOI 10.1086/318851; Hugot JP, 2001, NATURE, V411, P599, DOI 10.1038/35079107; Inohara N, 1999, J BIOL CHEM, V274, P14560, DOI 10.1074/jbc.274.21.14560; Kaniga K, 1996, MOL MICROBIOL, V21, P633, DOI 10.1111/j.1365-2958.1996.tb02571.x; Kawchuk LM, 2001, P NATL ACAD SCI USA, V98, P6511, DOI 10.1073/pnas.091114198; Kenny B, 1997, CELL, V91, P511, DOI 10.1016/S0092-8674(00)80437-7; Kjemtrup S, 2000, CURR OPIN MICROBIOL, V3, P73, DOI 10.1016/S1369-5274(99)00054-5; Knutton S, 1998, EMBO J, V17, P2166, DOI 10.1093/emboj/17.8.2166; Koch R, 1876, BEITR BIOL PFLANZ, V2, P277; Kubori T, 1998, SCIENCE, V280, P602, DOI 10.1126/science.280.5363.602; Leister RT, 2000, PLANT J, V22, P345, DOI 10.1046/j.1365-313x.2000.00744.x; Medzhitov R, 2000, TRENDS MICROBIOL, V8, P452, DOI 10.1016/S0966-842X(00)01845-X; Meyers BC, 1999, PLANT J, V20, P317, DOI 10.1046/j.1365-313X.1999.t01-1-00606.x; Miao EA, 1999, MOL MICROBIOL, V34, P850, DOI 10.1046/j.1365-2958.1999.01651.x; Mudgett MB, 2000, P NATL ACAD SCI USA, V97, P13324, DOI 10.1073/pnas.230450797; Ogura Y, 2001, NATURE, V411, P603, DOI 10.1038/35079114; Orth K, 2000, SCIENCE, V290, P1594, DOI 10.1126/science.290.5496.1594; Plotnikova JM, 2000, PLANT PHYSIOL, V124, P1766, DOI 10.1104/pp.124.4.1766; Rossier O, 1999, P NATL ACAD SCI USA, V96, P9368, DOI 10.1073/pnas.96.16.9368; Sauer FG, 2000, CURR OPIN MICROBIOL, V3, P65, DOI 10.1016/S1369-5274(99)00053-3; Soto GE, 1999, J BACTERIOL, V181, P1059, DOI 10.1128/JB.181.4.1059-1071.1999; STASKAWICZ BJ, 1995, SCIENCE, V268, P661, DOI 10.1126/science.7732374; Stebbins CE, 2000, MOL CELL, V6, P1449, DOI 10.1016/S1097-2765(00)00141-6; STUCKEY JA, 1994, NATURE, V370, P571, DOI 10.1038/370571a0; Van Gijsegem F, 2000, MOL MICROBIOL, V36, P249, DOI 10.1046/j.1365-2958.2000.01851.x; Van Gijsegem F, 1993, Trends Microbiol, V1, P175, DOI 10.1016/0966-842X(93)90087-8; Wattiau P, 1996, MOL MICROBIOL, V20, P255, DOI 10.1111/j.1365-2958.1996.tb02614.x; Wei WS, 2000, P NATL ACAD SCI USA, V97, P2247, DOI 10.1073/pnas.040570097; White FF, 2000, CURR OPIN PLANT BIOL, V3, P291, DOI 10.1016/S1369-5266(00)00082-0	49	266	285	2	37	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 22	2001	292	5525					2285	2289		10.1126/science.1062013	http://dx.doi.org/10.1126/science.1062013			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	445KD	11423652				2022-12-28	WOS:000169455900045
J	Aussillous, P; Quere, D				Aussillous, P; Quere, D			Liquid marbles	NATURE			English	Article							DROPS; SURFACES; SPACE	The transport of a small amount of liquid on a solid is not a simple process, owing to the nature of the contact between the two phases. Setting a liquid droplet in motion requires non-negligible forces (because the contact-angle hysteresis generates a force opposing the motion(1)), and often results in the deposition of liquid behind the drop. Different methods of levitation-electrostatic, electromagnetic, acoustic(2), or even simpler aerodynamic(2,3) techniques-have been proposed to avoid this wetting problem, but all have proved to be rather cumbersome. Here we propose a simple alternative, which consists of encapsulating an aqueous liquid droplet with a hydrophobic powder. The resulting 'liquid marbles' are found to behave like a soft solid, and show dramatically reduced adhesion to a solid surface. As a result, motion can be generated using gravitational, electrical and magnetic fields. Moreover, because the viscous friction associated with motion is very small(4), we can achieve quick displacements of the droplets without any leaks. All of these features are of potential benefit in microfluidic applications, and also permit the study of a drop in a non-wetting situation-an issue of renewed interest following the recent achievement of super-hydrophobic substrates(5).	Coll France, CNRS, URA 792, Phys Mat Condensee Lab, F-75231 Paris 05, France	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; College de France	Quere, D (corresponding author), Coll France, CNRS, URA 792, Phys Mat Condensee Lab, F-75231 Paris 05, France.							BROWN RA, 1980, P ROY SOC LOND A MAT, V371, P351; BRWON RA, 1980, PHYS REV LETT, V45, P180; CHANDRAS.S, 1965, PROC R SOC LON SER-A, V286, P1, DOI 10.1098/rspa.1965.0127; DUSSAN EB, 1983, J FLUID MECH, V137, P1, DOI 10.1017/S002211208300227X; FROHN A, 2000, DYNAMICS DROPLETS; Lee CP, 1998, J FLUID MECH, V354, P43, DOI 10.1017/S0022112097007544; Mahadevan L, 1999, PHYS FLUIDS, V11, P2449, DOI 10.1063/1.870107; Onda T, 1996, LANGMUIR, V12, P2125, DOI 10.1021/la950418o; Perez M, 1999, EUROPHYS LETT, V47, P189, DOI 10.1209/epl/i1999-00371-6; Plateau J. A. F., 1863, ANN REPORT BOARD REG, p[1863, 207]; RAYLEIGH, 1914, PHILOS MAG, V28, P161; Richard D, 1999, EUROPHYS LETT, V48, P286, DOI 10.1209/epl/i1999-00479-1; TAYLOR GI, 1973, J FLUID MECH, V58, P625, DOI 10.1017/S0022112073002375; WANG TG, 1994, J FLUID MECH, V276, P389, DOI 10.1017/S0022112094002612	14	868	893	20	521	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 21	2001	411	6840					924	927		10.1038/35082026	http://dx.doi.org/10.1038/35082026			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	444EN	11418851				2022-12-28	WOS:000169386200037
J	Hall, CB				Hall, CB			Medical progress - Respiratory syncytial virus and parainfluenza virus.	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							TRACT INFECTION; YOUNG-CHILDREN; VIRAL-INFECTIONS; CLINICAL CHARACTERISTICS; IMMUNOGLOBULIN TREATMENT; TRANSPLANT PATIENTS; VACCINE DEVELOPMENT; PEDIATRIC-PATIENTS; CYSTIC-FIBROSIS; NURSING-HOME		Univ Rochester, Sch Med & Dent, Rochester, NY 14642 USA	University of Rochester	Hall, CB (corresponding author), Univ Rochester, Sch Med & Dent, Rochester, NY 14642 USA.							Adams RH, 1999, BONE MARROW TRANSPL, V24, P661, DOI 10.1038/sj.bmt.1701959; ANDERSON LJ, 1995, J INFECT DIS, V171, P1, DOI 10.1093/infdis/171.1.1; Armstrong D, 1998, PEDIATR PULM, V26, P371, DOI 10.1002/(SICI)1099-0496(199812)26:6<371::AID-PPUL1>3.3.CO;2-E; Arnold SR, 1999, PEDIATR INFECT DIS J, V18, P866, DOI 10.1097/00006454-199910000-00006; Ball TM, 2000, NEW ENGL J MED, V343, P538, DOI 10.1056/NEJM200008243430803; BRADY MT, 1990, AM J INFECT CONTROL, V18, P18, DOI 10.1016/0196-6553(90)90206-8; Bukreyev A, 1999, P NATL ACAD SCI USA, V96, P2367, DOI 10.1073/pnas.96.5.2367; CHANOCK R, 1957, AM J HYG, V66, P281, DOI 10.1093/oxfordjournals.aje.a119901; CHANOCK RM, 1992, PEDIATRICS, V90, P137; CHIN J, 1969, AM J EPIDEMIOL, V89, P449, DOI 10.1093/oxfordjournals.aje.a120957; Collins P., 1996, FIELDS VIROLOGY, V1, P1313; COLLINS PL, 1995, P NATL ACAD SCI USA, V92, P11563, DOI 10.1073/pnas.92.25.11563; Collins PL, 1996, FIELDS VIROLOGY, V1, P1205; CRAIN EF, 1994, PEDIATRICS, V94, P356; CROWE JE, 1995, VACCINE, V13, P847, DOI 10.1016/0264-410X(94)00074-W; DeVincenzo JP, 2000, BONE MARROW TRANSPL, V25, P161, DOI 10.1038/sj.bmt.1702118; Dowell SF, 1996, J INFECT DIS, V174, P456, DOI 10.1093/infdis/174.3.456; Dudas RA, 1998, CLIN MICROBIOL REV, V11, P430, DOI 10.1128/CMR.11.3.430; Englund J, 1998, VACCINE, V16, P1456, DOI 10.1016/S0264-410X(98)00108-X; Englund Janet A., 1997, American Journal of Medicine, V102, P61, DOI 10.1016/S0002-9343(97)00014-4; Falsey AR, 1998, J INFECT DIS, V177, P463, DOI 10.1086/517376; Falsey AR, 1996, J AM GERIATR SOC, V44, P71, DOI 10.1111/j.1532-5415.1996.tb05641.x; FALSEY AR, 1995, J AM GERIATR SOC, V43, P30, DOI 10.1111/j.1532-5415.1995.tb06238.x; FALSEY AR, 1995, J INFECT DIS, V172, P389, DOI 10.1093/infdis/172.2.389; Fan J, 1998, CLIN INFECT DIS, V26, P1397, DOI 10.1086/516357; FULGINITI VA, 1969, AM J EPIDEMIOL, V89, P435, DOI 10.1093/oxfordjournals.aje.a120956; Glezen WP, 2000, JAMA-J AM MED ASSOC, V283, P499, DOI 10.1001/jama.283.4.499; GLEZEN WP, 1984, J INFECT DIS, V150, P851, DOI 10.1093/infdis/150.6.851; GLEZEN WP, 1986, AM J DIS CHILD, V140, P543, DOI 10.1001/archpedi.1986.02140200053026; GLEZEN WP, 1990, PEDIATR ANN, V19, P535, DOI 10.3928/0090-4481-19900901-09; GRAHAM BS, 1995, AM J RESP CRIT CARE, V152, pS63, DOI 10.1164/ajrccm/152.4_Pt_2.S63; HALL CB, 1981, INFECT IMMUN, V33, P779, DOI 10.1128/IAI.33.3.779-783.1981; HALL CB, 1980, J INFECT DIS, V141, P98, DOI 10.1093/infdis/141.1.98; HALL CB, 1976, NEW ENGL J MED, V294, P414, DOI 10.1056/NEJM197602192940803; HALL CB, 1990, J INFECT DIS, V162, P1283, DOI 10.1093/infdis/162.6.1283; HALL CB, 1986, NEW ENGL J MED, V315, P77, DOI 10.1056/NEJM198607103150201; HALL CB, 1991, J INFECT DIS, V163, P693, DOI 10.1093/infdis/163.4.693; HALL CB, 1981, J PEDIATR-US, V99, P100, DOI 10.1016/S0022-3476(81)80969-9; HALL CB, 2000, MANDELL DOUGLAS BENN, V2, P1782; HALL WJ, 1978, ANN INTERN MED, V88, P203, DOI 10.7326/0003-4819-88-2-203; Halsey NA, 1998, PEDIATRICS, V102, P1211, DOI 10.1542/peds.102.5.1211; HEMMING VG, 1987, ANTIMICROB AGENTS CH, V31, P1882, DOI 10.1128/AAC.31.12.1882; HENDERSON FW, 1982, NEW ENGL J MED, V306, P1377, DOI 10.1056/NEJM198206103062301; HENDERSON FW, 1979, NEW ENGL J MED, V300, P530, DOI 10.1056/NEJM197903083001004; HENRICKSON KJ, 1994, CLIN INFECT DIS, V18, P770, DOI 10.1093/clinids/18.5.770; HENRICKSON KJ, 1992, J INFECT DIS, V166, P995, DOI 10.1093/infdis/166.5.995; HETHERINGTON SV, 1994, J INFECT DIS, V169, P248, DOI 10.1093/infdis/169.2.248; Hiatt PW, 1999, PEDIATRICS, V103, P619, DOI 10.1542/peds.103.3.619; *I MED, 1986, NEW VACC DEV EST PRI, V2, P299; JOHNSTON SL, 1995, BRIT MED J, V310, P1225, DOI 10.1136/bmj.310.6989.1225; Kaiser L, 1999, ANTIVIR RES, V42, P149, DOI 10.1016/S0166-3542(99)00034-0; KAPIKIAN AZ, 1969, AM J EPIDEMIOL, V89, P405, DOI 10.1093/oxfordjournals.aje.a120954; KARRON R, 1999, RSV 43 YEARS S STUAR; Karron RA, 1997, J INFECT DIS, V176, P1428, DOI 10.1086/514138; Karron RA, 1996, PEDIATR INFECT DIS J, V15, P650, DOI 10.1097/00006454-199608000-00003; Kattan M, 1999, J PEDIATR-US, V135, pS8; KELLOGG JA, 1991, ARCH PATHOL LAB MED, V115, P451; KIM HW, 1976, PEDIATR RES, V10, P75, DOI 10.1203/00006450-197601000-00015; KIM HW, 1969, AM J EPIDEMIOL, V89, P422, DOI 10.1093/oxfordjournals.aje.a120955; King James C. Jr., 1997, American Journal of Medicine, V102, P19, DOI 10.1016/S0002-9343(97)80005-8; KNOTT AM, 1994, PEDIATR INFECT DIS J, V13, P269, DOI 10.1097/00006454-199404000-00005; Krilov LR, 2000, J INFECT DIS, V181, P349, DOI 10.1086/315203; LaMontagne JR, 1997, LANCET, V349, P149, DOI 10.1016/S0140-6736(05)60974-9; Langley JM, 1997, J PEDIATR-US, V131, P113, DOI 10.1016/S0022-3476(97)70133-1; Larsen GL, 1999, J PEDIATR-US, V135, pS21; Lewis VA, 1996, CLIN INFECT DIS, V23, P1033, DOI 10.1093/clinids/23.5.1033; Lindquist SW, 1997, PEDIATR INFECT DIS J, V16, P34, DOI 10.1097/00006454-199701000-00008; MACDONALD NE, 1986, J PEDIATR-US, V108, P378, DOI 10.1016/S0022-3476(86)80876-9; MARTINEZ FD, 1995, NEW ENGL J MED, V332, P133, DOI 10.1056/NEJM199501193320301; Marx A, 1997, J INFECT DIS, V176, P1423, DOI 10.1086/514137; Marx A, 1999, CLIN INFECT DIS, V29, P134, DOI 10.1086/520142; Mazzulli T, 1999, J INFECT DIS, V180, P1686, DOI 10.1086/315085; MORRIS JA, 1956, P SOC EXP BIOL MED, V92, P544, DOI 10.3181/00379727-92-22538; MURPHY BR, 1986, J CLIN MICROBIOL, V24, P197, DOI 10.1128/JCM.24.2.197-202.1986; Murphy BR, 1997, B WORLD HEALTH ORGAN, V75, P307; NICHOLSON KG, 1993, BRIT MED J, V307, P982, DOI 10.1136/bmj.307.6910.982; Nicholson KG, 1996, EPIDEMIOL INFECT, V116, P51, DOI 10.1017/S0950268800058957; Nicholson KG, 1997, BRIT MED J, V315, P1060, DOI 10.1136/bmj.315.7115.1060; Ontoso IA, 1999, MED CLIN-BARCELONA, V112, P171; Openshaw PJM, 1999, J ROY SOC MED, V92, P495, DOI 10.1177/014107689909201001; OSTERWEIL D, 1990, J AM GERIATR SOC, V38, P659, DOI 10.1111/j.1532-5415.1990.tb01425.x; PARADISO PR, 1994, PEDIATR INFECT DIS J, V13, P792, DOI 10.1097/00006454-199409000-00008; Peret TCT, 1998, J GEN VIROL, V79, P2221, DOI 10.1099/0022-1317-79-9-2221; PRINCE GA, 1985, VIRUS RES, V3, P193, DOI 10.1016/0168-1702(85)90045-0; Reed G, 1997, J INFECT DIS, V175, P807, DOI 10.1086/513975; Rimensberger PC, 1996, PEDIATR INFECT DIS J, V15, P209, DOI 10.1097/00006454-199603000-00007; Rodriguez WJ, 1997, PEDIATRICS, V100, P937, DOI 10.1542/peds.100.6.937; SABLE CA, 1995, INFECT DIS CLIN N AM, V9, P987; Shay DK, 1999, JAMA-J AM MED ASSOC, V282, P1440, DOI 10.1001/jama.282.15.1440; SORVILLO FJ, 1984, J INFECTION, V9, P252, DOI 10.1016/S0163-4453(84)90530-9; Teichtahl H, 1997, CHEST, V112, P591, DOI 10.1378/chest.112.3.591; Walsh EE, 1999, AM J RESP CRIT CARE, V160, P791, DOI 10.1164/ajrccm.160.3.9901004; Welliver RC, 1999, J PEDIATR-US, V135, pS14; Wendt C H, 1995, Semin Respir Infect, V10, P224; Whimbey E, 2000, CURR CLIN TOPICS INF, V20, P232; Wright Peter F., 1998, Pediatric Research, V43, p161A; Yao QZ, 1996, VIROLOGY, V223, P103, DOI 10.1006/viro.1996.0459; 1997, MMWR MORB MORTAL WKL, V46, P1163	99	782	829	1	61	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 21	2001	344	25					1917	1928		10.1056/NEJM200106213442507	http://dx.doi.org/10.1056/NEJM200106213442507			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	443VJ	11419430				2022-12-28	WOS:000169362100007
J	Stanhope, MJ; Lupas, A; Italia, MJ; Koretke, KK; Volker, C; Brown, JR				Stanhope, MJ; Lupas, A; Italia, MJ; Koretke, KK; Volker, C; Brown, JR			Phylogenetic analyses do not support horizontal gene transfers from bacteria to vertebrates	NATURE			English	Article							MONOAMINE-OXIDASE; GENOME SEQUENCE; BEHAVIOR; ARCHAEA	Horizontal gene transfer (HGT) has long been recognized as a principal force in the evolution of genomes(1). Genome sequences of Archaea and Bacteria have revealed the existence of genes whose similarity to loci in distantly related organisms is explained most parsimoniously by HGT events(2-4). In most multicellular organisms, such genetic fixation can occur only in the germ line. Therefore, it is notable that the publication of the human genome reports 113 incidents of direct HGT between bacteria and vertebrates(5), without any apparent occurrence in evolutionary intermediates, that is, non-vertebrate eukaryotes. Phylogenetic analysis arguably provides the most objective approach for determining the occurrence and directionality of HGT(6,7). Here we report a phylogenetic analysis of 28 proposed HGT genes, whose presence in the human genome had been confirmed by polymerase chain reaction (PCR)(5). The results indicate that most putative HGT genes are present in more anciently derived eukaryotes (many such sequences available in non-vertebrate EST databases) and can be explained in terms of descent through common ancestry. They are, therefore, unlikely to be examples of direct HGT from bacteria to vertebrates.	GlaxoSmithKline Inc, Bioinformat, Collegeville, PA 19426 USA	GlaxoSmithKline	Stanhope, MJ (corresponding author), GlaxoSmithKline Inc, Bioinformat, 1250 S Collegeville Rd,UP1345, Collegeville, PA 19426 USA.	Michael_J_Stanhope@sbphrd.com; James_R_Brown@sbphrd.com		Italia, Michael/0000-0002-6941-6181				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Brown JR, 1997, MICROBIOL MOL BIOL R, V61, P456, DOI 10.1128/.61.4.456-502.1997; BRUNNER HG, 1993, SCIENCE, V262, P578, DOI 10.1126/science.8211186; CASES O, 1995, SCIENCE, V268, P1763, DOI 10.1126/science.7792602; Deckert J, 1999, HUM MOL GENET, V8, P621, DOI 10.1093/hmg/8.4.621; Doolittle WF, 1999, SCIENCE, V284, P2124, DOI 10.1126/science.284.5423.2124; Eisen JA, 1998, GENOME RES, V8, P163, DOI 10.1101/gr.8.3.163; FELSENSTEIN J, 2000, PHYLIP PHYLOGENY INT; GRAY MW, 1992, INT REV CYTOL, V141, P233, DOI 10.1016/S0074-7696(08)62068-9; Kyrpides NC, 1999, TRENDS GENET, V15, P298, DOI 10.1016/S0168-9525(99)01811-9; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Logsdon JM, 1999, CURR BIOL, V9, pR747, DOI 10.1016/S0960-9822(99)80474-6; Nelson KE, 1999, NATURE, V399, P323, DOI 10.1038/20601; Ruepp A, 2000, NATURE, V407, P508, DOI 10.1038/35035069; SMITH MW, 1992, TRENDS BIOCHEM SCI, V17, P489, DOI 10.1016/0968-0004(92)90335-7; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673	16	157	164	0	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 21	2001	411	6840					940	944		10.1038/35082058	http://dx.doi.org/10.1038/35082058			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	444EN	11418856				2022-12-28	WOS:000169386200042
J	Lamont, EB; Christakis, NA				Lamont, EB; Christakis, NA			Prognostic disclosure to patients with cancer near the end of life	ANNALS OF INTERNAL MEDICINE			English	Article							INFORMATION NEEDS; ODDS RATIOS; SURVIVAL; PREFERENCES; PREDICTIONS; ATTITUDES; SUPPORT	Background: Patients' understanding of their prognosis informs numerous medical and nonmedical decisions, but patients with cancer and their physicians often have disparate prognostic expectations. Objective: To determine whether physician behavior might contribute to the disparity between patients' and physicians' prognostic expectations. Design: Prospective cohort study. Setting: Five hospices in Chicago, Illinois. Patients: 326 patients with cancer. Intervention: Physicians formulated survival estimates and also indicated the survival estimates that they would communicate to their patients if the patients insisted. Measurements: Comparison of the formulated and communicated prognoses. Results: For 300 of 311 evaluable patients (96.5%), physicians were able to formulate prognoses. Physicians reported that they would not communicate any survival estimate 22.7% (95% CI, 17.9% to 27.4%) of the time, would communicate the same survival estimate they formulated 37% (CI, 31.5% to 42.5%) of the time, and would communicate a survival estimate different from the one they formulated 40.3% (CI, 34.8% to 45.9%) of the time. Of the discrepant survival estimates, most (70.2%) were optimistically discrepant. Multivariate analysis revealed that older patients were more likely to receive frank survival estimates, that the most experienced physicians and the physicians who were least confident about their prognoses were more likely to favor no disclosure over frank disclosure, and that female physicians were less likely to favor frank disclosure over pessimistically discrepant disclosure. Conclusions: Physicians reported that even if patients with cancer requested survival estimates, they would provide a frank estimate only 37% of the time and would provide no estimate, a conscious overestimate, or a conscious underestimate most of the time (63%). This pattern may contribute to the observed disparities between physicians' and patients' estimates of survival.	Univ Chicago, Med Ctr, Chicago, IL 60637 USA	University of Chicago; University of Chicago Medical Center	Christakis, NA (corresponding author), Univ Chicago, Med Ctr, 5841 S Maryland Ave,MC 2007, Chicago, IL 60637 USA.	nchrista@medicine.bsd.uchicago.edu	Christakis, Nicholas A/C-3205-2009; Christakis, Nicholas A/B-6690-2008	Lamont, Elizabeth/0000-0001-6604-678X	NIA NIH HHS [K12 AG-0048-09] Funding Source: Medline	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AGRESTI A, 1990, CATEGORICAL DATA ANA, P125; Altman DG, 1998, BRIT MED J, V317, P1318, DOI 10.1136/bmj.317.7168.1318; [Anonymous], 1999, DEATH FORETOLD PROPH; Asch DA, 1997, J CLIN EPIDEMIOL, V50, P1129, DOI 10.1016/S0895-4356(97)00126-1; BILLINGS JA, 1985, OUTPATIENT MANAGEMEN; BLANCHARD CG, 1988, SOC SCI MED, V27, P1139, DOI 10.1016/0277-9536(88)90343-7; Buckman R., 1992, BREAK BAD NEWS GUIDE; Christakis NA, 1996, NEW ENGL J MED, V335, P172, DOI 10.1056/NEJM199607183350306; Christakis NA, 1998, ARCH INTERN MED, V158, P2389, DOI 10.1001/archinte.158.21.2389; Christakis NA, 2000, MED CARE, V38, P528, DOI 10.1097/00005650-200005000-00009; Christakis NA, 2000, BRIT MED J, V320, P469, DOI 10.1136/bmj.320.7233.469; CONNORS AF, 1992, MED DECIS MAKING, V12, P336; Davies HTO, 1998, BRIT MED J, V316, P989, DOI 10.1136/bmj.316.7136.989; Davison B J, 1995, Oncol Nurs Forum, V22, P1401; Degner LF, 1997, JAMA-J AM MED ASSOC, V277, P1485, DOI 10.1001/jama.277.18.1485; EIDINGER RN, 1984, CANCER, V53, P2736, DOI 10.1002/1097-0142(19840615)53:12<2736::AID-CNCR2820531233>3.0.CO;2-W; EVANS C, 1985, LANCET, V1, P1204; FIREBAUGH G, 1985, AM SOCIOL REV, V50, P713, DOI 10.2307/2095384; FITTS WT, 1953, JAMA-J AM MED ASSOC, V153, P901, DOI 10.1001/jama.1953.02940270007002; FORSTER LE, 1988, ARCH INTERN MED, V148, P2540, DOI 10.1001/archinte.148.12.2540; FRANKL D, 1989, AM J MED, V86, P645, DOI 10.1016/0002-9343(89)90436-1; Hobcraft J., 1985, COHORT ANAL SOCIAL R, P89; KNAUS WA, 1995, ANN INTERN MED, V122, P191, DOI 10.7326/0003-4819-122-3-199502010-00007; Kutner JS, 1999, SOC SCI MED, V48, P1341, DOI 10.1016/S0277-9536(98)00453-5; MACKILLOP WJ, 1988, BRIT J CANCER, V58, P355, DOI 10.1038/bjc.1988.218; MCCULLAGH P, 1999, GEN LINEAR MODELS, P125; MURPHY DJ, 1994, NEW ENGL J MED, V330, P545, DOI 10.1056/NEJM199402243300807; NOVACK DH, 1979, JAMA-J AM MED ASSOC, V241, P897, DOI 10.1001/jama.241.9.897; OKEN D, 1961, JAMA-J AM MED ASSOC, V175, P1120, DOI 10.1001/jama.1961.03040130004002; PARKES CM, 1972, BRIT MED J, V2, P29, DOI 10.1136/bmj.2.5804.29; POSES RM, 1990, ARCH INTERN MED, V150, P1874, DOI 10.1001/archinte.150.9.1874; STEIHAUSER KE, 2000, ANN INTERN MED, V132, P5825; Steinhauser AE, 2000, JAMA-J AM MED ASSOC, V284, P2476, DOI 10.1001/jama.284.19.2476; Weeks JC, 1998, JAMA-J AM MED ASSOC, V279, P1709, DOI 10.1001/jama.279.21.1709; Zhang J, 1998, JAMA-J AM MED ASSOC, V280, P1690, DOI 10.1001/jama.280.19.1690; Zubrod C.G., 1960, J CHRON DIS, V11, P7	36	365	369	0	13	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 19	2001	134	12					1096	1105		10.7326/0003-4819-134-12-200106190-00009	http://dx.doi.org/10.7326/0003-4819-134-12-200106190-00009			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	442YU	11412049				2022-12-28	WOS:000169313200002
J	Yu, XZ; Carpenter, P; Anasetti, C				Yu, XZ; Carpenter, P; Anasetti, C			Advances in transplantation tolerance	LANCET			English	Article							RENAL-ALLOGRAFT REJECTION; VERSUS-HOST DISEASE; BONE-MARROW TRANSPLANTATION; T-CELL TOLERANCE; CD28-DEFICIENT MICE; CARDIAC ALLOGRAFTS; DONOR LEUKOCYTES; LYMPHOCYTES-T; CD40 LIGAND; IN-VIVO	Immunosuppressive drugs developed in the past two decades have improved the short-term survival of organ allografts, but tolerance has not been achieved and almost all transplant recipients continue to require drugs throughout life. Graft rejection arises from the cognate interaction of T cells with antigen-presenting cells, the recognition of alloantigen through the T-cell receptor, and the delivery of accessory stimulation signals. Once activated by the specific antigen, replicating T cells die if they are re-exposed to the same antigen. Since depletion of antigen-activated T cells is one critical mechanism of transplantation tolerance, drugs such as ciclosporin that Interfere with activation-induced T-cell death could inhibit tolerance, whereas drugs such as mycophenolate mofetil, that induce the death of activated T cells, could facilitate tolerance. Other tolerance mechanisms depend on inactivation rather than elimination of allograft reactive T cells. When antigen recognition occurs without costimulation through the CD28 and CD154 accessory receptors, or in absence of cell division, T cells became unresponsive. Thus, inhibitors of CD28 and CD154, and inhibition of T-cell division by rapamycin promotes transplantation tolerance.	Fred Hutchinson Canc Res Ctr, Human Immunogenet Program, Seattle, WA 98109 USA; Univ Washington, Dept Med, Seattle, WA 98195 USA	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle	Anasetti, C (corresponding author), Fred Hutchinson Canc Res Ctr, Human Immunogenet Program, Seattle, WA 98109 USA.	canasett@fhcrc.org		Yu, Xue-Zhong/0000-0002-1751-2884	NATIONAL CANCER INSTITUTE [P01CA018029, K01CA084132] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R21AI040680, P01AI033484, R01AI040680] Funding Source: NIH RePORTER; NCI NIH HHS [CA18029, CA84132] Funding Source: Medline; NIAID NIH HHS [AI33484, AI40680] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARUFFO A, 1993, CELL, V72, P291, DOI 10.1016/0092-8674(93)90668-G; Aversa F, 1998, NEW ENGL J MED, V339, P1186, DOI 10.1056/NEJM199810223391702; Behrend M, 1999, TRANSPLANTATION, V68, P391; Blazar BR, 1997, J IMMUNOL, V158, P29; BOISE LH, 1995, IMMUNITY, V3, P87, DOI 10.1016/1074-7613(95)90161-2; Boussiotis VA, 2000, NAT MED, V6, P290, DOI 10.1038/73144; Carpenter PA, 2000, J IMMUNOL, V165, P6205, DOI 10.4049/jimmunol.165.11.6205; Chapuis AG, 2000, NAT MED, V6, P762, DOI 10.1038/77489; Chen HF, 2000, TRANSPLANTATION, V69, P1555; Childs R, 2000, NEW ENGL J MED, V343, P750, DOI 10.1056/NEJM200009143431101; COBBOLD SP, 1986, NATURE, V323, P164, DOI 10.1038/323164a0; CRITCHFIELD JM, 1994, SCIENCE, V263, P1139, DOI 10.1126/science.7509084; GREWAL IS, 1995, NATURE, V378, P617, DOI 10.1038/378617a0; HARDING FA, 1992, NATURE, V356, P607, DOI 10.1038/356607a0; ILDSTAD ST, 1984, NATURE, V307, P168, DOI 10.1038/307168a0; Kahan BD, 2000, LANCET, V356, P194, DOI 10.1016/S0140-6736(00)02480-6; KAPPLER JW, 1987, CELL, V49, P273, DOI 10.1016/0092-8674(87)90568-X; Kirk AD, 1997, P NATL ACAD SCI USA, V94, P8789, DOI 10.1073/pnas.94.16.8789; Kirk AD, 1999, NAT MED, V5, P686, DOI 10.1038/9536; Larsen CP, 1996, NATURE, V381, P434, DOI 10.1038/381434a0; Lenardo M, 1999, ANNU REV IMMUNOL, V17, P221, DOI 10.1146/annurev.immunol.17.1.221; LENARDO MJ, 1991, NATURE, V353, P858, DOI 10.1038/353858a0; Lenschow DJ, 1996, ANNU REV IMMUNOL, V14, P233, DOI 10.1146/annurev.immunol.14.1.233; LENSCHOW DJ, 1992, SCIENCE, V257, P789, DOI 10.1126/science.1323143; Li YS, 1999, NAT MED, V5, P1298, DOI 10.1038/15256; Lin H, 1998, J EXP MED, V188, P199, DOI 10.1084/jem.188.1.199; Mayer AD, 1997, TRANSPLANTATION, V64, P436, DOI 10.1097/00007890-199708150-00012; MCSWEENEY PA, IN PRESS BLOOD; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; Perez VL, 1997, IMMUNITY, V6, P411, DOI 10.1016/S1074-7613(00)80284-8; Powell JD, 1999, J IMMUNOL, V162, P2775; Ridge JP, 1998, NATURE, V393, P474, DOI 10.1038/30989; RODT H, 1974, EUR J IMMUNOL, V4, P25, DOI 10.1002/eji.1830040107; Salgar SK, 1999, J LEUKOCYTE BIOL, V66, P310, DOI 10.1002/jlb.66.2.310; SCHWARTZ RH, 1990, SCIENCE, V248, P1349, DOI 10.1126/science.2113314; SHAHINIAN A, 1993, SCIENCE, V261, P609, DOI 10.1126/science.7688139; Shapiro AMJ, 2000, NEW ENGL J MED, V343, P230, DOI 10.1056/NEJM200007273430401; Shlomchik WD, 1999, SCIENCE, V285, P412, DOI 10.1126/science.285.5426.412; Simpson E, 1997, ANNU REV IMMUNOL, V15, P39, DOI 10.1146/annurev.immunol.15.1.39; Storb R, 1997, BLOOD, V89, P3048, DOI 10.1182/blood.V89.8.3048; Sykes M, 1999, LANCET, V353, P1755, DOI 10.1016/S0140-6736(98)11135-2; Takahashi T, 2000, J EXP MED, V192, P303, DOI 10.1084/jem.192.2.303; Takemoto SK, 2000, NEW ENGL J MED, V343, P1078, DOI 10.1056/NEJM200010123431504; TAN P, 1993, J EXP MED, V177, P165, DOI 10.1084/jem.177.1.165; Thomson AW, 1999, TRANSPLANTATION, V68, P1; Vincenti F, 1998, NEW ENGL J MED, V338, P161, DOI 10.1056/NEJM199801153380304; VONBOEHMER H, 1990, SCIENCE, V248, P1369, DOI 10.1126/science.1972594; WATERHOUSE P, 1995, SCIENCE, V270, P985, DOI 10.1126/science.270.5238.985; Wells AD, 1999, NAT MED, V5, P1303, DOI 10.1038/15260; Werkele T, 2000, NAT MED, V6, P464, DOI 10.1038/74731; WOOD AJ, 1982, LANCET, V2, P57; Yu XZ, 1998, BLOOD, V92, P2963, DOI 10.1182/blood.V92.8.2963.420k13_2963_2970; Yu XZ, 2000, J IMMUNOL, V164, P4564, DOI 10.4049/jimmunol.164.9.4564; YU XZ, IN PRESS J IMMUNOL	55	44	50	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 16	2001	357	9272					1959	1963		10.1016/S0140-6736(00)05068-6	http://dx.doi.org/10.1016/S0140-6736(00)05068-6			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	444YZ	11425437				2022-12-28	WOS:000169431000034
J	Gollob, MH; Green, MS; Tang, ASL; Gollob, T; Karibe, A; Roberts, R; Ahmad, F; Lozado, R; Shah, G; Fananapazir, L; Bachinski, LL; Roberts, R; Tapscott, T; Gonzales, O; Begley, D; Mohiddin, S				Gollob, MH; Green, MS; Tang, ASL; Gollob, T; Karibe, A; Roberts, R; Ahmad, F; Lozado, R; Shah, G; Fananapazir, L; Bachinski, LL; Roberts, R; Tapscott, T; Gonzales, O; Begley, D; Mohiddin, S			Identification of a gene responsible for familial Wolff-Parkinson-White syndrome	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	22nd Annual Meeting of the North-American-Society-of-Pacing-and-Electrophysiology	MAY 02-05, 2001	BOSTON, MA	N Amer Soc Pacing & Electrophysiol			ACTIVATED PROTEIN-KINASE; ATRIAL-FIBRILLATION; CARDIAC-ARREST; PATTERNS; SUBUNIT; YOUNG	Background The Wolff Parkinson White syndrome, with a prevalence in Western countries of 1.5 to 3.1 per 1000 persons, causes considerable morbidity and may cause sudden death. We identified two families in which the Wolff Parkinson White syndrome segregated as an autosomal dominant disorder. Methods We studied 70 members of the two families (57 in Family 1 and 13 in Family 2). The subjects underwent 12-lead electrocardiography and two-dimensional echocardiography. Genotyping mapped the gene responsible to 7q34-q36, a locus previously identified to be responsible for an inherited form of Wolff Parkinson White syndrome. Candidate genes were identified, sequenced, and analyzed in normal and affected family members to identify the disease-causing gene. Results A total of 31 members (23 from Family 1 and 8 from Family 2) had the Wolff Parkinson White syndrome. Affected members of both families had ventricular preexcitation with conduction abnormalities and cardiac hypertrophy. The maximal combined two-point lod score was 9.82 at a distance of 5 cM from marker D7S636, which confirmed the linkage of the gene in both families to 7q34-q36. Haplotype analysis indicated that there were no alleles in common in the two families at this locus, suggesting that the two families do not have a common founder. We identified a missense mutation in the gene that encodes the gamma2 regulatory subunit of AMP-activated protein kinase (PRKAG2). The mutation results in the substitution of glutamine for arginine at residue 302 in the protein. Conclusions The identification of this genetic defect has important implications for elucidating the pathogenesis of ventricular preexcitation. Further understanding of how this molecular defect leads to supraventricular arrhythmias could influence the development of specific therapies for other forms of supraventricular arrhythmia. (N Engl J Med 2001;344:1823-31.) Copyright (C) 2001 Massachusetts Medical Society.	Baylor Coll Med, Dept Med, Cardiol Sect, Houston, TX 77030 USA; Univ Ottawa, Inst Heart, Ottawa, ON, Canada; NHLBI, Inherited Heart Dis Sect, NIH, Bethesda, MD 20892 USA	Baylor College of Medicine; University of Ottawa; University of Ottawa Heart Institute; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	Roberts, R (corresponding author), Baylor Coll Med, Dept Med, Cardiol Sect, 6550 Fannin,MS SM 677, Houston, TX 77030 USA.	rroberts@bcm.tmc.edu	Tang, Anthony S/E-6203-2014	Ahmad, Ferhaan/0000-0003-2877-4641; Gollob, Michael/0000-0003-0242-5208	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [Z01HL005058] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Al-Khatib SM, 1999, AM HEART J, V138, P403, DOI 10.1016/S0002-8703(99)70140-7; Aliot E, 1998, EUR HEART J, V19, pE25; BAUERNFEIND RA, 1981, AM J CARDIOL, V47, P562, DOI 10.1016/0002-9149(81)90539-7; BENSON DW, 1983, AM J CARDIOL, V52, P65, DOI 10.1016/0002-9149(83)90070-X; CAMPBELL RWF, 1977, AM J CARDIOL, V40, P514, DOI 10.1016/0002-9149(77)90065-0; Cheung PCF, 2000, BIOCHEM J, V346, P659, DOI 10.1042/0264-6021:3460659; COOPER DN, 1990, HUM GENET, V85, P55; Crute BE, 1998, J BIOL CHEM, V273, P35347, DOI 10.1074/jbc.273.52.35347; Dunnigan A., 1986, CARDIAC PREEXCITATIO, P21; FURLANELLO F, 1992, PACE, V15, P1403; GUIZE L, 1985, ANN MED INTERNE, V136, P474; HEJTMANCIK MR, 1957, AM HEART J, V54, P708, DOI 10.1016/0002-8703(57)90425-8; JACKMAN WM, 1991, NEW ENGL J MED, V324, P1605, DOI 10.1056/NEJM199106063242301; Kastor J A, 1974, Cardiovasc Clin, V6, P111; KLEIN GJ, 1988, J AM COLL CARDIOL, V11, P1035, DOI 10.1016/S0735-1097(98)90063-8; Leclerc I, 1998, FEBS LETT, V431, P180, DOI 10.1016/S0014-5793(98)00745-5; MACRAE CA, 1995, J CLIN INVEST, V96, P1216, DOI 10.1172/JCI118154; Moule SK, 1998, FEBS LETT, V439, P287, DOI 10.1016/S0014-5793(98)01392-1; NEITZEL H, 1986, HUM GENET, V73, P320, DOI 10.1007/BF00279094; Ott J., 1991, ANAL HUMAN GENETIC L; PACKARD JM, 1954, CIRCULATION, V10, P384, DOI 10.1161/01.CIR.10.3.384; Rosenblum BB, 1997, NUCLEIC ACIDS RES, V25, P4500, DOI 10.1093/nar/25.22.4500; Thompson MW, 1991, THOMPSON THOMPSON GE; TOPAZ O, 1989, AM HEART J, V118, P281, DOI 10.1016/0002-8703(89)90186-5; WAN Q, 1992, CHINESE MED J-PEKING, V105, P284; Winder WW, 2000, J APPL PHYSIOL, V88, P2219, DOI 10.1152/jappl.2000.88.6.2219; Woods A, 1996, J BIOL CHEM, V271, P10282, DOI 10.1074/jbc.271.17.10282	27	425	451	0	11	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 14	2001	344	24					1823	1831		10.1056/NEJM200106143442403	http://dx.doi.org/10.1056/NEJM200106143442403			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	441LC	11407343	Bronze			2022-12-28	WOS:000169231000003
J	McKenna, TJ				McKenna, TJ			Graves' disease	LANCET			English	Editorial Material									St Vincents Univ Hosp, Dept Endocrinol & Diabet Mellitus, Dublin 4, Ireland; Royal Coll Phys Ireland, Univ Coll Dublin Registrar, Dublin, Ireland	University College Dublin; Saint Vincent's University Hospital	McKenna, TJ (corresponding author), St Vincents Univ Hosp, Dept Endocrinol & Diabet Mellitus, Dublin 4, Ireland.							Bartalena L, 1997, BAILLIERE CLIN ENDOC, V11, P521, DOI 10.1016/S0950-351X(97)80738-0; COAKLEY D, 1996, R GRAVES EVANGELIST, P9; Franklyn JA, 1997, BAILLIERE CLIN ENDOC, V11, P561, DOI 10.1016/S0950-351X(97)80783-5; Fukata S, 1999, THYROID, V9, P29, DOI 10.1089/thy.1999.9.29; Lazarus JH, 2000, CLIN ENDOCRINOL, V53, P265, DOI 10.1046/j.1365-2265.2000.01087.x; Levy EG, 1997, BAILLIERE CLIN ENDOC, V11, P585, DOI 10.1016/S0950-351X(97)80798-7; Ludgate M, 1998, THYROID, V8, P411, DOI 10.1089/thy.1998.8.411; Taylor S., 1989, R GRAVES GOLDEN YEAR, P1; Weetman AP, 2000, NEW ENGL J MED, V343, P1236, DOI 10.1056/NEJM200010263431707; Woeber KA, 1999, ANN INTERN MED, V131, P959, DOI 10.7326/0003-4819-131-12-199912210-00009	10	12	16	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 2	2001	357	9270					1793	1796		10.1016/S0140-6736(00)04906-0	http://dx.doi.org/10.1016/S0140-6736(00)04906-0			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	440BN	11403836				2022-12-28	WOS:000169156200036
J	Wittmann, CW; Wszolek, MF; Shulman, JM; Salvaterra, PM; Lewis, J; Hutton, M; Feany, MB				Wittmann, CW; Wszolek, MF; Shulman, JM; Salvaterra, PM; Lewis, J; Hutton, M; Feany, MB			Tauopathy in Drosophila: Neurodegeneration without neurofibrillary tangles	SCIENCE			English	Article							PAIRED HELICAL FILAMENTS; HUMAN TAU; ALZHEIMERS-DISEASE; BRAIN DEGENERATION; GENE-EXPRESSION; MUTANT; PHOSPHORYLATION; DEMENTIA; PROTEINS; NEURONS	The microtubule-binding protein tau has been implicated in the pathogenesis of Alzheimer's disease and related disorders. However, the mechanisms underlying tau-mediated neurotoxicity remain unclear. We created a genetic model of tau-related neurodegenerative disease by expressing wild-type and mutant forms of human tau in the fruit fly Drosophila melanogaster. Transgenic flies showed key features of the human disorders: adult onset, progressive neurodegeneration, early death, enhanced toxicity of mutant tau, accumulation of abnormal tau, and relative anatomic selectivity. However, neurodegeneration occurred without the neurofibrillary tangle formation that is seen in human disease and some rodent tauopathy models. This fly model may allow a genetic analysis of the cellular mechanisms underlying tau neurotoxicity.	Brigham & Womens Hosp, Dept Pathol, Div Neuropathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; City Hope Natl Med Ctr, Beckman Res Inst, Div Neurosci, Duarte, CA 91010 USA; Mayo Clin Jacksonville, Jacksonville, FL 32224 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; City of Hope; Beckman Research Institute of City of Hope; Mayo Clinic	Feany, MB (corresponding author), Brigham & Womens Hosp, Dept Pathol, Div Neuropathol, 221 Longwood Ave,Room 514, Boston, MA 02115 USA.			Feany, Mel/0000-0003-0315-7970				Bird TD, 1999, BRAIN, V122, P741, DOI 10.1093/brain/122.4.741; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; BRAND AH, 1993, DEVELOPMENT, V118, P401; Brion JP, 1999, AM J PATHOL, V154, P255, DOI 10.1016/S0002-9440(10)65272-8; BUCHANAN RL, 1993, NEURON, V10, P839, DOI 10.1016/0896-6273(93)90200-B; COOMBE PE, 1986, J NEUROGENET, V3, P135, DOI 10.3109/01677068609106845; Feany MB, 2000, J NEUROPATH EXP NEUR, V59, P847, DOI 10.1093/jnen/59.10.847; Feany MB, 2000, NATURE, V404, P394, DOI 10.1038/35006074; Feany MB, 1996, ANN NEUROL, V40, P139, DOI 10.1002/ana.410400204; Fernandez-Funez P, 2000, NATURE, V408, P101, DOI 10.1038/35040584; GEDDES JF, 1993, BRAIN, V116, P281, DOI 10.1093/brain/116.1.281; GOEDERT M, 1992, NEURON, V8, P159, DOI 10.1016/0896-6273(92)90117-V; GREENBERG SG, 1990, P NATL ACAD SCI USA, V87, P5827, DOI 10.1073/pnas.87.15.5827; Hall GF, 1997, P NATL ACAD SCI USA, V94, P4733, DOI 10.1073/pnas.94.9.4733; Hutton M, 2000, ANN NY ACAD SCI, V920, P63; Ishihara T, 1999, NEURON, V24, P751, DOI 10.1016/S0896-6273(00)81127-7; Ishihara T, 2001, AM J PATHOL, V158, P555, DOI 10.1016/S0002-9440(10)63997-1; Jicha GA, 1997, J NEUROSCI RES, V48, P128, DOI 10.1002/(SICI)1097-4547(19970415)48:2<128::AID-JNR5>3.0.CO;2-E; Jicha GA, 1999, J NEUROSCI RES, V55, P713, DOI 10.1002/(SICI)1097-4547(19990315)55:6<713::AID-JNR6>3.0.CO;2-G; Kretzschmar D, 1997, J NEUROSCI, V17, P7425; Lewis J, 2000, NAT GENET, V25, P402, DOI 10.1038/78078; Warrick JM, 1999, NAT GENET, V23, P425, DOI 10.1038/70532; Yasuyama K, 1999, MICROSC RES TECHNIQ, V45, P65, DOI 10.1002/(SICI)1097-0029(19990415)45:2<65::AID-JEMT2>3.0.CO;2-0; YEH E, 1995, P NATL ACAD SCI USA, V92, P7036, DOI 10.1073/pnas.92.15.7036; Zoghbi HY, 2000, ANNU REV NEUROSCI, V23, P217, DOI 10.1146/annurev.neuro.23.1.217	25	663	686	1	46	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 27	2001	293	5530					711	714		10.1126/science.1062382	http://dx.doi.org/10.1126/science.1062382			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	458PW	11408621				2022-12-28	WOS:000170204600059
J	Reick, M; Garcia, JA; Dudley, C; McKnight, SL				Reick, M; Garcia, JA; Dudley, C; McKnight, SL			NPAS2: An analog of clock operative in the mammalian forebrain	SCIENCE			English	Article							CIRCADIAN CLOCK; GENE-EXPRESSION; DOUBLE-TIME; PROTEIN; MPER1; RHYTHMICITY; ORTHOLOG; CLONING; LOOP	Neuronal PAS domain protein 2 (NPAS2) is a transcription factor expressed primarily in the mammalian forebrain. NPAS2 is highly related in primary amino acid sequence to Clock, a transcription factor expressed in the suprachiasmatic nucleus that heterodimerizes with BMAL1 and regulates circadian rhythm. To investigate the biological role of NPAS2, we prepared a neuroblastoma cell Line capable of conditional induction of the NPAS2:BMAL1 heterodimer and identified putative target genes by representational difference analysis, DNA microarrays, and Northern blotting. Coinduction of NPAS2 and BMAL1 activated transcription of the endogenous Per1, Per2, and Cry1 genes, which encode negatively activating components of the circadian regulatory apparatus, and repressed transcription of the endogenous BMAL1 gene. Analysis of the frontal cortex of wild-type mice kept in a 24-hour Light-dark cycle revealed that Per1, Per2, and Cry1 mRNA Levels were elevated during darkness and reduced during Light, whereas BMAL1 mRNA displayed the opposite pattern. In situ hybridization assays of mice kept in constant darkness revealed that Per2 mRNA abundance did not oscillate as a function of the circadian cycle in NPAS2-deficient mice. Thus, NPAS2 likely functions as part of a molecular clock operative in the mammalian forebrain.	Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr, Dept Internal Med, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	McKnight, SL (corresponding author), Univ Texas, SW Med Ctr, Dept Biochem, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	smckni@biochem.swmed.edu	Jansen, Heiko T./A-5770-2008	Jansen, Heiko T./0000-0003-0178-396X; Garcia, Joseph/0000-0002-5621-7538	NIMH NIH HHS [1RO1MH59388] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH059388] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Albrecht U, 1997, CELL, V91, P1055, DOI 10.1016/S0092-8674(00)80495-X; Bae K, 2001, NEURON, V30, P525, DOI 10.1016/S0896-6273(01)00302-6; Balsalobre A, 1998, CELL, V93, P929, DOI 10.1016/S0092-8674(00)81199-X; BIEDLER JL, 1988, ADV NEUROBLASTOMA RE, V2, P265; Bruick RK, 2000, P NATL ACAD SCI USA, V97, P9082, DOI 10.1073/pnas.97.16.9082; DECOURSEY PJ, 1989, BRAIN RES, V500, P263, DOI 10.1016/0006-8993(89)90322-3; DRUCKERCOLIN R, 1984, BRAIN RES, V311, P353, DOI 10.1016/0006-8993(84)90099-4; Dunlap JC, 1999, CELL, V96, P271, DOI 10.1016/S0092-8674(00)80566-8; Franklin K. B. J., 2008, PAXINOS FRANKLINS MO; Garcia JA, 2000, SCIENCE, V288, P2226, DOI 10.1126/science.288.5474.2226; Gekakis N, 1998, SCIENCE, V280, P1564, DOI 10.1126/science.280.5369.1564; Hogenesch JB, 1998, P NATL ACAD SCI USA, V95, P5474, DOI 10.1073/pnas.95.10.5474; Hughes TR, 2001, NAT BIOTECHNOL, V19, P342, DOI 10.1038/86730; Jin XW, 1999, CELL, V96, P57, DOI 10.1016/S0092-8674(00)80959-9; King DP, 1997, CELL, V89, P641, DOI 10.1016/S0092-8674(00)80245-7; Klein D.C., 1991, SUPRACHIASMATIC NUCL; Kloss B, 1998, CELL, V94, P97, DOI 10.1016/S0092-8674(00)81225-8; Kume K, 1999, CELL, V98, P193, DOI 10.1016/S0092-8674(00)81014-4; Lowrey PL, 2000, SCIENCE, V288, P483, DOI 10.1126/science.288.5465.483; No D, 1996, P NATL ACAD SCI USA, V93, P3346, DOI 10.1073/pnas.93.8.3346; Price JL, 1998, CELL, V94, P83, DOI 10.1016/S0092-8674(00)81224-6; REICK M, UNPUB; Sangoram AM, 1998, NEURON, V21, P1101, DOI 10.1016/S0896-6273(00)80627-3; Sun ZS, 1997, CELL, V90, P1003, DOI 10.1016/S0092-8674(00)80366-9; Thresher RJ, 1998, SCIENCE, V282, P1490, DOI 10.1126/science.282.5393.1490; Tosini G, 1996, SCIENCE, V272, P419, DOI 10.1126/science.272.5260.419; Vitaterna MH, 1999, P NATL ACAD SCI USA, V96, P12114, DOI 10.1073/pnas.96.21.12114; Zhou YD, 1997, P NATL ACAD SCI USA, V94, P713, DOI 10.1073/pnas.94.2.713; Zylka MJ, 1998, NEURON, V20, P1103, DOI 10.1016/S0896-6273(00)80492-4	29	435	452	0	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 20	2001	293	5529					506	509		10.1126/science.1060699	http://dx.doi.org/10.1126/science.1060699			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	454HG	11441147				2022-12-28	WOS:000169966700050
J	Padian, K				Padian, K			Owen's Parthian shot - Charles Darwin may have had the science, but Richard Owen could write a lethal letter.	NATURE			English	Editorial Material									Univ Calif Berkeley, Dept Integrat Biol, Berkeley, CA 94720 USA; Univ Calif Berkeley, Museum Paleontol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; University of California System; University of California Berkeley	Padian, K (corresponding author), Univ Calif Berkeley, Dept Integrat Biol, Berkeley, CA 94720 USA.							Burkhardt Richard W., 1977, SPIRIT SYSTEM LAMARC; DESMOND A, 1991, DARWIN; Hull David L., 1973, DARWIN HIS CRITICS; RUPKE N, 1995, R OWEN VICTORIAN NAT	4	0	0	0	3	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUL 12	2001	412	6843					123	124		10.1038/35084289	http://dx.doi.org/10.1038/35084289			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	451AJ	11449244				2022-12-28	WOS:000169778700024
J	Richter, JD; Theurkauf, WE				Richter, JD; Theurkauf, WE			Development - The message is in the translation	SCIENCE			English	Editorial Material							MESSENGER-RNA; NANOS; DROSOPHILA; PUMILIO; PHOSPHORYLATION; RECRUITMENT; INTERACTS; CPEB		Univ Massachusetts, Sch Med, Dept Mol Genet & Microbiol, Worcester, MA 01605 USA; Univ Massachusetts, Sch Med, Program Mol Med, Worcester, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester	Richter, JD (corresponding author), Univ Massachusetts, Sch Med, Dept Mol Genet & Microbiol, Worcester, MA 01605 USA.	joel.richter@umassmed.edu; william.theurkauf@umassmed.edu		Theurkauf, William/0000-0001-7342-1912				Asaoka-Taguchi M, 1999, NAT CELL BIOL, V1, P431, DOI 10.1038/15666; DALBY B, 1993, EMBO J, V12, P1219, DOI 10.1002/j.1460-2075.1993.tb05763.x; Groisman I, 2000, CELL, V103, P435, DOI 10.1016/S0092-8674(00)00135-5; King RW, 1996, SCIENCE, V274, P1652, DOI 10.1126/science.274.5293.1652; Mendez R, 2000, MOL CELL, V6, P1253, DOI 10.1016/S1097-2765(00)00121-0; Mendez R, 2000, NATURE, V404, P302, DOI 10.1038/35005126; Nakahata S, 2001, J BIOL CHEM, V276, P20945, DOI 10.1074/jbc.M010528200; RICHTER JD, 2000, TRANSLATIONAL CONTRO, pCH27; Sonoda J, 1999, GENE DEV, V13, P2704, DOI 10.1101/gad.13.20.2704; Sonoda J, 2001, GENE DEV, V15, P762, DOI 10.1101/gad.870801; Stebbins-Boaz B, 1999, MOL CELL, V4, P1017, DOI 10.1016/S1097-2765(00)80230-0; Wreden C, 1997, DEVELOPMENT, V124, P3015	12	31	32	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 6	2001	293	5527					60	62		10.1126/science.1062237	http://dx.doi.org/10.1126/science.1062237			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	451BB	11441171				2022-12-28	WOS:000169780300026
J	Sutcliffe, AG; Taylor, B; Saunders, K; Thornton, S; Lieberman, BA; Grudzinskas, JG				Sutcliffe, AG; Taylor, B; Saunders, K; Thornton, S; Lieberman, BA; Grudzinskas, JG			Outcome in the second year of life after in-vitro fertilisation by intracytoplasmic sperm injection: a UK case-control study	LANCET			English	Article							CHILDREN BORN; FOLLOW-UP; PREGNANCIES; DISEASES; RISK	Background There have been reports suggesting that children born after in-vitro fertilisation by intracytoplasmic sperm injection (ICSI) are at increased risk of neurodevelopmental delay. We have undertaken a case-control study of this issue. Methods We studied 208 singleton children conceived by ICSI and a control group of 221 normally conceived singleton children. Children were recruited from 22 fertility centres and local nurseries throughout the UK. Controls were selected to match cases as closely as possible for social class, maternal educational attainment, region, sex, and race. The primary outcome measure was neurodevelopmental scoring; secondary measures were perinatal outcomes, postnatal health, and congenital abnormalities. A single examiner assessed all the children. Findings A follow-up rate of 90% for the ICSI group was achieved at a mean age of 17 months. No difference between the study children and controls was found in mean neurodevelopmental scores (98.08 [SD 10.93] vs 98.69 [9.99]) or any subscales on the Griffiths' scales of mental development. Perinatal outcome was similar apart from a higher rate of caesarean section (73 [35.1%] vs 53 [24.0%], p=0.015) and a lower mean birthweight (3163 [SD 642] vs 3341 [606] g, p=0.013) in the study group. Rates of major congenital abnormality were also similar overall (ten [4.8%] study vs ten [4.5%] control), although there were significantly more congenital anomalies among children born to fathers with oligozoospermia than in other children. Interpretation This population study did not show any significant difference between children conceived after ICSI and their naturally conceived peers in terms of physical health and development.	UCL Royal Free & Univ Coll Med Sch, Dept Paediat & Child Hlth, London NW3 2PF, England; Monash Univ, Monash Med Ctr, Dept Paediat, Melbourne, Vic 3004, Australia; Pk Hosp, CARE, Nottingham, England; St Marys Hosp, Dept Reprod Med, Manchester M13 0JH, Lancs, England; BUPA Hosp, Manchester Fertil Serv, Manchester, Lancs, England; St Bartholomews & Royal London Sch Med & Dent, Dept Obstet & Gynaecol, London, England	University of London; University College London; UCL Medical School; Monash University; University of Manchester; University of London; Queen Mary University London	Sutcliffe, AG (corresponding author), UCL Royal Free & Univ Coll Med Sch, Dept Paediat & Child Hlth, Royal Free Campus, London NW3 2PF, England.	icsi@rfc.ucl.ac.uk		Sutcliffe, Alastair/0000-0001-8542-6155				Bergh T, 1999, LANCET, V354, P1579, DOI 10.1016/S0140-6736(99)04345-7; Bonduelle M, 1999, HUM REPROD, V14, P243, DOI 10.1093/humrep/14.suppl_1.243; Bonduelle M, 1998, LANCET, V351, P1553, DOI 10.1016/S0140-6736(98)24021-9; Bowen JR, 1998, LANCET, V351, P1529, DOI 10.1016/S0140-6736(98)10168-X; Hawkins MM, 1999, LANCET, V354, P1906, DOI 10.1016/S0140-6736(05)76874-4; Kent-First MG, 1996, MOL HUM REPROD, V2, P943, DOI 10.1093/molehr/2.12.943; Kurinczuk JJ, 1997, BRIT MED J, V315, P1260, DOI 10.1136/bmj.315.7118.1260; Loft A, 1999, HUM REPROD, V14, P2143, DOI 10.1093/humrep/14.8.2143; PALERMO G, 1992, LANCET, V340, P17, DOI 10.1016/0140-6736(92)92425-F; Palermo GD, 1996, JAMA-J AM MED ASSOC, V276, P1893, DOI 10.1001/jama.276.23.1893; Stuppia L, 1998, HUM GENET, V102, P566, DOI 10.1007/s004390050741; Sutcliffe AG, 1999, BMJ-BRIT MED J, V318, P704; Sutcliffe AG, 1998, LANCET, V352, P578, DOI 10.1016/S0140-6736(05)79291-6; SUTCLIFFE AG, 2001, INT COLLABORATIVE ST; Vogt PH, 1999, LANCET, V354, P611, DOI 10.1016/S0140-6736(99)80147-0; Wennerholm UB, 1996, HUM REPROD, V11, P1113; Wennerholm UB, 2000, HUM REPROD, V15, P944, DOI 10.1093/humrep/15.4.944; World Health Organization (WHO), 1999, WHO LAB MANUAL EXAMI, V4th	18	179	185	0	5	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 30	2001	357	9274					2080	2084		10.1016/S0140-6736(00)05180-1	http://dx.doi.org/10.1016/S0140-6736(00)05180-1			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	447RQ	11445100				2022-12-28	WOS:000169586600010
J	Mungai, M; Tegtmeier, G; Chamberland, M; Parise, M				Mungai, M; Tegtmeier, G; Chamberland, M; Parise, M			Transfusion-transmitted malaria in the United States from 1963 through 1999	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BLOOD-DONOR SELECTION; COLLECTION; COMPONENTS; TRANSMISSION	Background: Transfusion-transmitted malaria is uncommon in the United States. After the report of three cases of complicated Plasmodium falciparum infection acquired by transfusion, we reviewed all cases of transfusion-transmitted malaria reported to the Centers for Disease Control and Prevention (CDC) from 1963 through 1999. Methods: Information on the patients was from surveillance reports sent to the CDC. Information about the implicated blood donors came from the National Malaria Surveillance System. To determine whether donors should have been excluded from donating blood, we compared their characteristics with the exclusion guidelines of the Food and Drug Administration and the American Association of Blood Banks. Results: Of 93 cases of transfusion-transmitted malaria reported in 28 states, 33 (35 percent) were due to P. falciparum, 25 (27 percent) were due to P. vivax, 25 (27 percent) were due to P. malariae, 5 (5 percent) were due to P. ovale, 3 (3 percent) were mixed infections, and 2 (2 percent) were due to unidentified species. Ten of the 93 patients (11 percent) died. There were potentially 91 donors (in two cases, two patients received blood from the same donor), 67 of whom (74 percent) could be identified as infective. Of 64 implicated donors whose country of origin was reported, 38 (59 percent) were foreign born. Among those for whom complete information was available, 37 of 60 donors (62 percent) would have been excluded from donating according to current guidelines (in place since 1994), and 30 of 48 donors (62 percent) should have been excluded under the guidelines in place at the time of donation. Conclusions: Careful screening of donors according to the recommended exclusion guidelines remains the best way to prevent transfusion-transmitted malaria. (N Engl J Med 2001;344:1973-8.) Copyright (C) 2001 Massachusetts Medical Society.	Ctr Dis Control & Prevent, Div Parasit Dis, Natl Ctr Infect Dis, Atlanta, GA 30341 USA; Ctr Dis Control & Prevent, Div Viral & Rickettsial Dis, Natl Ctr Infect Dis, Atlanta, GA 30341 USA; Publ Hlth Serv, US Dept HHS, Washington, DC USA; Community Blood Ctr Greater Kansas City, Kansas City, MO USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; United States Public Health Service	Parise, M (corresponding author), Ctr Dis Control & Prevent, Div Parasit Dis, Natl Ctr Infect Dis, Mailstop F-22,4770 Buford Hwy, Atlanta, GA 30341 USA.	mcp0@cdc.gov						*AM ASS BLOOD BANK, 1999, ASS B, V9910; *AM ASS BLOOD BANK, 1999, STAND BLOOD BANKS TR; BEADLE C, 1994, LANCET, V343, P564, DOI 10.1016/S0140-6736(94)91520-2; BESSON P, 1976, REV FR TRANSFUS IMMU, V19, P369, DOI 10.1016/S0338-4535(76)80076-1; BRASSEUR P, 1981, HEMATOLOGIE, V24, P597; BRUCECHW.LJ, 1974, B WORLD HEALTH ORGAN, V50, P337; Busch MP, 2000, VOX SANG, V78, P253; Chiodini PL, 1997, VOX SANG, V73, P143, DOI 10.1046/j.1423-0410.1997.7330143.x; CHWATT LJB, 1982, TROP DIS B, V79, P827; *GEN ACC OFF, 1997, GAOPEMD972; Gilles HM, 1993, ESSENTIAL MALARIOLOG, P124; Goodnough LT, 1999, NEW ENGL J MED, V340, P438, DOI 10.1056/NEJM199902113400606; GUERRERO IC, 1983, ANN INTERN MED, V99, P221, DOI 10.7326/0003-4819-99-2-221; HANG VTT, 1995, T ROY SOC TROP MED H, V89, P44, DOI 10.1016/0035-9203(95)90652-5; KACHUR SP, 1998, LAST PUBLIC HLTH PRE, P313; Linden JV, 2000, TRANSFUSION, V40, P285, DOI 10.1046/j.1537-2995.2000.40030285.x; LOPEZ CE, 1977, J INFECT DIS, V135, P875, DOI 10.1093/infdis/135.5.875; McQuiston JH, 2000, TRANSFUSION, V40, P274, DOI 10.1046/j.1537-2995.2000.40030274.x; MILLER LH, 1975, TRANSMISSIBLE DISEAS, P241; NAHLEN BL, 1991, TRANSFUSION, V31, P798, DOI 10.1046/j.1537-2995.1991.31992094665.x; Piper R, 1999, AM J TROP MED HYG, V60, P109, DOI 10.4269/ajtmh.1999.60.109; SHULMAN IA, 1994, ARCH PATHOL LAB MED, V118, P366; SULZER AJ, 1971, B WORLD HEALTH ORGAN, V45, P375; SURGENOR DM, 1990, NEW ENGL J MED, V322, P1646, DOI 10.1056/NEJM199006073222306; Talib V H, 1996, Indian J Pathol Microbiol, V39, P493; TURC JM, 1990, EMERGING GLOBAL PATTERNS IN TRANSFUSION-TRANSMITTED INFECTIONS, P31; VAMVAKAS EC, 1994, TRANSFUSION, V34, P464, DOI 10.1046/j.1537-2995.1994.34694295059.x; Wallace EL, 1998, TRANSFUSION, V38, P625, DOI 10.1046/j.1537-2995.1998.38798346630.x; WALLACE EL, 1995, TRANSFUSION, V35, P802, DOI 10.1046/j.1537-2995.1995.351096026360.x; WALLACE EL, 1993, TRANSFUSION, V33, P139, DOI 10.1046/j.1537-2995.1993.33293158046.x; WILLIAMSON W. C., 1848, ANN MAG NAT HIST, V1, P1, DOI 10.1080/03745485809494465; Zoon K, 1994, RECOMMENDATIONS DEFE, P64; 2000, FED REG, V65, P36452; 1999, MMWR MORB MORTAL WKL, V48, P253	34	179	196	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 28	2001	344	26					1973	1978		10.1056/NEJM200106283442603	http://dx.doi.org/10.1056/NEJM200106283442603			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	446HQ	11430326				2022-12-28	WOS:000169508200003
J	Roelofs, J; Van Haastert, PJM				Roelofs, J; Van Haastert, PJM			Genomics - Genes lost during evolution	NATURE			English	Article									Univ Groningen, Dept Biochem, NL-9747 AG Groningen, Netherlands	University of Groningen	Roelofs, J (corresponding author), Univ Groningen, Dept Biochem, Nijenborgh 4, NL-9747 AG Groningen, Netherlands.	p.j.m.van.haastert@chem.rug.nl	Roelofs, Jeroen/AAC-5119-2021	Roelofs, Jeroen/0000-0003-0944-2465				Baldauf SL, 2000, SCIENCE, V290, P972, DOI 10.1126/science.290.5493.972; Kay RR, 1999, TRENDS GENET, V15, P294, DOI 10.1016/S0168-9525(99)01770-9; Lander ES, 2001, NATURE, V409, P860, DOI 10.1038/35057062; Roelofs J, 2001, BIOCHEM J, V354, P697, DOI 10.1042/0264-6021:3540697	4	58	59	2	9	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JUN 28	2001	411	6841					1013	1014		10.1038/35082627	http://dx.doi.org/10.1038/35082627			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	446TF	11429590	Green Submitted, Green Published			2022-12-28	WOS:000169528500034
J	Guzman, J; Esmail, R; Karjalainen, K; Malmivaara, A; Irvin, E; Bombardier, C				Guzman, J; Esmail, R; Karjalainen, K; Malmivaara, A; Irvin, E; Bombardier, C			Multidisciplinary rehabilitation for chronic low back pain: systematic review	BMJ-BRITISH MEDICAL JOURNAL			English	Article							COGNITIVE-BEHAVIORAL TREATMENT; OUTPATIENT TREATMENT; FUNCTIONAL RESTORATION; INPATIENT; DISABILITY; CARE; PROGRAM	Objective To assess the effect of multidisciplinary biopsychosocial rehabilitation on clinically relevant outcomes in patients with chronic low back pain. Design Systematic literature review of randomised controlled trials. Participants A total of 1964 patients with disabling low back pain for more than three months. Main outcome measures Pain, function, employment, quality of life, and global assessments. Results Ten trials reported on a total of 12 randomised comparisons of multidisciplinary treatment and a control condition. There was strong evidence that intensive multidisciplinary biopsychosocial rehabilitation with functional restoration improves function when compared with inpatient or outpatient non-multidisciplinary treatments. There was moderate evidence that intensive multidisciplinary biopsychosocial rehabilitation with functional restoration reduces pain when compared without patient non-multidisciplinary rehabilitation or usual care. There was contradictory evidence regarding vocational outcomes of intensive multidisciplinary biopsychosocial intervention. Some trials reported improvements in work readiness, but others showed no significant reduction in sickness leaves. Less intensive outpatient psychophysical treatments did not improve pain, function, or vocational outcomes when compared with non-multidisciplinary outpatient therapy or usual care. Few trials reported effects on quality of life or global assessments. Conclusions The reviewed trials provide evidence that intensive multidisciplinary biopsychosocial rehabilitation with functional restoration reduces pain and improves function in patients with chronic low back pain. Less intensive interventions did not show improvements in clinically relevant outcomes.	Inst Work & Hlth, Toronto, ON M4W 1E6, Canada; Finnish Inst Occupat Hlth, Helsinki 00250, Finland	Institute for Work & Health; Finnish Institute of Occupational Health	Guzman, J (corresponding author), Univ Manitoba, Fac Med, S112-750,Bannatyne Ave, Winnipeg, MB R3E 0W3, Canada.		Guzman, Jaime/P-1836-2014	Guzman, Jaime/0000-0001-8977-2581				ABERG J, 1984, SPINE, V9, P317, DOI 10.1097/00007632-198404000-00018; ALARANTA H, 1994, SPINE, V19, P1339, DOI 10.1097/00007632-199406000-00007; BADLEY EM, 1994, J RHEUMATOL, V21, P505; Bailar JC, 1997, NEW ENGL J MED, V337, P559, DOI 10.1056/NEJM199708213370810; Basler HD, 1997, PATIENT EDUC COUNS, V31, P113, DOI 10.1016/S0738-3991(97)00996-8; Bendix A E, 1998, Eur Spine J, V7, P111, DOI 10.1007/s005860050040; Bendix A F, 1995, Eur Spine J, V4, P148, DOI 10.1007/BF00298239; Bendix AF, 1996, CLEV CLIN J MED, V63, P62, DOI 10.3949/ccjm.63.1.62; Bendix AF, 1997, SCAND J REHABIL MED, V29, P81; BIGOS SJ, 1994, CLIN PRACTICE GUIDEL, V14; Cook DJ, 1997, ANN INTERN MED, V126, P376, DOI 10.7326/0003-4819-126-5-199703010-00006; Corey DT, 1996, J OCCUP REHABIL, V6, P239, DOI 10.1007/BF02110886; CUTLER RB, 1994, SPINE, V19, P643, DOI 10.1097/00007632-199403001-00002; Deyo, 1999, SPINE, V24, P418; Deyo RA, 1998, SPINE, V23, P2003, DOI 10.1097/00007632-199809150-00018; Fisbain D A, 1995, Arch Fam Med, V4, P58; FLOR H, 1992, PAIN, V49, P221, DOI 10.1016/0304-3959(92)90145-2; GUZMAN J, 1998, COCHRANE DATABASE SY; HARKAPAA K, 1989, SCAND J REHABIL MED, V21, P81; HARKAPAA K, 1990, SCAND J REHABIL MED, V22, P181; Hutubessy RCW, 1999, PAIN, V80, P201, DOI 10.1016/S0304-3959(98)00204-8; JUCKEL WH, 1990, REHABILITATION, V29, P129; JUMI P, 1999, JAMA-J AM MED ASSOC, V282, P1054; LUKINMAA A, 1989, KANSANELAKELAITOKSEN; MAYER TG, 1987, JAMA-J AM MED ASSOC, V258, P1763, DOI 10.1001/jama.258.13.1763; MELLIN G, 1990, SCAND J REHABIL MED, V22, P189; MELLIN G, 1989, SCAND J REHABIL MED, V21, P91; MITCHELL RI, 1994, SPINE, V19, P633, DOI 10.1097/00007632-199403001-00001; NICHOLAS MK, 1991, BEHAV RES THER, V29, P225, DOI 10.1016/0005-7967(91)90112-G; NICHOLAS MK, 1992, PAIN, V48, P339, DOI 10.1016/0304-3959(92)90082-M; SINCLAIR JC, 1994, J CLIN EPIDEMIOL, V47, P881, DOI 10.1016/0895-4356(94)90191-0; TURK DC, 1987, BEHAV RES THER, V25, P237, DOI 10.1016/0005-7967(87)90002-7; vanTulder MW, 1997, SPINE, V22, P2128, DOI 10.1097/00007632-199709150-00012; vanTulder MW, 1997, SPINE, V22, P2323, DOI 10.1097/00007632-199710150-00001; VANTULDER MW, 1995, PAIN, V62, P233, DOI 10.1016/0304-3959(94)00272-G; vanTulder MW, 2000, COCHRANE DATABASE SY; Waddell G, 1996, SPINE, V21, P2820, DOI 10.1097/00007632-199612150-00002	37	594	605	1	64	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 23	2001	322	7301					1511	1516		10.1136/bmj.322.7301.1511	http://dx.doi.org/10.1136/bmj.322.7301.1511			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	446UF	11420271	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000169532000016
J	Moulin, L; Munive, A; Dreyfus, B; Boivin-Masson, C				Moulin, L; Munive, A; Dreyfus, B; Boivin-Masson, C			Nodulation of legumes by members of the beta-subclass of Proteobacteria	NATURE			English	Article							HOST-SPECIFICITY	Members of the Leguminosae form the largest plant family on Earth, with around 18,000 species. The success of legumes can largely be attributed to their ability to form a nitrogen-fixing symbiosis with specific bacteria known as rhizobia, manifested by the development of nodules on the plant roots in which the bacteria rx atmospheric nitrogen, a major contributor to the global nitrogen cycle. Rhizobia described so far belong exclusively to the a-subclass of Proteobacteria, where they are distributed in four distinct phylogenetic branches(1,2). Although nitrogen-fixing bacteria exist in other proteobacterial subclasses, for example Herbaspirillum and Azoarcus from the phylogenetically distant beta -subclass, none has been found to harbour the nod genes essential for establishing rhizobial symbiosis(3,4). Here we report the identification of proteobacteria from the b-subclass that nodulate legumes. This finding shows that the ability to establish a symbiosis with legumes is more widespread in bacteria than anticipated to date.	IRD INRA CIRAD ENSAM Baillarguet, Lab Symbioses Trop & Mediterraneennes, F-34398 Montpellier 5, France	Arts et Metiers Institute of Technology; CIRAD; INRAE; Institut de Recherche pour le Developpement (IRD); Universite de Montpellier	Boivin-Masson, C (corresponding author), IRD INRA CIRAD ENSAM Baillarguet, Lab Symbioses Trop & Mediterraneennes, PB 5035, F-34398 Montpellier 5, France.	Catherine.Boivin@mpl.ird.fr	Munive, José-Antonio/P-4379-2018; Moulin, Lionel/C-2921-2008	Munive, José-Antonio/0000-0003-4509-6563; Moulin, Lionel/0000-0001-9068-6912				Boone CM, 1999, CARBOHYD RES, V317, P155, DOI 10.1016/S0008-6215(99)00083-X; Denarie J, 1996, ANNU REV BIOCHEM, V65, P503, DOI 10.1146/annurev.bi.65.070196.002443; DESCHODT C C, 1976, Phytophylactica, V8, P103; KOKOTEK W, 1989, GENE, V84, P467, DOI 10.1016/0378-1119(89)90522-2; LEROUGE P, 1990, NATURE, V344, P781, DOI 10.1038/344781a0; Perret X, 2000, MICROBIOL MOL BIOL R, V64, P180, DOI 10.1128/MMBR.64.1.180-201.2000; Polhill R.M., 1981, ADV LEGUME SYSTEMATI, P191; QUANDT J, 1993, GENE, V127, P15, DOI 10.1016/0378-1119(93)90611-6; SPAINK HP, 1991, NATURE, V354, P125, DOI 10.1038/354125a0; Swofford D. L., 1998, PAUP PHYLOGENETIC AN; Sy A, 2001, J BACTERIOL, V183, P214, DOI 10.1128/JB.183.1.214-220.2001; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; van Berkum P, 1998, RHIZOBIACEAE MOL BIO, P124; Young JPW, 1996, NEW PHYTOL, V133, P87, DOI 10.1111/j.1469-8137.1996.tb04344.x; Zhang XX, 2000, APPL ENVIRON MICROB, V66, P2988, DOI 10.1128/AEM.66.7.2988-2995.2000	15	473	511	0	77	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JUN 21	2001	411	6840					948	950		10.1038/35082070	http://dx.doi.org/10.1038/35082070			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	444EN	11418858				2022-12-28	WOS:000169386200044
J	[Anonymous]				[Anonymous]			Deputies caught on the wrong side of the law	NATURE			English	News Item																			0	0	0	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 21	2001	411	6840					876	876						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	444EN	11418818				2022-12-28	WOS:000169386200010
J	Thompson, C; Macdonald, M; Sutherland, S				Thompson, C; Macdonald, M; Sutherland, S			Lesson of the week - A family cluster of Chlamydia trachomatis infection	BRITISH MEDICAL JOURNAL			English	Review							DIAGNOSIS; CHILDREN		Victoria Hosp, Fife Acute Hosp NHS Trust, Kirkcaldy KY2 5AH, Fife, Scotland; Univ Edinburgh, Sch Med, Dept Med Microbiol, Edinburgh EH8 9AG, Midlothian, Scotland	University of Edinburgh	Thompson, C (corresponding author), Victoria Hosp, Fife Acute Hosp NHS Trust, Kirkcaldy KY2 5AH, Fife, Scotland.							BELL TA, 1992, JAMA-J AM MED ASSOC, V267, P400, DOI 10.1001/jama.267.3.400; Dunlop E M, 1966, Trans Ophthalmol Soc U K, V86, P321; HAMMERSCHLAG MR, 1994, PEDIATR ANN, V23, P349, DOI 10.3928/0090-4481-19940701-08; INGRAM DL, 1992, PEDIATR INFECT DIS J, V11, P945, DOI 10.1097/00006454-199211110-00008; Johnson AM, 1996, BRIT MED J, V313, P1160, DOI 10.1136/bmj.313.7066.1160; LEE HH, 1995, LANCET, V345, P213, DOI 10.1016/S0140-6736(95)90221-X; MORDHORST CH, 1978, JAMA-J AM MED ASSOC, V239, P1765, DOI 10.1001/jama.239.17.1765; SCHACHTER J, 1986, JAMA-J AM MED ASSOC, V255, P3374, DOI 10.1001/jama.255.24.3374; STENBERG K, 1986, LANCET, V2, P1278; THOMPSON C, 1994, GENITOURIN MED, V70, P262	10	6	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 16	2001	322	7300					1473	1474		10.1136/bmj.322.7300.1473	http://dx.doi.org/10.1136/bmj.322.7300.1473			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	444FJ	11408308	Green Published			2022-12-28	WOS:000169389200034
J	Chyba, CF; Hand, KP				Chyba, CF; Hand, KP			Planetary science - Life without photosynthesis	SCIENCE			English	Editorial Material							EUROPA; OCEAN; EARTH; MARS; ICE		SETI Inst, Ctr Study Life Universe, Mt View, CA 94404 USA; Stanford Univ, Ctr Int Secur & Cooperat, Stanford, CA 94305 USA; Stanford Univ, Dept Geol & Environm Sci, Stanford, CA 94305 USA; Stanford Univ, Dept Mech Engn, Stanford, CA 94305 USA	Stanford University; Stanford University; Stanford University	Chyba, CF (corresponding author), SETI Inst, Ctr Study Life Universe, Mt View, CA 94404 USA.		Hand, Kevin Peter/I-8246-2018	Hand, Kevin Peter/0000-0002-3225-9426				Chyba CF, 2001, P NATL ACAD SCI USA, V98, P801, DOI 10.1073/pnas.98.3.801; COLBURN DS, 1985, ICARUS, V63, P39, DOI 10.1016/0019-1035(85)90019-3; Cooper JF, 2001, ICARUS, V149, P133, DOI 10.1006/icar.2000.6498; DRAGANIC IG, 1991, PRECAMBRIAN RES, V52, P337, DOI 10.1016/0301-9268(91)90087-Q; FREDRIKSSON K, 1988, METEORITICS, V23, P35, DOI 10.1111/j.1945-5100.1988.tb00894.x; Gaidos EJ, 1999, SCIENCE, V284, P1631, DOI 10.1126/science.284.5420.1631; Jakosky BM, 1998, J GEOPHYS RES-PLANET, V103, P19359, DOI 10.1029/98JE01892; Kargel JS, 2000, ICARUS, V148, P226, DOI 10.1006/icar.2000.6471; Kivelson MG, 2000, SCIENCE, V289, P1340, DOI 10.1126/science.289.5483.1340; McCollom TM, 1999, J GEOPHYS RES-PLANET, V104, P30729, DOI 10.1029/1999JE001126; McCord TB, 1999, J GEOPHYS RES-PLANET, V104, P11827, DOI 10.1029/1999JE900005; MOORE JC, 1994, J GEOPHYS RES-OCEANS, V99, P5171, DOI 10.1029/93JC02832; Nealson KH, 1997, J GEOPHYS RES-PLANET, V102, P23675, DOI 10.1029/97JE01996; WALKER JCG, 1977, EVOLUTION ATMOSPHERE, P93; ZOLOTOV MY, 2000, LUNAR PLANET SCI, V31	15	72	73	1	36	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 15	2001	292	5524					2026	2027		10.1126/science.1060081	http://dx.doi.org/10.1126/science.1060081			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	442KP	11408649				2022-12-28	WOS:000169284700036
J	Kuehni, CE; Davis, A; Brooke, AM; Silverman, M				Kuehni, CE; Davis, A; Brooke, AM; Silverman, M			Are all wheezing disorders in very young: (preschool) children increasing in prevalence?	LANCET			English	Article							RESPIRATORY SYMPTOMS; NATURAL-HISTORY; ASTHMA; CHILDHOOD; RISK; ADULTS; TRENDS; ATOPY	Background Distinct wheezing disorders co-exist in young (preschool) children, some of which (early transient wheeze and viral wheeze) are thought to be unrelated to atopy. Investigation of changes in prevalence of wheezing disorders in preschool children could provide important clues about underlying mechanisms responsible for increasing prevalence of asthma in schoolchildren. Methods Repeated population surveys of the prevalence of respiratory symptoms were done by parent-completed postal questionnaires in random samples of 1650 (1990) and 2600 (1998) caucasian children aged 1-5 years living in the county of Leicestershire, UK. Findings The response rates were 86% (1422 of 1650) in 1990 and 84% (2127 of 2522) in 1998. Between 1990 and 1998, there was a significant increase in the prevalence of reported wheeze ever (16% to 29%, p<0.0001), current wheeze (12% to 26%, p<0.0001), diagnosis of asthma (11% to 19%, p<0.0001), treatment for wheeze (15% to 26%, p<0.0001), and admission for wheeze or other chest trouble (6% to 10%, p<0.0001). The increase occurred both in children with viral wheeze (9% to 19%) and in those with the classic asthma pattern of wheezing with multiple triggers (6% to 10%). There was also an increase in transient early wheezers (3% to 5%), persistent wheezers (5% to 13%), and late-onset wheezers (6% to 8%), and in all severity groups. The increase could not be accounted for by putative household risk factors because these declined between the 2 years. Interpretation The fact that all preschool wheezing disorders increased (including viral wheeze) makes it probable that factors unrelated to atopy are implicated in the changing epidemiology of wheeze in childhood.	Univ Bern, Inselspital, Dept Paediat, CH-3010 Bern, Switzerland; Univ Leicester, Leicester Royal Infirm, Dept Child Hlth, Leicester, Leics, England; Leicestershire & Rutland Healthcare Trust, Childrens Directorate, Leicester LE1 7RG, Leics, England	University of Bern; University Hospital of Bern; University of Leicester	Kuehni, CE (corresponding author), Univ Bern, Inselspital, Dept Paediat, CH-3010 Bern, Switzerland.	claudia.kuehni@insel.ch		Kuehni, Claudia E./0000-0001-8957-2002				ANDERSON HR, 1994, BRIT MED J, V308, P1600, DOI 10.1136/bmj.308.6944.1600; ANDERSON HR, 1986, J EPIDEMIOL COMMUN H, V40, P121, DOI 10.1136/jech.40.2.121; BROOKE AM, 1995, AM J RESP CRIT CARE, V152, P1872, DOI 10.1164/ajrccm.152.6.8520749; Cane RS, 2000, ARCH DIS CHILD, V82, P327, DOI 10.1136/adc.82.4.327; Fleming DM, 2000, THORAX, V55, P657, DOI 10.1136/thorax.55.8.657; KELLY WJW, 1987, BRIT MED J, V294, P1059, DOI 10.1136/bmj.294.6579.1059; Kuehni CE, 2000, EUR RESPIR J, V16, P81, DOI 10.1034/j.1399-3003.2000.16a14.x; *LUNG ASTHM INF AG, 1996, 962 STGE HOSP MED SC; LUYT DK, 1994, ARCH DIS CHILD, V71, P24, DOI 10.1136/adc.71.1.24; LUYT DK, 1993, BMJ-BRIT MED J, V306, P1386, DOI 10.1136/bmj.306.6889.1386; LUYT DK, 1995, EUR RESPIR J, V8, P1736, DOI 10.1183/09031936.95.08101736; Magnus P, 1997, BRIT MED J, V314, P1795, DOI 10.1136/bmj.314.7097.1795; Martinez FD, 1998, EUR RESPIR J, V12, p3S; NINAN TK, 1992, BRIT MED J, V304, P873, DOI 10.1136/bmj.304.6831.873; Nystad W, 1998, EUR J EPIDEMIOL, V14, P247, DOI 10.1023/A:1007453322547; PARK ES, 1986, ARCH DIS CHILD, V61, P642, DOI 10.1136/adc.61.7.642; Pearce N, 1999, THORAX, V54, P268, DOI 10.1136/thx.54.3.268; PEAT JK, 1994, BMJ-BRIT MED J, V308, P1591, DOI 10.1136/bmj.308.6944.1591; Rusconi F, 1999, AM J RESP CRIT CARE, V160, P1617, DOI 10.1164/ajrccm.160.5.9811002; Russell G, 1997, BRIT MED J, V315, P1014, DOI 10.1136/bmj.315.7114.1014; Shaheen SO, 2000, THORAX, V55, P266, DOI 10.1136/thorax.55.4.266; Shaheen SO, 1999, THORAX, V54, P396, DOI 10.1136/thx.54.5.396; SILVERMAN M, 1993, THORAX, V48, P1200, DOI 10.1136/thx.48.12.1200; Silverman M, 1997, ARCH DIS CHILD, V77, P62, DOI 10.1136/adc.77.1.62; Stein RT, 1997, THORAX, V52, P946, DOI 10.1136/thx.52.11.946; Weiss ST, 1997, CIBA F SYMP, V206, P244	26	190	192	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 9	2001	357	9271					1821	1825		10.1016/S0140-6736(00)04958-8	http://dx.doi.org/10.1016/S0140-6736(00)04958-8			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	440DN	11410189				2022-12-28	WOS:000169160800009
J	Newell, ML				Newell, ML			Does breastfeeding really affect mortality among HIV-1 infected women?	LANCET			English	Editorial Material									Inst Child Hlth, Dept Paediat Epidemiol & Biostat, London WC1N 1EH, England	University of London; University College London	Newell, ML (corresponding author), Inst Child Hlth, Dept Paediat Epidemiol & Biostat, 30 Guilford St, London WC1N 1EH, England.		Newell, Marie-Louise/AAE-8222-2019	Newell, Marie-Louise/0000-0002-1074-7699				COUSTSOUDIS A, 2001, AIDS, V15, P653; Coutsoudis A, 2001, AIDS, V15, P379, DOI 10.1097/00002030-200102160-00011; Gigante DP, 2001, J NUTR, V131, P78, DOI 10.1093/jn/131.1.78; Gonzalez-Cossio T, 1998, J NUTR, V128, P1692, DOI 10.1093/jn/128.10.1692; Nduati R, 2000, JAMA-J AM MED ASSOC, V283, P1167, DOI 10.1001/jama.283.9.1167; Nicoll A, 2000, AIDS, V14, pS57; *UNFPA UNCIEF WHO, 2000, NEW DAT PREV MOTH CH	7	16	16	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAY 26	2001	357	9269					1634	1635		10.1016/S0140-6736(00)04857-1	http://dx.doi.org/10.1016/S0140-6736(00)04857-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	435UY	11425361				2022-12-28	WOS:000168901600002
J	Ben-Tovim, DI; Walker, K; Gilchrist, P; Freeman, R; Kalucy, R; Esterman, A				Ben-Tovim, DI; Walker, K; Gilchrist, P; Freeman, R; Kalucy, R; Esterman, A			Outcome in patients with eating disorders: a 5-year study	LANCET			English	Article							ANOREXIA-NERVOSA; BULIMIA-NERVOSA; 6-YEAR COURSE; MORTALITY; ATTITUDES	Background Eating disorders are disabling, unpredictable, and difficult to treat. We did a prospective 5-year investigation of a representative sample of patients with eating disorders. Our aim was to identify predictors of outcome and to assess effects of available treatments. Methods We prospectively investigated 95 patients with anorexia nervosa, 88 with bulimia nervosa, and 37 with eating disorders not otherwise specified (EDNOS), who sought treatment in Adelaide, South Australia. We divided patients into those who had, and had not, received treatment in specialist units and reached a safe body weight. Individuals were then further classified dependent on intensity of any treatment received. We assessed clinical symptoms, body-related attitudes, and psychosocial function. Findings 216 (98%) patients were available for follow-up after 5 years. Three patients with anorexia nervosa and two with EDNOS died. 65 (74%) bulimic, 29 (78%) EDNOS, and 53 (56%) anorexic patients had no diagnosable eating disorder. A small proportion of patients in every group had poor Morgan-Russell-Hayward scores at outcome. Final outcome was predicted by extent and intensity. but not duration, of initial symptoms in patients with anorexia nervosa, and by initial body-related attitudes and impaired psychosocial functioning in bulimia patients. We were unable to predict EDNOS outcome. Treatment did not affect outcome for any group. Interpretation Deaths in the study confirm the serious nature of eating disorders. However. our results suggest that the efficacy of existing interventions is questionable.	Flinders Med Ctr, Clin Epidemiol & Hlth Outcomes Unit, Bedford Pk, SA 5042, Australia; Flinders Med Ctr, Weight Disorders Unit, Bedford Pk, SA 5042, Australia	Flinders Medical Centre; Flinders Medical Centre	Ben-Tovim, DI (corresponding author), Flinders Med Ctr, Clin Epidemiol & Hlth Outcomes Unit, Bedford Pk, SA 5042, Australia.	David.Ben-Tovim@fmc.sa.gov.au	Esterman, Adrian J/D-1042-2009	Esterman, Adrian/0000-0001-7324-9171				BENTOVIM DI, 1991, PSYCHOL MED, V21, P775, DOI 10.1017/S0033291700022406; BENTOVIM DI, 1989, INT J EAT DISORDER, V8, P681; BENTOVIM DI, 1992, PSYCHOL MED, V22, P961, DOI 10.1017/S0033291700038538; CRISP AH, 1991, BRIT J PSYCHIAT, V159, P325, DOI 10.1192/bjp.159.3.325; Crow S, 1999, INT J EAT DISORDER, V26, P97, DOI 10.1002/(SICI)1098-108X(199907)26:1<97::AID-EAT13>3.3.CO;2-4; Fairburn CG, 2000, ARCH GEN PSYCHIAT, V57, P659, DOI 10.1001/archpsyc.57.7.659; Fichter MM, 1999, INT J EAT DISORDER, V26, P359; Fichter MM, 1997, INT J EAT DISORDER, V22, P361, DOI 10.1002/(SICI)1098-108X(199712)22:4&lt;361::AID-EAT2&gt;3.0.CO;2-K; Herzog W, 1997, PSYCHOL MED, V27, P269, DOI 10.1017/S0033291796004394; Herzog W., 1992, COURSE EATING DISORD; HSU LKG, 1988, PSYCHOL MED, V18, P807, DOI 10.1017/S0033291700009739; Keel PK, 1999, ARCH GEN PSYCHIAT, V56, P63, DOI 10.1001/archpsyc.56.1.63; Keel PK, 2000, AM J PSYCHIAT, V157, P136, DOI 10.1176/ajp.157.1.136; MORGAN HG, 1988, BRIT J PSYCHIAT, V152, P367, DOI 10.1192/bjp.152.3.367; Neumarker KJ, 1997, INT J EAT DISORDER, V21, P205, DOI 10.1002/(SICI)1098-108X(199704)21:3<205::AID-EAT1>3.0.CO;2-O; Nielsen S, 1998, J PSYCHOSOM RES, V44, P413, DOI 10.1016/S0022-3999(97)00267-5; ROSENBERG FR, 1978, J YOUTH ADOLESCENCE, V7, P279, DOI 10.1007/BF01537978; Sartorius N, 1996, SOC PSYCH PSYCH EPID, V31, P55, DOI 10.1007/BF00801901; STEINHAUSEN HC, 1991, PSYCHOL MED, V21, P447, DOI 10.1017/S0033291700020559; SULLIVAN PF, 1995, AM J PSYCHIAT, V152, P1073; VANDEREYCKEN W, 1994, INT J EAT DISORDER, V16, P105, DOI 10.1002/1098-108X(199409)16:2<105::AID-EAT2260160202>3.0.CO;2-E; Zipfel S, 2000, LANCET, V355, P721, DOI 10.1016/S0140-6736(99)05363-5; ZUNG WWK, 1965, ARCH GEN PSYCHIAT, V12, P63, DOI 10.1001/archpsyc.1965.01720310065008	23	150	154	0	13	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	APR 21	2001	357	9264					1254	1257		10.1016/S0140-6736(00)04406-8	http://dx.doi.org/10.1016/S0140-6736(00)04406-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	425YY	11418150				2022-12-28	WOS:000168323300012
J	Hermankova, M; Ray, SC; Ruff, C; Powell-Davis, M; Ingersoll, R; D'Aquila, RT; Quinn, TC; Siliciano, RF; Persaud, D				Hermankova, M; Ray, SC; Ruff, C; Powell-Davis, M; Ingersoll, R; D'Aquila, RT; Quinn, TC; Siliciano, RF; Persaud, D			HIV-1 drug resistance profiles in children and adults with viral load of < 50 copies/mL receiving combination therapy	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							IMMUNODEFICIENCY-VIRUS TYPE-1; ACTIVE ANTIRETROVIRAL THERAPY; REVERSE-TRANSCRIPTASE; LATENT RESERVOIR; GENOTYPIC RESISTANCE; PROTEASE INHIBITOR; CONFERS RESISTANCE; INFECTED PATIENTS; PLASMA VIREMIA; IN-VIVO	Context The continued release of human immunodeficiency virus type 1 (HIV-1) into plasma at very low levels during highly active antiretroviral therapy (HAART) can be detected using specialized techniques, but the nature and significance of this low-level viremia, especially as related to acquisition of drug resistance mutations, are unclear. Objective To determine genetic resistance profiles of low-level plasma HIV-1 in patients with prolonged viral suppression (<50 copies/mL of plasma HIV-1 RNA) while receiving HAART. Design and Setting Cross-sectional study conducted at a US academic hospital from November 1999 to February 2001 using a novel method for amplification of low levels of viral genomes in plasma. Patients Eighteen HIV-1-infected patients (7 children and 11 adults), enrolled in a longitudinal study of HIV-1 reservoirs, who had suppression of viral replication while receiving protease inhibitor-containing combination therapy. Two patients (1 adult and 1 child) with less optimal suppression of viral replication were included to assess virus predominating when plasma HIV-1 RNA levels are low but detectable (<1000 copies/mL). Follow-up analyses were conducted in 3 patients. Main Outcome Measure Detection of drug resistance mutations in clones amplified from low-level plasma virus. Results Viral sequences were amplified from 8 of the 18 patients with simultaneous plasma HIV-1 measurements of less than 50 copies/mL and from 2 patients with 231 and 50 copies/mL. Clones from 3 treatment-naive patients with less than 50 copies/mL of plasma HIV-1 RNA showed continued release, for as long as 42 months, of wild-type drug-sensitive virus. The 7 patients with prior nonsuppressive therapy, with viral loads below 50 copies/mL and during "blips" to 231 and 64 copies/mL, had only resistance mutations consistent with pre-HAART therapy (although reverse transcriptase inhibitor mutations may have continued to occur), New HAART-related mutations were seen in a control patient with prior viral load levels of about 400 to 1000 copies/mL. For phylogenetic analysis, sequences were available for both resting CD4(+) T cells and plasma HIV for 7 of 10 patients and showed patient-specific clustering of sequences and a close relationship between virus in the plasma and the latent reservoir. Conclusions Based on the samples that could be amplified, low-level viremia in children and adults receiving HAART with prolonged suppression of viremia to less than 50 copies/mL of HIV-1 RNA may result primarily from archival, pre-HAART virus, reflecting earlier treatment conditions, and does not appear to require development of new, HAART-selected mutations reflecting partial resistance to therapy. Low-level viremia below 50 copies/mL may represent less of a concern regarding impending drug failure of current HAART regimens, However, the archival drug-resistant virus may be relevant regarding future treatment strategies.	Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21287 USA; Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Inst Genet, Baltimore, MD USA; Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA USA; NIAID, NIH, Bethesda, MD 20892 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Persaud, D (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pediat, 600 N Wolfe St,256 Pk Bldg, Baltimore, MD 21287 USA.		Quinn, Thomas/A-2494-2010; Ray, Stuart C./B-7527-2008	Ray, Stuart C./0000-0002-1051-7260; , Roxann/0000-0002-4266-613X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P30HD027799] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI043222, R01AI029193, Z01AI000361] Funding Source: NIH RePORTER; NIAID NIH HHS [AI43222, AI29193] Funding Source: Medline; NICHD NIH HHS [P30HD27799] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Atkinson B, 2000, J INFECT DIS, V182, P420, DOI 10.1086/315726; Brown AJL, 1997, NAT MED, V3, P268, DOI 10.1038/nm0397-268; Chun TW, 2000, NAT MED, V6, P757, DOI 10.1038/77481; CHUN TW, 1995, NAT MED, V1, P1284, DOI 10.1038/nm1295-1284; Chun TW, 1997, NATURE, V387, P183, DOI 10.1038/387183a0; Chun TW, 1997, P NATL ACAD SCI USA, V94, P13193, DOI 10.1073/pnas.94.24.13193; de Mendoza C, 2000, J ACQ IMMUN DEF SYND, V23, P279; Demeter LM, 2000, ANTIMICROB AGENTS CH, V44, P794, DOI 10.1128/AAC.44.3.794-797.2000; Descamps D, 2000, JAMA-J AM MED ASSOC, V283, P205, DOI 10.1001/jama.283.2.205; Dornadula G, 1999, JAMA-J AM MED ASSOC, V282, P1627, DOI 10.1001/jama.282.17.1627; Felsenstein J., 1985, EVOLUTION 1985, V39, P783; Finzi D, 1999, NAT MED, V5, P512, DOI 10.1038/8394; Finzi D, 1997, SCIENCE, V278, P1295, DOI 10.1126/science.278.5341.1295; Furtado MR, 1999, NEW ENGL J MED, V340, P1614, DOI 10.1056/NEJM199905273402102; Grossman Z, 1998, IMMUNOL TODAY, V19, P528, DOI 10.1016/S0167-5699(98)01353-X; Gulick RM, 1997, NEW ENGL J MED, V337, P734, DOI 10.1056/NEJM199709113371102; Gunthard HF, 1999, J VIROL, V73, P9404; Gunthard HF, 1998, J VIROL, V72, P2422; Hammer SM, 1997, NEW ENGL J MED, V337, P725, DOI 10.1056/NEJM199709113371101; Havlir DV, 2000, JAMA-J AM MED ASSOC, V283, P229, DOI 10.1001/jama.283.2.229; Hertogs K, 2000, ANTIMICROB AGENTS CH, V44, P568, DOI 10.1128/AAC.44.3.568-573.2000; Hirsch MS, 2000, JAMA-J AM MED ASSOC, V283, P2417, DOI 10.1001/jama.283.18.2417; Ho DD, 2000, NAT MED, V6, P736, DOI 10.1038/77447; Imamichi H, 2001, J INFECT DIS, V183, P36, DOI 10.1086/317641; Learn GH, 1996, J VIROL, V70, P5720, DOI 10.1128/JVI.70.8.5720-5730.1996; Luzuriaga K, 1999, J VIROL, V73, P362, DOI 10.1128/JVI.73.1.362-367.1999; Luzuriaga K, 1997, NEW ENGL J MED, V336, P1343, DOI 10.1056/NEJM199705083361902; MARKOWITZ M, 1995, J VIROL, V69, P701, DOI 10.1128/JVI.69.2.701-706.1995; Martinez-Picado J, 2000, P NATL ACAD SCI USA, V97, P10948, DOI 10.1073/pnas.97.20.10948; Melvin AJ, 1999, J ACQ IMMUN DEF SYND, V20, P468, DOI 10.1097/00042560-199904150-00009; Molla A, 1996, NAT MED, V2, P760, DOI 10.1038/nm0796-760; Patick AK, 1998, ANTIMICROB AGENTS CH, V42, P2637, DOI 10.1128/AAC.42.10.2637; Perelson AS, 1997, NATURE, V387, P188, DOI 10.1038/387188a0; Persaud D, 2000, J CLIN INVEST, V105, P995, DOI 10.1172/JCI9006; Ramratnam B, 2000, NAT MED, V6, P82, DOI 10.1038/71577; RICHMAN DD, 1994, J VIROL, V68, P1660, DOI 10.1128/JVI.68.3.1660-1666.1994; Rouzine IM, 1999, P NATL ACAD SCI USA, V96, P10758, DOI 10.1073/pnas.96.19.10758; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SCHINAZI RF, 1993, ANTIMICROB AGENTS CH, V37, P875, DOI 10.1128/AAC.37.4.875; Sharkey ME, 2000, NAT MED, V6, P76, DOI 10.1038/71569; Smith DB, 1997, J GEN VIROL, V78, P1511, DOI 10.1099/0022-1317-78-7-1511; SWOFFORD DL, 2000, PAUP ASTERISK PHYLOG; TISDALE M, 1993, P NATL ACAD SCI USA, V90, P5653, DOI 10.1073/pnas.90.12.5653; Winters MA, 1998, J CLIN INVEST, V102, P1769, DOI 10.1172/JCI4948; Wong JK, 1997, SCIENCE, V278, P1291, DOI 10.1126/science.278.5341.1291; Yerly S, 2000, AIDS, V14, P243, DOI 10.1097/00002030-200002180-00006; Zhang LQ, 1999, NEW ENGL J MED, V340, P1605, DOI 10.1056/NEJM199905273402101	47	178	184	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 11	2001	286	2					196	207		10.1001/jama.286.2.196	http://dx.doi.org/10.1001/jama.286.2.196			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	451JJ	11448283	Bronze			2022-12-28	WOS:000169798700025
J	Lowenfels, AB; Maisonneuve, P; Whitcomb, DC; Lerch, MM; DiMagno, EP				Lowenfels, AB; Maisonneuve, P; Whitcomb, DC; Lerch, MM; DiMagno, EP			Cigarette smoking as a risk factor for pancreatic cancer in patients with hereditary pancreatitis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter									New York Med Coll, Dept Surg & Community & Prevent Med, Valhalla, NY 10595 USA; European Inst Oncol, Div Epidemiol & Biostat, Milan, Italy; Univ Pittsburgh, Dept Med, Div Gastroenterol Hepatol & Nutr, Pittsburgh, PA USA; Univ Pittsburgh, Ctr Genom Sci, Pittsburgh, PA USA; Univ Munster, Dept Med B, D-4400 Munster, Germany; Mayo Clin & Mayo Fdn, Gastroenterol Res Unit, Rochester, MN 55905 USA	New York Medical College; IRCCS European Institute of Oncology (IEO); Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Munster; Mayo Clinic	Lowenfels, AB (corresponding author), New York Med Coll, Dept Surg & Community & Prevent Med, Valhalla, NY 10595 USA.		Lowenfels, Albert/ABD-8388-2021; Lerch, Markus M./E-2206-2016; Maisonneuve, Patrick/U-9789-2018	Lerch, Markus M./0000-0002-9643-8263; Maisonneuve, Patrick/0000-0002-5309-4704	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK054709] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK54709] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		DEMESQUITA HBB, 1991, INT J CANCER, V49, P816, DOI 10.1002/ijc.2910490604; Efthimiou E, 2001, GUT, V48, P143, DOI 10.1136/gut.48.2.143; Lowenfels AB, 1997, J NATL CANCER I, V89, P442, DOI 10.1093/jnci/89.6.442; Schenk M, 2001, JNCI-J NATL CANCER I, V93, P640, DOI 10.1093/jnci/93.8.640; Whitcomb DC, 1996, NAT GENET, V14, P141, DOI 10.1038/ng1096-141	5	206	220	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 11	2001	286	2					169	170		10.1001/jama.286.2.169	http://dx.doi.org/10.1001/jama.286.2.169			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	451JJ	11448279				2022-12-28	WOS:000169798700020
J	Essex, C; Roper, H				Essex, C; Roper, H			Lesson of the week - Late diagnosis of Duchenne's muscular dystrophy presenting as global developmental delay	BRITISH MEDICAL JOURNAL			English	Review							FAILURE		Gulson Hosp, Child Dev Unit, Coventry CV1 2HR, W Midlands, England; Birmingham Heartlands Hosp, Birmingham B9 5SS, W Midlands, England	Heart of England NHS Foundation Trust; University of Birmingham	Essex, C (corresponding author), Gulson Hosp, Child Dev Unit, Coventry CV1 2HR, W Midlands, England.							Bushby KMD, 1999, LANCET, V353, P557, DOI 10.1016/S0140-6736(98)05279-9; DUBOWITZ V, 1995, MUSCLE DISORDERS CHI, P48; Emery A E, 1991, Neuromuscul Disord, V1, P19, DOI 10.1016/0960-8966(91)90039-U; NUDEL U, 1989, NATURE, V337, P76, DOI 10.1038/337076a0; RAPISARDA R, 1995, ARCH DIS CHILD, V72, P437, DOI 10.1136/adc.72.5.437; Tokarz SA, 1998, MOL GENET METAB, V65, P272, DOI 10.1006/mgme.1998.2763	6	26	27	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUL 7	2001	323	7303					37	38		10.1136/bmj.323.7303.37	http://dx.doi.org/10.1136/bmj.323.7303.37			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	451WA	11440945	Green Published			2022-12-28	WOS:000169824300025
J	Harnden, A; Shakespeare, J				Harnden, A; Shakespeare, J			10-minute consultation - MMR immunisation	BRITISH MEDICAL JOURNAL			English	Article									Inst Hlth Sci, Dept Primary Hlth Care, Oxford OX3 7LF, England; Summertown Hlth Ctr, Oxford OX2 7BS, England	University of Oxford	Harnden, A (corresponding author), Inst Hlth Sci, Dept Primary Hlth Care, Oxford OX3 7LF, England.								0	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUL 7	2001	323	7303					32	32		10.1136/bmj.323.7303.32	http://dx.doi.org/10.1136/bmj.323.7303.32			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	451WA	11440943	Bronze, Green Published			2022-12-28	WOS:000169824300023
J	Postma, HWC; Teepen, T; Yao, Z; Grifoni, M; Dekker, C				Postma, HWC; Teepen, T; Yao, Z; Grifoni, M; Dekker, C			Carbon nanotube single-electron transistors at room temperature	SCIENCE			English	Article							LUTTINGER-LIQUID; QUANTUM WIRES; TRANSPORT; DOT; JUNCTIONS	Room-temperature single-electron transistors are realized within individual metallic single-wall carbon nanotube molecules. The devices feature a short (down to similar to 20 nanometers) nanotube section that is created by inducing Local barriers into the tube with an atomic force microscope. Coulomb charging is observed at room temperature, with an addition energy of 120 millielectron volts, which substantially exceeds the thermal energy. At Low temperatures, we resolve the quantum energy Levels corresponding to the small island. We observe unconventional power-law dependencies in the measured transport properties for which we suggest a resonant tunneling Luttinger-liquid mechanism.	Delft Univ Technol, Dept Appl Phys, NL-2628 CJ Delft, Netherlands; Delft Univ Technol, DIMES, NL-2628 CJ Delft, Netherlands	Delft University of Technology; Delft University of Technology	Dekker, C (corresponding author), Delft Univ Technol, Dept Appl Phys, Lorentzweg 1, NL-2628 CJ Delft, Netherlands.		Postma, Henk W.Ch./A-8770-2014	Dekker, Cees/0000-0001-6273-071X				Auslaender OM, 2000, PHYS REV LETT, V84, P1764, DOI 10.1103/PhysRevLett.84.1764; Bachtold A, 2000, PHYS REV LETT, V84, P6082, DOI 10.1103/PhysRevLett.84.6082; BEENAKKER CWJ, 1991, PHYS REV B, V44, P1646, DOI 10.1103/PhysRevB.44.1646; Bockrath M, 2001, SCIENCE, V291, P283, DOI 10.1126/science.291.5502.283; Bockrath M, 1999, NATURE, V397, P598, DOI 10.1038/17569; Bockrath M, 1997, SCIENCE, V275, P1922, DOI 10.1126/science.275.5308.1922; Braggio A, 2000, EUROPHYS LETT, V50, P236, DOI 10.1209/epl/i2000-00260-6; Cobden DH, 1998, PHYS REV LETT, V81, P681, DOI 10.1103/PhysRevLett.81.681; Dekker C, 1999, PHYS TODAY, V52, P22, DOI 10.1063/1.882658; Egger R, 1997, PHYS REV LETT, V79, P5082, DOI 10.1103/PhysRevLett.79.5082; Fisher M. P. A., COMMUNICATION; Furusaki A, 1998, PHYS REV B, V57, P7141, DOI 10.1103/PhysRevB.57.7141; GRABERT H, 1992, SINGLE CHARGE TUNNEL; GRIFONI M, UNPUB; Iijima S, 1996, J CHEM PHYS, V104, P2089, DOI 10.1063/1.470966; Kane C, 1997, PHYS REV LETT, V79, P5086, DOI 10.1103/PhysRevLett.79.5086; KANE CL, 1992, PHYS REV LETT, V68, P1220, DOI 10.1103/PhysRevLett.68.1220; Matsumoto K, 1996, APPL PHYS LETT, V68, P34, DOI 10.1063/1.116747; Nygard J, 1999, APPL PHYS A-MATER, V69, P297, DOI 10.1007/s003390051004; Postma HWC, 2000, ADV MATER, V12, P1299, DOI 10.1002/1521-4095(200009)12:17<1299::AID-ADMA1299>3.0.CO;2-O; Postma HWC, 2000, J LOW TEMP PHYS, V118, P495, DOI 10.1023/A:1004618823190; Postma HWC, 2000, PHYS REV B, V62, P10653, DOI 10.1103/PhysRevB.62.R10653; TAKAHASHI Y, 1995, ELECTRON LETT, V31, P136, DOI 10.1049/el:19950082; Tans SJ, 2000, NATURE, V404, P834, DOI 10.1038/35009026; Tans SJ, 1997, NATURE, V386, P474, DOI 10.1038/386474a0; Tans SJ, 1998, NATURE, V393, P49, DOI 10.1038/29954; Yao Z, 1999, NATURE, V402, P273, DOI 10.1038/46241; Zhuang L, 1998, APPL PHYS LETT, V72, P1205, DOI 10.1063/1.121014; Zorin AB, 1996, PHYS REV B, V53, P13682, DOI 10.1103/PhysRevB.53.13682	29	1002	1053	3	252	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 6	2001	293	5527					76	79		10.1126/science.1061797	http://dx.doi.org/10.1126/science.1061797			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	451BB	11441175				2022-12-28	WOS:000169780300030
J	Nasser, SMS; Ewan, PW				Nasser, SMS; Ewan, PW			Lesson of the week - Depot corticosteroid treatment for hay fever causing avascular necrosis of both hips	BRITISH MEDICAL JOURNAL			English	Review							GRASS-POLLEN IMMUNOTHERAPY; DOUBLE-BLIND; FEMORAL-HEAD; FOLLOW-UP; EFFICACY; ASTHMA; THERAPY; EXTRACT; SAFETY		Univ Cambridge, Addenbrookes Hosp, Dept Allergy & Clin Immunol, Cambridge CB2 2QQ, England; Univ Cambridge, Addenbrookes Hosp, Sch Clin, Dept Med, Cambridge CB2 2QQ, England	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	Ewan, PW (corresponding author), Univ Cambridge, Addenbrookes Hosp, Dept Allergy & Clin Immunol, Cambridge CB2 2QQ, England.							ATKINSON K, 1987, BONE MARROW TRANSPL, V2, P421; *BASCI WORK PART, 1993, CLIN EXP ALLERGY  S3, V23, P1; BOUSQUET J, 1989, J ALLERGY CLIN IMMUN, V84, P546, DOI 10.1016/0091-6749(89)90369-2; *BRIT SOC ALL CLIN, 2000, RHIN MAN GUID; Colwell CW, 1996, ORTHOPEDICS, V19, P941; Dolz I, 1996, ALLERGY, V51, P489, DOI 10.1111/j.1398-9995.1996.tb00166.x; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; FLEMING DM, 1987, BRIT MED J, V294, P279, DOI 10.1136/bmj.294.6567.279; FRANKLAND AW, 1954, LANCET, V1, P1055; Jacobsen L, 1997, ALLERGY, V52, P914, DOI 10.1111/j.1398-9995.1997.tb01251.x; MCALLEN MK, 1969, ACTA ALLERGOL, V24, P421, DOI 10.1111/j.1398-9995.1969.tb03756.x; OBRIEN TJ, 1992, CLIN ORTHOP RELAT R, P176; PASTORELLO EA, 1992, ALLERGY, V47, P281, DOI 10.1111/j.1398-9995.1992.tb02054.x; VARNEY VA, 1991, BRIT MED J, V302, P265, DOI 10.1136/bmj.302.6771.265; WALKER SM, 1995, ALLERGY, V50, P405, DOI 10.1111/j.1398-9995.1995.tb01170.x; 1999, DRUG THER B, V37, P17	16	26	26	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 30	2001	322	7302					1589	1591		10.1136/bmj.322.7302.1589	http://dx.doi.org/10.1136/bmj.322.7302.1589			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	449QT	11431303	Green Published			2022-12-28	WOS:000169699200031
J	McNamara, P; Seo, SB; Rudic, RD; Sehgal, A; Chakravarti, D; FitzGerald, GA				McNamara, P; Seo, SB; Rudic, RD; Sehgal, A; Chakravarti, D; FitzGerald, GA			Regulation of CLOCK and MOP4 by nuclear hormone receptors in the vasculature: A humoral mechanism to reset a peripheral clock	CELL			English	Article							CIRCADIAN CLOCK; SUPRACHIASMATIC NUCLEUS; DIURNAL-VARIATION; RETINOIC ACID; MESSENGER-RNA; EXPRESSION; LOOP; TISSUES; TRANSCRIPTION; OSCILLATORS	Circadian clock genes are expressed in the suprachiasmatic nucleus and in peripheral tissues to regulate cyclically physiological processes. Synchronization of peripheral oscillators is thought to involve humoral signals, but the mechanisms by which these are mediated and integrated are poorly understood. We report a hormone-dependent interaction of the nuclear receptors, RAR alpha and RXR alpha, with CLOCK and MOP4. These interactions negatively regulate CLOCK/MOP4: BMAL1-mediated transcriptional activation of clock gene expression in vascular cells. MOP4 exhibits a robust rhythm in the vasculature, and retinoic acid can phase shift Per2 mRNA rhythmicity in vivo and in serum-induced smooth muscle cells in vitro, providing a molecular mechanism for hormonal central of clock gene expression. We propose that circadian or periodic availability of nuclear hormones may play a critical role in resetting a peripheral vascular clock.	Univ Penn, Sch Med, Ctr Expt Therapeut, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Howard Hughes Med Inst, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Neurosci, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; Howard Hughes Medical Institute; University of Pennsylvania; University of Pennsylvania	FitzGerald, GA (corresponding author), Univ Penn, Sch Med, Ctr Expt Therapeut, Philadelphia, PA 19104 USA.	garret@spirit.gcrc.upenn.edu	FitzGerald, Garret A/A-4222-2010; Rudic, Dan/B-3432-2016	Rudic, Dan/0000-0001-9122-3127; Chakravarti, Debabrata/0000-0001-8446-8599	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL062250, P50HL054500] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK057079] Funding Source: NIH RePORTER; NHLBI NIH HHS [1P50HL54500, P01 HL62250-01] Funding Source: Medline; NIDDK NIH HHS [R01 DK057079, R01-DK57079-01A1] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Akashi M, 2000, GENE DEV, V14, P645; Amir S, 1998, NEUROSCIENCE, V86, P345, DOI 10.1016/S0306-4522(98)00172-9; Andre E, 1998, EMBO J, V17, P3867, DOI 10.1093/emboj/17.14.3867; Balsalobre A, 2000, SCIENCE, V289, P2344, DOI 10.1126/science.289.5488.2344; Balsalobre A, 1998, CELL, V93, P929, DOI 10.1016/S0092-8674(00)81199-X; Czeisler CA, 1999, RECENT PROG HORM RES, V54, P97; Damiola F, 2000, GENE DEV, V14, P2950, DOI 10.1101/gad.183500; Darlington TK, 1998, SCIENCE, V280, P1599, DOI 10.1126/science.280.5369.1599; ESTOJAK J, 1995, MOL CELL BIOL, V15, P5820; FORMAN BM, 1995, CELL, V81, P541, DOI 10.1016/0092-8674(95)90075-6; Garcia JA, 2000, SCIENCE, V288, P2226, DOI 10.1126/science.288.5474.2226; Gekakis N, 1998, SCIENCE, V280, P1564, DOI 10.1126/science.280.5369.1564; Glass CK, 2000, GENE DEV, V14, P121; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; Hogenesch JB, 1997, J BIOL CHEM, V272, P8581, DOI 10.1074/jbc.272.13.8581; Hogenesch JB, 1998, P NATL ACAD SCI USA, V95, P5474, DOI 10.1073/pnas.95.10.5474; HOSSMANN V, 1980, CARDIOVASC RES, V14, P125, DOI 10.1093/cvr/14.3.125; Ishida N, 1999, P NATL ACAD SCI USA, V96, P8819, DOI 10.1073/pnas.96.16.8819; Jin XW, 1999, CELL, V96, P57, DOI 10.1016/S0092-8674(00)80959-9; King DP, 1997, CELL, V89, P641, DOI 10.1016/S0092-8674(00)80245-7; Kume K, 1999, CELL, V98, P193, DOI 10.1016/S0092-8674(00)81014-4; Lee C, 1999, MOL CELL BIOL, V19, P5316; Liu C, 1997, CELL, V91, P855, DOI 10.1016/S0092-8674(00)80473-0; MANGELSDORF DJ, 1995, CELL, V83, P841, DOI 10.1016/0092-8674(95)90200-7; MARSHALL J, 1977, STROKE, V8, P230, DOI 10.1161/01.STR.8.2.230; Miano JM, 1996, CIRCULATION, V93, P1886, DOI 10.1161/01.CIR.93.10.1886; MILLARCRAIG MW, 1978, LANCET, V1, P795; Muller JE, 1999, AM J HYPERTENS, V12, p35S, DOI 10.1016/S0895-7061(98)00278-7; Oishi K, 1998, BIOCHEM BIOPH RES CO, V253, P199, DOI 10.1006/bbrc.1998.9779; PANZA JA, 1991, NEW ENGL J MED, V325, P986, DOI 10.1056/NEJM199110033251402; Perlmann T, 1997, CELL, V90, P391, DOI 10.1016/S0092-8674(00)80498-5; Rajendran RR, 1996, J EXP BIOL, V199, P2775; Reppert SM, 2001, ANNU REV PHYSIOL, V63, P647, DOI 10.1146/annurev.physiol.63.1.647; RIDKER PM, 1990, CIRCULATION, V82, P897, DOI 10.1161/01.CIR.82.3.897; Sakamoto K, 1998, J BIOL CHEM, V273, P27039, DOI 10.1074/jbc.273.42.27039; Sarov-Blat L, 2000, CELL, V101, P647, DOI 10.1016/S0092-8674(00)80876-4; Schulman IG, 1996, MOL CELL BIOL, V16, P3807; Seo SB, 2001, CELL, V104, P119, DOI 10.1016/S0092-8674(01)00196-9; Shearman LP, 1999, NEUROSCIENCE, V89, P387, DOI 10.1016/S0306-4522(98)00325-X; Shearman LP, 2000, SCIENCE, V288, P1013, DOI 10.1126/science.288.5468.1013; Stokkan KA, 2001, SCIENCE, V291, P490, DOI 10.1126/science.291.5503.490; Tronche F, 1998, CURR OPIN GENET DEV, V8, P532, DOI 10.1016/S0959-437X(98)80007-5; TSEMENTZIS SA, 1985, NEUROSURGERY, V17, P901, DOI 10.1227/00006123-198512000-00005; WELSH DK, 1995, NEURON, V14, P697, DOI 10.1016/0896-6273(95)90214-7; Westin S, 2000, ADV PHARMACOL, V47, P89; Yamazaki S, 2000, SCIENCE, V288, P682, DOI 10.1126/science.288.5466.682; Zheng BH, 2001, CELL, V105, P683, DOI 10.1016/S0092-8674(01)00380-4; Zhou YD, 1997, P NATL ACAD SCI USA, V94, P713, DOI 10.1073/pnas.94.2.713; Zylka MJ, 1998, NEURON, V20, P1103, DOI 10.1016/S0896-6273(00)80492-4	49	364	376	2	27	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 29	2001	105	7					877	889		10.1016/S0092-8674(01)00401-9	http://dx.doi.org/10.1016/S0092-8674(01)00401-9			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	449BK	11439184	Bronze			2022-12-28	WOS:000169664300008
J	Wishart, MJ; Taylor, GS; Dixon, JE				Wishart, MJ; Taylor, GS; Dixon, JE			Phoxy lipids: Revealing PX domains as phosphoinositide binding modules	CELL			English	Review							NADPH OXIDASE; SORTING NEXIN; TRAFFICKING; RECEPTORS; 3-KINASES; HOMOLOG; YEAST; VAM7P		Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Inst Life Sci, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Dixon, JE (corresponding author), Univ Michigan, Sch Med, Dept Biol Chem, Ann Arbor, MI 48109 USA.							Babior BM, 1999, BLOOD, V93, P1464, DOI 10.1182/blood.V93.5.1464.405a32_1464_1476; Burg ND, 2001, CLIN IMMUNOL, V99, P7, DOI 10.1006/clim.2001.5007; Cheever ML, 2001, NAT CELL BIOL, V3, P613, DOI 10.1038/35083000; Ellson CD, 2001, NAT CELL BIOL, V3, P679, DOI 10.1038/35083076; Ford MGJ, 2001, SCIENCE, V291, P1051, DOI 10.1126/science.291.5506.1051; Gillooly DJ, 2001, BIOCHEM J, V355, P249, DOI 10.1042/0264-6021:3550249; Haft CR, 1998, MOL CELL BIOL, V18, P7278, DOI 10.1128/MCB.18.12.7278; Hiroaki H, 2001, NAT STRUCT BIOL, V8, P526, DOI 10.1038/88591; Hurley JH, 2001, CURR OPIN CELL BIOL, V13, P146, DOI 10.1016/S0955-0674(00)00191-5; Itoh T, 2001, SCIENCE, V291, P1047, DOI 10.1126/science.291.5506.1047; Kanai F, 2001, NAT CELL BIOL, V3, P675, DOI 10.1038/35083070; Kurten RC, 1996, SCIENCE, V272, P1008, DOI 10.1126/science.272.5264.1008; Noack D, 2001, BLOOD, V97, P305, DOI 10.1182/blood.V97.1.305; Odorizzi G, 2000, TRENDS BIOCHEM SCI, V25, P229, DOI 10.1016/S0968-0004(00)01543-7; Ponting CP, 1996, PROTEIN SCI, V5, P2353, DOI 10.1002/pro.5560051122; Sato TK, 1998, MOL CELL BIOL, V18, P5308, DOI 10.1128/MCB.18.9.5308; Schultz J, 2000, NUCLEIC ACIDS RES, V28, P231, DOI 10.1093/nar/28.1.231; Ungermann C, 1998, EMBO J, V17, P3269, DOI 10.1093/emboj/17.12.3269; Wymann MP, 2000, IMMUNOL TODAY, V21, P260, DOI 10.1016/S0167-5699(00)01649-2; Xu Y, 2001, NAT CELL BIOL, V3, P658, DOI 10.1038/35083051	20	126	127	0	2	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTES AVE,, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 29	2001	105	7					817	820		10.1016/S0092-8674(01)00414-7	http://dx.doi.org/10.1016/S0092-8674(01)00414-7			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	449BK	11439176	Bronze			2022-12-28	WOS:000169664300001
J	Takayama, S; Ostuni, E; LeDuc, P; Naruse, K; Ingber, DE; Whitesides, GM				Takayama, S; Ostuni, E; LeDuc, P; Naruse, K; Ingber, DE; Whitesides, GM			Laminar flows - Subcellular positioning of small molecules	NATURE			English	Article									Childrens Hosp, Dept Pathol, Boston, MA 02115 USA; Childrens Hosp, Dept Surg, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA; Harvard Univ, Dept Chem & Chem Biol, Cambridge, MA 02138 USA	Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Harvard University	Takayama, S (corresponding author), Univ Michigan, Dept Biomed Engn, Ann Arbor, MI 48109 USA.	gwhitesides@gmwgroup.harvard.edu	Ingber, Donald E/AAC-5894-2019; NARUSE, Keiji/B-1620-2011; Sokabe, Masahiro/I-1565-2012	naruse, keiji/0000-0003-4100-6444				Ayscough K, 1998, METHOD ENZYMOL, V298, P18, DOI 10.1016/S0076-6879(98)98004-1; BALL EH, 1982, P NATL ACAD SCI-BIOL, V79, P123, DOI 10.1073/pnas.79.1.123; Bradke F, 1999, SCIENCE, V283, P1931, DOI 10.1126/science.283.5409.1931; Duffy DC, 1998, ANAL CHEM, V70, P4974, DOI 10.1021/ac980656z; Huang S, 1999, NAT CELL BIOL, V1, pE131, DOI 10.1038/13043; Kenis PJA, 1999, SCIENCE, V285, P83, DOI 10.1126/science.285.5424.83; Takayama S, 1999, P NATL ACAD SCI USA, V96, P5545, DOI 10.1073/pnas.96.10.5545; WANG N, 1993, SCIENCE, V260, P1124, DOI 10.1126/science.7684161; Weigl BH, 1999, SCIENCE, V283, P346, DOI 10.1126/science.283.5400.346; Xia YN, 1998, ANGEW CHEM INT EDIT, V37, P550, DOI 10.1002/(SICI)1521-3773(19980316)37:5<550::AID-ANIE550>3.0.CO;2-G	10	428	455	4	99	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 28	2001	411	6841					1016	1016		10.1038/35082637	http://dx.doi.org/10.1038/35082637			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	446TF	11429594	Green Published, Bronze			2022-12-28	WOS:000169528500037
J	Burger, A; Sherman, HB				Burger, A; Sherman, HB			Left ventricular pseudoaneurysm.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center	Burger, A (corresponding author), Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.								0	2	2	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 21	2001	344	25					1910	1910		10.1056/NEJM200106213442505	http://dx.doi.org/10.1056/NEJM200106213442505			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	443VJ	11419428				2022-12-28	WOS:000169362100005
J	Cohen, M				Cohen, M			Glycoprotein IIb/IIIa receptor blockers in acute coronary syndromes: Gusto IV-ACS	LANCET			English	Editorial Material							REFRACTORY UNSTABLE ANGINA; ST-SEGMENT ELEVATION; TASK-FORCE; RECOMMENDATIONS; MANAGEMENT; ABCIXIMAB; TRIAL		Med Coll Penn & Hahnemann Univ, Sch Med, Div Cardiol, Philadelphia, PA 19102 USA	Drexel University	Cohen, M (corresponding author), Med Coll Penn & Hahnemann Univ, Sch Med, Div Cardiol, Philadelphia, PA 19102 USA.							Antman EM, 2000, JAMA-J AM MED ASSOC, V284, P835, DOI 10.1001/jama.284.7.835; Bertrand ME, 2000, EUR HEART J, V21, P1406, DOI 10.1053/euhj.2000.2301; Braunwald E, 2000, CIRCULATION, V102, P1193, DOI 10.1161/01.CIR.102.10.1193; Cohen M, 1999, CIRCULATION, V100, P641; Heeschen C, 1999, CIRCULATION, V100, P1509, DOI 10.1161/01.CIR.100.14.1509; Kereiakes DJ, 1999, AM J CARDIOL, V84, P391, DOI 10.1016/S0002-9149(99)00321-5; Quinn MJ, 2001, J PHARMACOL EXP THER, V297, P496; Scarborough RM, 1999, CIRCULATION, V100, P437, DOI 10.1161/01.CIR.100.4.437; SIMOONS ML, 1994, CIRCULATION, V89, P596, DOI 10.1161/01.CIR.89.2.596; van den Brand M, 1999, EUR HEART J, V20, P1572, DOI 10.1053/euhj.1999.1662	10	7	7	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 16	2001	357	9272					1899	1900		10.1016/S0140-6736(00)05088-1	http://dx.doi.org/10.1016/S0140-6736(00)05088-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	444YZ	11425405				2022-12-28	WOS:000169431000003
J	Pearson, DL; Dawling, S; Walsh, WF; Haines, JL; Christman, BW; Bazyk, A; Scott, N; Summar, ML				Pearson, DL; Dawling, S; Walsh, WF; Haines, JL; Christman, BW; Bazyk, A; Scott, N; Summar, ML			Neonatal pulmonary hypertension - Urea-cycle intermediates, nitric oxide production, and carbamoyl-phosphate synthetase function	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HYALINE-MEMBRANE DISEASE; L-ARGININE; RELAXING FACTOR; BIOLOGICAL-FLUIDS; VASCULAR TONE; END-PRODUCTS; NEWBORN; NITRATE; ENDOTHELIN-1; CIRCULATION	Background: Endogenous production of nitric oxide is vital for the decrease in pulmonary vascular resistance that normally occurs after birth. The precursor of nitric oxide is arginine, a urea-cycle intermediate. We hypothesized that low concentrations of arginine would correlate with the presence of persistent pulmonary hypertension in newborns and that the supply of this precursor would be affected by a functional polymorphism (the substitution of asparagine for threonine at position 1405 [T1405N]) in carbamoyl-phosphate synthetase, which controls the rate-limiting step of the urea cycle. Methods: Plasma concentrations of amino acids and genotypes of the carbamoyl-phosphate synthetase variants were determined in 65 near-term neonates with respiratory distress. Plasma nitric oxide metabolites were measured in a subgroup of 10 patients. The results in infants with pulmonary hypertension, as assessed by echocardiography, were compared with those in infants without pulmonary hypertension. The frequencies of the carbamoyl-phosphate synthetase genotypes in the study population were assessed for Hardy-Weinberg equilibrium. Results: As compared with infants without pulmonary hypertension, infants with pulmonary hypertension had lower mean (+/-SD) plasma concentrations of arginine (20.2+/-8.8 vs. 39.8+/-17.0 micromol per liter, P<0.001) and nitric oxide metabolites (18.8+/-12.7 vs. 47.2+/-11.2 micromol per liter, P = 0.05). As compared with the general population, the infants in the study had a significantly skewed distribution of the genotypes for the carbamoyl-phosphate synthetase variants at position 1405 (P<0.005). None of the infants with pulmonary hypertension were homozygous for the T1405N polymorphism. Conclusions: Infants with persistent pulmonary hypertension have low plasma concentrations of arginine and nitric oxide metabolites. The simultaneous presence of diminished concentrations of precursors and breakdown products suggests that inadequate production of nitric oxide is involved in the pathogenesis of neonatal pulmonary hypertension. Our preliminary observations suggest that the genetically predetermined capacity of the urea cycle - in particular, the efficiency of carbamoyl-phosphate synthetase - may contribute to the availability of precursors for nitric oxide synthesis. (N Engl J Med 2001;344:1832-8.) Copyright (C) 2001 Massachusetts Medical Society.	Vanderbilt Univ, Med Ctr, Div Med Genet, Dept Pediat, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Pediat, Div Neonatol, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Internal Med, Div Pulm Med, Nashville, TN 37232 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University	Summar, ML (corresponding author), Vanderbilt Univ, Med Ctr, Div Med Genet, Dept Pediat, DD 2205 Med Ctr N, Nashville, TN 37232 USA.	marshall.summar@mcmail.vanderbilt.edu	Haines, Jonathan/C-3374-2012	Haines, Jonathan/0000-0002-4351-4728; Summar, Marshall/0000-0001-8920-0110	NIEHS NIH HHS [R01 ES-09915] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES009915] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ABMAN SH, 1990, AM J PHYSIOL, V259, pH1921, DOI 10.1152/ajpheart.1990.259.6.H1921; [Anonymous], 1997, NEW ENGL J MED, V337, P434; BAIG MMA, 1992, PEDIATR RES, V31, P143, DOI 10.1203/00006450-199202000-00010; CASTILLO L, 1995, PEDIATR RES, V38, P17, DOI 10.1203/00006450-199507000-00004; Christou H, 1997, J PEDIATR-US, V130, P603, DOI 10.1016/S0022-3476(97)70245-2; Clark RH, 2000, NEW ENGL J MED, V342, P469, DOI 10.1056/NEJM200002173420704; CORNFIELD DN, 1992, AM J PHYSIOL, V262, pH1474, DOI 10.1152/ajpheart.1992.262.5.H1474; Diaz J, 1998, CLIN BIOCHEM, V31, P513, DOI 10.1016/S0009-9120(98)00051-4; DOLLBERG S, 1995, PEDIATR RES, V37, P31, DOI 10.1203/00006450-199501000-00007; Endo A, 1996, BIOL NEONATE, V70, P15; EVANS NJ, 1991, ARCH DIS CHILD-FETAL, V66, P6, DOI 10.1136/adc.66.1_Spec_No.6; FINEMAN JR, 1994, J CLIN INVEST, V93, P2675, DOI 10.1172/JCI117281; FINEMAN JR, 1995, ANNU REV PHYSIOL, V57, P115; GRANGER DL, 1990, J CLIN INVEST, V85, P264, DOI 10.1172/JCI114422; GREEN LC, 1982, ANAL BIOCHEM, V126, P131, DOI 10.1016/0003-2697(82)90118-X; Guevara I, 1998, CLIN CHIM ACTA, V274, P177, DOI 10.1016/S0009-8981(98)00060-6; HECKER M, 1990, P NATL ACAD SCI USA, V87, P8612, DOI 10.1073/pnas.87.21.8612; Lepage N, 1997, CLIN CHEM, V43, P2397; Lipsitz EC, 1996, J PEDIATR SURG, V31, P137, DOI 10.1016/S0022-3468(96)90336-X; Marzinzig M, 1997, NITRIC OXIDE-BIOL CH, V1, P177, DOI 10.1006/niox.1997.0116; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; NELIN LD, 1994, PEDIATR RES, V35, P20, DOI 10.1203/00006450-199401000-00006; PALMER RMJ, 1988, BIOCHEM BIOPH RES CO, V153, P1251, DOI 10.1016/S0006-291X(88)81362-7; RAIHA NCR, 1968, ACTA PAEDIATR SCAND, V57, P121, DOI 10.1111/j.1651-2227.1968.tb04663.x; RIVERA A, 1989, J PEDIATR-US, V115, P465, DOI 10.1016/S0022-3476(89)80858-3; Roberts JD, 1997, NEW ENGL J MED, V336, P605, DOI 10.1056/NEJM199702273360902; SHAUL PW, 1992, AM J PHYSIOL, V262, pH355, DOI 10.1152/ajpheart.1992.262.2.H355; SKINNER JR, 1992, ARCH DIS CHILD-FETAL, V67, P366, DOI 10.1136/adc.67.4_Spec_No.366; Stork E, 1997, NEW ENGL J MED, V336, P597; Summar ML, 1999, AM J HUM GENET, V65, pA25; VOSATKA RJ, 1994, BIOL NEONATE, V66, P65; Walsh-Sukys MC, 2000, PEDIATRICS, V105, P14, DOI 10.1542/peds.105.1.14; Xie LJ, 2000, SEMIN PERINATOL, V24, P42, DOI 10.1016/S0146-0005(00)80054-3	33	159	170	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUN 14	2001	344	24					1832	1838		10.1056/NEJM200106143442404	http://dx.doi.org/10.1056/NEJM200106143442404			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	441LC	11407344				2022-12-28	WOS:000169231000004
J	Parkin, J; Cohen, B				Parkin, J; Cohen, B			An overview of the immune system	LANCET			English	Article							CELL; INTERFERON; IMMUNOLOGY; CHEMOKINES; MIGRATION; MOLECULES; ANTIGENS; SUBSETS; THERAPY; GENE	We are continually exposed to organisms that are inhaled, swallowed, or inhabit our skin and mucous membranes. Whether these organisms penetrate and cause disease is a result of both the pathogenicity of the organism (the virulence factors at its disposal) and the integrity of host defence mechanisms. The immune system is an interactive network of lymphoid organs, cells, humoral factors, and cytokines. The essential function of the,immune system in host defence is best illustrated when it goes wrong; underactivity resulting in the severe infections and tumours of immunodeficiency, overactivity in allergic and autoimmune disease. In this review we have covered the normal function of the immune system in recognising, repelling, and eradicating pathogens and other foreign molecules.	Queen Mary Univ London, St Bartholomews & Royal London Hosp Sch Med & Den, Dept Immunol, London EC1A 7BE, England; Queen Mary Univ London, St Bartholomews & Royal London Hosp Sch Med & Den, Dept Med & Dent Educ, London EC1A 7BE, England	Barts Health NHS Trust; Royal London Hospital; University of London; Queen Mary University London; Barts Health NHS Trust; Royal London Hospital; University of London; Queen Mary University London	Parkin, J (corresponding author), Queen Mary Univ London, St Bartholomews & Royal London Hosp Sch Med & Den, Dept Immunol, W Smithfield, London EC1A 7BE, England.	Jackie.Parkin@bartsandthelondon.nhs.uk	jordan, sue/O-1297-2019	jordan, sue/0000-0002-5691-2987				ANDERSON DC, 1985, J INFECT DIS, V152, P668, DOI 10.1093/infdis/152.4.668; Aplin AE, 1999, CURR OPIN CELL BIOL, V11, P737, DOI 10.1016/S0955-0674(99)00045-9; Arstila TP, 1999, SCIENCE, V286, P958, DOI 10.1126/science.286.5441.958; Brown DA, 1998, ANNU REV CELL DEV BI, V14, P111, DOI 10.1146/annurev.cellbio.14.1.111; Brunstein CG, 2001, ONCOLOGY-NY, V15, P23; Cyster JG, 1999, SCIENCE, V286, P2098, DOI 10.1126/science.286.5447.2098; Delves PJ, 2000, NEW ENGL J MED, V343, P37, DOI 10.1056/NEJM200007063430107; Delves PJ, 2000, NEW ENGL J MED, V343, P108, DOI 10.1056/NEJM200007133430207; EZEKOWITZ RAB, 1991, NEW ENGL J MED, V324, P509, DOI 10.1056/NEJM199102213240801; Feldmann M, 2001, ANNU REV IMMUNOL, V19, P163, DOI 10.1146/annurev.immunol.19.1.163; GARRED P, 1995, LANCET, V346, P941, DOI 10.1016/S0140-6736(95)91559-1; HALL JG, 1965, BRIT J EXP PATHOL, V46, P450; Hoofnagle JH, 1997, NEW ENGL J MED, V336, P347, DOI 10.1056/NEJM199701303360507; Jamieson BD, 1999, IMMUNITY, V10, P569, DOI 10.1016/S1074-7613(00)80056-4; Klavinskis LS, 1997, VACCINE, V15, P818, DOI 10.1016/S0264-410X(96)00278-2; MACDONALD HR, 1990, NATURE, V343, P642, DOI 10.1038/343642a0; Mackay CR, 2001, NAT IMMUNOL, V2, P95, DOI 10.1038/84298; Medzhitov R, 2000, NEW ENGL J MED, V343, P338, DOI 10.1056/NEJM200008033430506; Metchnikoff E., 1887, ANN I PASTEUR PARIS, V1, P321; Min AD, 2001, AM J GASTROENTEROL, V96, P1143, DOI 10.1111/j.1572-0241.2001.03692.x; MOHAMMED AA, 2000, NAT IMMUNOL, V1, P3; MOND JJ, 1995, ANNU REV IMMUNOL, V13, P655, DOI 10.1146/annurev.iy.13.040195.003255; Morrow J, 1999, AUTOIMMUNE RHEUMATIC; Muzio M, 2000, J LEUKOCYTE BIOL, V67, P450, DOI 10.1002/jlb.67.4.450; Newport MJ, 1996, NEW ENGL J MED, V335, P1941, DOI 10.1056/NEJM199612263352602; OTTAWAY CA, 1994, IMMUNOL TODAY, V15, P511, DOI 10.1016/0167-5699(94)90206-2; Parkman R, 2000, ANNU REV MED, V51, P33, DOI 10.1146/annurev.med.51.1.33; Polman CH, 2000, BRIT MED J, V321, P490, DOI 10.1136/bmj.321.7259.490; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RIDDELL LA, IN PRESS AIDS RES HU; Sallusto F, 1999, NATURE, V401, P708, DOI 10.1038/44385; Serhan CN, 2000, NAT IMMUNOL, V1, P13, DOI 10.1038/76865; Sheikh NA, 2000, CURR OPIN MOL THER, V2, P37; SWAIN SL, 1991, IMMUNOL REV, V123, P115, DOI 10.1111/j.1600-065X.1991.tb00608.x; von Andrian UH, 2000, NEW ENGL J MED, V343, P1020, DOI 10.1056/NEJM200010053431407; Witko-Sarsat V, 2000, LAB INVEST, V80, P617, DOI 10.1038/labinvest.3780067	36	638	670	1	110	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	JUN 2	2001	357	9270					1777	1789		10.1016/S0140-6736(00)04904-7	http://dx.doi.org/10.1016/S0140-6736(00)04904-7			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	440BN	11403834				2022-12-28	WOS:000169156200034
J	Grodstein, F; Manson, JE; Stampfer, MJ				Grodstein, F; Manson, JE; Stampfer, MJ			Postmenopausal hormone use and secondary prevention of coronary events in the nurses' health study - A prospective, observational study	ANNALS OF INTERNAL MEDICINE			English	Article							ESTROGEN REPLACEMENT THERAPY; ARTERY-DISEASE; HEART-DISEASE; WOMEN; RISK; REPRODUCIBILITY; PROGESTIN; MORTALITY; VALIDITY; TRIAL	Background: The Heart and Estrogen/progestin Replacement Study (HERS) was the first randomized clinical trial of combined hormone therapy and secondary prevention of coronary events. The trial had overall null results but reported an unexpected increased risk for recurrent events in the initial year, followed by a decrease during the final years. Objective: To provide additional data on a time trend in risk for recurrent heart disease. Design: A prospective, observational cohort study of secondary prevention of coronary heart disease. Setting: Nurses' Health Study. Patients: 2489 postmenopausal women with previous myocardial infarction or documented atherosclerosis; 213 cases of recurrent nonfatal myocardial infarction or coronary death were identified from 1976 through 1996. Measurements: Information on hormone status and on recurrent disease was collected by using biennial questionnaires. Multi-variable-adjusted relative risks and 95% CIs were calculated from logistic regression models. Results: A trend of decreasing risk for recurrent major coronary heart disease events with increasing duration of hormone use was observed (P for trend = 0.002). For short-term current users, the multivariate-adjusted relative risk for major coronary heart disease was 1.25 (95% CI, 0.78 to 2.00) compared with never-users. However, after longer-term hormone use, the rate of second events was lower in current users than in never-users (relative risk, 0.38 [CI, 0.22 to 0.66]). No clear differences emerged between users of estrogen alone and users of estrogen combined with progestin. Overall, with up to 20 years of follow-up, the relative risk for a second event among current users of hormone therapy was 0.65 (CI, 0.45 to 0.95) compared with never-users. Conclusions: The risk for recurrent major coronary events seems to increase among short-term hormone users with previous coronary disease but to decrease with longer-term use.	Harvard Univ, Sch Med, Brigham & Womens Hosp, Channing Lab, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health	Grodstein, F (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Channing Lab, 181 Longwood Ave, Boston, MA 02115 USA.				NCI NIH HHS [CA40356] Funding Source: Medline; NHLBI NIH HHS [HL34594] Funding Source: Medline; NIA NIH HHS [AG13482] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA040356, R37CA040356] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034594] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R29AG013482] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BARRETTCONNOR E, 1991, ANN INTERN MED, V115, P455, DOI 10.7326/0003-4819-115-6-455; BUSH TL, 1987, CIRCULATION, V75, P1102, DOI 10.1161/01.CIR.75.6.1102; COLDITZ GA, 1987, AM J EPIDEMIOL, V126, P319, DOI 10.1093/aje/126.2.319; CUPPLES LA, 1988, STAT MED, V7, P205, DOI 10.1002/sim.4780070122; Cushman M, 1999, CIRCULATION, V100, P717, DOI 10.1161/01.CIR.100.7.717; DAGOSTINO RB, 1990, STAT MED, V9, P1501, DOI 10.1002/sim.4780091214; Daly E, 1996, LANCET, V348, P977, DOI 10.1016/S0140-6736(96)07113-9; GREENLAND S, 1985, AM J EPIDEMIOL, V122, P495, DOI 10.1093/oxfordjournals.aje.a114131; GRODSTEIN F, 1994, OBSTET GYNECOL, V83, P5; GRODSTEIN F, 1995, PROG CARDIOVASC DIS, V38, P199, DOI 10.1016/S0033-0620(95)80012-3; Grodstein F, 1996, NEW ENGL J MED, V335, P453, DOI 10.1056/NEJM199608153350701; Grodstein F, 1996, LANCET, V348, P983, DOI 10.1016/S0140-6736(96)07308-4; HENDERSON BE, 1991, ARCH INTERN MED, V151, P75, DOI 10.1001/archinte.151.1.75; Herrington DM, 2000, NEW ENGL J MED, V343, P522, DOI 10.1056/NEJM200008243430801; Herrington DM, 1999, ANN INTERN MED, V131, P463, DOI 10.7326/0003-4819-131-6-199909210-00012; Hodis HN, 2000, CIRCULATION, V102, P837; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; Khan MA, 2000, AM J CARDIOL, V86, P330, DOI 10.1016/S0002-9149(00)00926-7; KIM SC, 1995, CIRCULATION S1, V92, P674; Matthews KA, 1996, AM J EPIDEMIOL, V143, P971; NEWTON KM, 1997, AM J EPIDEMIOL, V145, P69; OKeefe JH, 1997, J AM COLL CARDIOL, V29, P1; *ORG WH, 1971, ID REG REP 5 WORK GR; Rimm E B, 1990, Epidemiology, V1, P466, DOI 10.1097/00001648-199011000-00009; ROSANO GMC, 1993, LANCET, V342, P133, DOI 10.1016/0140-6736(93)91343-K; Rothman K, 1986, MODERN EPIDEMIOLOGY; Rothman KJ, 1979, NIH PUBLICATION, V79-1649, P31; STAMPFER MJ, 1984, AM J EPIDEMIOL, V119, P837, DOI 10.1093/oxfordjournals.aje.a113804; SULLIVAN JM, 1990, ARCH INTERN MED, V150, P2557, DOI 10.1001/archinte.150.12.2557; SULLIVAN JM, 1994, J AM COLL CARDIOL, V23, pA49; WILLETT W, 1983, AM J EPIDEMIOL, V117, P651, DOI 10.1093/oxfordjournals.aje.a113598; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086	32	219	233	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUL 3	2001	135	1					1	8		10.7326/0003-4819-135-1-200107030-00003	http://dx.doi.org/10.7326/0003-4819-135-1-200107030-00003			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	449JC	11434726	Green Submitted, Green Published			2022-12-28	WOS:000169680500001
J	Eng, CM; Guffon, N; Wilcox, WR; Germain, DP; Lee, P; Waldek, S; Caplan, L; Linthorst, GE; Desnick, RJ				Eng, CM; Guffon, N; Wilcox, WR; Germain, DP; Lee, P; Waldek, S; Caplan, L; Linthorst, GE; Desnick, RJ		Int Collaborative Fabry Dis Study	Safety and efficacy of recombinant human alpha-galactosidase a replacement therapy in Fabry's disease.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PREVIOUSLY UNTREATED PATIENTS; ENZYME THERAPY; GAUCHER-DISEASE; FACTOR-VIII; GLOBOTRIAOSYLCERAMIDE; CLEARANCE; DIAGNOSIS; INFUSION; STORAGE; PLASMA	Background: Fabry's disease, lysosomal alpha- galactosidase A deficiency, results from the progressive accumulation of globotriaosylceramide and related glycosphingolipids. Affected patients have microvascular disease of the kidneys, heart, and brain. Methods: We evaluated the safety and effectiveness of recombinant alpha -galactosidase A in a multicenter, randomized, placebo-controlled, double-blind study of 58 patients who were treated every 2 weeks for 20 weeks. Thereafter, all patients received recombinant alpha- galactosidase A in an open-label extension study. The primary efficacy end point was the percentage of patients in whom renal microvascular endothelial deposits of globotriaosylceramide were cleared (reduced to normal or near-normal levels). We also evaluated the histologic clearance of microvascular endothelial deposits of globotriaosylceramide in the endomyocardium and skin, as well as changes in the level of pain and the quality of life. Results: In the double-blind study, 20 of the 29 patients in the recombinant alpha -galactosidase A group (69 percent) had no microvascular endothelial deposits of globotriaosylceramide after 20 weeks, as compared with none of the 29 patients in the placebo group (P<0.001). Patients in the recombinant <alpha>-galactosidase A group also had decreased microvascular endothelial deposits of globotriaosylceramide in the skin (P<0.001) and heart (P<0.001). Plasma levels of globotriaosylceramide were directly correlated with clearance of the microvascular deposits. After six months of open-label therapy, all patients in the former placebo group and 98 percent of patients in the former recombinant alpha -galactosidase A group who had biopsies had clearance of microvascular endothelial deposits of globotriaosylceramide. Mild-to-moderate infusion reactions (i.e., rigors and fever) were more common in the recombinant alpha -galactosidase A group than in the placebo group. Conclusions: Recombinant alpha -galactosidase A replacement therapy cleared microvascular endothelial deposits of globotriaosylceramide from the kidneys, heart, and skin in patients with Fabry's disease, reversing the pathogenesis of the chief clinical manifestations of this disease. (N Engl J Med 2001;345:9-16.) Copyright (C) 2001 Massachusetts Medical Society.	Mt Sinai Sch Med, Dept Human Genet, New York, NY 10029 USA; Hop Edouard Herriot, Lyon, France; Univ Calif Los Angeles, Sch Med, Cedars Sinai Burns & Allen Res Inst, Los Angeles, CA USA; Hop Europeen Georges Pompidou, Paris, France; UCL Hosp, London, England; Hope Hosp, Manchester, Lancs, England; Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA; Univ Amsterdam, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands	Icahn School of Medicine at Mount Sinai; CHU Lyon; Cedars Sinai Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; UDICE-French Research Universities; Universite Paris Cite; University College London Hospitals NHS Foundation Trust; University of London; University College London; Harvard University; Beth Israel Deaconess Medical Center; University of Amsterdam; Academic Medical Center Amsterdam	Desnick, RJ (corresponding author), Mt Sinai Sch Med, Dept Human Genet, Box 1498,5th Ave & 100 St, New York, NY 10029 USA.	rjd.fabry@mssm.edu	GERMAIN, Dominique P./AAD-6747-2020	GERMAIN, Dominique/0000-0002-8355-007X	NCRR NIH HHS [5 M01 RR00425, 5 M01 RR00071] Funding Source: Medline; NIDDK NIH HHS [5 R37 DK34045] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000071, M01RR000425] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK034045] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		[Anonymous], 2014, METABOLIC MOL BASES; BRADY RO, 1973, NEW ENGL J MED, V289, P9, DOI 10.1056/NEJM197307052890103; DESNICK RJ, 1971, NEW ENGL J MED, V284, P739, DOI 10.1056/NEJM197104082841401; DESNICK RJ, 1973, J LAB CLIN MED, V81, P157; DESNICK RJ, 1979, P NATL ACAD SCI USA, V76, P5326, DOI 10.1073/pnas.76.10.5326; ELLEDER M, 1990, VIRCHOWS ARCH A, V417, P449, DOI 10.1007/BF01606034; Eng CM, 2001, AM J HUM GENET, V68, P711, DOI 10.1086/318809; Gandek, 1997, SF 36 HLTH SURVEY MA; Goodeve AC, 2000, THROMB HAEMOSTASIS, V83, P844; Grabowski GA, 1998, BLOOD REV, V12, P115, DOI 10.1016/S0268-960X(98)90023-6; Ioannou YA, 2001, AM J HUM GENET, V68, P14, DOI 10.1086/316953; LUSHER JM, 1993, NEW ENGL J MED, V328, P453, DOI 10.1056/NEJM199302183280701; MAPES CA, 1970, SCIENCE, V169, P987, DOI 10.1126/science.169.3949.987; MELZACK R, 1987, PAIN, V30, P191, DOI 10.1016/0304-3959(87)91074-8; Mistry Pramod K., 1999, Journal of Hepatology, V30, P1; RICHARDS SM, 1993, BLOOD, V82, P1402; Rosenberg M, 1999, BLOOD, V93, P2081, DOI 10.1182/blood.V93.6.2081.406k07_2081_2088; Schiffmann R, 2000, P NATL ACAD SCI USA, V97, P365, DOI 10.1073/pnas.97.1.365; VONSCHEIDT W, 1991, NEW ENGL J MED, V324, P395, DOI 10.1056/NEJM199102073240607; Zeidner KM, 1999, ANAL BIOCHEM, V267, P104, DOI 10.1006/abio.1998.2966	20	1152	1234	0	69	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 1	2001	345	1					9	16		10.1056/NEJM200107053450102	http://dx.doi.org/10.1056/NEJM200107053450102			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	449QJ	11439963	Green Published			2022-12-28	WOS:000169697600002
J	Manson, JE; Martin, KA				Manson, JE; Martin, KA			Postmenopausal hormone-replacement therapy.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORONARY-HEART-DISEASE; ESTROGEN REPLACEMENT; SECONDARY PREVENTION; COLORECTAL-CANCER; RISK; PROGESTIN; EVENTS	Patient 1 is a 52-year-old woman at average risk for breast cancer and osteoporosis who is having menopause-related hot flashes and disturbed sleep. atient 2 is a 58-year-old woman with osteopenia whose mother had breast cancer. atient 3 is a 65-year-old woman with a history of coronary revascularization and documented osteoporosis. Each wants to know whether hormone-replacement therapy is right for her.	Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Prevent Med,Dept Med, Boston, MA 02215 USA; Harvard Univ, Massachusetts Gen Hosp, Sch Med, Reprod Endocrine Unit, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard Medical School; Massachusetts General Hospital	Manson, JE (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Prevent Med,Dept Med, 900 Commonwealth Ave E, Boston, MA 02215 USA.	jmanson@rics.bwh.harvard.edu	Davis, Susan R/A-3111-2009	Davis, Susan R/0000-0002-2955-0415				*AM COLL OBST GYN, 1998, ACOG ED B, V247; Barrett-Connor E, 1998, BMJ-BRIT MED J, V317, P457; Barrett-Connor E, 1998, ANNU REV PUBL HEALTH, V19, P55, DOI 10.1146/annurev.publhealth.19.1.55; Beral V, 1997, LANCET, V350, P1047, DOI 10.1016/S0140-6736(97)08233-0; CHAE CU, 1999, CLIN TRIALS CARDIOVA, P399; Clarke S, 2000, EUR HEART J, V21, P212; Col NF, 1999, ARCH INTERN MED, V159, P1458, DOI 10.1001/archinte.159.13.1458; Ettinger B, 1999, JAMA-J AM MED ASSOC, V282, P2124; ETTINGER B, 1994, MENOPAUSE, V1, P19; Grady D, 2000, ANN INTERN MED, V132, P689, DOI 10.7326/0003-4819-132-9-200005020-00002; GRADY D, 1995, OBSTET GYNECOL, V85, P304, DOI 10.1016/0029-7844(94)00383-O; Grodstein F, 2000, J AM GERIATR SOC, V48, P746, DOI 10.1111/j.1532-5415.2000.tb04748.x; Grodstein F, 2000, ANN INTERN MED, V133, P933, DOI 10.7326/0003-4819-133-12-200012190-00008; Hemminki E, 1997, BRIT MED J, V315, P149, DOI 10.1136/bmj.315.7101.149; Herrington DM, 2000, NEW ENGL J MED, V343, P522, DOI 10.1056/NEJM200008243430801; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; *JAC I WOM HLTH EX, 2000, GUID COUNS WOM MAN M; Kanis J, 1998, OSTEOPOROSIS INT, V8, pS1; Kanis JA, 1999, QJM-MON J ASSOC PHYS, V92, P143, DOI 10.1093/qjmed/92.3.143; Keating NL, 1999, ANN INTERN MED, V130, P545, DOI 10.7326/0003-4819-130-7-199904060-00002; LENFANT C, 2000, PRELIMINARY TRENDS W; MACLENNAN SC, 1995, MED J AUSTRALIA, V162, P491, DOI 10.5694/j.1326-5377.1995.tb140014.x; MANSON JE, 1994, AM HEART J, V128, P1337, DOI 10.1016/0002-8703(94)90257-7; MILLER VT, 1995, JAMA-J AM MED ASSOC, V273, P199, DOI 10.1001/jama.1995.03520270033028; Mosca L, 1999, CIRCULATION, V99, P2480, DOI 10.1161/01.CIR.99.18.2480; Mulnard RI, 2000, JAMA-J AM MED ASSOC, V283, P1007, DOI 10.1001/jama.283.8.1007; NAMS, 2000, MENOPAUSE, V7, P76; Nanda K, 1999, OBSTET GYNECOL, V93, P880, DOI 10.1016/S0029-7844(98)00424-4; Nawaz H, 1999, AM J PREV MED, V17, P250; *POSTM ESTR PROG I, 1995, JAMA-J AM MED ASSOC, V274, P1676; Psaty BM, 2001, JAMA-J AM MED ASSOC, V285, P906, DOI 10.1001/jama.285.7.906; Schairer C, 2000, JAMA-J AM MED ASSOC, V283, P485, DOI 10.1001/jama.283.4.485; Shlipak MG, 2000, JAMA-J AM MED ASSOC, V283, P1845, DOI 10.1001/jama.283.14.1845; US Preventive Services Task Force, 1996, GUID CLIN PREV SERV, P18; 1999, ENDOCR PRAC, V5, P355	35	144	152	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 1	2001	345	1					34	U6		10.1056/NEJM200107053450106	http://dx.doi.org/10.1056/NEJM200107053450106			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	449QJ	11439947				2022-12-28	WOS:000169697600006
J	Mitra, PP; Stark, JB				Mitra, PP; Stark, JB			Nonlinear limits to the information capacity of optical fibre communications	NATURE			English	Article								The exponential growth in the rate at which information can be communicated through an optical fibre is a key element in the 'information revolution'. However, as for all exponential growth laws, physical limits must be considered. The nonlinear nature of the propagation of light in optical fibre has made these limits difficult to elucidate. Here we use a key simplification to investigate the theoretical limits to the information capacity of an optical fibre arising from these nonlinearities. The success of our approach lies in relating the nonlinear channel to a linear channel with multiplicative noise, for which we are able to obtain analytical results. In fundamental distinction to linear channels with additive noise, the capacity of a nonlinear channel does not grow indefinitely with increasing signal power, but has a maximal value. The ideas presented here may have broader implications for other nonlinear information channels, such as those involved in sensory transduction in neurobiology. These have been often examined using additive noise linear channel models(1) but, as we show here, nonlinearities can change the picture qualitatively.	Bell Labs, Lucent Technol, Murray Hill, NJ 07974 USA	Alcatel-Lucent; Lucent Technologies; AT&T	Mitra, PP (corresponding author), Bell Labs, Lucent Technol, 600 Mt Ave, Murray Hill, NJ 07974 USA.	pmitra@bell-labs.com		Mitra, Partha/0000-0001-8818-6804				Agrawal G.P., 2006, NONLINEAR FIBER OPTI, V4th; Biglieri E, 1998, IEEE T INFORM THEORY, V44, P2619, DOI 10.1109/18.720551; COVER TM, 1991, INFORMATION THEORY, P374; DESURVIRE E, 1994, ERBIUM DOPED FIBRE A, P69; Feynman R.P., 1963, QUANTUM MECH PATH IN, V1 edn; Kogelnik H, 2000, IEEE J SEL TOP QUANT, V6, P1279, DOI 10.1109/2944.902179; SHANNON CE, 1948, BELL SYST TECH J, V27, P379, DOI 10.1002/j.1538-7305.1948.tb01338.x	7	445	464	2	57	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 28	2001	411	6841					1027	1030		10.1038/35082518	http://dx.doi.org/10.1038/35082518			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	446TF	11429598				2022-12-28	WOS:000169528500041
J	Lin, JD				Lin, JD			The role of apoptosis in autoimmune thyroid disorders and thyroid cancer	BRITISH MEDICAL JOURNAL			English	Review							FAS-MEDIATED APOPTOSIS; HASHIMOTOS-THYROIDITIS; CARCINOMA-CELLS; GRAVES-DISEASE; LIGAND; EXPRESSION; GOITER; DEATH; INVOLVEMENT; PREVALENCE		Chang Gung Univ, Chang Gung Mem Hosp, Dept Internal Med, Div Endocrinol & Metab, Taoyuan Hsien, Taiwan	Chang Gung Memorial Hospital; Chang Gung University	Lin, JD (corresponding author), Chang Gung Univ, Chang Gung Mem Hosp, Dept Internal Med, Div Endocrinol & Metab, 5 Fu Shin St, Taoyuan Hsien, Taiwan.							Arscott PL, 1998, CLIN IMMUNOL IMMUNOP, V87, P207, DOI 10.1006/clin.1998.4526; BARKER DJP, 1984, LANCET, V2, P567; Basolo F, 2000, LAB INVEST, V80, P1413, DOI 10.1038/labinvest.3780148; Basolo F, 1997, BRIT J CANCER, V75, P537, DOI 10.1038/bjc.1997.93; Batteux F, 1999, J IMMUNOL, V162, P603; Benoist C, 1997, CELL, V89, P1, DOI 10.1016/S0092-8674(00)80174-9; Bluher M, 1999, EUR J ENDOCRINOL, V141, P506, DOI 10.1530/eje.0.1410506; Bretz JD, 1999, J BIOL CHEM, V274, P25433, DOI 10.1074/jbc.274.36.25433; CHENG JH, 1994, SCIENCE, V263, P1759, DOI 10.1126/science.7510905; Dayan CM, 1996, NEW ENGL J MED, V335, P99, DOI 10.1056/NEJM199607113350206; DEGROOT LJ, 1989, ENDOCR REV, V10, P537, DOI 10.1210/edrv-10-4-537; Dilla T, 2000, ENDOCRINOLOGY, V141, P420, DOI 10.1210/en.141.1.420; Giordano C, 1997, SCIENCE, V275, P960, DOI 10.1126/science.275.5302.960; Hammond LJ, 1997, J PATHOL, V182, P138, DOI 10.1002/(SICI)1096-9896(199706)182:2<138::AID-PATH810>3.0.CO;2-F; Hiromatsu Y, 1999, THYROID, V9, P341, DOI 10.1089/thy.1999.9.341; Kawakami A, 1997, CLIN EXP IMMUNOL, V110, P434, DOI 10.1046/j.1365-2249.1997.4301447.x; Kiess W, 1998, EUR J ENDOCRINOL, V138, P482, DOI 10.1530/eje.0.1380482; Kurebayashi J, 2000, J CLIN ENDOCR METAB, V85, P2889, DOI 10.1210/jc.85.8.2889; Lin JD, 1997, CANCER J - FRANCE, V10, P217; Liu R, 1998, J BIOL CHEM, V273, P16985, DOI 10.1074/jbc.273.27.16985; Milas Luka, 1994, In Vivo (Attiki), V8, P665; Mitsiades N, 2000, CANCER RES, V60, P4122; Patel VA, 2000, J ENDOCRINOL, V164, P323, DOI 10.1677/joe.0.1640323; PETTERSSON B, 1991, INT J CANCER, V48, P28; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; Stassi G, 1999, J IMMUNOL, V162, P263; Tamura M, 1998, ENDOCRINOLOGY, V139, P3646, DOI 10.1210/en.139.8.3646; WEETMAN AP, 1994, ENDOCR REV, V15, P788, DOI 10.1210/er.15.6.788; WYLLIE AH, 1984, J PATHOL, V142, P67, DOI 10.1002/path.1711420112; Yin F, 1999, ANTICANCER RES, V19, P4297	30	25	25	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 23	2001	322	7301					1525	1527		10.1136/bmj.322.7301.1525	http://dx.doi.org/10.1136/bmj.322.7301.1525			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	446UF	11420275	Green Published			2022-12-28	WOS:000169532000020
J	Sjostrom, J; Bergh, J				Sjostrom, J; Bergh, J			How apoptosis is regulated, and what goes wrong in cancer	BRITISH MEDICAL JOURNAL			English	Article							BREAST-CANCER; BCL-2; MUTATIONS; THERAPY; GENE		Univ Helsinki Hosp, Dept Oncol, Hyks 00029, Finland; Univ Helsinki Hosp, Dept Pathol, Hyks 00029, Finland; Karolinska Hosp & Inst, Radiumhemmet, SE-17176 Stockholm, Sweden	University of Helsinki; Helsinki University Central Hospital; University of Helsinki; Helsinki University Central Hospital; Karolinska Institutet; Karolinska University Hospital	Sjostrom, J (corresponding author), Univ Helsinki Hosp, Dept Oncol, PL 180, Hyks 00029, Finland.			Bergh, Jonas/0000-0001-5526-1847				Hamilton A, 2000, ANN ONCOL, V11, P647, DOI 10.1023/A:1008390429428; HOLMGREN L, 1995, NAT MED, V1, P149, DOI 10.1038/nm0295-149; Rampino N, 1997, SCIENCE, V275, P967, DOI 10.1126/science.275.5302.967; Reed JC, 1997, SEMIN HEMATOL, V34, P9; Reed JC, 2000, AM J PATHOL, V157, P1415, DOI 10.1016/S0002-9440(10)64779-7; Schmitt CA, 1999, J PATHOL, V187, P127; Sjogren S, 1996, J NATL CANCER I, V88, P173, DOI 10.1093/jnci/88.3-4.173; TEIXEIRA C, 1995, CANCER RES, V55, P3902; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Wallace-Brodeur RR, 1999, CELL MOL LIFE SCI, V55, P64, DOI 10.1007/s000180050270; Waters JS, 2000, J CLIN ONCOL, V18, P1812, DOI 10.1200/JCO.2000.18.9.1812	11	56	58	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 23	2001	322	7301					1538	1539		10.1136/bmj.322.7301.1538	http://dx.doi.org/10.1136/bmj.322.7301.1538			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	446UF	11420280	Green Published			2022-12-28	WOS:000169532000024
J	Piperno, DR				Piperno, DR			Archaeology - On maize and the sunflower	SCIENCE			English	Editorial Material									Smithsonian Trop Res Inst, Ctr Trop Paleoecol & Archaeol, Balboa, Panama	Smithsonian Institution; Smithsonian Tropical Research Institute	Piperno, DR (corresponding author), Smithsonian Trop Res Inst, Ctr Trop Paleoecol & Archaeol, Box 2072, Balboa, Panama.							BUSH MB, 1989, NATURE, V340, P303, DOI 10.1038/340303a0; FRITZ GJ, 1994, CURR ANTHROPOL, V35, P305, DOI 10.1086/204280; Harris DR, 1996, ORIGINS SPREAD AGR P; LENTZ DL, IN PRESS EC BOT; PEARSALL DM, IN PRESS J ARCHAEOL; Piperno D.R., 1998, ORIGINS AGR LOWLAND; Piperno DR, 2001, P NATL ACAD SCI USA, V98, P2101, DOI 10.1073/pnas.98.4.2101; Pope KO, 2001, SCIENCE, V292, P1370, DOI 10.1126/science.292.5520.1370; Smith B. D., 1998, EMERGENCE AGR; Smith BD, 1997, SCIENCE, V276, P932, DOI 10.1126/science.276.5314.932	10	11	11	1	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUN 22	2001	292	5525					2260	2261		10.1126/science.1062689	http://dx.doi.org/10.1126/science.1062689			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	445KD	11423640				2022-12-28	WOS:000169455900034
J	Al Khawaja, U; Stoof, H				Al Khawaja, U; Stoof, H			Skyrmions in a ferromagnetic Bose-Einstein condensate	NATURE			English	Article							SPIN DOMAINS; STATES	Multi-component Bose-Einstein condensates(1-3) provide opportunities to explore experimentally the wealth of physics associated with the spin degrees of freedom(4-7). The ground-state properties(8-11) and line-like vortex excitations(8,12,13) of these quantum systems have been studied theoretically. In principle, nontrivial spin textures consisting of point-like topological excitations, orskyrmions(14,15), could exist in a multi-component Bose-Einstein condensate, owing to the superfluid nature of the gas. Although skyrmion excitations are already known in the context of nuclear physics and the quantum-Hall effect, creating these excitations in an atomic condensate would offer an opportunity to study their physical behaviour in much greater detail, while also enabling an ab initio comparison between theory and experiment. Here we investigate theoretically the stability of skyrmions in a fictitious spin-1/2 condensate of Rb-87 atoms. We find that skyrmions can exist in such a gas only as a metastable state, but with a lifetime comparable to (or even longer than) the typical lifetime of the condensate itself.	Univ Utrecht, Inst Theoret Phys, NL-3584 CC Utrecht, Netherlands	Utrecht University	Al Khawaja, U (corresponding author), Univ Utrecht, Inst Theoret Phys, Princetonplein 5, NL-3584 CC Utrecht, Netherlands.	u.alkhawaja@phys.uu.nl		Stoof, Henk/0000-0003-1993-2556				Cote R, 1997, PHYS REV LETT, V78, P4825, DOI 10.1103/PhysRevLett.78.4825; Hall DS, 1998, PHYS REV LETT, V81, P1539, DOI 10.1103/PhysRevLett.81.1539; Ho TL, 2000, PHYS REV LETT, V84, P4031, DOI 10.1103/PhysRevLett.84.4031; Ho TL, 1998, PHYS REV LETT, V81, P742, DOI 10.1103/PhysRevLett.81.742; Julienne PS, 1997, PHYS REV LETT, V78, P1880, DOI 10.1103/PhysRevLett.78.1880; Law CK, 1998, PHYS REV LETT, V81, P5257, DOI 10.1103/PhysRevLett.81.5257; Madison KW, 2000, PHYS REV LETT, V84, P806, DOI 10.1103/PhysRevLett.84.806; Matthews MR, 1999, PHYS REV LETT, V83, P3358, DOI 10.1103/PhysRevLett.83.3358; Matthews MR, 1999, PHYS REV LETT, V83, P2498, DOI 10.1103/PhysRevLett.83.2498; Myatt CJ, 1997, PHYS REV LETT, V78, P586, DOI 10.1103/PhysRevLett.78.586; Ohmi T, 1998, J PHYS SOC JPN, V67, P1822, DOI 10.1143/JPSJ.67.1822; SKYRME TH, 1961, PROC R SOC LON SER-A, V260, P127, DOI 10.1098/rspa.1961.0018; SKYRME THR, 1962, NUCL PHYS, V31, P556, DOI 10.1016/0029-5582(62)90775-7; Stamper-Kurn DM, 1998, PHYS REV LETT, V80, P2027, DOI 10.1103/PhysRevLett.80.2027; Stamper-Kurn DM, 1999, PHYS REV LETT, V83, P661, DOI 10.1103/PhysRevLett.83.661; Stenger J, 1998, NATURE, V396, P345, DOI 10.1038/24567; Stoof HTC, 1997, J STAT PHYS, V87, P1353, DOI 10.1007/BF02181289; Williams JE, 1999, NATURE, V401, P568, DOI 10.1038/44095; Yip SK, 1999, PHYS REV LETT, V83, P4677, DOI 10.1103/PhysRevLett.83.4677	19	234	234	3	65	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUN 21	2001	411	6840					918	920		10.1038/35082010	http://dx.doi.org/10.1038/35082010			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	444EN	11418849	Green Published, Green Submitted			2022-12-28	WOS:000169386200035
J	Boughman, JW				Boughman, JW			Divergent sexual selection enhances reproductive isolation in sticklebacks	NATURE			English	Article							SYMPATRIC STICKLEBACKS; INTRASPECIFIC VARIATION; GASTEROSTEUS-ACULEATUS; NATURAL-SELECTION; BRITISH-COLUMBIA; SPECIES-PAIR; SPECIATION; EVOLUTION; TRAITS; COMPETITION	Sexual selection may facilitate speciation because it can cause rapid evolutionary diversification of male mating signals and female preferences. Divergence in these traits can then contribute to reproductive isolation(1-3). The sensory drive hypothesis predicts that three mechanisms underlie divergence in sexually selected traits(4): (1) habitat-specific transmission of male signals(5-7); (2) adaptation of female perceptual sensitivity to local ecological conditions(8); and (3) matching of male signals to female perceptual sensitivity(4,9). I test these mechanisms in threespine sticklebacks (Gasterosteus spp.) that live in different light environments. Here I show that female perceptual sensitivity to red light varies with the extent of redshift in the light environment, and contributes to divergent preferences. Male nuptial colour varies with environment and is tuned to female perceptual sensitivity. The extent of divergence among populations in both male signal colour and female preference for red is correlated with the extent of reproductive isolation in these recently diverged species. These results demonstrate that divergent sexual selection generated by sensory drive contributes to speciation.	Univ British Columbia, Dept Zool, Vancouver, BC V6T 1Z4, Canada	University of British Columbia	Boughman, JW (corresponding author), Univ British Columbia, Dept Zool, 6270 Univ Blvd, Vancouver, BC V6T 1Z4, Canada.			Boughman, Janette/0000-0002-5731-7389				CRONLYDILLON J, 1968, J EXP BIOL, V49, P679; Endler J. A., 1992, AM NAT, V139, pS125; ENDLER JA, 1991, VISION RES, V31, P587, DOI 10.1016/0042-6989(91)90109-I; Fisher R.A., 1930, GENETICAL THEORY NAT; Higashi M, 1999, NATURE, V402, P523, DOI 10.1038/990087; Klump G.M., 1995, METHODS COMP PSYCHOA; KODRICBROWN A, 1984, AM NAT, V124, P309, DOI 10.1086/284275; LANDE R, 1981, P NATL ACAD SCI-BIOL, V78, P3721, DOI 10.1073/pnas.78.6.3721; LANDE R, 1988, J THEOR BIOL, V133, P85, DOI 10.1016/S0022-5193(88)80026-2; LEVINE JS, 1979, SENS PROCESS, V3, P95; LUTHGOSE JN, 1979, ECOLOGY VISION; MARCHETTI K, 1993, NATURE, V362, P149, DOI 10.1038/362149a0; Martins EP, 1997, AM NAT, V149, P646, DOI 10.1086/286013; MCDONALD CG, 1995, J COMP PHYSIOL A, V176, P255; MCFARLAND WN, 1975, VISION RES, V15, P1071, DOI 10.1016/0042-6989(75)90003-6; McPhail J.D., 1994, P399; MCPHAIL JD, 1984, CAN J ZOOL, V62, P1402, DOI 10.1139/z84-201; MCPHAIL JD, 1992, CAN J ZOOL, V70, P361, DOI 10.1139/z92-054; Nagel L, 1998, EVOLUTION, V52, P209, DOI 10.1111/j.1558-5646.1998.tb05154.x; Podos J, 2001, NATURE, V409, P185, DOI 10.1038/35051570; REIMCHEN TE, 1989, EVOLUTION, V43, P450, DOI 10.1111/j.1558-5646.1989.tb04239.x; Rundle HD, 2000, SCIENCE, V287, P306, DOI 10.1126/science.287.5451.306; RYAN M.J., 1990, OXFORD SURV EVOL BIO, V7, P156; RYAN MJ, 1991, BIOL J LINN SOC, V44, P249, DOI 10.1111/j.1095-8312.1991.tb00619.x; SCHLUTER D, 1993, P ROY SOC B-BIOL SCI, V253, P117, DOI 10.1098/rspb.1993.0089; SCHLUTER D, 1994, SCIENCE, V266, P798, DOI 10.1126/science.266.5186.798; Schluter D, 1998, ENDLESS FORMS, P114; Seehausen O, 1997, SCIENCE, V277, P1808, DOI 10.1126/science.277.5333.1808; TAYLOR EB, 2000, GASTROSTEUS P R SO B, V267, P2375, DOI DOI 10.1098/RSPB.2000.1294; WESTEBERHARD MJ, 1983, Q REV BIOL, V58, P155, DOI 10.1086/413215	30	513	520	1	215	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 21	2001	411	6840					944	948		10.1038/35082064	http://dx.doi.org/10.1038/35082064			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	444EN	11418857				2022-12-28	WOS:000169386200043
J	Topol, EJ; Moliterno, DJ; Herrmann, HC; Powers, ER; Grines, CL; Cohen, DJ; Cohen, EA; Bertrand, M; Neumann, FJ; Stone, GW; DiBattiste, PM; Demopoulos, L				Topol, EJ; Moliterno, DJ; Herrmann, HC; Powers, ER; Grines, CL; Cohen, DJ; Cohen, EA; Bertrand, M; Neumann, FJ; Stone, GW; DiBattiste, PM; Demopoulos, L		TARGET Investigators	Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MYOCARDIAL-INFARCTION; BLOCKADE; ANGIOPLASTY; DESIGN; 7E3	Background: In the setting of percutaneous coronary revascularization, agents in the class known as platelet glycoprotein IIb/IIIa inhibitors have significantly reduced the incidence of death or nonfatal myocardial infarction at 30 days. We assessed whether there are differences in safety or efficacy between two such inhibitors, tirofiban and abciximab. Methods: Using a double-blind, double-dummy design at 149 hospitals in 18 countries, we randomly assigned patients to receive either tirofiban or abciximab before undergoing percutaneous coronary revascularization with the intent to perform stenting. The primary end point was a composite of death, nonfatal myocardial infarction, or urgent target-vessel revascularization at 30 days. The trial was designed and statistically powered to demonstrate the noninferiority of tirofiban as compared with abciximab. Results: The primary end point occurred more frequently among the 2398 patients in the tirofiban group than among the 2411 patients in the abciximab group (7.6 percent vs. 6.0 percent; hazard ratio, 1.26; one-sided 95 percent confidence interval of 1.51, demonstrating lack of equivalence, and two-sided 95 percent confidence interval of 1.01 to 1.57, demonstrating the superiority of abciximab over tirofiban; P = 0.038). The magnitude and the direction of the effect were similar for each component of the composite end point (hazard ratio for death, 1.21; hazard ratio for myocardial infarction, 1.27; and hazard ratio for urgent target-vessel revascularization, 1.26), and the difference in the incidence of myocardial infarction between the tirofiban group and the abciximab group was significant (6.9 percent and 5.4 percent, respectively; P = 0.04). The relative benefit of abciximab was consistent regardless of age, sex, the presence or absence of diabetes, or the presence or absence of pretreatment with clopidogrel. There were no significant differences in the rates of major bleeding complications or transfusions, but tirofiban was associated with a lower rate of minor bleeding episodes and thrombocytopenia. Conclusions: Although the trial was intended to assess the noninferiority of tirofiban as compared with abciximab, the findings demonstrated that tirofiban offered less protection from major ischemic events than did abciximab. (N Engl J Med 2001;344:1888-94.) Copyright (C) 2001 Massachusetts Medical Society.	Cleveland Clin Fdn, Dept Cardiol, Cleveland, OH 44195 USA; Univ Penn, Med Ctr, Philadelphia, PA 19104 USA; Univ Virginia, Sch Med, Charlottesville, VA 22908 USA; William Beaumont Hosp, Royal Oak, MI 48072 USA; Beth Israel Deaconess Hosp, Boston, MA USA; Sunnybrook & Womens Coll, Hlth Sci Ctr, Toronto, ON, Canada; Hop Cardiol, F-59037 Lille, France; Tech Univ Munich, Med Klin, D-8000 Munich, Germany; Lenox Hill Hosp, New York, NY 10021 USA; Merck, W Point, PA USA; Riverside Methodist Hosp, Columbus, OH 43214 USA	Cleveland Clinic Foundation; University of Pennsylvania; University of Virginia; Beaumont Health; Harvard University; Beth Israel Deaconess Medical Center; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; Universite de Lille - ISITE; CHU Lille; Technical University of Munich; Northwell Health	Topol, EJ (corresponding author), Cleveland Clin Fdn, Dept Cardiol, Desk F25,9500 Euclid Ave, Cleveland, OH 44195 USA.			Topol, Eric/0000-0002-1478-4729				Bazzino O, 1998, NEW ENGL J MED, V338, P1498; Bazzino O, 1998, NEW ENGL J MED, V338, P1488; Bhatt DL, 2000, JAMA-J AM MED ASSOC, V284, P1549, DOI 10.1001/jama.284.12.1549; CALIFF RM, 1994, NEW ENGL J MED, V330, P956, DOI 10.1056/nejm199404073301402; *COMM PROPR MED PR, 1999, POINTS CONSIDER BIOS; Hanrath P, 1997, CIRCULATION, V96, P1445; Hauck WW, 1999, DRUG INF J, V33, P109, DOI 10.1177/009286159903300114; Heeschen C, 1999, LANCET, V354, P1757, DOI 10.1016/S0140-6736(99)10285-X; Kaul DK, 2000, BLOOD, V95, P368, DOI 10.1182/blood.V95.2.368; Kereiakes DJ, 1996, J AM COLL CARDIOL, V27, P536; Lincoff AM, 2000, JAMA-J AM MED ASSOC, V284, P1839, DOI 10.1001/jama.284.14.1839; Mickelson JK, 1999, J AM COLL CARDIOL, V33, P97, DOI 10.1016/S0735-1097(98)00532-4; Moliterno DJ, 2000, AM HEART J, V140, P722, DOI 10.1067/mhj.2000.110094; Morikawa T, 1995, J Biopharm Stat, V5, P297, DOI 10.1080/10543409508835115; Neumann FJ, 1999, J AM COLL CARDIOL, V34, P1420, DOI 10.1016/S0735-1097(99)00350-2; *PLAT REC INH ISCH, 1998, NEW ENGL J MED, V339, P415; RAO AK, 1988, J AM COLL CARDIOL, V11, P1; Simoons ML, 1997, LANCET, V349, P1429; Snapinn Steven M, 2000, Curr Control Trials Cardiovasc Med, V1, P19, DOI 10.1186/CVM-1-1-019; Steinhubl SR, 1999, CIRCULATION, V100, P1977, DOI 10.1161/01.CIR.100.19.1977; Tcheng JE, 1997, LANCET, V349, P1422; Tcheng JE, 2000, LANCET, V356, P2037; Thompson RD, 2000, J IMMUNOL, V165, P426, DOI 10.4049/jimmunol.165.1.426; Topol EJ, 1998, LANCET, V352, P87, DOI 10.1016/S0140-6736(98)85010-1; Topol EJ, 1999, LANCET, V353, P227, DOI 10.1016/S0140-6736(98)11086-3; Topol EJ, 1997, NEW ENGL J MED, V336, P1689; Topol EJ, 1998, CIRCULATION, V98, P1802, DOI 10.1161/01.CIR.98.17.1802; Topol EJ, 2000, CIRCULATION, V101, P570, DOI 10.1161/01.CIR.101.5.570; 1997, LANCET, V350, P744	29	512	539	0	16	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 21	2001	344	25					1888	1894		10.1056/NEJM200106213442502	http://dx.doi.org/10.1056/NEJM200106213442502			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	443VJ	11419425				2022-12-28	WOS:000169362100002
J	Farsides, B; Dunlop, RJ				Farsides, B; Dunlop, RJ			Measuring quality of life - Is there such a thing as a life not worth living?	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ASSISTED SUICIDE; HEALTH-CARE; VALUATIONS; ILLNESS		Kings Coll London, Ctr Med Law & Eth, London WC2R 2LS, England; St Thomas Hosp, Sch Med & Dent, London SE5 9PJ, England; Guys Hosp, Kings Coll, London, England	University of London; King's College London; Guy's & St Thomas' NHS Foundation Trust; Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London	Farsides, B (corresponding author), Kings Coll London, Ctr Med Law & Eth, London WC2R 2LS, England.	bobbie.farsides@kcl.ac.uk		Farsides, Bobbie/0000-0002-5477-0612				Addington-Hall J, 2001, BRIT MED J, V322, P1417, DOI 10.1136/bmj.322.7299.1417; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; Billingham LJ, 1999, HLTH TECHNOL ASSESS, V3, P55; BOYLE MH, 1983, NEW ENGL J MED, V308, P1330, DOI 10.1056/NEJM198306023082206; Chin AE, 1999, NEW ENGL J MED, V340, P577, DOI 10.1056/NEJM199902183400724; Chochinov HM, 1999, LANCET, V354, P816, DOI 10.1016/S0140-6736(99)80011-7; CHOCHINOV HM, 1995, AM J PSYCHIAT, V152, P1185; EMANUEL EJ, 1992, JAMA-J AM MED ASSOC, V267, P2067; Enck R E, 1999, Am J Hosp Palliat Care, V16, P500, DOI 10.1177/104990919901600301; Ganzini L, 1998, NEW ENGL J MED, V339, P967, DOI 10.1056/NEJM199810013391406; Haverkate I, 2000, BRIT MED J, V321, P865, DOI 10.1136/bmj.321.7265.865; Kaplan RM, 1998, OX MED PUBL, P69; MOUNT BM, 1983, J CHRON DIS, V36, P731, DOI 10.1016/0021-9681(83)90068-1; Orley J, 1998, BRIT J PSYCHIAT, V172, P291, DOI 10.1192/bjp.172.4.291; ROSSER R, 1978, INT J EPIDEMIOL, V7, P347, DOI 10.1093/ije/7.4.347; SPIEGELHALTER DJ, 1992, BRIT MED J, V305, P1205, DOI 10.1136/bmj.305.6863.1205; SPRANGERS MAG, 1992, J CLIN EPIDEMIOL, V45, P743, DOI 10.1016/0895-4356(92)90052-O; VANAGT HME, 1994, SOC SCI MED, V39, P1537, DOI 10.1016/0277-9536(94)90005-1	18	21	21	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 16	2001	322	7300					1481	1483		10.1136/bmj.322.7300.1481	http://dx.doi.org/10.1136/bmj.322.7300.1481			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	444FJ	11408312	Green Published			2022-12-28	WOS:000169389200037
J	Schibler, U; Ripperger, JA; Brown, SA				Schibler, U; Ripperger, JA; Brown, SA			Circadian rhythms - Chronobiology - Reducing time	SCIENCE			English	Editorial Material							CLOCK; LOOP		Univ Geneva, Dept Mol Biol Sci 2, CH-1211 Geneva 4, Switzerland	University of Geneva	Schibler, U (corresponding author), Univ Geneva, Dept Mol Biol Sci 2, CH-1211 Geneva 4, Switzerland.		Brown, Steven/E-4955-2013					Bunger MK, 2000, CELL, V103, P1009, DOI 10.1016/S0092-8674(00)00205-1; Devlin PF, 2000, PLANT CELL, V12, P2499, DOI 10.1105/tpc.12.12.2499; Emery P, 2000, NATURE, V404, P456, DOI 10.1038/35006558; Garcia JA, 2000, SCIENCE, V288, P2226, DOI 10.1126/science.288.5474.2226; GOTO K, 1985, SCIENCE, V228, P1284, DOI 10.1126/science.2988128; KAMINSKY YG, 1984, INT J BIOCHEM, V16, P629, DOI 10.1016/0020-711X(84)90032-6; King DP, 1997, CELL, V89, P641, DOI 10.1016/S0092-8674(00)80245-7; Kume K, 1999, CELL, V98, P193, DOI 10.1016/S0092-8674(00)81014-4; MCKNIGHT SL, COMMUNICATION; Reick M, 2001, SCIENCE, V293, P506, DOI 10.1126/science.1060699; Ripperger JA, 2001, CURR OPIN CELL BIOL, V13, P357, DOI 10.1016/S0955-0674(00)00220-9; ROBINSON JL, 1981, J NUTR, V111, P1711, DOI 10.1093/jn/111.10.1711; Rutter J, 2001, SCIENCE, V293, P510, DOI 10.1126/science.1060698; Shearman LP, 1999, NEUROSCIENCE, V89, P387, DOI 10.1016/S0306-4522(98)00325-X	14	22	22	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 20	2001	293	5529					437	438		10.1126/science.1063296	http://dx.doi.org/10.1126/science.1063296			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	454HG	11441150				2022-12-28	WOS:000169966700028
J	Campbell, FA; Tramer, MR; Carroll, D; Reynolds, DJ; Moore, RA; McQuay, HJ				Campbell, FA; Tramer, MR; Carroll, D; Reynolds, DJ; Moore, RA; McQuay, HJ			Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review	BMJ-BRITISH MEDICAL JOURNAL			English	Article							RANDOMIZED CLINICAL-TRIALS; MARIJUANA; DELTA-9-TETRAHYDROCANNABINOL; TETRAHYDROCANNABINOL; PLACEBO; SMOKING; RELIEF	Objective To establish whether cannabis is an effective and safe treatment option in the management of pain. Design Systematic review of randomised controlled trials. Data sources Electronic databases Medline, Embase, Oxford Pain Database, and Cochrane Library; references from identified papers; hand searches. Study selection Trials of cannabis given by any route of administration (experimental intervention) with any analgesic or placebo (control intervention) in patients with acute, chronic non-malignant, or cancer pain. Outcomes examined were pain intensity scores, pain relief scores, and adverse effects. Validity of trials was assessed independently with the Oxford score. Data extraction Independent data extraction; discrepancies resolved by consensus. Data synthesis 20 randomised controlled trials were identified, 11 of which were excluded. Of the 9 included trials (222 patients), 5 trials related to cancer pain, 2 to chronic non-malignant pain, and 2 to acute postoperative pain. No randomised controlled trials evaluated cannabis; all tested active substances were cannabinoids. Oral delta-9-tetrahydrocannabinol (THC) 5-20 mg, an oral synthetic nitrogen analogue of THC 1 mg, and intramuscular levonantradol 1.5-3 mg were about as effective as codeine 50-120 mg, and oral benzopyranoperidine 2-4 mg was less effective than codeine 60-120 mg and no better than placebo. Adverse effects, most often psychotropic, were common. Conclusion Cannabinoids are no more effective than codeine in controlling pain and have depressant effects on the central nervous system that limit their use. Their widespread introduction into clinical practice for pain management is therefore undesirable. In acute postoperative pain they should not be used. Before cannabinoids can be considered for treating spasticity and neuropathic pain, further valid randomised controlled studies are needed.	Queens Med Ctr, Pain Management Ctr, Nottingham NG7 2UH, England; Hop Univ, Dept APSIC, Div Anesthesiol, CH-1211 Geneva 14, Switzerland; Oxford Radcliffe Hosp, Nuffield Dept Anaesthet, Oxford OX3 7LJ, England; Radcliffe Infirm, Dept Clin Pharmacol, Oxford OX2 6HE, England	University of Nottingham; University of Geneva; University of Oxford; Radcliffe Infirmary	Campbell, FA (corresponding author), Queens Med Ctr, Pain Management Ctr, Undercroft,S Block, Nottingham NG7 2UH, England.	fiona.campbell@mail.qmcuh-tr.trent.nhs.uk						ARONOW WS, 1974, NEW ENGL J MED, V291, P65, DOI 10.1056/NEJM197407112910203; Ashton CH, 1999, BRIT J ANAESTH, V83, P637, DOI 10.1093/bja/83.4.637; *BM ASS, 1997, THER US CANN; *BM ASS, 1997, THERAPEUTIC USES CAN; CLARK WC, 1981, J CLIN PHARMACOL, V21, pS299, DOI 10.1002/j.1552-4604.1981.tb02608.x; CONSROE P, 1991, PHARMACOL BIOCHEM BE, V40, P701, DOI 10.1016/0091-3057(91)90386-G; GREENBERG HS, 1994, CLIN PHARMACOL THER, V55, P324, DOI 10.1038/clpt.1994.33; HILL SY, 1974, J PHARMACOL EXP THER, V188, P415; Holdcroft A, 1997, ANAESTHESIA, V52, P483, DOI 10.1111/j.1365-2044.1997.139-az0132.x; Jadad AR, 1996, PAIN, V66, P239, DOI 10.1016/0304-3959(96)03033-3; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; JAIN AK, 1981, J CLIN PHARMACOL, V21, pS320, DOI 10.1002/j.1552-4604.1981.tb02610.x; JOCHIMSEN PR, 1978, CLIN PHARMACOL THER, V24, P223; KANTOR T G, 1981, Pain, pS37; Martin WJ, 1999, PAIN, V82, P199, DOI 10.1016/S0304-3959(99)00045-7; MARTIN WJ, 1999, IASP NEWSLETTER  SUM, P3; MARTYN CN, 1995, LANCET, V345, P579, DOI 10.1016/S0140-6736(95)90485-9; MAURER M, 1990, EUR ARCH PSY CLIN N, V240, P1, DOI 10.1007/BF02190083; McQuay HJ, 1998, EVIDENCE BASED RESOU; MEEK C, 1994, BMA NEWS REV     FEB, P1; MILSTEIN SL, 1975, INT PHARMACOPSYCHIAT, V10, P177, DOI 10.1159/000468188; MOERTEL CG, 1974, JAMA-J AM MED ASSOC, V229, P55, DOI 10.1001/jama.229.1.55; Moher D, 1999, LANCET, V354, P1896, DOI 10.1016/S0140-6736(99)04149-5; NOYES R, 1975, CLIN PHARMACOL THER, V18, P84; NOYES R, 1975, J CLIN PHARMACOL, V15, P139, DOI 10.1002/j.1552-4604.1975.tb02348.x; PETRO DJ, 1981, J CLIN PHARMACOL, V21, pS413, DOI 10.1002/j.1552-4604.1981.tb02621.x; RAFT D, 1977, CLIN PHARMACOL THER, V21, P26; STAQUET M, 1978, CLIN PHARMACOL THER, V23, P397; Tramer MR, 2001, BMJ-BRIT MED J, V323, P16, DOI 10.1136/bmj.323.7303.16; UNGERLEIDER J T, 1987, Advances in Alcohol and Substance Abuse, V7, P39	30	235	263	3	42	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 7	2001	323	7303					13	16		10.1136/bmj.323.7303.13	http://dx.doi.org/10.1136/bmj.323.7303.13			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	451WA	11440935	Green Submitted, Bronze, Green Published			2022-12-28	WOS:000169824300016
J	Sakuta, H; Suzuki, R; Takahashi, H; Kato, A; Shintani, T; Iemura, S; Yamamoto, TS; Ueno, N; Noda, M				Sakuta, H; Suzuki, R; Takahashi, H; Kato, A; Shintani, T; Iemura, S; Yamamoto, TS; Ueno, N; Noda, M			Ventroptin: A BMP-4 antagonist expressed in a double-gradient pattern in the retina	SCIENCE			English	Article							GANGLION-CELL AXONS; RETINOTECTAL PROJECTION; EPHRINA LIGANDS; CHICK; MAP; ELF-1	In the visual system, the establishment of the anteroposterior and dorsoventral axes in the retina ana tectum during development is important for topographic retinotectal projection. We identified chick Ventroptin, an antagonist of bone morphogenetic protein 4 (BMP-4), which is mainly expressed in the ventral retina, not only with a ventral high-dorsal low gradient but also with a nasal high-temporal Low gradient at later stages, Misexpression of Ventroptin altered expression patterns of several topographic genes in the retina and projection of the retinal axons to the tectum along both axes. Thus, the topographic retinotectal projection appears to be specified by the double-gradient molecule Ventroptin along the two axes.	Grad Univ Adv Studies, Natl Inst Basic Biol, Div Mol Neurobiol, Okazaki, Aichi 4448585, Japan; Grad Univ Adv Studies, Natl Inst Basic Biol, Div Morphogenesis, Okazaki, Aichi 4448585, Japan; Grad Univ Adv Studies, Dept Mol Biomech, Okazaki, Aichi 4448585, Japan	Graduate University for Advanced Studies - Japan; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB); Graduate University for Advanced Studies - Japan; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Basic Biology (NIBB); Graduate University for Advanced Studies - Japan	Noda, M (corresponding author), Grad Univ Adv Studies, Natl Inst Basic Biol, Div Mol Neurobiol, 38 Nishigonaka, Okazaki, Aichi 4448585, Japan.		Noda, Masaharu/D-7146-2016	Noda, Masaharu/0000-0002-3796-524X; Sakuta, Hiraki/0000-0003-2375-0528; Ueno, Naoto/0000-0002-8375-2317; Shintani, Takafumi/0000-0002-6165-2307				Blitz IL, 2000, DEV BIOL, V223, P120, DOI 10.1006/dbio.2000.9740; CHENG HJ, 1995, CELL, V82, P371, DOI 10.1016/0092-8674(95)90426-3; CROSSLAND WJ, 1974, J COMP NEUROL, V155, P127, DOI 10.1002/cne.901550202; CROSSLAND WJ, 1975, BRAIN RES, V91, P1, DOI 10.1016/0006-8993(75)90463-1; Dudley AT, 1997, DEV DYNAM, V208, P349; Dutting D, 1999, DEV BIOL, V216, P297, DOI 10.1006/dbio.1999.9489; Fainsod A, 1997, MECH DEVELOP, V63, P39, DOI 10.1016/S0925-4773(97)00673-4; Hornberger MR, 1999, NEURON, V22, P731, DOI 10.1016/S0896-6273(00)80732-1; Hyatt GA, 1996, DEVELOPMENT, V122, P195; KAHN AJ, 1974, DEV BIOL, V38, P30, DOI 10.1016/0012-1606(74)90256-5; Koshiba-Takeuchi K, 2000, SCIENCE, V287, P134, DOI 10.1126/science.287.5450.134; MATSUNO T, 1992, NEUROSCI RES, V15, P96, DOI 10.1016/0168-0102(92)90022-5; Monschau B, 1997, EMBO J, V16, P1258, DOI 10.1093/emboj/16.6.1258; Schulte D, 1999, NEURON, V24, P541, DOI 10.1016/S0896-6273(00)81111-3; Schulte D, 2000, DEVELOPMENT, V127, P5033; Smith WC, 1999, TRENDS GENET, V15, P3, DOI 10.1016/S0168-9525(98)01641-2; SPERRY RW, 1963, P NATL ACAD SCI USA, V50, P703, DOI 10.1073/pnas.50.4.703; Suzuki H, 1996, NUCLEIC ACIDS RES, V24, P289, DOI 10.1093/nar/24.2.289; Suzuki R, 2000, MECH DEVELOP, V98, P37, DOI 10.1016/S0925-4773(00)00450-0; Yuasa J, 1996, NATURE, V382, P632, DOI 10.1038/382632a0	20	157	167	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JUL 6	2001	293	5527					111	115		10.1126/science.1058379	http://dx.doi.org/10.1126/science.1058379			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	451BB	11441185				2022-12-28	WOS:000169780300040
J	Tang, ZK; Zhang, LY; Wang, N; Zhang, XX; Wen, GH; Li, GD; Wang, JN; Chan, CT; Sheng, P				Tang, ZK; Zhang, LY; Wang, N; Zhang, XX; Wen, GH; Li, GD; Wang, JN; Chan, CT; Sheng, P			Superconductivity in 4 angstrom single-walled carbon nanotubes	SCIENCE			English	Article							DOPED C-60; CHANNELS; CRYSTALS	Investigation of the magnetic and transport properties of single-walled small-diameter carbon nanotubes embedded in a zeolite matrix revealed that at temperatures below 20 kelvin, 4 angstrom tubes exhibit superconducting behavior manifest as an anisotropic Meissner effect, with a superconducting gap and fluctuation supercurrent. The measured superconducting characteristics display smooth temperature variations owing to one-dimensional fluctuations, with a mean-field superconducting transition temperature of 15 kelvin. Statistical mechanic calculations based on the Ginzburg-Landau free-energy functional yield predictions that are in excellent agreement with the experiments.	Hong Kong Univ Sci & Technol, Dept Phys, Kowloon, Hong Kong, Peoples R China; Hong Kong Univ Sci & Technol, Inst Nano Sci & Technol, Kowloon, Hong Kong, Peoples R China	Hong Kong University of Science & Technology; Hong Kong University of Science & Technology	Sheng, P (corresponding author), Hong Kong Univ Sci & Technol, Dept Phys, Clear Water Bay, Kowloon, Hong Kong, Peoples R China.	phsheng@ust.hk	Tang, Zikang/G-8164-2011; Zhang, xixiang/D-7046-2011; Sheng, Ping/I-3733-2013; TANG, Zikang/AAJ-4156-2021; Wang, Ning/B-5436-2011	Zhang, xixiang/0000-0002-3478-6414; Sheng, Ping/0000-0001-9000-6366; Chan, Che Ting/0000-0002-9335-8110; wang, jiannong/0000-0002-6133-6371; Wang, Ning/0000-0002-4902-5589				BENEDICT LX, 1995, PHYS REV B, V52, P14935, DOI 10.1103/PhysRevB.52.14935; Binder K., 1979, Monte Carlo methods in statistical physics, P1; DEGENNES PG, 1966, SUPERCONDUCTIVITY ME, P171; Ginzburg V.L., 1950, J. Exp. Theor. Phys, V20, P1064, DOI DOI 10.1007/978-3-540-68008-6_4; HEBARD AF, 1991, NATURE, V350, P600, DOI 10.1038/350600a0; Ishiguro T., 1998, ORGANIC SUPERCONDUCT, V2nd; Jerome D., 1980, J PHYS LETT, V41, P95, DOI DOI 10.1051/JPHYSLET:0198000410409500; Kasumov AY, 1999, SCIENCE, V284, P1508, DOI 10.1126/science.284.5419.1508; Kociak M, 2001, PHYS REV LETT, V86, P2416, DOI 10.1103/PhysRevLett.86.2416; Launois P, 2000, SOLID STATE COMMUN, V116, P99, DOI 10.1016/S0038-1098(00)00270-2; METROPOLIS N, 1953, J CHEM PHYS, V21, P1087, DOI 10.1063/1.1699114; Schon JH, 2000, NATURE, V408, P549, DOI 10.1038/35046008; Sun HD, 1999, APPL PHYS A-MATER, V69, P381, DOI 10.1007/s003390051018; Tang ZK, 2000, PHYSICA B, V279, P200, DOI 10.1016/S0921-4526(99)00734-6; Tang ZK, 1998, APPL PHYS LETT, V73, P2287, DOI 10.1063/1.121704; TANIGAKI K, 1991, NATURE, V352, P222, DOI 10.1038/352222a0; Wang N, 2000, NATURE, V408, P50, DOI 10.1038/35040702	17	620	654	11	197	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 29	2001	292	5526					2462	2465		10.1126/science.1060470	http://dx.doi.org/10.1126/science.1060470			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	448YU	11431560				2022-12-28	WOS:000169658200033
J	Couch, S; Sparks, RSJ; Carroll, MR				Couch, S; Sparks, RSJ; Carroll, MR			Mineral disequilibrium in lavas explained by convective self-mixing in open magma chambers	NATURE			English	Article							SOUFRIERE HILLS VOLCANO; ORIGIN; PLAGIOCLASE; CALIFORNIA; COMPLEX; MONTSERRAT; INTRUSION; KINETICS; RAPAKIVI; LAKE	Characteristic features of many porphyritic andesite and dacite lavas are that they are rich in crystals and display a range of disequilibrium features, including reversely zoned crystals, resorption surfaces, wide ranges of mineral compositions and minerals which are not in equilibrium with the surrounding rock matrix. These features are often interpreted as evidence of the mixing of magmas of contrasting composition, temperature and origin(1,2). Here, however, we propose that such features can also be caused by convection within a magma body with a single composition, that is heated from below and cooled from above. We describe petrological observations of andesite lava erupted at the Soufriere Hills volcano, Montserrat, which indicate a heating event and the intermingling of crystals that have very different thermal histories. We present experimental data on a representative groundmass composition of this lava, which indicate that it is difficult to explain the calcic compositions of plagioclase overgrowth rims and microphenocrysts unless parts of the magma were at temperatures much higher than the inferred average temperature. The concept of convective self-mixing allows us to explain the occurrence of compositions of minerals that apparently cannot coexist under equilibrium conditions.	Univ Bristol, Dept Earth Sci, Bristol BS8 1RJ, Avon, England; Univ Camerino, Dipartimento Sci Terra, I-62032 Camerino, Italy; Univ Camerino, INFM, I-62032 Camerino, Italy	University of Bristol; University of Camerino; Consiglio Nazionale delle Ricerche (CNR); Istituto Nazionale per la Fisica della Materia (INFM-CNR); University of Camerino	Couch, S (corresponding author), Univ Bristol, Dept Earth Sci, Bristol BS8 1RJ, Avon, England.			Mitchell, Susan/0000-0001-8363-0507				Barclay J, 1998, GEOPHYS RES LETT, V25, P3437, DOI 10.1029/98GL00856; BLUNDY JD, 1992, J PETROL, V33, P1039, DOI 10.1093/petrology/33.5.1039; Clynne MA, 1999, J PETROL, V40, P105, DOI 10.1093/petrology/40.1.105; Devine JD, 1998, GEOPHYS RES LETT, V25, P3669, DOI 10.1029/98GL01330; DLemos RS, 1996, LITHOS, V38, P233, DOI 10.1016/0024-4937(96)00007-2; FURMAN T, 1985, J VOLCANOL GEOTH RES, V24, P151, DOI 10.1016/0377-0273(85)90031-9; Harford CL, 2001, EARTH PLANET SC LETT, V185, P285, DOI 10.1016/S0012-821X(00)00373-3; HEIKEN G, 1980, J VOLCANOL GEOTH RES, V7, P443, DOI 10.1016/0377-0273(80)90042-6; HIBBARD MJ, 1981, CONTRIB MINERAL PETR, V76, P158, DOI 10.1007/BF00371956; Jellinek AM, 1999, J GEOPHYS RES-SOL EA, V104, P7183, DOI 10.1029/1998JB900116; Jellinek AM, 1999, J GEOPHYS RES-SOL EA, V104, P7203, DOI 10.1029/1998JB900117; KAWAMOTO T, 1992, J VOLCANOL GEOTH RES, V49, P191, DOI 10.1016/0377-0273(92)90014-5; MUNCILL GE, 1988, AM MINERAL, V73, P982; Murphy MD, 2000, J PETROL, V41, P21, DOI 10.1093/petrology/41.1.21; Nakada S, 1999, J VOLCANOL GEOTH RES, V89, P173, DOI 10.1016/S0377-0273(98)00131-0; NEKVASIL H, 1991, AM MINERAL, V76, P1279; PALLISTER JS, 1992, NATURE, V356, P426, DOI 10.1038/356426a0; Sato H, 1999, J VOLCANOL GEOTH RES, V89, P197, DOI 10.1016/S0377-0273(98)00132-2; Snyder D, 2000, EARTH PLANET SC LETT, V175, P257, DOI 10.1016/S0012-821X(99)00301-5; STIMAC JA, 1992, GEOL SOC AM BULL, V104, P728, DOI 10.1130/0016-7606(1992)104<0728:PMOSIS>2.3.CO;2; SWANSON SE, 1977, AM MINERAL, V62, P966; TSUCHIYAMA A, 1985, CONTRIB MINERAL PETR, V89, P1, DOI 10.1007/BF01177585; Turcotte D. L., 1982, GEODYNAMICS APPL CON, DOI 10.1017/CBO9780511843877; VERNON RH, 1984, NATURE, V309, P438, DOI 10.1038/309438a0; WHITEHEAD JA, 1975, J GEOPHYS RES, V80, P705, DOI 10.1029/JB080i005p00705	25	313	327	3	54	MACMILLAN PUBLISHERS LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	JUN 28	2001	411	6841					1037	1039		10.1038/35082540	http://dx.doi.org/10.1038/35082540			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	446TF	11429601				2022-12-28	WOS:000169528500044
J	Winston, JA; Bruggeman, LA; Ross, MD; Jacobson, J; Ross, L; D'Agati, VD; Klotman, PE; Klotman, ME				Winston, JA; Bruggeman, LA; Ross, MD; Jacobson, J; Ross, L; D'Agati, VD; Klotman, PE; Klotman, ME			Nephropathy and establishment of a renal reservoir of HIV type 1 during primary infection	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ANTIRETROVIRAL THERAPY; GLOMERULOSCLEROSIS; EPIDEMIC; MICE		Mt Sinai Sch Med, Div Nephrol, New York, NY 10029 USA; Mt Sinai Sch Med, Div Infect Dis, New York, NY 10029 USA; Columbia Presbyterian Med Ctr, Dept Pathol, New York, NY 10032 USA	Icahn School of Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai; Columbia University; NewYork-Presbyterian Hospital	Klotman, ME (corresponding author), Mt Sinai Sch Med, Div Nephrol, Box 1090,1 Gustave L Levy Pl, New York, NY 10029 USA.		klotman, mary e/A-1921-2016		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK056492] Funding Source: NIH RePORTER; NIDDK NIH HHS [P01DK56492-01] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Barisoni L, 1999, J AM SOC NEPHROL, V10, P51; Bruggeman LA, 2000, J AM SOC NEPHROL, V11, P2079, DOI 10.1681/ASN.V11112079; Bruggeman LA, 1997, J CLIN INVEST, V100, P84, DOI 10.1172/JCI119525; Cara A, 1997, LEUKEMIA, V11, P1395, DOI 10.1038/sj.leu.2400776; COHEN AH, 1988, MODERN PATHOL, V1, P87; DAGATI V, 1989, KIDNEY INT, V35, P1358, DOI 10.1038/ki.1989.135; DAgati V, 1997, J AM SOC NEPHROL, V8, P138; Furtado MR, 1999, NEW ENGL J MED, V340, P1614, DOI 10.1056/NEJM199905273402102; GERDES J, 1991, AM J PATHOL, V138, P867; Ho DD, 2000, NAT MED, V6, P736, DOI 10.1038/77447; IFUDU O, 1995, AM J NEPHROL, V15, P217, DOI 10.1159/000168835; KOPP JB, 1992, P NATL ACAD SCI USA, V89, P1577, DOI 10.1073/pnas.89.5.1577; Wali RK, 1998, LANCET, V352, P783, DOI 10.1016/S0140-6736(98)24037-2; Winston JA, 2000, SEMIN NEPHROL, V20, P293; Winston JA, 1998, SEMIN NEPHROL, V18, P373; Winston JA, 1999, KIDNEY INT, V55, P1036, DOI 10.1046/j.1523-1755.1999.0550031036.x; Winston JA, 1996, J AM SOC NEPHROL, V7, P1	17	236	244	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUN 28	2001	344	26					1979	1984		10.1056/NEJM200106283442604	http://dx.doi.org/10.1056/NEJM200106283442604			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	446HQ	11430327				2022-12-28	WOS:000169508200004
J	Taylor, RB; Shakoor, O; Behrens, RH; Everard, M; Low, AS; Wangboonskul, J; Raid, RG; Kolawole, JA				Taylor, RB; Shakoor, O; Behrens, RH; Everard, M; Low, AS; Wangboonskul, J; Raid, RG; Kolawole, JA			Pharmacopoeial quality of drugs supplied by Nigerian pharmacies	LANCET			English	Article							SUBSTANDARD DRUGS	Background The quality of medicines available in some less-developed countries is inadequate in terms of content of active ingredient. Reasons for the poor quality of drugs include widespread counterfeiting of medicines in less-developed countries, excessive decomposition of active ingredient as a result of high temperature and humidity, and poor quality assurance during the manufacture of medicinal products. Our aim was to investigate the quality of different drugs obtained from retail pharmacies in two urban areas of Nigeria, and, in instances of poor quality, to ascertain the reason why. Methods We randomly collected 581 samples of 27 different drugs from 35 pharmacies in Lagos and Abuja in Nigeria. We analysed the medicines for drug content by validated chromatographic methods, and compared our results with pharmacopoeial requirements. Findings 279 (48%) samples did not comply with set pharmacopoeial limits, and this proportion was uniform for the various types of drugs tested. Although some preparations contained no active ingredient, most had amounts just outside the pharmacopoeial limits. We identified samples with both too much and too little active drug content. Interpretation The most probable cause of the poor quality of drugs is absence of adequate quality assurance during manufacture. Substandard drugs sold in the pharmacies of less-developed countries could contribute to global microbial resistance and therapeutic failure of infectious diseases.	Robert Gordon Univ, Sch Pharm, Aberdeen AB10 1FR, Scotland; London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1, England; Khon Kaen Univ, Fac Pharmaceut Sci, Khon Kaen, Thailand; Univ Jos, Dept Pharm, Jos, Nigeria	Robert Gordon University; University of London; London School of Hygiene & Tropical Medicine; Khon Kaen University; University of Jos	Taylor, RB (corresponding author), Robert Gordon Univ, Sch Pharm, Aberdeen AB10 1FR, Scotland.			Behrens, Ron/0000-0002-8166-2633				ABDI YA, 1995, LANCET, V346, P1161, DOI 10.1016/S0140-6736(95)91834-5; [Anonymous], 1990, ACUTE RESP INFECT CH; Arya S C, 1995, World Health Forum, V16, P269; CAMPBELL H, 1995, ARCH DIS CHILD, V73, P281, DOI 10.1136/adc.73.4.281; Dye C, 1999, JAMA-J AM MED ASSOC, V282, P677, DOI 10.1001/jama.282.7.677; HOGERZEIL HV, 1991, LANCET, V338, P754, DOI 10.1016/0140-6736(91)91470-F; KELLY JC, 1990, ANN EMERG MED, V19, P47, DOI 10.1016/S0196-0644(05)82141-9; KIBWAGE IO, 1992, E AFR MED J, V69, P577; Low AS, 1999, ANALYST, V124, P1589, DOI 10.1039/a907400g; PETRALANDA I, 1995, LANCET, V345, P1433, DOI 10.1016/S0140-6736(95)92620-8; Roy J, 1994, World Health Forum, V15, P406; Shakoor O, 1997, TROP MED INT HEALTH, V2, P839, DOI 10.1046/j.1365-3156.1997.d01-403.x; TENHAM M, 1992, ADVERSE DRUG REACT T, V11, P59; WONDEMAGEGNEHU E, 1995, COUNTERFEIT SUBSTAND; 1999, WORLD HLTH REPORT 19, P49	15	139	142	0	17	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	JUN 16	2001	357	9272					1933	1936		10.1016/S0140-6736(00)05065-0	http://dx.doi.org/10.1016/S0140-6736(00)05065-0			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	444YZ	11425415				2022-12-28	WOS:000169431000013
J	Dajani, R; Fraser, E; Roe, SM; Young, N; Good, V; Dale, TC; Pearl, LH				Dajani, R; Fraser, E; Roe, SM; Young, N; Good, V; Dale, TC; Pearl, LH			Crystal structure of glycogen synthase kinase 3 beta: Structural basis for phosphate-primed substrate specificity and autoinhibition	CELL			English	Article							BETA-CATENIN; PHOSPHORYLASE-KINASE; GSK-3-BETA-DEPENDENT PHOSPHORYLATION; 3-DIMENSIONAL STRUCTURE; CATALYTIC DOMAIN; AXIN; PEPTIDE; IDENTIFICATION; ACTIVATION; GSK-3	Glycogen synthase kinase 3 beta (GSK3 beta) plays a key role in insulin and Wnt signaling, phosphorylating downstream targets by default, and becoming inhibited following the extracellular signaling event. The crystal structure of human GSK3 beta shows a catalytically active conformation in the absence of activation-segment phosphorylation, with the sulphonate of a buffer molecule bridging the activation-segment and N-terminal domain in the same way as the phosphate group of the activation-segment phospho-Ser/Thr in other kinases. The location of this oxyanion binding site in the substrate binding cleft indicates direct coupling of P+4 phosphate-primed substrate binding and catalytic activation, explains the ability of GSK3 beta to processively hyperphosphorylate substrates with Ser/Thr pentad-repeats, and suggests a mechanism for autoinhibition in which the phosphorylated N terminus binds as a competitive pseudosubstrate with phospho-Ser 9 occupying the P+4 site.	Inst Canc Res, Chester Beatty Labs, Sect Struct Biol, London SW3 6JB, England; Inst Canc Res, Chester Beatty Labs, CRC, Ctr Cell & Mol Biol, London SW3 6JB, England	Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK	Pearl, LH (corresponding author), Inst Canc Res, Chester Beatty Labs, Sect Struct Biol, 237 Fulham Rd, London SW3 6JB, England.	laurence@icr.ac.uk	Dale, Trevor C/D-3749-2009; Fraser, Elizabeth/M-7049-2015	Dale, Trevor C/0000-0002-4880-9963; Fraser, Elizabeth/0000-0001-8420-3208; Roe, Mark/0000-0002-7371-9855; Pearl, Laurence/0000-0002-6910-1809				Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Canagarajah BJ, 1997, CELL, V90, P859, DOI 10.1016/S0092-8674(00)80351-7; Chen P, 2000, CELL, V100, P681, DOI 10.1016/S0092-8674(00)80704-7; Cobb MH, 2000, TRENDS BIOCHEM SCI, V25, P7, DOI 10.1016/S0968-0004(99)01508-X; Cohen P, 1999, PHILOS T R SOC B, V354, P485, DOI 10.1098/rstb.1999.0399; COX S, 1992, PROTEIN ENG, V5, P811, DOI 10.1093/protein/5.8.811; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Farr GH, 2000, J CELL BIOL, V148, P691, DOI 10.1083/jcb.148.4.691; FIOL CJ, 1990, J BIOL CHEM, V265, P6061; FIOL CJ, 1988, ARCH BIOCHEM BIOPHYS, V267, P797, DOI 10.1016/0003-9861(88)90089-6; FLOTOW H, 1990, J BIOL CHEM, V265, P14264; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; HUGHES K, 1993, EMBO J, V12, P803, DOI 10.1002/j.1460-2075.1993.tb05715.x; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Ikeda S, 2000, ONCOGENE, V19, P537, DOI 10.1038/sj.onc.1203359; Itoh K, 1995, DEVELOPMENT, V121, P3979; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kim L, 1999, CELL, V99, P399, DOI 10.1016/S0092-8674(00)81526-3; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LESLIE A, 1995, MOSFLM USERS GUIDE; Li L, 1999, EMBO J, V18, P4233, DOI 10.1093/emboj/18.15.4233; Longenecker KL, 1996, J MOL BIOL, V257, P618, DOI 10.1006/jmbi.1996.0189; Lowe ED, 1997, EMBO J, V16, P6646, DOI 10.1093/emboj/16.22.6646; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; Murai H, 1996, FEBS LETT, V392, P153, DOI 10.1016/0014-5793(96)00806-X; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1993, BIOPHYS J, V64, pA166; OWEN DJ, 1995, STRUCTURE, V3, P467, DOI 10.1016/S0969-2126(01)00180-0; PLYTE SE, 1992, BIOCHIM BIOPHYS ACTA, V1114, P147, DOI 10.1016/0304-419X(92)90012-N; Polakis P, 1999, CURR OPIN GENET DEV, V9, P15, DOI 10.1016/S0959-437X(99)80003-3; Polakis P, 2000, GENE DEV, V14, P1837; ROBBINS DJ, 1993, J BIOL CHEM, V268, P5097; Ross SE, 1999, MOL CELL BIOL, V19, P8433; Russo AA, 1996, NAT STRUCT BIOL, V3, P696, DOI 10.1038/nsb0896-696; Ryves WJ, 1998, ANAL BIOCHEM, V264, P124, DOI 10.1006/abio.1998.2832; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; Stambolic V, 1996, CURR BIOL, V6, P1664, DOI 10.1016/S0960-9822(02)70790-2; Thomas GM, 1999, FEBS LETT, V458, P247, DOI 10.1016/S0014-5793(99)01161-8; WANG YH, 1993, J BIOL CHEM, V268, P23876; Wang ZL, 1997, P NATL ACAD SCI USA, V94, P2327, DOI 10.1073/pnas.94.6.2327; Williams RSB, 2000, TRENDS PHARMACOL SCI, V21, P61, DOI 10.1016/S0165-6147(99)01428-5; XU RM, 1995, EMBO J, V14, P1015, DOI 10.1002/j.1460-2075.1995.tb07082.x; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; Yost C, 1998, CELL, V93, P1031, DOI 10.1016/S0092-8674(00)81208-8; ZHANG FM, 1994, NATURE, V367, P704, DOI 10.1038/367704a0; ZHANG JD, 1995, STRUCTURE, V3, P299, DOI 10.1016/S0969-2126(01)00160-5	55	543	577	1	32	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 15	2001	105	6					721	732		10.1016/S0092-8674(01)00374-9	http://dx.doi.org/10.1016/S0092-8674(01)00374-9			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	444AE	11440715	Bronze			2022-12-28	WOS:000169375100006
J	Dodson, KW; Pinkner, JS; Rose, T; Magnusson, G; Hultgren, SJ; Waksman, G				Dodson, KW; Pinkner, JS; Rose, T; Magnusson, G; Hultgren, SJ; Waksman, G			Structural basis of the interaction of the pyelonephritic E. coli adhesin to its human kidney receptor	CELL			English	Article							UROPATHOGENIC ESCHERICHIA-COLI; SIALOSYL GALACTOSYL GLOBOSIDE; PREFERRED BINDING-RECEPTOR; URINARY-TRACT-INFECTION; CYTOKINE RESPONSES; GLYCOLIPID RECEPTOR; BACTERIAL INVASION; COMMON THEMES; PAPG ADHESIN; P-FIMBRIAE	PapG is the adhesin at the tip of the P pilus that mediates attachment of uropathogenic Escherichia coli to the uroepithelium of the human kidney. The human specific allele of PapG binds to globoside (GbO4), which consists of the tetrasaccharide GalNAc beta1-3Gal alpha1-4Gal beta1-4Glc linked to ceramide. Here, we present the crystal structures of a binary complex of the PapG receptor binding domain bound to GbO4 as well as the unbound form of the adhesin. The biological importance of each of the residues involved in binding was investigated by site-directed mutagenesis. These studies provide a molecular snapshot of a host-pathogen interaction that determines the tropism of uropathogenic E. coli for the human kidney and is critical to the pathogenesis of pyelonephritis.	Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA; Lund Univ, Lund, Sweden	Washington University (WUSTL); Washington University (WUSTL); Lund University	Hultgren, SJ (corresponding author), Washington Univ, Sch Med, Dept Mol Microbiol, St Louis, MO 63110 USA.	hultgren@borcim.wustl.edu; waksman@biochem.wustl.edu		ROSE, Thierry/0000-0001-8863-0207; Pinkner, Jerome/0000-0002-7389-7440	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI049950, R01AI048689, R37AI029549, R01AI029549] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK051406] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054033] Funding Source: NIH RePORTER; NIAID NIH HHS [AI49950, AI48689, AI29549] Funding Source: Medline; NIDDK NIH HHS [DK51406] Funding Source: Medline; NIGMS NIH HHS [GM54033] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; BULLITT E, 1995, NATURE, V373, P164, DOI 10.1038/373164a0; Choudhury D, 1999, SCIENCE, V285, P1061, DOI 10.1126/science.285.5430.1061; CLEGG S, 1982, INFECT IMMUN, V38, P739, DOI 10.1128/IAI.38.2.739-744.1982; Finlay BB, 1997, MICROBIOL MOL BIOL R, V61, P136, DOI 10.1128/.61.2.136-169.1997; FOXMAN B, 1990, AM J PUBLIC HEALTH, V80, P331, DOI 10.2105/AJPH.80.3.331; Guex N, 1999, TRENDS BIOCHEM SCI, V24, P364, DOI 10.1016/S0968-0004(99)01427-9; Hedlund M, 1999, MOL MICROBIOL, V33, P693, DOI 10.1046/j.1365-2958.1999.01513.x; Hedlund M, 1996, J EXP MED, V183, P1037, DOI 10.1084/jem.183.3.1037; Hooton TM, 1997, INFECT DIS CLIN N AM, V11, P551, DOI 10.1016/S0891-5520(05)70373-1; HULTGREN SJ, 1989, P NATL ACAD SCI USA, V86, P4357, DOI 10.1073/pnas.86.12.4357; HULTGREN SJ, 1990, MOL MICROBIOL, V4, P1311, DOI 10.1111/j.1365-2958.1990.tb00710.x; JACOBDUBUISSON F, 1993, EMBO J, V12, P837, DOI 10.1002/j.1460-2075.1993.tb05724.x; Johnson JR, 1998, J INFECT DIS, V177, P97, DOI 10.1086/513824; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KIHLBERG J, 1989, J AM CHEM SOC, V111, P6364, DOI 10.1021/ja00198a056; KLANN AG, 1994, J BACTERIOL, V176, P2312, DOI 10.1128/JB.176.8.2312-2317.1994; KUEHN MJ, 1992, NATURE, V356, P252, DOI 10.1038/356252a0; LEFFLER H, 1980, FEMS MICROBIOL LETT, V8, P127, DOI 10.1111/j.1574-6968.1980.tb05064.x; LEMASTER DM, 1985, BIOCHEMISTRY-US, V24, P7263, DOI 10.1021/bi00346a036; LUND B, 1987, P NATL ACAD SCI USA, V84, P5898, DOI 10.1073/pnas.84.16.5898; Martinez JJ, 2000, EMBO J, V19, P2803, DOI 10.1093/emboj/19.12.2803; NICHOLLS A, 1991, J COMPUT CHEM, V12, P435, DOI 10.1002/jcc.540120405; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PASCHER I, 1992, BIOCHIM BIOPHYS ACTA, V1113, P339, DOI 10.1016/0304-4157(92)90006-V; PATTON JP, 1991, MED CLIN N AM, V75, P495, DOI 10.1016/S0025-7125(16)30466-7; Pernestig AK, 2000, ADV EXP MED BIOL, V485, P137; ROBERTS JA, 1994, P NATL ACAD SCI USA, V91, P11889, DOI 10.1073/pnas.91.25.11889; RONALD AR, 1991, MED CLIN N AM, V75, P299, DOI 10.1016/S0025-7125(16)30455-2; Roussel A, 1991, SILICON GRAPHICS GEO, P86; Sauer FG, 1999, SCIENCE, V285, P1058, DOI 10.1126/science.285.5430.1058; Sauer FG, 2000, SEMIN CELL DEV BIOL, V11, P27, DOI 10.1006/scdb.1999.0348; Schilling JD, 2001, J IMMUNOL, V166, P1148, DOI 10.4049/jimmunol.166.2.1148; Soto GE, 1999, J BACTERIOL, V181, P1059, DOI 10.1128/JB.181.4.1059-1071.1999; Stapleton AE, 1998, INFECT IMMUN, V66, P3856, DOI 10.1128/IAI.66.8.3856-3861.1998; STRIKER R, 1995, MOL MICROBIOL, V16, P1021, DOI 10.1111/j.1365-2958.1995.tb02327.x; STROMBERG N, 1990, EMBO J, V9, P2001, DOI 10.1002/j.1460-2075.1990.tb08328.x; STROMBERG N, 1991, P NATL ACAD SCI USA, V88, P9340, DOI 10.1073/pnas.88.20.9340; Stroud MR, 1998, BIOCHEMISTRY-US, V37, P17420, DOI 10.1021/bi9814639; Svanborg C, 1996, ANN NY ACAD SCI, V797, P177, DOI 10.1111/j.1749-6632.1996.tb52959.x; Svanborg C, 1997, INFECT DIS CLIN N AM, V11, P513, DOI 10.1016/S0891-5520(05)70371-8; TERWILLIGER TC, 1994, ACTA CRYSTALLOGR D, V50, P17, DOI 10.1107/S0907444993008236; Thanassi DG, 2000, METHODS, V20, P111, DOI 10.1006/meth.1999.0910; Warren John W., 1996, P3; Zhang JP, 1996, SCIENCE, V273, P1234, DOI 10.1126/science.273.5279.1234	48	197	205	0	6	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUN 15	2001	105	6					733	743		10.1016/S0092-8674(01)00388-9	http://dx.doi.org/10.1016/S0092-8674(01)00388-9			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	444AE	11440716	Bronze			2022-12-28	WOS:000169375100007
J	Bignall, J				Bignall, J			Accident or murder in children?	LANCET			English	News Item																		Plunkett J, 2001, AM J FOREN MED PATH, V22, P1, DOI 10.1097/00000433-200103000-00001; 1998, LANCET, V352, P335	2	7	8	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	MAR 10	2001	357	9258					776	776		10.1016/S0140-6736(05)71206-X	http://dx.doi.org/10.1016/S0140-6736(05)71206-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	409TC	11418180				2022-12-28	WOS:000167400900024
J	Prasad, AS				Prasad, AS			Blinding in placebo-controlled trials	ANNALS OF INTERNAL MEDICINE			English	Letter							COMMON COLD; ZINC		Wayne State Univ, Detroit, MI 48201 USA	Wayne State University	Prasad, AS (corresponding author), Wayne State Univ, Detroit, MI 48201 USA.							Desbiens NA, 2000, ANN INTERN MED, V133, P302, DOI 10.7326/0003-4819-133-4-200008150-00016; Prasad AS, 2000, ANN INTERN MED, V133, P245, DOI 10.7326/0003-4819-133-4-200008150-00006	2	1	1	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 19	2001	134	12					1150	1150		10.7326/0003-4819-134-12-200106190-00019	http://dx.doi.org/10.7326/0003-4819-134-12-200106190-00019			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	442YU	11412060				2022-12-28	WOS:000169313200011
J	Ehrlich, GE				Ehrlich, GE			Building in placebo-controlled trials	ANNALS OF INTERNAL MEDICINE			English	Letter							COMMON COLD; BLIND; ZINC		Univ Penn, Philadelphia, PA 19104 USA	University of Pennsylvania	Ehrlich, GE (corresponding author), Univ Penn, Philadelphia, PA 19104 USA.							Desbiens NA, 2000, ANN INTERN MED, V133, P302, DOI 10.7326/0003-4819-133-4-200008150-00016; Prasad AS, 2000, ANN INTERN MED, V133, P245, DOI 10.7326/0003-4819-133-4-200008150-00006	2	1	1	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JUN 19	2001	134	12					1150	1151		10.7326/0003-4819-134-12-200106190-00020	http://dx.doi.org/10.7326/0003-4819-134-12-200106190-00020			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	442YU	11412060				2022-12-28	WOS:000169313200012
J	Zhang, XM; Ramalho-Santos, M; McMahon, AP				Zhang, XM; Ramalho-Santos, M; McMahon, AP			Smoothened mutants reveal redundant roles for Shh and Ihh signaling including regulation of L/R asymmetry by the mouse node	CELL			English	Article							LEFT-RIGHT AXIS; SONIC-HEDGEHOG; SCLEROTOME INDUCTION; INDIAN HEDGEHOG; CARTILAGE DIFFERENTIATION; VERTEBRATE DEVELOPMENT; MAMMALIAN TOOTH; GENE; EXPRESSION; PROLIFERATION	Genetic analyses in Drosophila have demonstrated that the multipass membrane protein Smoothened (Smo) is essential for all Hedgehog signaling. We show that Smo acts epistatic to Ptc1 to mediate Shh and Ihh signaling in the early mouse embryo. Smo and Shh/Ihh compound mutants have identical phenotypes: embryos fail to turn, arresting at somite stages with a small, linear heart tube, an open gut and cyclopia. The absence of visible left/right (L/R) asymmetry led us to examine the pathways controlling L/R situs. We present evidence consistent with a model in which Hedgehog signaling within the node is required for activation of Gdf1, and induction of left-side determinants. Further, we demonstrate an absolute requirement for Hedgehog signaling in sclerotomal development and a role in cardiac morphogenesis.	Harvard Univ, Dept Mol & Cellular Biol, Biolabs, Cambridge, MA 02138 USA	Harvard University	McMahon, AP (corresponding author), Harvard Univ, Dept Mol & Cellular Biol, Biolabs, 16 Divin Ave, Cambridge, MA 02138 USA.		Ramalho-Santos, Miguel/L-9092-2018; McMahon, Andrew P/ABE-7520-2020	Ramalho-Santos, Miguel/0000-0003-0177-5556; 	NINDS NIH HHS [NS33642] Funding Source: Medline	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Akiyama H, 1997, BIOCHEM BIOPH RES CO, V235, P142, DOI 10.1006/bbrc.1997.6750; Alcedo J, 2000, MOL CELL, V6, P457, DOI 10.1016/S1097-2765(00)00044-7; Apelqvist A, 1997, CURR BIOL, V7, P801, DOI 10.1016/S0960-9822(06)00340-X; Barresi MJF, 2000, DEVELOPMENT, V127, P2189; Bitgood MJ, 1996, CURR BIOL, V6, P298, DOI 10.1016/S0960-9822(02)00480-3; BITGOOD MJ, 1995, DEV BIOL, V172, P126, DOI 10.1006/dbio.1995.0010; Borycki AG, 2000, CURR TOP DEV BIOL, V48, P165; Borycki AG, 1999, DEVELOPMENT, V126, P4053; Borycki AG, 1998, DEVELOPMENT, V125, P777; Burdine RD, 2000, GENE DEV, V14, P763; Capdevila J, 2000, CELL, V101, P9, DOI 10.1016/S0092-8674(00)80619-4; Carpenter D, 1998, P NATL ACAD SCI USA, V95, P13630, DOI 10.1073/pnas.95.23.13630; Chen Y, 1996, CELL, V87, P553, DOI 10.1016/S0092-8674(00)81374-4; Chiang C, 1996, NATURE, V383, P407, DOI 10.1038/383407a0; Chiang C, 1999, DEV BIOL, V205, P1, DOI 10.1006/dbio.1998.9103; Collignon J, 1996, NATURE, V381, P155, DOI 10.1038/381155a0; Cossu G, 1999, EMBO J, V18, P6867, DOI 10.1093/emboj/18.24.6867; Dassule HR, 2000, DEVELOPMENT, V127, P4775; Dassule HR, 1998, DEV BIOL, V202, P215, DOI 10.1006/dbio.1998.8992; Denef N, 2000, CELL, V102, P521, DOI 10.1016/S0092-8674(00)00056-8; Dockter JL, 2000, CURR TOP DEV BIOL, V48, P77; Dutton R, 1999, J NEUROSCI, V19, P2601; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; FAN CM, 1994, CELL, V79, P1175, DOI 10.1016/0092-8674(94)90009-4; FAN CM, 1995, CELL, V81, P457, DOI 10.1016/0092-8674(95)90398-4; Gaio U, 1999, CURR BIOL, V9, P1339, DOI 10.1016/S0960-9822(00)80059-7; Goodrich LV, 1997, SCIENCE, V277, P1109, DOI 10.1126/science.277.5329.1109; Hammerschmidt M, 1997, TRENDS GENET, V13, P14, DOI 10.1016/S0168-9525(96)10051-2; Hebrok M, 2000, DEVELOPMENT, V127, P4905; Hynes M, 2000, NAT NEUROSCI, V3, P41, DOI 10.1038/71114; Ingham PW, 2000, CURR BIOL, V10, P1315, DOI 10.1016/S0960-9822(00)00755-7; Karp SJ, 2000, DEVELOPMENT, V127, P543; Kos L, 1998, MECH DEVELOP, V70, P25, DOI 10.1016/S0925-4773(97)00168-8; Lassar AB, 1996, CURR OPIN NEUROBIOL, V6, P57, DOI 10.1016/S0959-4388(96)80009-2; LEVIN M, 1995, CELL, V82, P803, DOI 10.1016/0092-8674(95)90477-8; Litingtung Y, 1998, NAT GENET, V20, P58, DOI 10.1038/1717; Liu AM, 1998, MECH DEVELOP, V75, P107, DOI 10.1016/S0925-4773(98)00090-2; Lyons GE, 1996, CURR OPIN GENET DEV, V6, P454, DOI 10.1016/S0959-437X(96)80067-0; LYONS I, 1995, GENE DEV, V9, P1654, DOI 10.1101/gad.9.13.1654; Marcelle C, 1999, DEV BIOL, V214, P277, DOI 10.1006/dbio.1999.9389; Marigo V, 1996, NATURE, V384, P176, DOI 10.1038/384176a0; MASUYA H, 1995, GENE DEV, V9, P1645, DOI 10.1101/gad.9.13.1645; Meno C, 1997, GENES CELLS, V2, P513, DOI 10.1046/j.1365-2443.1997.1400338.x; Meno C, 1998, CELL, V94, P287, DOI 10.1016/S0092-8674(00)81472-5; Meyers EN, 1999, SCIENCE, V285, P403, DOI 10.1126/science.285.5426.403; Monkley SJ, 1996, DEVELOPMENT, V122, P3343; Murtaugh LC, 1999, GENE DEV, V13, P225, DOI 10.1101/gad.13.2.225; Nonaka S, 1998, CELL, V95, P829, DOI 10.1016/S0092-8674(00)81705-5; OBRIEN TX, 1993, P NATL ACAD SCI USA, V90, P5157, DOI 10.1073/pnas.90.11.5157; Parmantier E, 1999, NEURON, V23, P713, DOI 10.1016/S0896-6273(01)80030-1; PARR BA, 1995, NATURE, V374, P350, DOI 10.1038/374350a0; Pepicelli CV, 1998, CURR BIOL, V8, P1083, DOI 10.1016/S0960-9822(98)70446-4; Piedra ME, 1998, CELL, V94, P319, DOI 10.1016/S0092-8674(00)81475-0; Quirk J, 1997, COLD SPRING HARB SYM, V62, P217; Ramalho-Santos M, 2000, DEVELOPMENT, V127, P2763; Ramirez-Weber FA, 2000, MOL CELL, V6, P479, DOI 10.1016/S1097-2765(00)00046-0; Rankin CT, 2000, NAT GENET, V24, P262, DOI 10.1038/73472; Rowitch DH, 1999, J NEUROSCI, V19, P8954, DOI 10.1523/JNEUROSCI.19-20-08954.1999; Ryan AK, 1998, NATURE, V394, P545, DOI 10.1038/29004; Sarkar L, 2000, P NATL ACAD SCI USA, V97, P4520, DOI 10.1073/pnas.97.9.4520; Sato N, 1999, J CLIN INVEST, V104, P855, DOI 10.1172/JCI7691; Shen MM, 2000, TRENDS GENET, V16, P303, DOI 10.1016/S0168-9525(00)02006-0; St-Jacques B, 1998, CURR BIOL, V8, P1058, DOI 10.1016/S0960-9822(98)70443-9; St-Jacques B, 1999, GENE DEV, V13, P2072, DOI 10.1101/gad.13.16.2072; Stone DM, 1996, NATURE, V384, P129, DOI 10.1038/384129a0; Strutt H, 2001, CURR BIOL, V11, P608, DOI 10.1016/S0960-9822(01)00179-8; Teillet MA, 1998, DEVELOPMENT, V125, P2019; Tsukui T, 1999, P NATL ACAD SCI USA, V96, P11376, DOI 10.1073/pnas.96.20.11376; Vortkamp A, 1996, SCIENCE, V273, P613, DOI 10.1126/science.273.5275.613; Wallace VA, 1999, CURR BIOL, V9, P445, DOI 10.1016/S0960-9822(99)80195-X; Wechsler-Reya RJ, 1999, NEURON, V22, P103, DOI 10.1016/S0896-6273(00)80682-0; WHITING J, 1991, GENE DEV, V5, P2048, DOI 10.1101/gad.5.11.2048; Xie JW, 1998, NATURE, V391, P90, DOI 10.1038/34201; Yan YT, 1999, GENE DEV, V13, P2527, DOI 10.1101/gad.13.19.2527; Ye WL, 1998, CELL, V93, P755, DOI 10.1016/S0092-8674(00)81437-3; Yoshioka H, 1998, CELL, V94, P299, DOI 10.1016/S0092-8674(00)81473-7; Zhang YD, 2000, DEVELOPMENT, V127, P1431; Zuniga A, 1999, NATURE, V401, P598, DOI 10.1038/44157	78	458	472	1	14	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTES AVE,, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	JUN 15	2001	105	6					781	792		10.1016/S0092-8674(01)00385-3	http://dx.doi.org/10.1016/S0092-8674(01)00385-3			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	444AE	11440720	Bronze			2022-12-28	WOS:000169375100011
